PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	MALI, M; ANDTFOLK, H; MIETTINEN, HM; JALKANEN, M				MALI, M; ANDTFOLK, H; MIETTINEN, HM; JALKANEN, M			SUPPRESSION OF TUMOR-CELL GROWTH BY SYNDECAN-1 ECTODOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MAMMARY EPITHELIAL-CELLS; FIBROBLAST GROWTH; HEPARAN-SULFATE; CARCINOMA-CELLS; MOUSE SKIN; SURFACE; PROTEIN; EXPRESSION; ADHESION; BINDING	Syndecans are integral membrane proteoglycans characterized by the similarity of cytoplasmic and transmembrane domains of the core proteins. Syndecans may regulate cell behavior by participating in matrix recognition and growth factor binding. Using syndecan-1 deletion mutants, we show that the extracellular part of the molecule (ectodomain) can suppress malignant growth, stimulate actin polymerization, and induce epithelioid morphology in mouse mammary tumor Shionogi 115 (S115) cells. Free ectodomain isolated from the culture medium of either syndecan-1-transfected S115 cells or normal murine mammary gland (NMuMG) cells can suppress the growth of S115 tumor cells at nanomolar concentrations. The ectodomain of syndecan-1 inhibited also the growth of other carcinoma cell lines, such as CarB and MCF-7, but no such inhibition was observed for contact-inhibited cell lines, including MH 3T3 cells, NMuMG cells, and human HaCaT keratinocytes. Intact heparan sulfate structure of the ectodomain was required for the suppression because degradation of heparan sulfate chains completely abolished growth inhibition. These results suggest a tumor suppressor activity for the syndecan-1 ectodomain.	UNIV TURKU,CTR BIOTECHNOL,SF-20521 TURKU,FINLAND; UNIV TURKU,DEPT MED BIOCHEM,SF-20520 TURKU,FINLAND	University of Turku; University of Turku								AVIEZER D, 1994, J BIOL CHEM, V269, P114; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BUCHMANN A, 1991, CANCER RES, V51, P4097; BUSCH SJ, 1992, J CELL BIOL, V116, P31, DOI 10.1083/jcb.116.1.31; COUCHMAN JR, 1981, CANCER RES, V41, P263; INKI P, 1994, BRIT J CANCER, V70, P319, DOI 10.1038/bjc.1994.300; INKI P, 1991, AM J PATHOL, V139, P1333; INKI P, 1994, EUR J CELL BIOL, V63, P43; INKI P, 1994, J PATHOL, V172, P349, DOI 10.1002/path.1711720410; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; KIRJAVAINEN J, 1993, MOL BIOL CELL, V4, P849, DOI 10.1091/mbc.4.8.849; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; LEPPA S, 1991, CELL REGUL, V2, P1; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; MALI M, 1993, J BIOL CHEM, V268, P24215; MIETTINEN HM, 1994, J CELL SCI, V107, P1571; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rapraeger AC, 1993, CURR OPIN CELL BIOL, V5, P844, DOI 10.1016/0955-0674(93)90034-N; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SALMIVIRTA M, 1992, J BIOL CHEM, V267, P17606; SY MS, 1992, J EXP MED, V176, P623, DOI 10.1084/jem.176.2.623; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WOODS A, 1992, J CELL SCI, V101, P277; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YATES J, 1981, CANCER RES, V41, P258; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	30	92	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27795	27798						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961703				2022-12-27	WOS:A1994PV77200004
J	METZLER, DE; METZLER, CM; SCOTT, RD; MOLLOVA, ET; KAGAMIYAMA, H; YANO, T; KURAMITSU, S; HAYASHI, H; HIROTSU, K; MIYAHARA, I				METZLER, DE; METZLER, CM; SCOTT, RD; MOLLOVA, ET; KAGAMIYAMA, H; YANO, T; KURAMITSU, S; HAYASHI, H; HIROTSU, K; MIYAHARA, I			NMR-STUDIES OF H-1 RESONANCES IN THE 10-18-PPM RANGE FOR ASPARTATE-AMINOTRANSFERASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIOSEPHOSPHATE ISOMERASE; EXCHANGEABLE PROTONS; PYRIDOXAL-PHOSPHATE; MUTANT; PHENYLALANINE; TYROSINE-225; ENZYME	We have recorded 500-MHz H-1 MMR spectra in the 10-18-ppm range for aspartate aminotransferase from Escherichia coli and for three specific mutant forms. Histidine 143 has been replaced by either alanine or asparagine. In the third mutant, tryptophan 140 has been replaced by phenylalanine. The NMR spectrum of the native enzyme is very similar to that of porcine cytosolic aspartate aminotransferase in the most downfield region. However, the resonances of the proton on the ring nitrogen of the pyridoxal 5'-phosphate (peak A) and on the His-143 imidazole ring (peak B) of the E. coli enzyme are broader and more readily lost at low pH or higher temperatures than those of the porcine enzyme. The possible role of tautomerism in promoting such broadening is discussed. In the histidine mutant proteins, peak A of the pyridoxal 5'-phosphate form is too broad to see under most conditions but is clearly present in the pyridoxamine phosphate form. Peak B is missing in the 2 histidine mutants. Observation of nuclear Overhauser effects further confirms the identity of B as the resonance of HNepsilon 2 of His-143 and that of peak D at similar to 11.8 ppm as HNepsilon 2 of His-189. The mutant spectra also provide insight into electronic interactions between groups in and near the active site which confirm and supplement conclusions drawn from spectra of porcine cAspAT. While no clear loss of a peak was observed for the Trp-140 mutant in its free form, the spectrum of the succinate complex lacked a strong band at 11.26 ppm. This may represent the Trp-140 indole NH proton which has been shifted downfield by binding to a succinate carboxylate group. While our results confirm the basic similarity of cytosolic aspartate aminotransferase and E. coli aspartate aminotransferase 1H NMR spectra, they also point out differences that may be useful in identifying resonances. A large number of mutant proteins have been prepared for the E. coli enzyme. The present results provide essential information for future study of these mutants and for study of NMR spectra of isotopically labeled enzyme.	IOWA STATE UNIV SCI & TECHNOL, CHEM INSTRUMENT SERV, AMES, IA 50011 USA; OSAKA MED COLL, DEPT MED CHEM, TAKATSUKI, OSAKA 569, JAPAN; OSAKA CITY UNIV, DEPT CHEM, SUMIYOSHI KU, OSAKA 558, JAPAN	Iowa State University; Osaka Medical College; Osaka Metropolitan University	METZLER, DE (corresponding author), IOWA STATE UNIV SCI & TECHNOL, DEPT BIOCHEM & BIOPHYS, 4106 MOLEC BIOL BLDG, AMES, IA 50011 USA.				NIDDK NIH HHS [DK01549] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK001549] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		FURBISH FS, 1969, BIOCHEMISTRY-US, V8, P5169, DOI 10.1021/bi00840a071; GOLDBERG JM, 1993, BIOCHEMISTRY-US, V32, P8092, DOI 10.1021/bi00083a006; HAYASHI H, 1990, BIOCHEM BIOPH RES CO, V167, P407, DOI 10.1016/0006-291X(90)92037-Z; KALLEN RG, 1985, TRANSAMINASES, P37; KAMITORI S, 1987, J BIOCHEM, V101, P813, DOI 10.1093/jb/101.3.813; KAMITORI S, 1990, J BIOCHEM-TOKYO, V108, P175, DOI 10.1093/oxfordjournals.jbchem.a123178; KINTANAR A, 1991, J BIOL CHEM, V266, P17222; KOGO K, 1992, SEIKAGU, V64, P703; KOMIVES EA, 1991, BIOCHEMISTRY-US, V30, P3011, DOI 10.1021/bi00226a005; KONDO K, 1987, J BIOL CHEM, V262, P8648; LODI PJ, 1991, BIOCHEMISTRY-US, V30, P6948, DOI 10.1021/bi00242a020; METZLER CM, 1991, BIOCHEM BIOPH RES CO, V178, P385, DOI 10.1016/0006-291X(91)91825-W; METZLER DE, 1994, J BIOL CHEM, V269, P28017; METZLER DE, 1994, IN PRESS MODERN ENZY; OSAPAY K, 1991, J AM CHEM SOC, V113, P9436, DOI 10.1021/ja00025a002; SCOTT RD, 1985, BIOCHEMISTRY-US, V24, P7668, DOI 10.1021/bi00347a026; SCOTT RD, 1991, INT UNION B, V199, P129; YANO T, 1993, BIOCHEMISTRY-US, V32, P1810, DOI 10.1021/bi00058a015; YANO T, 1991, J BIOL CHEM, V266, P6079; ZIAK M, 1993, EUR J BIOCHEM, V211, P475, DOI 10.1111/j.1432-1033.1993.tb17573.x	20	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28027	28033						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961737				2022-12-27	WOS:A1994PV77200041
J	TATSUMI, E; TAKAHASHI, N; HIROSE, M				TATSUMI, E; TAKAHASHI, N; HIROSE, M			DENATURED STATE OF OVALBUMIN IN HIGH-CONCENTRATIONS OF UREA AS EVALUATED BY DISULFIDE REARRANGEMENT ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; FOLDING PATHWAY; RIBONUCLEASE-A; HEN OVALBUMIN; CROSS-LINK; PROTEIN; BONDS; STABILITY; CLEAVAGE; LYSOZYME	To investigate the highly denatured state of ovalbumin (molecular mass of 42.7 kDa, four cysteine sulfhydryls and one cystine disulfide) using the disulfide rearrangement approach, we established the peptide-mapping procedure using a cysteine-labeling technique with a fluorescent dye that allows the quantitative analyses for the disulfide-involved half-cystines. Ovalbumin denatured at a low protein concentration in 8-10 M urea, in which the protein showed complete unfolding as evaluated by far-UV CD spectra, was analyzed for the disulfide-involved half cystines using the peptide-mapping procedure. Data clearly showed that the number of free sulfhydryls and intrachain disulfides were four and one, respectively, but that all six half-cystines are labeled with the dye. These results strongly suggested that 15 disulfide isomers that are theoretically possible for a molecule having one disulfide and four sulfhydryls are all generated during the denaturation. The quantitative data for the ratios of the observed labeling values for the six half-cystines, relative to the overall labeling values, were consistent with the view that the distribution of the 15 possible disulfide isomers at equilibrium depends on the number of amino acid residues separating the two half-cystines to the power of -1.9 to -2.0. Essentially, the same non-gaussian chain nature was also observed with kinetic data for sulfhydryl-disulfide exchanges after denaturation of native ovalbumin.	KYOTO UNIV,FOOD SCI RES INST,UJI,KYOTO 611,JAPAN	Kyoto University				Hirose, Masaaki/0000-0003-2672-4384				AMIR D, 1988, BIOCHEMISTRY-US, V27, P8889, DOI 10.1021/bi00425a003; AMIR D, 1992, PROTEINS, V13, P162, DOI 10.1002/prot.340130210; AUNE KC, 1967, J BIOL CHEM, V242, P4486; BIERZYNSKI A, 1982, J MOL BIOL, V162, P173, DOI 10.1016/0022-2836(82)90167-X; CHAN HS, 1990, J CHEM PHYS, V92, P3118, DOI 10.1063/1.458605; CHAN HS, 1991, ANNU REV BIOPHYS BIO, V20, P447, DOI 10.1146/annurev.biophys.20.1.447; CREIGHTON TE, 1984, METHOD ENZYMOL, V107, P305; DARBY NJ, 1993, J MOL BIOL, V232, P873, DOI 10.1006/jmbi.1993.1437; GOTO Y, 1987, J BIOCHEM, V101, P319, DOI 10.1093/oxfordjournals.jbchem.a121916; GREENE RF, 1974, J BIOL CHEM, V249, P5388; Kauzmann W., 1959, SULFUR PROTEINS, P93; KITABATAKE N, 1988, AGR BIOL CHEM TOKYO, V52, P967; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN SH, 1984, BIOCHEMISTRY-US, V23, P5504, DOI 10.1021/bi00318a019; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; NERI D, 1992, SCIENCE, V257, P1559, DOI 10.1126/science.1523410; NISBET AD, 1981, EUR J BIOCHEM, V115, P335, DOI 10.1111/j.1432-1033.1981.tb05243.x; PACE CN, 1988, J BIOL CHEM, V263, P11820; POLAND DC, 1965, BIOPOLYMERS, V3, P379, DOI 10.1002/bip.1965.360030404; SORENSEN SPL, 1915, COMPT REND TRAV LAB, V12, P12; TAKAHASHI N, 1990, ANAL BIOCHEM, V188, P359, DOI 10.1016/0003-2697(90)90621-F; TAKAHASHI N, 1992, J BIOL CHEM, V267, P11565; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; Tanford C., 1961, PHYS CHEM MACROMOLEC; THOMPSON EOP, 1978, AUST J BIOL SCI, V31, P433, DOI 10.1071/BI9780433; UEDA T, 1985, BIOCHEMISTRY-US, V24, P6316, DOI 10.1021/bi00343a042; Walsh KA, 1970, METHOD ENZYMOL, V19, P31, DOI DOI 10.1016/0076-6879(70)19005-7; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	29	22	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28062	28067						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961742				2022-12-27	WOS:A1994PV77200046
J	LI, Y; MORTENSEN, R; NEER, EJ				LI, Y; MORTENSEN, R; NEER, EJ			REGULATION OF ALPHA(0) EXPRESSION BY THE 5'-FLANKING REGION OF THE ALPHA(0) GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; G0-ALPHA MESSENGER-RNA; INSULIN-RECEPTOR GENE; LLC-PK1 RENAL-CELLS; PROMOTER REGION; MAMMALIAN-CELLS; SUBUNIT GENES; BRAIN; IDENTIFICATION; TRANSLATION	Many responses of cells to external signals require activation of the heterotrimeric G proteins. These responses depend on the type and amount of G proteins that are expressed. Each cell has a characteristic complement of G protein subunits. For example, the alpha(o) subunit is very abundant in neural tissues. Very little is known about the mechanisms that determine cellular levels of G proteins. In the present study, we have isolated a genomic clone for mouse alpha(o) gene and identified the promoter region. There are multiple transcription initiation sites located about 750 base pairs upstream of the translational start site, The promoter region is GC-rich and contains neither a TATA-box nor a CAAT box. Transient expression assays using a series of constructs containing various lengths of the 5'-flanking region of the alpha(o) promoter demonstrated that the region 300-700 base pairs upstream of the transcription initiation sites is responsible for the basic promoter activity. The relative activity of alpha(o) promoter is 8-12-fold higher in cells expressing alpha(o) than in cells lacking alpha(o). The level of alpha(o) in cells may also be regulated at the level of protein translation because deletions in the 5'-noncoding region of alpha(o) gene increase reporter enzyme expression without a corresponding increase in reporter enzyme mRNA level. Our results suggest that both transcriptional and posttranscriptional mechanisms are involved in regulating the expression of alpha(o) in vivo. Transcriptional regulation probably is important for control of tissue-specific expression, while posttranscriptional mechanisms may be used to regulate the alpha(o) level in cells.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV ENDOCRINE HYPERTENS,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School	LI, Y (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV CARDIOVASC,75 FRANCIS ST,BOSTON,MA 02115, USA.				NIGMS NIH HHS [GM 49122, GM 46370] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049122, R01GM046370] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKI E, 1987, J BIOL CHEM, V262, P16186; ASANO T, 1989, BIOCHEMISTRY-US, V28, P4749, DOI 10.1021/bi00437a035; ASANO T, 1988, J NEUROCHEM, V51, P1711, DOI 10.1111/j.1471-4159.1988.tb01149.x; Ausubel F.M., 1987, CURRENT PROTOCOL MOL; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONAWAY JW, 1991, J BIOL CHEM, V266, P17721; COOKE DW, 1991, BIOCHEM BIOPH RES CO, V177, P1113, DOI 10.1016/0006-291X(91)90654-P; DEVARAJAN P, 1992, J BIOL CHEM, V267, P22435; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FABER PW, 1993, J BIOL CHEM, V268, P9296; GARIBAY JLR, 1991, BIOCHIM BIOPHYS ACTA, V1094, P193, DOI 10.1016/0167-4889(91)90008-L; GHOSH PK, 1981, P NATL ACAD SCI-BIOL, V78, P100, DOI 10.1073/pnas.78.1.100; GIERSCHIK P, 1986, P NATL ACAD SCI USA, V83, P2258, DOI 10.1073/pnas.83.7.2258; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; HOLTZMAN EJ, 1991, J BIOL CHEM, V266, P1763; HOLTZMAN EJ, 1993, J BIOL CHEM, V268, P3964; HSU WH, 1990, J BIOL CHEM, V265, P11220; HUFF RM, 1985, J BIOL CHEM, V260, P864; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; LAW SF, 1993, J BIOL CHEM, V268, P10721; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; MAMULA PW, 1988, DIABETES, V37, P1241, DOI 10.2337/diabetes.37.9.1241; MULLANEY I, 1989, FEBS LETT, V244, P113, DOI 10.1016/0014-5793(89)81174-3; MURTAGH JJ, 1991, MOL CELL BIOL, V11, P1146, DOI 10.1128/MCB.11.2.1146; NEER EJ, 1994, PROTEIN SCI, V3, P3; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PRICE SR, 1990, BIOCHEMISTRY-US, V29, P5069, DOI 10.1021/bi00473a011; PRICE SR, 1989, BIOCHEMISTRY-US, V28, P3803, DOI 10.1021/bi00435a027; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P784; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Sambrook J, 1989, MOL CLONING LABORATO; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SILBERT S, 1990, J BIOL CHEM, V265, P3102; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; TSUKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P2974, DOI 10.1073/pnas.88.8.2974; WEINSTEIN LS, 1990, MOL ENDOCRINOL, V4, P958, DOI 10.1210/mend-4-7-958; WU DQ, 1992, J BIOL CHEM, V267, P1811; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	50	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27589	27594						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961675				2022-12-27	WOS:A1994PV77100067
J	MORRIS, SR; SAKANARI, JA				MORRIS, SR; SAKANARI, JA			CHARACTERIZATION OF THE SERINE-PROTEASE AND SERINE-PROTEASE INHIBITOR FROM THE TISSUE-PENETRATING NEMATODE ANISAKIS SIMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOLYTIC-ENZYMES; INFECTIVE LARVAE; FACTOR-XA; PURIFICATION; SPECIFICITY; INVITRO; PARASITE; CLEAVAGE; PROTEINS; DISEASE	A serine protease and a serine protease inhibitor were purified from infective larvae of the parasitic nematode Anisakis simplex. The serine protease was found to be trypsin-like and preferentially cleaved substrates with the basic amino acid arginine at the P-1 position (Z-Gly-Pro-Arg-AMC (where Z is benzyloxycarbonyl), K-m = 0.019 mM, and Z-Phe-Pro-Arg-AMC, K-m = 0.013 mM) at rates similar to those determined for trypsin (0.002 mM and 0.006 mM, respectively). However, the presence of a bulky hydrophobic residue at the P-2 position (Z-Phe-Arg-AMC, K-m = 13.3 mM, and Z-Ile-Leu-Val-Arg-AMC, K-m = 24.7 mM) greatly decreased the rate of substrate hydrolysis. Internal amino acid sequence information was obtained from three endo Lys-C digestion fragments of the purified enzyme. These sequences were >89% (33:37) identical with that of porcine trypsin. A second serine protease 85% (11:13) identical with that of a secreted tissue destructive serine protease from the pathogenic bacterium Dichelobacter nodosus was also identified. The serine protease inhibitor was found to inhibit trypsin, elastase, and the Anisakis serine protease stoichiometrically, but did not inhibit chymotrypsin. The amino acid sequence of the amino terminus as well as two internal endo Lys-C fragments were determined. Approximately 96% (47:49) of the residues were identical with soybean trypsin inhibitor, indicating that this inhibitor belongs to the Kunitz-type family of inhibitors.			MORRIS, SR (corresponding author), UNIV CALIF SAN FRANCISCO, VET ADM MED CTR, SAN FRANCISCO, CA 94121 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI029457] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 29457] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEAVER PC, 1969, J PARASITOL, V55, P3, DOI 10.2307/3277335; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPPELLO M, 1993, J INFECT DIS, V167, P1474, DOI 10.1093/infdis/167.6.1474; COHEN FE, 1991, BIOCHEMISTRY-US, V30, P11221, DOI 10.1021/bi00111a005; DARBY NJ, 1990, BIOSCIENCE REP, V10, P1, DOI 10.1007/BF01116845; DIXON B, 1992, J MOL EVOL, V35, P131, DOI 10.1007/BF00183224; FOX AS, 1985, NEW ENGL J MED, V312, P1619, DOI 10.1056/NEJM198506203122507; GLICKMAN LT, 1981, EPIDEMIOL REV, V3, P230, DOI 10.1093/oxfordjournals.epirev.a036235; GOODMAN RB, 1982, ANAL BIOCHEM, V120, P387, DOI 10.1016/0003-2697(82)90362-1; GRAF R, 1985, INSECT BIOCHEM, V15, P611, DOI 10.1016/0020-1790(85)90122-2; GRONENBORN AM, 1990, BIOCHEMISTRY-US, V29, P183, DOI 10.1021/bi00453a025; GROPPE JC, 1993, ARCH BIOCHEM BIOPHYS, V305, P159, DOI 10.1006/abbi.1993.1406; HAWLEY JH, 1992, EXP PARASITOL, V75, P112, DOI 10.1016/0014-4894(92)90126-U; HIGGINS GA, 1990, P NATL ACAD SCI USA, V87, P3032, DOI 10.1073/pnas.87.8.3032; JOHNSON DA, 1976, ANAL BIOCHEM, V72, P573, DOI 10.1016/0003-2697(76)90568-6; KLEMM U, 1991, HUM GENET, V87, P635; KNOX DP, 1988, MOL BIOCHEM PARASIT, V28, P207, DOI 10.1016/0166-6851(88)90005-9; KOIVUNEN E, 1991, CANCER RES, V51, P2107; KORTT A, 1986, FOOTROT RUMINANTS; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; KUMAR S, 1992, J PARASITOL, V78, P917, DOI 10.2307/3283331; KUNITZ M, 1947, J GEN PHYSIOL, V30, P291, DOI 10.1085/jgp.30.4.291; LACKEY A, 1989, EXP PARASITOL, V68, P176, DOI 10.1016/0014-4894(89)90095-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LASSON A, 1984, SCAND J GASTROENTERO, V19, P1; MARTONE CB, 1991, ARCH BIOCHEM BIOPHYS, V289, P1, DOI 10.1016/0003-9861(91)90433-J; MATTHEWS BE, 1984, J HELMINTHOL, V58, P175, DOI 10.1017/S0022149X00026924; MATTHEWS BE, 1982, Z PARASITENKD, V68, P81, DOI 10.1007/BF00926660; MCKERROW JH, 1989, EXP PARASITOL, V68, P111, DOI 10.1016/0014-4894(89)90016-7; MCKERROW JH, 1985, J BIOL CHEM, V260, P3703; MOSES EK, 1989, GENE, V77, P219, DOI 10.1016/0378-1119(89)90070-X; NEURATH H, 1986, J CELL BIOCHEM, V32, P35, DOI 10.1002/jcb.240320105; NILSSON IM, 1987, SCAND J GASTROENTERO, V22, P11, DOI 10.3109/00365528709089754; PRITCHARD DI, 1987, BAILLIERES CLIN TROP, V2, P511; ROBERTSON BD, 1989, EXP PARASITOL, V69, P30, DOI 10.1016/0014-4894(89)90168-9; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; RYPNIEWSKI WR, 1994, PROTEIN ENG, V7, P57, DOI 10.1093/protein/7.1.57; SAKANARI JA, 1989, CLIN MICROBIOL REV, V2, P278, DOI 10.1128/CMR.2.3.278-284.1989; SAKANARI JA, 1990, J PARASITOL, V76, P625, DOI 10.2307/3282971; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHI YB, 1990, GENE DEV, V4, P1107, DOI 10.1101/gad.4.7.1107; SHIEH TC, 1985, J BIOCHEM, V98, P713, DOI 10.1093/oxfordjournals.jbchem.a135329; STONE KL, 1993, PRACTICAL GUIDE PROT; TAMASHIRO WK, 1987, J PARASITOL, V73, P149, DOI 10.2307/3282360; TETLEY TD, 1993, THORAX, V48, P560, DOI 10.1136/thx.48.5.560; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510; WILLOUGHBY DA, 1991, THERAPIE, V46, P461	49	65	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27650	27656						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961683				2022-12-27	WOS:A1994PV77100077
J	FREIMARK, BD; FEESER, WS; ROSENFELD, SA				FREIMARK, BD; FEESER, WS; ROSENFELD, SA			MULTIPLE SITES OF THE PROPEPTIDE REGION OF HUMAN STROMELYSIN-1 ARE REQUIRED FOR MAINTAINING A LATENT FORM OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST COLLAGENASE; HUMAN MATRIX METALLOPROTEINASE-3; RHEUMATOID SYNOVIAL FIBROBLASTS; CYSTEINE SWITCH; DIFFERENTIAL EXPRESSION; SCANNING MUTAGENESIS; CATALYTIC DOMAIN; INSULIN-RECEPTOR; TYROSINE KINASE; BETA-SUBUNIT	Latency of matrix metalloproteinase 3 (MMP-3) is regulated by the interaction of a free cysteine residue (Cys-75) in the conserved amino acid sequence Pro-Arg-Cys-Gly-Val-Pro-Asp located in the COOH-terminal portion of the propeptide with a chelated zinc atom in the active site of the catalytic domain, Proteolytic activation of full-length human pro-MMP-3 involves the removal of similar to 35 amino acids hom the NH2-terminal portion of the propeptide, forming a 53-kDa unstable intermediate that undergoes intermolecular autocatalysis to form the 45-kDa mature active enzyme. In this study, we have evaluated the contribution of the NH2-terminal 35 amino acids to the maintenance of latency. Full-length human pro-MMP-3 was expressed in Escherichia coli and refolded to form latent pro-MMP-3 capable of activation by chymotrypsin or aminophenylmercuric acetate. Renaturation of pro-MMP-3 expressed in bacteria with 20 or more amino acids removed from the NH2-terminal region of the propeptide yielded only an active enzyme. COS-7 cells transiently transfected with pro-MMP-3 expression vectors containing the single amino acid substitutions Y20A, L21A, and C75S also secreted active forms of the enzyme. These data suggest that simultaneous interactions of the NH2- and COOH-terminal regions of the propeptide are required for maintenance of the latent form of the enzyme.	DUPONT MERCK PHARMACEUT CO,DEPT INFLAMMATORY DIS RES,WILMINGTON,DE 19880; DUPONT MERCK PHARMACEUT CO,DEPT APPL BIOTECHNOL,WILMINGTON,DE 19880	DuPont; DuPont								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BUCHNER J, 1992, ANAL BIOCHEM, V205, P264; CHEN LC, 1993, BIOCHEMISTRY-US, V32, P10289, DOI 10.1021/bi00090a003; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; COOPER JA, 1984, J BIOL CHEM, V259, P7835; CRABBE T, 1992, BIOCHEMISTRY-US, V31, P8500, DOI 10.1021/bi00151a017; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GOMISRUTH FX, 1993, EMBO J, V12, P4151, DOI 10.1002/j.1460-2075.1993.tb06099.x; GRANT GA, 1987, J BIOL CHEM, V262, P5886; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KNAUPER V, 1990, EUR J BIOCHEM, V189, P295, DOI 10.1111/j.1432-1033.1990.tb15489.x; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; MACNAUL KL, 1990, J BIOL CHEM, V265, P17238; MARCY AI, 1991, BIOCHEMISTRY-US, V30, P6476, DOI 10.1021/bi00240a018; MARTELPELLETIER J, 1984, ARTHRITIS RHEUM, V27, P305, DOI 10.1002/art.1780270310; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; Nagase H, 1992, Matrix Suppl, V1, P421; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; OKADA Y, 1986, J BIOL CHEM, V261, P14245; PARK AJ, 1991, J BIOL CHEM, V266, P1584; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; ROSENFELD SA, 1994, GENE, V139, P281, DOI 10.1016/0378-1119(94)90770-6; SALOWE SP, 1992, BIOCHEMISTRY-US, V31, P4535, DOI 10.1021/bi00134a001; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUS J, 1988, J BIOL CHEM, V263, P6742; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SIRUM KL, 1989, BIOCHEMISTRY-US, V28, P8691, DOI 10.1021/bi00448a004; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	49	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26982	26987						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929438				2022-12-27	WOS:A1994PQ93100061
J	GOULD, GW; JESS, TJ; ANDREWS, GC; HERBST, JJ; PLEVIN, RJ; GIBBS, EM				GOULD, GW; JESS, TJ; ANDREWS, GC; HERBST, JJ; PLEVIN, RJ; GIBBS, EM			EVIDENCE FOR A ROLE OF PHOSPHATIDYLINOSITOL 3-KINASE IN THE REGULATION OF GLUCOSE-TRANSPORT IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-KINASE CASCADE; SUBSTRATE SPECIFICITIES; GENE-EXPRESSION; SUGAR-TRANSPORT; GROWTH-FACTORS; MESSENGER-RNA; INSULIN; FIBROBLASTS; INVITRO; TRANSFORMATION	We have used two experimental approaches to examine the possible role of phosphatidylinositol 3-kinase (PI 3-kinase) in the regulation of glucose transport in oocytes isolated from Xenopus laevis. Incubation of oocytes with the PI 3-kinase inhibitor wortmannin inhibited insulin-like growth factor-1-stimulated deoxyglucose uptake. Half-maximal inhibition was observed at concentrations similar to 20 nM. Conversely, we also examined the effects of microinjection of synthetic peptides designed to interact with Src homology 2 domains of the regulatory subunit of PI 3-kinase on deoxyglucose transport in oocytes. We show that a bifunctional synthetic peptide containing two YMXM consensus sequences for binding to SH2 domains stimulated both PI 3-kinase activity and deoxyglucose transport when both tyrosine residues were phosphorylated. However, non-phosphorylated or bisphosphonotyrosine peptides with the identical amino acid sequence failed to stimulate transport or PI 3-kinase activity. Taken together, these data argue strongly for a role for PI 3-kinase in the regulation of glucose transport in oocytes.	PFIZER INC,CENT RES,GROTON,CT 06340; UNIV STRATHCLYDE,DEPT PHYSIOL & PHARMACOL,GLASGOW G1 1XW,LANARK,SCOTLAND	Pfizer; University of Strathclyde	GOULD, GW (corresponding author), UNIV GLASGOW,DEPT BIOCHEM,GLASGOW G12 8QQ,LANARK,SCOTLAND.		Gould, Gwyn/AAF-6721-2019	Gould, Gwyn/0000-0001-6571-2875	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHN NG, 1991, J BIOL CHEM, V266, P4220; AUGER KR, 1992, J BIOL CHEM, V267, P5408; BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COLVILLE CA, 1993, BIOCHEM J, V290, P701, DOI 10.1042/bj2900701; COLVILLE CA, 1993, MEMBRANE PROTEIN EXP, P243; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOULD GW, 1989, BIOCHEMISTRY-US, V28, P9447, DOI 10.1021/bi00450a030; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; HAINAUT P, 1991, CELL REGUL, V2, P317, DOI 10.1091/mbc.2.4.317; HERBST JJ, 1994, BIOCHEMISTRY-US, V33, P9376, DOI 10.1021/bi00198a002; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; HIRAKI Y, 1989, P NATL ACAD SCI USA, V86, P8252, DOI 10.1073/pnas.86.21.8252; JANICOT M, 1989, P NATL ACAD SCI USA, V86, P2642, DOI 10.1073/pnas.86.8.2642; JIMENEZDEASUA L, 1974, NATURE, V251, P624, DOI 10.1038/251624a0; KAHN BB, 1990, DIABETES CARE, V13, P548, DOI 10.2337/diacare.13.6.548; KITAGAWA T, 1989, BIOCHIM BIOPHYS ACTA, V980, P100, DOI 10.1016/0005-2736(89)90205-8; KLETZIEN RF, 1974, J BIOL CHEM, V249, P3366; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KRUPKA RM, 1971, BIOCHEMISTRY-US, V10, P1143, DOI 10.1021/bi00783a007; LAMPHERE M, 1993, AM J PHYSIOL, V266, pE486; MERRALL NW, 1993, BIOCHEM J, V295, P351, DOI 10.1042/bj2950351; OKADA T, 1994, J BIOL CHEM, V269, P3563; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; ROLLINS BJ, 1988, J BIOL CHEM, V263, P16523; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P8622; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SKOLNIK EY, 1993, EMBO J, V12, P1937; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; THOMAS G, 1992, CELL, V68, P1; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; WHITE MF, 1994, J BIOL CHEM, V269, P1	35	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26622	26625						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929393				2022-12-27	WOS:A1994PQ93100009
J	HIASA, H; MARIANS, KJ				HIASA, H; MARIANS, KJ			TUS PREVENTS OVERREPLICATION OF ORIC PLASMID DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; REPLICATION FORK MOVEMENT; EXHIBIT POLAR INHIBITION; TERMINUS REGION; PBR322 DNA; BINDING-PROTEIN; TERMINATION SITES; BACILLUS-SUBTILIS; ANTIGEN HELICASE; TOPOISOMERASE-IV	Minichromosome plasmid DNA templates containing oriC and two Ter sites, oriented as they are on the Escherichia coli chromosome, have been used to study the role of Tus in termination of bidirectional replication. In replication reactions reconstituted with purified proteins where it could be demonstrated that each active template was replicating bidirectionally, Tus was required to prevent extensive overreplication. In the presence of Tus, both replication forks terminated DNA synthesis at one or the other Ter site in an apparent stepwise manner. First, the progress of one replication fork was arrested by a properly oriented Tus-Ter complex. Then, either because of steric hindrance resulting from the stalled replication machinery of the first fork or because of the formation of a branched DNA structure, the progression of the second opposing fork was halted at the same site on the DNA template. In the absence of Tus, overreplication required DNA ligase and arose via a template strand-switching mechanism. Thus, the role of Tus in E. coli is more likely to prevent overreplication rather than to ensure accurate termination.			HIASA, H (corresponding author), MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM34558] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIN AA, 1992, J BIOL CHEM, V267, P18612; ASAI T, 1990, EMBO J, V9, P4065, DOI 10.1002/j.1460-2075.1990.tb07628.x; BEDROSIAN CL, 1991, P NATL ACAD SCI USA, V88, P2618, DOI 10.1073/pnas.88.7.2618; BIRD RE, 1972, J MOL BIOL, V70, P549, DOI 10.1016/0022-2836(72)90559-1; BOHK JJ, 1983, GENE, V24, P265; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; DEMASSY B, 1987, P NATL ACAD SCI USA, V84, P1759; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; HIASA H, 1994, J BIOL CHEM, V269, P6058; HIASA H, 1992, J BIOL CHEM, V267, P11379; HIASA H, 1994, J BIOL CHEM, V269, P2093; HIDAKA M, 1992, J BIOL CHEM, V267, P5361; HIDAKA M, 1988, CELL, V55, P467, DOI 10.1016/0092-8674(88)90033-5; HIDAKA M, 1991, J BACTERIOL, V173, P391, DOI 10.1128/jb.173.1.391-393.1991; HILL TM, 1987, P NATL ACAD SCI USA, V84, P1754, DOI 10.1073/pnas.84.7.1754; HILL TM, 1989, P NATL ACAD SCI USA, V86, P1593, DOI 10.1073/pnas.86.5.1593; HILL TM, 1990, P NATL ACAD SCI USA, V87, P2481, DOI 10.1073/pnas.87.7.2481; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; HORIUCHI T, 1988, CELL, V54, P515, DOI 10.1016/0092-8674(88)90073-6; KAGUNI JM, 1982, NATURE, V296, P623, DOI 10.1038/296623a0; KHARTRI GS, 1989, CELL, V59, P667; KOBAYASHI T, 1989, EMBO J, V8, P2435, DOI 10.1002/j.1460-2075.1989.tb08374.x; Kornberg A., 1992, DNA REPLICATION, P524; KUEMPEL PL, 1977, P NATL ACAD SCI USA, V74, P3927, DOI 10.1073/pnas.74.9.3927; LEE EH, 1992, J BIOL CHEM, V267, P8778; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LEWIS PJ, 1990, J MOL BIOL, V214, P73, DOI 10.1016/0022-2836(90)90147-E; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LOUARN J, 1979, MOL GEN GENET, V172, P7, DOI 10.1007/BF00276208; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MOK M, 1987, J BIOL CHEM, V262, P2304; PARADA CA, 1991, J BIOL CHEM, V266, P18895; PELLETIER AJ, 1989, J BACTERIOL, V171, P1739, DOI 10.1128/jb.171.3.1739-1741.1989; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; PENG H, 1993, J BIOL CHEM, V268, P24481; PRESCOTT DM, 1972, P NATL ACAD SCI USA, V69, P2842, DOI 10.1073/pnas.69.10.2842; ROECKLEIN B, 1991, RES MICROBIOL, V142, P169, DOI 10.1016/0923-2508(91)90026-7; SHARMA B, 1992, J BACTERIOL, V174, P7854, DOI 10.1128/JB.174.23.7854-7858.1992; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WEISS AS, 1984, CELL, V39, P683, DOI 10.1016/0092-8674(84)90475-6; WU CA, 1992, J BIOL CHEM, V267, P4030	43	58	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26959	26968						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929435				2022-12-27	WOS:A1994PQ93100058
J	SCHULTZCHERRY, S; LAWLER, J; MURPHYULLRICH, JE				SCHULTZCHERRY, S; LAWLER, J; MURPHYULLRICH, JE			THE TYPE-1 REPEATS OF THROMBOSPONDIN-1 ACTIVATE LATENT TRANSFORMING GROWTH-FACTOR-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL THROMBOSPONDIN; HEPARIN-BINDING PEPTIDES; PLATELET THROMBOSPONDIN; I REPEATS; MONOCLONAL-ANTIBODIES; COMPLEX-FORMATION; ADHESION; PROTEINS; FIBRONECTIN; PROPERDIN	Thrombospondin (TSP) is complexed with transforming growth factor-beta (TGF-beta) in the alpha-granules of stimulated platelets. TSP stripped of associated TGF-beta activity (sTSP) activates latent TGF-beta secreted by bovine aortic endothelial cells (BAE) in culture. To better understand the interactions of TSP with TGF-beta, we investigated which region of sTSP interacts with TGF-beta. The chymotrypsin-resistant core of TSP, which contains the procollagen-like region and the properdin-like type 1 repeats, activated both latent TGF-beta secreted by BAE and a recombinant form of the small latent TGF-beta complex at levels similar to or better than sTSP. The core fragment bound I-125-TGF-beta in solution and shifted the elution profile of I-125-TGF-beta in gel permeation chromatography. Fusion constructs of the type 1, 2, and 3 repeats and the COOH terminus of TSP1 were tested for their ability to activate latent TGF-beta. Only the type 1 construct, containing the three properdin-like repeats of TSP found in the 50-kDa fragment, activated latent TGF-beta. In addition, a polyclonal antibody against the type 1 construct inhibits activation of latent TGF-beta by intact TSP, suggesting that this region is exposed in the intact molecule. These results show that the type 1 properdin-like repeats of TSP are responsible for activating recombinant and endothelial cell-derived latent TGF-beta and that this site is exposed in intact TSP.	UNIV ALABAMA,DEPT PATHOL,DIV CELLULAR & MOLEC PATHOL,BIRMINGHAM,AL 35294; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115	University of Alabama System; University of Alabama Birmingham; Harvard University; Brigham & Women's Hospital; Harvard Medical School			Schultz-Cherry, Stacey/N-2506-2018; Lawler, Jack/AAJ-1379-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050061, R01HL044575, R01HL028749] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44575, HL50061, HL28749] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLENHOFFMANN BL, 1988, MOL CELL BIOL, V8, P4234, DOI 10.1128/MCB.8.10.4234; BAGAVANDOSS P, 1990, BIOCHEM BIOPH RES CO, V170, P867, DOI 10.1016/0006-291X(90)92171-U; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; CATIMEL B, 1992, BIOCHEM J, V284, P231, DOI 10.1042/bj2840231; DARDIK R, 1989, EUR J BIOCHEM, V185, P581, DOI 10.1111/j.1432-1033.1989.tb15153.x; DARDIK R, 1991, BIOCHEMISTRY-US, V30, P9378, DOI 10.1021/bi00102a035; DEPOLI P, 1989, BLOOD, V73, P976; DIXIT VM, 1986, J BIOL CHEM, V261, P1962; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GALVIN NJ, 1985, J CELL BIOL, V101, P1434, DOI 10.1083/jcb.101.4.1434; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GOUNDIS D, 1988, NATURE, V335, P82, DOI 10.1038/335082a0; GUO NH, 1992, J BIOL CHEM, V267, P19349; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; HAVERSTICK DM, 1984, BIOCHEMISTRY-US, V23, P5597, DOI 10.1021/bi00318a033; KLAR A, 1992, CELL, V61, P1051; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHAV J, 1993, BIOCHIM BIOPHYS ACTA, V1182, P1, DOI 10.1016/0925-4439(93)90146-R; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LAWLER J, 1982, J BIOL CHEM, V257, P2257; LAWLER J, 1983, J BIOL CHEM, V258, P2098; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LEGRAND C, 1992, BLOOD, V79, P1995; LEUNG LLK, 1982, J CLIN INVEST, V70, P542, DOI 10.1172/JCI110646; MAJACK RA, 1986, P NATL ACAD SCI USA, V83, P9050, DOI 10.1073/pnas.83.23.9050; MOORADIAN DL, 1989, J CELL BIOCHEM, V41, P189, DOI 10.1002/jcb.240410404; MOSHER DF, 1990, ANNU REV MED, V41, P85; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; MURPHYULLRICH JE, 1987, J CELL BIOL, V105, P1603, DOI 10.1083/jcb.105.4.1603; MURPHYULLRICH JE, 1993, J BIOL CHEM, V268, P26784; PHAN SH, 1989, BIOCHEM BIOPH RES CO, V163, P56, DOI 10.1016/0006-291X(89)92098-6; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; ROBERTS DD, 1988, CANCER RES, V48, P6785; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26775; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SILVERSTEIN RL, 1984, J CLIN INVEST, V74, P1625, DOI 10.1172/JCI111578; SIPES JM, 1993, J CELL BIOL, V121, P469, DOI 10.1083/jcb.121.2.469; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOTTILE J, 1991, BIOCHEMISTRY-US, V30, P6556, DOI 10.1021/bi00240a028; SPEZIALE MV, 1990, J BIOL CHEM, V265, P17859; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TUSZYNSKI GP, 1993, J CELL BIOL, V120, P513, DOI 10.1083/jcb.120.2.513; TUSZYNSKI GP, 1992, J CELL BIOL, V116, P209, DOI 10.1083/jcb.116.1.209; VOGEL T, 1993, J CELL BIOCHEM, V53, P1; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214	51	190	205	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26783	26788						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929414				2022-12-27	WOS:A1994PQ93100033
J	VEIJOLA, J; KOIVUNEN, P; ANNUNEN, P; PIHLAJANIEMI, T; KIVIRIKKO, KI				VEIJOLA, J; KOIVUNEN, P; ANNUNEN, P; PIHLAJANIEMI, T; KIVIRIKKO, KI			CLONING, BACULOVIRUS EXPRESSION, AND CHARACTERIZATION OF THE ALPHA-SUBUNIT OF PROLYL 4-HYDROXYLASE FROM THE NEMATODE CAENORHABDITIS-ELEGANS - THIS ALPHA-SUBUNIT FORMS AN ACTIVE ALPHA-BETA DIMER WITH THE HUMAN PROTEIN DISULFIDE-ISOMERASE BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; SITE-DIRECTED MUTAGENESIS; HORMONE-BINDING-PROTEIN; ENDOPLASMIC-RETICULUM; MOLECULAR-CLONING; PEPTIDE BINDING; N-GLYCOSYLATION; CHICK-EMBRYOS; HYDROXYLASE; SEQUENCE	Prolyl 4-hydroxylase (EC 1.14.11.2) catalyzes the formation of 4-hydroxyproline in collagens. The vertebrate enzyme is an alpha(2) beta(2) tetramer, the beta subunit of which is identical to protein disulfide-isomerase (PDI). We report here on the cloning of the catalytically important alpha subunit from Caenorhabditis elegans. This polypeptide consists of 542 amino acids and a signal peptide of 16 additional residues. The C. elegans alpha subunit is 25 amino acids longer than the human alpha subunit, mainly because of a 32-amino-acid C-terminal extension present only in the former. The overall amino acid sequence identity between these two alpha subunits is 45%, a 127-amino acid region close to the C terminus being especially well conserved. When the C. elegans alpha subunit was expressed together with the human PDI/beta subunit in insect cells by baculovirus vectors, an active prolyl 4-hydroxylase was formed, but surprisingly this C. elegans/human enzyme appeared to be an alpha beta dimer. The specific activity of this C. elegans/human enzyme was comparable with that of the human enzyme, and most of the other catalytic properties were also highly similar. Nevertheless, the C. elegans/human enzyme was not inhibited by poly(L-proline). The data indicate that the multifunctional PDI/beta subunit can form an active prolyl 4-hydroxylase with alpha subunits having marked differences in their amino acid sequences.	UNIV OULU, DEPT MED BIOCHEM, SF-90220 OULU, FINLAND; UNIV OULU, BIOCTR, COLLAGEN RES UNIT, SF-90220 OULU, FINLAND	University of Oulu; University of Oulu				Pihlajaniemi, Taina/0000-0002-1664-9045				BASSUK JA, 1989, P NATL ACAD SCI USA, V86, P7382, DOI 10.1073/pnas.86.19.7382; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BERG RA, 1973, J BIOL CHEM, V248, P1175; CHENG SY, 1987, J BIOL CHEM, V262, P11221; FUJIMOTO D, 1969, J BIOL CHEM, V244, P205; GRUENWALD S, 1993, BACULOVIRUS EXPRESSI; GUNZLER V, 1988, J BIOL CHEM, V263, P19498; HANAUSKEABEL HM, 1982, J THEOR BIOL, V94, P421, DOI 10.1016/0022-5193(82)90320-4; HELAAKOSKI T, 1990, ANN NY ACAD SCI, V580, P473, DOI 10.1111/j.1749-6632.1990.tb17964.x; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; KAO WWY, 1988, CONNECT TISSUE RES, V18, P157, DOI 10.3109/03008208809016805; KASKA DD, 1988, BIOCHEM J, V256, P257, DOI 10.1042/bj2560257; KEDERSHA NL, 1985, BIOCHEMISTRY-US, V24, P5952, DOI 10.1021/bi00342a040; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; KIVIRIKKO KI, 1987, METHOD ENZYMOL, V144, P96; KIVIRIKKO KI, 1990, ANN NY ACAD SCI, V580, P132, DOI 10.1111/j.1749-6632.1990.tb17925.x; KOIVU J, 1987, J BIOL CHEM, V262, P6447; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MAJAMAA K, 1984, EUR J BIOCHEM, V138, P239, DOI 10.1111/j.1432-1033.1984.tb07907.x; MALITSCHEK B, 1991, BIOTECHNIQUES, V11, P177; MCCOMBIE WR, 1992, NAT GENET, V1, P124, DOI 10.1038/ng0592-124; MING LJ, 1990, INORG CHEM, V29, P1111, DOI 10.1021/ic00331a001; MONONEN I, 1984, BIOCHIM BIOPHYS ACTA, V788, P364, DOI 10.1016/0167-4838(84)90050-5; MYLLYLA R, 1992, BIOCHEM J, V286, P923, DOI 10.1042/bj2860923; MYLLYLA R, 1977, EUR J BIOCHEM, V80, P349, DOI 10.1111/j.1432-1033.1977.tb11889.x; NIETFELD JJ, 1981, BIOCHIM BIOPHYS ACTA, V661, P21, DOI 10.1016/0005-2744(81)90078-4; NOIVA R, 1993, J BIOL CHEM, V268, P19210; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, J BIOL CHEM, V266, P19645; PARKKONEN T, 1988, BIOCHEM J, V256, P1005, DOI 10.1042/bj2561005; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TUDERMAN L, 1975, EUR J BIOCHEM, V52, P9, DOI 10.1111/j.1432-1033.1975.tb03967.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; VUORI K, 1992, J BIOL CHEM, V267, P7211; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023	45	54	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26746	26753						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929409				2022-12-27	WOS:A1994PQ93100028
J	WOODFORD, KJ; HOWELL, RM; USDIN, K				WOODFORD, KJ; HOWELL, RM; USDIN, K			A NOVEL K+-DEPENDENT DNA-SYNTHESIS ARREST SITE IN A COMMONLY OCCURRING SEQUENCE MOTIF IN EUKARYOTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN GENE; REVERSE-TRANSCRIPTASE; REPLICATION INVITRO; INTERNAL REGIONS; POLYMERASE-ALPHA; STRAND TRANSFER; INSULIN GENE; AMPLIFICATION; COMPONENTS; TEMPLATES	We have found that a strong DNA synthesis arrest site forms in the chicken beta-globin promoter in vitro under physiological conditions. The arrest site is located in a G + C-rich region in which the guanines are located predominately on the top strand and the pyrimidines on the bottom strand. This region is non-palindromic and has no mirror symmetry. Arrest of DNA synthesis is only observed when the G-rich strand of the promoter is used as the template, and shows an absolute requirement for K+. The sequence G(16)CG(GGT)(3) is necessary and sufficient to arrest DNA synthesis. This arrest is template concentration independent and is eliminated by blocking the N7 positions of the last 4 guanine residues in the arrest site. These observations suggest that the basis of the block to chain extension is the formation of an unusual tetraplex-like structure by the template strand. Sequences able to form intrastrand tetraplexes are ubiquitous in eukaryotes. We show that known intrastrand tetraplex-forming sequences arrest DNA synthesis in vitro, suggesting that this may be a general property of DNA tetraplexes. We suggest that the arrest of DNA synthesis by some of these structures may account for some of the high frequency of recombination associated with these loci, perhaps by promoting strand slippage or providing an opportunity for strand exchange.	NIDDKD, GENOM STRUCT & FUNCT SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BARAN N, 1991, P NATL ACAD SCI USA, V88, P507, DOI 10.1073/pnas.88.2.507; BARAN N, 1987, MOL CELL BIOL, V7, P2636, DOI 10.1128/MCB.7.7.2636; BELTRAN R, 1993, J MOL BIOL, V230, P966, DOI 10.1006/jmbi.1993.1213; BOULIKAS T, 1993, J CELL BIOCHEM, V52, P14, DOI 10.1002/jcb.240520104; Boynton A. L., 1982, IONS CELL PROLIFERAT; BROWN WRA, 1990, CELL, V63, P119, DOI 10.1016/0092-8674(90)90293-N; BUISER RG, 1993, BIOCHIM BIOPHYS ACTA, V1216, P20, DOI 10.1016/0167-4781(93)90033-A; DAY LE, 1981, BIOCHEMISTRY-US, V20, P2091, DOI 10.1021/bi00511a005; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; DOLNICK BJ, 1979, J CELL BIOL, V83, P394, DOI 10.1083/jcb.83.2.394; FRY M, 1992, P NATL ACAD SCI USA, V89, P763, DOI 10.1073/pnas.89.2.763; GERMINO J, 1981, CELL, V23, P681, DOI 10.1016/0092-8674(81)90431-1; GIOVANNANGELI C, 1993, P NATL ACAD SCI USA, V90, P10013, DOI 10.1073/pnas.90.21.10013; HAMMONDKOSACK MCU, 1993, J MOL ENDOCRINOL, V10, P121, DOI 10.1677/jme.0.0100121; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HOFFMANN JS, 1993, CANCER RES, V53, P2895; ISHHOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989, DOI 10.1093/nar/9.13.2989; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; KOHWI Y, 1989, NUCLEIC ACIDS RES, V17, P4493, DOI 10.1093/nar/17.12.4493; KUNKEL TA, 1992, BIOESSAYS, V14, P303, DOI 10.1002/bies.950140503; LAPIDOT A, 1989, NUCLEIC ACIDS RES, V17, P883, DOI 10.1093/nar/17.3.883; LAU YT, 1988, SCIENCE, V240, P1321, DOI 10.1126/science.3375816; LING GN, 1984, SEARCH PHYSICAL BASI; NICKOL JM, 1983, CELL, V35, P467, DOI 10.1016/0092-8674(83)90180-0; OWERBACH D, 1993, DIABETES, V42, P1708, DOI 10.2337/diabetes.42.12.1708; PANYUTIN IG, 1990, P NATL ACAD SCI USA, V87, P867, DOI 10.1073/pnas.87.3.867; PAPANICOLAOU C, 1991, J MOL BIOL, V221, P805, DOI 10.1016/0022-2836(91)80177-V; PATHAK VK, 1992, J VIROL, V66, P3093, DOI 10.1128/JVI.66.5.3093-3100.1992; RAO BS, 1988, NUCLEIC ACIDS RES, V16, P8077, DOI 10.1093/nar/16.16.8077; SCHEIN CH, 1990, BIO-TECHNOL, V8, P308, DOI 10.1038/nbt0490-308; SCHIMKE RT, 1979, COLD SPRING HARB SYM, V43, P1297, DOI 10.1101/SQB.1979.043.01.148; SCHIMKE RT, 1978, SCIENCE, V202, P1051, DOI 10.1126/science.715457; SCHIMKE RT, 1977, COLD SPRING HARB SYM, V42, P649, DOI 10.1101/SQB.1978.042.01.067; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; TAPPER DP, 1980, CELL, V22, P97, DOI 10.1016/0092-8674(80)90158-0; TAUTZ D, 1984, NUCLEIC ACIDS RES, V12, P4127, DOI 10.1093/nar/12.10.4127; WEAVER DT, 1984, J MOL BIOL, V180, P961, DOI 10.1016/0022-2836(84)90266-3	39	87	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27029	27035						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929444				2022-12-27	WOS:A1994PQ93100067
J	JOST, CR; KURUCZ, I; JACOBUS, CM; TITUS, JA; GEORGE, AJT; SEGAL, DM				JOST, CR; KURUCZ, I; JACOBUS, CM; TITUS, JA; GEORGE, AJT; SEGAL, DM			MAMMALIAN EXPRESSION AND SECRETION OF FUNCTIONAL SINGLE-CHAIN FV MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTORS; ENDOPLASMIC-RETICULUM; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; LIGHT-CHAINS; GLYCOSYLATION SITES; VARIABLE PORTIONS; DISULFIDE BOND; PROTEIN; IMMUNOGLOBULIN	Single chain Fv (sFv) proteins are genetically engineered molecules that consist of the two variable domains of an antibody connected by a polypeptide linker; they contain the antigen binding function of the parental protein in a single 30-kDa polypeptide chain. sFvs are usually produced in bacteria where they are insoluble and therefore require extensive refolding in vitro. In this report we followed the processing of three antibody sFvs (145-2C11 directed against murine CD3 epsilon chain, OKT9 against the human transferrin receptor, and U7.6 against dinitrophenyl groups) by transfected mammalian (COS-7) cells to determine whether the mammalian protein folding machinery can produce and secrete active sFv with high efficiency. The sFvs contained an immunoglobulin light chain leader sequence, which directed them to the endoplasmic reticulum and allowed secretion into the medium. We found that the sFvs were secreted at different rates, with the rate-limiting step of secretion being their exit from the endoplasmic reticulum. We increased the secretion rate of one of the sFvs by introducing an asparagine-linked glycosylation site in FR1 of the heavy chain, and by using tunicamycin (an inhibitor of glycosylation) we found that glycosylated antibody sFvs were secreted faster than their nonglycosylated counterparts. All secreted sFvs specifically bound their antigens; where tested, at least 90% of the secreted sFv was functional. Therefore, mammalian cells can effectively fold and secrete sFv antibody and can provide a convenient system for testing and producing sFv proteins.	NCI, EXPTL IMMUNOL BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				George, Andrew/0000-0002-2866-0241				BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; CO MS, 1993, MOL IMMUNOL, V30, P1361; DAVIS LG, 1986, BASIC METHODS MOL BI, P286; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; ESHHAR Z, 1993, P NATL ACAD SCI USA, V90, P720, DOI 10.1073/pnas.90.2.720; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GEORGE AJT, 1994, J IMMUNOL, V152, P1802; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GODING JW, 1981, J IMMUNOL, V127, P1256; HAYANO T, 1991, BIOCHEMISTRY-US, V30, P3041, DOI 10.1021/bi00226a009; HOCHMAN J, 1976, BIOCHEMISTRY-US, V15, P2706, DOI 10.1021/bi00657a034; HOCHMAN J, 1973, BIOCHEMISTRY-US, V12, P1130, DOI 10.1021/bi00730a018; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HOLLAND IB, 1990, METHOD ENZYMOL, V182, P132; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Huston J S, 1993, Int Rev Immunol, V10, P195, DOI 10.3109/08830189309061696; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; HUSTON JS, 1991, METHOD ENZYMOL, V203, P46; HWU P, 1993, J EXP MED, V178, P361, DOI 10.1084/jem.178.1.361; INBAR D, 1972, P NATL ACAD SCI USA, V69, P2659, DOI 10.1073/pnas.69.9.2659; JOHNSON S, 1991, METHOD ENZYMOL, V203, P88; KEARSE KP, 1994, J IMMUNOL METHODS, V167, P75, DOI 10.1016/0022-1759(94)90076-0; KNAPPIK A, 1993, BIO-TECHNOL, V11, P77, DOI 10.1038/nbt0193-77; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MACHAMER CE, 1988, J BIOL CHEM, V263, P5948; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; MELNICK J, 1992, J BIOL CHEM, V267, P21303; NICHOLLS PJ, 1993, J IMMUNOL METHODS, V165, P81, DOI 10.1016/0022-1759(93)90109-K; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; SCHNEIDER C, 1982, J BIOL CHEM, V257, P8516; SEGAL DM, 1987, METHOD ENZYMOL, V150, P478; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; STANCOVSKI I, 1993, J IMMUNOL, V151, P6577; TARENTINO AL, 1974, J BIOL CHEM, V249, P818; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0	42	54	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26267	26273						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929344				2022-12-27	WOS:A1994PQ93000052
J	SEGER, R; SEGER, D; RESZKA, AA; MUNAR, ES; ELDARFINKELMAN, H; DOBROWOLSKA, G; JENSEN, AM; CAMPBELL, JS; FISCHER, EH; KREBS, EG				SEGER, R; SEGER, D; RESZKA, AA; MUNAR, ES; ELDARFINKELMAN, H; DOBROWOLSKA, G; JENSEN, AM; CAMPBELL, JS; FISCHER, EH; KREBS, EG			OVEREXPRESSION OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE (MAPKK) AND ITS MUTANTS IN NIH 3T3 CELLS - EVIDENCE THAT MAPKK INVOLVEMENT IN CELLULAR PROLIFERATION IS REGULATED BY PHOSPHORYLATION OF SERINE RESIDUES IN ITS KINASE SUBDOMAIN-VII AND SUBDOMAIN-VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S6 KINASE; THREONINE KINASE; BINDING PROTEINS; SWISS 3T3-CELLS; XENOPUS-LAEVIS; A431 CELLS; GROWTH; INVITRO; EXPRESSION; INSULIN	Mitogen-activated protein kinase kinase (MAPKK) is a dual specificity protein kinase that exhibits a high degree of specificity toward its downstream target, mitogen-activated protein kinase (MAPK). In this study, we used stable overexpression of MAPKK and its mutants in NIH 3T3 cells to study effects on downstream components of the MAPK signaling cascade and to correlate them to physiological responses. We have mutated the potential regulatory serine residue 222 to alanine (S222A) or to glutamate (S222E) and serines 212 and 218 together to alanine residues (S212A,S218A). Lysine 97 was mutated to alanine (K97A) to provide an inactive enzyme. Overexpression of the wild type MAPKK had no effect on any of the parameters examined. The K97A and S222A mutants served as dominant negatives by suppressing MAPKK, MAPK, and p90(rsk) activation in vivo. S222E enhanced all of these activities, and S212A,S218A had a small inhibitory effect. A similar trend was observed when cellular proliferation was examined and the different effects were accompanied by altered cellular shape. Taken together, our results demonstrate a direct linkage between the MAPK signaling pathway and the control of cellular proliferation and morphology and also establish that phosphorylation of: serine 222 is essential for MAPKK activation together with the phosphorylation of an additional serine(s) (probably serine 218).	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle			Eldar-Finkelman, Hagit/AAF-8329-2019	Eldar-Finkelman, Hagit/0000-0002-8460-9686; Dobrowolska, Grazyna/0000-0002-2598-9666; Campbell, Jean/0000-0002-9187-2204	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 42528] Funding Source: Medline; NIGMS NIH HHS [GM 42508] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1993, P NATL ACAD SCI USA, V90, P5143, DOI 10.1073/pnas.90.11.5143; AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1990, J BIOL CHEM, V265, P11495; AHN NG, 1992, CURR OPIN CELL BIOL, V4, P985; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAMPBELL JS, 1995, IN PRESS RECENT PROG, V50; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; ERIKSON E, 1985, P NATL ACAD SCI USA, V82, P742, DOI 10.1073/pnas.82.3.742; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; GAUSE KC, 1993, J BIOL CHEM, V268, P16124; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LEPEUCH CJ, 1983, P NATL ACAD SCI-BIOL, V80, P6858; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MASUDA N, 1991, FEBS LETT, V291, P9, DOI 10.1016/0014-5793(91)81091-L; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; NOVAKHOFER I, 1984, J BIOL CHEM, V259, P5995; OTSU M, 1993, FEBS LETT, V320, P246, DOI 10.1016/0014-5793(93)80596-M; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1992, SCIENCE, V255, P182; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROSENBERG N, 1976, J EXP MED, V143, P1453, DOI 10.1084/jem.143.6.1453; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1992, J BIOL CHEM, V267, P14373; SONNENBURG WK, 1993, J BIOL CHEM, V268, P645; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	55	210	212	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25699	25709						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929275				2022-12-27	WOS:A1994PQ49100071
J	WAYMAN, GA; IMPEY, S; WU, ZL; KINDSVOGEL, W; PRICHARD, L; STORM, DR				WAYMAN, GA; IMPEY, S; WU, ZL; KINDSVOGEL, W; PRICHARD, L; STORM, DR			SYNERGISTIC ACTIVATION OF THE TYPE-I ADENYLYL-CYCLASE BY CA2+ AND G(S)-COUPLED RECEPTORS IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONAL-STIMULATION; WHOLE CELLS; CALMODULIN; CALCIUM; DOPAMINE; BRAIN; EXPRESSION; RUTABAGA; MEMORY; MUTANT	The type I adenylyl cyclase is directly stimulated by Ca2+ and calmodulin in vivo (Choi, E. J., Wong, S. T., Hinds, T. R. and Storm, D. R. (1992) J. Biol. Chem. 267, 12440-12442; Wu, Z., Wong, S. T., and Storm, D. R. (1993) J. Biol. Chem. 268, 23766-23768). In this study, we examined the sensitivity of the type I adenylyl cyclase expressed in HEK-293 cells to beta-adrenergic agonists or glucagon when intracellular Ca2+ was elevated by Ca2+ ionophore or carbachol. Although previous studies have shown that this enzyme can be directly stimulated by activated G(s) in vitro, we demonstrate that it is not stimulated by G(s)-coupled receptors in vivo. However, the enzyme was stimulated by G(s)-coupled receptors in vivo when it was activated by intracellular Ca2+. For example, the Ca2+ ionophore A23187 stimulated the enzyme 3 +/- 0.5-fold (n = 9) and isoproterenol alone did not stimulate the enzyme, but the combination of the two stimulated type I adenylyl cyclase 13 +/- 2-fold (n = 9) in vivo. Similarly, 500 nM glucagon alone did not stimulate the enzyme but the combination of A23187 and glucagon activated the enzyme 90 +/- 8-fold (n = 4). Synergistic stimulation of type I adenylyl cyclase activity was also obtained with combinations of carbachol and isoproterenol or glucagon. This phenomenon was not observed with a mutant enzyme that is insensitive to Ca2+ and calmodulin, suggesting that conformational changes caused by binding of calmodulin to the type I adenylyl cyclase enhance binding or coupling to activated G(s). These data illustrate that this adenylyl cyclase can couple Ca2+ and neurotransmitter signals to generate optimal cAMP levels, a property of the enzyme that may be important for its role in learning and memory in mammals.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; ZYMOGENET INC,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; Zymogenet Inc.					NINDS NIH HHS [NS 20498] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020498] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; CHOI EJ, 1993, BIOCHEMISTRY-US, V32, P1891, DOI 10.1021/bi00059a001; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; DUDAI Y, 1985, J NEUROCHEM, V45, P355, DOI 10.1111/j.1471-4159.1985.tb03996.x; DUDAI Y, 1984, NEUROSCI LETT, V47, P19; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GNEGY M, 1981, MOL PHARMACOL, V19, P256; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HARRISON JK, 1988, J NEUROCHEM, V51, P345, DOI 10.1111/j.1471-4159.1988.tb01045.x; HARRISON JK, 1989, J BIOL CHEM, V264, P15880; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1985, P NATL ACAD SCI USA, V82, P5992, DOI 10.1073/pnas.82.17.5992; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; MASURE HR, 1984, BIOCHEM J, V218, P691, DOI 10.1042/bj2180691; NATSUKARI N, 1990, BRAIN RES, V534, P170, DOI 10.1016/0006-8993(90)90126-V; PIASCIK MT, 1981, MOL PHARMACOL, V20, P319; PYNE NJ, 1989, FEBS LETT, V243, P77, DOI 10.1016/0014-5793(89)81221-9; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SALTER RS, 1981, J BIOL CHEM, V256, P9830; SANO M, 1985, BRAIN RES, V345, P337, DOI 10.1016/0006-8993(85)91012-1; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TOSCANO WA, 1979, P NATL ACAD SCI USA, V76, P5582, DOI 10.1073/pnas.76.11.5582; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WU ZL, 1993, J BIOL CHEM, V268, P23766; XIA ZG, 1993, J NEUROCHEM, V60, P305, DOI 10.1111/j.1471-4159.1993.tb05852.x; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; XIA ZG, 1992, NEUROSCI LETT, V144, P169, DOI 10.1016/0304-3940(92)90742-P; YOVELL Y, 1992, P NATL ACAD SCI USA, V89, P6526, DOI 10.1073/pnas.89.14.6526	38	106	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25400	25405						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929237				2022-12-27	WOS:A1994PQ49100029
J	WILSON, DM; DEUTSCH, WA; KELLEY, MR				WILSON, DM; DEUTSCH, WA; KELLEY, MR			DROSOPHILA RIBOSOMAL-PROTEIN S3 CONTAINS AN ACTIVITY THAT CLEAVES DNA AT APURINIC APYRIMIDINIC SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; APURINIC ENDONUCLEASE; XERODERMA-PIGMENTOSUM; PYRIMIDINE DIMERS; REPAIR; GENE; CDNA; EXPRESSION; CLONING	A rat cDNA-encoding ribosomal protein S3 was used to clone the S3 homolog in Drosophila melanogaster. The Drosophila gene was in turn used to construct fusions between S3 and glutathione S-transferase that were overexpressed in Escherichia coli, purified on affinity columns, and subsequently used for antibody production and biochemical analysis. Antibody specific for S3 was originally tested to determine the subcellular location of S3 by Western (immunoblot) analysis. As expected, the S3 antigen was found associated with purified preparations of ribosomes, but notably the protein was also observed in the nucleus where it was found to be tightly associated with the nuclear matrix. This result, combined with the fact that S3 contains a nuclear localization signal and that the protein shares some homology to a yeast nuclease gene, suggested that S3 might possibly have a role in DNA metabolism. Tests were initially performed to see if S3 contained DNase activity, where it was subsequently determined that the protein specifically cleaved DNA containing an apurinic/apyrimidinic site via a beta-elimination reaction. The DNase activity was inactivated by antibody to S3, indicating that the apurinic/apyrimidinic lyase activity was associated with the Drosophila S3 protein. Taken together, these results suggest that S3 is among a growing class of multifunctional proteins with roles in transcription/translation and DNA repair.	LOYOLA UNIV,STRITCH SCH MED,PROGRAM MOLEC BIOL,MAYWOOD,IL 60153; LOUISIANA STATE UNIV,DEPT BIOCHEM,BATON ROUGE,LA 70803; INDIANA UNIV,SCH MED,WELLS CTR PEDIAT RES,DEPT PEDIAT,PEDIAT ENDOCRINOL SECT,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	Loyola University Chicago; Louisiana State University System; Louisiana State University; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis			Wilson, David M/AAK-5409-2021	Wilson, David M/0000-0002-8945-0395; Kelley, Mark/0000-0002-6120-9532	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR009884] Funding Source: NIH RePORTER; NCRR NIH HHS [RR09884] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ASHBURNER M, 1989, DROSOPHILA LABORATOR, P358; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BANDURSKI RS, 1951, J BIOL CHEM, V193, P405; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BRUCKNER RC, 1989, NUCLEIC ACIDS RES, V17, P3145, DOI 10.1093/nar/17.8.3145; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; DECOCK JGR, 1992, MUTAT RES, V293, P11, DOI 10.1016/0921-8777(92)90003-L; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DUKER NJ, 1982, BIOCHEM BIOPH RES CO, V105, P1433, DOI 10.1016/0006-291X(82)90948-2; ELKON KB, 1985, J EXP MED, V162, P459, DOI 10.1084/jem.162.2.459; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FISHER PA, 1982, J CELL BIOL, V92, P674, DOI 10.1083/jcb.92.3.674; FRORATH B, 1992, BIOTECHNIQUES, V12, P558; GATES FT, 1977, J BIOL CHEM, V252, P2802; GRABOWSKI DT, 1992, CARCINOGENESIS, V13, P259, DOI 10.1093/carcin/13.2.259; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; HARLOW E, 1988, ANTIBODIES LABORATOR; JOHNSON AW, 1988, J BIOL CHEM, V263, P18017; KELLEY MR, 1989, MOL CELL BIOL, V9, P965, DOI 10.1128/MCB.9.3.965; KELLY WG, 1989, CELL, V57, P243, DOI 10.1016/0092-8674(89)90962-8; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; KONGSUWAN K, 1985, NATURE, V317, P555, DOI 10.1038/317555a0; KUHNLEIN U, 1976, P NATL ACAD SCI USA, V73, P1169, DOI 10.1073/pnas.73.4.1169; LEVIN JD, 1990, NUCLEIC ACIDS RES, V18, P5069, DOI 10.1093/nar/18.17.5069; MALE R, 1982, NUCLEIC ACIDS RES, V10, P6305, DOI 10.1093/nar/10.20.6305; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MOUNKES LC, 1992, CELL, V71, P925, DOI 10.1016/0092-8674(92)90389-T; Pardue ML, 1986, DROSOPHILA PRACTICAL, P111; POGUEGEILE K, 1991, MOL CELL BIOL, V11, P3842, DOI 10.1128/MCB.11.8.3842; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; SANCHEZMADRID F, 1981, EUR J BIOCHEM, V114, P609, DOI 10.1111/j.1432-1033.1981.tb05187.x; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; TOLAN DR, 1983, BIOCHIMIE, V65, P427, DOI 10.1016/S0300-9084(83)80062-5; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WATSON KL, 1992, P NATL ACAD SCI USA, V89, P11302, DOI 10.1073/pnas.89.23.11302; WESTERMANN P, 1979, FEBS LETT, V97, P101, DOI 10.1016/0014-5793(79)80061-7; WILSON DM, 1993, NUCLEIC ACIDS RES, V21, P2516, DOI 10.1093/nar/21.10.2516; WOOL IG, 1979, ANNU REV BIOCHEM, V48, P719, DOI 10.1146/annurev.bi.48.070179.003443; WU C, 1979, CELL, V16, P797, DOI 10.1016/0092-8674(79)90095-3; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7	40	97	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25359	25364						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929231				2022-12-27	WOS:A1994PQ49100022
J	YE, JP; GHOSH, P; CIPPITELLI, M; SUBLESKI, J; HARDY, KJ; ORTALDO, JR; YOUNG, HA				YE, JP; GHOSH, P; CIPPITELLI, M; SUBLESKI, J; HARDY, KJ; ORTALDO, JR; YOUNG, HA			CHARACTERIZATION OF A SILENCER REGULATORY ELEMENT IN THE HUMAN INTERFERON-GAMMA PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; TRANSCRIPTION FACTOR; NEGATIVE CONTROL; DNA ELEMENT; C-MYC; ENHANCER; BINDS; EXPRESSION; PROTEIN; SITE	Previous analysis of the human interferon-gamma (IFN-gamma promoter indicated that the region of DNA from -251 to -215 (designated here as BE (binding element)) possessed silencer activity, as deletion of this region caused an increase in promoter activity. Based on this finding, we have conducted a series of experiments to characterize BE function and analyze the binding proteins which interact with this region. Transient transfection assays in the Jurkat T cell line revealed that the BE region possesses silencer activity, which is orientation-dependent when reinserted 5' to the IFN-gamma core promoter. However, when the BE region was inserted in front of a heterologous promoter (thymidine kinase (TK)), a mild enhancer activity was observed. Utilizing the electrophoretic mobility shift assay, we have identified two major DNA-protein complexes (designated as S and E complexes) which interact with this region. Mutational analysis indicated that the silencer activity observed with the IFN-gamma promoter correlated with the S complex and the enhancer activity correlated with the E complex. Preliminary characterization of these two DNA-protein complexes has demonstrated the presence of multiple proteins in each complex. We have found that the S protein complex has a recognition sequence similar to the nuclear factor AP2, and we have identified the nuclear factor Yin-Yang 1 (YY1) as one of the proteins in the E complex.	NCI, FREDERICK CANC RES & DEV CTR, EXPTL IMMUNOL LAB, BIOL RESPONSE MODIFIERS PROGRAM, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR, PROGRAM RESOURCES INC DYNCORP, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD 21702 USA; UNIV MISSISSIPPI, MED CTR, DEPT MED, JACKSON, MS 39216 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Mississippi; University of Mississippi Medical Center			Cippitelli, Marco/AAF-4857-2021; Ye, Jianping/N-1998-2017; Young, Howard/A-6350-2008	Cippitelli, Marco/0000-0002-9620-538X; Ye, Jianping/0000-0003-3875-365X; Young, Howard/0000-0002-3118-5111				CHRIVIA JC, 1990, J EXP MED, V172, P661, DOI 10.1084/jem.172.2.661; CICCARONE VC, 1990, J IMMUNOL, V144, P725; CLARK AR, 1989, NUCLEIC ACIDS RES, V17, P10130, DOI 10.1093/nar/17.23.10130; COWELL IG, 1993, TRENDS BIOCHEM SCI, V19, P40; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FLANAGAN JR, 1989, MOL CELL BIOL, V9, P739, DOI 10.1128/MCB.9.2.739; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; FONG CLW, 1994, NUCLEIC ACIDS RES, V22, P1108, DOI 10.1093/nar/22.6.1108; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KUHL D, 1987, CELL, V50, P1057, DOI 10.1016/0092-8674(87)90172-3; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE TC, 1994, ONCOGENE, V9, P1047; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; MICHELL PJ, 1987, CELL, V50, P847; MIN LW, 1992, J IMMUNOL, V148, P1913; MIYATAKE S, 1991, MOL CELL BIOL, V11, P5894, DOI 10.1128/MCB.11.12.5894; NABEL GJ, 1988, P NATL ACAD SCI USA, V85, P2934, DOI 10.1073/pnas.85.9.2934; NOMIYAMA H, 1993, MOL CELL BIOL, V13, P2787, DOI 10.1128/MCB.13.5.2787; NOURBAKHSH M, 1993, EMBO J, V12, P451, DOI 10.1002/j.1460-2075.1993.tb05677.x; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; RADBOUD JEM, 1993, J LEUKOCYTE BIOL, V54, P545; RAUGHT B, 1994, MOL CELL BIOL, V14, P1752, DOI 10.1128/MCB.14.3.1752; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; TANAKA N, 1992, ADV IMMUNOL, V52, P263, DOI 10.1016/S0065-2776(08)60877-9; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; YOUNG HA, 1990, PHARMACOL THERAPEUT, V45, P137, DOI 10.1016/0163-7258(90)90012-Q	36	68	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25728	25734						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929277				2022-12-27	WOS:A1994PQ49100074
J	NEWTON, CL; MIGNERY, GA; SUDHOF, TC				NEWTON, CL; MIGNERY, GA; SUDHOF, TC			COEXPRESSION IN VERTEBRATE TISSUES AND CELL-LINES OF MULTIPLE INOSITOL 1,4,5-TRISPHOSPHATE (INSP(3)) RECEPTORS WITH DISTINCT AFFINITIES FOR INSP(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; ESCHERICHIA-COLI; TRISPHOSPHATE; BINDING; PURIFICATION; MECHANISM; FORMS	Inositol 1,4,5-trisphosphate (InsP(3)) is a ubiquitous second messenger in eukaryotic cells that triggers Ca2+ release from intracellular stores. Three types of InsP(3) receptors have been identified in mammals. The three receptor types are encoded by homologous genes and are structurally similar, suggesting two alternative hypotheses about the biological significance of multiple InsP(3) receptors: (a) the different InsP(3) receptors could have similar functions as InsP(3)-gated Ca2+ channels, and the presence of multiple genes could then serve as a mechanism to allow tissue-specific differential expression of receptors; or (b) the different receptors are coexpressed in cells but have distinct biological roles in these cells. To test these hypotheses, we have investigated the similarities and differences between the expression, alternative splicing, and ligand binding of different receptors. Our results demonstrate co-expression of different InsP(3) receptors in almost all tissues and cell lines tested. Although all receptor types exhibit a similar specificity for inositol phosphates, the different receptors have different affinities for InsP(3), with a relative order of affinities of type II > type I > type III. These findings suggest that the presence of multiple InsP(3)-sensitive Ca2+ pools with differential responsiveness to InsP(3) may be a general property of all cells mediated by the presence of multiple types of InsP(3) receptors.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DEPT MOLEC GENET,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIMH NIH HHS [R01-MH47510] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH047510] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; KIJIMA Y, 1992, BIOCHEM BIOPH RES CO, V189, P728, DOI 10.1016/0006-291X(92)92262-V; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; MIGNERY GA, 1992, J BIOL CHEM, V267, P7450; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MIGNERY GA, 1993, METH NEUROSCI, V18, P247; PERIN MS, 1991, J BIOL CHEM, V266, P3877; PIETRI F, 1990, CELL SIGNAL, V2, P253, DOI 10.1016/0898-6568(90)90053-D; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPPATTAPONE S, 1988, J BIOL CHEM, V263, P1530	20	253	257	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28613	28619						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961809				2022-12-27	WOS:A1994PU16800018
J	CRESSMAN, DE; TAUB, R				CRESSMAN, DE; TAUB, R			PHYSIOLOGICAL TURNOVER OF NUCLEAR FACTOR KAPPA-B BY NUCLEAR PROTEOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSCRIPTION FACTOR; REGENERATING LIVER; RAPID PROTEOLYSIS; INHIBITOR; ALPHA; PROTEASOMES; PROMOTER; PATHWAY; COMPLEX; CELLS	Regenerating Liver is a physiologic animal system in which p50/p65 nuclear factor kappa B (NF-KR) DNA binding activity is induced and rapidly disappears in the remnant liver within minutes of partial hepatectomy. The activation of NF-kappa B may contribute to the mechanism by which hepatocytes regulate their mitogenic program during liver regeneration. A p50/NF-kappa B1-p35/RelA heterodimer that contains a proteolyzed amino-terminal DNA binding fragment of p65/RelA is also present in the nuclei of hepatic cells within minutes of partial hepatectomy. In the absence of I kappa B-alpha resynthesis, turnover of NF-kappa B occurs via conversion of p50/NF-kappa B1-p65/RelA to a p50/NF-kappa B1-p35/RelA DNA binding complex. Proteolytic conversion of p65/RelA into p35/RelA and subsequent degradation of p35/RelA account at least in part for the rapid turnover of NF-kappa B in the cell nuclei. Nuclear proteolysis provides a potential mechanism for tightly regulating the level of active NF-kappa B.	UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania								Arias I.M., 1994, LIVER BIOL PATHOBIOL, V3; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD D W, 1989, New Biologist, V1, P83; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; CRESSMAN DE, 1993, ONCOGENE, V8, P2567; CRESSMAN DE, 1994, IN PRESS J BIOL CHEM, V269; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; ELIASSON E, 1992, J BIOL CHEM, V267, P15765; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRILLI M, 1993, INT REV CYTOL, V143, P1; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Higgins GM, 1931, ARCH PATHOL, V12, P186; HOHMANN HP, 1991, MOL CELL BIOL, V11, P259, DOI 10.1128/MCB.11.1.259; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LIU JL, 1991, J IMMUNOL, V146, P1685; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; RICE NR, 1993, EMBO J, V12, P5043; RIVETT AJ, 1992, J HISTOCHEM CYTOCHEM, V40, P1165, DOI 10.1177/40.8.1619280; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TANAKA K, 1990, FEBS LETT, V271, P41, DOI 10.1016/0014-5793(90)80367-R; TANAKA K, 1989, J CELL PHYSIOL, V139, P34, DOI 10.1002/jcp.1041390107; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898	25	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26594	26597						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929386				2022-12-27	WOS:A1994PQ93100002
J	HARUKI, M; NOGUCHI, E; AKASAKO, A; OOBATAKE, M; ITAYA, M; KANAYA, S				HARUKI, M; NOGUCHI, E; AKASAKO, A; OOBATAKE, M; ITAYA, M; KANAYA, S			A NOVEL STRATEGY FOR STABILIZATION OF ESCHERICHIA-COLI RIBONUCLEASE HI INVOLVING A SCREEN FOR AN INTRAGENIC SUPPRESSOR OF CARBOXYL-TERMINAL DELETIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMUS-THERMOPHILUS HB8; PHAGE LAMBDA-REPRESSOR; PROTEIN STABILITY; RNASE-H; ALANINE SUBSTITUTIONS; SECONDARY-STRUCTURE; RANDOM MUTAGENESIS; MUTATIONS; THERMOSTABILIZATION; MUTANT	A strategy to genetically select Escherichia coli ribonuclease HI mutants with enhanced thermostability is described. E. coli strain MIC3001, which shows an RNase H-dependent, temperature-sensitive growth phenotype, was used for this purpose. Introduction of the rnhA gene permits the growth of this temperature-sensitive strain, whereas the gene for the truncated protein, 142-RNase HI, which lacks the carboxyl-terminal 13 residues, cannot. Analyses of the production levels and the stability of a series of mutant proteins with COOH-terminal truncations suggested that 142-RNase HI is nonfunctional in vivo because of a dramatic decrease in the protein stability. Polymerase chain reaction-mediated random mutagenesis of the rnhA142 gene, encoding 142-RNase HI, followed by selection of revertants, allowed us to isolate 11 single amino acid substitutions that render 142-RNase HI functional in vivo. Of them, eight substitutions were shown to enhance the thermal stability of the wild-type RNase HI protein, and of these, six were novel. The genetic selection strategy employed in this experiment was thus shown to be effective for identifying amino acid substitutions that enhance the thermal stability of E. coli RNase HI. Such a strategy would be versatile if a protein of interest could be destabilized by a deletion or a truncation and a conditional-lethal strain were available.	PROT ENGN RES INST, SUITA, OSAKA 565, JAPAN; MITSUBISHI KASEI INST LIFE SCI, MACHIDA, TOKYO 194, JAPAN									ALBER T, 1989, ANNU REV BIOCHEM, V58, P765, DOI 10.1146/annurev.biochem.58.1.765; [Anonymous], INTRO PROTEIN STRUCT; ARASE A, 1993, FEBS LETT, V316, P123, DOI 10.1016/0014-5793(93)81199-A; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; CAMPBELL AG, 1993, P NATL ACAD SCI USA, V90, P9350, DOI 10.1073/pnas.90.20.9350; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Crouch R. J., 1982, NUCLEASES, P211; DAS G, 1989, P NATL ACAD SCI USA, V86, P496, DOI 10.1073/pnas.86.2.496; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7135; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; GANTER C, 1990, BIOCHEMISTRY-US, V29, P9395, DOI 10.1021/bi00492a013; Goodwin T. W., 1946, BIOCHEM JOUR, V40, P628; HARUKI M, 1994, EUR J BIOCHEM, V220, P623, DOI 10.1111/j.1432-1033.1994.tb18664.x; HECHT MH, 1985, J MOL BIOL, V186, P53, DOI 10.1016/0022-2836(85)90256-6; HECHT MH, 1985, J CELL BIOCHEM, V29, P217, DOI 10.1002/jcb.240290306; HERMES JD, 1989, GENE, V84, P143, DOI 10.1016/0378-1119(89)90148-0; ISHIKAWA K, 1993, J MOL BIOL, V230, P529, DOI 10.1006/jmbi.1993.1169; ISHIKAWA K, 1993, BIOCHEMISTRY-US, V32, P7136, DOI 10.1021/bi00079a010; ISHIKAWA K, 1993, BIOCHEMISTRY-US, V32, P6171, DOI 10.1021/bi00075a009; ISHIKAWA K, 1993, PROTEIN ENG, V6, P85, DOI 10.1093/protein/6.1.85; ITAYA M, 1991, NUCLEIC ACIDS RES, V19, P4443, DOI 10.1093/nar/19.16.4443; ITAYA M, 1991, MOL GEN GENET, V227, P438, DOI 10.1007/BF00273935; ITAYA M, 1991, MOL GEN GENET, V227, P424, DOI 10.1007/BF00273933; KANAYA S, 1990, BIOCHEM J, V271, P59, DOI 10.1042/bj2710059; KANAYA S, 1993, J BIOTECHNOL, V28, P117, DOI 10.1016/0168-1656(93)90129-B; KANAYA S, 1992, J BIOL CHEM, V267, P10184; KANAYA S, 1983, J BIOL CHEM, V258, P1276; KANAYA S, 1991, J BIOL CHEM, V266, P6038; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KIM CWA, 1993, NATURE, V362, P267, DOI 10.1038/362267a0; KIMURA S, 1992, J BIOL CHEM, V267, P21535; KIMURA S, 1992, EUR J BIOCHEM, V206, P337, DOI 10.1111/j.1432-1033.1992.tb16932.x; KIMURA S, 1992, J BIOL CHEM, V267, P22014; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung DW, 1989, TECHNIQUE, V1, P11; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; Miller J. H., 1972, EXPT MOL GENETICS, P433; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; OOBATAKE M, 1993, PROG BIOPHYS MOL BIO, V59, P237, DOI 10.1016/0079-6107(93)90002-2; OOI T, 1988, J BIOCHEM-TOKYO, V104, P440, DOI 10.1093/oxfordjournals.jbchem.a122486; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH CK, 1994, BIOCHEMISTRY-US, V33, P5510, DOI 10.1021/bi00184a020; YAMAZAKI T, 1993, BIOCHEMISTRY-US, V32, P5656, DOI 10.1021/bi00072a023; YAMAZAKI T, 1991, BIOCHEMISTRY-US, V30, P6036, DOI 10.1021/bi00238a030; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	47	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26904	26911						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929430				2022-12-27	WOS:A1994PQ93100051
J	ASO, T; CONAWAY, JW; CONAWAY, RC				ASO, T; CONAWAY, JW; CONAWAY, RC			ROLE OF CORE PROMOTER STRUCTURE IN ASSEMBLY OF THE RNA-POLYMERASE-II PREINITIATION COMPLEX - A COMMON PATHWAY FOR FORMATION OF PREINITIATION INTERMEDIATES AT MANY TATA AND TATA-LESS PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE GENE; PURIFIED TRANSCRIPTION FACTORS; MAJOR LATE PROMOTER; INITIATION-FACTOR; BINDING PROTEIN; FACTOR-EPSILON; FACTOR-DELTA; DNA-BINDING; BOX-BINDING; TFIID COMPLEX	Efforts to understand the impact of core promoter architecture on the mechanism of transcription initiation by RNA polymerase II have been hampered by lack of well defined, reconstituted transcription systems responsive both to efficiently transcribed consensus and near consensus TATA box-containing promoters and to considerably weaker TATA-less promoters. In this report, we investigate the influence of core promoter structure on the mechanism of assembly of the RNA polymerase II preinitiation complex using a highly purified, holoTFIID-dependent transcription system that permits sensitive measurement of transcription initiation from a wide variety of TATA and TATA-less promoters in the absence of transactivators. A direct comparison of the requirements for formation of stable preinitiation intermediates at these promoters led to the discovery that, whereas holoTFIID binds avidly to the consensus TATA- and strong initiator-containing adenovirus major late (AdML) promoter to form the first stable intermediate on the pathway leading to formation of the complete preinitiation complex, it binds poorly not only to TATA-less promoters but also to promoters with consensus or near consensus TATA elements. With the exception of the AdML promoter, formation of stable preinitiation intermediates at each of the promoters tested was found to be strongly dependent on RNA polymerase II, holoTFIID, and TFIIB and was stimulated by TFIIF. Based on these observations, we suggest that RNA polymerase II assembles with many TATA and TATA-less promoters by a common pathway.	OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,OKLAHOMA CITY,OK 73104	Oklahoma Medical Research Foundation				Conaway, Joan/0000-0002-2786-0663	NIGMS NIH HHS [GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041628, R37GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASO T, 1994, EMBO J, V13, P435, DOI 10.1002/j.1460-2075.1994.tb06278.x; ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Battey, 1986, BASIC METHODS MOL BI; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CHEN MJ, 1984, J BIOL CHEM, V259, P3933; CONAWAY JW, 1990, J BIOL CHEM, V265, P7564; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1990, J BIOL CHEM, V265, P7552; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CONAWAY RC, 1990, J BIOL CHEM, V265, P7559; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; EMANUEL PA, 1993, P NATL ACAD SCI USA, V90, P8449, DOI 10.1073/pnas.90.18.8449; FARNHAM PJ, 1986, MOL CELL BIOL, V6, P2392, DOI 10.1128/MCB.6.7.2392; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1992, J BIOL CHEM, V267, P2786; GARFINKEL S, 1990, J BIOL CHEM, V265, P10309; GARRETT KP, 1992, J BIOL CHEM, V267, P23942; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; GREENBLATT J, 1992, NATURE, V360, P16, DOI 10.1038/360016a0; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; KADESCH TR, 1982, J MOL BIOL, V155, P1, DOI 10.1016/0022-2836(82)90489-2; KADONAGA JT, 1990, J BIOL CHEM, V265, P2624; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KILLEEN M, 1992, J BIOL CHEM, V267, P9463; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; LIEBERMAN PM, 1991, MOL CELL BIOL, V11, P63, DOI 10.1128/MCB.11.1.63; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MONCOLLIN V, 1984, EMBO J, V3, P2363; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON MG, 1991, NATURE, V354, P369; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; SAFER B, 1991, J BIOL CHEM, V266, P10989; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1994, TRANSCRIPTION MECHAN, P27; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SMALE S.T., 1994, TRANSCRIPTION MECHAN, P63; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; TSCHOCHNER H, 1992, P NATL ACAD SCI USA, V89, P11292, DOI 10.1073/pnas.89.23.11292; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; VANDYKE MW, 1990, MOL CELL BIOL, V10, P3415, DOI 10.1128/MCB.10.7.3415; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZHENG XM, 1987, CELL, V50, P361, DOI 10.1016/0092-8674(87)90490-9; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	81	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26575	26583						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929383				2022-12-27	WOS:A1994PQ93000096
J	LOWRY, DF; ROTH, AF; RUPERT, PB; DAHLQUIST, FW; MOY, FJ; DOMAILLE, PJ; MATSUMURA, P				LOWRY, DF; ROTH, AF; RUPERT, PB; DAHLQUIST, FW; MOY, FJ; DOMAILLE, PJ; MATSUMURA, P			SIGNAL-TRANSDUCTION IN CHEMOTAXIS - A PROPAGATING CONFORMATION CHANGE UPON PHOSPHORYLATION OF CHEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOSIGNALING PROTEIN CHEY; BACTERIAL CHEMOTAXIS; RESPONSE REGULATOR; F-19 NMR; ACTIVATION	The CheY protein from Escherichia coli and Salmonella typhimurium are among the best characterized proteins of the receiver domain family of two component signal transduction systems in bacteria. Phosphorylation of CheY plays a central role in bacterial chemo taxis. However, it is not entirely clear how its state of phosphorylation contributes to its function. Genetic evidence suggests that CheY changes its conformation upon phosphorylation. We present evidence for this con formation change by comparing the NMR N-15 - H-1 correlation spectra of CheY.Mg2+ complex and phospho-CheY in the presence of magnesium. Large changes in chemical shift are used as indicators of chemical changes and probable structural changes in the protein backbone. Our observations suggest that significant structural changes occur in CheY upon phosphorylation and that these changes are distinct from the changes produced by magnesium ion binding. In addition to residues Asn-59 and Gly-65 that are immediately adjacent to the site of phosphorylation at Asp-57, a large number of other residues show significant chemical shift changes as a result of phosphorylation. These include Met-17, Val-21, Asn-23, Gly-39, Met-60, Met-63, Asp-64, Leu-66, Glu-67, Leu-68, Leu-69, Met-85, Val-86, Thr-87, Ala-88, Asn-94, Val-107, Lys-109, Thr-112, Ala-113, Ala-114, and Asn-121. These results appear inconsistent with the recent suggestion that phosphorylation produces the same structural changes as magnesium binding (Bell-solell, L., Prieto, J., Serrano, L., and Cell, M. (1994) J. Mel. Biol. 238, 489-495). We find that some regions change overlap with a genetically defined motor binding face. We therefore propose that the conformation switch modulates the interaction of CheY with its target, the flagellar motor. Other regions also change, possibly reflecting the many different functions of CheY homologues.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA; DUPONT MERCK PHARMACEUT CO, WILMINGTON, DE 19880 USA; UNIV ILLINOIS, DEPT MICROBIOL & IMMUNOL, CHICAGO, IL 60612 USA	University of Oregon; DuPont; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NIAID NIH HHS [AI18985] Funding Source: Medline; NIGMS NIH HHS [GM33677] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033677, R37GM033677] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELLSOLELL L, 1994, J MOL BIOL, V238, P489, DOI 10.1006/jmbi.1994.1308; BOURRET RB, 1993, J BIOL CHEM, V268, P13089; BRUIX M, 1993, EUR J BIOCHEM, V215, P573, DOI 10.1111/j.1432-1033.1993.tb18068.x; DRAKE SK, 1993, J BIOL CHEM, V268, P13081; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MOY FJ, 1994, IN PRESS BIOCH; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; ROMAN SJ, 1992, J BACTERIOL, V174, P6247, DOI 10.1128/JB.174.19.6247-6255.1992; SOCKETT H, 1992, J BACTERIOL, V174, P793, DOI 10.1128/jb.174.3.793-806.1992; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOCK AM, 1993, BIOCHEMISTRY-US, V32, P13375, DOI 10.1021/bi00212a001; STOCK JB, 1992, J BIOL CHEM, V267, P19753; VOLZ K, 1991, J BIOL CHEM, V266, P15511; ZHANG O, 1994, IN PRESS J BIOMOL NM	15	78	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26358	26362						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929354				2022-12-27	WOS:A1994PQ93000064
J	MARTIN, G; CHAUVIN, MF; DUGELAY, S; BAVEREL, G				MARTIN, G; CHAUVIN, MF; DUGELAY, S; BAVEREL, G			NONSTEADY STATE MODEL APPLICABLE TO NMR-STUDIES FOR CALCULATING FLUX RATES IN GLYCOLYSIS, GLUCONEOGENESIS, AND CITRIC-ACID CYCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY-CORTEX; KREBS CYCLE; METABOLISM; GLUTAMATE; PYRUVATE; LIVER; HEART	We present a mathematical model for calculating most reaction rates of glycolysis, gluconeogenesis and citric acid cycle in mammalian cells. The model also includes cycles such as the ''phosphoenolpyruvate (PEP) --> pyruvate --> oxaloacetate --> PEP'' cycle and the ''pyruvate --> acetyl-CoA --> citrate --> citric acid cycle --> oxaloacetate --> PEP --> pyruvate'' cycle. The model, which does not require steady state conditions, is based on a set of equations, each one describing the fates of a given carbon of a selected intermediate. These fates are expressed as ratios of integrated transfer of this carbon to corresponding carbons in subsequent metabolites. At each bifurcation, the sum of all proportions adds up to 1. Among several calculation routes to determine a proportion value, we chose the one that was based on the most reliable parameter determined experimentally. The data introduced in the model are the micrograms of atom of traced carbon measured on each carbon of a number of products (corrected for natural tracer abundance). These incorporations can be measured by C-13 NMR, gas chromatography-mass spectroscopy, or C-14 counting. Thanks to its flexibility, this model can be applied to data obtained with substrates other than glucose under many experimental conditions.			MARTIN, G (corresponding author), HOP EDOUARD HERRIOT,CTR ETUD METAB SPECT RESONANCE MAGNET,CNRS,EP 18,PAVILLON P,PL ARSONVAL,F-69374 LYON 03,FRANCE.							CHANCE EM, 1983, J BIOL CHEM, V258, P3785; CHAUVIN MF, 1994, J BIOL CHEM, V269, P26025; COHEN SM, 1987, BIOCHEMISTRY-US, V26, P581, DOI 10.1021/bi00376a033; DIDONATO L, 1993, J BIOL CHEM, V268, P4170; KATZ J, 1989, J BIOL CHEM, V264, P12994; KELLEHER JK, 1985, AM J PHYSIOL, V248, pE252, DOI 10.1152/ajpendo.1985.248.2.E252; MAGNUSSON I, 1991, J BIOL CHEM, V266, P6975; MALLOY CR, 1990, AM J PHYSIOL, V259, pH987, DOI 10.1152/ajpheart.1990.259.3.H987; MALLOY CR, 1988, J BIOL CHEM, V263, P6964; MASON GF, 1992, J CEREBR BLOOD F MET, V12, P434, DOI 10.1038/jcbfm.1992.61; ROGNSTAD R, 1972, J BIOL CHEM, V247, P6047; WATFORD M, 1980, BIOCHEM J, V188, P741, DOI 10.1042/bj1880741	12	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26034	26039						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929314				2022-12-27	WOS:A1994PQ93000018
J	BRAVO, DA; GLEASON, JB; SANCHEZ, RI; ROTH, RA; FULLER, RS				BRAVO, DA; GLEASON, JB; SANCHEZ, RI; ROTH, RA; FULLER, RS			ACCURATE AND EFFICIENT CLEAVAGE OF THE HUMAN INSULIN PRORECEPTOR BY THE HUMAN PROPROTEIN-PROCESSING PROTEASE FURIN - CHARACTERIZATION AND KINETIC-PARAMETERS USING THE PURIFIED, SECRETED SOLUBLE PROTEASE EXPRESSED BY A RECOMBINANT BACULOVIRUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-N-ACETYLGLUCOSAMINIDASE; TYROSINE KINASE FAMILY; HAMSTER OVARY CELLS; SACCHAROMYCES-CEREVISIAE; POINT MUTATION; KEX2 PROTEASE; RECEPTOR; ENDOPROTEASE; CDNA; PRECURSOR	Maturation of the insulin proreceptor in a late Golgi compartment requires cleavage at an Arg-Lys-Arg-Arg processing site, suggesting involvement of furin, a transmembrane serine protease of the Kex2 family of processing enzymes. A genetically engineered secreted, soluble form of human furin (ss-furin), expressed by infection of insect cells with a recombinant baculovirus, was purified to near homogeneity. ss-furin exhibited rapid and efficient cleavage of both isoforms of the human insulin proreceptor in solubilized extracts of cultured mammalian cells expressing preproreceptor cDNA. Proreceptor cleavage occurred at the physiological processing site as judged by the effects of mutations in this site on cleavage by purified ss-furin. Moreover, purified ss-furin exhibited specificity for proreceptor cleavage identical to that of the endogenous insulin proreceptor-processing enzyme. Furin thus displays the properties expected of an insulin proreceptor processing enzyme in that it (i) cleaves the proreceptor efficiently and at the correct site; (ii) exhibits the same specificity in processing variant proreceptors as the endogenous enzyme; (iii) appears to be localized in the correct secretory compartment; and (iv) has the same broad pattern of tissue distribution as the insulin proreceptor.	STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT MOLEC PHARMACOL,STANFORD,CA 94305	Stanford University; Stanford University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034926, R01DK034926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM039697, R01GM039697] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34926] Funding Source: Medline; NIGMS NIH HHS [GM39697] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGLIKER H, 1993, BIOCHEM J, V293, P75, DOI 10.1042/bj2930075; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; CHIN JE, 1991, J BIOL CHEM, V266, P15587; DARDEVET D, 1991, AM J PHYSIOL, V261, pE562, DOI 10.1152/ajpendo.1991.261.5.E562; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HEDO JA, 1983, J BIOL CHEM, V258, P20; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; KOBAYASHI M, 1988, BIOCHEM BIOPH RES CO, V153, P657, DOI 10.1016/S0006-291X(88)81145-8; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; OLSON TS, 1987, J BIOL CHEM, V262, P6816; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PASHMFOROUSH M, 1992, DIABETES S1, V241, P55; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; ROBERTSON BJ, 1993, J BIOL CHEM, V268, P24274; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; SALZMAN A, 1984, BIOCHEMISTRY-US, V23, P6555, DOI 10.1021/bi00321a043; SEINO S, 1989, BIOCHEM BIOPH RES CO, V159, P312, DOI 10.1016/0006-291X(89)92439-X; SHIER P, 1989, J BIOL CHEM, V264, P14605; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; Summers MD, 1987, TEXAS AGR EXPT STATI; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TAYLOR SI, 1992, ENDOCR REV, V13, P566, DOI 10.1210/er.13.3.566; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; YOKOTA T, 1984, P NATL ACAD SCI-BIOL, V81, P1070, DOI 10.1073/pnas.81.4.1070; YOSHIMASA Y, 1988, SCIENCE, V240, P784, DOI 10.1126/science.3283938; YOSHIMASA Y, 1990, J BIOL CHEM, V265, P17230; ZHANG B, 1991, J BIOL CHEM, V266, P990	44	116	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25830	25837						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929288				2022-12-27	WOS:A1994PQ49100088
J	CULOTTA, VC; HOWARD, WR; LIU, XF				CULOTTA, VC; HOWARD, WR; LIU, XF			CRS5 ENCODES A METALLOTHIONEIN-LIKE PROTEIN IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION INITIATION SITES; ZINC SUPEROXIDE-DISMUTASE; DNA-BINDING PROTEIN; CUP2 GENE-PRODUCT; YEAST METALLOTHIONEIN; EXPRESSION; COPPER; ACE1; AMPLIFICATION; ACTIVATION	Protection from copper toxicity in the bakers' yeast Saccharomyces cerevisiae involves the action of a copper binding metallothionein encoded by the CUP1 locus. To identify additional factors contributing to copper ion homeostasis and detoxification, we screened a genomic library for genes that confer high levels of copper resistance to yeast strains lacking CUP1. This screen led to the identification of the CRS5 (copper resistant suppressor) gene. By sequence analyses, CRS5 encodes a small molecular weight cysteine-rich protein with an amino acid sequence bearing all the features of a eukaryotic metallothionein. The CRS5 polypeptide exhibits a striking similarity to a number of mammalian and invertebrate metallothioneins, yet shares surprisingly little homology with CUP1. In yeast, CRS5 is expressed as a 0.5-kilobase mRNA that is regulated both by copper ions and by oxidative stress, and expression is dependent upon ACE1, a copper and DNA binding transcription factor also known to regulate CUP1. Deletion of the chromosomal CRS5 locus was found to increase cellular sensitivity to copper, but not cadmium, toxicity. These studies support an important role for the CRS5 metallothionein-like protein in copper homeostasis and detoxification.			CULOTTA, VC (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT ENVIRONM HLTH SCI, DIV TOXICOL SCI, BALTIMORE, MD 21205 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES005794] Funding Source: NIH RePORTER; NIEHS NIH HHS [NIEHS R29 ES05794, NIEHS ES 07141] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BUCHMAN C, 1989, MOL CELL BIOL, V9, P4091, DOI 10.1128/MCB.9.9.4091; BUCHMAN C, 1990, MOL CELL BIOL, V10, P4778, DOI 10.1128/MCB.10.9.4778; BUTLER G, 1991, MOL CELL BIOL, V11, P476, DOI 10.1128/MCB.11.1.476; BUTT TR, 1984, P NATL ACAD SCI-BIOL, V81, P3332, DOI 10.1073/pnas.81.11.3332; CARRI MT, 1991, FEBS LETT, V278, P263, DOI 10.1016/0014-5793(91)80131-L; CHEN W, 1985, EMBO J, V4, P3273, DOI 10.1002/j.1460-2075.1985.tb04077.x; CRAWFORD BD, 1985, MOL CELL BIOL, V5, P320, DOI 10.1128/MCB.5.2.320; CULOTTA V, 1993, BIOINORGANIC CHEM CO, P124; CULOTTA VC, 1989, MOL CELL BIOL, V9, P1376, DOI 10.1128/MCB.9.3.1376; FOGEL S, 1982, P NATL ACAD SCI-BIOL, V79, P5342, DOI 10.1073/pnas.79.17.5342; FURST P, 1989, P NATL ACAD SCI USA, V86, P5267, DOI 10.1073/pnas.86.14.5267; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GRALLA EB, 1991, P NATL ACAD SCI USA, V88, P8558, DOI 10.1073/pnas.88.19.8558; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HAMER DH, 1985, SCIENCE, V228, P685, DOI 10.1126/science.3887570; HUIBREGTSE JM, 1989, P NATL ACAD SCI USA, V86, P65, DOI 10.1073/pnas.86.1.65; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; KARIN M, 1984, P NATL ACAD SCI-BIOL, V81, P337, DOI 10.1073/pnas.81.2.337; KOJIMA Y, 1991, METHOD ENZYMOL, V205, P8; KOJIMA Y, 1991, METHOD ENZYMOL, V205, P419; LI TY, 1980, P NATL ACAD SCI-BIOL, V77, P6334, DOI 10.1073/pnas.77.11.6334; LINK AJ, 1991, GENETICS, V127, P681; LIU XF, 1992, J BIOL CHEM, V267, P18298; Maniatis T., 1982, MOL CLONING; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; MICHALSKA AE, 1993, P NATL ACAD SCI USA, V90, P8088, DOI 10.1073/pnas.90.17.8088; NAGAWA F, 1985, P NATL ACAD SCI USA, V82, P8557, DOI 10.1073/pnas.82.24.8557; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; NAUMOV GI, 1992, GENE, V119, P65, DOI 10.1016/0378-1119(92)90067-Y; NEMER M, 1985, P NATL ACAD SCI USA, V82, P4992, DOI 10.1073/pnas.82.15.4992; RILES L, 1993, GENETICS, V134, P81; ROSE MR, 1990, UCLA SYM BI, V123, P19; SCHNEIDER JC, 1991, METHOD ENZYMOL, V194, P373; SIKORSKI RS, 1989, GENETICS, V122, P19; SZCZYPKA MS, 1989, MOL CELL BIOL, V9, P421, DOI 10.1128/MCB.9.2.421; TAMAI KT, 1993, P NATL ACAD SCI USA, V90, P8013, DOI 10.1073/pnas.90.17.8013; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; UDOM AO, 1980, BIOCHEM J, V187, P329, DOI 10.1042/bj1870329; UNGER ME, 1991, BIOCHIM BIOPHYS ACTA, V1074, P371, DOI 10.1016/0304-4165(91)90087-W; WAALKES MP, 1990, CHEM RES TOXICOL, V3, P281, DOI 10.1021/tx00016a001; WELCH J, 1989, EMBO J, V8, P255, DOI 10.1002/j.1460-2075.1989.tb03371.x	44	133	140	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25295	25302						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929222				2022-12-27	WOS:A1994PQ49100012
J	JOE, YA; PARK, MH				JOE, YA; PARK, MH			STRUCTURAL FEATURES OF THE EIF-5A PRECURSOR REQUIRED FOR POSTTRANSLATIONAL SYNTHESIS OF DEOXYHYPUSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION-FACTOR; HYPUSINE-CONTAINING PROTEIN; SACCHAROMYCES-CEREVISIAE; SEQUENCE DETERMINATION; FACTOR 4D; SPERMIDINE; CDNA; IDENTIFICATION; PURIFICATION; CLEAVAGE	Eukaryotic translation initiation factor 5A (eIF-5A, older nomenclature, eIF-4D) is a highly conserved protein that contains the unusual amino acid hypusine ((epsilon)-(4-amino-2-hydroxybutyl)lysine). The biosynthesis of hypusine occurs posttranslationally in only this protein by modification of a single lysine residue (Lys(50) in the human eIF-5A precursor). The basis for the specificity of this modification with respect to the substrate protein was investigated using fragments of eIF-5A precursor protein, each containing this lysine residue, as substrates for deoxyhypusine synthase, the first enzyme in hypusine synthesis. Proteolytic fragments (5-6 kDa) of ec-eIF-5A (the precursor form of eIF-5A produced in Escherichia coli by expression of the human eIF-5A cDNA) generated by specific cleavage by endoproteinases Arg-C, Asp-N, or Glu-C, did not act as substrates for deoxyhypusine synthesis. A series of truncated forms of the eIF-5A precursor protein generated by expression in E. coli of recombinant deletion constructs from the human eIF-5A cDNA were tested. Truncation of up to 9 amino acid residues (Met(1)-Thr(9)) from the NH, terminus or 64 amino acid residues (Leu(91)-Lys(154)) from the COOH terminus did not significantly decrease the substrate reactivity, but removal of an additional 10 amino acids from either side did, Deletion of 34 amino acid residues (Met(1)-Lys(34)) from the NH2 terminus or of 84 amino acid residues (Asp(71)-Lys(154)) from the carboxyl terminus caused complete loss of substrate property. The results obtained thus far define the minimum domain of the eIF-5A precursor protein required for enzymatic deoxyhypusine synthesis as Phe(30)-Asp(80), which corresponds to a region of high amino acid conservation in this protein throughout the eukaryotic kingdom.	NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								ABBRUZZESE A, 1986, J BIOL CHEM, V261, P3085; BENNE R, 1978, J BIOL CHEM, V253, P3078; BYERS TL, 1992, BIOCHEM J, V287, P717, DOI 10.1042/bj2870717; CHAMOT D, 1992, NUCLEIC ACIDS RES, V20, P665, DOI 10.1093/nar/20.4.665; GORDON ED, 1987, J BIOL CHEM, V262, P16585; JAKUS J, 1993, J BIOL CHEM, V268, P13151; KANG HA, 1994, J BIOL CHEM, V269, P3934; MURPHEY RJ, 1987, J BIOL CHEM, V262, P15033; PARK MH, 1983, METHOD ENZYMOL, V94, P458; PARK MH, 1982, J BIOL CHEM, V257, P7217; PARK MH, 1993, TRENDS BIOCHEM SCI, V18, P475, DOI 10.1016/0968-0004(93)90010-K; PARK MH, 1989, J BIOL CHEM, V264, P18531; PARK MH, 1993, BIOFACTORS, V4, P95; PARK MH, 1988, J BIOL CHEM, V263, P15264; PAY A, 1991, PLANT MOL BIOL, V17, P927, DOI 10.1007/BF00037075; RINAUDO MS, 1993, GENE, V137, P303, DOI 10.1016/0378-1119(93)90025-X; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; SANDHOLZER U, 1989, FEBS LETT, V246, P94, DOI 10.1016/0014-5793(89)80260-1; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P18527; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P1578; WOHL T, 1993, MOL GEN GENET, V241, P305; WOLFF EC, 1990, J BIOL CHEM, V265, P4793; YAN SCB, 1989, TRENDS BIOCHEM SCI, V14, P264, DOI 10.1016/0968-0004(89)90060-1	24	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25916	25921						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929297				2022-12-27	WOS:A1994PQ49100099
J	SCHENKER, T; LACH, C; KESSLER, B; CALDERARA, S; TRUEB, B				SCHENKER, T; LACH, C; KESSLER, B; CALDERARA, S; TRUEB, B			A NOVEL GTP-BINDING PROTEIN WHICH IS SELECTIVELY REPRESSED IN SV40-TRANSFORMED FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; VI COLLAGEN; CDNA LIBRARIES; CELLS; HYBRIDIZATION; EXPRESSION; CHAIN; GENE; DRG	We have used a subtractive hybridization procedure to isolate cDNA clones for proteins that are produced by human fibroblasts, but not by their SV40-transformed counterparts. With this technique we found, in addition to fibronectin and collagen VI, a novel GTP-binding protein. Sequencing of overlapping cDNA clones demonstrated that this protein is composed of 364 amino acids with a molecular mass of 41 kDa and a calculated isoelectric point of 9.4. It contains the five sequence motifs G1-G5 that are conserved in all GTP binding proteins. Apart from these characteristic motifs the amino acid sequence differs substantially from those of the well characterized G-proteins, but it is similar to those of some recently identified proteins from Caenorhabditis elegans, from Schizosaccharomyces pombe, and from an archaebacterium, suggesting the existence of a new subfamily within the superfamily of the GTP-binding proteins. The striking conservation of the primary structure between distantly related species indicates a fundamental function of the new protein. Since it is produced in normal, but not in virally transformed fibroblasts, it may play a role in the expression of the transformed phenotype or in growth control.	ETH ZENTRUM,BIOCHEM LAB 1,CH-8092 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich			Trueb, Beat/AAL-9621-2020; Kessler, Benedikt/AAY-8614-2021	Trueb, Beat/0000-0001-8684-6856; Kessler, Benedikt/0000-0002-8160-2446				BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BOLL W, 1993, J BIOL CHEM, V268, P12901; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; DUGUID JR, 1990, NUCLEIC ACIDS RES, V18, P2789, DOI 10.1093/nar/18.9.2789; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HUDSON JD, 1993, GENE, V125, P191, DOI 10.1016/0378-1119(93)90327-Y; KOLLER E, 1989, EMBO J, V8, P1073, DOI 10.1002/j.1460-2075.1989.tb03475.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LECO KJ, 1992, GENE, V117, P209, DOI 10.1016/0378-1119(92)90731-4; NEER EJ, 1994, PROTEIN SCI, V3, P3; PASTAN I, 1978, NATURE, V274, P645, DOI 10.1038/274645a0; ROWE DW, 1978, BIOCHEMISTRY-US, V17, P1581, DOI 10.1021/bi00602a001; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAZUKA T, 1992, BIOCHEM BIOPH RES CO, V189, P371, DOI 10.1016/0006-291X(92)91568-B; SAZUKA T, 1992, BIOCHEM BIOPH RES CO, V189, P363, DOI 10.1016/0006-291X(92)91567-A; SCHREIER T, 1988, BIOCHEM J, V253, P381, DOI 10.1042/bj2530381; SHIMMIN LC, 1989, EMBO J, V8, P1225, DOI 10.1002/j.1460-2075.1989.tb03496.x; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIVE HL, 1988, NUCLEIC ACIDS RES, V16, P10937, DOI 10.1093/nar/16.22.10937; SOMMER KA, 1994, MOL GEN GENET, V242, P391, DOI 10.1007/BF00281788; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; TRACH K, 1989, J BACTERIOL, V171, P1362, DOI 10.1128/jb.171.3.1362-1371.1989; TRUEB B, 1985, J CELL BIOL, V100, P638, DOI 10.1083/jcb.100.2.638; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	29	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25447	25453						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929244				2022-12-27	WOS:A1994PQ49100037
J	TOHGO, A; TAKASAWA, S; NOGUCHI, N; KOGUMA, T; NATA, K; SUGIMOTO, T; FURUYA, Y; YONEKURA, H; OKAMOTO, H				TOHGO, A; TAKASAWA, S; NOGUCHI, N; KOGUMA, T; NATA, K; SUGIMOTO, T; FURUYA, Y; YONEKURA, H; OKAMOTO, H			ESSENTIAL CYSTEINE RESIDUES FOR CYCLIC ADP-RIBOSE SYNTHESIS AND HYDROLYSIS BY CD38	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ANTIGEN CD38; BETA-CELLS; CYCLASE; SURFACE; ENZYME; GLYCOHYDROLASE; EXPRESSION; NAD+; ACID	We have recently demonstrated that cyclic ADP-ribose (cADPR) serves as a second messenger for glucose-induced insulin secretion (Takasawa, S., Nata, K., Yonekura, H., and Okamoto, H. (1993) Science 259, 370-373) and that human leukocyte antigen CD38 has both ADP-ribosyl cyclase and cADPR hydrolase activities (Takasawa, S., Tohgo, A., Noguchi, N., Koguma, T., Nata, K., Sugimoto, T., Yonekura, Il., and Okamoto, H. (1993) J. Biol. Chem. 268, 26052-26054). Although the amino acid sequence of Aplysia ADP-ribosyl cyclase exhibits a high degree of amino acid sequence identity with that of CD38, the Aplysia enzyme shows only ADP-ribosyl cyclase but not cADPR hydrolase. In the present study, me introduced site-directed mutations to CD38 and found that C119K- and/or C201E-CD38 exhibited only ADP-ribosyl cyclase activity. Furthermore, Aplysia ADP-ribosyl cyclase into which we introduced the mutations K95C and E176C, which correspond to residues 119 and 201 of human CD38, exhibited not only ADP-ribosyl cyclase activity but also cADPR hydrolase. These results indicate that cysteine residues 119 and 201 in CD38 have crucial roles in the synthesis and hydrolysis of cADPR.	TOHOKU UNIV, SCH MED, DEPT BIOCHEM, AOBA KU, SENDAI, MIYAGI 98077, JAPAN	Tohoku University								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; GLICK DL, 1991, CELL REGUL, V2, P211, DOI 10.1091/mbc.2.3.211; HARADA N, 1993, J IMMUNOL, V151, P3111; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; KNAPP W, 1989, TISSUE ANTIGENS, V33, P123; KOGUMA T, 1994, BBA-MOL CELL RES, V1223, P160, DOI 10.1016/0167-4889(94)90087-6; KONTANI K, 1993, J BIOL CHEM, V268, P16895; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1993, BIOCHIM BIOPHYS ACTA, V1164, P68, DOI 10.1016/0167-4838(93)90113-6; OKAMOTO H, 1993, DIABETES, V42, pA76; OKAMOTO H, 1992, 1ST C INT UN BIOCH M; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TAKASAWA S, 1993, SCIENCE, V262, P585, DOI 10.1126/science.262.5133.585-a; TAKASAWA S, 1993, SEIKAGAKU, V65, P1089; ZOCCHI E, 1993, BIOCHEM BIOPH RES CO, V196, P1459, DOI 10.1006/bbrc.1993.2416	23	98	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28555	28557						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961800				2022-12-27	WOS:A1994PU16800009
J	FULLER, CM; ISMAILOV, II; KEETON, DA; BENOS, DJ				FULLER, CM; ISMAILOV, II; KEETON, DA; BENOS, DJ			PHOSPHORYLATION AND ACTIVATION OF A BOVINE TRACHEAL ANION CHANNEL BY CA2+-CALMODULIN-DEPENDENT PROTEIN-KINASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL CHLORIDE CHANNEL; CA-2+-DEPENDENT CL CHANNELS; CYSTIC-FIBROSIS AIRWAY; PLANAR LIPID BILAYERS; COLONIC CELLS HT-29; FUNCTIONAL RECONSTITUTION; APICAL MEMBRANE; CALCIUM; CFTR	Secretion of Cl- by epithelial cells is fundamental to the processes of fluid and electrolyte transport by epithelia such as those of the airways, sweat-ducts, and gastrointestinal tract. In the present study, we show that a novel Cl- channel protein, immunoaffinity purified from bovine tracheal apical membrane vesicles, is sensitive to phosphorylation by Ca2+/calmodulin protein kinase II (CaMK II). The channel protein, which migrates with an M(r) of 140,000 under nonreducing conditions, is phosphorylated in vitro by CaMK II in a Ca2+- and calmodulin-dependent manner. When reconstituted into planar lipid bilayers, the protein behaves as an anion-selective, 4,4'-diisothiocyanostilbene- and dithiothreitol-sensitive channel. The open probability of this channel is significantly increased by Ca2+ alone but only at levels of Ca2+ (5-10 mu M) that lie outside the physiological range. Addition of CaMK II to the presumptive cytoplasmic side of the bilayer in the presence of ATP and calmodulin dramatically increased the sensitivity of the channel to free Ca2+, shifting the dose-response curve for Ca2+-dependent channel activation to lower [Ca2+](i) the maximum increase in channel P-o occurring between 0.6 and 1 mu M. The addition of kinase in the absence of ATP or calmodulin or the addition of ATP or calmodulin in the absence of kinase was without effect on channel P-o. Increasing [Ca2+] above 1 mu M decreased channel mean current, causing a flickery block that was maximal at 2 mu M. Increasing [Ca2+] as high as 10 mu M in the presence of kinase did not further alter channel behavior. In contrast to CaMK II, the addition of the catalytic subunit of protein kinase A either alone or together with ATP had no effect on channel P-o. These observations suggest that a novel Ca2+-sensitive anion channel isolated from bovine airway epithelium is regulated by CaMK II phosphorylation.			FULLER, CM (corresponding author), UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BHSB 705,UNIV STN,BIRMINGHAM,AL 35294, USA.		Fuller, Cathy/B-4046-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK042017] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 42017] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BOUCHER RC, 1989, J CLIN INVEST, V84, P1424, DOI 10.1172/JCI114316; CHAN HC, 1992, J BIOL CHEM, V267, P8411; CHAN HC, 1992, AM J PHYSIOL, V262, pC1237; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; Dubinsky William P., 1992, American Journal of Physiology, V263, pC888; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FINN AL, 1992, AM J PHYSIOL, V263, pC172, DOI 10.1152/ajpcell.1992.263.1.C172; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; FULLER CM, 1994, AM J PHYSIOL, V266, pC661, DOI 10.1152/ajpcell.1994.266.3.C661; FULLER CM, 1992, AM J PHYSIOL, V263, pC267, DOI 10.1152/ajpcell.1992.263.2.C267; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; GRAY MA, 1994, AM J PHYSIOL, V266, pC213, DOI 10.1152/ajpcell.1994.266.1.C213; ISMAILOV II, 1994, J BIOL CHEM, V269, P10235; ISMAILOV II, 1994, IN PRESS KIDNEY INT; LA BQ, 1991, AM J PHYSIOL, V260, pC1217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; LANGRIDGESMITH JE, 1983, BIOCHIM BIOPHYS ACTA, V731, P318, DOI 10.1016/0005-2736(83)90024-X; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; MCMANUS OB, 1991, J BIOENERG BIOMEMBR, V23, P537, DOI 10.1007/BF00785810; MORRIS AP, 1993, AM J PHYSIOL, V264, pC968, DOI 10.1152/ajpcell.1993.264.4.C968; MORRIS AP, 1993, AM J PHYSIOL, V264, pC977, DOI 10.1152/ajpcell.1993.264.4.C977; NISHIMOTO I, 1991, NEURON, V6, P547, DOI 10.1016/0896-6273(91)90057-7; OH YS, 1993, AM J PHYSIOL, V265, pC85, DOI 10.1152/ajpcell.1993.265.1.C85; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; PRESTON CL, 1992, AM J PHYSIOL, V263, pC879, DOI 10.1152/ajpcell.1992.263.4.C879; RAN S, 1992, J BIOL CHEM, V267, P20630; RAN S, 1991, J BIOL CHEM, V266, P4782; RAN S, 1992, J BIOL CHEM, V267, P3618; REDHEAD CR, 1992, P NATL ACAD SCI USA, V89, P3716, DOI 10.1073/pnas.89.9.3716; REEVES BW, 1994, AM J PHYSIOL, V266, pC741; SAKAKIBARA M, 1986, BIOPHYS J, V50, P319, DOI 10.1016/S0006-3495(86)83465-8; TILLY BC, 1992, J BIOL CHEM, V267, P9470; TSAI LM, 1991, J GEN PHYSIOL, V98, P723, DOI 10.1085/jgp.98.4.723; VALDIVIA HH, 1988, SCIENCE, V242, P1441, DOI 10.1126/science.2462280; VALVERDE MA, 1993, PFLUG ARCH EUR J PHY, V425, P434, DOI 10.1007/BF00374869; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WAGNER JA, 1992, P NATL ACAD SCI USA, V89, P6785, DOI 10.1073/pnas.89.15.6785; WORRELL RT, 1991, AM J PHYSIOL, V260, pC877, DOI 10.1152/ajpcell.1991.260.4.C877; YAMAYA M, 1993, AM J PHYSIOL, V265, pL170, DOI 10.1152/ajplung.1993.265.2.L170	47	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26642	26649						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929397				2022-12-27	WOS:A1994PQ93100013
J	SPRINGER, BA; PANTOLIANO, MW; BARBERA, FA; GUNYUZLU, PL; THOMPSON, LD; HERBLIN, WF; ROSENFELD, SA; BOOK, GW				SPRINGER, BA; PANTOLIANO, MW; BARBERA, FA; GUNYUZLU, PL; THOMPSON, LD; HERBLIN, WF; ROSENFELD, SA; BOOK, GW			IDENTIFICATION AND CONCERTED FUNCTION OF 2 RECEPTOR-BINDING SURFACES ON BASIC FIBROBLAST GROWTH-FACTOR REQUIRED FOR MITOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPILLARY ENDOTHELIAL-CELLS; HEPARIN-BINDING; 3-DIMENSIONAL STRUCTURE; EXTRACELLULAR DOMAIN; SIGNAL TRANSDUCTION; TYROSINE KINASES; AFFINITY; SULFATE; HORMONE; FAMILY	Members of the fibroblast growth factor (FGF) family promote angiogenesis and wound repair, modulate early developmental events and survival of neurons, and have been associated with the pathogenesis of various diseases. FGFs interact with specific FGF receptors (FGFRs) and heparan sulfate proteoglycans on cell surfaces to mediate mitogenesis. Using protein structure-based site-directed mutagenesis of basic FGF (bFGF), we have identified two FGFR binding sites on bFGF which act in concert to initiate signal transduction. Both FGFR binding surfaces are distinct from the heparan sulfate proteoglycan binding domain. The primary, higher affinity, binding interaction comprises a cluster of solvent exposed hydrophobic amino acids (Tyr-24, Tyr-103, Leu-140, and Met-142), and two polar residues (Arg-44 and Asn-101). The hydrophobic contacts dominate the primary binding interaction and provide similar to 75% of the binding affinity. The secondary FGFR binding site on bFGF has an similar to 250-fold lower affinity and is composed of amino acids Lys-110, Tyr-111, and Trp-114 in a surface-exposed type I beta-turn (formerly known as the putative receptor binding loop). Binding of FGFR to both bFGF surfaces in a stoichiometry of 2FGFR:1bFGF is required for growth factor mediated cell proliferation. This represents a mechanism for the fibroblast growth factor/receptor family in which FGF facilitates FGFR dimerization and subsequent signal transduction events as a monomeric ligand.	DUPONT MERCK PHARMACEUT CO,DEPT CRYSTALLOG & BIOPHYS,DUPONT EXPTL STN,WILMINGTON,DE 19880; DUPONT MERCK PHARMACEUT CO,DEPT CARDIOVASC DIS RES,DUPONT EXPTL STN,WILMINGTON,DE 19880; DUPONT MERCK PHARMACEUT CO,DEPT BIOTECHNOL,DUPONT EXPTL STN,WILMINGTON,DE 19880	DuPont; DuPont; DuPont			Thompson, Lester D. R./J-8404-2016	Thompson, Lester D. R./0000-0003-3714-1432				BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BURGESS WH, 1990, J CELL BIOL, V111, P2129, DOI 10.1083/jcb.111.5.2129; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEIGE JJ, 1989, P NATL ACAD SCI USA, V86, P3174, DOI 10.1073/pnas.86.9.3174; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; HARPER JW, 1988, BIOCHEMISTRY-US, V27, P671, DOI 10.1021/bi00402a027; HEATH WF, 1991, BIOCHEMISTRY-US, V30, P5608, DOI 10.1021/bi00236a039; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kiefer M C, 1991, Growth Factors, V5, P115, DOI 10.3109/08977199109000276; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SQUIRES CH, 1988, J BIOL CHEM, V263, P16297; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	32	133	150	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26879	26884						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929426				2022-12-27	WOS:A1994PQ93100047
J	VITTORIOSO, P; CARATTOLI, A; LONDEI, P; MACINO, G				VITTORIOSO, P; CARATTOLI, A; LONDEI, P; MACINO, G			INTERNAL TRANSLATIONAL INITIATION IN THE MESSENGER-RNA FROM THE NEUROSPORA-CRASSA ALBINO-3 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; AUG SELECTION; LEADER	The ''ribosome scanning model'' for translational initiation predicts that eukaryotic mRNAs should, as a rule, be monocistronic. However, cases have recently been described of eukaryotic mRNAs producing more than one protein through alternative translational initiation at several different AUG codons. The present work reports the occurrence of multiple translational start sites on the mRNA of the Neurospora crassa gene albino-3 (al-3), encoding the carotenoid biosynthetic enzyme geranylgeranyl-pyrophosphate synthase. This was revealed by the molecular analysis of an al-3 mutant carrying a deletion within the coding sequence, which was expected to prevent the synthesis of a functional geranylgeranyl-pyrophosphate synthase because of ribosome frameshifting and premature translational termination. However, the mutants could maintain appreciable geranylgeranyl-pyrophosphate synthase activity through a mechanism operating at the translational level, whereby a fraction of ribosomes initiated protein synthesis from either of two internal in-frame AUG codons located downstream of the deletion, thus producing a shortened but still active version of the geranylgeranyl-pyrophosphate synthase. The results presented indicate that the internal AUG codons are recognized mainly or solely by direct ribosome binding rather than by ''leaky scanning'' from the 5' end of the mRNA.	UNIV ROMA LA SAPIENZA,POLICLIN UMBERTO 1,DIPARTIMENTO BIOPATOL UMANA,SEZ BIOL CELLULARE,I-00161 ROME,ITALY	Sapienza University Rome; University Hospital Sapienza Rome			Carattoli, Alessandra/A-1324-2009	Carattoli, Alessandra/0000-0002-6120-6526; Vittorioso, Paola/0000-0002-4189-5168				CARATTOLI A, 1991, J BIOL CHEM, V266, P5854; Davis R.H., 1970, METHODS ENZYMOL, V17, P79, DOI [10.1016/0076-6879(71)17168-6, DOI 10.1016/0076-6879(71)17168-6]; HARDING RW, 1981, PLANT PHYSIOL, V68, P745, DOI 10.1104/pp.68.3.745; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KWEE L, 1992, J VIROL, V66, P4382, DOI 10.1128/JVI.66.7.4382-4389.1992; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; NELSON MA, 1989, MOL CELL BIOL, V9, P1271, DOI 10.1128/MCB.9.3.1271; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; ROMANO N, 1992, MOL MICROBIOL, V6, P3343, DOI 10.1111/j.1365-2958.1992.tb02202.x; Sambrook J, 1989, MOL CLONING LABORATO; SANDMANN G, 1993, J PHOTOCH PHOTOBIO B, V18, P245, DOI 10.1016/1011-1344(93)80071-G; SCHEPER CG, 1991, J BIOL CHEM, V267, P7269; SLUSHER LB, 1991, P NATL ACAD SCI USA, V88, P9789, DOI 10.1073/pnas.88.21.9789; TAHARA SM, 1991, J BIOL CHEM, V266, P3594; VOSS JW, 1991, J BIOL CHEM, V266, P12832	19	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26650	26654						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929398				2022-12-27	WOS:A1994PQ93100014
J	DILIBERTO, PA; KRISHNA, S; KWON, S; HERMAN, B				DILIBERTO, PA; KRISHNA, S; KWON, S; HERMAN, B			ISOFORM-SPECIFIC INDUCTION OF NUCLEAR FREE CALCIUM OSCILLATIONS BY PLATELET-DERIVED GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; CYTOSOLIC FREE CALCIUM; INTRACELLULAR FREE CALCIUM; C-FOS EXPRESSION; INOSITOL TRISPHOSPHATE; CONFOCAL MICROSCOPY; BALB/C-3T3 CELLS; CYTOPLASMIC CA2+; FACTOR RECEPTORS; LIVER NUCLEI	Confocal laser scanning microscopy was used to analyze alterations in nuclear free calcium (Ca-n(2+)) levels induced by platelet-derived growth factor (PDGF) iso forms in BALB/c3T3 fibroblasts loaded with the calcium-sensitive fluorescent indicator Fluo-3. Both AA-PDGF and BB-PDGF caused a transient increase in Ca-n(2+). Analysis of PDGF-induced Ca-n(2+) alterations as a function of time revealed that BB-PDGF stimulation resulted in the generation of Ca-n(2+) oscillations that diminished over time. The frequency of BB-PDGF-stimulated oscillations was modulated by extracellular Ca2+ and could not be mimicked by increasing intracellular inositol 1,4,5-trisphosphate levels in the absence of growth factor stimulation. Caffeine alone had no effect on Ca-n(2+) levels, but exposure of cells to caffeine after BB-PDGF stimulation augmented Ca-n(2+) oscillations, either by increasing the frequency or reinitiating preexisting oscillations. The genesis of these oscillations in Ca-n(2+), appears to be in the region just outside of the nucleus, as perinuclear cytoplasmic free calcium (Ca-i(2+)) increased just prior to Ca-n(2+). In contrast, AA-PDGF stimulation resulted in the generation of one or two irregular, transient Ca-n(2+) spikes. Caffeine pretreatment followed by AA-PDGF stimulation resulted in Ca-n(2+) oscillations very similar to those produced by BB-PDGF alone. Additionally, the AA-PDGF and BB-PDGF isoforms appeared to modulate distinct pools of cellular Ca2+, as BB-PDGF was still capable of inducing Ca-n(2+) oscillations subsequent to prior induction of oscillations by AA-PDGF/caffeine. These PDGF isoform-specific changes in nuclear free Ca2+ could serve as a mechanism by which isoform-specific cellular signaling pathways may be manifested by the growth factors.	UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CELL BIOL LABS,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER CANC RES CTR,SCH MED,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NIA NIH HHS [AG10104] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG010104] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLBRITTON NL, 1993, BIOPHYS, V66, P151; ALMOHANNA FA, 1994, NATURE, V367, P745, DOI 10.1038/367745a0; BERNACKI SH, 1990, OPTICAL MICROSCOPY FOR BIOLOGY, P307; BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BIRCH BD, 1992, P NATL ACAD SCI USA, V89, P7978, DOI 10.1073/pnas.89.17.7978; BURGOYNE RD, 1989, NATURE, V342, P72, DOI 10.1038/342072a0; CHANDRA S, 1989, P NATL ACAD SCI USA, V86, P1870, DOI 10.1073/pnas.86.6.1870; CONNOR JA, 1993, CELL CALCIUM, V14, P185, DOI 10.1016/0143-4160(93)90066-F; DILIBERTO PA, 1990, J CELL BIOCHEM, V44, P39, DOI 10.1002/jcb.240440104; DILIBERTO PA, 1991, J BIOL CHEM, V266, P12612; DILIBERTO PA, 1992, J BIOL CHEM, V267, P11888; DILIBERTO PA, 1991, RES COMMUN CHEM PATH, V72, P3; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; GLENNON MC, 1992, J BIOL CHEM, V267, P25568; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANOVER JA, 1992, FASEB J, V6, P2288, DOI 10.1096/fasebj.6.6.1312045; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HART CE, 1990, J INVEST DERMATOL, V94, pS53, DOI 10.1111/1523-1747.ep12875065; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HERMAN B, 1987, CELL MOTIL CYTOSKEL, V8, P91, DOI 10.1002/cm.970080202; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; HIMPENS B, 1992, AM J PHYSIOL, V263, pC978, DOI 10.1152/ajpcell.1992.263.5.C978; HIMPENS B, 1992, AM J PHYSIOL, V263, pC95, DOI 10.1152/ajpcell.1992.263.1.C95; HIMPENS B, 1993, AM J PHYSIOL, V265, pC966, DOI 10.1152/ajpcell.1993.265.4.C966; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LANINI L, 1992, J BIOL CHEM, V267, P11548; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MOOLENAAR WH, 1986, J EXP BIOL, V124, P359; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; NEYLON CB, 1990, AM J PHYSIOL, V259, pC675, DOI 10.1152/ajpcell.1990.259.4.C675; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6858, DOI 10.1073/pnas.87.17.6858; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; PETERSEN OH, 1991, CELL CALCIUM, V12, P135, DOI 10.1016/0143-4160(91)90015-7; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; ROONEY TA, 1993, CELL CALCIUM, V14, P674, DOI 10.1016/0143-4160(93)90094-M; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; STRICKER SA, 1992, DEV BIOL, V149, P370, DOI 10.1016/0012-1606(92)90292-O; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TUCKER RW, 1990, EUR J CELL BIOL, V51, P120; TUCKER RW, 1989, J CELL BIOCHEM, V39, P139, DOI 10.1002/jcb.240390206; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WAYBILL MM, 1991, AM J PHYSIOL, V261, pE49, DOI 10.1152/ajpendo.1991.261.1.E49; WHARTON W, 1982, J CELL PHYSIOL, V111, P201, DOI 10.1002/jcp.1041110212; WILLIAMS DA, 1987, SCIENCE, V235, P1644, DOI 10.1126/science.3103219; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; ZAGARI M, 1989, J CELL PHYSIOL, V139, P167, DOI 10.1002/jcp.1041390123	55	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26349	26357						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929353				2022-12-27	WOS:A1994PQ93000063
J	HIRSCHBERG, BT; SCHIMERLIK, MI				HIRSCHBERG, BT; SCHIMERLIK, MI			A KINETIC-MODEL FOR OXOTREMORINE-M BINDING TO RECOMBINANT PORCINE M2 MUSCARINIC RECEPTORS EXPRESSED IN CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; ADENYLATE-CYCLASE; AGONISTS; COMPLEX; SYSTEM; BRAIN	The kinetic mechanism of super high affinity [H-3]oxotremorine M binding to porcine m2 muscarinic receptors expressed in Chinese hamster ovary cells was examined. In cell lines expressing low receptor numbers (10(4) binding sites/cell) and in high expression (10(6) sites/cell) cell lines treated with cholate, [H-3]oxotremorine M association and dissociation kinetics were monophasic. The reciprocal relaxation time for the association reaction was independent of [H-3]oxotremorine M concentration and equaled the dissociation rate constant consistent with a special case for a mechanism involving a protein conformational change followed by ligand binding. Membranes from high expression cell lines and porcine atrial membranes showed complex kinetic behavior. Two kinetic phases were observed for [H-3]oxotremorine M association, and both reciprocal relaxation times were independent of Ligand concentration. The number of kinetic phases and their relative amplitudes seen in dissociation experiments were dependent on whether dissociation was initiated by dilution or by addition of unlabeled ligand(s) as well as on the fractional saturation of the receptor. Computer simulations of the data led to a model consistent with the existence of asymmetric receptor dimers as well as monomers and the ligand-dependent interconversion of fully occupied dimers and monomers.	OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331; OREGON STATE UNIV,CTR ENVIRONM HLTH SCI,CORVALLIS,OR 97331	Oregon State University; Oregon State University								BERNASCONI CF, 1976, RELAXATION KINETICS, P112; Bevington P. R, 1969, DATA REDUCTION ERROR; BIRDSALL NJM, 1980, PROC R SOC SER B-BIO, V207, P1, DOI 10.1098/rspb.1980.0011; BURGEN ASV, 1987, BRIT J PHARMACOL, V92, P327, DOI 10.1111/j.1476-5381.1987.tb11327.x; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; GALPER JB, 1987, MOL PHARMACOL, V32, P230; GILLARD M, 1987, MOL PHARMACOL, V32, P100; HARDEN TK, 1983, J PHARMACOL EXP THER, V277, P570; HERRON SG, 1982, BIOCHEMISTRY-US, V21, P515; HULME EC, 1991, BIOCHEM SOC T, V19, P133, DOI 10.1042/bst0190133; JARV J, 1980, J BIOL CHEM, V255, P2649; JARV J, 1979, J BIOL CHEM, V254, P5595; JARV J, 1988, HDB EXP PHARM, V86, P320; LEE TWT, 1986, BIOCHEMISTRY-US, V25, P7009, DOI 10.1021/bi00370a038; MATTERA R, 1985, J BIOL CHEM, V260, P7410; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PETERSON GL, 1984, PREP BIOCHEM, V14, P33, DOI 10.1080/10826068408070612; POTTER LT, 1991, MOL PHARMACOL, V39, P211; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHIMERLIK MI, 1989, ANNU REV PHYSIOL, V51, P217, DOI 10.1146/annurev.ph.51.030189.001245; SCHIMERLIK MI, 1980, BIOCHEMISTRY-US, V19, P3407, DOI 10.1021/bi00556a001; TOTA MR, 1987, BIOCHEMISTRY-US, V26, P8175, DOI 10.1021/bi00399a023; WONG HMS, 1986, BIOCHEMISTRY-US, V25, P6995, DOI 10.1021/bi00370a037	25	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26127	26135						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929325				2022-12-27	WOS:A1994PQ93000031
J	MENDOZA, JA; HOROWITZ, PM				MENDOZA, JA; HOROWITZ, PM			BOUND SUBSTRATE POLYPEPTIDES CAN GENERALLY STABILIZE THE TETRADECAMERIC STRUCTURE OF CPN6O AND INDUCE ITS REASSEMBLY FROM MONOMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI; MALATE-DEHYDROGENASE; CITRATE SYNTHASE; PROTEIN; CHAPERONIN; GROEL; PURIFICATION; CARBOXYLASE	We demonstrate that the previously observed stabilizing effect by the enzyme rhodanese of the oligomeric structure of Cpn60 is general and can be provided by six other proteins that can interact with Cpn60. All these substrate proteins, which include examples that are monomeric, as well as oligomeric polypeptides in their native states, were shown previously to be assisted in their refolding by the chaperonin. Strikingly, during the disassembly of Cpn60 in the presence of any of the substrate proteins, significant amounts of intermediates were detected. Furthermore, unfolded substrate proteins induce the reassembly of tetradecameric Cpn60 from monomers, and binding of each substrate protein stabilizes Cpn60 quaternary structure.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78240	University of Texas System; University of Texas Health San Antonio					NIGMS NIH HHS [NIGMSE05729, GM25177] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P9195; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GREGORY EM, 1971, J BIOL CHEM, V246, P5491; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; LORIMER GH, 1993, PHILOS T R SOC B, V339, P297, DOI 10.1098/rstb.1993.0028; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1992, J BIOL CHEM, V267, P17631; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; MILLER AD, 1993, BIOCHEM J, V291, P139, DOI 10.1042/bj2910139; Shapiro B., 1970, METHOD ENZYMOL, V17A, P910, DOI 10.1016/0076-6879(71)17305-3; THORNE CJR, 1963, J BIOL CHEM, V238, P1861; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WEST SM, 1990, BIOCHIM BIOPHYS ACTA, V1037, P332, DOI 10.1016/0167-4838(90)90034-D	19	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					25963	25965						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929305				2022-12-27	WOS:A1994PQ93000006
J	RUBBO, H; RADI, R; TRUJILLO, M; TELLERI, R; KALYANARAMAN, B; BARNES, S; KIRK, M; FREEMAN, BA				RUBBO, H; RADI, R; TRUJILLO, M; TELLERI, R; KALYANARAMAN, B; BARNES, S; KIRK, M; FREEMAN, BA			NITRIC-OXIDE REGULATION OF SUPEROXIDE AND PEROXYNITRITE-DEPENDENT LIPID-PEROXIDATION - FORMATION OF NOVEL NITROGEN-CONTAINING OXIDIZED LIPID DERIVATIVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; XANTHINE-OXIDASE; MYOCARDIAL-ISCHEMIA; TRYPANOSOMA-CRUZI; PEROXYL RADICALS; OXIDATION; IRON; REPERFUSION; MACROPHAGES; INJURY	Superoxide (O-2(radical-anion)), nitric oxide ((NO)-N-.), and their reaction product peroxynitrite (ONOO-) have all been shown to independently exert toxic target molecule reactions. Because these reactive species are often generated in excess during diverse inflammatory and other pathologic circumstances, we assessed the influence of (NO)-N-. on membrane lipid peroxidation induced by O-2(radical-anion), H2O2, and (OH)-O-. derived from xanthine oxidase (XO) and by ONOO-. Experimental conditions in lipid oxidation systems were adjusted to yield different rates of delivery of (NO)-N-., relative to rates of O-2(radical-anion) and H2O2 generation, by infusion of either (NO)-N-. or via (NO)-N-. released from S-nitroso-N-acetylpenicillamine or S-nitrosoglutathione. Peroxidation of phosphatidylcholine liposomes was assessed by formation of thiobarbituric acid-reactive products and by liquid chromatography-mass spectrometry. Liposomes exposed to XO derived reactive species in the presence of (NO)-N-. exhibited both stimulation and inhibition of lipid peroxidation, depending on the ratio of the rates of reactive oxygen species production and (NO)-N-. introduction into reaction systems. Nitric oxide alone did not induce lipid peroxidation. Linolenic acid emulsions peroxidized by XO-derived reactive species showed similar dose-dependent regulation of lipid peroxidation by (NO)-N-.. Mass spectral analysis of oxidation products showed formation of nitrito-, nitro-, nitrosoperoxo-, and/or nitrated lipid oxidation adducts, demonstrating that (NO)-N-. serves as a potent terminator of radical chain propagation reactions. Electron spin resonance (ESR) analysis of incubation mixtures provided no evidence for formation of paramagnetic iron-lipid-nitric oxide complexes in reaction systems. Peroxynitrite-dependent lipid peroxidation, which predominantly occurs by metal-independent mechanisms, was also inhibited by (NO)-N-.. Peroxynitrite-mediated benzoate hydroxylation was partially inhibited by (NO)-N-., inferring reaction between (NO)-N-. and ONOOH. It is concluded that (NO)-N-. can both stimulate O-2(radical-anion)/H2O2/(OH)-O-.-induced lipid oxidation and mediate oxidant-protective reactions in membranes at higher rates of (NO)-N-. production, with the prooxidant versus antioxidant outcome critically dependent on relative concentrations of individual reactive species. Prooxidant reactions of (NO)-N-. will occur after O-2(radical-anion) reaction with (NO)-N-. to yield potent secondary oxidants such as ONOO- and the antioxidant effects of (NO)-N-. a consequence of direct reaction with alkoxyl and peroxyl radical intermediates during lipid peroxidation, thus terminating lipid radical chain propagation reactions.	UNIV ALABAMA,DEPT ANESTHESIOL,BIRMINGHAM,AL 35233; UNIV ALABAMA,DEPT MOLEC GENET & BIOCHEM,BIRMINGHAM,AL 35233; UNIV ALABAMA,DEPT PEDIAT,BIRMINGHAM,AL 35233; UNIV ALABAMA,DEPT PHARMACOL,BIRMINGHAM,AL 35233; UNIV ALABAMA,CTR COMPREHENS CANC,MASS SPECTROMETRY SHARED FACIL,BIRMINGHAM,AL 35233; UNIV REPUBLICA,FAC MED,DEPT BIOQUIM,11800 MONTEVIDEO,URUGUAY; MED COLL WISCONSIN,BIOPHYS RES INST,MILWAUKEE,WI 53226	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Universidad de la Republica, Uruguay; Medical College of Wisconsin			Freeman, Bruce A/H-9342-2012	Trujillo, Madia/0000-0003-2087-017X; Rubbo, Homero/0000-0002-7897-6551	NHLBI NIH HHS [R01-HL51245, HL 47250, P01-HL48676] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047250, R01HL051245, P01HL048676] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIKENS J, 1993, ARCH BIOCHEM BIOPHYS, V305, P516, DOI 10.1006/abbi.1993.1455; AIKENS J, 1992, CHEM RES TOXICOL, V5, P263, DOI 10.1021/tx00026a018; BAKER MS, 1984, ARCH BIOCHEM BIOPHYS, V234, P258, DOI 10.1016/0003-9861(84)90348-5; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BRITIGAN BE, 1990, J BIOL CHEM, V265, P17533; CARRERAS MC, 1994, FEBS LETT, V341, P65, DOI 10.1016/0014-5793(94)80241-6; CHOI DW, 1993, P NATL ACAD SCI USA, V90, P9741, DOI 10.1073/pnas.90.21.9741; CLANCY RM, 1992, J CLIN INVEST, V90, P1116, DOI 10.1172/JCI115929; COMMONER B, 1970, CANCER RES, V30; CROW JP, 1994, FREE RADICAL BIO MED, V16, P331, DOI 10.1016/0891-5849(94)90034-5; DEE G, 1991, FEBS LETT, V294, P38, DOI 10.1016/0014-5793(91)81338-9; DENICOLA A, 1993, ARCH BIOCHEM BIOPHYS, V304, P279, DOI 10.1006/abbi.1993.1350; FEELISCH M, 1994, NATURE, V368, P62, DOI 10.1038/368062a0; FIELD L, 1978, J CHEM SOC CHEM COMM, V6, P249; FRIDOVICH I, 1985, HARVEY LECT, V79, P51; FRUEBIS J, 1992, P NATL ACAD SCI USA, V89, P10588, DOI 10.1073/pnas.89.22.10588; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; GRAHAM A, 1993, FEBS LETT, V330, P181, DOI 10.1016/0014-5793(93)80269-Z; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HOGG N, 1993, FEBS LETT, V334, P170, DOI 10.1016/0014-5793(93)81706-6; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; JESSUP W, 1993, ATHEROSCLEROSIS, V101, P145, DOI 10.1016/0021-9150(93)90111-7; Job P, 1928, ANN CHIM FRANCE, V9, P113; KANNER J, 1992, LIPIDS, V27, P46, DOI 10.1007/BF02537058; KANNER J, 1991, ARCH BIOCHEM BIOPHYS, V289, P130, DOI 10.1016/0003-9861(91)90452-O; KAVANAGH BP, 1994, J APPL PHYSIOL, V76, P1324, DOI 10.1152/jappl.1994.76.3.1324; KHARITONOV VG, 1994, J BIOL CHEM, V269, P5881; KING PA, 1992, J AM CHEM SOC, V114, P5430, DOI 10.1021/ja00039a068; KLUG D, 1972, J BIOL CHEM, V247, P4839; KNOWLES RG, 1992, TRENDS BIOCHEM SCI, V17, P399, DOI 10.1016/0968-0004(92)90008-W; KON H, 1968, J BIOL CHEM, V243, P4350; KOOY NW, 1994, ARCH BIOCHEM BIOPHYS, V310, P352, DOI 10.1006/abbi.1994.1178; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KUBES P, 1993, AM J PHYSIOL, V264, pG143, DOI 10.1152/ajpgi.1993.264.1.G143; KUROSE I, 1994, CIRC RES, V74, P376, DOI 10.1161/01.RES.74.3.376; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LEFER DJ, 1993, CIRCULATION, V88, P2337, DOI 10.1161/01.CIR.88.5.2337; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; MALORANTA U, 1994, FEBS LETT, V337, P179, DOI 10.1016/0014-5793(94)80269-6; MATHEIS G, 1992, AM J PHYSIOL, V262, pH616, DOI 10.1152/ajpheart.1992.262.2.H616; MCDONALD CC, 1965, J AM CHEM SOC, V87, P3319, DOI 10.1021/ja01093a007; MINOTTI G, 1992, LIPIDS, V27, P219, DOI 10.1007/BF02536182; MONCADA S, 1991, EUR J CLIN INVEST, V21, P361, DOI 10.1111/j.1365-2362.1991.tb01383.x; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULLIGAN MS, 1991, P NATL ACAD SCI USA, V88, P6338, DOI 10.1073/pnas.88.14.6338; MUNOZFERNANDEZ MA, 1992, EUR J IMMUNOL, V22, P301, DOI 10.1002/eji.1830220203; NAKAZAWA H, 1993, FREE RADICAL BIO MED, V15, P497, DOI 10.1016/0891-5849(93)90284-2; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; PADMAJA S, 1993, BIOCHEM BIOPH RES CO, V195, P539, DOI 10.1006/bbrc.1993.2079; PAYNE D, 1993, AM J PHYSIOL, V265, pG189, DOI 10.1152/ajpgi.1993.265.1.G189; PRYOR WA, 1985, J AM CHEM SOC, V107, P211, DOI 10.1021/ja00287a039; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; RADI R, 1993, BIOCHEM J, V290, P51, DOI 10.1042/bj2900051; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V286, P117, DOI 10.1016/0003-9861(91)90016-C; REIF DW, 1990, ARCH BIOCHEM BIOPHYS, V283, P537, DOI 10.1016/0003-9861(90)90680-W; Ross A.B., 1992, NDRL NIST SOLUTION K; RUBANYI GM, 1991, BIOCHEM BIOPH RES CO, V181, P1392, DOI 10.1016/0006-291X(91)92093-Y; RUBBO H, 1994, ARCH BIOCHEM BIOPHYS, V308, P96, DOI 10.1006/abbi.1994.1014; SCHAICH KM, 1988, LIPIDS, V23, P570, DOI 10.1007/BF02535600; SHERMAN MP, 1991, J PROTOZOOL, V38, pS234; SIEGFRIED MR, 1992, AM J PHYSIOL, V263, pH771, DOI 10.1152/ajpheart.1992.263.3.H771; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; STAMLER JS, 1992, ANAL CHEM, V64, P779, DOI 10.1021/ac00031a014; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; TAMIR S, 1993, CHEM RES TOXICOL, V6, P895, DOI 10.1021/tx00036a021; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; TSAI JHM, 1994, J AM CHEM SOC, V116, P4115, DOI 10.1021/ja00088a072; VOGEL A, 1978, PRACTICAL ORGANIC CH, P417; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; WINK DA, 1993, ARCH BIOCHEM BIOPHYS, V300, P115, DOI 10.1006/abbi.1993.1016; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813; YAMAZAKI I, 1990, J BIOL CHEM, V265, P589; YAO SK, 1992, CIRCULATION, V86, P1302, DOI 10.1161/01.CIR.86.4.1302; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	83	1186	1218	1	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26066	26075						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929318				2022-12-27	WOS:A1994PQ93000023
J	BIERMANN, BJ; MOREHEAD, TA; TATE, SE; PRICE, JR; RANDALL, SK; CROWELL, DN				BIERMANN, BJ; MOREHEAD, TA; TATE, SE; PRICE, JR; RANDALL, SK; CROWELL, DN			NOVEL ISOPRENYLATED PROTEINS IDENTIFIED BY AN EXPRESSION LIBRARY SCREEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING PROTEINS; TERMINAL CYSTEINE; MOLECULAR-CLONING; MEVALONIC ACID; NUCLEAR LAMINS; GAMMA-SUBUNIT; RAS PROTEINS; GENE; KINASE; YEAST	Isoprenylated proteins are involved in eukaryotic cell growth and signal transduction. The protein determinant for prenylation is a short carboxyl-terminal motif containing a cysteine, to which the isoprenoid is covalently attached via thioether linkage. To date, isoprenylated proteins have almost all been identified by demonstrating the attachment of an isoprenoid to previously known proteins. Thus, many isoprenylated proteins probably remain undiscovered. To identify novel isoprenylated proteins for subsequent biochemical study, colony blots of a Glycine max cDNA expression library were [H-3]farnesyl-labeled in vitro. Proteins identified by this screen contained several different carboxyl termini that conform to consensus farnesylation motifs. These proteins included known farnesylated proteins (DnaJ homologs) and several novel proteins, two of which contained six or more tandem repeats of a hexapeptide having the consensus sequence (E/G)(G/ P)EK(P/K)K. Thus, plants contain a diverse array of genes encoding farnesylated proteins, and our results indicate that fundamental differences in the identities of farnesylated proteins may exist between plants and other eukaryotes. Expression library screening by direct labeling can be adapted to identify isoprenylated proteins from other organisms, as well as proteins with other post-translational modifications.	INDIANA UNIV PURDUE UNIV,DEPT BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis				Randall, Stephen/0000-0002-8637-9407				ANANT JS, 1992, J BIOL CHEM, V267, P687; BATTEY NH, 1988, PLANTA, V176, P91, DOI 10.1007/BF00392484; BEDNAREK SY, 1994, PLANT PHYSIOL, V104, P591, DOI 10.1104/pp.104.2.591; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CROWELL DN, 1991, PLANT PHYSIOL, V95, P711, DOI 10.1104/pp.95.3.711; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; FREDERICK SE, 1992, EXP CELL RES, V199, P213, DOI 10.1016/0014-4827(92)90426-9; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUKUI Y, 1985, EMBO J, V4, P687, DOI 10.1002/j.1460-2075.1985.tb03684.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JAMES GL, 1994, J BIOL CHEM, V269, P14182; KEARNS EV, 1993, PLANT PHYSIOL, V102, P711, DOI 10.1104/pp.102.3.711; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MCNULTY AK, 1992, J CELL SCI, V103, P407; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RANDALL SK, 1993, PLANT CELL, V5, P433, DOI 10.1105/tpc.5.4.433; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; STEIN RB, 1984, J VIROL, V50, P343, DOI 10.1128/JVI.50.2.343-351.1984; TEMELES GL, 1985, NATURE, V313, P700, DOI 10.1038/313700a0; TERRYN N, 1993, PLANT MOL BIOL, V22, P143, DOI 10.1007/BF00039002; TONG CG, 1993, PLANT PHYSIOL, V101, P1005, DOI 10.1104/pp.101.3.1005; VORBURGER K, 1989, EMBO J, V8, P4007, DOI 10.1002/j.1460-2075.1989.tb08583.x; WILDMAN DE, 1993, P NATL ACAD SCI USA, V90, P794, DOI 10.1073/pnas.90.3.794; WOLDA SL, 1988, J BIOL CHEM, V263, P5997; YANG ZB, 1993, P NATL ACAD SCI USA, V90, P8732, DOI 10.1073/pnas.90.18.8732; ZHU JK, 1993, P NATL ACAD SCI USA, V90, P8557, DOI 10.1073/pnas.90.18.8557; ZHU JK, 1993, PLANT CELL, V5, P341, DOI 10.1105/tpc.5.3.341	42	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25251	25254						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929216				2022-12-27	WOS:A1994PQ49100005
J	CIRIOLO, MR; CIVITAREALE, P; CARRI, MT; DEMARTINO, A; GALIAZZO, F; ROTILIO, G				CIRIOLO, MR; CIVITAREALE, P; CARRI, MT; DEMARTINO, A; GALIAZZO, F; ROTILIO, G			PURIFICATION AND CHARACTERIZATION OF AG,ZN-SUPEROXIDE DISMUTASE FROM SACCHAROMYCES-CEREVISIAE EXPOSED TO SILVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE-SUPEROXIDE-DISMUTASE; ESCHERICHIA-COLI; METALLOTHIONEIN GENE; TRANSCRIPTION FACTOR; COPPER; YEAST; TOXICITY; OXYGEN; ACE1; ZINC	Cu,Zn-superoxide dismutase plays an important role in protecting cells from oxygen toxicity by catalyzing the dismutation of superoxide anion into hydrogen peroxide and oxygen. In Saccharomyces cerevisiae Cu,Zn-superoxide dismutase is coregulated with copper-thionein by copper via the transcription factor ACE 1. We demonstrate here that presence ofAgNO(3) in the culture medium leads to a five times increase of Cu,Zn-superoxide dismutase mRNA, with a concomitant six times decrease of the enzyme activity. Susceptibility of yeast to silver was apparently inversely related to Cu,Zn-superoxide dismutase activity. From silver-treated yeast a Cu,Zn-superoxide dismutase with impaired dismutase function was purified and was shown to contain silver, which was located to the copper site. These data suggest that Cu,Zn-superoxide dismutase may play an additional direct role in the defense of S. cerevisiae against metal stress by functioning as metal chelator.	UNIV ROMA TOR VERGATA, DEPT BIOL, I-00133 ROME, ITALY	University of Rome Tor Vergata			Ciriolo, Maria Rosa/K-6572-2016; Carri, Maria Teresa/K-5480-2016	Carri, Maria Teresa/0000-0002-1789-1546; Ciriolo, Maria Rosa/0000-0002-7863-9029				ARGESE E, 1983, ANAL BIOCHEM, V132, P110, DOI 10.1016/0003-2697(83)90432-3; AUTOR AP, 1982, J BIOL CHEM, V257, P2713; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BEYER WF, 1991, J BIOL CHEM, V266, P303; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; CARRI MT, 1991, FEBS LETT, V278, P263, DOI 10.1016/0014-5793(91)80131-L; CIVALLERI L, 1982, MOL CELL BIOCHEM, V47, P3; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DJINOVIC K, 1992, J MOL BIOL, V225, P791, DOI 10.1016/0022-2836(92)90401-5; FURST P, 1989, P NATL ACAD SCI USA, V86, P5267, DOI 10.1073/pnas.86.14.5267; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GALIAZZO F, 1988, BIOCHIM BIOPHYS ACTA, V965, P46, DOI 10.1016/0304-4165(88)90149-3; GALIAZZO F, 1991, EUR J BIOCHEM, V196, P545, DOI 10.1111/j.1432-1033.1991.tb15848.x; GHANDOUR W, 1988, APPL MICROBIOL BIOT, V28, P559, DOI 10.1007/BF00250412; GOSCIN SA, 1972, BIOCHIM BIOPHYS ACTA, V289, P276, DOI 10.1016/0005-2744(72)90078-2; GRALLA EB, 1991, P NATL ACAD SCI USA, V88, P8558, DOI 10.1073/pnas.88.19.8558; GRECO MA, 1990, J BACTERIOL, V172, P317, DOI 10.1128/JB.172.1.317-325.1990; HASSAN HM, 1977, J BACTERIOL, V129, P1574, DOI 10.1128/JB.129.3.1574-1583.1977; HASSAN HM, 1978, J BIOL CHEM, V253, P8143; KUMAMARU T, 1982, ANAL BIOCHEM, V126, P214, DOI 10.1016/0003-2697(82)90132-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE F-J, 1985, Journal of Free Radicals in Biology and Medicine, V1, P319, DOI 10.1016/0748-5514(85)90138-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; NIEDERHOFFER EC, 1990, J BACTERIOL, V172, P1930, DOI 10.1128/jb.172.4.1930-1938.1990; ONEILL P, 1988, BIOCHEM J, V251, P41, DOI 10.1042/bj2510041; PRIVALLE CT, 1992, J BIOL CHEM, V267, P9140; Rai L C, 1990, Biol Met, V2, P229, DOI 10.1007/BF01141365; RIGO A, 1975, ANAL BIOCHEM, V68, P1, DOI 10.1016/0003-2697(75)90672-7; RIGO A, 1977, BIOCHEM J, V161, P27, DOI 10.1042/bj1610027; ROE JA, 1990, J AM CHEM SOC, V112, P1538, DOI 10.1021/ja00160a037; ROSS IS, 1977, T BRIT MYCOL SOC, V69, P77, DOI 10.1016/S0007-1536(77)80118-6; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANLOON APGM, 1986, P NATL ACAD SCI USA, V83, P3820; WESTERBEEKMARRES CAM, 1988, EUR J BIOCHEM, V174, P611, DOI 10.1111/j.1432-1033.1988.tb14142.x	36	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25783	25787						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929283				2022-12-27	WOS:A1994PQ49100082
J	MARTINEZ, E; LAGNA, G; ROEDER, RG				MARTINEZ, E; LAGNA, G; ROEDER, RG			OVERLAPPING TRANSCRIPTION BY RNA POLYMERASE-II AND POLYMERASE-III OF THE XENOPUS TFIIIA GENE IN SOMATIC-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5S RNA; EUKARYOTIC TRANSCRIPTION; ALTERED LEVELS; LAEVIS; EXPRESSION; PROMOTER; INITIATOR; OOCYTES; INVITRO; REGION	Xenopus TFIIIA gene expression is developmentally regulated. The per cell level of steady-state TFIIIA mRNA present in oocytes is drastically reduced (10(6)-fold) in adult somatic cells, suggesting regulation at the transcriptional level. This is supported by the presence of TFIIIAmRNAs with different 5'-ends in oocytes and in somatic cells, which suggests the presence of distinct cell-/stage-specific promoters, i.e. a strong oocyte-specific and a weak somatic-specific promoter. Here, by mapping the 5'-ends of TFIIIA RNAs found in Xenopus somatic cells, we document the activity not only of an upstream somatic-specific promoter, but also of a downstream ''oocyte-specific'' promoter that gives rise to a minor population of somatic TFIIIA mRNAs initiated from the same transcription start site utilized in oocytes. This result explains the presence of an oocyte-type form of TFIIIA protein in somatic cells. Furthermore, by characterizing transcription from the Xenopus TFIIIA promoter in somatic cell nuclear extracts and comparing the in vitro transcription start sites with the 5'-ends of endogenous somatic TFIIIA transcripts in poly(A)(+) and poly(A)(-) RNA fractions, we show that RNA polymerase III initiates at position -70 of the ''oocyte-specific'' core promoter and transcribes through the promoter and into the TFIIIA coding sequences in somatic cells. These results suggest a possible polymerase III transcription-mediated down-regulation of the oocyte-specific TFIIIA promoter in Xenopus somatic cells.	ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021	Rockefeller University					NCI NIH HHS [CA 42567] Funding Source: Medline; NIAID NIH HHS [AI 27397] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027397] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHEN HJ, 1992, J BIOL CHEM, V267, P25457; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORTHESY B, 1989, MOL CELL BIOL, V9, P5548, DOI 10.1128/MCB.9.12.5548; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GINSBERG AM, 1984, CELL, V39, P479, DOI 10.1016/0092-8674(84)90455-0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALL RK, 1989, MOL CELL BIOL, V9, P5003, DOI 10.1128/MCB.9.11.5003; HANAS JS, 1990, NUCLEIC ACIDS RES, V18, P2923, DOI 10.1093/nar/18.10.2923; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HONDA BM, 1980, CELL, V22, P119, DOI 10.1016/0092-8674(80)90160-9; HUANG WL, 1994, P NATL ACAD SCI USA, V91, P1265, DOI 10.1073/pnas.91.4.1265; HULL MW, 1994, MOL CELL BIOL, V14, P1266, DOI 10.1128/MCB.14.2.1266; KAULEN H, 1991, MOL CELL BIOL, V11, P412, DOI 10.1128/MCB.11.1.412; KIM SH, 1990, GENE DEV, V4, P1602, DOI 10.1101/gad.4.9.1602; MATSUMOTO Y, 1988, NUCLEIC ACIDS RES, V16, P3801, DOI 10.1093/nar/16.9.3801; MATTAJ IW, 1988, CELL, V55, P435, DOI 10.1016/0092-8674(88)90029-3; Maxam A M, 1980, Methods Enzymol, V65, P499; MCKINNON RD, 1986, P NATL ACAD SCI USA, V83, P3751, DOI 10.1073/pnas.83.11.3751; MITCHELL MT, 1992, J BIOL CHEM, V267, P1995; PELHAM HRB, 1981, P NATL ACAD SCI-BIOL, V78, P1760, DOI 10.1073/pnas.78.3.1760; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PRUZAN R, 1992, NUCLEIC ACIDS RES, V20, P5705, DOI 10.1093/nar/20.21.5705; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCOTTO KW, 1989, GENE DEV, V3, P651, DOI 10.1101/gad.3.5.651; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHASTRY BS, 1984, J BIOL CHEM, V259, P1373; SISODIA SS, 1987, MOL CELL BIOL, V7, P3602, DOI 10.1128/MCB.7.10.3602; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STEINBERG TH, 1990, J BIOL CHEM, V265, P499; SUSSMAN DJ, 1991, NUCLEIC ACIDS RES, V19, P5045, DOI 10.1093/nar/19.18.5045; SUTCLIFFE JG, 1984, NATURE, V308, P237, DOI 10.1038/308237a0; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; TAYLOR W, 1986, NUCLEIC ACIDS RES, V14, P6185, DOI 10.1093/nar/14.15.6185; TSO JY, 1986, NUCLEIC ACIDS RES, V14, P2187, DOI 10.1093/nar/14.5.2187; WITTEK R, 1984, J VIROL, V49, P371, DOI 10.1128/JVI.49.2.371-378.1984	39	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25692	25698						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929274				2022-12-27	WOS:A1994PQ49100070
J	NYKJAER, A; KJOLLER, L; COHEN, RL; LAWRENCE, DA; GARNIWAGNER, BA; TODD, RF; VANZONNEVELD, AJ; GLIEMANN, J; ANDREASEN, PA				NYKJAER, A; KJOLLER, L; COHEN, RL; LAWRENCE, DA; GARNIWAGNER, BA; TODD, RF; VANZONNEVELD, AJ; GLIEMANN, J; ANDREASEN, PA			REGIONS INVOLVED IN BINDING OF UROKINASE-TYPE-1 INHIBITOR COMPLEX AND PROUROKINASE TO THE ENDOCYTIC ALPHA(2)-MACROGLOBULIN RECEPTOR LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN - EVIDENCE THAT THE UROKINASE RECEPTOR PROTECTS PROUROKINASE AGAINST BINDING TO THE ENDOCYTIC RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; TISSUE-TYPE; ALPHA-2-MACROGLOBULIN RECEPTOR; HEPATIC RECEPTOR; BOUND UROKINASE; SARCOMA-CELLS; DEGRADATION; INTERNALIZATION; LOCALIZATION; DOMAIN	The alpha(2)-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha(2)MR/LRP) binds several ligands, including complex between the two chain urokinase-type plasminogen activator (uPA) and type-1 plasminogen activator inhibitor (PAI-1), and the single chain zymogen pro-urokinase (pro-uPA). We have used truncated variants of uPA and PAI-1 as well as Fab fragments of monoclonal antibodies with known epitopes to identify regions in the uPA PAI-1 complex and in pro-uPA involved in binding to alpha(2)MR/LRP. uPA PAI-1 complex bound with high affinity (EC(50) about 0.4 nM) via contacts in the PAI-1 moiety as well as the uPA serine proteinase domain and the uPAA chain. Pro-uPA bound with lower affinity (EC(50) about 10 nM), and efficient binding to alpha(2)MR/LRP was dependent on contact with both the A chain and the serine proteinase domain. We analyzed the effect of complex formation with the urokinase receptor since this is the primary target for binding of uPA.PAI-1 and pro-uPA at the cell surface, and since it has been demonstrated that urokinase receptor-bound uPA PAI-1 complex is internalized following interaction with alpha(2)MR/LRP (Nykjaer, A., Petersen, C. M., Moller, B., Jensen, P. H., Moestrup, S. K., Holtet, T. L., Etzerodt, M., Thogersen, H. C., Munch, M., Andreasen, P. A., and Gliemann, J. (1992) J. Biol. Chem. 267, 14543-14546). Soluble recombinant urokinase receptor blocked the binding of pro-uPA to alpha(2)MR/LRP but caused only a slight reduction in the affinity for binding of uPA PAI-1. Moreover, pro-uPA bound to the urokinase receptor at the cell surface was not internalized and degraded unless activated to uPA and complexed with PAI-1. We conclude that pro-uPA is protected against degradation via alpha(2)MR/LRP when bound to uPAR due to shielding of a binding contact in the A chain, whereas the affinity of uPAR-bound uPA PAI-1 complex for binding to alpha(2)MR/LRP remains sufficient to allow rapid internalization and degradation.	AARHUS UNIV, DEPT BIOL MOLEC, DK-8000 AARHUS C, DENMARK; UNIV CALIF SAN FRANCISCO, CANC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV AMSTERDAM, DEPT BIOCHEM, 1105 AZ AMSTERDAM, NETHERLANDS	Aarhus University; University of California System; University of California San Francisco; University of Michigan System; University of Michigan; University of Amsterdam	NYKJAER, A (corresponding author), AARHUS UNIV, DEPT BIOCHEM MED, OLE WORMS ALLE, BLDG 170, DK-8000 AARHUS C, DENMARK.		van Zonneveld, Anton Jan/D-8060-2018; Todd, Robert/GWM-4486-2022	van Zonneveld, Anton Jan/0000-0002-1676-7738; Nykjaer, Anders/0000-0001-6422-6736				ANDREASEN PA, 1986, J BIOL CHEM, V261, P7644; ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; BACKMAN L, 1985, PARTITIONING AQUEOUS, P267; BASSELDUBY R, 1992, J BIOL CHEM, V267, P9668; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BIANCHI E, 1994, CANCER RES, V54, P861; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CAMANI C, 1994, J BIOL CHEM, V269, P5770; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; FAZIOLI F, 1994, TRENDS PHARMACOL SCI, V15, P25, DOI 10.1016/0165-6147(94)90130-9; GLIEMANN J, 1994, ANN NY ACAD SCI, V737, P20, DOI 10.1111/j.1749-6632.1994.tb44299.x; GLIEMANN J, 1986, BIOCHIM BIOPHYS ACTA, V885, P49, DOI 10.1016/0167-4889(86)90037-6; GROBMYER SR, 1993, J BIOL CHEM, V268, P13291; GRONDAHLHANSEN J, 1987, J INVEST DERMATOL, V88, P28, DOI 10.1111/1523-1747.ep12464827; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; JOHNSTONE A, 1987, IMMUNOCHEMISTRY PRAC, P58; KEIJER J, 1991, BLOOD, V78, P401; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MIN HY, 1992, J IMMUNOL, V148, P3636; MIZUKAMI IF, 1994, CLIN IMMUNOL IMMUNOP, V71, P96, DOI 10.1006/clin.1994.1057; MOESTRUP SK, 1993, J BIOL CHEM, V268, P16564; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MUNCH M, 1993, BIOCHIM BIOPHYS ACTA, V1202, P29, DOI 10.1016/0167-4838(93)90059-Z; MUNCH M, 1991, FEBS LETT, V281, P181; NYKJAER A, 1994, J IMMUNOL, V152, P505; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; NYKJAER A, 1994, ANN NY ACAD SCI, V737, P483, DOI 10.1111/j.1749-6632.1994.tb44346.x; NYKJAER A, 1992, FEBS LETT, V300, P13, DOI 10.1016/0014-5793(92)80154-9; NYKJAER A, 1990, BIOCHIM BIOPHYS ACTA, V1052, P399, DOI 10.1016/0167-4889(90)90149-8; OLSON D, 1992, J BIOL CHEM, V267, P9129; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; POLLANEN J, 1987, J CELL BIOL, V104, P1085, DOI 10.1083/jcb.104.4.1085; POLLANEN J, 1991, ADV CANCER RES, V57, P273; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; STEPHENS RW, 1992, BIOCHEMISTRY-US, V31, P7572, DOI 10.1021/bi00148a019; TODD RF, 1994, IN PRESS LEUKOCYTE T, V5; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405	46	135	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25668	25676						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929271				2022-12-27	WOS:A1994PQ49100067
J	WETMUR, JG; WONG, DM; ORTIZ, B; TONG, J; REICHERT, F; GELFAND, DH				WETMUR, JG; WONG, DM; ORTIZ, B; TONG, J; REICHERT, F; GELFAND, DH			CLONING, SEQUENCING, AND EXPRESSION OF RECA PROTEINS FROM 3 DISTANTLY RELATED THERMOPHILIC EUBACTERIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; DNA STRAND EXCHANGE; ESCHERICHIA-COLI; 3-STRANDED DNA; ENZYMATIC AMPLIFICATION; THERMUS-AQUATICUS; DUPLEX DNA; POLYMERASE; STABILITY; THERMOSTABILITY	Sequences of the recA genes of the highly divergent thermophilic eubacteria Thermus aquaticus (and Thermus thermophilus), Thermotoga maritima, and Aquifex pyrophilus were determined from fragments derived by polymerase chain reaction (PCR) with degenerate primers and from inverse PCR products obtained using unique primers based on the fragment sequences. The source of the PCR products was verified by Southern hybridization. Complete PCR-derived recA genes were cloned into an expression vector regulated by a temperature-sensitive lambda-repressor, and independently derived clones expressing thermostable RecA were selected. DNA sequences were verified to be authentic by direct cycle-sequencing of PCR products and/or sequencing of several clones. In contrast to Escherichia coli RecA protein, all the purified thermophilic RecA proteins exhibited single-stranded DNA-dependent ATPase activity optima above 70 degrees C. Phylogenetic analysis of RecA sequences suggested that the thermophilic RecA proteins were at least as different from one another as were Gram-positive organisms, mesophilic Gram-negative organisms, and cyanobacteria. In spite of substantial sequence divergence, interesting characteristics of the thermostable RecA proteins included increased valine content, common amino acid replacements at two highly conserved sites, and an increase in the calculated isoelectric point of approximately a full pH unit.	ROCHE MOLEC SYST INC,PROGRAM CORE RES,ALAMEDA,CA 94501		WETMUR, JG (corresponding author), CUNY MT SINAI SCH MED,DEPT MICROBIOL,BOX 1124,NEW YORK,NY 10029, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000446] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR00071] Funding Source: Medline; NHGRI NIH HHS [R01 HG00446] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BENSON D, 1993, NUCLEIC ACIDS RES, V21, P2963, DOI 10.1093/nar/21.13.2963; BURGGRAF S, 1992, SYST APPL MICROBIOL, V15, P352, DOI 10.1016/S0723-2020(11)80207-9; CAMERINIOTERO RD, 1993, CELL, V73, P217, DOI 10.1016/0092-8674(93)90224-E; CERUTTI H, 1992, P NATL ACAD SCI USA, V89, P8068, DOI 10.1073/pnas.89.17.8068; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUWAT P, 1992, J BACTERIOL, V174, P5171, DOI 10.1128/JB.174.15.5171-5175.1992; DYBVIG K, 1992, J BACTERIOL, V174, P2729, DOI 10.1128/jb.174.8.2729-2732.1992; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FERRIN LJ, 1991, SCIENCE, V254, P1494, DOI 10.1126/science.1962209; GOLUB EI, 1992, NUCLEIC ACIDS RES, V20, P3121, DOI 10.1093/nar/20.12.3121; HONIGBERG SM, 1986, P NATL ACAD SCI USA, V83, P9586, DOI 10.1073/pnas.83.24.9586; HSIEH P, 1990, GENE DEV, V4, P1951, DOI 10.1101/gad.4.11.1951; HSIEH P, 1992, P NATL ACAD SCI USA, V89, P6492, DOI 10.1073/pnas.89.14.6492; JAIN SK, 1992, J BIOL CHEM, V267, P4215; JWANG BR, 1992, P NATL ACAD SCI USA, V89, P7596, DOI 10.1073/pnas.89.16.7596; KANDPAL RP, 1992, METHOD ENZYMOL, V216, P39; KATO R, 1993, J BIOCHEM-TOKYO, V114, P926, DOI 10.1093/oxfordjournals.jbchem.a124278; KELLY CA, 1993, BIOCHEMISTRY-US, V32, P3913, DOI 10.1021/bi00066a010; KIDO M, 1992, EXP CELL RES, V198, P107, DOI 10.1016/0014-4827(92)90155-2; KOOB M, 1992, NUCLEIC ACIDS RES, V20, P5831, DOI 10.1093/nar/20.21.5831; Lawyer F C, 1993, PCR Methods Appl, V2, P275; LAWYER FC, 1989, J BIOL CHEM, V264, P6427; LEBEL D, 1978, ANAL BIOCHEM, V85, P86, DOI 10.1016/0003-2697(78)90277-4; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; MENENDEZARIAS L, 1989, J MOL BIOL, V206, P397, DOI 10.1016/0022-2836(89)90488-9; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PERUTZ MF, 1975, NATURE, V255, P256, DOI 10.1038/255256a0; RADDING CM, 1991, J BIOL CHEM, V266, P5355; RAO BJ, 1991, P NATL ACAD SCI USA, V88, P2984, DOI 10.1073/pnas.88.8.2984; RIGAS B, 1986, P NATL ACAD SCI USA, V83, P9591, DOI 10.1073/pnas.83.24.9591; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; STORY RM, 1993, SCIENCE, V259, P1892, DOI 10.1126/science.8456313; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TAIDILASKOWSKI B, 1988, NUCLEIC ACIDS RES, V16, P8157, DOI 10.1093/nar/16.16.8157; WOZNIAK JA, 1990, CRYSTALLOGRAPHIC MOD, P80; ZUBER H, 1988, BIOPHYS CHEM, V29, P171, DOI 10.1016/0301-4622(88)87037-6; ZULLI F, 1991, BIOL CHEM H-S, V372, P363, DOI 10.1515/bchm3.1991.372.1.363	40	30	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25928	25935						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929298				2022-12-27	WOS:A1994PQ49100101
J	AHMED, M; BORSCH, CM; TAYLOR, SS; VAZQUEZLASLOP, N; NEYFAKH, AA				AHMED, M; BORSCH, CM; TAYLOR, SS; VAZQUEZLASLOP, N; NEYFAKH, AA			A PROTEIN THAT ACTIVATES EXPRESSION OF A MULTIDRUG EFFLUX TRANSPORTER UPON BINDING THE TRANSPORTER SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; BACILLUS-SUBTILIS; P-GLYCOPROTEIN; DISINFECTANT RESISTANCE; PSEUDOMONAS-AERUGINOSA; ESCHERICHIA-COLI; GENE; INVOLVEMENT; SENSITIVITY; SPECIFICITY	Multidrug transporters are membrane proteins which, by an unknown mechanism, recognize diverse toxic compounds and efflux them from cells. We found that two substrates of the Bacillus subtilis multidrug transporter Bmr, rhodamine 6G and tetraphenylphosphonium (TPP), enhance Bmr expression at the level of transcription. Gene knock-out experiments demonstrated that an open reading frame located immediately downstream of the bmr gene is required for this enhancement. The protein product of this open reading frame, BmrR, shows distinct sequence homology to several known bacterial transcription activator proteins, such as MerR and TipA(L). Gel-mobility shift and DNase protection assays indicated that BmrR binds specifically, as a dimer, to the bmr gene promoter. Furthermore, the affinity of this binding was enhanced by rhodamine and TPP, thus suggesting that these structurally dissimilar molecules interact directly with BmrR. Indeed, we found that BmrR bound rhodamine 6G stoichiometrically, one rhodamine molecule/BmrR dimer, and that TPP competed with rhodamine for this binding. Our results indicate that the enhancement of Bmr expression by some of its substrates is due to the ability of the regulatory protein, BmrR, to bind structurally dissimilar compounds resulting in enhanced transcription of the transporter gene.	UNIV ILLINOIS, DEPT MED CHEM & PHARMACOGNOSY MC781, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049819] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM49819] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM I, 1987, MOL CELL BIOL, V7, P3098, DOI 10.1128/MCB.7.9.3098; AHMED M, 1993, J BIOL CHEM, V268, P11086; AMABILECUEVAS CF, 1991, NUCLEIC ACIDS RES, V19, P4479, DOI 10.1093/nar/19.16.4479; AUSUBEL FM, 1989, SHORT PROTOCOLS MOL, P147; BECK WT, 1992, BIOCHEM PHARMACOL, V43, P89, DOI 10.1016/0006-2952(92)90665-6; CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; DHIR R, 1993, BIOCHEMISTRY-US, V32, P9492, DOI 10.1021/bi00087a030; GEKELER V, 1988, BIOCHEM BIOPH RES CO, V155, P754, DOI 10.1016/S0006-291X(88)80559-X; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRINIUS L, 1992, PLASMID, V27, P119, DOI 10.1016/0147-619X(92)90012-Y; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HELMANN JD, 1990, SCIENCE, V247, P946, DOI 10.1126/science.2305262; HELMANN JD, 1989, J BACTERIOL, V171, P222, DOI 10.1128/jb.171.1.222-229.1989; HILLEN W, 1983, J MOL BIOL, V169, P707, DOI 10.1016/S0022-2836(83)80166-1; HINRICHS W, 1994, SCIENCE, V264, P418, DOI 10.1126/science.8153629; HOLMES DJ, 1993, EMBO J, V12, P3183, DOI 10.1002/j.1460-2075.1993.tb05987.x; KATO S, 1992, FEBS LETT, V308, P175, DOI 10.1016/0014-5793(92)81269-R; LITTLEJOHN TG, 1991, GENE, V101, P59, DOI 10.1016/0378-1119(91)90224-Y; LOMOVSKAYA O, 1992, P NATL ACAD SCI USA, V89, P8938, DOI 10.1073/pnas.89.19.8938; NEYFAKH AA, 1992, ANTIMICROB AGENTS CH, V36, P484, DOI 10.1128/AAC.36.2.484; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; NEYFAKH AA, 1993, ANTIMICROB AGENTS CH, V37, P128, DOI 10.1128/AAC.37.1.128; OHNISHI ST, 1978, ANAL BIOCHEM, V86, P193, DOI 10.1016/0003-2697(78)90334-2; POOLE K, 1993, J BACTERIOL, V175, P7363, DOI 10.1128/JB.175.22.7363-7372.1993; POOLE K, 1993, MOL MICROBIOL, V10, P529, DOI 10.1111/j.1365-2958.1993.tb00925.x; REINARD T, 1989, ANAL BIOCHEM, V176, P157, DOI 10.1016/0003-2697(89)90286-8; SADOWSKY MJ, 1991, P NATL ACAD SCI USA, V88, P637, DOI 10.1073/pnas.88.2.637; Sambrook J, 1989, MOL CLONING LABORATO; SUMMERS AO, 1992, J BACTERIOL, V174, P3097, DOI 10.1128/jb.174.10.3097-3101.1992; TENNENT JM, 1989, J GEN MICROBIOL, V135, P1; WU J, 1991, J BACTERIOL, V173, P2864, DOI 10.1128/JB.173.9.2864-2871.1991	33	169	183	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28506	28513						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961792				2022-12-27	WOS:A1994PV77200107
J	HE, DY; YU, L; YU, CA				HE, DY; YU, L; YU, CA			PROTEIN UBIQUINONE INTERACTION - SYNTHESIS AND BIOLOGICAL PROPERTIES OF 5-ALKYL UBIQUINONE DERIVATIVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-REDUCTASE; ELECTRON-TRANSFER; SUCCINATE-UBIQUINONE; LATERAL DIFFUSION; BINDING PROTEINS; TRANSPORT; COMPLEX; COLLISION; KINETICS; MODEL	For the investigation of the protein-ubiquinone interaction in the succinate-cytochrome c reductase region of the bovine heart mitochondrial electron transport chain, a series of 5-alkyl-substituted ubiquinone derivatives (5-R-Q(0)C(10)) were synthesized and characterized. Syntheses of 5-ethyl-Q(0)C(10), 5-propyl-Q(0)C(10), 5-isopropyl-Q(0)C(10), and 5-butyl-Q(0)C(10), were archived through radical coupling reactions between 2,3-dimethoxy-6-decyl-1,4-benzoquinone (5-H-Q(0)C(10)) and the corresponding alkanoyl peroxides. Although the spectral and redox properties of 5-R-Q(0)C(10) are very similar to those of 5-methyl-2,3 dimethoxy-6-decyl-1,4-benzoquinone, the biological electron transfer efficiencies of these derivatives differ significantly. The reducibility of these derivatives by succinate, as measured with succinate-Q reductase and the oxidizability as measured by ubiquinol-cytochrome c reductase, decreased as the size of the substituents increased. 5-Ethyl-Q(0)C(10) has about 50% of the activity of 5-methyl-2,3-dimethoxy-6-decyl-1,4-benzoquinone, whereas molecules with 5-alkyl groups of three or more carbon atoms are virtually inactive as electron accepters for succinate-and reductase. Reduced form of the derivative with no substitutent at the 5-position, 5-H derivative is more effectively oxidized by ubiquinol-cytochrome c reductase than does the 5-methyl derivative, the native form. The oxidation of 5-H derivative is in a concentration-dependent manner at low concentrations but exhibits a substrate inhibition at higher concentrations. No such substrate inhibition is observed when other 5-substituted Q derivatives are used. 5-H derivative is a better electron acceptor for succinate-and reductase than any other and derivatives and does not show substrate inhibition, even at high concentrations. These results indicate that the binding environment of the benzoquinone ring in succinate-Q reductase is more specific than that of ubiquinol-cytochrome c reductase.			HE, DY (corresponding author), OKLAHOMA STATE UNIV,DEPT BIOCHEM,STILLWATER,OK 74078, USA.				NIGMS NIH HHS [GM 30721] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030721, R37GM030721] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CRANE FL, 1977, ANNU REV BIOCHEM, V46, P439, DOI 10.1146/annurev.bi.46.070177.002255; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; ERNSTER L, 1969, EUR J BIOCHEM, V9, P299, DOI 10.1111/j.1432-1033.1969.tb00609.x; FATO R, 1986, BIOCHEMISTRY-US, V25, P3378, DOI 10.1021/bi00359a043; GREEN DE, 1960, QUINONES ELECTRON TR, P130; GU LQ, 1990, BIOCHIM BIOPHYS ACTA, V1015, P482, DOI 10.1016/0005-2728(90)90082-F; GUPTE S, 1984, P NATL ACAD SCI-BIOL, V81, P2606, DOI 10.1073/pnas.81.9.2606; GUTMAN M, 1985, COENZYME, P216; HACKENBROCK CR, 1986, J BIOENERG BIOMEMBR, V18, P331, DOI 10.1007/BF00743010; HE DY, 1994, BIOCHEMISTRY-US, V33, P880, DOI 10.1021/bi00170a005; KROGER A, 1973, EUR J BIOCHEM, V34, P358, DOI 10.1111/j.1432-1033.1973.tb02767.x; LENAZ G, 1986, J BIOENERG BIOMEMBR, V18, P369, DOI 10.1007/BF00743011; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; RAGAN CI, 1985, BIOCHIM BIOPHYS ACTA, V811, P13; SUZUKI H, 1986, BIOCHEM BIOPH RES CO, V138, P1237, DOI 10.1016/S0006-291X(86)80415-6; SUZUKI H, 1982, J BIOL CHEM, V257, P258; TAN AK, 1993, J BIOL CHEM, V268, P19328; UYU L, 1980, BIOCHEMISTRY-US, V19, P5717; YU C, 1980, BIOCHIM BIOPHYS ACTA, V591, P409, DOI 10.1016/0005-2728(80)90172-3; YU CA, 1981, BIOCHIM BIOPHYS ACTA, V639, P99, DOI 10.1016/0304-4173(81)90007-0; YU CA, 1980, BIOCHEMISTRY-US, V19, P3579, DOI 10.1021/bi00556a025; YU CA, 1985, BIOCHEMISTRY-US, V24, P3897, DOI 10.1021/bi00336a013; YU CA, 1982, BIOCHEMISTRY-US, V21, P4096, DOI 10.1021/bi00260a028; YU L, 1985, J BIOL CHEM, V260, P963; YU L, 1978, J BIOL CHEM, V253, P2657; YU L, 1982, J BIOL CHEM, V257, P2016; YU L, 1987, J BIOL CHEM, V262, P1137	27	9	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27885	27888						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961719				2022-12-27	WOS:A1994PV77200020
J	NARITA, M; GOJI, J; NAKAMURA, H; SANO, K				NARITA, M; GOJI, J; NAKAMURA, H; SANO, K			MOLECULAR-CLONING, EXPRESSION, AND LOCALIZATION OF A BRAIN-SPECIFIC PHOSPHODIESTERASE I/NUCLEOTIDE PYROPHOSPHATASE (PD-I-ALPHA) FROM RAT-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL MEMBRANE GLYCOPROTEIN; AMINO-ACID-SEQUENCE; INTESTINAL 5'-NUCLEOTIDE PHOSPHODIESTERASE; ANTIGEN PC-1; NUCLEOTIDE PYROPHOSPHATASE; CHOROID-PLEXUS; ACTIVE-SITE; ECTO-ATPASE; PLASMA; CDNA	We have isolated cDNA clones encoding the rat brain phosphodiesterase I/nucleotide pyrophosphatase (PD-I alpha), a novel member of the membrane phosphodiesterase I gene family. PD-I alpha cDNA has a 2,655-nucleotide open reading frame encoding a polypeptide of 885 amino acids with a calculated M(r) of 101,302. Northern blot analysis revealed that PD-I alpha transcript was abundantly present in cerebrum and cerebellum while its level was quite low in other tissues. In situ hybridization analysis revealed that PD-I alpha mRNA is localized in secretory epithelial cells in the brain and the eye including choroid plexus epithelial cells, ciliary epithelial cells, iris pigment epithelial cells, and retinal pigment cells. Localization of PD-I alpha mRNA was also observed in glial cells in the molecular layer of the cerebellum. These results indicate that this protein might be involved in the synthesis of adenosine as well as in the regulation of the secretion/transport of epithelial cells and glial cells in the central nervous system.	KOBE UNIV,SCH MED,DEPT PEDIAT,CHUO KU,KOBE 650,JAPAN	Kobe University								BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BRIVANLOU AH, 1989, DEVELOPMENT, V106, P611; BUCKLEY MF, 1990, J BIOL CHEM, V265, P17506; CULP JS, 1985, J BIOL CHEM, V260, P8320; FARACI FM, 1988, AM J PHYSIOL, V254, pH286, DOI 10.1152/ajpheart.1988.254.2.H286; GODING JW, 1982, J IMMUNOL, V129, P2636; HARAHAP AR, 1988, J IMMUNOL, V141, P2317; KELLY SJ, 1975, BIOCHEMISTRY-US, V14, P4983, DOI 10.1021/bi00693a030; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIN SH, 1989, J BIOL CHEM, V264, P14408; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOTOIKE T, 1993, NEUROSCI LETT, V156, P87, DOI 10.1016/0304-3940(93)90446-R; ODA Y, 1991, J BIOL CHEM, V266, P16791; PATTHY L, 1988, J MOL BIOL, V202, P689, DOI 10.1016/0022-2836(88)90550-5; PONTEN J, 1968, ACTA PATHOL MIC SC, V74, P465; REBBE NF, 1991, P NATL ACAD SCI USA, V88, P5192, DOI 10.1073/pnas.88.12.5192; REBBE NF, 1993, MOL IMMUNOL, V30, P87, DOI 10.1016/0161-5890(93)90429-F; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; SKINNER MA, 1991, NUCLEIC ACIDS RES, V19, P6049, DOI 10.1093/nar/19.21.6049; SPECTOR R, 1989, SCI AM, V261, P68, DOI 10.1038/scientificamerican1189-68; SPECTOR R, 1984, J NEUROCHEM, V42, P1048, DOI 10.1111/j.1471-4159.1984.tb12709.x; STEARNE PA, 1985, J IMMUNOL, V134, P443; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; TAKAHASHI T, 1970, J EXP MED, V131, P1325, DOI 10.1084/jem.131.6.1325; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; TOUSTER O, 1970, J CELL BIOL, V47, P604, DOI 10.1083/jcb.47.3.604; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VANDRIEL IR, 1985, P NATL ACAD SCI USA, V82, P8619, DOI 10.1073/pnas.82.24.8619; VANDRIEL IR, 1987, J BIOL CHEM, V262, P4882	32	85	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28235	28242						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961762				2022-12-27	WOS:A1994PV77200070
J	ZHOU, GC; DENU, JM; WU, L; DIXON, JE				ZHOU, GC; DENU, JM; WU, L; DIXON, JE			THE CATALYTIC ROLE OF CYS(124) IN THE DUAL-SPECIFICITY PHOSPHATASE VHR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; IMMEDIATE-EARLY GENE; VACCINIA VIRUS; MAP KINASE; INTERMEDIATE; ACTIVATION; EXPRESSION; CYSTEINE; ENCODES; CLONING	The recombinant human Vaccinia virus H1-related protein tyrosine phosphatase, (VHR PTPase) possesses intrinsic Tyr and Thr/Ser phosphatase activities. Both activities were abolished by a single amino acid substitution, C124S. When VHR was incubated with a P-32-labeled phosphotyrosine-containing substrate and then rapidly denatured, enzyme-associated P-32 was evident following SDS-polyacrylamide gel electrophoresis. The formation of P-32-labeled protein could be blocked in the presence of an unlabeled substrate. VHR-associated P-32 was sensitive to iodine but insensitive to pyridine and hydroxylamine. The catalytically inactive C124S mutant would not form a P-32-labeled enzyme. Furthermore, VBR phosphatase could be selectively inactivated by the alkylating agent iodoacetate. The inactivation resulted from the specific covalent modification of Cys(124). Collectively these results suggest that a thiol-phosphate enzyme intermediate is formed when Cys(124) of VHR accepts a phosphate from the substrate. Our results also demonstrate that the dual specificity phosphatases and the tyrosine-specific PTPases employ similar catalytic mechanisms.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; WALTHER CANC INST,INDIANAPOLIS,IN 46208	University of Michigan System; University of Michigan; Walther Cancer Institute					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018024, R01DK018849, T32DK007245, R01DK018024] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07245-17, NIDDKD 18024, NIDDKD 18849] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERFELDT S, 1960, ACTA CHEM SCAND, V14, P1980, DOI 10.3891/acta.chem.scand.14-1980; ALESSI DR, 1993, ONCOGENE, V8, P2015; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; Cleland W W, 1979, Methods Enzymol, V63, P103; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FISHER EH, 1991, SCIENCE, V253, P401; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GUAN K, 1992, P NATL ACAD SCI USA, V89, P12175, DOI 10.1073/pnas.89.24.12175; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUAN KL, 1991, J BIOL CHEM, V266, P17026; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; HIPPEN KL, 1993, BIOCHEMISTRY-US, V32, P12405, DOI 10.1021/bi00097a019; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; HUNTER T, 1989, ONCOGENES MOL ORIGIN, P149; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; POT DA, 1992, J BIOL CHEM, V267, P140; POT DA, 1991, J BIOL CHEM, V266, P19688; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	30	115	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28084	28090						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961745				2022-12-27	WOS:A1994PV77200049
J	ESNAULT, Y; FELDHEIM, D; BLONDEL, MO; SCHEKMAN, R; KEPES, F				ESNAULT, Y; FELDHEIM, D; BLONDEL, MO; SCHEKMAN, R; KEPES, F			SSS1 ENCODES A STABILIZING COMPONENT OF THE SEC61 SUBCOMPLEX OF THE YEAST PROTEIN TRANSLOCATION APPARATUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; POLYPEPTIDE TRANSLOCATION; SECRETORY PROTEINS; INSERTION; RIBOSOMES; PEPTIDES; MUTANTS; HOMOLOG; IMPORT; INVIVO	The yeast SSS1 gene has been isolated as an extragenic high copy suppressor of sec61, a mutant displaying defects in protein translocation into the endoplasmic reticulum (ER). We found that SSS1 is an essential gene required for transfer of secretory precursors through the ER membrane. Here we demonstrate that the SSS1 product (Sss1p) is firmly bound to the ER membrane and exposes its amino-terminal half on the cytosolic side. Only detergent, or an alkali treatment, is effective at extracting Sss1p from the membrane. Coimmunoprecipitation experiments revealed that Sss1p and Sec61p participate in the same multisubunit complex. Cross-linking followed by immunoprecipitation specifically yielded an additional polypeptide of molecular mass 73 kDa. Moreover, Sss1p and Sec61p show mutually stabilizing interactions: Sss1p is destabilized in a sec61 mutant context, and mutated Sec61p is stabilized by Sss1p overproduction. These observations account for the isolation of SSS1 as a dosage-dependent suppressor of sec61. Since the polytopic integral membrane protein Sec61p is adjacent to translocating precursors and to ribosomes, and given the comparable translocation deficiencies of sss1 or sec61 mutants, we propose that Sss1p belongs to the ''Sec61 subcomplex'' that constitutes the pore of the membrane-bound translocation apparatus.	CENS, CEA, DSV, DBCM, SERV BIOCHIM & GENET MOLEC, F-91191 GIF SUR YVETTE, FRANCE; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA; INST JACQUES MONOD, CNRS, F-75251 PARIS 05, FRANCE; UNIV PARIS 07, F-75251 PARIS 05, FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay; University of California System; University of California Berkeley; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite								BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FELDHEIM D, 1993, MOL BIOL CELL, V4, P931, DOI 10.1091/mbc.4.9.931; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; KURIHARA T, 1993, MOL BIOL CELL, V4, P919, DOI 10.1091/mbc.4.9.919; KUROIWA T, 1993, J BIOCHEM-TOKYO, V114, P541, DOI 10.1093/oxfordjournals.jbchem.a124213; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SHERMAN F, 1985, BIOESSAYS, V3, P27, DOI 10.1002/bies.950030108; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TOYN J, 1988, EMBO J, V7, P4347, DOI 10.1002/j.1460-2075.1988.tb03333.x; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; VOLLAND C, 1988, J BIOL CHEM, V263, P8294; WALWORTH NC, 1989, METHOD CELL BIOL, V31, P335	34	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27478	27485						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961662				2022-12-27	WOS:A1994PV77100052
J	HAFT, CR; KLAUSNER, RD; TAYLOR, SI				HAFT, CR; KLAUSNER, RD; TAYLOR, SI			INVOLVEMENT OF DILEUCINE MOTIFS IN THE INTERNALIZATION AND DEGRADATION OF THE INSULIN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL MEMBRANE GLYCOPROTEIN; MANNOSE 6-PHOSPHATE RECEPTOR; TYROSINE KINASE-ACTIVITY; FACTOR-II RECEPTOR; CYTOPLASMIC DOMAIN; JUXTAMEMBRANE REGION; TRANSFERRIN RECEPTOR; BETA-HEXOSAMINIDASE; AMINO-ACIDS; ENDOCYTOSIS	Dileucine motifs have been shown to be involved in trans Golgi sorting, lysosomal targeting, and internalization of a number of proteins. The insulin receptor contains four dileucine pairs in its cytoplasmic domain. To determine if these insulin receptor sequences can serve as lysosomal sorting sequences, chimeric molecules expressing the Tac antigen fused to each isolated insulin receptor motif were constructed. A chimera con taining the juxtamembrane dileucine motif (EKITLL), which closely resembles the sequences originally identified in the gamma- and delta-chains of the T cell receptor (DKQTLL and EVQALL), was shown to sort to lysosomes by immunofluorescence microscopy, as did a chimera expressing the dileucine motif (GGKGLL) found in the tyrosine kinase domain. Chimeras expressing either a second tyrosine kinase domain sequence (HVVRLL) or the carboxyl-terminal sequence (EIVNLL) localized to both lysosomes and the plasma membrane. In contrast, chimeras expressing two other potential sorting signals found in the cytoplasmic tail of the insulin receptor (NARDII and KNGRIL) localized predominantly to the plasma membrane. Exclusively cell surface staining was also seen for a chimera expressing a mutant motif (EKITAA), where the leucine residues were mutated to alanines. When the alanine pair was introduced into the juxtamembrane domain of the intact insulin receptor and the mutant receptor expressed in NM-3T3 cells, we found that the mutation did not impair insulin binding or receptor tyrosine kinase activity. However, the Ala-Ala mutant internalized insulin 5-fold slower than the wild-type receptor. Taken together, these findings suggest that the dileucine motif found in the juxtamembrane domain of the insulin receptor is involved in receptor internalization and that other insulin receptor sequences may mask the potential lysosomal targeting signals in the intact molecule.	NIDDKD, DIABET BRANCH, BETHESDA, MD 20892 USA; NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BACKER JM, 1989, J BIOL CHEM, V264, P1694; BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; CAMA A, 1992, J BIOL CHEM, V267, P8383; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CARPENTIER JL, 1992, P NATL ACAD SCI USA, V89, P162, DOI 10.1073/pnas.89.1.162; CARPENTIER JL, 1993, J CELL BIOL, V122, P1243, DOI 10.1083/jcb.122.6.1243; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHIN JE, 1991, J BIOL CHEM, V266, P15587; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DICKENS M, 1992, BIOCHEM J, V287, P201, DOI 10.1042/bj2870201; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FURUNO K, 1989, J BIOCHEM-TOKYO, V106, P717, DOI 10.1093/oxfordjournals.jbchem.a122922; FURUNO K, 1989, J BIOCHEM-TOKYO, V106, P708, DOI 10.1093/oxfordjournals.jbchem.a122921; GAVIN JR, 1974, P NATL ACAD SCI USA, V71, P84, DOI 10.1073/pnas.71.1.84; HAFT CR, 1994, BIOCHEMISTRY-US, V33, P9143, DOI 10.1021/bi00197a017; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KASUGA M, 1981, P NATL ACAD SCI-BIOL, V78, P6917, DOI 10.1073/pnas.78.11.6917; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LEVYTOLEDANO R, 1993, ENDOCRINOLOGY, V133, P1803, DOI 10.1210/en.133.4.1803; LEVYTOLEDANO R, 1994, EMBO J, V13, P835, DOI 10.1002/j.1460-2075.1994.tb06326.x; LIPPINCOTTSCHWARTZ J, 1986, J CELL BIOL, V102, P1593, DOI 10.1083/jcb.102.5.1593; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LUND KA, 1990, J BIOL CHEM, V265, P15713; MAIN HY, 1994, J BIOL CHEM, V269, P3928; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; MYERS MG, 1991, J BIOL CHEM, V266, P10616; OPRESKO LK, 1987, J BIOL CHEM, V262, P4116; PAVLAKIS GN, 1983, P NATL ACAD SCI-BIOL, V80, P397, DOI 10.1073/pnas.80.2.397; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; PROIA RL, 1984, J BIOL CHEM, V259, P3350; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; RENFREW CA, 1991, J BIOL CHEM, V266, P21265; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; SHIN JY, 1991, J BIOL CHEM, V266, P10658; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; THIES RS, 1990, J BIOL CHEM, V265, P10132; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VEGA MA, 1991, J BIOL CHEM, V266, P16269; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; WEITZ G, 1992, J BIOL CHEM, V267, P10039; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	59	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26286	26294						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929346				2022-12-27	WOS:A1994PQ93000055
J	ODA, K; TAKAHASHI, T; TOKUDA, Y; SHIBANO, Y; TAKAHASHI, S				ODA, K; TAKAHASHI, T; TOKUDA, Y; SHIBANO, Y; TAKAHASHI, S			CLONING, NUCLEOTIDE-SEQUENCE, AND EXPRESSION OF AN ISOVALERYL PEPSTATIN-INSENSITIVE CARBOXYL PROTEINASE GENE FROM PSEUDOMONAS SP-101	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SCYTALIDIUM-LIGNICOLUM M-133; PROTEASE-B; ESCHERICHIA-COLI; PEPSIN; PURIFICATION; INHIBITOR; DNA; INACTIVATION; BACTERIUM	A unique carboxyl proteinase (EC 3.4.23.33), insensitive to the classical inhibitor isovaleryl pepstatin and isolated from Pseudomonas sp. 101 (PCP), is the first example of a prokaryotic enzyme of this class. The gene coding for PCP was cloned, sequenced, and expressed in Escherichia coli. The gene consists of 1,761 base pairs encoding a protein of 587 amino acid residues. The NH2-terminal 215-amino acid preprosequence flanks the 372-amino acid mature protein, which is identical with the primary structure of an authentic PCP determined by chemical methods. E. coli carrying a plasmid containing the cloned wild-type PCP gene produced a 62-kDa protein. This molecule was processed and secreted into the periplasm as a 43-kDa protein, which converted to mature PCP under acidic conditions. This autocatalytic conversion was completely blocked by tyrostatin, a PCP-specific peptidic inhibitor from Kitasatosporia sp. 55. The purified recombinant PCP has the same characteristics as authentic PCP. When several preprosequence deletion mutants were expressed in E. coli, mutant proteins were accumulated as insoluble forms with no proteinase activities. These results suggest that the prepropeptide of PCP plays an essential role in the formation of functional PCP.	SUNTORY LTD, INST FUNDAMENTAL RES, SHIMAMOTO, OSAKA 618, JAPAN	Suntory Holdings Ltd	ODA, K (corresponding author), KYOTO INST TECHNOL, FAC TEXT SCI, DEPT APPL BIOL, SAKYO KU, KYOTO 606, JAPAN.							CHANG WJ, 1976, J BIOCHEM-TOKYO, V80, P975, DOI 10.1093/oxfordjournals.jbchem.a131385; DELANEY R, 1987, J BIOL CHEM, V262, P1461; FRAZEE RW, 1993, J BACTERIOL, V175, P6194, DOI 10.1128/JB.175.19.6194-6202.1993; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HORIUCHI H, 1988, J BACTERIOL, V170, P272, DOI 10.1128/jb.170.1.272-278.1988; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; Kay J., 1985, Aspartic proteinases and their inhibitors, P1; KOBAYASHI H, 1985, AGR BIOL CHEM TOKYO, V49, P2393, DOI 10.1080/00021369.1985.10867083; KRAMER W, 1987, METHOD ENZYMOL, V154, P350; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAITA T, 1984, J BIOCHEM-TOKYO, V95, P465, DOI 10.1093/oxfordjournals.jbchem.a134628; Maniatis T., 1982, MOL CLONING; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORIHARA K, 1979, J BIOCHEM, V85, P661; Morihara K., 1981, PROTEINASES THEIR IN, P213; MURAO S, 1970, AGR BIOL CHEM TOKYO, V34, P1265, DOI 10.1080/00021369.1970.10859764; MURAO S, 1988, AGR BIOL CHEM TOKYO, V52, P1629; MURAO S, 1973, AGR BIOL CHEM TOKYO, V37, P1417, DOI 10.1080/00021369.1973.10860841; MURAO S, 1972, AGR BIOL CHEM TOKYO, V36, P1647, DOI 10.1080/00021369.1972.10860454; Murao S., 1985, ASPARTIC PROTEINASES, P379; ODA K, 1991, ADV EXP MED BIOL, V306, P185; ODA K, 1989, AGR BIOL CHEM TOKYO, V53, P405, DOI 10.1080/00021369.1989.10869302; ODA K, 1976, AGR BIOL CHEM TOKYO, V40, P1221, DOI 10.1080/00021369.1976.10862184; ODA K, 1981, AGR BIOL CHEM TOKYO, V45, P2339, DOI 10.1080/00021369.1981.10864881; ODA K, 1976, AGR BIOL CHEM TOKYO, V40, P859, DOI 10.1080/00021369.1976.10862145; ODA K, 1975, AGR BIOL CHEM TOKYO, V39, P477, DOI 10.1080/00021369.1975.10861610; ODA K, 1986, AGR BIOL CHEM TOKYO, V50, P651, DOI 10.1080/00021369.1986.10867441; ODA K, 1992, BIOCHIM BIOPHYS ACTA, V1120, P208, DOI 10.1016/0167-4838(92)90272-F; ODA K, 1974, AGR BIOL CHEM TOKYO, V38, P2435, DOI 10.1080/00021369.1974.10861522; ODA K, 1987, AGR BIOL CHEM TOKYO, V51, P3073; ODA K, 1987, BIOCHIM BIOPHYS ACTA, V923, P463, DOI 10.1016/0304-4165(87)90055-9; RAJAGOPALAN TG, 1966, J BIOL CHEM, V241, P4295; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TANG J, 1971, J BIOL CHEM, V246, P4510; TANG J, 1973, P NATL ACAD SCI USA, V70, P3437, DOI 10.1073/pnas.70.12.3437; TERASHITA T, 1981, AGR BIOL CHEM TOKYO, V45, P1937, DOI 10.1080/00021369.1981.10864821; TERASHITA T, 1984, AGR BIOL CHEM TOKYO, V48, P1029, DOI 10.1080/00021369.1984.10866245; TONOUCHI N, 1986, NUCLEIC ACIDS RES, V14, P7557, DOI 10.1093/nar/14.19.7557; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSURU D, 1986, J BIOCHEM-TOKYO, V99, P1537, DOI 10.1093/oxfordjournals.jbchem.a135624; TSURU D, 1989, AGR BIOL CHEM TOKYO, V53, P2751, DOI 10.1080/00021369.1989.10869723; UMEZAWA H, 1970, J ANTIBIOT, V23, P259, DOI 10.7164/antibiotics.23.259; WEST EH, 1988, NUCLEIC ACIDS RES, V16, P9293	47	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26518	26524						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929375				2022-12-27	WOS:A1994PQ93000088
J	PRESTA, L; SHIELDS, R; OCONNELL, L; LAHR, S; PORTER, J; GORMAN, C; JARDIEU, P				PRESTA, L; SHIELDS, R; OCONNELL, L; LAHR, S; PORTER, J; GORMAN, C; JARDIEU, P			THE BINDING-SITE ON HUMAN-IMMUNOGLOBULIN-E FOR ITS HIGH-AFFINITY RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; EPIDERMAL LANGERHANS CELLS; RAT MAST-CELLS; IGE RECEPTOR; CHIMERIC IG; MURINE IGE; ANTIBODIES; PROTEIN; REGION; HUMANIZATION	Immunoglobulin (Ig)E antibodies mediate allergic responses by binding to specific high affinity receptors, Fc epsilon RI, on mast cells and basophils. Previous studies have shown that the principal Fc epsilon RI binding site is located on the third constant domain, Fc epsilon 3, of IgE. Based on a model of the IgE Fc epsilon 3 (which is homologous to the second constant domain of IgG), homology scanning mutagenesis and replacement of individual residues were used to determine the specific amino acids of human IgE involved in binding to human Fc epsilon RI. The amino acids are localized in three loops, which form a putative ridge on the most exposed side of the Fc epsilon 3 domain of IgE and include Arg-408, Ser-411, Lys-415, Glu-452, Arg-465, and Met-469. The preponderance of charged residues suggests that IgE-Fc epsilon RI binding is mediated primarily by electrostatic interaction. Furthermore, it is possible to confer Fc epsilon RI binding to an IgG molecule by introducing these three IgE loops into the IgG C gamma 2 domain.	GENENTECH INC,DEPT IMMUNOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MED & ANALYT CHEM,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	PRESTA, L (corresponding author), GENENTECH INC,DEPT PROT ENGN,S SAN FRANCISCO,CA 94080, USA.							AUSTEN KF, 1968, MOL ASPECTS ACUTE AL, P293; BAIRD B, 1993, ACCOUNTS CHEM RES, V26, P428, DOI 10.1021/ar00032a006; BANIYASH M, 1988, MOL IMMUNOL, V25, P705, DOI 10.1016/0161-5890(88)90106-X; BASU M, 1993, J BIOL CHEM, V268, P13118; BENNICH HH, 1978, IMMEDIATE HYPERSENSI, P1; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; BURT DS, 1987, MOL IMMUNOL, V24, P379, DOI 10.1016/0161-5890(87)90180-5; BURT DS, 1987, EUR J IMMUNOL, V17, P437, DOI 10.1002/eji.1830170323; CAPRON A, 1986, IMMUNOL TODAY, V7, P15, DOI 10.1016/0167-5699(86)90184-2; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; CONRAD DH, 1983, J IMMUNOL, V130, P327; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; FLANAGAN JG, 1982, EMBO J, V1, P655, DOI 10.1002/j.1460-2075.1982.tb01223.x; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HAKIMI J, 1990, J BIOL CHEM, V265, P22079; HELM B, 1989, P NATL ACAD SCI USA, V86, P9465, DOI 10.1073/pnas.86.23.9465; HELM B, 1988, NATURE, V331, P180, DOI 10.1038/331180a0; HELM BA, 1991, EUR J IMMUNOL, V21, P1543, DOI 10.1002/eji.1830210631; ISHIZAKA K, 1970, IMMUNOCHEMISTRY, V7, P687, DOI 10.1016/0019-2791(70)90175-8; ISHIZAKA T, 1984, PROG ALLERGY, V34, P188; JEFFERIS R, 1990, MOL IMMUNOL, V27, P1237, DOI 10.1016/0161-5890(90)90027-W; KABAT EA, 1991, SEQUENCES PROTEINS I, P103; KEEGAN AD, 1991, MOL IMMUNOL, V28, P1149, DOI 10.1016/0161-5890(91)90030-N; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MENDOZA G, 1976, NATURE, V264, P548, DOI 10.1038/264548a0; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MISHELL BB, 1980, SELECTED METHODS CEL, P292; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NILSSON K, 1970, CLIN EXP IMMUNOL, V7, P477; NIO N, 1990, PEPTIDE CHEMISTRY 1989, P203; NISSIM A, 1991, EMBO J, V10, P101, DOI 10.1002/j.1460-2075.1991.tb07925.x; NISSIM A, 1993, J IMMUNOL, V150, P1365; PADLAN EA, 1986, MOL IMMUNOL, V23, P1063, DOI 10.1016/0161-5890(86)90005-2; PRESTA LG, 1993, J IMMUNOL, V151, P2623; ROBERTSON MW, 1988, MOL IMMUNOL, V25, P103, DOI 10.1016/0161-5890(88)90057-0; SCHWARZBAUM S, 1989, EUR J IMMUNOL, V19, P1015, DOI 10.1002/eji.1830190610; SENO M, 1983, NUCLEIC ACIDS RES, V11, P719, DOI 10.1093/nar/11.3.719; SHOPES B, 1990, J IMMUNOL, V145, P3842; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; WEETALL M, 1990, J IMMUNOL, V145, P3849; WOOF JM, 1986, MOL IMMUNOL, V23, P319, DOI 10.1016/0161-5890(86)90059-3; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X	48	160	180	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26368	26373						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929356				2022-12-27	WOS:A1994PQ93000066
J	DONG, AC; NAGAI, M; YONEYAMA, Y; CAUGHEY, WS				DONG, AC; NAGAI, M; YONEYAMA, Y; CAUGHEY, WS			DETERMINATION OF THE AMOUNTS AND OXIDATION-STATES OF HEMOGLOBINS-M BOSTON AND M-SASKATOON IN SINGLE ERYTHROCYTES BY INFRARED MICROSPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH-FLAVIN REDUCTASE; SUBUNITS; SPECTROSCOPY; GEOMETRY; HEME	The reduced abnormal subunits of two M-type hemoglobins, Boston (His(alpha 58) --> Tyr) and Saskatoon (His(beta 63) --> Tyr), have been determined in the presence of normal human hemoglobin A by measurement of C-O stretch bands in infrared spectra of carbon monoxide complexes. Use of an infrared microscope coupled to a Fourier transform infrared spectrometer of high sensitivity permitted measurements to be made on as small a hemoglobin mixture as is contained in a single erythrocyte. The abnormal subunits of both Hbs M exhibit bands near 1970 cm(-1) compared with bands near 1951 cm(-1) for the normal subunits. The increase in 1970 cm(-1) band intensity upon erythrocyte reduction with dithionite provided a measure of the extent of abnormal subunit oxidation; in cell suspensions about 60% of the abnormal subunits of Hb M Boston and 80% for Hb M Saskatoon remained reduced. The amount of Hb present as abnormal Hb averaged about 25% for Hb M Boston cells and about 50% for Hb M Saskatoon cells. However, the ratio of Hb M to Hb A in individual cells varied markedly, with the ratio expected to decrease as the cell ages. These results demonstrate the unique utility of infrared microspectroscopy for the study of differences in abnormal Hb status among individual erythrocytes.	COLORADO STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, FT COLLINS, CO 80523 USA; KANAZAWA UNIV, SCH ALLIED HLTH PROFESS, BIOL LAB, KANAZAWA, ISHIKAWA 920, JAPAN; KANAZAWA UNIV, SCH MED, DEPT BIOCHEM, KANAZAWA, ISHIKAWA 920, JAPAN	Colorado State University; Kanazawa University; Kanazawa University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL015980] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-15980] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBEN JO, 1966, HEMES HEMOPROTEINS, P139; ARBANEDAHMANE M, 1985, HEMOGLOBIN, V9, P509, DOI 10.3109/03630268508997029; BAINE RM, 1980, HEMOGLOBIN, V4, P201; BUNN HF, 1986, HEMOGLOBIN MOL GENET, P381; BYCKOVA V, 1971, BIOCHIM BIOPHYS ACTA, V243, P117, DOI 10.1016/0005-2795(71)90045-6; Caughey W. S., 1980, METHODS DETERMINING, P95; CAUGHEY WS, 1969, BIOCHEMISTRY-US, V8, P59, DOI 10.1021/bi00829a009; DONG AC, 1994, METHOD ENZYMOL, V232, P139; DONG AC, 1988, BIOCHEM BIOPH RES CO, V156, P752, DOI 10.1016/S0006-291X(88)80907-0; GERALD PS, 1961, P NATL ACAD SCI USA, V47, P1758, DOI 10.1073/pnas.47.11.1758; GERALD PS, 1958, BLOOD, V13, P936, DOI 10.1182/blood.V13.10.936.936; GERALD PS, 1957, SCIENCE, V126, P300, DOI 10.1126/science.126.3268.300; GIBSON QH, 1966, J BIOL CHEM, V241, P1650; HAYASHI A, 1966, SCIENCE, V152, P207, DOI 10.1126/science.152.3719.207; HAYASHI A, 1968, BIOCHIM BIOPHYS ACTA, V168, P262, DOI 10.1016/0005-2795(68)90149-9; HORLEIN H., 1948, DEUTSCHE MED WOCHENSCHR, V73, P476; HULTQUIST DE, 1971, NATURE-NEW BIOL, V229, P252, DOI 10.1038/newbio229252a0; Kiese M., 1974, METHEMOGLOBINEMIA CO; LAMAR GN, 1980, BIOCHEM BIOPH RES CO, V96, P1172, DOI 10.1016/0006-291X(80)90075-3; LIAN T, 1993, BIOCHEMISTRY-US, V32, P5809, DOI 10.1021/bi00073a013; MAKINO N, 1979, J BIOL CHEM, V254, P862; MOTOKAWA Y, 1964, ARCH BIOCHEM BIOPHYS, V105, P612, DOI 10.1016/0003-9861(64)90058-X; MURAWSKIK, 1965, ARCH BIOCH BIOPHS, V111, P197; NAGAI M, 1980, J BIOL CHEM, V255, P4599; NAGAI M, 1989, BIOCHEMISTRY-US, V28, P2418, DOI 10.1021/bi00432a012; NAGAI M, 1987, ACTA HAEMATOL-BASEL, V78, P95, DOI 10.1159/000205853; NAGAI M, 1991, BIOCHEMISTRY-US, V30, P6495, DOI 10.1021/bi00240a021; NAGAI M, 1985, BIOCHEM BIOPH RES CO, V128, P689, DOI 10.1016/0006-291X(85)90101-9; NISHIKURA K, 1975, J BIOL CHEM, V250, P6679; PISCIOTTA AV, 1959, J LAB CLIN MED, V54, P73; POTTER WT, 1990, BIOCHEMISTRY-US, V29, P6283, DOI 10.1021/bi00478a025; POTTER WT, 1983, BIOCHEM BIOPH RES CO, V116, P719, DOI 10.1016/0006-291X(83)90584-3; PULSINELLI PD, 1973, P NATL ACAD SCI USA, V70, P3870, DOI 10.1073/pnas.70.12.3870; SCOTT EM, 1968, HERED DISORD, P102; SINGER K, 1955, AM J MED, V18, P633, DOI 10.1016/0002-9343(55)90464-2; SUGITA Y, 1971, J BIOL CHEM, V246, P6072; SUZUKI T, 1966, BIOCHIM BIOPHYS ACTA, V127, P280, DOI 10.1016/0304-4165(66)90510-1; YUBISUI T, 1979, J BIOCHEM, V85, P719	38	6	6	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25365	25368						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929232				2022-12-27	WOS:A1994PQ49100023
J	GREENBURG, G; BLOBEL, G				GREENBURG, G; BLOBEL, G			CDNA-DERIVED PRIMARY STRUCTURE OF THE 25-KDA SUBUNIT OF CANINE MICROSOMAL SIGNAL PEPTIDASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI LEADER PEPTIDASE; YEAST SEC11 PROTEIN; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; GENE; GLYCOPROTEIN; PURIFICATION	We purified the 25-kDa subunit of the pentameric signal peptidase complex (SPC 25) from canine pancreas microsomes and utilized amino acid sequence data from tryptic fragments for its molecular cloning and sequencing. Its primary structure (calculated molecular mass of 25,831 Da) shows the presence of two hydrophobic domains of which one is likely to serve as a transmembrane segment. Consistent with being the only SPC subunit with at least one intrachain disulfide bond, SPC 25 contains 4 Cys residues. SPC 25 does not contain a cleavable signal peptide, and it is proposed that the transmembrane segment doubles as signal sequence. The primary structure of SPC 25 is unrelated to any of the other three SPC subunits (SPC 22/23, SPC 21, and SPC 18) that have so far been molecularly cloned and sequenced. Neither is it similar to any protein in the data bases, except that it is 95% identical to an open reading frame of an incomplete and randomly isolated human cDNA clone.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,CELL BIOL LAB,NEW YORK,NY 10021	Howard Hughes Medical Institute; Rockefeller University								BAKER RK, 1987, BIOCHEMISTRY-US, V26, P8561, DOI 10.1021/bi00400a010; BEHRENS M, 1991, MOL GEN GENET, V228, P167, DOI 10.1007/BF00282462; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; CHANG CN, 1978, P NATL ACAD SCI USA, V75, P361, DOI 10.1073/pnas.75.1.361; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; EVNS EA, 1986, THESIS ROCKEFELLER U; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FROHMAN MA, 1990, AMPLIFICATIONS, V5, P11; GREENBURG G, 1989, J BIOL CHEM, V264, P15762; INNIS MA, 1984, P NATL ACAD SCI-BIOL, V81, P3708, DOI 10.1073/pnas.81.12.3708; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NEWSOME AL, 1992, BIOCHEM J, V282, P447, DOI 10.1042/bj2820447; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SHELNESS GS, 1988, J BIOL CHEM, V263, P17063; SHELNESS GS, 1990, J BIOL CHEM, V265, P9512; SHELNESS GS, 1993, J BIOL CHEM, V268, P5201; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SUNG M, 1992, J BIOL CHEM, V267, P13154; TOKUNAGA M, 1982, J BIOL CHEM, V257, P9922; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VANDIJL JM, 1990, MOL GEN GENET, V223, P233, DOI 10.1007/BF00265059; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WOLFE PB, 1983, J BIOL CHEM, V258, P2073; YADEAU JT, 1991, P NATL ACAD SCI USA, V88, P517, DOI 10.1073/pnas.88.2.517; YU F, 1984, FEBS LETT, V173, P264, DOI 10.1016/0014-5793(84)81060-1	32	15	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25354	25358						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929230				2022-12-27	WOS:A1994PQ49100021
J	MONBOISSE, JC; GARNOTEL, R; BELLON, G; OHNO, N; PERREAU, C; BOREL, JP; KEFALIDES, NA				MONBOISSE, JC; GARNOTEL, R; BELLON, G; OHNO, N; PERREAU, C; BOREL, JP; KEFALIDES, NA			THE ALPHA-3 CHAIN OF TYPE-IV COLLAGEN PREVENTS ACTIVATION OF HUMAN POLYMORPHONUCLEAR LEUKOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR-BASEMENT-MEMBRANE; GOODPASTURE ANTIGEN; LENS CAPSULE; IDENTIFICATION; NEUTROPHILS; MONOPHOSPHATE; PROCOLLAGEN; GENERATION; PEPTIDES; REGION	Our initial observation that type I collagen activates polymorphonuclear leukocytes (PMN) prompted the testing of the activating potential of type IV collagen. It was noted, however, that type IV collagen isolated from bovine lens capsule did not activate PMN but rather prevented their stimulation by N-formylmethionyl-leucyl-phenylalanine, phorbol myristate acetate, or type I collagen. This observation led to the present study, which demonstrates that the inhibitory effect of lens capsule type IV collagen resides in the noncollagenous (NC1) domain of the alpha 3 chain and specifically in the region comprising residues 185-203 of the NC1 domain of both the human and bovine molecules. Synthetic peptides from the same region of the NC1 domains of the alpha 1, alpha 2, alpha 4, and alpha 5 chains did not possess the inhibitory effect seen with the alpha 3 chain. The sequence S-N-S (residues 189-191) is unique to the peptide of the alpha 3 chain, and substitution of either serine with alanine abolishes the inhibition. Type IV collagen isolated from the mouse Engelbreth-Holm-Swarm (EHS) tumor, a molecule that lacks the alpha 3 chain, did not prevent PMN activation but instead stimulated the secretion of elastase and type TV collagenase. Incubation of PMN with intact lens capsule type IV collagen or a peptide comprising residues 185-203 of the alpha 3(IV) chain resulted in a and fold increase of intracellular cAMP, whereas, Ca2+ levels remained unchanged. Incubating PMN with forskolin or with dibutyryl-cAMP resulted in the inhibition of O-2(-) production and degranulation by PMN, thus mimicking the effects of type IV collagen and the alpha 3(IV) 185-203 peptide. The data suggest that type TV collagen, through its alpha 3 chain, down-regulates PMN activation and thus decreases the potential for damage as these cells traverse the capillary wall. Our in vitro experiments suggest that the higher the content of the alpha 3(IV) chain is in a basement membrane, the wider would be its capacity for self-protection.	UNIV PENN,CONNECT TISSUE RES INST,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104; UNIV CITY SCI CTR,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania	MONBOISSE, JC (corresponding author), UNIV REIMS,BIOCHEM LAB,CNRS,ERS 0017,51 RUE COGNACQ JAY,F-51095 REIMS,FRANCE.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR020553] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-29492] Funding Source: Medline; NIAMS NIH HHS [AR-20553] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAGGIOLINI M, 1993, FASEB J, V7, P1004, DOI 10.1096/fasebj.7.11.8396540; BARANY G, 1980, PEPTIDES, V2; BRINKER JM, 1985, P NATL ACAD SCI USA, V82, P3649, DOI 10.1073/pnas.82.11.3649; BRINKER JM, 1985, COLLAGEN REL RES, V5, P233; BUTKOWSKI RJ, 1985, J BIOL CHEM, V260, P3739; CAILLA HL, 1973, ANAL BIOCHEM, V56, P394, DOI 10.1016/0003-2697(73)90205-4; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; DEHM P, 1978, J BIOL CHEM, V253, P6680; ENGLISH D, 1981, J IMMUNOL, V126, P165; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; HUBER AR, 1989, J CLIN INVEST, V83, P1122, DOI 10.1172/JCI113992; JOHANSSON C, 1992, J BIOL CHEM, V267, P24533; KEFALIDES NA, 1993, KIDNEY INT, V43, P94, DOI 10.1038/ki.1993.16; KILLEN PD, 1988, J BIOL CHEM, V263, P8706; KLEPPEL MM, 1987, J CLIN INVEST, V80, P263, DOI 10.1172/JCI113057; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MARIYAMA M, 1992, J BIOL CHEM, V267, P1253; MARTINY L, 1992, CELL SIGNAL, V4, P219, DOI 10.1016/0898-6568(92)90085-M; MONBOISSE JC, 1990, BIOCHEM J, V270, P459, DOI 10.1042/bj2700459; MONBOISSE JC, 1987, BIOCHEM J, V246, P599, DOI 10.1042/bj2460599; MONBOISSE JC, 1991, FEBS LETT, V294, P129, DOI 10.1016/0014-5793(91)81358-F; MORRISON KE, 1991, J BIOL CHEM, V266, P34; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; PIEZ KA, 1963, BIOCHEMISTRY-US, V2, P58, DOI 10.1021/bi00901a012; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P13758; SAUS J, 1988, J BIOL CHEM, V263, P13374; SIMCHOWITZ L, 1980, J IMMUNOL, V124, P1482; TYAGI SR, 1991, J BIOL CHEM, V266, P3498; WILKINSON MJ, 1990, ANAL BIOCHEM, V185, P294, DOI 10.1016/0003-2697(90)90295-K; WISDOM BJ, 1992, CONNECT TISSUE RES, V27, P225, DOI 10.3109/03008209209006998	32	62	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25475	25482						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929248				2022-12-27	WOS:A1994PQ49100041
J	PLATT, KA; CLAFFEY, KP; WILKISON, WO; SPIEGELMAN, BM; ROSS, SR				PLATT, KA; CLAFFEY, KP; WILKISON, WO; SPIEGELMAN, BM; ROSS, SR			INDEPENDENT REGULATION OF ADIPOSE TISSUE-SPECIFICITY AND OBESITY RESPONSE OF THE ADIPSIN PROMOTER IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEASE HOMOLOG; MESSENGER-RNA; GENE; EXPRESSION; PROTEINS; CLONING	Transcription of the adipocyte specific adipsin gene is dramatically reduced in the adipose tissue of a number of genetically and chemically-induced obese rodents. To map the region of the adipsin gene that confers this response to obesity transgenic mice were made containing -114, -250, -400, -700, and -938 base pairs (bp) to +35 bp of the promoter linked to the bacterial chloramphenicol acetyltransferase gene. Transgenic mice containing as few as 114 bp of the adipsin promoter had high levels of chloramphenicol acetyltransferase activity in adipose tissue. However, only those mice with 938 bp of the adipsin upstream regulatory region showed suppression of expression in adipose tissue in mice that were induced to become obese with monosodium glutamate. Using gel retardation assays, we showed that a 56-bp fragment of DNA mapping between -687 and -743 bp upstream from the start of adipsin expression was bound by protein factors in nuclear extracts prepared from adipose tissue. There was much greater retardation of this fragment with nuclear extracts prepared from adipose tissue of lean versus obese mice. These results indicate that a tissue-specific transcription factor(s) that regulates adipsin expression is less active in the adipose tissue of obese animals.	UNIV ILLINOIS, SCH MED, DEPT BIOCHEM MC 536, CHICAGO, IL 60612 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 01225 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 01225 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK 42539] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042539] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHWELL N, 1987, BIOL ADIPOCYTE, P255; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; CELANDER D, 1987, J VIROL, V61, P269, DOI 10.1128/JVI.61.2.269-275.1987; CELANDER D, 1984, NATURE, V312, P159, DOI 10.1038/312159a0; COOK KS, 1987, SCIENCE, V237, P402, DOI 10.1126/science.3299705; COOK KS, 1985, P NATL ACAD SCI USA, V82, P6480, DOI 10.1073/pnas.82.19.6480; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FLIER JS, 1987, SCIENCE, V237, P405, DOI 10.1126/science.3299706; FLIER JS, 1989, RECENT PROG HORM RES, V45, P567; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; LUBON H, 1987, NUCLEIC ACIDS RES, V15, P2103, DOI 10.1093/nar/15.5.2103; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; PLATT KA, 1989, P NATL ACAD SCI USA, V86, P7490, DOI 10.1073/pnas.86.19.7490; ROSEN BS, 1989, SCIENCE, V244, P1483, DOI 10.1126/science.2734615; ROSS SR, 1992, P NATL ACAD SCI USA, V89, P7561, DOI 10.1073/pnas.89.16.7561; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; SPIEGELMAN BM, 1989, J BIOL CHEM, V264, P1811; WILKISON WO, 1990, J BIOL CHEM, V265, P477	20	12	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28558	28562						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961801				2022-12-27	WOS:A1994PU16800010
J	VALERA, A; SOLANES, G; FERNANDEZALVAREZ, J; PUJOL, A; FERRER, J; ASINS, G; GOMIS, R; BOSCH, F				VALERA, A; SOLANES, G; FERNANDEZALVAREZ, J; PUJOL, A; FERRER, J; ASINS, G; GOMIS, R; BOSCH, F			EXPRESSION OF GLUT-2 ANTISENSE RNA IN BETA-CELLS OF TRANSGENIC MICE LEADS TO DIABETES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							STIMULATED INSULIN-SECRETION; GLUCOSE TRANSPORTER; ISLET CELLS; LIVER; HYPERGLYCEMIA; GLUCOKINASE; GENE; RATS	An insulin response to glucose is required to correct hyperglycemia, Two proteins, the glucose transporter GLUT-2 and the glucose-phosphorylating enzyme glucokinase, have been implicated in the control of glucose metabolism in beta cells. To study the role of glucose transporter GLUT-2 in the regulation of insulin secretion and in the development of diabetes mellitus, we have obtained transgenic mice expressing high levels of GLUT-2 antisense RNA in beta cells. Western blot analysis showed an 80% reduction in GLUT-2 protein in the beta cells of these animals. Islets from transgenic mice showed impaired glucose-stimulated insulin secretion. In addition, much higher levels of blood glucose were detected in transgenic mice than in controls when glucose tolerance tests were performed. These results suggest that the reduction of GLUT-2 in the pancreas could be a crucial step in the development of diabetes mellitus.	UNIV AUTONOMA BARCELONA,SCH VET MED,DEPT BIOCHEM & MOLEC BIOL,E-08193 BARCELONA,SPAIN; UNIV BARCELONA,HOSP CLIN BARCELONA,DEPT ENDOCRINOL,E-08036 BARCELONA,SPAIN	Autonomous University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona			Ferrer, Jorge/A-3176-2012; Pujol, Anna/J-7939-2017	Ferrer, Jorge/0000-0002-5959-5729; Pujol, Anna/0000-0002-3484-598X; BOSCH, FATIMA/0000-0002-7705-5515				CHEN L, 1990, P NATL ACAD SCI USA, V87, P4088, DOI 10.1073/pnas.87.11.4088; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANDOYDRON F, 1991, NUCLEIC ACIDS RES, V19, P4925, DOI 10.1093/nar/19.18.4925; HOGAN B, 1986, MANIPULATING MOUSE E; HUGHES SD, 1992, P NATL ACAD SCI USA, V89, P688, DOI 10.1073/pnas.89.2.688; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; JOHNSON JH, 1990, SCIENCE, V250, P546, DOI 10.1126/science.2237405; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; LIANG Y, 1990, J BIOL CHEM, V265, P16863; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MUECKLER M, 1994, J BIOL CHEM, V269, P17765; NEWGARD CB, 1990, BIOCHEM SOC T, V18, P851, DOI 10.1042/bst0180851; OGAWA A, 1992, J CLIN INVEST, V90, P497, DOI 10.1172/JCI115886; OHNEDA M, 1993, DIABETES, V42, P1065, DOI 10.2337/diabetes.42.7.1065; ORCI L, 1990, P NATL ACAD SCI USA, V87, P9953, DOI 10.1073/pnas.87.24.9953; Sokal R.R., 2011, BIOMETRY, V4th; SUZUE K, 1989, NUCLEIC ACIDS RES, V17, P10099, DOI 10.1093/nar/17.23.10099; TAYLOR R, 1988, BIOCHEM J, V250, P625, DOI 10.1042/bj2500625; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; THORENS B, 1990, P NATL ACAD SCI USA, V87, P6492, DOI 10.1073/pnas.87.17.6492; THORENS B, 1992, J CLIN INVEST, V90, P77, DOI 10.1172/JCI115858; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; WINSTON SE, 1991, CURRENT PROTOCOLS IM	24	82	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28543	28546						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961797				2022-12-27	WOS:A1994PU16800006
J	KRONMAN, C; ORDENTLICH, A; BARAK, D; VELAN, B; SHAFFERMAN, A				KRONMAN, C; ORDENTLICH, A; BARAK, D; VELAN, B; SHAFFERMAN, A			THE BACK DOOR HYPOTHESIS FOR PRODUCT CLEARANCE IN ACETYLCHOLINESTERASE CHALLENGED BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RECOMBINANT HUMAN ACETYLCHOLINESTERASE; CATALYTIC CENTER; LIGAND-BINDING; ACTIVE-CENTER; RESIDUES; BUTYRYLCHOLINESTERASE; IDENTIFICATION; SPECIFICITY; SECRETION; TORPEDO	The active site of acetylcholinesterase is near the bottom of a long and narrow gorge. The dimensions of the gorge and the strong electrostatic field generated by the enzyme appear inconsistent with the enzyme's high turnover rate. Consequently, a ''back door'' mechanism involving movement of the reaction products through a transient opening near the active center was recently suggested. We investigated this hypothesis in human acetylcholinesterase by testing mutants at key residues (Glu-84, Trp-86, Asp-131, and Val-132) located near or along the putative back door channel. The turnover rates of all mutants tested, and in particular of V132K, where the channel is expected to be sealed by salt bridge Lys-132-Glu-452, are similar to that of the wild type enzyme. This indicates that the proposed back door is not a route for product clearance from the active site gorge of acetylcholinesterase and is probably of no functional relevance to its catalytic activity.	ISRAEL INST BIOL RES,DEPT BIOCHEM,IL-70450 NESS ZIONA,ISRAEL									AXELSEN PH, 1994, PROTEIN SCI, V3, P188; BARAK D, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P195; BARAK D, 1994, J BIOL CHEM, V264, P6296; CHANGEUX JP, 1966, MOL PHARMACOL, V2, P369; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; GIBNEY G, 1990, P NATL ACAD SCI USA, V87, P7546, DOI 10.1073/pnas.87.19.7546; GILSON MK, 1994, SCIENCE, V263, P1276, DOI 10.1126/science.8122110; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; HAREL M, 1992, P NATL ACAD SCI USA, V89, P10827, DOI 10.1073/pnas.89.22.10827; KREIENKAMP HJ, 1991, P NATL ACAD SCI USA, V88, P6117, DOI 10.1073/pnas.88.14.6117; KRONMAN C, 1992, GENE, V121, P295, DOI 10.1016/0378-1119(92)90134-B; MASSOULIE J, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P285; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MILLARD CB, 1992, BIOCHEM BIOPH RES CO, V189, P1280, DOI 10.1016/0006-291X(92)90212-4; ORDENTLICH A, 1993, FEBS LETT, V334, P215, DOI 10.1016/0014-5793(93)81714-B; ORDENTLICH A, 1993, J BIOL CHEM, V268, P17083; RIPOLL DR, 1993, P NATL ACAD SCI USA, V90, P5128, DOI 10.1073/pnas.90.11.5128; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; SHAFFERMAN A, 1994, EMBO J, V13, P3448, DOI 10.1002/j.1460-2075.1994.tb06650.x; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; SHAFFERMAN A, 1992, J BIOL CHEM, V267, P17640; SHAFFERMAN A, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P165; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAN RC, 1993, BIOCHEMISTRY-US, V32, P401, DOI 10.1021/bi00053a003; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; VELAN B, 1991, J BIOL CHEM, V266, P23977; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216	28	53	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27819	27822						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961709				2022-12-27	WOS:A1994PV77200010
J	OKAZAKI, T; CHUNG, UI; NISHISHITA, T; EBISU, S; USUDA, S; MISHIRO, S; XANTHOUDAKIS, S; IGARASHI, T; OGATA, E				OKAZAKI, T; CHUNG, UI; NISHISHITA, T; EBISU, S; USUDA, S; MISHIRO, S; XANTHOUDAKIS, S; IGARASHI, T; OGATA, E			A REDOX FACTOR PROTEIN, REF1, IS INVOLVED IN NEGATIVE GENE-REGULATION BY EXTRACELLULAR CALCIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARATHYROID-HORMONE GENE; ELEMENT-BINDING PROTEIN; RETINOID X-RECEPTOR; DNA-REPAIR ENZYME; TRANSCRIPTIONAL REGULATION; DEOXYRIBONUCLEIC-ACID; THYROID-HORMONE; CYCLIC-AMP; JUN; PHOSPHORYLATION	A rise in extracellular calcium (Ca-e(2+)) suppresses not only secretion of parathyroid hormone (PTH) but also expression of the PTH gene to ensure constant plasma Ca2+ level. A nuclear protein(s) in a wide variety of cells bound to the specific DNA elements (negative Ca2+ responsive elements, nCaREs) in the human PTH gene in sequence-specific and Ca(2+)e concentration-dependent manners. Our Southwestern cloning revealed that a redox factor protein (ref1), which was known to activate several transcription factors via alterations of their redox state, belonged to an nCaRE binding protein. The level of ref1 mRNA as well as of its protein was elevated by an increase in Ca-e(2+) concentration. In gel shift assay, anti-ref1 antibody eliminated formation of the nCaRE-protein complex. We also found that there was another protein(s) interacting with nCaREs and ref1. Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that DNA (nCaRE)-ref1 interaction led to Ca-e(2+)-mediated transcriptional suppression. Thus, it is concluded that ref1 possesses transcription repressor activity in addition to its function as a transcriptional auxiliary protein.	UNIV TOKYO,CTR HLTH SERV,BUNKYO KU,TOKYO 113,JAPAN; HIGETA SHOYU CO LTD,RES LAB,CHOSHI,CHIBA 288,JAPAN; INST IMMUNOL,BUNKYO KU,TOKYO 112,JAPAN; CANC INST HOSP,TOSHIMA KU,TOKYO 170,JAPAN; ROCHE INST MOLEC BIOL,DEPT MOLEC ONCOL & VIROL,NUTLEY,NJ 07110	University of Tokyo; Japanese Foundation for Cancer Research	OKAZAKI, T (corresponding author), UNIV TOKYO,SCH MED,DEPT INTERNAL MED 4,ENDOCRINE GENET UNIT,BUNKYO KU,3-28-6 MEJIRODAI,TOKYO 112,JAPAN.			Mishiro, Shunji/0000-0001-9618-6468				ALKON DL, 1988, SCIENCE, V239, P998, DOI 10.1126/science.2830669; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; CAMPOS RV, 1992, MOL ENDOCRINOL, V6, P1642, DOI 10.1210/me.6.10.1642; CHEN CJ, 1987, ENDOCRINOLOGY, V121, P958, DOI 10.1210/endo-121-3-958; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEBERNARDI MA, 1991, P NATL ACAD SCI USA, V88, P9257, DOI 10.1073/pnas.88.20.9257; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOGGARD N, 1991, MOL ENDOCRINOL, V5, P1748, DOI 10.1210/mend-5-11-1748; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P3889; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; MCCARTY NA, 1992, PHYSIOL REV, V72, P1037, DOI 10.1152/physrev.1992.72.4.1037; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OKAZAKI T, 1991, J BIOL CHEM, V266, P21903; OKAZAKI T, 1988, J BIOL CHEM, V263, P2203; OKAZAKI T, 1992, J CLIN INVEST, V89, P1268, DOI 10.1172/JCI115711; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PRIBNOW D, 1992, MOL ENDOCRINOL, V6, P1003, DOI 10.1210/me.6.7.1003; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; SAMBROOK S, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO N, 1990, AM J MED SCI, V299, P309, DOI 10.1097/00000441-199005000-00004; SCHAFFNER W, 1989, TRENDS GENET, V5, P37, DOI 10.1016/0168-9525(89)90017-6; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGT PK, 1989, ADV CANCER RES, V55, P1; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; YAMAMOTO M, 1989, J CLIN INVEST, V83, P1053, DOI 10.1172/JCI113946; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	46	132	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27855	27862						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961715				2022-12-27	WOS:A1994PV77200016
J	VANWIJK, KJ; NILSSON, LO; STYRING, S				VANWIJK, KJ; NILSSON, LO; STYRING, S			SYNTHESIS OF REACTION-CENTER PROTEINS AND REACTIVATION OF REDOX COMPONENTS DURING REPAIR OF PHOTOSYSTEM-II AFTER LIGHT-INDUCED INACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RES; CHLAMYDOMONAS-REINHARDTII; D1 PROTEIN; SPECTROSCOPIC CHARACTERIZATION; TRANSLATION INTERMEDIATE; CHLOROPLAST MEMBRANES; KINETIC RESOLUTION; GREEN-ALGA; PHOTOINHIBITION; D1-PROTEIN	The D1 reaction center protein in photosystem II (PSII) has a high turnover rate due to light-induced inactivation of the redox components. We have studied the reactivation kinetics of the redox components of PSII after strong illumination and compared these kinetics with the turnover of the D1 protein and translation kinetics of the plastid-encoded PSII core proteins in Chlamydomonas reinhardtii cells. Repair of PSII was to a large extent dependent on protein translation. During the first hours of repair, D1 translation was highly accelerated as compared to the other PSII core proteins. By addition of protein synthesis inhibitors during the recovery process, it was found that the time from protein synthesis to full reassembly and reactivation of the individual PSII complexes was about 55 +/- 10 min. Inactivation and reactivation of the redox components in PSII were followed by electron spin resonance and electron transport measurements. Combining the data shows that reactivation of the individual components proceeded together or shortly after one another. Thus, no accumulation of any partially active reactivation intermediate occurred. We conclude that the rate-limiting step of the repair cycle of PSII lies in the degradation and synthesis of the PSII reaction center proteins. Once stable synthesis of the PSII core proteins is achieved, reactivation of the redox components occurs very quickly.			VANWIJK, KJ (corresponding author), UNIV STOCKHOLM, DEPT BIOCHEM, ARRHENIUS LABS NAT SCI, S-10691 STOCKHOLM, SWEDEN.		Styring, Stenbjörn/L-8414-2016	Styring, Stenbjörn/0000-0002-2803-9244				ADIR N, 1990, J BIOL CHEM, V265, P12563; ANDERSSON B, 1992, J PHOTOCH PHOTOBIO B, V15, P15, DOI 10.1016/1011-1344(92)87003-R; ANDERSSON B., 1991, CURR TOP BIOENERG, V16, P1; ARNON DI, 1948, PLANT PHYSIOL, V24, P1; ARO EM, 1990, BIOCHIM BIOPHYS ACTA, V1019, P269, DOI 10.1016/0005-2728(90)90204-H; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; ARO EM, 1994, PLANT PHYSIOL, V104, P1033, DOI 10.1104/pp.104.3.1033; BARBATO R, 1992, J CELL BIOL, V119, P325, DOI 10.1083/jcb.119.2.325; BLACK MT, 1986, PHOTOSYNTH RES, V8, P193, DOI 10.1007/BF00037128; DANON A, 1994, EMBO J, V13, P2227, DOI 10.1002/j.1460-2075.1994.tb06500.x; DEBUS RJ, 1988, BIOCHEMISTRY-US, V27, P9071, DOI 10.1021/bi00426a001; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEVITRY C, 1989, J CELL BIOL, V109, P999; ERIKSEN JM, 1992, TOPICS PHOTOSYNTHESI, V11, P101; FALK S, 1990, PHYSIOL PLANTARUM, V78, P173; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; GREER DH, 1986, PLANTA, V168, P253, DOI 10.1007/BF00402971; HUNDAL T, 1990, BIOCHIM BIOPHYS ACTA, V1017, P285; IKEUCHI M, 1992, RES PHOTOSYNTHESIS, V2, P175; INAGAKI N, 1992, FEBS LETT, V300, P5, DOI 10.1016/0014-5793(92)80152-7; KETTUNEN R, 1991, FEBS LETT, V290, P153, DOI 10.1016/0014-5793(91)81247-6; KIM JH, 1993, PLANT PHYSIOL, V103, P181, DOI 10.1104/pp.103.1.181; KIM JM, 1991, J BIOL CHEM, V266, P14931; KIRILOVSKY DL, 1990, BIOCHEMISTRY-US, V29, P8100, DOI 10.1021/bi00487a016; KRAUSE GH, 1991, ANNU REV PLANT PHYS, V42, P313, DOI 10.1146/annurev.pp.42.060191.001525; KYLE DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4070, DOI 10.1073/pnas.81.13.4070; LAEMMLI VK, 1975, NATURE, V227, P680; MARDER JB, 1984, J BIOL CHEM, V259, P3900; MICHAELS A, 1990, BIOCHEM BIOPH RES CO, V170, P1082, DOI 10.1016/0006-291X(90)90503-F; NEALE PJ, 1990, PLANT PHYSIOL, V92, P1196, DOI 10.1104/pp.92.4.1196; NEALE PJ, 1991, BIOCHIM BIOPHYS ACTA, V1056, P195, DOI 10.1016/S0005-2728(05)80287-7; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P10859, DOI 10.1021/bi00159a029; OHAD I, 1984, J CELL BIOL, V99, P481, DOI 10.1083/jcb.99.2.481; OHAD I, 1990, J BIOL CHEM, V265, P1972; Okamura MY., 1987, PROGR PHOTOSYNTHESIS, V1, P379; PAKRASI HB, 1992, CURRENT TOPICS PHOTO, V11, P231; PRASIL O, 1992, PHOTOSYSTEMS TOPICS, V11, P220; Rochaix J. D., 1988, PLANT MOL BIOL PRACT, P253; RUTHERFORD AW, 1988, BIOCHIM BIOPHYS ACTA, V932, P171, DOI 10.1016/0005-2728(88)90152-1; SATOH K, 1992, NATO ADV SCI I A-LIF, V226, P375; SATOH K, 1993, PHOTOSYNTHETIC REACT, V1, P289; SCHNETTGER B, 1992, PHOTOSYNTHETICA, V27, P261; SCHUSTER G, 1988, EUR J BIOCHEM, V177, P403, DOI 10.1111/j.1432-1033.1988.tb14389.x; Seibert M, 1993, PHOTOSYNTHETIC REACT, VI, P319, DOI DOI 10.1016/B978-0-12-208661-8.50016-4; STYRING S, 1990, BIOCHIM BIOPHYS ACTA, V1015, P269, DOI 10.1016/0005-2728(90)90031-X; STYRING S, 1994, PHOTOINHIBITION PHOT, P51; SUNDBY C, 1993, J BIOL CHEM, V268, P25476; TANIGUCHI M, 1993, FEBS LETT, V317, P57, DOI 10.1016/0014-5793(93)81491-H; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANMIEGHEM FJE, 1989, BIOCHIM BIOPHYS ACTA, V977, P207, DOI 10.1016/S0005-2728(89)80073-8; VANWIJK KJ, 1992, BIOCHIM BIOPHYS ACTA, V1100, P207; VANWIJK KJ, 1993, BIOCHIM BIOPHYS ACTA, V1142, P59, DOI 10.1016/0005-2728(93)90084-S; VANWIJK KJ, 1993, PHYSIOL PLANTARUM, V87, P187, DOI 10.1034/j.1399-3054.1993.870210.x; VASS I, 1992, BIOCHEMISTRY-US, V31, P5957, DOI 10.1021/bi00141a002; VASS I, 1991, BIOCHEMISTRY-US, V30, P830, DOI 10.1021/bi00217a037; VERMAAS WFJ, 1988, P NATL ACAD SCI USA, V85, P8477, DOI 10.1073/pnas.85.22.8477; VERMAAS WFJ, 1984, FEBS LETT, V175, P243, DOI 10.1016/0014-5793(84)80744-9; VIRGIN I, 1988, FEBS LETT, V233, P408, DOI 10.1016/0014-5793(88)80472-1	58	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28382	28392						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961778				2022-12-27	WOS:A1994PV77200090
J	BABCOCK, GG; FOWLER, VM				BABCOCK, GG; FOWLER, VM			ISOFORM-SPECIFIC INTERACTION OF TROPOMODULIN WITH SKELETAL-MUSCLE AND ERYTHROCYTE TROPOMYOSINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; THIN-FILAMENTS; MEMBRANE; ACTIN; PURIFICATION; IDENTIFICATION; CLEAVAGE; SPECTRIN; ENDS	Tropomodulin is a tropomyosin-binding protein that localizes to the pointed end of striated muscle thin filaments and caps the pointed end of tropomyosin-actin filaments in vitro. Results from previous studies have suggested that tropomyosin-tropomodulin interactions are isoform-specific. To investigate the molecular basis for the isoform specific interactions of tropomyosin and tropomodulin, we isolated a cDNA for chicken skeletal muscle tropomodulin. The derived amino acid sequence of muscle tropomodulin is 86% identical with that of human erythrocyte tropomodulin, indicating that tropomodulins are highly conserved proteins. Multiple mRNAS seen on Northern blots of chicken skeletal muscle mRNA can be accounted for by multiple polyadenylation signals in the 3'-untranslated region of the cDNA. I-125-Labeled skeletal muscle and erythrocyte tropomyosins were assayed for binding bacterially expressed muscle tropomodulin using a solid phase binding assay. Unexpectedly, skeletal muscle and erythrocyte tropomyosins bound with similar affinities to muscle tropomodulin (K-d values approximately 0.2 mu M). However, cross-competition studies using erythrocyte and skeletal muscle tropomyosins indicated that they bound different sites on tropomodulin. Competition studies using recombinant fragments of tropomodulin to map the binding domains for the two tropomyosins demonstrated that residues 6-94 contained the skeletal muscle tropomyosin binding site and residues 90-184 contained the erythrocyte tropomyosin binding site. Binding of different regions of tropomodulin to muscle and non-muscle tropomyosins may permit interaction of tropomodulin with tissue-specific components or may influence the pointed end capping activity of tropomodulin.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NIGMS NIH HHS [GM 34225] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034225] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BROSCHAT KO, 1990, J BIOL CHEM, V265, P21323; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOWLER VM, 1993, J CELL BIOL, V120, P411, DOI 10.1083/jcb.120.2.411; FOWLER VM, 1990, J CELL BIOL, V111, P471, DOI 10.1083/jcb.111.2.471; FOWLER VM, 1987, J BIOL CHEM, V262, P12792; FOWLER VM, 1984, J BIOL CHEM, V259, P5978; GREGORIO CG, 1992, MOL BIOL CELL, V3, pA336; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HUXLEY HE, 1963, J MOL BIOL, V111, P159; ISHIWATA S, 1985, J CELL BIOL, V100, P282, DOI 10.1083/jcb.100.1.282; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAK AS, 1987, BIOCHIM BIOPHYS ACTA, V912, P157, DOI 10.1016/0167-4838(87)90084-7; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANGER JW, 1984, J CELL BIOL, V98, P825, DOI 10.1083/jcb.98.3.825; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHEN BW, 1986, J CELL BIOL, V102, P997, DOI 10.1083/jcb.102.3.997; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SUNG LA, 1992, J BIOL CHEM, V267, P2616; SUSSMAN MA, 1992, EUR J BIOCHEM, V205, P355, DOI 10.1111/j.1432-1033.1992.tb16787.x; WEBER A, 1994, IN PRESS J CELL BIOL	27	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27510	27518						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961666				2022-12-27	WOS:A1994PV77100056
J	COLAMONICI, OR; PORTERFIELD, B; DOMANSKI, P; HANDA, RK; FLEX, S; SAMUEL, CE; PINE, R; DIAZ, MO				COLAMONICI, OR; PORTERFIELD, B; DOMANSKI, P; HANDA, RK; FLEX, S; SAMUEL, CE; PINE, R; DIAZ, MO			LIGAND-INDEPENDENT ANTI-ONCOGENIC ACTIVITY OF THE ALPHA SUBUNIT OF THE TYPE-I INTERFERON RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CELL-LINES; HUMAN-LEUKEMIA; GENES; EXPRESSION; DELETION; CLONING; CDNA; INDUCTION; SYSTEM	Two interferon (IFN) alpha-regulated genes, 1RF1/ISGF2 and PKR/p68 kinase, may function as tumor suppressor genes suggesting that the IFN system may function as a tumor suppressor system. We report that the expression of the alpha subunit of the type I IFN receptor in human K-562 cells had anti-oncogenic effects that include a marked decrease in: (i) cell proliferation rate, (ii) the cell density at which grow th arrest normally occurs, and (iii) the tumorigenicity in nude mice. Furthermore, expression of the alpha subunit in R-562 cells induced erythroid differentiation. While most cytokine receptors become activated after binding their corresponding ligands, the overexpression of the alpha subunit has a physiological effect in the absence of its natural ligand, type I IFNs, suggesting a novel function for this type I IFN receptor subunit. The anti-oncogenic effect of the alpha subunit is mediated by a pathway that does not involve two tumor suppressor genes induced by type I IFNs, the transcriptional regulator IFN response factor-1 and the RNA-dependent protein kinase, or the p135(tyk2) tyrosine kinase that directly associates and phosphorylates the or subunit.	LOYOLA UNIV,INST ONCOL,MAYWOOD,IL 60153; UNIV CALIF SANTA BARBARA,GRAD PROGRAM BIOCHEM & MOLEC BIOL,SANTA BARBARA,CA 93106; PUBL HLTH RES INST CITY NEW YORK INC,NEW YORK,NY 10016	Loyola University Chicago; University of California System; University of California Santa Barbara	COLAMONICI, OR (corresponding author), UNIV TENNESSEE,DEPT PATHOL,BMH RM 576,800 MADISON AVE,MEMPHIS,TN 38163, USA.				NCI NIH HHS [CA49133, CA55079] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055079, R01CA049133] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUET M, 1980, NATURE, V284, P459, DOI 10.1038/284459a0; COLAMONICI OR, 1992, BLOOD, V80, P744; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COLAMONICI OR, 1994, J BIOL CHEM, V269, P9598; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; COLAMONICI OR, 1991, PHARMACOL THERAPEUT, V52, P227, DOI 10.1016/0163-7258(91)90010-J; COLAMONICI OR, 1903, J BIOL CHEM, V268, P10899; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; FUHR JE, 1981, BLOOD CELLS, V7, P389; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MIYAKOSHI J, 1990, CANCER RES, V50, P278; MOORE RN, 1984, SCIENCE, V223, P178, DOI 10.1126/science.6606850; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; ONOZAKI K, 1988, J IMMUNOL, V140, P112; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; SEN GC, 1992, J BIOL CHEM, V267, P5017; THOMIS DC, 1992, VIROLOGY, V188, P33, DOI 10.1016/0042-6822(92)90732-5; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VILLEVAL JL, 1983, EXP CELL RES, V146, P428, DOI 10.1016/0014-4827(83)90145-3; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1	28	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27275	27279						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961637				2022-12-27	WOS:A1994PV77100022
J	KOVALSKY, OI; GROSSMAN, L				KOVALSKY, OI; GROSSMAN, L			THE USE OF MONOCLONAL-ANTIBODIES FOR STUDYING INTERMEDIATES IN DNA-REPAIR BY THE ESCHERICHIA-COLI UVR(A)BC ENDONUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; SITE-SPECIFIC MUTAGENESIS; TURN-HELIX MOTIF; UVRABC ENDONUCLEASE; (A)BC EXCINUCLEASE; DAMAGED DNA; ENZYMATIC-PROPERTIES; SUPERCOILED DOMAINS; PROTEIN COMPLEXES; INCISION REACTION	The Escherichia coli Uvr(A)BC endonuclease acts in a progression of several distinct steps accompanied by changes in the conformation of macromolecular constituents, the overall architecture of the complex, and its stoichiometry. In order to probe these structural changes, we generated monoclonal antibodies (mAbs) to Uvr proteins. The anti-UvrA mAb, A2D1, recognizing the N-terminal zinc-finger region of UvrA, and the anti-UvrB mAb, B2E2, having an epitope within the 43 C-terminal amino acids of UvrB, were purified and further characterized It was found that A2D1 mAb interacts in solution both with UvrA-UvrB and UvrA-DNA complexes in the presence of the requisite ATP. This implies that the N-terminal zinc-finger of UvrA doesn't play a direct role in its interactions with UvrB and DNA. On the other hand, A2D1 does inhibit formation of the UvrB-damaged DNA preincision complex, apparently by preventing UvrB delivery by UvrA. The interaction of B2E2 with UvrA-UvrB and nucleoprotein complexes, including UvrB, suggests that the highly hydrophobic C-terminal domain of UvrB (i) doesn't participate in its interaction with UvrA, (ii) is accessible to this mAb in an intermediate UvrA-UvrB DNA helix-tracking complex, and (iii) seems to be directly involved in the formation of the preincision complex. These conclusions are supported by the finding that the neutralizing effect of A2D1 and B2E2 on the Uvr(A)BC endonuclease is significantly decreased if the preincision complex is preformed prior to mAbs addition.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022846, R01GM022846] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-22846] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG JM, 1990, J BIOL CHEM, V265, P6513; BERTRANDBURGGRAF E, 1991, J MOL BIOL, V219, P27, DOI 10.1016/0022-2836(91)90854-Y; CARON PR, 1988, NUCLEIC ACIDS RES, V16, P10891, DOI 10.1093/nar/16.22.10891; CLAASSEN LA, 1991, J BIOL CHEM, V266, P11380; CLAASSEN LA, 1991, J BIOL CHEM, V266, P11388; FRIGUET B, 1989, PROTEIN STRUCTURE PR, P287; GOLDBERG ME, 1991, TRENDS BIOCHEM SCI, V16, P358, DOI 10.1016/0968-0004(91)90148-O; GRAFSTROM RH, 1982, J BIOL CHEM, V257, P13465; GROSSMAN L, 1993, J BIOL CHEM, V268, P16871; GROSSMAN L, 1990, MUTAT RES, V236, P213, DOI 10.1016/0921-8777(90)90006-Q; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; IKEDA M, 1993, J BIOL CHEM, V268, P10296; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; LIN JJ, 1992, J BIOL CHEM, V267, P17693; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; MYLES GM, 1991, BIOCHEMISTRY-US, V30, P3824, DOI 10.1021/bi00230a004; MYLES GM, 1991, BIOCHEMISTRY-US, V30, P3834, DOI 10.1021/bi00230a005; NAVARATNAM S, 1989, J BIOL CHEM, V264, P16067; OH EY, 1989, NUCLEIC ACIDS RES, V17, P4145, DOI 10.1093/nar/17.11.4145; OH EY, 1986, NUCLEIC ACIDS RES, V14, P8557, DOI 10.1093/nar/14.21.8557; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SEELEY TW, 1990, J BIOL CHEM, V265, P7158; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P6577, DOI 10.1073/pnas.86.17.6577; SHI Q, 1992, J MOL BIOL, V226, P425, DOI 10.1016/0022-2836(92)90957-L; SNOWDEN A, 1991, J MOL BIOL, V220, P19, DOI 10.1016/0022-2836(91)90378-J; THIAGALINGAM S, 1991, J BIOL CHEM, V266, P11395; THIAGALINGAM S, 1993, J BIOL CHEM, V268, P18382; VANHOUTEN B, 1993, BIOESSAYS, V15, P51, DOI 10.1002/bies.950150108; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VISSE R, 1992, J BIOL CHEM, V267, P6736; WANG JT, 1993, J BIOL CHEM, V268, P5323; WANG JT, 1994, J BIOL CHEM, V269, P10771; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P2567, DOI 10.1093/nar/14.6.2567; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157	41	11	13	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27421	27426						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961654				2022-12-27	WOS:A1994PV77100044
J	UJITA, M; SHINOMURA, T; ITO, K; KITAGAWA, Y; KIMATA, K				UJITA, M; SHINOMURA, T; ITO, K; KITAGAWA, Y; KIMATA, K			EXPRESSION AND BINDING-ACTIVITY OF THE CARBOXYL-TERMINAL PORTION OF THE CORE PROTEIN OF PG-M, A LARGE CHONDROITIN SULFATE PROTEOGLYCAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE HOMING RECEPTOR; ASPARAGINE-LINKED OLIGOSACCHARIDES; LEUKOCYTE ADHESION MOLECULE-1; ENDOTHELIAL LIGAND; L-SELECTIN; LIMB BUD; CLONING; FIBRONECTIN; VERSICAN; AGGRECAN	PG-M is a large chondroitin sulfate proteoglycan that has been shown to be expressed in the prechondrogenic condensation area of the developing chick limb buds. We previously isolated cDNA clones encoding the core protein of PG-M (Shinomura, T., Nishida, Y., Ito, H., and Kimata, K. (1993) J. Biol. Chem. 268, 14461-14469). The amino acid sequence deduced from the cDNA analysis revealed the presence of two epidermal growth factor-like domains, a C-type lectin-like domain, and a complement regulatory protein (CRP)-like domain at the COOH terminus. The COOH-terminal portion has been expressed as a fusion protein with glutathione S-transferase in Escherichia coli to test its carbohydrate binding activity using affinity chromatography. The purified fusion protein binds to immobilized D-mannose, D-galactose, L-fucose, and N-acetyl-D-glucosamine in a calcium-dependent manner. Furthermore, the fusion protein binds to heparin- or heparan sulfate-Sepharose. To investigate roles of each COOH-terminal domain, we have made a truncated construct which lacks the CRP-like domain and determined if the CRP-like domain is involved in the binding activity. The removal of this domain resulted in the complete loss of both C-type lectin-like and heparin binding activities. The results suggest that a whole set of epidermal growth factor-, lectin-, and CRP-like domains may serve a functional structure for these bindings.	AICHI MED UNIV,INST MOLEC SCI MED,NAGAKUTE,AICHI 48011,JAPAN; NAGOYA UNIV,CTR BIOSCI,NAGOYA,AICHI 46401,JAPAN; NAGOYA UNIV,SCH AGR SCI,GRAD PROGRAM BIOCHEM REGULAT,NAGOYA,AICHI 46401,JAPAN	Aichi Medical University; Nagoya University; Nagoya University								ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; AULTHOUSE AL, 1987, DEV BIOL, V120, P377, DOI 10.1016/0012-1606(87)90240-5; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; CHANDRASEKARAN L, 1992, BIOCHEM J, V288, P903, DOI 10.1042/bj2880903; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; FUNAHASHI M, 1982, ANAL BIOCHEM, V126, P414, DOI 10.1016/0003-2697(82)90537-1; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HALBERG DF, 1988, J BIOL CHEM, V263, P9486; HAYASHI M, 1982, J BIOL CHEM, V257, P5263; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KANSAS GS, 1994, J CELL BIOL, V124, P609, DOI 10.1083/jcb.124.4.609; KANSAS GS, 1991, J CELL BIOL, V114, P351, DOI 10.1083/jcb.114.2.351; KIJIMOTOOCHIAI S, 1985, ANAL BIOCHEM, V147, P222, DOI 10.1016/0003-2697(85)90031-4; KIMATA K, 1986, J BIOL CHEM, V261, P3517; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; MATSUTANI E, 1982, DEV BIOL, V92, P544, DOI 10.1016/0012-1606(82)90199-3; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; PIGOTT R, 1991, J IMMUNOL, V147, P130; RAUCH U, 1992, J BIOL CHEM, V267, P19536; SALEQUE S, 1993, GLYCOBIOLOGY, V3, P185, DOI 10.1093/glycob/3.2.185; SHINOMURA T, 1992, J BIOL CHEM, V267, P1265; SHINOMURA T, 1990, ANAT EMBRYOL, V181, P227; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; SHINOMURA T, 1990, DEV GROWTH DIFFER, V32, P243; SHINOMURA T, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P35; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; SUZUKI Y, 1993, BIOCHEM BIOPH RES CO, V190, P426, DOI 10.1006/bbrc.1993.1065; TAKAMOTO M, 1989, J BIOCHEM-TOKYO, V105, P742, DOI 10.1093/oxfordjournals.jbchem.a122738; TAKAMOTO M, 1989, J BIOCHEM-TOKYO, V106, P228, DOI 10.1093/oxfordjournals.jbchem.a122837; TAKASAKI S, 1980, J BIOCHEM-TOKYO, V88, P1587, DOI 10.1093/oxfordjournals.jbchem.a133133; TRUE DD, 1990, J CELL BIOL, V111, P2757, DOI 10.1083/jcb.111.6.2757; WATSON SR, 1991, J CELL BIOL, V115, P235, DOI 10.1083/jcb.115.1.235; YAMAGATA M, 1993, ANAT EMBRYOL, V187, P433; YAMAGATA M, 1986, J BIOL CHEM, V261, P3526; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	45	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27603	27609						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961677				2022-12-27	WOS:A1994PV77100069
J	DICKSON, R; LARSEN, B; VIITANEN, PV; TORMEY, MB; GESKE, J; STRANGE, R; BEMIS, LT				DICKSON, R; LARSEN, B; VIITANEN, PV; TORMEY, MB; GESKE, J; STRANGE, R; BEMIS, LT			CLONING, EXPRESSION, AND PURIFICATION OF A FUNCTIONAL NONACETYLATED MAMMALIAN MITOCHONDRIAL CHAPERONIN-10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI GROEL; EARLY-PREGNANCY FACTOR; HEAT-SHOCK PROTEIN; YEAST MITOCHONDRIA; ATP HYDROLYSIS; IDENTIFICATION; GENE; BACTERIAL; HOMOLOG; BINDING	An intact mouse mitochondrial chaperonin 10 has been cloned, sequenced, and overexpressed in Escherichia coli as a fusion protein harboring an oligohistidine tail at its COOH terminus. The latter was added to simplify protein purification. The purified protein is free of contaminating groES from the bacterial host cells. Edman degradation reveals that the initiator Met residue of the recombinant protein is removed in vivo, similar to the authentic chaperonin 10 purified from rat liver mitochondria. However, in contrast to the latter, the amino-terminal Ala residue of the recombinant protein is not acetylated; the molecular mass determined by electrospray ionization mass spectrometry is 12,350.9 +/- 2.6 daltons, in agreement with that predicted for the nonacetylated protein (12,351.2 daltons). Facilitated protein folding experiments with ribulose-bisphosphate carboxylase, under ''nonpermissive'' in vitro conditions, demonstrate that the recombinant protein is fully functional with groEL. Thus, both the initial rates of protein folding and final yields observed with this heterologous combination are virtually identical to those obtained with groEL and groES. More important, like the authentic protein purified hom mitochondria, the recombinant mitochondrial chaperonin 10, but not groES, is functionally compatible with the heptameric chaperonin 60 of mammalian mitochondria.	DUPONT CO INC,DEPT CENT RES & DEV,DIV MOLEC BIOL,EXPTL STN,WILMINGTON,DE 19880; AMC CANC RES CTR,DENVER,CO 80214	DuPont; AMC Cancer Research Center				Bemis, Lynne/0000-0001-9986-7154	NATIONAL CANCER INSTITUTE [R25CA049981] Funding Source: NIH RePORTER; NCI NIH HHS [CA49981] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BERTSCH U, 1992, P NATL ACAD SCI USA, V89, P8696, DOI 10.1073/pnas.89.18.8696; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CAVANAGH AC, 1994, EUR J BIOCHEM, V222, P551, DOI 10.1111/j.1432-1033.1994.tb18897.x; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; GATENBY AA, 1994, ANNU REV PLANT PHYS, V45, P469; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; HARTMAN DJ, 1993, BIOCHIM BIOPHYS ACTA, V1164, P219, DOI 10.1016/0167-4838(93)90251-L; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MILLER AD, 1993, BIOCHEM J, V291, P139, DOI 10.1042/bj2910139; MORTON H, 1992, REPROD FERT DEVELOP, V4, P411, DOI 10.1071/RD9920411; PICKETTS DJ, 1989, J BIOL CHEM, V264, P12001; PILKINGTON SJ, 1993, J DNA SEQ MAPPING, V3, P291; QUINN KA, 1990, CLIN EXP IMMUNOL, V80, P101; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROLFE BE, 1983, AM J REPROD IMMUNOL, V3, P97, DOI 10.1111/j.1600-0897.1983.tb00223.x; ROSPERT S, 1993, P NATL ACAD SCI USA, V90, P10967, DOI 10.1073/pnas.90.23.10967; ROSPERT S, 1993, FEBS LETT, V335, P358, DOI 10.1016/0014-5793(93)80419-U; RYAN MT, 1994, FEBS LETT, V337, P152, DOI 10.1016/0014-5793(94)80263-7; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; WEAVER AJ, 1993, BIOPHYS J, V64, pA350; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	53	32	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26858	26864						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929423				2022-12-27	WOS:A1994PQ93100044
J	VELASCO, G; FERRANDO, AA; PUENTE, XS; SANCHEZ, LM; LOPEZOTIN, C				VELASCO, G; FERRANDO, AA; PUENTE, XS; SANCHEZ, LM; LOPEZOTIN, C			HUMAN CATHEPSIN-O - MOLECULAR-CLONING FROM A BREAST-CARCINOMA, PRODUCTION OF THE ACTIVE ENZYME IN ESCHERICHIA-COLI, AND EXPRESSION ANALYSIS IN HUMAN TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCES; CYSTEINE PROTEINASES; RNA; INHIBITORS; TUMORS; FIBROBLASTS; DEGRADATION; NUCLEOTIDE; RESOLUTION; PROTEASES	A cDNA encoding a novel member of the cysteine proteinase family of proteins has been cloned from a human breast carcinoma cDNA library, by using a polymerase chain reaction-based cloning strategy. The isolated cDNA contains an open reading frame coding for a polypeptide of 321 amino acids that has been tentatively called cathepsin O. This protein presents all the structural features characteristic of the different cysteine proteinases identified to date, including the active site cysteine residue that is involved in covalent intermediate formation during peptide hydrolysis. The cathepsin O cDNA was expressed in Escherichia coli, and after purification and refolding, the recombinant protein was able to degrade the synthetic peptides benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin and benzyloxycarbonyl-Arg-Arg-7-amido- 4-methylcoumarin widely used as substrates for cysteine proteinases. Cathepsin O proteolytic activity was abolished by trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane (E-64), an inhibitor of this subclass of proteolytic enzymes, thus providing additional evidence that the isolated cDNA codes for an authentic cysteine proteinase. Northern blot analysis of poly(A)(+) RNAs isolated from a variety of human tissues demonstrated that cathepsin O is expressed in all examined tissues, which is consistent with a putative role of this protein as a proteolytic enzyme involved in normal cellular protein degradation and turnover.	UNIV OVIEDO,FAC MED,DEPT BIOL FUNC,E-33006 OVIEDO,SPAIN	University of Oviedo			Puente, Xosé S./ADB-0672-2022; Velasco, Gloria/AAS-5842-2021; Lopez-Otin, Carlos/AAB-2106-2020	Puente, Xosé S./0000-0001-9525-1483; Velasco, Gloria/0000-0001-8032-5056; Lopez-Otin, Carlos/0000-0001-6964-1904				BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; CHAMBERS AF, 1992, MOL CARCINOGEN, V5, P238, DOI 10.1002/mc.2940050311; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; CHAUHAN SS, 1991, CANCER RES, V51, P1478; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELAISSE JM, 1984, BIOCHEM BIOPH RES CO, V125, P441, DOI 10.1016/0006-291X(84)90560-6; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIEZITZA I, 1993, BRIT J CANCER, V68, P637, DOI 10.1038/bjc.1993.399; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; FUCHS R, 1988, BIOL CHEM H-S, V369, P469, DOI 10.1515/bchm3.1988.369.1.469; GAL S, 1988, BIOCHEM J, V253, P303, DOI 10.1042/bj2530303; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GONG QM, 1993, DNA CELL BIOL, V12, P299, DOI 10.1089/dna.1993.12.299; Gottesman M., 1990, SEMIN CANCER BIOL, V1, P97; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; KAMPHUIS IG, 1985, J MOL BIOL, V182, P317, DOI 10.1016/0022-2836(85)90348-1; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; KIRSCHKE H, 1982, BIOCHEM J, V201, P367, DOI 10.1042/bj2010367; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KRIEGER TJ, 1991, J BIOL CHEM, V266, P8376; Lopez-Otin C, 1988, Virus Genes, V1, P291, DOI 10.1007/BF00572708; MACIEWICZ RA, 1988, BIOCHEM J, V256, P433, DOI 10.1042/bj2560433; Maniatis T., 1982, MOL CLONING; MASON RW, 1985, BIOCHEM J, V226, P233, DOI 10.1042/bj2260233; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MORT JS, 1984, ARTHRITIS RHEUM, V27, P509, DOI 10.1002/art.1780270505; MOTTRAM JC, 1992, MOL MICROBIOL, V6, P1925, DOI 10.1111/j.1365-2958.1992.tb01365.x; MURNANE MJ, 1991, CANCER RES, V51, P1137; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; PETANCESKA S, 1992, J BIOL CHEM, V267, P26038; QIAN F, 1989, CANCER RES, V49, P4870; RECKLIES AD, 1982, BIOCHEM J, V207, P633, DOI 10.1042/bj2070633; RITONJA A, 1988, FEBS LETT, V228, P341, DOI 10.1016/0014-5793(88)80028-0; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROUGHLEY PJ, 1977, BIOCHEM J, V167, P629, DOI 10.1042/bj1670629; SANCHEZ LM, 1992, J BIOL CHEM, V267, P24725; SANCHEZ LM, 1993, BRIT J CANCER, V67, P1076, DOI 10.1038/bjc.1993.197; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHI GP, 1992, J BIOL CHEM, V267, P7258; Sloane B F, 1990, Semin Cancer Biol, V1, P137; SLOANE BF, 1981, SCIENCE, V212, P1151, DOI 10.1126/science.7233209; SLOANE BF, 1992, BIOL CHEM H-S, V373, P589, DOI 10.1515/bchm3.1992.373.2.589; SMITH SM, 1989, J BIOL CHEM, V264, P20487; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; THOMAS GJ, 1989, BIOCHIM BIOPHYS ACTA, V990, P246, DOI 10.1016/S0304-4165(89)80041-8; URIA JA, 1994, CANCER RES, V54, P2091; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WIEDERANDERS B, 1992, J BIOL CHEM, V267, P13708	51	80	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27136	27142						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929457				2022-12-27	WOS:A1994PQ93100081
J	BROWN, NF; ESSER, V; FOSTER, DW; MCGARRY, JD				BROWN, NF; ESSER, V; FOSTER, DW; MCGARRY, JD			EXPRESSION OF A CDNA FOR RAT-LIVER CARNITINE PALMITOYLTRANSFERASE-I IN YEAST ESTABLISHES THAT CATALYTIC ACTIVITY AND MALONYL-COA SENSITIVITY RESIDE IN A SINGLE POLYPEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME-SYSTEM; MITOCHONDRIAL OUTER; BINDING; INHIBITORS; MEMBRANES; DEFICIENCY; COMPONENTS; AFFINITY; CLONING; TISSUES	A cDNA encoding full-length carnitine palmitoyltransferase I (CPT I) from rat liver was expressed in Saccharomyces cerevisiae, a system devoid of endogenous CPT activity. The recombinant enzyme was of the expected size (as deduced from immunoblots), membrane-bound, and detergent-labile. It was also potently inhibited by malonyl-CoA, with an I-50 value (concentration causing 50% inhibition) of similar to 5 mu M, similar to that of the native enzyme in rat liver mitochondria. A truncated variant of the enzyme that lacked the amino-terminal 82 residues encompassing the first hydrophobic domain retained catalytic function but was much less sensitive to malonyl-CoA (I-50 > 80 mu M). Deletion of the cDNA segment encoding amino acids 31-148 (which includes both first and second hydrophobic stretches) resulted in no detectable product. The data establish unequivocally that a single polypeptide possesses both catalytic and malonyl-CoA binding domains, as well as the other properties previously attributed by us to native CPT I in mammalian mitochondria, and should thus put to rest the controversy surrounding this issue (Kerner, J., Zaluzec, E., Gage, D., and Bieber, L. L. (1994) J. Biol. Chem. 269, 8209-8219). In addition, the results strengthen the view that one site of interaction of malonyl-CoA with the rat liver enzyme involves the NH2-terminal region of the molecule.	UNIV TEXAS,SW MED CTR,SW MED SCH,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,SW MED SCH,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,SW MED SCH,GIFFORD LABS DIABET RES,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK18573] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018573, R37DK018573] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BONNEFONT JP, 1990, PROG CLIN BIOL RES, V321, P451; BROWN NF, 1994, J BIOL CHEM, V269, P19157; CHUNG CH, 1992, BIOCHEMISTRY-US, V31, P9777, DOI 10.1021/bi00155a034; COOK GA, 1994, J BIOL CHEM, V269, P8803; DECLERCQ PE, 1987, J BIOL CHEM, V262, P9812; DEMAUGRE F, 1988, PEDIATR RES, V24, P308, DOI 10.1203/00006450-198809000-00006; ESSER V, 1993, J BIOL CHEM, V268, P5817; ESSER V, 1993, J BIOL CHEM, V268, P5810; FOLEY JE, 1992, DIABETES CARE, V15, P773, DOI 10.2337/diacare.15.6.773; GHADIMINEJAD I, 1990, BIOCHEM J, V270, P787, DOI 10.1042/bj2700787; GHADIMINEJAD I, 1991, BIOCHEM J, V277, P611, DOI 10.1042/bj2770611; GHADIMINEJAD I, 1991, BIOCHIM BIOPHYS ACTA, V1083, P166, DOI 10.1016/0005-2760(91)90038-J; GRANTHAM BD, 1986, BIOCHEM J, V233, P589, DOI 10.1042/bj2330589; KASHFI K, 1992, BIOCHEM J, V282, P909, DOI 10.1042/bj2820909; KASHFI K, 1994, BBA-LIPID LIPID MET, V1212, P245, DOI 10.1016/0005-2760(94)90259-3; KERNER J, 1994, J BIOL CHEM, V269, P8209; KOLODZIEJ MP, 1990, BIOCHEM J, V267, P85, DOI 10.1042/bj2670085; KOLODZIEJ MP, 1990, BIOCHEM J, V272, P421, DOI 10.1042/bj2720421; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUND H, 1986, BIOCHIM BIOPHYS ACTA, V878, P243, DOI 10.1016/0005-2760(86)90152-9; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MCGARRY JD, 1992, PROG CLIN BIOL RES, V375, P47; MILLS SE, 1983, BIOCHEM J, V214, P83, DOI 10.1042/bj2140083; MURTHY MSR, 1987, P NATL ACAD SCI USA, V84, P378, DOI 10.1073/pnas.84.2.378; MURTHY MSR, 1987, BIOCHEM J, V248, P727, DOI 10.1042/bj2480727; MYNATT RL, 1984, BIOCHEM J, V299, P761; PANDE SV, 1986, BIOCHIM BIOPHYS ACTA, V877, P223, DOI 10.1016/0005-2760(86)90298-5; Sambrook J, 1989, MOL CLONING LABORATO; TARONI F, 1992, P NATL ACAD SCI USA, V89, P8429, DOI 10.1073/pnas.89.18.8429; TEIN I, 1994, J PEDIATR-US, V124, P938, DOI 10.1016/S0022-3476(05)83187-7; WEIS BC, 1994, J BIOL CHEM, V269, P18712; WOELTJE KF, 1987, J BIOL CHEM, V262, P9822; WOELTJE KF, 1990, J BIOL CHEM, V265, P10720; WOELTJE KF, 1990, J BIOL CHEM, V265, P10714; WOLDEGIORGIS G, 1992, ARCH BIOCHEM BIOPHYS, V295, P348, DOI 10.1016/0003-9861(92)90527-4	36	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26438	26442						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929364				2022-12-27	WOS:A1994PQ93000076
J	JEZEK, P; OROSZ, DE; MODRIANSKY, M; GARLID, KD				JEZEK, P; OROSZ, DE; MODRIANSKY, M; GARLID, KD			TRANSPORT OF ANIONS AND PROTONS BY THE MITOCHONDRIAL UNCOUPLING PROTEIN AND ITS REGULATION BY NUCLEOTIDES AND FATTY-ACIDS - A NEW LOOK AT OLD HYPOTHESES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN-ADIPOSE-TISSUE; INNER MEMBRANE; PURINE NUCLEOTIDES; LIGHT-SCATTERING; RECONSTITUTION; CONDUCTANCE; UNIPORT; H+; CONTRACTION; ACTIVATION	The uncoupling protein generates heat by catalyzing electrophoretic proton transport across the inner membrane of brown adipose tissue mitochondria. It also transports Cl- and other monovalent anions, and both proton and anion transport are inhibited by purine nucleotides. Several long standing hypotheses bear on specific aspects of Cl- transport, H+ transport, and nucleotide gating mechanisms in uncoupling protein. We reevaluated these hypotheses in mitochondria and liposomes reconstituted with purified uncoupling protein; GDP inhibition is strictly noncompetitive with Cl- and unaffected by either transmembrane electrical potential or fatty acids. The K-m and V-max values for Cl- are independent of pH, arguing against a common binding site for Cl- and OH- ions. Cl- transport was inhibited by fatty acids and stimulated by fatty acid removal, refuting the consensus hypothesis that there is no interaction between fatty acids and anion transport through uncoupling protein. These results support a mechanism in which the transport pathway for anions is identical with the fatty acid binding site and distinct from the nucleotide binding site.	OREGON GRAD INST SCI & TECHNOL, DEPT CHEM BIOCHEM & MOLEC BIOL, PORTLAND, OR 97291 USA; ACAD SCI CZECH REPUBL, INST PHYSIOL, CR-14220 PRAGUE, CZECH REPUBLIC; CASE WESTERN RESERVE UNIV, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA	Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; Case Western Reserve University			Modriansky, Martin/A-6338-2008; Jezek, Petr/B-9264-2012	Modriansky, Martin/0000-0001-7692-0338; Jezek, Petr/0000-0002-2720-9395; Garlid, Keith/0000-0002-6777-1235	FIC NIH HHS [TW00120] Funding Source: Medline; NIGMS NIH HHS [GM31086] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031086] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; CANNON B, 1977, FEBS LETT, V74, P43, DOI 10.1016/0014-5793(77)80748-5; Chinet A, 1978, Experientia Suppl, V32, P25; CUNNINGHAM SA, 1986, EUR J BIOCHEM, V157, P415, DOI 10.1111/j.1432-1033.1986.tb09683.x; DIRESTA DJ, 1986, AM J PHYSIOL, V251, pR787, DOI 10.1152/ajpregu.1986.251.4.R787; GARLID KD, 1989, BIOCHIM BIOPHYS ACTA, V976, P109, DOI 10.1016/S0005-2728(89)80219-1; GARLID KD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P151, DOI 10.1016/0005-2728(90)90237-X; GARLID KD, 1985, J BIOL CHEM, V260, P3434; GARLID KD, 1986, BIOCHIM BIOPHYS ACTA, V853, P187, DOI 10.1016/0304-4173(87)90001-2; JEZEK P, 1988, J BIOENERG BIOMEMBR, V20, P603, DOI 10.1007/BF00768922; JEZEK P, 1990, J BIOL CHEM, V265, P19303; JEZEK P, 1989, AM J PHYSIOL, V257, pC1142, DOI 10.1152/ajpcell.1989.257.6.C1142; JEZEK P, 1990, J BIOL CHEM, V265, P19296; JEZEK P, 1990, J LIPID MEDIATOR, V2, P85; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KLINGENBERG M, 1985, EMBO J, V4, P3087, DOI 10.1002/j.1460-2075.1985.tb04049.x; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; LANOUE KF, 1986, J BIOL CHEM, V261, P298; LOCKE RM, 1982, EUR J BIOCHEM, V129, P373, DOI 10.1111/j.1432-1033.1982.tb07060.x; MURDZAINGLIS DL, 1994, J BIOL CHEM, V269, P7435; MURDZAINGLIS DL, 1991, J BIOL CHEM, V266, P11871; NEDERGAARD J, 1994, BBA-BIOENERGETICS, V1185, P311, DOI 10.1016/0005-2728(94)90246-1; NEDERGAARD J, 1992, NEW COMPREHENSIVE BI, V23, P385; NICHOLLS DG, 1976, EUR J BIOCHEM, V62, P223, DOI 10.1111/j.1432-1033.1976.tb10151.x; NICHOLLS DG, 1977, EUR J BIOCHEM, V77, P349, DOI 10.1111/j.1432-1033.1977.tb11674.x; NICHOLLS DG, 1974, EUR J BIOCHEM, V49, P585, DOI 10.1111/j.1432-1033.1974.tb03862.x; NICHOLLS DG, 1984, BIOCHEM SOC T, V12, P388, DOI 10.1042/bst0120388; NICHOLLS DG, 1979, BIOCHIM BIOPHYS ACTA, V549, P1, DOI 10.1016/0304-4173(79)90016-8; OROSZ DE, 1993, ANAL BIOCHEM, V210, P7, DOI 10.1006/abio.1993.1143; RIAL E, 1989, ANION CARRIERS OF MITOCHONDRIAL MEMBRANES, P261; RIAL E, 1983, EUR J BIOCHEM, V137, P197, DOI 10.1111/j.1432-1033.1983.tb07815.x; RICQUIER D, 1991, FASEB J, V5, P2237, DOI 10.1096/fasebj.5.9.1860614; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; STRIELEMAN PJ, 1985, AM J PHYSIOL, V248, pE699, DOI 10.1152/ajpendo.1985.248.6.E699; STRIELEMAN PJ, 1985, J BIOL CHEM, V260, P3402; WINKLER E, 1994, J BIOL CHEM, V269, P2508; WINKLER E, 1992, EUR J BIOCHEM, V207, P135, DOI 10.1111/j.1432-1033.1992.tb17030.x	37	103	105	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26184	26190						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929332				2022-12-27	WOS:A1994PQ93000039
J	WANG, JB; JOHNSON, PS; WU, JM; WANG, WF; UHL, GR				WANG, JB; JOHNSON, PS; WU, JM; WANG, WF; UHL, GR			HUMAN KAPPA-OPIATE RECEPTOR 2ND EXTRACELLULAR LOOP ELEVATES DYNORPHINS AFFINITY FOR HUMAN MU/KAPPA CHIMERAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DELTA-OPIOID RECEPTOR; FORMYL PEPTIDE RECEPTOR; LIGAND-BINDING; EXPRESSION; CLONING; DOMAINS; ANTAGONIST; AGONISTS; CDNA	To investigate roles of second extracellular loop sequences in peptide and nonpeptide ligand recognition by human opiate receptors, we have constructed a chimeric receptor in which this domain of the human mu opiate receptor has been replaced with that of the human kappa opiate receptor. The chimeric opiate receptor displays dramatically increased affinity for dynorphin peptides. Affinities for dynorphin A-(1-17), dynorphin A-(1-13), and alpha-neoendorphin increase by up to 250-fold when compared with the wild-type human mu opiate receptor. The chimera maintains recognition of the mu-selective ligands morphine and [D-Ala(2),MePhe(4),Gly-ol(5)] enkephalin and displays no significant changes in affinity for the kappa-selective small molecule ligand U50,488. The chimeric opiate receptor displays evidence for effective G-protein coupling; 100 nM dynorphin A-(1-17) is as effective as 100 nM morphine at inhibiting forskolin-stimulated adenyl cyclase activity through actions at the chimeric receptor. These data suggest that the putative second extracellular loop contributes substantially to the kappa receptor's selectivity in dynorphin ligand recognition.	NIDA,MOLEC NEUROBIOL BRANCH,BALTIMORE,MD 21224; NIDA,INTRAMURAL RES PROGRAM,OFF DIRECTOR,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21224	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); Johns Hopkins University; Johns Hopkins University								EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FONG TM, 1992, J BIOL CHEM, V267, P25664; FUKUDA K, 1993, FEBS LETT, V327, P311, DOI 10.1016/0014-5793(93)81011-N; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GETHER U, 1993, J BIOL CHEM, V268, P7893; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KNAPP RJ, 1994, LIFE SCI, V54, P463; KONG HY, 1993, J BIOL CHEM, V268, P23055; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PEREZ HD, 1993, J BIOL CHEM, V268, P2292; QUEHENBERGER O, 1993, J BIOL CHEM, V268, P18167; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; TAKEMORI AE, 1992, ANNU REV PHARMACOL, V32, P239, DOI 10.1146/annurev.pa.32.040192.001323; UHL GR, 1994, TRENDS NEUROSCI, V17, P89, DOI 10.1016/0166-2236(94)90110-4; WANG JB, 1993, P NATL ACAD SCI USA, V90, P10230, DOI 10.1073/pnas.90.21.10230; WANG JB, 1994, FEBS LETT, V338, P217, DOI 10.1016/0014-5793(94)80368-4; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736	21	116	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					25966	25969						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929306				2022-12-27	WOS:A1994PQ93000007
J	WINDSOR, LJ; BODDEN, MK; BIRKEDALHANSEN, B; ENGLER, JA; BIRKEDALHANSEN, H				WINDSOR, LJ; BODDEN, MK; BIRKEDALHANSEN, B; ENGLER, JA; BIRKEDALHANSEN, H			MUTATIONAL ANALYSIS OF RESIDUES IN AND AROUND THE ACTIVE-SITE OF HUMAN FIBROBLAST-TYPE COLLAGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASES; CYSTEINE SWITCH; ACTIVATION; PROCOLLAGENASE; THERMOLYSIN; FAMILY; IDENTIFICATION; INHIBITORS; PRINCIPLE; PROTEINS	Mutants in and around the catalytic zinc-binding site of human fibroblast-type collagenase have been expressed in Escherichia coli. Replacement of each of the three zinc ligands, His-199, His-203, and His-209, in the active site sequence: VAAHEXGHXXGXXH, not only destroyed catalytic activity but also led to improper folding of the polypeptide, suggesting that this sequence also serves as a structural zinc-binding site. By comparison, mutation of His-194 immediately preceding this sequence had no measurable effect on catalytic activity or on folding. Replacement of Glu-200 in the active site yielded enzymes that either were completely inactive (E200Q) or had greatly diminished (E200D) catalytic activity. Both Glu-200 mutants, however, were fully capable of forming complexes with tissue inhibitor of metalloproteinases-1 (TIMP-1) after reaction with organomercurials. Formation of complexes with TIMP-1 appear to require a properly folded, but not necessarily catalytically competent, active site. By contrast, complexes with alpha(2)-macroglobulin form only with mutants with a catalytically competent active site. Two mutants identified in this study (E200Q and D212E) appeared to be properly folded but unable to generate any catalytic activity when exposed to either p-aminophenylmercuric acetate, trypsin, or SDS.	UNIV ALABAMA,SCH DENT,DEPT ORAL BIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,ORAL BIOL RES CTR,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,DEPT DIAGNOST SCI,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,DEPT RESTORAT DENT,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT PATHOL,BIRMINGHAM,AL 35294; NIDR,BETHESDA,MD 20892	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	WINDSOR, LJ (corresponding author), UNIV ALABAMA,DEPT MOLEC GENET & BIOCHEM,BIRMINGHAM,AL 35294, USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE006028, R01DE009122, P50DE008228] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE08228, DE06028, DE09122] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BIRKEDALHANSEN B, 1988, BIOCHEMISTRY-US, V27, P6751, DOI 10.1021/bi00418a016; BIRKEDALHANSEN H, 1982, BIOCHEM BIOPH RES CO, V107, P1173, DOI 10.1016/S0006-291X(82)80120-4; BIRKEDALHANSEN H, 1987, METHOD ENZYMOL, V144, P140; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BIRKEDALHANSEN H, 1976, J BIOL CHEM, V251, P3162; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; GRANT GA, 1987, J BIOL CHEM, V262, P5886; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGENDRE N, 1990, Biotechniques, V9, P788; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P37, DOI 10.1038/newbio238037a0; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P41, DOI 10.1038/newbio238041a0; Nagase H, 1992, Matrix Suppl, V1, P421; SALOWE SP, 1992, BIOCHEMISTRY-US, V31, P4535, DOI 10.1021/bi00134a001; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P393; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1992, MATRIX METALLOPROTEI, P5; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	33	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26201	26207						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929334				2022-12-27	WOS:A1994PQ93000042
J	KUMAR, R; KORUTLA, L; ZHANG, KR				KUMAR, R; KORUTLA, L; ZHANG, KR			CELL CYCLE-DEPENDENT MODULATION OF ALPHA-INTERFERON-INDUCIBLE GENE-EXPRESSION AND ACTIVATION OF SIGNALING COMPONENTS IN DAUDI CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-REGULATION; 2'-5'-OLIGOADENYLATE SYNTHETASE; GAMMA-INTERFERON; TYROSINE KINASE; MESSENGER-RNA; A431 CELLS; PROTEIN; BINDING; DIFFERENTIATION; PHOSPHORYLATION	To investigate cell cycle-dependent expression of interferon (IFN)-induced genes and signaling pathways, we examined the modulation of IPN inducible gene expression and p91 activation, and JAK-1 and Tyk-2 kinases' activation in human Burkitt's lymphoma Daudi cells which were synchronized at different points in the cell cycle progression. We observed that each one of 100-, 67-, and 46-kDa 2'-5'-oligoadenylate synthetase (2-5(A)synthetase) proteins had a unique expression pattern in different phases of the cell cycle which was different from the expression of 2-5(A)-synthetase proteins in exponentially growing Daudi cells. The cell cycle-dependent changes in the overall levels of expression of 2-5(A)synthetase proteins correlated well with the induction of expression of 2-5(A)-synthetase mRNA as well as the appearance of IFN stimulatory gene factor-3 and expression and activation of p91 in cells released from the C-1/S block in the absence of exogenous IFN-LU. In addition, cells from the C-1/S phase exhibited increased tyrosine phosphorylation of JAK-1 and Tyk-2 kinases and p91 by IFN-alpha as compared with asynchronized cells. Enhanced stimulation of activation of JAK-1, Tyk-2, and p91 by IFN-alpha was progressively reduced from C-1/S to G(2)/M to pass G(2)/M. These findings demonstrate that the levels of constitutive and inducible expression of IBN-alpha-inducible genes, activation of p91, and tyrosine phosphorylation of JAK-1 and Tyk-2 kinases are differentially influenced by the state of the cell cycle.	PENN STATE UNIV,COLL MED,DEPT MED,HERSHEY,PA 17033; PENN STATE UNIV,COLL MED,DEPT CELLULAR & MOLEC PHYSIOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NCI NIH HHS [CA56564] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BANDYOPADHYAY SK, 1990, MOL CELL BIOL, V10, P5055, DOI 10.1128/MCB.10.10.5055; BANDYOPADHYAY SK, 1992, CELL GROWTH DIFFER, V3, P369; CHEBATH J, 1987, J BIOL CHEM, V262, P3852; CLEMENS MJ, 1985, BIOCHEM J, V226, P345, DOI 10.1042/bj2260345; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; CREASEY AA, 1983, MOL CELL BIOL, V3, P780, DOI 10.1128/MCB.3.5.780; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KUMAR R, 1988, J VIROL, V62, P3175, DOI 10.1128/JVI.62.9.3175-3181.1988; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; KUMAR R, 1987, J VIROL, V61, P2727, DOI 10.1128/JVI.61.9.2727-2732.1987; KUMAR R, 1990, J BIOL CHEM, V265, P4578; KUMAR R, 1989, CANCER RES, V49, P5180; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PFEFFER LM, 1990, CANCER RES, V50, P2654; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SEN GC, 1992, J BIOL CHEM, V267, P5017; WELLS V, 1985, EXP CELL RES, V159, P27, DOI 10.1016/S0014-4827(85)80034-3; WELLS V, 1988, J INTERFERON RES, V8, P293; ZHANG KR, 1994, BIOCHEM BIOPH RES CO, V200, P522, DOI 10.1006/bbrc.1994.1479	32	35	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25437	25441						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929242				2022-12-27	WOS:A1994PQ49100035
J	SAKAMOTO, T; WADA, H; NISHIDA, I; OHMORI, M; MURATA, N				SAKAMOTO, T; WADA, H; NISHIDA, I; OHMORI, M; MURATA, N			DELTA-9 ACYL-LIPID DESATURASES OF CYANOBACTERIA - MOLECULAR-CLONING AND SUBSTRATE SPECIFICITIES IN TERMS OF FATTY-ACIDS, SN-POSITIONS, AND POLAR HEAD GROUPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARRIER-PROTEIN DESATURASE; STEAROYL-COA DESATURASE; BLUE-GREEN-ALGA; SYNECHOCYSTIS PCC6803; NUCLEOTIDE-SEQUENCE; ANABAENA-VARIABILIS; COMPLEMENTARY-DNA; RICINUS-COMMUNIS; GENE; EXPRESSION	In cyanobacteria, the biosynthesis of unsaturated fatty acids is initiated by Delta 9 acyl-lipid desaturase which introduces the first double bond at the Delta 9 position of a saturated fatty acid that has been esterified to a glycerolipid. We have cloned genes, designated desC, for Delta 9 acyl-lipid desaturases from two cyanobacteria, namely Anabaena variabilis and Synechocystis sp. PCC 6803. These desaturases, when expressed in Escherichia coli, desaturated stearic acid to yield oleic acid at the C-1 positions of phosphatidylethanolamine and phosphatidylglycerol, but did not desaturate palmitic acid, palmitoleic acid, and cis-vaccenic acid. These results indicate that the Delta 9 acyl-lipid desaturases are specific to stearic acid esterified at the C-1 position of a glycerolipid and are nonspecific with respect to the polar head group of the glycerolipid. The deduced amino acid sequences of the Delta 9 acyl-lipid desaturases are similar in part to those of stearoyl-CoA desaturases of the rat, the mouse, and Saccharomyces cerevisiae, but not to those of acyl-(acyl-carrier-protein) desaturases of higher plants.	NATL INST BASIC BIOL,OKAZAKI,AICHI 444,JAPAN; GRAD UNIV ADV STUDIES,DEPT MOLEC BIOMECH,OKAZAKI,AICHI 444,JAPAN; KYUSHU UNIV,BIOL LAB,FUKUOKA 810,JAPAN; UNIV TOKYO,COLL ARTS & SCI,DEPT BIOL,MEGURO KU,TOKYO 153,JAPAN	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan; Kyushu University; University of Tokyo			Wada, Hajime/K-2186-2015; Nishida, Ikuo/W-8007-2019; Nishida, Ikuo/E-3339-2010; Murata, Norio/E-6569-2010	Nishida, Ikuo/0000-0002-9669-4005; Sakamoto, Toshio/0000-0003-0993-0805				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARONDEL V, 1992, SCIENCE, V258, P1353, DOI 10.1126/science.1455229; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CAHOON EB, 1994, PLANT PHYSIOL, V104, P827, DOI 10.1104/pp.104.3.827; CAHOON EB, 1992, P NATL ACAD SCI USA, V89, P11184, DOI 10.1073/pnas.89.23.11184; FISCHER W, 1973, H-S Z PHYSIOL CHEM, V354, P1115, DOI 10.1515/bchm2.1973.354.2.1115; FOX BG, 1993, P NATL ACAD SCI USA, V90, P2486, DOI 10.1073/pnas.90.6.2486; GOMBOS Z, 1992, P NATL ACAD SCI USA, V89, P9959, DOI 10.1073/pnas.89.20.9959; GOMBOS Z, 1994, IN PRESS P NATL ACAD; HARWOOD JL, 1988, ANNU REV PLANT PHYS, V39, P101, DOI 10.1146/annurev.arplant.39.1.101; HOLLOWAY PW, 1983, ENZYMES, V16, P63; IBA K, 1993, J BIOL CHEM, V268, P24099; Jaworski JG., 1987, BIOCH PLANTS COMPREH, P159; KNOELL HE, 1974, EUR J BIOCHEM, V50, P245, DOI 10.1111/j.1432-1033.1974.tb03893.x; KNUTZON DS, 1991, PLANT PHYSIOL, V96, P344, DOI 10.1104/pp.96.1.344; KNUTZON DS, 1992, P NATL ACAD SCI USA, V89, P2624, DOI 10.1073/pnas.89.7.2624; MCKEON TA, 1982, J BIOL CHEM, V257, P2141; MURATA N, 1992, PLANT CELL PHYSIOL, V33, P933; NISHIDA I, 1992, PLANT MOL BIOL, V19, P711, DOI 10.1007/BF00026799; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; OKULEY J, 1994, PLANT CELL, V6, P147, DOI 10.1105/tpc.6.1.147; REDDY AS, 1993, PLANT MOL BIOL, V27, P283; ROCK CO, 1981, J BIOL CHEM, V256, P736; SAKAMOTO T, 1994, PLANT MOL BIOL, V24, P643, DOI 10.1007/BF00023560; SAKAMOTO T, IN PRESS PLANT MOL B; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO N, 1986, PLANT CELL PHYSIOL, V27, P819, DOI 10.1093/oxfordjournals.pcp.a077168; SATO N, 1982, BIOCHIM BIOPHYS ACTA, V710, P279; SHANKLIN J, 1991, P NATL ACAD SCI USA, V88, P2510, DOI 10.1073/pnas.88.6.2510; SHANKLIN J, 1991, PLANT PHYSIOL, V97, P467, DOI 10.1104/pp.97.1.467; STRITTMATTER P, 1974, P NATL ACAD SCI USA, V71, P4565, DOI 10.1073/pnas.71.11.4565; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUKEY JE, 1990, J BIOL CHEM, V265, P20144; STUMPF PK, 1981, TRENDS BIOCHEM SCI, V6, P173, DOI 10.1016/0968-0004(81)90064-5; THIEDE MA, 1986, J BIOL CHEM, V261, P3230; THOMPSON GA, 1991, P NATL ACAD SCI USA, V88, P2578, DOI 10.1073/pnas.88.6.2578; WADA H, 1990, PLANT PHYSIOL, V92, P1062, DOI 10.1104/pp.92.4.1062; WADA H, 1994, P NATL ACAD SCI USA, V91, P4273, DOI 10.1073/pnas.91.10.4273; WADA H, 1993, J BACTERIOL, V175, P544, DOI 10.1128/JB.175.2.544-547.1993; WADA H, 1990, NATURE, V347, P200, DOI 10.1038/347200a0; WADA H, 1989, PLANT CELL PHYSIOL, V30, P971; YADAV NS, 1993, PLANT PHYSIOL, V103, P467, DOI 10.1104/pp.103.2.467	42	51	57	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25576	25580						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929259				2022-12-27	WOS:A1994PQ49100054
J	ARAKAWA, T; HANIU, M; NARHI, LO; MILLER, JA; TALVENHEIMO, J; PHILO, JS; CHUTE, HT; MATHESON, C; CARNAHAN, J; LOUIS, JC; YAN, Q; WELCHER, AA; ROSENFELD, R				ARAKAWA, T; HANIU, M; NARHI, LO; MILLER, JA; TALVENHEIMO, J; PHILO, JS; CHUTE, HT; MATHESON, C; CARNAHAN, J; LOUIS, JC; YAN, Q; WELCHER, AA; ROSENFELD, R			FORMATION OF HETERODIMERS FROM 3 NEUROTROPHINS, NERVE GROWTH-FACTOR, NEUROTROPHIN-3, AND BRAIN-DERIVED NEUROTROPHIC FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; FACTOR FAMILY; RECEPTORS; SIMILARITIES; EXPRESSION; STABILITY; MEMBER; CELLS	Three neurotrophic factors, brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and nerve growth factor (NGF) form noncovalent homodimers in solution. Since they are highly homologous proteins, it seemed probable that two monomers of these proteins might associate together to form a heterodimer. This was tested by denaturing the two different proteins together in 6 M guanidine HCl and refolding them in phosphate-buffered saline. When the refolded mixture of BDNF and NT-3 was subjected to Mono S cation exchange chromatography, a new peak was observed eluting between NT-3 and BDNF, which accounted for about 30% of the protein used. This new protein species migrated as a single band upon native gel electrophoresis with mobility between that of the NT-3 homodimer and the BDNF homodimer, indicating that a complex had been formed. Sedimentation equilibrium data show that the dissociation constant of this heterodimer is <3 x 10-(10) M. The heterodimer was stable upon incubation at 37 degrees C in phosphate-buffered saline over 11 days. Having determined that the heterodimer is highly stable, it was subjected to various biological assays. Autophosphorylation assay using TrkB receptor showed that the heterodimer is indistinguishable from the BDNF or NT-3 homodimer in the ability to induce phosphorylation of the receptor. It was also indistinguishable from the homodimers in the neurotrophic activity using chick dorsal root ganglion explant. In the sympathetic neuron survival assay, the heterodimer behaved more similarly to NT-3, whereas in the dopamine uptake assay, it was intermediate between the two homodimers. In addition, the heterodimer was shown to be retrogradely transported in the dorsal root ganglion neurons. A heterodimer between NGF and BDNF is formed but much less effectively than the NT-3 BDNF heterodimer, and it is not stable even at 4 degrees C. These results indicate that BDNF and NT-3 have an intersubunit contact surface for dimerization resembling each other's but different from the contact surface of NGF.			ARAKAWA, T (corresponding author), AMGEN INC,AMGEN CTR,1840 DEHAVILLAND DR,THOUSAND OAKS,CA 91320, USA.		Philo, John S/A-8804-2009	Philo, John S/0000-0003-3418-0356				ACKLIN C, 1993, INT J PEPT PROT RES, V41, P548; ANGLETTI RH, 1971, BIOCHEMISTRY-US, V10, P463; BARBACID M, 1993, ONCOGENE, V8, P2033; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; DECHANT G, 1993, J NEUROSCI, V13, P2610, DOI 10.1523/JNEUROSCI.13-06-02610.1993; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; MAISONPIERRE PC, 1990, SCIENCE, V247, P446; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P229; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; NARHI LO, 1993, J BIOL CHEM, V268, P13309; PHILO J, 1994, J BIOL CHEM, V269, P27840; PHILO JS, 1993, BIOCHEMISTRY-US, V32, P10812, DOI 10.1021/bi00091a036; RADZIEJEWSKI C, 1992, BIOCHEMISTRY-US, V31, P4431, DOI 10.1021/bi00133a007; RADZIEWJEWSKI C, 1993, BIOCHEMISTRY-US, V32, P13350, DOI 10.1021/bi00211a049; ROSENFELD R, 1993, J CHROMATOGR, V632, P29, DOI 10.1016/0021-9673(93)80022-Z; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; ROTHWELL M, 1977, J BIOL CHEM, V252, P8532; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YAN Q, 1991, SOC NEUR ABSTR	23	26	42	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27833	27839						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961712				2022-12-27	WOS:A1994PV77200013
J	BOYAN, BD; SCHWARTZ, Z; PARKSNYDER, S; DEAN, DD; YANG, FM; TWARDZIK, D; BONEWALD, LF				BOYAN, BD; SCHWARTZ, Z; PARKSNYDER, S; DEAN, DD; YANG, FM; TWARDZIK, D; BONEWALD, LF			LATENT TRANSFORMING GROWTH-FACTOR-BETA IS PRODUCED BY CHONDROCYTES AND ACTIVATED BY EXTRACELLULAR-MATRIX VESICLES UPON EXPOSURE TO 1,25-(OH)(2)D-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D METABOLITES; ARACHIDONIC-ACID TURNOVER; MOLECULAR-WEIGHT COMPLEX; CARTILAGE CELLS-INVITRO; RESTING ZONE; ALKALINE-PHOSPHATASE; PLATE CHONDROCYTES; FACTOR-BETA-1 GENE; MESSENGER-RNA; BONE CULTURES	Resting zone and growth zone (GC) costochondral chondrocytes constitutively release latent, but not active, transforming growth factor-beta (TGF-beta) into the culture medium. When exogenous TGF-beta is added to the culture medium, no autocrine effect is observed. However, when 1,25-(OH)(2)D-3 is added, a dose-dependent inhibition of latent TGF-beta release is found. Messenger RNA levels for TGF-beta 1 are unchanged by treatment with either 1,25-(OH)(2)D-3 or TGF-beta 1. Since active growth factor was not observed in the conditioned medium, we tested the hypothesis that latent TGF-beta could be activated in the matrix. GC matrix vesicles, extracellular organelles associated with matrix calcification, were able to activate latent TGF-beta 1 and TGF-beta 2 when preincubated with 1,25-(OH)(2)D-3. In contrast, GC plasma membranes activated latent TGF-beta, and addition of 1,25-(OH)(2)D-3 inhibited this activation. The 1,25-(OH)(2)D-3-dependent decrease in latent TGF-beta in the medium, with no detectable change in mRNA level, and the inhibition of plasma membrane activation of latent TGF-beta by 1,25-(OH)(2)D-3 suggest that 1,25-(OH)(2)D-3 may act through post-transcriptional and/or nongenomic mechanisms. The results also suggest that latent TGF-beta is activated in the matrix and that 1,25-(OH)(2)D-3 regulates this activation by a direct, non-genomic action on the matrix vesicle membrane.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DEPT PERIODONT,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DEPT MED ENDOCRINOL & METAB,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DEPT STRUCT & CELLULAR BIOL,SAN ANTONIO,TX 78284; HEBREW UNIV JERUSALEM,HADASSAH FAC DENT MED,DEPT PERIODONT,JERUSALEM,ISRAEL; ADV TISSUE SCI,LA JOLLA,CA 92037; UNIV WASHINGTON,SCH MED,DEPT DERMATOL,SEATTLE,WA 98195; AUDIE MURPHY VET AFFAIRS MED CTR,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Hebrew University of Jerusalem; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	BOYAN, BD (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT ORTHOPAED,SAN ANTONIO,TX 78284, USA.		Bonewald, Lynda/Q-3638-2019	Dean, David/0000-0002-4512-9065	NIDCR NIH HHS [DE08603, DE05937, DE08569] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE005937, R01DE008603, P01DE008569] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANDERSON HC, 1969, J CELL BIOL, V41, P59, DOI 10.1083/jcb.41.1.59; BASCOM CC, 1989, MOL CELL BIOL, V9, P5508, DOI 10.1128/MCB.9.12.5508; BONEWALD LF, 1992, J BIOL CHEM, V267, P8943; BONEWALD LF, 1990, J CELL PHYSIOL, V145, P200, DOI 10.1002/jcp.1041450203; BONEWALD LF, 1994, J CELL BIOCHEM, V55, P350, DOI 10.1002/jcb.240550312; BONEWALD LF, 1991, MOL ENDOCRINOL, V5, P741, DOI 10.1210/mend-5-6-741; BOSKEY AL, 1992, BONE MINER, V17, P257, DOI 10.1016/0169-6009(92)90747-2; BOSKEY AL, 1986, BONE, V7, P277, DOI 10.1016/8756-3282(86)90208-5; BOYAN BD, 1988, ENDOCRINOLOGY, V122, P2851, DOI 10.1210/endo-122-6-2851; BOYAN BD, 1988, BONE, V9, P185, DOI 10.1016/8756-3282(88)90008-7; BOYAN BD, 1989, J BIOL CHEM, V264, P11879; BOYAN BD, 1992, CRIT REV ORAL BIOL M, V3, P15, DOI 10.1177/10454411920030010401; BRETAUDIERE JP, 1984, METHOD ENZYMAT AN, V4, P75; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRABB ID, 1990, J BONE MINER RES, V5, P1105; DALLAS SL, 1994, J BIOL CHEM, V269, P6815; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; DAVIES LG, 1977, BASIC METHODS MOL BI, P143; DEAN DD, 1992, CALCIFIED TISSUE INT, V50, P342, DOI 10.1007/BF00301632; DEAN DD, 1994, CALCIFIED TISSUE INT, V54, P399, DOI 10.1007/BF00305527; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; ECAROTCHARRIER B, 1988, BONE, V9, P147, DOI 10.1016/8756-3282(88)90004-X; EINHORN TA, 1989, J ORTHOPAED RES, V7, P792, DOI 10.1002/jor.1100070604; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FITZPATRICK DF, 1969, J BIOL CHEM, V244, P3561; Fourney R.M., 1988, FOCUS, V10, P5; GELB DE, 1990, ENDOCRINOLOGY, V127, P1941, DOI 10.1210/endo-127-4-1941; GENTRY LE, 1987, MOL CELL BIOL, V7, P3418, DOI 10.1128/MCB.7.10.3418; GINSBURG I, 1992, INFLAMMATION, V16, P519, DOI 10.1007/BF00918977; HIRSCHMAN A, 1983, CALCIFIED TISSUE INT, V35, P791, DOI 10.1007/BF02405125; JINGUSHI S, 1990, CALCIUM REGULATION B, V10, P298; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KIM SJ, 1989, J BIOL CHEM, V264, P7041; KIM SJ, 1989, J BIOL CHEM, V264, P402; LANGSTON GG, 1990, CALCIFIED TISSUE INT, V47, P230, DOI 10.1007/BF02555924; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Madisen L, 1990, GROWTH FACTORS, V3, P129, DOI 10.3109/08977199009108275; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; OKEEFE R, 1988, J BONE MINER RES, V3, pS67; OREFFO ROC, 1989, BIOCHEM BIOPH RES CO, V158, P817, DOI 10.1016/0006-291X(89)92795-2; OURSLER MJ, 1994, J BONE MINER RES, V9, P443; PFEILSCHIFTER J, 1987, P NATL ACAD SCI USA, V84, P2024, DOI 10.1073/pnas.84.7.2024; ROSIER RN, 1989, CONNECT TISSUE RES, V20, P295, DOI 10.3109/03008208909023900; SAITO S, 1993, CLIN EXP IMMUNOL, V94, P220, DOI 10.1111/j.1365-2249.1993.tb06004.x; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SCHWARTZ Z, 1991, J BONE MINER RES, V6, P709; SCHWARTZ Z, 1993, J BIOMED MATER RES, V27, P1029, DOI 10.1002/jbm.820270808; SCHWARTZ Z, 1988, ENDOCRINOLOGY, V123, P2878, DOI 10.1210/endo-123-6-2878; SCHWARTZ Z, 1990, BIOCHIM BIOPHYS ACTA, V1027, P278, DOI 10.1016/0005-2736(90)90319-J; SCHWARTZ Z, 1988, ENDOCRINOLOGY, V122, P2191, DOI 10.1210/endo-122-5-2191; SCHWARTZ Z, 1992, ENDOCRINOLOGY, V130, P2495, DOI 10.1210/en.130.5.2495; SCHWARTZ Z, 1988, J BIOL CHEM, V263, P6023; SCHWARTZ Z, 1989, BONE, V10, P53, DOI 10.1016/8756-3282(89)90147-6; SCHWARTZ Z, 1993, ENDOCRINOLOGY, V132, P1544, DOI 10.1210/en.132.4.1544; SEYEDIN SM, 1986, J BIOL CHEM, V261, P5693; SEYEDIN SM, 1985, P NATL ACAD SCI USA, V82, P2267, DOI 10.1073/pnas.82.8.2267; SEYEDIN SM, 1987, J BIOL CHEM, V262, P1946; SWAIN LD, 1992, BIOCHIM BIOPHYS ACTA, V1136, P45, DOI 10.1016/0167-4889(92)90083-N; SWAIN LD, 1993, BONE, V14, P609, DOI 10.1016/8756-3282(93)90082-L; SYLVIA VL, 1993, J CELL PHYSIOL, V157, P271, DOI 10.1002/jcp.1041570209; SYLVIA VL, 1994, J BONE MINER RES, V9, P1477; TSUJI T, 1990, P NATL ACAD SCI USA, V87, P8835, DOI 10.1073/pnas.87.22.8835; TWARDZIK DR, 1990, ANN NY ACAD SCI, V593, P276, DOI 10.1111/j.1749-6632.1990.tb16119.x; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646; WEGEDAHL JE, 1992, METABOLISM, V41, P42; WUTHIER RE, 1985, J BIOL CHEM, V260, P5972; WUTHIER RE, 1973, CLIN ORTHOP RELAT R, V90, P191	69	90	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28374	28381						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961777				2022-12-27	WOS:A1994PV77200089
J	LOCKER, JK; KLUMPERMAN, J; OORSCHOT, V; HORZINEK, MC; GEUZE, HJ; ROTTIER, PJM				LOCKER, JK; KLUMPERMAN, J; OORSCHOT, V; HORZINEK, MC; GEUZE, HJ; ROTTIER, PJM			THE CYTOPLASMIC TAIL OF MOUSE HEPATITIS-VIRUS M-PROTEIN IS ESSENTIAL BUT NOT SUFFICIENT FOR ITS RETENTION IN THE GOLGI-COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-SPANNING DOMAIN; CORONAVIRUS-M-PROTEIN; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; PLASMA-MEMBRANE; E1 GLYCOPROTEIN; LATE ENDOSOMES; LOCALIZATION; SIGNAL; TRANSPORT	The M protein of mouse hepatitis virus (MHV) is a triple-spanning membrane glycoprotein that is exclusively O-glycosylated. When expressed independently, it accumulates in late Gels and the trans-Golgi network (TGN) (Locker, J. K., Griffiths, G., Horzinek, M. C., and Rottier, P. J. M. (1992) (J. Biol. Chem. 267, 14094-14101). To analyze the domains of this protein responsible for its localization, we have generated deletion mutants by site-directed mutagenesis and analyzed their intracellular transport. The intracellular distribution of the mutant proteins was determined by following the extent of O-glycosylation in pulse-chase experiments, by electron microscopic immunocytochemistry, and by surface immunoprecipitation. Mutant proteins lacking the first or the first and second transmembrane domains were not efficiently retained in the Golgi complex or TGN. The latter mutant proteins also localized to endocytic compartments but were not subject to rapid lysosomal degradation. Deletion of the COOH-terminal 22 amino acids, including a tyrosine residue in the context of a potential internalization signal, resulted in plasma membrane exposure of the respective mutant protein. We show that the wild-type MHV-M protein does not recycle between the plasma membrane and the TGN, but rather behaves as a late Golgi/TGN resident in our assays. We propose that the MHV-M protein is retained in the Golgi by two signals, one contained in the cytoplasmic tail and the other determined by the transmembrane domains.	UNIV UTRECHT, INST VIROL, FAC VET MED, DEPT IMMUNOL & INFECT DIS, 3584 CL UTRECHT, NETHERLANDS; UNIV UTRECHT, FAC MED, CTR ELECTRONMICROSCOPY, DEPT CELL BIOL, 3584 CX UTRECHT, NETHERLANDS	Utrecht University; Utrecht University			Locker, Jacomine Krijnse/AAX-1185-2020; Locker, Jacomine Krijnse/E-1009-2016					AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; ARMSTRONG J, 1991, J CELL SCI, V98, P567; ARMSTRONG J, 1990, J CELL SCI, V95, P191; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; GEUZE HJ, 1985, J CELL BIOL, V101, P2253, DOI 10.1083/jcb.101.6.2253; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; HURTLEY SM, 1989, ANN REV CELL BIOL, V5, P227; KLUMPERMAN J, 1994, J VIROL, V68, P6523, DOI 10.1128/JVI.68.10.6523-6534.1994; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LOCKER JK, 1992, J BIOL CHEM, V267, P21911; LOCKER JK, 1992, J BIOL CHEM, V267, P14094; LOCKER JK, 1994, J CELL BIOL, V124, P55; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; MACHAMER CE, 1993, MOL BIOL CELL, V4, P695, DOI 10.1091/mbc.4.7.695; MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944; MAYER T, 1988, J BIOL CHEM, V263, P14956; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; NOTHWEHR SF, 1993, J CELL BIOL, V121, P1197, DOI 10.1083/jcb.121.6.1197; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; ORCI L, 1984, CELL, V39, P39, DOI 10.1016/0092-8674(84)90189-2; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; ROTTIER P, 1984, P NATL ACAD SCI-BIOL, V81, P1421, DOI 10.1073/pnas.81.5.1421; ROTTIER PJM, 1981, J VIROL, V40, P350, DOI 10.1128/JVI.40.2.350-357.1981; ROTTIER PJM, 1986, BIOCHEMISTRY-US, V25, P1335, DOI 10.1021/bi00354a022; SLOT JW, 1988, METHOD MICROBIOL, V20, P211, DOI 10.1016/S0580-9517(08)70053-9; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SODEIK B, 1993, J CELL BIOL, V121, P521, DOI 10.1083/jcb.121.3.521; STOORVOGEL W, 1991, CELL, V65, P417, DOI 10.1016/0092-8674(91)90459-C; SUISSA M, 1983, ANAL BIOCHEM, V133, P511, DOI 10.1016/0003-2697(83)90117-3; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; WILCOX CA, 1992, MOL BIOL CELL, V3, P1353, DOI 10.1091/mbc.3.12.1353; WONG SH, 1993, J BIOL CHEM, V268, P22853; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245	45	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28263	28269						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961764				2022-12-27	WOS:A1994PV77200074
J	MOLINARI, M; ANAGLI, J; CARAFOLI, E				MOLINARI, M; ANAGLI, J; CARAFOLI, E			CA2+-ACTIVATED NEUTRAL PROTEASE IS ACTIVE IN THE ERYTHROCYTE-MEMBRANE IN ITS NONAUTOLYZED 80-KDA FORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALPAIN-II; BRAIN SPECTRIN; CALCIUM; DEGRADATION; PROTEINASES; DOMAIN; INVOLVEMENT; CALPASTATIN; INHIBITORS; ACTIVATION	The aim of this study was to investigate the process leading to Ca2+-activated neutral protease (CANP) activation in vivo. The unautolyzed form of CANP has been targeted to the erythrocyte membrane by increasing, in a controlled way, the Ca2+ concentration in the cells; this was achieved by incubating erythrocytes with the Ca2+ ionophore A23187 and fixed Ca2+ concentrations. After isolation of the CANP-bearing erythrocyte membrane, we could observe that CANP remained bound to the membrane in the 80-kDa unautolyzed form in the presence of low Ca2+ concentrations (1.75 mu M); under these conditions, the preferred CANP substrates (the Ca2+-ATPase and Band 3) were cleaved. That the cleavage was due to CANP was shown by the finding that the two substrates were not degraded in the presence of a membrane-permeable irreversible CANP inhibitor, Cbz-Leu-Leu-Tyr-CHN2, nor when the free Ca2+ concentration was decreased to sub mu M levels with EDTA. The findings suggest an activation mechanism of CANP based on its translocation to the membrane rather than on its autolysis. In this mechanism, CANP would become reversibly activated on the membrane and would return to the quiescent state after dissociating from it when the cell Ca2+ concentration has returned to the physiological, submicromolar level.	ETH ZURICH, INST BIOCHEM 3, CH-8092 ZURICH, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich			Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094; Molinari, Maurizio/0000-0002-7636-5829				ANAGLI J, 1993, BIOCHEM J, V289, P93, DOI 10.1042/bj2890093; ARAI A, 1990, BRAIN RES, V532, P63, DOI 10.1016/0006-8993(90)91742-Y; BANIK NL, 1987, NEUROCHEM PATHOL, V7, P57, DOI 10.1007/BF02834292; CONG JY, 1989, J BIOL CHEM, V264, P10096; CONG JY, 1993, J BIOL CHEM, V268, P25740; CRAWFORD C, 1993, BIOCHEM J, V296, P135, DOI 10.1042/bj2960135; CRAWFORD C, 1988, BIOCHEM J, V253, P751, DOI 10.1042/bj2530751; CRAWFORD C, 1990, BIOCHEM J, V265, P575, DOI 10.1042/bj2650575; DAVID LL, 1993, J BIOL CHEM, V268, P1937; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; INOMATA M, 1990, BIOCHEM BIOPH RES CO, V171, P625, DOI 10.1016/0006-291X(90)91192-U; JAMES P, 1989, J BIOL CHEM, V264, P8289; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYNCH G, 1987, BRAIN RES BULL, V18, P809, DOI 10.1016/0361-9230(87)90220-6; PONTREMOLI S, 1988, BIOCHEM BIOPH RES CO, V157, P867, DOI 10.1016/S0006-291X(88)80955-0; PONTREMOLI S, 1985, BIOCHEM INT, V11, P35; PONTREMOLI S, 1986, ANNU REV BIOCHEM, V55, P455, DOI 10.1146/annurev.biochem.55.1.455; PONTREMOLI S, 1985, BIOCHIM BIOPHYS ACTA, V831, P335, DOI 10.1016/0167-4838(85)90116-5; SALAMINO F, 1994, CELL CALCIUM, V15, P28, DOI 10.1016/0143-4160(94)90101-5; SALAMINO F, 1993, BIOCHEM J, V290, P191, DOI 10.1042/bj2900191; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SHIMOHAMA S, 1991, BRAIN RES, V558, P105, DOI 10.1016/0006-8993(91)90722-8; SIMAN R, 1990, FID RES FDN, V4, P145; SORIMACHI H, 1990, BIOL CHEM H-S, V371, P171; SORIMACHI H, 1993, J BIOL CHEM, V268, P19476; SUZUKI K, 1987, TRENDS BIOCHEM SCI, V12, P103, DOI 10.1016/0968-0004(87)90048-X; SUZUKI K, 1990, FID RES FDN, V4, P79; Vanaman T. C., 1977, CALCIUM BINDING PROT, P107	30	91	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27992	27995						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961733				2022-12-27	WOS:A1994PV77200036
J	NISHIYAMA, T; MCDONOUGH, AM; BRUNS, RR; BURGESON, RE				NISHIYAMA, T; MCDONOUGH, AM; BRUNS, RR; BURGESON, RE			TYPE-XII AND TYPE-XIV COLLAGENS MEDIATE INTERACTIONS BETWEEN BANDED COLLAGEN-FIBERS IN-VITRO AND MAY MODULATE EXTRACELLULAR-MATRIX DEFORMABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORING FIBRILS; GEL CONTRACTION; VII COLLAGEN; VONWILLEBRAND-FACTOR; GROWTH-FACTOR; IX COLLAGEN; FIBROBLASTS; IDENTIFICATION; FORM; REORGANIZATION	Type XII and XIV collagens are very large molecules containing three extended globular domains derived from the amino terminus of each cu chain and an interrupted triple helix. Both collagens are genetically and immunologically unique and have distinct distributions in many tissues. These collagens localize near the surface of banded collagen fibrils. The function of the molecules is unknown. We have prepared a mixture of native type XII and XIV collagens that is free of contaminating proteins by electrophoretic criteria. In addition, we have purified the collagenase-resistant globular domains of type XII or XIV collagens (XII-NC-3 or XIV-NC-3). In this study, we have investigated the effect of intact type XII and XIV and XII-NC-3 or XIV-NC-3 on the interactions between fibroblasts and type I collagen fibrils. We find that both type XII and XIV collagens promote collagen gel contraction mediated by fibroblasts, even in the absence of serum, The activity is present in the NC-3 domains. The effect is dose-dependent and is inhibited by denaturation. The effect of type XII NC-3 is inhibited by the addition of anti-XII antiserum. To elucidate the mechanism underlying this phenomenon, we examined the effect of XII-NC-3 or XIV-NC-3 on deformability of collagen gels by centrifugal force. XII-NC-3 or XIV-NC-3 markedly promotes gel compression after centrifugation. The effect is also inhibited by denaturation, and the activity of type XII-NC3 is inhibited by the addition of anti-MT antiserum. The results indicate that the effect of XII-NC-3 or XIV-NC-3 on collagen gel contraction by fibroblasts is not due to activation of cellular events but rather results from the increase in mobility of hydrated collagen fibrils within the gel. These studies suggest that collagen types XII and XIV may modulate the biomechanical properties of tissues.	MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT DERMATOL,BOSTON,MA 02129	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Nishiyama, Toshio/C-5434-2013	Nishiyama, Toshio/0000-0002-3459-2636	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM035689] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM35689] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACHINGER HP, 1990, J BIOL CHEM, V265, P10095; BROWN JC, 1993, J CELL BIOL, V120, P557, DOI 10.1083/jcb.120.2.557; GERECKE DR, 1993, J BIOL CHEM, V268, P12177; GORDON MK, 1989, J BIOL CHEM, V264, P19772; GUIDRY C, 1987, J CELL BIOL, V104, P1097, DOI 10.1083/jcb.104.4.1097; GULLBERG D, 1990, EXP CELL RES, V186, P264, DOI 10.1016/0014-4827(90)90305-T; HEINO J, 1989, J BIOL CHEM, V264, P380; KEENE DR, 1991, J CELL BIOL, V113, P971, DOI 10.1083/jcb.113.4.971; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; KOCH M, 1992, EUR J BIOCHEM, V207, P847, DOI 10.1111/j.1432-1033.1992.tb17116.x; KUPPER TS, 1993, FASEB J, V7, P1401, DOI 10.1096/fasebj.7.14.8224612; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LETHIAS C, 1993, J INVEST DERMATOL, V101, P92, DOI 10.1111/1523-1747.ep12360433; LUNSTRUM GP, 1986, J BIOL CHEM, V261, P9042; LUNSTRUM GP, 1991, J CELL BIOL, V113, P963, DOI 10.1083/jcb.113.4.963; LUNSTRUM GP, 1992, J BIOL CHEM, V267, P20087; MORRIS NP, 1986, J BIOL CHEM, V261, P5638; NISHIYAMA T, 1988, COLLAGEN REL RES, V8, P259; NISHIYAMA T, 1993, MATRIX, V13, P447, DOI 10.1016/S0934-8832(11)80111-3; NISHIYAMA T, 1989, MATRIX, V9, P193, DOI 10.1016/S0934-8832(89)80050-2; SAKAI LY, 1986, J CELL BIOL, V103, P1577, DOI 10.1083/jcb.103.4.1577; SCHAFER IA, 1989, EXP CELL RES, V183, P112, DOI 10.1016/0014-4827(89)90422-9; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; SUGRUE SP, 1989, J CELL BIOL, V109, P939, DOI 10.1083/jcb.109.2.939; TINGSTROM A, 1992, J CELL SCI, V102, P315; TRUEB J, 1992, EUR J BIOCHEM, V207, P549, DOI 10.1111/j.1432-1033.1992.tb17081.x; WATT SL, 1992, J BIOL CHEM, V267, P20093; YAMAGATA M, 1991, J CELL BIOL, V115, P209, DOI 10.1083/jcb.115.1.209	29	132	136	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28193	28199						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961756				2022-12-27	WOS:A1994PV77200064
J	SCHMIDT, M; BUCHELER, U; KALUZA, B; BUCHNER, J				SCHMIDT, M; BUCHELER, U; KALUZA, B; BUCHNER, J			CORRELATION BETWEEN THE STABILITY OF THE GROEL-PROTEIN LIGAND COMPLEX AND THE RELEASE MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN LIGHT CHAIN; INTRACHAIN DISULFIDE BOND; ESCHERICHIA-COLI; CONSTANT FRAGMENT; RIBULOSEBISPHOSPHATE CARBOXYLASE; CHAPERONIN 60; ATP; PURIFICATION; HYDROLYSIS; ANTIBODY	The protein-protein interactions during GroE-mediated protein refolding are of crucial importance for understanding how the assisted refolding of non-native proteins is achieved. Since GroEL seems to be a rather promiscuous polypeptide-binding protein it is not surprising that conditions for efficient dissociation fi om GroEL are promiscuous as well. To understand assisted protein refolding it is necessary of elucidate the underlying principles of the different partial steps of the functional cycle. Here we show a correlation between the overall stability of the complex between GroEL and ligand protein and the conditions for functional release from the chaperonin. As a model system, differently denatured species of an antibody Fab fragment were used. While weakly bound Fab fragments are functionally released in the absence of GroES, stably associated nonnative forms of the same protein are dependent on the presence of the co-chaperonin for optimal GroE-mediated reactivation, suggesting that complex stability determines the release requirement. However, the observed overall stability of the complex between GroEL and substrate protein may be regarded as the net product of constant binding and rebinding of the ligand protein, once associated with GroEL, as shown by competition experiments.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,D-93040 REGENSBURG,GERMANY; BOEHRINGER MANNHEIM GMBH,RES CTR,D-82377 PENZBERG,GERMANY	University of Regensburg				Buchner, Johannes/0000-0003-1282-7737				AZUMA T, 1976, J BIOCHEM-TOKYO, V80, P1023, DOI 10.1093/oxfordjournals.jbchem.a131358; BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BROSIUS J, 1981, PLASMID, V6, P112, DOI 10.1016/0147-619X(81)90058-5; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; BUCKEL P, 1987, GENE, V51, P13, DOI 10.1016/0378-1119(87)90469-0; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOTO Y, 1981, J MOL BIOL, V146, P321, DOI 10.1016/0022-2836(81)90391-0; GOTO Y, 1982, J MOL BIOL, V156, P911, DOI 10.1016/0022-2836(82)90147-4; GOTO Y, 1982, J MOL BIOL, V156, P891, DOI 10.1016/0022-2836(82)90146-2; GRAY TE, 1993, EMBO J, V12, P4145, DOI 10.1002/j.1460-2075.1993.tb06098.x; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; HANSEN JE, 1993, J BIOL CHEM, V268, P21632; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JAENICKE R, 1993, CURR OPIN STRUC BIOL, V3, P104, DOI 10.1016/0959-440X(93)90209-4; JOHNSTONE A, 1987, IMMUNOCHEMISTRY PRAC, P55; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LILIE H, 1994, J BIOL CHEM, V269, P14290; LILIE H, 1993, PROTEIN SCI, V2, P1490, DOI 10.1002/pro.5560020913; Maniatis T, 1989, DECONTAMINATION DILU; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1992, J PROTEIN CHEM, V11, P589, DOI 10.1007/BF01024958; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; MORINAGA Y, 1984, BIO-TECHNOL, V2, P636, DOI 10.1038/nbt0784-636; PADLAN EA, 1986, MOL IMMUNOL, V23, P951, DOI 10.1016/0161-5890(86)90125-2; PAJOT P, 1976, EUR J BIOCHEM, V63, P263, DOI 10.1111/j.1432-1033.1976.tb10228.x; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VANDERVIES SM, 1992, BIOCHEMISTRY-US, V31, P3635, DOI 10.1021/bi00129a012; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WAXMAN L, 1986, SCIENCE, V232, P500, DOI 10.1126/science.2938257; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0; ZAHN R, 1992, BIOCHEMISTRY-US, V31, P3249, DOI 10.1021/bi00127a029; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505	53	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27964	27972						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961729				2022-12-27	WOS:A1994PV77200032
J	WATERMAN, MR				WATERMAN, MR			BIOCHEMICAL DIVERSITY OF CAMP-DEPENDENT TRANSCRIPTION OF STEROID HYDROXYLASE GENES IN THE ADRENAL-CORTEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CLEAVAGE CYTOCHROME-P450 GENE; RESPONSIVE ELEMENT; REGULATES EXPRESSION; P450 SUPERFAMILY; PROMOTER REGION; P-450SCC GENE; P-45017-ALPHA; SEQUENCES; CELLS; CYP17				WATERMAN, MR (corresponding author), VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, 607 LIGHT HALL, NASHVILLE, TN 37232 USA.				NIDDK NIH HHS [DK28350] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028350] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHLGREN R, 1990, J BIOL CHEM, V265, P3313; BRENTANO ST, 1990, MOL ENDOCRINOL, V4, P1972, DOI 10.1210/mend-4-12-1972; CHANG CY, 1992, MOL ENDOCRINOL, V6, P1362, DOI 10.1210/me.6.9.1362; CHEN JY, 1992, BIOCHEMISTRY-US, V31, P2400, DOI 10.1021/bi00123a027; DOMALIK LJ, 1991, MOL ENDOCRINOL, V5, P1853, DOI 10.1210/mend-5-12-1853; GUO IC, 1994, J BIOL CHEM, V269, P6362; HASHIMOTO T, 1992, J BIOCHEM-TOKYO, V112, P573, DOI 10.1093/oxfordjournals.jbchem.a123941; HONDA S, 1993, J BIOL CHEM, V268, P7494; HONDA SI, 1990, J BIOCHEM-TOKYO, V108, P1042, DOI 10.1093/oxfordjournals.jbchem.a123303; INOUE H, 1991, EUR J BIOCHEM, V195, P563, DOI 10.1111/j.1432-1033.1991.tb15738.x; JOHN ME, 1986, P NATL ACAD SCI USA, V83, P4715, DOI 10.1073/pnas.83.13.4715; KAGAWA N, 1992, J BIOL CHEM, V267, P25213; KAGAWA N, 1994, J BIOL CHEM, V269, P18716; KIMURA T, 1969, ENDOCRINOLOGY, V85, P492, DOI 10.1210/endo-85-3-492; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LUND J, 1990, J BIOL CHEM, V265, P3304; LUND J, 1988, J BIOL CHEM, V263, P16195; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MOMOI K, 1992, MOL ENDOCRINOL, V6, P1682, DOI 10.1210/me.6.10.1682; MOORE CCD, 1990, MOL CELL BIOL, V10, P6013, DOI 10.1128/MCB.10.11.6013; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OONK RB, 1990, J BIOL CHEM, V265, P22392; PANG S, 1992, ENDOCRINOLOGY, V131, P181, DOI 10.1210/en.131.1.181; PARISSENTI AM, 1993, MOL ENDOCRINOL, V7, P283, DOI 10.1210/me.7.2.283; PURVIS JL, 1973, ANN NY ACAD SCI, V212, P319, DOI 10.1111/j.1749-6632.1973.tb47605.x; RICE DA, 1989, J BIOL CHEM, V264, P14011; RICE DA, 1990, J BIOL CHEM, V265, P11713; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; WATANABE N, 1993, EUR J BIOCHEM, V214, P521, DOI 10.1111/j.1432-1033.1993.tb17950.x; WATERMAN MR, 1992, HORM RES, V38, P217, DOI 10.1159/000182546; WATERMAN MR, 1989, RECENT PROG HORM RES, V45, P533; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; YOUNGBLOOD GL, 1992, MOL ENDOCRINOL, V6, P927, DOI 10.1210/me.6.6.927; ZANGER UM, 1992, FASEB J, V6, P719, DOI 10.1096/fasebj.6.2.1311271; ZUBER MX, 1986, J BIOL CHEM, V261, P2475	36	122	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27783	27786						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961700				2022-12-27	WOS:A1994PV77200001
J	FEAVER, WJ; HENRY, NL; BUSHNELL, DA; SAYRE, MH; BRICKNER, JH; GILEADI, O; KORNBERG, RD				FEAVER, WJ; HENRY, NL; BUSHNELL, DA; SAYRE, MH; BRICKNER, JH; GILEADI, O; KORNBERG, RD			YEAST TFIIE - CLONING, EXPRESSION, AND HOMOLOGY TO VERTEBRATE PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR TFIIE; SACCHAROMYCES-CEREVISIAE; INITIATION-FACTORS; CTD KINASE; FACTOR-B; PURIFICATION; MOTIFS; SUBUNIT; IDENTIFICATION	Genes encoding both the 66- and the 43-kDa subunits of yeast RNA polymerase II initiation factor a, designated TFA1 and TFA2, have been isolated. Both genes are essential for cell viability. The bacterially expressed gene products could replace factor a in transcription in vitro, and both recombinant subunits were required for activity. The deduced amino acid sequences of the TFA1 and TFA2 gene products were homologous to those of the large and small subunits of human TFIIE, respectively, identifying factor a as the yeast homolog of TFIIE.	STANFORD UNIV, SCH MED, DEPT CELL BIOL, STANFORD, CA 94305 USA	Stanford University			Gileadi, Opher/F-1105-2013	Gileadi, Opher/0000-0001-6886-898X; Brickner, Jason/0000-0001-8019-3743	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007599, R37GM036659, R01GM036659] Funding Source: NIH RePORTER; NIGMS NIH HHS [2T32-GM07599, GM36659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHER L, 1992, SCIENCE, V257, P1392; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HENRY NL, 1992, J BIOL CHEM, V267, P23388; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KEAN LS, 1993, J CELL BIOL, V123, P1403, DOI 10.1083/jcb.123.6.1403; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; OHKUMA Y, 1992, NUCLEIC ACIDS RES, V20, P4363, DOI 10.1093/nar/20.16.4363; PETERSON MG, 1991, NATURE, V354, P369; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; TSCHOCHNER H, 1992, P NATL ACAD SCI USA, V89, P11292, DOI 10.1073/pnas.89.23.11292	36	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27549	27553						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961670				2022-12-27	WOS:A1994PV77100061
J	XU, LZ; ZHANG, W; WEBER, IT; HARRISON, RW; PILKIS, SJ				XU, LZ; ZHANG, W; WEBER, IT; HARRISON, RW; PILKIS, SJ			SITE-DIRECTED MUTAGENESIS STUDIES ON THE DETERMINANTS OF SUGAR SPECIFICITY AND COOPERATIVE BEHAVIOR OF HUMAN BETA-CELL GLUCOKINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER GLUCOKINASE; TYPE-2 DIABETES-MELLITUS; HEXOKINASE-D GLUCOKINASE; SIGMOIDAL RATE BEHAVIOR; HEPATIC GLUCOKINASE; MECHANISTIC ORIGIN; SLOW TRANSITION; GENE; EXPRESSION; GLUCOSE	The determinants of sugar specificity and cooperative behavior of human beta-cell glucokinase were studied by mutating several active site residues and performing a steady-state kinetic analysis of the purified mutant and wild-type enzymes after their expression in Escherichia coli. Asn-204, Glu-256, and Glu-290 were predicted from molecular modeling to interact with the 3-OH, 4-OH, 2-OH, and 1-OH groups of glucose. Mutation of these residues resulted in enzymes with decreased values of k(cat) and increased values of K-m for glucose, mannose, and 2-deoxyglucose. Lys-56 is also predicted to make an interaction with the side chain of Glu-256 and its mutation increased the K-m for glucose, deoxyglucose, mannose, and fructose by 4-, 4-, 3-, and 10-fold, respectively, and also increased the k(cat) for fructose by 5-fold. The K-i values for N-acetylglucosamine and mannoheptulose for the wild type enzyme were 0.2 and 0.8 mm, respectively, and mutation of glucose binding residues to alanine resulted in an increase of about 3 orders of magnitude in these K-i values. Mutation of residues that directly hydrogen bond glucose hydroxyls (Asn-204, Glu-256, and Glu-290) to alanine resulted in enzymes that did not exhibit cooperative behavior, but mutation of Lys-56 or other residues that do not directly contact glucose had no effect on the Hill coefficient. Only glucose and deoxyglucose exhibited cooperative behavior. The results 1) confirm the predictions of the model that Asn-204, Glu-256, and Glu-290 are important residues involved in catalysis and hydrogen bonding glucose hydroxyl groups, 2) provide evidence for a role of Lys-56 in hexose binding, and 3) are consistent with the cooperative behavior of glucokinase being mediated by interactions of other regions of the protein with the highly conserved active site glucose binding residues.	SUNY STONY BROOK,HLTH SCI CTR,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11780; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Jefferson University				Harrison, Robert/0000-0003-2449-1214	NIDDK NIH HHS [DK 4730A] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON CM, 1979, SCIENCE, V204, P375, DOI 10.1126/science.220706; CARDENAS ML, 1984, EUR J BIOCHEM, V145, P163, DOI 10.1111/j.1432-1033.1984.tb08536.x; CARDENAS ML, 1984, BIOCHEM J, V222, P363, DOI 10.1042/bj2220363; CHARLES RS, 1994, DIABETES, V43, P784, DOI 10.2337/diab.43.6.784; CHEIN CT, 1989, BIOCHEM BIOPH RES CO, V165, P817; CORNISHBOWDEN A, 1986, BIOCHEM J, V240, P293, DOI 10.1042/bj2400293; GIDHJAIN M, 1993, P NATL ACAD SCI USA, V90, P1932, DOI 10.1073/pnas.90.5.1932; GRANNER DK, 1990, J BIOL CHEM, V265, P16012; HARRISON RW, 1993, J COMPUT CHEM, V14, P1112, DOI 10.1002/jcc.540140912; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANGE AJ, 1991, BIOCHEM J, V277, P159, DOI 10.1042/bj2770159; Lin K, 1990, Protein Expr Purif, V1, P169, DOI 10.1016/1046-5928(90)90012-N; LIN SX, 1990, J BIOL CHEM, V265, P9670; MATSCHINSKY F, 1993, J CLIN INVEST, V92, P2092, DOI 10.1172/JCI116809; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; NEET KE, 1990, BIOCHEMISTRY-US, V29, P770, DOI 10.1021/bi00455a026; PETTERSSON G, 1986, BIOCHEM J, V233, P347, DOI 10.1042/bj2330347; PILKIS SJ, 1972, ARCH BIOCHEM BIOPHYS, V149, P349, DOI 10.1016/0003-9861(72)90333-5; PILKIS SJ, J BIOL CHEM, V269, P21925; POLONSKY KS, 1986, J CLIN INVEST, V77, P98, DOI 10.1172/JCI112308; STOFFEL M, 1992, NAT GENET, V2, P153, DOI 10.1038/ng1092-153; STOFFEL M, 1992, P NATL ACAD SCI USA, V89, P7698, DOI 10.1073/pnas.89.16.7698; STORER AC, 1977, BIOCHEM J, V165, P61, DOI 10.1042/bj1650061; STORER AC, 1976, BIOCHEM J, V159, P7, DOI 10.1042/bj1590007; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STURIS J, 1994, DIABETES, V43, P718, DOI 10.2337/diabetes.43.5.718; TAKEDA J, 1993, J BIOL CHEM, V268, P15200; VANDERCAMMEN A, 1991, EUR J BIOCHEM, V200, P545, DOI 10.1111/j.1432-1033.1991.tb16217.x; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; WEINHOUSE S, 1976, CURR TOP CELL REGUL, V11, P1	30	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27458	27465						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961659				2022-12-27	WOS:A1994PV77100049
J	JOHNSON, GR; WONG, L				JOHNSON, GR; WONG, L			HEPARAN-SULFATE IS ESSENTIAL TO AMPHIREGULIN-INDUCED MITOGENIC SIGNALING BY THE EPIDERMAL GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; FIBROBLAST GROWTH; CELL-SURFACE; EPITHELIAL-CELLS; TYROSINE PHOSPHORYLATION; COLORECTAL TUMORS; FACTOR FAMILY; EXPRESSION; BINDING; PROTEOGLYCANS	Human amphiregulin (AR) is a heparin-binding growth factor which functions by binding to and activating the epidermal growth factor (EGF) receptor tyrosine kinase. AR contains an EGF-like domain (residues 44-84) and a Lys/Arg-rich NH2-terminal extension (residues 1-43). Synthetic peptides corresponding to residues 8-26, 26-44, and 68-84 of AR were tested for their ability to compete for the binding of AR to immobilized heparin. AR(8-26) and AR(68-84) had no significant effect on the binding of AR to heparin, whereas AR(26-44) bound to heparin and blocked the binding of AR to heparin. Both soluble heparin and heparan sulfate inhibited AR-induced mitogenesis in MCF-10A human mammary epithelial cells with an IC50 of 5 and 2 mu g/ml, respectively, whereas soluble chondroitin sulfate had only a slight inhibitory effect. When MCF-10A cells were grown in the presence of chlorate, an inhibitor of sulfation, or exposed to the glycosaminoglycan-degrading enzymes heparitinase or heparinase, the ability of AR to evoke mitogenesis in these cells was lost. Chlorate, heparitinase, or heparinase treatment inhibited AR-induced autophosphorylation of tyrosine residues in the EGF receptor. None of these treatments had any significant effect on EGF-triggered mitogenic signaling by the EGF receptor. These results indicate that extracellular heparan sulfate glycosaminoglycan is essential to AR-induced mitogenic signaling by the EGF receptor tyrosine kinase.			JOHNSON, GR (corresponding author), US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,HFM-511,BLDG 29A,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; CAREY DJ, 1990, J CELL BIOL, V111, P2053, DOI 10.1083/jcb.111.5.2053; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; COOK PW, 1992, CANCER RES, V52, P3224; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; EBERT M, 1994, CANCER RES, V54, P3959; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; FARLEY JR, 1978, ARCH BIOCHEM BIOPHYS, V185, P376, DOI 10.1016/0003-9861(78)90180-7; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JOHNSON GR, 1992, J CELL BIOL, V118, P741, DOI 10.1083/jcb.118.3.741; JOHNSON GR, 1991, BIOCHEM BIOPH RES CO, V180, P481, DOI 10.1016/S0006-291X(05)81090-3; JOHNSON GR, 1993, J BIOL CHEM, V268, P18835; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kenney Nicholas, 1993, Molecular and Cellular Differentiation, V1, P163; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P2165, DOI 10.1073/pnas.90.6.2165; KIMURA H, 1990, NATURE, V348, P257, DOI 10.1038/348257a0; KITADAI Y, 1993, JPN J CANCER RES, V84, P879, DOI 10.1111/j.1349-7006.1993.tb02061.x; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LEJEUNE S, 1993, CANCER RES, V53, P3597; LI SW, 1992, J CELL PHYSIOL, V153, P103, DOI 10.1002/jcp.1041530114; Modrell B, 1992, GROWTH FACTORS, V7, P305, DOI 10.3109/08977199209046413; NORMANNO N, 1994, P NATL ACAD SCI USA, V91, P2790, DOI 10.1073/pnas.91.7.2790; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; OTOTANI N, 1981, CARBOHYD RES, V88, P291, DOI 10.1016/S0008-6215(00)85542-1; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; QI CF, 1994, BRIT J CANCER, V69, P903, DOI 10.1038/bjc.1994.174; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAEKI T, 1992, CANCER RES, V52, P3467; SAEKI T, 1994, INT J ONCOL, V5, P215; SAKAGUCHI K, 1991, J BIOL CHEM, V266, P7270; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; THOMPSON SA, 1994, J BIOL CHEM, V269, P2541; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	52	66	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27149	27154						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929459				2022-12-27	WOS:A1994PQ93100083
J	MOLLA, A; HARRIS, KS; PAUL, AV; SHIN, SH; MUGAVERO, J; WIMMER, E				MOLLA, A; HARRIS, KS; PAUL, AV; SHIN, SH; MUGAVERO, J; WIMMER, E			STIMULATION OF POLIOVIRUS PROTEINASE 3C(PRO)-RELATED PROTEOLYSIS BY THE GENOME-LINKED PROTEIN VPG AND ITS PRECURSOR 3AB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; CYSTEINE PROTEASES; ESCHERICHIA-COLI; SERINE PROTEASES; POLYPEPTIDE 3CD; CELL-FREE; CLEAVAGE; INVITRO; EXPRESSION; REPLICATION	Purified recombinant poliovirus polypeptide 3AB interacts with 3CD(pro) and 3D(pol) as shown by coimmunoprecipitation with anti-3D(pol) antibodies. A consequence of this interaction is an accelerated autoprocessing of 3CD(pro) to produce 3C(pro) and 3D(pol). The activation of 3D(pol) polymerase activity by cleavage of 3CD(pro), a polypeptide that has no polymerase activity, can be shown by template- and primer-dependent poly(U) synthesis. Anti-VPg antibodies (VPg = 3B) added to HeLa translation extracts programmed with poliovirion RNA inhibit cleavage of 3CD(pro) whereas addition of purified 3AB or VPg to these translation reactions increases 3CD(pro) processing. 3AB stimulates also 3C(pro)-related proteolysis of 2BC, a poliovirus-specific, nonstructural processing intermediate. In contrast, 3CD(pro)-specific cleavage of the structural precursor P1 is inhibited by the addition of 3AB as shown by a decrease in the production of VPO and VP3. These data shed new light on a phenomenon in the regulation of expression of poliovirus genetic information: whereas the proteinase 3CD(pro) is needed for processing of the capsid precursor, the cleavage product of this relatively stable precursor is required for RNA replication.	SUNY STONY BROOK, HLTH SCI CTR, SCH MED, DEPT MOLEC GENET & MICROBIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NCI NIH HHS [CA-28146] Funding Source: Medline; NIAID NIH HHS [AI-32100, AI-15122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032100, R37AI015122, R01AI015122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDINO R, 1990, J VIROL, V64, P607, DOI 10.1128/JVI.64.2.607-612.1990; ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; ANDINO R, 1993, EMBO J, V12, P3587, DOI 10.1002/j.1460-2075.1993.tb06032.x; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; BLAIR WS, 1993, J VIROL, V67, P2336, DOI 10.1128/JVI.67.4.2336-2343.1993; DORNER AJ, 1981, FEBS LETT, V132, P219, DOI 10.1016/0014-5793(81)81164-7; DOUGHERTY WG, 1993, MICROBIOL REV, V57, P781, DOI 10.1128/MMBR.57.4.781-822.1993; FLANEGAN JB, 1977, P NATL ACAD SCI USA, V74, P3677, DOI 10.1073/pnas.74.9.3677; GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7; HAMMERLE T, 1991, J BIOL CHEM, V266, P5412; HANECAK R, 1982, P NATL ACAD SCI-BIOL, V79, P3973, DOI 10.1073/pnas.79.13.3973; HANECAK R, 1984, CELL, V37, P1063, DOI 10.1016/0092-8674(84)90441-0; HARRIS KS, 1992, J VIROL, V66, P7481, DOI 10.1128/JVI.66.12.7481-7489.1992; HARRIS KS, 1994, J BIOL CHEM, V269, P27004; Harris KS, 1990, SEMINARS VIROLOGY, V1, P323; HELLEN CUT, 1991, J VIROL, V65, P4226, DOI 10.1128/JVI.65.8.4226-4231.1991; JORE J, 1988, J GEN VIROL, V69, P1627, DOI 10.1099/0022-1317-69-7-1627; KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; LAMA J, 1994, J BIOL CHEM, V269, P66; LAWSON MA, 1990, CURR TOP MICROBIOL, V161, P49; LAWSON MA, 1992, VIROLOGY, V191, P309, DOI 10.1016/0042-6822(92)90193-S; LEE CK, 1988, VIROLOGY, V166, P405, DOI 10.1016/0042-6822(88)90511-9; LONG AC, 1989, FEBS LETT, V258, P75, DOI 10.1016/0014-5793(89)81619-9; MOLLA A, 1993, J VIROL, V67, P5932, DOI 10.1128/JVI.67.10.5932-5938.1993; MOLLA A, 1988, J BIOCHEM, V104, P616, DOI 10.1093/oxfordjournals.jbchem.a122521; MOLLA A, 1991, SCIENCE, V254, P1647, DOI 10.1126/science.1661029; MOLLA A, 1993, J VIROL, V67, P4688, DOI 10.1128/JVI.67.8.4688-4695.1993; NICKLIN MJH, 1987, P NATL ACAD SCI USA, V84, P4002, DOI 10.1073/pnas.84.12.4002; NICKLIN MJH, 1988, J VIROL, V62, P4586, DOI 10.1128/JVI.62.12.4586-4593.1988; NICKLIN MJH, 1986, BIO-TECHNOL, V4, P33, DOI 10.1038/nbt0186-33; ORR DC, 1989, J GEN VIROL, V70, P2931, DOI 10.1099/0022-1317-70-11-2931; PALLAI PV, 1989, J BIOL CHEM, V264, P9738; PALMENBERG AC, 1979, J VIROL, V32, P770, DOI 10.1128/JVI.32.3.770-778.1979; PINCUS SE, 1986, J VIROL, V60, P793, DOI 10.1128/JVI.60.2.793-796.1986; RICHARDS OC, 1990, CURR TOP MICROBIOL, V161, P89; SEMLER BL, 1987, J CELL BIOCHEM, V33, P39, DOI 10.1002/jcb.240330105; SEMLER BL, 1981, P NATL ACAD SCI-BIOL, V78, P3464, DOI 10.1073/pnas.78.6.3464; SEMLER BL, 1982, CELL, V28, P405, DOI 10.1016/0092-8674(82)90358-0; TAKEDA N, 1986, J VIROL, V60, P43, DOI 10.1128/JVI.60.1.43-53.1986; TAKEGAMI T, 1983, VIROLOGY, V128, P33, DOI 10.1016/0042-6822(83)90316-1; TOYODA H, 1986, CELL, V45, P761, DOI 10.1016/0092-8674(86)90790-7; TOYODA H, 1987, J VIROL, V61, P2816, DOI 10.1128/JVI.61.9.2816-2822.1987; VANDERWERF S, 1986, P NATL ACAD SCI USA, V83, P2330; VANDYKE TA, 1980, J VIROL, V35, P732, DOI 10.1128/JVI.35.3.732-740.1980; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033; YPMAWONG MF, 1988, VIROLOGY, V166, P265, DOI 10.1016/0042-6822(88)90172-9	47	75	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27015	27020						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929442				2022-12-27	WOS:A1994PQ93100065
J	LEEBLUNDBERG, LMF; MATHIS, SA; HERZIG, MCS				LEEBLUNDBERG, LMF; MATHIS, SA; HERZIG, MCS			ANTAGONISTS OF BRADYKININ THAT STABILIZE A G-PROTEIN-UNCOUPLED STATE OF THE B2 RECEPTOR ACT AS INVERSE AGONISTS IN RAT MYOMETRIAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TERNARY COMPLEX MODEL; SMOOTH-MUSCLE CELLS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; MEDIATED INTERNALIZATION; INTRINSIC ACTIVITY; KININ RECEPTORS; BINDING; HYDROLYSIS; ACTIVATION; STIMULATION	Several B2 bradykinin (BK) receptor-specific antagonists including HOE140, NPC17731, and NPC567 exhibited negative intrinsic activity, which was observed as a decrease in basal phosphoinositide hydrolysis in primary cultures of rat myometrial cells, and this response was opposite to that elicited by the agonist BK. The order of potency of the antagonists in attenuating basal activity was essentially the same as that in competing both [H-3]BK and [H-3]NPC17731 for binding to B2 receptors on both intact rat myometrial cells and bovine myometrial membranes. We previously proposed a three-state model for the binding of agonists to G-protein-coupled B2 receptors in bovine myometrial membranes (Leeb-Lundberg, L. M. F and Mathis, S. A. (1990) J. Biol. Chem. 265, 9621-9627). This model was based on the ability of BK to promote the sequential formation of three receptor binding states where formation of the third, equilibrium state was blocked by Gpp(NH)p (guanyl-5'-yl imidodiphosphate) identifying it as the G-protein-coupled state of the receptor. Here, we show that, in contrast to BK, these antagonists bound preferentially to a G-protein uncoupled state of the receptor. These results indicate that B2 receptor antagonists that stabilize a G-protein-uncoupled state of the receptor act as inverse agonists. Furthermore, these results provide strong evidence that endogenous G-protein coupled receptors exhibit spontaneous activity in their natural environment in the absence of agonist occupancy.			LEEBLUNDBERG, LMF (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.				NIGMS NIH HHS [GM41659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041659, R01GM041659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARKER EL, 1994, J BIOL CHEM, V269, P11687; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAESTRUP C, 1982, SCIENCE, V216, P1241, DOI 10.1126/science.6281892; BURCH RM, 1992, DUPONT BIOTECH UPDAT, V4, P127; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; Colquhoun D., 1973, DRUG RECEPTORS, P149, DOI [10.1007/978-1-349-00910-7_11, DOI 10.1007/978-1-349-00910-7_11]; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; COSTA T, 1992, MOL PHARMACOL, V41, P549; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DERIAN CK, 1986, J BIOL CHEM, V261, P3831; FARMER SG, 1992, ANNU REV PHARMACOL, V32, P511; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HILF G, 1992, EUR J PHARM-MOLEC PH, V225, P245, DOI 10.1016/0922-4106(92)90026-R; HOCK FJ, 1991, BRIT J PHARMACOL, V102, P769, DOI 10.1111/j.1476-5381.1991.tb12248.x; KARLIN A, 1967, J THEOR BIOL, V16, P306, DOI 10.1016/0022-5193(67)90011-2; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KYLE DJ, 1991, J MED CHEM, V34, P2649, DOI 10.1021/jm00112a047; KYLE DJ, 1991, J MED CHEM, V34, P1230, DOI 10.1021/jm00107a052; KYLE DJ, 1991, BRADYKININ ANTAGONIS, P181; LEEBLUNDBERG LMF, 1990, J BIOL CHEM, V265, P9621; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MUNOZ CM, 1993, ARCH BIOCHEM BIOPHYS, V301, P336, DOI 10.1006/abbi.1993.1153; MUNOZ CM, 1992, J BIOL CHEM, V267, P303; MURRAY R, 1989, CELL SIGNAL, V1, P173, DOI 10.1016/0898-6568(89)90007-7; REGOLI D, 1980, PHARMACOL REV, V32, P1; REN Q, 1993, J BIOL CHEM, V268, P16483; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; SCHUTZ W, 1992, TRENDS PHARMACOL SCI, V13, P376, DOI 10.1016/0165-6147(92)90116-N; STEWART JM, 1991, BRADYKININ ANTAGONIS, P51; TILLY BC, 1987, BIOCHEM J, V244, P129, DOI 10.1042/bj2440129; TROPEA MM, 1992, CAN J PHYSIOL PHARM, V70, P1360, DOI 10.1139/y92-191; VAVREK RJ, 1985, PEPTIDES, V6, P161, DOI 10.1016/0196-9781(85)90033-6; YANO K, 1984, J BIOL CHEM, V259, P201	36	83	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					25970	25973						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929307				2022-12-27	WOS:A1994PQ93000008
J	LUSITANI, DM; QTAISHAT, N; LABRAKE, CC; YU, RN; DAVIS, J; KELLEY, MR; FUNG, LWM				LUSITANI, DM; QTAISHAT, N; LABRAKE, CC; YU, RN; DAVIS, J; KELLEY, MR; FUNG, LWM			THE FIRST HUMAN ALPHA-SPECTRIN STRUCTURAL DOMAIN BEANS WITH SERINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TETRAMER BINDING-SITE; ERYTHROCYTE SPECTRIN; MEMBRANE SKELETON; BETA-SPECTRIN; I DOMAIN; SEGMENTS; ELLIPTOCYTOSIS; POLYPEPTIDES; SEQUENCE	The 106-amino acid sequence motifs of spectrin have been suggested to fold into stable structural domains, consisting mostly of coiled coils of triple helices. With the advent of molecular biology and biophysical techniques, structural studies of these spectrin 106-amino acid structural domains became approachable. However, one of the difficulties in such an approach is determination of the correct phasing of the structural do mains, which may or may not coincide with the phasing of the sequence motifs. Proper identification of the domain phasing is vital to the construction of stable spectrin domains for molecular studies. A previously published phasing shift for Drosophila alpha-spectrin indicated a downstream phase-shift of 26 amino acids for the structural domain (Winograd, E., Hume, D., and Branton, D. (1991) Proc, Natl. Acad. Sci. U. S. A. 88, 10788-10791). Using this phase-shift, we prepared a recombinant spectrin peptide with the sequence from residue 49 to residue 155 of human erythrocyte alpha-spectrin and found this peptide to be unstable relative to other peptides that we prepared. Using several other recombinant alpha-spectrin peptides and following the protease digestion approach, we digested spectrin peptides with elastase and chymotrypsin and analyzed the amino acid sequence of the digestive products. We provide the first experimental evidence in identifying the first amino acid residue of the first spectrin domain in human erythrocyte alpha-spectrin as residue 52 (Ser).	LOYOLA UNIV,DEPT CHEM,CHICAGO,IL 60626; NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611; INDIANA UNIV,JAMES WHITCOMB RILEY HOSP CHILDREN,SCH MED,WELLS CTR PEDIAT RES,DEPT PEDIAT,INDIANAPOLIS,IN 46202; INDIANA UNIV,JW RILEY HOSP CHILDREN,SCH MED,WELLS CTR PEDIAT RES,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	Loyola University Chicago; Northwestern University; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children				Kelley, Mark/0000-0002-6120-9532	NCRR NIH HHS [RR09884] Funding Source: Medline; NHLBI NIH HHS [R01-HL38361] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR009884] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038361] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BYERS TJ, 1992, P NATL ACAD SCI USA, V89, P6187, DOI 10.1073/pnas.89.13.6187; DELAUNAY J, 1993, SEMIN HEMATOL, V30, P21; GARBARZ M, 1990, BLOOD, V75, P1691; KAHANA E, 1994, J MOL BIOL, V235, P1271, DOI 10.1006/jmbi.1994.1080; KENNEDY SP, 1994, J BIOL CHEM, V269, P11400; KOTULA L, 1993, J BIOL CHEM, V268, P14788; MACDONALD RI, 1994, P NATL ACAD SCI USA, V91, P1299, DOI 10.1073/pnas.91.4.1299; MARCHESI SL, 1987, J CLIN INVEST, V80, P191, DOI 10.1172/JCI113047; MARCHESI SL, 1989, RED BLOOD CELL MEMBR, P77; MCGUIRE M, 1988, Hematologic Pathology, V2, P1; PALEK J, 1990, SEMIN HEMATOL, V27, P290; PARRY DAD, 1992, BIOPHYS J, V61, P858, DOI 10.1016/S0006-3495(92)81893-3; PARRY DAD, 1991, AIP CONF PROC, V226, P367; SAHR KE, 1990, J BIOL CHEM, V265, P4434; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPEICHER DW, 1983, J BIOL CHEM, V258, P4938; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; SPEICHER DW, 1993, J BIOL CHEM, V268, P4227; WINKELMANN JC, 1990, J BIOL CHEM, V265, P20449; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097	22	23	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					25955	25958						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929303				2022-12-27	WOS:A1994PQ93000004
J	OH, BH; AMES, GFL; KIM, SH				OH, BH; AMES, GFL; KIM, SH			STRUCTURAL BASIS FOR MULTIPLE LIGAND SPECIFICITY OF THE PERIPLASMIC LYSINE, ARGININE, ORNITHINE-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; ESCHERICHIA-COLI; TRANSPORT-SYSTEMS; ACTIVE-TRANSPORT; MECHANISM; CHEMOTAXIS; BACTERIA; AFFINITY; LEUCINE	The substrate-binding site of a protein with multiple specificity should satisfy geometric and energetic complementarity for several different substrates. The structural basis of the multiple ligand specificity of the periplasmic lysine-, arginine-, ornithine-binding protein (LAO) was investigated by determining and analyzing the structures of the protein unliganded and liganded with each of the three high-affinity ligands (L-lysine, L-arginine, and L-ornithine) and with one low-affinity ligand (L-histidine). The geometric complementarity is achieved primarily by virtue of the large size of the ligand-binding site which can accommodate the maximum common volume of the four ligands plus three water molecules. The optimization of energetic complementarity is achieved by the relocation of protein-bound water molecules and by the movement of the Asp-11 side chain. The structure of the LAO-histidine complex indicates that the 30-fold reduced affinity of the protein for histidine is primarily due to unavailability of one ionic interaction of the histidine side chain with the protein which is present in the other three complexes.	UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DEPT CHEM,BERKELEY,CA 94720; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV STRUCT BIOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley			Oh, Byung-Ha/C-2061-2011		NIAID NIH HHS [AI30725] Funding Source: Medline; NIDDK NIH HHS [DK12121, DK43747] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030725] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043747, R01DK012121, R37DK012121] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS MD, 1991, J BIOL CHEM, V266, P6209; AMANUMA H, 1976, J BIOCHEM, V79, P1167, DOI 10.1093/oxfordjournals.jbchem.a131172; AMES GFL, 1972, J BIOL CHEM, V247, P4309; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; AREVALO JH, 1993, NATURE, V365, P859, DOI 10.1038/365859a0; BLOMBACK B, 1967, NATURE, V215, P1445, DOI 10.1038/2151445a0; BRUNGER AT, 1991, X PLOR VERSION 3 0; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; DONELLADEANA A, 1990, EUR J BIOCHEM, V194, P773, DOI 10.1111/j.1432-1033.1990.tb19468.x; FURLONG CE, 1987, ESCHERICHIA COLI SAL, P768; Hardy R. W. F., 1979, A treatise on dinitrogen fixation. Inorganic and physical chemistry and biochemistry, P515; HIGGINS CF, 1981, P NATL ACAD SCI-BIOL, V78, P6038, DOI 10.1073/pnas.78.10.6038; KOSHLAND DE, 1988, BIOCHEMISTRY-US, V27, P5835; MA YT, 1992, BIOCHEMISTRY-US, V31, P11772, DOI 10.1021/bi00162a014; Markland F. S., 1971, ENZYMES, V3, P561, DOI 10.1016/S1874-6047(08)60407-2; MILLER DM, 1983, J BIOL CHEM, V258, P3665; NIEHRS C, 1990, J BIOL CHEM, V265, P8525; NIKAIDO K, 1992, J BIOL CHEM, V267, P20706; OH BH, 1993, J BIOL CHEM, V268, P11348; OIZUMI J, 1990, BIOCHEM J, V271, P45, DOI 10.1042/bj2710045; PETRONILLI V, 1991, J BIOL CHEM, V266, P16293; POWERS JC, 1989, J CELL BIOCHEM, V39, P33, DOI 10.1002/jcb.240390105; PROUD CG, 1991, EUR J BIOCHEM, V195, P1771; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628	29	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26323	26330						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929349				2022-12-27	WOS:A1994PQ93000059
J	PINNER, E; PADAN, E; SCHULDINER, S				PINNER, E; PADAN, E; SCHULDINER, S			KINETIC-PROPERTIES OF NHAB, A NA+/H+ ANTIPORTER FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-VESICLES; PROTON GRADIENT; H+ ANTIPORT; SODIUM; EXPRESSION; GENE; ANT; PH; PROTEINS; CELLS	NhaB, a Na+/H+ antiporter from Escherichia coli, was overproduced, purified, and reconstituted in a functional state, demonstrating that a single polypeptide, the product of the nhaB gene, can catalyze full activity. NhaB is a minor protein that accounts for less than 0.1% of the total membrane protein. The use of proteoliposomes made possible the determination of important kinetic and pharmacological properties in the absence of passive and mediated leaks. The activity of NhaB was found to have some pH dependence; the apparent K-m for Na+ changes by 10-fold from 1.55 mM at pH 8.5 to 16.66 mM at pH 7.2, while the V-max remains constant. It was demonstrated that NhaB is electrogenic and translocates more H+ than Na+ per cycle; the rate of sodium efflux from proteoliposomes was accelerated by a membrane potential, negative inside, and NhaB activity generated a membrane potential as monitored by two techniques. The stoichiometry of NhaB was estimated by a thermodynamic method in which the magnitude of Delta psi generated by NhaB was measured at various Na+ gradients. A kinetic method, in which the electrophoretic movement of Rb-86(+) (in the presence of valinomycin) was monitored in parallel with measurements of NhaB-mediated Na-22(+) uptake, allowed us to determine a stoichiometry of 3H(+)/ 2Na(+). The significance of the existence of two antiporters with different stoichiometries, NhaA and NhaB, active in the same cell, is discussed.			PINNER, E (corresponding author), HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,DIV MICROBIAL & MOLEC ECOL,IL-91904 JERUSALEM,ISRAEL.		Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237				BASSILANA M, 1984, BIOCHEMISTRY-US, V23, P1015, DOI 10.1021/bi00300a033; BASSILANA M, 1984, BIOCHEMISTRY-US, V23, P5288, DOI 10.1021/bi00317a029; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARMEL O, 1994, EMBO J, V13, P1981, DOI 10.1002/j.1460-2075.1994.tb06467.x; CASTLE AM, 1986, J BIOL CHEM, V261, P7797; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; KARPEL R, 1988, J BIOL CHEM, V263, P10408; KARPEL R, 1991, J BIOL CHEM, V266, P21753; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PADAN E, 1993, J BIOENERG BIOMEMBR, V25, P647; PADAN E, 1989, J BIOL CHEM, V264, P20297; PADAN E, 1994, BBA-BIOENERGETICS, V1185, P129, DOI 10.1016/0005-2728(94)90204-6; PADAN E, 1981, BIOCHIM BIOPHYS ACTA, V650, P151, DOI 10.1016/0304-4157(81)90004-6; PAN JW, 1990, J BIOL CHEM, V265, P9247; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PINNER E, 1992, J BIOL CHEM, V267, P11064; PINNER E, 1993, J BIOL CHEM, V268, P1729; RAHAVMANOR O, 1992, J BIOL CHEM, V267, P10433; SCHULDINER S, 1978, BIOCHEMISTRY-US, V17, P706, DOI 10.1021/bi00597a023; Schuldiner S., 1992, ALKALI CATION TRANSP, P25; SHAHAK Y, 1982, FEBS LETT, V150, P27, DOI 10.1016/0014-5793(82)81298-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; TAGLICHT D, 1993, J BIOL CHEM, V268, P5382; WEST IC, 1974, BIOCHEM J, V144, P87, DOI 10.1042/bj1440087; ZILBERSTEIN D, 1979, BIOCHEMISTRY-US, V18, P669, DOI 10.1021/bi00571a018	26	71	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26274	26279						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929345				2022-12-27	WOS:A1994PQ93000053
J	WESTWICK, JK; WEITZEL, C; MINDEN, A; KARIN, M; BRENNER, DA				WESTWICK, JK; WEITZEL, C; MINDEN, A; KARIN, M; BRENNER, DA			TUMOR-NECROSIS-FACTOR-ALPHA STIMULATES AP-1 ACTIVITY THROUGH PROLONGED ACTIVATION OF THE C-JUN KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; EPIDERMAL GROWTH-FACTOR; SIGNAL-REGULATED KINASE-2; PROTEIN-KINASE; FACTOR RECEPTOR; DNA-BINDING; MOLECULAR-CLONING; GENE-EXPRESSION; TNF RECEPTORS; MAP KINASES	Tumor necrosis factor alpha (TNF alpha) has multiple biological functions including the prolonged activation of the collagenase and c-jun genes, which are regulated via their AP-1 binding sites. We show that incubating human fibroblasts with TNF alpha induces prolonged activation of JNK, the c-Jun kinase, which phosphorylates the transactivation domain of c-Jun. Furthermore, an immune complex kinase assay specifically demonstrates that TNF alpha stimulates the activity of JNK1, the recently described predominant form of JNK. TNF alpha also produces a small and transient increase in extracellular signal-regulated kinase (ERK) activity and no measured increase in Raf-1 kinase activity. On the other hand, epidermal growth factor causes a prolonged activation of Raf-1 kinase and ERK activity and a smaller, more transient activation of JNK, whereas the phorbol ester phorbol 12-myristate 13-acetate causes a small stimulation of Raf-1 kinase and a pronounced stimulation of ERK activity. The activation of JNK by TNF alpha does not correlate with Raf-1 or ERK activity. The kinetics of Raf-1, ERK, and JNK induction by epidermal growth factor, phorbol 12-myristate 13-acetate, or TNF alpha indicate distinct mechanisms of activation in human fibroblasts.	UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599; UNIV CALIF SAN DIEGO,SCH MED,PROGRAM MOLEC PATHOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,LA JOLLA,CA 92093	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California San Diego; University of California System; University of California San Diego				Brenner, David/0000-0003-2573-525X	NCI NIH HHS [CA50528] Funding Source: Medline; NIDDK NIH HHS [DK34987] Funding Source: Medline; NIGMS NIH HHS [GM41804] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041804] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CHOU SY, 1992, MOL BIOL CELL, V3, P1117, DOI 10.1091/mbc.3.10.1117; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; GARDNER AM, 1993, IN PRESS METHODS ENZ; GUY GR, 1992, J BIOL CHEM, V267, P1846; GUY GR, 1993, J BIOL CHEM, V268, P2141; HATTORI M, 1993, AM J PHYSIOL, V264, pG95, DOI 10.1152/ajpgi.1993.264.1.G95; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HELLER RA, 1992, CELL, V70, P47; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; KAHARI VM, 1992, J BIOL CHEM, V267, P26134; KALTHOFF H, 1993, J BIOL CHEM, V268, P2762; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LIU J, 1994, J BIOL CHEM, V269, P3047; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RIPPE RA, 1990, MOL CELL BIOL, V10, P689, DOI 10.1128/MCB.10.2.689; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VANDENABEELE P, 1992, J EXP MED, V176, P1015, DOI 10.1084/jem.176.4.1015; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YANG ZH, 1993, J BIOL CHEM, V268, P20520; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	61	267	269	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26396	26401						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929360				2022-12-27	WOS:A1994PQ93000070
J	CHEN, ZP; SHEMSHEDINI, L; DURAND, B; NOY, N; CHAMBON, P; GRONEMEYER, H				CHEN, ZP; SHEMSHEDINI, L; DURAND, B; NOY, N; CHAMBON, P; GRONEMEYER, H			PURE AND FUNCTIONALLY HOMOGENEOUS RECOMBINANT RETINOID-X RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; THYROID-HORMONE; ACID RECEPTORS; NUCLEAR RECEPTORS; RESPONSE ELEMENTS; RXR-BETA; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID RECEPTOR; ESTROGEN-RECEPTOR; ALL-TRANS	Mouse retinoid X receptor alpha (RXR alpha) lacking the amino-terminal region A/B (RXR alpha Delta AB) has been purified to more than 98% purity and functional homogeneity from bacterial and baculovirus-based recombinant expression systems with yields of 2-8 mg/liter of culture. The purified protein is soluble, and fluorescence quenching analysis demonstrated that it binds its cognate ligand 9-cis-retinoic acid (9-cis-RA) stoichiometrically, and with high affinity. Compared with RXR Delta AB expressed in COS-1 cells, bacterially and baculovirus-expressed proteins bind approximately 10 and 5 times less efficiently to direct repeat 1 (DR1) DNA elements, respectively, suggesting that animal cell specific modification of RXR or interaction with other animal cell-specific factors may modulate DNA binding. 9-cis-RA did not stimulate DR1 binding of functional RXR Delta AB expressed in Escherichia coli, Sf9 or COS-1 cells. The previously reported ligand effect that can be observed with in vitro made receptor may therefore be a consequence of a conformational stabilization of improperly folded in vitro synthesized protein.	FAC MED STRASBOURG, CNRS, GENET MOLEC EUCARYOTES LAB, F-67085 STRASBOURG, FRANCE; FAC MED STRASBOURG, INST CHIM BIOL, INSERM, UNITE BIOL MOLEC & GEN GENET 184, F-67085 STRASBOURG, FRANCE; CORNELL UNIV, DIV NUTR SCI, ITHACA, NY 14853 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Cornell University			Gronemeyer, Hinrich/AAH-5575-2019; DURAND, Beatrice C/J-6387-2015; Gronemeyer, Hinrich/H-7002-2016; Gronemeyer, Hinrich/G-6240-2011	Gronemeyer, Hinrich/0000-0001-9454-2449; DURAND, Beatrice C/0000-0002-0047-288X; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449				ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN Y, 1993, BIOCHEMISTRY-US, V32, P11311, DOI 10.1021/bi00093a007; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FIORELLA PD, 1991, J BIOL CHEM, V266, P16572; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; GRONEMEYER H, 1992, FASEB J, V6, P2524, DOI 10.1096/fasebj.6.8.1592204; HALL BL, 1993, P NATL ACAD SCI USA, V90, P6929, DOI 10.1073/pnas.90.15.6929; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HEERY DM, 1993, P NATL ACAD SCI USA, V90, P4281, DOI 10.1073/pnas.90.9.4281; HERRY DM, 1994, NUCLEIC ACIDS RES, V22, P726; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MADER S, 1993, J BIOL CHEM, V268, P591; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NOY N, 1990, BIOCHEMISTRY-US, V29, P3878, DOI 10.1021/bi00468a012; NOY N, 1991, BIOCHEMISTRY-US, V30, P6380, DOI 10.1021/bi00240a005; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1993, STRUCTURE, V1, P187, DOI 10.1016/0969-2126(93)90020-H; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	48	62	63	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25770	25776						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929281				2022-12-27	WOS:A1994PQ49100080
J	HAUSER, N; PAULSSON, M				HAUSER, N; PAULSSON, M			NATIVE CARTILAGE MATRIX PROTEIN (CMP) - A COMPACT TRIMER OF SUBUNITS ASSEMBLED VIA A COILED-COIL ALPHA-HELIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; VONWILLEBRAND-FACTOR; STRUCTURAL FEATURES; DOMAIN; LAMININ; BINDING; SITES; GENE	Cartilage matrix protein (CMP), a major component of many types of cartilage, is a noncollagenous glycoprotein with a molecular mass of 148 kDa consisting of three identical subunits. With the aim of performing a more comprehensive characterization, we purified CMP in a native conformation from fetal bovine rib cartilage avoiding the denaturing solvents previously used. CMP could be selectively extracted with EDTA-containing buffer which indicates a divalent cation-dependent anchorage in the cartilage matrix. Determination of the amino-terminal sequence of the bovine protein confirmed its identity when compared with published cDNA sequences of chicken and human CMP. Electron microscopy revealed the presence of three ellipsoid subunits which are connected at one end. Sequence analysis indicated the presence of a coiled-coil alpha-helical assembly domain formed by the COOH-terminal end of the subunits. The trimeric structure was retained after complete reduction under native conditions which shows that the coiled-coil domain is stable also in the absence of interchain disulfide bonds.			HAUSER, N (corresponding author), UNIV BERN,ME MULLER INST BIOMECH,POB 30,CH-3010 BERN,SWITZERLAND.							ARGRAVES WS, 1987, P NATL ACAD SCI USA, V84, P464, DOI 10.1073/pnas.84.2.464; BECK K, 1993, J MOL BIOL, V231, P311, DOI 10.1006/jmbi.1993.1284; BECK K, 1992, PATTERNS PROTEIN SEQ, P229; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COLOMBATTI A, 1991, BLOOD, V77, P2305; CONWAY JF, 1990, INT J BIOL MACROMOL, V12, P328, DOI 10.1016/0141-8130(90)90023-4; DOOLITTLE RF, 1978, J MOL BIOL, V120, P311, DOI 10.1016/0022-2836(78)90070-0; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; ENGEL J, 1987, METHOD ENZYMOL, V145, P1; FOWLER WE, 1989, COAGULATION BLEEDING, P181; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; JENKINS RN, 1990, J BIOL CHEM, V265, P19624; KISS I, 1989, J BIOL CHEM, V264, P8126; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MORGELIN M, 1992, J BIOL CHEM, V267, P6137; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; PAULSSON M, 1979, BIOCHEM J, V183, P539, DOI 10.1042/bj1830539; PAULSSON M, 1982, BIOCHEM J, V207, P207, DOI 10.1042/bj2070207; PAULSSON M, 1984, BIOCHEM J, V221, P623, DOI 10.1042/bj2210623; PAULSSON M, 1981, BIOCHEM J, V197, P367, DOI 10.1042/bj1970367; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; SOTTILE J, 1991, BIOCHEMISTRY-US, V30, P6556, DOI 10.1021/bi00240a028; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; WINTERBOTTOM N, 1992, DEV DYNAM, V193, P266, DOI 10.1002/aja.1001930307	26	66	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25747	25753						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929279				2022-12-27	WOS:A1994PQ49100077
J	SATHER, SK; KING, J				SATHER, SK; KING, J			INTRACELLULAR TRAPPING OF A CYTOPLASMIC FOLDING INTERMEDIATE OF THE PHAGE-P22 TAILSPIKE USING IODOACETAMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAIL-SPIKE PROTEIN; INCLUSION BODY FORMATION; HEAD FORMATION GROE; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; SALMONELLA PHAGE-P22; MOLECULAR CHAPERONES; RAMAN-SPECTROSCOPY; POLYPEPTIDE-CHAIN; DISULFIDE BONDS	Critical steps in polypeptide chain folding within the bacterial cytoplasm have been difficult to identify. Salmonella cells infected with temperature-sensitive folding mutants of the P22 tailspike protein at restrictive temperature accumulated a metastable folding intermediate with a half-life of 6 min at 39 degrees C. The native trimeric tailspike contains 24 buried cysteines (8/chain) but neither disulfide bonds nor active site cysteines. Eighteen of the 24 cysteines are involved in strong hydrogen bonds (Thomas, G. J., Jr., Becka, R., Sargent, D., Yu, M.-H., and King, J. (1990) Biochemistry 29, 4181-4187). Cyanide and iodoacetamide prevented the folding and association of the restrictive temperature folding intermediate to the native state after shift to permissive temperature. The cytoplasmic folding intermediate was covalently modified by iodoacetamide within infected cells. Chains which had reacted with iodoacetamide were unable to proceed through the folding pathway. Iodoacetamide also reacted with a folding intermediate during the refolding of purified tailspike chains in vitro, inhibiting further folding. No reaction occurred with native tailspike in vivo or in vitro. The target residues in the intermediates were in the carboxyl terminus of the chain and may be a unique set of cysteine residues that are activated during protein folding, but not in the native state.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)					NIGMS NIH HHS [NIGMS 17980] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017980, R37GM017980] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MH, 1959, BACTERIOPHAGES; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BEISSINGER M, 1994, IN PRESS PROTEIN PEP; BERGET PB, 1980, J VIROL, V34, P234, DOI 10.1128/JVI.34.1.234-243.1980; BOTSTEIN D, 1973, J MOL BIOL, V80, P669, DOI 10.1016/0022-2836(73)90204-0; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; CHEN BL, 1991, BIOCHEMISTRY-US, V30, P6260, DOI 10.1021/bi00239a026; COPPO A, 1973, J MOL BIOL, V76, P61, DOI 10.1016/0022-2836(73)90081-8; Creighton T. E., 1984, PROTEINS, P242; CREIGHTON TE, 1988, BIOESSAYS, V8, P57, DOI 10.1002/bies.950080204; Creighton Thomas E., 1992, P301; DANNER M, 1993, PROTEIN SCI, V2, P1869, DOI 10.1002/pro.5560021109; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; DRAHOS DJ, 1982, J BACTERIOL, V149, P1050, DOI 10.1128/JB.149.3.1050-1063.1982; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FANE B, 1987, GENETICS, V117, P157; FRIGUET B, 1990, J BIOL CHEM, V265, P10347; FUCHS A, 1991, BIOCHEMISTRY-US, V30, P6598, DOI 10.1021/bi00240a032; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GEORGOPOULOS CP, 1972, NATURE-NEW BIOL, V239, P38, DOI 10.1038/newbio239038a0; GOLDENBERG D, 1982, P NATL ACAD SCI-BIOL, V79, P3403, DOI 10.1073/pnas.79.11.3403; GOLDENBERG DP, 1981, J MOL BIOL, V145, P633, DOI 10.1016/0022-2836(81)90307-7; GOLDENBERG DP, 1983, P NATL ACAD SCI-BIOL, V80, P7060, DOI 10.1073/pnas.80.23.7060; GOLDENBERG DP, 1982, J BIOL CHEM, V257, P7864; GORDON CL, 1994, IN PRESS J BIOL CHEM, V269; GURD FRN, 1967, METHOD ENZYMOL, V11, P532; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; IWASHITA S, 1976, EUR J BIOCHEM, V65, P87, DOI 10.1111/j.1432-1033.1976.tb10392.x; KING J, 1971, J MOL BIOL, V62, P465, DOI 10.1016/0022-2836(71)90148-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY F, 1991, CELL, V67, P265, DOI 10.1016/0092-8674(91)90178-2; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MEANS GE, 1971, CHEM MODIFICATION PR, P110; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; MURIALDO H, 1979, VIROLOGY, V96, P341, DOI 10.1016/0042-6822(79)90094-1; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; REVEL HR, 1980, J VIROL, V33, P366, DOI 10.1128/JVI.33.1.366-376.1980; SARGENT D, 1988, J MOL BIOL, V199, P491, DOI 10.1016/0022-2836(88)90620-1; SAUER RT, 1982, BIOCHEMISTRY-US, V21, P5811, DOI 10.1021/bi00266a014; SCHWARZ JJ, 1989, J BIOL CHEM, V264, P20112; SECKLER R, 1989, J BIOL CHEM, V264, P11750; SMITH DH, 1981, J MOL BIOL, V145, P653, DOI 10.1016/0022-2836(81)90308-9; SMITH DH, 1980, GENETICS, V96, P331; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; STERNBERG N, 1973, J MOL BIOL, V76, P25, DOI 10.1016/0022-2836(73)90079-X; STERNBERG N, 1973, J MOL BIOL, V76, P1, DOI 10.1016/0022-2836(73)90078-8; STUDIER FW, 1972, SCIENCE, V176, P367, DOI 10.1126/science.176.4033.367; STURTEVANT JM, 1989, J BIOL CHEM, V264, P10693; TAKANO T, 1972, NATURE-NEW BIOL, V239, P34, DOI 10.1038/newbio239034a0; THOMAS GJ, 1990, BIOCHEMISTRY-US, V29, P4181, DOI 10.1021/bi00469a022; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VILLAFANE R, 1988, J MOL BIOL, V204, P607, DOI 10.1016/0022-2836(88)90359-2; WINSTON F, 1979, J BACTERIOL, V137, P433, DOI 10.1128/JB.137.1.433-439.1979; YU MH, 1988, J BIOL CHEM, V263, P1424; ZWEIG M, 1973, J MOL BIOL, V80, P505, DOI 10.1016/0022-2836(73)90418-X	63	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25268	25276						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929218				2022-12-27	WOS:A1994PQ49100008
J	SINGH, L; WADHWA, R; NAIDU, S; NAGARAJ, R; GANESAN, M				SINGH, L; WADHWA, R; NAIDU, S; NAGARAJ, R; GANESAN, M			SEX-SPECIFIC AND TISSUE-SPECIFIC BKM(GATA)-BINDING PROTEIN IN THE GERM-CELLS OF HETEROGAMETIC SEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE Y-CHROMOSOME; UBIQUITIN-ACTIVATING ENZYME-E1; TRANSCRIPTION FACTOR GATA-1; DNA-BINDING PROTEIN; PROXIMAL CHROMOSOME-17; DETERMINING REGION; EXPRESSED GENES; SATELLITE DNA; SEQUENCES; MICE	The ZZ male/ZW female system of sex determination (female heterogamety) is found in snakes and birds whereas XY male/XX female system of sex determination (male heterogamety) operates in mammals including humans. The W and Y chromosomes are largely heterochromatic and undergo cycles of condensation and decondensation in the germ cells of ovary and testis, respectively, whereas they remain highly condensed and transcriptionally inactive in all somatic cells. Both chromosomes have enriched stretches of GATA repeats along their entire length (which is identified as banded krait minor satellite DNA and called Bkm) that are highly conserved through widely separated orders of eukaryotes. Here we report the existence of a factor, which specifically binds to Bkm, in the germ cells of the heterogametic sex (ovary in female heterogamety and testis in male heterogamety) where decondensation (activation) of the W and Y chromosomes, respectively, occurs; it has been purified as a polypeptide of 57.5 kDa from the rat snake ovary and designated as Bkm-binding protein (BBP) by virtue of its binding to GATA repeats of Bkm. Such a sex- and tissue specific BBP is also present in the ovary of other species of snakes and in the testis of mouse and human where the Y chromosome is highly decondensed. We suggest that GATA repeats of Bkm brings about a coordinated decondensation of the W and Y sex chromosomes in the germ cells of the heterogametic sex in response to BBP which may serve as a ''switch'' for the activation of the genes present on the W and Y chromosomes.			SINGH, L (corresponding author), CTR CELLULAR & MOLEC BIOL, HYDERABAD 500007, ANDHRA PRADESH, INDIA.		Wadhwa, Renu/L-8898-2018	Wadhwa, Renu/0000-0001-8248-5192				ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; BURGOYNE PS, 1986, NATURE, V320, P170, DOI 10.1038/320170a0; BURGOYNE PS, 1987, DEVELOPMENT, V101, P133; DURBIN EJ, 1989, CHROMOSOMA, V97, P301, DOI 10.1007/BF00371970; EPPLEN JT, 1982, P NATL ACAD SCI-BIOL, V79, P3798, DOI 10.1073/pnas.79.12.3798; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HARATA M, 1988, J BIOL CHEM, V263, P13952; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; JONES KW, 1985, TRENDS GENET, V1, P55, DOI 10.1016/0168-9525(85)90024-1; KAY GF, 1991, NATURE, V354, P486, DOI 10.1038/354486a0; KIELMETZGER K, 1984, NATURE, V310, P579, DOI 10.1038/310579a0; KOOPMAN P, 1989, NATURE, V342, P940, DOI 10.1038/342940a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MCLAREN A, 1984, NATURE, V312, P552, DOI 10.1038/312552a0; MITCHELL MJ, 1991, NATURE, V354, P483, DOI 10.1038/354483a0; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PRADO VF, 1992, CYTOGENET CELL GENET, V61, P87, DOI 10.1159/000133375; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SINGH L, 1994, NUCLEIC ACIDS RES, V22, P2289, DOI 10.1093/nar/22.12.2289; SINGH L, 1980, CHROMOSOMA, V79, P137, DOI 10.1007/BF01175181; SINGH L, 1972, CHROMOSOMA, V38, P185, DOI 10.1007/BF00326193; SINGH L, 1976, CHROMOSOMA, V59, P43, DOI 10.1007/BF00327708; SINGH L, 1979, CHROMOSOMA, V71, P167, DOI 10.1007/BF00292821; SINGH L, 1982, CELL, V28, P205, DOI 10.1016/0092-8674(82)90338-5; SINGH L, 1980, COLD SPRING HARB SYM, V45, P805, DOI 10.1101/SQB.1981.045.01.099; SINGH L, 1984, CELL, V36, P111, DOI 10.1016/0092-8674(84)90079-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAUT W, 1978, EXP CELL RES, V113, P85, DOI 10.1016/0014-4827(78)90090-3; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VISVADER JE, 1992, EMBO J, V11, P4557, DOI 10.1002/j.1460-2075.1992.tb05557.x; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YEOM YI, 1992, P NATL ACAD SCI USA, V89, P773, DOI 10.1073/pnas.89.2.773	38	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25321	25327						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929225				2022-12-27	WOS:A1994PQ49100016
J	MADDELEIN, ML; LIBESSART, N; BELLANGER, F; DELRUE, B; DHULST, C; VANDENKOORNHUYSE, N; FONTAINE, T; WIERUSZESKI, JM; DECQ, A; BALL, S				MADDELEIN, ML; LIBESSART, N; BELLANGER, F; DELRUE, B; DHULST, C; VANDENKOORNHUYSE, N; FONTAINE, T; WIERUSZESKI, JM; DECQ, A; BALL, S			TOWARD AN UNDERSTANDING OF THE BIOGENESIS OF THE STARCH GRANULE - DETERMINATION OF GRANULE-BOUND AND SOLUBLE STARCH SYNTHASE FUNCTIONS IN AMYLOPECTIN SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-GLUCOSE PYROPHOSPHORYLASE; CHLAMYDOMONAS-REINHARDTII; BRANCHING ENZYME; INHIBITION; EXPRESSION; STORAGE; POTATO; MUTANT; GENES	Plant starch synthesis can be distinguished from those of bacterial, fungal, and animal glycogen by the presence of multiple elongation (starch synthases) and branching enzymes. This complexity has precluded genetic assignment of functions to the various soluble starch synthases in the building of amylopectin. In Chlamydomonas, we have recently shown that defects in the major soluble starch synthase lead to a specific decrease in the amount of a subset of amylopectin chains whose length ranges between 8 and 40 glucose residues (Fontaine, T., D'Hulst, C., Maddelein, M.-L., Routier, F., Marianne-Pepin, T., Decq, A., Wieruszeski, J. M., Delrue, B., Van Den Koornhuyse, N., Bossu, J.-P., Fournet, B., and Ball, S. G. (1993) J. Biol. Chem. 268, 16223-16230). We now demonstrate that granule-bound starch synthase, the enzyme that was thought to be solely responsible for amylose synthesis, is involved in amylopectin synthesis. Disruption of the Chlamydomonas granule-bound starch synthase structural gene establishes that synthesis of long chains by this enzyme can become an absolute requirement for amylopectin synthesis in particular mutant backgrounds, In the sole presence of soluble starch synthase I, Chlamydomonas directs the synthesis of a major water-soluble polysaccharide fraction and minute amounts of a new type of highly branched granular material, whose structure is intermediate between those of glycogen and amylopectin. These results lead us to propose that the nature of the elongation enzyme conditions the synthesis of distinct size classes of glucans in all starch fractions.	UNIV SCI & TECH LILLE FLANDRES ARTOIS,CNRS,UMR 111,CHIM BIOL LAB,F-59655 VILLENEUVE DASCQ,FRANCE; ROQUETTE FRERES,F-62136 LESTREM,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille			D'Hulst, Christophe/AAX-2809-2020; Fontaine, thierry/Q-2201-2018; D'HULST, Christophe/B-2072-2012; Fontaine, Thierry/F-8227-2011; MADDELEIN, Marie-Lise/G-5395-2010	D'Hulst, Christophe/0000-0002-5556-9099; Fontaine, thierry/0000-0002-8184-789X; D'HULST, Christophe/0000-0002-5556-9099; Ball, Steven/0000-0003-1629-1650				BABA T, 1987, STARCH-STARKE, V39, P52, DOI 10.1002/star.19870390207; BALL S, 1991, PLANTA, V185, P17, DOI 10.1007/BF00194509; BALL SG, 1990, PLANT SCI, V66, P1, DOI 10.1016/0168-9452(90)90162-H; BANKS W, 1971, CARBOHYD RES, V17, P25, DOI 10.1016/S0008-6215(00)81539-6; CREECH RG, 1965, GENETICS, V52, P1175; DELRUE B, 1992, J BACTERIOL, V174, P3612, DOI 10.1128/JB.174.11.3612-3620.1992; FONTAINE T, 1993, J BIOL CHEM, V268, P16223; GIDLEY MJ, 1985, CARBOHYD RES, V139, P85; Harris E.H., 1989, CHLAMYDOMONAS SOURCE, P399; Harris EH, 1989, CHLAMYDOMONAS SOURCE, P25, DOI [DOI 10.1016/B978-0-12-326880-8.50007-9, DOI 10.1126/SCIENCE.246.4936.1503-A]; HARRIS EH, 1989, CHLAMYDOMONAS SOURCE, P581; HIZUKURI S, 1986, CARBOHYD RES, V147, P342, DOI 10.1016/S0008-6215(00)90643-8; KINDLE KL, 1990, P NATL ACAD SCI USA, V87, P1228, DOI 10.1073/pnas.87.3.1228; KRISMAN CR, 1985, ANAL BIOCHEM, V147, P491, DOI 10.1016/0003-2697(85)90303-3; KUIPERS AGJ, 1994, PLANT CELL, V6, P43, DOI 10.1105/tpc.6.1.43; LELOIR LF, 1961, J BIOL CHEM, V236, P636; LIN TP, 1988, PLANT PHYSIOL, V88, P1175, DOI 10.1104/pp.88.4.1175; MACDONALD FD, 1985, PLANT PHYSIOL, V78, P849, DOI 10.1104/pp.78.4.849; MANNERS DJ, 1989, CARBOHYD POLYM, V11, P87, DOI 10.1016/0144-8617(89)90018-0; MULLERROBER B, 1992, EMBO J, V11, P1229, DOI 10.1002/j.1460-2075.1992.tb05167.x; NELSON OE, 1962, BIOCHEM BIOPH RES CO, V9, P297, DOI 10.1016/0006-291X(62)90043-8; PARENTE JP, 1985, CARBOHYD RES, V141, P41, DOI 10.1016/S0008-6215(00)90753-5; Preiss J., 1980, MECHANISMS SACCHARID, P161; Preiss J, 1991, OXFORD SURVEYS PLANT, V7, P59; Shannon J., 1984, STARCH CHEM TECHNOLO, P25, DOI 10.1016/B978-0-12-746270-7.50009-4; TAM LW, 1993, GENETICS, V135, P375; THON VJ, 1992, J BIOL CHEM, V267, P15224; TSAI CY, 1966, SCIENCE, V151, P341, DOI 10.1126/science.151.3708.341; VISSER RGF, 1991, MOL GEN GENET, V225, P289, DOI 10.1007/BF00269861	29	84	96	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25150	25157						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929203				2022-12-27	WOS:A1994PQ49000093
J	POLLESELLO, P; OVASKA, M; KAIVOLA, J; TILGMANN, C; LUNDSTROM, K; KALKKINEN, N; ULMANEN, I; NISSINEN, E; TASKINEN, J				POLLESELLO, P; OVASKA, M; KAIVOLA, J; TILGMANN, C; LUNDSTROM, K; KALKKINEN, N; ULMANEN, I; NISSINEN, E; TASKINEN, J			BINDING OF A NEW CA2+ SENSITIZER, LEVOSIMENDAN, TO RECOMBINANT HUMAN CARDIAC TROPONIN-C - A MOLECULAR MODELING, FLUORESCENCE PROBE, AND PROTON NUCLEAR-MAGNETIC-RESONANCE STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATECHOL-O-METHYLTRANSFERASE; SKELETAL-MUSCLE; CONFORMATIONAL TRANSITION; ESCHERICHIA-COLI; CALCIUM-BINDING; TERMINAL DOMAIN; DISULFIDE BOND; RAT-LIVER; PROTEINS; PURIFICATION	The binding of a new calcium sensitizer, levosimendan, to human cardiac troponin C (cTnC) is described. Fluorescence studies done on dansylated recombinant human cTnC and a site-directed mutant showed that levosimendan modulated the calcium-induced conformational change in cTnC, and revealed the role of Asp-88 in the binding of the drug to the NH2-terminal domain of cTnC. Furthermore, NMR studies performed on the NH2-terminal fragment of cTnC showed a spatial proximity between levosimendan and Met(81), Met(85), and Phe(77) in the drug-protein complex. These data were used to build an optimized model of the drug protein complex, in which levosimendan binds cTnC at the hydrophobic pocket of the NH2 terminal domain. The role of the binding of levosimendan to cTnC in the pharmacological action of this drug in vivo is discussed.	UNIV HELSINKI,INST BIOTECHNOL,SF-00014 HELSINKI,FINLAND	University of Helsinki	POLLESELLO, P (corresponding author), ORION CORP,ORION FARMOS,ORION RES,CHEM RES DEPT,POB 65,SF-02101 ESPOO,FINLAND.		Kalkkinen, Nisse EJ/B-3923-2010	Tilgmann, Carola/0000-0001-6241-2359; pollesello, piero/0000-0001-6994-768X				BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BLANCHARD EM, 1984, CIRC RES, V55, P382, DOI 10.1161/01.RES.55.3.382; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRITO RMM, 1991, BIOCHEMISTRY-US, V30, P10236, DOI 10.1021/bi00106a023; DASILVA ACR, 1991, TRENDS BIOCHEM SCI, V16, P53, DOI 10.1016/0968-0004(91)90024-P; DASILVA ACR, 1993, EUR J BIOCHEM, V213, P599; DRABIKOWSKI W, 1985, EUR J BIOCHEM, V151, P17, DOI 10.1111/j.1432-1033.1985.tb09063.x; EVANS JS, 1980, BIOCHIM BIOPHYS ACTA, V623, P10, DOI 10.1016/0005-2795(80)90003-3; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FUJIMORI K, 1990, NATURE, V345, P182, DOI 10.1038/345182a0; Geguchadze R N, 1990, Biomed Sci, V1, P37; GRABAREK Z, 1990, NATURE, V345, P132, DOI 10.1038/345132a0; GRABAREK Z, 1992, J MUSCLE RES CELL M, V13, P383, DOI 10.1007/BF01738034; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUSEV NB, 1991, J BIOL CHEM, V266, P16622; HAIKALA H, 1992, Journal of Molecular and Cellular Cardiology, V24, pS260; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HERZIG JW, 1992, Z KARDIOL, V81, P49; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HOLROYDE MJ, 1979, BIOCHIM BIOPHYS ACTA, V586, P63, DOI 10.1016/0304-4165(79)90405-7; JOHNSON JD, 1980, J BIOL CHEM, V255, P9635; KALKKINEN N, 1988, J PROTEIN CHEM, V7, P242; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; LEE JA, 1990, BRIT MED J, V300, P551, DOI 10.1136/bmj.300.6724.551; LI MX, 1994, BIOCHEMISTRY-US, V33, P917, DOI 10.1021/bi00170a010; LUNDSTROM K, 1992, BIOCHIM BIOPHYS ACTA, V1129, P149, DOI 10.1016/0167-4781(92)90479-J; LUNDSTROM K, 1991, SITE-DIRECTED MUTAGENESIS AND PROTEIN ENGINEERING, P119; MACLACHLAN LK, 1990, J BIOL CHEM, V265, P9764; MACLACHLAN LK, 1990, J BIOL CHEM, V265, P9754; OVASKA M, 1991, PROTEINS, V11, P79, DOI 10.1002/prot.340110202; OVASKA M, 1992, Journal of Molecular and Cellular Cardiology, V24, pS260; PARMACEK MS, 1991, CIRCULATION, V84, P991, DOI 10.1161/01.CIR.84.3.991; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; STEVENSON WG, 1989, AM HEART J, V118, P1182, DOI 10.1016/0002-8703(89)90007-0; THOMSEN J, 1988, J PROTEIN CHEM, V7, P295; TILGMANN C, 1990, FEBS LETT, V264, P95, DOI 10.1016/0014-5793(90)80774-D; VANEERD JP, 1973, BIOCHEMISTRY-US, V12, P4972, DOI 10.1021/bi00748a024; WANG Y, 1988, BIOTECHNIQUES, V6, P843; WETZEL B, 1988, TRENDS PHARMACOL SCI, V9, P166, DOI 10.1016/0165-6147(88)90031-4; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	46	224	227	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28584	28590						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961805				2022-12-27	WOS:A1994PU16800014
J	ROBINS, P; PAPPIN, DJC; WOOD, RD; LINDAHL, T				ROBINS, P; PAPPIN, DJC; WOOD, RD; LINDAHL, T			STRUCTURAL AND FUNCTIONAL HOMOLOGY BETWEEN MAMMALIAN DNASE-IV AND THE 5'-NUCLEASE DOMAIN OF ESCHERICHIA-COLI DNA-POLYMERASE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							5'->3' EXONUCLEASE; 5'-3' EXONUCLEASE; CELLS; IDENTIFICATION; REPLICATION; EXCISION; PROTEINS; REPAIR; SITES; YEAST	A nuclear 42-kDa 5' --> 3'-exonuclease, DNase TV, was found previously in animal tissues. The enzyme has been purified from HeLa cells and shown to possess two catalytic properties characteristic of the 5'-nuclease function of Escherichia coli DNA polymerase I; DNase IV removes single-stranded 5' regions from splayed-arm DNA structures by endonucleolytic incision at the bifurcation point and possesses RNase H activity. Determination of the molecular masses of tryptic and V8 peptides of DNase IV by mass spectrometry identified the enzyme as the human homolog of the Schizosaccharomyces pombe Rad2 protein. The protein sequence retains conserved residues and shows significant homology to the sequences of the 5'-nuclease domain of E. coli DNA polymerase I and related microbial enzymes.	LINCOLNS INN FIELDS LABS,LONDON WC2A 3PX,ENGLAND		ROBINS, P (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.		Wood, Richard/M-6319-2018	Wood, Richard/0000-0002-9495-6892; Pappin, Darryl/0000-0002-8981-8401				CARR AM, 1993, NUCLEIC ACIDS RES, V21, P1345, DOI 10.1093/nar/21.6.1345; COULL J M, 1990, Journal of Protein Chemistry, V9, P259; CRUTE JJ, 1989, J BIOL CHEM, V264, P19266; ENGLER MJ, 1983, J BIOL CHEM, V258, P1197; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; GUTMAN PD, 1993, NUCLEIC ACIDS RES, V21, P4406, DOI 10.1093/nar/21.18.4406; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JACQUIER A, 1992, YEAST, V8, P122; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KELLY RB, 1969, NATURE, V224, P495, DOI 10.1038/224495a0; KENNY MK, 1988, J BIOL CHEM, V263, P9801; Kornberg A., 1992, DNA REPLICATION; LINDAHL T, 1971, EUR J BIOCHEM, V18, P415, DOI 10.1111/j.1432-1033.1971.tb01258.x; LINDAHL T, 1969, J BIOL CHEM, V244, P5014; LINDAHL T, 1971, EUR J BIOCHEM, V18, P407, DOI 10.1111/j.1432-1033.1971.tb01257.x; LINDAHL T, 1969, P NATL ACAD SCI USA, V62, P597, DOI 10.1073/pnas.62.2.597; LINDAHL T, 1971, METHODS ENZYMOL D, V21, P148; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; LUNDQUIST RC, 1982, CELL, V31, P53, DOI 10.1016/0092-8674(82)90404-4; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MOCK KK, 1992, RAPID COMMUN MASS SP, V6, P233, DOI 10.1002/rcm.1290060402; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; PRICE A, 1991, BIOCHEMISTRY-US, V30, P8631, DOI 10.1021/bi00099a020; PRICE A, 1992, FEBS LETT, V300, P101, DOI 10.1016/0014-5793(92)80173-E; SAYERS JR, 1990, J BIOL CHEM, V265, P18311; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; UYEMURA D, 1976, J BIOL CHEM, V251, P4085; WAGA S, 1994, J BIOL CHEM, V269, P10923	34	123	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28535	28538						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961795				2022-12-27	WOS:A1994PU16800004
J	ATKINSON, MR; KAMBEROV, ES; WEISS, RL; NINFA, AJ				ATKINSON, MR; KAMBEROV, ES; WEISS, RL; NINFA, AJ			REVERSIBLE URIDYLYLATION OF THE ESCHERICHIA-COLI PII SIGNAL-TRANSDUCTION PROTEIN REGULATES ITS ABILITY TO STIMULATE THE DEPHOSPHORYLATION OF THE TRANSCRIPTION FACTOR NITROGEN REGULATOR-I (NRI OR NTRC)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMINE-SYNTHETASE; CASCADE CONTROL; REMOVING ENZYME; GLNALG OPERON; URIDYLYLTRANSFERASE; PHOSPHORYLATION; GENE; PHOSPHATASE; GLNL; AUTOPHOSPHORYLATION	We have reconstituted the signal transduction system responsible for the negative regulation of the transcription of the Escherichia coli glnA gene, encoding glutamine synthetase, by glutamine. This signal transduction system consists of four proteins: the transcription factor NRI (NtrC), which activates glnA transcription when it is phosphorylated, the kinase/phosphatase protein NRII (NtrB) that directly controls the extent of NRI phosphorylation, the PII signal transduction protein that controls the phosphatase activity of NRII and the uridylyl-transferase/uridylyl-removing (UTase/UR) enzyme that is regulated by glutamine and controls the activity of PII. In the reconstituted system, the removal of uridylyl groups from the PII protein, catalyzed by the UTase/UR protein in the presence of glutamine, resulted in the stimulation of NRI similar to P dephosphorylation. In contrast, the uridylylated form of the PII protein had no discernible effect on NRI phosphorylation. The uridylylation of the trimeric PII protein by the monomeric UTase/LTR protein is a non-cooperative reaction in which the partially modified species accumulated and were readily observed. Partially modified PII trimers were partially active in stimulating the dephosphorylation of NRI similar to P. Thus, both the PII-UTase/UR and PII-NRII interactions display the continuous variability characteristic of rheostats as opposed to the binary variability characteristic of toggle switches.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047460] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47460] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER SP, 1975, J BIOL CHEM, V250, P6264; ATKINSON MR, 1992, J BACTERIOL, V174, P4538, DOI 10.1128/JB.174.14.4538-4548.1992; ATKINSON MR, 1993, J BACTERIOL, V175, P7016, DOI 10.1128/jb.175.21.7016-7023.1993; BLOOM FR, 1978, J BACTERIOL, V134, P569, DOI 10.1128/JB.134.2.569-577.1978; BROWN MS, 1971, P NATL ACAD SCI USA, V68, P2949, DOI 10.1073/pnas.68.12.2949; BUENO R, 1985, J BACTERIOL, V164, P816, DOI 10.1128/JB.164.2.816-822.1985; ENGLEMAN EG, 1978, ARCH BIOCHEM BIOPHYS, V191, P602, DOI 10.1016/0003-9861(78)90398-3; FENG JL, 1992, J BACTERIOL, V174, P6061, DOI 10.1128/JB.174.19.6061-6070.1992; FRANCIS SH, 1978, ARCH BIOCHEM BIOPHYS, V191, P590, DOI 10.1016/0003-9861(78)90397-1; GARCIA E, 1983, J BIOL CHEM, V258, P2246; HOLTEL A, 1989, MOL GEN GENET, V217, P474, DOI 10.1007/BF02464920; KAMBEROV ES, 1994, J BIOL CHEM, V269, P28294; KAMBEROV ES, 1994, IN PRESS CELLULAR MO; KAMBEROV ES, 1994, IN PRESS CELL MOL BI; KEENER J, 1988, P NATL ACAD SCI USA, V82, P8453; MACNEIL T, 1982, MOL GEN GENET, V188, P325, DOI 10.1007/BF00332696; MAGASANIK B, 1988, TRENDS BIOCHEM SCI, V13, P475, DOI 10.1016/0968-0004(88)90234-4; NINFA AJ, 1991, J BIOL CHEM, V266, P6888; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; NINFA EG, 1993, J BACTERIOL, V175, P7024, DOI 10.1128/jb.175.21.7024-7032.1993; PAHEL G, 1978, J BACTERIOL, V133, P139, DOI 10.1128/JB.133.1.139-148.1978; RHEE SG, 1985, CURR TOP CELL REGUL, V27, P221; SANDERS DA, 1992, J BACTERIOL, V174, P5117, DOI 10.1128/JB.174.15.5117-5122.1992; SON HS, 1987, J BIOL CHEM, V262, P8690; Stadtman ER, 1980, GLUTAMINE METABOLISM, P41; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919	26	86	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28288	28293						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961766				2022-12-27	WOS:A1994PV77200077
J	OLSZEWSKI, S; DEENEY, JT; SCHUPPIN, GT; WILLIAMS, KP; CORKEY, BE; RHODES, CJ				OLSZEWSKI, S; DEENEY, JT; SCHUPPIN, GT; WILLIAMS, KP; CORKEY, BE; RHODES, CJ			RAB3A EFFECTOR DOMAIN PEPTIDES INDUCE INSULIN EXOCYTOSIS VIA A SPECIFIC INTERACTION WITH A CYTOSOLIC PROTEIN DOUBLET	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; SYNAPTIC VESICLES; GUANINE-NUCLEOTIDES; SYNTHETIC PEPTIDE; EXCHANGE PROTEIN; TARGET PROTEIN; KINASE-C; SMG P25A; B-CELLS; SECRETION	A key protein involved in the regulated exocytotic mechanism in neuroendocrine cells is the GTP-binding protein, Rab3A. Rab3A is thought to mediate exocytosis by an interaction of its effector domain with a putative effector protein. we demonstrate here that Rab3A effector domain peptides specifically stimulated insulin exocytosis in electroporated insulin-secreting cells (K-0.5 activation, 6-8 mu M) in a Ca2+-independent manner, although in the presence of Ca2+ insulin exocytosis was further potentiated. By using a I-125-radiolabeled photoactivated cross-linking Rab3A effector domain peptide, we identified a cytosolic protein doublet (REEF-1 and REEP-2), which specifically interacted with the Rab3A effector domain. Competitive inhibition studies revealed this protein-protein interaction to be at a concentration equivalent to that required for Rab3A effector domain peptides to trigger insulin exocytosis (K-i, 6-8 mu M) Furthermore, under basal secretory conditions REEF-1 and -2 were membrane associated, but upon stimulation of exocytosis they were released into a cytosolic fraction. Our results suggest that REEF-I and -2 are part of the regulated exocytotic machinery, and their dissociation upon stimulation of hormone release (likely from a protein complex) may be essential to the mechanism that triggers regulated exocytosis in pancreatic beta-cells.	BRIGHAM & WOMENS HOSP,JOSLIN DIABET CTR,EP JOSLIN RES LAB,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215; BOSTON UNIV,SCH MED,DEPT DIABET & METAB,BOSTON,MA 02118	Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Boston University			; Corkey, Barbara/E-7712-2015	Deeney, Jude/0000-0003-0988-9419; Corkey, Barbara/0000-0002-5467-1630	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047919, R37DK035914, R01DK035914, P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35914, DK47919, DK36836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALARCON C, 1993, J BIOL CHEM, V268, P4276; ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ASHCROFT FM, 1992, INSULIN MOL BIOL PAT, P97; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DEENEY JT, 1992, J BIOL CHEM, V267, P19840; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; LI GD, 1993, FEBS LETT, V327, P145, DOI 10.1016/0014-5793(93)80159-R; LLEDO PM, 1993, NATURE, V364, P540, DOI 10.1038/364540a0; MIZOGUCHI A, 1989, BIOCHEM BIOPH RES CO, V162, P1438, DOI 10.1016/0006-291X(89)90835-8; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; OBERHAUSER AF, 1992, NATURE, V360, P270, DOI 10.1038/360270a0; PADFIELD PJ, 1992, P NATL ACAD SCI USA, V89, P1656, DOI 10.1073/pnas.89.5.1656; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; REGAZZI R, 1992, EUR J BIOCHEM, V208, P729, DOI 10.1111/j.1432-1033.1992.tb17241.x; REGAZZI R, 1989, J BIOL CHEM, V264, P9939; RHODES CJ, 1992, J BIOL CHEM, V267, P22719; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; RICHMOND J, 1993, FEBS LETT, V326, P124, DOI 10.1016/0014-5793(93)81775-U; ROEP BO, 1990, NATURE, V345, P632, DOI 10.1038/345632a0; SENYSHYN J, 1992, FEBS LETT, V309, P41, DOI 10.1016/0014-5793(92)80735-Y; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STORER AC, 1976, BIOCHEM J, V159, P1; VALLAR L, 1987, J BIOL CHEM, V262, P5049; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WILLIAMS KP, 1993, J BIOL CHEM, V268, P5361; WOLLHEIM CB, 1990, FEBS LETT, V268, P376, DOI 10.1016/0014-5793(90)81289-Z; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	42	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27987	27991						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961732				2022-12-27	WOS:A1994PV77200035
J	PHILO, J; TALVENHEIMO, J; WEN, J; ROSENFELD, R; WELCHER, A; ARAKAWA, T				PHILO, J; TALVENHEIMO, J; WEN, J; ROSENFELD, R; WELCHER, A; ARAKAWA, T			INTERACTIONS OF NEUROTROPHIN-3 (NT-3), BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF), AND THE NT-3 BDNF HETERODIMER WITH THE EXTRACELLULAR DOMAINS OF THE TRKB AND TRKC RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; LASER-LIGHT SCATTERING; PROTOONCOGENE PRODUCT; ACTIN REORGANIZATION; NGF; DIMERIZATION; ACTIVATION; INDUCTION; CSF-1	Interactions of three neurotrophin dimers, brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and a NT-3-BDNF heterodimer with extracellular, soluble TrkB and TrkC receptors were studied using native gels, light scattering, and sedimentation equilibrium. These three neurotrophins showed binding of two TrkB receptors per neurotrophin dimer, with a tendency to dissociate into one TrkB per dimer for NT-3 and the heterodimer, as determined by native gels, Light scattering, and sedimentation equilibrium. For TrkC, native gels suggested binding of NT-3, heterodimer, and BDNF but not of nerve growth factor. Sedimentation equilibrium revealed that all three neurotrophin molecules bind to TrkC at two receptors per dimer but that BDNF binds much more weakly and that the heterodimer has an intermediate binding strength. Light scattering/size exclusion chromatography showed complexes with two TrkC receptors per NT-3 dimer and one TrkC per heterodimer but did not detect binding of BDNF to TrkC. This latter result is not inconsistent with the sedimentation data, because the weak binding of BDNF to TrkC may be easily dissociated by nonspecific interactions of BDNF with the size exclusion column. The relative binding constants for these neurotrophins and the soluble receptor extracellular domains, as determined by sedimentation equilibrium, are correlated with their biological activity. However, the magnitude of these binding constants is insufficient by similar to 3 orders of magnitude to promote receptor dimerization at physiologically active concentrations.	AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320	Amgen			Philo, John S/A-8804-2009	Philo, John S/0000-0003-3418-0356				ANGLETTI RM, 1972, BIOCHEMISTRY-US, V10, P463; ARAKAWA T, 1994, J BIOL CHEM, V269, P27833; ARAKAWA T, 1992, ANAL BIOCHEM, V203, P53, DOI 10.1016/0003-2697(92)90042-6; ARAKAWA T, 1991, J BIOL CHEM, V266, P18942; ARAKAWA T, 1994, ARCH BIOCHEM BIOPHYS, V308, P267, DOI 10.1006/abbi.1994.1037; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BOTHWELL MA, 1977, J BIOL CHEM, V252, P8532; DAS SK, 1982, J BIOL CHEM, V257, P13679; DURCHSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JOHNSON ML, 1992, METHOD ENZYMOL, V210, P1; JOHNSSON A, 1989, EMBO J, V8, P2489; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; NARHI LO, 1993, J BIOL CHEM, V268, P13309; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; RADZIEJEWSKI C, 1992, BIOCHEMISTRY-US, V31, P4431, DOI 10.1021/bi00133a007; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SHIRE SJ, 1992, DS837 BECKM INSTR TE; TAKAGI T, 1990, J CHROMATOGR, V506, P409, DOI 10.1016/S0021-9673(01)91596-1; TESSAROLLO L, 1993, DEVELOPMENT, V118, P463	30	63	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27840	27846						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961713				2022-12-27	WOS:A1994PV77200014
J	RABAULT, B; GHYSDAEL, J				RABAULT, B; GHYSDAEL, J			CALCIUM-INDUCED PHOSPHORYLATION OF ETS1 INHIBITS ITS SPECIFIC DNA-BINDING ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; LONG TERMINAL REPEAT; TRANSCRIPTIONAL ACTIVATION; C-ETS-1 PROTEIN; LEUKEMIA-VIRUS; DOMAIN PROTEIN; GENE PROMOTER; V-ETS; EXPRESSION; RECEPTOR	Ets1, the founding member of the Ets gene family of transcriptional regulators, is a phosphoprotein which is highly expressed in cells of the T and B lymphoid lineages. Previous studies have shown that Ets1 becomes rapidly and transiently phosphorylated following antigen receptor (T cell (antigen) receptor (TCR) and membrane Ig) triggering a response which is absolutely dependent on ligand-induced calcium mobilization. By a combination of two-dimensional tryptic phosphopeptide and mutational analyses, the target residues of these calcium-dependent phosphorylation events are identified as 4 serine residues clustered in a domain of Ets1 adjacent to its DNA binding domain (Ets domain). From the comparison of the properties of wild type Ets1 with those of mutant proteins carrying serine-to-alanine substitution in target residues, calcium-dependent phosphorylation of Ets1 is shown to inhibit its binding to specific DNA sequences but does not affect its ability to accumulate in the nucleus, another property dependent on the Ets domain. Our data are consistent with a model in which the calcium-dependent phosphorylation of Ets1 represent the first step of a general clearance of Ets1 function during T and B cell activation.	CTR UNIV ORSAY,INST CURIE,ONCOL VIRALE & CELLULAIRE LAB,CNRS,URA 1443,BIOL SECT,F-91405 ORSAY,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay			GHYSDAEL, Jacques/F-3377-2013					BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P56718; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; FISHER CL, 1991, J IMMUNOL, V146, P1743; FISHER RJ, 1991, ONCOGENE, V6, P2249; FLEISCHMAN LF, 1993, ONCOGENE, V8, P771; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GEGONNE A, 1992, NEW BIOL, V4, P512; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOIZUMI S, 1990, ONCOGENE, V5, P675; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEUNG S, 1993, ONCOGENE, V8, P989; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; LIN JX, 1993, MOL CELL BIOL, V13, P6201, DOI 10.1128/MCB.13.10.6201; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; POGNONEC P, 1989, ONCOGENE, V4, P691; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; POGNONEC P, 1990, ONCOGENE, V5, P603; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; REDDY ESP, 1988, ONCOGENE RES, V3, P239; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; SETH A, 1994, ONCOGENE, V9, P469; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	58	102	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28143	28151						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961750				2022-12-27	WOS:A1994PV77200057
J	SIEBENLIST, KR; MOSESSON, MW				SIEBENLIST, KR; MOSESSON, MW			PROGRESSIVE CROSS-LINKING OF FIBRIN GAMMA-CHAINS INCREASES RESISTANCE TO FIBRINOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROMOLECULAR-SOLUBLE COMPLEXES; FACTOR-XIII CONCENTRATIONS; DEEP-VEIN THROMBOSIS; CROSSLINKED FIBRIN; ALPHA-2-PLASMIN INHIBITOR; PLASMIC DEGRADATION; SUBUNIT STRUCTURE; LIGHT-SCATTERING; STABILIZING FACTOR; FIBRINOPEPTIDE-B	In the presence of plasma transglutaminase (factor XIIIa) fibrin first undergoes intermolecular covalent cross-linking between its gamma chains to create gamma dimers followed by slower cross-linking among its alpha chains to form alpha polymers. Progressive cross-linking of gamma chain dimers occurs at the slowest rate, resulting in gamma trimers and gamma tetramers (''gamma multimers''). Most studies indicate that cross-linked fibrin clots become resistant to fibrinolysis, but the basis for this event is not clear. In this study, we explored the role of gamma chain multimerization compared with alpha polymerization as causal factors in time-dependent development of resistance to fibrinolysis. Fibrin clots prepared from native (intact) fibrinogen were incubated for up to 120 h at near physiological ionic strength and a factor XIIIa level approximating that in plasma. These clots were lysed by plasmin at rates that were inversely proportional to the level of gamma multimers, which increased progressively with the time of incubation. In contrast, fibrin cross-linked at high ionic strength (a condition under which only gamma dimers and alpha polymers form) or fibrin formed in the absence of factor XIII showed no time dependent decrease in lysis rates. Fibrin cross-linked for a fixed time period with increasing amounts of factor XIIIa contained gamma multimer levels that were proportional to the factor XIIIa concentration and lysed at rates that were inversely proportional to the gamma multimer level. Furthermore, cross-linked fibrin formed from fibrinogen fraction I-9, which has limited potential for alpha polymerization, showed the same reduction in the lysis rate as native cross-linked fibrin. These findings indicate that development of resistance to fibrinolysis of cross-linked fibrin is not measurably dependent upon gamma dimer or alpha polymer formation but develops solely as a function of gamma multimerization.	MARQUETTE UNIV, SCH DENT, DEPT BASIC HLTH SCI, MILWAUKEE, WI 53233 USA	Marquette University	SIEBENLIST, KR (corresponding author), UNIV WISCONSIN, SINAI SAMARITAN MED CTR,SCH MED,WINTER RES BLDG, 836 N 12TH ST, MILWAUKEE CLIN CAMP, MILWAUKEE, WI 53233 USA.				NHLBI NIH HHS [HL-47000] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047000] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALKJAERSIG N, 1977, THROMB HAEMOSTASIS, V38, P524, DOI 10.1055/s-0038-1651859; AOKI N, 1993, THROMB HAEMOSTASIS, V70, P376; ASTEDT B, 1974, SURG GYNECOL OBSTET, V139, P387; BLOMBACK B, 1978, NATURE, V275, P501, DOI 10.1038/275501a0; BROMMER EJP, 1992, BLOOD COAGUL FIBRIN, V3, P717, DOI 10.1097/00001721-199212000-00003; CARR ME, 1977, BIOPOLYMERS, V16, P1, DOI 10.1002/bip.1977.360160102; CHEN R, 1969, P NATL ACAD SCI USA, V63, P420, DOI 10.1073/pnas.63.2.420; CHEN R, 1971, BIOCHEMISTRY-US, V10, P4486, DOI 10.1021/bi00800a021; DOOLITTL.RF, 1973, THROMB DIATH HAEMOST, P155; ERICKSON HP, 1983, ANN NY ACAD SCI, V408, P146, DOI 10.1111/j.1749-6632.1983.tb23242.x; FERRY JD, 1952, P NATL ACAD SCI USA, V38, P566, DOI 10.1073/pnas.38.7.566; FINLAYSON J S, 1973, Thrombosis Research, V2, P467, DOI 10.1016/0049-3848(73)90001-7; FINLAYSON JS, 1963, BIOCHEMISTRY-US, V2, P42, DOI 10.1021/bi00901a010; FINLAYSON JS, 1972, J BIOL CHEM, V247, P5220; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FOWLER WE, 1981, P NATL ACAD SCI-BIOL, V78, P4872, DOI 10.1073/pnas.78.8.4872; FRANCIS CW, 1987, THROMB HAEMOSTASIS, V57, P110; FRANCIS CW, 1987, J CLIN INVEST, V80, P1459, DOI 10.1172/JCI113226; FRANCIS CW, 1980, BLOOD, V56, P456; FRANCIS CW, 1980, J CLIN INVEST, V66, P1033, DOI 10.1172/JCI109931; FRANCIS CW, 1988, BLOOD, V71, P1361; GAFFNEY PJ, 1983, ANN NY ACAD SCI, V408, P407, DOI 10.1111/j.1749-6632.1983.tb23261.x; GAFFNEY PJ, 1973, BIOCHIM BIOPHYS ACTA, V295, P308, DOI 10.1016/0005-2795(73)90098-6; GAFFNEY PJ, 1980, THROMB RES, V20, P647, DOI 10.1016/0049-3848(80)90153-X; GAFFNEY PJ, 1979, THROMB RES, V14, P85, DOI 10.1016/0049-3848(79)90027-6; GLADNER JA, 1983, THROMB RES, V30, P273, DOI 10.1016/0049-3848(83)90081-6; GORMSEN J, 1967, ARCH BIOCHEM BIOPHYS, V120, P654, DOI 10.1016/0003-9861(67)90531-0; HANTGAN R, 1983, ANN NY ACAD SCI, V408, P344, DOI 10.1111/j.1749-6632.1983.tb23256.x; HANTGAN R, 1980, THROMB HAEMOSTASIS, V44, P119; HANTGAN RR, 1979, J BIOL CHEM, V254, P1272; HAVERKATE F, 1975, THROMB DIATH HAEMOST, V34, P584; HAVERKATE F, 1977, THROMB RES, V10, P803, DOI 10.1016/0049-3848(77)90137-2; HENDERSON KW, 1969, BRIT J HAEMATOL, V17, P445, DOI 10.1111/j.1365-2141.1969.tb01392.x; HERMANS J, 1982, SEMIN THROMB HEMOST, V8, P11, DOI 10.1055/s-2007-1005039; HESS H, 1967, 1966 S THROMB THER M, P1; HEWAT EA, 1983, J MOL BIOL, V170, P203, DOI 10.1016/S0022-2836(83)80233-2; ICHINOSE A, 1982, BIOCHIM BIOPHYS ACTA, V706, P158, DOI 10.1016/0167-4838(82)90482-4; KAZAL LA, 1963, P SOC EXP BIOL MED, V113, P989; KRAKOW W, 1972, J MOL BIOL, V71, P95, DOI 10.1016/0022-2836(72)90403-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUDANO AP, 1978, P NATL ACAD SCI USA, V75, P3085, DOI 10.1073/pnas.75.7.3085; LAUDANO AP, 1980, BIOCHEMISTRY-US, V19, P1013, DOI 10.1021/bi00546a028; LOEWY AG, 1961, J BIOL CHEM, V236, P2625; LORAND J, 1966, NATURE, V210, P1273, DOI 10.1038/2101273a0; Lorand L., 1970, METHOD ENZYMOL, V19, P770; MARDER VJ, 1977, J LAB CLIN MED, V89, P1018; MATACIC S, 1968, BIOCHEM BIOPH RES CO, V30, P356, DOI 10.1016/0006-291X(68)90750-X; MCDONAGH RP, 1971, BRIT J HAEMATOL, V21, P323, DOI 10.1111/j.1365-2141.1971.tb03444.x; MCKEE PA, 1970, P NATL ACAD SCI USA, V66, P738, DOI 10.1073/pnas.66.3.738; MIRSHAHI M, 1991, J LAB CLIN MED, V117, P274; Mosesson M W, 1976, Prog Hemost Thromb, V3, P61; MOSESSON MW, 1966, BIOCHEMISTRY-US, V5, P2829, DOI 10.1021/bi00873a008; MOSESSON MW, 1972, J BIOL CHEM, V247, P5223; MOSESSON MW, 1963, J LAB CLIN MED, V62, P663; MOSESSON MW, 1989, P NATL ACAD SCI USA, V86, P1113, DOI 10.1073/pnas.86.4.1113; MOSESSON MW, 1972, J BIOL CHEM, V247, P5210; NIEUWENHUIZEN W, 1982, BIOCHIM BIOPHYS ACTA, V707, P190, DOI 10.1016/0167-4838(82)90349-1; NIEUWENHUIZEN W, 1981, BIOCHIM BIOPHYS ACTA, V667, P321, DOI 10.1016/0005-2795(81)90198-7; OLEXA SA, 1980, P NATL ACAD SCI-BIOL, V77, P1374, DOI 10.1073/pnas.77.3.1374; PISANO JJ, 1968, SCIENCE, V160, P892, DOI 10.1126/science.160.3830.892; PIZZO SV, 1973, J BIOL CHEM, V248, P4574; PURVES L, 1987, BIOCHEMISTRY-US, V26, P4640, DOI 10.1021/bi00389a008; PURVES LR, 1978, THROMB RES, V12, P473, DOI 10.1016/0049-3848(78)90318-3; RAMPLING MW, 1978, THROMB RES, V12, P287, DOI 10.1016/0049-3848(78)90299-2; REGANON E, 1978, THROMB HAEMOSTASIS, V40, P368; Robbins K C, 1976, Methods Enzymol, V45, P257; Robbins K. C., 1970, METHOD ENZYMOL, V19, P184; SAKATA Y, 1980, J CLIN INVEST, V65, P290, DOI 10.1172/JCI109671; SAKATA Y, 1984, BLOOD, V63, P1393; SAKATA Y, 1982, J CLIN INVEST, V69, P536, DOI 10.1172/JCI110479; SCHWARTZ ML, 1973, J BIOL CHEM, V248, P1395; SEAMAN AJ, 1976, ANGIOLOGY, V27, P549, DOI 10.1177/000331977602701001; SHAINOFF JR, 1991, J BIOL CHEM, V266, P6429; SHAINOFF JR, 1983, ANN NY ACAD SCI, V408, P254, DOI 10.1111/j.1749-6632.1983.tb23249.x; SHAINOFF JR, 1979, SCIENCE, V204, P200, DOI 10.1126/science.155308; SHARP JJ, 1972, FEBS LETT, V25, P334, DOI 10.1016/0014-5793(72)80517-9; SIEBENLIST KR, 1992, BIOCHEMISTRY-US, V31, P936, DOI 10.1021/bi00118a040; STRYER L, 1963, NATURE, V197, P793, DOI 10.1038/197793a0; THEISS W, 1983, ANGIOLOGY, V34, P61, DOI 10.1177/000331978303400108; TRANTHANG C, 1984, J CLIN INVEST, V74, P2009, DOI 10.1172/JCI111623; UCHINO R, 1991, FIBRINOLYSIS, V5, P93, DOI 10.1016/0268-9499(91)90049-A; VANGIEZEN JJJ, 1993, BLOOD COAGUL FIBRIN, V4, P869, DOI 10.1097/00001721-199304060-00002; WEBER K, 1969, J BIOL CHEM, V244, P4406; WILLIAMS RC, 1981, J MOL BIOL, V150, P399, DOI 10.1016/0022-2836(81)90555-6; WILLIAMS RC, 1983, ANN NY ACAD SCI, V408, P180, DOI 10.1111/j.1749-6632.1983.tb23244.x	85	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28414	28419						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961782				2022-12-27	WOS:A1994PV77200094
J	GOORMAGHTIGH, E; VIGNERON, L; SCARBOROUGH, GA; RUYSSCHAERT, JM				GOORMAGHTIGH, E; VIGNERON, L; SCARBOROUGH, GA; RUYSSCHAERT, JM			TERTIARY CONFORMATIONAL-CHANGES OF THE NEUROSPORA-CRASSA PLASMA-MEMBRANE H+-ATPASE MONITORED BY HYDROGEN-DEUTERIUM EXCHANGE KINETICS - A FOURIER-TRANSFORM INFRARED-SPECTROSCOPY APPROACH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; SARCOPLASMIC-RETICULUM; CIRCULAR-DICHROISM; E1->E2 TRANSITION; CATALYTIC CYCLE; PROTEINS; BINDING; MODEL	Attenuated total reflection Fourier transform infrared spectroscopy of hydrated films of the Neurospora crassa plasma membrane H+-ATPase has been used to monitor the alpha-helix and beta-sheet contents and amide hydrogen exchange rates of the enzyme in the absence of ligands or locked in several stages of the enzyme catalytic cycle by MgADP, Mg-vanadate, and MgATP-vanadate. No difference larger than 2% was found in the alpha-helix or beta-sheet content of the H+-ATPase in different conformational states. However, when the rate of hydrogen/deuterium exchange monitored by the evolution of the area of amide II and amide II' is decomposed into three components, the number of amide protons characterized by a short exchange rate (1.1 min) falls from 38% of the protein amide protons (or 37% in the presence of Mg2+ alone) to 24-27% in the presence of Mg-vanadate and MgATP-vanadate and to 19% in the presence of MgADP. These results suggest that the conformational changes known to occur when the H+-ATPase interacts with the above ligands are predominantly tertiary structure changes.	UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, CHAPEL HILL, NC 27514 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	GOORMAGHTIGH, E (corresponding author), FREE UNIV BRUSSELS, CHIM PHYS MACROMOLEC INTERFACES LAB, ULB CAMPUS PLAINE, CP 206-2, BD TRIOMPHE, B-1050 BRUSSELS, BELGIUM.			Goormaghtigh, Erik/0000-0002-2071-2262	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024784, R55GM024784] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24784] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDISON R, 1986, J BIOL CHEM, V261, P4896; ADDISON R, 1982, J BIOL CHEM, V257, P421; AMORY A, 1982, J BIOL CHEM, V257, P4723; ARRONDO JLR, 1987, J BIOL CHEM, V262, P9037; BARTH A, 1991, BIOCHIM BIOPHYS ACTA, V1057, P115, DOI 10.1016/S0005-2728(05)80091-X; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BROOKER RJ, 1983, J BIOL CHEM, V258, P222; BUCHET R, 1991, BIOCHIM BIOPHYS ACTA, V1068, P201, DOI 10.1016/0005-2736(91)90211-P; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CABIAUX V, 1989, J BIOL CHEM, V264, P4928; CHADWICK CC, 1987, ARCH BIOCHEM BIOPHYS, V252, P348, DOI 10.1016/0003-9861(87)90041-5; CHETVERIN AB, 1986, J BIOL CHEM, V260, P7817; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; CSERMELY P, 1987, BIOCHEM J, V241, P663, DOI 10.1042/bj2410663; DEMEL RA, 1990, BIOCHIM BIOPHYS ACTA, V1027, P155, DOI 10.1016/0005-2736(90)90079-4; ENGLANDER SW, 1984, Q REV BIOPHYS, V16, P521; FETTIPLACE R, 1980, PHYSIOL REV, V60, P510, DOI 10.1152/physrev.1980.60.2.510; Finkelstein A., 1987, WATER MOVEMENT LIPID; Fringeli U P, 1981, Mol Biol Biochem Biophys, V31, P270; GOORMAGHTIGH E, 1993, BIOCHEMISTRY-US, V32, P6104, DOI 10.1021/bi00074a023; GOORMAGHTIGH E, 1986, J BIOL CHEM, V261, P7466; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; GOORMAGHTIGH E, 1990, MOL DESCRIPTION BIOL, P285; GRESALFI TJ, 1984, J BIOL CHEM, V259, P2622; Harrick N.J., 1967, INTERNAL REFLECTION; HENNESSEY JP, 1990, J BIOL CHEM, V265, P532; HENNESSEY JP, 1988, J BIOL CHEM, V263, P3123; KIM KS, 1993, BIOCHEMISTRY-US, V32, P9600, DOI 10.1021/bi00088a012; Kim P S, 1986, Methods Enzymol, V131, P136; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDALA SM, 1988, J BIOL CHEM, V263, P15122; ROSENBERG A, 1986, METHOD ENZYMOL, V127, P630; SCARBOROUGH GA, 1984, J BIOL CHEM, V259, P9109; SCARBOROUGH GA, 1985, MICROBIOL REV, V49, P214, DOI 10.1128/MMBR.49.3.214-231.1985; SCARBOROUGH GA, 1992, MOL ASPECTS MEMBRANE, P117; SCARBOROUGH GA, 1988, METHOD ENZYMOL, V157, P574; SCHINKEL JE, 1985, BIOCHEMISTRY-US, V24, P352, DOI 10.1021/bi00323a018; SMITH R, 1984, ANAL BIOCHEM, V138, P156, DOI 10.1016/0003-2697(84)90784-X; WOODWARD C, 1982, MOL CELL BIOCHEM, V48, P135, DOI 10.1007/BF00421225	41	72	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27409	27413						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961652				2022-12-27	WOS:A1994PV77100042
J	KINDREGAN, HC; ROSENBAUM, SE; OHNO, S; NILES, RM				KINDREGAN, HC; ROSENBAUM, SE; OHNO, S; NILES, RM			CHARACTERIZATION OF CONVENTIONAL PROTEIN-KINASE-C (PKC) ISOTYPE EXPRESSION DURING F9 TERATOCARCINOMA DIFFERENTIATION - OVEREXPRESSION OF PKC-ALPHA ALTERS THE EXPRESSION OF SOME DIFFERENTIATION-DEPENDENT GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; PHORBOL ESTER RECEPTOR; RETINOIC ACID; JUN EXPRESSION; STEM-CELLS; RAT-BRAIN; FOS; INDUCTION; GROWTH; TRANSCRIPTION	F9 teratocarcinoma is a useful model for studying early embryogenesis since these cells can differentiate into primitive or parietal endoderm under the influence of retinoic acid or retinoic acid and cyclic AMP, respectively. We have found that three isoforms of protein kinase C (PKC alpha, -beta, and -gamma) were expressed in undifferentiated stem cells. When the cells were treated with retinoic acid either alone or in the presence of cAMP for 120 h, PKC alpha mRNA and protein levels increased, whereas those of PKC beta and PKC gamma became undetectable. These changes began within 24 h of drug treatment and were complete by 48-72 h. In order to determine the functional significance of the induction of PKC alpha during F9 differentiation, we established two stable transfectants that overexpressed PKC alpha protein between 4- and 5-fold compared to wild type cells. Characterization of these cell lines revealed an altered pattern of expression of some of the markers of F9 differentiation. The clone that had the highest amount of PKC alpha protein constitutively expressed mRNA for type IV collagen and c-Jun, which are not normally expressed until 24-48 h of treatment with differentiation agents. In the other overexpressing clone, these markers were induced much faster than in wild type cells. The growth rate of both overexpressing clones was less than wild type cells, while the expression of the PKC beta protein in these clones was similar to the levels found in differentiated F9 cells. However, other markers of differentiation, including the cellular morphology and levels of pST6-135 and c-myc RNA, responded to agents identically in both wild type and PKC-alpha-overexpressing clones. Therefore, overexpression of PKC alpha is not sufficient to induce full differentiation of F9 cells. However, our data suggest that certain pathways that lead to the expression of differentiation-dependent genes are regulated by PKC alpha protein levels.	YOKOHAMA CITY UNIV,SCH MED,DEPT BIOL MOLEC,KAMAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN	Yokohama City University	KINDREGAN, HC (corresponding author), BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118, USA.		Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; FINKLESTEIN R, 1988, ONCOGENE RES, V3, P287; GOLDSTEIN B, 1990, J CELL PHYSIOL, V143, P205, DOI 10.1002/jcp.1041430202; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HALLAHAN DE, 1991, INT J RADIAT ONCOL, V21, P1677, DOI 10.1016/0360-3016(91)90352-5; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRAFT AS, 1983, J BIOL CHEM, V258, P9178; Kuo J F, 1989, Adv Exp Med Biol, V255, P8; LEVINE RA, 1984, MOL CELL BIOL, V4, P2142, DOI 10.1128/MCB.4.10.2142; MUFSON RA, 1992, J IMMUNOL, V148, P1129; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NIINO YS, 1992, J BIOL CHEM, V267, P6158; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OHNO S, 1987, NATURE, V325, P1611; OTTE AP, 1991, SCIENCE, V251, P570, DOI 10.1126/science.1990433; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; POWELL CT, 1992, P NATL ACAD SCI USA, V89, P147, DOI 10.1073/pnas.89.1.147; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; ROSENBAUM SE, 1992, ARCH BIOCHEM BIOPHYS, V294, P123, DOI 10.1016/0003-9861(92)90145-M; RUBIN E, 1992, CANCER RES, V52, P878; SAMBROOK J, 1989, MOL CLONING LABORATO, P1630; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SNOEK GT, 1986, DEV BIOL, V115, P282, DOI 10.1016/0012-1606(86)90249-6; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SPOSI NM, 1989, MOL CELL BIOL, V9, P2284, DOI 10.1128/MCB.9.5.2284; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STRICKLAND S, 1981, CELL, V24, P277, DOI 10.1016/0092-8674(81)90313-5; TAKEBE Y, 1988, MOL CELL BIOL, V8, P446; TANAKA Y, 1992, J BIOCHEM-TOKYO, V111, P265, DOI 10.1093/oxfordjournals.jbchem.a123747; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WANG SY, 1985, DEV BIOL, V107, P75, DOI 10.1016/0012-1606(85)90377-X; YANG-YEN H-F, 1990, New Biologist, V2, P351; YOSHIDA Y, 1988, J BIOL CHEM, V263, P9868	48	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27756	27761						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961696				2022-12-27	WOS:A1994PV77100092
J	KLOCKE, R; STEINMEYER, K; JENTSCH, TJ; JOCKUSCH, H				KLOCKE, R; STEINMEYER, K; JENTSCH, TJ; JOCKUSCH, H			ROLE OF INNERVATION, EXCITABILITY, AND MYOGENIC FACTORS IN THE EXPRESSION OF THE MUSCULAR CHLORIDE CHANNEL CLC-1 - A STUDY ON NORMAL AND MYOTONIC MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR ALPHA-SUBUNIT; CREATINE-KINASE GENE; ACETYLCHOLINE-RECEPTOR; SKELETAL-MUSCLE; MESSENGER-RNAS; RAT MUSCLE; DEVELOPMENTAL REGULATION; FUNCTIONAL EXPRESSION; MAMMALIAN MUSCLE; BINDING PROTEIN	The muscular chloride channel(ClC-1) is essential for a normal excitability of mature mammalian muscle fibers; inactivation of the corresponding gene by mutations leads to hyperexcitability of muscle, the hallmark of the disease myotonia. In the mouse, there is very little ClC-1 mRNA in myotubes, and its concentration increases steeply during postnatal development, suggesting a role of the motor nerve in ClC-1 expression. We investigated the response of the expression of the corresponding gene Clc-1 to different patterns of muscle activity as controlled by sarcolemmal excitability and by innervation. In rat and mouse, the level of ClC-1 mRNA was higher in fast (extensor digitorum longus) than in slow (soleus) muscle. Myotonia in the ADR mouse is caused by an insertional mutation leading to the adr allele of the Clc-1 gene and to grossly abnormal ClC-1 mRNAs. Nevertheless, in +/adr heterozygous, phenotypically wild type (WT) animals, the expression levels of both alleles correspond to the gene dosage. However, in the myotonic ADR mouse in which both Clc-1 genes are defective, ClC-1 mRNA levels in slow muscle were nearly as high as in WT fast muscle. In WT muscle, denervation within 2 days caused a drastic reduction of the ClC-1 mRNA level and at the same time an increase of myogenin and MyoD mRNAs. Neither effect of denervation was observed in myotonic mice (homozygous for the alleles adr or adr(K)), suggesting that spontaneous electrical activity of the hyperexcitable sarcolemma may substitute for nerve activity. Furthermore, potential MyoD/myogenin-binding sequence motifs were identified in the 5' regulatory region of the Clc-1 gene. These findings suggest that the activity-dependent regulation of the muscular chloride channel 1 gene is mediated by myogenic factors.	UNIV BIELEFELD,DEV BIOL UNIT,D-33501 BIELEFELD,GERMANY; UNIV HAMBURG,CTR MOLEC NEUROBIOL,D-20251 HAMBURG,GERMANY	University of Bielefeld; University of Hamburg				Jentsch, Thomas/0000-0002-3509-2553				BARTON PJR, 1985, J BIOL CHEM, V260, P8578; BASSELDUBY R, 1992, MOL CELL BIOL, V12, P5024, DOI 10.1128/MCB.12.11.5024; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BRETAG AH, 1987, PHYSIOL REV, V67, P618, DOI 10.1152/physrev.1987.67.2.618; CAMERINO DC, 1989, PFLUG ARCH EUR J PHY, V413, P568, DOI 10.1007/BF00594192; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EFTIMIE R, 1991, P NATL ACAD SCI USA, V88, P1349, DOI 10.1073/pnas.88.4.1349; EVANS S, 1987, J BIOL CHEM, V262, P4911; FAKLER B, 1990, PFLUG ARCH EUR J PHY, V415, P693, DOI 10.1007/BF02584007; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUCHTBAUER EM, 1991, J HISTOCHEM CYTOCHEM, V39, P355, DOI 10.1177/39.3.1825216; GEORGE AL, 1993, NAT GENET, V3, P305, DOI 10.1038/ng0493-305; GOBLET C, 1994, J CELL BIOCHEM     S, V18, P528; GOLDMAN D, 1988, NEURON, V1, P329, DOI 10.1016/0896-6273(88)90081-5; GRONEMEIER M, 1994, J BIOL CHEM, V269, P5963; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HORLICK RA, 1989, MOL CELL BIOL, V9, P2396, DOI 10.1128/MCB.9.6.2396; HUGHES SM, 1993, DEVELOPMENT, V118, P1137; ISENBERG KE, 1986, NUCLEIC ACIDS RES, V14, P5111, DOI 10.1093/nar/14.12.5111; JOCKUSCH H, 1988, EUR J BIOCHEM, V171, P101, DOI 10.1111/j.1432-1033.1988.tb13764.x; JOCKUSCH H, 1990, DYNAMIC STATE OF MUSCLE FIBERS, P429; JOCKUSCH H, 1994, PROG NEUROBIOL, V42, P313, DOI 10.1016/0301-0082(94)90071-X; JOCKUSCH H, 1994, J CELL BIOCHEM     S, V18, P528; KLOCKE R, 1994, THESIS U BIELEFELD G; KLUXEN FW, 1988, EUR J BIOCHEM, V176, P153, DOI 10.1111/j.1432-1033.1988.tb14262.x; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; KROCZEK RA, 1990, ANAL BIOCHEM, V184, P90, DOI 10.1016/0003-2697(90)90017-4; LASKEY RA, 1977, FEBS LETT, V82, P314, DOI 10.1016/0014-5793(77)80609-1; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LORENZ C, 1994, HUM MOL GENET, V3, P941, DOI 10.1093/hmg/3.6.941; LORKOVIC H, 1977, AM J PHYSIOL, V232, pC109, DOI 10.1152/ajpcell.1977.232.3.C109; LYONS GE, 1991, DEVELOPMENT, V113, P1017; MEHRKE G, 1988, MUSCLE NERVE, V11, P440, DOI 10.1002/mus.880110505; PETTE D, 1985, MUSCLE NERVE, V8, P676, DOI 10.1002/mus.880080810; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; SANES JR, 1991, DEVELOPMENT, V113, P1181; SCHLEEF M, 1994, NEUROMUSCULAR DISORD, V4, P205, DOI 10.1016/0960-8966(94)90021-3; SCHLEEF M, 1992, THESIS U BIELEFELD G; STEINMEYER K, 1994, EMBO J, V13, P737, DOI 10.1002/j.1460-2075.1994.tb06315.x; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; STUHLFAUTH I, 1984, P NATL ACAD SCI-BIOL, V81, P4814, DOI 10.1073/pnas.81.15.4814; WANG XM, 1990, EMBO J, V9, P783, DOI 10.1002/j.1460-2075.1990.tb08174.x; WELLER PA, 1986, MOL CELL BIOL, V6, P4539, DOI 10.1128/MCB.6.12.4539; WISCHMEYER E, 1993, NEUROMUSCULAR DISORD, V3, P267, DOI 10.1016/0960-8966(93)90019-G; WITZEMANN V, 1989, FEBS LETT, V242, P419, DOI 10.1016/0014-5793(89)80514-9; WITZEMANN V, 1991, J CELL BIOL, V114, P125, DOI 10.1083/jcb.114.1.125; WITZEMANN V, 1990, EUR J BIOCHEM, V194, P437, DOI 10.1111/j.1432-1033.1990.tb15637.x; ZUHLKE C, 1989, GENET RES, V54, P37, DOI 10.1017/S0016672300028354	53	68	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27635	27639						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961681				2022-12-27	WOS:A1994PV77100074
J	ENGLISH, N; HUGHES, V; WOLF, CR				ENGLISH, N; HUGHES, V; WOLF, CR			COMMON PATHWAYS OF CYTOCHROME-P450 GENE-REGULATION BY PEROXISOME PROLIFERATORS AND BARBITURATES IN BACILLUS-MEGATERIUM ATCC14581	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACIDS; ACTIVATED RECEPTOR; CLOFIBRIC ACID; ENZYME-SYSTEM; LAURIC ACID; INDUCTION; HYDROXYLATION; CARCINOGENESIS; EXPRESSION; PROTEINS	Bacillus megaterium contains a barbiturate-inducible cytochrome P450(BM-3), which catalyzes the hydroxylation of fatty acids. We report the intriguing finding that peroxisome proliferators, a major class of epigenetic carcinogen, are also extremely potent inducers of this enzyme being up to 50-fold more potent than one of the most effective barbiturates, secobarbital. Similar to barbiturates, the mechanism of induction appears to involve the direct binding of the peroxisome proliferator to the transcriptional repressor (Bm3R1), resulting in its dissociation from its DNA operator. These observations provide evidence that peroxisome proliferators can interact with a transcription factor to modulate gene expression. The data also demonstrate that the effects of these compounds are highly conserved through evolution and that there are important common denominators in the regulation of gene expression by peroxisome proliferators and the barbiturates. Evidence is presented to indicate that this may involve effects on unsaturated fatty acid homeostasis.	UNIV DUNDEE,NINEWELLS HOSP & MED SCH,CTR BIOMED RES,IMPERIAL CANC RES FUND,MOLEC PHARMACOL UNIT,DUNDEE DD1 9SY,SCOTLAND	University of Dundee								BARS RG, 1993, BIOCHEM PHARMACOL, V45, P2045, DOI 10.1016/0006-2952(93)90015-O; CONSTANTINIDES PP, 1985, J BIOL CHEM, V260, P7573; EIMERHAND A, 1993, EUR J BIOCHEM, V214, P323; FILIPITS M, 1993, GENE, V132, P49, DOI 10.1016/0378-1119(93)90513-3; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN S, 1992, CANCER SURV, V14, P221; GRELET N, 1951, ANN I PASTEUR PARIS, V81, P430; HENRY MF, 1992, CELL, V70, P671, DOI 10.1016/0092-8674(92)90435-F; HERMANN R, 1990, TOXICOL APPL PHARM, V106, P482; HESS R, 1965, NATURE, V208, P856, DOI 10.1038/208856a0; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JIRTLE R, 1993, SCHERING WORKSHOP NO; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KIM BH, 1983, BIOCHEM BIOPH RES CO, V116, P843, DOI 10.1016/S0006-291X(83)80219-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKE BG, 1984, XENOBIOTICA, V14, P269, DOI 10.3109/00498258409151411; LEWIS AD, 1988, P NATL ACAD SCI USA, V85, P8511, DOI 10.1073/pnas.85.22.8511; LOCK EA, 1989, ANNU REV PHARMACOL, V29, P145; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIURA Y, 1975, BIOCHIM BIOPHYS ACTA, V388, P305, DOI 10.1016/0005-2760(75)90089-2; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; NARHI LO, 1982, J BIOL CHEM, V257, P2147; NEBERT DW, 1989, XENOBIOTICA, V19, P1149, DOI 10.3109/00498258909043167; OMURA T, 1964, J BIOL CHEM, V239, P2370; ORTON TC, 1982, DRUG METAB DISPOS, V10, P110; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; RUETTINGER RT, 1981, J BIOL CHEM, V256, P5728; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SHAW GC, 1992, J BIOL CHEM, V267, P5515; SHAW GC, 1993, J BIOL CHEM, V268, P2997; STOTT WT, 1988, REGUL TOXICOL PHARM, V8, P125, DOI 10.1016/0273-2300(88)90026-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WORKMAN JL, 1993, CURRENT PROTOCOLS MO, V2	35	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26836	26841						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929421				2022-12-27	WOS:A1994PQ93100041
J	HANSEN, WJ; LINGAPPA, VR; WELCH, WJ				HANSEN, WJ; LINGAPPA, VR; WELCH, WJ			COMPLEX ENVIRONMENT OF NASCENT POLYPEPTIDE-CHAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HEAT-SHOCK; CHLORAMPHENICOL ACETYLTRANSFERASE; CYTOPLASMIC CHAPERONIN; PROTEINS; ATP; TRANSLOCATION; TRANSLATION; SUBUNITS; TUBULIN; BINDING	Nascent polypeptides enter into high molecular weight complexes with other proteins during chain elongation in vitro and in vivo. The nature of these complexes was investigated using an in vitro translation system programmed with a single mRNA lacking a translational termination codon. Complexes containing nascent polypeptides (molecular mass < 20 kDa), the molecular chaperone hsp 73 and other unidentified proteins can be released from the translationally arrested polysomes by puromycin treatment. The apparent native molecular mass of the nascent chain binding complex was determined to be >700 kDa by gel-filtration analysis. Complexes between the nascent polypeptide and at least hsp 73 appear to be sensitive to (disrupted by) ATP. The presence of ATP also dramatically alters the sensitivity of the nascent polypeptide chains to digestion by exogenous protease. Collectively, our data indicate that there may be a cytoplasmic machinery, including hsp 70, which comprises a nascent polypeptide chain binding complex.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	HANSEN, WJ (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,BOX 0854,SAN FRANCISCO,CA 94143, USA.			Lingappa, Vishwanath R./0000-0003-0962-6571	NIGMS NIH HHS [R01 GM33551] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033551] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P390, DOI 10.1073/pnas.68.2.390; BROWN CR, 1993, J CELL BIOL, V120, P1101, DOI 10.1083/jcb.120.5.1101; BUTLER ET, 1982, J BIOL CHEM, V257, P5772; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LESLIE AGW, 1988, P NATL ACAD SCI USA, V85, P4133, DOI 10.1073/pnas.85.12.4133; LINGAPPA JR, 1994, J CELL BIOL, V125, P99, DOI 10.1083/jcb.125.1.99; MCCONAHEY P, 1980, IMMUNOCHEMICAL TEC A, V70, P210; MURRAY IA, 1988, BIOCHEM J, V252, P173, DOI 10.1042/bj2520173; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; NUNNARI J, 1992, Current Opinion in Cell Biology, V4, P573, DOI 10.1016/0955-0674(92)90074-M; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; RIABOWOL KT, 1988, SCIENCE, V242, P433, DOI 10.1126/science.3175665; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0	26	58	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26610	26613						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929390				2022-12-27	WOS:A1994PQ93100006
J	NEWTON, DL; NICHOLLS, PJ; RYBAK, SM; YOULE, RJ				NEWTON, DL; NICHOLLS, PJ; RYBAK, SM; YOULE, RJ			EXPRESSION AND CHARACTERIZATION OF RECOMBINANT HUMAN EOSINOPHIL-DERIVED NEUROTOXIN AND EOSINOPHIL-DERIVED NEUROTOXIN-ANTI-TRANSFERRIN RECEPTOR SFV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN FV; RICIN-A-CHAIN; MONOCLONAL-ANTIBODIES; PSEUDOMONAS EXOTOXIN; FUSION PROTEINS; CYTOTOXIC RIBONUCLEASE; OVERLAP EXTENSION; ESCHERICHIA-COLI; IMMUNOTOXINS; BINDING	The gene for the human recombinant eosinophil-derived neurotoxin (rEDN) was synthesized and fused to the gene encoding a single chain antibody (sFv) to the human transferrin receptor (EDNsFv). Both rEDN and EDNsFv were expressed as insoluble proteins in inclusion bodies in Escherichia coli BL21(DE3). Following denaturation and renaturation, EDN and EDNsFv were partially purified by chromatography on heparin-Sepharose. Final purification of EDN was achieved by Sephadex G-100, whereas EDNsFv which contained a g-histidyl residue carboxyl terminus was highly purified using the metal chelate resin, Ni2+-nitriloacetic acid. Whereas the recombinant EDN had ribonuclease activity that was similar to the native protein, the fusion protein had enzymatic activity that was 6-13% that of native EDN. The fusion protein was able to bind to the human transferrin receptor. In contrast to rEDN that had no inherent cytotoxicity to human tumor cells, the EDNsFv fusion protein was cytotoxic to human leukemia cells that express the human transferrin receptor with an IC50, 0.2-1 nM. At 1.3 nM EDNsFv, no cytotoxicity was observed on cells that lack the human transferrin receptor. Free antibody to the human transferrin receptor, E6, inhibited the cytotoxicity of the EDNsFv. Human enzymes may be engineered to acquire cytotoxic properties by fusing them to antibodies. Thus, they may be candidates for the construction of immunofusion proteins that may be less immunogenic than immunotoxins containing bacterial- or plant-derived toxin moieties.	NINCDS, SURG NEUROL BRANCH, BIOCHEM SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)								ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; BATRA JK, 1991, MOL CELL BIOL, V11, P2200, DOI 10.1128/MCB.11.4.2200; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BRINKMANN U, 1992, P NATL ACAD SCI USA, V89, P3075, DOI 10.1073/pnas.89.7.3075; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; BUTTERWORTH AE, 1984, ADV PARASIT, V23, P143, DOI 10.1016/S0065-308X(08)60287-0; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; COLCHER D, 1990, JNCI-J NATL CANCER I, V82, P1191, DOI 10.1093/jnci/82.14.1191; COVELL DG, 1986, CANCER RES, V46, P3969; DARZYNKIEWICZ Z, 1988, CELL TISSUE KINET, V21, P169, DOI 10.1111/j.1365-2184.1988.tb00855.x; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GRANTHAM R, 1981, NUCLEIC ACIDS RES, V9, pR43; HEYLIGEN H, 1985, FED PROC, V44, P787; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOOGENBOOM HR, 1990, J IMMUNOL, V144, P3211; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HUSTON JS, 1991, METHOD ENZYMOL, V203, P46; JOHNSON S, 1991, METHOD ENZYMOL, V203, P88; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; KNAPPIK A, 1993, BIO-TECHNOL, V11, P77, DOI 10.1038/nbt0193-77; MILENIC DE, 1991, CANCER RES, V51, P6363; NEVILLE DM, 1982, IMMUNOL REV, V62, P75, DOI 10.1111/j.1600-065X.1982.tb00390.x; NEWTON DL, 1992, J BIOL CHEM, V267, P19572; NEWTON DL, 1994, J NEUROSCI, V14, P538; NICHOLLS PJ, 1993, J BIOL CHEM, V268, P5302; PAI LH, 1993, EUR J CANCER, V29A, P1606, DOI 10.1016/0959-8049(93)90306-Z; Rybak S.M., 1993, DRUG DELIV, V1, P3; RYBAK SM, 1992, P NATL ACAD SCI USA, V89, P3165, DOI 10.1073/pnas.89.8.3165; RYBAK SM, 1991, J BIOL CHEM, V266, P21202; RYBAK SM, 1991, IMMUNOL ALLERGY CLIN, V11, P359; SAXENA SK, 1992, J BIOL CHEM, V267, P21982; SAXENA SK, 1991, J BIOL CHEM, V266, P21208; SHEALY D, 1990, Journal of Nuclear Medicine, V31, P776; SKERRA A, 1991, PROTEIN ENG, V4, P971, DOI 10.1093/protein/4.8.971; SLIFMAN NR, 1986, J IMMUNOL, V137, P2913; SOLERRODRIGUEZ AM, 1993, EXP CELL RES, V206, P227, DOI 10.1006/excr.1993.1142; SORRENTINO S, 1992, J BIOL CHEM, V267, P14859; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUTHERLAND R, 1987, CANCER RES, V47, P1627; TAI MS, 1990, BIOCHEMISTRY-US, V29, P8024, DOI 10.1021/bi00487a005; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; TEPPER RI, 1992, SCIENCE, V257, P548, DOI 10.1126/science.1636093; WU YN, 1993, J BIOL CHEM, V268, P10686; YAMASHITA K, 1986, ARCH BIOCHEM BIOPHYS, V250, P263, DOI 10.1016/0003-9861(86)90725-3; YOKOTA T, 1992, CANCER RES, V52, P3402; YOULE RJ, 1993, CRIT REV THER DRUG, V10, P1	48	78	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26739	26745						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929408				2022-12-27	WOS:A1994PQ93100027
J	FU, DX; SINE, SM				FU, DX; SINE, SM			COMPETITIVE ANTAGONISTS BRIDGE THE ALPHA-GAMMA SUBUNIT INTERFACE OF THE ACETYLCHOLINE-RECEPTOR THROUGH QUATERNARY AMMONIUM-AROMATIC INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; RESIDUES; SITE; IDENTIFICATION; SELECTIVITY; CURARE	We recently demonstrated that conserved tyrosines Tyr(198) of the alpha subunit and Tyr(117) of the gamma subunit of the acetylcholine receptor stabilize binding of the curariform antagonist dimethyl-d-tubocurarine (DMT). To test the hypothesis that DMT interacts directly with these tyrosines, and therefore bridges the alpha-gamma subunit interface, we introduced point mutations into these key positions and expressed one or both mutant subunits in alpha(2) beta gamma(2) acetylcholine receptors in 293 HEK cells. Binding of DMT, measured by competition against the initial rate of I-125-alpha-bungarotoxin binding, shows high affinity for aromatic mutations, reduced affinity for polar mutations, and lowest affinity for arginine mutations. Similar side chain dependences were observed for both Tyr(alpha 198) and Tyr(gamma 117), indicating interaction of these residues with two symmetrical chemical groups in DMT. Two more bisquaternary antagonists, pancuronium and gallamine, show side chain dependences similar to that of DMT, indicating that the primary stabilizing interactions are aromatic-quaternary in both subunits. For the rigid ligands DMT and pancuronium, co-expressing mutant alpha and gamma subunits revealed independent contributions by each determinant, but strict independence was not observed for the flexible ligand gallamine. The free energy contributed by each aromatic quaternary interaction was estimated to be 2-4 kcal/mol, as determined from the free energy difference between aromatic and alkyl hydroxyl mutations. Our results suggest that bis-quaternary competitive antagonists bridge the alpha-gamma subunit interface by fitting into a pocket bounded by tyrosines at positions 198 of the alpha subunit and 117 of the gamma subunit.	MAYO CLIN & MAYO FDN, DEPT PHYSIOL & BIOPHYS, RECEPTOR BIOL LAB, ROCHESTER, MN 55905 USA	Mayo Clinic				Fu, Dax/0000-0002-2663-1316	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS031744, R01NS031744] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31744] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; COHEN JB, 1991, J BIOL CHEM, V266, P23354; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; FILATOV GN, 1993, MOL PHARMACOL, V44, P237; GALZI JL, 1990, J BIOL CHEM, V265, P10430; GAO J, 1993, BIOPHYS J, V65, P43, DOI 10.1016/S0006-3495(93)81031-2; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; KAO P, 1986, J BIOL CHEM, V259, P286; LAU FTK, 1994, J MOL BIOL, V236, P1049, DOI 10.1016/0022-2836(94)90011-6; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; PAULING P, 1973, CHEM-BIOL INTERACT, V6, P351, DOI 10.1016/0009-2797(73)90056-2; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; SINE SM, 1991, J BIOL CHEM, V266, P19369; SINE SM, 1994, J BIOL CHEM, V269, P8808; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1981, J BIOL CHEM, V256, P6692; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107	22	62	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26152	26157						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929328				2022-12-27	WOS:A1994PQ93000034
J	VENABLE, ME; BLOBE, GC; OBEID, LM				VENABLE, ME; BLOBE, GC; OBEID, LM			IDENTIFICATION OF A DEFECT IN THE PHOSPHOLIPASE-D DIACYLGLYCEROL PATHWAY IN CELLULAR SENESCENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN-DIPLOID FIBROBLASTS; DNA-SYNTHESIS; CELLS; DIFFERENTIATION; TRANSCRIPTION; ACTIVATION; PHOSPHORYLATION; PROLIFERATION; HYDROLYSIS	Normal cells become senescent in culture after a limited number of population doublings becoming unable to respond to mitogens. This raises the possibility of defects in mitogenic signaling pathways in cellular senescence. In contrast to young human diploid fibroblasts (HDF), their senescent counterparts failed to undergo protein kinase C translocation in response to serum stimulation. On the other hand, phorbol 12-myristate 13-acetate was equally active in inducing protein kinase C translocation in young and senescent HDF. This suggested a defect in generation of the endogenous activator of protein kinase C, diacylglycerol. Stimulation of young HDF with serum resulted in 3-4-fold generation of diacylglycerol (DAG). In contrast, senescent cells displayed insignificant DAG: formation in response to serum. The mechanism of DAG generation was investigated next. In young HDF, serum induced a 5-fold activation of the phospholipase D (PLD) pathway as measured by the incorporation of exogenous ethanol into phosphatidylethanol, which is a measure of the transphosphatidylation reaction of PLD. In contrast, PLD in senescent cells was not activated by serum. Since senescent cells demonstrate significant elevations in the level of endogenous ceramide, the impact of ceramide on the PLD/DAG pathway was also investigated. A soluble analog of ceramide, C-6-ceramide, was found to inhibit serum-stimulated DAG accumulation and PLD activation in young cells. These data demonstrate for the first time a defect in PLD activation in cellular senescence and suggest that ceramide may be responsible for the inhibition of this pathway.	DUKE UNIV,MED CTR,DEPT MED,DIV GERIATR,DURHAM,NC 27710; DURHAM VET ADM GERIATR RES EDUC & CLIN CTR,DURHAM,NC 27710	Duke University; Geriatric Research Education & Clinical Center			Blobe, Gerard/AAJ-5945-2020	Blobe, Gerard/0000-0002-4274-8901; obeid, lina/0000-0002-0734-0847; Venable, Mark/0000-0003-1708-9163	NATIONAL INSTITUTE ON AGING [T32AG000029] Funding Source: NIH RePORTER; NIA NIH HHS [5T32AG00029] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ASOAKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKSFREDERICH KM, 1993, EXP CELL RES, V205, P412, DOI 10.1006/excr.1993.1106; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DETATA V, 1993, EXP CELL RES, V205, P261, DOI 10.1006/excr.1993.1085; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KIM MY, 1991, J BIOL CHEM, V266, P484; KIRKLAND JL, 1992, CLIN BIOCHEM, V25, P61, DOI 10.1016/0009-9120(92)80047-K; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LISCOVITCH M, 1991, BIOCHEM SOC T, V19, P402, DOI 10.1042/bst0190402; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NORWOOD TH, 1974, P NATL ACAD SCI USA, V71, P2231, DOI 10.1073/pnas.71.6.2231; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PEACOCKE M, 1991, J CELL BIOCHEM, V45, P147, DOI 10.1002/jcb.240450205; PREISS J, 1986, J BIOL CHEM, V261, P8597; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SMITH JR, 1992, AM J CLIN NUTR, V55, P1215; STEIN GH, 1986, P NATL ACAD SCI USA, V83, P9030, DOI 10.1073/pnas.83.23.9030; SUBLETTE E, 1993, NEUROSCI LETT, V159, P175, DOI 10.1016/0304-3940(93)90827-8; WADHWA R, 1993, J BIOL CHEM, V268, P22239; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121	32	103	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26040	26044						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929315				2022-12-27	WOS:A1994PQ93000019
J	CLARK, WA; RUDNICK, SJ; ANDERSEN, LC; LAPRES, JJ				CLARK, WA; RUDNICK, SJ; ANDERSEN, LC; LAPRES, JJ			MYOSIN HEAVY-CHAIN SYNTHESIS IS INDEPENDENTLY REGULATED IN HYPERTROPHY AND ATROPHY OF ISOLATED ADULT CARDIAC MYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RAT MYOCARDIAL-CELLS; ATRIAL-NATRIURETIC-FACTOR; BETA-ADRENERGIC STIMULATION; ALPHA-ACTIN GENE; II-INDUCED HYPERTROPHY; MESSENGER-RNA LEVELS; HEART-CELLS; VENTRICULAR MYOCYTES; LIGHT CHAIN-2	Hypertrophy of isolated adult feline cardiac muscle cells may be induced in culture by either alpha- or beta-adrenergic agonists. However, it has been shown previously that each of these agonists activate different subsets of immediate-early response genes and have different effects on expression of ''fetal'' protein isoforms and stimulation of protein synthesis. Moreover, in adult feline heart cells, beta-adrenergic agonists, such as isoproterenol, activate sustained synchronous beating and sarcomeric reorganization while alpha-adrenergic agonists, such as phenylephrine, do not. The objective of the present study was to determine whether these differences in proximal signaling events converged in a common signal pathway during activation of contractile protein synthesis. By direct comparisons of actin and myosin heavy chain (HC) synthesis and accumulation following isoproterenol and phenylephrine, it was determined that both agonists stimulate a coordinated accumula tion of these proteins during cardiomyocyte growth. However, each agonist stimulated a very different program of contractile protein synthesis. During phenylephrine-induced hypertrophy, actin and myosin HC syntheses were rapidly and coordinately activated and continuously maintained at rates 10-25% greater than untreated cultures. The pattern of myosin HC synthesis following isoproterenol was very much more complex with periods during which it was as much as 40% greater or 25% less than in control cultures. Furthermore, there was no correlation between rates of actin and myosin HC synthesis following isoproterenol. It was concluded that actin and myosin HC syntheses and accumulation were regulated independently and in a very different manner following isoproterenol or phenylephrine. Since protein accumulation was not correlated with synthesis rates during development of hypertrophy, it was also concluded that post-translational mechanisms played a significant role in the maintenance of contractile protein stoichiometry during beta-adrenergic/beating-induced hypertrophy. Myosin HC synthesis also appeared to be independently regulated during cardiomyocyte atrophy induced by the calcium channel blocker nifedipine. Unlike the case in hypertrophy, however, protein balance was not maintained in nifedipine, and the depression of myosin HC synthesis and loss of myosin HC content were much greater than in the case of other contractile proteins.	NORTHWESTERN UNIV, SCH MED, FEINBERG CARDIOVASC RES INST, CHICAGO, IL 60611 USA	Northwestern University	CLARK, WA (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT MED, CHICAGO, IL 60611 USA.				NHLBI NIH HHS [HL 19648] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019648] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLO SN, 1992, AM J PHYSIOL, V263, pC319, DOI 10.1152/ajpcell.1992.263.2.C319; BAKER KM, 1990, AM J PHYSIOL, V259, pH610, DOI 10.1152/ajpheart.1990.259.2.H610; BEINLICH CJ, 1993, J MOL CELL CARDIOL, V25, P395, DOI 10.1006/jmcc.1993.1046; BISHOPRIC NH, 1987, J CLIN INVEST, V80, P1194, DOI 10.1172/JCI113179; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; BOGOYEVITCH MA, 1993, AM J PHYSIOL, V265, pC1247, DOI 10.1152/ajpcell.1993.265.5.C1247; BUTTRICK PM, 1994, J MOL CELL CARDIOL, V26, P61, DOI 10.1006/jmcc.1994.1008; CARAVATTI M, 1982, J MOL BIOL, V160, P59, DOI 10.1016/0022-2836(82)90131-0; CHEVALIER B, 1989, J MOL CELL CARDIOL, V21, P71, DOI 10.1016/0022-2828(89)90773-6; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CLARK WA, 1993, AM J PHYSIOL, V264, pH573, DOI 10.1152/ajpheart.1993.264.2.H573; CLARK WA, 1981, J BIOL CHEM, V256, P4863; CLARK WA, 1993, J BIOL CHEM, V268, P20243; CLARK WA, 1993, CIRC RES, V73, P1163, DOI 10.1161/01.RES.73.6.1163; CLARK WA, 1991, AM J PHYSIOL, V261, pC530, DOI 10.1152/ajpcell.1991.261.3.C530; COOPER G, 1986, CIRC RES, V58, P692, DOI 10.1161/01.RES.58.5.692; COOPER G, 1987, ANNU REV PHYSIOL, V49, P501, DOI 10.1146/annurev.ph.49.030187.002441; CZERWINSKI SM, 1991, J APPL PHYSIOL, V70, P300, DOI 10.1152/jappl.1991.70.1.300; DECKER RS, 1993, AM J PHYSIOL, V265, pH329, DOI 10.1152/ajpheart.1993.265.1.H329; DUBUS I, 1993, AM J PHYSIOL, V265, pC62, DOI 10.1152/ajpcell.1993.265.1.C62; DUBUS I, 1990, CIRC RES, V66, P867, DOI 10.1161/01.RES.66.3.867; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; EVERETT AW, 1984, BIOCHEMISTRY-US, V23, P1596, DOI 10.1021/bi00303a002; EVERETT AW, 1983, J BIOL CHEM, V258, P2421; EVERETT AW, 1983, ANAL BIOCHEM, V130, P102, DOI 10.1016/0003-2697(83)90655-3; FULLER SJ, 1988, AM J PHYSIOL, V255, pE537, DOI 10.1152/ajpendo.1988.255.4.E537; FULLER SJ, 1990, BIOCHEM J, V266, P727, DOI 10.1042/bj2660727; GREGORY P, 1990, BIOCHEM J, V265, P525, DOI 10.1042/bj2650525; GUNNING P, 1987, MOL CELL BIOL, V7, P4100, DOI 10.1128/MCB.7.11.4100; GUSTAFSON TA, 1987, J BIOL CHEM, V262, P13316; HANEDA T, 1991, MOL CELL BIOCHEM, V104, P169; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1081, DOI 10.1016/0022-2828(88)90588-3; IKEDA U, 1991, AM J PHYSIOL, V260, pH953, DOI 10.1152/ajpheart.1991.260.3.H953; IMAMURA SI, 1991, AM J PHYSIOL, V260, pH73, DOI 10.1152/ajpheart.1991.260.1.H73; ITO H, 1993, J CLIN INVEST, V92, P398, DOI 10.1172/JCI116579; IVESTER CT, 1993, AM J PHYSIOL, V265, pH666; IWAKI K, 1990, J BIOL CHEM, V265, P13809; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; JOHNSON TB, 1994, CIRC RES, V74, P448, DOI 10.1161/01.RES.74.3.448; KARIYA K, 1994, J BIOL CHEM, V269, P3775; KENT RL, 1991, J CARDIOVASC PHARM, V17, pS7, DOI 10.1097/00005344-199117002-00003; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; KOMURO I, 1991, J BIOL CHEM, V266, P1265; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HR, 1988, J BIOL CHEM, V263, P7352; MANN DL, 1989, CIRC RES, V64, P1079, DOI 10.1161/01.RES.64.6.1079; MATSUBARA H, 1988, AM J PHYSIOL, V255, pH405, DOI 10.1152/ajpheart.1988.255.3.H405; MCDONOUGH PM, 1992, J BIOL CHEM, V267, P11665; MEIDELL RS, 1986, AM J PHYSIOL, V251, P1076; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; MORKIN E, 1993, CIRCULATION, V87, P1451, DOI 10.1161/01.CIR.87.5.1451; NADALGINARD B, 1989, J CLIN INVEST, V84, P1693, DOI 10.1172/JCI114351; NAGAI R, 1987, CIRC RES, V60, P692, DOI 10.1161/01.RES.60.5.692; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; PINSON A, 1993, J MOL CELL CARDIOL, V25, P477, DOI 10.1006/jmcc.1993.1053; RUPP H, 1990, J APPL PHYSIOL, V68, P973, DOI 10.1152/jappl.1990.68.3.973; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SAMAREL AM, 1992, AM J PHYSIOL, V263, pC642, DOI 10.1152/ajpcell.1992.263.3.C642; SAMUEL JL, 1990, EUR HEART J, V11, P1; SCHLUTER KD, 1992, AM J PHYSIOL, V263, pH1739, DOI 10.1152/ajpheart.1992.263.6.H1739; SEI CA, 1991, J BIOL CHEM, V266, P15910; SHANI M, 1981, DEV BIOL, V86, P483, DOI 10.1016/0012-1606(81)90206-2; SHARP WW, 1993, CIRC RES, V73, P172, DOI 10.1161/01.RES.73.1.172; SHIELDS PP, 1989, J BIOL CHEM, V264, P9322; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMPSON DG, 1993, J CELL BIOL, V123, P323, DOI 10.1083/jcb.123.2.323; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; SIMPSON P, 1982, CIRC RES, V50, P101, DOI 10.1161/01.RES.50.1.101; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; SIMPSON PC, 1991, MOL CELL BIOCHEM, V104, P35; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPRINGHORN JP, 1992, J BIOL CHEM, V267, P14360; STARKSEN NF, 1986, P NATL ACAD SCI USA, V83, P8348, DOI 10.1073/pnas.83.21.8348; SUGDEN PH, 1993, BIOCHIM BIOPHYS ACTA, V1175, P327, DOI 10.1016/0167-4889(93)90225-E; SUGDEN PH, 1991, BIOCHEM J, V273, P21, DOI 10.1042/bj2730021; SUZUKI T, 1990, FEBS LETT, V268, P149, DOI 10.1016/0014-5793(90)80995-U; TAKAHASHI T, 1992, J CLIN INVEST, V89, P939, DOI 10.1172/JCI115675; THORBURN A, 1993, J BIOL CHEM, V268, P2244; VANVENROOIJ WJ, 1974, EUR J BIOCHEM, V50, P297; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; WEBER K, 1969, J BIOL CHEM, V244, P4406; ZILVERSMIT DB, 1960, AM J MED, V29, P832, DOI 10.1016/0002-9343(60)90117-0	92	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25562	25569						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929258				2022-12-27	WOS:A1994PQ49100052
J	MOLINALOPEZ, JA; GOVANTES, F; SANTERO, E				MOLINALOPEZ, JA; GOVANTES, F; SANTERO, E			GEOMETRY OF THE PROCESS OF TRANSCRIPTION ACTIVATION AT THE SIGMA-54-DEPENDENT NIFH PROMOTER OF KLEBSIELLA-PNEUMONIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; NITROGEN-FIXATION GENES; ESCHERICHIA-COLI; RNA-POLYMERASE; POSITIONAL REQUIREMENTS; ALPHA-SUBUNIT; TOL PLASMID; DNA; PROTEIN; NIFA	The Klebsiella pneumoniae nifH promoter is very strictly controlled by nitrogen availability and highly dependent on sigma 54 and integration host factor (IHF) for expression. This promoter region has been used to examine the role of IHF in the activation of transcription from sigma 54-dependent promoters and to analyze the positional restrictions which may exist for an activation mechanism from distant sites such as this one. By functionally replacing the binding site of MF by sequence-directed curved DNA fragments, it has been shown that the role of IHF in stimulating transcription is structural; it brings the molecules directly involved in the process into close proximity. Unlike other promoter regions with an activation mechanism at a distance, this IHF-dependent promoter requires a precise geometry for efficient transcription. In this sense, it resembles an activation mechanism from near sites. However, alternative functional structures which are very different from the native one can be isolated.	UNIV SEVILLA,FAC BIOL,DEPT GENET,E-41080 SEVILLE,SPAIN	University of Sevilla			Govantes, Fernando/E-4790-2017; Santero, Eduardo/K-6510-2014	Govantes, Fernando/0000-0002-4866-6798; Santero, Eduardo/0000-0002-6111-7160				ABRIL MA, 1993, MOL GEN GENET, V239, P281, DOI 10.1007/BF00281629; BUCK M, 1992, NATURE, V358, P422, DOI 10.1038/358422a0; BUCK M, 1986, NATURE, V320, P374, DOI 10.1038/320374a0; BUCK M, 1987, MOL MICROBIOL, V1, P243, DOI 10.1111/j.1365-2958.1987.tb00518.x; BUCK M, 1987, MOL GEN GENET, V210, P140, DOI 10.1007/BF00337770; CALI BM, 1989, J BACTERIOL, V171, P2666, DOI 10.1128/jb.171.5.2666-2672.1989; CLAVERIEMARTIN F, 1992, J MOL BIOL, V227, P996, DOI 10.1016/0022-2836(92)90516-M; CLAVERIEMARTIN F, 1991, P NATL ACAD SCI USA, V88, P1631, DOI 10.1073/pnas.88.5.1631; DELORENZO V, 1991, EMBO J, V10, P1159, DOI 10.1002/j.1460-2075.1991.tb08056.x; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GILADI H, 1992, J MOL BIOL, V227, P985, DOI 10.1016/0022-2836(92)90514-K; GOBER JW, 1990, GENE DEV, V4, P1494, DOI 10.1101/gad.4.9.1494; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; KOO HS, 1988, P NATL ACAD SCI USA, V85, P1763, DOI 10.1073/pnas.85.6.1763; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; LEE HS, 1993, P NATL ACAD SCI USA, V90, P2266, DOI 10.1073/pnas.90.6.2266; LEE HS, 1993, J BACTERIOL, V175, P2479, DOI 10.1128/JB.175.8.2479-2482.1993; MACNEIL T, 1978, J BACTERIOL, V134, P821, DOI 10.1128/JB.134.3.821-829.1978; Miller J. H, 1972, EXPT MOL GENETICS; MORETT E, 1989, J MOL BIOL, V210, P65, DOI 10.1016/0022-2836(89)90291-X; MORETT E, 1988, P NATL ACAD SCI USA, V85, P9401, DOI 10.1073/pnas.85.24.9401; MULLIN DA, 1993, J BACTERIOL, V175, P2067, DOI 10.1128/JB.175.7.2067-2076.1993; NINFA AJ, 1987, CELL, V50, P1039, DOI 10.1016/0092-8674(87)90170-X; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; OW DW, 1983, NATURE, V301, P307, DOI 10.1038/301307a0; POPHAM D, 1991, J BIOL CHEM, V266, P19510; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; REITZER LJ, 1989, J BACTERIOL, V171, P5512, DOI 10.1128/jb.171.10.5512-5522.1989; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; SANTERO E, 1989, P NATL ACAD SCI USA, V86, P7346, DOI 10.1073/pnas.86.19.7346; SANTERO E, 1992, J MOL BIOL, V227, P602, DOI 10.1016/0022-2836(92)90211-2; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; THONY B, 1989, FEMS MICROBIOL LETT, V63, P341; VALENTINHANSEN P, 1986, EMBO J, V5, P2015, DOI 10.1002/j.1460-2075.1986.tb04458.x; WEDEL A, 1990, SCIENCE, V248, P486, DOI 10.1126/science.1970441; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	41	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25419	25425						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929239				2022-12-27	WOS:A1994PQ49100032
J	BONNER, G; LAFER, EM; SOUSA, R				BONNER, G; LAFER, EM; SOUSA, R			CHARACTERIZATION OF A SET OF T7 RNA-POLYMERASE ACTIVE-SITE MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; BACTERIOPHAGE-T7; DNA; PROCESSIVITY; MUTATIONS	We have evaluated the elongation rates, processivities, and abortive transcription characteristics of a set of T7 RNA polymerase mutants that map to the polymerase active site. The effects of these mutations on transcription are complex: they cause decreases in activity and processivity during both the processive and abortive phases of transcription and exhibit disproportionate decreases in activity and processivity on poly(dA).poly(dT) or poly(dT) versus poly(dG).poly(dC) templates. They also exhibit an increase in the proportion of slippage dependent poly(G) transcript synthesis during the initial stages of transcription. It is shown that these multiple, distinct effects on transcription can be attributed to decreases in the mutant enzymes' phosphodiester bond formation rates. Estimates of the decreases in these rates are derived from the measured transcript elongation rates and processivities of the mutant enzymes.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,PROGRAM MOLEC MED,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio				Lafer, Eileen/0000-0002-0493-6522; Sousa, Rui/0000-0003-4314-121X				ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BONNER G, 1992, EMBO J, V11, P3767, DOI 10.1002/j.1460-2075.1992.tb05462.x; BONNER G, 1994, J BIOL CHEM, V269, P25129; DELARUE M, 1990, J PROTEIN ENG, V10, P461; GOLOMB M, 1974, J BIOL CHEM, V249, P2858; GROSS L, 1992, J MOL BIOL, V228, P488, DOI 10.1016/0022-2836(92)90837-A; IKEDA RA, 1987, J BIOL CHEM, V262, P3790; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; MACDONALD LE, 1993, J MOL BIOL, V232, P1030, DOI 10.1006/jmbi.1993.1458; MARTIN CT, 1987, BIOCHEMISTRY-US, V26, P2690, DOI 10.1021/bi00384a006; McClure W R, 1980, Methods Enzymol, V64, P277; MOOKHTIAR KA, 1991, BIOCHEMISTRY-US, V30, P6305, DOI 10.1021/bi00239a032; MULLER DK, 1988, BIOCHEMISTRY-US, V27, P5763, DOI 10.1021/bi00415a055; OLLIS DL, 1985, NATURE, V313, P765; OSUMIDAVIS PA, 1992, J MOL BIOL, V226, P37, DOI 10.1016/0022-2836(92)90122-Z; OSUMIDAVIS PA, 1994, J MOL BIOL, V237, P5, DOI 10.1006/jmbi.1994.1205; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; SANKAR S, 1992, J BIOL CHEM, V267, P10168; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074	22	59	74	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25120	25128						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929200				2022-12-27	WOS:A1994PQ49000089
J	DAVLETOV, BA; SUDHOF, TC				DAVLETOV, BA; SUDHOF, TC			CA2+-DEPENDENT CONFORMATIONAL CHANGE IN SYNAPTOTAGMIN-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-KINASE-C; P65; CALCIUM; BINDING; DOMAIN	Synaptotagmin I is a Ca2+/phospholipid binding protein of synaptic vesicles with a proposed function as a Ca2+ sensor in synaptic vesicle exocytosis. Using controlled partial proteolysis as an assay, we now show that synaptotagmin I undergoes a conformational change as a function of Ca2+ binding. As observed for phospholipid binding, Ba2+ and SR(2+) but not Mg2+, substitute for Ca2+ in effecting this conformational change. The first C-2 domain from synaptotagmin I that represents the Ca2+-dependent phospholipid binding domain of synaptotagmin also undergoes a Ca2+-dependent change in controlled partial proteolysis. In contrast, no effect of Ca2+ was observed with mutant C-2 domains containing point mutations that abolish Ca2+ binding. The Ca2+ concentration dependence of the effect of Ca2+ on proteolysis mirrors the Ca2+ dependence of phospholipid binding. The conformational shift in synaptotagmin I caused by Ca2+/phospholipid binding could be the basis for its Ca2+-regulated function in triggering neurotransmitter release.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Davletov, Bazbek/ABA-8569-2021	Davletov, Bazbek/0000-0003-4658-3275				BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OHNISHI M, 1987, BIOCHEMISTRY-US, V26, P7458, DOI 10.1021/bi00397a039; ORR JW, 1994, J BIOL CHEM, V269, P8383; PERIN MS, 1994, J BIOL CHEM, V269, P8576; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; WISE BC, 1982, J BIOL CHEM, V257, P8481; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	23	68	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28547	28550						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961798				2022-12-27	WOS:A1994PU16800007
J	GORDON, CL; SATHER, SK; CASJENS, S; KING, J				GORDON, CL; SATHER, SK; CASJENS, S; KING, J			SELECTIVE IN-VIVO RESCUE BY GROEL/ES OF THERMOLABILE FOLDING INTERMEDIATES TO PHAGE-P22 STRUCTURAL PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; TAIL-SPIKE PROTEIN; INCLUSION-BODY FORMATION; ESCHERICHIA-COLI; TAILSPIKE PROTEIN; MOLECULAR CHAPERONE; RIBULOSEBISPHOSPHATE CARBOXYLASE; LACTATE-DEHYDROGENASE; SCAFFOLDING PROTEIN; BETA-LACTAMASE	The in vivo conformational substrates of the GroE chaperonins have been difficult to identify, in part because of limited information on in vivo polypeptide chain folding pathways. Temperature-sensitive folding (tsf) mutants have been characterized for the coat protein and tailspike protein of phage P22. These mutations block intracellular folding at restrictive temperature by increasing the lability of folding intermediates without impairing the stability or function of the native state. Overexpression of GroEL/ES suppressed the defects of tsf mutants at 17 sites in the coat protein, by improving folding efficiency rather than assembly efficiency or protein stability. Immunoprecipitation experiments demonstrated that GroEL interacted transiently with newly synthesized mild-type coat protein and that this interaction was prolonged by the tsf mutations. Folding defects of the tailspike polypeptide chains were not suppressed. A fraction of the tsf mutant tailspike chains bound to GroEL but were inefficiently discharged. The results suggest that 1) thermolabile folding intermediates are natural substrates of GroEL/ES; 2) although GroEL may bind such intermediates for many proteins, the chaperoning function is limited to a subset of substrate proteins; and 3) a key reason for the heat-shock response may be to stabilize thermolabile folding intermediates at elevated temperatures.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; UNIV UTAH,MED CTR,DEPT CELLULAR VIRAL & MOLEC BIOL,SALT LAKE CITY,UT 84112	Massachusetts Institute of Technology (MIT); Utah System of Higher Education; University of Utah					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017980, R01GM017980] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM17980] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANG D, 1991, J BIOL CHEM, V266, P24233; BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BERTSCH U, 1992, P NATL ACAD SCI USA, V89, P8696, DOI 10.1073/pnas.89.18.8696; BOTSTEIN D, 1973, VIROLOGY, V49, P268; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CASJENS S, 1991, GENETICS, V127, P637; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHRUNYK BA, 1993, J BIOL CHEM, V268, P18053; COPPO A, 1973, J MOL BIOL, V76, P61, DOI 10.1016/0022-2836(73)90081-8; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; DANNER M, 1993, PROTEIN SCI, V2, P1869, DOI 10.1002/pro.5560021109; DONNELLY CE, 1992, J BACTERIOL, V174, P3133, DOI 10.1128/jb.174.10.3133-3139.1992; EPPLER K, 1991, VIROLOGY, V183, P519, DOI 10.1016/0042-6822(91)90981-G; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; FUCHS A, 1991, BIOCHEMISTRY-US, V30, P6598, DOI 10.1021/bi00240a032; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GEORGOPOULOS CP, 1972, NATURE-NEW BIOL, V239, P38, DOI 10.1038/newbio239038a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; GOLDENBERG D, 1982, P NATL ACAD SCI-BIOL, V79, P3403, DOI 10.1073/pnas.79.11.3403; GOLDENBERG DP, 1981, J MOL BIOL, V145, P633, DOI 10.1016/0022-2836(81)90307-7; GOLDENBERG DP, 1983, P NATL ACAD SCI-BIOL, V80, P7060, DOI 10.1073/pnas.80.23.7060; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GORDON CL, 1993, J BIOL CHEM, V268, P9358; GORDON CL, 1994, GENETICS, V136, P427; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; HARRISON SC, 1978, NATURE, V276, P368, DOI 10.1038/276368a0; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANN REV BIOCH, V62, P49; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; JARVIK J, 1975, P NATL ACAD SCI USA, V72, P2738, DOI 10.1073/pnas.72.7.2738; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KING J, 1978, CELL, V15, P551, DOI 10.1016/0092-8674(78)90023-5; KING J, 1974, NATURE, V251, P112, DOI 10.1038/251112a0; KING J, 1973, J MOL BIOL, V80, P697, DOI 10.1016/0022-2836(73)90205-2; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P279, DOI 10.1038/366279a0; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; PARSELL DA, 1989, GENE DEV, V3, P1226, DOI 10.1101/gad.3.8.1226; PRASAD BVV, 1993, J MOL BIOL, V231, P65, DOI 10.1006/jmbi.1993.1257; PREVELIGE PE, 1988, J MOL BIOL, V202, P743, DOI 10.1016/0022-2836(88)90555-4; REVEL HR, 1980, J VIROL, V33, P366, DOI 10.1128/JVI.33.1.366-376.1980; Sambrook J., 1989, MOL CLONING; SAUER RT, 1982, BIOCHEMISTRY-US, V21, P5811, DOI 10.1021/bi00266a014; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SECKLER R, 1989, J BIOL CHEM, V264, P11750; SMITH DH, 1980, GENETICS, V96, P331; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; STERNBERG N, 1973, J MOL BIOL, V76, P25, DOI 10.1016/0022-2836(73)90079-X; STURTEVANT JM, 1989, J BIOL CHEM, V264, P10693; SUGIHARA J, 1988, BIOCHEMISTRY-US, V27, P2872, DOI 10.1021/bi00408a031; TAKANO T, 1972, NATURE-NEW BIOL, V239, P34, DOI 10.1038/newbio239034a0; TESCHKE CM, 1993, BIOCHEMISTRY-US, V32, P10658, DOI 10.1021/bi00091a016; TESCHKE CM, 1993, BIOCHEMISTRY-US, V32, P10839, DOI 10.1021/bi00091a040; TRUONG HTN, 1991, BIOCHEMISTRY-US, V30, P10722; VANDERVIES SM, 1994, NATURE, V368, P654, DOI 10.1038/368654a0; VANDERVIES SM, 1992, BIOCHEMISTRY-US, V31, P3635, DOI 10.1021/bi00129a012; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WINSTON F, 1979, J BACTERIOL, V137, P433, DOI 10.1128/JB.137.1.433-439.1979; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; ZAHN R, 1992, BIOCHEMISTRY-US, V31, P3249, DOI 10.1021/bi00127a029; ZWICKL P, 1990, J STRUCT BIOL, V103, P197, DOI 10.1016/1047-8477(90)90037-D	87	77	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27941	27951						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961726				2022-12-27	WOS:A1994PV77200029
J	IKEBE, M; IKEBE, R; KAMISOYAMA, H; REARDON, S; SCHWONEK, JP; SANDERS, CR; MATSUURA, M				IKEBE, M; IKEBE, R; KAMISOYAMA, H; REARDON, S; SCHWONEK, JP; SANDERS, CR; MATSUURA, M			FUNCTION OF THE NH2-TERMINAL DOMAIN OF THE REGULATORY LIGHT-CHAIN ON THE REGULATION OF SMOOTH-MUSCLE MYOSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN GIZZARD MUSCLE; VERTEBRATE NON-MUSCLE; PHOSPHORYLATION; CONFORMATION; KINASE; IDENTIFICATION; PROTEOLYSIS; MOLECULES; SEQUENCE; SUBFRAGMENT-1	The role of the NH2-terminal domain of the 20,000-dalton light chain on the regulatory function of smooth muscle myosin was studied by exchanging it in myosin with various mutant forms. The 10 S to 6 S conformational transition as well as the thick filament formation were significantly influenced by the deletion or substitution of the amino acid residues at the NH2-terminal side of the phosphorylation site (Ser(19)). Whereas the deletion of Ser(1)-Thr(10) did not significantly affect these functions, further deletion of Lys(11)-Arg(16) completely abolished the formation of 10 S conformation and induced thick filament formation. Among the residues in this region, Arg(13) and Arg(16) were most important for these functions since substitution of these residues by Glu or Ala significantly altered these functions. Similar substitutions of Lys(11) and Lys(12) also stabilized the 6 S conformation and thick filament formation but less effectively. While the 6 S conformation was stabilized, the deletion of NH2-terminal residues did not activate the actin-activated ATPase activity. This suggests that stabilization of the 6 S conformation is not directly coupled with activation of actomyosin ATPase activity but rather a more defined conformational change around the phosphorylation site is necessary for activation. Such a change also influences the 6 S to 10 S conformation and, therefore, the filament formation. To support this notion, substitution of Lys(11) and Lys(12) by Glu-Glu inhibited the phosphorylation-induced activation of actomyosin ATPase activity.	MEIJI MILK PROD CO LTD,CENT RES INST,TOKYO 189,JAPAN	Central Research Institute of Electric Power Industry - Japan; Meiji Holdings Co., Ltd.	IKEBE, M (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL037117, P01HL047530] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47530, HL37117] Funding Source: Medline; NIAMS NIH HHS [AR41653] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDO S, 1989, BIOCHEMISTRY-US, V28, P2974, DOI 10.1021/bi00433a035; CRAIG R, 1983, NATURE, V302, P436, DOI 10.1038/302436a0; CROSS RA, 1986, EMBO J, V5, P2637, DOI 10.1002/j.1460-2075.1986.tb04545.x; EVANS RM, 1988, FEBS LETT, V234, P73, DOI 10.1016/0014-5793(88)81306-1; GEISLER N, 1988, EMBO J, V7, P15, DOI 10.1002/j.1460-2075.1988.tb02778.x; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V1, P423; Higashihara M, 1989, J BIOL CHEM, V264, P5218; HOOVER WG, 1985, PHYS REV A, V31, P1695, DOI 10.1103/PhysRevA.31.1695; IKEBE M, 1994, J BIOL CHEM, V269, P28165; IKEBE M, 1983, BIOCHEMISTRY-US, V22, P4580, DOI 10.1021/bi00288a036; IKEBE M, 1984, J BIOL CHEM, V259, P1639; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1991, J BIOL CHEM, V266, P21339; IKEBE M, 1990, BIOCHEMISTRY-US, V29, P2713, DOI 10.1021/bi00463a014; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; IKEBE M, 1987, J BIOL CHEM, V262, P13828; IKEBE M, 1988, J BIOL CHEM, V263, P6432; IKEBE M, 1986, J BIOL CHEM, V261, P36; IKEBE M, 1985, J BIOL CHEM, V260, P27; IKEBE M, 1993, 17TH C INT UN PHYS S, P79; ITO T, 1989, NATURE, V338, P164; KAMISOYAMA H, 1994, BIOCHEMISTRY-US, V33, P840, DOI 10.1021/bi00169a027; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KENDRICKJONES J, 1987, J MOL BIOL, V198, P241, DOI 10.1016/0022-2836(87)90310-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORITA JI, 1991, BIOCHEMISTRY-US, V30, P9539, DOI 10.1021/bi00103a022; ONISHI H, 1983, J BIOCHEM-TOKYO, V94, P1147, DOI 10.1093/oxfordjournals.jbchem.a134459; ONISHI H, 1982, J BIOCHEM-TOKYO, V92, P871, DOI 10.1093/oxfordjournals.jbchem.a134001; PEARSON RB, 1984, FEBS LETT, V168, P108, DOI 10.1016/0014-5793(84)80216-1; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUZUKI H, 1978, J BIOCHEM, V84, P1529, DOI 10.1093/oxfordjournals.jbchem.a132278; Trybus KM, 1991, CURR OPIN CELL BIOL, V3, P105, DOI 10.1016/0955-0674(91)90172-U; TRYBUS KM, 1988, J BIOL CHEM, V263, P16485; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564	40	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28173	28180						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961753				2022-12-27	WOS:A1994PV77200061
J	LAWSON, TG; GRONROS, DL; WERNER, JA; WEY, AC; DIGEORGE, AM; LOCKHART, JL; WILSON, JW; WINTRODE, PL				LAWSON, TG; GRONROS, DL; WERNER, JA; WEY, AC; DIGEORGE, AM; LOCKHART, JL; WILSON, JW; WINTRODE, PL			THE ENCEPHALOMYOCARDITIS VIRUS 3C PROTEASE IS A SUBSTRATE FOR THE UBIQUITIN-MEDIATED PROTEOLYTIC SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; HEPATITIS-A VIRUS; RETICULOCYTE LYSATE; ESCHERICHIA-COLI; DEGRADATION; CLEAVAGE; PROTEINS; LIGASE; TRANSLATION; EXPRESSION	The encephalomyocarditis virus 3C protease has been shown to be rapidly degraded in infected cells and in vitro in rabbit reticulocyte lysate. The in vitro degradation, at least, is accomplished by a virus-independent, ATP-dependent proteolytic system. Here we identify this proteolytic system as the ubiquitin-mediated system. Incubation of the 3C protease in rabbit reticulocyte or cultured mouse cell lysate preparations, alone or in the presence of added ubiquitin or methylated ubiquitin, resulted in the generation of new higher molecular weight species. These new products were shown to be 3C protease-ubiquitin conjugates by their ability to bind antibodies against both the 3C protease and ubiquitin. Supplemental ubiquitin also stimulated the degradation of the 3C protease in these preparations. Large 3C protease-polyubiquitin conjugates were observed to accumulate in reticulocyte lysate in the presence of adenosine 5'-O-(3-thiotriphosphate), an inhibitor of the 26 S multicatalytic protease. This, combined with the fact that the proteolytic activity could be removed from the lysate by sedimentation, implicates the multicatalytic protease in the degradation of the 3C protease-ubiquitin conjugates. It was also found that the slow rate of degradation of a model polyprotein, which resembles the stable viral 3CD diprotein produced in vivo, is likely due to the fact that the polyprotein is a poor substrate for the ubiquitin conjugating system.			LAWSON, TG (corresponding author), BATES COLL, DEPT CHEM, LEWISTON, ME 04240 USA.				NIAID NIH HHS [1 R15 AI 32666-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI032666] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASCHAUER B, 1991, VIROLOGY, V184, P587, DOI 10.1016/0042-6822(91)90429-F; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BERLETH ES, 1990, BIOCHEM BIOPH RES CO, V171, P705, DOI 10.1016/0006-291X(90)91203-5; BERLETH ES, 1992, J BIOL CHEM, V267, P16403; BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; CORDINGLEY MG, 1989, J VIROL, V63, P5037, DOI 10.1128/JVI.63.12.5037-5045.1989; DASSO MC, 1989, NUCLEIC ACIDS RES, V17, P3129, DOI 10.1093/nar/17.8.3129; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; GAUSSMULLER V, 1991, VIROLOGY, V182, P861, DOI 10.1016/0042-6822(91)90630-T; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gray W R, 1972, Methods Enzymol, V25, P121, DOI 10.1016/S0076-6879(72)25010-8; HAAS AL, 1988, UBIQUITIN, P173; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HELLER H, 1990, J BIOL CHEM, V265, P6532; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P1619, DOI 10.1073/pnas.81.6.1619; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; JEN G, 1982, J VIROL, V43, P250, DOI 10.1128/JVI.43.1.250-261.1982; JIA XY, 1991, J VIROL, V65, P2595, DOI 10.1128/JVI.65.5.2595-2600.1991; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON TG, 1989, J VIROL, V63, P5013, DOI 10.1128/JVI.63.12.5013-5022.1989; OBERST MD, 1993, VIROLOGY, V193, P28, DOI 10.1006/viro.1993.1100; PALMENBERG AC, 1990, ANNU REV MICROBIOL, V44, P603, DOI 10.1146/annurev.mi.44.100190.003131; PALMENBERG AC, 1984, NUCLEIC ACIDS RES, V12, P2969, DOI 10.1093/nar/12.6.2969; PALMENBERG AC, 1979, J VIROL, V32, P770, DOI 10.1128/JVI.32.3.770-778.1979; PARKS GD, 1987, J VIROL, V61, P3680, DOI 10.1128/JVI.61.12.3680-3687.1987; PARKS GD, 1986, J VIROL, V60, P376, DOI 10.1128/JVI.60.2.376-384.1986; PARKS GD, 1989, J VIROL, V60, P1054; RAMABHADRAN TV, 1981, J VIROL, V39, P573, DOI 10.1128/JVI.39.2.573-583.1981; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; REISS Y, 1988, J BIOL CHEM, V263, P2693; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SHANKLIN J, 1987, P NATL ACAD SCI USA, V84, P359, DOI 10.1073/pnas.84.2.359; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMAS AAM, 1983, J VIROL, V48, P309, DOI 10.1128/JVI.48.1.309-313.1983	46	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28429	28435						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961784				2022-12-27	WOS:A1994PV77200096
J	PETERS, JW; FISHER, K; DEAN, DR				PETERS, JW; FISHER, K; DEAN, DR			IDENTIFICATION OF A NITROGENASE PROTEIN-PROTEIN INTERACTION SITE DEFINED BY RESIDUES 59 THROUGH 67 WITHIN THE AZOTOBACTER-VINELANDII FE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLEBSIELLA-PNEUMONIAE NITROGENASE; STRUCTURAL GENE-CLUSTER; AMINO-ACID-SEQUENCE; IRON-PROTEIN; ELECTRON-TRANSFER; SUBSTRATE REDUCTION; COMPONENT PROTEINS; CROSS-LINKING; COMPLEX; DINITROGENASE	During nitrogenase catalysis the Fe protein and the MoFe protein associate and dissociate in a MgATP-dependent process involving electron transfer from the Fe protein to the MoFe protein. A docking model, based primarily on the crystal structures of the separate components from Azotobacter vinelandii, was previously proposed in which the g-fold symmetric surface of the homodimeric Fe protein interacts with the exposed surface of a MoFe protein pseudosymmetric alpha beta-unit interface. In this model, a loop, which is included within residues 59 through 67 of the Fe protein primary sequence, is likely to interact with the MoFe protein during component protein docking. In the present study, evidence supporting the component protein docking model was obtained by construction of an A. vinelandii strain that produces a hybrid Fe protein for which residues 59 through 67 have been replaced by the corresponding residues from the Fe protein of Clostridium pasteurianum. Biochemical analyses of the hybrid Fe protein revealed the following features when compared with the unaltered Fe protein. First, the hybrid Fe protein exhibited half the maximum specific activity of the normal Fe protein and was insensitive to inhibition by low levels of NaCl. Second, the hybrid Fe protein activity was hypersensitive to a molar excess of MoFe protein, which also resulted in the uncoupling of MgATP hydrolysis from substrate reduction. Third, stopped-now spectrophotometry experiments showed that during catalysis the hybrid Fe protein dissociates from the MoFe protein at only half the normal rate of Fe protein-MoFe protein dissociation. Thus, the salient feature of the hybrid Fe protein is that it appears to form a relatively tighter complex with the MoFe protein. This property is in line with previous biochemical reconstitution experiments where it was shown that a heterologous mixture of Fe protein hom C. pasteurianum and MoFe protein from A. vinelandii form a tight, inactive complex and supports the proposal that a region defined by residues 59 through 67 within the Fe protein is involved in component protein interaction.	VIRGINIA POLYTECH INST & STATE UNIV, DEPT BIOCHEM & ANAEROB MICROBIOL, BLACKSBURG, VA 24061 USA	Virginia Polytechnic Institute & State University			Fisher, Karl/A-5956-2013	Fisher, Karl/0000-0003-3539-8939; Peters, John/0000-0001-9117-9568	NIDDK NIH HHS [DK37255] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037255] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRIGLE KE, 1985, GENE, V37, P37, DOI 10.1016/0378-1119(85)90255-0; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; Dean D.R., 1992, BIOL NITROGEN FIXATI, P763; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; DEITS TL, 1990, J BIOL CHEM, V265, P3859; DILWORTH MJ, 1992, ANAL BIOCHEM, V207, P6, DOI 10.1016/0003-2697(92)90491-O; EADY RR, 1972, BIOCHEM J, V128, P655, DOI 10.1042/bj1280655; EMERICH DW, 1976, P NATL ACAD SCI USA, V73, P4369, DOI 10.1073/pnas.73.12.4369; EMERICH DW, 1978, BIOCHIM BIOPHYS ACTA, V527, P359, DOI 10.1016/0005-2744(78)90350-9; ENNOR AH, 1957, METHOD ENZYMOL, V3, P850, DOI 10.1016/S0076-6879(57)03460-6; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HAGEMAN RV, 1978, BIOCHEMISTRY-US, V17, P4117, DOI 10.1021/bi00613a002; HAGEMAN RV, 1980, BIOCHIM BIOPHYS ACTA, V591, P63, DOI 10.1016/0005-2728(80)90220-0; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; HAUSINGER RP, 1983, J BIOL CHEM, V258, P3486; HAUSINGER RP, 1982, J BIOL CHEM, V257, P2483; HOWARD JB, 1989, J BIOL CHEM, V264, P11270; HOWARD JB, 1993, ACS SYM SER, V535, P271; JACOBSON MR, 1990, J BIOL CHEM, V265, P19429; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; JENG DY, 1970, J BIOL CHEM, V245, P2809; KIM J, 1994, BIOCHEMISTRY-US, V33, P389, DOI 10.1021/bi00168a001; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; KLUGKIST J, 1986, EUR J BIOCHEM, V155, P33, DOI 10.1111/j.1432-1033.1986.tb09455.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LJONES T, 1972, BIOCHIM BIOPHYS ACTA, V283, P339; LOWE DJ, 1990, BIOCHEM J, V272, P621, DOI 10.1042/bj2720621; LOWERY RG, 1989, BIOCHEMISTRY-US, V28, P1206, DOI 10.1021/bi00429a038; LOWRY OH, 1951, J BIOL CHEM, V193, P265; ORMEJOHNSON WH, 1976, IRON SULFUR PROTEINS, P15; PAGE WJ, 1979, J BACTERIOL, V139, P1058, DOI 10.1128/JB.139.3.1058-1061.1979; ROBINSON AC, 1986, J BACTERIOL, V166, P180, DOI 10.1128/jb.166.1.180-186.1986; ROBSON RL, 1984, FEBS LETT, V173, P394, DOI 10.1016/0014-5793(84)80812-1; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; SHAH VK, 1972, BIOCHIM BIOPHYS ACTA, V256, P498, DOI 10.1016/0005-2728(72)90078-3; STRANDBERG GW, 1968, CAN J MICROBIOL, V14, P25, DOI 10.1139/m68-005; THORNELEY RNF, 1984, BIOCHEM J, V224, P903, DOI 10.1042/bj2240903; THORNELEY RNF, 1988, BIOCHEM J, V253, P587, DOI 10.1042/bj2530587; THORNELEY RNF, 1983, BIOCHEM J, V215, P393, DOI 10.1042/bj2150393; THORNELEY RNF, 1975, BIOCHEM J, V145, P391, DOI 10.1042/bj1450391; THORNELEY RNF, 1991, BIOCHEM J, V277, P735, DOI 10.1042/bj2770735; THORNELEY RNF, 1985, MOLYBDENUM ENZYMES, P222; WHERLAND S, 1981, BIOCHEMISTRY-US, V20, P5132, DOI 10.1021/bi00521a006; WILLING A, 1990, J BIOL CHEM, V265, P6596; WILLING AH, 1989, J BIOL CHEM, V264, P8499; WOLLE D, 1992, J BIOL CHEM, V267, P3667; WOLLE D, 1992, SCIENCE, V258, P992, DOI 10.1126/science.1359643	48	39	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28076	28083						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961744				2022-12-27	WOS:A1994PV77200048
J	REISER, J; MUHEIM, A; HARDEGGER, M; FRANK, G; FIECHTER, A				REISER, J; MUHEIM, A; HARDEGGER, M; FRANK, G; FIECHTER, A			ARYL-ALCOHOL DEHYDROGENASE FROM THE WHITE-ROT FUNGUS PHANEROCHAETE-CHRYSOSPORIUM - GENE CLONING, SEQUENCE-ANALYSIS, EXPRESSION, AND PURIFICATION OF THE RECOMBINANT ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGNIN PEROXIDASE GENES; ESCHERICHIA-COLI; ANTIBODY PROBES; NUCLEOTIDE-SEQUENCES; GEL-ELECTROPHORESIS; CHROMOSOME-III; TAC PROMOTER; DNA-SEQUENCE; ORGANIZATION; DEGRADATION	A cDNA clone encoding a ligninolytic aryl-alcohol dehydrogenase (AAD; EC 1.1.1.91) from the white-rot basidiomycete fungus Phanerochaete chrysosporium was isolated and characterized. The nucleotide sequence obtained reveals an open reading frame encoding a protein of 385 amino acids. Substantial homology (49.3% identity and 67.3% similarity, respectively) was observed between AAD and an open reading frame sequence present on chromosome III of Saccharomyces cerevisiae. A Southern blot analysis showed the presence of multiple AAD gene-related sequences in P. chrysosporium and in other white-rot fungi including Bjerkandera adusta and Fomes lignosus. Northern blot analyses are in line with the view that the levels and appearance of AAD mRNA correlate with the level and appearance of AAD activity and that, under conditions of nitrogen limitation, the AAD mRNA levels are higher than in carbon limited cultures. This is consistent with the regulation of the enzyme by carbon or nitrogen Limitation being at the level of transcription. Moreover, the appearance of AAD-specific transcripts correlates with the appearance of lignin peroxidase-specific transcripts in the same cultures. This co-appearance is in line with the proposed synergistic interaction of the two enzymes in lignin biodegradation, which suggests a similar regulation. The AAD encoding cDNA was expressed in Escherichia coli to yield high levels of active enzyme, and the recombinant enzyme was purifed by using metal chelate affinity chromatography.	ETH ZURICH, INST BIOTECHNOL, CH-8093 ZURICH, SWITZERLAND; ETH ZURICH, INST MOLEK BIOL & BIOPHYS, CH-8093 ZURICH, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich								ALIC M, 1985, APPL ENVIRON MICROB, V50, P27, DOI 10.1128/AEM.50.1.27-30.1985; AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; ANDRAWIS A, 1989, BIOCHEM BIOPH RES CO, V162, P673, DOI 10.1016/0006-291X(89)92363-2; Battey, 1986, BASIC METHODS MOL BI; BOWDEN GA, 1990, J BIOL CHEM, V265, P16760; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CHUNG CT, 1988, NUCLEIC ACIDS RES, V16, P3580, DOI 10.1093/nar/16.8.3580; CONSTAM D, 1991, J GEN MICROBIOL, V137, P2209, DOI 10.1099/00221287-137-9-2209; COVERT SF, 1992, APPL ENVIRON MICROB, V58, P2168, DOI 10.1128/AEM.58.7.2168-2175.1992; DEBOER HA, 1987, GENE, V60, P93, DOI 10.1016/0378-1119(87)90217-4; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FARMER VC, 1959, BIOCHIM BIOPHYS ACTA, V35, P202, DOI 10.1016/0006-3002(59)90349-X; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FIECHTER A, 1993, J BIOTECHNOL, V30, P49, DOI 10.1016/0168-1656(93)90026-J; FRANK G, 1993, METHODS IN PROTEIN SEQUENCE ANALYSIS, P79; FRANK G, 1989, METHODS PROTEIN SEQU, P116; FRISCHAUF AM, 1980, NUCLEIC ACIDS RES, V8, P5541, DOI 10.1093/nar/8.23.5541; GASKELL J, 1991, NUCLEIC ACIDS RES, V19, P599, DOI 10.1093/nar/19.3.599; GLENN JK, 1983, BIOCHEM BIOPH RES CO, V114, P1077, DOI 10.1016/0006-291X(83)90672-1; GOLD MH, 1979, ARCH MICROBIOL, V121, P37, DOI 10.1007/BF00409203; Gurr SJ, 1987, GENE STRUCTURE EUKAR, P93; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HUOPONEN K, 1990, GENE, V89, P145, DOI 10.1016/0378-1119(90)90218-G; KIRK TK, 1987, ANNU REV MICROBIOL, V41, P465, DOI 10.1146/annurev.mi.41.100187.002341; KIRK TK, 1978, ARCH MICROBIOL, V117, P277, DOI 10.1007/BF00738547; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEGENDRE N, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P49; LEISOLA MSA, 1988, CELL CHEM TECHNOL, V22, P267; LOENEN WAM, 1980, GENE, V10, P249, DOI 10.1016/0378-1119(80)90054-2; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MUHEIM A, 1991, EUR J BIOCHEM, V195, P369, DOI 10.1111/j.1432-1033.1991.tb15715.x; MUHEIM A, 1991, THESIS SWISS FEDERAL; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; NIELSON K, 1993, STRATEGIES MOL BIOL, V6, P29; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; Pease E. A., 1991, BIOCATALYSTS IND, P115; PEASE EA, 1989, J BIOL CHEM, V264, P13531; PRIBNOW D, 1989, J BIOL CHEM, V264, P5036; RAEDER U, 1989, MOL MICROBIOL, V3, P911, DOI 10.1111/j.1365-2958.1989.tb00240.x; RAEDER U, 1988, METHOD ENZYMOL, V161, P211; REISER J, 1983, METHOD ENZYMOL, V96, P205; REISER J, 1993, APPL ENVIRON MICROB, V59, P2897, DOI 10.1128/AEM.59.9.2897-2903.1993; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOEMAKER HE, 1989, ACS SYM SER, V399, P454; SNYDER M, 1987, METHOD ENZYMOL, V154, P107; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TANAKA S, 1993, NUCLEIC ACIDS RES, V21, P1149, DOI 10.1093/nar/21.5.1149; TEERI TT, 1987, ANAL BIOCHEM, V164, P60, DOI 10.1016/0003-2697(87)90367-8; TIEN M, 1983, SCIENCE, V221, P661, DOI 10.1126/science.221.4611.661; VANDERZAAL EJ, 1987, PLANT MOL BIOL, V10, P145, DOI 10.1007/BF00016152; VANDYKE MW, 1992, GENE, V111, P99, DOI 10.1016/0378-1119(92)90608-R; WALDNER R, 1988, APPL MICROBIOL BIOT, V29, P400, DOI 10.1007/BF00265826; WALTHER I, 1988, GENE, V70, P127, DOI 10.1016/0378-1119(88)90111-4; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; ZENK M. H., 1965, Z PFLAN ZENPHYSIOL Z BOT, V53, P356; [No title captured]	64	29	30	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28152	28159						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961751				2022-12-27	WOS:A1994PV77200058
J	WALKER, KW; GILBERT, HF				WALKER, KW; GILBERT, HF			EFFECT OF REDOX ENVIRONMENT ON THE IN-VITRO AND IN-VIVO FOLDING OF RTEM-1 BETA-LACTAMASE AND ESCHERICHIA COLI ALKALINE-PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DISULFIDE-ISOMERASE; BOND FORMATION INVIVO; ENDOPLASMIC-RETICULUM; COLI; CATALYSIS; INVITRO; DSBA; IDENTIFICATION; TEMPERATURE; MUTATIONS	The oxidative folding mechanisms of two Escherichia coli periplasmic proteins, alkaline phosphatase and RTEM-1 beta-lactamase, have been examined in vitro and in vivo. In contrast to eukaryotic proteins, which require a relatively reducing environment for optimal folding rates, both alkaline phosphatase and beta-lactamase fold fastest under very oxidizing conditions. For example, bovine pancreatic ribonuclease exhibits an optimal folding rate in a redox buffer consisting of 1 mM GSH and 0.2 mM GSSG (Lyles, M. M., and Gilbert, H. F (1991) Biochemistry 30, 613-619); however, both E. coli alkaline phosphatase and beta-lactamase exhibit optimal in vitro folding rates at low concentrations of GSH (< 0.4 mM) and very high concentrations of GSSG (4-8 mM). For both bacterial proteins, GSH inhibits oxidative folding. Under optimal redox conditions, the rate-limiting step for the in vitro oxidative folding of alkaline phosphatase depends on the concentration of the protein, consistent with a mechanism involving rapid oxidation followed by slow dimerization. With beta-lactamase, the oxidative folding mechanism involves a competition between disulfide bond formation and folding of the molecule into a catalytically active conformation that buries the 2 reduced cysteines in the core of the enzyme. The effects of including a thiol reductant in the growth medium on the in vivo folding of alkaline phosphatase and beta-lactamase are similar to the effects observed during in vitro folding of these enzymes. The levels of both oxidized proteins are decreased by GSH in the growth medium. However, addition of a disulfide oxidant to the growth medium does not positively affect the production of either enzyme. These observations are consistent with the idea that the oxidative folding mechanisms of E. coli periplasmic proteins and, by inference, proteins of the eukaryotic endoplasmic reticulum have evolved to accommodate constraints placed on the folding reaction by the folding environment, The consequences of differences between the folding mechanisms in eukaryotic and prokaryotic disulfide containing proteins on the expression of eukaryotic proteins in the bacterial periplasm are discussed.	BAYLOR COLL MED, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA	Baylor College of Medicine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040379] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; AKIYAMA Y, 1993, J BIOL CHEM, V268, P8146; BANEYX F, 1991, J BACTERIOL, V173, P2696, DOI 10.1128/jb.173.8.2696-2703.1991; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BESSEY OA, 1946, J BIOL CHEM, V164, P321; BOWDEN GA, 1990, J BIOL CHEM, V265, P16760; CHALMERS JJ, 1990, APPL ENVIRON MICROB, V56, P104, DOI 10.1128/AEM.56.1.104-111.1990; COLEMAN JE, 1983, ADV ENZYMOL RAMB, V55, P381; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; Georgiou G., 1990, RECOMBINANT DNA TECH, P333; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; Gilbert HF, 1994, MECH PROTEIN FOLDING, P104; GRANA D, 1988, GENETICS, V120, P319; GUZMAN LM, 1992, J BACTERIOL, V174, P7716, DOI 10.1128/JB.174.23.7717-7728.1992; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; HUTH JR, 1993, J BIOL CHEM, V268, P16472; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; IMITIAZ U, 1993, ANTIMICROB AGENTS CH, V37, P2438; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KOSHLAND D, 1980, CELL, V20, P749, DOI 10.1016/0092-8674(80)90321-9; LAMINET AA, 1989, EMBO J, V8, P1469, DOI 10.1002/j.1460-2075.1989.tb03530.x; LANG K, 1988, NATURE, V331, P453, DOI 10.1038/331453a0; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; OLIVER DB, 1987, ESCHERICHIA COLI SAL, P56; PALZKILL T, 1994, MOL MICROBIOL, V12, P217, DOI 10.1111/j.1365-2958.1994.tb01011.x; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; SCHEIN CH, 1988, BIO-TECHNOL, V6, P291, DOI 10.1038/nbt0388-291; SCHLESINGER MJ, 1965, J BIOL CHEM, V240, P4284; SCHULTZ SC, 1987, PROTEINS, V2, P290, DOI 10.1002/prot.340020405; SOWADSKI JM, 1981, J MOL BIOL, V150, P245, DOI 10.1016/0022-2836(81)90451-4; SUTTER KD, 1992, MOL MICROBIOL, V6, P2201; Thatcher DR, 1994, MECH PROTEIN FOLDING, P229; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WUNDERLICH M, 1993, J BIOL CHEM, V268, P24547; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	37	41	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28487	28493						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961790				2022-12-27	WOS:A1994PV77200104
J	BERGERAT, A; GADELLE, D; FORTERRE, P				BERGERAT, A; GADELLE, D; FORTERRE, P			PURIFICATION OF A DNA TOPOISOMERASE-II FROM THE HYPERTHERMOPHILIC ARCHAEON SULFOLOBUS-SHIBATAE - A THERMOSTABLE ENZYME WITH BOTH BACTERIAL AND EUCARYAL FEATURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HALOPHILIC ARCHAEBACTERIA; REVERSE GYRASE; DROSOPHILA-MELANOGASTER; ANTITUMOR DRUGS; CALF THYMUS; ACIDOCALDARIUS; COMPONENT; HOMOLOGY; CLEAVAGE	A type II DNA topoisomerase has been purified to homogeneity from the hyperthermophilic archaeon Sulfolobus shibatae. The enzyme is composed of two subunits of 60 and 47 kDa. It has a Stokes radius of 69 Angstrom and has a sedimentation coefficient of 7.8 S which gives a calculated native molecular mass of approximately 230 kDa, indicating a heterotetrameric structure. This enzyme is ATP and Mg2+ dependent and can relax both negatively and positively supercoiled DNA, but presents no supercoiling activity. The S. shibatae DNA topoisomerase II is more efficient in decatenation than in relaxation. The optimal temperature for the enzymatic activity is similar to 80 degrees C. This archaeal enzyme is not inhibited by the gyrase inhibitor novobiocin but is sensitive to several inhibitors of eucaryotic DNA topoisomerases of type II such as amsacrines, ellipticine, and the quinolone CP-115,953. Like all prokaryotic DNA topoisomerase II, the S. shibatae DNA topoisomerase II is a heterotetramer but the absence of supercoiling activity, the strong decatenase activity, and the pattern of antibiotic sensitivity of the S. shibatae DNA topoisomerase II is reminiscent of eucaryotic enzymes.			BERGERAT, A (corresponding author), UNIV PARIS 11,INST GENET & MICROBIOL,CNRS,URA 1354,BAT 409,F-91405 ORSAY,FRANCE.							BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN PO, 1979, P NATL ACAD SCI USA, V76, P6110, DOI 10.1073/pnas.76.12.6110; CHARBONNIER F, 1992, J BACTERIOL, V174, P6103, DOI 10.1128/JB.174.19.6103-6108.1992; DELATOUR CB, 1990, J BACTERIOL, V172, P6803, DOI 10.1128/jb.172.12.6803-6808.1990; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; ELIE C, 1989, EUR J BIOCHEM, V178, P619, DOI 10.1111/j.1432-1033.1989.tb14490.x; Forterre P, 1992, Biochem Soc Symp, V58, P99; FORTERRE P, 1985, EMBO J, V4, P2123, DOI 10.1002/j.1460-2075.1985.tb03902.x; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; GOTO T, 1982, J BIOL CHEM, V257, P5866; GROGAN DW, 1989, J BACTERIOL, V171, P6710, DOI 10.1128/jb.171.12.6710-6719.1989; HALLIGAN BD, 1985, J BIOL CHEM, V260, P2475; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; HOLMES ML, 1991, J BACTERIOL, V173, P642, DOI 10.1128/jb.173.2.642-648.1991; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO J, 1992, J BIOL CHEM, V267, P25676; KIKUCHI A, 1986, SYST APPL MICROBIOL, V7, P72, DOI 10.1016/S0723-2020(86)80126-6; KIKUCHI A, 1984, NATURE, V309, P677, DOI 10.1038/309677a0; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P5498, DOI 10.1073/pnas.78.9.5498; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LIU LF, 1978, P NATL ACAD SCI USA, V75, P2098, DOI 10.1073/pnas.75.5.2098; LYNN R, 1986, SCIENCE, V233, P647, DOI 10.1126/science.3014661; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; MELENDY T, 1989, J BIOL CHEM, V264, P1870; MILLER KG, 1981, J BIOL CHEM, V256, P9334; NADAL M, 1994, J BIOL CHEM, V269, P5255; PULLEYBLANK D, 1983, MOL BIOL REP, V9, P191, DOI 10.1007/BF00775367; REECE RJ, 1991, CRC CRIT REV BIOCH M, V26, P235; ROBINSON MJ, 1991, J BIOL CHEM, V266, P14585; SCHOMBURG U, 1986, EUR J BIOCHEM, V160, P451, DOI 10.1111/j.1432-1033.1986.tb10061.x; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SIOUD M, 1988, NUCLEIC ACIDS RES, V16, P1379, DOI 10.1093/nar/16.4.1379; SIOUD M, 1987, EUR J BIOCHEM, V169, P231, DOI 10.1111/j.1432-1033.1987.tb13602.x; SLESAREV AI, 1993, NATURE, V364, P735, DOI 10.1038/364735a0; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WANG JC, 1987, BIOCHIM BIOPHYS ACTA, V909, P1, DOI 10.1016/0167-4781(87)90040-6; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WHEELIS ML, 1992, P NATL ACAD SCI USA, V89, P2930, DOI 10.1073/pnas.89.7.2930; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6	47	88	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27663	27669						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961685				2022-12-27	WOS:A1994PV77100079
J	BRONSON, SK; SMITHIES, O				BRONSON, SK; SMITHIES, O			ALTERING MICE BY HOMOLOGOUS RECOMBINATION USING EMBRYONIC STEM-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GERM-LINE TRANSMISSION; N-MYC GENE; CYSTIC-FIBROSIS; MOUSE EMBRYOS; PLURIPOTENTIAL CELLS; SWITCH RECOMBINATION; TARGETED DISRUPTION; TRANSGENIC MICE; LOCUS; MUTATION				BRONSON, SK (corresponding author), UNIV N CAROLINA, DEPT PATHOL, CHAPEL HILL, NC 27599 USA.			Bronson, Sarah/0000-0002-5456-953X	NHLBI NIH HHS [HL37001, HL49277] Funding Source: Medline; NIGMS NIH HHS [GM20069] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049277, R01HL037001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020069, R37GM020069] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKEW GR, 1993, MOL CELL BIOL, V13, P4115, DOI 10.1128/MCB.13.7.4115; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; BRAUN RE, 1990, BIOL REPROD, V43, P684, DOI 10.1095/biolreprod43.4.684; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; COLLEDGE WH, 1992, LANCET, V340, P680, DOI 10.1016/0140-6736(92)92223-3; DETLOFF PJ, 1994, MOL CELL BIOL, V14, P6936, DOI 10.1128/MCB.14.10.6936; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DORIN JR, 1992, NATURE, V359, P211, DOI 10.1038/359211a0; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FIERING S, 1993, P NATL ACAD SCI USA, V90, P8469, DOI 10.1073/pnas.90.18.8469; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; HERMISTON ML, 1993, P NATL ACAD SCI USA, V90, P8866, DOI 10.1073/pnas.90.19.8866; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; KIM HS, 1988, NUCLEIC ACIDS RES, V16, P8887, DOI 10.1093/nar/16.18.8887; KOLLER BH, 1992, ANNU REV IMMUNOL, V10, P705, DOI 10.1146/annurev.iy.10.040192.003421; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8927, DOI 10.1073/pnas.86.22.8927; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; MANSOUR SL, 1990, P NATL ACAD SCI USA, V87, P7688, DOI 10.1073/pnas.87.19.7688; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MOENS CB, 1993, DEVELOPMENT, V119, P485; MOENS CB, 1992, GENE DEV, V6, P691, DOI 10.1101/gad.6.5.691; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MORTENSEN RM, 1993, HYPERTENSION, V22, P646, DOI 10.1161/01.HYP.22.4.646; MORTENSEN RM, 1991, P NATL ACAD SCI USA, V88, P7036, DOI 10.1073/pnas.88.16.7036; ONEAL WK, 1993, HUM MOL GENET, V2, P1561, DOI 10.1093/hmg/2.10.1561; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; REID LH, 1991, MOL CELL BIOL, V11, P2769, DOI 10.1128/MCB.11.5.2769; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSSANT J, 1993, PHILOS T R SOC B, V339, P207, DOI 10.1098/rstb.1993.0018; RUBINSTEIN M, 1993, NUCLEIC ACIDS RES, V21, P2613, DOI 10.1093/nar/21.11.2613; SAWAI S, 1993, DEVELOPMENT, V117, P1445; SHESELY EG, 1991, P NATL ACAD SCI USA, V88, P4294, DOI 10.1073/pnas.88.10.4294; SMITHIES O, 1993, TRENDS GENET, V9, P112, DOI 10.1016/0168-9525(93)90204-U; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; SMITHIES O, 1994, P NATL ACAD SCI USA, V91, P3612, DOI 10.1073/pnas.91.9.3612; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; STACEY A, 1994, MOL CELL BIOL, V14, P1009, DOI 10.1128/MCB.14.2.1009; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; TARLETON RL, 1992, NATURE, V356, P338, DOI 10.1038/356338a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; VALANCIUS V, 1991, MOL CELL BIOL, V11, P1402, DOI 10.1128/MCB.11.3.1402; VALANCIUS V, 1991, MOL CELL BIOL, V11, P4389, DOI 10.1128/MCB.11.9.4389; WALDMAN AS, 1992, CRIT REV ONCOL HEMAT, V12, P49, DOI 10.1016/1040-8428(92)90064-W; WU H, 1994, P NATL ACAD SCI USA, V91, P2819, DOI 10.1073/pnas.91.7.2819	55	152	162	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27155	27158						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961620				2022-12-27	WOS:A1994PV77100001
J	JENKINS, CM; WATERMAN, MR				JENKINS, CM; WATERMAN, MR			FLAVODOXIN AND NADPH-FLAVODOXIN REDUCTASE FROM ESCHERICHIA-COLI SUPPORT BOVINE CYTOCHROME P450C17 HYDROXYLASE-ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-450 REDUCTASE; SACCHAROMYCES-CEREVISIAE; NADPH-CYTOCHROME-P-450 REDUCTASE; ELECTROSTATIC INTERACTIONS; HEME OXYGENASE; EXPRESSION; SYSTEM; CDNA; ACTIVATION; MECHANISM	Two soluble flavoproteins, purified from Escherichia coli cytosol and identified as flavodoxin and NADPH flavodoxin (ferredoxin) reductase (flavodoxin reductase), have been found in combination to support the 17 alpha-hydroxylase activities of heterologously expressed bovine 17 alpha-hydroxylase cytochrome P450 (P450c17). Physical characteristics of the two flavoproteins including absorbance spectra, molecular weights, and amino terminal sequences are identical with those reported previously for E. coli flavodoxin and flavodoxin reductase. Flavodoxin reductase, possessing FAD as a cofactor, is able to reconstitute P450c17 activities only in the presence of flavodoxin, an FMN containing protein, and NAD(P)H. Reducing equivalents are utilized more effectively from NADPH than NADH by flavodoxin reductase. E. coli flavodoxin binds P450c17 directly and with relatively high affinity (apparent K-s similar to 0.2 mu M) at low ionic strength, as evidenced by a change in spin state of the P450c17 heme iron upon titration with flavodoxin. This apparent spin shift is attenuated at moderate ionic strengths (100-200 mM KCl). In addition, bovine P450c17 binds reversibly to flavodoxin Sepharose in an ionic strength dependent manner. These data implicate charge pairing as being important for the interaction between flavodoxin and P450c17. We propose that the amino acid sequence similarity between E. coli flavodoxin-flavodoxin reductase and the putative FMN, FAD, and NAD(P)H binding regions of cytochrome P450 reductase provides the basis for the reconstitution of P450c17 activities by this bacterial system.			JENKINS, CM (corresponding author), VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,626 MRB,NASHVILLE,TN 37232, USA.				NIEHS NIH HHS [ES00267, ES07028] Funding Source: Medline; NIGMS NIH HHS [GM37942] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267, T32ES007028] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037942, R37GM037942] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASSEFFA A, 1989, ARCH BIOCHEM BIOPHYS, V274, P481, DOI 10.1016/0003-9861(89)90461-X; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; BIANCHI V, 1993, J BACTERIOL, V175, P1590, DOI 10.1128/JB.175.6.1590-1595.1993; BLASCHKOWSKI HP, 1982, EUR J BIOCHEM, V123, P563; BRIAN WR, 1989, BIOCHEMISTRY-US, V28, P4993, DOI 10.1021/bi00438a014; COON MJ, 1973, DRUG METAB DISPOS, V1, P92; ELIASSON R, 1992, J BIOL CHEM, V267, P25541; ENOCH HG, 1979, J BIOL CHEM, V254, P8976; ESTABROOK RW, 1988, OXIDASES RELATED RED, P525; FEVOLD HR, 1989, MOL ENDOCRINOL, V3, P968, DOI 10.1210/mend-3-6-968; FRENCH JS, 1980, J BIOL CHEM, V255, P4112; FRENCH JS, 1980, MICROSOMES DRUG OXID, P387; FUJII K, 1974, J BIOL CHEM, V249, P6745; HANUKOGLU I, 1981, J BIOL CHEM, V256, P4321, DOI 10.1016/S0021-9258(19)69436-6; HIGASHI Y, 1988, P NATL ACAD SCI USA, V85, P7486, DOI 10.1073/pnas.85.20.7486; ILAN Z, 1981, J BIOL CHEM, V256, P66; IMAI T, 1993, J BIOL CHEM, V268, P19681; ISHIKAWA K, 1991, EUR J BIOCHEM, V202, P161, DOI 10.1111/j.1432-1033.1991.tb16357.x; IYANAGI T, 1981, BIOCHEMISTRY-US, V20, P1722, DOI 10.1021/bi00510a004; IYANAGI T, 1973, BIOCHEMISTRY-US, V12, P2297, DOI 10.1021/bi00736a018; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON JR, 1991, J BIOL CHEM, V266, P7321; LI YC, 1991, J BIOL CHEM, V266, P19186; LU AYH, 1969, J BIOL CHEM, V244, P3714; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Masters B, 1967, METHOD ENZYMOL, V10, P565; NADLER SG, 1988, ARCH BIOCHEM BIOPHYS, V261, P418, DOI 10.1016/0003-9861(88)90358-X; NADLER SG, 1991, ARCH BIOCHEM BIOPHYS, V290, P277, DOI 10.1016/0003-9861(91)90542-Q; NARHI LO, 1986, J BIOL CHEM, V261, P7160; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NISIMOTO Y, 1986, J BIOL CHEM, V261, P14232; OEDA K, 1985, DNA-J MOLEC CELL BIO, V4, P203, DOI 10.1089/dna.1985.4.203; OHTA D, 1991, BIOCHEM BIOPH RES CO, V175, P394, DOI 10.1016/0006-291X(91)91577-Y; OMURA T, 1964, J BIOL CHEM, V239, P2370; OSBORNE C, 1991, J BACTERIOL, V173, P1729, DOI 10.1128/jb.173.5.1729-1737.1991; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; RENAUD JP, 1990, EUR J BIOCHEM, V194, P889, DOI 10.1111/j.1432-1033.1990.tb19483.x; RENAUD JP, 1993, TOXICOLOGY, V82, P39, DOI 10.1016/0300-483X(93)90058-Z; SAKAKI T, 1989, DNA-J MOLEC CELL BIO, V8, P409, DOI 10.1089/dna.1.1989.8.409; SERIZAWA N, 1991, BIOCHIM BIOPHYS ACTA, V1084, P35, DOI 10.1016/0005-2760(91)90052-J; SUZUKI T, 1992, BIOCHEM INT, V28, P887; TAMBURINI PP, 1986, MOL PHARMACOL, V30, P178; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; VERMILION JL, 1978, J BIOL CHEM, V253, P2694; VERMILION JL, 1981, J BIOL CHEM, V256, P266; VERMILION JL, 1978, J BIOL CHEM, V253, P8812; VETTER H, 1971, H-S Z PHYSIOL CHEM, V352, P433, DOI 10.1515/bchm2.1971.352.1.433; WEBER PC, 1985, J BIOL CHEM, V260, P5568; ZUBER MX, 1986, SCIENCE, V234, P1258, DOI 10.1126/science.3535074; 1991, PRIMARY STRUCTURE PI	51	150	154	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27401	27408						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961651				2022-12-27	WOS:A1994PV77100041
J	MINEGISHI, N; MINEGISHI, M; TSUCHIYA, S; FUJIE, H; NAGAI, T; HAYASHI, N; YAMAMOTO, M; KONNO, T				MINEGISHI, N; MINEGISHI, M; TSUCHIYA, S; FUJIE, H; NAGAI, T; HAYASHI, N; YAMAMOTO, M; KONNO, T			ERYTHROPOIETIN-DEPENDENT INDUCTION OF HEMOGLOBIN-SYNTHESIS IN A CYTOKINE-DEPENDENT CELL-LINE M-TAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; ERYTHROID PROGENITOR CELLS; GENE-EXPRESSION; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; RECEPTOR GENE; GM-CSF; DIFFERENTIATION; INTERLEUKIN-3; ESTABLISHMENT	M-TAT is a cytokine-dependent cell line with the potential to differentiate along the erythroid and megakaryocytic lineages. We cultured M-TAT cells long term (>1 year) in the continuous presence of erythropoietin (EPO), granulocyte-macrophage colony-stimulating factor (GM-CSF), or stem cell factor (SCF). These long term cultures are referred to as M-TAT/EPO, M-TAT/GM-CSF, and M-TAT/SCF cells, respectively. Hemoglobin concentration and gamma-globin and erythroid delta-aminolevulinate synthase mRNA levels were significantly higher in M-TAT/EPO cells than in M-TAT/GM-CSF cells. When the supplemented cytokine was switched from GM-CSF to EPO, hemoglobin synthesis in M-TAT/GM-CSF cells increased rapidly (within 5 h), and the level of GATA-1 mRNA increased. In contrast, the addition of GM-CSF to the M-TAT/EPO cell culture decreased the amount of hemoglobin, even in the presence of EPO, indicating that the EPO signal for erythroid differentiation is suppressed by GM-CSF. Thus, erythroid development of M-TAT cells is promoted by EPO and suppressed by GM-CSF. These results support the hypothesis that EPO actively influences the programming of gene expression required for erythroid progenitor cell differentiation.	TOHOKU UNIV,SCH MED,DEPT BIOCHEM,AOBA KU,SENDAI,MIYAGI 980,JAPAN; TOHOKU UNIV,INST DEV AGING & CANC,DEPT PEDIAT ONCOL,SENDAI,MIYAGI,JAPAN	Tohoku University; Tohoku University			Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436				BOYER SH, 1992, BLOOD, V80, P2503; BROUDY VC, 1990, BLOOD, V75, P1622; CHIBA S, 1991, BLOOD, V78, P2261; CHIBA T, 1993, P NATL ACAD SCI USA, V90, P11593, DOI 10.1073/pnas.90.24.11593; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DAMEN JE, 1993, BLOOD, V82, P2296; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; ENDO K, 1993, BRIT J HAEMATOL, V85, P653, DOI 10.1111/j.1365-2141.1993.tb03205.x; ENGEL JD, 1991, SEMIN HEMATOL, V28, P158; ENVER T, 1988, P NATL ACAD SCI USA, V85, P9091, DOI 10.1073/pnas.85.23.9091; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUIMARAES JE, 1984, EXP HEMATOL, V12, P535; HANAZONO Y, 1993, BLOOD, V81, P3193; HARA K, 1988, EXP HEMATOL, V16, P256; HERMINE O, 1992, BLOOD, V80, P3060; KENNEDY M, 1992, BLOOD, V79, P180; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KOMATSU N, 1993, BLOOD, V82, P456; KOMATSU N, 1991, CANCER RES, V51, P341; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; NAGAIT, 1994, BLOOD, V84, P1074; NAKAMURA Y, 1992, SCIENCE, V257, P1138, DOI 10.1126/science.257.5073.1138; ORKIN SH, 1992, BLOOD, V80, P575; SUDA J, 1986, BLOOD, V67, P1002; UMEMURA T, 1989, BLOOD, V73, P1993; WICKREMA A, 1992, BLOOD, V80, P1940, DOI 10.1182/blood.V80.8.1940.1940; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YAMAMOTO M, 1991, J BIOL CHEM, V266, P3317; YAMAMOTO M, 1994, REGULATION HEME PROT, P11; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638; ZON LI, 1992, NUCLEIC ACIDS RES, V20, P1812, DOI 10.1093/nar/20.7.1812; ZON LI, 1990, P NATL ACAD SCI USA, V87, P668, DOI 10.1073/pnas.87.2.668	39	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27700	27704						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961690				2022-12-27	WOS:A1994PV77100084
J	PIKULA, S; HAYDEN, JB; AWASTHI, S; AWASTHI, YC; ZIMNIAK, P				PIKULA, S; HAYDEN, JB; AWASTHI, S; AWASTHI, YC; ZIMNIAK, P			ORGANIC ANION-TRANSPORTING ATPASE OF RAT-LIVER .1. PURIFICATION, PHOTOAFFINITY-LABELING, AND REGULATION BY PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; HEREDITARY-CONJUGATED HYPERBILIRUBINEMIA; BILE CANALICULAR MEMBRANE; GLUTATHIONE S-CONJUGATE; DEPENDENT TRANSPORT; MULTIDRUG-RESISTANCE; MUTANT RATS; HUMAN-ERYTHROCYTES; CYSTIC-FIBROSIS; DUBIN-JOHNSON	An ATP-dependent transport system specific for nonbile acid organic anions such as S-(2,4-dinitrophenyl)glutathione is present in the canalicular plasma membrane of hepatocytes. It has been shown recently that transport of these anions by isolated hepatocytes is modulated by the activity of cellular protein kinase C (Roelofsen, H., Ottenhoff, R., Oude Elferink, R. P., and Jansen, P. L. (1991) Biochem. J. 278, 637-641, 1991). Using a series of affinity chromatography steps, we have purified to apparent homogeneity a 90-kDa glycoprotein which has S-(2,4-dinitrophenyl) glutathione dependent ATPase activity As shown by binding to immobilized S-(2,4-dinitrophenyl)glutathione and by photoaffinity labeling with 8-azido-ATP, the binding sites for organic anions and for ATP of the 90-kDa protein are interdependent, a behavior that is consistent with an ATP-dependent pendent transport function. The ATP binding site has been further characterized using a fluorescent ATP analog. The 90-kDa protein was phosphorylated by protein kinase C, and the V-max (but not the K-m) of the S-(2,4-dinitrophenyl)glutathione-dependent ATPase activity increased at least a-fold upon phosphorylation. On the basis of its enzymatic properties, we propose that the 90-kDa protein is identical with the multispecific organic anion transporter (MOAT) of the hepatic canalicular plasma membrane. The size and oligosaccharide content of the 90-kDa protein indicate that it does not belong to the family of mammalian plasma membrane P-glycoproteins.	UNIV ARKANSAS MED SCI HOSP,DEPT MED,LITTLE ROCK,AR 72205; UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205; VET ADM JOHN MCCLELLAN MEM HOSP,LITTLE ROCK,AR 72205; UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,GALVESTON,TX 77555; UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77555	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston			Awasthi, Sanjay/R-4904-2019	Awasthi, Sanjay/0000-0002-5214-5717; Pikula, Slawomir/0000-0003-4640-3094	NCI NIH HHS [CA-63660] Funding Source: Medline; NIGMS NIH HHS [GM-32304] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA063660] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032304] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKERBOOM TPM, 1991, J BIOL CHEM, V266, P13147; ARIAS IM, 1993, HEPATOLOGY, V17, P318, DOI 10.1002/hep.1840170225; AWASTHI S, 1994, J CLIN INVEST, V93, P958, DOI 10.1172/JCI117102; AWASTHI YC, 1991, BIOCHEM BIOPH RES CO, V175, P1090, DOI 10.1016/0006-291X(91)91677-5; BALLATORI N, 1992, AM J PHYSIOL, V263, pG617, DOI 10.1152/ajpgi.1992.263.5.G617; BOARD P, 1992, HEPATOLOGY, V15, P722, DOI 10.1002/hep.1840150428; BODMER JG, 1992, TISSUE ANTIGENS, V39, P161, DOI 10.1111/j.1399-0039.1992.tb01932.x; BUSCHMAN E, 1992, J BIOL CHEM, V267, P18093; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DEVRIES MH, 1989, N-S ARCH PHARMACOL, V340, P588, DOI 10.1007/BF00260615; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; ELFERINK RPJO, 1993, BIOCHEM J, V290, P759, DOI 10.1042/bj2900759; FERNANDEZCHECA JC, 1992, J BIOL CHEM, V267, P1667; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; HOSOKAWA S, 1992, LAB ANIM SCI, V42, P27; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; INOUE M, 1984, J BIOL CHEM, V259, P4998; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; JANSEN PLM, 1987, HEPATOLOGY, V7, P71, DOI 10.1002/hep.1840070116; JANSEN PLM, 1985, HEPATOLOGY, V5, P573, DOI 10.1002/hep.1840050408; KAST C, 1994, J BIOL CHEM, V269, P5179; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KNOWLES AF, 1984, J BIOL CHEM, V259, P919; KOBAYASHI K, 1988, FEBS LETT, V240, P55, DOI 10.1016/0014-5793(88)80339-9; KOBAYASHI K, 1990, J BIOL CHEM, V265, P7737; KUIPERS F, 1988, J CLIN INVEST, V81, P1593, DOI 10.1172/JCI113493; KUNST M, 1989, BIOCHIM BIOPHYS ACTA, V983, P123, DOI 10.1016/0005-2736(89)90389-1; LABELLE EF, 1986, BIOCHEM J, V238, P443, DOI 10.1042/bj2380443; LABELLE EF, 1988, FEBS LETT, V228, P53, DOI 10.1016/0014-5793(88)80583-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN SH, 1990, ANN NY ACAD SCI, V603, P394; LINDWALL G, 1987, J BIOL CHEM, V262, P5151; Meier Peter J., 1993, P587; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; NICOTERA P, 1985, FEBS LETT, V187, P121, DOI 10.1016/0014-5793(85)81226-6; NISHIDA T, 1992, J CLIN INVEST, V90, P2130, DOI 10.1172/JCI116098; NISHIDA T, 1992, AM J PHYSIOL, V262, pG629, DOI 10.1152/ajpgi.1992.262.4.G629; PIKULA S, 1994, J BIOL CHEM, V269, P27574; ROELOFSEN H, 1991, BIOCHEM J, V278, P637, DOI 10.1042/bj2780637; RUETZ S, 1987, J BIOL CHEM, V262, P11324; SAXENA M, 1992, ARCH BIOCHEM BIOPHYS, V298, P231, DOI 10.1016/0003-9861(92)90117-F; SCHAUB T, 1991, FEBS LETT, V279, P83, DOI 10.1016/0014-5793(91)80256-3; SHARMA R, 1990, BIOCHEM BIOPH RES CO, V171, P155, DOI 10.1016/0006-291X(90)91370-8; SINGHAL SS, 1991, FEBS LETT, V281, P255, DOI 10.1016/0014-5793(91)80405-R; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; SIPPEL CJ, 1994, J BIOL CHEM, V269, P2820; SIPPEL CJ, 1990, AM J PHYSIOL, V258, pG728, DOI 10.1152/ajpgi.1990.258.5.G728; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; THOMAS PJ, 1993, J BIOENERG BIOMEMBR, V25, P11, DOI 10.1007/BF00768063; VINCE R, 1971, J MED CHEM, V14, P402, DOI 10.1021/jm00287a006; ZIMNIAK P, 1992, ARCH BIOCHEM BIOPHYS, V292, P534, DOI 10.1016/0003-9861(92)90027-T; ZIMNIAK P, 1993, HEPATOLOGY, V17, P330, DOI 10.1002/hep.1840170226; ZIMNIAK P, 1993, SEMIN LIVER DIS, V13, P248, DOI 10.1055/s-2007-1007353	59	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27566	27573						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961673				2022-12-27	WOS:A1994PV77100064
J	LOPEZBOADO, YS; TOLIVIA, J; LOPEZOTIN, C				LOPEZBOADO, YS; TOLIVIA, J; LOPEZOTIN, C			APOLIPOPROTEIN-D GENE INDUCTION BY RETINOIC ACID IS CONCOMITANT WITH GROWTH ARREST AND CELL-DIFFERENTIATION IN HUMAN BREAST-CANCER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROSS CYSTIC-DISEASE; MESSENGER-RNA; HUMAN-PLASMA; CHOLESTEROL ACYLTRANSFERASE; INSITU HYBRIDIZATION; TISSUE DISTRIBUTION; PERIPHERAL-NERVE; RESPONSE ELEMENT; FLUID PROTEINS; X-RECEPTOR	We have examined the regulation by retinoic acid of the gene encoding apolipoprotein D (apoD), a human plasma protein belonging to the superfamily of the lipocalins that is produced by a specific subtype of highly differentiated breast carcinomas. Northern blot analysis revealed that all-trans-retinoic acid (RA) strongly induced the accumulation of apoD mRNA in T-47D and ZR-75-1 estrogen receptor-positive human breast cancer cells in a time- and dose-dependent manner, while no inductive effect was observed in estrogen receptor-negative cell lines, including MDA-MB-231 and MDA-MB-435. The effect of RA on apoD expression by T-47D cells was at least 12-fold more potent than the effect of the steroids dihydrotestosterone and dexamethasone, which had been previously described as hormonal up-regulators of apoD expression in these cells. A time course study demonstrated that the induction of apoD mRNA reached a level of 15-fold over the untreated control cells after 48 h of incubation in the presence of a 10(-7) M concentration of RA. A dose-response analysis showed that as little as 10(-13) M RA produced an accumulation of 5-fold over the control, while incubation of the cells in the presence of 10(-5) M RA induced a maximal accumulation of 24-fold over the control untreated cells. The induction of apoD mRNA was independent of the synthesis of proteins de novo, as demonstrated by the fact that the induction was also detected in the presence of cycloheximide. The incubation of the cells in the presence of RA did not affect significantly the stability of apoD mRNA By contrast, treatment of the T-47D cells with RA produced an increase of approximately 8-fold in the rate of transcription of the apoD gene. Furthermore, treatment of the T-47D cells with RA induced the synthesis and secretion to the culture medium of apoD. This increased expression of apoD was accompanied by an inhibition of cell proliferation and a progression through a more differentiated phenotype, suggesting that the mechanisms controlling RA-induced growth arrest, cell differentiation, and apoD synthesis may be directly coordinated in human breast cancer cells.	UNIV OVIEDO, DEPT BIOL FUNC, E-33006 OVIEDO, SPAIN	University of Oviedo			Tolivia, Jorge/A-6950-2008; Tolivia, Jorge/D-2248-2010; Lopez-Otin, Carlos/AAB-2106-2020	Tolivia, Jorge/0000-0001-8984-8849; Lopez-Otin, Carlos/0000-0001-6964-1904				ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; BALBIN M, 1990, BIOCHEM J, V271, P803, DOI 10.1042/bj2710803; BLANCOVACA F, 1992, J LIPID RES, V33, P1785; BOYLES JK, 1990, J LIPID RES, V31, P2243; BOYLES JK, 1990, J BIOL CHEM, V265, P17805; CHAMBON P, 1993, GENE, V135, P223, DOI 10.1016/0378-1119(93)90069-F; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DE LUCA LM, 1991, FASEB J, V5, P2924; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DIEZITZA I, 1994, AM J PATHOL, V144, P310; DILLEY WG, 1990, BREAST CANCER RES TR, V16, P253, DOI 10.1007/BF01806333; DILORENZO D, 1993, BIOCHEM BIOPH RES CO, V192, P1066, DOI 10.1006/bbrc.1993.1525; DRAYNA D, 1986, J BIOL CHEM, V261, P6535; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; FIELDING PE, 1980, P NATL ACAD SCI-BIOL, V77, P3327, DOI 10.1073/pnas.77.6.3327; FONTANA JA, 1987, EXP CELL BIOL, V55, P136; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; GODOVAC-ZIMMERMANN J, 1988, TRENDS BIOCHEM SCI, V13, P64, DOI 10.1016/0968-0004(88)90031-X; HAAGENSEN DE, 1992, BREAST CANCER RES TR, V23, P77, DOI 10.1007/BF01831479; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOLDER MJ, 1993, INT IMMUNOL, V5, P1059, DOI 10.1093/intimm/5.9.1059; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KAVANAUGH WM, 1988, J BIOL CHEM, V263, P8470; KOGA M, 1991, J STEROID BIOCHEM, V39, P455, DOI 10.1016/0960-0760(91)90238-Z; LAMBERT J, 1993, BIOCHIM BIOPHYS ACTA, V1172, P190, DOI 10.1016/0167-4781(93)90292-L; LEA OA, 1987, CANCER RES, V47, P6189; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOPEZBOADO YS, 1994, BREAST CANCER RES TR, V29, P247, DOI 10.1007/BF00666478; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MAZOUJIAN G, 1990, ANN NY ACAD SCI, V586, P188, DOI 10.1111/j.1749-6632.1990.tb17806.x; MCCONATH.WJ, 1973, FEBS LETT, V37, P178, DOI 10.1016/0014-5793(73)80453-3; MILNE RW, 1993, CURR OPIN LIPIDOL, V4, P100, DOI 10.1097/00041433-199304000-00005; PEARLMAN WH, 1973, J BIOL CHEM, V248, P5736; Peitsch M C, 1990, New Biol, V2, P197; PROVOST PR, 1991, FEBS LETT, V290, P139, DOI 10.1016/0014-5793(91)81244-3; PROVOST PR, 1990, J LIPID RES, V31, P2057; PROVOST PR, 1991, J LIPID RES, V32, P1959; ROMAN SD, 1992, CANCER RES, V52, P2236; ROMAN SD, 1993, CANCER RES, V53, P5940; SANCHEZ LM, 1992, CANCER RES, V52, P95; SANCHEZ LM, 1992, CLIN CHEM, V38, P695; SAWYER L, 1987, NATURE, V327, P659, DOI 10.1038/327659a0; SILVA JS, 1982, SURGERY, V92, P443; SIMARD J, 1991, CANCER RES, V51, P4336; SIMARD J, 1992, ENDOCRINOLOGY, V130, P1115, DOI 10.1210/en.130.3.1115; SIMARD J, 1990, ENDOCRINOLOGY, V126, P3223, DOI 10.1210/endo-126-6-3223; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SMITH KM, 1990, J LIPID RES, V31, P995; SPREYER P, 1990, EMBO J, V9, P2479, DOI 10.1002/j.1460-2075.1990.tb07426.x; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TOLIVIA J, 1985, J NEUROSCI METH, V13, P305, DOI 10.1016/0165-0270(85)90078-0; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; WEECH PK, 1991, PROG LIPID RES, V30, P259, DOI 10.1016/0163-7827(91)90023-X; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	58	73	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26871	26878						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929425				2022-12-27	WOS:A1994PQ93100046
J	NOVIKOV, DK; VANHOVE, GF; CARCHON, H; ASSELBERGHS, S; EYSSEN, HJ; VANVELDHOVEN, PP; MANNAERTS, GP				NOVIKOV, DK; VANHOVE, GF; CARCHON, H; ASSELBERGHS, S; EYSSEN, HJ; VANVELDHOVEN, PP; MANNAERTS, GP			PEROXISOMAL BETA-OXIDATION - PURIFICATION OF 4 NOVEL 3-HYDROXYACIL-COA DEHYDROGENASES FROM RAT-LIVER PEROXISOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA OXIDASE; 3-HYDROXYACYL-COA DEHYDROGENASE; 3-KETOACYL-COA THIOLASE; ENOYL-COA; DELTA-3,DELTA-2-ENOYL-COA ISOMERASE; 2-ENOYL-COA HYDRATASE; MOLECULAR-CLONING; ACID; MITOCHONDRIAL; ENZYME	Peroxisomes are capable of beta-oxidizing a variety of substrates including the CoA esters of straight chain fatty acids, 2-methyl-branched fatty acids and the bile acid intermediates di- and trihydroxycoprostanic acids. The first reaction of peroxisomal beta-oxidation is catalyzed by an acyl-CoA oxidase. Rat liver peroxisomes contain three acyl-CoA oxidases: 1) palmitoyl-CoA oxidase, oxidizing straight chain acyl-CoAs; 2) pristanoyl-CoA oxidase, oxidizing 2-methyl-branched acyl-CoAs; and 3) trihydroxycoprostanoyl-CoA oxidase, oxidizing the CoA esters of the bile acid intermediates (Van Veldhoven, P. P., Vanhove, G., Asselberghs, S., Eyssen, H. J., and Mannaerts, G. P. (1992) J. Biol. Chem. 267, 20065-20074). We have now investigated whether the third step of peroxisomal beta-oxidation, catalyzed by a 3-hydroxyacyl-CoA dehydrogenase, is also catalyzed by multiple enzymes, using the 3-hydroxyacyl-CoA derivatives of palmitic acid, 2-methylpalmitic acid, and trihydroxycoprostanic acid as the substrates to monitor the dehydrogenase activities. In order to avoid contamination with mitochondrial 3-hydroxyacyl-CoA dehydrogenases, highly purified peroxisomes from untreated rats were employed as the enzyme source. Subfractionation of the peroxisomes revealed that the major portion of the dehydrogenase activities with all three substrates was present in the peripheral membrane protein fraction. Separation of this fraction on various chromatographic columns resulted in the purification of the well known multifunctional protein, a 78-kDa monomeric protein that displays 3-hydroxyacyl-CoA dehydrogenase plus hydratase activity, as well as of four additional novel dehydrogenases with different substrate specificities. Three of the enzymes are monomeric proteins of 35 kDa, 56 kDa, and 79 kDa, respectively. The latter enzyme also displays hydratase activity. The fourth enzyme is a dimer of 89 kDa, the subunits of which form a doublet at 40 kDa. The exact physiological role of each of the 3-hydroxyacyl-CoA dehydrogenases requires further investigation.	KATHOLIEKE UNIV LEUVEN,DEPT PHARMACOL,B-3000 LOUVAIN,BELGIUM; KATHOLIEKE UNIV LEUVEN,DEPT PEDIAT,B-3000 LOUVAIN,BELGIUM; CATHOLIC UNIV LEUVEN,REGA INST MED RES,B-3000 LOUVAIN,BELGIUM	KU Leuven; KU Leuven; KU Leuven			, Van Veldhoven Paul/U-6359-2019	, Van Veldhoven Paul/0000-0002-4478-2564				ALEXSON SEH, 1985, J CELL BIOL, V101, P294, DOI 10.1083/jcb.101.1.294; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BODNAR AG, 1990, GENE, V91, P193, DOI 10.1016/0378-1119(90)90088-9; BOUT A, 1991, BIOCHIM BIOPHYS ACTA, V1090, P43, DOI 10.1016/0167-4781(91)90035-K; CHEN RF, 1967, J BIOL CHEM, V242, P173; DECLERCQ PE, 1984, J BIOL CHEM, V259, P9064; FURATA S, 1980, J BIOCH, V88, P1059; GUEVARA J, 1982, ELECTROPHORESIS, V3, P197, DOI 10.1002/elps.1150030404; HAN BH, 1982, J ORG CHEM, V47, P5030, DOI 10.1021/jo00146a044; HIJIKATA M, 1990, J BIOL CHEM, V265, P4600; HILTUNEN JK, 1989, J BIOL CHEM, V264, P13536; HORIE S, 1989, ARCH BIOCHEM BIOPHYS, V274, P64, DOI 10.1016/0003-9861(89)90415-3; KAMIJO T, 1993, J BIOL CHEM, V268, P26452; KAWAGUCHI A, 1981, J BIOCHEM-TOKYO, V89, P337, DOI 10.1093/oxfordjournals.jbchem.a133207; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LI JX, 1990, J BIOL CHEM, V265, P13629; MANNAERTS GP, 1993, BIOCHIMIE, V75, P147, DOI 10.1016/0300-9084(93)90072-Z; MIYAZAWA S, 1981, J BIOCHEM, V90, P511, DOI 10.1093/oxfordjournals.jbchem.a133499; OSUMI T, 1980, ARCH BIOCHEM BIOPHYS, V203, P372, DOI 10.1016/0003-9861(80)90189-7; OSUMI T, 1979, BIOCHEM BIOPH RES CO, V89, P580, DOI 10.1016/0006-291X(79)90669-7; OSUMI T, 1985, J BIOL CHEM, V260, P8905; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; PALOSAARI PM, 1991, J BIOL CHEM, V266, P10750; PARMENTIER GG, 1993, STEROIDS, V58, P351, DOI 10.1016/0039-128X(93)90037-N; REDDY MK, 1987, P NATL ACAD SCI USA, V84, P3214, DOI 10.1073/pnas.84.10.3214; SCHEPERS L, 1990, J BIOL CHEM, V265, P5242; Steinman H M, 1975, Methods Enzymol, V35, P136, DOI 10.1016/0076-6879(75)35149-5; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; UNE M, 1992, J BIOCHEM, V112, P576, DOI 10.1093/oxfordjournals.jbchem.a123942; UNE M, 1983, J LIPID RES, V24, P924; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VANHOVE G, 1991, J BIOL CHEM, V266, P24670; VANHOVE GF, 1993, J BIOL CHEM, V268, P10335; VANVELDHOVEN PP, 1994, EUR J BIOCHEM, V222, P795; VANVELDHOVEN PP, 1987, J BIOL CHEM, V262, P4310; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P24676; VANVELDHOVEN PP, 1992, J BIOL CHEM, V267, P20065; VERHEYDEN K, 1992, BIOCHIM BIOPHYS ACTA, V1109, P48, DOI 10.1016/0005-2736(92)90185-O	39	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27125	27135						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929456				2022-12-27	WOS:A1994PQ93100080
J	PESQUERO, JB; LINDSEY, CJ; ZEH, K; PAIVA, ACM; GANTEN, D; BADER, M				PESQUERO, JB; LINDSEY, CJ; ZEH, K; PAIVA, ACM; GANTEN, D; BADER, M			MOLECULAR-STRUCTURE AND EXPRESSION OF RAT BRADYKININ B2 RECEPTOR GENE - EVIDENCE FOR ALTERNATIVE SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHARMACOLOGICAL CHARACTERIZATION; GENOMIC ORGANIZATION; BETA-2-ADRENERGIC RECEPTOR; ANGIOTENSIN RECEPTOR; MAMMALIAN-CELLS; MESSENGER-RNAS; CLONING; SEQUENCE; PROTEIN; LOCALIZATION	Bradykinin is a potent vasodilatory peptide hormone involved in a broad range of physiological actions. While it acts through at least two types of receptors which are named B1 and B2, most of its effects are mediated via activation of the B2 receptor. The gene for this receptor was isolated hom a rat genomic library and shown to span more than 28 kilobases, including four introns. The relative positions of the exons were mapped and all exons, intron-exon boundaries, and 5'- and 3'-flanking regions were sequenced. While the 5'-untranslated region of the mRNA is distributed on all four exons, the coding and the 3'-untranslated region are located entirely on the fourth exon. Characterization of the region upstream to the transcriptional start site detected by primer extension analysis shows that the bradykinin B2 receptor promoter contains no typical TATA or CCAAT boxes. Nevertheless, the promoter sequence was shown to be functional in NG108-15 cells transfected with a construct bearing 1.1 kilobases of 5'-flanking sequence fused to a luciferase reporter gene. Reverse transcription-polymerase chain reaction analysis detected two different bradykinin B2 receptor mRNAs containing or lacking exon 3 in all rat tissues tested, providing evidence for alternative splicing of the 5'-untranslated sequence.	MAX DELBRUCK CTR MOLEC MED,D-13122 BERLIN,GERMANY; ESCOLA PAULISTA MED,DEPT BIOPHYS,BR-04034970 SAO PAULO,BRAZIL	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Universidade Federal de Sao Paulo (UNIFESP)			Bader, Michael/K-2124-2013; Pesquero, Joao/C-1470-2012	Pesquero, Joao/0000-0002-4507-632X; Bader, Michael/0000-0003-4780-4164				ASSONBATRES MA, 1994, P NATL ACAD SCI USA, V91, P1318, DOI 10.1073/pnas.91.4.1318; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BURCH RM, 1992, LIFE SCI, V50, P829, DOI 10.1016/0024-3205(92)90201-Y; CHEN K, 1992, MOL BRAIN RES, V14, P20, DOI 10.1016/0169-328X(92)90005-V; CURNOW KM, 1992, MOL ENDOCRINOL, V6, P1113, DOI 10.1210/me.6.7.1113; DALTON S, 1988, EMBO J, V7, P49, DOI 10.1002/j.1460-2075.1988.tb02782.x; DEUSCHLE U, 1989, P NATL ACAD SCI USA, V86, P5400, DOI 10.1073/pnas.86.14.5400; DEWET JR, 1985, P NATL ACAD SCI USA, V82, P7870; EGGERICKX D, 1992, BIOCHEM BIOPH RES CO, V187, P1306, DOI 10.1016/0006-291X(92)90445-Q; EMORINE LJ, 1987, P NATL ACAD SCI USA, V84, P6995, DOI 10.1073/pnas.84.20.6995; FARHY RD, 1992, BIOCHEM BIOPH RES CO, V182, P283, DOI 10.1016/S0006-291X(05)80142-1; FARMER SG, 1992, ANNU REV PHARMACOL, V32, P511; FERES T, 1992, BRIT J PHARMACOL, V107, P991, DOI 10.1111/j.1476-5381.1992.tb13396.x; FIOR DR, 1993, AM J PHYSIOL, V265, pH1000, DOI 10.1152/ajpheart.1993.265.3.H1000; GERARD C, 1992, J IMMUNOL, V149, P2600; GERARD NP, 1990, J BIOL CHEM, V265, P20455; GOHLKE P, 1994, HYPERTENSION, V23, P411, DOI 10.1161/01.HYP.23.4.411; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARTMAN JC, 1993, J CARDIOVASC PHARM, V21, P996, DOI 10.1097/00005344-199306000-00022; HERSHEY AD, 1991, J BIOL CHEM, V266, P4366; HERZOG H, 1993, J BIOL CHEM, V268, P6703; HESS JF, 1994, MOL PHARMACOL, V45, P1; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; HINNEBUSCH AG, 1990, TRENDS BIOCHEM SCI, V15, P148, DOI 10.1016/0968-0004(90)90215-W; HIRSCH MR, 1991, FEBS LETT, V287, P197, DOI 10.1016/0014-5793(91)80050-D; HOSODA K, 1992, J BIOL CHEM, V267, P18797; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KLEE WA, 1974, P NATL ACAD SCI USA, V71, P3474, DOI 10.1073/pnas.71.9.3474; KOBILKA BK, 1987, J BIOL CHEM, V262, P7321; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANGFORD K, 1992, BIOCHEM BIOPH RES CO, V183, P1025, DOI 10.1016/S0006-291X(05)80293-1; LINDSEY CJ, 1989, BRIT J PHARMACOL, V97, P763, DOI 10.1111/j.1476-5381.1989.tb12014.x; LINZ W, 1993, J HYPERTENS, V11, pS96; MADEDDU P, 1994, HYPERTENSION, V23, pI189, DOI 10.1161/01.HYP.23.1_Suppl.I189; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MCINTYRE P, 1993, MOL PHARMACOL, V44, P346; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MINOWA MT, 1992, P NATL ACAD SCI USA, V89, P3045, DOI 10.1073/pnas.89.7.3045; MIZUNO T, 1992, BIOCHEM J, V287, P305, DOI 10.1042/bj2870305; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURPHY PM, 1993, GENE, V133, P285, DOI 10.1016/0378-1119(93)90653-K; NAKAJIMA M, 1993, BIOCHEM BIOPH RES CO, V197, P393, DOI 10.1006/bbrc.1993.2492; NUSING RM, 1993, J BIOL CHEM, V268, P25253; OMALLEY KL, 1990, BIOCHEMISTRY-US, V29, P1367, DOI 10.1021/bi00458a003; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; POWELL SJ, 1993, GENOMICS, V15, P435, DOI 10.1006/geno.1993.1084; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RAMARAO CS, 1992, J BIOL CHEM, V267, P21936; REGOLI D, 1980, PHARMACOL REV, V32, P1; REISER G, 1982, BRAIN RES, V239, P191, DOI 10.1016/0006-8993(82)90841-1; REN HZ, 1994, J BIOL CHEM, V269, P3104; RHALEB NE, 1992, EUR J PHARMACOL, V210, P115, DOI 10.1016/0014-2999(92)90661-M; Roberts R A, 1989, Prog Growth Factor Res, V1, P237, DOI 10.1016/0955-2235(89)90013-6; ROSCIGNO RF, 1993, J BIOL CHEM, V268, P11222; RUPP RAW, 1987, NUCLEIC ACIDS RES, V15, P9707, DOI 10.1093/nar/15.23.9707; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOLKENS BA, 1991, J CARDIOVASC PHARM, V18, pS26; SEYFRIED CE, 1992, GENOMICS, V13, P832, DOI 10.1016/0888-7543(92)90162-L; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2; SILVA MRE, 1949, AM J PHYSIOL, V156, P261, DOI 10.1152/ajplegacy.1949.156.2.261; SNELL PH, 1990, BIOCHEM PHARMACOL, V39, P1921, DOI 10.1016/0006-2952(90)90610-W; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPRENGER H, 1994, J BIOL CHEM, V269, P11065; STERANKA LR, 1989, FASEB J, V3, P2019, DOI 10.1096/fasebj.3.9.2545496; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; TAKEUCHI K, 1993, CIRC RES, V73, P612, DOI 10.1161/01.RES.73.4.612; TIO RA, 1991, BASIC RES CARDIOL, V86, P107, DOI 10.1007/BF02190543; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767	73	70	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26920	26925						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929432				2022-12-27	WOS:A1994PQ93100053
J	PLOEMEN, JHTM; JOHNSON, WW; JESPERSEN, S; VANDERWALL, D; VANOMMEN, B; VANDERGREEF, J; VANBLADEREN, PJ; ARMSTRONG, RN				PLOEMEN, JHTM; JOHNSON, WW; JESPERSEN, S; VANDERWALL, D; VANOMMEN, B; VANDERGREEF, J; VANBLADEREN, PJ; ARMSTRONG, RN			ACTIVE-SITE TYROSYL RESIDUES ARE TARGETS IN THE IRREVERSIBLE INHIBITION OF A CLASS MU-GLUTATHIONE TRANSFERASE BY 2-(S-GLUTATHIONYL)-3,5,6-TRICHLORO-1,4-BENZOQUINONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-TRANSFERASE; CLASS-PI; 3-DIMENSIONAL STRUCTURE; CHEMICAL MODIFICATION; CATALYTIC MECHANISM; CYSTEINE RESIDUES; ISOENZYME 3-3; RAT-LIVER; TETRACHLORO-1,4-BENZOQUINONE; CONJUGATE	The mode of inactivation of glutathione S-transferase isoenzyme 3-3 from rat by the active site-directed inhibitor 2-(S-glutathionyl)-3,5,6-trichloro-1,4-benzoquinone (GSTCBQ) has been investigated by a combination of site specific mutagenesis and mass spectrometric analysis of the sites of reaction of the reagent with the enzyme. This very reactive reagent is shown to target 3 residues in or near the active site, including the hydroxyl groups of Tyr-6 and Tyr-115 and the sulfhydryl group of Cys-114. Although the covalent attachment of one 2-(S-glutathionyl)dichloro-1,4-benzoquinonyl group/active site is sufficient to inactivate the enzyme (<5% residual activity), the 1 mol of reagent appears to be distributed among all three target sites. Mutant enzymes in which the reactive functional groups of these 3 residues have been individually removed remain susceptible to GSTCBQ. Evidence from amino acid sequencing and peptide maps visualized by matrix-assisted laser desorption/ionization mass spectrometry suggests that both Tyr-6 and Tyr-115 are primary targets of the reagent in the native enzyme. Docking of a model of GSTCBQ in a model of the active site derived from the crystal structure of the enzyme indicates that the trichlorobenzoquinonyl group can be positioned so that both tyrosine hydroxyl groups can act as nucleophiles to add to the reagent or alternatively act as electrophiles to assist in the nucleophilic addition of the other. The reaction of GSTCBQ with Cys-114 appears to require a conformation different from that in the crystal structure.	TNO,INST TOXICOL,DEPT BIOL TOXICOL,3700 ZEIST,NETHERLANDS; TNO,INST TOXICOL,DEPT STRUCT ELUCIDAT & INSTRUMENTAL ANAL,3700 ZEIST,NETHERLANDS; UNIV MARYLAND,DEPT CHEM & BIOCHEM,COLLEGE PK,MD 20742	Netherlands Organization Applied Science Research; Netherlands Organization Applied Science Research; University System of Maryland; University of Maryland College Park				Vanderwall, Dana/0000-0003-1076-8788	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030910] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30910] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armstrong R N, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P1; ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; ASKELOF P, 1975, BIOCHEM J, V147, P513, DOI 10.1042/bj1470513; BARYCKI JJ, 1993, BIOCHEMISTRY-US, V32, P13002, DOI 10.1021/bi00211a008; BLACK SM, 1991, PHARMACOL THERAPEUT, V51, P139, DOI 10.1016/0163-7258(91)90044-M; CACCURI AM, 1992, ARCH BIOCHEM BIOPHYS, V297, P119, DOI 10.1016/0003-9861(92)90648-G; CHEN WL, 1992, BIOCHEM J, V286, P205, DOI 10.1042/bj2860205; Cleland W W, 1979, Methods Enzymol, V63, P103; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HSIEH JC, 1991, BIOCHEM J, V278, P293, DOI 10.1042/bj2780293; JI X, 1993, BIOCHEMISTRY-US, V32, P12949, DOI 10.1021/bi00211a001; JI XH, 1994, BIOCHEMISTRY-US, V33, P1043, DOI 10.1021/bi00171a002; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; JOHNSON WW, 1993, J BIOL CHEM, V268, P11508; KATUSZ RM, 1991, BIOCHEMISTRY-US, V30, P11230, DOI 10.1021/bi00111a006; KATUSZ RM, 1992, ARCH BIOCHEM BIOPHYS, V298, P667, DOI 10.1016/0003-9861(92)90464-8; KOLM RH, 1992, BIOCHEM J, V285, P537, DOI 10.1042/bj2850537; KONG KH, 1992, BIOCHEM BIOPH RES CO, V184, P194, DOI 10.1016/0006-291X(92)91177-R; LIU SX, 1992, J BIOL CHEM, V267, P4296; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; MEYER DJ, 1993, BIOCHEM J, V293, P351, DOI 10.1042/bj2930351; PLOEMEN JHTM, 1991, BIOCHEM PHARMACOL, V41, P1665, DOI 10.1016/0006-2952(91)90167-4; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; Smith B J, 1988, Methods Mol Biol, V3, P57, DOI 10.1385/0-89603-126-8:57; TAMAI K, 1990, BIOCHEM BIOPH RES CO, V167, P331, DOI 10.1016/0006-291X(90)91769-O; TEW KD, 1988, CANCER RES, V48, P3622; VANBLADEREN PJ, 1991, PHARMACOL THERAPEUT, V51, P35, DOI 10.1016/0163-7258(91)90040-S; VANOMMEN B, 1988, J BIOL CHEM, V263, P12939; VANOMMEN B, 1989, EUR J BIOCHEM, V181, P423; VANOMMEN B, 1991, BIOCHEM J, V276, P661, DOI 10.1042/bj2760661; WAXMAN DJ, 1990, CANCER RES, V50, P6449; WIDERSTEN M, 1991, FEBS LETT, V293, P156, DOI 10.1016/0014-5793(91)81175-8; ZHANG PH, 1990, BIOPOLYMERS, V29, P159, DOI 10.1002/bip.360290121	38	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26890	26897						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929428				2022-12-27	WOS:A1994PQ93100049
J	AGARWAL, AK; MUNE, T; MONDER, C; WHITE, PC				AGARWAL, AK; MUNE, T; MONDER, C; WHITE, PC			NAD(+)-DEPENDENT ISOFORM OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE - CLONING AND CHARACTERIZATION OF CDNA FROM SHEEP KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							APPARENT MINERALOCORTICOID EXCESS; CORTICOSTEROID 11-BETA-DEHYDROGENASE; EXPRESSION; TISSUE; LOCALIZATION; GENE; PURIFICATION; RECEPTOR; DEFECTS; ENZYME	11 beta-Hydroxysteroid dehydrogenase (11-HSD) catalyzes the conversion of cortisol to cortisone and corticosterone to 11-dehydrocorticosterone. This activity may be required to confer normal ligand specificity upon the mineralocorticoid receptor. Although an isozyme of 11-HSD was previously isolated from rat liver, a different isozyme is apparently expressed in mineralocorticoid target tissues. We isolated a sheep kidney cDNA clone encoding this isozyme by expression screening using Xenopus oocytes. The cDNA is 1.8 kilobase pairs in length and encodes a protein of 427 amino acid residues with a predicted M(r) of 46,700. When expressed in oocytes, this enzyme functions as an NAD(+)-dependent 11 beta-dehydrogenase with very high affinity for steroids, but it has no detectable reductase activity. It is 37% identical in amino acid sequence to an NAD(+)-dependent isozyme of 17 beta-hydroxysteroid dehydrogenase but only 20% identical to the NADP(+)-dependent liver isozyme of 11-HSD. It is expressed at high levels in the kidney and adrenal and at lower levels in the colon. The corresponding gene is present in a single copy in the sheep genome. In humans, this gene is a candidate locus for the syndrome of apparent mineralocorticoid excess, a form of hypertension postulated to result from 11-HSD deficiency in mineralocorticoid target tissues.	NEW YORK HOSP,CORNELL MED CTR,DEPT PEDIAT,NEW YORK,NY 10021; POPULAT COUNCIL,NEW YORK,NY 10021	Cornell University; NewYork-Presbyterian Hospital; Population Council					NIDDK NIH HHS [DK42169, DK37094] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042169, R01DK037094] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGARWAL AK, 1990, MOL ENDOCRINOL, V4, P1827, DOI 10.1210/mend-4-12-1827; AGARWAL AK, 1989, J BIOL CHEM, V264, P18939; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; BROWN RW, 1993, ENDOCRINOLOGY, V132, P2614, DOI 10.1210/en.132.6.2614; CHEN Z, 1993, BIOCHEMISTRY-US, V32, P3342, DOI 10.1021/bi00064a017; EDWARDS CRW, 1988, LANCET, V2, P986, DOI 10.1016/S0140-6736(88)90742-8; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAKSHMI V, 1988, ENDOCRINOLOGY, V123, P2390, DOI 10.1210/endo-123-5-2390; MONDER C, 1989, ENDOCRINOLOGY, V125, P1046, DOI 10.1210/endo-125-2-1046; MONDER C, 1993, VITAM HORM, V47, P187, DOI 10.1016/S0083-6729(08)60447-1; NIKKILA H, 1993, J CLIN ENDOCR METAB, V77, P687, DOI 10.1210/jc.77.3.687; OBEID J, 1992, BIOCHEM BIOPH RES CO, V188, P222, DOI 10.1016/0006-291X(92)92373-6; OBERFIELD SE, 1983, J CLIN ENDOCR METAB, V56, P332, DOI 10.1210/jcem-56-2-332; RUNDLE SE, 1989, ENDOCRINOLOGY, V125, P1700, DOI 10.1210/endo-125-3-1700; RUSVAI E, 1993, J BIOL CHEM, V268, P10717; STEWART PM, 1994, J CLIN ENDOCR METAB, V78, P1529, DOI 10.1210/jc.78.6.1529; TAKAHASHI T, 1992, GENET ANAL-BIOMOL E, V9, P91, DOI 10.1016/1050-3862(92)90004-O; TANNIN GM, 1991, J BIOL CHEM, V266, P16653; ULICK S, 1979, J CLIN ENDOCR METAB, V49, P757, DOI 10.1210/jcem-49-5-757; WU L, 1993, J BIOL CHEM, V268, P12964; YANG K, 1994, J STEROID BIOCHEM, V49, P245, DOI 10.1016/0960-0760(94)90016-7; YANG K, 1992, ENDOCRINOLOGY, V131, P2120, DOI 10.1210/en.131.5.2120	26	251	255	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					25959	25962						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929304				2022-12-27	WOS:A1994PQ93000005
J	BIRMAN, S; MORGAN, B; ANZIVINO, M; HIRSH, J				BIRMAN, S; MORGAN, B; ANZIVINO, M; HIRSH, J			A NOVEL AND MAJOR ISOFORM OF TYROSINE-HYDROXYLASE IN DROSOPHILA IS GENERATED BY ALTERNATIVE RNA PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPA-DECARBOXYLASE GENE; CATECHOLAMINE-CONTAINING NEURONS; MULTIPLE MESSENGER-RNAS; NERVOUS-SYSTEM; MELANOGASTER; EXPRESSION; PHOSPHORYLATION; ENZYME; TRANSCRIPTS; DOMAINS	We report that two isoforms of Drosophila tyrosine hydroxylase protein are encoded via alternatively spliced exons. The major isoform (Type II) contains a novel acidic extension of 71 amino acids in the aminoterminal regulatory domain, which is likely to alter the regulatory properties of the tyrosine hydroxylase protein. The minor isoform (Type I) corresponds to the cDNA sequence reported previously (1). We also report the structure of the Drosophila tyrosine hydroxylase (DTH) gene and the diversity and tissue localization of its transcripts. At least three types of DTH mRNA are generated from a single primary transcript through alternative splicing and polyadenylation. Type II mRNA is the most abundant tyrosine hydroxylase transcript in Drosophila and is found predominantly in the hypoderm throughout all stages of development. Type I mRNA is present only in the CNS, where it is the primary form. The DTH transcripts detected in the CNS contain a longer 3'-untranslated region than the transcript expressed in the hypoderm, due to differential polyadenylation. In contrast, the same start site is used for DTH gene transcription in both tissues. These results show unexpected diversity in the DTH transcripts and point out possible mechanisms for differential regulation of tyrosine hydroxylase activity in the CNS and in the hypoderm.			BIRMAN, S (corresponding author), UNIV VIRGINIA,DEPT BIOL,CHARLOTTESVILLE,VA 22903, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027318] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27318] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1988, BIOCHEM BIOPH RES CO, V151, P1446, DOI 10.1016/S0006-291X(88)80524-2; AKAM ME, 1985, EMBO J, V4, P1689, DOI 10.1002/j.1460-2075.1985.tb03838.x; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BANERJEE SA, 1992, J NEUROSCI, V12, P4460; BEALL CJ, 1987, GENE DEV, V1, P510, DOI 10.1101/gad.1.5.510; BOURDELLES BL, 1991, J BIOL CHEM, V266, P17124; BRAY SJ, 1988, EMBO J, V7, P177, DOI 10.1002/j.1460-2075.1988.tb02798.x; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BROWN ER, 1987, BIOCHEMISTRY-US, V26, P5208, DOI 10.1021/bi00390a046; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BUDNIK V, 1988, J COMP NEUROL, V268, P400, DOI 10.1002/cne.902680309; BUDNIK V, 1986, J NEUROSCI, V6, P3682; BUDNIK V, 1987, J NEUROGENET, V4, P309, DOI 10.3109/01677068709102351; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; D'MELLO SR, 1989, J NEUROSCI RES, V23, P31, DOI 10.1002/jnr.490230105; DAUBNER SC, 1993, PROTEIN SCI, V2, P1452, DOI 10.1002/pro.5560020909; DAUBNER SC, 1992, J BIOL CHEM, V267, P12639; EVELETH DD, 1986, EMBO J, V5, P2663, DOI 10.1002/j.1460-2075.1986.tb04549.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GRIMA B, 1987, NATURE, V326, P707, DOI 10.1038/326707a0; GRIMA B, 1985, P NATL ACAD SCI USA, V82, P617, DOI 10.1073/pnas.82.2.617; HAYCOCK JW, 1990, J BIOL CHEM, V265, P11682; HIRSH J, 1981, MOL CELL BIOL, V1, P475, DOI 10.1128/MCB.1.6.475; HIRSH J, 1989, DEV GENET, V10, P232, DOI 10.1002/dvg.1020100312; HOPKINS TL, 1992, ANNU REV ENTOMOL, V37, P273, DOI 10.1146/annurev.en.37.010192.001421; HORTSCH M, 1990, NEURON, V4, P697, DOI 10.1016/0896-6273(90)90196-M; ICHIKAWA S, 1990, BIOCHEM BIOPH RES CO, V173, P1331, DOI 10.1016/S0006-291X(05)80933-7; IWATA N, 1992, BIOCHEM BIOPH RES CO, V182, P348, DOI 10.1016/S0006-291X(05)80151-2; JOHNSON WA, 1989, GENE DEV, V3, P676, DOI 10.1101/gad.3.5.676; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KOBAYASHI K, 1988, J BIOCHEM, V103, P907, DOI 10.1093/oxfordjournals.jbchem.a122386; KONRAD KD, 1987, DEV BIOL, V122, P172, DOI 10.1016/0012-1606(87)90343-5; KORNFELD K, 1989, GENE DEV, V3, P243, DOI 10.1101/gad.3.2.243; LEDLEY FD, 1985, BIOCHEMISTRY-US, V24, P3389, DOI 10.1021/bi00335a001; LEVITT M, 1965, J PHARMACOL EXP THER, V148, P1; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; LIVINGSTONE MS, 1983, NATURE, V303, P67, DOI 10.1038/303067a0; LUNDELL MJ, 1992, DEV BIOL, V154, P84, DOI 10.1016/0012-1606(92)90050-Q; Maniatis T, 1989, DECONTAMINATION DILU; MARKEY KA, 1980, MOL PHARMACOL, V17, P79; MARSH JL, 1980, DEV BIOL, V80, P379, DOI 10.1016/0012-1606(80)90412-1; MARTINEZRAMIREZ AC, 1992, INSECT BIOCHEM MOLEC, V22, P491, DOI 10.1016/0965-1748(92)90145-5; MASTICK GS, 1992, MOL CELL BIOL, V12, P5659, DOI 10.1128/MCB.12.12.5659; MORGAN BA, 1986, EMBO J, V5, P3335, DOI 10.1002/j.1460-2075.1986.tb04648.x; NAGATSU T, 1991, NEUROSCI RES, V12, P315, DOI 10.1016/0168-0102(91)90001-F; NAGATSU T, 1991, COMP BIOCHEM PHYS C, V98, P203; NASSEL DR, 1992, CELL TISSUE RES, V267, P147, DOI 10.1007/BF00318701; NECKAMEYER WS, 1993, J NEUROGENET, V8, P189, DOI 10.3109/01677069309083448; NECKAMEYER WS, 1989, NEURON, V2, P1167, DOI 10.1016/0896-6273(89)90183-9; NEVINS JR, 1978, CELL, V15, P1477, DOI 10.1016/0092-8674(78)90071-5; OKUNO S, 1991, J NEUROCHEM, V57, P53, DOI 10.1111/j.1471-4159.1991.tb02098.x; OMALLEY KL, 1987, BIOCHEMISTRY-US, V26, P6910, DOI 10.1021/bi00396a007; ORCHARD I, 1990, J INSECT PHYSIOL, V36, P593, DOI 10.1016/0022-1910(90)90028-E; OWEN MD, 1992, INSECT BIOCHEM MOLEC, V22, P193, DOI 10.1016/0965-1748(92)90159-C; RESTIFO LL, 1990, ADV INSECT PHYSL, V22, P116; RIBEIRO P, 1993, J MOL NEUROSCI, V4, P125, DOI 10.1007/BF02782125; ROSENFELD MG, 1984, SCIENCE, V225, P1315, DOI 10.1126/science.6089345; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOLNICK SB, 1986, SCIENCE, V234, P998, DOI 10.1126/science.3095924; SHEN J, 1993, MOL CELL BIOL, V13, P4549, DOI 10.1128/MCB.13.8.4549; STROEHER VL, 1988, MOL CELL BIOL, V8, P4143, DOI 10.1128/MCB.8.10.4143; VALLES AM, 1986, J NEUROSCI, V6, P1482; VIGNY A, 1982, BIOCHEM BIOPH RES CO, V106, P1, DOI 10.1016/0006-291X(82)92049-6; VIGNY A, 1981, J NEUROCHEM, V36, P483, DOI 10.1111/j.1471-4159.1981.tb01618.x; VYAS S, 1990, EMBO J, V9, P3707, DOI 10.1002/j.1460-2075.1990.tb07583.x; WRIGHT TRF, 1976, GENETICS, V84, P287; WRIGHT TRF, 1976, GENETICS, V84, P267; WRIGHT TRF, 1987, ADV GENET, V24, P127, DOI 10.1016/s0065-2660(08)60008-5; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	69	65	67	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26559	26567						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929381				2022-12-27	WOS:A1994PQ93000094
J	SHERMAN, JA; MATSON, SW				SHERMAN, JA; MATSON, SW			ESCHERICHIA-COLI DNA HELICASE-I CATALYZES A SEQUENCE-SPECIFIC CLEAVAGE LIGATION REACTION AT THE F-PLASMID ORIGIN OF TRANSFER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; SEX FACTOR; BACTERIAL CONJUGATION; NICKING REACTION; GENE-PRODUCT; PROTEIN; PURIFICATION; ENZYME; FLAC; TRAI	Recent studies have shown that the Escherichia coli F plasmid-encoded traI gene product (TraIp), also known as DNA helicase I, catalyzes the formation of the site- and strand-specific nick that initiates F plasmid DNA transfer. Scission of the phosphodiester bond at the nic site within the origin of transfer (oriT) is accompanied by the covalent attachment of TraIp to the 5'-phosphate of the nicked DNA strand. This mechanism suggests that TraIp may also be capable of catalyzing a DNA ligation reaction using the energy stored in the protein-DNA intermediate. To test this possibility, an in vitro assay was designed that utilized short single-stranded DNA oligonucleotides of different lengths derived from the region within oriT that spanned the nic site. Purified TraIp was capable of efficiently cleaving single-stranded DNA that contained a nic site, and upon cleavage, the protein became covalently linked to the 5-'end of the nic site. When TraIp was incubated with two oligonucleotides of different length that contained the nic site, there was formation of novel recombinant products resulting from a TraIp-catalyzed cleavage/ligation reaction. Furthermore, the cleavage and ligation reactions were both sequence-specific. These data suggest that TraIp plays an important role in the initiation and termination of conjugative DNA transfer.	UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, CURRICULUM GENET & MOLEC BIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NIGMS NIH HHS [GM 33476] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033476] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P441, DOI 10.1111/j.1432-1033.1976.tb10359.x; ABDELMONEM M, 1983, P NATL ACAD SCI-BIOL, V80, P4659, DOI 10.1073/pnas.80.15.4659; ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P431, DOI 10.1111/j.1432-1033.1976.tb10358.x; ACHTMAN M, 1972, J BACTERIOL, V110, P831, DOI 10.1128/JB.110.3.831-842.1972; Ausubel FM, 1994, CURRENT PROTOCOLS MO; DILAURENZIO L, 1992, MOL MICROBIOL, V6, P2951; EISENBERG S, 1977, P NATL ACAD SCI USA, V74, P3198, DOI 10.1073/pnas.74.8.3198; EVERETT R, 1980, J MOL BIOL, V136, P129, DOI 10.1016/0022-2836(80)90309-5; GAO Q, 1994, MOL MICROBIOL, V11, P449, DOI 10.1111/j.1365-2958.1994.tb00326.x; Ippen-Ihler K., 1993, BACTERIAL CONJUGATIO, P23; KINGSMAN A, 1978, J MOL BIOL, V122, P287, DOI 10.1016/0022-2836(78)90191-2; KLINE BC, 1971, BIOCHEMISTRY-US, V10, P4975, DOI 10.1021/bi00802a022; LAHUE EE, 1988, J BIOL CHEM, V263, P3208; MATSON SW, 1991, J BIOL CHEM, V266, P16232; MATSON SW, 1993, J BACTERIOL, V175, P2599, DOI 10.1128/JB.175.9.2599-2606.1993; NELSON WC, 1993, J BACTERIOL, V175, P2221, DOI 10.1128/JB.175.8.2221-2228.1993; PANICKER MM, 1992, J BIOL CHEM, V267, P12761; PANSEGRAU W, 1993, P NATL ACAD SCI USA, V90, P11538, DOI 10.1073/pnas.90.24.11538; PANSEGRAU W, 1993, P NATL ACAD SCI USA, V90, P2925, DOI 10.1073/pnas.90.7.2925; REYGERS U, 1991, EMBO J, V10, P2689, DOI 10.1002/j.1460-2075.1991.tb07812.x; SCHERZINGER E, 1993, EUR J BIOCHEM, V217, P929, DOI 10.1111/j.1432-1033.1993.tb18323.x; SILVERMAN P, 1986, BACTERIAL OUTER MEMB, P277; Wilkins B, 1993, BACTERIAL CONJUGATIO, P105; WILLETTS N, 1984, MICROBIOL REV, V48, P24, DOI 10.1128/MMBR.48.1.24-41.1984; WILLETTS N, 1980, ANNU REV GENET, V14, P41, DOI 10.1146/annurev.ge.14.120180.000353	25	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26220	26226						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929337				2022-12-27	WOS:A1994PQ93000045
J	DELPIRE, E; RAUCHMAN, MI; BEIER, DR; HEBERT, SC; GULLANS, SR				DELPIRE, E; RAUCHMAN, MI; BEIER, DR; HEBERT, SC; GULLANS, SR			MOLECULAR-CLONING AND CHROMOSOME LOCALIZATION OF A PUTATIVE BASOLATERAL NA+-K+-2CL(-) COTRANSPORTER FROM MOUSE INNER MEDULLARY COLLECTING DUCT (MIMCD-3) CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORT; RECOMBINANT INBRED STRAINS; H-3 BUMETANIDE BINDING; SHARK RECTAL GLAND; TRANSPORT MECHANISMS; EPITHELIAL TISSUES; ACINAR-CELLS; PROTEIN; PHOSPHORYLATION; SECRETION	Electroneutral Na+-K+-2Cl(-) cotransporters represent one of the major routes for Cl- movement in epithelia. A secretory form of the cotransporter has been described in the basolateral membrane of a variety of epithelia from fish to mammals. We isolated a putative bumetanide-sensitive Na+-K+-2Cl(-) cotransporter cDNA, BSC2, from mIMCD-3 cells. Northern analysis indicates that in contrast to BSC1, the recently cloned renal-specific apical isoform of the cotransporter, BSC2 is expressed in secretory epithelia and thus appears to represent the basolateral isoform. Furthermore, BSC2 is also expressed in non polarized cells, such as red cells and myocytes. Sequence comparison and chromosome localization demonstrate that BSC2 and BSC1 are different genes that diverged before the evolution of vertebrates.	HARVARD UNIV,SCH MED,HARVARD CTR STUDY KIDNEY DIS,DIV RENAL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital					NHLBI NIH HHS [HL49251] Funding Source: Medline; NIDDK NIH HHS [DK36031, DK36803] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL049251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036031, R01DK036803] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEIER DR, 1992, P NATL ACAD SCI USA, V89, P9102, DOI 10.1073/pnas.89.19.9102; COOK DI, 1989, HDB PHYSL, P1; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FORBUSH B, 1983, J BIOL CHEM, V258, P1787; FRANKLIN CC, 1989, J BIOL CHEM, V264, P6667; FRIZZELL RA, 1979, AM J PHYSIOL, V236, pF1, DOI 10.1152/ajprenal.1979.236.1.F1; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; GAMBA G, 1994, J BIOL CHEM, V269, P17713; GOUGH NM, 1988, ANAL BIOCHEM, V173, P73; GREGER R, 1985, PHYSIOL REV, V65, P760, DOI 10.1152/physrev.1985.65.3.760; GRUPP C, 1989, KIDNEY INT, V36, P201, DOI 10.1038/ki.1989.180; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; HEBERT SC, 1988, AM J PHYSIOL, V255, pF962, DOI 10.1152/ajprenal.1988.255.5.F962; KINNE R, 1985, ANN NY ACAD SCI, V456, P198, DOI 10.1111/j.1749-6632.1985.tb14865.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LYTLE C, 1992, J BIOL CHEM, V267, P25428; LYTLE C, 1992, J BIOL CHEM, V267, P25438; MANLY KF, 1991, MAMM GENOME, V1, P123, DOI 10.1007/BF02443789; Nei M., 1987, MOL EVOLUT GENET, P293; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177, DOI 10.1152/ajpcell.1987.253.2.C177; Palfrey H. Clive, 1992, Cellular Physiology and Biochemistry, V2, P293; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; PEWITT EB, 1990, J BIOL CHEM, V265, P20747; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; SAITO Y, 1987, J MEMBRANE BIOL, V98, P135, DOI 10.1007/BF01872126; Sambrook J, 1989, MOL CLONING LABORATO; WELSH MJ, 1987, PHYSIOL REV, V67, P1143, DOI 10.1152/physrev.1987.67.4.1143; WHISENANT N, 1991, AM J PHYSIOL, V261, pC433, DOI 10.1152/ajpcell.1991.261.3.C433; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201; ZEIDEL ML, 1993, AM J PHYSIOL, V265, pF159, DOI 10.1152/ajprenal.1993.265.2.F159; ZEIDEL ML, 1986, AM J PHYSIOL, V251, pF379, DOI 10.1152/ajprenal.1986.251.2.F379	32	243	244	0	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25677	25683						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929272				2022-12-27	WOS:A1994PQ49100068
J	MIZOKAMI, A; CHANG, CS				MIZOKAMI, A; CHANG, CS			INDUCTION OF TRANSLATION BY THE 5'-UNTRANSLATED REGION OF HUMAN ANDROGEN RECEPTOR MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' UNTRANSLATED REGION; MESSENGER-RNA; SECONDARY STRUCTURE; HUMAN TISSUES; GROWTH-FACTOR; GENE; EFFICIENCY; RESISTANCE; FERRITIN; ELEMENT	Androgens and androgen receptor (AR) play important roles in sexual differentiation and prostatic cancer cell proliferation. To investigate the regulation of AR expression, a 2-kilobase pair 5'-flanking region of human AR gene including a 0.6-kilobase pair 5'-untranslated region (5'-UTR) was ligated to a chloramphenicol acetyltransferase (CAT) gene and characterized by CAT assay after transfection into HeLa cells. The results revealed that AR 5'-UTR was absolutely needed for the induction of CAT activity, but could not function as an enhancer for the AR transcription. A further study using a 180 base pairs (+21 to +202 including a stem-loop secondary structure at +109 to +129) within the AR 5'-UTR demonstrated that this region was sufficient to induce more CAT activity without changing the CAT mRNA expression. Taken together, these results strongly suggested that 5'-UTR of AR mRNA plays an essential role in the induction of AR translation, which may represent the first reported translational induction mechanism in the steroid receptor superfamily.	UNIV WISCONSIN,CTR COMPREHENS CANC,DEPT HUMAN ONCOL,MADISON,WI 53792; UNIV WISCONSIN,ENDOCRINOL REPROD PHYSIOL PROGRAM,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					PHS HHS [55639] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARRICK BA, 1991, MOL CELL BIOL, V11, P4306, DOI 10.1128/MCB.11.9.4306; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHODAK GW, 1992, J UROLOGY, V147, P798, DOI 10.1016/S0022-5347(17)37389-5; FABER PW, 1993, J BIOL CHEM, V268, P9296; FALCONE D, 1991, MOL CELL BIOL, V11, P2656, DOI 10.1128/MCB.11.5.2656; GALLIE DR, 1988, NUCLEIC ACIDS RES, V16, P883, DOI 10.1093/nar/16.3.883; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; HENTZE MW, 1987, P NATL ACAD SCI USA, V84, P6730, DOI 10.1073/pnas.84.19.6730; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; KIM SJ, 1992, J BIOL CHEM, V267, P13702; KIMURA N, 1993, J HISTOCHEM CYTOCHEM, V41, P671, DOI 10.1177/41.5.8468448; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MARCELLI M, 1992, J ENDOCRINOL INVEST, V15, P149, DOI 10.1007/BF03348684; MELEFORS O, 1993, BIOESSAYS, V15, P85, DOI 10.1002/bies.950150203; MIZOKAMI A, 1992, ENDOCRINOL JAPON, V39, P235; MIZOKAMI A, 1994, MOL ENDOCRINOL, V8, P77, DOI 10.1210/me.8.1.77; MOWSZOWICZ I, 1993, MOL ENDOCRINOL, V7, P861, DOI 10.1210/me.7.7.861; MOWSZOWICZ I, 1993, ENDOCR J, V1, P203; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PATEL RC, 1992, J BIOL CHEM, V267, P1159; PIEKARZ RL, 1993, J BIOL CHEM, V268, P7613; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; RAO SM, 1993, J BIOL CHEM, V268, P22164; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; ROMEO DS, 1993, MOL ENDOCRINOL, V7, P759, DOI 10.1210/me.7.6.759; ROUAULT TA, 1989, P NATL ACAD SCI USA, V86, P5768, DOI 10.1073/pnas.86.15.5768; Sambrook J, 1989, MOL CLONING LABORATO; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; TILLEY WD, 1990, J BIOL CHEM, V265, P13776; TIMMER RT, 1993, J BIOL CHEM, V268, P9504; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; YOUNG W, 1994, ENDOCRINE, V2, P321	35	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25655	25659						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929269				2022-12-27	WOS:A1994PQ49100065
J	SPEAR, DH; ERICSSON, J; JACKSON, SM; EDWARDS, PA				SPEAR, DH; ERICSSON, J; JACKSON, SM; EDWARDS, PA			IDENTIFICATION OF A 6-BASE PAIR ELEMENT INVOLVED IN THE STEROL-MEDIATED TRANSCRIPTIONAL REGULATION OF FARNESYL DIPHOSPHATE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; MOLECULAR-CLONING; PROTEIN-BINDING; RECEPTOR GENE; PROMOTER; PRENYLTRANSFERASE; EXPRESSION; SEQUENCE; PATHWAY	Previous studies identified a 115-base pair (bp) region of the farnesyl diphosphate (FPP) synthase promoter which is involved in the transcriptional regulation of this gene by sterols (Spear, D. H., Kutsunai, S. Y., Correll, C. C., and Edwards, P A. (1992) J. Biol. Chem. 267, 14462-14469). In the current study we fused a 117-bp fragment, containing this region of interest, upstream of the heterologous minimal promoter of the herpes simplex virus thymidine kinase gene linked to the chloramphenicol acetyltransferase (CAT) reporter gene. Chinese hamster ovary (CHO) cells were stably transfected with this fusion gene and incubated in the absence or presence of sterols. Analysis of CAT mRNA by primer extension indicated that transcription of the fusion gene was under sterol-mediated control, Thus, when cellular sterols were present, the CAT mRNA levels were reduced 2-4-fold. To further localize the FPP synthase sterol-responsive element(s), additional promoter-reporter gene constructs containing either deletions or mutations were constructed and transfected into CHO or CV-1 cells. These studies localized a 6-bp region (ATTGGC) that is required for both transcriptional induction in the absence of sterols and transcriptional repression in the presence of sterols. Gel shift and footprinting analyses demonstrated that nuclear proteins isolated from CHO cells bound to six distinct regions of the promoter between nucleotides -293 to -47. Taken together, these results further define both the cis-acting elements controlling normal transcription of the FPP synthase gene and identify a novel sequence involved in sterol regulation.	UNIV CALIF LOS ANGELES,CTR HLTH SCI,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles			Ericsson, Johan/AAA-6664-2020	Ericsson, Johan/0000-0003-1186-6574	NHLBI NIH HHS [HL 30568] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; ARCOT SS, 1989, J BIOL CHEM, V264, P2343; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; Maniatis T., 1982, MOL CLONING; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; PANG JH, 1993, J BIOL CHEM, V268, P2909; POULTER CD, 1981, BIOSYNTHESIS ISOPREN, V1, P162; RILLING HC, 1985, STEROLS BILE ACIDS, P17; ROSSER DSE, 1989, J BIOL CHEM, V264, P12653; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SMITH JR, 1988, J BIOL CHEM, V263, P18480; SPEAR D, 1993, SRATEGIES MOL BIOL, V6, P10; SPEAR DH, 1992, J BIOL CHEM, V267, P14462; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; TERUYA JH, 1990, MOL CELL BIOL, V10, P2315, DOI 10.1128/MCB.10.5.2315; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WILLIAMS GT, 1989, MOL CELL BIOL, V9, P2574, DOI 10.1128/MCB.9.6.2574; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	31	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25212	25218						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929210				2022-12-27	WOS:A1994PQ49000102
J	BERNIER, F; LEBLANC, G; LABRIE, F; LUUTHE, V				BERNIER, F; LEBLANC, G; LABRIE, F; LUUTHE, V			STRUCTURE OF HUMAN ESTROGEN AND ARYL SULFOTRANSFERASE GENE - 2 MESSENGER-RNA SPECIES ISSUED FROM A SINGLE-GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; DEHYDROEPIANDROSTERONE SULFOTRANSFERASE; MAMMARY-CANCER; MESSENGER-RNA; HUMAN LIVER; RAT-LIVER; EXPRESSION; CDNA; N-HYDROXY-2-ACETYLAMINOFLUORENE; METABOLISM	Estrone sulfate is the predominant form of estrogens found in the circulation in women and could thus serve as precursor for active estrogens in target tissues by removal of the sulfate group through the action of endogenous steroid sulfatase. Recently, we isolated a cDNA encoding human placental estrogen sulfotransferase that differs fi om brain aryl sulfotransferase only in the 5'-noncoding sequence. To increase our knowledge of the regulation and tissue-specific expression of the sulfotransferase gene, we screened a lambda EMBL3 Library of human leucocyte genomic DNA using the estrogen sulfotransferase cDNA as probe and isolated a clone containing almost the whole gene sequence. Sequencing of the gene indicates that it is included in approximately 7.7 kilobases and contains nine short exons separated by eight introns. The two first exons, named exon la and exon Ib, are noncoding and correspond to the 5'-untranslated sequences of human brain and human placental estrogen sulfotransferase cDNAs, respectively. Transfection of chloramphenicol acetyltransferase reporter gene vectors containing the 5'-flanking sequence upstream from exon la and exon Ib in human adrenal adenocarcinoma cells indicates that both sequences possess promoter activity. The present results thus indicate that brain aryl sulfotransferase and placental human placental estrogen sulfotransferase mRNA species are transcribed from a single gene by alternate exon 1a and exon 1b promoters, respectively. Using DNA from panels of human/rodent somatic cell hybrids and amplification of the gene by polymerase chain reaction, the human placental estrogen sulfotransferase gene was assigned to chromosome 16.	CHUL,RES CTR,MRC,MOLEC ENDOCRINOL GRP,MONTREAL G1V 4G2,PQ,CANADA; UNIV LAVAL,MONTREAL G1V 4G2,PQ,CANADA	Laval University; Laval University			Bernier, Francois/V-7150-2018; Bernier, Francois/AAP-2174-2020					ADAMS JB, 1990, J STEROID BIOCHEM, V36, P695, DOI 10.1016/0022-4731(90)90190-4; BERNIER F, 1994, MOL CELL ENDOCRINOL, V99, pR11, DOI 10.1016/0303-7207(94)90159-7; BERWAER M, 1994, MOL ENDOCRINOL, V8, P635, DOI 10.1210/me.8.5.635; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BUIRCHELL BJ, 1975, J STEROID BIOCHEM, V6, P1489, DOI 10.1016/0022-4731(75)90202-2; COMER KA, 1992, MOL PHARMACOL, V41, P645; DEBAUN JR, 1970, CANCER RES, V30, P577; DEMYAN WF, 1992, MOL ENDOCRINOL, V6, P589, DOI 10.1210/me.6.4.589; DICZFALUSY E, 1969, FOETUS PLACENTA, P191; DRWINGA HL, 1993, GENOMICS, V16, P311, DOI 10.1006/geno.1993.1190; DUMONT M, 1992, J INVEST DERMATOL, V99, P415, DOI 10.1111/1523-1747.ep12616131; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P199; KAREN L, 1987, CURRENT PROTOCOLS MO; KINGSTON RE, 1991, CURRENT PROTOCOLS MO; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; LABRIE F, 1991, MOL CELL ENDOCRINOL, V78, pC113, DOI 10.1016/0303-7207(91)90116-A; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LORIAUX DL, 1971, STEROIDS, V18, P463, DOI 10.1016/0039-128X(71)90059-6; MANCINI MA, 1992, ENDOCRINOLOGY, V131, P1541, DOI 10.1210/en.131.3.1541; Maniatis T., 1982, MOL CLONING; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Mulder G.J., 1990, CONJUGATION REACTION, P107; NABESHIMA YI, 1984, NATURE, V308, P333, DOI 10.1038/308333a0; NAGATA K, 1993, J BIOL CHEM, V268, P24720; NASH AR, 1988, AUST J BIOL SCI, V41, P507; OEDA T, 1992, MOL ENDOCRINOL, V6, P1216, DOI 10.1210/me.6.8.1216; OGURA K, 1990, BIOCHEM BIOPH RES CO, V166, P1494, DOI 10.1016/0006-291X(90)91036-R; OTTERNESS DM, 1992, MOL PHARMACOL, V41, P865; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; RUDER HJ, 1972, J CLIN INVEST, V51, P1020, DOI 10.1172/JCI106862; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTNER SJ, 1984, J CLIN ENDOCR METAB, V59, P29, DOI 10.1210/jcem-59-1-29; SIMPSON E, 1992, J STEROID BIOCHEM, V41, P409, DOI 10.1016/0960-0760(92)90366-Q; THE VL, 1989, MOL ENDOCRINOL, V3, P1301, DOI 10.1210/mend-3-8-1301; VIGNON F, 1980, ENDOCRINOLOGY, V106, P1079, DOI 10.1210/endo-106-4-1079; WILBORN TW, 1993, MOL PHARMACOL, V43, P70; YOUNG RA, 1981, CELL, V23, P451, DOI 10.1016/0092-8674(81)90140-9; ZHU XY, 1993, BIOCHEM BIOPH RES CO, V192, P671, DOI 10.1006/bbrc.1993.1467; ZHU XY, 1993, BIOCHEM BIOPH RES CO, V195, P120, DOI 10.1006/bbrc.1993.2018	40	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28200	28205						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961757				2022-12-27	WOS:A1994PV77200065
J	HO, AM; JAIN, J; RAO, A; HOGAN, PG				HO, AM; JAIN, J; RAO, A; HOGAN, PG			EXPRESSION OF THE TRANSCRIPTION FACTOR NFATP IN A NEURONAL CELL-LINE AND IN THE MURINE NERVOUS-SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED T-CELLS; CIS-ACTING ELEMENT; NUCLEAR FACTOR; CYCLOSPORINE-A; GENE-EXPRESSION; SPINAL-CORD; NF-AT; FOS; PROTEIN; BINDING	The transcription factor NFATp, which has a central role in cytokine gene induction in T cells, was previously thought to be expressed only in T cells and other immune cells. Here we report that NFATp, is also expressed in the rat PC12 pheochromocytoma cell line and in the murine nervous system. Antisera against T cell NFATp recognize proteins of similar apparent molecular weight in T cells, PC12 cells, and murine olfactory bulb. The immunoreactive proteins from PC12 cells and from olfactory bulb bind to an NFAT site of the murine interleukin-2 promoter with the same specificity as T cell NFATp. Immunohistochemical staining localizes NFATp to neurons, specifically to olfactory receptor neurons and to their terminals in the olfactory bulb. The presence of NFATp in the nervous system suggests that it has a role in the transcription of specific neuronal genes in response to increases in cytosolic calcium.	HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NCI NIH HHS [CA42471] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA042471, R01CA042471] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTIGLI E, 1993, J IMMUNOL, V150, P3284; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1993, J IMMUNOL, V151, P837; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NARDONE J, 1994, P NATL ACAD SCI USA, V91, P4412, DOI 10.1073/pnas.91.10.4412; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TOKUMITSU H, 1993, BIOCHEM BIOPH RES CO, V196, P737, DOI 10.1006/bbrc.1993.2311; VALGEARCHER VE, 1990, J IMMUNOL, V145, P4355; VENKATARAMAN L, 1994, IMMUNITY, V1, P189, DOI 10.1016/1074-7613(94)90097-3; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; YASEEN NR, 1993, J BIOL CHEM, V268, P14285	38	117	118	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28181	28186						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961754				2022-12-27	WOS:A1994PV77200062
J	ISHIBASHI, S; HAMMER, RE; HERZ, J				ISHIBASHI, S; HAMMER, RE; HERZ, J			ASIALOGLYCOPROTEIN RECEPTOR DEFICIENCY IN MICE LACKING THE MINOR RECEPTOR SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							APOLIPOPROTEIN-E; RAT-LIVER; CELLS; CDNA; HYPERCHOLESTEROLEMIA; CLEARANCE; PROTEINS; SEQUENCE; SURFACE; TRANSFECTION	The asialoglycoprotein receptor is an abundant heterooligomeric endocytic receptor that is predominantly expressed on the sinusoidal surface of the hepatocytes. Proposed physiological and pathophysiological functions ascribed to this hepatic lectin (HL) include the removal of desialylated serum glycoproteins and apoptotic cells, clearance of chylomicron remnants, and a role as a homing receptor for lymphatic and metastatic cells. The assembly of two homologous subunits, HL-1 and HL-2, is required to form functional, high affinity receptors on the cell surface. However, the importance of the individual subunits for receptor transport to the cell surface has been controversial. To explore the significance of the minor HL-2 subunit for receptor expression and function in vivo, we have disrupted the HL-2 gene in mice. Homozygous HL-a-deficient animals are superficially normal. However, HL-1 expression in the liver is greatly reduced, indicating that HL-2 may promote HL-1 stability. Although these mice are completely unable to clear asialoorosomucoid, a high affinity ligand for asialoglycoprotein receptor, they do not accumulate desialylated glycoproteins or lipoproteins in their circulation.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	ISHIBASHI, S (corresponding author), UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA.			Hammer, Robert E./0000-0001-5487-7551	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRAITERMAN LT, 1989, J BIOL CHEM, V264, P1682; CROSS AS, 1991, J CLIN INVEST, V88, P2067, DOI 10.1172/JCI115536; DINI L, 1992, FEBS LETT, V296, P174, DOI 10.1016/0014-5793(92)80373-O; DRICKAMER K, 1991, CELL, V67, P1029, DOI 10.1016/0092-8674(91)90278-7; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; GEFFEN I, 1992, INT REV CYTOL, V137B, P181; GEFFEN I, 1989, EMBO J, V8, P2855, DOI 10.1002/j.1460-2075.1989.tb08433.x; GRAEVE L, 1990, J BIOL CHEM, V265, P1216; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; MCPHAUL M, 1987, MOL CELL BIOL, V7, P1841, DOI 10.1128/MCB.7.5.1841; MCPHAUL M, 1986, P NATL ACAD SCI USA, V83, P8863, DOI 10.1073/pnas.83.23.8863; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OZAKI K, 1992, J BIOL CHEM, V267, P9229; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; SAMLOWSKI WE, 1984, CELL IMMUNOL, V88, P309, DOI 10.1016/0008-8749(84)90164-3; SANFORD JP, 1990, BIOCHIM BIOPHYS ACTA, V1087, P259, DOI 10.1016/0167-4781(90)90216-O; SCHAUER R, 1985, TRENDS BIOCHEM SCI, V10, P357, DOI 10.1016/0968-0004(85)90112-4; SCHLEPPERSCHAFER J, 1981, EUR J CELL BIOL, V25, P95; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; SPIESS M, 1985, J BIOL CHEM, V260, P1979; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WIKSTROM L, 1992, J BIOL CHEM, V267, P5; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WINDLER E, 1991, BIOCHEM J, V276, P79, DOI 10.1042/bj2760079; YEATMAN TJ, 1989, J SURG RES, V46, P567, DOI 10.1016/0022-4804(89)90021-8; YUK MH, 1993, J CELL BIOL, V123, P1735, DOI 10.1083/jcb.123.6.1735; ZANNIS VI, 1984, J BIOL CHEM, V259, P5495; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	36	77	92	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27803	27806						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961705				2022-12-27	WOS:A1994PV77200006
J	JOHNSON, RE; PRAKASH, S; PRAKASH, L				JOHNSON, RE; PRAKASH, S; PRAKASH, L			YEAST DNA-REPAIR PROTEIN RADS THAT PROMOTES INSTABILITY OF SIMPLE REPETITIVE SEQUENCES IS A DNA-DEPENDENT ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; COLORECTAL-CANCER; POLYMERASE-III; MUTATIONS; HOMOLOG	The RAD5 gene of Saccharomyces cerevisiae functions in postreplication repair of ultraviolet damaged DNA, and interestingly, it also has a role in increasing the instability of simple repetitive sequences in the genome. In contrast to DNA mismatch repair genes which function in maintaining constant length of repeat sequences, RADS promotes alterations in the length of repeat sequences. In this work, we purify the RADS protein to near homogeneity from yeast cells and show that it is a single-stranded DNA dependent ATPase. The possible roles of RADS ATPase in postreplication gap filling and in increasing the incidence of length alterations of repeat sequences are discussed.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555; UNIV ROCHESTER,DEPT BIOPHYS,ROCHESTER,NY 14642	University of Texas System; University of Texas Medical Branch Galveston; University of Rochester			Prakash, Satya/C-6420-2013; Prakash, Louise/C-7891-2012	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019261] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19261] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ARMSTRONG JD, 1994, IN PRESS MUTAT RES; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; HAN HJ, 1993, CANCER RES, V53, P5087; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; HUANG CC, 1981, J BIOL CHEM, V256, P4087; IONOV Y, 1993, NATURE, V363, P553; JOHNSON RE, 1992, MOL CELL BIOL, V12, P3807, DOI 10.1128/MCB.12.9.3807; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEE SH, 1987, P NATL ACAD SCI USA, V84, P2713, DOI 10.1073/pnas.84.9.2713; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; MACE DC, 1984, J MOL BIOL, V177, P313, DOI 10.1016/0022-2836(84)90459-5; MADDOX J, 1994, NATURE, V368, P685, DOI 10.1038/368685a0; MIRONOV NM, 1994, CANCER RES, V54, P41; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PRAKASH L, 1981, MOL GEN GENET, V184, P471, DOI 10.1007/BF00352525; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790	24	87	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28259	28262						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961763				2022-12-27	WOS:A1994PV77200073
J	OHNISHI, K; TAKEMORI, T				OHNISHI, K; TAKEMORI, T			MOLECULAR-COMPONENTS AND ASSEMBLY OF MU-SURROGATE LIGHT-CHAIN COMPLEXES IN PRE-B-CELL LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN GENE REARRANGEMENT; ANTIGEN-RECEPTOR COMPLEX; HEAVY-CHAIN; LYMPHOCYTES-B; TARGETED DISRUPTION; ALLELIC EXCLUSION; TYROSINE KINASES; BINDING-PROTEIN; MEMBRANE EXON; CROSS-LINKING	We describe the molecular components, subunit assembly, and cell surface expression of mu-chain complexes in mu(+)kappa(-) pre-E cell lines as revealed by two-dimensional gel electrophoresis. The mu-chain complexes of these cell lines contain several previously unreported components, p42(6.4), p39(6.7), p18(8.6), and p14(7.0), in addition to lambda 5, VpreB1, VpreB3 (formerly named 8HS20), MB-1(Ig-alpha), and B29(Ig-P). These new components are not detected in mu(+)kappa(+) immature B cell lines. The mu-chain associates with lambda 5, VpreB3, and p56(5.0) at an early phase of assembly, preceding the association of other molecules. mu-Associated VpreB3 decreased during assembly as the association of VpreB1 became dominant, suggesting that the change in the ratio of these two V-L-like surrogate light chains is involved in the mechanism of assembly. lambda 5, VpreB1, p56(5.0), p32(5.0), p36(5.5), and p14(7.0) were shown to be expressed on the cell surface in association with mu-chain. The association of the other molecules with mu-chain is most likely restricted to the intracellular compartment. An interaction between VpreB1 and VpreB3 was also suggested. These findings might be important for understanding the function of mu-chain complexes in pre-B cells. A possible signaling mechanism of mu/surrogate light chain complexes is discussed.	NATL INST HLTH,DEPT IMMUNOL,SHINJUKU KU,TOKYO 162,JAPAN				Takemori, Toshitada/A-5909-2016					BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BROUNS GS, 1993, EUR J IMMUNOL, V23, P1088, DOI 10.1002/eji.1830230517; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL KS, 1991, J IMMUNOL, V147, P1575; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHEN JZ, 1993, INT IMMUNOL, V5, P647, DOI 10.1093/intimm/5.6.647; CHERAYIL BJ, 1991, J EXP MED, V173, P111, DOI 10.1084/jem.173.1.111; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; DAVIDSON WF, 1984, J IMMUNOL, V133, P744; FRIEDRICH RJ, 1993, J IMMUNOL, V150, P2814; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; IGLESIAS A, 1991, EMBO J, V10, P2147, DOI 10.1002/j.1460-2075.1991.tb07749.x; ISHIHARA K, 1992, P NATL ACAD SCI USA, V89, P633, DOI 10.1073/pnas.89.2.633; Ishihara K, 1991, Dev Immunol, V1, P149, DOI 10.1155/1991/79721; ISHIHARA K, 1993, J IMMUNOL, V150, P2253; JAKOBOVITS A, 1993, P NATL ACAD SCI USA, V90, P2551, DOI 10.1073/pnas.90.6.2551; KARASUYAMA H, 1993, J EXP MED, V178, P469, DOI 10.1084/jem.178.2.469; KARASUYAMA H, 1994, CELL, V77, P133, DOI 10.1016/0092-8674(94)90241-0; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KINCADE PW, 1981, J IMMUNOL, V127, P2262; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSOUED K, 1993, CELL, V73, P73, DOI 10.1016/0092-8674(93)90161-I; LENNY N, 1991, J BIOL CHEM, V266, P20532; MATSUO T, 1993, J IMMUNOL, V150, P3766; MATSUO T, 1991, J IMMUNOL, V146, P1584; MATSUUCHI L, 1992, P NATL ACAD SCI USA, V89, P3404, DOI 10.1073/pnas.89.8.3404; MELCHERS F, 1993, IMMUNOL TODAY, V14, P60, DOI 10.1016/0167-5699(93)90060-X; MISENER V, 1991, INT IMMUNOL, V3, P1129, DOI 10.1093/intimm/3.11.1129; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NAKAMURA T, 1992, P NATL ACAD SCI USA, V89, P8522, DOI 10.1073/pnas.89.18.8522; NISHIKAWA SI, 1988, EUR J IMMUNOL, V18, P1767, DOI 10.1002/eji.1830181117; NISHIMOTO N, 1991, P NATL ACAD SCI USA, V88, P6284, DOI 10.1073/pnas.88.14.6284; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; RATHBUN G, 1993, INT IMMUNOL, V5, P997, DOI 10.1093/intimm/5.8.997; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; RUSCONI S, 1985, NATURE, V314, P330, DOI 10.1038/314330a0; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SHIRASAWA T, 1993, EMBO J, V12, P1827, DOI 10.1002/j.1460-2075.1993.tb05831.x; TAKEMORI T, 1987, EMBO J, V6, P951, DOI 10.1002/j.1460-2075.1987.tb04844.x; TAKEMORI T, 1990, EMBO J, V9, P2493, DOI 10.1002/j.1460-2075.1990.tb07428.x; TSUBATA T, 1992, INT IMMUNOL, V4, P637, DOI 10.1093/intimm/4.6.637; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WARNER NL, 1979, IMMUNOL REV, V48, P197, DOI 10.1111/j.1600-065X.1979.tb00304.x; WEAVER D, 1985, CELL, V42, P117, DOI 10.1016/S0092-8674(85)80107-0; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P118; YELLENSHAW AJ, 1992, J EXP MED, V176, P129, DOI 10.1084/jem.176.1.129	57	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28347	28353						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961773				2022-12-27	WOS:A1994PV77200085
J	SAITO, K; TATSUGUCHI, K; TAKAGI, Y; MURAKOSHI, I				SAITO, K; TATSUGUCHI, K; TAKAGI, Y; MURAKOSHI, I			ISOLATION AND CHARACTERIZATION OF CDNA THAT ENCODES A PUTATIVE MITOCHONDRION-LOCALIZING ISOFORM OF CYSTEINE SYNTHASE (O-ACETYLSERINE(THIOL)-LYASE) FROM SPINACIA-OLERACEA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; EXPRESSION; CLONING; PLANTS; GENE; SEQUENCES; SULFUR	The cDNA clones that encode a putative mitochondrion-localizing isoform of cysteine synthase (O-acetyl-L-serine(thiol)-lyase, O-acetyl-L-serine acetate-lyase (adding hydrogen sulfide), EC 4.2.99.8), which is denoted as cysteine synthase C, were isolated from spinach (Spinacia oleracea L.). The cDNA encodes a polypeptide of 368 amino acids containing a putative transit peptide of 30-40 amino acids at the N terminus. This leader peptide sequence exhibited several structural features common to other mitochondrion-targeting transit peptides. Homology was also detected between the putative transit peptide sequence of cysteine synthase C and other mitochondrion-targeting leader sequences. A deduced amino acid sequence of cysteine synthase C exhibited a homology of 61% with cytoplasmic isoform A and 63% with chloroplastic isoform B. Abacterial expression vector of the cDNA clone could genetically complement an Escherichia coli auxotroph lacking cysteine synthase loci and could produce the functionally active and immunoreactive cysteine synthase in E. coli. DNA blot hybridization analysis showed the presence of one or two copies of cysC gene in the genome of spinach. RNA blot hybridization analysis indicated that the expression level of cysC gene was lower than those of cysA and cysB and that the mode of cysC expression was constitutive in green and etiolated seedlings of spinach. The molecular evolutionary study of cysteine synthase proteins from plants and bacteria suggested that a common ancestor cysteine synthase gene has evolved into five cysteine synthase gene families, plant isoform A family, plant isoform B family, plant isoform C family bacterial cysK family, and bacterial cysM family.			SAITO, K (corresponding author), CHIBA UNIV, FAC PHARMACEUT SCI, MED RESOURCES RES CTR, MOLEC BIOL & BIOTECHNOL LAB, INAGE KU, CHIBA 263, JAPAN.		Saito, Kazuki/D-2670-2009	Saito, Kazuki/0000-0001-6310-5342				AKHTAR M, 1984, CHEM ENZYME ACTION, P303; ANDERSON JW, 1978, SULFUR BIOL; BYRNE CR, 1988, J BACTERIOL, V170, P3150, DOI 10.1128/jb.170.7.3150-3157.1988; GAITONDE MK, 1967, BIOCHEM J, V104, P627, DOI 10.1042/bj1040627; GIOVANELLI J, 1990, SULFUR NUTRITION AND SULFUR ASSIMILATION IN HIGHER PLANTS, P33; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; Higuchi R., 1989, PCR TECHNOLOGY, P61; LEA PJ, 1985, CHEM BIOCH AMINO ACI, P197; LEVY S, 1988, MOL MICROBIOL, V2, P777, DOI 10.1111/j.1365-2958.1988.tb00089.x; LUNN JE, 1990, PLANT PHYSIOL, V94, P1345, DOI 10.1104/pp.94.3.1345; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; NALABOLU S R, 1992, Amino Acids (Vienna), V2, P119, DOI 10.1007/BF00806082; NOJI M, 1994, MOL GEN GENET, V244, P57, DOI 10.1007/BF00280187; RENNENBERG H, 1984, ANNU REV PLANT PHYS, V35, P121, DOI 10.1146/annurev.pp.35.060184.001005; RIDDLE RD, 1989, P NATL ACAD SCI USA, V86, P792, DOI 10.1073/pnas.86.3.792; ROLLAND N, 1992, PLANT PHYSIOL, V98, P927, DOI 10.1104/pp.98.3.927; ROLLAND N, 1993, ARCH BIOCHEM BIOPHYS, V300, P213, DOI 10.1006/abbi.1993.1030; ROLLAND N, 1993, BIOCHEM J, V293, P829, DOI 10.1042/bj2930829; ROMER S, 1992, J BIOL CHEM, V267, P17966; RUFFET ML, 1994, PLANT PHYSIOL, V104, P597, DOI 10.1104/pp.104.2.597; SAITO K, 1993, FEBS LETT, V324, P247, DOI 10.1016/0014-5793(93)80127-G; SAITO K, 1992, P NATL ACAD SCI USA, V89, P8078, DOI 10.1073/pnas.89.17.8078; SAITO K, 1991, P NATL ACAD SCI USA, V88, P7041, DOI 10.1073/pnas.88.16.7041; SAITO K, 1993, FEBS LETT, V328, P111, DOI 10.1016/0014-5793(93)80976-2; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT A, 1992, ANNU REV PLANT PHYS, V43, P325, DOI 10.1146/annurev.pp.43.060192.001545; SIMOENS CR, 1988, GENE, V67, P1, DOI 10.1016/0378-1119(88)90002-9; SIRKO A, 1990, J BACTERIOL, V172, P3351, DOI 10.1128/jb.172.6.3351-3357.1990; SUZUKI T, 1989, J BIOL CHEM, V264, P2581; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; YOUSSEFIAN S, 1993, PLANT J, V4, P759, DOI 10.1046/j.1365-313X.1993.04050759.x	32	70	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28187	28192						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961755				2022-12-27	WOS:A1994PV77200063
J	DAVIS, JQ; BENNETT, V				DAVIS, JQ; BENNETT, V			ANKYRIN BINDING-ACTIVITY SHARED BY THE NEUROFASCIN/L1/NRCAM FAMILY OF NERVOUS-SYSTEM CELL-ADHESION MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IMMUNOGLOBULIN SUPERFAMILY; ERYTHROCYTE ANKYRIN; BRAIN ANKYRIN; SPECTRIN; MEMBRANE; L1; DOMAIN; SITES	Neurofascin, L1, NrCAM, NgCAM, and neuroglian are membrane-spanning cell adhesion molecules with conserved cytoplasmic domains that are believed to play important roles in development of the nervous system. This report presents biochemical evidence that the cytoplasmic domains of these molecules associate directly with ankyrins, a family of spectrin-binding proteins located on the cytoplasmic surface of specialized plasma membrane domains. Rat neurofascin and NrCAM together comprise over 0.5% of the membrane protein in adult brain tissue. Linkage of these ankyrin-binding cell adhesion molecules to spectrin-based structures may provide a major class of membrane-cytoskeletal connections in adult brain as well as earlier stages of development.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University								BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; CHAN W, 1993, J CELL BIOL, V123, P1463, DOI 10.1083/jcb.123.6.1463; DAVIS J, 1989, J BIOL CHEM, V264, P6417; DAVIS J, 1983, J BIOL CHEM, V258, P7757; DAVIS JQ, 1993, J CELL BIOL, V121, P121, DOI 10.1083/jcb.121.1.121; DAVIS JQ, 1984, J BIOL CHEM, V259, P3550; DAVIS LH, 1992, J BIOL CHEM, V267, P18966; FELSENFELD DP, 1994, NEURON, V12, P675, DOI 10.1016/0896-6273(94)90222-4; Grumet M, 1991, Curr Opin Neurobiol, V1, P370, DOI 10.1016/0959-4388(91)90055-C; HORTSCH M, 1991, ANNU REV CELL BIOL, V7, P505, DOI 10.1146/annurev.cb.07.110191.002445; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; KAYYEM JF, 1992, J CELL BIOL, V118, P1259, DOI 10.1083/jcb.118.5.1259; KORDELI E, 1991, J CELL BIOL, V114, P1243, DOI 10.1083/jcb.114.6.1243; LINNEMANN D, 1988, DEV NEUROSCI-BASEL, V10, P34, DOI 10.1159/000111953; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; MORALES G, 1993, NEURON, V11, P1113, DOI 10.1016/0896-6273(93)90224-F; Rathjen F. G, 1991, SEMIN NEUROSCI, V3, P297, DOI 10.1016/1044-5765(91)90047-R; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; SONDEREGGER P, 1992, J CELL BIOL, V119, P1387, DOI 10.1083/jcb.119.6.1387; VOLKMER H, 1992, J CELL BIOL, V118, P149, DOI 10.1083/jcb.118.1.149; WILLIAMS EJ, 1992, J CELL BIOL, V119, P883, DOI 10.1083/jcb.119.4.883	23	276	281	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27163	27166						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961622				2022-12-27	WOS:A1994PV77100003
J	KUMAR, KN; BABCOCK, KK; JOHNSON, PS; CHEN, XY; EGGEMAN, KT; MICHAELIS, EK				KUMAR, KN; BABCOCK, KK; JOHNSON, PS; CHEN, XY; EGGEMAN, KT; MICHAELIS, EK			PURIFICATION AND PHARMACOLOGICAL AND IMMUNOCHEMICAL CHARACTERIZATION OF SYNAPTIC MEMBRANE-PROTEINS WITH LIGAND-BINDING PROPERTIES OF N-METHYL-D-ASPARTATE RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-3 MK-801 BINDING; NMDA-RECEPTOR; GLUTAMATE-RECEPTOR; RAT-BRAIN; COMPETITIVE ANTAGONISTS; PHENCYCLIDINE RECEPTOR; FUNCTIONAL EXPRESSION; HIPPOCAMPAL-NEURONS; MOLECULAR-CLONING; CHANNEL COMPLEX	A method was developed for the solubilization of approximately 50% of proteins in synaptic membranes that have ligand-binding characteristics of N-methyl-D-aspartate (NMDA) receptors. Affinity chromatographic separation of the solubilized proteins through L-glutamate-derivatized matrices and subsequent elution by NMDA-containing buffers led to the purification of four predominant proteins with estimated sizes of 67-70, 53-62, 41-43, and 28-36 kDa. The co purification of NMDA-sensitive L-glutamate binding, dizocilpine-sensitive thienylcyclohexyl piperidine (TCP)-binding, and strychnine-insensitive glycine-binding proteins was achieved by this affinity chromatographic procedure. Glutamate, glycine, and the polyamine spermidine increased both the ''on'' rate and the equilibrium level of [H-3]TCP binding to the isolated proteins. The group of proteins eluted by NMDA from the glutamate-derivatized matrices could be further purified through size exclusion chromatography without loss of ligand binding activity or separation of the NMDA-sensitive glutamate-binding from the dizocilpine-sensitive TCP-binding proteins. Polyclonal and monoclonal antibodies to the cloned NMDA receptor protein NMDAR1 did not react with any proteins in the solubilized membrane proteins or the purified fractions. However, immunoreaction of antibodies raised against a glutamate binding protein and a phosphonoaminocarboxylic acid-binding protein indicated that these are two of the major proteins in the purified fractions. These studies indicate that these two proteins might be components of a complex that has some of the characteristics of NMDA receptors and that neuronal membranes may contain varieties of NMDA-like receptors composed of protein subunits that differ from the NMDAR1 and NMDAR2 receptor proteins.	UNIV KANSAS, DEPT PHARMACOL & TOXICOL, LAWRENCE, KS 66045 USA; UNIV KANSAS, CTR NEUROBIOL & IMMUNOL RES, LAWRENCE, KS 66045 USA; NIDA, MOLEC NEUROBIOL LAB, BALTIMORE, MD 21224 USA; UNIV COLORADO, HLTH SCI CTR, DEPT PHARMACOL, DENVER, CO 80262 USA	University of Kansas; University of Kansas; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA004732, R01AA004732] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [F31DA005472] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA04732] Funding Source: Medline; NIDA NIH HHS [DA 05472] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AMBAR I, 1988, J NEUROCHEM, V51, P133, DOI 10.1111/j.1471-4159.1988.tb04846.x; BAKKER MHM, 1991, J NEUROCHEM, V57, P39, DOI 10.1111/j.1471-4159.1991.tb02096.x; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BINPARK K, 1989, ANAL BIOCHEM, V180, P55, DOI 10.1016/0003-2697(89)90086-9; BONHAUS DW, 1988, MOL PHARMACOL, V34, P250; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BROSE N, 1993, J BIOL CHEM, V268, P22663; CHEN JW, 1988, J BIOL CHEM, V263, P417; COTMAN CW, 1987, PSYCHOPHARMACOLOGY 3, P197; CUNNINGHAM MD, 1990, J BIOL CHEM, V265, P7768; EATON MJ, 1990, J BIOL CHEM, V265, P16195; EGGEMAN KT, 1993, NEUROSCI LETT, V158, P173, DOI 10.1016/0304-3940(93)90257-L; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; HARING R, 1986, BIOCHEMISTRY-US, V25, P612, DOI 10.1021/bi00351a015; HENLEY JM, 1992, P NATL ACAD SCI USA, V89, P4806, DOI 10.1073/pnas.89.11.4806; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HONORE T, 1989, EUR J PHARM-MOLEC PH, V172, P239, DOI 10.1016/0922-4106(89)90054-0; HUNTER C, 1992, J NEUROCHEM, V58, P1379, DOI 10.1111/j.1471-4159.1992.tb11353.x; IKIN AF, 1990, BIOCHEMISTRY-US, V29, P2290, DOI 10.1021/bi00461a012; JAVITT DC, 1989, MOL PHARMACOL, V35, P387; JAVITT DC, 1990, MOL PHARMACOL, V37, P603; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KERRY CJ, 1993, MOL PHARMACOL, V44, P142; KUMAR KN, 1991, J BIOL CHEM, V266, P14947; KUMAR KN, 1991, NATURE, V354, P70, DOI 10.1038/354070a0; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LY AM, 1991, BIOCHEMISTRY-US, V30, P4307, DOI 10.1021/bi00231a029; MATTSON MP, 1991, BRAIN RES, V565, P94, DOI 10.1016/0006-8993(91)91740-R; MATTSON MP, 1993, J NEUROSCI, V13, P4575; MCKERNAN RM, 1989, J NEUROCHEM, V52, P777, DOI 10.1111/j.1471-4159.1989.tb02522.x; MCVITTIE LD, 1989, LIFE SCI, V44, P1793, DOI 10.1016/0024-3205(89)90567-5; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; PETRALIA RS, 1994, J NEUROSCI, V14, P667; RANSOM RW, 1988, J NEUROCHEM, V51, P830, DOI 10.1111/j.1471-4159.1988.tb01818.x; SMIRNOVA T, 1993, SCIENCE, V262, P430, DOI 10.1126/science.8105537; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; WANG H, 1992, NEUROSCIENCE, V46, P793, DOI 10.1016/0306-4522(92)90186-6; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A	41	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27384	27393						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961649				2022-12-27	WOS:A1994PV77100039
J	LAWRENCE, DA; OLSON, ST; PALANIAPPAN, S; GINSBURG, D				LAWRENCE, DA; OLSON, ST; PALANIAPPAN, S; GINSBURG, D			SERPIN REACTIVE CENTER LOOP MOBILITY IS REQUIRED FOR INHIBITOR FUNCTION BUT NOT FOR ENZYME RECOGNITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; ALPHA-1-PROTEINASE INHIBITOR; CONFORMATIONAL STABILITY; AFFINITY CHROMATOGRAPHY; PROTEINASE-INHIBITORS; SUBSTRATE PROPERTIES; CRYSTAL-STRUCTURE; ALPHA-1-ANTITRYPSIN; ANTITHROMBIN; THROMBOSIS	One feature that distinguishes all of the inhibitory members of the serpin gene family is the presence of a small uncharged residue at the P14 position of the reactive center loop. In this report we examine the effects of mutations at this position, in the serpin, plasminogen activator inhibitor type 1 (PAI-1). Replacement of the native P14 Thr-333 residue by an Arg (Thr-333 --> Arg) resulted in complete loss of inhibitory activity toward tissue-type plasminogen activator and urokinase-type plasminogen activator. Comparison of the binding of the mutant inhibitor and wild type PAI-1 (WTPAI-I) to anhydrotrypsin indicated that the initial interaction of the two inhibitors with proteases was identical. However, whereas WTPAI-1 forms SDS-stable complexes with both plasminogen activators, the mutant PAI-1 was efficiently cleaved as a substrate. Amino-terminal sequence analysis indicated that cleavage of the mutant PAI-I occurred at its reactive center P1-P1' Arg-Met bond. Thermal denaturation studies of native and cleaved PAIs indicated that native Thr-333 --> Arg mutant had a thermal stability identical to active WTPAI-1 and that both proteins became significantly more stable following cleavage by elastase (cleaved at the P4-P3 bond). Finally the function of recombinant PAI-I variants containing 15 of the possible 19 amino acid substitutions at P14 were analyzed. While residue size appeared to have little effect on inhibitory activity, the presence of either a positive or a negative charge at P14, converted PAI-1 to a substrate. Taken together, these results suggest that while insertion of the reactive center loop is not essential for protease binding, it is a necessary second step required for inhibitor function. The presence of a charged residue at P14 can retard this insertion, resulting in conversion of the serpin to a substrate.	UNIV MICHIGAN,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV ILLINOIS,CTR MOLEC BIOL ORAL DIS,CHICAGO,IL 60612	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	LAWRENCE, DA (corresponding author), UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109, USA.			Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008572, R29HL039888, R01HL039137, R01HL039888] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 39888, HL 39137, HL 08572] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKO H, 1972, BIOCHEM BIOPH RES CO, V47, P1402, DOI 10.1016/0006-291X(72)90228-8; AKO H, 1974, BIOCHEMISTRY-US, V13, P132, DOI 10.1021/bi00698a021; BJORK I, 1992, J BIOL CHEM, V267, P1976; BRUCH M, 1988, J BIOL CHEM, V263, P16626; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Carrell RW, 1992, CURR OPIN STRUC BIOL, V2, P438; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DECLERCK PJ, 1992, J BIOL CHEM, V267, P11693; EVANS SA, 1982, J BIOL CHEM, V257, P3014; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; GETTINS P, 1988, BIOCHEMISTRY-US, V27, P3634, DOI 10.1021/bi00410a017; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LAWRENCE DA, 1994, BIOCHEMISTRY-US, V33, P3643, DOI 10.1021/bi00178a022; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; LAWRENCE DA, 1995, IN PRESS MOL BIOL TH; LEVIN EG, 1987, J CELL BIOL, V105, P2543, DOI 10.1083/jcb.105.6.2543; LINDAHL P, 1991, BIOCHEM J, V276, P387, DOI 10.1042/bj2760387; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MIKUS P, 1993, EUR J BIOCHEM, V218, P1071, DOI 10.1111/j.1432-1033.1993.tb18467.x; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; ROBINSON NC, 1971, BIOCHEMISTRY-US, V10, P2743; SCHECHTER NM, 1993, J BIOL CHEM, V268, P23626; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SCHULZE AJ, 1991, EUR J BIOCHEM, V202, P1147, DOI 10.1111/j.1432-1033.1991.tb16483.x; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; YUNG BY, 1975, BIOCHEM BIOPH RES CO, V65, P927, DOI 10.1016/S0006-291X(75)80474-8; YUNG BYK, 1980, J BIOL CHEM, V255, P9724	45	134	141	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27657	27662						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961684				2022-12-27	WOS:A1994PV77100078
J	LUO, ZG; FUENTES, ME; TAYLOR, P				LUO, ZG; FUENTES, ME; TAYLOR, P			REGULATION OF ACETYLCHOLINESTERASE MESSENGER-RNA STABILITY BY CALCIUM DURING DIFFERENTIATION FROM MYOBLASTS TO MYOTUBES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; RYANODINE RECEPTOR; MESSENGER-RNA; CHARGE MOVEMENT; RELEASE CHANNEL; CA-2+ RELEASE; SUBUNIT GENE; MOUSE MUSCLE; CELL-LINE	The expression of acetylcholinesterase (AChE), nicotinic acetylcholine receptors (nAChR), and their corresponding mRNAs increases dramatically during the conversion of myoblasts to myotubes in C2-C12 cells. The increase in expression of nAChR arises from transcriptional activation of the genes encoding the receptor subunits, whereas stabilization of labile transcripts is primarily responsible for enhanced AChE expression. In a search for the signaling pathways responsible for stabilization of the AChE mRNA, we found that ryanodine, synthetic ryanodine receptor antagonists and L-type, but not N-type, Ca2+ channel blockers inhibit the differentiation-induced expression of AChE mRNA, but not the nAChR mRNA. Selective inhibition of increased expression of AChE is also evident. Inhibition by ryanodine and nifedipine is additive suggesting different target sites for the two Ca2+ channel ligands. Ryanodine binding sites can be detected in both myoblasts and myotubes, but they increase substantially during differentiation. Rates of AChE gene transcription are not altered by ryanodine and nifedipine, indicating that decreased Ca2+ availability prevents stabilization of the mRNA normally seen with differentiation. Muscle cells still undergo elongation and fusion in the presence of ryanodine or L-type Ca2+ channel antagonists. Ryanodine block is fully reversible, indicating functional integrity of the cellular expression system after the drug treatment. These findings indicate that intracellular ryanodine-sensitive calcium channels and extracellular L-type Ca2+ channels link to play an important role in stabilizing AChE mRNA and suggest that transient increases in intracellular Ca2+ may be critical for the commitment of AChE expression during myogenesis.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL 0636,LA JOLLA,CA 92093	University of California System; University of California San Diego			Fuentes, Maria/HGA-8617-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360, R01GM018360] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 18360] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS BA, 1990, NATURE, V346, P569, DOI 10.1038/346569a0; ARAI M, 1992, AM J PHYSIOL, V262, pC614, DOI 10.1152/ajpcell.1992.262.3.C614; BALDWIN TJ, 1988, J CELL BIOL, V107, P2271, DOI 10.1083/jcb.107.6.2271; BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BUONANNO A, 1986, J BIOL CHEM, V261, P1452; CAFFREY JM, 1989, J NEUROSCI, V9, P3443; CARTAUD J, 1993, EUR J NEUROSCI, V5, P191, DOI 10.1111/j.1460-9568.1993.tb00485.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECKER MM, 1990, J BIOL CHEM, V265, P11796; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; EVANS S, 1987, J BIOL CHEM, V262, P4911; FRAIL DE, 1989, NEURON, V2, P1077, DOI 10.1016/0896-6273(89)90232-8; FRANZINI.C, 1970, J CELL BIOL, V47, P488, DOI 10.1083/jcb.47.2.488; FUENTES ME, 1993, NEURON, V10, P1; GILMAN M, 1989, CURRENT PROTOCOLS MO, V7; GREENBERG ME, 1989, CURRENT PROTOCOLS MO, V9; HAHN S, 1991, ONCOGENE, V6, P2327; HALL ZW, 1993, NEURON S, V10, P99; HASTINGS KEM, 1982, P NATL ACAD SCI-BIOL, V79, P1553, DOI 10.1073/pnas.79.5.1553; HOWE JG, 1986, P NATL ACAD SCI USA, V83, P9006, DOI 10.1073/pnas.83.23.9006; HWANG KS, 1987, BIOCHEM BIOPH RES CO, V142, P674, DOI 10.1016/0006-291X(87)91467-7; INESTROSA NC, 1983, EXP CELL RES, V147, P393, DOI 10.1016/0014-4827(83)90221-5; Janis RA, 1987, ADV DRUG RES, V16, P309; LATTANZIO FA, 1987, J BIOL CHEM, V262, P2711; LI Y, 1993, J BIOL CHEM, V268, P3563; LU XY, 1994, J BIOL CHEM, V269, P6511; MARKS AR, 1991, J CELL BIOL, V114, P303, DOI 10.1083/jcb.114.2.303; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MITCHELL RD, 1983, J CELL BIOL, V96, P1008, DOI 10.1083/jcb.96.4.1008; NUMA S, 1990, COLD SPRING HARB SYM, V45, P1; OHMURA T, 1990, INT IMMUNOL, V2, P1073, DOI 10.1093/intimm/2.11.1073; OMALLEY K, 1985, MOL CELL BIOL, V5, P3476, DOI 10.1128/MCB.5.12.3476; PESSAH IN, 1985, BIOCHEM BIOPH RES CO, V128, P449, DOI 10.1016/0006-291X(85)91699-7; RIOS E, 1992, ANNU REV PHYSIOL, V54, P109, DOI 10.1146/annurev.ph.54.030192.000545; RIVIER J, 1987, J BIOL CHEM, V262, P1194; RUBIN LL, 1985, P NATL ACAD SCI USA, V82, P7121, DOI 10.1073/pnas.82.20.7121; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SCHWARTZ LM, 1985, NATURE, V314, P747, DOI 10.1038/314747a0; SILMAN I, 1978, FEBS LETT, V94, P166, DOI 10.1016/0014-5793(78)80929-6; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; WANG Y, 1988, NEURON, V1, P527, DOI 10.1016/0896-6273(88)90183-3; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; YUAN SH, 1991, J CELL BIOL, V112, P289, DOI 10.1083/jcb.112.2.289	47	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27216	27223						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961631				2022-12-27	WOS:A1994PV77100013
J	MCLEAN, RH; NIBLACK, G; JULIAN, B; WANG, T; WYATT, R; PHILLIPS, JA; COLLINS, TS; WINKELSTEIN, J; VALLE, D				MCLEAN, RH; NIBLACK, G; JULIAN, B; WANG, T; WYATT, R; PHILLIPS, JA; COLLINS, TS; WINKELSTEIN, J; VALLE, D			HEMOLYTICALLY INACTIVE C4B COMPLEMENT ALLOTYPE CAUSED BY A PROLINE TO LEUCINE MUTATION IN THE C5-BINDING SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID 21-HYDROXYLASE GENES; BETA-CHAIN RESIDUE-458; PATHWAY C5 CONVERTASE; 4TH COMPONENT; STRUCTURAL BASIS; SINGLE ARGININE; NULL ALLELES; POLYMORPHISM; DNA; ORGANIZATION	The fourth component of complement (C4) is encoded by two highly homologous genes, C4A and C4B. Only one hemolytically inactive C4A allotype (C4A*6) has been reported. No hemolytically inactive C4B allotype has been described. We report the first hemolytically inactive (hi) allotype of C4B, C4B*1(hi). This unique variant was first recognized by hemolytic overlay assays and confirmed to segregate in the affected pedigree with the major histocompatibility complex haplotype A28,B35,CW4,DR6, C4A3,C4B1(hi), BFF,C2C. By single strand conformational polymorphism, we detected only a migration variant in exon 12 caused by a C to T transition in the second base of codon 459. This mutation results in a leucine substitution for proline (P459L) 1 residue down-stream of a residue known to contribute to the C5-binding site. Allele-specific oligonucleotide analysis of samples demonstrated cosegregation of the mutation with the hemolytically inactive allotype in the affected pedigree. Site-directed mutagenesis and expression studies showed that the P459L mutation causes loss of hemolytic function. C4B*1(hi) is the first example of a circulating C4B protein lacking detectable hemolytic activity and the P459L mutation expands our knowledge of the C5-binding site of C4.	GENE PROOF LABS,NASHVILLE,TN 37205; UNIV ALABAMA,DEPT MED,BIRMINGHAM,AL 35294; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; LEBONHEUR CHILDRENS HOSP & MED CTR,DEPT PEDIAT,TENNESSEE CTR HLTH SCI,MEMPHIS,TN 38103; VANDERBILT UNIV,SCH MED,DIV GENET,NASHVILLE,TN 37232; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205	University of Alabama System; University of Alabama Birmingham; Howard Hughes Medical Institute; Johns Hopkins University; University of Tennessee System; University of Tennessee Health Science Center; Vanderbilt University; Johns Hopkins University	MCLEAN, RH (corresponding author), UNIV MARYLAND,SCH MED,DEPT PEDIAT,DIV PEDIAT NEPHROL N5W70,22 S GREENE ST,BALTIMORE,MD 21201, USA.			Wyatt, Robert/0000-0001-6077-0259	NICHD NIH HHS [HD 28819] Funding Source: Medline; NIDDK NIH HHS [DK 35592, F33 DK08693] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035592, F33DK008693] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AINSWORTH PJ, 1991, NUCLEIC ACIDS RES, V19, P405, DOI 10.1093/nar/19.2.405; ANDERSON MJ, 1992, J IMMUNOL, V148, P2795; AWDEH ZL, 1979, NATURE, V282, P205, DOI 10.1038/282205a0; BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I; BELT KT, 1985, IMMUNOGENETICS, V21, P173; BELT KT, 1984, CELL, V36, P907; BRODY LC, 1992, J BIOL CHEM, V267, P3302; CAMPBELL RD, 1988, ANNU REV IMMUNOL, V6, P161, DOI 10.1146/annurev.iy.06.040188.001113; CARROLL MC, 1985, P NATL ACAD SCI USA, V82, P521, DOI 10.1073/pnas.82.2.521; CARROLL MC, 1985, IMMUNOL REV, V87, P39, DOI 10.1111/j.1600-065X.1985.tb01144.x; CARROLL MC, 1990, P NATL ACAD SCI USA, V87, P6868, DOI 10.1073/pnas.87.17.6868; CARROLL MC, 1984, NATURE, V307, P236; DODDS AW, 1985, EMBO J, V4, P2239, DOI 10.1002/j.1460-2075.1985.tb03920.x; EBANKS RO, 1992, J IMMUNOL, V148, P2803; FASANO MB, 1992, J CLIN INVEST, V90, P1180, DOI 10.1172/JCI115978; GAITHER TA, 1974, J IMMUNOL, V113, P574; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; HORTIN GL, 1989, P NATL ACAD SCI USA, V86, P1338, DOI 10.1073/pnas.86.4.1338; ISENMAN DE, 1984, J IMMUNOL, V132, P3019; KIM YU, 1992, J BIOL CHEM, V267, P4171; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; REVEILLE JD, 1985, IMMUNOGENETICS, V21, P299, DOI 10.1007/BF00430796; SCHNEIDER PM, 1986, J CLIN INVEST, V78, P650, DOI 10.1172/JCI112623; WINKELSTEIN JA, 1982, J IMMUNOL, V129, P2598; YAP EPH, 1992, TRENDS GENET, V8, P49, DOI 10.1016/0168-9525(92)90339-6; YU CY, 1987, IMMUNOGENETICS, V25, P383; YU CY, 1986, EMBO J, V5, P2873, DOI 10.1002/j.1460-2075.1986.tb04582.x; YU CY, 1991, J IMMUNOL, V146, P1057; 1992, B WORLD HEALTH ORGAN, V70, P527	30	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27727	27731						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961694				2022-12-27	WOS:A1994PV77100088
J	TSUCHIYA, M; HARA, N; YAMADA, K; OSAGO, H; SHIMOYAMA, M				TSUCHIYA, M; HARA, N; YAMADA, K; OSAGO, H; SHIMOYAMA, M			CLONING AND EXPRESSION OF CDNA FOR ARGININE-SPECIFIC ADP-RIBOSYLTRANSFERASE FROM CHICKEN BONE-MARROW CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; RHODOSPIRILLUM-RUBRUM; TURKEY ERYTHROCYTES; SKELETAL-MUSCLE; SIGNAL SEQUENCES; IRON PROTEIN; ANTIGEN CD38; SURFACE; DIFFERENTIATION; GLYCOHYDROLASE	Two arginine-specific ADP-ribosyltransferase cDNAs (designated AT1 and AT2) were cloned from chicken bone marrow cells. Each cDNA encodes a different peptide of 312 amino acid residues. Homology of deduced amino acid sequences between ATI and AT2 was 78.3%. We found all six combined peptide sequences of 222 amino acid residues derived from purified chicken heterophil ADP-ribosyltransferase (Mishima, H., Terashima, M., Obara, S., Yamada, K., Imai, K., and Shimoyama, M. (1991) J. Biochem. (Tokyo) 110, 388-394) in the deduced amino acid sequence of AT1, with two amino acid mismatches. Arginine-specific ADP-ribosyltransferase activity was detected in culture medium of COS 7 cells transiently transfected with AT1 cDNA, while activity from the cells transfected with AT2 cDNA was found in both culture medium and cell lysate. AT1 transferase required a-mercaptoethanol for the activity The activity was inhibited in the presence of NaCl while AT2 enzyme was activated by either agent. On zymographic in situ gel analysis, estimated molecular masses of the ATI, AT2 and purified chicken heterophil transferases were 32, 34, and 27.5 kDa, respectively Northern blot analysis with specific probes to AT1 or AT2 cDNAs revealed about a 1.5-kilobase message in chicken bone marrow cells but no signals were observed in heterophils, spleen, and liver of chicken or human HL-60 cells. Highly conserved regions were observed among the deduced amino acid sequences of AT1, AT2, rabbit skeletal muscle transferase, and rodent T-cell surface antigen RTGs.	SHIMANE MED UNIV,DEPT BIOCHEM,IZUMO,SHIMANE 693,JAPAN; SHIMANE MED UNIV,CENT RES LABS,IZUMO,SHIMANE 693,JAPAN	Shimane University; Shimane University								AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GODEAU F, 1984, ANAL BIOCHEM, V137, P287, DOI 10.1016/0003-2697(84)90087-3; HAAG F, 1990, NUCLEIC ACIDS RES, V18, P1047, DOI 10.1093/nar/18.4.1047; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KOCH F, 1990, P NATL ACAD SCI USA, V87, P964, DOI 10.1073/pnas.87.3.964; KOCH F, 1990, NUCLEIC ACIDS RES, V18, P3636, DOI 10.1093/nar/18.12.3636; KONTANI K, 1993, J BIOL CHEM, V268, P16895; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; KUROSAKI T, 1987, J BIOL CHEM, V262, P15990; LOWERY RG, 1988, J BIOL CHEM, V263, P16714; LUBBERT M, 1991, BLOOD, V77, P909; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MISHIMA K, 1991, J BIOCHEM-TOKYO, V110, P388, DOI 10.1093/oxfordjournals.jbchem.a123591; MOSS J, 1981, J BIOL CHEM, V256, P1452; MOSS J, 1980, J BIOL CHEM, V255, P5838; MULLER HM, 1983, BIOCHEM J, V212, P459, DOI 10.1042/bj2120459; MYERS TW, 1991, BIOCHEMISTRY-US, V30, P7761; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; PETERSON JE, 1990, J BIOL CHEM, V265, P17062; POPE MR, 1985, P NATL ACAD SCI USA, V82, P3173, DOI 10.1073/pnas.82.10.3173; POPE MR, 1986, J BIOL CHEM, V261, P104; SAARI LL, 1986, J BIOL CHEM, V261, P4973; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; TAKADA T, 1994, J BIOL CHEM, V269, P9420; TROUTT AB, 1992, P NATL ACAD SCI USA, V89, P9823, DOI 10.1073/pnas.89.20.9823; TSUCHIYA M, 1986, ANAL BIOCHEM, V157, P381, DOI 10.1016/0003-2697(86)90641-X; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; VERSHNEY U, 1991, BIOCHEMISTRY-US, V30, P4055; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Williamson K., 1990, ADP RIBOSYLATING TOX, P493; YAMADA K, 1992, FEBS LETT, V311, P203, DOI 10.1016/0014-5793(92)81102-R; YAMADA K, 1994, ARCH BIOCHEM BIOPHYS, V308, P31, DOI 10.1006/abbi.1994.1004; YOST DA, 1983, J BIOL CHEM, V258, P4926; ZOLKIEWSKA A, 1993, J BIOL CHEM, V268, P25273; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352	39	66	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27451	27457						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961658				2022-12-27	WOS:A1994PV77100048
J	KUWABARA, S				KUWABARA, S			PURIFICATION AND PROPERTIES OF PEDITOXIN AND THE STRUCTURE OF ITS PROSTHETIC GROUP, PEDOXIN, FROM THE SEA-URCHIN TOXOPNEUSTES PILEOLUS (LAMARCK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAST ATOM BOMBARDMENT; MASS-SPECTROMETRY	A protein toxin, termed peditoxin, containing an active prosthetic group was isolated and purified hom the globiferous pedicellariae of the sea urchin Toxopneustes pileolus (Lamarck). The prosthetic group, called pedoxin, is a small molecular mass substance (206 daltons) with an empirical formula of C10H10N2O3 and is comprised of a heterocyclic lactone structure formed from pyridoxal and glycine. Administered subcutaneously or intramuscularly to mice in sublethal doses, pedoxin markedly reduced basal body temperature and led to sedation and anesthetic coma accompanied by muscular relaxation. At higher doses, it leads to convulsion and death (LD(50) 200 mg/kg). The apoprotein, a cytochrome b-like heme protein called pedin (molecular mass, 10,000 daltons) is itself not toxic, but the purified holoprotein is extremely toxic, causing anaphylaxis-like shock and death in experimental animals at low doses (LD(50) 70 mu g/kg). Small amounts of the prosthetic group added to holoprotein preparations caused the toxicity to be greatly enhanced, suggesting that holoprotein preparations also contain apoprotein capable of being activated by the low molecular weight toxin. The structure of pedoxin was determined to be 3-hydroxy-2-methyl-5-methoxy-4-pyridineformyl-glycyliden ester and was confirmed by total synthesis.	UNIV TOKYO,INST MED SCI,TOKYO 108,JAPAN; UNIV OCCUPAT & ENVIRONM HLTH,SCH MED,YAHATANISHI KU,KITAKYUSHU,FUKUOKA 807,JAPAN	University of Tokyo; University of Occupational & Environmental Health - Japan								ALENDER CHARLES B., 1965, TOXICON, V3, P9, DOI 10.1016/0041-0101(65)90062-0; BACH SJ, 1946, BIOCHEM J, V40, P229, DOI 10.1042/bj0400229; Barthels Philipp, 1906, Zoologischer Anzeiger Leipzig, V29; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BECKEY HD, 1969, PRINCIPLES FIELD ION, P20; BERGMANN M, 1926, PHYSIOL CHEM PHYS M, V152, P282; BOJESEN G, 1986, INT J MASS SPECTROM, V68, P239, DOI 10.1016/0168-1176(86)87050-1; CHILDS B, 1961, PEDIATRICS, V27, P522; Cu?not L., 1891, ARCH BIOL, V11, P313, DOI 10.5038/bin.books.1014; DALGLIESH CE, 1947, J CHEM SOC, P559; DAYHOFF MO, 1972, ATLAS PROTEIN SEQUEN, V5, pD7; FEIGEN GA, 1966, TOXICON, V4, P161, DOI 10.1016/0041-0101(66)90046-8; FENSELAU C, 1987, CHEM REV, V87, P501, DOI 10.1021/cr00079a002; FOETTINGER A, 1881, ARCH BIOL, V2, P455; FREDERICQ L, 1924, WINTERSTEINS HDB VER, V2, P36; Fujiwara T., 1935, Annotationes Zoologicae Japonenses, V15, P62; GOWER JL, 1985, BIOMED MASS SPECTROM, V12, P191, DOI 10.1002/bms.1200120502; HAMANN O, 1887, Z NATURWISS, V21, P91; HEYL D, 1948, J AM CHEM SOC, V70, P3429, DOI 10.1021/ja01190a061; HEYL D, 1951, J AM CHEM SOC, V73, P3430, DOI 10.1021/ja01151a126; HOLIDAY ER, 1936, BIOCHEM J, V36, P1794; KATZ AM, 1959, J BIOL CHEM, V234, P2897; KIERNIK E, 1906, ZOOL ANZ, V29, P610; KOUGE K, 1987, B CHEM SOC JPN, V60, P2409, DOI 10.1246/bcsj.60.2409; KUMMLER D, 1975, ORG MASS SPECTROM, V10, P813, DOI 10.1002/oms.1210100918; KUWABARA S, 1975, J BIOL CHEM, V250, P2563; KUWABARA S, 1975, J BIOL CHEM, V250, P2556; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MENDES EG, 1936, SCIENCE, V139, P408; MOORE S, 1958, ANAL CHEM, V30, P1185, DOI 10.1021/ac60139a005; MOORE S, 1963, J BIOL CHEM, V238, P235; OSHIMA H, 1951, DOBUTSUGAKU ZASSHI, V27, P605; POSO O, 1908, ZOOL ANZ, V32, P14; Reichensperger A, 1908, Z WISS ZOOL ABT A, V91, P304; ROMANES GJ, 1984, J LINN SOC LOND ZOOL, V17, P131; Sarasin C. F., 1886, ZOOL ANZ, V9, P80; SCHULTEN JR, 1975, METHOD BIOCHEM ANAL, V24, P313; Sladen W P, 1880, ANN MAG NAT HIST, V6, P101, DOI 10.1080/00222938009458904; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; UEXKULL J, 1899, Z BIOL, V19, P335; UEXKULL J, 1899, Z BIOL, V37, P298	41	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26734	26738						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929407				2022-12-27	WOS:A1994PQ93100026
J	MACKMAN, N				MACKMAN, N			PROTEASE INHIBITORS BLOCK LIPOPOLYSACCHARIDE INDUCTION OF TISSUE FACTOR GENE-EXPRESSION IN HUMAN MONOCYTIC CELLS BY PREVENTING ACTIVATION OF C-REL/P65 HETERODIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FACTOR MESSENGER-RNA; AMP-DEPENDENT MECHANISM; PROCOAGULANT ACTIVITY; MONONUCLEAR PHAGOCYTES; INTRAVASCULAR COAGULATION; THROMBOPLASTIN GENERATION; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; ENDOTOXIN	Tissue factor (TF) is expressed rapidly by human monocytes exposed to bacterial endotoxin (lipopolysaccharide, or LPS). Transcriptional regulation is mediated by binding of c-Rel/p65 heterodimers to a KB-like site in the TF promoter. Nuclear translocation of cytosolic c-Rel/p65 heterodimers and other members of the NF-kappa B/Rel family requires dissociation and proteolytic degradation of the inhibitor protein, I kappa B alpha. The protease inhibitors N-alpha-tosylphenylalanyl chloromethyl ketone (TPCK) and N-alpha-tosyl-L-lysine chloromethyl ketone (TLCK) block activation of NF-kappa B/Rel proteins by preventing degradation of I kappa B alpha. To determine if TPCK and TLCK inhibited LPS induction of TF expression, freshly isolated human monocytes and monocytic THP-1 cells were pretreated with these inhibitors for 30 min before LPS stimulation. Both TPCK and TLCK inhibited LPS induction of TF protein, TF mRNA and TF promoter activity in a dose-dependent manner. These inhibitors specifically prevented degradation of I kappa B alpha and nuclear translocation of c-Rel/p65 heterodimers. In contrast, TPCK and TLCK did not block induction of an immediate early gene encoding the transcription factor, Egr-1. Taken together, these data indicated that inhibiting nuclear translocation of c-Rel/p65 heterodimers prevented LPS induction of TF gene transcription in monocytic cells.			MACKMAN, N (corresponding author), Scripps Res Inst, DEPT IMMUNOL, 10666 N TORREY PINES RD, IMM-17, LA JOLLA, CA 92037 USA.				NHLBI NIH HHS [HL-48872] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048872] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMDAHL SM, 1987, THROMB RES, V47, P37, DOI 10.1016/0049-3848(87)90238-6; ANDERSEN OK, 1985, ACTA CHIR SCAND, V151, P205; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BRAND K, 1991, MOL CELL BIOL, V11, P4732, DOI 10.1128/MCB.11.9.4732; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; CRUTCHLEY DJ, 1991, BLOOD, V78, P382; CRUTCHLEY DJ, 1992, ARTERIOSCLER THROMB, V12, P664, DOI 10.1161/01.ATV.12.6.664; DEPROST D, 1990, MOL PHARMACOL, V38, P562; DRAKE TA, 1993, AM J PATHOL, V142, P1; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; GREGORY SA, 1989, MOL CELL BIOL, V9, P2752, DOI 10.1128/MCB.9.6.2752; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HERBERT JM, 1993, FEBS LETT, V328, P268, DOI 10.1016/0014-5793(93)80941-M; HERBERT JM, 1992, FEBS LETT, V310, P31, DOI 10.1016/0014-5793(92)81139-D; KHARBANDA S, 1991, J CLIN INVEST, V88, P571, DOI 10.1172/JCI115341; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LEVI M, 1994, J CLIN INVEST, V93, P114, DOI 10.1172/JCI116934; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; MORRISSEY JH, 1988, THROMB RES, V52, P247, DOI 10.1016/0049-3848(88)90084-9; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; NIEMETZ J, 1972, J CLIN INVEST, V51, P307, DOI 10.1172/JCI106815; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; OKAJIMA K, 1991, AM J HEMATOL, V36, P265, DOI 10.1002/ajh.2830360408; OLLIVIER V, 1993, BLOOD, V81, P973; OLLIVIER V, 1993, FEBS LETT, V322, P231, DOI 10.1016/0014-5793(93)81576-L; PARRY GCN, 1994, FASEB J, V8, P5902; PRADIER O, 1993, EUR J IMMUNOL, V23, P2700, DOI 10.1002/eji.1830231048; RAMANI M, 1993, BRIT J HAEMATOL, V85, P462; RAMANI M, 1993, FEBS LETT, V334, P114, DOI 10.1016/0014-5793(93)81693-T; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; VIRCA GD, 1990, BIOTECHNIQUES, V8, P370; WARR TA, 1990, BLOOD, V75, P1481	39	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26363	26367						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929355				2022-12-27	WOS:A1994PQ93000065
J	ROSHAK, A; SATHE, G; MARSHALL, LA				ROSHAK, A; SATHE, G; MARSHALL, LA			SUPPRESSION OF MONOCYTE 85-KDA PHOSPHOLIPASE A(2) BY ANTISENSE AND EFFECTS ON ENDOTOXIN-INDUCED PROSTAGLANDIN BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE-A2; ARACHIDONIC-ACID; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; SYNTHASE CYCLOOXYGENASE; HUMAN FIBROBLASTS; SYNOVIAL-FLUID; MACROPHAGES; CELLS; PURIFICATION; EXPRESSION	Studies were conducted to characterize a human monocyte model where the role of the 85-kDa phospholipase A(2) (PLA(2)) in prostanoid formation could be evaluated. The presence of an immunologically related 85-kDa PLA, and type II 14-kDa PLA(2) was demonstrated in human monocytes and their roles examined in lipopolysaccharide (LPS)-induced monocyte prostaglandin E(2) (PGE(2)) formation. Exposure of human monocytes to LPS over 18 h resulted in the up-regulation of the mitogen-inducible cyclooxygenase-a and was accompanied by production and release of prostaglandin E(2) but not leukotriene C-4. This coincided with a 2-fold increase in the 85-kDa PLA(2) protein and activity levels. In contrast, there was no effect on the type II 14-kD-like PLA(2) activity measured in the 100,000 x g particulate fraction nor did LPS induce the release of type II 14-kDa PLA(2) into the medium. Treatment with cycloheximide over 18 h resulted in a time dependent decrease in cytosolic 85-kDa PLA(2) protein and activity (half life = 4 h), but there was no change in the particulate type II 14-kDa-like PLA(2) activity. Monocytes were therefore exposed to an 85-kDa PLA(2) initiation site directed antisense oligonucleotide which specifically decreased the cytosolic 85-kDa PLA(2) protein levels and activity in a concentration-dependent manner. This had no effect on the cyclooxygenase-2 (protein mass or the ability to convert arachidonic acid to PGE(2)) or the particulate fraction sn-2 acylhydrolytic activity but was associated with a decrease in LPS-induced PGE(2) production. Taken together, these data support a role for the cytosolic 85-kDa PLA(2) in LPS induced monocyte PGE(2) formation.	SMITHKLINE BEECHAM PHARMACEUT,DEPT INFLAMMAT & RESP PHARMACOL,UW2532,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC GENET,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline								AMEGADZIE BY, 1993, GENE, V128, P307, DOI 10.1016/0378-1119(93)90580-V; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; CAVAILLON J-M, 1990, Cytokine, V2, P313, DOI 10.1016/1043-4666(90)90061-W; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CROOKE RM, 1991, ANTI-CANCER DRUG DES, V6, P609; CROOKE ST, 1992, BIO-TECHNOL, V10, P882, DOI 10.1038/nbt0892-882; DECARVALHO MS, 1993, ARCH BIOCHEM BIOPHYS, V306, P534, DOI 10.1006/abbi.1993.1549; DENNIS EA, 1983, ENZYMES, V16, P308; DIEZ E, 1992, J BIOL CHEM, V267, P18342; DIEZ E, 1990, J BIOL CHEM, V265, P14654; FU JY, 1990, J BIOL CHEM, V265, P16737; GOPPELTSTRUEBE M, 1992, BIOCHIM BIOPHYS ACTA, V1127, P163, DOI 10.1016/0005-2760(92)90273-X; HULKOWER KI, 1992, BIOCHEM BIOPH RES CO, V184, P712, DOI 10.1016/0006-291X(92)90648-5; HUMES JL, 1982, J BIOL CHEM, V257, P1591; KADA A, 1989, BIOCHEM BIOPH RES CO, V163, P42; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LAI CY, 1988, BIOCHEM BIOPH RES CO, V157, P488, DOI 10.1016/S0006-291X(88)80275-4; LEE SH, 1992, J BIOL CHEM, V267, P25934; LIN L, 1992, P NATL ACAD SCI USA, V89, P6146; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MANSON J, 1990, LYMPHOKINE RES, V9, P35; MARSHALL LA, 1994, J PHARMACOL EXP THER, V268, P709; MARSHALL LA, 1993, BIOCHEM CELL BIOL, V71, P331, DOI 10.1139/o93-050; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MCKEARN TJ, 1979, IMMUNOL REV, V47, P91, DOI 10.1111/j.1600-065X.1979.tb00290.x; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MIRABELLI CK, 1991, ANTI-CANCER DRUG DES, V6, P647; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; NAKAGAWA Y, 1989, PROG LIPID RES, V28, P205, DOI 10.1016/0163-7827(89)90013-1; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; RAZ A, 1990, ADV PROSTAG THROMB L, V20, P22; SCHALKWIJK CG, 1992, EUR J BIOCHEM, V248, P1; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SPAARGAREN M, 1992, BIOCHEM J, V287, P37, DOI 10.1042/bj2870037; Stadel J. M., 1992, Journal of Molecular Recognition, V5, P145, DOI 10.1002/jmr.300050405; SVENSSON U, 1993, EUR J BIOCHEM, V213, P81, DOI 10.1111/j.1432-1033.1993.tb17736.x; TRINCHIERI G, 1991, IMMUNOL RES, V10, P89, DOI 10.1007/BF02918157; ZON G, 1991, ANTI-CANCER DRUG DES, V6, P539; ZUCALI JR, 1990, PROG LEUC B, V10, P315	43	113	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					25999	26005						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929310				2022-12-27	WOS:A1994PQ93000013
J	WEISS, J; INADA, M; ELSBACH, P; CROWL, RM				WEISS, J; INADA, M; ELSBACH, P; CROWL, RM			STRUCTURAL DETERMINANTS OF THE ACTION AGAINST ESCHERICHIA-COLI OF A HUMAN INFLAMMATORY FLUID PHOSPHOLIPASE A(2) IN CONCERT WITH POLYMORPHONUCLEAR LEUKOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY-INCREASING PROTEIN; GROUP-II PHOSPHOLIPASE-A2; SYNOVIAL-FLUID; SNAKE-VENOM; PURIFICATION; CELLS; BINDING; GENE; EXPRESSION; BACTERIA	Extracellular 14-kDa phospholipases A(2) (PLA(2)) in inflammatory exudates can contribute to bacterial phospholipid (PL) degradation during phagocytosis of Escherichia coli by polymorphonuclear leukocytes (PMN) and are highly active toward E. coli treated with the bactericidal/permeability-increasing protein (BPI) purified from PMN. PLA(2) activity toward BPI-treated E. coli varies greatly among members of this conserved family of enzymes and apparently depends on a cluster of basic residues in a variable surface region near the NH2 terminus for recognition of this biological target (Weiss, J., Wright, G. W., Bekkers, A. C. A. P. A., van den Bergh, C. J., and Verheij, H. M. (1991) J. Biol. Chem. 266, 4162-4167). We have examined by site specific mutagenesis of a recombinant PLA(2) that is identical to an enzyme in human synovial fluid (containing His-6, Arg-7, Lys-10, and Lys-15 and a global net charge of +15) the role of basic residues in this region in PLA(2), action against PLA-deficient (pldA(-)) E. coli. Substitution of Ser for Arg-7 +/- Gln for Lys-15 caused, respectively, about a 10- and 25-fold reduction in BPI-dependent PLA(2) binding and activity to E. coli, but had no effect on hydrolysis of PL of autoclaved E. coli or dispersions of purified PL. PL degradation during phagocytosis was increased after pretreatment off. coli (or PMN) with wild-type PLA(2) followed by removal of unbound PLA(2). Thus, the PLA(2) binds to cells before phagocytosis followed by internalization of the enzyme along with E. coli and intracellular action. Mutant (e.g. R7S +/- K15Q) PLA(2) show the same BPI-inde pendent binding to E. coli as the wild-type enzyme but 10-30-fold reduced activity during phagocytosis, reflecting lower intracellular activity of these enzymes. Thus, structural determinants first implicated in PLA(2) action toward E. coli treated with purified BPI apparently are also important in the intracellular action of PLA(2) during phagocytosis by PMN.	NYU, SCH MED, DEPT MED, NEW YORK, NY 10016 USA; HOFFMANN LA ROCHE INC, DEPT MOLEC GENET, NUTLEY, NJ 07110 USA	New York University; Roche Holding	WEISS, J (corresponding author), NYU, SCH MED, DEPT MICROBIOL, 550 1ST AVE, NEW YORK, NY 10016 USA.			Weiss, Jerrold/0000-0003-1476-4485	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK005472] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 18571] Funding Source: Medline; NIDDK NIH HHS [R37 DK 05472] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASAOKA Y, 1993, P NATL ACAD SCI USA, V90, P716, DOI 10.1073/pnas.90.2.716; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CROWL R, 1990, ADV EXP MED BIOL, V279, P173; CROWL RM, 1991, J BIOL CHEM, V266, P2647; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DEGEUS P, 1983, MOL GEN GENET, V190, P150, DOI 10.1007/BF00330338; DENNIS EA, 1987, DRUG DEVELOP RES, V10, P205, DOI 10.1002/ddr.430100404; ELSBACH P, 1985, J BIOL CHEM, V260, P1618; ELSBACH P, 1988, BIOCHIM BIOPHYS ACTA, V947, P29, DOI 10.1016/0304-4157(88)90018-4; ELSBACH P, 1991, METHOD ENZYMOL, V197, P24; ELSBACH P, 1979, J BIOL CHEM, V254, P1000; ELSBACH P, 1973, J BACTERIOL, V115, P490, DOI 10.1128/JB.115.2.490-497.1973; Elsbach P, 1992, INFLAMMATION BASIC P, P603; ELSBACH P, 1989, CELL ACTIVATION SIGN, P323; FORST S, 1982, J BIOL CHEM, V257, P4055; FORST S, 1986, BIOCHEMISTRY-US, V25, P4309, DOI 10.1021/bi00363a020; FORST S, 1986, BIOCHEMISTRY-US, V25, P8381, DOI 10.1021/bi00374a008; FORST S, 1987, BIOCHIM BIOPHYS ACTA, V920, P221, DOI 10.1016/0005-2760(87)90098-1; GROSS RW, 1992, TRENDS CARDIOVAS MED, V2, P115, DOI 10.1016/1050-1738(92)90016-L; HANASAKI K, 1992, J BIOL CHEM, V267, P6414; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HOMMA H, 1984, J BIOCHEM-TOKYO, V96, P1645, DOI 10.1093/oxfordjournals.jbchem.a134996; INADA M, 1994, J BIOL CHEM, V269, P26338; KINI RM, 1987, J BIOL CHEM, V262, P14402; KINI RM, 1989, TOXICON, V27, P613, DOI 10.1016/0041-0101(89)90013-5; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBEAU G, 1990, J BIOL CHEM, V265, P9526; LEVIN W, 1992, PROTEIN EXPRES PURIF, V3, P27, DOI 10.1016/1046-5928(92)90052-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNION BA, 1989, J IMMUNOL, V142, P2807; MANNION BA, 1990, J CLIN INVEST, V86, P631, DOI 10.1172/JCI114755; Means G E, 1977, Methods Enzymol, V47, P469; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MURAKAMI M, 1992, EUR J BIOCHEM, V209, P257, DOI 10.1111/j.1432-1033.1992.tb17284.x; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; OOI CE, 1990, J BIOL CHEM, V265, P15956; PRUZANSKI W, 1991, IMMUNOL TODAY, V12, P143, DOI 10.1016/0167-5699(91)90077-7; SCHALKWIJK C, 1992, J BIOL CHEM, V267, P8846; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; STONER CR, 1991, J IMMUNOL METHODS, V145, P127, DOI 10.1016/0022-1759(91)90318-A; VANDENBOSCH H, 1992, ADV EXP MED BIOL, V318, P1; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; WEISS J, 1991, J BIOL CHEM, V266, P4162; WEISS J, 1982, J CLIN INVEST, V69, P959, DOI 10.1172/JCI110535; WEISS J, 1979, J BIOL CHEM, V254, P1010; WEISS J, 1985, J CLIN INVEST, V76, P206, DOI 10.1172/JCI111947; WEISS J, 1990, PHOSPHOLIPASE A2, P103; WRIGHT GC, 1990, J CLIN INVEST, V85, P1925, DOI 10.1172/JCI114655; WRIGHT GW, 1990, J BIOL CHEM, V265, P6675	51	119	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26331	26337						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929350				2022-12-27	WOS:A1994PQ93000060
J	BUBB, MR; LEWIS, MS; KORN, ED				BUBB, MR; LEWIS, MS; KORN, ED			ACTOBINDIN BINDS WITH HIGH-AFFINITY TO A COVALENTLY CROSS-LINKED ACTIN DIMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACANTHAMOEBA-CASTELLANII; POLYMERIZATION; PURIFICATION; GELSOLIN; PROTEIN; MOTIF	Actobindin, a 9.8-kDa protein purified from Acanthamoeba castellanii, contains two actin-binding sites that can simultaneously bind two actin monomers. However, actobindin inhibits actin polymerization to a greater extent than can be explained by its affinity for actin monomers (site specific K-D = 3.3 mu M). This paradox would be resolved if actobindin could interfere with the nucleation phase of polymerization by using both binding sites to bind simultaneously to an actin oligomer because the interaction with oligomer would be thermodynamically favored over that with actin monomer. We now show that a covalently cross-linked actin dimer prepared from cross linked F-actin binds to actobindin with high affinity (apparent K-D = 11 nM) in accordance with theoretical predictions for simultaneous binding of two actin subunits per single actobindin and consistent with the hypothesis that actobindin might bind to native actin oligomers and prevent them from nucleating polymerization. Furthermore, the interaction with cross-linked dimer exhibits specificity in that an isomeric cross-linked actin dimer with more rapid electrophoretic mobility binds weakly to actobindin. However, only this isomeric dimer is produced when cross-linking reagents are added to actin undergoing polymerization in the presence of actobindin. Therefore, if actobindin inhibits polymerization by interacting with a native dimer whose conformation is similar to that of the cross-linked dimer with slower electrophoretic mobility, then actobindin must either block the cross linking sites or convert the dimer to a different conformation.	NHLBI, CELL BIOL LAB, BETHESDA, MD 20892 USA; NIH, NATL CTR RES RESOURCES, BIOMED ENGN & INSTRUMENTAT PROGRAM, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA			Korn, Edward D/F-9929-2012	Korn, Edward/0000-0003-3867-6295				BUBB MR, 1991, J BIOL CHEM, V266, P3820; BUBB MR, 1994, J BIOL CHEM, V269, P25592; BUBB MR, 1991, METHOD ENZYMOL, V196, P119; CHATELIER RC, 1987, BIOPHYS CHEM, V28, P121, DOI 10.1016/0301-4622(87)80081-9; DOI Y, 1992, BIOCHEMISTRY-US, V31, P10061, DOI 10.1021/bi00156a028; ELZINGA M, 1984, P NATL ACAD SCI-BIOL, V81, P6599, DOI 10.1073/pnas.81.21.6599; HESTERKAMP T, 1993, EUR J BIOCHEM, V218, P507, DOI 10.1111/j.1432-1033.1993.tb18403.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBOOY PK, 1988, J BIOL CHEM, V263, P12836; LAMBOOY PK, 1986, J BIOL CHEM, V261, P7150; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; MILLONIG R, 1988, J CELL BIOL, V106, P785, DOI 10.1083/jcb.106.3.785; MOCKRIN SC, 1981, J BIOL CHEM, V256, P8228; SPUDICH JA, 1971, J BIOL CHEM, V246, P4865; VANCOMPERNOLLE K, 1991, J BIOL CHEM, V266, P15427; ZARBOCK J, 1990, BIOCHEMISTRY-US, V29, P7814, DOI 10.1021/bi00486a006	16	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25587	25591						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929261				2022-12-27	WOS:A1994PQ49100056
J	INTRES, R; GOLDFLAM, S; COOK, JR; CRABB, JW				INTRES, R; GOLDFLAM, S; COOK, JR; CRABB, JW			MOLECULAR-CLONING AND STRUCTURAL-ANALYSIS OF THE HUMAN GENE ENCODING CELLULAR RETINALDEHYDE-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING; BOVINE RETINA; PINEAL-GLAND; RAT RETINA; S-ANTIGEN; EXPRESSION; PROMOTER; REGION; TRANSCRIPTION; LOCALIZATION	Cellular retinaldehyde-binding protein (CRALBP) appears to play a role in the vertebrate visual process as a substrate-routing protein, influencing the enzymatic partitioning of 11-cis-retinol at a key branch point in the visual cycle. Genomic clones spanning 29 kilobases and encompassing the human CRALBP gene have been isolated by screening two human genomic libraries and from polymerase chain reaction amplification of human leukocyte DNA. The sequence of 13,647 contiguous nucleotides has been determined, including 3130 and 516 bases from the 5'- and 3'-flanking regions, respectively. The human CRALBP gene exists as a single copy in the genome based on Southern analyses and localization to a single site on human chromosome 15 (Sparkes, R. S., Heinzmann, C., Goldflam, S., Kojis, T., Saari, J. C., Mohandes, T., Klisak, I., Bateman, J. B., and Crabb, J. W. (1992) Genomics 12, 58-62). The gene is composed of eight exons and seven introns with average lengths of 198 base pairs and 1.2 kilobases, respectively, and which exhibit conventional vertebrate splicing. Alu repetitive sequences exist in introns 4 and 5 as well as in the 5'- and 3'-flanking regions of the gene. RNase protection and primer extension analyses indicate that the human CRALBP gene transcription start site is 922 bases upstream of the initiation codon. The first exon is entirely untranslated and both exon 2 and exon 8 contain untranslated regions. The proximal 5'-flanking region lacks GC boxes and consensus TATA and CCAAT boxes at the usual positions. The 3'-untranslated region of CRALBP exon 8 is essentially identical to a partial cDNA clone reportedly isolated from a human hippocampus cDNA library, suggesting that the protein may be expressed in a wider spectrum of tissues than previously recognized. The human CRALBP genomic clones and structure provide valuable tools for studying the physiological role of the protein in vision and visual disorders,	W ALTON JONES CELL SCI CTR,PROT CHEM FACIL,LAKE PLACID,NY 12946						NEI NIH HHS [EY06603, EY06271] Funding Source: Medline; NATIONAL EYE INSTITUTE [F32EY006271] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BREITMAN ML, 1991, J BIOL CHEM, V266, P15505; BRIDGES CDB, 1987, VISION RES, V27, P2049, DOI 10.1016/0042-6989(87)90119-2; BRITTEN RJ, 1994, P NATL ACAD SCI USA, V91, P5992, DOI 10.1073/pnas.91.13.5992; BUNTMILAM AH, 1983, J CELL BIOL, V97, P703, DOI 10.1083/jcb.97.3.703; CHEN Y, 1994, TECHNIQUES PROTEIN C, V5, P371; CRABB JW, 1988, J BIOL CHEM, V263, P18678; CRABB JW, 1988, J BIOL CHEM, V263, P18688; CRABB JW, 1991, J BIOL CHEM, V266, P16674; DELEEUW AM, 1990, J NEUROCYTOL, V19, P253, DOI 10.1007/BF01217303; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EISENFELD AJ, 1985, EXP EYE RES, V41, P299, DOI 10.1016/S0014-4835(85)80020-8; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; GHOSH D, 1990, NUCLEIC ACIDS RES, V18, P1749, DOI 10.1093/nar/18.7.1749; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; KIKUCHI T, 1993, MOL CELL BIOL, V13, P4400, DOI 10.1128/MCB.13.7.4400; KROCZEK RA, 1990, ANAL BIOCHEM, V184, P90, DOI 10.1016/0003-2697(90)90017-4; LECH K, 1990, CURRENT PROTOCOLS MO, V1; LEVIN B, 1980, GENE EXPRESSION EUCA, V1, P958; LIOU GI, 1991, BIOCHEM BIOPH RES CO, V181, P159, DOI 10.1016/S0006-291X(05)81395-6; Maniatis T., 1982, MOL CLONING; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MARTINALONSO JM, 1993, EXP EYE RES, V56, P659, DOI 10.1006/exer.1993.1083; MORABITO MA, 1991, J BIOL CHEM, V266, P9667; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAPORT CJ, 1989, J BIOL CHEM, V264, P7122; Saari J.C., 1990, Progress in Retinal Research, V9, P363, DOI 10.1016/0278-4327(90)90011-6; SAARI JC, 1994, BIOCHEMISTRY-US, V33, P3106, DOI 10.1021/bi00176a045; SAARI JC, 1987, J BIOL CHEM, V262, P7618; SALAMA SR, 1990, J BACTERIOL, V172, P4510, DOI 10.1128/jb.172.8.4510-4521.1990; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO Y, 1993, J BIOL CHEM, V268, P17705; SPARKES RS, 1992, GENOMICS, V12, P58, DOI 10.1016/0888-7543(92)90406-I; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; YAMAKI K, 1990, J BIOL CHEM, V265, P20757; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4	39	33	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25411	25418						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929238				2022-12-27	WOS:A1994PQ49100031
J	LOFTUS, JC; SMITH, JW; GINSBERG, MH				LOFTUS, JC; SMITH, JW; GINSBERG, MH			INTEGRIN-MEDIATED CELL-ADHESION - THE EXTRACELLULAR FACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GLYCOPROTEIN-IIB-IIIA; LIGAND-BINDING SITE; PLATELET FIBRINOGEN RECEPTOR; MONOCLONAL-ANTIBODY EPITOPES; INTRACHAIN DISULFIDE BONDS; DIVALENT-CATION REGULATION; HUMAN VONWILLEBRAND-FACTOR; AMINO-ACID-SEQUENCE; ALPHA-SUBUNIT; VITRONECTIN RECEPTOR		Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NHLBI NIH HHS [HL48728, HL28235] Funding Source: Medline; NIAMS NIH HHS [AR27214] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728, R01HL028235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027214, R37AR027214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALIG L, 1992, J MED CHEM, V35, P4393, DOI 10.1021/jm00101a017; ANDERSON DC, 1984, J CLIN INVEST, V74, P536, DOI 10.1172/JCI111451; ANDRIEUX A, 1991, J BIOL CHEM, V266, P14202; BAJT ML, 1992, J BIOL CHEM, V267, P22211; BAJT ML, 1992, J BIOL CHEM, V267, P3789; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BARBAS CF, 1993, P NATL ACAD SCI USA, V90, P10003, DOI 10.1073/pnas.90.21.10003; BENNETT JS, 1982, J BIOL CHEM, V257, P8049; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BONALDO P, 1989, J BIOL CHEM, V264, P5575; BONTHRON D, 1986, NUCLEIC ACIDS RES, V14, P7125, DOI 10.1093/nar/14.17.7125; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; BRASS LF, 1985, J BIOL CHEM, V260, P7875; Buck C A, 1992, Semin Cell Biol, V3, P179; BUCK CA, 1986, J CELL BIOL, V103, P2421, DOI 10.1083/jcb.103.6.2421; CALVETE JJ, 1991, BIOCHEM J, V274, P457, DOI 10.1042/bj2740457; CALVETE JJ, 1992, BIOCHEM J, V282, P523, DOI 10.1042/bj2820523; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CALVETE JJ, 1989, BIOCHEM J, V261, P551, DOI 10.1042/bj2610551; CALVETE JJ, 1994, BIOCHEM J, V298, P1; CALVETE JJ, 1991, BIOCHEM J, V273, P767, DOI 10.1042/bj2730767; CALVETE JJ, 1989, BIOCHEM J, V261, P561, DOI 10.1042/bj2610561; CALVETE JJ, 1990, FEBS LETT, V27, P237; CAMPANERO MR, 1993, J CELL BIOL, V123, P1007, DOI 10.1083/jcb.123.4.1007; CAMPANERO MR, 1990, J CELL BIOL, V110, P2157, DOI 10.1083/jcb.110.6.2157; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CHARO IF, 1991, J BIOL CHEM, V266, P1414; CHENG S, 1994, J MED CHEM, V37, P1, DOI 10.1021/jm00027a001; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DSOUZA SE, 1994, IN PRESS CELL; DU XP, 1993, J BIOL CHEM, V268, P23087; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; FERNANDEZ MA, 1993, EUR J IMMUNOL, V23, P552, DOI 10.1002/eji.1830230238; FITZGERALD LA, 1985, J BIOL CHEM, V260, P1366; FLEMING JC, 1993, J IMMUNOL, V150, P480; FOURNIER DJ, 1989, THROMB HAEMOSTASIS, V62, P977; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GINSBERG MH, 1983, J CLIN INVEST, V71, P619, DOI 10.1172/JCI110808; GINSBERG MH, 1987, J BIOL CHEM, V262, P5437; GINSBERG MH, 1992, COLD SPRING HARB SYM, V57, P221, DOI 10.1101/SQB.1992.057.01.027; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; GREENSPOON N, 1993, BIOCHEMISTRY-US, V32, P1001, DOI 10.1021/bi00055a002; GULINO D, 1992, J BIOL CHEM, V267, P1001; HAAS TA, 1993, THROMB HAEMOSTASIS, V69, pA786; HANTGAN RR, 1993, BIOCHEMISTRY-US, V32, P3935, DOI 10.1021/bi00066a013; HEMLER ME, 1989, J BIOL CHEM, V264, P6529; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HEMLER ME, 1994, INTEGRIN; HERRLICH P, 1993, IMMUNOL TODAY, V14, P395, DOI 10.1016/0167-5699(93)90141-7; HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HORTON MA, 1993, J BONE MINER RES, V8, P239; HUANG X, 1994, MOL BIOL CELL, V4, pA282; HUGHES AL, 1992, MOL BIOL EVOL, V9, P216; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; JULIANO R, 1994, CANCER METAST REV, V13, P25, DOI 10.1007/BF00690416; KAJIJI S, 1989, EMBO J, V8, P673, DOI 10.1002/j.1460-2075.1989.tb03425.x; KAMATA T, 1994, J BIOL CHEM, V269, P9659; Kincade P W, 1993, Curr Top Microbiol Immunol, V184, P215; KISS I, 1989, J BIOL CHEM, V264, P8126; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KUNICKI TJ, 1981, BLOOD, V58, P268; LAM SCT, 1992, J BIOL CHEM, V267, P5649; LAMPUGNANI MG, 1991, J CELL BIOL, V112, P479, DOI 10.1083/jcb.112.3.479; LANZA F, 1992, J CLIN INVEST, V89, P1995, DOI 10.1172/JCI115808; LARJAVA H, 1990, J CELL BIOL, V110, P803, DOI 10.1083/jcb.110.3.803; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LI R, 1993, J BIOL CHEM, V268, P21474; LOFTUS JC, 1988, J BIOL CHEM, V263, P11025; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MACKRELL AJ, 1988, P NATL ACAD SCI USA, V85, P2633, DOI 10.1073/pnas.85.8.2633; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MARTINPADURA I, 1994, J BIOL CHEM, V269, P6124; McEver Rodger P., 1992, Current Opinion in Cell Biology, V4, P840, DOI 10.1016/0955-0674(92)90109-P; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MILES LA, 1986, J CLIN INVEST, V77, P2001, DOI 10.1172/JCI112529; MYOHANEN HT, 1993, J HISTOCHEM CYTOCHEM, V41, P1291; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; NOWLIN DM, 1993, J BIOL CHEM, V268, P20352; NURDEN AT, 1974, BRIT J HAEMATOL, V28, P253, DOI 10.1111/j.1365-2141.1974.tb06660.x; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; OTOOLE TE, 1989, BLOOD, V74, P14; PARISE LV, 1985, J BIOL CHEM, V260, P1750; PARISE LV, 1986, J BIOL CHEM, V261, P14011; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PHILLIPS DR, 1977, J BIOL CHEM, V252, P2121; PIDARD D, 1986, BLOOD, V67, P604; PIDARD D, 1991, EUR J BIOCHEM, V200, P437, DOI 10.1111/j.1432-1033.1991.tb16202.x; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PIERSCHBACHER MD, 1984, P NATL ACAD SCI-BIOL, V81, P5985, DOI 10.1073/pnas.81.19.5985; PULIDO R, 1991, J BIOL CHEM, V266, P10241; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; RELMAN D, 1990, CELL, V61, P1375, DOI 10.1016/0092-8674(90)90701-F; Rivas G A, 1991, Protein Expr Purif, V2, P248, DOI 10.1016/1046-5928(91)90080-3; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; ROCCO M, 1993, PROTEIN SCI, V2, P2154, DOI 10.1002/pro.5560021215; ROSS L, 1992, J BIOL CHEM, V267, P8537; RUGGERI ZM, 1986, P NATL ACAD SCI USA, V83, P5708, DOI 10.1073/pnas.83.15.5708; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; SHADLE PJ, 1982, J CELL BIOL, V95, P361, DOI 10.1083/jcb.95.1.361; SHATTIL SJ, 1985, BLOOD, V66, P92; SHAW SK, 1994, J BIOL CHEM, V269, P6016; SHELTONINLOES BB, 1986, BIOCHEMISTRY-US, V25, P3164, DOI 10.1021/bi00359a014; SINGER SJ, 1992, SCIENCE, V255, P1671, DOI 10.1126/science.1313187; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SMITH JW, 1991, J BIOL CHEM, V266, P11429; SPRINGER TA, 1984, J EXP MED, V160, P1901, DOI 10.1084/jem.160.6.1901; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SRIRAMARAO P, 1993, J BIOL CHEM, V268, P22036; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; STAATZ WD, 1990, BIOCHEM BIOPH RES CO, V168, P107, DOI 10.1016/0006-291X(90)91681-H; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STANLEY P, 1994, EMBO J, V13, P1790, DOI 10.1002/j.1460-2075.1994.tb06447.x; STEINER B, 1991, J BIOL CHEM, V266, P14986; STEINER B, 1993, J BIOL CHEM, V268, P6870; STRYNADKA NCJ, 1990, PROTEINS, V7, P234, DOI 10.1002/prot.340070305; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TAUB R, 1989, J BIOL CHEM, V264, P259; TAYLOR DB, 1992, J BIOL CHEM, V267, P11729; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; TOMIYAMA Y, 1992, J BIOL CHEM, V267, P18085; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; WANG RG, 1992, J CLIN INVEST, V90, P2038, DOI 10.1172/JCI116084; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; WILCOX DA, 1994, J BIOL CHEM, V269, P4450; WILCOX M, 1984, EMBO J, V3, P2307, DOI 10.1002/j.1460-2075.1984.tb02131.x; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; WIPPLER J, 1994, J BIOL CHEM, V269, P8754; YANG JT, 1993, DEVELOPMENT, V119, P1093	169	189	193	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25235	25238						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929213				2022-12-27	WOS:A1994PQ49100001
J	POWELL, CM; JOHNSTON, D; SWEATT, JD				POWELL, CM; JOHNSTON, D; SWEATT, JD			AUTONOMOUSLY ACTIVE PROTEIN-KINASE-C IN THE MAINTENANCE PHASE OF N-METHYL-D-ASPARTATE RECEPTOR-INDEPENDENT LONG-TERM POTENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT NEUTRAL PROTEASE; HIPPOCAMPAL-NEURONS; DIVALENT-CATIONS; 2 COMPONENTS; MUTANT MICE; RAT-BRAIN; ACTIVATION; INDUCTION; CALMODULIN; CHANNELS	In area CA1 of the hippocampus, the induction of long term potentiation (LTP) requires activation of either N-methyl-D-aspartate receptors (NMDA receptor-dependent LTP) or voltage-gated Ca2+ channels (NMDA receptor-independent LTP). We have investigated biochemical sequelae of NMDA receptor-independent LTP induction. We find that a persistent increase in second messenger-independent protein kinase C activity is associated with the maintenance phase of NMDA receptor independent LTP. This increase in protein kinase C activity is prevented by blocking LTP with nifedipine, a Ca2+ channel antagonist, or kynurenic acid, a nonselective glutamate receptor antagonist. Additionally, we find an increase in the catalytic fragment of protein kinase C (PKM) in the maintenance phase of NMDA receptor-independent LTP, indicating that proteolytic activation of protein kinase C may account for its autonomous activation. This increase in the catalytic fragment of protein kinase C is also prevented by blocking LTP induction. These results are the first to demonstrate that persistent protein kinase C activation is a possible mechanism for the maintenance of NMDA receptor-independent LTP.	BAYLOR COLL MED, DIV NEUROSCI, HOUSTON, TX 77030 USA	Baylor College of Medicine				Sweatt, J. David/0000-0003-3567-485X; Powell, Craig/0000-0001-5451-2165	NIMH NIH HHS [F30 MH010338-04, F30 MH010338, MH44754, R01 MH048432, R37 MH044754, MH48432, F30 MH010338-03, MH48186] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048186, F30MH010338, R01MH048432, R37MH044754] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANIKSZTEJN L, 1991, NATURE, V349, P67, DOI 10.1038/349067a0; AQUINO A, 1988, CANCER RES, V48, P3324; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BLISS T V P, 1988, P3; CHEN SJ, 1993, BIOCHEMISTRY-US, V32, P1032, DOI 10.1021/bi00055a006; COLLEY PA, 1990, J NEUROSCI, V10, P3353; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; GONZALEZ A, 1993, ANAL BIOCHEM, V215, P184, DOI 10.1006/abio.1993.1574; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GROVER LM, 1990, NEUROSCI LETT, V113, P309, DOI 10.1016/0304-3940(90)90603-7; GROVER LM, 1992, NEUROSCIENCE, V49, P7, DOI 10.1016/0306-4522(92)90072-A; GROVER LM, 1990, NATURE, V347, P477, DOI 10.1038/347477a0; GUSTAFSSON B, 1990, SEMIN NEUROSCI, V2, P321; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; HARRIS EW, 1984, BRAIN RES, V323, P132, DOI 10.1016/0006-8993(84)90275-0; HOPKINS WF, 1988, J NEUROPHYSIOL, V59, P667, DOI 10.1152/jn.1988.59.2.667; HUANG KP, 1986, BIOCHEM BIOPH RES CO, V139, P320, DOI 10.1016/S0006-291X(86)80116-4; HUANG KP, 1986, J BIOL CHEM, V261, P4781; HUANG YY, 1993, J NEUROSCI, V13, P568; INOUE M, 1977, J BIOL CHEM, V252, P7610; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; JOHNSTON D, 1992, ANNU REV PHYSIOL, V54, P489; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; KLANN E, 1993, P NATL ACAD SCI USA, V90, P8337, DOI 10.1073/pnas.90.18.8337; KLANN E, 1991, J BIOL CHEM, V266, P24253; KULLMANN DM, 1992, NEURON, V9, P1175, DOI 10.1016/0896-6273(92)90075-O; LOVINGER DM, 1987, BRAIN RES, V436, P177, DOI 10.1016/0006-8993(87)91573-3; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; REYMANN KG, 1988, BRAIN RES, V440, P305, DOI 10.1016/0006-8993(88)91000-1; SACKTOR TC, 1993, P NATL ACAD SCI USA, V90, P8342, DOI 10.1073/pnas.90.18.8342; Sessoms J. Suzanne, 1992, Second Messengers and Phosphoproteins, V14, P109; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG JH, 1992, P NATL ACAD SCI USA, V89, P2576, DOI 10.1073/pnas.89.7.2576	42	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27958	27963						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961728				2022-12-27	WOS:A1994PV77200031
J	FAN, Z; LU, Y; WU, XP; MENDELSOHN, J				FAN, Z; LU, Y; WU, XP; MENDELSOHN, J			ANTIBODY-INDUCED EPIDERMAL GROWTH-FACTOR RECEPTOR DIMERIZATION MEDIATES INHIBITION OF AUTOCRINE PROLIFERATION OF A431 SQUAMOUS CARCINOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST CANCER; HUMAN-TUMOR CELLS; MONOCLONAL-ANTIBODIES; EGF RECEPTOR; FACTOR-ALPHA; SIGNAL-TRANSDUCTION; KINASE-ACTIVITY; TYROSINE KINASE; ACTIVATION; BLOCKADE	We previously reported that anti-epidermal growth factor (EGF) receptor monoclonal antibody (mAb) 225 can block receptor activation and inhibit proliferation of tumor cells bearing EGF receptors. To further explore the mechanism of mAb-mediated growth inhibition, we compared the capacities of bivalent 225 mAb and 225 F(ab')(2), and monovalent 225 Fab' fragment to block ligand binding to EGF receptors, inhibit activation of receptor tyrosine kinase by exogenous and endogenous ligand, produce receptor dimerization, down-regulate receptors, and inhibit proliferation of cultured A431 squamous carcinoma cells. Unlike 225 mAb and 225 F(ab')(2), 225 Fab' fragment was a poor inhibitor of A431 cell proliferation. The weak antiproliferative capacity of 225 Fab' was not due to depletion of active fragment from cultures. When cells were exposed to exogenous EGF, monovalent 225 Fab' remaining in conditioned culture medium could act as well as the bivalent forms of mAb to block binding and tyrosine kinase activation by exogenous EGF. However unlike the bivalent forms, 225 Fab' fragment was unable to induce receptor dimerization and down-regulation, and it lacked the capacity to block autocrine activation of EGF receptors by endogenous ligand. These deficiencies were corrected by addition of rabbit anti-mouse IgG antibody, which also enabled 225 Fab' fragment to inhibit cell proliferation. We conclude that in A431 cells, inhibition of autocrine-stimulated proliferation by anti-EGF receptor mAbs requires antibody bivalency, which provides the capacity to produce EGF receptor dimerization accompanied by receptor down-regulation. These properties may explain the greater efficacy of bivalent mAb and F(ab')(2), compared with monovalent Fab' fragment, in inhibiting proliferation of a variety of malignant and nonmalignant cultured cell lines.	CORNELL UNIV, COLL MED, NEW YORK, NY 10021 USA	Cornell University	FAN, Z (corresponding author), MEM SLOAN KETTERING CANC CTR, DEPT MED, RECEPTOR BIOL LAB, 1275 YORK AVE, NEW YORK, NY 10021 USA.				NATIONAL CANCER INSTITUTE [R01CA042060, R37CA042060, U01CA037641, U19CA037641] Funding Source: NIH RePORTER; NCI NIH HHS [CA37641, CA42060] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ARTEAGA CL, 1988, MOL ENDOCRINOL, V2, P1064, DOI 10.1210/mend-2-11-1064; ATLAS I, 1992, CANCER RES, V52, P3335; BARNES D, 1980, CELL, V22, P649, DOI 10.1016/0092-8674(80)90540-1; BASELGA J, 1993, J NATL CANCER I, V85, P1327, DOI 10.1093/jnci/85.16.1327; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; DERYNCK R, 1987, CANCER RES, V47, P707; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; FAN Z, 1993, CANCER RES, V53, P4322; FAN Z, 1993, CANCER RES, V53, P4637; FAN Z, 1993, J BIOL CHEM, V268, P21073; GILL GN, 1984, J BIOL CHEM, V259, P7755; HARRIS AL, 1989, CANCER CEL, V7, P353; Hendler F., 1989, P AN M AM SOC CLIN, V8, P223; HOFER DR, 1991, CANCER RES, V51, P2780; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KARNES WE, 1992, GASTROENTEROLOGY, V102, P474, DOI 10.1016/0016-5085(92)90093-E; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KAWAMOTO T, 1984, J BIOL CHEM, V259, P7761; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI W, 1991, MOL CELL BIOL, V11, P3756, DOI 10.1128/MCB.11.7.3756; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MASUI H, 1984, CANCER RES, V44, P1002; MASUI H, 1986, CANCER RES, V46, P5592; MASUI H, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P394; MASUI H, 1993, J CELL BIOL, V120, P85, DOI 10.1083/jcb.120.1.85; MENDELSOHN J, 1989, CANCER CEL, V7, P359; Mendelsohn J, 1987, Trans Assoc Am Physicians, V100, P173; MENDELSOHN J, 1993, CANCER PRINCIPLES PR, P114; NEAL DE, 1985, LANCET, V1, P366; PRYWES R, 1986, EMBO J, V5, P2179, DOI 10.1002/j.1460-2075.1986.tb04482.x; REISS M, 1991, CANCER RES, V51, P6254; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; SAINSBURY JRC, 1985, J CLIN PATHOL, V38, P1225, DOI 10.1136/jcp.38.11.1225; Sato J D, 1983, Mol Biol Med, V1, P511; SPAARGAREN M, 1991, J BIOL CHEM, V266, P1733; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; SUNADA H, 1986, P NATL ACAD SCI USA, V83, P3825, DOI 10.1073/pnas.83.11.3825; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; VEALE D, 1987, BRIT J CANCER, V55, P513, DOI 10.1038/bjc.1987.104; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; Wu Xipu, 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P3; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	55	249	261	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27595	27602						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961676				2022-12-27	WOS:A1994PV77100068
J	SMITH, L; SMITH, JB				SMITH, L; SMITH, JB			REGULATION OF SODIUM-CALCIUM EXCHANGER BY GLUCOCORTICOIDS AND GROWTH-FACTORS IN VASCULAR SMOOTH-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOLEMMAL NA+-CA2+ EXCHANGER; ANGIOTENSIN-II; FREE CA-2+; CELLS; EXPRESSION; RAT; DEXAMETHASONE; TRANSCRIPTION; PURIFICATION; RECEPTORS	The findings presented in this paper indicate that glucocorticoids down-regulate Na+-Ca2+ exchanger (NCX) mRNA and activity in aortic myocytes. Serum and purified growth factors reversed NCX down-regulation. Dexamethasone, cortisol, or aldosterone decreased NCX activity by similar to 55% in 24 h. Dexamethasone was >100 times more potent than aldosterone, indicating that a glucocorticoid receptor mediates the down-regulation of NCX activity. Dexamethasone decreased the NCX transcript to similar to 10% of the control level in 24 h without affecting plasma membrane Ca2+ ATPase transcripts. Fetal bovine serum increased NCX mRNA 10-fold in 4 h in dexamethasone-treated cells and restored full NCX activity in 16 h. The increase in NCX mRNA produced by serum required RNA and protein synthesis. Thrombin moderately increased NCX mRNA and partially restored NCX activity in dexamethasone-treated cells. Insulin, platelet-derived growth factor, or epidermal growth factor increased NCX mRNA similarly to thrombin. Tunicamycin, which inhibits N-linked glycosylation, prevented the restoration of NCX activity. These observations suggest that changes in the level of NCX mRNA mediate the opposing influences of glucocorticoids and growth factors on NCX activity. NCX induction by growth stimuli would increase the capacity for Ca2+ efflux and cycling between the cell and the environment.	UNIV ALABAMA,SCH MED,DEPT PHARMACOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NHLBI NIH HHS [HL44408] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044408] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BERK BC, 1993, J CELL PHYSIOL, V154, P368, DOI 10.1002/jcp.1041540221; BURNSTEIN KL, 1989, ANNU REV PHYSIOL, V51, P683, DOI 10.1146/annurev.ph.51.030189.003343; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHROUSOS GP, 1988, KIDNEY INT, V34, pS18; DUKSIN D, 1982, J BIOL CHEM, V257, P3105; DURKIN JT, 1991, ARCH BIOCHEM BIOPHYS, V290, P369, DOI 10.1016/0003-9861(91)90553-U; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GRUNFELD JP, 1988, KIDNEY INT, V34, pS24; GRUNFELD JP, 1987, HYPERTENSION, V10, P608, DOI 10.1161/01.HYP.10.6.608; HAMMES A, 1994, FASEB J, V8, P428, DOI 10.1096/fasebj.8.6.8168693; HAYASHI T, 1991, AM J PHYSIOL, V261, pC106, DOI 10.1152/ajpcell.1991.261.1.C106; HOECK W, 1989, J BIOL CHEM, V264, P14396; IIJIMA F, 1985, HYPERTENSION, V7, P783, DOI 10.1161/01.HYP.7.5.783; IIJIMA F, 1988, HYPERTENSION DALL SI, V11, pI42; KADOWITZ PJ, 1971, EUR J PHARMACOL, V13, P281, DOI 10.1016/0014-2999(71)90215-9; KEETON TP, 1993, J BIOL CHEM, V268, P2740; KENT RL, 1993, AM J PHYSIOL, V265, pH1024, DOI 10.1152/ajpheart.1993.265.3.H1024; KOFUJI P, 1993, AM J PHYSIOL, V265, pF598, DOI 10.1152/ajprenal.1993.265.4.F598; LI ZP, 1991, J BIOL CHEM, V266, P1014; LI ZP, 1992, J BIOL CHEM, V267, P7828; LIU J, 1992, J ENDOCRINOL, V133, P405, DOI 10.1677/joe.0.1330405; LONGENECKER JP, 1982, J CELL PHYSIOL, V113, P197, DOI 10.1002/jcp.1041130203; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYU RM, 1992, AM J PHYSIOL, V263, pC623; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; NAKASAKI Y, 1993, J BIOCHEM-TOKYO, V114, P528, DOI 10.1093/oxfordjournals.jbchem.a124211; NAMBI P, 1992, J BIOL CHEM, V267, P19555; NICOLL DA, 1991, ANN NY ACAD SCI, V639, P181, DOI 10.1111/j.1749-6632.1991.tb17305.x; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; NORRIS JS, 1984, BIOCHEM BIOPH RES CO, V122, P124, DOI 10.1016/0006-291X(84)90448-0; ORLOWSKI J, 1990, J BIOL CHEM, V265, P3462; PHILIPSON KD, 1988, BIOCHIM BIOPHYS ACTA, V945, P298, DOI 10.1016/0005-2736(88)90492-0; PIJUAN V, 1993, AM J PHYSIOL, V264, pC1066, DOI 10.1152/ajpcell.1993.264.4.C1066; PORZIG H, 1993, AM J PHYSIOL, V265, pC748, DOI 10.1152/ajpcell.1993.265.3.C748; REEVES JP, 1985, CURR TOP MEMBR TRANS, V25, P77; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RUSSO D, 1990, J HYPERTENS, V8, P817; SAKAUE M, 1991, J CLIN INVEST, V88, P385, DOI 10.1172/JCI115315; SATO A, 1992, HYPERTENSION, V19, P109, DOI 10.1161/01.HYP.19.1.109; SMITH JB, 1984, J CELL PHYSIOL, V118, P298, DOI 10.1002/jcp.1041180313; SMITH JB, 1989, AM J PHYSIOL, V256, pC147, DOI 10.1152/ajpcell.1989.256.1.C147; SMITH JB, 1987, J BIOL CHEM, V262, P17455; SMITH JB, 1991, BIOCHEM PHARMACOL, V41, P601, DOI 10.1016/0006-2952(91)90633-G; SMITH JB, 1991, ANN NY ACAD SCI, V639, P505, DOI 10.1111/j.1749-6632.1991.tb17344.x; WEINSTEIN R, 1981, SCIENCE, V212, P818, DOI 10.1126/science.7013068; WHITWORTH JA, 1987, KIDNEY INT, V31, P1213, DOI 10.1038/ki.1987.131	48	52	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27527	27531						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961668				2022-12-27	WOS:A1994PV77100058
J	CAMPBELL, P; HANNESSON, HH; SANDBACK, D; RODEN, L; LINDAHL, U; LI, JP				CAMPBELL, P; HANNESSON, HH; SANDBACK, D; RODEN, L; LINDAHL, U; LI, JP			BIOSYNTHESIS OF HEPARIN/HEPARAN SULFATE - PURIFICATION OF THE D-GLUCURONYL C-5 EPIMERASE FROM BOVINE LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN; SUBSTRATE; 5-EPIMERASE; CLEAVAGE; PROTEINS; ASSAY	The D-glucuronyl C-5 epimerase involved in the biosynthesis of heparin/heparan sulfate was purified from the high speed supernatant fraction of a homogenate of bovine liver by chromatography on immobilized O-desulfated heparin, red Sepharose, phenyl Sepharose, and concanavalin A-Sepharose. After close to 1 million-fold purification, in 10-15% yield, the product gave a single band on SDS-polyacrylamide gel electrophoresis with silver staining and had a mobility corresponding to an M(r) of similar to 52,000. Since the epimerase assay used in the course of purification was based on release of tritium, as [H-3]H2O, from a [5-H-3]uronyl-labeled substrate, it was important to establish that the purified enzyme did indeed catalyze the actual conversion of D-glucuronyl to L-iduronyl residues. Upon incubation of the purified enzyme with H-3-labeled heparosan N-sulfate, prepared by metabolic labeling (with D-[1-H-3]glucose) of a capsular polysaccharide from Escherichia coli K5 and subsequent chemical partial N-deacetylation and N-sulfation, approximately 30% of the D-glucuronyl residues located between two N-sulfated glucosamine units were converted to L-iduronyl units.	UNIV UPPSALA,DEPT MED & PHYSIOL CHEM,S-75123 UPPSALA,SWEDEN; UNIV ALABAMA,BIRMINGHAM,AL 35294	Uppsala University; University of Alabama System; University of Alabama Birmingham					NIDCR NIH HHS [DE 08252] Funding Source: Medline; NINDS NIH HHS [NS 27353] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027353] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL P, 1983, ANAL BIOCHEM, V131, P146, DOI 10.1016/0003-2697(83)90146-X; DMITRIEV BA, 1973, CARBOHYD RES, V29, P451, DOI 10.1016/S0008-6215(00)83031-1; HOOK M, 1974, J BIOL CHEM, V249, P3908; JACOBSSON I, 1984, J BIOL CHEM, V259, P1056; JACOBSSON I, 1979, J BIOL CHEM, V254, P2975; JACOBSSON I, 1979, BIOCHEM J, V179, P77, DOI 10.1042/bj1790077; JENSEN JW, 1983, CARBOHYD RES, V117, P241, DOI 10.1016/0008-6215(83)88090-2; KUSCHE M, 1991, BIOCHEM J, V275, P151, DOI 10.1042/bj2750151; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY L, 1962, P SOC EXP BIOL MED, V109, P901; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; Lindahl U., 1989, HEPARIN, P159; MALMSTROM A, 1980, J BIOL CHEM, V255, P3878; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; PEJLER G, 1987, J BIOL CHEM, V262, P5036; PODUSLO JF, 1981, ANAL BIOCHEM, V114, P131, DOI 10.1016/0003-2697(81)90463-2; PRIHAR HS, 1980, BIOCHEMISTRY-US, V19, P495, DOI 10.1021/bi00544a016; SHALTIEL S, 1973, P NATL ACAD SCI USA, V70, P778, DOI 10.1073/pnas.70.3.778; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005	21	34	40	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26953	26958						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929434				2022-12-27	WOS:A1994PQ93100057
J	ISHIGURO, N; OHZONO, T; SHINAGAWA, T; HORIUCHI, M; SHINAGAWA, M				ISHIGURO, N; OHZONO, T; SHINAGAWA, T; HORIUCHI, M; SHINAGAWA, M			A SPONTANEOUS INTERNAL DELETION OF THE C-MYB PROTOONCOGENE ENHANCES TRANSCRIPTIONAL ACTIVATION IN BOVINE T-LYMPHOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; AVIAN-MYELOBLASTOSIS VIRUS; AMINO-TERMINAL REGION; NUCLEOTIDE-SEQUENCE; V-MYB; DIFFERENTIAL EXPRESSION; HEMATOPOIETIC-CELLS; FUNCTIONAL DOMAINS; GENE-EXPRESSION; LEUKEMIA-VIRUS	Three double negative (BoCD4(-), BoCD8(-)) bovine T cell lines, BTL-PC3, BLT-2, and Pr2181, which have been established from bovine lymphosarcomas, were examined for expression and molecular function of bovine c-myb genes. BTL-PC3 expressed 4.0- and 3.6-kilobase c-myb transcripts, and BLT2 and Pr2181 expressed a 3.8-kilobase c-myb message. The c-Myb protein (75 kDa) was detected in Pr2181 but not as a clear band in BLT2, while BTL-PC3 exhibited a 65-kDa c-Myb band in immunoprecipitation tests with anti-Myb antiserum. Nucleotide sequences for c-myb cDNA clones from BTL-PC3 and BLT2 indicated that the predicted bovine wild-type c-Myb from BLT2 consists of 640 amino acids whereas that from BTL-PC3 consists of 555 amino acids lacking 85 internal amino acids. This deleted DNA region (255 base pairs consisting of 85 amino acids) corresponds to the human genomic exon 9 encoding a negative regulatory domain in the c-myb gene. Upon cotransfections with reporter plasmids containing myb binding sites, the internally deleted c-Myb exhibited a 3-fold higher transcriptional activity than the wild-type c-Myb in chloramphenicol acetyltransferase assays. These results indicate that internal DNA deletion in the c-myb gene is directly involved in the enhancement of transcriptional activation in bovine T lymphoma cells.			ISHIGURO, N (corresponding author), OBIHIRO UNIV AGR & VET MED,DEPT VET PUBL HLTH,OBIHIRO,HOKKAIDO 080,JAPAN.							ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; BENDER TP, 1987, J IMMUNOL, V139, P3822; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; BROWN KE, 1992, J BIOL CHEM, V267, P4625; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DUDEK H, 1989, ONCOGENE, V4, P1061; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P266; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; ISHIGURO N, 1993, AM J VET RES, V54, P2010; ISHIGURO N, 1985, J BACTERIOL, V164, P977, DOI 10.1128/JB.164.3.977-982.1985; ISHIGURO N, 1990, GENE, V91, P281, DOI 10.1016/0378-1119(90)90101-V; ISHIGURO N, 1994, VET IMMUNOL IMMUNOP, V41, P1, DOI 10.1016/0165-2427(94)90053-1; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KIMURA S, 1968, JPN J MICROBIOL, V12, P293, DOI 10.1111/j.1348-0421.1968.tb00398.x; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NOMURA T, 1993, J BIOL CHEM, V268, P21914; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; SHENONG GLC, 1990, MOL CELL BIOL, V10, P2715, DOI 10.1128/MCB.10.6.2715; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; TAKAI T, 1990, BIOCHIM BIOPHYS ACTA, V1048, P105, DOI 10.1016/0167-4781(90)90029-2; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKEUCHI N, 1992, IMMUNOGENETICS, V35, P89, DOI 10.1007/BF00189517; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; WATSON CJ, 1985, DNA CLONING PRACTICA, V1, P79; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043	56	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26822	26829						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929419				2022-12-27	WOS:A1994PQ93100039
J	SONG, WJ; JACKOWSKI, S				SONG, WJ; JACKOWSKI, S			KINETICS AND REGULATION OF PANTOTHENATE KINASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A BIOSYNTHESIS; ATP-BINDING SITE; PROTEIN; HEART; GENE; RAT; TRANSFORMATION; PURIFICATION; EXPRESSION; TRANSPORT	Pantothenate kinase catalyzes the rate controlling step in coenzyme A (CoA) biosynthesis and is regulated by feedback inhibition by CoA. Pantothenate kinase was purified to homogeneity from Escherichia coli and was shown to exist as a homodimer. Kinetic analysis indicated the presence of two ATP binding sites that exhibited positive cooperativity with a Hill coefficient of 1.46. Site-directed mutagenesis of lysine 101 to methionine (K101M) resulted in the inactivation of the enzyme, although dimer formation was not altered. The K101M mutant was unable to bind either adenosine 5'-O-(3-thiotriphosphate) or CoA, supporting the conclusion from kinetic analysis that both the substrate and inhibitor bind to the same site on the enzyme. CoA binding was not cooperative. Coexpression of the K101M mutant gene on a high copy number plasmid in the presence of a chromosomal copy of the wild-type gene resulted in the production of heterodimers between active and inactive subunits. Kinetic analysis of the chimeric heterodimers showed the absence of cooperative ATP interactions and indicated a sequential kinetic mechanism for pantothenate kinase with ATP binding first and pantothenate second. Thus, pantothenate kinase regulation involves the competitive binding of CoA to the ATP site, which blocks ATP binding at one site and prevents positive cooperative ATP binding to the second site on the dimer.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center			Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034496, R37GM034496] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 34496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abiko Y., 1975, Metabolism of sulphur compounds., P1; ABIKO Y, 1972, BIOCHIM BIOPHYS ACTA, V268, P364, DOI 10.1016/0005-2744(72)90331-2; BARBARAT B, 1986, J BIOL CHEM, V261, P4455; BOOTH BR, 1980, BIOCHEM BIOPH RES CO, V94, P1029, DOI 10.1016/0006-291X(80)90522-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIN DT, 1988, J BIOL CHEM, V263, P11718; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P173, DOI 10.1016/0926-6569(63)90226-8; DAWES EA, 1982, BIOCH BACTERIAL GROW, P125; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; FALK KL, 1993, ARCH BIOCHEM BIOPHYS, V301, P424, DOI 10.1006/abbi.1993.1166; FISHER MN, 1985, J BIOL CHEM, V260, P5745; FISHER MN, 1985, FEBS LETT, V190, P293, DOI 10.1016/0014-5793(85)81303-X; GOLD AM, 1970, J BIOL CHEM, V245, P2564; HALVORSEN O, 1982, EUR J BIOCHEM, V124, P211, DOI 10.1111/j.1432-1033.1982.tb05927.x; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; HARLOW E, 1988, ANTIBODIES LAB MANUA, P519; JACKOWSKI S, 1986, J BACTERIOL, V166, P866, DOI 10.1128/jb.166.3.866-871.1986; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; JACKOWSKI S, 1990, J BACTERIOL, V172, P3842, DOI 10.1128/jb.172.7.3842-3848.1990; KARASAWA T, 1972, J BIOCHEM-TOKYO, V71, P1065, DOI 10.1093/oxfordjournals.jbchem.a129854; LOPASCHUK GD, 1987, J BIOL CHEM, V262, P3615; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; Miller J. H., 1972, EXPT MOL GENETICS, P433; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; ROBISHAW JD, 1985, AM J PHYSIOL, V248, pE1, DOI 10.1152/ajpendo.1985.248.1.E1; ROBISHAW JD, 1982, J BIOL CHEM, V257, P967; ROBISHAW JD, 1984, AM J PHYSIOL, V246, pH532, DOI 10.1152/ajpheart.1984.246.4.H532; SNYDER MA, 1985, MOL CELL BIOL, V5, P1772, DOI 10.1128/MCB.5.7.1772; SONG WJ, 1992, J BACTERIOL, V174, P6411, DOI 10.1128/JB.174.20.6411-6417.1992; TABOR S, 1990, CURRENT PROTOCOLS MO; VALLARI DS, 1985, J BACTERIOL, V162, P1156, DOI 10.1128/JB.162.3.1156-1161.1985; VALLARI DS, 1987, J BACTERIOL, V169, P5795, DOI 10.1128/jb.169.12.5795-5800.1987; VALLARI DS, 1985, J BACTERIOL, V164, P136, DOI 10.1128/JB.164.1.136-142.1985; VALLARI DS, 1988, J BACTERIOL, V170, P3961, DOI 10.1128/jb.170.9.3961-3966.1988; VALLARI DS, 1987, J BIOL CHEM, V262, P2468	35	61	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27051	27058						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929447				2022-12-27	WOS:A1994PQ93100070
J	CHAMBERS, RS; DAHMUS, ME				CHAMBERS, RS; DAHMUS, ME			PURIFICATION AND CHARACTERIZATION OF A PHOSPHATASE FROM HELA-CELLS WHICH DEPHOSPHORYLATES THE C-TERMINAL DOMAIN OF RNA-POLYMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGEST SUBUNIT; PROTEIN PHOSPHATASES; PHOSPHORYLATION; TRANSCRIPTION; PROMOTER; KINASE; INITIATION; SPECIFICITY; ENCODES; INVITRO	The repetitive C-termin al domain (CTD) of RNA polymerase (RNAP) II is extensively phosphorylated concomitant with the initiation of transcription and must be dephosphorylated before RNAP LT: can begin another round of transcription. A CTD phosphatase was purified more than 7,500-fold from a HeLa cell extract. SDS-polyacrylamide gel electrophoresis shows a predominant protein of 205 kDa and a less abundant protein of 150 kDa co-eluting with the CTD phosphatase activity. Sedimentation and gel filtration analysis suggest that CTD phosphatase has an elongated structure with a M(r) of 200,000. This enzyme is a type 2C phosphatase in that it requires Mg2+ for activity and is resistant to okadaic acid. CTD phosphatase appears to processively dephosphorylate the CTD and is specific in that it does not dephosphorylate phosphorylase a, the alpha or beta subunits of phosphorylase kinase or RNAP II phosphorylated with casein kinase II. CTD phosphatase dephosphorylates RNAP IIO purified from calf thymus or generated in vitro by two previously described CTD kinases. These results suggest that CTD phosphatase has the properties expected for a protein phosphatase that catalyzes the conversion of RNAP IIO to RNAP IIA and may play a key role in the transcription cycle of RNAP II.	UNIV CALIF DAVIS,DIV BIOL SCI,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616	University of California System; University of California Davis					NIGMS NIH HHS [GM33300] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033300] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x; ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ARIAS JA, 1991, J BIOL CHEM, V266, P8055; ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BUERMEYER AB, 1992, MOL CELL BIOL, V12, P2250, DOI 10.1128/MCB.12.5.2250; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CHAMBON P, 1974, ENZYMES, P261; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CORDEN JL, 1992, TRANSCRIPTIONAL REGU, P81; DAHMUS ME, 1994, TRANSCRIPTION MECHAN, P243; DEANA AD, 1990, BIOCHIM BIOPHYS ACTA, V1051, P199, DOI 10.1016/0167-4889(90)90194-I; DVIR A, 1993, J BIOL CHEM, V268, P10440; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; KANG ME, 1993, J BIOL CHEM, V268, P25033; KIM WY, 1986, J BIOL CHEM, V261, P14219; KIM YH, 1993, J BIOL CHEM, V268, P18513; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; NEWSHOLME P, 1992, BIOCHEM J, V283, P845, DOI 10.1042/bj2830845; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; PATO MD, 1990, ARCH BIOCHEM BIOPHYS, V276, P116, DOI 10.1016/0003-9861(90)90017-S; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PAYNE JM, 1993, J BIOL CHEM, V268, P80; PERUSKI LF, 1993, ADV PROTEIN PHOSPHAT, V7, P9; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEWART AA, 1981, EUR J BIOCHEM, V115, P197; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698; ZHANG J, 1991, J BIOL CHEM, V266, P2290	39	124	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26243	26248						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929341				2022-12-27	WOS:A1994PQ93000049
J	CHAUVIN, MF; MEGNINCHANET, F; MARTIN, G; LHOSTE, JM; BAVEREL, G				CHAUVIN, MF; MEGNINCHANET, F; MARTIN, G; LHOSTE, JM; BAVEREL, G			THE RABBIT KIDNEY TUBULE UTILIZES GLUCOSE FOR GLUTAMINE SYNTHESIS - A C-13 NMR-STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CITRIC-ACID-CYCLE; NUCLEAR MAGNETIC-RESONANCE; RAT-BRAIN INVIVO; KREBS CYCLE; METABOLISM; LIVER; GLUCONEOGENESIS; SPECTROSCOPY; PYRUVATE; CARBON	The metabolism of variously labeled [C-13]- and [C-14]glucoses, used at a physiological concentration (5 mM), has been studied in isolated rabbit kidney tubules both in the absence and the presence of NH4Cl. When present as sole exogenous substrate, glucose was metabolized at high rates and converted not only into CO2 and lactate but also, in contrast to a previous conclusion of Krebs (Krebs, H. A. (1935) Biochem. J. 29, 1951-1969), into glutamine. Absolute fluxes through enzymes of glycolysis and gluconeogenesis and of enzymes of three different cycles operating simultaneously were assessed by using a novel model describing reactions of glucose metabolism in conjunction with the C-13 MMR and, to a lesser extent, the radioactive data obtained. The presence of NH4Cl (5 mM) caused a large stimulation of glucose removal and a large increase in lactate, glutamine, and glycerol 3-phosphate accumulation. Under this condition, the stimulation of glutamine synthesis was accompanied not by an activation of citrate synthesis but by an inhibition of flux through alpha-ketoglutarate dehydrogenase. The resulting depletion of citric acid cycle intermediates was compensated by anaplerosis at the level of pyruvate carboxylase. The ''futile'' cycle involving oxaloacetate, phosphoenolpyruvate and pyruvate, which was intense in the presence of glucose alone, was greatly stimulated by the addition of NH4Cl.	HOP EDOUARD HERRIOT, CTR ETUD METAB SPECT RESONANCE MAGNET, CNRS, EP 18, F-69374 LYON 03, FRANCE; INSERM, U350, UNITE BIOPHYS MOLEC, F-91405 ORSAY, FRANCE	Centre National de la Recherche Scientifique (CNRS); CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm)			Chanet, Frédérique Megnin/M-1983-2018					[Anonymous], METHODS ENZYMATIC AN; BAVEREL G, 1980, BIOCHEM J, V188, P873, DOI 10.1042/bj1880873; BAVEREL G, 1979, BIOCHEM J, V184, P599, DOI 10.1042/bj1840599; BAVEREL G, 1978, KIDNEY INT, V14, P567, DOI 10.1038/ki.1978.165; BURCH HB, 1982, J BIOL CHEM, V257, P3676; CANIONI P, 1983, BIOCHEMISTRY-US, V22, P4974, DOI 10.1021/bi00290a015; CERDAN S, 1990, J BIOL CHEM, V265, P12916; CHANCE EM, 1983, J BIOL CHEM, V258, P3785; COHEN SM, 1981, P NATL ACAD SCI-BIOL, V78, P60, DOI 10.1073/pnas.78.1.60; COHEN SM, 1987, BIOCHEMISTRY-US, V26, P581, DOI 10.1021/bi00376a033; COHEN SM, 1981, J BIOL CHEM, V256, P3428; COHEN SM, 1979, P NATL ACAD SCI USA, V76, P4808, DOI 10.1073/pnas.76.10.4808; DAMIAN AC, 1970, AM J PHYSIOL, V218, P1249, DOI 10.1152/ajplegacy.1970.218.5.1249; DIDONATO L, 1993, J BIOL CHEM, V268, P4170; DUGELAY S, 1991, BIOCHIM BIOPHYS ACTA, V1075, P191, DOI 10.1016/0304-4165(91)90251-B; FITZPATRICK SM, 1990, J CEREBR BLOOD F MET, V10, P170, DOI 10.1038/jcbfm.1990.32; GUDER WG, 1980, INT J BIOCHEM, V42, P529; GUDER WG, 1992, HDB PHYSL 8, V2, P2119; GULLANS SR, 1984, J MEMBRANE BIOL, V78, P257, DOI 10.1007/BF01925973; HOWARTH OW, 1978, PROG NUCL MAG RES SP, V12, P1, DOI 10.1016/0079-6565(78)80001-6; JANICKI RH, 1969, AM J PHYSIOL, V216, P1107, DOI 10.1152/ajplegacy.1969.216.5.1107; JANS AWH, 1989, BIOCHEM J, V263, P231, DOI 10.1042/bj2630231; KALDERON B, 1987, FEBS LETT, V213, P209, DOI 10.1016/0014-5793(87)81493-X; KATZ J, 1989, J BIOL CHEM, V264, P12994; KELLEHER JK, 1985, AM J PHYSIOL, V248, pE252, DOI 10.1152/ajpendo.1985.248.2.E252; Krebs HA, 1932, H-S Z PHYSIOL CHEM, V210, P33, DOI 10.1515/bchm2.1932.210.1-2.33; KREBS HA, 1963, BIOCHEM J, V89, P398, DOI 10.1042/bj0890398; KREBS HANS ADOLF, 1935, BIOCHEM JOUR, V29, P1951; MAGNUSSON I, 1991, J BIOL CHEM, V266, P6975; MALLOY CR, 1990, AM J PHYSIOL, V259, pH987, DOI 10.1152/ajpheart.1990.259.3.H987; MALLOY CR, 1988, J BIOL CHEM, V263, P6964; MARTIN G, 1994, J BIOL CHEM, V269, P26034; MASON GF, 1992, J CEREBR BLOOD F MET, V12, P434, DOI 10.1038/jcbfm.1992.61; RICHTERICH RW, 1958, AM J PHYSIOL, V195, P316, DOI 10.1152/ajplegacy.1958.195.2.316; ROGNSTAD R, 1972, J BIOL CHEM, V247, P6047; Ross BD, 1982, METABOLIC COMPARTMEN, P363; ROTHMAN DL, 1992, P NATL ACAD SCI USA, V89, P9603, DOI 10.1073/pnas.89.20.9603; ROTHMAN DL, 1985, P NATL ACAD SCI USA, V82, P1633, DOI 10.1073/pnas.82.6.1633; SHAKA AJ, 1983, J MAGN RESON, V52, P335, DOI 10.1016/0022-2364(83)90207-X; WATFORD M, 1980, BIOCHEM J, V188, P741, DOI 10.1042/bj1880741	40	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26025	26033						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929313				2022-12-27	WOS:A1994PQ93000017
J	SUN, LZ; WU, GF; WILLSON, JKV; ZBOROWSKA, E; YANG, JH; RAJKARUNANAYAKE, I; WANG, J; GENTRY, LE; WANG, XF; BRATTAIN, MG				SUN, LZ; WU, GF; WILLSON, JKV; ZBOROWSKA, E; YANG, JH; RAJKARUNANAYAKE, I; WANG, J; GENTRY, LE; WANG, XF; BRATTAIN, MG			EXPRESSION OF TRANSFORMING GROWTH-FACTOR-BETA TYPE-II RECEPTOR LEADS TO REDUCED MALIGNANCY IN HUMAN BREAST-CANCER MCF-7 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CARCINOMA-CELLS; ATHYMIC MICE; C-MYC; INHIBITION; FACTOR-BETA-1; PROLIFERATION; TUMORIGENICITY; CLONING; FORMS; DIFFERENTIATION	The role of transforming growth factor (TGF) beta type II receptor in reversing the malignant phenotype of human breast cancer MCF-7 cells was examined. MCF-7 cells were insensitive to TGF beta(1) and expressed undetectable levels of cell surface TGF beta type I receptor (RI) and type II receptor (RII) by cross-linking with I-125-TGF beta(1). Stable transfection of a RII expression vector yielded 3 transfectants with varying levels of exogenous RII mRNA and protein levels. Expression of RII also increased TGF beta(1) binding to RI in all 3 clones. Proliferation of RII-positive clones was inhibited by exogenous TGF beta(1) in a dose-dependent manner, whereas the control clones remained TGF beta-insensitive. The RII transfectants were growth arrested in monolayer culture at saturation densities which were 41-66% of that of the Neo controls. They also showed reduced clonogenicity in soft-agarose. Tumorigenicity in ovariectomized, estrogen-supplemented nude mice was delayed in transfectants with low RII levels. Transfectants expressing high levels of RII showed a large reduction in tumorigenicity as well as a longer delay in tumor formation. Tumor growth was associated with loss of exogenous RII expression in transfectants. The results indicate that when systems for TGF beta signal transduction are intact, reconstitution of the TGF beta receptor system can lead to reversion of malignancy in cells lacking RII.	MED COLL OHIO,DEPT BIOCHEM & MOLEC BIOL,TOLEDO,OH 43614; CASE WESTERN RESERVE UNIV,DEPT MED,CLEVELAND,OH 44106; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	Case Western Reserve University; Duke University			, LuZhe/AAW-4095-2021		NATIONAL CANCER INSTITUTE [R01CA038173, R01CA050457, R01CA060848, R37CA038173] Funding Source: NIH RePORTER; NCI NIH HHS [CA38173, CA50457, CA60848] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; ARTEAGA CL, 1993, CELL GROWTH DIFFER, V4, P193; ARTEAGA CL, 1988, CANCER RES, V48, P3898; ARTEAGA CL, 1993, J CLIN INVEST, V92, P2569, DOI 10.1172/JCI116871; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BRATTAIN MG, 1993, ADV MOL CELL BIOL BI, V7, P35; CARMICHAEL J, 1987, CANCER RES, V47, P936; CHANG HL, 1993, CANCER RES, V53, P4391; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOTTARDIS MM, 1988, J STEROID BIOCHEM, V30, P311, DOI 10.1016/0022-4731(88)90113-6; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HOOSEIN NM, 1989, EXP CELL RES, V181, P442, DOI 10.1016/0014-4827(89)90101-8; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MOSES HL, 1992, MOL REPROD DEV, V32, P179, DOI 10.1002/mrd.1080320215; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; MULDER KM, 1989, MOL ENDOCRINOL, V3, P1215, DOI 10.1210/mend-3-8-1215; MURPHY CS, 1991, COLD SPRING HARB SYM, V56, P129; OSBORNE CK, 1987, BREAST CANCER RES TR, V9, P111, DOI 10.1007/BF01807363; Roberts A., 1991, PEPTIDE GROWTH FACTO, P419; RUFF E, 1986, BIOCHEM BIOPH RES CO, V138, P714, DOI 10.1016/S0006-291X(86)80555-1; SEGARINI PR, 1987, J BIOL CHEM, V262, P14655; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SING GK, 1990, CELL GROWTH DIFFER, V1, P549; STEINER MS, 1992, MOL ENDOCRINOL, V6, P15, DOI 10.1210/me.6.1.15; TWARDZIK DR, 1989, J NATL CANCER I, V81, P1182, DOI 10.1093/jnci/81.15.1182; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WU SP, 1993, CELL GROWTH DIFFER, V4, P115; WU SP, 1992, J CELL BIOL, V116, P186; ZUGMAIER G, 1991, CANCER RES, V51, P3590	42	307	319	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26449	26455						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929366				2022-12-27	WOS:A1994PQ93000078
J	TOYOFUKU, T; KURZYDLOWSKI, K; NARAYANAN, N; MACLENNAN, DH				TOYOFUKU, T; KURZYDLOWSKI, K; NARAYANAN, N; MACLENNAN, DH			IDENTIFICATION OF SER(38) AS THE SITE IN CARDIAC SARCOPLASMIC-RETICULUM CA2+-ATPASE THAT IS PHOSPHORYLATED BY CA2+ CALMODULIN-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL CONSEQUENCES; CA-2+-ATPASE; ATPASE; MUSCLE; PHOSPHOLAMBAN; EXPRESSION; CALCIUM; DOMAIN; MUTAGENESIS; AFFINITY	In previous studies (Xu, A., Hawkins, C., and Narayanan, N. (1993) J. Biol. Chem. 268, 8394-8397), the Ca2+-ATPase of cardiac muscle sarcoplasmic reticulum (SERCA2) was shown to be phosphorylated by Ca2+/calmodulin-dependent protein kinase II (CaM kinase) on a serine residue, likely to be either Ser(38), Ser(167), or Ser(531). SERCA2 and SERCA2 mutants S38A, S167A, and S531A were expressed in HEK-293 cells and tested for phosphorylation with CaM kinase. Mutant S38A was not phosphorylated, while mutants S167A and S531A were phosphorylated, suggesting that Ser(38) is the site of CaM kinase phosphorylation in SERCA2. This conclusion was supported by the observation that phosphorylation of SERCA2 and mutants S167A and S531A by CaM kinase increased the V-max for Ca2+ transport, while the V-max for Ca2+ transport by mutant S38A was unaffected by exposure to a phosphorylation reaction mix. SERCA1, containing a potential CaM kinase phosphorylation site at Ser(167) and two SERCA1 mutants, K35R plus H38S and T532S, in which potential CaM kinase sites were created, were not phosphorylated by CaM kinase, and V-max for Ca2+ transport was unaffected by exposure to a phosphorylation reaction mix. Thus phosphorylation of Ser(38) in SERCA2 results in a unique activation of V-max for Ca2+ transport, providing a potential regulatory mechanism for Ca2+ removal from cardiac and other tissues in which SERCA2 is expressed.	UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO M5G 1L6, ON, CANADA; UNIV WESTERN ONTARIO, DEPT PHYSIOL, LONDON N6A 5C1, ON, CANADA	University of Toronto; Western University (University of Western Ontario)								BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; BRIGGS FN, 1992, J BIOL CHEM, V267, P26056; BURK SE, 1989, J BIOL CHEM, V264, P18561; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; HOLROYDE MJ, 1980, J BIOL CHEM, V255, P1688; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LYTTON J, 1989, J BIOL CHEM, V264, P7059; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MORRIS GL, 1991, J BIOL CHEM, V266, P11270; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; TADA M, 1988, METHOD ENZYMOL, V157, P107; THOMLISON RJ, 1990, CHILD MALTREATMENT : EXPANDING OUR CONCEPT OF HELPING, P127; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; TOYOFUKU T, 1993, J BIOL CHEM, V268, P2809; TOYOFUKU T, 1992, J BIOL CHEM, V267, P14490; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; XU A, 1993, J BIOL CHEM, V268, P8394	25	115	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26492	26496						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929371				2022-12-27	WOS:A1994PQ93000084
J	BAKER, RT; SMITH, SA; MARANO, R; MCKEE, J; BOARD, PG				BAKER, RT; SMITH, SA; MARANO, R; MCKEE, J; BOARD, PG			PROTEIN EXPRESSION USING COTRANSLATIONAL FUSION AND CLEAVAGE OF UBIQUITIN - MUTAGENESIS OF THE GLUTATHIONE-BINDING SITE OF HUMAN PI-CLASS GLUTATHIONE-S-TRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; 3-DIMENSIONAL STRUCTURE; FUNCTIONAL-ANALYSIS; HUMAN-LIVER; PURIFICATION; RESOLUTION; CLONING; COMPLEX	Expression of cloned genes in prokaryotes such as Escherichia coli is a widely used technique in both basic research and biotechnology. Despite the availability of several E. coli expression vector systems, adequate levels of expression may not be achieved. Expressing proteins as fusions to the highly conserved eukaryotic protein ubiquitin has been reported by several investigators to enhance protein yield in both bacterial and eukaryotic systems. We have modified this technique by the co-expression in E. coli of a ubiquitin-fusion protein and the Saccharomyces cerevisiae ubiquitin-specific protease Ubp2. This allows the co-translational cleavage of engineered ubiquitin-fusion proteins expressed in E. coli. This system was used to express a human Pi class glutathione S-transferase (GST) GSTP1 as well as two mutant GSTP1 derivatives, Trp(39)-->Cys and Gln(52)-->Glu. The yield of these enzymes was improved 40-fold by using the ubiquitin-fusion/co-translational cleavage technique, and no uncleaved product was detected. The Trp(39)-->Cys mutant was totally devoid of GST activity, while the activity of the Gln(52)-->Glu mutant was reduced to 6% of wild type GSTP1-1. As both of the mutated residues map within the glutathione binding site, the reduced GST activity is consistent with a marked reduction in glutathione binding ability.			BAKER, RT (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,MOLEC GENET GRP,POB 334,CANBERRA,ACT 2601,AUSTRALIA.		Marano, Robert/A-3552-2015	Marano, Robert/0000-0001-9565-3167				ALIN P, 1985, FEBS LETT, V182, P319, DOI 10.1016/0014-5793(85)80324-0; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1992, J BIOL CHEM, V267, P23364; BOARD P, 1993, J BIOL CHEM, V268, P15655; BOARD PG, 1987, BIOCHEM J, V248, P937, DOI 10.1042/bj2480937; BORA PS, 1991, J BIOL CHEM, V266, P16774; BROSIUS J, 1987, METHOD ENZYMOL, V153, P54; BUTT TR, 1989, P NATL ACAD SCI USA, V86, P2540, DOI 10.1073/pnas.86.8.2540; DANIELSON UH, 1985, BIOCHEM J, V231, P263, DOI 10.1042/bj2310263; ECKER DJ, 1989, J BIOL CHEM, V264, P7715; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GONDA DK, 1989, J BIOL CHEM, V264, P16700; Habig W H, 1981, Methods Enzymol, V77, P398; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; KOLM RH, 1992, BIOCHEM J, V285, P537, DOI 10.1042/bj2850537; KONG KH, 1991, BIOCHEM BIOPH RES CO, V181, P748, DOI 10.1016/0006-291X(91)91254-A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MANOHARAN TH, 1992, J BIOL CHEM, V267, P18940; MONIA BP, 1989, J BIOL CHEM, V264, P4093; NISHIHIRA J, 1992, BIOCHEM BIOPH RES CO, V185, P1069, DOI 10.1016/0006-291X(92)91735-9; PENNINGTON CJ, 1992, BIOCHEMISTRY-US, V31, P2912; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; SABIN EA, 1989, BIO-TECHNOL, V7, P705, DOI 10.1038/nbt0789-705; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMONS PC, 1977, ANAL BIOCHEM, V82, P334, DOI 10.1016/0003-2697(77)90169-5; SMITH DB, 1988, MOL BIOCHEM PARASIT, V27, P249, DOI 10.1016/0166-6851(88)90044-8; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUZUKI T, 1987, ANN HUM GENET, V51, P95, DOI 10.1111/j.1469-1809.1987.tb01051.x; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; UHLEN M, 1990, METHOD ENZYMOL, V185, P129; WIDERSTEIN M, 1992, BIOCHEM J, V285, P377, DOI 10.1042/bj2850377; YOO Y, 1989, J BIOL CHEM, V264, P17078	36	64	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25381	25386						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929235				2022-12-27	WOS:A1994PQ49100026
J	FUJINAMI, K; TANAHASHI, N; TANAKA, K; ICHIHARA, A; CEJKA, Z; BAUMEISTER, W; MIYAWAKI, M; SATO, T; NAKAGAWA, H				FUJINAMI, K; TANAHASHI, N; TANAKA, K; ICHIHARA, A; CEJKA, Z; BAUMEISTER, W; MIYAWAKI, M; SATO, T; NAKAGAWA, H			PURIFICATION AND CHARACTERIZATION OF THE 26-S PROTEASOME FROM SPINACH LEAVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; RABBIT RETICULOCYTE LYSATE; MOLECULAR-WEIGHT PROTEASES; UBIQUITIN-LIGATED PROTEINS; PROTEOLYTIC COMPLEX; DEPENDENT PROTEOLYSIS; ELECTRON-MICROSCOPY; MULTIPLE FORMS; HIGHER-PLANT; ATP	The 26 S proteasome complex catalyzing ATP-dependent breakdown of ubiquitin-ligated proteins was purified from spinach leaves 60 near homogeneity by chromatography on DEAE-cellulose, gel filtration on Biogel A-1.5, and glycerol density gradient centrifugation. The purified enzyme was shown to degrade multi-ubiquitinated, but not unmodified, lysozymes in an ATP-dependent fashion coupled with ATPase activity supplying energy for proteolysis and isopeptidase activity to generate free ubiquitin. By nondenaturing electrophoresis, the purified enzyme was separated into two distinct forms of the 26 S complex, named 26 S alpha and 26 S beta proteasomes, with different electrophoretic mobilities, The 26 S proteasome was found to consist of multiple polypeptides with molecular masses of 23-35 and 39-115 kDa, which were thought to be those of a 20 S proteasome with multicatalytic proteinase activity and an associated regulatory part with ATPase and deubiquitinating activities, respectively. The subunit multiplicity of the spinach 26 S proteasome closely resembled that of rat liver with minor differences in certain components. No sulfhydryl bond was involved in the assembly of this multicomponent polypeptide complex. Electron microscopy showed that the 26 S proteasome complex had a ''caterpillar''-like shape, consisting of four central protein layers, assumed to be the 20 S proteasome, with asymmetric V-shaped layers at each end. These structural and functional characteristics of the spinach 26 S proteasome showed marked similarity to those of the mammalian 26 S proteasomes reported recently, suggesting that the 26 S proteasome is widely distributed in eukaryotic cells and is of general importance for catalyzing the soluble energy- and ubiquitin-dependent proteolytic pathway.	CHIBA UNIV,FAC HORT,DEPT AGR CHEM,MATSUDO,CHIBA 271,JAPAN; UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	Chiba University; Tokushima University; Max Planck Society								ARMON T, 1990, J BIOL CHEM, V265, P20723; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; EYTAN E, 1993, J BIOL CHEM, V268, P4668; FRANK J, 1982, J MOL BIOL, V161, P1134; GOLDBERG AL, 1992, EUR J BIOCHEM, V205, P9; HATFIELD PM, 1989, BIOCHEMISTRY-US, V28, P735, DOI 10.1021/bi00428a048; HEGERL R, 1991, FEBS LETT, V283, P117, DOI 10.1016/0014-5793(91)80567-M; HEGERL R, 1982, ULTRAMICROSCOPY, V9, P109, DOI 10.1016/0304-3991(82)90233-9; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOUGH R, 1987, J BIOL CHEM, V262, P8303; IKAI A, 1991, FEBS LETT, V292, P21, DOI 10.1016/0014-5793(91)80824-M; KANAYAMA HO, 1992, EUR J BIOCHEM, V206, P567, DOI 10.1111/j.1432-1033.1992.tb16961.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; NAKAGAWA H, 1985, PLANT CELL REP, V4, P148, DOI 10.1007/BF00571303; ORINO E, 1991, FEBS LETT, V284, P206, DOI 10.1016/0014-5793(91)80686-W; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; OZAKI M, 1992, J BIOL CHEM, V267, P21678; PETERS JM, 1991, EUR J CELL BIOL, V56, P422; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RIVETT AJ, 1993, BIOCHEM J, V291, P1; SAXTON WO, 1979, ULTRAMICROSCOPY, V4, P343, DOI 10.1016/S0304-3991(79)80044-3; SKODA B, 1992, PLANT PHYSIOL, V99, P1515, DOI 10.1104/pp.99.4.1515; TAMURA T, 1991, FEBS LETT, V292, P154, DOI 10.1016/0014-5793(91)80856-X; TANAKA K, 1992, NEW BIOL, V4, P173; TANAKA K, 1988, J BIOL CHEM, V263, P16209; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; UGAI S, 1993, J BIOCHEM, V113, P754, DOI 10.1093/oxfordjournals.jbchem.a124116; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/0304-3991(81)90059-0; VIERSTRA RD, 1988, BIOCHEMISTRY-US, V27, P3290, DOI 10.1021/bi00409a025; VIERSTRA RD, 1993, ANNU REV PLANT PHYS, V44, P385, DOI 10.1146/annurev.pp.44.060193.002125; WAXMAN L, 1987, J BIOL CHEM, V262, P2451; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050	38	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25905	25910						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929295				2022-12-27	WOS:A1994PQ49100097
J	ZHANG, B; SZALKOWSKI, D; DIAZ, E; HAYES, N; SMITH, R; BERGER, J				ZHANG, B; SZALKOWSKI, D; DIAZ, E; HAYES, N; SMITH, R; BERGER, J			POTENTIATION OF INSULIN STIMULATION OF PHOSPHATIDYLINOSITOL 3-KINASE BY THIAZOLIDINEDIONE-DERIVED ANTIDIABETIC AGENTS IN CHINESE-HAMSTER OVARY CELLS EXPRESSING HUMAN INSULIN-RECEPTORS AND L6 MYOTUBES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; INTACT RAT; TYROSINE PHOSPHORYLATION; HYPOGLYCEMIC AGENT; SKELETAL-MUSCLE; KINASE-ACTIVITY; SIGNAL TRANSDUCTION; CYTOPLASMIC DOMAIN; GLUCOSE-TRANSPORT; 85-KDA SUBUNIT	Thiazolidinones derivatives are insulin sensitizing agents with proven antidiabetic activities in vivo. To explore the mechanism of action of this class of compounds, the effects of pioglitazone, CP-86,325, and AD-5075 on elements of the insulin signal transduction pathways were studied in Chinese hamster ovary cells overexpressing human insulin receptor (CHO.T) and L6 myotubes. In CHO.T cells, the binding of insulin to its receptor and the insulin-stimulated tyrosine kinase activity of the receptor were not altered by pioglitazone or CP-86,325. In contrast, treatment of CHO.T cells with the compounds resulted in significant increases in insulin-stimulated phosphatidylinositol (PI) 3-kinase activity. This insulin-enhancing effect was also observed in L6 myotubes treated with CP-86,325. The augmentations in kinase activity observed in CHO.T cells correlated with increases in the amount of PI 3-kinase (p85 subunit) in anti-phosphotyrosine immunoprecipitates of cell lysates. No gross changes in the tyrosine phosphorylation state of the insulin receptor substrate-1 were detected in insulin-stimulated CHO.T cells following treatment with the compounds. Furthermore, the compounds did not enhance insulin stimulation of mitogen-activated protein kinase or DNA synthesis in CHO.T cells. Thus, thiazolidinedione-derived antidiabetic agents may act as insulin sensitizers by augmenting insulin stimulation of PI 3-kinase activity in a rather specific manner.			ZHANG, B (corresponding author), MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT MOLEC ENDOCRINOL,POB 2000,80W250,RAHWAY,NJ 07065, USA.							BACKER JM, 1993, J BIOL CHEM, V268, P8204; BLACKMORE PF, 1993, METABOLISM, V42, P1583, DOI 10.1016/0026-0495(93)90154-G; BRESSLER R, 1992, DIABETES CARE, V15, P792, DOI 10.2337/diacare.15.6.792; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CHANG AY, 1983, DIABETES, V32, P830, DOI 10.2337/diabetes.32.9.830; CHANG AY, 1983, DIABETOLOGIA, V25, P514; COBB MH, 1989, J BIOL CHEM, V264, P18701; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FOLLI F, 1993, J CLIN INVEST, V92, P1787, DOI 10.1172/JCI116768; FOLLI F, 1992, J BIOL CHEM, V267, P22171; FUJITA T, 1983, DIABETES, V32, P804, DOI 10.2337/diabetes.32.9.804; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HARLOW E, 1988, ANTIBODIES LABORATOR; HAYASHI H, 1993, J BIOL CHEM, V268, P7107; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; HAYES N, 1993, BIOCHEM BIOPH RES CO, V190, P881, DOI 10.1006/bbrc.1993.1131; HERRERA R, 1988, J BIOL CHEM, V263, P5560; HEYDRICK SJ, 1993, J CLIN INVEST, V91, P1358, DOI 10.1172/JCI116337; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAZUYA T, 1991, DIABETES RES CLIN PR, V11, P147; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KLEIN HH, 1986, J BIOL CHEM, V261, P4691; KLIP A, 1992, J CELL BIOCHEM, V48, P51, DOI 10.1002/jcb.240480109; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SAAD MJA, 1993, J CLIN INVEST, V92, P2065, DOI 10.1172/JCI116803; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; STURGILL TW, 1986, BIOCHEM BIOPH RES CO, V134, P565, DOI 10.1016/S0006-291X(86)80457-0; SUGIYAMA Y, 1990, ARZNEIMITTEL-FORSCH, V40-1, P263; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUTER SL, 1992, DIABETES CARE, V15, P193, DOI 10.2337/diacare.15.2.193; TOBE K, 1992, J BIOL CHEM, V267, P21089; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WEINSTEIN SP, 1993, METABOLISM, V42, P1365, DOI 10.1016/0026-0495(93)90139-F; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YU KT, 1986, J BIOL CHEM, V261, P4715; ZHANG B, 1991, J BIOL CHEM, V266, P990	49	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25735	25741						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929278				2022-12-27	WOS:A1994PQ49100075
J	BRADYKALNAY, SM; TONKS, NK				BRADYKALNAY, SM; TONKS, NK			IDENTIFICATION OF THE HOMOPHILIC BINDING-SITE OF THE RECEPTOR PROTEIN-TYROSINE-PHOSPHATASE PTP-MU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; IMMUNOGLOBULIN SUPERFAMILY; RECOGNITION MOLECULE; EXTRACELLULAR REGION; HOMOPHILIC BINDING; IG SUPERFAMILY; NG-CAM; FAMILY; LOCALIZATION; EXPRESSION	The receptor-type protein tyrosine phosphatase PTP mu comprises an extracellular segment containing a MAM domain, an immunoglobulin domain and four fibronectin type III repeats, a transmembrane segment, and two intracellular PTP domains. We have previously shown that PTP mu binds homophilically, i.e. PTP mu on the surface of one cell binds to PTP mu on an apposing cell, and that the extracellular segment alone is sufficient for homophilic binding. In this study we report that in MvLu cells PTP mu is proteolytically processed into two noncovalently associated fragments, one comprising most of the extracellular segment (similar to 100 kDa) and the other containing predominantly the transmembrane and intracellular portions (similar to 100 kDa). We have also identified the hemophilic binding site within the extracellular segment. We have generated, expressed, and purified various fragments of the extracellular segment of PTP mu and have used fluorescent beads (Covaspheres) coated with these fragments in three binding assays: (i) measurement of bead aggregation, (ii) binding of beads to surfaces of dishes coated with purified PTP mu or (iii) binding to MvLu cells. Only beads coated with recombinant fragments that contained the immunoglobulin domain underwent aggregation or bound to surfaces displaying PTP mu, suggesting that neither the MAM domain nor the fibronectin type III repeats bound homophilically in these assays. The fragment containing the Ig domain alone bound as well as any other Ig domain-containing fragment, suggesting that the Ig domain is both necessary and sufficient for homophilic binding under these conditions.			BRADYKALNAY, SM (corresponding author), COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA.				NCI NIH HHS [CA53840, 5T32CA09311] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053840, R37CA053840, T32CA009311] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; BRACKENBURY R, 1977, J BIOL CHEM, V252, P6835; Brady-Kalnay S, 1994, ADV PROTEIN PHOSPHAT, V8, P241; BRADYKALNAY SM, 1993, MOL CELL BIOCHEM, V128, P131, DOI 10.1007/BF01076764; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BURGOON MP, 1991, J CELL BIOL, V112, P1017, DOI 10.1083/jcb.112.5.1017; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; COLE GJ, 1986, J CELL BIOL, V103, P1739, DOI 10.1083/jcb.103.5.1739; FAISSNER A, 1985, EMBO J, V4, P3105, DOI 10.1002/j.1460-2075.1985.tb04052.x; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FREI T, 1992, J CELL BIOL, V118, P177, DOI 10.1083/jcb.118.1.177; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; GRUMET M, 1991, J CELL BIOL, V113, P1399, DOI 10.1083/jcb.113.6.1399; GRUMET M, 1994, J BIOL CHEM, V269, P12142; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HE HT, 1986, EMBO J, V5, P2489, DOI 10.1002/j.1460-2075.1986.tb04526.x; JIANG WP, 1992, J BIOL CHEM, V267, P9185; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; KAYYEM JF, 1992, J CELL BIOL, V118, P1259, DOI 10.1083/jcb.118.5.1259; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; SAP J, 1994, MOL CELL BIOL, V14, P1; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1992, EMBO J, V11, P897, DOI 10.1002/j.1460-2075.1992.tb05128.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; Tonks N K, 1993, Semin Cell Biol, V4, P373, DOI 10.1006/scel.1993.1044; VOLKMER H, 1992, J CELL BIOL, V118, P149, DOI 10.1083/jcb.118.1.149; YU Q, 1992, ONCOGENE, V7, P1051; ZHOU H, 1993, J CELL BIOL, V122, P951, DOI 10.1083/jcb.122.4.951	31	101	103	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28472	28477						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961788				2022-12-27	WOS:A1994PV77200102
J	KO, KWS; OHNISHI, T; YOKOYAMA, S				KO, KWS; OHNISHI, T; YOKOYAMA, S			TRIGLYCERIDE TRANSFER IS REQUIRED FOR NET CHOLESTERYL ESTER TRANSFER BETWEEN LIPOPROTEINS IN PLASMA BY LIPID TRANSFER PROTEIN - EVIDENCE FOR A HETERO-EXCHANGE TRANSFER MECHANISM DEMONSTRATED BY USING NOVEL MONOCLONAL-ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY LIPOPROTEIN; DEFICIENT PLASMA; APOLIPOPROTEINS; PURIFICATION; INHIBITION; RABBIT; ASSOCIATION; INVITRO	In order to investigate the role of lipid transfer protein (LTP) in plasma lipoprotein metabolism, monoclonal antibodies (mAbs) have been raised against LTP isolated from rabbit plasma. mAbs 2-8G and 3-9F inhibited both [H-3]cholesteryl ester (CE) and [H-3]triglyceride (TG) transfer from low density lipoprotein (LDL) to high density lipoprotein (HDL) mediated by LTP. Although 3-9F cross-reacted with human LTP, 2-8G was species specific for rabbit LTP. mAb 14-8H inhibited only [H-3]TG but not [H-3]CE transfer and was cross-reactive with human LTP. mAbs 2-8G and 3-9F interfered with association of LTP with lipid microemulsions, again 2-8G with species specificity, whereas 14-8H did not affect LTP-microemulsion binding. Thus, mAbs 3-9F and 14-8H were used for further study in human plasma. By total inhibition of CE and TG transfer by 3-9F, LTP was shown to be responsible for net mass transfer of neutral Lipids between Lipoprotein classes in plasma, namely of CE from HDL to very low density lipoprotein (VLDL) and TG from VLDL to LDL and HDL. Selective inhibition of TG transfer by mAb 14-8H was also able to inhibit such net neutral lipid transfer. Such effect of these antibodies was demonstrated more remarkably in the presence of cholesterol esterification. Thus, TG transfer activity of LTP was shown to be required for net CE transfer, suggesting that net neutral Lipid transfer in plasma between lipoproteins occurred mainly by a hetero-exchange mechanism. Inhibition of net neutral lipid transfer in plasma did not affect cholesterol esterification occurring predominantly on HDL. Consequently, mAb inhibition of TG transfer in plasma leads to CE accumulation in HDL. It is possible that hyperalphalipoproteinemia may be induced by a mutation in LTP that causes a selective defect in TG transfer activity.	UNIV ALBERTA,HERITAGE MED RES CTR 303,DEPT MED,EDMONTON T6G 2S2,AB,CANADA; UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON T6G 2S2,AB,CANADA	University of Alberta; University of Alberta								BARTER PJ, 1979, ATHEROSCLEROSIS, V34, P67, DOI 10.1016/0021-9150(79)90107-2; BARTER PJ, 1980, J LIPID RES, V21, P238; FRANCIS GA, 1991, BIOCHIM BIOPHYS ACTA, V1084, P159, DOI 10.1016/0005-2760(91)90215-4; FUKASAWA M, 1992, J BIOCHEM-TOKYO, V111, P696, DOI 10.1093/oxfordjournals.jbchem.a123821; GLOMSET JA, 1968, J LIPID RES, V9, P155; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; HA YC, 1982, COMP BIOCHEM PHYS B, V71, P265, DOI 10.1016/0305-0491(82)90252-8; Harlow E., 1988, ANTIBODIES LAB MANUA, P298; HESLER CB, 1988, J BIOL CHEM, V263, P5020; HOPKINS GJ, 1980, METABOLISM, V29, P546, DOI 10.1016/0026-0495(80)90080-3; HOPKINS GJ, 1982, METABOLISM, V31, P78, DOI 10.1016/0026-0495(82)90048-8; IHM J, 1982, J LIPID RES, V23, P1328; KO KWS, 1993, BIOCHEMISTRY-US, V32, P6729, DOI 10.1021/bi00077a028; KURASAWA T, 1985, J BIOCHEM, V98, P1499, DOI 10.1093/oxfordjournals.jbchem.a135418; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILNER TG, 1991, BIOCHIM BIOPHYS ACTA, V1082, P71, DOI 10.1016/0005-2760(91)90301-W; MORTON RE, 1985, J BIOL CHEM, V260, P2593; MORTON RE, 1982, J LIPID RES, V23, P1058; MORTON RE, 1983, J BIOL CHEM, V258, P1751; NAGASHIMA M, 1988, J LIPID RES, V29, P1643; NISHIKAWA O, 1986, J BIOCHEM, V99, P295, DOI 10.1093/oxfordjournals.jbchem.a135473; OHNISHI T, 1993, BIOCHEMISTRY-US, V32, P5029, DOI 10.1021/bi00070a009; OHNISHI T, 1994, BIOCHEMISTRY-US, V33, P6093, DOI 10.1021/bi00186a008; OHNISHI T, 1990, J LIPID RES, V31, P397; OHNISHI T, 1994, BIOCHEMISTRY-US, V33, P4533, DOI 10.1021/bi00181a014; PATTNAIK NM, 1979, J BIOL CHEM, V254, P2782; SWENSON TL, 1989, J BIOL CHEM, V264, P14318; TAJIMA S, 1983, J BIOL CHEM, V258, P73; TALL A, 1987, J CLIN INVEST, V79, P1217, DOI 10.1172/JCI112940; TALL AR, 1993, J LIPID RES, V34, P1255; WANG S, 1991, BIOCHEMISTRY-US, V30, P3484, DOI 10.1021/bi00228a019; WANG SK, 1993, J BIOL CHEM, V268, P1955; WHITLOCK ME, 1989, J CLIN INVEST, V84, P129, DOI 10.1172/JCI114132; YEN FT, 1989, J CLIN INVEST, V83, P2018, DOI 10.1172/JCI114112	34	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28206	28213						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961758				2022-12-27	WOS:A1994PV77200066
J	PHILLIPPY, BQ; ULLAH, AHJ; EHRLICH, KC				PHILLIPPY, BQ; ULLAH, AHJ; EHRLICH, KC			PURIFICATION AND SOME PROPERTIES OF INOSITOL 1,3,4,5,6-PENTAKISPHOSPHATE 2-KINASE FROM IMMATURE SOYBEAN SEEDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL GLOMERULOSA CELLS; PHYTIC ACID; MYOINOSITOL HEXAKISPHOSPHATE; ION CHROMATOGRAPHY; PENTAKISPHOSPHATE; METABOLISM; PHOSPHORYLATION; PHOSPHATES; TETRAKISPHOSPHATES; IDENTIFICATION	Inositol 1,3,4,5,6-pentakisphosphate S-kinase was purified from immature soybean seeds harvested approximately 5 weeks post-anthesis. A crude extract was clarified using polyethyleneimine and purified by chromatography on DEAE-cellulose, Cibacron Blue 3GA-agarose, Toyopearl DEAE 650M, and Toyopearl phenyl 650M columns. The enzyme had a relative molecular mass, M(r), of 52,000 as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and retained 50% of its activity after 6 weeks at 0 degrees C. The K-m values for inositol 1,3,4,5,6-pentakisphosphate and MgATP, respectively, were 2.3 mu M and 8.4 mu M, and the V-max was 243 nmol/min/mg. The pH and temperature optima, respectively, were 6.8 and 42 degrees C. Maximum activity was obtained when the magnesium ion concentration was 4 mM. The kinase specifically phosphorylated the 2-position on the inositol ring and could also utilize D-inositol 1,4,5,6-tetrakisphosphate as a substrate. The K for the reaction was 14, indicating that the enzyme may be involved in both inositol hexakisphosphate formation in maturing seeds and ATP resynthesis in germinating seeds. Substrate concentrations in mature seeds were favorable for ATP formation, whereas additional factors appeared to drive the accumulation of inositol hexakisphosphate in maturing seeds.			PHILLIPPY, BQ (corresponding author), USDA ARS,SO REG RES CTR,1100 ROBERT E LEE BLVD,NEW ORLEANS,LA 70124, USA.							ASADA K, 1969, ANN NY ACAD SCI, V165, P801, DOI 10.1111/j.1749-6632.1970.tb56445.x; ATTUCCI S, 1991, PLANT PHYSIOL, V95, P390, DOI 10.1104/pp.95.2.390; BALLA T, 1989, J BIOL CHEM, V264, P9386; BISWAS S, 1978, ARCH BIOCHEM BIOPHYS, V185, P557, DOI 10.1016/0003-9861(78)90201-1; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CECCONI O, 1994, J BIOL CHEM, V289, P15060; CHAKRABARTI S, 1981, PHYTOCHEMISTRY, V20, P1815, DOI 10.1016/0031-9422(81)84010-1; CHATTAWAY JA, 1992, PLANTA, V187, P542, DOI 10.1007/BF00199975; CHING TM, 1974, PLANT PHYSIOL, V54, P748, DOI 10.1104/pp.54.5.748; COSGROVE DJ, 1969, ANN NY ACAD SCI, V165, P677; CRAXTON A, 1994, J BIOL CHEM, V269, P4337; GRAF E, 1987, J BIOL CHEM, V262, P11647; GRAF E, 1983, ANAL BIOCHEM, V131, P351, DOI 10.1016/0003-2697(83)90182-3; HAWKINS PT, 1993, BIOCHEM J, V294, P929, DOI 10.1042/bj2940929; HESLOP JP, 1985, J EXP BIOL, V119, P395; HUNYADY L, 1988, BIOCHEM BIOPH RES CO, V157, P1247, DOI 10.1016/S0006-291X(88)81008-8; IRVINE RF, 1992, BIOCHEM J, V281, P261, DOI 10.1042/bj2810261; IRVING GCJ, 1972, J BACTERIOL, V112, P434, DOI 10.1128/JB.112.1.434-438.1972; JI H, 1989, J BIOL CHEM, V264, P20185; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYR GW, 1988, BIOCHEM J, V254, P585, DOI 10.1042/bj2540585; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; OLIVER KG, 1992, J BIOL CHEM, V267, P21528; PERL M, 1986, PHYSIOL PLANTARUM, V66, P177, DOI 10.1111/j.1399-3054.1986.tb01253.x; PHILLIPPY BQ, 1987, ANAL BIOCHEM, V162, P115, DOI 10.1016/0003-2697(87)90015-7; PHILLIPPY BQ, 1988, ANAL BIOCHEM, V175, P162, DOI 10.1016/0003-2697(88)90374-0; PHILLIPPY BQ, 1989, J AGR FOOD CHEM, V37, P1261, DOI 10.1021/jf00089a013; PHILLIPPY BQ, 1985, J FOOD SCI, V50, P541, DOI 10.1111/j.1365-2621.1985.tb13449.x; PRATTLEY CA, 1983, J FOOD BIOCHEM, V6, P243; RABOY V, 1987, PLANT PHYSIOL, V85, P841, DOI 10.1104/pp.85.3.841; Reddy N.R., 1989, PHYTATES CEREALS LEG; SASAKAWA N, 1990, J BIOL CHEM, V265, P17700; SHEARS SB, 1989, J BIOL CHEM, V264, P19879; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; STEPHENS LR, 1988, BIOCHEM J, V253, P721, DOI 10.1042/bj2530721; STEPHENS LR, 1990, NATURE, V346, P580, DOI 10.1038/346580a0; STEPHENS LR, 1991, BIOCHEM J, V275, P485, DOI 10.1042/bj2750485; STEPHENS LR, 1988, BIOCHEM J, V249, P283, DOI 10.1042/bj2490283; TOMLINSON RV, 1962, BIOCHEMISTRY-US, V1, P166, DOI 10.1021/bi00907a025; VALLEJO M, 1987, NATURE, V330, P656, DOI 10.1038/330656a0	41	49	53	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28393	28399						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961779				2022-12-27	WOS:A1994PV77200091
J	TERUI, T; KAHN, RA; RANDAZZO, PA				TERUI, T; KAHN, RA; RANDAZZO, PA			EFFECTS OF ACID PHOSPHOLIPIDS ON NUCLEOTIDE EXCHANGE PROPERTIES OF ADP-RIBOSYLATION FACTOR-1 - EVIDENCE FOR SPECIFIC INTERACTION WITH PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLERA-TOXIN; REGULATORY COMPONENT; ADENYLATE-CYCLASE; PROTEIN COFACTOR; GOLGI MEMBRANES; BINDING; GTP; ARF; IDENTIFICATION; EXPRESSION	ADP-ribosylation factors (ARFs) have been implicated as ubiquitous regulators of multiple steps in both exocytic and endocytic membrane traffic in yeast and mammalian cells. More specific interactions have also been described for ARF proteins with an ARF-specific GTPase-activating protein and as activators of phospholipase D activity. These protein interactions have defined requirements for phosphatidylinositol 4,5-bisphosphate (PIP2). Direct interactions between ARF1 and PIP2 or other phospholipids were tested by examining effects on guanine nucleotide binding kinetics. PIP2 (400 mu M) increased the rate of GDP dissociation >100-fold. Several other acid phospholipids had more modest effects (4-7-fold) on GDP dissociation rates, while other phospholipids had no effect. PIP2 also had the greatest effect on the rate of binding of guanosine 5'-(gamma-thio)triphosphate (GTP gamma S), increasing it almost 100-fold at early time points. However, at later times (>5 min), PIP2 caused a paradoxical loss of nucleotide binding to ARF1. PIP2 was found to stabilize the nucleotide-free form of ARF1 as subsequent dilution of PIP2 allowed ARF1 to bind GTP gamma S to high stoichiometry. The demonstration of direct interaction between ARF1 and PIP2 provides the basis for a model in which PIP2 acts as a cofactor in some of the interactions between ARF1 and other proteins.	NCI, DIV CANC TREATMENT, BIOL CHEM LAB, DEV THERAPEUT PROGRAM, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601				BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COHEN P, 1971, J CLIN INVEST, V50, P762, DOI 10.1172/JCI106547; DECLUE JE, 1991, MOL CELL BIOL, V11, P3132, DOI 10.1128/MCB.11.6.3132; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; HANEY SA, 1994, J BIOL CHEM, V269, P16541; JAIN MK, 1987, BIOCHIM BIOPHYS ACTA, V906, P33, DOI 10.1016/0304-4157(87)90004-9; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1993, GTPASES BIOL, V1, P529; MITCHELL KT, 1986, ANAL BIOCHEM, V158, P447, DOI 10.1016/0003-2697(86)90574-9; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; RANDAZZO PA, 1994, IN PRESS J BIOL CHEM; ROSENWALD AG, 1994, CHALL MOD MED, V6, P143; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SCHLEIFER LS, 1982, J BIOL CHEM, V257, P20; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; VOLWERK JJ, 1994, BIOCHEMISTRY-US, V33, P3464, DOI 10.1021/bi00178a002; WALKER MW, 1992, J BIOL CHEM, V267, P3230; WEISS O, 1989, J BIOL CHEM, V264, P21066	29	97	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28130	28135						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961749				2022-12-27	WOS:A1994PV77200055
J	URA, K; WOLFFE, AP; HAYES, JJ				URA, K; WOLFFE, AP; HAYES, JJ			CORE HISTONE ACETYLATION DOES NOT BLOCK LINKER HISTONE BINDING TO A NUCLEOSOME INCLUDING A XENOPUS-BOREALIS 5-S RIBOSOMAL-RNA GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CHROMATIN; HYPERACETYLATION; DNA; PARTICLE; TRANSITIONS; EXPRESSION; TAILS	We demonstrate that acetylation of core histone tails does not significantly impair the ability of linker histones to bind preferentially and asymmetrically to a defined sequence mononucleosome core reconstituted in vitro. Thus a simple inhibition mechanism cannot explain models whereby acetylation is causal for the observed reduction in the linker histone content in chromatin. Other models to explain this correlation are discussed.	NICHHD,MOLEC EMBRYOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								ALLAN J, 1982, J CELL BIOL, V93, P285, DOI 10.1083/jcb.93.2.285; ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; ANNUNZIATO AT, 1983, J BIOL CHEM, V258, P2675; ANNUNZIATO AT, 1988, CHROMOSOMA, V96, P132, DOI 10.1007/BF00331045; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; BAUER WR, 1994, J MOL BIOL, V236, P685, DOI 10.1006/jmbi.1994.1180; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; CLARK DJ, 1986, J MOL BIOL, V187, P569, DOI 10.1016/0022-2836(86)90335-9; DIMITROV S, 1993, DEV BIOL, V160, P214, DOI 10.1006/dbio.1993.1299; DIMITROV S, 1986, FEBS LETT, V197, P217, DOI 10.1016/0014-5793(86)80329-5; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; HAYES JJ, 1994, P NATL ACAD SCI USA, V91, P7817, DOI 10.1073/pnas.91.16.7817; HAYES JJ, 1993, P NATL ACAD SCI USA, V90, P6415, DOI 10.1073/pnas.90.14.6415; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; IMAI BS, 1986, J BIOL CHEM, V261, P8784; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LIBERTINI LJ, 1988, BIOPHYS J, V53, P477, DOI 10.1016/S0006-3495(88)83126-6; MCGHEE JD, 1983, NUCLEIC ACIDS RES, V11, P4065, DOI 10.1093/nar/11.12.4065; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; OLIVA R, 1990, NUCLEIC ACIDS RES, V18, P2739, DOI 10.1093/nar/18.9.2739; PANYIM S, 1969, BIOCHEMISTRY-US, V8, P3972, DOI 10.1021/bi00838a013; PERRY CA, 1991, EXP CELL RES, V196, P337, DOI 10.1016/0014-4827(91)90269-Z; RIDSDALE JA, 1990, J BIOL CHEM, V265, P5150; ROBERGE M, 1991, FEBS LETT, V288, P215, DOI 10.1016/0014-5793(91)81037-9; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; TATCHELL K, 1977, BIOCHEMISTRY-US, V16, P5295, DOI 10.1021/bi00643a021; THOMA F, 1979, J CELL BIOL, V83, P407; TURNER BM, 1991, J CELL SCI, V99, P13; van Holde KE., 1989, SPRINGER SERIES MOL; WEST MHP, 1980, BIOCHEMISTRY-US, V19, P3238, DOI 10.1021/bi00555a022; WOLFFE A, 1992, CHROMATIN STRUCTURE	37	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27171	27174						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961624				2022-12-27	WOS:A1994PV77100005
J	WATERS, KM; NTAMBI, JM				WATERS, KM; NTAMBI, JM			INSULIN AND DIETARY FRUCTOSE INDUCE STEAROYL-COA DESATURASE-1 GENE-EXPRESSION IN LIVER OF DIABETIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; POST-TRANSCRIPTIONAL REGULATION; MALIC ENZYME-SYNTHESIS; PYRUVATE-KINASE GENE; RAT-LIVER; MESSENGER-RNA; INVIVO; CELLS; ACID	The transcription and mRNA levels of murine liver stearoyl-CoA desaturase 1 (SCD1) are induced 11- and 45-fold, respectively, by feeding fasted normal mice with a fat-free, high carbohydrate diet (Ntambi, J. M. (1992) J. Biol. Chem. 267, 10925-10930). In this study, we used streptozotocin-induced diabetic mice to study the regulatory role of carbohydrate and insulin on expression of the SCD1 gene in liver. Fructose administration to fasted diabetic mice induced a 2-fold increase in SCD1 mRNA within 6 h and a 23-fold increase within 24 h. Similarly, insulin administration to diabetic mice induced SCD1 mRNA from 4-fold within 4 h to 22-fold within 24 h. Insulin plus fructose, however, achieved full induction, with a 45-fold increase of SCD1 mRNA and a 10-fold increase in SCD1 transcription within 24 h. Additionally, the effect of insulin on SCD1 mRNA was inhibited 75% with dibutyryl-cAMP and theophylline administration and 70% by cycloheximide administration. Synthesis of liver albumin mRNA showed little change upon dietary manipulation or insulin treatment. Our data demonstrate that insulin and dietary fructose or a metabolite of fructose positively regulate the expression of the SCD1 gene in mouse liver.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Waters, Katrina/0000-0003-4696-5396	NIDDK NIH HHS [DK42825] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042825] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELMAN RC, 1966, J BIOL CHEM, V241, P5467; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DETOMAS ME, 1973, BIOCHIM BIOPHYS ACTA, V306, P149, DOI 10.1016/0005-2760(73)90220-8; DIORON B, 1994, J BIOL CHEM, V269, P10213; ENOCH HG, 1976, J BIOL CHEM, V251, P5095; GELLHORN A, 1964, BIOCHIM BIOPHYS ACTA, V84, P167, DOI 10.1016/0926-6542(64)90073-3; GELLHORN A, 1965, ANN NY ACAD SCI, V131, P344, DOI 10.1111/j.1749-6632.1965.tb34802.x; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; JUMP DB, 1990, MOL ENDOCRINOL, V4, P1655, DOI 10.1210/mend-4-11-1655; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; KASTURI I, 1982, J BIOL CHEM, V257, P12224; KATSURADA A, 1989, BIOCHIM BIOPHYS ACTA, V1004, P103, DOI 10.1016/0005-2760(89)90219-1; KATSURADA A, 1988, BIOCHIM BIOPHYS ACTA, V950, P113, DOI 10.1016/0167-4781(88)90003-6; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; MUNNICH A, 1987, J BIOL CHEM, V262, P17065; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; NOGUCHI T, 1982, EUR J BIOCHEM, V128, P583; NOGUCHI T, 1985, J BIOL CHEM, V260, P4393; NTAMBI JM, 1992, J BIOL CHEM, V267, P10925; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; PRASAD MR, 1979, J BIOL CHEM, V254, P997; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SZEPESI B, 1972, LIFE SCI 2-BIOCH GEN, V11, P113, DOI 10.1016/0024-3205(72)90143-9; THIEDE MA, 1985, J BIOL CHEM, V260, P4459; THIEDE MA, 1986, J BIOL CHEM, V261, P3230; WEINER FR, 1991, J BIOL CHEM, V266, P23525; ZIEGLER M, 1988, J IMMUNOL, V14, P4144	30	105	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27773	27777						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961698				2022-12-27	WOS:A1994PV77100095
J	YUDKOFF, M; NELSON, D; DAIKHIN, Y; ERECINSKA, M				YUDKOFF, M; NELSON, D; DAIKHIN, Y; ERECINSKA, M			TRICARBOXYLIC-ACID CYCLE IN RAT-BRAIN SYNAPTOSOMES - FLUXES AND INTERACTIONS WITH ASPARTATE-AMINOTRANSFERASE AND MALATE ASPARTATE SHUTTLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL GLUTAMINE UTILIZATION; AMINO-ACIDS; OXIDATIVE-METABOLISM; MITOCHONDRIA; TRANSPORT; CHROMATOGRAPHY; DERIVATIVES; GLUCOSE; ENZYMES; ATP	The flux through different segments of the tricarboxylic acid cycle was measured in rat brain synaptosomes with gas chromatography-mass spectrometry using either deuterated glutamine or [C-13]aspartate. The flux between 2-oxoglutarate and oxaloacetate was estimated to be 3.14 and 4.97 nmol/min/mg protein with and without glucose, respectively. These values were 3-5-fold faster than the flux between oxaloacetate and a 2-oxoglutarate (0.92 nmol/min per mg protein) measured in the presence of glucose. The pattern of intermediates labeling suggests that the overall rate-controlling reaction involves either citrate synthase or pyruvate dehydrogenase but not 2-oxoglutarate or isocitrate dehydrogenase. The enrichment in [3,3,4,4-H-2(4)]glutamate from [2,3,3,4,4-H-2(5)]glutamine was as rapid as in [2,3,3,4,4-H-2(5)]glutamate, which indicates that the aspartate aminotransferase reaction is severalfold faster than the flux through the tricarboxylic acid cycle. [C-13]Aspartate was rapidly converted to [C-13]malate, suggesting that in intact synaptosomes aspartate entry into the mitochondrion is very slow. The finding that aspartate is taken up by mitochondria as malate, along with the observed high enrichment in [3-H-2]malate (from [2,3,3,4,4-H-2(5)]glutamine), is consistent with the substantial synaptosomal activity of the malate/aspartate shuttle.	UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19104; CHILDRENS HOSP,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia					NINDS NIH HHS [NS 28329, NS 27889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028329, R01NS027889] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENUCK M, 1971, J NEUROCHEM, V18, P1555, DOI 10.1111/j.1471-4159.1971.tb00017.x; Biemann K., 1962, ORGANIC CHEM APPL, P223; BOOTH RFG, 1980, J NEUROCHEM, V34, P17, DOI 10.1111/j.1471-4159.1980.tb04616.x; BOOTH RFG, 1978, BIOCHEM J, V176, P365, DOI 10.1042/bj1760365; BRAND MD, 1974, BIOCHEM J, V140, P205, DOI 10.1042/bj1400205; BRUICE PY, 1978, J AM CHEM SOC, V100, P4793, DOI 10.1021/ja00483a027; CHEESEMAN AJ, 1988, J NEUROCHEM, V50, P1559, DOI 10.1111/j.1471-4159.1988.tb03044.x; COOPER AJ, 1983, CHEM REV, V83, P321, DOI 10.1021/cr00055a004; COOPER AJL, 1987, PHYSIOL REV, V67, P440, DOI 10.1152/physrev.1987.67.2.440; DAGANI F, 1987, J NEUROCHEM, V49, P1229, DOI 10.1111/j.1471-4159.1987.tb10015.x; DENNIS SC, 1976, BIOCHEM J, V156, P323, DOI 10.1042/bj1560323; DUFFY TE, 1972, J NEUROCHEM, V19, P959, DOI 10.1111/j.1471-4159.1972.tb01417.x; ERECINSKA M, 1989, J CEREBR BLOOD F MET, V9, P2, DOI 10.1038/jcbfm.1989.2; ERECINSKA M, 1994, J NEUROCHEM, V63, P1033; ERECINSKA M, 1990, PROG NEUROBIOL, V35, P245, DOI 10.1016/0301-0082(90)90013-7; ERECINSKA M, 1993, J NEUROCHEM, V60, P1696, DOI 10.1111/j.1471-4159.1993.tb13393.x; ERECINSKA M, 1988, J NEUROCHEM, V51, P892, DOI 10.1111/j.1471-4159.1988.tb01826.x; ERECINSKA M, 1990, J NEUROCHEM, V54, P2057, DOI 10.1111/j.1471-4159.1990.tb04911.x; FITZPATRICK SM, 1990, J CEREBR BLOOD F MET, V10, P170, DOI 10.1038/jcbfm.1990.32; FITZPATRICK SM, 1983, J NEUROCHEM, V41, P1370, DOI 10.1111/j.1471-4159.1983.tb00835.x; GARFINKEL D, 1966, J BIOL CHEM, V241, P3918; GORNALL AG, 1949, J BIOL CHEM, V177, P751; Hansford R.G., 1980, CURR TOP BIOENERG, VVolume 10, P217, DOI 10.1016/B978-0-12-152510-1.50012-2; HSSEL B, 1994, J NEUROCHEM, V62, P2187; JARRETT HW, 1986, ANAL BIOCHEM, V153, P189, DOI 10.1016/0003-2697(86)90079-5; KAUPPINEN RA, 1987, BIOCHIM BIOPHYS ACTA, V930, P173, DOI 10.1016/0167-4889(87)90029-2; Krebs H.A., 1970, PYRIDINE NUCL DEPEND, P413; LANOUE KF, 1971, METABOLISM, V20, P119, DOI 10.1016/0026-0495(71)90087-4; LANOUE KF, 1979, ANNU REV BIOCHEM, V48, P871, DOI 10.1146/annurev.bi.48.070179.004255; MASON GF, 1992, J CEREBR BLOOD F MET, V12, P434, DOI 10.1038/jcbfm.1992.61; MAWHINNEY TP, 1986, J CHROMATOGR, V358, P231, DOI 10.1016/S0021-9673(01)90333-4; MILLER AL, 1973, J NEUROCHEM, V20, P1393, DOI 10.1111/j.1471-4159.1973.tb00251.x; MINN A, 1977, J NEUROCHEM, V29, P873, DOI 10.1111/j.1471-4159.1977.tb10731.x; Palmieri F, 1971, EXPERIMENTIA       S, V18, P505; RATNAKUMARI L, 1989, NEUROCHEM RES, V14, P221, DOI 10.1007/BF00971314; SHUG AL, 1994, LIFE SCI, V54, P567, DOI 10.1016/0024-3205(94)90008-6; VANDENBE.CJ, 1971, BIOCHEM J, V123, P211, DOI 10.1042/bj1230211; YUDKOFF M, 1989, J NEUROCHEM, V53, P632, DOI 10.1111/j.1471-4159.1989.tb07380.x	38	115	116	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27414	27420						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961653				2022-12-27	WOS:A1994PV77100043
J	CHAN, WK; CHU, RY; JAIN, S; REDDY, JK; BRADFIELD, CA				CHAN, WK; CHU, RY; JAIN, S; REDDY, JK; BRADFIELD, CA			BACULOVIRUS EXPRESSION OF THE AH RECEPTOR AND AH RECEPTOR NUCLEAR TRANSLOCATOR - EVIDENCE FOR ADDITIONAL DIOXIN-RESPONSIVE ELEMENT-BINDING SPECIES AND FACTORS REQUIRED FOR SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; TRANSCRIPTIONAL REGULATION; INDUCIBLE EXPRESSION; GENE-EXPRESSION; BASAL LEVEL; LIGAND; IDENTIFICATION; CLONING; DOMAIN; HSP90	In an effort to facilitate the structural and biochemical cal analyses of the Ah receptor (AKR) and the Ah receptor nuclear translocator (ARNT), a baculovirus system was developed to express microgram-milligram quantities of the human version of these proteins. To simplify purification, a polyhistidine tag was cloned at their C termini so that the recombinant proteins could be specifically adsorbed to nickel-nitriloacetic acid-Sepharose. Expression studies revealed that approximately 23% of the overexpressed AHR was recovered in cell extracts with the remaining 77% forming insoluble aggregates. ARNT was found to be more soluble, with 90% recovery from cell extracts and only 10% aggregation. Photoaffinity labeling and gel shift assays demonstrated that the recombinant proteins bound ligand, heterodimerized, and recognized their cognate ''dioxin response element'' (DRE) in a manner similar to their native counterparts. Coexpression of the AHR and ARNT in Sf9 cells resulted in the in vivo generation of heterodimers that bound the DRE in the absence of ligand. Studies with the nickel-nitriloacetic acid-purified recombinant proteins demonstrated that the AHR and ARNT could bind DRE only when reconstituted with a heat-sensitive factor(s) present in soluble extracts from a variety of cell types. Use of these proteins also demonstrated the existence of at least three AHR-dependent DRE-binding species, suggesting that the AHR can bind to DRE in at least three distinct conformations.	NORTHWESTERN UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT PATHOL,CHICAGO,IL 60611	Northwestern University; Northwestern University				jain, sanjay/0000-0003-2804-127X	NIEHS NIH HHS [ES-05703] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005703, R29ES005703, R37ES005703] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALNEMRI ES, 1993, BIOCHEMISTRY-US, V32, P5387, DOI 10.1021/bi00071a014; ALVARES K, 1992, P NATL ACAD SCI USA, V89, P4908, DOI 10.1073/pnas.89.11.4908; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BRADFIELD CA, 1991, MOL PHARMACOL, V39, P3; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DALMAN FC, 1990, J BIOL CHEM, V265, P3615; DENISON MS, 1991, ARCH BIOCHEM BIOPHYS, V284, P158, DOI 10.1016/0003-9861(91)90278-Q; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DOLWICK KM, 1993, MOL PHARMACOL, V44, P911; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; GASIEWICZ TA, 1987, J BIOL CHEM, V262, P2116; GONZALEZ FJ, 1984, MOL PHARMACOL, V26, P117; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; ISREAL DI, 1983, J BIOL CHEM, V258, P10390; JACKSON FR, 1986, NATURE, V320, P185, DOI 10.1038/320185a0; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JONES PBC, 1985, SCIENCE, V227, P1499, DOI 10.1126/science.3856321; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; MANCHESTER DK, 1987, CANCER RES, V47, P4861; MASON GGF, 1994, J BIOL CHEM, V269, P4438; MERCHANT M, 1992, ARCH BIOCHEM BIOPHYS, V292, P250, DOI 10.1016/0003-9861(92)90076-9; MITSUI K, 1993, J BIOL CHEM, V268, P24415; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; PAPOULAS O, 1992, J BIOL CHEM, V267, P10470; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; POLAND A, 1986, J BIOL CHEM, V261, P6352; POLAND A, 1991, MOL PHARMACOL, V39, P20; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; TELAKOWSKIHOPKINS CA, 1988, P NATL ACAD SCI USA, V85, P1000, DOI 10.1073/pnas.85.4.1000; THAYER MJ, 1993, P NATL ACAD SCI USA, V90, P6483, DOI 10.1073/pnas.90.14.6483; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x	38	40	41	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26464	26471						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929368				2022-12-27	WOS:A1994PQ93000080
J	HILFIKER, H; GUERINI, D; CARAFOLI, E				HILFIKER, H; GUERINI, D; CARAFOLI, E			CLONING AND EXPRESSION OF ISOFORM-2 OF THE HUMAN PLASMA-MEMBRANE CA2+ ATPASE - FUNCTIONAL-PROPERTIES OF THE ENZYME AND ITS SPLICING PRODUCTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP; MESSENGER-RNAS; CA-2+ PUMP; MOLECULAR CHARACTERIZATION; LIMITED PROTEOLYSIS; PEPTIDE COMPLEX; RAT-BRAIN; CALMODULIN; BINDING; DOMAINS	Full-length cDNAs for the three human plasma membrane Ca2+ pump isoforms 2 (PMCA2) differently spliced at the A site were constructed and transferred to baculovirus. The corresponding proteins were expressed after infection in Sf9 insect cells. The proteins were expressed at high levels and retained the canonical properties of the plasma membrane Ca2+ pump. The alternative splicing process failed to produce functional differences detectable with the methods used. The Ca2+-dependent ATPase activity of the PMCA2 pumps had a 5-10-fold higher affinity for calmodulin than the PMCA4 pump expressed in the same system. Experiments on the formation of the phosphoenzyme intermediate from ATP revealed that the PMCA2 pumps had higher affinity for ATP than did the PMCA4 counterpart. The response of the two pump types to activating acidic phospholipids was the same.	ETH ZENTRUM,INST BIOCHEM,CH-8092 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich			Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				ADAMO HP, 1992, BIOCHEM J, V283, P355, DOI 10.1042/bj2830355; Ausubel F.M., 1989, CURRENT PROTOCOLS MO, V2; BRANDT P, 1992, GENOMICS, V14, P484, DOI 10.1016/S0888-7543(05)80246-0; BRANDT P, 1992, J BIOL CHEM, V267, P4376; BRODIN P, 1992, EUR J BIOCHEM, V204, P939, DOI 10.1111/j.1432-1033.1992.tb16715.x; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1993, TRENDS CARDIOVAS MED, V3, P177, DOI 10.1016/1050-1738(93)90003-O; CARAFOLI E, 1994, IN PRESS FASEB J; CARIDE AJ, 1988, BIOCHEM J, V255, P663; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; ENYEDI A, 1994, J BIOL CHEM, V269, P41; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FALCHETTO R, 1992, PROTEIN SCI, V1, P1613, DOI 10.1002/pro.5560011209; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; HEIM R, 1992, EUR J BIOCHEM, V205, P333, DOI 10.1111/j.1432-1033.1992.tb16784.x; HEIM R, 1992, J BIOL CHEM, V267, P24476; HEINKOFF S, 1984, GENE, V28, P351; HOFMANN F, 1993, J BIOL CHEM, V268, P10252; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KEETON TP, 1993, J BIOL CHEM, V268, P2740; KESSLER F, 1990, J BIOL CHEM, V265, P16012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LATIF F, 1993, CANCER RES, V53, P861; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; NIGGLI V, 1981, J BIOL CHEM, V256, P8588; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STAHL WL, 1992, MOL BRAIN RES, V16, P223, DOI 10.1016/0169-328X(92)90229-5; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG MG, 1994, CYTOGENET CELL GENET, V67, P41, DOI 10.1159/000133794; ZVARITCH E, 1990, BIOCHEMISTRY-US, V29, P8070, DOI 10.1021/bi00487a012	38	102	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26178	26183						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929331				2022-12-27	WOS:A1994PQ93000038
J	RUBLEVSKAYA, I; MAINES, MD				RUBLEVSKAYA, I; MAINES, MD			INTERACTION OF FE-PROTOPORPHYRIN-IX AND HEME ANALOGS WITH PURIFIED RECOMBINANT HEME OXYGENASE-2, THE CONSTITUTIVE ISOZYME OF THE BRAIN AND TESTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; CARBON-MONOXIDE; MESSENGER-RNA; BILIVERDIN REDUCTASE; ZINC-PROTOPORPHYRIN; HEAT-SHOCK; LIVER; EXPRESSION; CDNA; PROTEIN	Heme oxygenase-2 (HO-2) is the predominant form of heme oxygenase in the brain and testes. The enzyme is not readily amenable to isolation from mammalian tissues and has not been characterized for its kinetic properties and interaction with metalloporphyrins. Presently a rat HO-2 cDNA (Rotenberg, M. O., and Maines, M. D. (1990) J. Biol. Chem. 265, 7501-7506) was used to generate a construct with a neutral hydrophobicity profile at its COOH terminus for expression of nearly full-length HO-2 protein in Escherichia coli. The procedures used for HO-1 were of no utility in purification of HO-2. A multistep protocol developed for isolation of HO-2 resulted in a homogeneous protein with a specific activity up to 6,500 nmol of bilirubin/mg/h. Based on SDS-polyacrylamide gel electrophoresis and Western blot analyses, the protein had an apparent molecular mass of similar to 34 kDa. HO-2 binds Fe-protoporphyrin (heme) at near molar unity to give a complex with the absorption maximum at 403 nm. The Soret band has a blue shift to 430 nm when heme iron is reduced, with distinct alpha and beta bands at 485 and 550 nm, respectively. The Soret band of the CO complex of ferrous heme.HO-2 is at 420 nm, and alpha and beta bands are at 540 and 572 nm, respectively. The apparent K-m for Fe-protoporphyrin is 0.33 mu M, with a V-max of 0.45 mmol of bilirubin/mg/h. Zn-protoporphyrin is a strong mixed inhibitor of enzyme activity, whereas Co-protoporphyrin is a poor competitive inhibitor of activity. When HO-2 was preincubated (10 min at 4 degrees C) with Feprotoporphyrin, the cobalt complex did not inhibit enzyme activity, whereas the Zn-protoporphyrin effectively inhibited activity. Calorimetric measurements suggest that HO-2/heme interaction involves one type of association producing a single heat absorption peak upon melting of the complex and that the unfolding is not reversible. The association increases the enthalpy of HO-2 (130 kcal/mol versus 184 kcal/mol) and increases the stability to heat denaturation by 9 degrees C. Heat duration of zinc complex involves at least two stages of unfolding.	UNIV ROCHESTER,SCH MED,DEPT BIOPHYS,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED,DEPT ENVIRONM MED,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NIEHS NIH HHS [ES04066, ES03968, ES01247] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247, R01ES004066, R01ES003968] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BRAGGINS PE, 1986, BIOCHEM BIOPH RES CO, V141, P528, DOI 10.1016/S0006-291X(86)80205-4; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CRUSE I, 1988, J BIOL CHEM, V263, P3348; DRUMMOND GS, 1981, P NATL ACAD SCI-BIOL, V78, P6466, DOI 10.1073/pnas.78.10.6466; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; EVANS CO, 1991, BIOCHEM J, V273, P659, DOI 10.1042/bj2730659; EWING JF, 1991, P NATL ACAD SCI USA, V88, P5364, DOI 10.1073/pnas.88.12.5364; EWING JF, 1992, MOL CELL NEUROSCI, V3, P559, DOI 10.1016/1044-7431(92)90068-D; HAMORI CJ, 1989, J PEDIATR GASTR NUTR, V8, P110, DOI 10.1097/00005176-198901000-00020; HUANG TJ, 1989, J BIOL CHEM, V264, P7844; KAGEYAMA H, 1988, CANCER RES, V48, P4795; KUTTY RK, 1981, J BIOL CHEM, V256, P3956; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAINES MD, 1975, J BIOL CHEM, V250, P4171; MAINES MD, 1993, MOL CELL NEUROSCI, V4, P389, DOI 10.1006/mcne.1993.1049; MAINES MD, 1977, BIOCHEMISTRY-US, V16, P419, DOI 10.1021/bi00622a012; MAINES MD, 1974, P NATL ACAD SCI USA, V71, P4293, DOI 10.1073/pnas.71.11.4293; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MAINES MD, 1981, BIOCHIM BIOPHYS ACTA, V673, P339, DOI 10.1016/0304-4165(81)90465-7; MAINES MD, 1986, J BIOL CHEM, V261, P411; MAINES MD, 1992, HEME OXYGENASE CLIN, P1; MARK JA, 1992, PEDIATR RES, V32, P324, DOI 10.1203/00006450-199209000-00016; MCCOUBREY WK, 1993, ARCH BIOCHEM BIOPHYS, V302, P402, DOI 10.1006/abbi.1993.1231; MCCOUBREY WK, 1992, ARCH BIOCHEM BIOPHYS, V295, P13, DOI 10.1016/0003-9861(92)90481-B; MCCOUBREY WK, 1994, GENE, V139, P155, DOI 10.1016/0378-1119(94)90749-8; MULLER RM, 1987, J BIOL CHEM, V262, P6795; Privalov P L, 1986, Methods Enzymol, V131, P4; ROTENBERG MO, 1990, J BIOL CHEM, V265, P7501; ROTENBERG MO, 1991, ARCH BIOCHEM BIOPHYS, V290, P336, DOI 10.1016/0003-9861(91)90549-X; SCOPES R, 1982, PROTEIN PURIFICATION, P21; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; SUN Y, 1990, J BIOL CHEM, V265, P8212; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAKSHEL GM, 1988, ARCH BIOCHEM BIOPHYS, V260, P732, DOI 10.1016/0003-9861(88)90503-6; TRAKSHEL GM, 1986, J BIOL CHEM, V261, P1131; TRAKSHEL GM, 1991, BIOCHEM J, V275, P159, DOI 10.1042/bj2750159; TRAKSHEL GM, 1989, J BIOL CHEM, V264, P1323; VALAES T, 1994, PEDIATRICS, V93, P1; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WEBER CM, 1994, J NEUROCHEM, V63, P953; WILKS A, 1993, J BIOL CHEM, V268, P22357; WU ML, 1993, BIOCHEMISTRY-US, V32, P7216, DOI 10.1021/bi00079a018; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; YOSHIDA T, 1978, J BIOL CHEM, V253, P4224; YOSHIDA T, 1988, EUR J BIOCHEM, V171, P457, DOI 10.1111/j.1432-1033.1988.tb13811.x; YOSHIDA T, 1974, J BIOCHEM, V75, P1187, DOI 10.1093/oxfordjournals.jbchem.a130494; YOSHIDA T, 1978, J BIOL CHEM, V253, P8479; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	53	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26390	26395						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929359				2022-12-27	WOS:A1994PQ93000069
J	PUIG, A; GILBERT, HF				PUIG, A; GILBERT, HF			ANTI-CHAPERONE BEHAVIOR OF BIP DURING THE PROTEIN DISULFIDE ISOMERASE-CATALYZED REFOLDING OF REDUCED DENATURED LYSOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEIN; CHAIN-BINDING-PROTEIN; ENDOPLASMIC-RETICULUM; SECRETORY PROTEINS; PEPTIDE-BINDING; 3-DIMENSIONAL STRUCTURE; MAMMALIAN-CELLS; BOND FORMATION; HEAT-SHOCK; YEAST	Folding catalysts of the endoplasmic reticulum (ER), such as protein disulfide isomerase (PDI), accelerate the slow chemical steps, such as disulfide bond formation, that accompany protein folding. Molecular chaperones of the ER, notably the heavy chain-binding protein, BiP (grp78), bind and release unfolded proteins in an ATP-dependent fashion. In vitro, the fate of reduced, denatured lysozyme is dependent on whether the substrate interacts first with BiP or PDI. Depending on the ratio of PDI to substrate and order in which the components of the reaction are mixed, PDI can exhibit a foldase/ chaperone activity, which increases the rate and extent of lysozyme refolding, or it can function as an anti-chaperone that promotes the formation of inactive, disulfide linked lysozyme aggregates (Puig, A., and Gilbert, H. F. (1994) J. Biol. Chem. 269, 7764-7771). Reduced, denatured lysozyme, but not the native protein, interacts with BiP and efficiently stimulates its peptide-dependent ATPase activity. When present at substoichiometric amounts, BiP, like PDI, facilitates the formation of large, inactive lysozyme aggregates that are non-covalently associated with BiP. BiP and PDI compete for a limited number of sites in these insoluble aggregates. If Bip is present at a high molar excess, the chaperone binds unfolded lysozyme and inhibits its aggregation by maintaining it in a soluble, yet inactive, conformation, both in the presence or absence of ATP. Increasing concentrations of BiP decrease the extent, but not the initial rate, of refolding, suggesting that Bip and PDI compete for unfolded lysozyme and that the BiP-lysozyme complex is not a very good substrate for PDI either in the presence or absence of ATP. Depending on the BiP and PDI concentrations, unfolded lysozyme may either be efficiently refolded into the native conformation in a PDI-catalyzed reaction, or it may form both soluble and insoluble BiP-lysozyme complexes. In vitro, PDI- and BiP-facilitated aggregation, as well as the competition of the two proteins for substrate, reproduces many of the features of the quality control system of the ER.	BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030	Baylor College of Medicine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040379] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; CARLINO A, 1992, P NATL ACAD SCI USA, V89, P2081, DOI 10.1073/pnas.89.6.2081; CARLSSON L, 1983, P NATL ACAD SCI-BIOL, V80, P4664, DOI 10.1073/pnas.80.15.4664; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; DORNER AJ, 1988, MOL CELL BIOL, V8, P4063, DOI 10.1128/MCB.8.10.4063; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FRIEDMAN PJ, 1992, EMBO J, V11, P63; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gilbert H F, 1991, Protein Expr Purif, V2, P194, DOI 10.1016/1046-5928(91)90071-P; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; HUTH JR, 1992, J BIOL CHEM, V267, P21396; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KIM PS, 1993, J BIOL CHEM, V268, P4873; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LEMANTIA M, 1993, CELL, V74, P899; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NOIVA R, 1993, J BIOL CHEM, V268, P19210; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OTSU M, 1994, J BIOL CHEM, V269, P6874; PUIG A, 1994, J BIOL CHEM, V269, P7764; PUIG A, 1994, J BIOL CHEM, V269, P19128; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; SCHERENS B, 1991, YEAST, V7, P185, DOI 10.1002/yea.320070212; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; SHIELDS D, 1978, J BIOL CHEM, V253, P3753; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WETLAUFER DB, 1974, LYSOZYME, P269; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	45	46	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25889	25896						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929293				2022-12-27	WOS:A1994PQ49100095
J	KAMBEROV, ES; ATKINSON, MR; CHANDRAN, P; NINFA, AJ				KAMBEROV, ES; ATKINSON, MR; CHANDRAN, P; NINFA, AJ			EFFECT OF MUTATIONS IN ESCHERICHIA-COLI GLNL (NTRB), ENCODING NITROGEN REGULATOR-II (NRII OR NTRB), ON THE PHOSPHATASE-ACTIVITY INVOLVED IN BACTERIAL NITROGEN REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN NTRC; GLUTAMINE-SYNTHETASE; ATPASE ACTIVITY; GLNALG OPERON; PHOSPHORYLATION; TRANSCRIPTION; ENHANCER; GENE; PRODUCTS; KINASE	We examined the effects of mutations in glnL, encoding the signal-transducing kinase/phosphatase nitrogen regulator II (NRII), on the regulated phosphatase activity involved in nitrogen regulation. With wild-type NRII, this phosphatase activity was only observed in the presence of the signal transduction protein II (PII). Three different glnL mutations result in altered NRII proteins that had phosphatase activity in the absence of PII. The most active of these contained an alteration of the site of NRII autophosphorylation, histidine 139, to asparagine (H139N). The phosphatase activity of the NRII-H139N protein was further stimulated by the PII protein and by ATP. This suggests that the PII protein is not directly involved in a catalytic step of the regulated phosphatase activity but rather plays a regulatory role. me also measured the effect on the regulated phosphatase activity of alterations at conserved residues in the kinase/ phosphatase domain of NRII and the effect of deleting the non-conserved N-terminal domain of NRII. For this we used fusion proteins containing the Escherichia coli maltose-binding protein (MBP) linked 60 the protein of interest. A protein consisting of MBP linked to wild-type NRII was a less active kinase than was wild-type NRII but in the presence of PII had wild-type phosphatase activity. A protein consisting of MBP Linked to just the C-terminal domain of wild-type NRII had kinase activity but lacked phosphatase activity. Alterations at the highly conserved residues Asp-287, Gly-289, and Gly-291 in NRII affected both activities. A fusion of MBP to the NRII-H139N protein lacked kinase activity but had phosphatase activity in the absence of PII. Thus, while the kinase and phosphatase activities of NRII could be genetically separated, some of the highly conserved residues in the C-terminal domain of NRII (Asp-287, Gly-289, Gly-291) are apparently important for both activities.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM,DETROIT,MI 48201	University of Michigan System; University of Michigan; Wayne State University					NIGMS NIH HHS [GM47460] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047460] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON MR, 1992, J BACTERIOL, V174, P4538, DOI 10.1128/JB.174.14.4538-4548.1992; ATKINSON MR, 1994, J BIOL CHEM, V269, P28288; ATKINSON MR, 1993, J BACTERIOL, V175, P7016, DOI 10.1128/jb.175.21.7016-7023.1993; AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; BUENO R, 1985, J BACTERIOL, V164, P816, DOI 10.1128/JB.164.2.816-822.1985; FENG JL, 1992, J BACTERIOL, V174, P6061, DOI 10.1128/JB.174.19.6061-6070.1992; HUNT TP, 1985, P NATL ACAD SCI USA, V82, P8453, DOI 10.1073/pnas.82.24.8453; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; KAMBEROV ES, 1994, IN PRESS CELL MOL BI; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; MACNEIL T, 1982, MOL GEN GENET, V188, P325, DOI 10.1007/BF00332696; MACNEIL T, 1982, J BACTERIOL, V150, P1302, DOI 10.1128/JB.150.3.1302-1313.1982; MAGASANIK B, 1988, TRENDS BIOCHEM SCI, V13, P475, DOI 10.1016/0968-0004(88)90234-4; MAGASANIK B, 1987, CELLULAR MOL BIOL, P1318; Maniatis T, 1982, MOL CLONING LABORATO, P68; NINFA AJ, 1986, J BACTERIOL, V168, P1002, DOI 10.1128/jb.168.2.1002-1004.1986; NINFA AJ, 1991, J BIOL CHEM, V266, P6888; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; NINFA EG, 1993, J BACTERIOL, V175, P7024, DOI 10.1128/jb.175.21.7024-7032.1993; PAHEL G, 1978, J BACTERIOL, V133, P139, DOI 10.1128/JB.133.1.139-148.1978; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PORTER SC, 1993, GENE DEV, V7, P2258, DOI 10.1101/gad.7.11.2258; REITZER LJ, 1985, P NATL ACAD SCI USA, V82, P1979, DOI 10.1073/pnas.82.7.1979; REITZER LJ, 1983, P NATL ACAD SCI-BIOL, V80, P5554, DOI 10.1073/pnas.80.18.5554; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; RHEE SG, 1985, CURR TOP CELL REGUL, V27, P221; Saiki R. K., 1990, PCR PROTOCOLS GUIDE, P13; SANDERS DA, 1992, J BACTERIOL, V174, P5117, DOI 10.1128/JB.174.15.5117-5122.1992; Stadtman ER, 1980, GLUTAMINE METABOLISM, P41; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919	32	61	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28294	28299						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961767				2022-12-27	WOS:A1994PV77200078
J	PORTER, DJT				PORTER, DJT			REACTION OF 5-ETHYNYLURACIL WITH RAT-LIVER XANTHINE-OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM-BASED INACTIVATION; DIHYDROPYRIMIDINE DEHYDROGENASE; THYMINE HYDROXYLASE; 5-FLUOROURACIL; CONVERSION	5-Ethynyluracil is a time-dependent and tight binding inhibitor of xanthine oxidase. The maximal value of the first-order rate constant for onset of inhibition is 0.01 s(-1), and the concentration of 5-ethynyluracil which gives one-half of this value is 190 mu M. Because the t(1/2) for formation of active enzyme from inhibited enzyme is greater than 30 h in the absence of NADH inhibition of xanthine oxidase by 5-ethynyluracil is functionally irreversible. One equivalent of 5-[2-C-14]ethynyluracil/equivalent of active enzyme is required for complete inhibition. Allopurinol (100 mu M), a potent inhibitor of xanthine oxidase, and cyanide (5 mM), an inactivator of the enzyme, do not abolish the binding of 5-[2-C-14]ethynyluracil to the enzyme. Because radiolabel is released from 5-[2-C-14]ethynyluracil-treated enzyme by treatment with 6 M guanidine HCl, a stable covalent bond is not formed between the inhibitor and the enzyme. However, the radiolabel released from inhibited enzyme is not 5-ethynyluracil. Moreover, NADH restores catalytic activity to the inhibited enzyme and displaces the radiolabel as 5-acetyluracil. Thermal denaturation of 5-ethynyluracil-inhibited xanthine oxidase results in the release of approximately equal amounts of 5-acetyluracil and a more hydrophilic product. Consequently, the 5-ethynyluracil-xanthine oxidase complex yields different degradation products of 5-ethynyluracil under different denaturation conditions. Seven uracil analogues with B-substituents were tested as time dependent inhibitors of xanthine oxidase. 5-Ethynyluracil is the only uracil analogue that potently inhibited xanthine oxidase. The reactivity of these uracil derivatives with sulfite was also determined. 5-Ethynyluracil is many fold more susceptible to nonenzymatic nucleophilic addition of sulfite than are the other analogues. Thus, the potency of these uracil analogues as inhibitors of xanthine oxidase is related to the nonenzymatic reactivity of the analogues with sulfite.			PORTER, DJT (corresponding author), WELLCOME RES LABS,DIV EXPTL THERAPY,3030 CORNWALLIS RD,RES TRIANGLE PK,NC 27709, USA.							ALSTON TA, 1987, BIOCHEMISTRY-US, V26, P4082, DOI 10.1021/bi00387a051; BACCANARI DP, 1993, P NATL ACAD SCI USA, V90, P11064, DOI 10.1073/pnas.90.23.11064; BARR PJ, 1983, BIOCHEMISTRY-US, V22, P1696, DOI 10.1021/bi00276a027; CAO SS, 1994, CANCER RES, V54, P1507; DEMONTELLANO PRO, 1985, J BIOL CHEM, V260, P3330; DESGRANGES C, 1986, CANCER RES, V46, P1094; EDMONDSON D, 1972, J BIOL CHEM, V247, P1597; ELION GB, 1966, ANN RHEUM DIS, V25, P608, DOI 10.1136/ard.25.Suppl_6.608; ENGERSON TD, 1987, J CLIN INVEST, V79, P1564, DOI 10.1172/JCI112990; HARRIS BE, 1990, CANCER RES, V50, P197; HAYATSU H, 1975, J ORG CHEM, V40, P3862, DOI 10.1021/jo00914a009; HILLE R, 1981, PHARMACOL THERAPEUT, V14, P249, DOI 10.1016/0163-7258(81)90063-2; IKEGAMI T, 1986, ARCH BIOCHEM BIOPHYS, V247, P254, DOI 10.1016/0003-9861(86)90582-5; IVANETICH KM, 1992, PROG NUCLEIC ACID RE, V42, P127, DOI 10.1016/S0079-6603(08)60575-9; KRENITSKY TA, 1986, ARCH BIOCHEM BIOPHYS, V247, P108, DOI 10.1016/0003-9861(86)90539-4; POMALES R, 1965, BIOCHIM BIOPHYS ACTA, V95, P505, DOI 10.1016/0005-2787(65)90196-6; PORTER DJT, 1994, BIOCHEM PHARMACOL, V47, P1165, DOI 10.1016/0006-2952(94)90388-3; PORTER DJT, 1992, J BIOL CHEM, V267, P5236; RORK GS, 1975, J AM CHEM SOC, V97, P5559, DOI 10.1021/ja00852a040; RORK GS, 1975, J AM CHEM SOC, V97, P5566, DOI 10.1021/ja00852a041; SAITO T, 1989, J BIOL CHEM, V264, P10015; SEDOR FA, 1975, J AM CHEM SOC, V97, P5572, DOI 10.1021/ja00852a042; SPECTOR T, 1993, BIOCHEM PHARMACOL, V46, P2243, DOI 10.1016/0006-2952(93)90615-4; THORNBURG LD, 1993, BIOCHEMISTRY-US, V32, P14034, DOI 10.1021/bi00213a037; THORNBURG LD, 1989, J AM CHEM SOC, V111, P7632, DOI 10.1021/ja00201a064; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P365, DOI 10.1016/0003-9861(76)90088-6	26	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27932	27940						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961725				2022-12-27	WOS:A1994PV77200028
J	YOUNG, P; OHMAN, M; SJOBERG, BM				YOUNG, P; OHMAN, M; SJOBERG, BM			BACTERIOPHAGE-T4 GENE-55.9 ENCODES AN ACTIVITY REQUIRED FOR ANAEROBIC RIBONUCLEOTIDE REDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PYRUVATE-FORMATE-LYASE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; ACTIVATING ENZYME; SYSTEM; STATE; RNA; DNA	Bacteriophage T4 contains a phage-encoded anaerobic ribonucleoside triphosphate reductase, nrdD, previously named sunY. An open reading frame, 55.9, that resides downstream of the phage reductase was observed to have amino acid sequence similarity with the E. coli pyruvate formate-lyase (Pfl) activating enzyme. A stop codon was engineered into the cloned 55.9 gene and then recombined back into the phage genome. Phage-infected extracts that lack a functional 55.9 product have a B-fold reduction in anaerobic ribonucleotide reductase activity and are unable to activate overexpressed T4 NrdD. Restoration of reductase activity was possible when 55.9(-) and nrdD(-) T4-infected Escherichia coli extracts were conjointly assayed. Comparing the anaerobic burst size of 55.9(-) infections to that of the parental phage indicates that anaerobic de novo synthesis of deoxyribonucleotides is nearly abolished in phage lacking the 55.9 product. We propose that T4 55.9 encodes an enzyme that activates T4 NrdD by generating a glycyl radical in the phage-encoded reductase. The homology between the Pfl activating enzyme and T4 55.9 product (in this communication renamed NrdG) in function as well as amino acid sequence is presumably a remnant of an ancient heritage between Pfl and the anaerobic ribonucleotide reductases.	UNIV STOCKHOLM,DEPT MOLEC BIOL,S-10691 STOCKHOLM,SWEDEN	Stockholm University				Sjoberg, Britt-Marie/0000-0001-5953-3360				CONRADT H, 1984, ARCH BIOCHEM BIOPHYS, V228, P133, DOI 10.1016/0003-9861(84)90054-7; ELIASSON R, 1992, J BIOL CHEM, V267, P25541; FONTECAVE M, 1989, P NATL ACAD SCI USA, V86, P2147, DOI 10.1073/pnas.86.7.2147; FREY M, 1994, J BIOL CHEM, V269, P12432; GOTT JM, 1986, CELL, V47, P81, DOI 10.1016/0092-8674(86)90368-5; HARDER J, 1992, J BIOL CHEM, V267, P25548; KARLSSON M, 1992, J BIOL CHEM, V267, P12622; KNAPPE J, 1990, FEMS MICROBIOL LETT, V75, P383, DOI 10.1111/j.1574-6968.1990.tb04108.x; KNAPPE J, 1984, P NATL ACAD SCI-BIOL, V81, P1332, DOI 10.1073/pnas.81.5.1332; KREUZBERG K, 1985, PLANTA, V163, P60, DOI 10.1007/BF00395898; KREUZBERG K, 1987, PHYSIOL PLANTARUM, V69, P481, DOI 10.1111/j.1399-3054.1987.tb09229.x; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; RODEL W, 1988, EUR J BIOCHEM, V177, P153, DOI 10.1111/j.1432-1033.1988.tb14356.x; SAWERS G, 1989, J BACTERIOL, V171, P2485, DOI 10.1128/jb.171.5.2485-2498.1989; SAWERS G, 1988, J BACTERIOL, V170, P5330, DOI 10.1128/jb.170.11.5330-5336.1988; SOUTHER A, 1972, J VIROL, V10, P979, DOI 10.1128/JVI.10.5.979-984.1972; SUN XY, 1993, P NATL ACAD SCI USA, V90, P577, DOI 10.1073/pnas.90.2.577; TOMASCHEWSKI J, 1987, NUCLEIC ACIDS RES, V15, P3632, DOI 10.1093/nar/15.8.3632; UNKRIG V, 1989, EUR J BIOCHEM, V184, P723, DOI 10.1111/j.1432-1033.1989.tb15072.x; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; WONG KK, 1993, BIOCHEMISTRY-US, V32, P14102, DOI 10.1021/bi00214a005; YOUNG P, 1994, J BIOL CHEM, V269, P20229; ZEEH A, 1991, J BACTERIOL, V173, P6980, DOI 10.1128/jb.173.21.6980-6985.1991	23	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27815	27818						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961708				2022-12-27	WOS:A1994PV77200009
J	RAO, Y; ZHAO, XN; SIU, CH				RAO, Y; ZHAO, XN; SIU, CH			MECHANISM OF HOMOPHILIC BINDING MEDIATED BY THE NEURAL CELL-ADHESION MOLECULE NCAM - EVIDENCE FOR ISOLOGOUS INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN-LIKE DOMAINS; MONOCLONAL-ANTIBODY EPITOPES; MEMBRANE-SPANNING REGION; N-CAM; DICTYOSTELIUM-DISCOIDEUM; HOMOPHILIC BINDING; NEURITE OUTGROWTH; SKELETAL-MUSCLE; FUNCTIONAL DETERMINANTS; EXTRACELLULAR DOMAIN	We have previously shown that a decapeptide sequence between Lys-243 and Glu-252 (KYSFNYDGSE) in the third immunoglobulin (Ig) like domain of chick neural cell adhesion molecule NCAM is directly involved in NCAM-to-NCAM binding. To identify the domain that interacts with this decapeptide sequence, the Ig-like domain 3 of NCAM was expressed in bacteria and the refolded protein was assayed for its NCAM binding activity. Covaspheres conjugated with domain 3 protein bound to a substratum coated with either NCAM or the domain 3 protein, suggesting that NCAM-NCAM binding is mediated by interactions between domain 3 sequences on apposing molecules. Further studies were carried out using a cell-to-substratum binding assay. Mouse L cells stably transformed with different deletion constructs of NCAM were assayed for their ability to attach to substratum coated with different peptide conjugates. The results indicated that a site in NCAM Ig-like domain 3 bound specifically to the decapeptide sequence. To identify this site, cells expressing mutant NCAMs with alterations in the amino acid sequence of the homophilic binding site were subjected to the same cell-to substratum assay. Mutant NCAMs that had lost their homophilic binding activity also failed to attach to the peptide substrate. Taken together, these results suggest that the NCAM homophilic binding site interacts isologously with the same sequence on apposing molecules.	UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO M5G 1L6, ON, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO M5G 1L6, ON, CANADA	University of Toronto; University of Toronto								BARTHELS D, 1987, EMBO J, V6, P907, DOI 10.1002/j.1460-2075.1987.tb04837.x; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; COLE GJ, 1985, J CELL BIOL, V100, P1192, DOI 10.1083/jcb.100.4.1192; COLMAN PM, 1976, J MOL BIOL, V100, P257, DOI 10.1016/S0022-2836(76)80062-9; COVAULT J, 1987, J CELL BIOL, V105, P2479, DOI 10.1083/jcb.105.6.2479; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DEISENHOFER J, 1976, H-S Z PHYSIOL CHEM, V357, P1421, DOI 10.1515/bchm2.1976.357.2.1421; DICKSON G, 1987, CELL, V50, P1119, DOI 10.1016/0092-8674(87)90178-4; DICKSON G, 1990, NATURE, V344, P348, DOI 10.1038/344348a0; DOHERTY P, 1990, NATURE, V343, P464, DOI 10.1038/343464a0; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; DOHERTY P, 1992, NATURE, V356, P791, DOI 10.1038/356791a0; DOHERTY P, 1989, J CELL BIOL, V109, P789, DOI 10.1083/jcb.109.2.789; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EDELMAN GM, 1988, BIOCHEMISTRY-US, V27, P3533, DOI 10.1021/bi00410a001; EDELMAN GM, 1987, P NATL ACAD SCI USA, V84, P8502, DOI 10.1073/pnas.84.23.8502; FRELINGER AL, 1986, J CELL BIOL, V103, P1729, DOI 10.1083/jcb.103.5.1729; GLOCKSHUBER R, 1992, BIOCHEMISTRY-US, V31, P1270, DOI 10.1021/bi00120a002; GRUMET M, 1982, NATURE, V295, P693, DOI 10.1038/295693a0; HALL AK, 1985, DEV BIOL, V110, P39, DOI 10.1016/0012-1606(85)90061-2; HE HT, 1986, EMBO J, V5, P2489, DOI 10.1002/j.1460-2075.1986.tb04526.x; HEMPERLY JJ, 1986, P NATL ACAD SCI USA, V83, P9822, DOI 10.1073/pnas.83.24.9822; HOCHMAN J, 1976, BIOCHEMISTRY-US, V15, P2706, DOI 10.1021/bi00657a034; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; HORSTKORTE R, 1993, J CELL BIOL, V121, P1409, DOI 10.1083/jcb.121.6.1409; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; KADMON G, 1990, J CELL BIOL, V110, P209, DOI 10.1083/jcb.110.1.209; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; KAMBOJ RK, 1989, CELL, V59, P615, DOI 10.1016/0092-8674(89)90007-X; KAMBOJ RK, 1988, J CELL BIOL, V107, P1835, DOI 10.1083/jcb.107.5.1835; KEILHAUER G, 1985, NATURE, V316, P728, DOI 10.1038/316728a0; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; MATSUNAGA T, 1987, SCAND J IMMUNOL, V25, P485, DOI 10.1111/j.1365-3083.1987.tb02220.x; MOORE SE, 1987, J CELL BIOL, V105, P1377, DOI 10.1083/jcb.105.3.1377; MURRAY BA, 1986, J CELL BIOL, V102, P189, DOI 10.1083/jcb.102.1.189; OWENS GC, 1987, P NATL ACAD SCI USA, V84, P294, DOI 10.1073/pnas.84.1.294; PECK D, 1993, J CELL BIOL, V123, P1587, DOI 10.1083/jcb.123.6.1587; PIZZEY JA, 1989, J CELL BIOL, V109, P3465, DOI 10.1083/jcb.109.6.3465; POLJAK RJ, 1972, NATURE-NEW BIOL, V235, P137, DOI 10.1038/newbio235137a0; POLLERBERG GE, 1987, CELL TISSUE RES, V250, P227, DOI 10.1007/BF00214676; RAO Y, 1993, J BIOL CHEM, V268, P20630; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; RECNY MA, 1990, J BIOL CHEM, V265, P8542; REYES AA, 1990, CELL REGUL, V1, P567, DOI 10.1091/mbc.1.8.567; RUTISHAUSER U, 1982, P NATL ACAD SCI-BIOL, V79, P685, DOI 10.1073/pnas.79.2.685; RUTISHAUSER U, 1983, J CELL BIOL, V97, P145, DOI 10.1083/jcb.97.1.145; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; Sambrook J, 1989, MOL CLONING LABORATO; SANDIG M, 1994, J BIOL CHEM, V269, P14841; SANTONI MJ, 1988, J NEUROSCI RES, V20, P304, DOI 10.1002/jnr.490200304; SIU CH, 1990, DEV GENET, V11, P377, DOI 10.1002/dvg.1020110509; SIU CH, 1987, J CELL BIOL, V105, P2523, DOI 10.1083/jcb.105.6.2523; SMALL SJ, 1988, NEURON, V1, P1007, DOI 10.1016/0896-6273(88)90158-4; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; THIERY JP, 1977, J BIOL CHEM, V252, P6841; THOMPSON J, 1989, GENE DEV, V3, P348, DOI 10.1101/gad.3.3.348; THOR G, 1986, NEUROSCI LETT, V66, P121, DOI 10.1016/0304-3940(86)90176-X; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WATANABE M, 1986, J CELL BIOL, V103, P1721, DOI 10.1083/jcb.103.5.1721; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WYSOCKI LJ, 1978, P NATL ACAD SCI USA, V75, P2844, DOI 10.1073/pnas.75.6.2844; ZHOU H, 1993, J CELL BIOL, V122, P951, DOI 10.1083/jcb.122.4.951	66	49	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27540	27548						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961669				2022-12-27	WOS:A1994PV77100060
J	FACCHINI, PJ; DELUCA, V				FACCHINI, PJ; DELUCA, V			DIFFERENTIAL AND TISSUE-SPECIFIC EXPRESSION OF A GENE FAMILY FOR TYROSINE DOPA DECARBOXYLASE IN OPIUM POPPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SUSPENSION-CULTURES; AMINO-ACID DECARBOXYLASE; DOPA DECARBOXYLASE; TRYPTOPHAN DECARBOXYLASE; CATHARANTHUS-ROSEUS; PAPAVER-SOMNIFERUM; MOLECULAR-CLONING; CDNA; BIOSYNTHESIS; SEQUENCE	Two early and potential rate-limiting steps in the biosynthesis of isoquinoline alkaloids, such as morphine and codeine, in opium poppy (Papaver somniferum) involve decarboxylation of L-tyrosine and L-dihydroxyphenylalanine (L-dopa) to yield tyramine and dopamine, respectively. ADNA fragment was amplified by polymerase chain reaction (PCR) using degenerate primers designed to two highly conserved domains found in other aromatic amino acid decarboxylases. A poppy seedling cDNA Library was screened with this PCR product and a cDNA (cTYDC1) for tyrosine/dopa decarboxylase (TYDC/DODC) was isolated. Two other independent cDNAs (cTYDC2 and cTYDC3) encoding TYDC/DODC were isolated by heterologous screening with a plant tryptophan decarboxylase (TDC) cDNA as probe. A poppy genomic Library was screened with cTYDC1 and two intronless genomic clones (gTYDC1 and gTYDC4) were isolated. The deduced amino acid sequences of all poppy clones share extensive identity with other reported pyridoxal phosphate-dependent decarboxylases from both plants and animals. Based on sequence homology, members of the gene family were divided into two subsets (cTYDC1 and gTYDC4; cTYDC2 and cTYDC3) of proteins with predicted M(r) = 56,983 and 59,323, respectively. Within each subset the clones exhibit greater than 90% identity, whereas clones between subsets share less than 75% identity. Expression of gTYDC1 and cTYDC2 as beta-galactosidase fusion proteins in Escherichia coli resulted in catalytically active enzymes immunodetectable with TDC-specific polyclonal antibodies. Each enzyme showed marginally higher substrate specificity for L-dopa over L-tyrosine, but did not accept L-tryptophan and L-phenylalanine as substrates. Genomic DNA blot-hybridization analysis revealed 6 to 8 genes homologous to cTYDC1 and 4 to 6 genes homologous to cTYDC2 in the tetraploid poppy genome. A premature translation stop codon was found in the gTYDC4 clone suggesting that it may not encode a functional protein. RNA blot-hybridization with probes specific to the gTYDC1- or cTYDC2-like subsets showed that members of the TYDC gene family are differentially expressed in various plant tissues.	UNIV MONTREAL,INST RECH BIOL VEGETALE,DEPT BIOL SCI,MONTREAL H1X 2B2,PQ,CANADA	Universite de Montreal				Facchini, Peter/0000-0002-7693-290X				ALBERT VR, 1987, J BIOL CHEM, V262, P9404; BAUM G, 1993, J BIOL CHEM, V268, P19610; CHRISTENSON JG, 1972, P NATL ACAD SCI USA, V69, P343, DOI 10.1073/pnas.69.2.343; COHEN E, 1982, PLANT PHYSIOL, V70, P540, DOI 10.1104/pp.70.2.540; Conn EE., 1981, BIOCH PLANTS, pP. 317; CRAMER CL, 1989, PLANT MOL BIOL, V12, P367, DOI 10.1007/BF00017577; DELUCA V, 1989, P NATL ACAD SCI USA, V86, P2582; EILERT U, 1985, J PLANT PHYSIOL, V119, P65, DOI 10.1016/S0176-1617(85)80216-9; EVELETH DD, 1986, EMBO J, V5, P2663, DOI 10.1002/j.1460-2075.1986.tb04549.x; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERNANDEZ JA, 1989, PLANT PHYSIOL, V91, P79, DOI 10.1104/pp.91.1.79; FERNANDEZ JA, 1994, PHYTOCHEMISTRY, V36, P1123, DOI 10.1016/S0031-9422(00)89624-7; GODDIJN OJM, 1992, PLANT MOL BIOL, V18, P1113, DOI 10.1007/BF00047714; GODDIJN OJM, 1994, PLANT MOL BIOL, V242, P217; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAHLBROCK K, 1989, ANNU REV PLANT PHYS, V40, P347, DOI 10.1146/annurev.pp.40.060189.002023; ICHINOSE H, 1989, BIOCHEM BIOPH RES CO, V164, P1024, DOI 10.1016/0006-291X(89)91772-5; JACKSON FR, 1990, J MOL EVOL, V31, P325, DOI 10.1007/BF02101126; JONES JDG, 1985, EMBO J, V4, P2411, DOI 10.1002/j.1460-2075.1985.tb03949.x; KAWALLECK P, 1993, J BIOL CHEM, V268, P2189; KUTCHAN TM, 1985, CHEM BIOL ISOQUINOLI, P281; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; MANECKJEE R, 1983, BIOCHEMISTRY-US, V22, P6058, DOI 10.1021/bi00295a003; MARQUES IA, 1988, PLANT PHYSIOL, V88, P46, DOI 10.1104/pp.88.1.46; MARQUES IA, 1988, PLANT PHYSIOL, V88, P52, DOI 10.1104/pp.88.1.52; MORGAN BA, 1986, EMBO J, V5, P3335, DOI 10.1002/j.1460-2075.1986.tb04648.x; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; NAKAJIMA K, 1993, P NATL ACAD SCI USA, V90, P9591, DOI 10.1073/pnas.90.20.9591; NEGREL J, 1987, PHYTOCHEMISTRY, V26, P2185, DOI 10.1016/S0031-9422(00)84681-6; NESSLER CL, 1990, PLANTA, V180, P487, DOI 10.1007/BF02411445; NESSLER CL, 1976, PLANTA, V129, P83, DOI 10.1007/BF00390918; NESSLER CL, 1981, AM J BOT, V57, P675; NOE W, 1984, PLANT MOL BIOL, V3, P281, DOI 10.1007/BF00017782; PALAVAN N, 1982, PHYSIOL PLANTARUM, V55, P438, DOI 10.1111/j.1399-3054.1982.tb04524.x; PASQUALI G, 1992, PLANT MOL BIOL, V18, P1121, DOI 10.1007/BF00047715; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROBERTS MF, 1983, ARCH BIOCHEM BIOPHYS, V222, P599, DOI 10.1016/0003-9861(83)90558-1; ROBERTS MF, 1978, PHYTOCHEMISTRY, V17, P1083, DOI 10.1016/S0031-9422(00)94293-6; RUSH MD, 1985, PLANT CELL REP, V4, P237, DOI 10.1007/BF00269366; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V83, P8073; SCHMELZER E, 1989, PLANT CELL, V1, P993, DOI 10.1105/tpc.1.10.993; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; STADLER R, 1989, PHYTOCHEMISTRY, V28, P1083, DOI 10.1016/0031-9422(89)80187-6; STADLER R, 1987, TETRAHEDRON LETT, V28, P1251, DOI 10.1016/S0040-4039(00)95338-3; TANAKA T, 1989, P NATL ACAD SCI USA, V86, P8142, DOI 10.1073/pnas.86.20.8142; TOCHER RD, 1972, PHYTOCHEMISTRY, V11, P1661, DOI 10.1016/0031-9422(72)85014-3; TREZZINI GF, 1993, PLANT MOL BIOL, V21, P385, DOI 10.1007/BF00019954; VARIN L, 1992, P NATL ACAD SCI USA, V89, P1286, DOI 10.1073/pnas.89.4.1286; WALLER G.R., 1978, ALKALOID BIOL METABO, DOI DOI 10.1007/978-1-4684-0772-3; Zahnow C A, 1991, DNA Seq, V1, P395, DOI 10.3109/10425179109020795	52	113	132	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26684	26690						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929401				2022-12-27	WOS:A1994PQ93100019
J	MOTOHASHI, K; TAGUCHI, H; ISHII, N; YOSHIDA, M				MOTOHASHI, K; TAGUCHI, H; ISHII, N; YOSHIDA, M			ISOLATION OF THE STABLE HEXAMERIC DNAK-CENTER-DOT-DNAJ COMPLEX FROM THERMUS-THERMOPHILUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI-DNAJ; LAMBDA-P-PROTEIN; RNA-POLYMERASE; MOLECULAR CHAPERONES; REPLICATION PROTEIN; GEL-ELECTROPHORESIS; NUCLEOTIDE-SEQUENCE; ATP HYDROLYSIS; GENE-PRODUCT	A Dnak homolog (T.Dnak) has been purified as a stable complex with a DnaJ homolog (T.DnaJ) from a thermophilic bacterium, Thermus thermophilus. This complex has an approximate molecular size of 300 kDa and appears to contain three copies of each of T.Dnak and T.DnaJ molecules. Consistently, trigonal ring structures with a diameter (trigonal apex-to-apex) of about 11 nm were observed with electron microscopy. The complex has no endogenously bound AT(D)P and is stable in the presence of Mg-AT(D)P. It possesses a weak ATPase activity and retains about 3 mol of ADP/mole of the complex when incubated with Mg-ATP. This complex is able to interact with the reduced carboxymethylated cr-lactalbumin which we used as a model unfolded protein.	TOKYO INST TECHNOL,RESOURCES UTILIZAT RES LAB,YOKOHAMA,KANAGAWA 227,JAPAN; INST PHYS & CHEM RES,WAKO,SAITAMA 35101,JAPAN	Tokyo Institute of Technology; RIKEN			Ishii, Noriyuki/E-5661-2011	Ishii, Noriyuki/0000-0002-4120-6203; Motohashi, Ken/0000-0002-8414-2836				BARDWELL JCA, 1986, J BIOL CHEM, V261, P1782; BARDWELL JCA, 1984, P NATL ACAD SCI-BIOL, V81, P848, DOI 10.1073/pnas.81.3.848; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; GAO BC, 1993, J BIOL CHEM, V268, P8507; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Harlow E, 1988, ANTIBODIES LAB MANUA, P60; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HENDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HERENDEEN SL, 1979, J BACTERIOL, V139, P185, DOI 10.1128/JB.139.1.185-194.1979; HISABORI T, 1991, J BIOCHEM BIOPH METH, V22, P253, DOI 10.1016/0165-022X(91)90073-6; HOFFMANN HJ, 1992, P NATL ACAD SCI USA, V89, P12108, DOI 10.1073/pnas.89.24.12108; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1992, P NATL ACAD SCI USA, V89, P3516, DOI 10.1073/pnas.89.8.3516; NEIDHARDT FC, 1984, ANNU REV GENET, V18, P295, DOI 10.1146/annurev.ge.18.120184.001455; OHKI M, 1986, J BIOL CHEM, V261, P1778; OSHIMA T, 1974, INT J SYST BACTERIOL, V24, P102, DOI 10.1099/00207713-24-1-102; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PALLEROS DR, 1992, J BIOL CHEM, V267, P5279; ROTHE GM, 1982, ELECTROPHORESIS, V3, P33, DOI 10.1002/elps.1150030107; SCHMID D, 1992, EUR J BIOCHEM, V208, P699, DOI 10.1111/j.1432-1033.1992.tb17237.x; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SHERMAN MY, 1991, J BACTERIOL, V173, P7249, DOI 10.1128/jb.173.22.7249-7256.1991; SHERMAN MY, 1992, EMBO J, V11, P71; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; SKELLY S, 1988, P NATL ACAD SCI USA, V85, P5497, DOI 10.1073/pnas.85.15.5497; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WILD J, 1992, GENE DEV, V6, P1165, DOI 10.1101/gad.6.7.1165; YOKOYAMA K, 1994, J BIOL CHEM, V269, P12248; YOSHIDA M, 1979, J BIOL CHEM, V254, P9525; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	46	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27074	27079						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929450				2022-12-27	WOS:A1994PQ93100073
J	SUGIMOTO, T; SAITO, M; MOCHIZUKI, S; WATANABE, Y; HASHIMOTO, S; KAWASHIMA, H				SUGIMOTO, T; SAITO, M; MOCHIZUKI, S; WATANABE, Y; HASHIMOTO, S; KAWASHIMA, H			MOLECULAR-CLONING AND FUNCTIONAL EXPRESSION OF A CDNA-ENCODING THE HUMAN V-1B VASOPRESSIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADENOHYPOPHYSIS; BINDING-SITES; PITUITARY; BRAIN; AUTORADIOGRAPHY; LOCALIZATION; ANTAGONISTS; SPECIFICITY; OXYTOCIN; ACIDS	Arginine vasopressin modulates the release of adrenocorticotropic hormone, beta-endorphin, and prolactin from the anterior pituitary. Release is mediated by the V-1b receptor through the mobilization of intracellular Ca2+ by phosphatidylinositol hydrolysis. In contrast to its well characterized peripheral actions, such as antidiuresis, contraction of vascular smooth muscle, and stimulation of hepatic glycogenolysis, the exact site and mechanism of vasopressin action in the pituitary remain unclear. This is largely due to a lack of information on the molecular identity and exact localization of the V-1b receptor. This lack prompted us to try to isolate this receptor subtype. Here we report the molecular cloning and functional expression of a complementary DNA encoding the human V-1b receptor. The deduced 424-amino acid sequence of the receptor has highest overall homology with the V-1a, V-2, and oxytocin receptors, with homologies of 45, 39, and 45%, respectively. The receptor expressed in COS-1 cells has a single binding site for arginine vasopressin with a K-d of 0.17 +/- 0.04 nM. It binds various agonists and antagonists of vasopressin with affinities distinct hom those of V-1a and V-2 receptors but consistent with those anticipated for the V-1b receptor on the basis of the pharmacological studies. Furthermore, arginine vasopressin evoked calcium-dependent chloride current in Xenopus oocytes transfected with the receptor, which was not affected by a V-1a/V-2 antagonist. In contrast, the current evoked in oocytes transfected with V-1a receptor was abolished by the antagonist. Northern blot analysis revealed that the receptor expression is restricted to the pituitary. These data clearly indicate that the cloned cDNA encodes the V-1b receptor.	YAMANOUCHI INST DRUG DISCOVERY RES,MOLEC MED RES LABS,TSUKUBA,IBARAKI 305,JAPAN									ANTONI FA, 1984, NEUROENDOCRINOLOGY, V39, P186, DOI 10.1159/000123976; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; BUCKINGHAM JC, 1987, J ENDOCRINOL, V113, P389, DOI 10.1677/joe.0.1130389; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CLEMENTS JA, 1986, ENDOCR REV, V7, P449, DOI 10.1210/edrv-7-4-449; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; HORSTMAN DA, 1990, J BIOL CHEM, V265, P21590; JARD S, 1986, MOL PHARMACOL, V30, P171; JARD S, 1987, AM J PHYSIOL, V253, pF41, DOI 10.1152/ajprenal.1987.253.1.F41; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; KJAER A, 1993, ACTA ENDOCRINOL-COP, V129, P489; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; LASZLO FA, 1991, PHARMACOL REV, V43, P73; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; MIYAKE A, 1994, BIOCHEM PHARMACOL, V47, P1339; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; OSTROWSKI NL, 1992, ENDOCRINOLOGY, V131, P533, DOI 10.1210/en.131.1.533; PAROLA AL, 1994, J BIOL CHEM, V269, P4497; PHILLIPS PA, 1988, NEUROSCIENCE, V27, P749, DOI 10.1016/0306-4522(88)90180-7; PITTEL Z, 1994, MOL PHARMACOL, V45, P61; REN HZ, 1994, P NATL ACAD SCI USA, V91, P4864, DOI 10.1073/pnas.91.11.4864; RYMOND V, 1985, FEBS LETT, V182, P196; SCHWARTZ J, 1991, ENDOCRINOLOGY, V129, P1107, DOI 10.1210/endo-129-2-1107; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; THIBONNIER M, 1994, J BIOL CHEM, V269, P3304; TRIBOLLET E, 1988, BRAIN RES, V442, P105, DOI 10.1016/0006-8993(88)91437-0	28	293	308	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27088	27092						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929452				2022-12-27	WOS:A1994PQ93100075
J	WILCOX, RA; CHALLISS, RAJ; TRAYNOR, JR; FAUQ, AH; OGNAYANOV, VI; KOZIKOWSKI, AP; NAHORSKI, SR				WILCOX, RA; CHALLISS, RAJ; TRAYNOR, JR; FAUQ, AH; OGNAYANOV, VI; KOZIKOWSKI, AP; NAHORSKI, SR			MOLECULAR RECOGNITION AT THE MYOINOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR - 3-POSITION SUBSTITUTED MYOINOSITOL 1,4,5-TRISPHOSPHATE ANALOGS REVEAL THE BINDING AND CA2+ RELEASE REQUIREMENTS FOR HIGH-AFFINITY INTERACTION WITH THE MYOINOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOLIC ENZYMES; MYOINOSITOL 1,4,5-TRISPHOSPHATE; TRISPHOSPHATE ANALOGS; CA-2+ RELEASE; 3T3 CELLS; CALCIUM; MOBILIZATION; SITES; 5-PHOSPHATASE; PHOSPHATASE	Several novel D-myo-inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3] analogues equatorially substituted at the and position have been synthesized to probe the structure-activity relationship of the Ins(1,4,5)P-3-receptor subsite adjacent to the native 3-hydroxy (3-OH) of Ins(1,4,5)P-3. This study was prompted, in part, by our observation that myo-inositol 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P-4), the 3-position phosphorylated product of Ins(1,4,5)P-3 was a full agonist at the Ca2+-mobilizing Ins(1,4,5)P-3 receptor of SH-SY5Y cells (Wilcox, R. A., Challiss, R. A. J., Liu, C., Potter, B. V. I., and Nahorski, S. R. (1993) Mol. Pharmacol. 44, 810-817). The 3-position Ins(1,4,5)P-3 analogues were equatorially substituted with groups spanning the steric range between the 3-OH of Ins(1,4,5)P-3 and the 3-phosphate of Ins(1,3,4,5)P-4; in order of increasing 3-position steric bulk these were: 3-fluoro, 3-chloro-, 3-amino-, 3-bromo-, 3-methoxy-, and 3-phosphorothioate-Ins(1,4,5)P-3. The analogues were assessed at the specific Ins(1,4,5)P-3 binding site of bovine adrenal cortex and for Ca2+ mobilizing activity in saponin-permeabilized SH-SY5Y human neuroblastoma cells. A correlation was observed between increasing molecular volume of the 3-position substituent and respective decreases in both affinity and Ca2+ mobilizing efficacy. Further analysis of the data also revealed that Ins(1,4,5)P-3 analogues with equatorial 3-OH, 3-phosphate, and 3-phosphorothioate substituents interacted more favorably with Ins(1,4,5)P-3 recognition sites than would be predicted by purely steric considerations. In contrast, 3-C-trifluoromethyl-Ins(1,4,5)P-3 (which is axially substituted, but retains the native 3-OH of Ins(1,4,5)P-3) interacted with Ins(1,4,5)P-3 recognition sites with virtually the same potency as Ins(1,4,5)P-3, indicating that the binding pocket of the Ins(1,4,5)P-3-receptor was not sterically restrictive with respect to axially oriented 3-position substituents. We conclude that the Ins(1,4,5)P-3 receptor has favorable non-covalent binding interactions with the equatorial 3-position substituents of Ins(1,4,5)P-3 and Ins(1,3,4,5)P-4 and that these interactions significantly ameliorate the steric constraints of the Ins(1,4,5)P-3 receptor binding pocket.	LOUGHBOROUGH UNIV TECHNOL, DEPT CHEM, LOUGHBOROUGH LE11 3TU, LEICS, ENGLAND; MAYO CLIN, DEPT NEUROCHEM RES, JACKSONVILLE, FL 32224 USA	Loughborough University; Mayo Clinic	WILCOX, RA (corresponding author), UNIV LEICESTER, DEPT CELL PHYSIOL & PHARMACOL, POB 138, MED SCI BLDG, UNIV RD, LEICESTER LE1 9HN, LEICS, ENGLAND.		Wilcox, Robert A/A-3135-2014; Challiss, R.A. John/A-9412-2008	Challiss, John/0000-0001-5506-2848; Wilcox, Robert/0000-0001-9911-8743	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CARD PJ, 1985, J CARBOHYD CHEM, V4, P451, DOI 10.1080/07328308508082671; CHALLISS RAJ, 1991, FEBS LETT, V281, P101, DOI 10.1016/0014-5793(91)80368-D; CHALLISS RAJ, 1990, BIOCHEM J, V265, P421, DOI 10.1042/bj2650421; CHALLISS RAJ, 1991, BIOCHEM J, V274, P861, DOI 10.1042/bj2740861; FAUQ AH, 1994, J CHEM SOC CHEM COMM, P1301, DOI 10.1039/c39940001301; Hansch C, 1979, SUBSTITUENT CONSTANT; HIRATA M, 1990, BIOCHEM BIOPH RES CO, V168, P379, DOI 10.1016/0006-291X(90)91719-9; HIRATA M, 1989, J BIOL CHEM, V264, P20303; HIRATA M, 1993, J BIOL CHEM, V268, P19260; HIRATA M, 1990, J BIOL CHEM, V265, P8404; IRVINE RF, 1992, FASEB J, V6, P3085, DOI 10.1096/fasebj.6.12.1325932; IRVINE RF, 1993, CURR BIOL, V3, P540, DOI 10.1016/0960-9822(93)90052-P; Irvine Robin F., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P161; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; KOZIKOWSKI AP, 1994, J ORG CHEM, V59, P2279, DOI 10.1021/jo00088a003; KOZIKOWSKI AP, 1993, J AM CHEM SOC, V115, P4429, DOI 10.1021/ja00064a002; KOZIKOWSKI AP, 1990, J AM CHEM SOC, V112, P7403, DOI 10.1021/ja00176a055; KOZIKOWSKI AP, 1994, J MED CHEM, V37, P368; KOZIKOWSKI AP, 1993, J CHEM SOC CHEM COMM, V5, P599; LAMBERT DG, 1989, EUR J PHARMACOL, V165, P71, DOI 10.1016/0014-2999(89)90771-1; NAHORSKI SR, 1989, TRENDS PHARMACOL SCI, V10, P139, DOI 10.1016/0165-6147(89)90165-X; NAHORSKI SR, 1992, ALFRED BENZON SYMP S, V33, P211; NUNN DL, 1990, BIOCHEM J, V270, P227, DOI 10.1042/bj2700227; POLOKOFF MA, 1988, J BIOL CHEM, V263, P11922; POTTER BVL, 1990, NAT PROD REP, V7, P1, DOI 10.1039/np9900700001; POTTER BVL, 1993, PHARM LIBR, V20, P185; Putney James W. Jr, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P143; PUTNEY JW, 1993, SCIENCE, V262, P676, DOI 10.1126/science.8235587; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; SAFRANY ST, 1990, FEBS LETT, V276, P91, DOI 10.1016/0014-5793(90)80515-K; SAFRANY ST, 1991, FEBS LETT, V278, P252, DOI 10.1016/0014-5793(91)80128-P; SAFRANY ST, 1992, EUR J PHARM-MOLEC PH, V226, P265, DOI 10.1016/0922-4106(92)90071-3; SCHLOSSER M, 1978, TETRAHEDRON, V34, P3, DOI 10.1016/0040-4020(78)88031-4; SEEWALD MJ, 1990, J CHEM SOC CHEM COMM, P1638, DOI 10.1039/c39900001638; Shears Stephen B., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P63; WILCOX RA, 1993, BIOCHEM J, V294, P191, DOI 10.1042/bj2940191; WILCOX RA, 1993, MOL PHARMACOL, V44, P810; WILCOX RA, 1994, EUR J BIOCHEM, V223, P115, DOI 10.1111/j.1432-1033.1994.tb18972.x; WILCOX RA, 1993, FEBS LETT, V336, P267, DOI 10.1016/0014-5793(93)80817-E; WILCOX RA, 1992, CARBOHYD RES, V234, P237, DOI 10.1016/0008-6215(92)85051-Z	42	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26815	26821						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929418				2022-12-27	WOS:A1994PQ93100038
J	FUKUDOME, K; ESMON, CT				FUKUDOME, K; ESMON, CT			IDENTIFICATION, CLONING, AND REGULATION OF A NOVEL ENDOTHELIAL-CELL PROTEIN-C ACTIVATED PROTEIN-C RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; AMINO-ACID SEQUENCES; C4B-BINDING PROTEIN; PURPURA FULMINANS; ESCHERICHIA-COLI; GROWTH-FACTOR; THROMBOMODULIN; ANTICOAGULANT; DEFICIENCY; ACTIVATION	Human protein C and activated protein C are shown to bind to endothelium specifically, selectively and saturably (K-d = 30 nM, 7000 sites per cell) in a Ca2+ dependent fashion. Expression cloning revealed a 1.3-kilobase pair cDNA that coded for a novel type 1 transmembrane glycoprotein capable of binding protein C. This protein appears to be a member of the CD1/major histocompatibility complex superfamily. Like thrombomodulin, the receptor involved in protein C activation, the endothelial cell protein C receptor function and message are both down-regulated by exposure of endothelium to tumor necrosis factor. Identification of endothelial cell protein C receptor as a member of the CD1/major histocompatibility complex superfamily provides insights into the role of protein C in regulating the inflammatory response.	OKLAHOMA MED RES FDN,HOWARD HUGHES MED INST,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,HOWARD HUGHES MED INST,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT PATHOL,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73104	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; Howard Hughes Medical Institute; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center								BALK SP, 1989, P NATL ACAD SCI USA, V86, P252, DOI 10.1073/pnas.86.1.252; BALK SP, 1991, J IMMUNOL, V146, P768; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; CONWAY EM, 1988, MOL CELL BIOL, V8, P5588, DOI 10.1128/MCB.8.12.5588; DAHLBACK B, 1992, BIOCHEMISTRY-US, V31, P12769, DOI 10.1021/bi00166a009; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBACK B, 1986, J BIOL CHEM, V261, P2022; DITTMAN WA, 1990, BLOOD, V75, P329; DITTMAN WA, 1991, TRENDS CARDIOVAS MED, V1, P331, DOI 10.1016/1050-1738(91)90070-U; DREYFUS M, 1991, NEW ENGL J MED, V325, P1565, DOI 10.1056/NEJM199111283252207; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON CT, 1992, TRENDS CARDIOVAS MED, V2, P214, DOI 10.1016/1050-1738(92)90027-P; GERSON WT, 1993, PEDIATRICS, V91, P418; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREY S, 1993, TRANSPLANT P, V25, P2913; GRINNELL BW, 1994, GLYCOBIOLOGY, V4, P221, DOI 10.1093/glycob/4.2.221; HOGG PJ, 1992, J BIOL CHEM, V267, P703; KAISHO T, 1994, P NATL ACAD SCI USA, V91, P5325, DOI 10.1073/pnas.91.12.5325; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P6970; LEDBETTER JA, 1985, J IMMUNOL, V134, P4250; LENTZ SR, 1991, BLOOD, V77, P543; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; OLSEN PH, 1992, BIOCHEMISTRY-US, V31, P746, DOI 10.1021/bi00118a016; PANJA A, 1993, J EXP MED, V178, P1115, DOI 10.1084/jem.178.3.1115; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REZAIE AR, 1992, J BIOL CHEM, V267, P11701; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROTHBARTH K, 1993, J CELL SCI, V104, P19; SELIGSOHN U, 1984, NEW ENGL J MED, V310, P559, DOI 10.1056/NEJM198403013100904; STERN DM, 1986, J BIOL CHEM, V261, P713; TAYLOR F, 1991, BLOOD, V78, P357, DOI 10.1182/blood.V78.2.357.357; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	41	436	456	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26486	26491						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929370				2022-12-27	WOS:A1994PQ93000083
J	MANGUS, DA; JANG, SH; JAEHNING, JA				MANGUS, DA; JANG, SH; JAEHNING, JA			RELEASE OF THE YEAST MITOCHONDRIAL RNA-POLYMERASE SPECIFICITY FACTOR FROM TRANSCRIPTION COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; TERNARY COMPLEXES; GENE-EXPRESSION; SIGMA-FACTORS; PROMOTER; PURIFICATION; INITIATION; PROTEINS; BINDING	The yeast mitochondrial RNA polymerase is composed of two nuclear encoded subunits, a catalytic core (Rpo41p), which resembles the enzymes from bacteriophage T7 and T3, and a specificity factor required for promoter recognition (Mtf1p), which is similar to members of the eubacterial sigma factor family. Using mitochondrial RNA polymerase reconstituted from highly purified subunits, we have determined that Rpo41p and Mtf1p interact to form a holoenzyme in solution prior to DNA binding and promoter recognition. We analyzed the composition of the polymerase during and after the initiation of transcription and found that, like the eubacterial a factors, Mtf1p is released after initiation and is available to catalyze transcription on a second template. By analyzing gel mobility shift complexes of the RNA polymerase and DNA at different stages of the transcription reaction, we found that both subunits were associated with DNA prior to initiation and after the formation of two phosphodiester bonds. After the formation of a 13-nucleotide transcript, Mtf1p is no longer associated with Rpo41p on the DNA. These data establish that Mtf1p is functionally as well as structurally similar to eubacterial sigma factors.	INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405; INDIANA UNIV,INST MOLEC & CELLULAR BIOL,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI000874] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036692] Funding Source: NIH RePORTER; NIAID NIH HHS [KO4 AI 00874] Funding Source: Medline; NIGMS NIH HHS [R01 GM 36692] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHAMBAULT J, 1993, MICROBIOL REV, V57, P703, DOI 10.1128/MMBR.57.3.703-724.1993; BISWAS TK, 1987, J BIOL CHEM, V262, P13690; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; BURGESS RR, 1971, METHOD ENZYMOL, V21, P500; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; DEZAMAROCZY M, 1986, GENE, V47, P155, DOI 10.1016/0378-1119(86)90060-0; ENGBAEK F, 1976, MOL GEN GENET, V143, P291, DOI 10.1007/BF00269405; GILL SC, 1991, J MOL BIOL, V220, P307, DOI 10.1016/0022-2836(91)90015-X; GOUGH JA, 1983, J MOL BIOL, V166, P1, DOI 10.1016/S0022-2836(83)80047-3; GREENBLATT J, 1981, CELL, V24, P421, DOI 10.1016/0092-8674(81)90332-9; GRIMES GW, 1974, SCIENCE, V185, P630, DOI 10.1126/science.185.4151.630; Guthrie C, 1991, METHODS ENZYMOL, V194; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; HARLOW E, 1988, ANTIBODIES LABORATOR; HELMANN JD, 1994, ANN REV BIOCH, P1; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; JAEHNING JA, 1991, SCIENCE, V253, P859, DOI 10.1126/science.1876846; JANG SH, 1991, J BIOL CHEM, V266, P22671; JANG SH, 1994, TRANSCRIPTION, P171; KELLY JL, 1986, J BIOL CHEM, V261, P348; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISOWSKY T, 1988, MOL GEN GENET, V214, P218, DOI 10.1007/BF00337714; MALIK S, 1987, NUCLEIC ACIDS RES, V15, P8521, DOI 10.1093/nar/15.20.8521; MANGUS DA, 1994, FUNCTIONAL ANAL YEAS; MANGUS DA, 1994, IN PRESS METHODS ENZ; MARCZYNSKI GT, 1989, MOL CELL BIOL, V9, P3193, DOI 10.1128/MCB.9.8.3193; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; MCALLISTER WT, 1993, MOL MICROBIOL, V10, P1, DOI 10.1111/j.1365-2958.1993.tb00897.x; PARTHUN MR, 1990, J BIOL CHEM, V265, P209; RANISH JA, 1991, J BIOL CHEM, V266, P19320; RIEMEN G, 1993, MOL GEN GENET, V237, P49, DOI 10.1007/BF00282783; Sambrook J, 1989, MOL CLONING LABORATO; SCHINKEL AH, 1987, J BIOL CHEM, V262, P12785; SCHINKEL AH, 1988, EMBO J, V7, P3255, DOI 10.1002/j.1460-2075.1988.tb03192.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TRAVERS AA, 1969, NATURE, V222, P537, DOI 10.1038/222537a0; ULERY TL, 1994, MOL CELL BIOL, V14, P1160, DOI 10.1128/MCB.14.2.1160; ULERY TL, 1993, COORDINATED REGULATI; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WILCOXEN SE, 1988, J BIOL CHEM, V263, P12346; WINKLEY CS, 1985, J BIOL CHEM, V260, P4214; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	45	80	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26568	26574						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929382				2022-12-27	WOS:A1994PQ93000095
J	KASHIWAYA, Y; SATO, K; TSUCHIYA, N; THOMAS, S; FELL, DA; VEECH, RL; PASSONNEAU, JV				KASHIWAYA, Y; SATO, K; TSUCHIYA, N; THOMAS, S; FELL, DA; VEECH, RL; PASSONNEAU, JV			CONTROL OF GLUCOSE-UTILIZATION IN WORKING PERFUSED RAT-HEART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUX CONTROL COEFFICIENTS; SKELETAL-MUSCLE HEXOKINASE; METABOLIC CONTROL ANALYSIS; TRICARBOXYLIC-ACID CYCLE; FRUCTOSE 2,6-BISPHOSPHATE; DICTYOSTELIUM-DISCOIDEUM; TRANSPORTER GLUT4; LIVER CELLS; GLYCOLYSIS; KINETICS	Metabolic control analyses of glucose utilization were performed for four groups of working rat hearts perfused with Krebs-Henseleit buffer containing 10 mu M glucose only, or with the addition of 4 mM D-beta-hydroxybutyrate/1 mM acetoacetate, 100 ana insulin (0.05 unit/ml), or both. Net glycogen breakdown occurred in the glucose group only and was converted to net glycogen synthesis in the presence of all additions. The flux of [2-H-3]glucose through P-glucoisomerase (EC 5.3.1.9) was reduced with ketones, elevated with insulin, and unchanged with the combination. Net glycolytic flux was reduced in the presence of ketones and the combination. The flux control coefficients were determined for the portion of the pathway involving glucose transport to the branches of glycogen synthesis and glycolysis. Major control was divided between the glucose transporter and hexokinase (EC 2.7.1.1) in the glucose group. The distribution of the control was slightly shifted to hexokinase with ketones, and control at the glucose transport step was abolished in the presence of insulin. Analysis of the pathway from 3-P-glycerate to pyruvate determined that the major control was shared by enolase (EC 4.2.1.1) and pyruvate kinase (EC 2.7.1.40) in the glucose group. Addition of ketones, insulin, or the combination shifted the control to P-glycerate mutase (EC 5.4.2.1) and pyruvate kinase. These results illustrate that the control of the metabolic flux in glucose metabolism of rat heart is not exerted by a single enzyme but variably distributed among enzymes depending upon substrate availability, hormonal stimulation, or other changes of conditions.	NIAAA, ROCKVILLE, MD 20852 USA; OXFORD BROOKES UNIV, SCH BIOL & MOLEC SCI, OXFORD OX3 0BP, ENGLAND	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Oxford Brookes University			Fell, David A/B-2109-2009	Fell, David A/0000-0001-6669-2247				ALBE KR, 1992, J BIOL CHEM, V267, P3106; BRAND MD, 1988, BIOCHEM J, V255, P535; Brown DH., 1961, ENZYMES, V5, P207; BROWN GC, 1990, EUR J BIOCHEM, V188, P321, DOI 10.1111/j.1432-1033.1990.tb15406.x; BURNS JA, 1985, TRENDS BIOCHEM SCI, V10, P16, DOI 10.1016/0968-0004(85)90008-8; CASAZZA JP, 1986, J BIOL CHEM, V261, P690; CHEUNG JY, 1978, AM J PHYSIOL, V234, pE70, DOI 10.1152/ajpendo.1978.234.1.E70; CLARK MG, 1978, INT J BIOCHEM, V9, P17, DOI 10.1016/0020-711X(78)90131-3; CORNELL NW, 1979, J BIOL CHEM, V254, P6522; DEPRE C, 1993, J BIOL CHEM, V268, P13274; ESTABROOK RW, 1958, J BIOL CHEM, V233, P1014; FELL DA, 1985, EUR J BIOCHEM, V148, P555, DOI 10.1111/j.1432-1033.1985.tb08876.x; FELL DA, 1992, BIOCHEM J, V286, P313, DOI 10.1042/bj2860313; GANSON NJ, 1985, J BIOL CHEM, V260, P2099; GLIEMANN J, 1983, CURR TOP MEMBR TRANS, V18, P339; GOLDBERG RN, 1989, J BIOL CHEM, V264, P9901; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; GROEN AK, 1986, BIOCHEM J, V237, P379, DOI 10.1042/bj2370379; GUYNN RW, 1974, J BIOL CHEM, V249, P3248; Haldane JBS, 1930, ENZYMES, P74; HESTRIN S, 1949, J BIOL CHEM, V179, P943; HOFMEYR JHS, 1991, EUR J BIOCHEM, V200, P223, DOI 10.1111/j.1432-1033.1991.tb21071.x; HUTTER OF, 1961, J PHYSIOL-LONDON, V157, P335, DOI 10.1113/jphysiol.1961.sp006726; KACSER H, 1981, GENETICS, V97, P639; Kacser H, 1973, Symp Soc Exp Biol, V27, P65; KAHANA SE, 1960, J BIOL CHEM, V235, P2178; Katz J, 1976, Curr Top Cell Regul, V10, P237; KIM YA, 1992, AM J PHYSIOL, V262, pE344, DOI 10.1152/ajpendo.1992.262.3.E344; KOLTER T, 1992, BIOCHEM BIOPH RES CO, V189, P1207, DOI 10.1016/0006-291X(92)92333-S; KREBS EG, 1959, J BIOL CHEM, V234, P2867; KREBS HA, 1961, BIOCHEM J, V80, P225, DOI 10.1042/bj0800225; KREBS HA, 1961, ARCH INTERN MED, V107, P51, DOI 10.1001/archinte.1961.03620010055010; KRUCKEBERG AL, 1989, BIOCHEM J, V261, P457, DOI 10.1042/bj2610457; Langendorff O., 1895, PFLUGERS ARCH, V61, P291, DOI [10.1007/BF01812150, 10.1007/bf01812150, DOI 10.1007/BF01812150]; LAWSON JWR, 1987, J BIOL CHEM, V262, P3165; LAWSON JWR, 1976, GLUCONEOGENESIS ITS, P481; LEVINE R, 1949, J BIOL CHEM, V179, P985; LOWRY OH, 1964, J BIOL CHEM, V239, P31; LOWRY OH, 1964, J BIOL CHEM, V239, P18; LUECK JD, 1974, J BIOL CHEM, V249, P1341; Lundsgaard E., 1939, UPSALA LAK FOREN FOR, V45, P143; MASUDA T, 1990, J BIOL CHEM, V265, P20321; MCQUATE JT, 1959, J BIOL CHEM, V234, P2151; Michaelis L, 1913, BIOCHEM Z, V49, P333; MILNER Y, 1964, ISRAEL J CHEM, V2, P316; MORGAN HE, 1964, J BIOL CHEM, V239, P369; NAJJAR VA, 1962, ENZYMES, V6, P161; NEELY JR, 1967, AM J PHYSIOL, V212, P804; NEELY JR, 1967, AM J PHYSIOL, V212, P815; NEELY JR, 1972, BIOCHEM J, V128, P147, DOI 10.1042/bj1280147; PAGE RA, 1991, BIOCHEM J, V278, P659, DOI 10.1042/bj2780659; Passonneau J.V., 1993, ENZYMATIC ANAL PRACT; PASSONNEAU JV, 1975, J BIOL CHEM, V250, P2287; PILKIS SJ, 1981, J BIOL CHEM, V256, P3171; PLOUG T, 1987, AM J PHYSIOL, V253, pE12, DOI 10.1152/ajpendo.1987.253.1.E12; QUANT PA, 1993, TRENDS BIOCHEM SCI, V18, P26; REGEN DM, 1984, J THEOR BIOL, V111, P635, DOI 10.1016/S0022-5193(84)80259-3; REN JM, 1993, J BIOL CHEM, V268, P16113; REN JM, 1994, J BIOL CHEM, V269, P14396; ROSE ZB, 1970, ANAL BIOCHEM, V35, P177, DOI 10.1016/0003-2697(70)90023-0; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22912; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SMALL JR, 1993, BIOCHEM J, V296, P423, DOI 10.1042/bj2960423; SOLA MM, 1993, J BIOL CHEM, V268, P19352; TAEGTMEYER H, 1980, BIOCHEM J, V186, P701, DOI 10.1042/bj1860701; TEWARI YB, 1991, BIOPHYS CHEM, V40, P59, DOI 10.1016/0301-4622(91)85029-P; THOMAS S, 1993, BIOCHEM J, V292, P351, DOI 10.1042/bj2920351; TORRES NV, 1986, BIOCHEM J, V234, P169, DOI 10.1042/bj2340169; UYEDA K, 1981, J BIOL CHEM, V256, P8394; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; VANSCHAFTINGEN E, 1980, BIOCHEM J, V192, P897, DOI 10.1042/bj1920897; VEECH RL, 1969, BIOCHEM J, V115, P837, DOI 10.1042/bj1150837; VEECH RL, 1979, J BIOL CHEM, V254, P6538; VEECH RL, 1994, IN PRESS ALCOHOL CLI; VEECH RL, 1975, FRONTIERS PINEAL PHY, P177; VELOSO D, 1973, J BIOL CHEM, V248, P4811; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WESTERHOFF HV, 1992, CURR TOP CELL REGUL, V33, P361; WESTERHOFF HV, 1984, BIOSCIENCE REP, V4, P1, DOI 10.1007/BF01120819; WHEELER TJ, 1988, J BIOL CHEM, V263, P19447; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514	82	253	257	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25502	25514						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929251				2022-12-27	WOS:A1994PQ49100044
J	OLAH, Z; LEHEL, C; ANDERSON, WB; EIDEN, MV; WILSON, CA				OLAH, Z; LEHEL, C; ANDERSON, WB; EIDEN, MV; WILSON, CA			THE CELLULAR RECEPTOR FOR GIBBON APE LEUKEMIA-VIRUS IS A NOVEL HIGH-AFFINITY SODIUM-DEPENDENT PHOSPHATE TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECOTROPIC RETROVIRUS RECEPTOR; AMINO-ACID TRANSPORTER; MURINE RETROVIRUSES; NUCLEOTIDE-SEQUENCE; NEUROSPORA-CRASSA; SURFACE RECEPTOR; GENE ENCODES; CELLS; INFECTION; SYSTEM	The primate type C retrovirus gibbon ape leukemia virus (GaLV) has been shown to use a widely expressed, multiple membrane-spanning protein of unknown function as its cell surface receptor on human cells (GLVR1) (Johann, S. V., Gibbons, J. J., and O'Hara, B. (1992) J. Virol. 66, 1635-1640; O'Hara, B., Johann, S. V., Klinger, H. P., Blair, D. G., Rubinson, H., Dunni, K. J., Sass, P., Vitek, S. M., and Robins, T. (1990) Cell Growth Diff. 1, 119-127). Here we present evidence that the receptor for GaLV (GLVR1) functions as a sodium dependent transporter of inorganic phosphate. GLVR1 is shown to have approximately 3-4-fold higher affinity for phosphate than other mammalian phosphate transporters described to date. Productive infection of GLVR1-expressing cells by GaLV, but not other retroviruses, results in the complete blockade of GLVR1-specific uptake of inorganic phosphate. Since productive infection of cells with GaLV is generally not cytotoxic, it is likely that more than one phosphate transporter exists on the cell surface. Our data suggest that GLVR1 represents a sodium-dependent phosphate transporter that differs from other mammalian phosphate transporters in structure, affinity for phosphate, and function.	NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892; NIMH,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)								ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BIBER J, 1993, RENAL PHYSIOL BIOCH, V16, P37; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DEGUCHI Y, 1990, J BIOL CHEM, V265, P21704; EGLITIS MA, 1993, J VIROL, V67, P4572; ESCOUBET B, 1991, AM J PHYSIOL, V260, pF235, DOI 10.1152/ajprenal.1991.260.2.F235; JOHANN SV, 1993, J VIROL, V67, P6733, DOI 10.1128/JVI.67.11.6733-6736.1993; JOHANN SV, 1992, J VIROL, V66, P1635, DOI 10.1128/JVI.66.3.1635-1640.1992; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; LIFSON JD, 1989, IMMUNOL REV, V109, P93, DOI 10.1111/j.1600-065X.1989.tb00021.x; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MAGAGNIN S, 1993, P NATL ACAD SCI USA, V90, P5979, DOI 10.1073/pnas.90.13.5979; MANN BJ, 1989, GENE, V83, P281, DOI 10.1016/0378-1119(89)90114-5; MCLACHLIN JR, 1993, VIROLOGY, V195, P1, DOI 10.1006/viro.1993.1340; MILLER AD, 1991, J VIROL, V65, P2220, DOI 10.1128/JVI.65.5.2220-2224.1991; MILLER AD, 1984, J VIROL, V49, P214, DOI 10.1128/JVI.49.1.214-222.1984; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; OHARA B, 1990, CELL GROWTH DIFFER, V1, P119; OLAH Z, 1993, BIOCHIM BIOPHYS ACTA, V1176, P333, DOI 10.1016/0167-4889(93)90063-U; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; REIN A, 1982, VIROLOGY, V120, P251, DOI 10.1016/0042-6822(82)90024-1; SICILIANO RF, 1988, CELL, V54, P561; SITBON M, 1990, J VIROL, V64, P2135, DOI 10.1128/JVI.64.5.2135-2140.1990; SOMMERFELT MA, 1990, VIROLOGY, V176, P58, DOI 10.1016/0042-6822(90)90230-O; TAILOR CS, 1993, J VIROL, V67, P6737, DOI 10.1128/JVI.67.11.6737-6741.1993; WANG H, 1992, J BIOL CHEM, V267, P23617; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9608, DOI 10.1073/pnas.88.21.9608; WILSON CA, 1994, J GEN VIROL, V75, P1901, DOI 10.1099/0022-1317-75-8-1901; WILSON CA, 1994, J VIROL METHODS, V48, P109, DOI 10.1016/0166-0934(94)90093-0	32	163	166	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25426	25431						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929240				2022-12-27	WOS:A1994PQ49100033
J	REDDY, SAG; CHATURVEDI, MM; DARNAY, BG; CHAN, H; HIGUCHI, M; AGGARWAL, BB				REDDY, SAG; CHATURVEDI, MM; DARNAY, BG; CHAN, H; HIGUCHI, M; AGGARWAL, BB			RECONSTITUTION OF NUCLEAR FACTOR KAPPA-B ACTIVATION-INDUCED BY TUMOR-NECROSIS-FACTOR REQUIRES MEMBRANE-ASSOCIATED COMPONENTS - COMPARISON WITH PATHWAY ACTIVATED BY CERAMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; PROTEIN-KINASE; FACTOR-ALPHA; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; TRANSLOCATION; EXPRESSION; MECHANISM; PRECURSOR; INDUCTION	Tumor necrosis factor (TNF) is known to induce the activation of a nuclear transcription factor, nuclear factor kappa B (NF-kappa B), in a wide variety of cell types. The post-receptor binding events that culminate in TNF-dependent NF-kappa B activation are not understood. To dissect this pathway, we developed a reconstitution system consisting of membrane, cytosolic, and post-nuclear fractions. Our results indicate that when incubated with the post-nuclear fraction derived from TNF-untreated cells, the membrane fraction from TNF-treated cells causes the activation of NF-kappa B with kinetics similar to that observed in intact cells. Under these conditions, the cytosolic fraction has no effect. This activation is tyrosine kinase-dependent since erbstatin completely abolished the effect. Furthermore, as revealed by immunoblotting, no degradation of the inhibitory subunit of NF-kappa B was observed. In this reconstitution system, we can also demonstrate the activation of NF-kappa B by ceramide, but this activation is not tyrosine kinase-dependent. Overall, our results indicate that intermediates required for NF-kappa B activation by TNF or ceramide are membrane-bound, but the mechanism of activation by TNF is most likely different from that of ceramide.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CLIN IMMUNOL & BIOL THERAPY,CYTOKINE RES LAB,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Aggarwal, Bharat B/G-3388-2013					BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BETTS JC, 1994, J BIOL CHEM, V269, P8455; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; EICHER DM, 1994, J IMMUNOL, V152, P2710; FINCO TS, 1993, J BIOL CHEM, V268, P17676; GENG Y, 1993, J IMMUNOL, V151, P6692; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JOHNS LD, 1994, J IMMUNOL, V152, P5877; KIM MY, 1991, J BIOL CHEM, V266, P484; KOONG AC, 1994, CANCER RES, V54, P1425; KROENKE M, 1992, TUMOR NECROSIS FACTO, P189; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; UMEZAWA K, 1990, FEBS LETT, V260, P198, DOI 10.1016/0014-5793(90)80102-O; WOLCHOK JD, 1993, J LEUKOCYTE BIOL, V55, P7; YANAGA F, 1994, BIOCHEM J, V298, P733, DOI 10.1042/bj2980733; YANG ZH, 1993, J BIOL CHEM, V268, P20520	30	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25369	25372						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929233				2022-12-27	WOS:A1994PQ49100024
J	DELARIA, K; FIORENTINO, L; WALLACE, L; TAMBURINI, P; BROWNELL, E; MULLER, D				DELARIA, K; FIORENTINO, L; WALLACE, L; TAMBURINI, P; BROWNELL, E; MULLER, D			INHIBITION OF CATHEPSIN L-LIKE CYSTEINE PROTEASES BY CYTOTOXIC T-LYMPHOCYTE ANTIGEN-2-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASES; CELLS; PRECURSOR; PEPTIDES; BINDING	The protein sequence of cytotoxic T-lymphocyte antigen-2 beta (CTLA-2 beta) is 36% identical to the proregion of mouse cathepsin L (Denizot, F., Brunet, J. F., Roustan, P., Harper, K., Suzan, M., Luciani, M. F., Mattei, M. G., and Golstein, P. (1989) Eur. J. Immunol. 19, 631-635). Here we report the expression, purification, and characterization of recombinant murine CTLA-2 beta. The protein was purified by consecutive pel-filtration, anion exchange, and reverse-phase (C4) chromatography. Purified CTLA-2 beta exists in solution primarily as a dimer but also as a disulfide-linked tetramer as judged by size exclusion chromatography. Circular dichroism studies suggest that the dimeric form of the protein contains 8% alpha-helix, 67% beta-sheet, and 21% random coil and also indicates that there is a conformational change upon formation of the tetramer. The protein is a competitive inhibitor of certain cysteine proteases including papain (K-i = 25 nM), cathepsins L (K-i = 24 nM) and H (IC50 = 67 nM) but not cathepsin B. CTLA-2 beta forms a noncovalent complex with cathepsin L and has a stoichiometry of binding to papain of 1 mol. of CTLA-2 beta/mol of papain. There is no homology between CTLA-2 beta and any of the known cysteine protease inhibitors, including the kininogens and cystatins. Therefore, CTLA-2 beta represents a novel Glass of cysteine protease inhibitor that is specific for the cathepsin L family of proteases.	MILES INC,DIV PHARMACEUT,W HAVEN,CT 06516									AOYAMA A, 1990, P NATL ACAD SCI USA, V87, P8296, DOI 10.1073/pnas.87.21.8296; BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; DALETFUMERON V, 1991, J CHROMATOGR-BIOMED, V568, P55, DOI 10.1016/0378-4347(91)80340-I; DENIZOT F, 1989, EUR J IMMUNOL, V19, P631, DOI 10.1002/eji.1830190409; DIXON M, 1979, ENZYMES, P365; EVIN G, 1984, P NATL ACAD SCI-BIOL, V81, P48, DOI 10.1073/pnas.81.1.48; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; FUSEK M, 1991, FEBS LETT, V287, P160, DOI 10.1016/0014-5793(91)80040-A; GABRIJELCIC D, 1992, EUR J CLIN CHEM CLIN, V30, P69; KARRER KM, 1993, P NATL ACAD SCI USA, V90, P3063, DOI 10.1073/pnas.90.7.3063; LINDAHL P, 1991, BIOCHEM J, V276, P387, DOI 10.1042/bj2760387; MACIEWICZ RA, 1991, BIOMED BIOCHIM ACTA, V50, P561; Segundo B S, 1982, Biochim Biophys Acta, V707, P74; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; VANNOORDEN CJF, 1987, ADV BIOSCI, V65, P27	19	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25172	25177						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929206				2022-12-27	WOS:A1994PQ49000096
J	EMORI, Y; SAIGO, K				EMORI, Y; SAIGO, K			CALPAIN LOCALIZATION CHANGES IN COORDINATION WITH ACTIN-RELATED CYTOSKELETAL CHANGES DURING EARLY EMBRYONIC-DEVELOPMENT OF DROSOPHILA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT PROTEASE; CA-2+-ACTIVATED NEUTRAL PROTEASE; MICROTUBULE-ASSOCIATED PROTEINS; HOMEO BOX GENES; ENDOGENOUS INHIBITOR; BINDING PROTEINS; F-ACTIN; MOLECULAR-CLONING; THIOL PROTEASE; LARGE SUBUNIT	Calpain, a calcium-dependent intracellular protease, was identified in Drosophila melanogaster. Drosophila calpain has an amino acid sequence highly homologous to those of mammalian calpains and exhibits a distinct domain structure consisting of cysteine protease and calcium-binding domains. Specific antibodies raised against a recombinant calpain fragment were used to identify the localization of calpain in developing Drosophila embryos. Calpain was first detected near the anterior pole and in posterior region of the embryo just after fertilization. The anterior calpain disappeared during the cleavage cycles. On the other hand, the posterior calpain moved to the posterior pole when polar buds were formed, and condensed just below the pole cells. At cleavage cycles 8 and 9, when nuclei reached the egg surface, calpain was localized between the nuclei at the surface beneath the precleavage furrows. Co-staining experiments with anti-actin antibody revealed that calpain condenses specifically at the edge of and between actin caps that underlie the plasma membrane immediately above each nucleus. These results indicate that calpain is involved in the dynamic changes in the embryonic cytoskeleton, especially actin-related structures, during early embryogenesis prior to cellularization.			EMORI, Y (corresponding author), UNIV TOKYO, FAC SCI, DEPT BIOPHYS & BIOCHEM, BUNKYO KU, HONGO 7-3-1, TOKYO 113, JAPAN.							AOKI K, 1986, FEBS LETT, V205, P313, DOI 10.1016/0014-5793(86)80919-X; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; Dustin P., 1984, MICROTUBULES; EMORI Y, 1987, P NATL ACAD SCI USA, V84, P3590, DOI 10.1073/pnas.84.11.3590; EMORI Y, 1986, J BIOL CHEM, V261, P9465; EMORI Y, 1988, J BIOL CHEM, V263, P2364; EMORI Y, 1985, NATURE, V315, P773, DOI 10.1038/315773a0; ENGELS WR, 1986, FOCUS, V8, P6; FREEMAN M, 1986, CELL, V46, P457, DOI 10.1016/0092-8674(86)90666-5; HARRIS AS, 1989, J BIOL CHEM, V264, P17401; HIGASHIJIMA S, 1992, GENE DEV, V6, P1005, DOI 10.1101/gad.6.6.1005; HIGASHIJIMA SI, 1992, GENE DEV, V6, P50, DOI 10.1101/gad.6.1.50; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; IBNSOUDA S, 1993, DEVELOPMENT, V119, P471; IMAJOH S, 1988, BIOCHEMISTRY-US, V27, P8122, DOI 10.1021/bi00421a022; KARR TL, 1986, J CELL BIOL, V102, P1494, DOI 10.1083/jcb.102.4.1494; KELLOGG DR, 1989, J CELL BIOL, V109, P2977, DOI 10.1083/jcb.109.6.2977; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLER KG, 1985, COLD SPRING HARB SYM, V50, P79, DOI 10.1101/SQB.1985.050.01.012; MILLER KG, 1989, J CELL BIOL, V109, P2963, DOI 10.1083/jcb.109.6.2963; MINAMI Y, 1987, J BIOCHEM-TOKYO, V101, P889, DOI 10.1093/oxfordjournals.jbchem.a121956; MURACHI T, 1989, BIOCHEM INT, V18, P263; ODA A, 1993, J BIOL CHEM, V268, P12603; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; OLMSTED JB, 1986, ANNU REV CELL BIOL, V2, P421, DOI 10.1146/annurev.cb.02.110186.002225; PINTER M, 1988, BIOCHEM J, V253, P467, DOI 10.1042/bj2530467; PINTER M, 1992, BIOCHEMISTRY-US, V31, P8201, DOI 10.1021/bi00150a012; POSTNER MA, 1992, J CELL BIOL, V119, P1205, DOI 10.1083/jcb.119.5.1205; RIVETT AJ, 1993, BIOCHEM J, V291, P1; SCHEJTER ED, 1993, CELL, V75, P373, DOI 10.1016/0092-8674(93)80078-S; SCHEJTER ED, 1992, COLD SPRING HARB SYM, V57, P653, DOI 10.1101/SQB.1992.057.01.071; SCHEJTER ED, 1993, ANNU REV CELL BIOL, V9, P67, DOI 10.1146/annurev.cellbio.9.1.67; SIMPSON L, 1990, DEVELOPMENT, V110, P851; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; SORIMACHI H, 1993, J BIOL CHEM, V268, P19476; SULLIVAN W, 1993, DEVELOPMENT, V118, P1245; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WARN RM, 1984, J CELL BIOL, V98, P156, DOI 10.1083/jcb.98.1.156; WARN RM, 1985, J CELL BIOL, V100, P1010, DOI 10.1083/jcb.100.4.1010; WEEDS A, 1982, NATURE, V296, P811, DOI 10.1038/296811a0; WIEDMER T, 1990, BIOCHEMISTRY-US, V29, P623, DOI 10.1021/bi00455a005	44	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25137	25142						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929201				2022-12-27	WOS:A1994PQ49000091
J	GEERTS, D; SCHUBERT, H; DEVRIEZE, G; BORRIAS, M; MATTHIJS, HCP; WEISBEEK, PJ				GEERTS, D; SCHUBERT, H; DEVRIEZE, G; BORRIAS, M; MATTHIJS, HCP; WEISBEEK, PJ			EXPRESSION OF ANABAENA PCC-7937 PLASTOCYANIN IN SYNECHOCOCCUS PGC-7942 ENHANCES PHOTOSYNTHETIC ELECTRON-TRANSFER AND ALTERS THE ELECTRON-DISTRIBUTION BETWEEN PHOTOSYSTEM-I AND CYTOCHROME-C-OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII; CYANOBACTERIUM SYNECHOCOCCUS; TRANSCRIPTIONAL REGULATION; NADP+ OXIDOREDUCTASE; SP PCC-7937; GENE; COPPER; ALGAE; SEQUENCE; PROTEINS	The petE gene encoding plastocyanin precursor protein from the cyanobacterium Anabaena PCC 7937 was introduced in the cyanobacterial host strain Synechococcus PCC 7942. The host normally only uses cytochrome c(553) as Photosystem I (PS I) donor. The heterologous gene was efficiently expressed using the inducible Escherichia coli trc promoter. Accumulation of plastocyanin protein depended on the presence of Cu2+. Th, protein was accurately targeted to the thylakoid lumen, from which it could be isolated in the mature form. Redox difference spectroscopy proved the presence of a Cu2+ ion in the holoenzyme. Isolated heterologous plastocyanin was functional in reconstitution of in vitro electron transfer to PS I. The presence of Anabaena plastocyanin in Synechococcus thylakoid membranes increased PS I electron transfer rate 2.5 times. Analysis of P700 redox and PS II fluorescence transients in vivo showed a faster electron transfer through PS I because of enhanced electron supply in the presence of plastocyanin. In addition, the distribution of electrons between photosynthetic and respiratory electron transfer changed. Plastocyanin preferentially donates electrons to PS I rather than to the respiratory cytochrome-c oxidase complex and is not functionally equivalent to cytochrome c(553).	UNIV ROSTOCK, FACHBEREICH BIOL, WB EXPT ONKOL, D-18051 ROSTOCK, GERMANY; UNIV AMSTERDAM, EC SLATER INST BIOCHEM RES, MICROBIOL LAB, 1018 WS AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, AMSTERDAM RES INST SUBST ENVIRONM, 1018 WS AMSTERDAM, NETHERLANDS	University of Rostock; University of Amsterdam; University of Amsterdam	GEERTS, D (corresponding author), UNIV UTRECHT, DEPT MOLEC CELL BIOL, PADUALAAN 8, 3584 CH UTRECHT, NETHERLANDS.		Geerts, Dirk/K-8260-2015; Matthijs, Hans/B-4503-2009	Geerts, Dirk/0000-0002-6386-8187; 				AITKEN A, 1976, NATURE, V263, P793, DOI 10.1038/263793a0; Allen J. F., 1986, Photosynthesis: energy transduction: a practical approach, P103; AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; AOKI M, 1983, PLANT CELL PHYSIOL, V24, P517; BENGIS C, 1977, J BIOL CHEM, V252, P4564; Boulter D., 1977, INT REV BIOCH PLANT, V13, P1; BOVY A, 1992, MOL MICROBIOL, V6, P1507, DOI 10.1111/j.1365-2958.1992.tb00871.x; BOVY A, 1992, PLANT MOL BIOL, V19, P491, DOI 10.1007/BF00023397; BRIGGS LM, 1990, PLANT MOL BIOL, V15, P633, DOI 10.1007/BF00017837; BRYANT DA, 1992, CURRENT TOPICS PHOTO, V11, P501; CHITNIS PR, 1991, J BIOL CHEM, V266, P20146; DAVIS DJ, 1980, PLANT PHYSIOL, V65, P697, DOI 10.1104/pp.65.4.697; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HAEHNEL W, 1980, BIOCHIM BIOPHYS ACTA, V593, P384, DOI 10.1016/0005-2728(80)90075-4; HAEHNEL W, 1989, J CELL BIOL, V108, P1397, DOI 10.1083/jcb.108.4.1397; HAGEMAN J, 1986, NATURE, V324, P567, DOI 10.1038/324567a0; HILL KL, 1992, PLANT PHYSIOL, V100, P319, DOI 10.1104/pp.100.1.319; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; HO KK, 1984, BIOCHIM BIOPHYS ACTA, V766, P310, DOI 10.1016/0005-2728(84)90246-9; HOWE G, 1992, EMBO J, V11, P2789, DOI 10.1002/j.1460-2075.1992.tb05346.x; JEFFREY SW, 1975, BIOCHEM PHYSIOL PFL, V167, P191, DOI 10.1016/s0015-3796(17)30778-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUDENBACH DE, 1990, PLANT CELL, V2, P913, DOI 10.1105/tpc.2.9.913; LI HH, 1992, J BIOL CHEM, V267, P9368; LIGHTBODY JJ, 1967, BIOCHIM BIOPHYS ACTA, V131, P508, DOI 10.1016/0005-2728(67)90010-2; LOCKAU W, 1981, ARCH MICROBIOL, V128, P336, DOI 10.1007/BF00422541; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTHIJS HCP, 1987, PHOTOSYNTH RES, V12, P273, DOI 10.1007/BF00055127; MATTHIJS HCP, 1986, J BIOL CHEM, V261, P2154; MATTHIJS HCP, 1988, BIOCH ALGAE CYANOBAC, P131; MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X; MERCHANT S, 1986, MOL CELL BIOL, V6, P462, DOI 10.1128/MCB.6.2.462; MERCHANT S, 1991, EMBO J, V10, P1383, DOI 10.1002/j.1460-2075.1991.tb07658.x; MERCHANT S, 1987, J BIOL CHEM, V262, P9062; MERCHANT S, 1986, J BIOL CHEM, V261, P5850; MI HL, 1992, PLANT CELL PHYSIOL, V33, P1099; NANBA M, 1983, BIOCHIM BIOPHYS ACTA, V725, P272, DOI 10.1016/0005-2728(83)90200-1; Peschek G.A., 1987, CYANOBACTERIA COMPRE, P119; PESCHEK GA, 1989, HIGHLIGHTS MODERN BI, V1, P893; RATAJCZAK R, 1988, BIOCHIM BIOPHYS ACTA, V933, P306, DOI 10.1016/0005-2728(88)90038-2; REDINBO MR, 1993, BIOCHEMISTRY-US, V32, P10560, DOI 10.1021/bi00091a005; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Sambrook J, 1989, MOL CLONING LABORATO; SANDMANN G, 1986, ARCH MICROBIOL, V145, P76, DOI 10.1007/BF00413030; SANDMANN G, 1983, ARCH MICROBIOL, V134, P23, DOI 10.1007/BF00429401; SCHERER S, 1990, TRENDS BIOCHEM SCI, V15, P458, DOI 10.1016/0968-0004(90)90296-N; SCHREIBER U, 1986, PHOTOSYNTH RES, V10, P51, DOI 10.1007/BF00024185; SCHREIBER U, 1988, Z NATURFORSCH C, V43, P686; STEPPUHN J, 1988, FEBS LETT, V237, P218, DOI 10.1016/0014-5793(88)80205-9; TAUTZ D, 1983, ANAL BIOCHEM, V132, P14, DOI 10.1016/0003-2697(83)90419-0; VANDERPLAS J, 1990, GENE, V95, P39, DOI 10.1016/0378-1119(90)90411-J; VANDERPLAS J, 1989, MOL MICROBIOL, V3, P275; VISSER JWM, 1974, BIOCHIM BIOPHYS ACTA, V333, P279, DOI 10.1016/0005-2728(74)90011-5; VORST O, 1988, GENE, V65, P59, DOI 10.1016/0378-1119(88)90417-9; WIDGER WR, 1991, PHOTOSYNTH RES, V30, P71, DOI 10.1007/BF00042005; WOOD PM, 1978, EUR J BIOCHEM, V87, P9, DOI 10.1111/j.1432-1033.1978.tb12346.x; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; ZHANG L, 1992, J BIOL CHEM, V267, P19054	59	15	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28068	28075						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961743				2022-12-27	WOS:A1994PV77200047
J	SINGER, L; WHITEHEAD, WT; AKAMA, H; KATZ, Y; FISHELSON, Z; WETSEL, RA				SINGER, L; WHITEHEAD, WT; AKAMA, H; KATZ, Y; FISHELSON, Z; WETSEL, RA			INHERITED HUMAN-COMPLEMENT C3 DEFICIENCY - AN AMINO ACID SUBSTITUTION IN THE BETA-CHAIN (ASP(549) TO ASN) IMPAIRS C3 SECRETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3RD COMPONENT; HEREDITARY-DEFICIENCY; CLONED COMPLEMENTARY; NUCLEOTIDE-SEQUENCE; REPEATED INFECTIONS; COMPLETE ABSENCE; MOLECULAR-BASIS; C-3 DEFICIENCY; DNA-POLYMERASE; GENE DELETION	We recently described a case of hereditary complement C3 deficiency (C3D) in a New Zealand male who has a small amount of serum C3 (7 mu g/ml), a normal size 5.2-kilobase C3 mRNA that is present in normal quantities, and a normal size M(r) 180,000 proC3 molecule that is synthesized in normal amounts. Secretion of C3 from this patient's cells was greatly diminished, however, and an aberrant C3 trypsin cleavage profile indicated an abnormality in the proC3 structure. To determine the primary structure of the C3D proC3 molecule, the corresponding cDNA was cloned and sequenced in the present study, revealing a normal signal peptide, tetra-arginine linker, and thiolester domain. One nucleotide substitution in exon 13 (G(1705)AC to AAC) was found, however, that resulted in an amino acid change in a highly conserved region of the C3 beta-chain (Asp(549) to Asn). This substitution has not been described in any individual with either C3 Fast or C3 Slow phenotypes. Immunoprecipitation of C3 from L-cells transfected with full-length normal and C3D cDNAs demonstrated that C3 was secreted by the cells transfected with the normal C3 cDNA; however, only a C3 precursor was detected in the intracellular compartment of the cells transfected with the C3D cDNA and none detected extracellularly. Immunofluorescence studies revealed a perinuclear localization of C3 in the C3D transfectants, suggesting that transport of the mutant precursor C3 is arrested early in the secretory pathway. Allele-specific polymerase chain reaction analysis demonstrated that this New Zealand family is a compound heterozygous C3D kindred, with the Asn(549) point mutation being inherited from the mother and a yet undescribed C3 defect being inherited from the father. Taken together, these data indicate that 1) C3 deficiency is caused in a New Zealand kindred by two distinct molecular genetic mutations, one being an amino acid substitution in a highly conserved region of the beta-chain that results in impaired C3 secretion, and 2) the molecular basis of this deficiency has not been described in any other C3-deficient individual, providing additional evidence that multiple defects cause inherited C3 deficiency in humans.	WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; TEL AVIV UNIV,SACKLER FAC MED,SCH MED,ALLERGY & IMMUNOL UNIT,IL-69978 TEL AVIV,ISRAEL; TEL AVIV UNIV,SACKLER FAC MED,SCH MED,DEPT PEDIAT,IL-69978 TEL AVIV,ISRAEL; TEL AVIV UNIV,SACKLER SCH MED,DEPT CELL BIOL & HISTOL,IL-69978 TEL AVIV,ISRAEL	Washington University (WUSTL); Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	SINGER, L (corresponding author), WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024739, R55AI025011, R01AI024739, R01AI025011] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL17461] Funding Source: Medline; NIAID NIH HHS [AI25011, AI24739] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALPER CA, 1972, LANCET, V2, P1179; ALPER CA, 1968, J CLIN INVEST, V47, P2181, DOI 10.1172/JCI105904; ALPER CA, 1969, SCIENCE, V163, P286, DOI 10.1126/science.163.3864.286; ALSENZ J, 1992, DEV COMP IMMUNOL, V16, P63, DOI 10.1016/0145-305X(92)90052-E; AUERBACH HS, 1990, J CLIN INVEST, V86, P96, DOI 10.1172/JCI114721; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BALLOW M, 1975, J CLIN INVEST, V56, P703, DOI 10.1172/JCI108141; BECHERER JD, 1989, CURR TOP MICROBIOL I, V153, P45; BOKISCH VA, 1975, P NATL ACAD SCI USA, V72, P1989, DOI 10.1073/pnas.72.6.1989; BORZY MS, 1988, AM J DIS CHILD, V142, P79, DOI 10.1001/archpedi.1988.02150010089032; BOTTO M, 1990, J CLIN INVEST, V86, P1158, DOI 10.1172/JCI114821; BOTTO M, 1992, P NATL ACAD SCI USA, V89, P4957, DOI 10.1073/pnas.89.11.4957; BOTTO M, 1992, J IMMUNOL, V149, P1348; BRADE V, 1977, J EXP MED, V146, P759, DOI 10.1084/jem.146.3.759; BRODBECK RM, 1993, J BIOL CHEM, V268, P6771; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLTEN HR, 1972, J IMMUNOL, V108, P1184; COLTEN HR, 1993, PROGR IMMUNOLOGY, V8, P483; DAVIS AE, 1977, CLIN IMMUNOL IMMUNOP, V8, P543, DOI 10.1016/0090-1229(77)90019-8; DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708; DUL JL, 1990, P NATL ACAD SCI USA, V87, P8135, DOI 10.1073/pnas.87.20.8135; ESPARZA I, 1991, EUR J IMMUNOL, V21, P2829, DOI 10.1002/eji.1830211126; FEARON DT, 1993, CURR OPIN IMMUNOL, V5, P341, DOI 10.1016/0952-7915(93)90051-S; FISHELSON Z, 1991, MOL IMMUNOL, V28, P545, DOI 10.1016/0161-5890(91)90169-K; FONG KY, 1990, GENOMICS, V7, P579, DOI 10.1016/0888-7543(90)90202-6; FRITZINGER DC, 1992, J IMMUNOL, V149, P3554; GRACE HJ, 1976, S AFR MED J, V50, P139; GRUMACH AS, 1988, BRAZ J MED BIOL RES, V21, P247; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; Harlow E, 1988, ANTIBODIES LABORATOR, P359; HASE S, 1985, J BIOCHEM-TOKYO, V98, P863, DOI 10.1093/oxfordjournals.jbchem.a135366; HAYASHI I, 1993, J BIOL CHEM, V268, P17219; HSIEH KH, 1981, CLIN IMMUNOL IMMUNOP, V20, P305, DOI 10.1016/0090-1229(81)90140-9; IMAI K, 1991, NEPHRON, V59, P148, DOI 10.1159/000186535; ISHIGURO H, 1992, EMBO J, V11, P829, DOI 10.1002/j.1460-2075.1992.tb05120.x; JOHNSON CA, 1992, J BIOL CHEM, V267, P9347; KATZ Y, 1994, EUR J IMMUNOL, V24, P1517, DOI 10.1002/eji.1830240709; KATZ Y, 1989, J IMMUNOL, V142, P3862; Kulics J., 1993, Molecular Immunology, V30, P26; LAMBRIS JD, 1993, J IMMUNOL, V151, P6123; Lin Ching-Yuang, 1993, Molecular Immunology, V30, P29, DOI 10.1016/0161-5890(93)90274-F; LUNDWALL A, 1984, J BIOL CHEM, V259, P3851; LYONS SE, 1992, J BIOL CHEM, V267, P4424; MISUMI Y, 1990, NUCLEIC ACIDS RES, V18, P2178, DOI 10.1093/nar/18.8.2178; NICHOLS RL, 1962, J IMMUNOL, V89, P545; NONAKA M, 1992, J IMMUNOL, V148, P3290; OSOFSKY SG, 1977, J PEDIATR-US, V90, P180, DOI 10.1016/S0022-3476(77)80626-4; PELEG D, 1992, PEDIATR INFECT DIS J, V11, P401, DOI 10.1097/00006454-199205000-00011; PUSSELL BA, 1980, LANCET, V1, P675, DOI 10.1016/S0140-6736(80)92827-5; ROORD JJ, 1983, PEDIATRICS, V71, P81; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANAL O, 1992, EUR J PEDIATR, V151, P676; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO Y, 1981, ARTHRITIS RHEUM-US, V24, P1255, DOI 10.1002/art.1780241005; SCHIFFERLI JA, 1988, BAILLIERE CLIN IMMUN, V2, P319; SINGER L, 1994, PATHOBIOLOGY, V62, P14, DOI 10.1159/000163873; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TACK BF, 1976, BIOCHEMISTRY-US, V15, P4513, DOI 10.1021/bi00665a028; TOMANA M, 1985, MOL IMMUNOL, V22, P107, DOI 10.1016/S0161-5890(85)80004-3; VANNOESEL CJM, 1993, IMMUNOL TODAY, V14, P8, DOI 10.1016/0167-5699(93)90316-D; Verpy E., 1993, Molecular Immunology, V30, P59; VIK DP, 1991, BIOCHEMISTRY-US, V30, P1080, DOI 10.1021/bi00218a029; VOLANAKIS JE, 1989, CURR TOP MICROBIOL, P1; Watanabe Yoshihisa, 1993, Molecular Immunology, V30, P62, DOI 10.1016/0161-5890(93)90407-3; WETSEL RA, 1984, J BIOL CHEM, V259, P3857; WHITEHEAD AS, 1982, P NATL ACAD SCI-BIOL, V79, P5021, DOI 10.1073/pnas.79.16.5021	67	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28494	28499						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961791				2022-12-27	WOS:A1994PV77200105
J	SVEJSTRUP, JQ; FEAVER, WJ; LAPOINTE, J; KORNBERG, RD				SVEJSTRUP, JQ; FEAVER, WJ; LAPOINTE, J; KORNBERG, RD			RNA-POLYMERASE TRANSCRIPTION FACTOR IIH HOLOENZYME FROM YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-LOOP MUTATION; SACCHAROMYCES-CEREVISIAE; FACTOR-B; CTD KINASE; DNA-REPAIR; PURIFICATION; INITIATION; SUPPRESSOR; COMPONENT; CLONING	An RNA polymerase transcription factor IIH holoenzyme (holoTFIIH) has been resolved to near homogeneity from Saccharomyces cerevisiae. HoloTFIIH comprises the five-subunit core transcription factor described previously (Feaver, W. J., Svejstrup, J. Q., Bardwell, A. J., Bardwell, L., Buratowski, S., Gulyas, K. D., Donahue, T. F., Friedberg, E. C. and Kornberg, R. D. (1993) Cell 75, 1379-1387) and in addition, SSL2 and three further, as yet unidentified, polypeptides. HoloTFIIH possesses C-terminal repeat domain kinase activity and, together with other pure yeast transcription proteins, enables RNA polymerase II transcription in a fully defined system. By contrast, core TFIIH is inert in both C-terminal repeat domain kinase and reconstituted transcription assays.	STANFORD UNIV,SCH MED,DEPT CELL BIOL,STANFORD,CA 94305	Stanford University				Svejstrup, Jesper/0000-0003-4964-6147	NIGMS NIH HHS [GM36659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036659, R37GM036659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL AJ, 1994, MOL CELL BIOL, V14, P3569, DOI 10.1128/MCB.14.6.3569; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; FLORES O, 1992, J BIOL CHEM, V267, P2786; GERARD M, 1991, J BIOL CHEM, V266, P20940; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; HENRY NL, 1992, J BIOL CHEM, V267, P23388; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; NAUMOVSKI L, 1983, P NATL ACAD SCI-BIOL, V80, P4818, DOI 10.1073/pnas.80.15.4818; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; YOON H, 1992, GENE DEV, V6, P2463, DOI 10.1101/gad.6.12b.2463	29	80	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28044	28048						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961739				2022-12-27	WOS:A1994PV77200043
J	BLONDEL, O; BELL, GI; MOODY, M; MILLER, RJ; GIBBONS, SJ				BLONDEL, O; BELL, GI; MOODY, M; MILLER, RJ; GIBBONS, SJ			CREATION OF AN INOSITOL 1,4,5-TRISPHOSPHATE-SENSITIVE CA2+ STORE IN SECRETORY GRANULES OF INSULIN-PRODUCING CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; BETA-CELLS; RECEPTOR; CA-2+; TRISPHOSPHATE; LOCALIZATION; CA-2+-ATPASE; NEURONS; RELEASE	A rapid rise in the cytosolic free Ca2+ concentration due to influx of extracellular Ca2+ or mobilization from intracellular stores is the primary trigger for exocytosis from secretory cells. Our understanding as to the precise role of Ca2+ mobilization has been complicated by the presence of several types of Ca2+ stores in most cells. We now demonstrate that overexpression of the type 3 inositol 1,4,5-trisphosphate (IP2) receptor in insulin-secreting beta TC-3 cells results in the creation of a unique IP3-sensitive Ca2+ pool, restricted to the insulin secretory granules of these cells.	UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago				Gibbons, Simon/0000-0001-5311-5993				ANDERSSON T, 1982, BIOMED RES-TOKYO, V3, P29, DOI 10.2220/biomedres.3.29; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIDEN TJ, 1992, BIOCHEM J, V285, P541, DOI 10.1042/bj2850541; BINDOKAS VP, 1993, NEUROPHARMACOLOGY, V32, P1213, DOI 10.1016/0028-3908(93)90015-U; BLONDEL O, 1994, P NATL ACAD SCI USA, V91, P7777, DOI 10.1073/pnas.91.16.7777; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; CUNNINGHAM AM, 1993, NEUROSCIENCE, V57, P339, DOI 10.1016/0306-4522(93)90067-P; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; HUTTON JC, 1983, BIOCHEM J, V210, P297, DOI 10.1042/bj2100297; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; MARANTO AR, 1994, J BIOL CHEM, V269, P1223; NICAISE G, 1992, BIOL CELL, V75, P89, DOI 10.1016/0248-4900(92)90128-N; PENG YW, 1991, NEURON, V6, P525, DOI 10.1016/0896-6273(91)90055-5; PRENTKI M, 1988, J BIOL CHEM, V263, P11044; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; UYAMA Y, 1992, BRIT J PHARMACOL, V106, P208, DOI 10.1111/j.1476-5381.1992.tb14316.x; YOO SH, 1990, J BIOL CHEM, V265, P13446; ZAWALICH WS, 1988, DIABETES, V37, P137, DOI 10.2337/diabetes.37.2.137	23	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27167	27170						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961623				2022-12-27	WOS:A1994PV77100004
J	GERHARDINGER, C; TANEDA, S; MARION, MS; MONNIER, VM				GERHARDINGER, C; TANEDA, S; MARION, MS; MONNIER, VM			ISOLATION, PURIFICATION, AND CHARACTERIZATION OF AN AMADORI PRODUCT BINDING-PROTEIN FROM A PSEUDOMONAS SP SOIL STRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLATION END-PRODUCTS; EXPERIMENTAL DIABETES-MELLITUS; MONOCLONAL-ANTIBODY; CELL-SURFACE; AMINOGUANIDINE; COMPLICATIONS; PENTOSIDINE; OXIDASE; QUANTITIES; SEQUENCE	Sugars react nonenzymatically with protein amino groups to form a ketoamine adduct (Amadori product), which leads to the formation of advanced glycation endproducts. These compounds are involved in the development of tissue modifications such as cross-linking and fluorescence in diabetes and aging. Searching for an en zyme to reverse protein glycation, we isolated a Pseudomonas sp. soil strain growing selectively on the Amadori product epsilon-fructosyl-aminocaproate. An Amadori product binding protein (ABP) was purified from the bacterial extract by single-step affinity chromatography on glycated lysine-Sepharose. The protein, a monomer of 45 kDa, did not bind to unglycated or NaBH4-reduced glycated lysine-Sepharose suggesting specificity for the Amadori compound. The concentration dependent binding of glycated aminocaproate showed saturation with K-d = 1.49 mu M and B-max = 17.63 nnol/mg of protein corresponding to 0.8 mol/mol of protein. The binding of epsilon-[C-14]fructosyl-aminocaproate to the protein was inhibited by other glucose-derived Amadori products, but not by free sugars, unglycated amines, or ribated lysine. The sequence of the first 16 NH2-terminal amino acids and a GenBank search revealed that ABP is a novel protein. Its synthesis was inducible by growth of the organism in Amadori product. Immunoblotting studies showed that ABP is not found in cell extracts from other prokaryotes, yeast, or liver homogenate and does not bind Amadori products in glycated proteins. ABP has no enzymatic activity toward glycated substrates and may thus have transport or permease function for glycated amino acids.	CASE WESTERN RESERVE UNIV,SCH MED,INST PATHOL,CLEVELAND,OH 44106	Case Western Reserve University			Monnier, Vincent M/B-1371-2009		NATIONAL EYE INSTITUTE [R01EY007099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005601] Funding Source: NIH RePORTER; NEI NIH HHS [EY 07099] Funding Source: Medline; NIA NIH HHS [AG 05601] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHMED MU, 1986, J BIOL CHEM, V261, P4889; ANRAKU Y, 1968, J BIOL CHEM, V243, P3116; BEISSWENGER PJ, 1993, J CLIN INVEST, V92, P212, DOI 10.1172/JCI116552; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; CERAMI A, 1979, METABOLISM, V28, P421; EAGON RG, 1971, CAN J BIOCHEM CELL B, V49, P1031, DOI 10.1139/o71-151; ELLIS EN, 1991, METABOLISM, V40, P1016, DOI 10.1016/0026-0495(91)90122-D; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; FINOT PA, 1969, HELV CHIM ACTA, V52, P1488, DOI 10.1002/hlca.19690520609; GERHARDINGER C, 1994, DIABETES, V43, P161; GRANDHEE SK, 1991, J BIOL CHEM, V266, P11649; GUYMON LF, 1973, J BACTERIOL, V117, P1261; HAMMES HP, 1991, P NATL ACAD SCI USA, V88, P11555, DOI 10.1073/pnas.88.24.11555; HODGE JE, 1953, J AGR FOOD CHEM, V1, P928, DOI 10.1021/jf60015a004; HORIUCHI T, 1991, AGR BIOL CHEM TOKYO, V55, P333, DOI 10.1080/00021369.1991.10870584; HORIUCHI T, 1989, AGR BIOL CHEM TOKYO, V53, P103, DOI 10.1080/00021369.1989.10869245; HOSHINO T, 1980, J BACTERIOL, V141, P1055, DOI 10.1128/JB.141.3.1055-1063.1980; IDO Y, 1990, DIABETES S1, V39, pA93; KAETZEL CS, 1984, BIOCHEM J, V219, P917, DOI 10.1042/bj2190917; KRANTZ S, 1993, BIOCHIM BIOPHYS ACTA, V1177, P15, DOI 10.1016/0167-4889(93)90151-E; KU V, 1993, BIOCHEM BIOPH RES CO, V193, P1131; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCANCE DR, 1993, J CLIN INVEST, V91, P2470, DOI 10.1172/JCI116482; MIYATA S, 1992, J CLIN INVEST, V89, P1102, DOI 10.1172/JCI115690; MONNIER VM, 1981, PROG FOOD NUTR SCI, V5, P315; MONNIER VM, 1981, SCIENCE, V211, P491, DOI 10.1126/science.6779377; OXLUND H, 1992, DIABETOLOGIA, V35, P19, DOI 10.1007/BF00400847; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Resmini P., 1990, ITAL J FOOD SCI, V3, P173; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SCHULMAN M, 1978, Nature (London), V276, P269; SELL DR, 1992, DIABETES, V41, P1286, DOI 10.2337/diabetes.41.10.1286; TANEDA S, 1993, CLIN CHEM, V40, P1766; VLASSARA H, 1992, P NATL ACAD SCI USA, V89, P12043, DOI 10.1073/pnas.89.24.12043; WATANABE N, 1990, AGR BIOL CHEM TOKYO, V54, P1063, DOI 10.1080/00021369.1990.10870059; YAGIHASHI S, 1992, DIABETES, V41, P47, DOI 10.2337/diabetes.41.1.47; [No title captured]	40	20	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27297	27302						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961640				2022-12-27	WOS:A1994PV77100026
J	HOLTZ, JK; TOPAL, MD				HOLTZ, JK; TOPAL, MD			LOCATION OF PUTATIVE BINDING AND CATALYTIC SITES OF NAEI BY RANDOM MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECORI ENDONUCLEASE; RESTRICTION ENDONUCLEASE; RECOGNITION SITES; CRYSTAL-STRUCTURE; CLEAVAGE CENTER; DNA; SPERMIDINE; GLU-111	Endonuclease NaeI is a prototype for an unusual group of type II restriction endonucleases that must bind two DNA recognition sequences to cleave DNA. The naeIR gene, expressed from a Ptac promotor construct, was toxic to Escherichia coli in the absence of NaeI-sequence specific methylases. The naeIR gene was mu tagenized with N-methyl-N'-nitrosoguanidine; four classes of NaeI variants were isolated in the absence of protecting methylase activity. Class I variants (T60I, E70K) lacked detectable cleavage activity, but displayed good sequence-specific DNA binding. Class II variants (D95N, G141D) displayed 1-5% of the wild-type cleavage activity and normal DNA binding, Class III variants (G131E, G131R, G155D, G245E) displayed significantly attenuated cleavage and binding activities. Class IV variants (G197D, G214/A219T, G236S, L241P, G245E, G245R, G250E, G270E) lacked both cleavage and binding activities. These results imply two amino acids (Thr-60, Glu-70) essential for catalysis. In addition, two domains are indicated in NaeI: one (Thr-60 to Gly-155) mediates substrate binding and catalysis, the other (Gly-197 to Gly-270) may mediate binding of the activating DNA sequence. Our results are compared with the active site residues of EcoRI, EcoRV, and BamHI.	UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, SCH MED, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT PATHOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine								BAXTER BK, 1993, BIOCHEMISTRY-US, V32, P8291, DOI 10.1021/bi00083a033; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONRAD M, 1989, P NATL ACAD SCI USA, V86, P9707, DOI 10.1073/pnas.86.24.9707; FOSTER PL, 1991, METHOD ENZYMOL, V204, P114; GABBARA S, 1992, J BIOL CHEM, V267, P18623; Heitman J, 1993, Genet Eng (N Y), V15, P57; HEITMAN J, 1992, BIOESSAYS, V14, P445, DOI 10.1002/bies.950140704; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KING K, 1989, J BIOL CHEM, V264, P11807; KRUGER DH, 1988, NUCLEIC ACIDS RES, V16, P3997; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; McClelland M, 1985, Nucleic Acids Res, V13 Suppl, pr201; Miller J.H., 1972, EXPT MOL GENETICS; NEWMAN M, 1994, NATURE, V368, P660, DOI 10.1038/368660a0; OLLER AR, 1991, BIOCHEMISTRY-US, V30, P2543, DOI 10.1021/bi00223a035; Sambrook J, 1989, MOL CLONING LABORATO; SELENT U, 1992, BIOCHEMISTRY-US, V31, P4808, DOI 10.1021/bi00135a010; TARON CH, 1994, IN PRESS GENE; THIELKING V, 1992, BIOCHEMISTRY-US, V31, P3727, DOI 10.1021/bi00130a001; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; WRIGHT DJ, 1989, J BIOL CHEM, V264, P11816; XU SY, 1991, J BIOL CHEM, V266, P4425; YANG CC, 1992, BIOCHEMISTRY-US, V31, P9657, DOI 10.1021/bi00155a019	23	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27286	27290						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961638				2022-12-27	WOS:A1994PV77100024
J	HARRIS, KS; XIANG, WK; ALEXANDER, L; LANE, WS; PAUL, AV; WIMMER, E				HARRIS, KS; XIANG, WK; ALEXANDER, L; LANE, WS; PAUL, AV; WIMMER, E			INTERACTION OF POLIOVIRUS POLYPEPTIDE 3CD(PRO) WITH THE 5'-TERMINI AND 3'-TERMINI OF THE POLIOVIRUS GENOME - IDENTIFICATION OF VIRAL AND CELLULAR COFACTORS NEEDED FOR EFFICIENT BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; RNA-SYNTHESIS; PROTEIN-SYNTHESIS; NONCODING REGION; REPLICATION; PRECURSOR; INVITRO; 3CD; POLYMERASE; CLEAVAGE	Poliovirus proteinase 3CD(pro) by itself is not an RNA-binding protein. Two cellular proteins have been purified from HeLa cells (p50 and p36) which interact with purified 3CD(pro) but only p36-3CD(pro) bind to the 5'-terminal 110 nucleotides of polioviral RNA genome, an RNA segment whose secondary structure resembles a cloverleaf. The identity of these factors was determined by microsequencing tryptic digests of the purified proteins. Host protein p50 is the eukaryotic elongation factor EF-1 alpha, and p36 an N-terminal fragment thereof. p36, referred to as host factor, did not appear to interact with purified 3C(pro) or 3D(pol). Significantly, the formation of a 3CD(pro)-cloverleaf complex was also observed in the presence of purified poliovirus polypeptide 3AB, the precursor of VPg. 3AB by itself does not stably bind to the cloverleaf. Competition experiments have demonstrated that the RNA-protein interactions are specific for the full-length cloverleaf. UV cross-linking studies were employed to examine the protein components of the cloverleaf ribonucleoproteins. RNA footprinting was used to determine the site on the cloverleaf where the viral and cellular factors bind. Finally, we have discovered that 3AB-3CD(pro) also interacts with the 3'-terminal sequence of poliovirus RNA. In contrast to the 5'-terminal cloverleaf, the 3'-terminal RNA can bind 3AB in the absence of other proteins. A model for initiation of poliovirus RNA synthesis is presented.	SUNY STONY BROOK,HLTH SCI CTR,SCH MED,DEPT MOLEC GENET & MICROBIOL,STONY BROOK,NY 11794; HARVARD UNIV,MICROCHEM FACIL,CAMBRIDGE,MA 02138	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Harvard University					NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015122, R01AI032100, R01AI015122] Funding Source: NIH RePORTER; NCI NIH HHS [CA-28146] Funding Source: Medline; NIAID NIH HHS [AI-15122, AI-32100] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDINO R, 1990, J VIROL, V64, P607, DOI 10.1128/JVI.64.2.607-612.1990; ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; ANDINO R, 1993, EMBO J, V12, P3587, DOI 10.1002/j.1460-2075.1993.tb06032.x; BERNSTEIN HD, 1986, J VIROL, V60, P1040, DOI 10.1128/JVI.60.3.1040-1049.1986; BLUMENTHAL T, 1979, ANNU REV BIOCHEM, V48, P525, DOI 10.1146/annurev.bi.48.070179.002521; CUI T, 1993, J BIOL CHEM, V268, P26093; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GIACHETTI C, 1992, J VIROL, V66, P6045, DOI 10.1128/JVI.66.10.6045-6057.1992; HAMMERLE T, 1992, J VIROL, V66, P6028; HARRIS KS, 1992, J VIROL, V66, P7481, DOI 10.1128/JVI.66.12.7481-7489.1992; Harris KS, 1990, SEMINARS VIROLOGY, V1, P323; HELLEN CUT, 1989, BIOCHEMISTRY-US, V28, P9881, DOI 10.1021/bi00452a001; IIZUKA N, 1987, VIROLOGY, V156, P64, DOI 10.1016/0042-6822(87)90436-3; JACOBSON SJ, 1993, J VIROL, V67, P2961, DOI 10.1128/JVI.67.6.2961-2971.1993; JORE J, 1988, J GEN VIROL, V69, P1627, DOI 10.1099/0022-1317-69-7-1627; LAMA J, 1994, J BIOL CHEM, V269, P66; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LARSEN GR, 1981, J VIROL, V37, P328, DOI 10.1128/JVI.37.1.328-335.1981; LEONG LEC, 1993, J BIOL CHEM, V268, P25735; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MIRZAYAN C, 1994, VIROLOGY, V199, P176, DOI 10.1006/viro.1994.1110; MOLLA A, 1994, J BIOL CHEM, V269, P27015; NICKLIN MJH, 1988, J VIROL, V62, P4586, DOI 10.1128/JVI.62.12.4586-4593.1988; NOMOTO A, 1977, NATURE, V268, P208, DOI 10.1038/268208a0; PILIPENKO EV, 1992, NUCLEIC ACIDS RES, V20, P1739, DOI 10.1093/nar/20.7.1739; RIVERA VM, 1988, VIROLOGY, V165, P42, DOI 10.1016/0042-6822(88)90656-3; SARNOW P, 1986, P NATL ACAD SCI USA, V83, P571, DOI 10.1073/pnas.83.3.571; SEMLER BL, 1983, VIROLOGY, V126, P624, DOI 10.1016/S0042-6822(83)80018-X; SEMLER BL, 1982, CELL, V28, P405, DOI 10.1016/0092-8674(82)90358-0; TAKEDA N, 1986, J VIROL, V60, P43, DOI 10.1128/JVI.60.1.43-53.1986; TAKEGAMI T, 1983, VIROLOGY, V128, P33, DOI 10.1016/0042-6822(83)90316-1; TAKEGAMI T, 1983, P NATL ACAD SCI-BIOL, V80, P7447, DOI 10.1073/pnas.80.24.7447; TOYODA H, 1987, J VIROL, V61, P2816, DOI 10.1128/JVI.61.9.2816-2822.1987; TRONO D, 1988, J VIROL, V62, P2291, DOI 10.1128/JVI.62.7.2291-2299.1988; WIMMER E, 1982, CELL, V28, P199, DOI 10.1016/0092-8674(82)90335-X; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033; YPMAWONG MF, 1988, VIROLOGY, V166, P265, DOI 10.1016/0042-6822(88)90172-9	39	223	229	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27004	27014						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929441				2022-12-27	WOS:A1994PQ93100064
J	JOKINEN, EV; LANDSCHULZ, KT; WYNE, KL; HO, YK; FRYKMAN, PK; HOBBS, HH				JOKINEN, EV; LANDSCHULZ, KT; WYNE, KL; HO, YK; FRYKMAN, PK; HOBBS, HH			REGULATION OF THE VERY-LOW-DENSITY LIPOPROTEIN RECEPTOR BY THYROID-HORMONE IN RAT SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; LDL RECEPTOR; LIPASE GENE; SEQUENCE; EXPRESSION; PROTEIN; CELLS; HYPOTHYROIDISM; ADIPOSE; RABBIT	A new member of the low density lipoprotein receptor gene family that binds and internalizes very low density lipoprotein (VLDL) particles was previously cloned and characterized from the rabbit and human. The physiological role of this putative VLDL receptor is not known, but its tissue distribution and ligand specificity suggest a possible role in the delivery of triglycerides to peripheral tissue. To learn more about the potential function of this receptor, we measured the changes in VLDL receptor mRNA and protein in various tissues following dietary or hormonal manipulation of rats. No significant changes in the VLDL receptor mRNA or protein were seen after a 48-h fast and subsequent to refeeding. A striking change in receptor mRNA and protein was ob served in skeletal muscle of hypothyroid and hyperthyroid rats. In hypothyroid rats, the amount of immunodetectable VLDL receptor was reduced by 80%, while in the hyperthyroid animals it was increased by 300%. These maneuvers did not affect VLDL receptor mRNA or protein levels in adipose tissue or heart. The changes in VLDL receptor mRNA in muscle were opposite to those observed with lipoprotein lipase. These studies suggest that the VLDL receptor plays a role in a metabolic process in muscle that is regulated by thyroid hormone.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	JOKINEN, EV (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-20948] Funding Source: Medline; NIGMS NIH HHS [GM 08014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAULT D, 1992, GENE, V121, P237, DOI 10.1016/0378-1119(92)90127-B; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN JC, 1992, GENOMICS, V14, P153, DOI 10.1016/S0888-7543(05)80298-8; COOPER DA, 1989, BIOCHIM BIOPHYS ACTA, V1008, P92, DOI 10.1016/0167-4781(89)90174-7; DAVIS CG, 1986, J BIOL CHEM, V261, P2828; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P4570; ERNEBACK S, 1988, GENE AMST, V64, P97; GAFVELS ME, 1993, SOMAT CELL MOLEC GEN, V19, P557, DOI 10.1007/BF01233382; GILL TJ, 1989, SCIENCE, V245, P269, DOI 10.1126/science.2665079; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; HERZ J, 1990, J BIOL CHEM, V265, P21355; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; KAJINAMI K, 1988, ARTERIOSCLEROSIS, V8, P187, DOI 10.1161/01.ATV.8.2.187; KIEFFER JD, 1974, ACTA ENDOCRINOL-COP, V76, P495; KIRCHGESSNER TG, 1989, J BIOL CHEM, V264, P1473; KOIVISTO PVI, 1992, ARTERIOSCLER THROMB, V12, P584, DOI 10.1161/01.ATV.12.5.584; KOVANEN PT, 1979, ENDOCRINOLOGY, V104, P610, DOI 10.1210/endo-104-3-610; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KUBISTA V, 1971, EUR J BIOCHEM, V18, P553, DOI 10.1111/j.1432-1033.1971.tb01276.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMAX RB, 1992, J ENDOCRINOL, V133, P375, DOI 10.1677/joe.0.1330375; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; Mayrand P E, 1992, Appl Theor Electrophor, V3, P1; MCALLISTER RM, 1991, AM J PHYSIOL, V260, pE272, DOI 10.1152/ajpendo.1991.260.2.E272; MEHTA KD, 1991, J BIOL CHEM, V266, P10406; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; OKA K, 1994, GENOMICS, V20, P298, DOI 10.1006/geno.1994.1171; REICHL D, 1973, CLIN SCI MOL MED, V45, P313, DOI 10.1042/cs0450313; SAFFARI B, 1992, J LIPID RES, V33, P241; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TORCZYNSKI R, 1983, NUCLEIC ACIDS RES, V11, P4879, DOI 10.1093/nar/11.14.4879; VANMIDDLESWORTH L, 1992, ENDOCRINOLOGY, V106, P1686; WEBB JC, 1994, HUM MOL GENET, V3, P531, DOI 10.1093/hmg/3.4.531; YAMAMOTO T, 1993, TRENDS CARDIOVAS MED, V3, P144, DOI 10.1016/1050-1738(93)90015-X; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	40	125	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26411	26418						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929362				2022-12-27	WOS:A1994PQ93000072
J	MUCHOWSKI, PJ; ZHANG, L; CHANG, ER; SOULE, HR; PLOW, EF; MOYLE, M				MUCHOWSKI, PJ; ZHANG, L; CHANG, ER; SOULE, HR; PLOW, EF; MOYLE, M			FUNCTIONAL INTERACTION BETWEEN THE INTEGRIN ANTAGONIST NEUTROPHIL INHIBITORY FACTOR AND THE I-DOMAIN OF CD11B/CD18	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT RECEPTOR TYPE-3; MONOCLONAL-ANTIBODIES; VONWILLEBRAND-FACTOR; CELLULAR ADHESION; RECOGNITION SITE; MAC-1; FIBRINOGEN; MONOCYTES; BINDING; LFA-1	Neutrophil inhibitory factor (NIF) is a hookworm-derived glycoprotein ligand of the integrin CD11b/ CD18 that inhibits human neutrophil function (Moyle, M., Foster, D. L., McGrath, D. E., Brown, S. M., Laroche, A., De Meutter, J., Stanssens, P., Bogowitz, C. A., Fried, V. A., Ely, J. A., Soule, H. R., and Vlasuk, G. P. (1994) J. Biol. Chem. 269, 10008-10015). Here, we present evidence that recombinant NIF (rNIF) associates with the similar to 200-amino acid residue I domain of CD11b/CD18 and that this interaction is essential for inhibition of neutrophil function by NIF. First, radiolabeled rNIF binds to a recombinant glutathione S-transferase fusion protein that contains the CD11b I domain. This high affinity interaction has a partial dependence on divalent cations. The association of rNIF with the CD11b I domain is specific because I-125-rNIF does not bind either a glutathione S-transferase fusion protein that contains the I domain of the integrin CD11a/CD18 or recombinant glutathione S-transferase without the I domain. Second, the CD11b I domain fusion protein effectively competes with CD11b/ CD18 on human neutrophils for I-125-rNIF binding. Third, the CD11b I domain fusion protein blocks the inhibition of certain neutrophil functions by rNIF, including adhesion of neutrophils to human endothelial cell monolayers and adhesion dependent release of hydrogen peroxide from neutrophils. Specificity is demonstrated by the inability of the CD11a I domain fusion protein to block either rNIF binding to neutrophils or rNIF activity. Fourth, rNIF blocks the interaction between neutrophils and fibrinogen, a CD11b/CD18 ligand that is also thought to bind the I domain of CD11b. In contrast, rNIF does not appear to block the binding of factor X to CD11b/CD18 on neutrophils. These results suggest that CD11b/CD18 has multiple distinct binding sites for its cognate ligands, including, but not limited to, the I domain. NIF interferes with the binding of a subset of these CD11b/CD18 ligands in a highly selective manner.	CORVAS INT INC,SAN DIEGO,CA 92121; CLEVELAND CLIN FDN,CTR THROMBOSIS & VASC BIOL,DEPT MOLEC CARDIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038292] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38292] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ALTIERI DC, 1990, J BIOL CHEM, V265, P12119; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ARNAOUT MA, 1983, J CLIN INVEST, V72, P171, DOI 10.1172/JCI110955; ARNAOUT MA, 1993, CURR OPIN HEMATOL, V1, P113; BILSLAND CAG, 1994, J IMMUNOL, V152, P4582; COLOMBATTI A, 1991, BLOOD, V77, P2305; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; KAMATA T, 1994, J BIOL CHEM, V269, P9659; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOYLE M, 1994, J BIOL CHEM, V269, P10008; MURRAY MJ, 1983, MOL CELL BIOL, V3, P32, DOI 10.1128/MCB.3.1.32; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	21	121	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26419	26423						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929363				2022-12-27	WOS:A1994PQ93000073
J	OTOOLE, GA; TRZEBIATOWSKI, JR; ESCALANTESEMERENA, JC				OTOOLE, GA; TRZEBIATOWSKI, JR; ESCALANTESEMERENA, JC			THE COBC GENE OF SALMONELLA-TYPHIMURIUM CODES FOR A NOVEL PHOSPHATASE INVOLVED IN THE ASSEMBLY OF THE NUCLEOTIDE LOOP OF COBALAMIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-B12 BIOSYNTHETIC GENES; PROSTATIC ACID-PHOSPHATASE; SITE-DIRECTED MUTAGENESIS; PHOSPHOGLYCERATE MUTASE; SEQUENCE-ANALYSIS; 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; TETRACYCLINE RESISTANCE; ESCHERICHIA-COLI; MUTANTS; CLONING	We report the identification of a new locus, designated cobC, involved in the assembly of the nucleotide loop of cobalamin in Salmonella typhimurium. The cobC gene has been mapped, cloned, and sequenced. DNA sequence analysis suggested that cobC is divergently transcribed from the adjacent cobD gene and suggests that the regulatory region of these genes overlap. The cobC gene codes for a predicted polypeptide of 26 kDa with striking homology to phosphoglycerate mutase, fructose-2,6-bisphosphatase, and acid phosphatase enzymes. In vitro experiments demonstrated that CobC dephosphorylated the cobalamin biosynthetic intermediate N-1-(5 phospho-alpha-D-ribosyl)-5,6-dimethylbenzimidazole to generate N-1-alpha-D-ribosyl-5,6-dimethylbenzimidazole. In vivo data showed that the lack of cobC function blocks the synthesis of cobalamin from its precursors cobinamide and 5,6-dimethylbenzimidazole, i.e. it prevents the assembly of the nucleotide loop of cobalamin. Additionally, exogenous N-1-alpha-D-ribosyl-5,6-dimethylbenzimidazole rescues the defect of a cobC mutant. We propose that cobC codes for a novel phosphatase whose primary role is in cobalamin biosynthesis. A model for the sequence of biosynthetic steps that as semble the nucleotide loop of cobalamin in S. typhimurium is presented.	UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [R01 GM040313, GM40313] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040313, R37GM040313] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1988, MOL REPROD DEV; BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; BENSON NR, 1992, J BACTERIOL, V174, P1673, DOI 10.1128/jb.174.5.1673-1681.1992; BOCHNER BR, 1980, J BACTERIOL, V143, P926, DOI 10.1128/JB.143.2.926-933.1980; BROWN KL, 1984, INORG CHEM, V23, P1463, DOI 10.1021/ic00178a032; CAMERON B, 1991, J BACTERIOL, V173, P6066, DOI 10.1128/jb.173.19.6066-6073.1991; CASTELLAESCOLA J, 1989, BIOCHEM BIOPH RES CO, V165, P1345, DOI 10.1016/0006-291X(89)92751-4; CHANG GW, 1975, NATURE, V254, P150, DOI 10.1038/254150a0; COLOSIA AD, 1987, BIOCHEM BIOPH RES CO, V143, P1092, DOI 10.1016/0006-291X(87)90364-0; CROUZET J, 1990, J BACTERIOL, V172, P5980, DOI 10.1128/jb.172.10.5980-5990.1990; DAVIES WD, 1982, NUCLEIC ACIDS RES, V10, P4045, DOI 10.1093/nar/10.13.4045; DAVIS RW, 1980, MANUAL GENETIC ENG A; ESCALANTESEMERENA JC, 1992, J BACTERIOL, V174, P24, DOI 10.1128/jb.174.1.24-29.1992; ESCALANTESEMERENA JC, 1987, J BACTERIOL, V169, P2251, DOI 10.1128/jb.169.5.2251-2258.1987; ESCALANTESEMERENA JC, 1990, J BACTERIOL, V172, P273, DOI 10.1128/JB.172.1.273-280.1990; FRIEDMAN.HC, 1965, J BIOL CHEM, V240, P413; FYFE JA, 1969, J BIOL CHEM, V244, P1659; GRABAU C, 1992, J BACTERIOL, V174, P2138, DOI 10.1128/JB.174.7.2138-2144.1992; HICKEY ME, 1973, ARCH BIOCHEM BIOPHYS, V153, P423; JETER RM, 1987, J BACTERIOL, V169, P3189, DOI 10.1128/jb.169.7.3189-3198.1987; JOHNSON MG, 1992, J BIOL CHEM, V267, P13302; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALOY SR, 1981, J BACTERIOL, V145, P1110, DOI 10.1128/JB.145.2.1110-1111.1981; Maniatis T., 1982, MOL CLONING; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; MCTIGUE JJ, 1978, BIOCHIM BIOPHYS ACTA, V523, P407, DOI 10.1016/0005-2744(78)90043-8; OSTANIN K, 1992, J BIOL CHEM, V267, P22830; OTOOLE GA, 1993, J BACTERIOL, V175, P6328, DOI 10.1128/JB.175.19.6328-6336.1993; OTOOLE GA, 1993, J BACTERIOL, V175, P3317, DOI 10.1128/jb.175.11.3317-3326.1993; PARAVICINI G, 1992, BIOCHEMISTRY-US, V31, P7126, DOI 10.1021/bi00146a014; ROOF DM, 1988, J BACTERIOL, V170, P3855, DOI 10.1128/jb.170.9.3855-3863.1988; ROTH JR, 1993, J BACTERIOL, V175, P3303, DOI 10.1128/jb.175.11.3303-3316.1993; SAKATA J, 1990, P NATL ACAD SCI USA, V87, P4951, DOI 10.1073/pnas.87.13.4951; SCHMIEGER H, 1973, MOL GEN GENET, V120, P181, DOI 10.1007/BF00267246; SCHMIEGER H, 1971, MOL GEN GENET, V100, P378; SHANSKE S, 1987, J BIOL CHEM, V262, P14612; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUH SJ, 1993, GENE, V129, P93, DOI 10.1016/0378-1119(93)90701-4; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TABOR S, 1990, CURRENT PROTOCOLS MO; TAULER A, 1990, J BIOL CHEM, V265, P15617; TAYLOR RT, 1973, ENZYMES; TRZEBIATOWSKI JR, 1994, J BACTERIOL, V176, P3568, DOI 10.1128/JB.176.12.3568-3575.1994; VANETTEN RL, 1991, J BIOL CHEM, V266, P2313; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X; WHITE PJ, 1992, J BACTERIOL, V174, P434, DOI 10.1128/jb.174.2.434-440.1992	47	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26503	26511						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929373				2022-12-27	WOS:A1994PQ93000086
J	OUTRAM, SV; OWEN, MJ				OUTRAM, SV; OWEN, MJ			THE HELIX-LOOP-HELIX CONTAINING TRANSCRIPTION FACTOR USF ACTIVATES THE PROMOTER OF THE CD2 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE THY-1 GENE; NON-TATA PROMOTER; PROTEIN-KINASE-C; TRANSGENIC MICE; FUNCTIONAL DOMAINS; SURFACE-ANTIGENS; ZIPPER PROTEIN; EXPRESSION; MAX; MYC	T cell development within the thymus involves the ordered expression of a number of tissue-specific components such as the CD2 gene. Control of expression of this gene is regulated by a well characterized 3' enhancer together with a promoter and upstream elements. The CD2 promoter is typical of a group of T cell-specific promoters that lack a TATA box and use multiple sites for initiation of transcription. An ''E box'' motif CACGTG, located just upstream from the most 5' initiation start site, was found to contribute a major effect to the level of basal transcription of a reporter gene. Analysis of the proteins in T cell extracts that bound to this site revealed that the bHLH-LZ protein USF was the major component. A functional role for USF was established in transient transfection experiments. Thus, this protein restored full promoter activity following repression caused by cotransfection with the E box binding bHLH-LZ protein Max. Taken together, these results indicate that an E box motif is critical to expression of the CD2 gene during T cell development and that the HLH protein USF acts as a transcriptional activator of the CD2 promoter.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK								AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CANN AJ, 1988, ONCOGENE, V3, P123; CANTRELL DA, 1988, EUR J IMMUNOL, V18, P1391, DOI 10.1002/eji.1830180914; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CLEVERS HC, 1988, P NATL ACAD SCI USA, V85, P8156, DOI 10.1073/pnas.85.21.8156; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISANTO JP, 1993, EUR J IMMUNOL, V23, P320, DOI 10.1002/eji.1830230203; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KRENSKY AM, 1983, J IMMUNOL, V131, P611; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAKE RA, 1990, EMBO J, V9, P3129, DOI 10.1002/j.1460-2075.1990.tb07510.x; LANG G, 1988, EMBO J, V7, P1675, DOI 10.1002/j.1460-2075.1988.tb02995.x; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; MONOSTORI E, 1991, IMMUNOLOGY, V74, P369; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MURAGUCHI A, 1992, INT IMMUNOL, V4, P841, DOI 10.1093/intimm/4.8.841; OWEN MJ, 1988, EUR J IMMUNOL, V18, P187, DOI 10.1002/eji.1830180129; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHANBERG LE, 1991, P NATL ACAD SCI USA, V88, P603, DOI 10.1073/pnas.88.2.603; SEN J, 1989, EUR J IMMUNOL, V19, P1297, DOI 10.1002/eji.1830190722; Sirito Mario, 1992, Gene Expression, V2, P231; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SPANOPOULOU E, 1991, MOL CELL BIOL, V11, P2216, DOI 10.1128/MCB.11.4.2216; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; TUNNACLIFFE A, 1987, EMBO J, V6, P2953, DOI 10.1002/j.1460-2075.1987.tb02600.x; TUNNACLIFFE A, 1986, EMBO J, V5, P1245, DOI 10.1002/j.1460-2075.1986.tb04353.x; WOTTON D, 1993, J BIOL CHEM, V268, P17975; WOTTON D, 1989, P NATL ACAD SCI USA, V86, P4195, DOI 10.1073/pnas.86.11.4195; YAGITA H, 1989, P NATL ACAD SCI USA, V86, P645, DOI 10.1073/pnas.86.2.645; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	46	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26525	26530						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929376				2022-12-27	WOS:A1994PQ93000089
J	WONG, AKC; DELAFAILLE, MAC; WIRTH, DF				WONG, AKC; DELAFAILLE, MAC; WIRTH, DF			IDENTIFICATION OF A CIS-ACTING GENE REGULATORY ELEMENT FROM THE LEMDR1 LOCUS OF LEISHMANIA-ENRIETTI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRYPANOSOMA-BRUCEI; LARGEST SUBUNIT; STABLE TRANSFECTION; EXPRESSION SITE; MESSENGER-RNAS; PROMOTER; DNA; SEQUENCES; PROTEIN	The goal of this work is to identify those elements which control gene expression in the parasitic protozoan, Leishmania enriettii. To date there has been no report of a transcriptional controlling element identified in this parasite. In the present study, we have found that a region of the lemdr1 locus of L. enriettii can down-regulate the steady state mRNA level of the reporter neomycin phosphotransferase gene when it is placed in an extrachromosomal expression vector, pALTneo. Through deletion analysis, we have mapped a putative regulatory sequence to the flanking region upstream of the lemdr1 gene. This cis regulatory element is shown to control gene expression in an orientation-dependent and position independent manner. By performing nuclear run on analysis, we have demonstrated that this element mainly exerts its effect at the transcriptional level by determining the strandedness of transcription on the pALTneo vector. The identification of this novel cis regulatory element should further our understanding of the transcriptional process in Leishmania and other related trypanosomatids.	HARVARD UNIV,SCH PUBL HLTH,DEPT TROP PUBL HLTH,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI027872, R01AI027872, R01AI021365] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-27872, AI-21365] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHARONI A, 1993, NUCLEIC ACIDS RES, V21, P5221, DOI 10.1093/nar/21.22.5221; ALY R, 1993, GENE, V127, P155, DOI 10.1016/0378-1119(93)90714-E; BELLOFATTO V, 1991, P NATL ACAD SCI USA, V88, P6711, DOI 10.1073/pnas.88.15.6711; BENAMAR MF, 1991, NUCLEIC ACIDS RES, V19, P5857, DOI 10.1093/nar/19.21.5857; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; CHOW LMC, 1993, MOL BIOCHEM PARASIT, V60, P195, DOI 10.1016/0166-6851(93)90131-G; CHUNG HMM, 1993, MOL CELL BIOL, V13, P3734, DOI 10.1128/MCB.13.6.3734; DELAFAILLE MAC, 1992, J BIOL CHEM, V267, P23839; DELAFAILLE MAC, 1992, P NATL ACAD SCI USA, V89, P2703, DOI 10.1073/pnas.89.7.2703; DIETRICH P, 1993, GENE, V125, P103, DOI 10.1016/0378-1119(93)90753-P; DONELSON JE, 1990, PARASITOL TODAY, V6, P327, DOI 10.1016/0169-4758(90)90177-6; EVERS R, 1989, CELL, V56, P585, DOI 10.1016/0092-8674(89)90581-3; FANTONI A, 1994, MOL CELL BIOL, V14, P2021, DOI 10.1128/MCB.14.3.2021; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GRONDAL EJM, 1989, EMBO J, V8, P3383, DOI 10.1002/j.1460-2075.1989.tb08502.x; HEHL A, 1994, P NATL ACAD SCI USA, V91, P370, DOI 10.1073/pnas.91.1.370; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIGUCHI RG, 1989, NUCLEIC ACIDS RES, V17, P5865, DOI 10.1093/nar/17.14.5865; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; HUANG J, 1991, EMBO J, V10, P3877, DOI 10.1002/j.1460-2075.1991.tb04957.x; HUG M, 1993, MOL BIOCHEM PARASIT, V61, P87, DOI 10.1016/0166-6851(93)90161-P; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KAPOTAS N, 1993, NUCLEIC ACIDS RES, V21, P4067, DOI 10.1093/nar/21.17.4067; KOCK J, 1988, NUCLEIC ACIDS RES, V16, P8753, DOI 10.1093/nar/16.18.8753; KOOTER JM, 1987, CELL, V51, P261, DOI 10.1016/0092-8674(87)90153-X; LABAN A, 1990, NATURE, V343, P572, DOI 10.1038/343572a0; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996; LEE MGS, 1990, SCIENCE, V250, P1583, DOI 10.1126/science.2177225; LIU X, 1992, P NATL ACAD SCI USA, V89, P4991, DOI 10.1073/pnas.89.11.4991; PERRY K, 1991, EXPERIENTIA, V47, P118, DOI 10.1007/BF01945412; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERMAN DR, 1991, EMBO J, V10, P3379, DOI 10.1002/j.1460-2075.1991.tb04902.x; TSCHUDI C, 1990, CELL, V61, P459, DOI 10.1016/0092-8674(90)90527-L; TSCHUDI C, 1988, EMBO J, V7, P455, DOI 10.1002/j.1460-2075.1988.tb02833.x; WEBB JR, 1993, J BIOL CHEM, V268, P13994; WILSON ME, 1993, J BIOL CHEM, V268, P15731; WONG AKC, 1994, MOL BIOCHEM PARASIT, V64, P75, DOI 10.1016/0166-6851(94)90136-8; YEE HA, 1991, NUCLEIC ACIDS RES, V19, P949, DOI 10.1093/nar/19.4.949; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P5153, DOI 10.1093/nar/19.19.5153	41	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26497	26502						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929372				2022-12-27	WOS:A1994PQ93000085
J	BUSCH, AE; HERZER, T; WALDEGGER, S; SCHMIDT, F; PALACIN, M; BIBER, J; MARKOVICH, D; MURER, H; LANG, F				BUSCH, AE; HERZER, T; WALDEGGER, S; SCHMIDT, F; PALACIN, M; BIBER, J; MARKOVICH, D; MURER, H; LANG, F			OPPOSITE DIRECTED CURRENTS INDUCED BY THE TRANSPORT OF DIBASIC AND NEUTRAL AMINO-ACIDS IN XENOPUS OOCYTES EXPRESSING THE PROTEIN RBAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAEVIS OOCYTES; KIDNEY; CLONING; CYSTINE; SYSTEM; CDNA; AFFINITY; RECEPTOR	Voltage- and current-clamp studies have been performed on a renal and intestinal protein (rBAT) which induces transport for neutral and dibasic amino acids when expressed in Xenopus oocytes. In current-clamp mode, superfusion with L-leucine caused a hyperpolarization while superfusion with L-arginine depolarized the oocyte. Accordingly, in voltage-clamp experiments dibasic amino acids and neutral amino acids induced inward and outward currents, respectively. The relationship between currents and substrate concentrations could be fitted by simple Michaelis Menten kinetics. Currents induced by L-arginine and L-leucine were also voltage-dependent, pH changes from 6.25 to 8.75 did not affect the currents induced by saturating concentrations of L-arginine and L-leucine, but reversed the direction of L-histidine-induced currents from inward to outward. The reversal potentials as well as the apparent K-m for L-histidine-induced currents were altered by the ambient pH. Currents induced by individual amino acids decreased during extended superfusion periods. However, extended superfusion with neutral amino acids increased dibasic amino acid induced currents, while prior superfusion with dibasic amino acid resulted in an increase of currents induced by neutral amino acids. The reversal potentials for L-leucine- and L-arginine-induced currents were depending on their intra- (after preloading) and extracellular concentrations. In conclusion, rBAT mediated transport of neutral and dibasic amino acids is associated with net outward or inward currents, respectively, which may be caused by an exchange of neutral with dibasic amino acids.	UNIV ZURICH,INST PHYSIOL,CH-8057 ZURICH,SWITZERLAND; UNIV BARCELONA,DEPT BIOCHEM & PHYSIOL,E-08028 BARCELONA,SPAIN	University of Zurich; University of Barcelona	BUSCH, AE (corresponding author), UNIV TUBINGEN,INST PHYSIOL,GMELINSTR 5,D-72076 TUBINGEN,GERMANY.		Markovich, Daniel/F-7884-2012; Palacín, Manuel/G-9786-2015	Palacin, Manuel/0000-0002-8670-293X				BERTRAN J, 1994, CELL PHYSIOL BIOCHEM, V4, P217, DOI 10.1159/000154728; BERTRAN J, 1993, J BIOL CHEM, V268, P14842; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; BUSCH AE, 1992, J PHYSIOL-LONDON, V450, P491, DOI 10.1113/jphysiol.1992.sp019138; CALONGE MT, 1994, NAT GENET, V6, P420, DOI 10.1038/ng0494-420; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; FURRIOLS M, 1993, J BIOL CHEM, V268, P27060; JUNG D, 1983, CELL BIOL INT REP, V7, P697, DOI 10.1016/0309-1651(83)90198-4; KANAI Y, 1992, AM J PHYSIOL, V263, pF1087, DOI 10.1152/ajprenal.1992.263.6.F1087; KAVANAUGH MP, 1993, BIOCHEMISTRY-US, V32, P5781, DOI 10.1021/bi00073a009; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; LEE WS, 1993, J CLIN INVEST, V91, P1959, DOI 10.1172/JCI116415; MIRCHEFF AK, 1982, J MEMBRANE BIOL, V64, P113, DOI 10.1007/BF01870773; MOSCKOVITZ R, 1993, P NATL ACAD SCI USA, V90, P4022, DOI 10.1073/pnas.90.9.4022; SILBERNAGL S, 1988, PHYSIOL REV, V68, P911, DOI 10.1152/physrev.1988.68.3.911; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; VANWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5606	20	74	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25581	25586						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929260				2022-12-27	WOS:A1994PQ49100055
J	SUTER, U; SNIPES, GJ; SCHOENERSCOTT, R; WELCHER, AA; PAREEK, S; LUPSKI, JR; MURPHY, RA; SHOOTER, EM; PATEL, PI				SUTER, U; SNIPES, GJ; SCHOENERSCOTT, R; WELCHER, AA; PAREEK, S; LUPSKI, JR; MURPHY, RA; SHOOTER, EM; PATEL, PI			REGULATION OF TISSUE-SPECIFIC EXPRESSION OF ALTERNATIVE PERIPHERAL MYELIN PROTEIN-22 (PMP22) GENE TRANSCRIPTS BY 2 PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOOTH DISEASE TYPE-1A; SCHWANN-CELL EXPRESSION; ARREST-SPECIFIC GENE; TREMBLER-J MOUSE; POINT MUTATION; GROWTH ARREST; CYCLIC-AMP; FUNCTIONAL-ANALYSIS; MAMMALIAN-CELLS; NERVOUS-SYSTEM	Mutations affecting the peripheral myelin protein-22 (PMP22) gene have been shown to be associated with inherited peripheral neuropathies. To provide the molecular basis for the analysis of such mutations, we have cloned and characterized the human PMP22 gene. It spans approximately 40 kilobases and contains four coding exons. Detailed analysis of its 5'-flanking region suggested the presence of two alternatively transcribed, but untranslated exons. Mapping of separate PMP22 mRNA transcription initiation sites to each of these exons indicates that PMP22 expression is regulated by two alternatively used promoters. In support of this hypothesis, both putative promoter sequences demonstrated the ability to drive expression of reporter genes in transfection experiments. Furthermore, the structures of the 5'-portions of the PMP22 genes appear to be identical in rat and human, supporting the biological significance of the observed arrangement of regulatory regions. The relative expression of the alternative PMP22 transcripts is tissue-specific, and high levels of the exon 1A-containing transcript are tightly coupled to myelin formation. In contrast, exon 1B-containing transcripts are predominant in non-neural tissues and in growth-arrested primary fibroblasts. Interestingly, although a strong upregulation of PMP22 mRNA was observed in cultured Schhwann cells in the presence of the adenylate cyclase activator forskolin under various culture conditions, the regulation of the different PMP22 mRNA species did not mimic the regulation that occurs during myelin formation in vivo. The observed regulation of the PMP22 gene by a complex molecular mechanism is consistent with the proposed dual role of PMP22 in neural and non-neural tissue.	STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROPATHOL,STANFORD,CA 94305; BAYLOR COLL MED,DEPT NEUROL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; BAYLOR COLL MED,CTR HUMAN GENOME,HOUSTON,TX 77030; MCGILL UNIV,MONTREAL NEUROL INST,MONTREAL H3A 2B4,PQ,CANADA	Stanford University; Stanford University; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; McGill University	SUTER, U (corresponding author), ETH HONGGERBERG,DEPT CELL BIOL,CH-8093 ZURICH,SWITZERLAND.		Suter, Ueli/A-1624-2010; Patel, Pragna/H-9129-2017	Patel, Pragna/0000-0003-3584-1072	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001559, R01NS027042, R01NS004270] Funding Source: NIH RePORTER; NINDS NIH HHS [NS27042, NS01559, NS04270] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AOYAMA A, 1990, BIOCHEM BIOPH RES CO, V167, P648, DOI 10.1016/0006-291X(90)92074-A; BERNDT JA, 1992, J BIOL CHEM, V267, P14730; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; CHANCE PF, 1993, CELL, V72, P143, DOI 10.1016/0092-8674(93)90058-X; CHEN M, 1993, J BIOL CHEM, V268, P24138; CHERBAS L, 1993, INSECT BIOCHEM MOLEC, V23, P81, DOI 10.1016/0965-1748(93)90085-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELEON M, 1991, J NEUROSCI RES, V29, P437; EDOMI P, 1993, GENE, V126, P289, DOI 10.1016/0378-1119(93)90384-F; FORS L, 1993, J NEUROCHEM, V60, P513, DOI 10.1111/j.1471-4159.1993.tb03179.x; FUSCOE JC, 1983, MOL CELL BIOL, V3, P1086, DOI 10.1128/MCB.3.6.1086; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOW A, 1992, J CELL BIOL, V119, P605, DOI 10.1083/jcb.119.3.605; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAYASAKA K, 1992, BIOCHEM BIOPH RES CO, V186, P827, DOI 10.1016/0006-291X(92)90820-B; HOOGENDIJK JE, 1992, LANCET, V339, P1081, DOI 10.1016/0140-6736(92)90668-S; HORIUCHI T, 1990, J BIOL CHEM, V265, P6521; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IONASESCU VV, 1993, MUSCLE NERVE, V16, P1232, DOI 10.1002/mus.880161114; KITAMURA K, 1976, BIOCHIM BIOPHYS ACTA, V455, P806, DOI 10.1016/0005-2736(76)90050-X; KUHN G, 1993, GLIA, V8, P256, DOI 10.1002/glia.440080406; LEMKE G, 1988, NEURON, V1, P73, DOI 10.1016/0896-6273(88)90211-5; LEMKE G, 1988, DEVELOPMENT, V102, P499; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUPSKI JR, 1993, JAMA-J AM MED ASSOC, V270, P2326, DOI 10.1001/jama.270.19.2326; LUPSKI JR, 1992, NAT GENET, V1, P29, DOI 10.1038/ng0492-29; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; MACKLIN WB, 1987, J NEUROSCI RES, V18, P383, DOI 10.1002/jnr.490180302; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MATSUNAMI N, 1992, NAT GENET, V1, P176, DOI 10.1038/ng0692-176; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MORGAN L, 1991, J CELL BIOL, V112, P457, DOI 10.1083/jcb.112.3.457; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAVE KA, 1991, J NEUROSCI, V11, P3060; NICHOLSON GA, 1994, NAT GENET, V6, P263, DOI 10.1038/ng0394-263; NIELSEN FC, 1990, J BIOL CHEM, V265, P13431; OWENS GC, 1990, J CELL BIOL, V111, P1171, DOI 10.1083/jcb.111.3.1171; PAREEK S, 1993, J BIOL CHEM, V268, P10372; PATEL PI, 1994, TRENDS GENET, V10, P128, DOI 10.1016/0168-9525(94)90214-3; PATEL PI, 1992, NAT GENET, V1, P159, DOI 10.1038/ng0692-159; POLITIS MJ, 1982, J NEUROSCI, V2, P1252; Raeymaekers P, 1991, Neuromuscul Disord, V1, P93, DOI 10.1016/0960-8966(91)90055-W; ROA BB, 1993, AM J MED SCI, V306, P177, DOI 10.1097/00000441-199309000-00010; ROA BB, 1993, NAT GENET, V5, P189, DOI 10.1038/ng1093-189; ROA BB, 1993, NEW ENGL J MED, V329, P96, DOI 10.1056/NEJM199307083290205; ROA BB, 1993, NAT GENET, V5, P269, DOI 10.1038/ng1193-269; SCHNEIDER A, 1992, NATURE, V358, P758, DOI 10.1038/358758a0; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; Snipes G J, 1993, Curr Opin Neurobiol, V3, P694; SNIPES GJ, 1992, J CELL BIOL, V117, P225, DOI 10.1083/jcb.117.1.225; SOBUE G, 1986, BRAIN RES, V362, P23, DOI 10.1016/0006-8993(86)91394-6; SPREYER P, 1991, EMBO J, V10, P3661, DOI 10.1002/j.1460-2075.1991.tb04933.x; SUTER U, 1994, HUM MUTAT, V3, P95, DOI 10.1002/humu.1380030203; SUTER U, 1993, TRENDS NEUROSCI, V16, P50, DOI 10.1016/0166-2236(93)90015-E; SUTER U, 1992, P NATL ACAD SCI USA, V89, P4382, DOI 10.1073/pnas.89.10.4382; SUTER U, 1992, NATURE, V356, P241, DOI 10.1038/356241a0; TAMURA T, 1988, NUCLEIC ACIDS RES, V16, P11441, DOI 10.1093/nar/16.24.11441; TIMMERMAN V, 1992, NAT GENET, V1, P171, DOI 10.1038/ng0692-171; VALENTIJN LJ, 1992, NAT GENET, V2, P288, DOI 10.1038/ng1292-288; VALENTIJN LJ, 1992, NAT GENET, V1, P166, DOI 10.1038/ng0692-166; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P7195, DOI 10.1073/pnas.88.16.7195; WISE CA, 1993, AM J HUM GENET, V53, P853; WOODS A, 1992, J CELL SCI, V101, P277; ZHANG XP, 1993, J NEUROCHEM, V60, P2010, DOI 10.1111/j.1471-4159.1993.tb03485.x	64	164	167	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25795	25808						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929285				2022-12-27	WOS:A1994PQ49100084
J	URBAN, RJ; SHUPNIK, MA; BODENBURG, YH				URBAN, RJ; SHUPNIK, MA; BODENBURG, YH			INSULIN-LIKE GROWTH-FACTOR-I INCREASES EXPRESSION OF THE PORCINE P-450 CHOLESTEROL SIDE-CHAIN CLEAVAGE GENE THROUGH A GC-RICH DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYSTIC-OVARY-SYNDROME; FOLLICLE-STIMULATING-HORMONE; MESSENGER-RIBONUCLEIC-ACID; SWINE GRANULOSA-CELLS; BOX-BINDING-PROTEINS; HUMAN SOMATOMEDIN-C; TUMOR-CELLS; DEVELOPMENTAL REGULATION; PRIMARY CULTURES; PROMOTER REGION	The promoter/regulatory region of the porcine P-450 cholesterol side chain cleavage (P450scc) gene was cloned from a porcine genomic library. This gene contains a GC-rich region (-130-100) that mediates insulinlike growth factor I (IGF-I) and cAMP stimulation of gene expression in porcine granulosa cells. Stimulation of gene expression by cAMP occurs in 6 h, while IGF-I stimulation occurs in 24-48 h. This region is also responsive to insulin but not fibroblast growth factor. The effects of IGF-I and cAMP on gene expression in porcine granulosa cells are additive. In Y1 adrenal cells, the same region is responsive to cAMP but not to IGF-I. Gel shift assays using an oligonucleotide of this region and nuclear extract protein from porcine granulosa and Y1 adrenal cells identified three DNA protein complexes (C-1-C-3). The binding activity of the complexes did not change with IGF-I or forskolin treatment of granulosa cells. Mutational analysis results were consistent with IGF-I regulating gene expression through the C-2 DNA protein complex. Moreover, this complex binds differently in gel shift assay to mutant oligonucleotides with porcine and Y1 and nuclear extract protein. We conclude that IGF-I stimulates porcine P450scc gene expression through a distinct, cell-specific protein complex binding to a GC-rich domain.	UNIV VIRGINIA,DEPT INTERNAL MED,DIV ENDOCRINOL,CHARLOTTESVILLE,VA 22908	University of Virginia	URBAN, RJ (corresponding author), UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,DIV ENDOCRINOL,3142 MRB,1060,GALVESTON,TX 77555, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028393] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038942] Funding Source: NIH RePORTER; NCRR NIH HHS [2S07 RR05427-30] Funding Source: Medline; NICHD NIH HHS [HD28393] Funding Source: Medline; NIDDK NIH HHS [DK 38942] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADASHI EY, 1985, ENDOCRINOLOGY, V116, P2135, DOI 10.1210/endo-116-6-2135; ADASHI EY, 1993, ANN NY ACAD SCI, V687, P10; ADASHI EY, 1985, ENDOCR REV, V6, P400, DOI 10.1210/edrv-6-3-400; AHLGREN R, 1990, J BIOL CHEM, V265, P3313; ALEMANY J, 1992, BIOCHEM BIOPH RES CO, V183, P659, DOI 10.1016/0006-291X(92)90533-Q; ALEMANY J, 1990, P NATL ACAD SCI USA, V87, P3353, DOI 10.1073/pnas.87.9.3353; Arber W., 1983, LAMBDA; BARNES R, 1989, ANN INTERN MED, V110, P386, DOI 10.7326/0003-4819-110-5-386; BEGEOT M, 1993, J BIOL CHEM, V268, P17317; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERGH C, 1991, ACTA ENDOCRINOL-COP, V125, P177, DOI 10.1530/acta.0.1250177; BRASIER AR, 1991, METHODS NEUROSCI, V5, P108; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHUNG B, 1986, P NATL ACAD SCI USA, V83, P8962, DOI 10.1073/pnas.83.23.8962; CIARALDI TP, 1992, J CLIN ENDOCR METAB, V75, P577, DOI 10.1210/jc.75.2.577; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DOMDEY H, 1984, CELL, V39, P611, DOI 10.1016/0092-8674(84)90468-9; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; FUNKENSTEIN B, 1984, J BIOL CHEM, V259, P8572; GOLDRING NB, 1987, ENDOCRINOLOGY, V120, P1942, DOI 10.1210/endo-120-5-1942; GUO IC, 1994, J BIOL CHEM, V269, P6362; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HATEY F, 1992, J STEROID BIOCHEM, V43, P869, DOI 10.1016/0960-0760(92)90314-9; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; INOUE H, 1991, EUR J BIOCHEM, V195, P563, DOI 10.1111/j.1432-1033.1991.tb15738.x; INOUE H, 1988, EUR J BIOCHEM, V171, P435, DOI 10.1111/j.1432-1033.1988.tb13808.x; JOHN ME, 1984, P NATL ACAD SCI-BIOL, V81, P5628, DOI 10.1073/pnas.81.18.5628; KAHN CR, 1993, RECENT PROG HORM RES, V48, P291; KAMIKUBO K, 1990, MOL ENDOCRINOL, V4, P2021, DOI 10.1210/mend-4-12-2021; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KAZER RR, 1990, J CLIN ENDOCR METAB, V71, P958, DOI 10.1210/jcem-71-4-958; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KNOLL BJ, 1983, NUCLEIC ACIDS RES, V11, P6733, DOI 10.1093/nar/11.19.6733; LAATIKAINEN T, 1993, ANN NY ACAD SCI, V687, P90; LARA HE, 1993, ENDOCRINOLOGY, V133, P2690, DOI 10.1210/en.133.6.2690; LAUBER ME, 1993, MOL CELL ENDOCRINOL, V94, P235, DOI 10.1016/0303-7207(93)90172-G; LOWE WL, 1987, P NATL ACAD SCI USA, V84, P8946, DOI 10.1073/pnas.84.24.8946; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MOORE CCD, 1990, MOL CELL BIOL, V10, P6013, DOI 10.1128/MCB.10.11.6013; MOROHASHI K, 1987, J BIOCHEM-TOKYO, V101, P879, DOI 10.1093/oxfordjournals.jbchem.a121955; MULHERON GW, 1989, NUCLEIC ACIDS RES, V17, P1773, DOI 10.1093/nar/17.4.1773; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OONK RB, 1990, J BIOL CHEM, V265, P22392; REIN M S, 1982, Biology of Reproduction, V26, p113A; RICE DA, 1990, J BIOL CHEM, V265, P11713; RICH CB, 1993, BIOCHEM BIOPH RES CO, V196, P1316, DOI 10.1006/bbrc.1993.2396; ROSENBAUM D, 1993, AM J PHYSIOL, V264, pE197, DOI 10.1152/ajpendo.1993.264.2.E197; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIMMER BP, 1985, METHOD ENZYMOL, V109, P350; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SIMPSON ER, 1990, MOL CELL ENDOCRINOL, V70, pC25, DOI 10.1016/0303-7207(90)90151-W; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; URBAN RJ, 1990, ENDOCRINOLOGY, V127, P2481, DOI 10.1210/endo-127-5-2481; URBAN RJ, 1991, ENDOCRINOLOGY, V128, P2000, DOI 10.1210/endo-128-4-2000; VELDHUIS JD, 1985, BIOCHEM BIOPH RES CO, V130, P234, DOI 10.1016/0006-291X(85)90407-3; VELDHUIS JD, 1985, ENDOCRINOLOGY, V116, P1235, DOI 10.1210/endo-116-4-1235; VELDHUIS JD, 1986, ENDOCRINOLOGY, V119, P530, DOI 10.1210/endo-119-2-530; VELDHUIS TD, 1984, BIOCHEM BIOPH RES CO, V120, P144, DOI 10.1016/0006-291X(84)91425-6; VOSS JW, 1993, MOL ENDOCRINOL, V7, P1551, DOI 10.1210/me.7.12.1551; WERNER H, 1989, P NATL ACAD SCI USA, V86, P7451, DOI 10.1073/pnas.86.19.7451; WHITE MF, 1994, J BIOL CHEM, V269, P1; WOLFE BL, 1993, J BIOL CHEM, V268, P12418; WONG M, 1989, J BIOL CHEM, V264, P12867	65	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25761	25769						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929280				2022-12-27	WOS:A1994PQ49100079
J	SOREGHAN, B; KOSMOSKI, J; GLABE, C				SOREGHAN, B; KOSMOSKI, J; GLABE, C			SURFACTANT PROPERTIES OF ALZHEIMERS A-BETA PEPTIDES AND THE MECHANISM OF AMYLOID AGGREGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LYSOSOMOTROPIC DETERGENTS; SECONDARY STRUCTURE; DISEASE; PROTEIN; INVITRO; PATHOGENESIS; DEPOSITION; TOXICITY; FIBRILS; ANALOGS	The major proteinaceous component of amyloid deposits associated with Alzheimer's disease is a self-assembling 40-42-residue peptide, known as A beta, which is generated by the proteolytic processing of the amyloid precursor protein (Kang, J., Lemaire, H. G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K. H., Multhaup, G., Beyreuther, K., and Muller-Hill, B. (1987) Nature 325, 733-736; Haass, C., Hung, A. Y., Schlossmacher, M. G., Oltersdorf, T., Teplow, D. B., and Selkoe, D. J. (1993) Ann. N. Y.: Acad. Sci. 695, 109-116; Estus, S., Golde, T. E., and Younkin S. G. (1992) Ann. N. Y. Acad. Sci. 674, 138-148) and is implicated as one of the causal factors in the pathology of the disease. A beta is now shown to display properties commonly associated with surfactants or detergents, which form micelles in solution. Increasing concentrations of A beta lower the surface tension of water up to a critical concentration, above which little further decrease in surface tension is observed. At concentrations above this critical concentration, increasing amounts of non-covalent aggregates of A beta are observed. A beta aggregation is also correlated with the formation of a hydrophobic environment that excludes water. The extent of this hydrophobic environment, as reflected by the partitioning of hydrophobic fluorescent probes, is much higher for the longer A beta 1-42 isoform, which may be more intimately associated with Alzheimer's disease pathology than A beta 1-40. Although the solution structure of A beta is not yet known, these results suggest that the structure of A beta has the same type of axial amphipathic organization as detergent molecules and that the same principles that govern micelle formation may also apply to A beta aggregation and amyloid fibril self-assembly.	UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717	University of California System; University of California Irvine					NATIONAL INSTITUTE ON AGING [P01AG000538] Funding Source: NIH RePORTER; NIA NIH HHS [AG00538] Funding Source: Medline; NINDS NIH HHS [NS31230] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; BENNES R, 1991, J CARDIOVASC PHAR S7, V17, P44; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; BURDICK D, 1992, J BIOL CHEM, V267, P546; CHATTOPADHYAY A, 1984, ANAL BIOCHEM, V139, P408, DOI 10.1016/0003-2697(84)90026-5; ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0; FIRESTONE RA, 1979, J MED CHEM, V22, P1130, DOI 10.1021/jm00195a026; FORSTER S, 1987, BIOCHIM BIOPHYS ACTA, V924, P452, DOI 10.1016/0304-4165(87)90160-7; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; INOUYE H, 1993, BIOPHYS J, V64, P502, DOI 10.1016/S0006-3495(93)81393-6; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MAY PC, 1992, NEUROBIOL AGING, V13, P605, DOI 10.1016/0197-4580(92)90064-5; MAYER RJ, 1992, LANCET, V340, P156, DOI 10.1016/0140-6736(92)93224-B; MILLER DK, 1983, J CELL BIOL, V97, P1841, DOI 10.1083/jcb.97.6.1841; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MIYAKAWA T, 1986, VIRCHOWS ARCH B, V52, P99, DOI 10.1007/BF02889954; NIXON RA, 1992, ANN NY ACAD SCI, V674, P65; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; RADLICK LW, 1992, BIOCHIM BIOPHYS ACTA, V1120, P193, DOI 10.1016/0167-4838(92)90269-J; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SPENCER RGS, 1991, BIOCHEMISTRY-US, V30, P10382, DOI 10.1021/bi00107a004; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TANFORD C, 1980, HYDROPHOBIC EFFECT; WISNIEWSKI HM, 1988, CIBA F SYMP, V135, P224; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	38	242	254	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28551	28554						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961799				2022-12-27	WOS:A1994PU16800008
J	PRALONG, WF; SPAT, A; WOLLHEIM, CB				PRALONG, WF; SPAT, A; WOLLHEIM, CB			DYNAMIC PACING OF CELL-METABOLISM BY INTRACELLULAR CA2+ TRANSIENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; ADRENAL GLOMERULOSA CELLS; INDUCED INSULIN-SECRETION; MITOCHONDRIAL FREE CA2+; RAT HEPATOCYTES; CYTOSOLIC CA2+; FREE CALCIUM; GLUCOSE; OSCILLATIONS; ISLETS	During cell activation, Ca2+, by stimulating the NADH-producing mitochondrial dehydrogenases, triggers the generation of reducing equivalents whereby ATP production is sustained. In cell populations, [Ca2+] changes in the mitochondrial matrix were demonstrated to parallel rapidly those in the cytosol ([Ca2+](i)). There is still no indication as to whether metabolic activation follows oscillatory patterns similar to those of [Ca2+](i). Therefore, changes in NAD(P)H were monitored in single pancreatic beta-cells, adrenal glomerulosa cells, and liver cells during oscillatory [Ca2+](i) transients, Rapid NAD(P)H and [Ca2+](i) oscillations with similar frequency and sensitive both to changes in glucose concentration and to extracellular Ca2+ removal were identified in a subpopulation of pancreatic beta-cells in primary culture. Furthermore, Ca2+-dependent oscillatory NAD(P)H formation could be evoked by the pulsatile application of depolarizing [K+], demonstrating the pacing effect of increased [Ca2+](i) on beta-cell metabolism. In adrenal glomerulosa cells, angiotensin II, a physiological stimulator of aldosterone production, could be shown to elicit the oscillatory formation of mitochondrial NAD(P)H through frequency modulation of [Ca2+](i) transients. In contrast to the two former endocrine cell types, in hepatocytes, [Arg(8)]vasopressin and epinephrine caused the amplitude modulation of NAD(P)H formation. Taken together, these results provide unprecedented evidence for a cell-specific pacing of metabolism by [Ca2+](i) transients coordinated with cell activation and function.	SEMMELWEIS UNIV MED, SCH MED, DEPT PHYSIOL, H-1444 BUDAPEST, HUNGARY	Semmelweis University	PRALONG, WF (corresponding author), UNIV GENEVA, CTR MED, DEPT MED, DIV CLIN BIOCHEM, CH-1211 GENEVA, SWITZERLAND.		Spat, Andras/AAE-9981-2019					ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BALABAN RS, 1982, AM J PHYSIOL, V242, pC172, DOI 10.1152/ajpcell.1982.242.3.C172; BERGSTEN P, 1993, DIABETES, V42, P670, DOI 10.2337/diabetes.42.5.670; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; COHEN E, 1979, SCIENCE, V204, P862; CRIVELLO JF, 1982, ENDOCRINOLOGY, V111, P469, DOI 10.1210/endo-111-2-469; DUCHEN MR, 1993, BIOCHEM J, V294, P35, DOI 10.1042/bj2940035; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; GILON P, 1993, J BIOL CHEM, V268, P22265; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEIMBERG H, 1993, EMBO J, V12, P2873, DOI 10.1002/j.1460-2075.1993.tb05949.x; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; KAWANISHI T, 1991, J BIOL CHEM, V266, P20062; LONGO EA, 1991, J BIOL CHEM, V266, P9314; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MCCORMACK JG, 1989, BIOCHIM BIOPHYS ACTA, V973, P420, DOI 10.1016/S0005-2728(89)80384-6; MEDA P, 1984, Q J EXP PHYSIOL CMS, V69, P719; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; MURPHY E, 1980, J BIOL CHEM, V255, P6600; OPARA EC, 1988, PANCREAS, V3, P484, DOI 10.1097/00006676-198808000-00019; PIPELEERS DG, 1992, DIABETES, V41, P777, DOI 10.2337/diabetes.41.7.777; PRALONG WF, 1992, P NATL ACAD SCI USA, V89, P132, DOI 10.1073/pnas.89.1.132; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; REBER BFX, 1990, BIOCHIM BIOPHYS ACTA, V1018, P190, DOI 10.1016/0005-2728(90)90246-Z; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; RUTTER GA, 1993, J BIOL CHEM, V268, P22385; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SPAT A, 1991, EXP PHYSIOL, V76, P859, DOI 10.1113/expphysiol.1991.sp003550; THELER JM, 1992, J BIOL CHEM, V267, P18110; THORN P, 1992, PFLUG ARCH EUR J PHY, V422, P173, DOI 10.1007/BF00370417; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	34	164	166	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27310	27314						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961642				2022-12-27	WOS:A1994PV77100028
J	SZALLASI, Z; SMITH, CB; BLUMBERG, PM				SZALLASI, Z; SMITH, CB; BLUMBERG, PM			DISSOCIATION OF PHORBOL ESTERS LEADS TO IMMEDIATE REDISTRIBUTION TO THE CYTOSOL OF PROTEIN-KINASES C-ALPHA AND C-DELTA IN MOUSE KERATINOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ISOZYMES; BINDING; CELLS; ACTIVATION; MEMBRANE; GROWTH; BRAIN	We have measured the dissociation rate of phorbol 12-myristate 13-acetate (PMA), a potent tumor promoter, phorbol 12,13-dibutyrate (PDBu), a weak tumor promoter, and 12-deoxyphorbol 13-phenylacetate (dPP), an antitumor promoter, from intact mouse keratinocytes. PDBu and dPP showed a very rapid release from the cells (t(1/2) = 1 min), whereas PMA showed a slower release (t(1/2) = 9 min). Western blot analysis of the amounts of protein kinase C alpha (PKC alpha) and PHC delta in the soluble fraction and the Triton X-100-soluble particulate fraction revealed that translocation of both isozymes from the soluble to the particulate fraction was reversible when the phorbol esters were washed off. Washes of 5-15 min resulted in complete redistribution of the PKC isozymes when the cells were previously treated with 1 mu M dPP or 1 mu M PDBu for 5 min. In the case of treatment with 100 or 10 nar PMA, the redistribution required a longer time; nevertheless, the PHC isozymes returned to the soluble fraction within 60 min. Longer initial treatments with PMA dPP, and PDBu (up to 60 min) translocated PHC in a very similar, completely reversible fashion. We conclude that in this cell line phorbol esters do not induce the conversion of PHC isozymes to an integral membrane state.	NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Szallasi, Zoltan/0000-0001-5395-7509				ALKON DL, 1988, SCIENCE, V239, P998, DOI 10.1126/science.2830669; BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P9317, DOI 10.1021/bi00450a011; BAZZI MD, 1988, BIOCHEM BIOPH RES CO, V152, P336, DOI 10.1016/S0006-291X(88)80719-8; DEISHER TA, 1993, BIOCHEM BIOPH RES CO, V193, P1283, DOI 10.1006/bbrc.1993.1764; DUNPHY WG, 1981, CANCER RES, V41, P2640; HA KS, 1993, J BIOL CHEM, V268, P10534; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KILEY SC, 1994, CARCINOGENESIS, V15, P319, DOI 10.1093/carcin/15.2.319; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LEE MH, 1989, J BIOL CHEM, V264, P14797; NELSESTUEN GL, 1991, J BIOENERG BIOMEMBR, V23, P43; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; SCRIBNER JD, 1972, EUR J CANCER, V8, P617, DOI 10.1016/0014-2964(72)90142-9; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1993, CANCER RES, V53, P2507	22	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27159	27162						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961621				2022-12-27	WOS:A1994PV77100002
J	TAYLOR, RG; MCINNES, RR				TAYLOR, RG; MCINNES, RR			SITE-DIRECTED MUTAGENESIS OF CONSERVED SERINES IN RAT HISTIDASE - IDENTIFICATION OF SERINE-254 AS AN ESSENTIAL ACTIVE-SITE RESIDUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLALANINE AMMONIA-LYASE; THYROID-HORMONE SYNTHESIS; DEHYDROALANINE RESIDUES; RIBONUCLEIC-ACID; EXPRESSION; THYROGLOBULIN; MECHANISM; PROTEINS; TRANSFORMATION; HISTIDINEMIA	We have identified serine 254 as an essential residue in rat histidase (histidine ammonia-lyase, EC 4.3.1.3). Histidase and phenylalanine ammonia-lyase are the only two enzymes that have been postulated to require the modified amino acid, dehydroalanine, for enzyme activity. In the bacterial peptides nisin and subtilin, and in the pyruvoyl enzymes, the precursor for dehydroalanine is a serine. To determine whether serine may be the dehydroalanine precursor in rat histidase, we substituted four highly conserved serines with alanines, and expressed the mutated histidase cDNAs in COS cells, which have no endogenous histidase activity. Substitution of serines 223, 254, 508, and 533 resulted in the production of approximately equal amounts of histidase protein with histidase activities of 2.4, 0.0, 75, and 16%, respectively. The abrogation of histidase activity by the substitution of alanine for serine 254, together with the modification by L-cysteine of the corresponding residue in Pseudomonas putida histidase (Hernandez, C., Stroh, J. G., and Phillips, A. T. (1993) Arch. Biochem. Biophys. 307, 126-132), is strong evidence that this residue is the precursor of the essential electrophilic moiety of histidase.	HOSP SICK CHILDREN,RES INST,DEPT GENET,TORONTO M5G 1X8,ON,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5G 1X8,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								BANERJEE S, 1988, J BIOL CHEM, V263, P9508; BARTONE NA, 1991, J PROTEIN CHEM, V10, P603, DOI 10.1007/BF01025712; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONSEVAGE MW, 1985, BIOCHEMISTRY-US, V24, P301, DOI 10.1021/bi00323a010; DEMEIRLEIR L, 1988, J BIOL CHEM, V263, P1991; GAVARET JM, 1981, J BIOL CHEM, V256, P9167; GAVARET JM, 1980, J BIOL CHEM, V255, P5281; GIVOT IL, 1969, J BIOL CHEM, V244, P6341; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HANSON KR, 1970, ARCH BIOCHEM BIOPHYS, V141, P1, DOI 10.1016/0003-9861(70)90100-1; Hanson KR, 1972, ENZYMES, P75; HAVIR EA, 1975, BIOCHEMISTRY-US, V14, P1620, DOI 10.1021/bi00679a012; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; HERMES JD, 1985, BIOCHEMISTRY-US, V24, P2959, DOI 10.1021/bi00333a023; HERNANDEZ D, 1993, ARCH BIOCHEM BIOPHYS, V307, P126, DOI 10.1006/abbi.1993.1570; HODGINS DS, 1971, J BIOL CHEM, V246, P2977; JONES AJ, 1983, BIOCHEM J, V211, P499, DOI 10.1042/bj2110499; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASRI MS, 1982, BIOCHEM BIOPH RES CO, V104, P321, DOI 10.1016/0006-291X(82)91977-5; OHMIYA Y, 1990, J BIOL CHEM, V265, P9066; RECSEI PA, 1983, P NATL ACAD SCI-BIOL, V80, P973, DOI 10.1073/pnas.80.4.973; RECSEI PA, 1984, ANNU REV BIOCHEM, V53, P357, DOI 10.1146/annurev.bi.53.070184.002041; Sambrook J, 1989, MOL CLONING LABORATO; SCHULZ W, 1989, FEBS LETT, V258, P335, DOI 10.1016/0014-5793(89)81687-4; TAYLOR RG, 1990, J BIOL CHEM, V265, P18192; TAYLOR RG, 1993, GENOMICS, V16, P231, DOI 10.1006/geno.1993.1164; TAYLOR RG, 1991, MOL BIOL MED, V8, P101; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333; WICKNER RB, 1969, J BIOL CHEM, V244, P6550; ZALE SE, 1986, BIOCHEMISTRY-US, V25, P5432, DOI 10.1021/bi00367a014	34	15	16	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27473	27477						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961661				2022-12-27	WOS:A1994PV77100051
J	BOEHLEIN, SK; RICHARDS, NGJ; WALWORTH, ES; SCHUSTER, SM				BOEHLEIN, SK; RICHARDS, NGJ; WALWORTH, ES; SCHUSTER, SM			ARGININE-30 AND ASPARAGINE-74 HAVE FUNCTIONAL ROLES IN THE GLUTAMINE DEPENDENT ACTIVITIES OF ESCHERICHIA-COLI ASPARAGINE SYNTHETASE-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMYL-PHOSPHATE SYNTHETASE; AMINO-ACID-SEQUENCE; PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE; LINKED GLYCOSYLATION; SERINE PROTEASES; MECHANISM; PURF; CONFORMATION; CYSTEINE; TRIAD	Although Arg-30, Asn-74, and Asn-79 appear totally conserved throughout the purF glutamine-dependent amidotransferases, their potential roles in catalysis and binding remain unexplored for any member of the enzyme family. Here we report the overexpression, purification, and kinetic characterization of a series of AS-B mutants which allow an examination of the functional roles of these 3 residues in glutamine dependent nitrogen transfer. While Asn-79 appears to possess no catalytic function in AS-B, site-directed mutagenesis of Asn-74 has implicated this residue as playing a role in catalysis of nitrogen transfer from glutamine. The kinetic properties of the Asn-74 AS-B mutant enzymes appear consistent with both ammonia-mediated nitrogen transfer and two apparently novel mechanistic suggestions for this reaction involving either an oxyanion or imide intermediate (Richards, N. G. J., and Schuster, S. M. (1992) FEBS Lett. 313, 98-102). We also demonstrate that replacement of Arg-30 by an alanine residue yields an AS-B mutant for which the apparent K-m for glutamine is increased in the glutamine-dependent synthesis of asparagine. In addition, ATP-dependent stimulation of the glutaminase activity of AS-B is modified or completely eliminated when Arg-30 is replaced by other amino acids. The latter observation may indicate the existence of a molecular switch involving Arg-30 which coordinates the two half-reactions catalyzed by the glutamine-dependent amidotransferases and synthetase domains of cellular AS-B.	UNIV FLORIDA,ICBR,GAINESVILLE,FL 32611; UNIV FLORIDA,DEPT BIOCHEM & MOLEC BIOL,GAINESVILLE,FL 32611; UNIV FLORIDA,DEPT CHEM,GAINESVILLE,FL 32611	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida					NATIONAL CANCER INSTITUTE [R01CA028725] Funding Source: NIH RePORTER; NCI NIH HHS [CA-28725] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3157, DOI 10.1021/bi00874a012; BAKER EN, 1976, J MOL BIOL, V101, P185, DOI 10.1016/0022-2836(76)90371-5; BENEDETTI E, 1980, J CHEM SOC PERK T 2, P500, DOI 10.1039/p29800000500; Bernt E., 1974, METHODS ENZYMATIC AN, P1704, DOI [10.1016/B978-0-12-091304-6.50017-3, DOI 10.1016/B978-0-12-091304-6.50017-3]; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; BOEHLEIN SK, 1994, J BIOL CHEM, V269, P7450; CEDAR H, 1969, J BIOL CHEM, V244, P4112; CHEAH E, 1993, PROTEIN ENG, V6, P575, DOI 10.1093/protein/6.6.575; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRENTH J, 1971, ENZYMES, V3, P609; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; IMPERIALI B, 1991, BIOCHEMISTRY-US, V30, P4374, DOI 10.1021/bi00232a002; IMPERIALI B, 1992, J AM CHEM SOC, V114, P7944, DOI 10.1021/ja00046a069; IMPERIALI B, 1992, J AM CHEM SOC, V114, P7942, DOI 10.1021/ja00046a068; Jencks W. P., 1987, CATALYSIS CHEM ENZYM; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; KRIEGER M, 1974, J MOL BIOL, V83, P209, DOI 10.1016/0022-2836(74)90388-X; LEVITZKI A, 1971, BIOCHEMISTRY-US, V10, P3371, DOI 10.1021/bi00794a009; LUEHR CA, 1985, ARCH BIOCHEM BIOPHYS, V237, P335, DOI 10.1016/0003-9861(85)90285-1; LUSTY CJ, 1993, BIOCHEMISTRY-US, V32, P1278, DOI 10.1021/bi00056a012; MEI B, 1989, J BIOL CHEM, V264, P16613; MILMAN HA, 1979, BIOCHEM J, V181, P51, DOI 10.1042/bj1810051; RICHARDS NGJ, 1992, FEBS LETT, V313, P98, DOI 10.1016/0014-5793(92)81421-H; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; RUBINO SD, 1986, J BIOL CHEM, V261, P1320; SHENG S, 1993, J BIOL CHEM, V268, P16771; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; STERNBERG MJE, 1987, NATURE, V330, P86, DOI 10.1038/330086a0; STEWART WE, 1970, CHEM REV, V70, P517, DOI 10.1021/cr60267a001; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TSO JY, 1982, J BIOL CHEM, V257, P3525; TSO JY, 1982, J BIOL CHEM, V257, P3532; VANHEEKE G, 1989, J BIOL CHEM, V264, P19475; WARSHEL A, 1989, BIOCHEMISTRY-US, V28, P3629, DOI 10.1021/bi00435a001; WINTERBU.PJ, 1971, BIOCHEM J, V121, P701, DOI 10.1042/bj1210701; Zalkin H, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P203; ZALKIN H, 1977, J BIOL CHEM, V252, P5341	37	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26789	26795						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929415				2022-12-27	WOS:A1994PQ93100034
J	BROWN, DA; KANG, SH; GRYAZNOV, SM; DEDIONISIO, L; HEIDENREICH, O; SULLIVAN, S; XU, X; NERENBERG, MI				BROWN, DA; KANG, SH; GRYAZNOV, SM; DEDIONISIO, L; HEIDENREICH, O; SULLIVAN, S; XU, X; NERENBERG, MI			EFFECT OF PHOSPHOROTHIOATE MODIFICATION OF OLIGODEOXYNUCLEOTIDES ON SPECIFIC PROTEIN-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GENE-EXPRESSION; ANTISENSE OLIGONUCLEOTIDES; IL-6 GENE; INHIBITION; CELLS; TRANSCRIPTION; LEUKEMIA; INVITRO; ELEMENT	Phosphorothioate modification of internucleoside linkages is widely used to prevent degradation of oligodeoxynucleotide (ODN) therapeutic agents in serum and cells. This modification generally increases ODN potency, but in many instances it is associated with an increase of poorly understood nonspecific effects. In this study, we have found that both cellular retention and nonspecific protein binding are dependent upon the extent of the oligonucleotide's modification. Flow cytometry of cells treated with fluorescein-labeled single-stranded (ss) or double-stranded (ds) ODNs demonstrated that fully phosphorothioate-modified ODNs exhibit much greater cellular association than 3'-terminally modified ODNs (with three 3'-terminal phosphorothioate linkages). Additionally gel shift assays with either ss- or ds-probes showed that fully phosphorothioate-modified ODNs also exhibit much greater cytoplasmic and nuclear protein binding than either 3'-terminally modified or unmodified ODNs. However, gel shift competition assays showed that transcription factor binding by fully phosphorothioate-modified ds-ODNs was completely nonspecific relative to 3'-terminally modified and unmodified ds-ODNs. These results suggest that the benefits derived from full phosphorothioate modification of ODNs may be negated by increases of nonspecific protein binding and associated sequence-independent effects.	Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; LYNX THERAPEUT INC, HAYWARD, CA 94545 USA; RIBOZYME PHARMACEUT INC, BOULDER, CO 80301 USA	Scripps Research Institute; Scripps Research Institute			Heidenreich, Olaf/AAP-5045-2021	Heidenreich, Olaf/0000-0001-5404-6483; DeDionisio, Lawrence/0000-0001-5109-2388	NCI NIH HHS [CA50234] Funding Source: Medline; NINDS NIH HHS [NS12428] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS012428] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444; BROWN DA, 1992, EUR J IMMUNOL, V22, P2419, DOI 10.1002/eji.1830220935; CALABRETTA B, 1991, CANCER RES, V51, P4505; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CHUBB JM, 1992, TRENDS BIOTECHNOL, V10, P132, DOI 10.1016/0167-7799(92)90195-2; CLUSEL C, 1993, NUCLEIC ACIDS RES, V21, P3405, DOI 10.1093/nar/21.15.3405; GAO WY, 1992, MOL PHARMACOL, V41, P223; GAO WY, 1993, MOL PHARMACOL, V43, P45; Ghosh M K, 1992, Antisense Res Dev, V2, P111; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; Ho P T, 1991, Antisense Res Dev, V1, P329; Holt J T, 1991, Antisense Res Dev, V1, P365; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; Iversen P L, 1992, Antisense Res Dev, V2, P211; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KIBLERHERZOG L, 1991, NUCLEIC ACIDS RES, V19, P2979, DOI 10.1093/nar/19.11.2979; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KITAJIMA I, 1992, J BIOL CHEM, V267, P25881; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LISZIEWICZ J, 1992, P NATL ACAD SCI USA, V89, P11209, DOI 10.1073/pnas.89.23.11209; MAJUMDAR C, 1989, BIOCHEMISTRY-US, V28, P1340, DOI 10.1021/bi00429a060; MILLIGAN JF, 1993, J MED CHEM, V36, P1923, DOI 10.1021/jm00066a001; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P11823, DOI 10.1073/pnas.89.24.11823; RIORDAN ML, 1991, NATURE, V350, P442, DOI 10.1038/350442a0; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; TANABE O, 1988, J IMMUNOL, V141, P3875; THIERRY AR, 1992, NUCLEIC ACIDS RES, V20, P5691, DOI 10.1093/nar/20.21.5691; VICKERS T, 1991, NUCLEIC ACIDS RES, V19, P3359, DOI 10.1093/nar/19.12.3359; WU H, 1990, GENE, V89, P203, DOI 10.1016/0378-1119(90)90007-E; Yaswen P, 1993, Antisense Res Dev, V3, P67; Zhao Q, 1993, Antisense Res Dev, V3, P53	33	302	315	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26801	26805						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929417				2022-12-27	WOS:A1994PQ93100036
J	FALLON, RJ; DANAHER, M; SAXENA, A				FALLON, RJ; DANAHER, M; SAXENA, A			THE ASIALOGLYCOPROTEIN RECEPTOR IS ASSOCIATED WITH A TYROSINE KINASE IN HEPG2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ENDOCYTOSIS; PURIFICATION; SEQUENCE	The asialoglycoprotein (ASGP) receptor undergoes constitutive endocytosis in HepG2 cells, which is regulated by tyrosine kinase activity (Fallen, R. J., Danaher, M., Saylors, R. L., and Saxena, A (1994) J. Biol. Chem. 269, 11011-11017). In this study we show that the receptor copurifies with a tyrosine kinase activity, as defined by tyrosine phosphorylation of an exogenous substrate (reduced carboxyamidomethylated and maleylated lysozyme). Analysis of cells transfected with one subunit of the ASGP receptor showed that signals in the cytoplasmic domain of the H1 subunit are sufficient for receptor kinase association. In addition, receptor kinase association is not dependent on the single cytoplasmic tyrosine at position 5. Analysis of the components of anti-ASGP receptor immunoprecipitates revealed the presence of a 127-kDa protein (p127), which becomes phosphorylated on tyrosine upon addition of gamma-[P-32]ATP and which is capable of binding ATP. p127 was also demonstrated in anti-transferrin receptor immunoprecipitates but not in immunoprecipitates of a resident membrane protein, human HLA. In conclusion, these data demonstrate that the ASGP receptor, a protein that participates in constitutive, rapid endocytosis, is associated with a cellular tyrosine kinase.	CARDINAL GLENNON MEM HOSP CHILDREN, PEDIAT RES INST, ST LOUIS, MO 63110 USA		FALLON, RJ (corresponding author), ST LOUIS UNIV, SCH MED, DEPT PEDIAT, 1465 S GRAND BLVD, ST LOUIS, MO 63104 USA.				NIDDK NIH HHS [DK42081] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042081] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CARPENTIER JL, 1993, J CELL BIOL, V122, P1243, DOI 10.1083/jcb.122.6.1243; EISEMAN E, 1992, NATURE, V355, P78; FALLON RJ, 1994, J BIOL CHEM, V269, P11011; FALLON RJ, 1990, J BIOL CHEM, V265, P3401; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; GEFFEN I, 1989, EMBO J, V8, P2855, DOI 10.1002/j.1460-2075.1989.tb08433.x; KRIEGLER M, 1990, GENE TRANSFER EXPRES, P96; SAROSI GA, 1992, INT IMMUNOL, V4, P1211, DOI 10.1093/intimm/4.11.1211; SHUM L, 1994, J CELL BIOL, V125, P903, DOI 10.1083/jcb.125.4.903; SMYTHE E, 1992, METHOD ENZYMOL, V219, P223; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; SPIESS M, 1985, J BIOL CHEM, V260, P1979; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; TONKS NK, 1988, J BIOL CHEM, V263, P6722; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WILEY HS, 1991, J BIOL CHEM, V263, P13159	19	20	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26626	26629						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929394				2022-12-27	WOS:A1994PQ93100010
J	LEE, YH; KIM, HS; PAI, JK; RYU, SH; SUH, PG				LEE, YH; KIM, HS; PAI, JK; RYU, SH; SUH, PG			ACTIVATION OF PHOSPHOLIPASE-D INDUCED BY PLATELET-DERIVED GROWTH-FACTOR IS DEPENDENT UPON THE LEVEL OF PHOSPHOLIPASE C-GAMMA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SMOOTH-MUSCLE CELLS; PHOSPHATIDYLCHOLINE HYDROLYSIS; SIGNAL TRANSDUCTION; TYROSINE PHOSPHORYLATION; MITOGENIC SIGNAL; DIACYLGLYCEROL FORMATION; HL-60 GRANULOCYTES; PHOSPHATIDIC-ACID; NIH-3T3 CELLS	The mechanism of phospholipase D (PLD) activation by platelet derived growth factor (PDGF) was examined using a NIH 3T3 fibroblast cell line (3T3-gamma 1) that stably overexpresses PLC-gamma 1 isozyme. Immunoblot analysis revealed that 3T3-gamma 1 cells contained about 10-fold more PLC-gamma 1 than a control cell line (3T3-C) transfected with expression vector lacking PLC-gamma 1 cDNA. PDGF-stimulated PLD activation was 10-fold greater in 3T3-gamma 1 cells than in 3T3-C cells, indicating that PLD activation is dependent upon the level of PLC-gamma 1. Phorbol 12-myristate 13-acetate (PMA) treatment increased PLD activity to a similar extent in both 3T3-gamma 1 cells and control cells. Pretreatment with tyrosine kinase inhibitors including staurosporine and genistein decreased PLD activity by 82.6% and 87.2%, respectively, and completely blocked tyrosine phosphorylation of PDGF receptor and PLC-gamma 1 in 3T3-gamma 1 cells stimulated with PDGF. Moreover, downregulation of protein kinase C by pretreatment of PMA caused complete inhibition of PDGF- and PMA-stimulated PLD activation. Therefore, these results suggest that PDGF-induced PLD activation may be a consequence of primary stimulation of PLC-gamma 1 and that PLD may play a role downstream hom PLC-gamma 1 in PDGF-triggered mitogenesis.	POHANG UNIV SCI & TECHNOL HYOHA DONG,DEPT LIFE SCI,POHANG 790784,SOUTH KOREA; KYUNGSUNG UNIV,DEPT FOOD SCI & TECHNOL,PUSAN 609736,SOUTH KOREA; SCHERING PLOUGH CORP,DEPT MOLEC PHARMACOL,KENILWORTH,NJ 07033	Pohang University of Science & Technology (POSTECH); Kyungsung University; Merck & Company; Schering Plough Corporation			Suh, Pann-Ghill/F-3610-2010	Ryu, Sung Ho/0000-0003-0913-3048				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANTHES JC, 1989, BIOCHEM BIOPH RES CO, V163, P657, DOI 10.1016/0006-291X(89)92187-6; ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; AUGERT G, 1989, J BIOL CHEM, V264, P21689; BENAV P, 1989, FEBS LETT, V259, P64, DOI 10.1016/0014-5793(89)81495-4; BENAV P, 1993, EUR J BIOCHEM, V215, P455, DOI 10.1111/j.1432-1033.1993.tb18054.x; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; BRADFORD PG, 1986, BIOCHEM J, V239, P97, DOI 10.1042/bj2390097; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; DOWNES CP, 1986, BIOCHEM J, V238, P501, DOI 10.1042/bj2380501; EXTON JH, 1990, J BIOL CHEM, V265, P1; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KONDO T, 1992, J BIOL CHEM, V267, P23609; LISCOVITCH M, 1989, J BIOL CHEM, V264, P1450; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARTIN TW, 1989, J BIOL CHEM, V264, P8847; MARTINSON EA, 1989, J BIOL CHEM, V264, P14748; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MUIR JG, 1987, J CELL PHYSIOL, V130, P382, DOI 10.1002/jcp.1041300311; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V312, P315; NOH DY, 1994, CANCER, V73, P36, DOI 10.1002/1097-0142(19940101)73:1<36::AID-CNCR2820730108>3.0.CO;2-5; PACHTER JA, 1992, J BIOL CHEM, V267, P9826; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; PAI JK, 1991, CELL REGUL, V2, P897, DOI 10.1091/mbc.2.11.897; PARK JG, 1994, CANCER RES, V54, P2240; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; ROSENGURT E, 1986, SCIENCE, V234, P161; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; SMITH MR, 1989, P NATL ACAD SCI USA, V86, P3659, DOI 10.1073/pnas.86.10.3659; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; SUH PG, 1988, J BIOL CHEM, V263, P14497; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; UINGS IJ, 1992, BIOCHEM J, V281, P597, DOI 10.1042/bj2810597; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WELSH CJ, 1991, IN VITRO CELL DEV B, V27, P425; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; Zhang Wei, 1992, Neurological Research, V14, P397	53	92	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26842	26847						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929422				2022-12-27	WOS:A1994PQ93100042
J	LORIS, R; STAS, PPG; WYNS, L				LORIS, R; STAS, PPG; WYNS, L			CONSERVED WATERS IN LEGUME LECTIN CRYSTAL-STRUCTURES - THE IMPORTANCE OF BOUND WATER FOR THE SEQUENCE-STRUCTURE RELATIONSHIP WITHIN THE LEGUME LECTIN FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; PROTEIN-STRUCTURE; ANGSTROM RESOLUTION; SECONDARY STRUCTURE; LATHYRUS-OCHRUS; CONCANAVALIN-A; ISOLECTIN-I; BETA-BULGES; COMPLEX; REFINEMENT	An analysis of the water structure in the crystals of different legume lectins has been carried out. Protein hydration is found to be mainly dependent on the detailed local surface characteristics of the protein and will adapt upon the limited conformational changes that are the resultant of crystal packing forces and point mutations. Yet a significant portion of the water positions determined by x-ray crystallography appears to be conserved in all independent crystal structures of a given protein. Some of these waters are specific to this one specific protein, while others are conserved in crystal structures of homologous proteins as well. For those conserved waters, a clear structural role is often evident. Seven water sites were found to be completely conserved in all legume lectin crystal structures, independent of their degree of sequence homology or carbohydrate specificity. Of these, four waters are ligands to the manganese and calcium ions, and one water is located in the saccharide binding site interacting with a conserved Asp and Asn residue. Of the remaining two conserved waters, one of them stabilizes a beta-hairpin, while the other interacts with a beta-bulge structure of the back sheet.	FREE UNIV BRUSSELS,INST MOLEC BIOL,CELLULAIRE IMMUNOL LAB,B-1640 RHODE ST GENESE,BELGIUM		LORIS, R (corresponding author), FREE UNIV BRUSSELS,INST MOLEC BIOL,ULTRASTRUCTUUR LAB,PAARDENSTR 65,B-1640 RHODE ST GENESE,BELGIUM.		Loris, Remy/GPG-0894-2022	Loris, Remy/0000-0002-8862-3338				BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOURNE Y, 1990, J BIOL CHEM, V265, P18161; BOURNE Y, 1992, J BIOL CHEM, V267, P197; BOURNE Y, 1990, PROTEINS, V8, P365, DOI 10.1002/prot.340080410; BOURNE Y, 1990, J MOL BIOL, V214, P571, DOI 10.1016/0022-2836(90)90199-V; Brtinger A. T., 1990, X PLOR VERSION 2 1; CHAN AWE, 1993, PROTEIN SCI, V2, P1574, DOI 10.1002/pro.5560021004; DELBAERE LTJ, 1993, J MOL BIOL, V230, P950, DOI 10.1006/jmbi.1993.1212; DELHAISE P, 1984, J MOL GRAPHICS, V2, P103, DOI 10.1016/0263-7855(84)80002-8; EDSALL JT, 1983, ADV BIOPHYS, V16, P53; EINSPAHR H, 1986, J BIOL CHEM, V261, P6518; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FINERMOORE JS, 1992, PROTEINS, V12, P203, DOI 10.1002/prot.340120302; HAHN M, 1993, ACTA CRYSTALLOGR D, V49, P468, DOI 10.1107/S0907444993004858; HANEEF I, 1985, ACTA CRYSTALLOGR A, V41, P426, DOI 10.1107/S0108767385000915; HARDMAN KD, 1982, J MOL BIOL, V157, P69, DOI 10.1016/0022-2836(82)90513-7; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; LISGARTEN JN, 1993, ACTA CRYSTALLOGR D, V49, P541, DOI 10.1107/S090744499300719X; LORIS R, 1993, BIOCHEMISTRY-US, V32, P8772, DOI 10.1021/bi00085a007; LORIS R, 1994, IN PRESS PROTEINS; MALIN R, 1991, J BIOL CHEM, V266, P4848; MEYER E, 1992, PROTEIN SCI, V1, P1543, DOI 10.1002/pro.5560011203; MILNERWHITE EJ, 1987, BIOCHIM BIOPHYS ACTA, V911, P261, DOI 10.1016/0167-4838(87)90017-3; NAISMITH JH, 1993, ACTA CRYSTALLOGR D, V49, P561, DOI 10.1107/S0907444993006390; PLETINCKX J, 1994, BIOCHEMISTRY-US, V33, P1654, DOI 10.1021/bi00173a006; RASHIN AA, 1986, BIOCHEMISTRY-US, V25, P3619, DOI 10.1021/bi00360a021; RICHARDSON JS, 1978, P NATL ACAD SCI USA, V75, P2574, DOI 10.1073/pnas.75.6.2574; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; SREENIVASAN U, 1992, BIOCHEMISTRY-US, V31, P12785, DOI 10.1021/bi00166a011; SUNDARALINGAM M, 1989, SCIENCE, V244, P1333, DOI 10.1126/science.2734612; THANKI N, 1991, J MOL BIOL, V221, P669, DOI 10.1016/0022-2836(91)80080-E	32	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26722	26733						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929406				2022-12-27	WOS:A1994PQ93100025
J	MALCOLM, KC; ROSS, AH; QIU, RG; SYMONS, M; EXTON, JH				MALCOLM, KC; ROSS, AH; QIU, RG; SYMONS, M; EXTON, JH			ACTIVATION OF RAT-LIVER PHOSPHOLIPASE-D BY THE SMALL GTP-BINDING PROTEIN RHOA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADP-RIBOSYLATION; REGULATORY PROTEIN; NADPH OXIDASE; TOXIN; MECHANISM; GDI; PHOSPHATIDYLCHOLINE; ACCUMULATION; PURIFICATION; HYDROLYSIS	Stimulation of phospholipase D by guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) in rat liver plasma membranes indicates the involvement of GTP-binding proteins. We used RhoGDI, an inhibitor of GDP dissociation from small GTP-binding proteins of the Rho family, to determine the involvement of these proteins. Incuba tion, and subsequent washing, of plasma membranes with RhoGDI dose-dependently diminished GTP gamma S-stimulated phospholipase D activity, as determined by accumulation of phosphatidylethanol in the presence of ethanol. Incubation with RhoGDI also caused a rapid and dose dependent appearance of RhoA in the wash, which was associated with the inhibition of phospholipase D. RhoGDI also rapidly extracted Cdc42 from membranes, but Rad was not extracted. Full reconstitution of GTP gamma S-stimulated phospholipase D in RhoGDI-washed membranes was achieved with recombinant RhoA. There was partial reconstitution with Rac1 and no enhancement with Cdc42 or ADP-ribosylation factor. The response to RhoA was dose-dependent (EC(50) = 0.5 mu M). ADP-ribosylation of RhoA by Clostridium botulinum C3 exoenzyme did not affect its ability to recover GTP gamma S-stimulated phospholipase D activity in RhoGDI-washed membranes. These findings support a role for GTP-binding proteins of the Rho family in the activation of membrane-associated phospholipase D and implicate RhoA as the major protein involved.	VANDERBILT UNIV,SCH MED,HOWARD HUGHES MED INST,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232; ONYX PHARMACEUT,RICHMOND,CA 94806	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University				Malcolm, Kenneth/0000-0002-8097-6059				BALBOA MA, 1994, J BIOL CHEM, V269, P10511; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1988, J BIOL CHEM, V263, P16744; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DUBYAK GR, 1993, BIOCHEM J, V292, P121, DOI 10.1042/bj2920121; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; GUSTAVSSON L, 1994, J BIOL CHEM, V269, P849; HART MJ, 1994, J BIOL CHEM, V269, P62; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; KANAHO Y, 1991, FEBS LETT, V279, P249, DOI 10.1016/0014-5793(91)80160-5; KUSNER DJ, 1993, J BIOL CHEM, V268, P19973; LEONARD D, 1992, J BIOL CHEM, V267, P22860; MACNULTY EE, 1992, J BIOL CHEM, V267, P2149; MANSER E, 1992, J BIOL CHEM, V267, P16025; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MORII N, 1991, J BIOL CHEM, V266, P7646; MORII N, 1992, J BIOL CHEM, V267, P20921; MOSS J, 1993, CELL SIGNAL, V5, P367, DOI 10.1016/0898-6568(93)90076-X; OLSEN SC, 1991, J BIOL CHEM, V266, P17236; PRPIC V, 1984, J BIOL CHEM, V259, P1382; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SASAKI T, 1993, J BIOL CHEM, V268, P23959; SONG JG, 1993, BIOCHEM J, V294, P711, DOI 10.1042/bj2940711; SUGIYAMA T, 1994, BIOCHEM J, V298, P479, DOI 10.1042/bj2980479; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	40	270	271	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					25951	25954						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929302				2022-12-27	WOS:A1994PQ93000003
J	NASTRI, HG; KNIGHT, KL				NASTRI, HG; KNIGHT, KL			IDENTIFICATION OF RESIDUES IN THE L1 REGION OF THE RECA PROTEIN WHICH ARE IMPORTANT TO RECOMBINATION OR COPROTEASE ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; SINGLE-STRANDED-DNA; NUCLEOSIDE TRIPHOSPHATE; LEXA CLEAVAGE; MUTAGENESIS; REPRESSOR; MUTANTS; REPAIR; ACTIVATION; INDUCTION	Using a combinatorial cassette mutagenesis procedure we have introduced a large number of single and multiple amino acid substitutions into an area of the RecA protein defined by residues 152-159. This sequence overlaps the disordered loop 1 region (L1) in the RecA crystal structure which has been hypothesized to be involved in DNA binding. Assays for recombinational DNA repair and LexA coprotease activities identify Glu(154) as the only one of these 8 residues which is critical to RecA function. Several other mutations observed at nearby residues support the identity of Glu(154) as the most important of the 14 residues in the area defined by Pro(151) to, Met(164). In addition, Gly(157) and Glu(158) appear to be hot spots for the occurrence of mutation-induced constitutive coprotease activity.	UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044772] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 44772] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; BRYANT FR, 1988, J BIOL CHEM, V263, P8716; COX MM, 1993, BIOESSAYS, V15, P617, DOI 10.1002/bies.950150908; COX MM, 1991, MOL MICROBIOL, V5, P1295, DOI 10.1111/j.1365-2958.1991.tb00775.x; EGELMAN EH, 1989, SCIENCE, V245, P404, DOI 10.1126/science.2667137; ENNIS DG, 1993, J BACTERIOL, V175, P7373, DOI 10.1128/JB.175.22.7373-7382.1993; FREITAG NE, 1991, J BIOL CHEM, V266, P7058; HANAHAN D, 1991, METHOD ENZYMOL, V204, P63; KNIGHT KL, 1988, BIOCHEMISTRY-US, V27, P2088, DOI 10.1021/bi00406a041; KONOLA JT, 1994, J MOL BIOL, V237, P20, DOI 10.1006/jmbi.1994.1206; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P538; LAVERY PE, 1992, J BIOL CHEM, V267, P20648; LEAHY MC, 1986, J BIOL CHEM, V261, P6954; LEVINSON A, 1984, Journal of Molecular and Applied Genetics, V2, P507; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; LITTLE JW, 1993, J BACTERIOL, V175, P4943, DOI 10.1128/JB.175.16.4943-4950.1993; LIU SK, 1993, J BACTERIOL, V175, P6518, DOI 10.1128/jb.175.20.6518-6529.1993; LOGAN KM, 1993, J MOL BIOL, V232, P1048, DOI 10.1006/jmbi.1993.1459; MCENTEE K, 1981, P NATL ACAD SCI-BIOL, V78, P6061, DOI 10.1073/pnas.78.10.6061; MEAH YS, 1993, J BIOL CHEM, V268, P23991; Miller J.H., 1992, SHORT COURSE BACTERI, P150; OLIPHANT AR, 1986, GENE, V44, P177, DOI 10.1016/0378-1119(86)90180-0; PETERSON KR, 1988, J BACTERIOL, V170, P1; PHIZICKY EM, 1981, CELL, V25, P259, DOI 10.1016/0092-8674(81)90251-8; QUILLARDET P, 1982, MOL GEN GENET, V188, P37, DOI 10.1007/BF00332993; REIDHAAROLSON JF, 1991, METHOD ENZYMOL, V208, P564; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; Sambrook J, 1989, MOL CLONING LABORATO; SKIBA MC, 1994, J BIOL CHEM, V269, P3823; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TESSMAN ES, 1985, J BACTERIOL, V163, P677, DOI 10.1128/JB.163.2.677-687.1985; TESSMAN ES, 1985, J BACTERIOL, V163, P688, DOI 10.1128/JB.163.2.688-695.1985; WANG TCV, 1986, J BACTERIOL, V168, P940, DOI 10.1128/jb.168.2.940-946.1986; WANG WB, 1988, J BACTERIOL, V170, P4823, DOI 10.1128/jb.170.10.4823-4827.1988; WANG WB, 1986, J BACTERIOL, V168, P901, DOI 10.1128/jb.168.2.901-910.1986; WANG WB, 1988, J BACTERIOL, V170, P4816, DOI 10.1128/jb.170.10.4816-4822.1988; WEISEMANN JM, 1988, DNA-J MOLEC CELL BIO, V7, P389, DOI 10.1089/dna.1.1988.7.389; YU X, 1993, J MOL BIOL, V231, P29, DOI 10.1006/jmbi.1993.1254; ZAGURSKY RJ, 1984, GENE, V27, P183, DOI 10.1016/0378-1119(84)90139-2	41	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26311	26322						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929348				2022-12-27	WOS:A1994PQ93000058
J	SIVAKUMAR, B; JAHOOR, F; BURRIN, DG; FRAZER, EM; REEDS, PJ				SIVAKUMAR, B; JAHOOR, F; BURRIN, DG; FRAZER, EM; REEDS, PJ			FRACTIONAL SYNTHESIS RATES OF RETINOL-BINDING PROTEIN, TRANSTHYRETIN, AND A NEW PEPTIDE MEASURED BY STABLE-ISOTOPE TECHNIQUES IN NEONATAL PIGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL MEMBRANE-RECEPTOR; LIVER PARENCHYMAL-CELLS; VITAMIN-A; CALORIE MALNUTRITION; PREALBUMIN CONCENTRATIONS; PLASMA; METABOLISM; COMPLEX; TRANSPORT; TURNOVER	Our objective was to develop a stable isotopic method to measure the synthesis rates of retinol-binding protein (RBP) and transthyretin (TTR). Both proteins were isolated from human and pig plasma by sequential immunoprecipitation and purified by SDS-polyacrylamide gel electrophoresis under denaturing conditions. Both human and pig anti RBP precipitates contained a peptide (TTR2) that had a molecular mass that was similar but not identical to that of TTR subunit. The N-terminal amino acid sequence of porcine TTR2 was highly but not completely homologous with porcine TTR. Human TTR2 showed no homology with TTR but was completely ho mologous with an internal sequence of human fibrinogen alpha chain. To measure the fractional rates of synthesis (FRS) of these peptides, six infant pigs were infused with [H-2(3)]leucine at a constant rate for 6 h, and the amount of [H-2(3)]leucine incorporated into the proteins was measured by negative chemical ionization gas chromatography-mass spectrometry. The plateau isotope ratio of plasma very low density lipoprotein apoB-100-bound leucine was used to estimate the isotopic enrichment of hepatic protein synthetic precursor pool. The mean FRS (% h +/- S.E.) of TTR (1.97 +/- 0.13) and RBP (3.89 +/- 0.07) were significantly different. The FRS of TTR2 was low (0.31 +/- 0.19) relative to that of RBP and TTR. Thus, three different peptides with different turnover rates seem to be involved in the transport of retinol.			SIVAKUMAR, B (corresponding author), BAYLOR COLL MED,DEPT PEDIAT,USDA ARS,CHILDRENS NUTR RES CTR,1100 BATES ST,HOUSTON,TX 77030, USA.		Burrin, Douglas/AID-0081-2022	Burrin, Douglas/0000-0002-8792-3339				BAVIK CO, 1991, J BIOL CHEM, V266, P14978; BAVIK CO, 1993, J BIOL CHEM, V268, P20540; CLAWITTER J, 1990, J BIOL CHEM, V265, P3248; COSTA PMP, 1993, SCAND J IMMUNOL, V38, P177, DOI 10.1111/j.1365-3083.1993.tb01710.x; FARER LS, 1962, ENDOCRINOLOGY, V70, P686, DOI 10.1210/endo-70-5-686; FURLAN M, 1988, FIBRINOEN FIBRIN STA, P18; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; HUANG CC, 1972, J COMP BIOCH PHYSL B, V42, P57; INGENBLEEK Y, 1975, METABOLISM, V24, P633, DOI 10.1016/0026-0495(75)90143-2; JAHOOR F, 1994, AM J PHYSIOL, V267, pR221, DOI 10.1152/ajpregu.1994.267.1.R221; LARGE S, 1980, BRIT J NUTR, V43, P393, DOI 10.1079/BJN19800107; MALABA L, 1993, BIOCHEM J, V291, P187, DOI 10.1042/bj2910187; MOTIL KJ, 1989, J APPL PHYSIOL, V66, P370, DOI 10.1152/jappl.1989.66.1.370; MUTO Y, 1972, J BIOL CHEM, V247, P2542; MUTO Y, 1973, J LIPID RES, V14, P525; MUTO Y, 1972, J BIOL CHEM, V247, P2533; ONG DE, 1979, J BIOL CHEM, V254, P8733; PATTERSON BW, 1991, J LIPID RES, V32, P1063; Peterson P A, 1974, Vitam Horm, V32, P181; PETERSON PA, 1971, EUR J CLIN INVEST, V1, P437, DOI 10.1111/j.1365-2362.1971.tb00555.x; REEDS PJ, 1992, J NUTR, V122, P457; SCHIREIBER G, 1993, COMP BIOCH PHYSL B, V105, P317; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P561; SMITH FR, 1973, AM J CLIN NUTR, V26, P982, DOI 10.1093/ajcn/26.9.982; SMITH FR, 1975, AM J CLIN NUTR, V28, P732, DOI 10.1093/ajcn/28.7.732; SZIALAGYI AK, 1993, ELECTROPHORESIS, V14, P1079; VAHLQUIS.A, 1973, J BIOL CHEM, V248, P4040; VAHLQUIS.A, 1973, EUR J CLIN INVEST, V3, P352, DOI 10.1111/j.1365-2362.1973.tb00362.x; VAHLQUIST A, 1972, SCAND J CLIN LAB INV, V30, P349, DOI 10.3109/00365517209080270; VANBENNEKUM AM, 1993, BIOCHEMISTRY-US, V32, P1727, DOI 10.1021/bi00058a005	30	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26196	26200						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929333				2022-12-27	WOS:A1994PQ93000041
J	ZHUO, SQ; CLEMENS, JC; STONE, RL; DIXON, JE				ZHUO, SQ; CLEMENS, JC; STONE, RL; DIXON, JE			MUTATIONAL ANALYSIS OF A SER/THR PHOSPHATASE - IDENTIFICATION OF RESIDUES IMPORTANT IN PHOSPHOESTERASE SUBSTRATE-BINDING AND CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; ESCHERICHIA-COLI K-12; NUCLEOTIDE-SEQUENCE; GENE; EXPRESSION; 5'-NUCLEOTIDASE; SUBUNIT; CLONING; ENZYME; BACTERIOPHAGE-T4	The Ser/Thr phosphoprotein phosphatases (PPases) display similarities in amino acid sequence and biochemical properties. Most members of this family require transition metal ions for activity. The smallest family member, the bacteriophage lambda PPase (lambda-PPase), has been successfully overexpressed in Escherichia coli, purified, and characterized (Zhuo, S., Clemens, J. C., Hakes, D. J., Barford, D., and Dixon, J. E. (1993) J. Biol. Chem. 268, 17754-17761). Site-directed mutagenesis has now been employed to define amino acid residues in lambda-PPase required for metal ion binding and catalysis. Conservative amino acid substitutions at residues Asp(20), His(22), ASp(49), His(76), and Glu(77) affected lambda-PPase catalysis and metal ion binding, whereas substitutions at residues Arg(53) and Arg(73) affected catalysis and substrate binding. Each of these residues is invariant in all phosphoprotein phosphatases, suggesting that these residues may play important roles in binding and catalysis in all of the PPases. Computer-assisted sequence alignment further revealed that lambda-PPase residues Asp(20), His(22), Asp(49), His(76), Arg(53), and Arg(73) lie within three larger regions of PPase sequence identity with the consensus sequence (DXH-(similar to 25)-GDXXD-(similar to 25)-GNHD/E). This motif can be found in a wide variety of phosphoesterases unrelated to the PPases and defines structural and catalytic features utilized by a diverse group of enzymes for the hydrolysis of phosphate esters.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; WALTHER CANC INST,INDIANAPOLIS,IN 46208	University of Michigan System; University of Michigan; Walther Cancer Institute					NIDDK NIH HHS [NIDDKD 18024] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018024, R01DK018024] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALLOU LM, 1986, ENZYMES, V17; BARKER HM, 1990, GENOMICS, V7, P159, DOI 10.1016/0888-7543(90)90536-4; BARTON GJ, 1994, EUR J BIOCHEM, V220, P225, DOI 10.1111/j.1432-1033.1994.tb18618.x; BLANCHINROLAND S, 1986, MOL GEN GENET, V205, P515, DOI 10.1007/BF00338091; BROOKS SPJ, 1992, BIOTECHNIQUES, V13, P906; BURNS DM, 1986, NUCLEIC ACIDS RES, V14, P4325, DOI 10.1093/nar/14.10.4325; CHAPMAN KB, 1991, CELL, V65, P483, DOI 10.1016/0092-8674(91)90466-C; Cohen P, 1978, Curr Top Cell Regul, V14, P117; COHEN PTW, 1988, GENE, V69, P131, DOI 10.1016/0378-1119(88)90385-X; COHEN PTW, 1989, BIOCHEM J, V260, P931, DOI 10.1042/bj2600931; Dixon N. E., 1983, ZINC ENZYMES; Eadie GS, 1942, J BIOL CHEM, V146, P85; GOOSEN N, 1989, J BACTERIOL, V171, P447, DOI 10.1128/jb.171.1.447-455.1989; GRAM H, 1985, EMBO J, V4, P257, DOI 10.1002/j.1460-2075.1985.tb02344.x; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; HOFSTEE BHJ, 1959, NATURE, V184, P1296, DOI 10.1038/1841296b0; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KOOISTRA J, 1991, J BACTERIOL, V173, P3644, DOI 10.1128/JB.173.12.3644-3655.1991; KOONIN EV, 1994, PROTEIN SCI, V3, P356; KREBS EG, 1986, ENZYMES, V17; KUMANO M, 1986, MOL GEN GENET, V202, P173, DOI 10.1007/BF00331633; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU J, 1986, J BACTERIOL, V165, P1002, DOI 10.1128/jb.165.3.1002-1010.1986; MISUMI Y, 1990, EUR J BIOCHEM, V191, P563, DOI 10.1111/j.1432-1033.1990.tb19158.x; NAOM IS, 1989, NUCLEIC ACIDS RES, V17, P8033, DOI 10.1093/nar/17.20.8033; OCHIAI EI, 1987, GENERAL PRINCIPLES B; POSAS F, 1992, J BIOL CHEM, V267, P11734; RIORDAN JF, 1977, SCIENCE, V195, P884, DOI 10.1126/science.190679; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEELE FR, 1992, CELL, V69, P669, DOI 10.1016/0092-8674(92)90230-A; STONE SR, 1988, NUCLEIC ACIDS RES, V16, P11365, DOI 10.1093/nar/16.23.11365; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAMAO Y, 1991, J BIOCHEM-TOKYO, V109, P24, DOI 10.1093/oxfordjournals.jbchem.a123345; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; ZHUO S, 1993, J BIOL CHEM, V268, P17754; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345	41	150	153	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26234	26238						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929339				2022-12-27	WOS:A1994PQ93000047
J	DIKOV, MM; SPRINGMAN, EB; YEOLA, S; SERAFIN, WE				DIKOV, MM; SPRINGMAN, EB; YEOLA, S; SERAFIN, WE			PROCESSING OF PROCARBOXYPEPTIDASE-A AND OTHER ZYMOGENS IN MURINE MAST-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL PEPTIDASE-I; TOXIC LYMPHOCYTES-T; NATURAL-KILLER-CELLS; LEUCINE METHYL-ESTER; SERINE-PROTEASE; MOLECULAR-CLONING; CARBOXYPEPTIDASE-A; CYTOTOXIC LYMPHOCYTES; SECRETORY GRANULES; CATHEPSIN-G	By cDNA sequence analyses the proteases found within the secretory granules of immune/inflammatory cells appear to be translated initially as zymogens, but by amino-terminal sequencing they are stored within the granules in an active form. We now show that murine mast cell carboxypeptidase A (MC-CPA) is produced in a zymogen form (MC-pro-CPA) that is present at similar to 0.5% of the level of MC-CPA. MC-pro-CPA is an inactive precursor of MC-CPA and is located within the secretory granules of the mast cells. We have identified one mast cell line, KiSV-MC9, that produces MC-pro-CPA yet cannot process it to the active form despite the fact that these cells can process prochymase and protryptase to their active forms, indicating that a separate mechanism exists for activation of the serine proteases. We show that dipeptidylpeptidase-I is involved in the processing of murine mast cell prochymase and procathepsin G, but does not process MC-pro-CPA or protryptase. Thus, mast cell carboxypeptidase, tryptase, and chymase zymogens are each processed to their active forms by different mechanisms.	VANDERBILT UNIV,SCH MED,DEPT MED,DIV ALLERGY,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PHARMACOL,DIV CLIN PHARMACOL,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, T32GM007569] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31273] Funding Source: Medline; NIGMS NIH HHS [GM15431, GM07569] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMADOR E, 1963, CLIN CHEM, V9, P391; ANGLIKER H, 1989, BIOCHEM J, V262, P63, DOI 10.1042/bj2620063; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P561; BROWN GR, 1993, J IMMUNOL, V150, P4733; CAUGHEY GH, 1990, BIOCHEMISTRY-US, V29, P5166, DOI 10.1021/bi00473a024; CAUGHEY GH, 1990, NEUTRAL PROTEASES MA, P67; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; COLE KR, 1991, BIOCHEMISTRY-US, V30, P648, DOI 10.1021/bi00217a009; DEYOUNG MB, 1987, ARCH BIOCHEM BIOPHYS, V254, P222, DOI 10.1016/0003-9861(87)90098-1; EVERITT MT, 1980, FEBS LETT, V110, P292, DOI 10.1016/0014-5793(80)80095-0; GERSHENFELD HK, 1986, SCIENCE, V232, P854, DOI 10.1126/science.2422755; GOLDSTEIN SM, 1987, J IMMUNOL, V139, P2724; GOLDSTEIN SM, 1989, J CLIN INVEST, V83, P1630, DOI 10.1172/JCI114061; GREEN GDJ, 1981, J BIOL CHEM, V256, P1923; GUASCH A, 1992, J MOL BIOL, V224, P141, DOI 10.1016/0022-2836(92)90581-4; HADDAD P, 1990, GENE, V87, P265, DOI 10.1016/0378-1119(90)90311-E; HAMMEL I, 1993, VIRCHOWS ARCH B, V64, P83, DOI 10.1007/BF02915099; HENKART PA, 1987, J IMMUNOL, V139, P2398; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HUANG RY, 1991, EUR J IMMUNOL, V21, P1611, DOI 10.1002/eji.1830210706; JENNE D, 1988, P NATL ACAD SCI USA, V85, P4814, DOI 10.1073/pnas.85.13.4814; JENNE D, 1988, J IMMUNOL, V140, P318; JENNE DE, 1988, IMMUNOL REV, V103, P53, DOI 10.1111/j.1600-065X.1988.tb00749.x; JENNE DE, 1989, BIOCHEMISTRY-US, V28, P7953, DOI 10.1021/bi00445a060; JOHNSON RG, 1990, FEBS LETT, V120, P75; KAMADA MM, 1989, J IMMUNOL, V142, P609; KINOSHITA A, 1991, J BIOL CHEM, V266, P19192; KRAHENBUHL O, 1988, J IMMUNOL, V141, P3471; KURIBAYASHI M, 1993, J BIOCHEM-TOKYO, V113, P441, DOI 10.1093/oxfordjournals.jbchem.a124064; LAGUNOFF D, 1983, EXP CELL RES, V144, P353, DOI 10.1016/0014-4827(83)90414-7; LETRONG H, 1987, P NATL ACAD SCI USA, V84, P2266; LOBE CG, 1986, SCIENCE, V232, P858, DOI 10.1126/science.3518058; MALLORY PA, 1975, BIOCHEMISTRY-US, V14, P722, DOI 10.1021/bi00675a012; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; MCGUIRE MJ, 1992, ARCH BIOCHEM BIOPHYS, V295, P280, DOI 10.1016/0003-9861(92)90519-3; MCNEIL HP, 1992, J IMMUNOL, V149, P2466; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; MEIER M, 1990, BIOCHEMISTRY-US, V29, P4042, DOI 10.1021/bi00469a003; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; NEURATH H, 1989, TRENDS BIOCHEM SCI, V14, P268, DOI 10.1016/0968-0004(89)90061-3; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; RAZIN E, 1984, J IMMUNOL, V132, P1479; REYNOLDS DS, 1989, P NATL ACAD SCI USA, V86, P9480, DOI 10.1073/pnas.86.23.9480; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1988, J BIOL CHEM, V263, P12783; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; REYNOLDS DS, 1993, ROLE MAST CELL HLTH, P247; ROBINSON D, 1968, BIOCHEM J, V107, P321, DOI 10.1042/bj1070321; RUOSS SJ, 1991, J CLIN INVEST, V88, P493, DOI 10.1172/JCI115330; SALVESEN G, 1987, BIOCHEMISTRY-US, V26, P2289, DOI 10.1021/bi00382a032; SALVESEN G, 1990, BIOCHEMISTRY-US, V29, P5304, DOI 10.1021/bi00474a013; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARID J, 1989, J BIOL CHEM, V264, P1022; SAYERS TJ, 1994, J IMMUNOL, V152, P2289; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHECHTER NM, 1988, ARCH BIOCHEM BIOPHYS, V262, P232, DOI 10.1016/0003-9861(88)90185-3; SCHECHTER NM, 1986, J IMMUNOL, V137, P962; SCHECHTER NM, 1990, J IMMUNOL, V145, P2652; SCHWARTZ LB, 1982, J IMMUNOL, V128, P1128; SCHWARTZ LB, 1990, NEUTRAL PROTEASES MA, P90; SEKIZAWA K, 1989, J CLIN INVEST, V83, P175, DOI 10.1172/JCI113855; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SERAFIN WE, 1991, P NATL ACAD SCI USA, V88, P5984, DOI 10.1073/pnas.88.14.5984; SERAFIN WE, 1987, J IMMUNOL, V139, P3771; SERAFIN WE, 1993, J ALLERGY CLIN IMMUN, V91, P255; SERAFIN WE, 1986, J BIOL CHEM, V261, P5017; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMYTH MJ, 1992, J BIOL CHEM, V267, P24418; SMYTH MJ, 1993, J IMMUNOL, V151, P6195; SOMMERHOFF CP, 1989, J IMMUNOL, V142, P2450; SPRINGMAN EB, 1994, BIOL MAST CELL PROTE; TCHEKNEVA E, 1994, J IMMUNOL, V152, P5912; THIELE DL, 1990, J EXP MED, V172, P183, DOI 10.1084/jem.172.1.183; THIELE DL, 1990, P NATL ACAD SCI USA, V87, P83, DOI 10.1073/pnas.87.1.83; URATA H, 1990, J BIOL CHEM, V265, P22348; URATA H, 1993, J BIOL CHEM, V268, P24318; VANDERSLICE P, 1989, BIOCHEMISTRY-US, V28, P4148, DOI 10.1021/bi00436a004; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; VENSEL WH, 1971, BIOCHIM BIOPHYS ACTA, V250, P395, DOI 10.1016/0005-2744(71)90196-3; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; ZUNINO SJ, 1990, J IMMUNOL, V144, P2001	86	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25897	25904						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929294				2022-12-27	WOS:A1994PQ49100096
J	MOSSIER, B; TOGEL, M; FUCHS, K; SIEGHART, W				MOSSIER, B; TOGEL, M; FUCHS, K; SIEGHART, W			IMMUNOAFFINITY PURIFICATION OF GAMMA-AMINOBUTYRIC ACID(A) (GABA(A)) RECEPTORS CONTAINING GAMMA(1)-SUBUNITS - EVIDENCE FOR THE PRESENCE OF A SINGLE TYPE OF GAMMA-SUBUNIT IN GABA(A) RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BENZODIAZEPINE RECEPTORS; RAT-BRAIN; ALPHA-SUBUNIT; MESSENGER-RNAS; EXISTENCE; HETEROGENEITY; PHARMACOLOGY; POPULATIONS	Two polyclonal antibodies were raised against the gamma 1-subunit of gamma-aminobutyric acid(A) (GABA(A)) receptors. One of these antibodies could be used for the immunopurification of GABA(A) receptors containing gamma(1)-subunits. These receptors exhibited [H-3]muscimol and [H-3]flunitrazepam binding, and their benzodiazepine binding properties were dramatically different from those of receptors precipitated by anti-gamma(2)- or anti-gamma(3)-antibodies. Western blot analysis of the immunopurified GABA(A) receptors indicated that the gamma(1)-subunit exhibits an apparent molecular mass of 45-51 kDa. Furthermore, in addition to gamma(1)-subunits, beta(2/3)-, alpha(1)-, alpha(2)-, alpha(3)- and alpha(5)-subunits could be detected in immunoaffinity column eluates from total brain. In contrast, gamma(2)- or gamma(3)-subunits could not be identified in GABA(A) receptors immunopurified by anti-gamma(1)-antibodies. Similarly, gamma(1)- and gamma(3)-subunits or gamma(1)- and gamma(2)-subunits could not be identified in GABA(A) receptors purified by anti-gamma(2)- or anti-gamma(3)-antibodies, respectively. These data seem to indicate that GABA(A) receptors contain only a single type of gamma-subunit.	UNIV VIENNA,PSYCHIAT CLIN,DEPT BIOCHEM PSYCHIAT,A-1090 VIENNA,AUSTRIA	University of Vienna			Sieghart, Werner/A-4877-2013	Sieghart, Werner/0000-0002-0443-0302				BENKE D, 1991, J BIOL CHEM, V266, P4478; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DREXLER G, 1986, J IMMUNOL METHODS, V95, P117, DOI 10.1016/0022-1759(86)90325-X; DUGGAN MJ, 1991, J BIOL CHEM, V266, P24778; EWERT M, 1990, J CELL BIOL, V110, P2043, DOI 10.1083/jcb.110.6.2043; FUCHS K, 1989, NEUROSCI LETT, V97, P329, DOI 10.1016/0304-3940(89)90619-8; KHAN ZU, 1993, J NEUROCHEM, V60, P961, DOI 10.1111/j.1471-4159.1993.tb03243.x; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; MERTENS S, 1993, J BIOL CHEM, V268, P5965; NAYEEM N, 1994, J NEUROCHEM, V62, P815; POLLARD S, 1993, J BIOL CHEM, V268, P3753; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; Sambrook J, 1989, MOL CLONING LABORATO; SIEGHART W, 1992, TRENDS PHARMACOL SCI, V13, P446, DOI 10.1016/0165-6147(92)90142-S; SIEGHART W, 1993, J NEUROCHEM, V60, P93, DOI 10.1111/j.1471-4159.1993.tb05826.x; SIEGHART W, 1992, CELL SIGNAL, V4, P231, DOI 10.1016/0898-6568(92)90062-D; Silviotti L, 1991, PROG NEUROBIOL, V36, P35; TOGEL M, 1994, J BIOL CHEM, V269, P12993; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WISDEN W, 1992, J NEUROSCI, V12, P1040; YMER S, 1990, EMBO J, V9, P3261, DOI 10.1002/j.1460-2075.1990.tb07525.x; ZEZULA J, 1991, FEBS LETT, V284, P15, DOI 10.1016/0014-5793(91)80750-W	23	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25777	25782						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929282				2022-12-27	WOS:A1994PQ49100081
J	MUDGETT, MB; CLARKE, S				MUDGETT, MB; CLARKE, S			HORMONAL AND ENVIRONMENTAL RESPONSIVENESS OF A DEVELOPMENTALLY-REGULATED PROTEIN REPAIR L-ISOASPARTYL METHYLTRANSFERASE IN WHEAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABSCISIC-ACID; ASPARTYL RESIDUES; CARBOXYL METHYLTRANSFERASE; SPONTANEOUS DEGRADATION; GENE-EXPRESSION; SUBCELLULAR-DISTRIBUTION; ASPARAGINYL RESIDUES; OSMOTIC-STRESS; MESSENGER-RNAS; EM POLYPEPTIDE	The L-isoaspartyl protein methyltransferase (EC 2.1.1.77) has been proposed to be involved in the repair of spontaneously damaged proteins by facilitating the conversion of abnormal L-isoaspartyl residues to normal L-aspartyl residues. Based on the abundance of this enzyme in the seeds of a variety of plants and its unique substrate specificity, it has been hypothesized that it functions to prevent the accumulation of abnormal aspartyl residues in the proteins of aging seeds that can limit the viability of the embryo or its chances for germination. In this work, we show that the expression of the L-isoaspartyl methyltransferase is under developmental regulation in the winter wheat, Triticum aestivum. Methyltransferase mRNA and active enzyme are first detected in seeds during the late stages (III-IV) of caryopsis development. As mature seeds germinate, methyltransferase mRNA levels decline and are nearly undetectable by 72 h post-imbibition. Enzyme activity remains constant for 24 h post-imbibition and then decreases rapidly following the reduction of its corresponding mRNA. Methyltransferase activity is very low or undetectable in wheat seedlings, including leaf and root tissues. We show, however, that the L-isoaspartyl methyltransferase can be induced in vegetative tissues in response to hormone treatment and environmental stress. Abscisic acid, a phytohormone involved in seed development and desiccation tolerance, induces both methyltransferase mRNA and enzyme activity in 4-day-old wheat seedlings. Dehydration and salt stress also induce its transcription and enzymatic activity in seedlings. The ability of a plant to regulate methyltransferase activity in its seeds and vegetative tissues in response to desiccation, aging, and environmental stress may allow the plant to efficiently repair protein damage associated with these physiological changes.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	MUDGETT, MB (corresponding author), UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,405 HILGARD AVE,LOS ANGELES,CA 90024, USA.				NIGMS NIH HHS [GM 26020] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, R37GM026020] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON JW, 1967, PHYTOCHEMISTRY, V6, P1047, DOI 10.1016/S0031-9422(00)86061-6; ASWAD DW, 1987, TRENDS BIOCHEM SCI, V12, P155, DOI 10.1016/0968-0004(87)90073-9; Bailey JL, 1967, TECHNIQUES PROTEIN C, P340; BARTEN DM, 1990, LIFE SCI, V47, P181, DOI 10.1016/0024-3205(90)90319-M; BERGE SK, 1989, MOL BASIS PLANT DEV, P193; BLACK M, 1991, ABSCISIC ACID PHYSL, P99; BOSTOCK RM, 1992, PLANT PHYSIOL, V98, P1356, DOI 10.1104/pp.98.4.1356; Bray E. A, 1991, ABSCISIC ACID PHYSL, P81; BRENNAN TV, 1993, PROTEIN SCI, V2, P331; Chandler P. M., 1988, J CELL BIOCHEM     S, V12, P143; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; COHEN A, 1990, PLANTA, V182, P27, DOI 10.1007/BF00239979; CUMING AC, 1984, EUR J BIOCHEM, V145, P351, DOI 10.1111/j.1432-1033.1984.tb08561.x; DILIBERTO EJ, 1976, J NEUROCHEM, V26, P1159, DOI 10.1111/j.1471-4159.1976.tb07001.x; DURE L, 1989, PLANT MOL BIOL, V12, P475, DOI 10.1007/BF00036962; Dure L. III, 1993, Control of plant gene expression., P325; GALAU GA, 1986, PLANT MOL BIOL, V7, P155, DOI 10.1007/BF00021327; GALLETTI P, 1988, BIOCHEMISTRY-US, V27, P1752, DOI 10.1021/bi00405a055; GALUS A, 1994, ARCH BIOCHEM BIOPHYS, V312, P524, DOI 10.1006/abbi.1994.1341; GEIGER T, 1987, J BIOL CHEM, V262, P785; GEORGENASCIMENTO C, 1990, BIOCHEMISTRY-US, V29, P9584, DOI 10.1021/bi00493a012; GOLDBERG RB, 1989, CELL, V56, P149, DOI 10.1016/0092-8674(89)90888-X; GOMEZ J, 1988, NATURE, V334, P262, DOI 10.1038/334262a0; GRZELCZAK ZF, 1982, CAN J BIOCHEM CELL B, V60, P389, DOI 10.1139/o82-046; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; GUILTINAN MJ, 1990, SCIENCE, V250, P20131; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; LADINO CA, 1992, J CELL PHYSIOL, V153, P297, DOI 10.1002/jcp.1041530209; LANE BG, 1991, FASEB J, V5, P2893, DOI 10.1096/fasebj.5.14.1752357; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LI C, 1992, P NATL ACAD SCI USA, V89, P9885, DOI 10.1073/pnas.89.20.9885; LITTS JC, 1987, NUCLEIC ACIDS RES, V15, P3607, DOI 10.1093/nar/15.8.3607; LOWENSON JD, 1991, GERONTOLOGY, V37, P128; LOWENSON JD, 1992, J BIOL CHEM, V267, P5985; MARCOTTE WR, 1988, NATURE, V335, P454, DOI 10.1038/335454a0; MARCOTTE WR, 1989, PLANT CELL, V1, P969, DOI 10.2307/3868997; MCFADDEN PN, 1987, P NATL ACAD SCI USA, V84, P2595, DOI 10.1073/pnas.84.9.2595; MIZOBUCHI M, 1994, J NEUROCHEM, V62, P322; MORRIS PC, 1990, EUR J BIOCHEM, V190, P625, DOI 10.1111/j.1432-1033.1990.tb15618.x; MUDGETT MB, 1993, BIOCHEMISTRY-US, V32, P11100, DOI 10.1021/bi00092a020; MUNDY J, 1990, P NATL ACAD SCI USA, V87, P1406, DOI 10.1073/pnas.87.4.1406; MUNDY J, 1988, EMBO J, V7, P2279, DOI 10.1002/j.1460-2075.1988.tb03070.x; OCONNOR CM, 1989, GAMETE RES, V22, P307, DOI 10.1002/mrd.1120220308; OCONNOR CM, 1987, J BIOL CHEM, V262, P10398; OEDA K, 1991, EMBO J, V10, P1793, DOI 10.1002/j.1460-2075.1991.tb07704.x; PLA M, 1989, PLANT MOL BIOL, V13, P385, DOI 10.1007/BF00015550; Quatrano R. S., 1986, Oxford Surveys of Plant Molecular and Cell Biology, V3, P467; QUATRANO RS, 1992, CONTROL PLANT GENE E, P69; ROGERS SO, 1983, AM J BOT, V70, P308, DOI 10.2307/2443277; ROMANIK EA, 1992, GENE, V118, P217, DOI 10.1016/0378-1119(92)90191-Q; Sambrook J, 1989, MOL CLONING LABORATO; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; TRIVEDI L, 1982, EUR J BIOCHEM, V128, P349; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362; WILLIAMSON JD, 1985, EUR J BIOCHEM, V152, P501, DOI 10.1111/j.1432-1033.1985.tb09224.x; WILLIAMSON JD, 1988, PLANT PHYSIOL, V86, P208, DOI 10.1104/pp.86.1.208; ZEEVAART JAD, 1988, ANNU REV PLANT PHYS, V39, P439, DOI 10.1146/annurev.arplant.39.1.439	59	49	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25605	25612						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929264				2022-12-27	WOS:A1994PQ49100059
J	PAN, P; JAKOB, CA; SANDMEIER, E; CHRISTEN, P; GEHRING, H				PAN, P; JAKOB, CA; SANDMEIER, E; CHRISTEN, P; GEHRING, H			MODULATION OF THE ACTIVITY OF MITOCHONDRIAL ASPARTATE-AMINOTRANSFERASE H352C BY THE REDOX STATE OF THE ENGINEERED INTERDOMAIN DISULFIDE BOND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL-CHANGES; ENZYME; MUTAGENESIS; EXCHANGE	Molecular modeling suggested that the large and small domain of mitochondrial aspartate aminotransferase might be linked by an engineered disulfide bond that could be expected to interfere with ligand-induced and syncatalytic changes in conformation and thus to assist in the elucidation of their significance for the catalytic mechanism. His-352, which is situated in the small domain close to Cys-166 of the large domain, was replaced with a cysteine residue by oligonucleotide-directed mutagenesis. Aspartate aminotransferase H352C, that had not been exposed to reducing conditions, in part contained a disulfide bond between Cys-166 and Cys-352. Exposure to a reducing agent cleaved the cross-link completely and produced an enzyme derivative with 8% of the activity of the wild type enzyme. Cu2+-mediated autoxidation resulted in complete formation of the disulfide bond and a decrease in enzymic activity to 2%. Independently of the redox state of the disulfide bond, the H352C substitution seems to shift the equilibrium from the open toward the closed conformation of the enzyme. This change in conformation was accompanied by an increase in the binding affinity for both the amino and oxo acid substrate by one order of magnitude. Apparently, 1-2 kcal/mol of the binding energy of the substrates are no longer diverted to shift the conformational equilibrium toward the closed conformation. The k(cat)/K-m values were unchanged or even increased in the reduced form of the mutant enzyme and only slightly decreased in its oxidized form, Both the disulfide-independent decrease in enzymic activity, as observed in reduced aspartate aminotransferase H352C and also in two other mutant enzymes (C166H/H352C and H352Q), and the redox-dependent modulation of activity indicate that unhindered domain movements are essential for full catalytic competence of aspartate aminotransferase.	UNIV ZURICH,INST BIOCHEM,CH-8057 ZURICH,SWITZERLAND	University of Zurich								Christen P, 1982, Methods Biochem Anal, V28, P151, DOI 10.1002/9780470110485.ch3; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GEHRING H, 1978, J BIOL CHEM, V253, P3158; HOHENESTER E, 1994, J MOL BIOL, V236, P963, DOI 10.1016/0022-2836(94)90001-9; Jocelyn P. C., 1972, BIOCH SH GROUP, P94; KIRSCH JF, 1984, J MOL BIOL, V174, P497, DOI 10.1016/0022-2836(84)90333-4; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MALASHKEVICH VN, 1993, BIOCHEMISTRY-US, V32, P13451, DOI 10.1021/bi00212a010; MATSUMURA M, 1989, SCIENCE, V243, P792, DOI 10.1126/science.2916125; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; MEER L, 1984, CHEM BIOL ASPECTS  B, P277; PAN P, 1994, BIOCHEMISTRY-US, V33, P2757, DOI 10.1021/bi00176a003; PEDERSEN AO, 1980, EUR J BIOCHEM, V106, P291; PERRY LJ, 1986, BIOCHEMISTRY-US, V25, P733, DOI 10.1021/bi00351a034; PFISTER K, 1985, J BIOL CHEM, V260, P1414; PICOT D, 1991, EUR J BIOCHEM, V196, P329, DOI 10.1111/j.1432-1033.1991.tb15821.x; SANDMEIER E, 1980, J BIOL CHEM, V255, P284; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOWDHAMINI R, 1989, PROTEIN ENG, V3, P95, DOI 10.1093/protein/3.2.95; STERK M, 1994, EUR J BIOCHEM, V219, P993, DOI 10.1111/j.1432-1033.1994.tb18582.x; ZIAK M, 1993, EUR J BIOCHEM, V211, P475, DOI 10.1111/j.1432-1033.1993.tb17573.x	21	5	5	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25432	25436						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929241				2022-12-27	WOS:A1994PQ49100034
J	NAKAMURA, H; IZUMOTO, Y; KAMBE, H; KURODA, T; MORI, T; KAWAMURA, K; YAMAMOTO, H; KISHIMOTO, T				NAKAMURA, H; IZUMOTO, Y; KAMBE, H; KURODA, T; MORI, T; KAWAMURA, K; YAMAMOTO, H; KISHIMOTO, T			MOLECULAR-CLONING OF COMPLEMENTARY-DNA FOR A NOVEL HUMAN HEPATOMA-DERIVED GROWTH-FACTOR - ITS HOMOLOGY WITH HIGH-MOBILITY GROUP-1 PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL-PROTEINS; CELLS; EXPRESSION; SEQUENCE; HMG1; NUCLEAR; LOCALIZATION; AMPHOTERIN; AUTOCRINE; HMG-I(Y)	A novel hepatoma-derived growth factor was purified from the conditioned medium of human hepatoma-derived cell line, HuH-7, by the assay of [H-3]thymidine incorporation into Swiss 3T3 cells. Molecular cloning of a complementary DNA from the cDNA Library of HuH-7 cells was done on the basis of the N-terminal amino acid sequence. This protein was acid- and heat-labile heparin-binding protein and inactivated by reducing condition. The cDNA is 2.4 kilobase pairs long, and the deduced amino acid sequence from cDNA contained 240 amino acids without a signal peptide-like N-terminal hydrophobic sequence. Heparin column-eluted fraction of the conditioned medium of Cos-7 cells transfected by the cDNA stimulated the DNA synthesis. Northern blot analysis revealed its ubiquitous expression in several tumor-derived cell lines, as well as in normal tissues. The primary sequence shares homology with the high mobility group (HMG)-1 protein (23.4% amino acid identity and 35.6% similarity). However, its hydrophobic profile was distinct from that of HMG-1 except for the C-terminal acidic region, and it contained no apparent HMG box motif. Immunofluorescence study showed that it is localized in the cytoplasma of hepatoma cells. These findings suggest that this factor is a novel heparin-binding protein, with mitogenic activity for fibroblasts.	SEKISUI CHEM CO LTD,CHEM RES INST,BIOTECHNOL RES LAB,SHIMAMOTO,OSAKA 618,JAPAN	Sekisui Chemical Co Ltd	NAKAMURA, H (corresponding author), OSAKA UNIV,SCH MED,DEPT MED 3,YAMADA OKA 2-2,SUITA,OSAKA 565,JAPAN.		Kishimoto, Tadamitsu/C-8470-2009					AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BIANCHI ME, 1992, NUCLEIC ACIDS MOL BI, V6, P112; BONNEANDREA C, 1984, EMBO J, V3, P1193, DOI 10.1002/j.1460-2075.1984.tb01950.x; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; DANG CV, 1989, J BIOL CHEM, V264, P18019; EINCK L, 1985, EXP CELL RES, V156, P295, DOI 10.1016/0014-4827(85)90539-7; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; HAMADA H, 1985, BIOCHEMISTRY-US, V24, P1428, DOI 10.1021/bi00327a022; JAVAHERIAN K, 1978, SCIENCE, V199, P1345, DOI 10.1126/science.628842; JAVAHERIAN K, 1979, NUCLEIC ACIDS RES, V6, P3569, DOI 10.1093/nar/6.11.3569; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; KAN M, 1989, P NATL ACAD SCI USA, V86, P7432, DOI 10.1073/pnas.86.19.7432; KLAGSBRUN M, 1986, P NATL ACAD SCI USA, V83, P2448, DOI 10.1073/pnas.83.8.2448; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUEHL L, 1985, J BIOL CHEM, V260, P361; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; MIGNATTI P, 1991, P NATL ACAD SCI USA, V88, P11007, DOI 10.1073/pnas.88.24.11007; MOSEVITSKY MI, 1989, EUR J BIOCHEM, V185, P303, DOI 10.1111/j.1432-1033.1989.tb15116.x; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; NAKAMURA H, 1989, CLIN CHIM ACTA, V183, P273, DOI 10.1016/0009-8981(89)90361-6; PARKKINEN J, 1993, J BIOL CHEM, V268, P19726; RAECK GR, 1982, NATURE, V300, P76; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIRAKAWA H, 1990, BIOCHEMISTRY-US, V29, P4419, DOI 10.1021/bi00470a022; SINGH J, 1990, BIOCHEMISTRY-US, V29, P6295, DOI 10.1021/bi00478a026; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA K, 1990, FEBS LETT, V271, P41, DOI 10.1016/0014-5793(90)80367-R; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TREMETHICK DJ, 1986, J BIOL CHEM, V261, P6986; VERTIANEN EJ, 1988, FEBS LETT, V288, P445; WEN L, 1989, NUCLEIC ACIDS RES, V17, P1197, DOI 10.1093/nar/17.3.1197; YE RD, 1988, J BIOL CHEM, V263, P4869	37	182	202	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25143	25149						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929202				2022-12-27	WOS:A1994PQ49000092
J	STOECKLIN, G; HAHN, S; MORONI, C				STOECKLIN, G; HAHN, S; MORONI, C			FUNCTIONAL HIERARCHY OF AUUUA MOTIFS IN MEDIATING RAPID INTERLEUKIN-3 MESSENGER-RNA DECAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; MAST-CELLS; GM-CSF; MURINE INTERLEUKIN-3; EUKARYOTIC CELLS; RICH SEQUENCES; C-FOS; TRANSFORMATION; DEGRADATION	In mast cells, expression of interleukin 3 (IL-3) is induced following IgE-receptor activation via calcium-dependent mRNA stabilization. We performed a mutational analysis of the 8 AUUUA motifs located in the 3'-untranslated region of IL-3 mRNA, and analyzed the effect on mRNA stability in PB-3c mast cells. Similar to endogenous IL-3 mRNA, exogenous IL-3 transcripts had a short half-life and were stabilized following stimulation of calcium influx by ionomycin. Specific mutation of 3 AUUUA motifs had almost the same stabilizing effect as deletion of the entire AU-rich region. Mutating even a single critical motif led to a weak, but significant mRNA stabilization. Ionomycin treatment did not further enhance the expression of mutationally stabilized transcripts. Our data fit a model, where within a cluster of 6 AUUUA motifs, 3 adjacent motifs are required for binding of a factor which mediates rapid IL-3 mRNA decay, Activity of such a factor might be under control of a calcium-dependent pathway.	UNIV BASEL,DEPT MED MICROBIOL,CH-4003 BASEL,SWITZERLAND	University of Basel				Stoecklin, Georg/0000-0001-9284-9834				ALBERTA JA, 1994, J BIOL CHEM, V269, P4532; ALGATE PA, 1993, ONCOGENE, V8, P1221; BALL PE, 1983, DIFFERENTIATION, V24, P74, DOI 10.1111/j.1432-0436.1983.tb01305.x; BICKEL M, 1992, P NATL ACAD SCI USA, V89, P10001, DOI 10.1073/pnas.89.21.10001; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BONNIEU A, 1990, ONCOGENE, V5, P1585; CAMPBELL HD, 1985, EUR J BIOCHEM, V150, P297, DOI 10.1111/j.1432-1033.1985.tb09020.x; CARTER BZ, 1991, LAB INVEST, V65, P610; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HAHN S, 1991, ONCOGENE, V6, P2327; HAHN S, 1994, LYMPHOKINE CYTOK RES, V13, P245; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HATFIELD SM, 1992, J PHARMACOL EXP THER, V260, P680; HENTZE MW, 1991, BIOCHIM BIOPHYS ACTA, V1090, P281, DOI 10.1016/0167-4781(91)90191-N; HIRSCH HH, 1993, J EXP MED, V178, P403, DOI 10.1084/jem.178.2.403; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Kelso A, 1989, GROWTH FACTORS, V1, P165, DOI 10.3109/08977198909029126; KINDLER V, 1986, P NATL ACAD SCI USA, V83, P1001, DOI 10.1073/pnas.83.4.1001; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; NAIR APK, 1992, ONCOGENE, V7, P1963; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; NAIR APK, 1994, NATURE, V369, P239, DOI 10.1038/369239a0; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHIAVI SC, 1992, BIOCHIM BIOPHYS ACTA, V1114, P95, DOI 10.1016/0304-419X(92)90009-N; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777	42	101	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28591	28597						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961806				2022-12-27	WOS:A1994PU16800015
J	CZERNIK, PJ; SHIN, DS; HURLBURT, BK				CZERNIK, PJ; SHIN, DS; HURLBURT, BK			FUNCTIONAL SELECTION AND CHARACTERIZATION OF DNA-BINDING SITES FOR TRP REPRESSOR OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL GENE; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; L-TRYPTOPHAN; OPERATOR; APOREPRESSOR; AFFINITY; AROH; RESOLUTION; EXPRESSION	trp repressor of Escherichia coli controls transcription initiation in operons involved in tryptophan biosynthesis by binding to operator sequences within the regulated promoters. Naturally occurring operators are homologous over an 18-base pair region and display dyad symmetry. We have examined the sequence determinants of a repressor binding site using a functional selection/polymerase chain reaction (PCR) amplification strategy. A trp repressor affinity column was generated and used to select binding-competent DNAs from a randomized pool of synthetic double-stranded DNA. DNAs that showed tryptophan-dependent high-affinity binding were eluted by addition of the tryptophan analog beta-indole acrylic acid and amplified by PCR. Following iterative cycles of affinity chromatography and PCR, the selected DNAs were cloned and sequenced. The CTAG tetranucleotide, present in the consensus sequence of all natural operators, was found in all selected DNAs. Mapping experiments utilizing the repressor affinity column showed the CTAG motif to be a critical determinant for repressor binding. Quantitative electrophoretic mobility shift assays with purified trp repressor revealed that although some of the DNAs were bound by one repressor dimer, others were bound by two repressor dimers with cooperativity. Measured binding constants ranged from 0.035 to 0.5 nM for the selected DNAs, compared with 0.1 nM for the trp operator.	UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205	University of Arkansas System; University of Arkansas Medical Sciences					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047264] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47264] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARROWSMITH C, 1991, EUR J BIOCHEM, V202, P53, DOI 10.1111/j.1432-1033.1991.tb16344.x; ARROWSMITH CH, 1989, BIOCHEMISTRY-US, V28, P3875, DOI 10.1021/bi00435a037; ARVIDSON DN, 1986, J BIOL CHEM, V261, P238; BASS S, 1987, GENE DEV, V1, P565, DOI 10.1101/gad.1.6.565; BENNETT GN, 1978, J MOL BIOL, V121, P179, DOI 10.1016/S0022-2836(78)80004-7; CAREY J, 1989, J BIOL CHEM, V264, P1941; CAREY J, 1991, J BIOL CHEM, V266, P24509; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; CHOU WY, 1989, J BIOL CHEM, V264, P18309; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GUNSALUS RP, 1980, P NATL ACAD SCI-BIOL, V77, P7117, DOI 10.1073/pnas.77.12.7117; HARAN TE, 1992, EMBO J, V11, P3021, DOI 10.1002/j.1460-2075.1992.tb05372.x; HEATWOLE VM, 1991, J BACTERIOL, V173, P108, DOI 10.1128/jb.173.1.108-115.1991; HURLBURT BK, 1992, NUCLEIC ACIDS RES, V20, P337, DOI 10.1093/nar/20.2.337; HURLBURT BK, 1990, J BIOL CHEM, V265, P7853; JOACHIMIAK A, 1983, P NATL ACAD SCI-BIOL, V80, P668, DOI 10.1073/pnas.80.3.668; KLIG LS, 1988, J MOL BIOL, V202, P769, DOI 10.1016/0022-2836(88)90557-8; KUMAMOTO AA, 1987, GENE DEV, V1, P556, DOI 10.1101/gad.1.6.556; LAWSON CL, 1993, NATURE, V366, P178, DOI 10.1038/366178a0; LIU YC, 1993, J BIOL CHEM, V268, P23239; MARMORSTEIN RQ, 1991, BIOCHEMISTRY-US, V30, P1141, DOI 10.1021/bi00218a036; MARMORSTEIN RQ, 1989, J BIOL CHEM, V264, P9149; MARTIN KS, 1994, BIOPHYS J, V66, P1167, DOI 10.1016/S0006-3495(94)80898-7; MAZZARELLI JM, 1992, BIOCHEMISTRY-US, V31, P5925, DOI 10.1021/bi00140a032; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PENG L, 1987, APPL BIOCHEM BIOTECH, V14, P91, DOI 10.1007/BF02798427; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; SARSERO JP, 1991, J BACTERIOL, V173, P4133, DOI 10.1128/jb.173.13.4133-4143.1991; SCHEVITZ RW, 1985, NATURE, V317, P782, DOI 10.1038/317782a0; SIGLER PB, 1992, TRANSCRIPTIONAL REGU; SQUIRES CL, 1975, J MOL BIOL, V92, P93, DOI 10.1016/0022-2836(75)90093-5; STAACKE D, 1990, EMBO J, V9, P1963, DOI 10.1002/j.1460-2075.1990.tb08324.x; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; ZHANG H, 1994, J MOL BIOL, V238, P592, DOI 10.1006/jmbi.1994.1317; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0; ZHAO D, 1993, J MOL BIOL, V229, P735, DOI 10.1006/jmbi.1993.1076; ZURAWSKI G, 1981, J MOL BIOL, V145, P47, DOI 10.1016/0022-2836(81)90334-X	38	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27869	27875						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961717				2022-12-27	WOS:A1994PV77200018
J	HARNISH, DC; MALIK, S; KARATHANASIS, SK				HARNISH, DC; MALIK, S; KARATHANASIS, SK			ACTIVATION OF APOLIPOPROTEIN AI GENE-TRANSCRIPTION BY THE LIVER-ENRICHED FACTOR HNF-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; NUCLEAR FACTOR-III; I GENE; SYNERGISTIC INTERACTIONS; CONTROL EXPRESSION; PROMOTER ELEMENTS; BINDING PROTEINS; MESSENGER-RNA; B GENE; C-III	Liver-specific expression of the apolipoprotein AI (apoA-I) gene is controlled by the coordinate action of transcription factors bound to three sites (A, B, and C) located within a powerful liver-specific enhancer which spans the -222 to -110 region upstream of the apoA-I gene transcription start site (+1). Sites A and C bind various members of the nuclear receptor superfamily including the Liver-enriched factor HNF-4. In the current report, enhancer derivatives with mutagenized protein-binding sites were tested for their ability to stimulate the apoA-I basal promoter in hepatoblastoma HepG2 cells. The results revealed that occupation of both sites A and B, but not C is essential for high level expression. Electrophoretic mobility shift assays showed that in HepG2 cells site B is occupied by the liver-enriched factor HNF-3 beta. Binding of HNF-3 beta to site B transactivates the apoA-I basal promoter in hepatic and nonhepatic cells. HNF-3 beta binding and transactivation were dependent upon the close proximity of two HNF-3 beta binding motifs within site B. Furthermore, HNF-3 beta and HNF-4, bound to their cognate sites within the apoA-I enhancer exhibited strong synergy in transactivation of the apoA-I basal promoter in nonhepatic cells, highlighting the central role of HNF-3 beta in liver-specific transcription of the apoA-I gene. It is concluded that cooperative binding of HNF-3 beta to site B and synergistic interactions between HNF-4 and HNF-3 beta bound to their cognate sites in the apoA-I enhancer may play a fundamental role in apoA-I gene expression in liver.	AMER CYANAMID CO,LEDERLE LABS,DEPT CARDIOVASC MOLEC BIOL,PEARL RIVER,NY 10965									APOSTOLOPOULOS JJ, 1988, BIOCHEM BIOPH RES CO, V154, P997, DOI 10.1016/0006-291X(88)90238-0; BLAU HM, 1992, ANNU REV BIOCHEM, V61, P1213, DOI 10.1146/annurev.bi.61.070192.010025; BROOKS AR, 1991, J BIOL CHEM, V266, P7848; CHAN J, 1993, NUCLEIC ACIDS RES, V21, P1205, DOI 10.1093/nar/21.5.1205; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; COSTA RH, 1991, NUCLEIC ACIDS RES, V19, P4139, DOI 10.1093/nar/19.15.4139; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; DREWES T, 1991, NUCLEIC ACIDS RES, V19, P6383, DOI 10.1093/nar/19.23.6383; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P8242, DOI 10.1073/pnas.82.23.8242; ETTINGER WH, 1994, ARTERIOSCLER THROMB, V14, P8, DOI 10.1161/01.ATV.14.1.8; FREEDMAN A, 1989, GENE DEV, V3, P1314; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GE RW, 1994, J BIOL CHEM, V269, P13185; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREGORI C, 1993, NUCLEIC ACIDS RES, V21, P897, DOI 10.1093/nar/21.4.897; HADDAD IA, 1986, J BIOL CHEM, V261, P3268; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; KARATHANASIS SK, 1992, MONOGR HUM GENET, V14, P140; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEMAIGRE FP, 1993, J BIOL CHEM, V268, P19896; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MOLOWA DT, 1992, BIOCHEMISTRY-US, V31, P2539, DOI 10.1021/bi00124a014; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; PAULWEBER B, 1993, MOL CELL BIOL, V13, P1534, DOI 10.1128/MCB.13.3.1534; PETROPOULOS I, 1991, J BIOL CHEM, V266, P24220; POTTER JJ, 1992, ARCH BIOCHEM BIOPHYS, V295, P360, DOI 10.1016/0003-9861(92)90529-6; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; Sambrook J, 1989, MOL CLONING LABORATO; SASTRY KN, 1988, MOL CELL BIOL, V8, P605, DOI 10.1128/MCB.8.2.605; SORCITHOMAS M, 1989, J LIPID RES, V30, P1397; STAELS B, 1992, ARTERIOSCLER THROMB, V12, P286, DOI 10.1161/01.ATV.12.3.286; TAM SP, 1986, P NATL ACAD SCI USA, V83, P3111, DOI 10.1073/pnas.83.10.3111; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WIDOM RL, 1991, MOL CELL BIOL, V11, P677, DOI 10.1128/MCB.11.2.677; WU AL, 1979, J BIOL CHEM, V254, P7316; XANTHOPOULOS KG, 1993, EUR J BIOCHEM, V216, P353, DOI 10.1111/j.1432-1033.1993.tb18152.x; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469	49	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28220	28226						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961760				2022-12-27	WOS:A1994PV77200068
J	IKEBE, M; REARDON, S; SCHWONEK, JP; SANDERS, CR; IKEBE, R				IKEBE, M; REARDON, S; SCHWONEK, JP; SANDERS, CR; IKEBE, R			STRUCTURAL REQUIREMENT OF THE REGULATORY LIGHT-CHAIN OF SMOOTH-MUSCLE MYOSIN AS A SUBSTRATE FOR MYOSIN LIGHT-CHAIN KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CHICKEN GIZZARD; BASIC RESIDUES; CALMODULIN BINDING; SYNTHETIC PEPTIDES; PHOSPHORYLATION; PROTEIN; PURIFICATION; BACTERIOPHAGE-T7; IDENTIFICATION	The substrate structure required for skeletal and smooth muscle myosin light chain kinases (MLC kinase) was studied by using various mutant regulatory light chains of smooth muscle myosin. The deletion of the NH2-terminal 10 residues did not greatly affect the kinetic parameters of smooth MLC kinase; however, deletion of an additional 3 residues, Lys(11)-Arg(13), prevented phosphorylation. In contrast, deletion of Lys(11)-Arg(13) did not completely abolish the phosphorylation for skeletal MLC kinase, and deletion of three additional residues was required for complete inhibition. Substitution of Arg(16) with Glu markedly decreased V-max for both smooth and skeletal MLC kinases. Substitution of Lys(11)-Arg(13) with acidic or noncharged residues decreased V-max, but these changes were much lower than that occurring on substitution of Arg(16). Replacement of Lys(11)-Arg(13) with acidic residues reduced the affinity of the free LC(20) but had little effect on the myosin-incorporated LC(20). These results were different from those previously obtained with synthetic peptide analogs (Kemp, B. E., Pearson, R. B., and House, C. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 7471-7475) and suggest that a cluster of the basic amino acid residues are not fundamentally important for substrate recognition. The structural simulation revealed that the guanidyl group of Arg(16) but not the corresponding Glu(13) of skeletal Light chain resides in close proximity to Ser(19), suggesting that the guanidyl group of Arg(16) stabilizes the phosphate transfer and that the introduction of Glu at the 16th position would significantly destabilize this reaction.			IKEBE, M (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106, USA.				NHLBI NIH HHS [HL37117] Funding Source: Medline; NIAMS NIH HHS [AR41653] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL037117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; COLLINGE M, 1992, MOL CELL BIOL, V12, P2359, DOI 10.1128/MCB.12.5.2359; DABROWSKA R, 1977, BIOCHEM BIOPH RES CO, V78, P1263, DOI 10.1016/0006-291X(77)91429-2; FITZSIMONS DP, 1992, J BIOL CHEM, V267, P23903; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; GAN ZH, 1992, BIOCHEMISTRY-US, V31, P6126; HATHAWAY DR, 1979, P NATL ACAD SCI USA, V76, P1653, DOI 10.1073/pnas.76.4.1653; HATHAWAY DR, 1983, ANAL BIOCHEM, V135, P37, DOI 10.1016/0003-2697(83)90726-1; HERRING BP, 1991, J BIOL CHEM, V266, P11838; HERRING BP, 1992, J BIOL CHEM, V267, P25945; HOOVER WG, 1985, PHYS REV A, V31, P1695, DOI 10.1103/PhysRevA.31.1695; IKEBE M, 1992, FEBS LETT, V312, P245, DOI 10.1016/0014-5793(92)80944-C; IKEBE M, 1994, J BIOL CHEM, V269, P28173; IKEBE M, 1987, J BIOL CHEM, V262, P13828; IKEBE M, 1986, J BIOL CHEM, V261, P36; IKEBE M, 1985, J BIOL CHEM, V260, P27; KAMISOYAMA H, 1994, BIOCHEMISTRY-US, V33, P840, DOI 10.1021/bi00169a027; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KANOH S, 1993, BIOCHEMISTRY-US, V32, P8902, DOI 10.1021/bi00085a023; KEMP BE, 1983, P NATL ACAD SCI-BIOL, V80, P7471, DOI 10.1073/pnas.80.24.7471; KEMP BE, 1985, J BIOL CHEM, V260, P3355; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAITA T, 1981, EUR J BIOCHEM, V117, P417, DOI 10.1111/j.1432-1033.1981.tb06354.x; MAYO SL, 1990, J PHYS CHEM-US, V94, P8897, DOI 10.1021/j100389a010; MICHNOFF CH, 1986, J BIOL CHEM, V261, P8320; NUNNALLY MH, 1985, J BIOL CHEM, V260, P1020; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; PEARSON RB, 1986, J BIOL CHEM, V261, P25; PEARSON RB, 1991, EUR J BIOCHEM, V200, P723, DOI 10.1111/j.1432-1033.1991.tb16237.x; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; PIRES EMV, 1977, BIOCHEM J, V187, P137; RAPPE AK, 1991, J PHYS CHEM-US, V95, P3358, DOI 10.1021/j100161a070; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; STULL JT, 1986, ENZYMES, V17, P114; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAKIO K, 1986, BIOCHEMISTRY-US, V25, P8049, DOI 10.1021/bi00372a038; TBKUI T, 1994, BIOPHYS J, V66, pA31; WALSH MP, 1983, METHOD ENZYMOL, V99, P279; WALSH MP, 1979, J BIOL CHEM, V254, P2136; WATERSON DM, 1976, J BIOL CHEM, V251, P4501; YANO K, 1993, BIOCHEMISTRY-US, V32, P12054, DOI 10.1021/bi00096a016; YOSHIKAI S, 1992, ARCH BIOCHEM BIOPHYS, V299, P242, DOI 10.1016/0003-9861(92)90270-7; ZHI G, 1993, BIOPHYS J, V64, pA143	49	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28165	28172						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961752				2022-12-27	WOS:A1994PV77200060
J	KISHIMOTO, I; YOSHIMASA, T; SUGA, S; OGAWA, Y; KOMATSU, Y; NAKAGAWA, O; ITOH, H; NAKAO, K				KISHIMOTO, I; YOSHIMASA, T; SUGA, S; OGAWA, Y; KOMATSU, Y; NAKAGAWA, O; ITOH, H; NAKAO, K			NATRIURETIC PEPTIDE CLEARANCE RECEPTOR IS TRANSCRIPTIONALLY DOWN-REGULATED BY BETA(2)-ADRENERGIC STIMULATION IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; GUANYLATE-CYCLASE; CARDIAC MYOCYTES; GENE-EXPRESSION; ALPHA-HUMAN; A RECEPTOR; ATRIAL; POLYPEPTIDE; BRAIN; HYPERTROPHY	Three natriuretic peptide receptors (the ANP-A, ANP-B, and clearance (C) receptors) have been reported. The regulation of these receptors by catecholamines was examined in cultured rat vascular smooth muscle cells. Treatment with norepinephrine decreased the maximum I-125-ANP binding. The competitive binding assay with des[Gln(18),Ser(19),Gly(20),Leu(21),Gly(22)]ANP-(4-23)-NH2 (C-ANF-4-23), a specific ligand for the C receptor, revealed that the decrease in the I-125-ANP binding by norepinephrine was caused by the down-regulation of the C receptor. Isoproterenol also down-regulated the C receptor in a time- and dose-dependent manner. The catecholamine-induced downregulation of the C receptor was antagonized by a beta(2)-selective adrenergic antagonist, ICI 118,551 but not by an alpha(1)-, alpha(2)-, or beta(1)-adrenergic antagonist. Forskolin, NaF and, 8-bromo-cyclic AMP also decreased the C receptor density. The isoproterenol-induced decrease in the C receptor level was further confirmed by affinity crosslinking and Western blot analysis. Northern blot analysis revealed that isoproterenol and 8-bromo-cyclic AMP decreased the steady-state level of C receptor mRNA. By contrast, neither the ANP-A receptor nor the ANP-B receptor mRNA level was affected by 8-bromo-cyclic AMP. The nuclear run-on assay showed that the transcriptional rate of the C receptor gene was decreased by isoproterenol, whereas those of the ANP-A and ANP-B receptor genes were unchanged. Isoproterenol attenuated the clearance of exogenously added ANP and augmented the ANP-stimulated intracellular cyclic GMP production to the same extent as the selective occupancy of the C receptor with C-ANF-(4-23), suggesting that the isoproterenol-induced enhancement of responsiveness to ANP could result not from the sensitization of the ANP-A or ANP-B receptor but from the down-regulation of the C receptor, which leads to the attenuated clearance of ANP. These findings suggest that the beta(2)-adrenergic receptor stimulation down-regulates the C receptor through the decrease in the transcriptional rate of the C receptor gene and that the activation of the sympathetic nervous system augments the biological responsiveness to natriuretic peptides by attenuating their metabolic clearance in vascular walls.	KYOTO UNIV,FAC MED,DEPT MED,DIV 2,SAKYO KU,KYOTO 606,JAPAN	Kyoto University				Ogawa, Yoshihiro/0000-0002-0834-2836				BRAUNWALD E, 1992, HEART DISEASE, P408; CHABRIER PE, 1988, J BIOL CHEM, V263, P13199; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; DEBOLD AJ, 1985, SCIENCE, V230, P767, DOI 10.1126/science.2932797; DOERNER D, 1988, NEURON, V1, P693, DOI 10.1016/0896-6273(88)90168-7; FULLER F, 1988, J BIOL CHEM, V263, P9395; HIRATA Y, 1989, EUR J PHARMACOL, V164, P603, DOI 10.1016/0014-2999(89)90273-2; HIRATA Y, 1988, BIOCHEM BIOPH RES CO, V152, P1097, DOI 10.1016/S0006-291X(88)80397-8; HOSODA K, 1992, J BIOL CHEM, V267, P18797; ITOH H, 1990, J CLIN INVEST, V86, P1690, DOI 10.1172/JCI114893; JIANG H, 1992, J BIOL CHEM, V267, P1015; KATO J, 1991, J BIOL CHEM, V266, P14681; KISHIMOTO I, 1993, AM J PHYSIOL, V265, pH1373, DOI 10.1152/ajpheart.1993.265.4.H1373; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOMATSU Y, 1991, ENDOCRINOLOGY, V129, P1104, DOI 10.1210/endo-129-2-1104; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KUCHEL O, 1987, LIFE SCI, V40, P1545, DOI 10.1016/0024-3205(87)90119-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RT, 1988, J CLIN INVEST, V81, P431, DOI 10.1172/JCI113337; LINCOLN TM, 1990, AM J PHYSIOL, V258, pC399, DOI 10.1152/ajpcell.1990.258.3.C399; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MACFARLAND RT, 1991, J BIOL CHEM, V266, P136; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; MUKOYAMA M, 1988, HYPERTENSION, V12, P117, DOI 10.1161/01.HYP.12.2.117; MUKOYAMA M, 1990, NEW ENGL J MED, V323, P757; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKAO K, 1992, J HYPERTENS, V10, P907; NAKAO K, 1984, BIOCHEM BIOPH RES CO, V124, P815, DOI 10.1016/0006-291X(84)91030-1; NEEDLEMAN P, 1985, HYPERTENSION, V7, P469, DOI 10.1161/01.HYP.7.4.469; NUGLOZEH E, 1990, AM J PHYSIOL, V259, pF130, DOI 10.1152/ajprenal.1990.259.1.F130; NUSSENZVEIG DR, 1990, J BIOL CHEM, V265, P20952; POTTER LR, 1992, J BIOL CHEM, V267, P14531; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SHIMONAKA M, 1987, J BIOL CHEM, V262, P5510; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUGA S, 1992, HYPERTENSION, V19, P762, DOI 10.1161/01.HYP.19.6.762; SUGA S, 1992, J CLIN INVEST, V90, P1145, DOI 10.1172/JCI115933; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; SUGA SI, 1992, CIRC RES, V71, P34, DOI 10.1161/01.RES.71.1.34; SUGAWARA A, 1988, J CLIN INVEST, V81, P1962, DOI 10.1172/JCI113544	42	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28300	28308						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961768				2022-12-27	WOS:A1994PV77200079
J	OLIVARES, L; ARAGON, C; GIMENEZ, C; ZAFRA, F				OLIVARES, L; ARAGON, C; GIMENEZ, C; ZAFRA, F			CARBOXYL-TERMINUS OF THE GLYCINE TRANSPORTER GLYT1 IS NECESSARY FOR CORRECT PROCESSING OF THE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; HIGH AFFINITY UPTAKE; SPINAL-CORD; RAT-BRAIN; L-GLUTAMATE; EXPRESSION; CLONING; CELLS; GABA; LOCALIZATION	The high affinity glycine transporter in neurons and glial cells is the primary means of inactivating synaptic glycine. To understand the structure-function relationships, especially the role of the intracellular carboxyl- and amino-terminal domains, we have modified the glycine transporter GLYT1 by using a polymerase chain reaction-based mutagenesis approach. Deletion of the first 30 amino acids of the amino terminus does not alter transport of glycine. Truncation of the last 34 amino acids of the carboxyl terminus did not impair glycine transport, but progressively more extensive deletions produced a progressive decrease in transport activity. AU the fully active or partially active forms of the transporter retain the characteristic sodium and chloride dependence of the wild type. When the nonfunctional mutants of the carboxyl terminus were examined by an immunofluorescence technique, the carrier was no longer found in the membrane. This suggests that the carboxyl terminus of GLYT1 may be involved in the membrane insertion process. Moreover, the transporter that is not fully processed is not functional, because transport activity cannot be rescued in a solubilization-reconstitution experiment.	UNIV AUTONOMA MADRID,FAC CIENCIAS,CSIC,CTR BIOL MOLEC SEVERO OCHOA,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Aragon, Carmen/K-9783-2014; Zafra, Francisco/A-6121-2008; Gimenez, Cecilio/K-8027-2014	Aragon, Carmen/0000-0001-8287-9386; Zafra, Francisco/0000-0003-3801-3109; Gimenez, Cecilio/0000-0001-6726-8405				BALCAR VJ, 1973, J NEUROCHEM, V20, P529, DOI 10.1111/j.1471-4159.1973.tb12152.x; BENDAHAN A, 1993, FEBS LETT, V318, P41, DOI 10.1016/0014-5793(93)81323-R; BOROWSKY B, 1993, NEURON, V10, P851, DOI 10.1016/0896-6273(93)90201-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASADO M, 1993, J BIOL CHEM, V268, P27313; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; FEDELE E, 1992, BRAIN RES, V572, P154, DOI 10.1016/0006-8993(92)90464-K; GUASTELLA J, 1992, P NATL ACAD SCI USA, V89, P7189, DOI 10.1073/pnas.89.15.7189; HENN FA, 1971, P NATL ACAD SCI USA, V68, P2686, DOI 10.1073/pnas.68.11.2686; IVERSEN LL, 1971, BRIT J PHARMACOL, V41, P571, DOI 10.1111/j.1476-5381.1971.tb07066.x; JOHNSTON GA, 1971, J NEUROCHEM, V18, P1951, DOI 10.1111/j.1471-4159.1971.tb09601.x; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KUHAR MJ, 1978, J NEUROCHEM, V31, P251, DOI 10.1111/j.1471-4159.1978.tb12456.x; LIU QR, 1993, J BIOL CHEM, V268, P22802; LIU QR, 1992, FEBS LETT, V305, P110, DOI 10.1016/0014-5793(92)80875-H; LOGAN WJ, 1972, BRAIN RES, V42, P413, DOI 10.1016/0006-8993(72)90540-9; LOPEZCORCUERA B, 1991, J BIOL CHEM, V266, P24809; LOPEZCORCUERA B, 1989, EUR J BIOCHEM, V181, P519, DOI 10.1111/j.1432-1033.1989.tb14754.x; MABJEESH NJ, 1992, J BIOL CHEM, V267, P2563; PETERSON GL, 1977, ANAL BIOCHEM, V83, P246; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; Schousboe A, 1981, Int Rev Neurobiol, V22, P1, DOI 10.1016/S0074-7742(08)60289-5; SERSHEN H, 1979, J NEUROCHEM, V32, P719, DOI 10.1111/j.1471-4159.1979.tb04554.x; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; ZAFRA F, 1986, BRAIN RES, V397, P108, DOI 10.1016/0006-8993(86)91374-0	27	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28400	28404						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961780				2022-12-27	WOS:A1994PV77200092
J	SOLEIMANI, M; SINGH, G; BIZAL, GL; GULLANS, SR; MCATEER, JA				SOLEIMANI, M; SINGH, G; BIZAL, GL; GULLANS, SR; MCATEER, JA			NA+/H+ EXCHANGER ISOFORMS NHE-2 AND NHE-1 IN INNER MEDULLARY COLLECTING DUCT CELLS - EXPRESSION, FUNCTIONAL LOCALIZATION, AND DIFFERENTIAL REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THICK ASCENDING LIMB; RAT NA/H EXCHANGER; INTRACELLULAR PH; H+ EXCHANGER; MOLECULAR-CLONING; VOLUME REGULATION; PROTEIN-KINASE; ANTIPORTER; TRANSPORT; MECHANISMS	Recent cloning experiments have identified the existance of four distinct Na+/H+ exchanger isoforms designated as NHE-1, NHE-2, NHE-3, and NHE-4. The cellular distribution, subcellular localization, and regulation of one of these isoforms, NHE-2, in the kidney remains unknown. Northern hybridization showed that NHE-2, along with NHE-1, is expressed in cultured renal medullary collecting duct (mIMCD-3) cells. Acid-stimulated, dimethyl amiloride-sensitive Na-22(+) uptake and sodium-dependent pH(i) recovery occurred only from the basolateral surface of the cells, indicating localization of Na+/H+ exchanger to the basolateral membrane domain. Incubation of IMCD cells in high osmolality media (510 mosm/liter) for 72 h stimulated the Na+/H+ exchanger activity by 59% (p < 0.001). NHE-1 mRNA abundance decreased, whereas NHE-2 mRNA increased in high osmolality media. Incubation of IMCD cells in acid media (pH 7.1) for 48 h did not affect the Na+/H+ exchanger activity compared with control (pH 7.4) (p > 0.05). Northern hybridization, however, indicated that NHE-1 mRNA increased, whereas NHE-2 mRNA decreased in acid media. In conclusion, mIMCD-3 cells express NHE-1 and NHE-2 mRNAs. The cell functional studies in mIMCD-3 cells strongly suggest that NHE-2, along with NRE-1, is expressed in the basolateral membrane domain, They further demonstrate differential regulation of NHE-1 and NHE-2 mRNAs in response to acidosis and high osmolality and suggest that NHE-2 may be involved in volume regulation of IMCD cells.	INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT ANAT,INDIANAPOLIS,IN 46202; RICHARD L ROUDEBUSH VET AFFAIRS MED CTR,INDIANAPOLIS,IN 46202; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Harvard University; Harvard Medical School								Bergman JA, 1991, J TISSUE CULTURE MET, V13, P205; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; BIEMESDERFER D, 1992, AM J PHYSIOL, V263, pF833, DOI 10.1152/ajprenal.1992.263.5.F833; BOOKSTEIN C, 1994, J CLIN INVEST, V93, P106, DOI 10.1172/JCI116933; CHAILLET JR, 1985, J GEN PHYSIOL, V86, P795, DOI 10.1085/jgp.86.6.795; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK JD, 1991, AM J PHYSIOL, V261, pC945, DOI 10.1152/ajpcell.1991.261.6.C945; FRIEDMAN PA, 1982, J GEN PHYSIOL, V80, P683, DOI 10.1085/jgp.80.5.683; GOOD DW, 1985, AM J PHYSIOL, V248, pF821, DOI 10.1152/ajprenal.1985.248.6.F821; GRINSTEIN S, 1986, CURR TOP MEMBR TRANS, V26, P115; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GULLANS SR, 1988, AM J PHYSIOL, V255, pF626, DOI 10.1152/ajprenal.1988.255.4.F626; HAGGERTY JG, 1988, P NATL ACAD SCI USA, V85, P6797, DOI 10.1073/pnas.85.18.6797; HART D, 1991, J BIOL CHEM, V266, P2374; HAYS SR, 1990, AM J PHYSIOL, V259, pF628, DOI 10.1152/ajprenal.1990.259.4.F628; HERINGSMITH KS, 1991, AM J PHYSIOL, V260, pC1300, DOI 10.1152/ajpcell.1991.260.6.C1300; IGARASHI P, 1992, AM J PHYSIOL, V263, pF83, DOI 10.1152/ajprenal.1992.263.1.F83; KIKERI D, 1990, AM J PHYSIOL, V258, pF445, DOI 10.1152/ajprenal.1990.258.3.F445; KRAPF R, 1988, J CLIN INVEST, V82, P234, DOI 10.1172/JCI113576; KRAPF R, 1993, J MEMBRANE BIOL, V131, P1, DOI 10.1007/BF02258529; KRAPF R, 1991, J CLIN INVEST, V87, P747, DOI 10.1172/JCI115057; MAHNENSMITH RL, 1985, CIRC RES, V56, P773, DOI 10.1161/01.RES.56.6.773; MATSUSHIMA Y, 1990, PFLUG ARCH EUR J PHY, V416, P715, DOI 10.1007/BF00370620; MOE OW, 1991, J CLIN INVEST, V88, P1703, DOI 10.1172/JCI115487; MONTROSERAFIZADEH C, 1990, ANNU REV PHYSIOL, V52, P761; MORAN A, 1987, AM J PHYSIOL, V252, pC63, DOI 10.1152/ajpcell.1987.252.1.C63; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; ROCHA AS, 1990, KIDNEY INT, V38, P654, DOI 10.1038/ki.1990.256; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SELDIN DW, 1992, KIDNEY PHYSL PATHOPH, P1693; SOLEIMANI M, 1994, J BIOL CHEM, V269, P15613; SOLEIMANI M, 1994, IN PRESS BIOCH BIOPH; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, P NATL ACAD SCI USA, V90, P9110, DOI 10.1073/pnas.90.19.9110; TSE CM, 1993, J BIOL CHEM, V268, P11917; WANG T, 1993, J CLIN INVEST, V91, P2776, DOI 10.1172/JCI116519; WANG X, 1990, AM J PHYSIOL, V259, pC365, DOI 10.1152/ajpcell.1990.259.2.C365; WANG Z, 1993, J BIOL CHEM, V268, P11925; WEINER ID, 1990, J CLIN INVEST, V85, P274, DOI 10.1172/JCI114423	42	103	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27973	27978						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961730				2022-12-27	WOS:A1994PV77200033
J	BOGGARAM, V; MARGANA, RK				BOGGARAM, V; MARGANA, RK			DEVELOPMENTAL AND HORMONAL-REGULATION OF SURFACTANT PROTEIN-C (SP-C) GENE-EXPRESSION IN FETAL LUNG - ROLE OF TRANSCRIPTION AND MESSENGER-RNA STABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC GLOBIN GENE; ADULT ERYTHROID-CELLS; MESSENGER-RNA; SP-A; PULMONARY SURFACTANT; RAT LUNG; RABBIT LUNG; HALF-LIFE; SP-B; GLUCOCORTICOIDS	Pulmonary surfactant protein C (SP-C) gene expression is developmentally and hormonally regulated in fetal lung. In the present study we investigated the role of transcriptional and posttranscriptional mechanisms in the developmental, cAMP, and dexamethasone induction of SP-C mRNA. We found that developmental induction of SP-C mRNA was not coincident with induction of SP-C gene transcription. SP-C mRNA levels reached similar to 90% of levels in adult lung on day 24 of gestation, whereas SP-C gene transcription was only similar to 4% of level in adult lung and did not increase until day 28 of gestation (term in rabbit = 31 days). Treatment of fetal lung tissues in vitro with dibutyryl cyclic AMP (Bt(2)cAMP) and dexamethasone increased SP-C mRNA accumulation by different mechanisms. Increase in SP-C mRNA accumulation by Bt(2)cAMP was the result of increased SP-C gene transcription, whereas increased SP-C mRNA accumulation by dexamethasone was due to stabilization of RNA. In control tissues the SP-C mRNA half-life (t(1/2)) was 11.2 h, and after dexamethasone treatment it increased to 30 h. These data show that both transcriptional and mRNA stabilization mechanisms regulate induction of SP-C gene expression during fetal lung development and by cAMP and dexamethasone in fetal lung in vitro.			BOGGARAM, V (corresponding author), UNIV TEXAS, CTR HLTH, DEPT BIOL MOLEC, POB 2003, TYLER, TX 75710 USA.							ACARREGUI MJ, 1990, ENDOCRINOLOGY, V127, P1105, DOI 10.1210/endo-127-3-1105; AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ALCORN JL, 1993, MOL ENDOCRINOL, V7, P1072, DOI 10.1210/me.7.8.1072; AVERY ME, 1959, AMA J DIS CHILD, V97, P517, DOI 10.1001/archpedi.1959.02070010519001; AVIV H, 1976, CELL, V8, P495, DOI 10.1016/0092-8674(76)90217-8; BOGGARAM V, 1988, J BIOL CHEM, V263, P19060; BOGGARAM V, 1992, AM J PHYSIOL, V263, pL634, DOI 10.1152/ajplung.1992.263.6.L634; BOGGARAM V, 1989, J BIOL CHEM, V264, P11421; BOGGARAM V, 1991, MOL ENDOCRINOL, V5, P414, DOI 10.1210/mend-5-3-414; BOGGARAM V, 1994, AM J RESP CRIT CARE, V149, pA523; Brawerman G., 1993, CONTROL MESSENGER RN, P149; CONNELLY IH, 1991, ENDOCRINOLOGY, V129, P2583, DOI 10.1210/endo-129-5-2583; COX A, 1989, NUCLEIC ACIDS RES, V17, P10439, DOI 10.1093/nar/17.24.10439; DEAN DC, 1988, J CELL BIOL, V106, P2159, DOI 10.1083/jcb.106.6.2159; DELEON V, 1983, DEV BIOL, V98, P400, DOI 10.1016/0012-1606(83)90369-X; DURHAM PL, 1993, ANAT REC, V237, P365, DOI 10.1002/ar.1092370310; DURHAM PL, 1992, EXP LUNG RES, V18, P775, DOI 10.3109/01902149209031707; FEI HH, 1993, BIOTECHNIQUES, V15, P838; FISHER JH, 1991, AM J RESP CELL MOL, V5, P63, DOI 10.1165/ajrcmb/5.1.63; FLOROS J, 1991, AM J RESP CELL MOL, V4, P449, DOI 10.1165/ajrcmb/4.5.449; GENOVESE C, 1990, MOL IMMUNOL, V27, P733, DOI 10.1016/0161-5890(90)90082-B; GINDER GD, 1984, P NATL ACAD SCI-BIOL, V81, P3954, DOI 10.1073/pnas.81.13.3954; GLAUBER JG, 1991, MOL CELL BIOL, V11, P4690, DOI 10.1128/MCB.11.9.4690; GOERKE J, 1986, HDB PHYSL RESPIRATOR, V3, P47; HOD Y, 1988, J BIOL CHEM, V263, P7747; KALINA M, 1992, AM J RESP CELL MOL, V6, P594, DOI 10.1165/ajrcmb/6.6.594; KIKKAWA Y, 1968, AM J PATHOL, V52, P177; KING RJ, 1985, ANNU REV PHYSIOL, V47, P775, DOI 10.1146/annurev.ph.47.030185.004015; KROCZEK RA, 1990, ANAL BIOCHEM, V184, P90, DOI 10.1016/0003-2697(90)90017-4; LEE SW, 1988, P NATL ACAD SCI USA, V85, P1204, DOI 10.1073/pnas.85.4.1204; LILEY HG, 1989, J CLIN INVEST, V83, P1191, DOI 10.1172/JCI114000; LODISH HF, 1976, CELL, V7, P59, DOI 10.1016/0092-8674(76)90255-5; MENDELSON CR, 1991, ANNU REV PHYSIOL, V53, P415, DOI 10.1146/annurev.ph.53.030191.002215; MENDELSON CR, 1986, J BIOL CHEM, V261, P9938; ODOM MW, 1990, AM J PHYSIOL, V259, pL283, DOI 10.1152/ajplung.1990.259.4.L283; PAEK I, 1987, MOL CELL BIOL, V7, P1496, DOI 10.1128/MCB.7.4.1496; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; PETEREC SM, 1994, AM J PHYSIOL, V267, pL9, DOI 10.1152/ajplung.1994.267.1.L9; PETERSEN DD, 1989, P NATL ACAD SCI USA, V86, P7800, DOI 10.1073/pnas.86.20.7800; PHELPS DS, 1991, EXP LUNG RES, V17, P985, DOI 10.3109/01902149109064330; POSSMAYER F, 1990, AM REV RESPIR DIS, V142, P749, DOI 10.1164/ajrccm/142.4.749; POSSMAYER F, 1988, AM REV RESPIR DIS, V138, P990, DOI 10.1164/ajrccm/138.4.990; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; SCHELLHASE DE, 1989, PEDIATR RES, V26, P167, DOI 10.1203/00006450-198909000-00001; SCHELLHASE DE, 1991, AM J RESP CELL MOL, V4, P304, DOI 10.1165/ajrcmb/4.4.304; SIMONET WS, 1989, J BIOL CHEM, V264, P569; SNYDER JM, 1981, DEV BIOL, V85, P129, DOI 10.1016/0012-1606(81)90242-6; SNYDER JM, 1991, ANAT REC, V229, P73, DOI 10.1002/ar.1092290109; VELETZA SV, 1992, AM J PHYSIOL, V262, pL684, DOI 10.1152/ajplung.1992.262.6.L684; VENKATESH VC, 1993, AM J RESP CELL MOL, V8, P222, DOI 10.1165/ajrcmb/8.2.222; WHITSETT JA, 1987, J BIOL CHEM, V262, P15618; WILLIAMS DL, 1993, CONTROL MESSENGER RN, P161; WOHLFORDLENANE CL, 1992, AM J RESP CELL MOL, V6, P225, DOI 10.1165/ajrcmb/6.2.225	54	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27767	27772						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961697				2022-12-27	WOS:A1994PV77100094
J	CAHOON, EB; CRANMER, AM; SHANKLIN, J; OHLROGGE, JB				CAHOON, EB; CRANMER, AM; SHANKLIN, J; OHLROGGE, JB			DELTA(6) HEXADECENOIC ACID IS SYNTHESIZED BY THE ACTIVITY OF A SOLUBLE DELTA(6) PALMITOYL-ACYL CARRIER PROTEIN DESATURASE IN THUNBERGIA-ALATA ENDOSPERM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; HIGHER-PLANTS; CDNA CLONE; SEED; FERREDOXIN; EXPRESSION; SAFFLOWER; PRECURSOR; RNA	Delta(6) Hexadecenoic acid (16:1 Delta(6)) composes more than 80% of the seed oil of Thunbergia alata. Studies were conducted to determine the biosynthetic origin of the double bond of this unusual fatty acid. Assays of fractions of developing T. alata seed endosperm with [1-C-14]palmitoyl (16:0)-acyl carrier protein (ACP) revealed the presence of a soluble Delta(6) desaturase activity. This activity was greatest when 16:0-ACP was provided as a substrate, whereas no desaturation of the coenzyme A ester of this fatty acid was detected. In addition, Delta(6)16:0-ACP desaturase activity in T. alata endosperm extracts was dependent on the presence of ferredoxin and molecular oxygen and was stimulated by catalase. To further characterize this enzyme, a cDNA encoding a diverged acyl-ACP desaturase was isolated from a T. alata endosperm cDNA library using polymerase chain reaction with degenerate oligonucleotides corresponding to conserved amino acid sequences in Delta(9)stearoyl (18:0) and Delta(4)16:0-ACP desaturases. The primary structure of the mature peptide encoded by this cDNA shares 66% identity with the mature castor Delta(9)18:0-ACP desaturase and 57% identity with the mature coriander Delta(4)16:0-ACP desaturase. Extracts of Escherichia coli that express the T. alata cDNA catalyzed the Delta(6) desaturation of 16:0-ACP. These results demonstrate that 16:1 Delta(6) in T. alata endosperm is formed by the activity of a soluble Delta(6)16:0-ACP desaturase that is structurally related to the Delta(9)18:0- and Delta(4)16:0-ACP desaturases. Implications of this work to an understanding of active site structures of acyl-ACP desaturases are discussed.	MICHIGAN STATE UNIV,DEPT BOT & PLANT PATHOL,E LANSING,MI 48824; CALGENE INC,DAVIS,CA 95616	Michigan State University	CAHOON, EB (corresponding author), BROOKHAVEN NATL LAB,DEPT BIOL,BLDG 463,UPTON,NY 11973, USA.			Shanklin, John/0000-0002-6774-8043				BATTEY JF, 1989, TRENDS BIOTECHNOL, V7, P122, DOI 10.1016/0167-7799(89)90088-7; BUBECK DM, 1989, CROP SCI, V29, P652, DOI 10.2135/cropsci1989.0011183X002900030021x; CAHOON EB, 1994, PLANT PHYSIOL, V104, P827, DOI 10.1104/pp.104.3.827; CAHOON EB, 1994, PLANT PHYSIOL, V104, P845, DOI 10.1104/pp.104.3.845; CAHOON EB, 1992, P NATL ACAD SCI USA, V89, P11184, DOI 10.1073/pnas.89.23.11184; CAHOON EB, 1994, IN PRESS PLANT PHYSL; CHEESBROUGH TM, 1990, PLANT PHYSIOL, V93, P555, DOI 10.1104/pp.93.2.555; CHEESBROUGH TM, 1990, PLANT LIPID BIOCHEMISTRY, STRUCTURE AND UTILIZATION, P129; Christie W.W., 2003, LIPID ANAL; Cronan Jr. J.E., 1987, ESCHERICHIA COLI SAL, P474; DORMANN P, 1994, PLANT PHYSIOL, V104, P839, DOI 10.1104/pp.104.3.839; FRANCIS GW, 1981, CHEM PHYS LIPIDS, V29, P369, DOI 10.1016/0009-3084(81)90070-0; GIBSON KJ, 1993, BIOCHIM BIOPHYS ACTA, V1169, P231, DOI 10.1016/0005-2760(93)90245-5; HALL TC, 1978, P NATL ACAD SCI USA, V75, P3196, DOI 10.1073/pnas.75.7.3196; HAY B, 1992, STRATEGIES, V5, P16; Heinz Ernst, 1993, P33; JAWORSKI JG, 1974, ARCH BIOCHEM BIOPHYS, V162, P158, DOI 10.1016/0003-9861(74)90114-3; KINNEY AJ, 1990, PLANT LIPID BIOCHEMISTRY, STRUCTURE AND UTILIZATION, P126; KNOELL HE, 1974, EUR J BIOCHEM, V50, P245, DOI 10.1111/j.1432-1033.1974.tb03893.x; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; McKeon T., 1981, METHOD ENZYMOL, V71, P275, DOI 10.1016/0076-6879(81)71036-X; MCKEON TA, 1982, J BIOL CHEM, V257, P2141; MIQUEL M, 1993, P NATL ACAD SCI USA, V90, P6208, DOI 10.1073/pnas.90.13.6208; MORRISON WR, 1964, J LIPID RES, V5, P600; MURPHY DJ, 1992, TRENDS BIOTECHNOL, V10, P84, DOI 10.1016/0167-7799(92)90179-Y; NAGAI J, 1968, J BIOL CHEM, V243, P4626; NAGAI J, 1965, J BIOL CHEM, V240, P3702; NISHIDA I, 1992, PLANT MOL BIOL, V19, P711, DOI 10.1007/BF00026799; OHLROGGE JB, 1994, PLANT PHYSIOL, V104, P821, DOI 10.1104/pp.104.3.821; ROCK CO, 1979, J BIOL CHEM, V254, P7123; ROCK CO, 1982, J BIOL CHEM, V257, P10579; Sambrook J, 1989, MOL CLONING LABORATO; SATO A, 1992, PLANT PHYSIOL, V99, P362, DOI 10.1104/pp.99.1.362; SCHNEIDER G, 1992, J MOL BIOL, V225, P561, DOI 10.1016/0022-2836(92)90941-C; SHANKLIN J, 1991, P NATL ACAD SCI USA, V88, P2510, DOI 10.1073/pnas.88.6.2510; SINGH S, 1994, PLANT PHYSIOL, V104, P1075, DOI 10.1104/pp.104.3.1075; SLOCOMBE SP, 1992, PLANT MOL BIOL, V20, P151, DOI 10.1007/BF00029157; SPENCER GF, 1971, LIPIDS, V6, P712, DOI 10.1007/BF02531295; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAYLOR MA, 1992, PLANT PHYSIOL, V100, P533, DOI 10.1104/pp.100.1.533; THOMPSON GA, 1991, P NATL ACAD SCI USA, V88, P2578, DOI 10.1073/pnas.88.6.2578; WADA H, 1990, NATURE, V347, P200, DOI 10.1038/347200a0; YAMAMOTO K, 1991, CHEM PHYS LIPIDS, V60, P39, DOI 10.1016/0009-3084(91)90013-2; [No title captured]	44	66	75	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27519	27526						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961667				2022-12-27	WOS:A1994PV77100057
J	KENNEDY, TA; SMITH, CJ; MARNETT, LJ				KENNEDY, TA; SMITH, CJ; MARNETT, LJ			INVESTIGATION OF THE ROLE OF CYSTEINES IN CATALYSIS BY PROSTAGLANDIN ENDOPEROXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H SYNTHASE; TYROSYL RADICALS; CYCLOOXYGENASE CATALYSIS; COMPLEMENTARY-DNA; BINDING-SITES; HEME-BINDING; OXIDATION; KINETICS; ASPIRIN; BIOSYNTHESIS	The importance of cysteine residues in the cyclooxygenase activity of prostaglandin endoperoxide synthase (PGHS) was investigated using cysteine-specific reagents and site-directed mutagenesis. N-(7-Dimethylamino-4-methyl-3-coumarinyl)maleimide (DACM), a hydrophobic maleimide, inactivated both cyclooxygenase and peroxidase activities of apoPGHS in a time-dependent manner but did not affect holoPGHS. Heme titration experiments indicated that modification of apoPGHS with DACM prevented heme binding. Peptide mapping revealed that DACM modified Cys(313), Cys(512), and Cys(540). N-Ethylmaleimide inactivated cyclooxygenase and peroxidase activities of holoPGHS in a time-dependent manner but did not affect apoPGHS. Peptide mapping demonstrated that N-ethylmaleimide reacted primarily with Cys(313) in holoPGHS and with Cys(540) in apoPGHS. Each of the 3 cysteines was changed to serine by site-directed mutagenesis, and the mutant proteins were expressed in COS-1 cells. The C512S mutant converted arachidonic acid to products to the same extent as wildtype PGHS. In contrast, the C313S and C540S mutants converted arachidonic acid to products to the extent of 10% of wild-type PGHS. These results indicate that Cys(313), Cys(512), and Cys(540) are not essential for cyclooxygenase activity but that alteration of Cys(540) Or Cys(313) dramatically decreases enzyme activity. Both residues are well removed from the cyclooxygenase and peroxidase active sites so our findings reveal that subtle changes, such as substitution of a single oxygen for sulfur atom as far as 30 Angstrom from the heme prosthetic group, can significantly alter enzyme activity.	VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, AB HANCOCK JR MEM LAB CANC RES, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT CHEM, NASHVILLE, TN 37232 USA	Vanderbilt University; Vanderbilt University					NATIONAL CANCER INSTITUTE [R35CA047479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [CA47479] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAKOVIC M, 1994, BIOCHEMISTRY-US, V33, P6475, DOI 10.1021/bi00187a013; BAKOVIC M, 1993, BIOCHEMISTRY-US, V32, P833, DOI 10.1021/bi00054a014; BARNETT J, 1993, EICOSANOIDS OTHER BI, P139; CHEN YNP, 1987, J BIOL CHEM, V262, P16892; CHEN YNP, 1989, FASEB J, V3, P2294, DOI 10.1096/fasebj.3.11.2506093; DAVIES MJ, 1993, FREE RADICAL RES COM, V18, P353, DOI 10.3109/10715769309147502; DEGRAY JA, 1992, J BIOL CHEM, V267, P23583; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; FARAGGI M, 1990, BIOCHEM BIOPH RES CO, V166, P867, DOI 10.1016/0006-291X(90)90890-Y; HAMBERG M, 1967, J BIOL CHEM, V242, P5329; HAMBERG M, 1973, P NATL ACAD SCI USA, V70, P899, DOI 10.1073/pnas.70.3.899; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P345, DOI 10.1073/pnas.71.2.345; Howard JA, 1972, ADV FREE RADICAL CHE, V4, P49; INGOLD KU, 1969, ACCOUNTS CHEM RES, V2, P1, DOI 10.1021/ar50013a001; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KENNEDY TA, 1993, EICOSANOIDS OTHER BI, P161; KULMACZ RJ, 1984, J BIOL CHEM, V259, P6358; KULMACZ RJ, 1989, PROSTAGLANDINS, V38, P277, DOI 10.1016/0090-6980(89)90133-0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LASSMANN G, 1993, ARCH BIOCHEM BIOPHYS, V300, P132, DOI 10.1006/abbi.1993.1018; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; Marnett L. J., 1991, PEROXIDASES CHEM BIO, V1, P293; MARNETT LJ, 1984, MOL PHARMACOL, V26, P328; MARSHALL PJ, 1988, ARCH BIOCHEM BIOPHYS, V266, P162, DOI 10.1016/0003-9861(88)90246-9; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MOBASHERY S, 1988, BIOCHEMISTRY-US, V27, P3691, DOI 10.1021/bi00410a025; NUGTEREN DH, 1973, BIOCHIM BIOPHYS ACTA, V326, P448, DOI 10.1016/0005-2760(73)90145-8; ODENWALLER R, 1990, METHOD ENZYMOL, V187, P479; OTTO JC, 1993, J BIOL CHEM, V268, P18234; PEDERSEN JZ, 1993, FEBS LETT, V325, P53, DOI 10.1016/0014-5793(93)81412-S; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; SCHONEICH C, 1992, ARCH BIOCHEM BIOPHYS, V292, P456, DOI 10.1016/0003-9861(92)90016-P; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SHIMOKAWA T, 1992, J BIOL CHEM, V267, P12387; SMITH WL, 1992, BIOCHEMISTRY-US, V31, P3, DOI 10.1021/bi00116a001; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; Smyth DG, 1960, J AM CHEM SOC, V82, P4600, DOI 10.1021/ja01502a039; SMYTH DG, 1964, BIOCHEM J, V91, P589, DOI 10.1042/bj0910589; TSAI AL, 1994, J BIOL CHEM, V269, P5085; TSAI AL, 1992, J BIOL CHEM, V267, P17753; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; WELLS I, 1993, BIOCHEMISTRY-US, V32, P2710, DOI 10.1021/bi00061a032; YAMAMOTO K, 1977, ANAL BIOCHEM, V79, P83, DOI 10.1016/0003-2697(77)90381-5; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5	48	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27357	27364						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961646				2022-12-27	WOS:A1994PV77100035
J	WALKER, RK; KRISHNASWAMY, S				WALKER, RK; KRISHNASWAMY, S			THE ACTIVATION OF PROTHROMBIN BY THE PROTHROMBINASE COMPLEX - THE CONTRIBUTION OF THE SUBSTRATE-MEMBRANE INTERACTION TO CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FACTOR-V; FACTOR-XA; PHOSPHOLIPID-VESICLES; ACTIVE-SITE; COFACTOR DEPENDENCE; BLOOD-COAGULATION; ENZYME COMPLEXES; ALPHA-THROMBIN; BINDING-SITE; MEIZOTHROMBIN	The conversion of prothrombin to thrombin requires the cleavage of two peptide bonds and is catalyzed by the prothrombinase complex composed of factors Xa and Va assembled on a membrane surface. Presteady-state kinetic studies of the effects of membranes on the proteolytic reaction were undertaken using model membranes composed of phosphatidylcholine and phosphatidylserine (PCPS). The concentration of PCPS was varied to alter the concentration of free phospholipid available for substrate binding without influencing the concentration of membrane-assembled prothrombinase. In fluorescence stopped-flow measurements, increasing concentrations of PCPS resulted in an increase in the rate of product formation. Assessment of bond cleavage by sodium dodecyl sulfate-polyacrylamide gel electrophoresis following rapid chemical quench using I-125-prothrombin revealed that the activation reaction proceeded through the ordered cleavage at Arg(323)-Ile(324) followed by cleavage at Arg(274)-Thr(275) at all concentrations of PCPS. Increasing the PCPS concentration resulted in a large increase in the Arg(323)-Ile(324) cleavage reaction with a much smaller effect on the subsequent cleavage at Arg(274)-Thr(275), thereby leading to an increase in the extent of accumulation of the intermediate, meizothrombin. Fluorescence stopped flow and rapid chemical quench measurements were also conducted using prethrombin 2 plus fragment 1.2 or meizothrombin as substrates to assess the influence of PCPS on the individual cleavage reactions. The rate of cleavage at Arg(323)-Ile(324) by prothrombinase was increased similar to 60-fold with increasing PCPS, whereas the cleavage at Arg(274)-Thr(275) was increased by a factor of similar to 5. These differential effects of PCPS on the two cleavage reactions adequately explain changes in the extent of accumulation of meizothrombin during prothrombin activation. Proteolytic removal of the membrane binding fragment 1 domain of the substrates, meizothrombin and prethrombin 2-fragment 1.2, had no effect on the cleavage at Arg(274)-Thr(275) at saturating PCPS but completely eliminated the membrane-dependent rate enhancement for cleavage at Arg(323)-Ile(324). Thus, membrane binding by the substrate is essential for the first cleavage reaction at Arg(323)-Ile(324), which leads to the conversion of prothrombin to meizothrombin, In contrast, the substrate-membrane interaction mediated by the fragment 1 domain has no detectable effect on the second cleavage reaction at Arg(274)-Thr(275) which is required for the conversion of meizothrombin to thrombin.	EMORY UNIV,DEPT MED,DIV HEMATOL ONCOL,ATLANTA,GA 30322	Emory University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047465, R01HL052883] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-52883, HL-47465] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; BOVILL EG, 1993, THROMB HAEMOSTASIS, V69, P779; CHASE T, 1970, METHOD ENZYMOL, V19, P20; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; DAVID GS, 1972, BIOCHEM BIOPH RES CO, V48, P464, DOI 10.1016/S0006-291X(72)80074-3; DOYLE MF, 1993, METHOD ENZYMOL, V222, P299; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; ESMON CT, 1974, J BIOL CHEM, V249, P7798; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P5290, DOI 10.1021/bi00723a006; GIESEN PLA, 1991, J BIOL CHEM, V266, P1379; GITEL SN, 1973, P NATL ACAD SCI USA, V70, P1344, DOI 10.1073/pnas.70.5.1344; HIBBARD LS, 1982, BIOCHEMISTRY-US, V21, P2285, DOI 10.1021/bi00539a003; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; JACKSON CM, 1968, BIOCHEMISTRY-US, V7, P4492, DOI 10.1021/bi00852a046; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; Jesty J, 1976, Methods Enzymol, V45, P95; KALAFATIS M, 1993, METHOD ENZYMOL, V222, P224; KRISHNASWAMY S, 1993, METHOD ENZYMOL, V222, P260; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUE TM, 1984, BIOCHEMISTRY-US, V23, P1339, DOI 10.1021/bi00302a001; Lundblad R L, 1976, Methods Enzymol, V45, P156; Mann K G, 1976, Methods Enzymol, V45, P123; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; Mason J T, 1978, Ann N Y Acad Sci, V308, P29, DOI 10.1111/j.1749-6632.1978.tb22012.x; MYRMEL KH, 1976, BIOCHEMISTRY-US, V15, P1767, DOI 10.1021/bi00653a027; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1981, J BIOL CHEM, V256, P6537; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NESHEIM ME, 1983, J BIOL CHEM, V258, P5386; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; PAPAHADJOPOULOS D, 1964, BIOCHIM BIOPHYS ACTA, V90, P436, DOI 10.1016/0304-4165(64)90220-X; PUSEY ML, 1983, BIOCHEM BIOPH RES CO, V114, P526, DOI 10.1016/0006-291X(83)90812-4; RIEMSLAG JWG, 1992, BIOCHEMISTRY-US, V31, P10000; ROSING J, 1988, THROMB HAEMOSTASIS, V60, P355; ROSING J, 1986, J BIOL CHEM, V261, P4224; ROSING J, 1980, J BIOL CHEM, V255, P274; SCHOEN P, 1987, J BIOL CHEM, V262, P11268; SEGEL IH, 1975, ENZYME KINETICS, P606; TANS G, 1994, J BIOL CHEM, V269, P15969; TANS G, 1991, J BIOL CHEM, V266, P21864; TANS G, 1986, NEW COMPREHENSIVE BI, V13, P59; VANRIJN JLML, 1984, BIOCHEMISTRY-US, V23, P4557, DOI 10.1021/bi00315a008; WALKER RK, 1993, J BIOL CHEM, V268, P13920; WALKER RK, 1990, FASEB J, V7, pA1191	52	65	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27441	27450						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961657				2022-12-27	WOS:A1994PV77100047
J	ARGENT, RH; ROBERTS, LM; WALES, R; ROBERTUS, JD; LORD, JM				ARGENT, RH; ROBERTS, LM; WALES, R; ROBERTUS, JD; LORD, JM			INTRODUCTION OF A DISULFIDE BOND INTO RICIN-A CHAIN DECREASES THE CYTOTOXICITY OF THE RICIN HOLOTOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIRABILIS ANTIVIRAL PROTEIN; DIPHTHERIA-TOXIN; A-CHAIN; ENDOPLASMIC-RETICULUM; EUKARYOTIC RIBOSOMES; ENGINEERED DISULFIDE; SUBSTANTIAL INCREASE; GALACTOSE BINDING; ESCHERICHIA-COLI; IDENTIFICATION	Wild type ricin A chain (RTA) contains two cysteine residues (Cys(171) and Cys(259)). Cys(259) forms the interchain disulfide bond of ricin holotoxin with Cys(4) of ricin B chain (RTB). We have used site-directed mutagenesis of RTA cDNA to convert Cys(171) to Ser and to introduce a disulfide bond into RTA by converting Ser(215) and Met(255) to Cys residues. Mutant RTA was expressed in Escherichia coli and directed to the oxidizing environment of the periplasmic space where the Cys(215)-Cys(255) disulfide bond was formed. The disulfide-containing RTA mutant had an in vitro catalytic activity similar to that of an identical form of recombinant RTA that lacked the S215C and M255C mutations. In the presence of glutathione and protein disulfide isomerase, this RTA variant reassociated with RTB to form ricin holotoxin. Incubation of this holotoxin with increasing concentrations of dithiothreitol showed that the interchain disulfide bond joining RTA and RTB was more readily reduced than the intrachain disulfide bond in RTA. Ricin in which the RTA moiety contained the disulfide bond was 15-18-fold less cytotoxic to HeLa or Vero cells than ricin in which the RTA did not contain the stabilizing disulfide crosslink. Since these ricin molecules had identical RTB cell binding and RTA catalytic activities, we suggest that the observed reduction in cytotoxicity caused by the introduced disulfide bond resulted from a constraint on the unfolding of RTA, indicating that such unfolding is necessary for the membrane translocation of RTA during its entry into the cytosol.	UNIV WARWICK, DEPT BIOL SCI, COVENTRY CV4 7AL, W MIDLANDS, ENGLAND; UNIV TEXAS, DEPT CHEM, AUSTIN, TX 78712 USA	University of Warwick; University of Texas System; University of Texas Austin								BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAN HS, 1989, J CHEM PHYS, V90, P492, DOI 10.1063/1.456500; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; ENDO Y, 1987, J BIOL CHEM, V262, P8128; ENDO Y, 1987, J BIOL CHEM, V262, P5908; FALNES PO, 1994, J BIOL CHEM, V269, P8402; Gibson T.J., 1984, THESIS U CAMBRIDGE; HABUKA N, 1991, J BIOL CHEM, V266, P23558; HABUKA N, 1989, J BIOL CHEM, V264, P6629; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KATZIN BJ, 1991, PROTEINS, V10, P251, DOI 10.1002/prot.340100309; LORD JM, 1994, FASEB J, V8, P201, DOI 10.1096/fasebj.8.2.8119491; MACER DRJ, 1988, J CELL SCI, V91, P61; MATSUMURA M, 1989, P NATL ACAD SCI USA, V86, P6562, DOI 10.1073/pnas.86.17.6562; MATSUMURA M, 1989, NATURE, V342, P291, DOI 10.1038/342291a0; MAY MJ, 1989, EMBO J, V8, P301, DOI 10.1002/j.1460-2075.1989.tb03377.x; MEKADA E, 1981, J BIOL CHEM, V256, P1225; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; NEWTON DL, 1992, J BIOL CHEM, V267, P11917; OHARE M, 1987, FEBS LETT, V216, P73, DOI 10.1016/0014-5793(87)80759-7; PACE CN, 1988, J BIOL CHEM, V263, P11820; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; PERRY LJ, 1986, BIOCHEMISTRY-US, V25, P733, DOI 10.1021/bi00351a034; RICHARDSON J, 1984, ADV PROTEIN CHEM, V34, P223; Robertus J, 1991, Semin Cell Biol, V2, P23; SANDVIG K, 1984, J CELL BIOL, V98, P963, DOI 10.1083/jcb.98.3.963; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; WALES R, 1991, J BIOL CHEM, V266, P19172; WALES R, 1992, EXP CELL RES, V203, P1, DOI 10.1016/0014-4827(92)90032-4; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z	32	51	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26705	26710						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929403				2022-12-27	WOS:A1994PQ93100022
J	JANTSCHPLUNGER, V; FIRE, A				JANTSCHPLUNGER, V; FIRE, A			COMBINATORIAL STRUCTURE OF A BODY MUSCLE-SPECIFIC TRANSCRIPTIONAL ENHANCER IN CAENORHABDITIS-ELEGANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS; CELL-INTERACTIONS; MYOGENIN GENE; DNA; EXPRESSION; PROTEIN; SITE; BINDS	We describe the dissection of a body muscle-specific enhancer sequence contained within the Caenorhabditis elegans myosin heavy chain gene unc-54. A 90-base pair segment that was sufficient for both enhancer function and tissue specificity was subjected to mutational analysis. Several separated sites within this region were required for activity; mutations in these sites led to dramatic decreases in enhancer activity, while substitutions in the intervening regions had minimal effects on activity. The individual sites appear to function as semi-independent and partially interchangeable enhancer subelements, as seen by our ability to create functional enhancers by constructing novel multimers and combinations. Four different enhancer subelements (designated 0, I, II, and III) were identified in this way. Although partially interchangeable, some differences between these subelements were evident. In particular, concatamers of site III exhibited the highest levels of activity but had a broader tissue specificity than the intact enhancer, including both hypodermal and muscle tissue. The specificity of the intact enhancer thus reflects a combinatorial function of the specificities of the constituent subelements.	CARNEGIE INST WASHINGTON,DEPT EMBRYOL,BALTIMORE,MD 21210	Carnegie Institution for Science			; Jantsch, Verena/A-3910-2017	Fire, Andrew/0000-0001-6217-8312; Jantsch, Verena/0000-0002-1978-682X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037706] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM037706, R01-GM37706] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; CARRA JH, 1993, EMBO J, V12, P35, DOI 10.1002/j.1460-2075.1993.tb05629.x; CHEN L, 1992, SCIENCE, V256, P240, DOI 10.1126/science.1314423; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; EPSTEIN HF, 1974, J MOL BIOL, V90, P291, DOI 10.1016/0022-2836(74)90374-X; EPSTEIN HF, 1992, DEV BIOL, V154, P231, DOI 10.1016/0012-1606(92)90064-N; FIRE A, 1992, GENET ANAL-BIOMOL E, V9, P151, DOI 10.1016/1050-3862(92)90042-4; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HARDY S, 1989, MOL CELL BIOL, V9, P4495, DOI 10.1128/MCB.9.10.4495; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; KRAUSE M, 1994, IN PRESS DEV BIOL; LAMBIE EJ, 1991, ANNU REV GENET, V25, P411, DOI 10.1146/annurev.ge.25.120191.002211; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; OKKEMA P, 1993, GENETICS, V135, P384; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; STOCKDALE FE, 1992, DEV BIOL, V154, P284, DOI 10.1016/0012-1606(92)90068-R; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; Waterston R., 1988, NEMATODE C ELEGANS, P281; White J., 1988, NEMATODE CAENORHABDI, V17, P81; WILLIAMS BD, 1994, J CELL BIOL, V124, P475, DOI 10.1083/jcb.124.4.475; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	30	19	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27021	27028						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929443				2022-12-27	WOS:A1994PQ93100066
J	DIX, DR; BRIDGHAM, JT; BRODERIUS, MA; BYERSDORFER, CA; EIDE, DJ				DIX, DR; BRIDGHAM, JT; BRODERIUS, MA; BYERSDORFER, CA; EIDE, DJ			THE FET4 GENE ENCODES THE LOW-AFFINITY FE(II) TRANSPORT PROTEIN OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT IRON TRANSPORT; TRANSFERRIN-BOUND IRON; FERRIC REDUCTASE; ESCHERICHIA-COLI; UPTAKE SYSTEM; YEAST; MEMBRANE; CELLS; DNA; TRANSFORMATION	Previous studies on Fe(II) uptake in Saccharomyces cerevisiae suggested the presence of two uptake systems with different affinities for this substrate. We demonstrate that the FET3 gene is required for high affinity uptake but not for the low affinity system. This requirement has enabled a characterization of the low affinity system. Low affinity uptake is time-, temperature-, and concentration-dependent and prefers Fe(II) over Fe(III) as substrate. We have isolated a new gene, FET4, that is required for low affinity uptake, and our results suggest that FET4 encodes an Fe(II) transporter protein. FET4's predicted amino acid sequence contains six potential transmembrane domains. Overexpressing FET4 increased low affinity uptake, whereas disrupting this gene eliminated that activity. In contrast, overexpressing FET4 decreased high affinity activity, while disrupting FET4 increased that activity. Therefore, the high affinity system may be regulated to compensate for alterations in low affinity activity. These analyses, and the analysis of the iron-dependent regulation of the plasma membrane Fe(III) reductase, demonstrate that the low affinity system is a biologically relevant mechanism of iron uptake in yeast. Furthermore, our results indicate that the high and low affinity systems are separate uptake pathways.	UNIV MINNESOTA, DEPT BIOCHEM & MOLEC BIOL, DULUTH, MN 55812 USA	University of Minnesota System; University of Minnesota Duluth					NIGMS NIH HHS [GM48139] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048139] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Borson N D, 1992, PCR Methods Appl, V2, P144; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ECKER DJ, 1983, J BACTERIOL, V155, P616, DOI 10.1128/JB.155.2.616-622.1983; EGYED A, 1988, BRIT J HAEMATOL, V68, P483, DOI 10.1111/j.1365-2141.1988.tb04241.x; EIDE D, 1992, J BIOL CHEM, V267, P20774; EVANS SL, 1986, J BACTERIOL, V168, P1096, DOI 10.1128/jb.168.3.1096-1099.1986; FUHRMANN GF, 1968, BIOCHIM BIOPHYS ACTA, V163, P325, DOI 10.1016/0005-2736(68)90117-X; GRUSAK MA, 1990, PLANT PHYSIOL, V94, P1353, DOI 10.1104/pp.94.3.1353; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; INMAN RS, 1993, J BIOL CHEM, V268, P8521; JOHNSON W, 1991, INFECT IMMUN, V59, P2376, DOI 10.1128/IAI.59.7.2376-2381.1991; KAMMLER M, 1993, J BACTERIOL, V175, P6212, DOI 10.1128/JB.175.19.6212-6219.1993; KAPLAN J, 1991, J BIOL CHEM, V266, P2997; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LESUISSE E, 1989, J GEN MICROBIOL, V135, P257; LESUISSE E, 1987, J GEN MICROBIOL, V133, P3229; LIU HP, 1992, GENETICS, V132, P665; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MORGAN EH, 1988, BIOCHIM BIOPHYS ACTA, V943, P428, DOI 10.1016/0005-2736(88)90374-4; NEILANDS JB, 1987, IRON TRANSPORT MICRO, P24; NORRIS PR, 1977, J GEN MICROBIOL, V99, P317, DOI 10.1099/00221287-99-2-317; NUNEZ MT, 1992, J BIOL CHEM, V267, P11490; NUNEZ MT, 1990, J BIOL CHEM, V265, P6688; OSHIRO S, 1993, J BIOL CHEM, V268, P21586; ROMAN DG, 1993, MOL CELL BIOL, V13, P4342, DOI 10.1128/MCB.13.7.4342; ROMHELD V, 1983, PLANT PHYSIOL, V71, P949, DOI 10.1104/pp.71.4.949; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J, 1989, MOL CLONING LABORATO; Sherman F., 1986, METHODS YEAST GENETI; STURROCK A, 1990, J BIOL CHEM, V265, P3139; THORSTENSEN K, 1988, J BIOL CHEM, V263, P8844; THORSTENSEN K, 1988, J BIOL CHEM, V263, P16837; Winkelmann G, 1987, IRON TRANSPORT MICRO; WRIGHT TL, 1986, J BIOL CHEM, V261, P909	41	255	263	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26092	26099						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929320				2022-12-27	WOS:A1994PQ93000026
J	ERICSON, ML; SUNDSTROM, M; SANSOM, DM; CHARRON, DJ				ERICSON, ML; SUNDSTROM, M; SANSOM, DM; CHARRON, DJ			MUTUALLY EXCLUSIVE BINDING OF PEPTIDE AND INVARIANT CHAIN TO MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II ANTIGENS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; STAPHYLOCOCCAL ENTEROTOXIN-A; ALPHA-BETA-HETERODIMERS; HLA-DR MOLECULES; SURFACE EXPRESSION; ENDOPLASMIC-RETICULUM; MHC MOLECULES; MICE LACKING; GAMMA-CHAIN; PROTEIN	The invariant chain is a membrane protein associated with the major histocompatibility complex class II antigens both intra- and extracellularly. The extracellular portion of the human invariant chain (Ii) was expressed in Escherichia coli as a fusion protein with a polyhistidine tail and purified by metal affinity chromatography. The recombinant Ii was used as a ligand to probe binding to the cell surface of Chinese hamster ovary cells stably transfected with human class II alpha and beta genes of the DR4 isotype. We show that recombinant Ii inhibits peptide loading on class II polypeptides and also the converse; the presence of peptide in the antigen groove prevents binding of fluorescein conjugated Ii. Moreover, blocking of Ii binding by peptide did not require a transition of the class II dimers to an SDS stable state. A monoclonal antibody, L243, known to bind to (or close to) the peptide pocket of the class II molecule likewise blocked Ii-fluorescein binding. Further, we investigated whether or not the Ii, a variety of bacterial superantigens or the CD4 molecule, have overlapping binding sites on the class II heterodimer. Of the class II ligands tested, reduced binding was detected for the Staphylococcus superantigen type SEB on cells precincubated with soluble Ii while the binding of the other ligands was either unchanged or marginally changed. These data clarify by a direct biochemical approach the binding characteristics of Ii in comparison with other class II Ligands.	INST BIOMED CORDELIERS,IMMUNOGENET HUMAINE LAB,INSERM,U396,F-75006 PARIS,FRANCE; KAROLINSKA INST,CTR STRUCT BIOCHEM,S-10401 STOCKHOLM,SWEDEN; BATH INST RHEUMATOL DIS,BATH BA1 1HD,AVON,ENGLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Karolinska Institutet				Sansom, David/0000-0001-6506-3115				AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; ANDERSON MS, 1992, P NATL ACAD SCI USA, V89, P2282, DOI 10.1073/pnas.89.6.2282; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BONNEROT C, 1994, EMBO J, V13, P934, DOI 10.1002/j.1460-2075.1994.tb06338.x; BUSCH R, 1990, INT IMMUNOL, V2, P443, DOI 10.1093/intimm/2.5.443; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CHARRON DJ, 1979, P NATL ACAD SCI USA, V76, P6567, DOI 10.1073/pnas.76.12.6567; CHEN BP, 1990, J EXP MED, V172, P779, DOI 10.1084/jem.172.3.779; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; CLAESSON L, 1983, P NATL ACAD SCI-BIOL, V80, P7395, DOI 10.1073/pnas.80.24.7395; CLAESSONWELSH L, 1986, J IMMUNOL, V136, P484; CLEMENTS VK, 1992, J IMMUNOL, V149, P2391; FISCHER H, 1989, J IMMUNOL, V142, P3151; FLEISCHER B, 1991, J IMMUNOL, V146, P11; FRASER JD, 1989, NATURE, V339, P221, DOI 10.1038/339221a0; FREISEWINKEL IM, 1993, P NATL ACAD SCI USA, V90, P9703, DOI 10.1073/pnas.90.20.9703; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; JENSEN PE, 1992, J EXP MED, V176, P793, DOI 10.1084/jem.176.3.793; JONES PP, 1978, IMMUNOCHEMISTRY, V16, P51; KARP DR, 1992, P NATL ACAD SCI USA, V89, P9657, DOI 10.1073/pnas.89.20.9657; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOCH N, 1989, TRENDS BIOCHEM SCI, V14, P383, DOI 10.1016/0968-0004(89)90013-3; KOCH N, 1991, J IMMUNOL, V147, P2643; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; LOSS GE, 1993, J IMMUNOL, V150, P3187; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MARKS MS, 1990, J CELL BIOL, V111, P839, DOI 10.1083/jcb.111.3.839; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MAX H, 1993, HUM IMMUNOL, V38, P193, DOI 10.1016/0198-8859(93)90540-H; MOLLICK JA, 1989, SCIENCE, V244, P817, DOI 10.1126/science.2658055; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NUCHTERN JG, 1990, NATURE, V343, P75; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PETERSON M, 1990, NATURE, V345, P172, DOI 10.1038/345172a0; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; REAY PA, 1992, EMBO J, V11, P2829, DOI 10.1002/j.1460-2075.1992.tb05350.x; REYES VE, 1991, J IMMUNOL, V146, P3877; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; ROCHE PA, 1992, EMBO J, V11, P2841, DOI 10.1002/j.1460-2075.1992.tb05351.x; ROMAGNOLI P, 1993, J EXP MED, V177, P583, DOI 10.1084/jem.177.3.583; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SADEGHNASSERI S, 1992, IMMUNOL TODAY, V13, P43, DOI 10.1016/0167-5699(92)90131-P; SANSOM DM, 1993, IMMUNOLOGY, V80, P242; SCHOLL PR, 1989, J IMMUNOL, V143, P2583; SETTE A, 1992, J IMMUNOL, V148, P844; SHERMAN LA, 1993, ANNU REV IMMUNOL, V11, P385, DOI 10.1146/annurev.immunol.11.1.385; SILICIANO RF, 1988, CELL, V54, P561, DOI 10.1016/0092-8674(88)90078-5; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; VIGUIER M, 1990, P NATL ACAD SCI USA, V87, P7170, DOI 10.1073/pnas.87.18.7170; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; WEISS S, 1991, CELL, V64, P767, DOI 10.1016/0092-8674(91)90506-T; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0; WRAIGHT CJ, 1990, J BIOL CHEM, V265, P5787	65	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26531	26538						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929377				2022-12-27	WOS:A1994PQ93000090
J	TEPEL, M; KUHNAPFEL, S; THEILMEIER, G; TEUPE, C; SCHLOTMANN, R; ZIDEK, W				TEPEL, M; KUHNAPFEL, S; THEILMEIER, G; TEUPE, C; SCHLOTMANN, R; ZIDEK, W			FILLING STATE OF INTRACELLULAR CA2+ POOLS TRIGGERS TRANS PLASMA-MEMBRANE NA+ AND CA2+ INFLUX BY A TYROSINE KINASE-DEPENDENT PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC FREE NA+; CAPACITATIVE CALCIUM ENTRY; PAROTID ACINAR-CELLS; SMOOTH-MUSCLE CELLS; HUMAN PLATELETS; TUMOR PROMOTER; CYCLOPIAZONIC ACID; THAPSIGARGIN; STORES; CA-2+	The relations between the filling state of intracellular calcium stores that are regulated by the endoplasmic Ca2+-ATPase and trans plasma membrane sodium and calcium influx were investigated. The effects of specific inhibition of endoplasmic Ca2+-ATPase by thapsigargin, cyclopiazonic acid, and 2,5 di-(tert-butyl)-1,4-benzohydroquinone (BHQ) on cytosolic free sodium concentration ([Na+](i)) and cytosolic free calcium concentration ([Ca2+](i)) were evaluated in lymphocytes from healthy subjects using the fluorescent dyes sodium-binding benzofuran isophthalate and fura2. The specific inhibition of endoplasmic Ca2+-ATPase by thapsigargin, cyclopia tonic acid, or BHQ increased lymphocytic [Na+](i) and [Ca2+](i). The thapsigargin-induced [Na+](i) increase was abolished in the absence of external sodium, indicating that thapsigargin induced a trans plasma membrane sodium influx. In the absence of external calcium the thapsigargin-induced [Ca2+](i) increase was significantly reduced, whereas the thapsigargin induced [Na+](i) increase remained the same. This finding indicates that the filling state of intracellular calcium pools rather than the elevation of [Ca2+](i) per se regulates the plasma membrane permeability for sodium in lymphocytes. The inhibition of the tyrosine kinase by genistein inhibited the thapsigargin-induced increases of both [Na+](i) and [Ca2+](i) in lymphocytes. The present study shows that the filling state of intracellular thapsigargin-sensitive calcium pools regulates trans plasma membrane sodium and calcium influx via a tyrosine kinase-dependent pathway.			TEPEL, M (corresponding author), UNIV MUNSTER,MED POLIKLIN,D-48129 MUNSTER,GERMANY.		Tepel, Martin/GRS-9581-2022	Tepel, Martin/0000-0002-0086-0997				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BALASUBRAMANYAM M, 1993, AM J PHYSIOL, V265, pC321, DOI 10.1152/ajpcell.1993.265.2.C321; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BORIN M, 1990, J BIOL CHEM, V265, P19543; BORIN ML, 1993, AM J PHYSIOL, V264, pC1513, DOI 10.1152/ajpcell.1993.264.6.C1513; BRUNE B, 1991, J BIOL CHEM, V266, P19232; DEAN NM, 1989, BIOCHEM BIOPH RES CO, V165, P258; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAROOTUNIAN AT, 1989, J BIOL CHEM, V264, P19458; ISHIDA T, 1993, J HYPERTENS, V11, P1089, DOI 10.1097/00004872-199310000-00013; ISHIKAWA S, 1993, BIOCHEM BIOPH RES CO, V194, P287, DOI 10.1006/bbrc.1993.1817; KIMURA M, 1993, J PHYSIOL-LONDON, V464, P1; LEE KM, 1993, J BIOL CHEM, V268, P9945; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MARKS F, 1991, CARCINOGENESIS, V12, P1491, DOI 10.1093/carcin/12.8.1491; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MONTERO M, 1990, BIOCHEM J, V271, P535, DOI 10.1042/bj2710535; NASMITH PE, 1987, FEBS LETT, V221, P95, DOI 10.1016/0014-5793(87)80359-9; OKADA K, 1991, AM J PHYSIOL, V261, pF1007; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PEPER RJ, 1968, J LAB CLIN MED, V72, P842; PRITCHARD K, 1989, CLIN SCI, V76, P631, DOI 10.1042/cs0760631; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RADRIAMAMPITA C, 1993, NATURE, V364, P809; SARGEANT P, 1993, J BIOL CHEM, V268, P18151; TAKEMURA H, 1989, BIOCHEM J, V258, P409, DOI 10.1042/bj2580409; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TEPEL M, 1992, J HYPERTENS, V10, P991; TEPEL M, 1991, BIOCHEM BIOPH RES CO, V177, P991, DOI 10.1016/0006-291X(91)90636-L; TEPEL M, 1994, HYPERTENSION S1, V23, P198; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; VERMA A, 1990, BIOCHEM BIOPH RES CO, V172, P811, DOI 10.1016/0006-291X(90)90747-B; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911	36	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26239	26242						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929340				2022-12-27	WOS:A1994PQ93000048
J	DOI, T; KURASAWA, M; HIGASHINO, K; IMANISHI, T; MORI, T; NAITO, M; TAKAHASHI, K; KAWABE, Y; WADA, Y; MATSUMOTO, A; KODAMA, T				DOI, T; KURASAWA, M; HIGASHINO, K; IMANISHI, T; MORI, T; NAITO, M; TAKAHASHI, K; KAWABE, Y; WADA, Y; MATSUMOTO, A; KODAMA, T			THE HISTIDINE INTERRUPTION OF AN ALPHA-HELICAL COILED-COIL ALLOSTERICALLY MEDIATES A PH-DEPENDENT LIGAND DISSOCIATION FROM MACROPHAGE SCAVENGER RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; EPIDERMAL GROWTH-FACTOR; LEUCINE ZIPPER; CHOLESTEROL DEPOSITION; MOLECULAR FLYPAPER; INSULIN-RECEPTOR; RAT-LIVER; ENDOCYTOSIS; BINDING; ATHEROSCLEROSIS	Macrophage scavenger receptors uptake modified low density lipoproteins (LDLs) through receptor mediated endocytosis. In the alpha-helical coiled coil domain, 2 histidines (His(168) and His(260)) disrupt leucine or isoleucine heptad repeats. Substitution of His(168) or/and His(260) to leucine had no effect on AcLDL binding activities, However, the His(260)-replaced receptors had their ligand degradation activities diminished. Cell surface ligand release experiments under acidic pH clarified that His(260) mutants lost their ligand dissociation activities at 37 degrees C. Furthermore, immunoelectron microscopic experiments using anti-scavenger receptor antibody showed that the His(260) replaced receptors were not able to release gold-labeled AcLDL in endosomes. Here we propose an allosterical ligand dissociation mechanism by His(260) in macrophage scavenger receptors.	KUMAMOTO UNIV,SCH MED,DEPT PATHOL 2,KUMAMOTO 860,JAPAN; UNIV TOKYO,DEPT INTERNAL MED 3,TOKYO 113,JAPAN	Kumamoto University; University of Tokyo	DOI, T (corresponding author), OSAKA UNIV,FAC PHARMACEUT SCI,SUITA,OSAKA 565,JAPAN.			Kawabe, Yoshiki/0000-0002-6465-7146				ACTON S, 1993, J BIOL CHEM, V268, P3530; ANDERSON RGW, 1982, J CELL BIOL, V93, P523, DOI 10.1083/jcb.93.3.523; BARKA T, 1962, J HISTOCHEM CYTOCHEM, V10, P741, DOI 10.1177/10.6.741; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DAVIS CG, 1987, NATURE, V326, P760, DOI 10.1038/326760a0; DIPAOLA M, 1984, J BIOL CHEM, V259, P9163; DOI T, 1993, J BIOL CHEM, V268, P2126; DUNN WA, 1984, J CELL BIOL, V98, P2148, DOI 10.1083/jcb.98.6.2148; EMI M, 1993, J BIOL CHEM, V268, P2120; GEUZE HJ, 1984, CELL, V37, P195, DOI 10.1016/0092-8674(84)90315-5; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HANDLEY DA, 1981, P NATL ACAD SCI-BIOL, V78, P368, DOI 10.1073/pnas.78.1.368; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; KRIEGER M, 1992, TRENDS BIOCHEM SCI, V17, P141, DOI 10.1016/0968-0004(92)90322-Z; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; KRUPP MN, 1982, J BIOL CHEM, V257, P1372; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MORI T, 1994, IN PRESS LAB INVEST; MUEHLPFORDT H, 1982, Experientia (Basel), V38, P1127; OAS TG, 1990, BIOCHEMISTRY-US, V29, P2891, DOI 10.1021/bi00464a001; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PASTAN I, 1983, TRENDS BIOCHEM SCI, V8, P250, DOI 10.1016/0968-0004(83)90351-1; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; TERASAKI T, 1989, J PHARMACOL EXP THER, V251, P351; WALL DA, 1980, CELL, V21, P79, DOI 10.1016/0092-8674(80)90116-6; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WOODS JW, 1986, J CELL BIOL, V103, P277, DOI 10.1083/jcb.103.1.277	39	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25598	25604						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929263				2022-12-27	WOS:A1994PQ49100058
J	MODARRESS, KJ; CAVANAUGH, AH; CHAKRABORTI, PK; SIMONS, SS				MODARRESS, KJ; CAVANAUGH, AH; CHAKRABORTI, PK; SIMONS, SS			METAL OXYANION STABILIZATION OF THE RAT GLUCOCORTICOID RECEPTOR IS INDEPENDENT OF THIOLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; DNA-BINDING DOMAIN; CALF THYMUS DNA; STEROID-BINDING; PROGESTERONE-RECEPTOR; SULFHYDRYL-GROUPS; 59-KILODALTON PROTEIN; MONOCLONAL-ANTIBODY; COMPLEX; MOLYBDATE	The ability of sodium molybdate, both to stabilize the steroid binding activity of glucocorticoid receptors and to prevent the activation of receptor-steroid complexes to a DNA binding species, has long been thought to involve thiols. Two receptor thiols in particular, Cys-656 and Cys-661 of rat receptors, have been suspected. The requirements for the action of molybdate, as well as two other metal oxyanions (tungstate and vanadate) known to exert the same effects as molybdate, have now been examined with receptors in which these thiols, or a third cysteine in the steroid binding cavity (Cys-640), have been mutated to serine. No mutation prevented any metal oxyanion from either stabilizing steroid-free receptors or blocking the activation of complexes for binding to nonspecific or specific DNA sequences. Thus, Cys-640, Cys-656, and Cys-661 are not required for any of the effects of molybdate, tungstate, or vanadate with rat glucocorticoid receptors. Studies with hybrid receptors, and with a 16-kDa steroid binding core fragment containing only 3 cysteines at positions 640, 656, and 661, indicated that no cysteine of the rat receptor was needed to maintain responsiveness to molybdate. Even when all of the thiol groups in crude cytosol were blocked by reaction with excess methyl methanethiol-sulfonate, each metal oxyanion was still able to stabilize the steroid binding of receptors. These results argue that molybdate, tungstate, and vanadate each interact with the receptor or an associated nonreceptor protein(s) in a manner that does not require thiols. An indirect mechanism of molybdate action was evaluated in light of the recent report that the whole cell actions are mediated by increased levels of intracellular cGMP. Under cell-free conditions, however, the effects of molybdate could not be reproduced by cGMP derivatives. Evidence consistent with a direct effect was that molybdate, tungstate, or vanadate each modified the kinetics of proteolysis of wild type receptors at 0 degrees C by trypsin, presumably due to induced conformational changes of the receptor. This alteration of trypsin digestion constitutes yet another effect of metal oxyanions on the glucocorticoid receptor.	NIDDK,LMCB,STEROID HORMONE SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ALLAN GF, 1992, J BIOL CHEM, V267, P19513; BARSONY J, 1992, J BIOL CHEM, V267, P24457; BENJAMIN WSV, 1990, BIOCHEM BIOPH RES CO, V166, P931, DOI 10.1016/0006-291X(90)90900-8; Bodine P V, 1990, Receptor, V1, P83; BODINE PV, 1988, J BIOL CHEM, V263, P3501; BODINE PV, 1988, P NATL ACAD SCI USA, V85, P1462, DOI 10.1073/pnas.85.5.1462; BODINE PV, 1990, J BIOL CHEM, V265, P9544; BRESNICK EH, 1990, BIOCHEMISTRY-US, V29, P520, DOI 10.1021/bi00454a028; BRESNICK EH, 1988, BIOCHEMISTRY-US, V27, P2866, DOI 10.1021/bi00408a030; CAVANAUGH AH, 1990, BIOCHEMISTRY-US, V29, P989, DOI 10.1021/bi00456a022; CAVANAUGH AH, 1990, BIOCHEMISTRY-US, V29, P996, DOI 10.1021/bi00456a023; CAVANAUGH AH, 1994, J STEROID BIOCHEM, V48, P433, DOI 10.1016/0960-0760(94)90191-0; CHAKRABORTI PK, 1991, J BIOL CHEM, V266, P22075; CHAKRABORTI PK, 1992, J BIOL CHEM, V267, P11366; CHAKRABORTI PK, 1991, BIOCHEM BIOPH RES CO, V176, P1338, DOI 10.1016/0006-291X(91)90433-8; CRANS DC, 1992, BIOCHEMISTRY-US, V31, P6812, DOI 10.1021/bi00144a023; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; CUTHILL S, 1987, J BIOL CHEM, V262, P3477; CZAR MJ, 1994, J BIOL CHEM, V269, P11155; DAHMER MK, 1984, ANNU REV PHYSIOL, V46, P67; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; EISEN LP, 1985, J BIOL CHEM, V260, P1805; FERRARI S, 1994, MOL ENDOCRINOL, V8, P173, DOI 10.1210/me.8.2.173; HARMON JM, 1988, J STEROID BIOCHEM, V31, P275, DOI 10.1016/0022-4731(88)90350-0; HOECK W, 1989, J BIOL CHEM, V264, P14396; HOUSLEY PR, 1985, J BIOL CHEM, V260, P3810; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; HUTCHISON KA, 1992, J BIOL CHEM, V267, P13952; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; KAY A, 1968, NATURE, V219, P267, DOI 10.1038/219267a0; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; LEACH KL, 1979, J BIOL CHEM, V254, P1884; LOPEZ S, 1990, J BIOL CHEM, V265, P16039; MESHINCHI S, 1988, J BIOL CHEM, V263, P16809; MESHINCHI S, 1990, J BIOL CHEM, V265, P4863; MESHINCHI S, 1991, BIOCHEMISTRY-US, V30, P8617, DOI 10.1021/bi00099a018; MESHINCHI S, 1990, J BIOL CHEM, V265, P11643; MILLER NR, 1988, J BIOL CHEM, V263, P15217; NEMOTO T, 1992, J STEROID BIOCHEM, V42, P803, DOI 10.1016/0960-0760(92)90088-Z; NEWTON WE, 1979, MOLYBDENUM CHEM BIOL; NIELSEN CJ, 1977, J BIOL CHEM, V252, P7568; NISHIGORI H, 1980, BIOCHEMISTRY-US, V19, P77, DOI 10.1021/bi00542a012; OPOKU J, 1994, J BIOL CHEM, V269, P503; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; PRATT WB, 1987, J CELL BIOCHEM, V35, P51, DOI 10.1002/jcb.240350105; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RAFESTINOBLIN ME, 1989, J BIOL CHEM, V264, P9304; RAFESTINOBLIN ME, 1986, J STEROID BIOCHEM, V25, P527, DOI 10.1016/0022-4731(86)90398-5; REICHMAN ME, 1984, BIOCHEMISTRY-US, V23, P5376, DOI 10.1021/bi00317a042; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; SCHERRER LC, 1993, BIOCHEMISTRY-US, V32, P5381, DOI 10.1021/bi00071a013; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHMIDT TJ, 1985, J BIOL CHEM, V260, P6255; SCHMIDT TJ, 1982, PHYSIOL REV, V62, P1131, DOI 10.1152/physrev.1982.62.4.1131; SHERMAN MR, 1983, J BIOL CHEM, V258, P366; SIMONS SS, 1990, J BIOL CHEM, V265, P1938; SIMONS SS, 1976, J BIOL CHEM, V251, P334; SIMONS SS, 1984, BIOCHEMISTRY-US, V23, P6876, DOI 10.1021/bi00321a092; SIMONS SS, 1987, J BIOL CHEM, V262, P9669; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; SIMONS SS, 1977, BIOCHIM BIOPHYS ACTA, V496, P339; SIMONS SS, 1994, IN PRESS VITAM HORM, V48; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STANCATO LF, 1993, BIOCHEMISTRY-US, V32, P3729, DOI 10.1021/bi00065a027; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TIENRUNGROJ W, 1987, J BIOL CHEM, V262, P6992; TOFT D, 1979, J STEROID BIOCHEM, V11, P413, DOI 10.1016/0022-4731(79)90060-8; VANETTEN RL, 1974, J AM CHEM SOC, V96, P6782, DOI 10.1021/ja00828a053; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; WEATHERS BJ, 1979, J AM CHEM SOC, V101, P917, DOI 10.1021/ja00498a020; WHEELER RH, 1981, J BIOL CHEM, V256, P434; WILHELMSSON A, 1986, J BIOL CHEM, V261, P3456; Yamanouchi K., 1980, MOLYBDENUM CHEM BIOL, P309	76	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25621	25628						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929266				2022-12-27	WOS:A1994PQ49100061
J	TEMESVARI, L; RODRIGUEZPARIS, J; BUSH, J; STECK, TL; CARDELLI, J				TEMESVARI, L; RODRIGUEZPARIS, J; BUSH, J; STECK, TL; CARDELLI, J			CHARACTERIZATION OF LYSOSOMAL MEMBRANE-PROTEINS OF DICTYOSTELIUM-DISCOIDEUM - A COMPLEX POPULATION OF ACIDIC INTEGRAL MEMBRANE-GLYCOPROTEINS, RAB GTP-BINDING PROTEINS AND VACUOLAR ATPASE SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME ALPHA-MANNOSIDASE; GROWING-CELLS; GENE-EXPRESSION; H+-ATPASE; BIOSYNTHESIS; OLIGOSACCHARIDES; ENDOCYTOSIS; INDUCTION; SECRETION; DENSITY	Highly purified lysosomes, prepared by magnetic fractionation of homogenates from Dictyostelium discoideum cells fed colloidal iron, were lysed under hypoosmotic conditions, and the membrane associated proteins were subjected to gel electrophoresis. Thirteen major membrane polypeptides, ranging in molecular weight from 25,000 to 100,000 were identified. The isoelectric points of these proteins ranged from below 3.8 to greater than 7.0. Most of these proteins were stripped from membranes exposed to a chaotropic agent, 3,5-diiodo-2-hydroxybenzoic acid lithium salt, and were therefore classified as peripheral membrane proteins. Twenty five glycoprotein species were detected by lectin blot analysis; 19 were classified as integral membrane proteins, and were, in general,larger than 45 kDa and negatively charged due in part to the presence of mannose B-sulfate. Western blot analysis also demonstrated that a Rab 4-like GTPase, a Rab 7-like GTPase, and at least three subunits of the vacuolar ATPase were associated with the lysosomal membrane; the ATPase subunits appeared to be major proteins in lysosomal membranes. Finally, based on N-terminal sequence analysis of a major 41-kDa lysosome-associated membrane protein, we cloned a cDNA that encodes a protein (DVA41) highly homologous to a yeast and a bovine vacuolar ATPase subunit of approximately 41 kDa. The D. discoideum DVA41 gene was apparently a single copy gene, expressed at constant levels during growth and development.	LOUISIANA STATE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,SHREVEPORT,LA 71130; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Chicago					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK039232, R01DK039232] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047282] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39232-05] Funding Source: Medline; NIGMS NIH HHS [GM 47282] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUBRY L, 1993, J CELL SCI, V105, P861; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BOF M, 1992, J CELL SCI, V101, P139; BUSH J, 1994, IN PRESS GUIDEBOOK S; BUSH J, 1994, IN PRESS J CELL SCI; BUSH J, 1993, J BIOL CHEM, V269, P1468; CARDELLI JA, 1986, ARCH BIOCHEM BIOPHYS, V244, P338, DOI 10.1016/0003-9861(86)90122-0; CARDELLI JA, 1985, DEV BIOL, V110, P147, DOI 10.1016/0012-1606(85)90072-7; CARDELLI JA, 1986, J CELL BIOL, V102, P1264, DOI 10.1083/jcb.102.4.1264; CARDELLI JA, 1989, J BIOL CHEM, V264, P3454; CARDELLI JA, 1987, METHOD CELL BIOL, V28, P139; Cardelli JA, 1993, ENDOSOMES LYSOSOMES, P341; CLARKE M, 1987, DIFFERENTIATION, V34, P79, DOI 10.1111/j.1432-0436.1987.tb00053.x; CLARKE M, 1988, DEV GENET, V9, P315, DOI 10.1002/dvg.1020090413; DEDUVE C, 1983, EUR J BIOCHEM, V137, P391, DOI 10.1111/j.1432-1033.1983.tb07841.x; EBERT DL, 1989, J CELL BIOL, V109, P1445, DOI 10.1083/jcb.109.4.1445; FOK AK, 1993, J CELL SCI, V106, P1103; FREE SJ, 1974, BIOCHIMIE, V56, P1525; FREEZE HH, 1985, ARCH BIOCHEM BIOPHYS, V243, P690, DOI 10.1016/0003-9861(85)90547-8; FREEZE HH, 1986, J BIOL CHEM, V261, P135; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; Holtzman E, 1989, LYSOSOMES; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIERENDORF RC, 1985, J CELL BIOL, V100, P1777, DOI 10.1083/jcb.100.5.1777; MIERENDORF RC, 1983, J BIOL CHEM, V258, P5878; NOLTA KV, 1991, J BIOL CHEM, V266, P18318; NOLTA KV, 1994, IN PRESS BIOCH BIOPH; OHALLORAN TJ, 1992, J CELL BIOL, V118, P1371, DOI 10.1083/jcb.118.6.1371; PADH H, 1993, J BIOL CHEM, V268, P6742; PANNELL R, 1982, J BIOL CHEM, V257, P9861; PISONI RL, 1991, BIOCHIM BIOPHYS ACTA, V1071, P351, DOI 10.1016/0304-4157(91)90002-E; RATHI A, 1991, DEV GENET, V12, P82, DOI 10.1002/dvg.1020120115; RODRIGUEZPARIS JM, 1993, J BIOL CHEM, V268, P9110; RUSCETTI T, 1994, J CELL BIOL, V126, P343, DOI 10.1083/jcb.126.2.343; Sambrook J, 1989, MOL CLONING LABORATO; SCHATZLE J, 1991, MOL CELL BIOL, V11, P3339, DOI 10.1128/MCB.11.6.3339; SCHATZLE J, 1992, J BIOL CHEM, V267, P4000; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; WANG SY, 1988, J BIOL CHEM, V263, P17638; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726	42	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25719	25727						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929276				2022-12-27	WOS:A1994PQ49100073
J	NIBU, Y; TAKAHASHI, S; TANIMOTO, K; MURAKAMI, K; FUKAMIZU, A				NIBU, Y; TAKAHASHI, S; TANIMOTO, K; MURAKAMI, K; FUKAMIZU, A			IDENTIFICATION OF CELL TYPE-DEPENDENT ENHANCER CORE ELEMENT LOCATED IN THE 3'-DOWNSTREAM REGION OF THE HUMAN ANGIOTENSINOGEN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE RESPONSE ELEMENT; DNA-BINDING PROTEINS; TRANSGENIC MICE; TRANSCRIPTION FACTORS; INDUCED HYPERTROPHY; MOLECULAR-BIOLOGY; CARDIAC MYOCYTES; BLOOD-PRESSURE; NUCLEAR FACTOR; HUMAN RENIN	We previously demonstrated that the 3.8-kilobase DNA fragment containing exons 4 and 5 of the human angiotensinogen (hAG) gene enhances the expression of chloramphenicol acetyltransferase gene, under control of the hAG promoter, in human hepatoma HepG2 cells. In the present study, to define regulatory elements of the hAG gene, we have functionally dissected this downstream region and localized a cell type-dependent enhancer to the 832-base pair sequence containing the exon 5 and 3'-flanking region. Further deletion analyses revealed that the 24-base pair core DNA fragment present in the 3'-flanking region was responsible for this enhancement, Electrophoretic mobility shift assay demonstrated that the 3'-enhancer core element interacts specifically with two nuclear factors from the HepG2 cells, one of which is an uncharacterized factor (human angiotensinogen enhancer factor-1: hAEF-1), the other is an AP-3-related factor. Mutation analyses indicated that the disruption of hAEF-1 binding alone completely impaired the enhancer activity of the core element. These results suggested that the downstream enhancer core element interacting with hAEF-1 plays an important role in activating the angiotensinogen promoter in a cell type dependent manner.	UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN	University of Tsukuba			fukamizu, akiyoshi/J-5350-2012; Tanimoto, Keiji/B-2600-2014	fukamizu, akiyoshi/0000-0002-8786-6020; Tanimoto, Keiji/0000-0003-1971-6546; Nibu, Yutaka/0000-0002-4696-7503				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.physiol.54.1.227; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BRASIER AR, 1989, MOL ENDOCRINOL, V3, P1022, DOI 10.1210/mend-3-6-1022; BRASIER AR, 1990, MOL ENDOCRINOL, V4, P1921, DOI 10.1210/mend-4-12-1921; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; CHUI R, 1987, NATURE, V329, P648; CLOUSTON WM, 1989, EMBO J, V8, P3337, DOI 10.1002/j.1460-2075.1989.tb08495.x; CONGIU M, 1992, J MOL ENDOCRINOL, V9, P19, DOI 10.1677/jme.0.0090019; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FUKAMIZU A, 1990, J BIOL CHEM, V265, P7576; FUKAMIZU A, 1990, J CARDIOVASC PHARM, V16, pS11, DOI 10.1097/00005344-199016004-00004; FUKAMIZU A, 1993, J BIOL CHEM, V268, P11617; FUKAMIZU A, 1991, BIOMED BIOCHIM ACTA, V50, P659; GANTEN D, 1992, P NATL ACAD SCI USA, V89, P7806, DOI 10.1073/pnas.89.16.7806; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; GRIENDLING KK, 1993, CIRCULATION, V87, P1816, DOI 10.1161/01.CIR.87.6.1816; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KIMURA S, 1992, EMBO J, V11, P821, DOI 10.1002/j.1460-2075.1992.tb05119.x; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LYNCH KR, 1991, HYPERTENSION, V17, P263, DOI 10.1161/01.HYP.17.3.263; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MERCURIO F, 1989, EMBO J, V8, P1455, DOI 10.1002/j.1460-2075.1989.tb03528.x; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MULLER MM, 1988, EUR J BIOCHEM, V176, P485, DOI 10.1111/j.1432-1033.1988.tb14306.x; REID IA, 1978, ANNU REV PHYSIOL, V40, P377, DOI 10.1146/annurev.ph.40.030178.002113; RON D, 1990, MOL CELL BIOL, V10, P1023, DOI 10.1128/MCB.10.3.1023; RON D, 1990, MOL CELL BIOL, V10, P4389, DOI 10.1128/MCB.10.8.4389; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SERFLING E, 1985, TRENDS GENET, V1, P224, DOI 10.1016/0168-9525(85)90088-5; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TAKAHASHI S, 1991, BIOCHEM BIOPH RES CO, V180, P1103, DOI 10.1016/S0006-291X(05)81180-5; TAMURA K, 1993, J BIOL CHEM, V268, P15024; TAMURA K, 1992, NUCLEIC ACIDS RES, V20, P3617, DOI 10.1093/nar/20.14.3617; TAMURA K, 1994, J CLIN INVEST, V93, P1370, DOI 10.1172/JCI117113; TANIMOTO K, 1993, ARCH BIOCHEM BIOPHYS, V302, P409, DOI 10.1006/abbi.1993.1232; VERRI A, 1990, NUCLEIC ACIDS RES, V18, P5775, DOI 10.1093/nar/18.19.5775; WARD K, 1993, NAT GENET, V4, P59, DOI 10.1038/ng0593-59	45	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28598	28605						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961807				2022-12-27	WOS:A1994PU16800016
J	YEO, EJ; KAZLAUSKAS, A; EXTON, JH				YEO, EJ; KAZLAUSKAS, A; EXTON, JH			ACTIVATION OF PHOSPHOLIPASE C-GAMMA IS NECESSARY FOR STIMULATION OF PHOSPHOLIPASE-D BY PLATELET-DERIVED GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RECEPTOR-BETA-SUBUNIT; INOSITOL-LIPID HYDROLYSIS; PROTEIN-KINASE-C; SWISS 3T3 CELLS; SIGNAL TRANSDUCTION; PHOSPHATIDYLCHOLINE BREAKDOWN; TYROSINE PHOSPHORYLATION; PDGF RECEPTOR; MITOGENIC SIGNAL; FIBROBLASTS	Platelet-derived growth factor (PDGF) stimulates phosphatidylcholine hydrolysis via phospholipase D (PLD) in several tissues. To determine whether PLD activation is dependent on phosphoinositide hydrolysis by phospholipase C (PLC), we measured the formation of phosphatidylbutanol (PtdBut), in TRMP cells overexpressing wild type or various mutant PDGF receptors. Both PLC and PLD were stimulated by PDGF in cells expressing wild type receptors whereas they were not in cells expressing kinase-deficient (R634) receptors. These data indicate that tyrosine phosphorylation is required for activation of both PLC and PLD. Mutation of Tyr-1021 of the PDGF receptor to Phe caused loss of PDGF stimulation of both PLC and PLD. On the other hand, a mutant PDGF receptor that was able to bind PLC gamma 1 but not other signaling proteins (including the Ras GTPase-activating protein, phosphatidylinositol 3-kinase, and a SH2-containing phosphotyrosine phosphatase (Syp)) restored the stimulatory effect of PDGF on PLC and PLD. Furthermore, receptors in which association with the GTPase-activating protein, phosphatidylinositol S-kinase, or Syp was individually restored were unable to mediate PDGF stimulation of PLC or PLD. These data indicate that these other signal transduction proteins are not involved in the activation of PLD by PDGF Treatment of the cells with the protein kinase C inhibitor, Ro-31-8220, and depletion of cellular protein kinase C by pretreatment with 4 beta-phorbol 12-myristate 13-acetate resulted in loss of PLD activation by PDGF indicating a PKC-dependent mechanism. In summary, these results indicate that activation of PLC gamma 1 and protein kinase C are necessary for the stimulation of PLD by PDGF and provide no evidence for alternative mechanisms.	VANDERBILT UNIV,SCH MED,HOWARD HUGHES MED INST,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PHYSIOL & MOLEC BIOPHYS,NASHVILLE,TN 37232; NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80206	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University; National Jewish Health					NCI NIH HHS [CA 55063, CA 58187] Funding Source: Medline; NIGMS NIH HHS [GM 48339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058187, R29CA055063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED A, 1994, AM J PHYSIOL, V266, pC206, DOI 10.1152/ajpcell.1994.266.1.C206; BENAV P, 1993, EUR J BIOCHEM, V215, P455, DOI 10.1111/j.1432-1033.1993.tb18054.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; COOK SJ, 1990, BIOCHEM J, V265, P617, DOI 10.1042/bj2650617; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; COOK SJ, 1991, BIOCHIM BIOPHYS ACTA, V1092, P265, DOI 10.1016/0167-4889(91)90166-U; COOK SJ, 1992, BIOCHEM J, V285, P247, DOI 10.1042/bj2850247; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DUBYAK GR, 1993, BIOCHEM J, V292, P121, DOI 10.1042/bj2920121; ESCOBEDO JA, 1988, MOL CELL BIOL, V8, P5126, DOI 10.1128/MCB.8.12.5126; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; EXTON JH, 1990, J BIOL CHEM, V265, P1; HA KS, 1993, J BIOL CHEM, V268, P10534; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KONDO T, 1994, CLIN EXP HYPERTENS, V16, P17, DOI 10.3109/10641969409068581; KUMADA T, 1994, BIOCHEM BIOPH RES CO, V199, P792, DOI 10.1006/bbrc.1994.1299; KUSNER DJ, 1993, J BIOL CHEM, V268, P19973; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PARIS S, 1988, J BIOL CHEM, V263, P12893; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; PRICE BD, 1989, BIOCHEM J, V264, P509, DOI 10.1042/bj2640509; SIMPSON CMF, 1987, NEUROCHEMISTRY PRACT, P193; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WRIGHT TM, 1990, BIOCHEM J, V267, P501, DOI 10.1042/bj2670501; Zhang Wei, 1992, Neurological Research, V14, P397	36	89	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27823	27826						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961710				2022-12-27	WOS:A1994PV77200011
J	FOURNIER, T; MEJDOUBI, N; LAPOUMEROULIE, C; HAMELIN, J; ELION, J; DURAND, G; PORQUET, D				FOURNIER, T; MEJDOUBI, N; LAPOUMEROULIE, C; HAMELIN, J; ELION, J; DURAND, G; PORQUET, D			TRANSCRIPTIONAL REGULATION OF RAT ALPHA(1)-ACID GLYCOPROTEIN GENE BY PHENOBARBITAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HEPATOCYTE-STIMULATING FACTOR; PLASMA-PROTEIN GENES; ACUTE-PHASE PROTEINS; TUMOR NECROSIS FACTOR; ALPHA-1-ACID GLYCOPROTEIN; NADPH-CYTOCHROME-P-450 OXIDOREDUCTASE; LIVER CYTOCHROME-P-450; MICROSOMAL-ENZYMES; CYTOKINE-RESPONSE; MESSENGER-RNA	Phenobarbital induces gene transcription of both cytochrome P450IIB (the barbiturate inducible cytochrome P450 in mammals) and alpha(1)-acid glycoprotein, one of the major acute-phase proteins in rats and humans. Analysis of the 5'-regulatory sequences of cytochrome P450IIB and alpha(1)-acid glycoprotein genes in rats revealed the presence of a consensus sequence of 10 base pairs, termed the phenobarbital-responsive element or Barbie box, located in a region extending from positions -136 to -127 from the transcription start site of the alpha(1)-acid glycoprotein gene. A 17-base pair oligonucleotide probe specific for alpha(1)-acid glycoprotein and including the consensus sequence showed, in mobility shift assays, slight binding to liver nuclear protein from untreated animals. This binding was strongly and specifically increased with protein extracts from phenobarbital-treated rats. Transfection of rat primary hepatocytes with the pAGPcat construct induced basal expression of chloramphenicol acetyltransferase activity, which was increased by phenobarbital and dexamethasone treatment of cells. Induction of chloramphenicol acetyltransferase activity by phenobarbital was abolished when hepatocytes were transfected by constructs with a mutation or deletion of the Barbie box sequence. These results strongly suggest that the Barbie box sequence is involved in alpha(1)-acid glycoprotein gene regulation by phenobarbital.	UNITE FORMAT & RECH PHARM,UA 1595,BIOCHIM GEN LAB,F-92290 CHATENAY MALABRY,FRANCE; HOP ROBERT DEBRE,INSERM,U120,F-75019 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Fournier, Thierry C/E-5836-2016; Elion, Jacques/A-1048-2014; HAMELIN, Jocelyne JH/R-4590-2018; Lapoumeroulie, Claudine/P-3515-2018; MEJDOUBI-CHAREF, Najet/R-4683-2018	Elion, Jacques/0000-0002-8407-1783; HAMELIN, Jocelyne JH/0000-0003-4222-0792; LAPOUMEROULIE, Claudine/0000-0001-6665-3598				ADESNIK M, 1981, J BIOL CHEM, V256, P340; ADESNIK M, 1986, CRIT REV BIOCHEM MOL, V19, P247, DOI 10.3109/10409238609084657; ANDUS T, 1988, EUR J IMMUNOL, V18, P739, DOI 10.1002/eji.1830180513; BAUMANN H, 1989, J BIOL CHEM, V264, P8046; BAUMANN H, 1989, IN VITRO CELL DEV B, V25, P115; BAUMANN H, 1987, J IMMUNOL, V139, P4122; BAUMANN H, 1989, J IMMUNOL, V143, P1163; BAUMANN H, 1990, MOL BIOL MED, V7, P147; BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BAUMANN H, 1990, J BIOL CHEM, V265, P22275; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BERTAUX O, 1992, EUR J BIOCHEM, V203, P655, DOI 10.1111/j.1432-1033.1992.tb16595.x; BERTINI R, 1989, J LEUKOCYTE BIOL, V46, P254, DOI 10.1002/jlb.46.3.254; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONNEY AH, 1967, PHARMACOL REV, V19, P317; CONNEY AH, 1982, CANCER RES, V42, P4875; DANNAN GA, 1986, J BIOL CHEM, V261, P728; DUNN TJ, 1989, J BIOL CHEM, V264, P13057; FRANCIS VNK, 1986, NUCLEIC ACIDS RES, V14, P2497, DOI 10.1093/nar/14.6.2497; GAULDIE J, 1989, ANN NY ACAD SCI, V557, P46; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GAULDIE J, 1988, MONOKINES OTHER NONL, P15; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HARDWICK JP, 1983, J BIOL CHEM, V258, P8081; HE JS, 1991, J BIOL CHEM, V266, P7864; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; KLEIN ES, 1987, J BIOL CHEM, V262, P520; KLEIN ES, 1988, MOL ENDOCRINOL, V2, P1343, DOI 10.1210/mend-2-12-1343; KULKARNI AB, 1985, J BIOL CHEM, V260, P5386; KUSHNER I, 1987, DIS MARKERS, V5, P1; KUTT H, 1989, ANTIEPILEPTIC DRUGS; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P626; OMIECINSKI CJ, 1985, J BIOL CHEM, V260, P3247; PORTER TD, 1990, BIOCHEMISTRY-US, V29, P9814, DOI 10.1021/bi00494a009; PROWSE KR, 1989, J LEUKOCYTE BIOL, V45, P55, DOI 10.1002/jlb.45.1.55; PROWSE KR, 1988, MOL CELL BIOL, V8, P42, DOI 10.1128/MCB.8.1.42; RANGARAJAN PN, 1989, P NATL ACAD SCI USA, V86, P3963, DOI 10.1073/pnas.86.11.3963; RATAJCZAK T, 1992, J BIOL CHEM, V267, P11111; RICHARDS CD, 1992, J IMMUNOL, V148, P1731; SAYERS JR, 1992, BIOTECHNIQUES, V13, P592; SHAW GC, 1993, J BIOL CHEM, V268, P2997; STANLEY LA, 1988, EUR J BIOCHEM, V174, P31, DOI 10.1111/j.1432-1033.1988.tb14058.x; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; SUJITA K, 1990, BIOCHEM BIOPH RES CO, V168, P1217, DOI 10.1016/0006-291X(90)91158-O; VANNICE JL, 1984, P NATL ACAD SCI-BIOL, V81, P4241, DOI 10.1073/pnas.81.14.4241; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577; WHITLOCK JP, 1986, ANNU REV PHARMACOL, V26, P333; WILLIAMS JF, 1991, BIOCHEM BIOPH RES CO, V178, P1049, DOI 10.1016/0006-291X(91)90998-M; WON KA, 1990, MOL CELL BIOL, V10, P3965, DOI 10.1128/MCB.10.8.3965	52	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27175	27178						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961625				2022-12-27	WOS:A1994PV77100006
J	ODONNELL, JK; BIRCH, P; PARSONS, CT; WHITE, SP; OKABE, J; MARTIN, MJ; ADAMS, C; SUNDARAPANDIYAN, K; MANJULA, BN; ACHARYA, AS; LOGAN, JS; KUMAR, R				ODONNELL, JK; BIRCH, P; PARSONS, CT; WHITE, SP; OKABE, J; MARTIN, MJ; ADAMS, C; SUNDARAPANDIYAN, K; MANJULA, BN; ACHARYA, AS; LOGAN, JS; KUMAR, R			INFLUENCE OF THE CHEMICAL NATURE OF SIDE-CHAIN AT BETA-108 OF HEMOGLOBIN A ON THE MODULATION OF THE OXYGEN-AFFINITY BY CHLORIDE-IONS - LOW-OXYGEN AFFINITY VARIANTS OF HUMAN HEMOGLOBIN EXPRESSED IN TRANSGENIC PIGS - HEMOGLOBINS PRESBYTERIAN AND YOSHIZUKA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITES; BLOOD SUBSTITUTE; HUMAN DEOXYHEMOGLOBIN; X-RAY; IDENTIFICATION; RESOLUTION; SWINE	Hemoglobin A (HbA) and two low oxygen affinity variants of HbA, Hb(Presbyterian) and Hb(Yoshizuka), were produced in transgenic pigs and purified to homogeneity by ion-exchange chromatography. These two variants contain either lysine (Hb(Presbyterian)) or aspartic acid (Hb(Yoshizuka)) instead of the normal asparagine residue at position beta 108 in HbA. Transgenic pigs expressed these variants at a level up to 11% and were healthy. Both Hb(Presbyterian) and Hb(Yoshizuka) exhibited low O-2 affinity (P-50 of 21.2 and 18.9, respectively, compared with control HbA value of 11.8 in 0.1 M NaCl, pH 7.5) and retained normal cooperativity with Hill coefficients of 2.9 and 2.5, respectively. Hb(Presbyterian) exhibited Bohr effect comparable with HbA. In contrast, Hb(Yoshizuka) had a diminished response to changes in pH. Thus the structural basis of reduced O-2 affinity of these variants appears to be distinct: the consequence of mutation at beta 108 is a function of the chemical nature of the side chain. This is further confirmed by the sensitivity of the O-2 affinity of the variants to the presence of Cl-. The O-2 affinity of Hb(Yoshizuka) is insensitive to changes in Cl- concentration, whereas the O-2 affinity of Hb(Presbyterian) exhibited a pronounced and dramatic chloride effect. In fact, P-50 of Hb(Presbyterian) was identical to that of HbA at very low Cl- concentrations, and the P-50 increased to >40 at 0.5 M Cl-. The chloride effect was completely abolished when Hb(Presbyterian) was stabilized at the 2,3-diphosphoglycerate pocket by interdimeric cross-linking. Molecular modeling studies demonstrate that in Hb(Presbyterian), Cl- can bridge the epsilon-amino group of Lys(beta 108) with either the guanidino group of Arg(beta 104) or the epsilon-amino group of Lys(alpha 99), resulting in the stabilization of the ''T'' structure. The utility of these low O-2 affinity hemoglobins as cell-free oxygen carriers is discussed.	DNX BIOTHERAPEUT INC,PRINCETON,NJ 08540; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,DIV HEMATOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NHLBI NIH HHS [HL-38665] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM DJ, 1992, BIOCHEMISTRY-US, V31, P9141, DOI 10.1021/bi00153a005; ALTER BP, 1980, BRIT J HAEMATOL, V44, P527, DOI 10.1111/j.1365-2141.1980.tb08706.x; BENESCH R, 1967, BIOCHEM BIOPH RES CO, V26, P162, DOI 10.1016/0006-291X(67)90228-8; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Bohr C, 1904, SKAND ARCH PHYSIOL, V16, P402, DOI 10.1111/j.1748-1716.1904.tb01382.x; BONAVENTURA C, 1994, BIOPHYS J, V66, pA270; BONAVENTURA J, 1976, J BIOL CHEM, V251, P7563; BUNN HF, 1993, AM J HEMATOL, V42, P112, DOI 10.1002/ajh.2830420122; Bunn HF, 1986, HEMOGLOBIN MOL GENET; CHIANCONE E, 1975, EUR J BIOCHEM, V55, P385, DOI 10.1111/j.1432-1033.1975.tb02173.x; DELLANO JJM, 1993, P NATL ACAD SCI USA, V90, P918, DOI 10.1073/pnas.90.3.918; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; GACON G, 1977, FEBS LETT, V82, P243, DOI 10.1016/0014-5793(77)80593-0; GREAVES DR, 1990, NATURE, V343, P183, DOI 10.1038/343183a0; HANSCOMBE O, 1989, GENE DEV, V3, P1572, DOI 10.1101/gad.3.10.1572; HOFFMAN SJ, 1991, BIOTECHNOLOGY, V9, P57; HUISMAN THJ, 1987, J CHROMATOGR-BIOMED, V418, P277, DOI 10.1016/0378-4347(87)80012-9; IMAMURA T, 1969, J CLIN INVEST, V48, P2341, DOI 10.1172/JCI106200; KAVANAUGH JS, 1992, BIOCHEMISTRY-US, V31, P4111, DOI 10.1021/bi00131a030; KEIPERT PE, 1989, TRANSFUSION, V29, P768, DOI 10.1046/j.1537-2995.1989.29990070179.x; KELLY RM, 1994, BIOPHYS J, V66, pA70; LOGAN JS, 1993, METHOD ENZYMOL, V231, P435; LOOKER D, 1992, NATURE, V356, P258, DOI 10.1038/356258a0; MANITIS T, 1982, MOL CLONING LABORATO; MANJULA BM, 1994, ARTIF CELLS BLOOD SU, V2, P747; MOOPENN WF, 1978, FEBS LETT, V92, P53, DOI 10.1016/0014-5793(78)80720-0; NIGEN AM, 1980, J BIOL CHEM, V255, P5525; ODONNELL JK, 1993, CANCER DETECT PREV, V17, P307; ODONNELL S, 1979, J BIOL CHEM, V254, P2204; PERUTZ MF, 1993, J MOL BIOL, V233, P536, DOI 10.1006/jmbi.1993.1530; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; POYART C, 1980, J BIOL CHEM, V255, P9465; RAO MJ, 1994, ARTIF CELL BLOOD SUB, V22, P695, DOI 10.3109/10731199409117900; Riggs A., 1981, Methods in Enzymology, V76, P5; ROLLEMA HS, 1975, J BIOL CHEM, V250, P1333; ROSSIFANELLI A, 1961, J BIOL CHEM, V236, P391; SCHMIDTNEILSEN K, 1958, AM J PHYSIOL, V195, P424, DOI 10.1152/ajplegacy.1958.195.2.424; SHARMA A, 1993, BIOTECHNOLOGY, V12, P55; SHEN TJ, 1993, P NATL ACAD SCI USA, V90, P8108, DOI 10.1073/pnas.90.17.8108; SWANSON ME, 1992, BIO-TECHNOL, V10, P557, DOI 10.1038/nbt0592-557; UENO H, 1992, J PROTEIN CHEM, V11, P177, DOI 10.1007/BF01025223; UENO H, 1993, J PROTEIN CHEM, V12, P561, DOI 10.1007/BF01025120; VANBEEK GGM, 1980, EUR J BIOCHEM, V105, P353; [No title captured]	44	24	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27692	27699						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961689				2022-12-27	WOS:A1994PV77100083
J	FERNANDEZ, B; BALBOA, MA; SOLISHERRUZO, JA; BALSINDE, J				FERNANDEZ, B; BALBOA, MA; SOLISHERRUZO, JA; BALSINDE, J			PHOSPHATIDATE-INDUCED ARACHIDONIC-ACID MOBILIZATION IN MOUSE PERITONEAL-MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PLATELET-ACTIVATING-FACTOR; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; STIMULATED PHOSPHOLIPASE-A2 ACTIVATION; RAT KUPFFER CELLS; HUMAN-NEUTROPHILS; EXTRACELLULAR CALCIUM; MESANGIAL CELLS; FATTY-ACIDS; MOBILIZING PHOSPHOLIPASE-A2	Phosphatidate (PA) is synthesized by a variety of cells in response to physiological agonists. Addition of PA vesicles to [H-3]arachidonic acid (AA)-labeled macrophages was found to induce the release of radiolabel in a dose- and time-dependent manner. This effect correlated with the uptake of PA by the macrophages and appeared to be attributable to PA itself and not to a PA metabolite. In parallel with AA release, PA induced a rapid increase in lysophosphatidylcholine in cells prelabeled with [C-14]glycerol. Down-regulation of protein kinase C by long term exposure of the cells to phorbol myristate acetate or cell treatment with the protein kinase C inhibitor staurosporine did not affect the PA response. Also, removal of external calcium or cell treatment with the calmodulin antagonist trifluoperazine did not affect PA-induced AA release, while inhibiting the responses to zymosan, phorbol 12-myristate 13-acetate, and ionophore A23187. PA-induced AA release was not affected by intracellular calcium depletion by treatment with quin2/AM in the presence of EGTA. When assayed toward an AA-containing substrate, PA was able to enhance phospholipase A(2) activity from cell homogenates in the absence of calcium. The dose dependence and magnitude of the PA effect correlated with those observed for PA-induced AA release in whole cells. Inclusion of ATP in the assay mixture did not affect the activity of the PA-stimulated phospholipase A. These findings suggest a role for PA in the cascade of events leading to AA release in macrophages through Ca2+-independent stimulation of an AA-selective phospholipase A.	HOSP UNIV DOCE OCTUBRE,CTR INVEST,E-28041 MADRID,SPAIN	Hospital Universitario 12 de Octubre			Balsinde, Jesús/C-7833-2018; Balboa, María A./V-9493-2018	Balsinde, Jesús/0000-0002-4157-6714; Balboa, María A./0000-0002-2130-5298				ADEREM AA, 1986, J EXP MED, V163, P139, DOI 10.1084/jem.163.1.139; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; BALBOA MA, 1992, J EXP MED, V176, P9, DOI 10.1084/jem.176.1.9; BALSINDE J, 1992, BIOCHIM BIOPHYS ACTA, V1136, P75, DOI 10.1016/0167-4889(92)90087-R; BALSINDE J, 1991, J BIOL CHEM, V266, P18726; BALSINDE J, 1990, J IMMUNOL, V144, P4298; BALSINDE J, 1994, EUR J BIOCHEM, V221, P1013, DOI 10.1111/j.1432-1033.1994.tb18818.x; BALSINDE J, 1988, J BIOL CHEM, V263, P1929; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BILLAH MM, 1981, J BIOL CHEM, V256, P5399; BILLAH MM, 1993, CURR OPIN IMMUNOL, V5, P114; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BROOKS RC, 1989, J BIOL CHEM, V264, P20147; BUCKLEY BJ, 1991, BIOCHEM J, V280, P281, DOI 10.1042/bj2800281; BURSTEN SL, 1991, J BIOL CHEM, V266, P20732; CHAO W, 1992, J BIOL CHEM, V267, P6725; COCKCROFT S, 1984, BIOCHIM BIOPHYS ACTA, V795, P37, DOI 10.1016/0005-2760(84)90102-4; DIETER P, 1988, EUR J BIOCHEM, V177, P61, DOI 10.1111/j.1432-1033.1988.tb14345.x; DIEZ E, 1990, BIOCHIM BIOPHYS ACTA, V1047, P83, DOI 10.1016/0005-2760(90)90264-X; DIVIRGILIO F, 1984, NATURE, V310, P691, DOI 10.1038/310691a0; DUYSTER J, 1992, J CELL BIOCHEM, V48, P288, DOI 10.1002/jcb.240480309; EMILSSON A, 1986, BIOCHIM BIOPHYS ACTA, V876, P533, DOI 10.1016/0005-2760(86)90041-X; ENGLISH D, 1991, BLOOD, V77, P2746; FERNANDEZ B, 1990, FEBS LETT, V268, P107, DOI 10.1016/0014-5793(90)80984-Q; FERNANDEZ B, 1991, BIOCHEM BIOPH RES CO, V180, P1036, DOI 10.1016/S0006-291X(05)81170-2; FERNANDEZ B, 1992, EICOSANOIDS, V5, P115; FERNANDEZ B, 1993, BIOCHIM BIOPHYS ACTA, V1176, P169, DOI 10.1016/0167-4889(93)90193-S; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; HALENDA SP, 1989, BIOCHEMISTRY-US, V28, P7356, DOI 10.1021/bi00444a031; HOFFMAN T, 1991, J IMMUNOL, V146, P692; INSEL PA, 1991, BIOCHEM SOC T, V19, P329, DOI 10.1042/bst0190329; JALINK K, 1990, J BIOL CHEM, V265, P12232; JONES GA, 1993, J BIOL CHEM, V268, P20845; KANAHO Y, 1991, J IMMUNOL, V146, P3536; KESTER M, 1993, J CELL PHYSIOL, V156, P317, DOI 10.1002/jcp.1041560214; KNAUSS TC, 1990, J BIOL CHEM, V265, P14457; KRAUSE H, 1991, BIOCHEM BIOPH RES CO, V175, P532, DOI 10.1016/0006-291X(91)91597-6; KROLL MH, 1989, J CELL PHYSIOL, V139, P558, DOI 10.1002/jcp.1041390315; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; MAHONEY EM, 1980, J BIOL CHEM, V255, P4910; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MURAYAMA T, 1987, J BIOL CHEM, V262, P5522; OHTSUKA T, 1989, J BIOCHEM-TOKYO, V106, P259, DOI 10.1093/oxfordjournals.jbchem.a122841; PFANNKUCHE HJ, 1989, BIOCHEM J, V260, P471, DOI 10.1042/bj2600471; QIAN Z, 1991, FASEB J, V5, P315, DOI 10.1096/fasebj.5.3.2001791; QIU ZH, 1993, J BIOL CHEM, V268, P24506; QIU ZH, 1994, J BIOL CHEM, V269, P19480; RAAFLAUB J, 1956, Methods Biochem Anal, V3, P301; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; SATO T, 1992, J BIOCHEM-TOKYO, V112, P756, DOI 10.1093/oxfordjournals.jbchem.a123971; SCHATZMUNDING M, 1991, EUR J BIOCHEM, V197, P487, DOI 10.1111/j.1432-1033.1991.tb15936.x; SCHATZMUNDING M, 1992, EUR J BIOCHEM, V204, P705, DOI 10.1111/j.1432-1033.1992.tb16685.x; SCOTT WA, 1980, J EXP MED, V152, P324, DOI 10.1084/jem.152.2.324; STEWART SJ, 1991, CELL REGUL, V2, P841, DOI 10.1091/mbc.2.10.841; SVENSSON U, 1993, EUR J BIOCHEM, V213, P81, DOI 10.1111/j.1432-1033.1993.tb17736.x; SVENSSON U, 1991, EUR J BIOCHEM, V200, P699, DOI 10.1111/j.1432-1033.1991.tb16234.x; TAMURA M, 1993, ARCH BIOCHEM BIOPHYS, V305, P477, DOI 10.1006/abbi.1993.1450; TOU JS, 1991, BIOCHEM J, V280, P625, DOI 10.1042/bj2800625; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; WEBER C, 1993, EUR J IMMUNOL, V23, P852, DOI 10.1002/eji.1830230413; WEISS BA, 1991, J BIOL CHEM, V266, P2126; WIJKANDER J, 1992, BIOCHEM BIOPH RES CO, V184, P118, DOI 10.1016/0006-291X(92)91166-N; WIJKANDER J, 1989, BIOCHIM BIOPHYS ACTA, V1010, P78, DOI 10.1016/0167-4889(89)90187-0; WIJKANDER J, 1992, FEBS LETT, V311, P299, DOI 10.1016/0014-5793(92)81124-5; XING MZ, 1992, J BIOL CHEM, V267, P25966; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	71	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26711	26716						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929404				2022-12-27	WOS:A1994PQ93100023
J	HEYMAN, HC; STAVNEZER, E				HEYMAN, HC; STAVNEZER, E			A CARBOXYL-TERMINAL REGION OF THE SKI ONCOPROTEIN MEDIATES HOMODIMERIZATION AS WELL AS HETERODIMERIZATION WITH THE RELATED PROTEIN SNON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDNA CLONES; ONCOGENE; DNA; SEQUENCE; GENE; CONTAINS; COMPLEX; DOMAIN; ZIPPER; MUSCLE	Ski is a nuclear oncoprotein, and possibly a transcriptional factor, that has been shown to be involved in both transformation and myogenesis. In attempts to understand the molecular mechanisms underlying the function of Ski, the protein-protein interactions of Ski with itself and with its close relative, SnoN, were investigated. It was found that while both v-Ski and c-Ski bound themselves and each other as bacterial fusion proteins, only c-Ski formed homodimers that could be detected by covalent cross-linking of the native in vitro translated protein in solution. The results also showed that c-Ski formed heterodimers with SnoN. Deletion analysis showed that the carboxyl-terminal third of c-Ski, which is deleted in v-Ski, was required for stable dimer formation in solution. This region consists of two predicted structural motifs that constitute the c-Ski dimerization domain. The more amino-terminal motif is predicted to be mostly alpha helical and is comprised of five tandem repeats of 25 amino acids each and was required for c-Ski dimerization. The second motif is a predicted leucine zipper that was not required for dimerization but greatly increased the fraction of Ski protein detected as dimers. This minor c-Ski homodimerization domain appeared to be required for Ski-Sno heterodimer formation.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	Case Western Reserve University; University System of Ohio; University of Cincinnati					NATIONAL CANCER INSTITUTE [R01CA043600] Funding Source: NIH RePORTER; NCI NIH HHS [CA43600] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARKAS AE, 1986, VIROLOGY, V151, P131, DOI 10.1016/0042-6822(86)90111-X; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOYER PL, 1993, ONCOGENE, V8, P457; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; GRIMES HL, 1992, NUCLEIC ACIDS RES, V20, P1511, DOI 10.1093/nar/20.7.1511; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAGASE T, 1993, J BIOL CHEM, V268, P13710; NAGASE T, 1990, NUCLEIC ACIDS RES, V18, P337, DOI 10.1093/nar/18.2.337; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; PEARSONWHITE S, 1993, NUCLEIC ACIDS RES, V21, P4632, DOI 10.1093/nar/21.19.4632; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SLEEMAN JP, 1993, ONCOGENE, V8, P67; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1989, MOL CELL BIOL, V9, P4046, DOI 10.1128/MCB.9.9.4046; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462	23	47	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26996	27003						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929440				2022-12-27	WOS:A1994PQ93100063
J	ELIASSON, R; PONTIS, E; ECKSTEIN, F; REICHARD, P				ELIASSON, R; PONTIS, E; ECKSTEIN, F; REICHARD, P			INTERACTIONS OF 2'-MODIFIED AZIDOANALOGS AND HALOANALOGS OF DEOXYCYTIDINE 5'-TRIPHOSPHATE WITH THE ANAEROBIC RIBONUCLEOTIDE REDUCTASE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2'-AZIDO-2'-DEOXYURIDINE 5'-DIPHOSPHATE; LACTOBACILLUS-LEICHMANNII; DIPHOSPHATE REDUCTASE; INACTIVATION; MECHANISM; GENE; ACTIVATION; GENERATION; CLONING	The anaerobic Escherichia coli ribonucleotide reductase (class III reductase) responsible for the synthesis of the deoxyribonucleotides required for anaerobic DNA replication contains an oxygen-sensitive glycyl radical (Gly-681) suggesting involvement of radical chemistry in catalysis. The amino acid sequence of this enzyme completely differs from that of earlier described aerobic class I (prototype, aerobic E. coli) and class II (proto type, Lactobacillus leichmanii) reductases that use radical chemistry but employ other means for radical generation. Here, we study the interaction between the anaerobic E. coli reductase with the 5'-triphosphates of 2'-chloro-2'-deoxycytidine, 2'-fluoro-2'-deoxycytidine, and 2'-azido-2' deoxycytidine (N3CTP), which are mechanism-based inhibitors of class I and II reductases and, on interaction with these enzymes, decompose to base, inorganic di(tri)phosphate and 2'-methylene-3(2H)-furanone. Also, with the anaerobic E. coli reductase, the 2'-substituted nucleotides act as mechanism-based inhibitors and decompose. N3CTP scavenges the glycyl radical of the enzyme similar to the interaction of N3CDP with the tyrosyl radical of class I enzymes. However we found no evidence for a new transient radical species as is the case with class I enzymes. Our results suggest that the chemistry at the nucleotide level for the reduction of ribose by class III enzymes is similar to the chemistry employed by class I and II enzymes.	KAROLINSKA INST, INST MED NOBEL, DEPT BIOCHEM 1, MBB, S-17177 STOCKHOLM, SWEDEN; MAX PLANCK INST EXPTL MED, CHEM ABT, W-3400 GOTTINGEN, GERMANY	Karolinska Institutet; Max Planck Society								ASHLEY GW, 1988, BIOCHEMISTRY-US, V27, P7841, DOI 10.1021/bi00420a038; ATOR M, 1984, J AM CHEM SOC, V106, P1886, DOI 10.1021/ja00318a082; ATOR MA, 1985, BIOCHEMISTRY-US, V24, P7214, DOI 10.1021/bi00346a029; AURUP H, 1992, BIOCHEMISTRY-US, V31, P9636, DOI 10.1021/bi00155a016; BIANCHI V, 1993, J BACTERIOL, V175, P1590, DOI 10.1128/JB.175.6.1590-1595.1993; ELIASSON R, 1992, J BIOL CHEM, V267, P25541; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; HARDER J, 1992, J BIOL CHEM, V267, P25548; HARRIS G, 1987, BIOCHEMISTRY-US, V26, P1895, DOI 10.1021/bi00381a017; HARRIS G, 1984, BIOCHEMISTRY-US, V23, P5214, DOI 10.1021/bi00317a020; HOBBS J, 1972, BIOCHEMISTRY-US, V11, P4336, DOI 10.1021/bi00773a021; LOWE PN, 1982, BIOORG CHEM, V11, P55, DOI 10.1016/0045-2068(82)90048-7; LUDWIG J, 1989, J ORG CHEM, V54, P631, DOI 10.1021/jo00264a024; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; OSBORNE C, 1991, J BACTERIOL, V173, P1729, DOI 10.1128/jb.173.5.1729-1737.1991; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SALOWE S, 1993, BIOCHEMISTRY-US, V32, P12749, DOI 10.1021/bi00210a026; SALOWE SP, 1987, BIOCHEMISTRY-US, V26, P3408, DOI 10.1021/bi00386a024; SJOBERG BM, 1983, J BIOL CHEM, V258, P8060; STUBBE J, 1983, J BIOL CHEM, V258, P1619; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; SUN XY, 1993, P NATL ACAD SCI USA, V90, P577, DOI 10.1073/pnas.90.2.577; THELANDER L, 1976, J BIOL CHEM, V251, P1398	23	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26116	26120						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929323				2022-12-27	WOS:A1994PQ93000029
J	KUROKI, Y; VOELKER, DR				KUROKI, Y; VOELKER, DR			PULMONARY SURFACTANT PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							RAT ALVEOLAR MACROPHAGES; CARBOHYDRATE-BINDING PROTEIN; BOVINE LUNG SURFACTANT; AMINO-ACID-SEQUENCE; C-TERMINAL DOMAIN; APOPROTEIN SP-A; II CELLS; SP-B; PHOSPHOLIPID SECRETION; HIGH-AFFINITY		NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,LORD & TAYLOR LAB LUNG BIOCHEM,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,ANNA PERACHIA ADATTO CLIN RES CTR,DENVER,CO 80206; SAPPORO MED UNIV,SCH MED,DEPT BIOCHEM,SAPPORO,HOKKAIDO 060,JAPAN	National Jewish Health; National Jewish Health; Sapporo Medical University					NHLBI NIH HHS [HL45286, HL29891] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL029891, R01HL029891, R01HL045286] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAATZ JE, 1990, BIOCHEMISTRY-US, V29, P6714, DOI 10.1021/bi00480a022; BARITUSSIO A, 1992, AM J PHYSIOL, V263, pL607, DOI 10.1152/ajplung.1992.263.5.L607; BATES SR, 1992, AM J PHYSIOL, V263, pL333, DOI 10.1152/ajplung.1992.263.3.L333; BEERS MF, 1992, AM J PHYSIOL, V263, pL151, DOI 10.1152/ajplung.1992.263.2.L151; BEERS MF, 1992, AM J RESP CELL MOL, V7, P368, DOI 10.1165/ajrcmb/7.4.368; BRESLIN JS, 1992, AM J PHYSIOL, V262, pL699, DOI 10.1152/ajplung.1992.262.6.L699; CHILDS RA, 1992, J BIOL CHEM, V267, P9972; CLAYPOOL WD, 1984, J CLIN INVEST, V74, P677, DOI 10.1172/JCI111483; CREUWELS LAJM, 1993, J BIOL CHEM, V268, P26752; CROUCH E, 1991, AM J RESP CELL MOL, V5, P13, DOI 10.1165/ajrcmb/5.1.13; CROUCH E, 1993, J BIOL CHEM, V268, P2976; CROUCH E, 1994, J BIOL CHEM, V269, P15808; CURSTEDT T, 1988, EUR J BIOCHEM, V172, P521, DOI 10.1111/j.1432-1033.1988.tb13918.x; CURSTEDT T, 1990, P NATL ACAD SCI USA, V87, P2985, DOI 10.1073/pnas.87.8.2985; DAY AJ, 1994, BIOCHEM SOC T, V22, P83, DOI 10.1042/bst0220083; DOBBS LG, 1986, BIOCHIM BIOPHYS ACTA, V877, P305, DOI 10.1016/0005-2760(86)90308-5; DOBBS LG, 1979, J CLIN INVEST, V63, P378, DOI 10.1172/JCI109313; DOBBS LG, 1987, P NATL ACAD SCI USA, V84, P1010, DOI 10.1073/pnas.84.4.1010; FUJITA Y, 1988, EXP LUNG RES, V14, P247, DOI 10.3109/01902148809115127; GILFILLAN AM, 1987, BIOCHIM BIOPHYS ACTA, V917, P18, DOI 10.1016/0005-2760(87)90278-5; GLASSER SW, 1987, P NATL ACAD SCI USA, V84, P4007, DOI 10.1073/pnas.84.12.4007; Goerke J., 1986, HDB PHYSL RESP SYSTE, P247; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; HAWGOOD S, 1987, P NATL ACAD SCI USA, V84, P66, DOI 10.1073/pnas.84.1.66; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; HAWGOOD S, 1991, ANNU REV PHYSIOL, V53, P375, DOI 10.1146/annurev.ph.53.030191.002111; JOHANSSON J, 1991, BIOCHEMISTRY-US, V30, P6917, DOI 10.1021/bi00242a015; KELLER A, 1992, AM J RESP CELL MOL, V6, P601, DOI 10.1165/ajrcmb/6.6.601; KELLER A, 1991, BIOCHEM J, V277, P493, DOI 10.1042/bj2770493; KING RJ, 1989, BIOCHIM BIOPHYS ACTA, V1001, P294, DOI 10.1016/0005-2760(89)90114-8; KING RJ, 1973, AM J PHYSIOL, V224, P788, DOI 10.1152/ajplegacy.1973.224.4.788; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; KUROKI Y, 1991, BIOCHEM J, V279, P115, DOI 10.1042/bj2790115; KUROKI Y, 1988, J BIOL CHEM, V263, P17596; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; KUROKI Y, 1992, ARCH BIOCHEM BIOPHYS, V299, P261, DOI 10.1016/0003-9861(92)90273-Y; KUROKI Y, 1992, BIOCHEM BIOPH RES CO, V187, P963, DOI 10.1016/0006-291X(92)91291-W; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; LIM BL, 1993, IMMUNOLOGY, V78, P159; LU JH, 1993, EUR J BIOCHEM, V215, P793, DOI 10.1111/j.1432-1033.1993.tb18094.x; MALHOTRA R, 1992, EUR J IMMUNOL, V22, P1437, DOI 10.1002/eji.1830220616; MCCORMACK FX, 1994, J BIOL CHEM, V269, P5833; MENDELSON CR, 1991, ANNU REV PHYSIOL, V53, P415, DOI 10.1146/annurev.ph.53.030191.002215; MIYAMURA K, 1994, BIOCHEM J, V300, P237, DOI 10.1042/bj3000237; MURATA Y, 1993, BIOCHEM J, V291, P71, DOI 10.1042/bj2910071; NOGEE LM, 1993, NEW ENGL J MED, V328, P406, DOI 10.1056/NEJM199302113280606; OGASAWARA Y, 1992, J BIOL CHEM, V267, P21244; OOSTERLAKENDIJKSTERHUIS MA, 1992, BIOCHIM BIOPHYS ACTA, V1110, P45, DOI 10.1016/0005-2736(92)90292-T; OOSTERLAKENDIJKSTERHUIS MA, 1991, BIOCHEMISTRY-US, V30, P10965, DOI 10.1021/bi00109a022; OOSTERLAKENDIJKSTERHUIS MA, 1991, BIOCHEMISTRY-US, V30, P8276, DOI 10.1021/bi00247a024; OREILLY MA, 1989, BIOCHIM BIOPHYS ACTA, V1011, P140, DOI 10.1016/0167-4889(89)90201-2; PERSSON A, 1990, J BIOL CHEM, V265, P5755; PERSSON A, 1988, BIOCHEMISTRY-US, V27, P8576, DOI 10.1021/bi00423a011; PERSSON AV, 1992, BIOCHEMISTRY-US, V31, P12183, DOI 10.1021/bi00163a030; PHELPS DS, 1991, EXP LUNG RES, V17, P985, DOI 10.3109/01902149109064330; PINTO RA, 1993, J APPL PHYSIOL, V74, P1005, DOI 10.1152/jappl.1993.74.3.1005; PISON U, 1992, AM J PHYSIOL, V262, pL412, DOI 10.1152/ajplung.1992.262.4.L412; REVAK SD, 1988, J CLIN INVEST, V81, P826, DOI 10.1172/JCI113391; RICE WR, 1989, BIOCHIM BIOPHYS ACTA, V1006, P237, DOI 10.1016/0005-2760(89)90202-6; RICE WR, 1987, J APPL PHYSIOL, V63, P692, DOI 10.1152/jappl.1987.63.2.692; ROSS GF, 1986, J BIOL CHEM, V261, P14283; RYAN RM, 1989, J HISTOCHEM CYTOCHEM, V37, P429, DOI 10.1177/37.4.2926121; SANO K, 1985, J BIOL CHEM, V260, P2725; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853; STRAYER DS, 1993, J BIOL CHEM, V268, P18679; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; TAKAHASHI A, 1986, BIOCHEM BIOPH RES CO, V135, P527, DOI 10.1016/0006-291X(86)90026-4; TENNER AJ, 1989, J BIOL CHEM, V264, P13923; VANDENBUSSCHE G, 1992, BIOCHEMISTRY-US, V31, P9169, DOI 10.1021/bi00153a008; VANDENBUSSCHE G, 1992, EUR J BIOCHEM, V203, P201, DOI 10.1111/j.1432-1033.1992.tb19848.x; VANIWAARDEN F, 1990, AM J RESP CELL MOL, V2, P91, DOI 10.1165/ajrcmb/2.1.91; VANIWAARDEN JF, 1991, AM J PHYSIOL, V261, pL204, DOI 10.1152/ajplung.1991.261.2.L204; VANIWAARDEN JF, 1992, BIOCHEM J, V286, P5, DOI 10.1042/bj2860005; VOORHOUT WF, 1992, J HISTOCHEM CYTOCHEM, V40, P1589, DOI 10.1177/40.10.1527377; VOORHOUT WF, 1992, AM J PHYSIOL, V263, pL479, DOI 10.1152/ajplung.1992.263.4.L479; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; WEAVER TE, 1989, AM J PHYSIOL, V257, pL100, DOI 10.1152/ajplung.1989.257.2.L100; WEAVER TE, 1991, BIOCHEM J, V273, P249, DOI 10.1042/bj2730249; WEAVER TE, 1992, AM J PHYSIOL, V263, pL95, DOI 10.1152/ajplung.1992.263.1.L95; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; WRIGHT JR, 1991, ANNU REV PHYSIOL, V53, P395, DOI 10.1146/annurev.physiol.53.1.395; WRIGHT JR, 1993, AM J PHYSIOL, V264, pL338, DOI 10.1152/ajplung.1993.264.4.L338; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; WRIGHT JR, 1989, P NATL ACAD SCI USA, V86, P5410, DOI 10.1073/pnas.86.14.5410; YU SH, 1986, BIOCHEM J, V236, P85, DOI 10.1042/bj2360085; ZIMMERMAN PE, 1992, J CLIN INVEST, V89, P143, DOI 10.1172/JCI115554	86	195	195	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					25943	25946						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929300				2022-12-27	WOS:A1994PQ93000001
J	LEWIS, RE; VOLLE, DJ; SANDERSON, SD				LEWIS, RE; VOLLE, DJ; SANDERSON, SD			PHORBOL ESTER STIMULATES PHOSPHORYLATION ON SERINE-1327 OF THE HUMAN INSULIN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; PROTEIN-KINASE; BETA-SUBUNIT; HEPATOMA-CELLS; INTACT-CELLS; PHOSPHATIDYLINOSITOL 3'-KINASE; THREONINE PHOSPHORYLATION; SIGNALING COMPLEXES; CARBOXYL-TERMINUS; GROWTH-FACTORS	Phorbol esters stimulate the phosphorylation of the insulin receptor on discrete serine and threonine residues in intact cells. Phosphorylation of the insulin receptor cytoplasmic domain on serine, threonine, and tyrosine residues regulates receptor tyrosine kinase activity and signaling. In these studies, we demonstrate that phorbol ester treatment of intact COS-1 cells transiently expressing the human insulin receptor stimulates phosphorylation of serine 1327 within the carboxyl-terminal tail of the insulin receptor beta subunit. Phosphopeptide maps of wild-type (Ser(1327)) and mutant (Ala(1327)) human insulin receptors revealed the absence of a single phosphopeptide in the Ala(1327) receptors when compared with wild-type receptors from phorbol ester treated cells. Phosphoamino acid analysis revealed phosphoserine within the phosphopeptide from wildtype receptors that is absent in the Ala(1327) receptor. The synthetic peptide 1327S (KRSYEEHIPYTHMNGGKK) corresponding to amino acids 1325-1342 of the human insulin receptor is phosphorylated on serine by protein kinase C. After digestion with trypsin, the phosphorylated synthetic peptide comigrated with the serine-phosphorylated peptide isolated from wild-type insulin receptors that was absent from the Ala(1327) mutant. Ser(1327) is proximal to autophosphorylation sites Tyr(1328) and Tyr(1334). The potential effects of serine phosphorylation at position 1327 on subsequent phosphorylation of these tyrosines by the insulin receptor kinase were examined using synthetic peptides. The chemically modified peptide 1327S(P) was synthesized with the stoichiometric addition of phosphate to the side chain hydroxyl of a serine corresponding to position 1327 of the insulin receptor. Kinetic analysis revealed that the addition of phosphate to the serine improved substrate recognition by the insulin receptor tyrosine kinase almost a-fold. The average K-m was 1.44 mM for the peptide 1327S(P) versus 2.64 mM for peptide 1327S. However, when compared with the unphosphorylated control peptide, 1327S, the serine-phosphorylated peptide 1327S(P) also reduced the V-max of the insulin receptor tyrosine kinase 53%. Radiosequence analysis revealed that the chemical addition of phosphate to the serine in peptide 1327S(P) inhibited insulin receptor-catalyzed phosphorylation of the tyrosine on 1327S(P) corresponding to Tyr(1334) but not of the tyrosine corresponding to Tyr(1328). These data suggest that the juxtaposition of a serine phosphorylation site adjacent to receptor tyrosine phosphorylation sites provides the potential for regulation of insulin receptor autophosphorylation and signaling through its carboxyl-terminal tail.	UNIV NEBRASKA, MED CTR, EPPLEY INST RES CANC & ALLIED DIS, OMAHA, NE 68198 USA; UNIV NEBRASKA, MED CTR, DEPT BIOCHEM & MOLEC BIOL, OMAHA, NE 68198 USA; UNIV NEBRASKA, MED CTR, DEPT PHARMACEUT SCI, OMAHA, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center			Lewis, Robert E./H-3404-2019		NCI NIH HHS [CA36727] Funding Source: Medline; NIDDK NIH HHS [DK41896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041896] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABERNATHY JL, 1992, TECHNIQUES PROTEIN C, V3, P277; ADASHI EY, 1993, ANN NY ACAD SCI, V687, P10; AHN J, 1993, J BIOL CHEM, V268, P16839; AHN JC, 1993, J BIOL CHEM, V268, P7571; ANDERSON CM, 1991, J BIOL CHEM, V266, P21760; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BALTENSPERGER K, 1992, P NATL ACAD SCI USA, V89, P7885, DOI 10.1073/pnas.89.17.7885; BEGUM N, 1993, J BIOL CHEM, V268, P7917; BOLLAG GE, 1986, P NATL ACAD SCI USA, V83, P5822, DOI 10.1073/pnas.83.16.5822; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHIN JE, 1993, J BIOL CHEM, V268, P6338; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COGHLAN MP, 1993, BIOCHEM BIOPH RES CO, V193, P371, DOI 10.1006/bbrc.1993.1633; DURONIO V, 1990, ENDOCRINOLOGY, V127, P481, DOI 10.1210/endo-127-1-481; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FEENER EP, 1993, J BIOL CHEM, V268, P11256; FISCHER PM, 1991, INT J PEPT PROT RES, V38, P491; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; GANDERTON RH, 1992, BIOCHEM J, V288, P195, DOI 10.1042/bj2880195; GRIMES RW, 1992, ENDOCRINOLOGY, V131, P553, DOI 10.1210/en.131.2.553; HEIDENREICH K, 1994, BIOL CHEM H-S, V375, P99, DOI 10.1515/bchm3.1994.375.2.99; JACOBS S, 1986, J BIOL CHEM, V261, P934; JACOBS S, 1983, P NATL ACAD SCI-BIOL, V80, P6211, DOI 10.1073/pnas.80.20.6211; KOHANSKI RA, 1993, BIOCHEMISTRY-US, V32, P5766, DOI 10.1021/bi00073a007; KOHANSKI RA, 1993, BIOCHEMISTRY-US, V32, P5773, DOI 10.1021/bi00073a008; KOSHIO O, 1989, FEBS LETT, V254, P22, DOI 10.1016/0014-5793(89)81001-4; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LEVINE BA, 1991, J BIOL CHEM, V266, P12369; LEWIS RE, 1990, BIOCHEMISTRY-US, V29, P1807, DOI 10.1021/bi00459a020; LEWIS RE, 1990, J BIOL CHEM, V265, P947; LIU F, 1994, BIOCHEM J, V298, P471, DOI 10.1042/bj2980471; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; PANG DT, 1985, J BIOL CHEM, V260, P7131; PILLAY TS, 1991, FEBS LETT, V288, P206, DOI 10.1016/0014-5793(91)81035-7; PILLAY TS, 1991, BIOCHEM BIOPH RES CO, V179, P962, DOI 10.1016/0006-291X(91)91912-V; PRONK GJ, 1992, J BIOL CHEM, V267, P24058; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROTH RA, 1987, DIABETES, V36, P123, DOI 10.2337/diabetes.36.1.123; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; STADTMAUER L, 1986, J BIOL CHEM, V261, P3402; SUNG CK, 1994, J BIOL CHEM, V269, P12503; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TAVARE JM, 1991, J BIOL CHEM, V266, P21804; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TAVARE JM, 1992, BIOCHEM BIOPH RES CO, V188, P86, DOI 10.1016/0006-291X(92)92353-Y; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; WOLFE L, 1992, J BIOL CHEM, V267, P9749; YONEZAWA K, 1991, MOL ENDOCRINOL, V5, P194, DOI 10.1210/mend-5-2-194; YU KT, 1984, J BIOL CHEM, V259, P5277; YU KT, 1986, J BIOL CHEM, V261, P4715; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	66	28	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26259	26266						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929343				2022-12-27	WOS:A1994PQ93000051
J	CONDON, PJ; ROYER, WE				CONDON, PJ; ROYER, WE			CRYSTAL-STRUCTURE OF OXYGENATED SCAPHARCA DIMERIC HEMOGLOBIN AT 1.7-ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; LIGAND-BINDING; MACROMOLECULAR STRUCTURES; REFINEMENT; STEREOCHEMISTRY; COOPERATIVITY; INAEQUIVALVIS; REPRESSOR; KINETICS; MODELS	The crystal structure of the cooperative dimeric hemoglobin from the blood clam Scapharca inaequivalvis has been determined in the oxygenated state and refined to an R-factor of 0.157 at 1.7-Angstrom resolution. The structure is very similar to the carbon monoxide-liganded form with subtle differences in ligand binding geometry. Oxygen binds to the heme iron in a bent conformation with Fe-O-O angles of 135 degrees and 150 degrees for the two subunits. These observed angles are lower than the equivalent angles in the carbon monoxide liganded form and intermediate between the angles observed in structures of oxygenated sperm whale myoglobin and oxygenated human hemoglobin. This third high resolution structure of Scapharca dimeric hemoglobin permits a detailed analysis of the water structure in the highly hydrated interface between subunits.	UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NIDDK NIH HHS [DK 43323] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; ANTONINI E, 1984, J BIOL CHEM, V259, P6730; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BORGESE TA, 1987, COMP BIOCHEM PHYS B, V86, P155, DOI 10.1016/0305-0491(87)90191-X; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1988, PROTEINS, V4, P148, DOI 10.1002/prot.340040208; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHIANCONE E, 1981, J MOL BIOL, V152, P577, DOI 10.1016/0022-2836(81)90270-9; COLLMAN JP, 1976, P NATL ACAD SCI USA, V73, P3333, DOI 10.1073/pnas.73.10.3333; COMO PF, 1980, AUST J BIOL SCI, V33, P643, DOI 10.1071/BI9800643; DEREWENDA Z, 1990, J MOL BIOL, V211, P515, DOI 10.1016/0022-2836(90)90262-K; DJANGMAH JS, 1978, COMP BIOCHEM PHYS B, V60, P245, DOI 10.1016/0305-0491(78)90095-0; FURUTA H, 1977, J BIOCHEM, V82, P1723, DOI 10.1093/oxfordjournals.jbchem.a131870; GEORGE RCS, 1985, J BIOL CHEM, V260, P4331; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; JAMESON GB, 1980, J AM CHEM SOC, V102, P3224, DOI 10.1021/ja00529a055; JOHNSON AD, 1981, NATURE, V294, P217, DOI 10.1038/294217a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; OHNOKI S, 1973, J BIOCHEM, V73, P717, DOI 10.1093/oxfordjournals.jbchem.a130134; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; PHILLIPS SEV, 1981, NATURE, V292, P81, DOI 10.1038/292081a0; PHILLIPS SEV, 1989, NATURE, V341, P711, DOI 10.1038/341711a0; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; Royer W.E. Jr, 1992, Advances in Comparative and Environmental Physiology, V13, P87; ROYER WE, 1985, NATURE, V316, P277, DOI 10.1038/316277a0; ROYER WE, 1994, J MOL BIOL, V235, P657, DOI 10.1006/jmbi.1994.1019; ROYER WE, 1989, J BIOL CHEM, V264, P21052; ROYER WE, 1990, SCIENCE, V249, P518, DOI 10.1126/science.2382132; SCHACHMAN HK, 1988, J BIOL CHEM, V263, P18583; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; WYMAN J, 1982, BIOPOLYMERS, V21, P1735, DOI 10.1002/bip.360210905	36	40	40	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25259	25267						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929217				2022-12-27	WOS:A1994PQ49100007
J	BROWNAUGSBURGER, P; BROEKELMANN, T; MECHAM, L; MERCER, R; GIBSON, MA; CLEARY, EG; ABRAMS, WR; ROSENBLOOM, J; MECHAM, RP				BROWNAUGSBURGER, P; BROEKELMANN, T; MECHAM, L; MERCER, R; GIBSON, MA; CLEARY, EG; ABRAMS, WR; ROSENBLOOM, J; MECHAM, RP			MICROFIBRIL-ASSOCIATED GLYCOPROTEIN BINDS TO THE CARBOXYL-TERMINAL DOMAIN OF TROPOELASTIN AND IS A SUBSTRATE FOR TRANSGLUTAMINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELASTIN-ASSOCIATED MICROFIBRILS; MARFAN-SYNDROME; PROTEIN; GENE; MAGP; LOCALIZATION; VITRONECTIN; FIBRILLIN; SEQUENCE; PRODUCT	Microfibril-associated glycoprotein (MAGP) is an integral component of microfibrillar structures that play a critical role in the organization of elastic fibers in the extracellular matrix. To study possible molecular interactions between MAGP and other elastic fiber components, we have generated native MAGP using a baculovirus expression system and tested its ability to associate with tropoelastin and fibrillin. MAGP produced by SF9 cells underwent processing similar to the mammalian protein, including correct cleavage of the signal peptide and sulfation of tyrosine residues. When tested in solid-phase binding assays, native MAGP specifically bound to tropoelastin but not fibrillin-1. Binding to tropoelastin was divalent cation-independent and was completely blocked by reduction and alkylation of either protein. Antibody inhibition studies indicated that the carboxyl terminus of tropoelastin mediated its interaction with MAGP. In addition to binding to elastin, MAGP was also a substrate for transglutaminase, which might explain its propensity to form high molecular weight aggregates that cannot be dissociated with reduction or denaturation, Together, the results of this study provide new insights into the functional relationship between microfibrillar proteins and have important implications for understanding elastic fiber assembly.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; UNIV ADELAIDE, DEPT PATHOL, ADELAIDE, SA 5001, AUSTRALIA; UNIV PENN, DEPT DENT MED, PHILADELPHIA, PA 19104 USA	Washington University (WUSTL); Washington University (WUSTL); University of Adelaide; University of Pennsylvania					NHLBI NIH HHS [HL-41926, HL-26499] Funding Source: Medline; NIAMS NIH HHS [AR-41474] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041926, R01HL026499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041474] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; BASHIR MM, 1994, BIOCHEMISTRY-US, V33, P593, DOI 10.1021/bi00168a026; BROWN PL, 1992, BIOCHEM BIOPH RES CO, V186, P549, DOI 10.1016/S0006-291X(05)80843-5; CHEN YP, 1993, J BIOL CHEM, V268, P27381; DAHLBACK K, 1989, J INVEST DERMATOL, V92, P727, DOI 10.1111/1523-1747.ep12721619; DAVIS EC, 1994, J CELL SCI, V107, P727; GIBSON MA, 1986, J BIOL CHEM, V261, P1429; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; GIBSON MA, 1991, J BIOL CHEM, V266, P7596; GIBSON MA, 1987, IMMUNOL CELL BIOL, V65, P345, DOI 10.1038/icb.1987.39; HINEK A, 1993, J BIOL CHEM, V268, P1405; INDIK Z, 1990, GENES EXTRACELLULAR, P221; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; Mecham R.P., 1991, CELL BIOL EXTRACELLU, V2nd, P79; MECHAM RP, 1987, METHOD ENZYMOL, V144, P232; NIEHRS C, 1990, EMBO J, V9, P35, DOI 10.1002/j.1460-2075.1990.tb08077.x; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; PROSSER IW, 1991, CONNECT TISSUE RES, V25, P265, DOI 10.3109/03008209109029162; PROSSER IW, 1984, AUST J EXP BIOL MED, V62, P485, DOI 10.1038/icb.1984.46; Ross R, 1977, Adv Exp Med Biol, V79, P7; SCHWARTZ E, 1985, J HISTOCHEM CYTOCHEM, V33, P268, DOI 10.1177/33.4.3980980; TOMASINIJOHANSSON BR, 1993, MATRIX, V13, P203, DOI 10.1016/S0934-8832(11)80004-1; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	25	103	105	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28443	28449						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961786				2022-12-27	WOS:A1994PV77200098
J	CHEN, CT; PAN, BT				CHEN, CT; PAN, BT			ONCOGENIC RAS STIMULATES A 96-KDA HISTONE H2B KINASE-ACTIVITY IN ACTIVATED XENOPUS EGG EXTRACTS - CORRELATION WITH THE SUPPRESSION OF P34(CDC2) KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL PROTEIN-S6 KINASE; EPIDERMAL GROWTH-FACTOR; CELL-CYCLE; SIGNAL-TRANSDUCTION; MAP KINASE; TYROSINE PHOSPHORYLATION; M-PHASE; MEIOTIC MATURATION; OOCYTE MATURATION; S6 KINASES	We previously showed that purified, bacterially expressed oncogenic human rasH protein blocks or delays the progression of the embryonic cell cycle into M-phase in activated Xenopus egg extracts. This block correlates with the suppression of the activation of p34(cdc2) kinase (Pan, B.-T., Chen, C.-T., and Lin, S.-M. (1994) J. Biol. Chem. 269, 5968-5975). In an attempt to identify kinases that are involved in mediating the effect of oncogenic Pas on the cell cycle, we assayed aliquots of activated Xenopus egg extracts, which were incubated at 25 degrees C for various times in the absence and presence of oncogenic Pas, for their kinase activities toward a calf thymus histone fraction (Hf1). We find that the suppression of the histone H1 kinase activity of p34(cdc2) by oncogenic Pas correlates with a simultaneous stimulation of a histone H2b serine kinase activity. Using a histone H2b in-the-gel kinase assay, we further show that the stimulated histone H2b kinase activity is attributed mainly to a 96-kDa kinase and slightly to p42(mapk). Although Xenopus p90(rsh) is also activated by oncogenic Pas, we demonstrate that activated p90(rsh) is not responsible for the 96-kDa histone H2b kinase activity. The identity of the 96-kDa kinase remains unclear. Our data suggests that the 96-kDa kinase may be involved in mediating the effect of oncogenic Ras on the embryonic cell cycle of Xenopus.	UNIV KENTUCKY, MED CTR, LUCILLE P MARKEY CANC CTR, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, MED CTR, DEPT SURG, DIV NEUROSURG, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, MED CTR, DEPT MICROBIOL & IMMUNOL, LEXINGTON, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky				CHEN, CHIN-TIN/0000-0002-7439-8774				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CAMPOSGONZALEZ R, 1991, CELL REGUL, V2, P663, DOI 10.1091/mbc.2.8.663; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CICIRELLI MF, 1988, J BIOL CHEM, V263, P2009; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DER CJ, 1991, CANCER CELL-MON REV, V3, P331; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ERIKSON E, 1991, J BIOL CHEM, V266, P5249; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; HACCARD O, 1990, EUR J BIOCHEM, V192, P633, DOI 10.1111/j.1432-1033.1990.tb19270.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HEINZE H, 1988, J BIOL CHEM, V263, P4139; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; ITOH T, 1993, J BIOL CHEM, V268, P3025; IWAI K, 1972, J BIOCHEM-TOKYO, V72, P357, DOI 10.1093/oxfordjournals.jbchem.a129911; JOHNS EW, 1964, BIOCHEM J, V92, P55, DOI 10.1042/bj0920055; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NEBREDA AR, 1993, ONCOGENE, V8, P467; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAN BT, 1994, J BIOL CHEM, V269, P5968; PAN BT, 1990, MOL CELL BIOL, V10, P923, DOI 10.1128/MCB.10.3.923; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; POMERANCE M, 1992, J BIOL CHEM, V267, P16155; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAPP UR, 1991, ONCOGENE, V6, P495; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	66	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28034	28043						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961738				2022-12-27	WOS:A1994PV77200042
J	CLARK, BJ; WELLS, J; KING, SR; STOCCO, DM				CLARK, BJ; WELLS, J; KING, SR; STOCCO, DM			THE PURIFICATION, CLONING, AND EXPRESSION OF A NOVEL LUTEINIZING HORMONE-INDUCED MITOCHONDRIAL PROTEIN IN MA-10 MOUSE LEYDIG TUMOR-CELLS - CHARACTERIZATION OF THE STEROIDOGENIC ACUTE REGULATORY PROTEIN (STAR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL-CORTEX CELLS; SIDE-CHAIN CLEAVAGE; DIAZEPAM BINDING INHIBITOR; STEROL CARRIER PROTEIN-2; CONTACT SITES; CYCLIC-AMP; ADRENOCORTICOTROPIC HORMONE; BENZODIAZEPINE RECEPTOR; ACTIVATOR POLYPEPTIDE; POLYACRYLAMIDE GELS	The acute response of steroidogenic cells to trophic hormone stimulation is the mobilization of cholesterol hom cellular stores to the mitochondrial outer membrane and the transfer of this cholesterol to the mitochondrial inner membrane where the first enzymatic step in steroidogenesis occurs. The transfer of cholesterol across the mitochondrial membranes is dependent upon de novo protein synthesis, and this is the regulated step in the process. Although the newly synthesized regulatory protein(s) have yet 60 be identified, we previously have proposed a candidate protein which we identified in MA-10 cells that is synthesized in response to luteinizing hormone stimulation and that is localized to the mitochondria. In the present study, we report the isolation of a cDNA that encodes this luteinizing hormone-induced protein. Analysis of the cDNA and protein sequences reveals this is a novel protein. Importantly, we demonstrate for the first time that expression of the protein in MA-10 cells in the absence of hormone stimulation is sufficient 60 induce steroid production. We conclude that this protein is required in the acute regulation of steroidogenesis and propose to call this protein the Steroidogenic Acute Regulatory protein (StAR).			CLARK, BJ (corresponding author), TEXAS TECH UNIV, HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, LUBBOCK, TX 79430 USA.		King, Steven/AAN-1385-2021	Clark, Barbara/0000-0003-1558-1904	NICHD NIH HHS [HD 17481, HD 07688] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD007688, R01HD017481, R37HD017481] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBERTA JA, 1989, J BIOL CHEM, V264, P2368; ALMAHBOBI G, 1992, EXP CELL RES, V200, P361, DOI 10.1016/0014-4827(92)90184-A; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARDAIL D, 1991, J BIOL CHEM, V266, P7978; ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN AS, 1992, MOL CELL ENDOCRINOL, V83, P1, DOI 10.1016/0303-7207(92)90189-D; CHANDERBHAN R, 1982, J BIOL CHEM, V257, P8928; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK BJ, 1991, J BIOL CHEM, V266, P5898; COOKE BA, 1975, BIOCHEM J, V150, P413, DOI 10.1042/bj1500413; CRIVELLO JF, 1980, J BIOL CHEM, V255, P8144; DAVIS WW, 1968, J BIOL CHEM, V243, P5153; Deutscher M, 1990, METHODS ENZYMOLOGY, V182; ELLIOTT ME, 1993, ENDOCRINOLOGY, V133, P1669, DOI 10.1210/en.133.4.1669; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; FERGUSON JJ, 1963, J BIOL CHEM, V238, P2754; FREEMAN DA, 1987, J BIOL CHEM, V262, P13061; GARNIER M, 1993, ENDOCRINOLOGY, V132, P444, DOI 10.1210/en.132.1.444; GARREN LD, 1965, P NATL ACAD SCI USA, V53, P1443, DOI 10.1073/pnas.53.6.1443; Glick B, 1991, Trends Cell Biol, V1, P99, DOI 10.1016/0962-8924(91)90037-A; GREEN EG, 1991, J STEROID BIOCHEM, V40, P421, DOI 10.1016/0960-0760(91)90211-M; HALL PF, 1992, J STEROID BIOCHEM, V43, P769, DOI 10.1016/0960-0760(92)90306-4; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HAWLEY-NELSON P, 1993, FOCUS MADISON, V15, P73; HAYNES RC, 1959, J BIOL CHEM, V234, P1421; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; JEFCOATE CR, 1974, EUR J BIOCHEM, V42, P539, DOI 10.1111/j.1432-1033.1974.tb03369.x; JEFCOATE CR, 1986, ENDOCR RES, V12, P315, DOI 10.3109/07435808609035444; JEFCOATE CR, 1992, J STEROID BIOCHEM, V43, P751, DOI 10.1016/0960-0760(92)90305-3; JEFCOATE CR, 1987, J STEROID BIOCHEM, V27, P721, DOI 10.1016/0022-4731(87)90142-7; KALOUSEK F, 1988, P NATL ACAD SCI USA, V85, P7536, DOI 10.1073/pnas.85.20.7536; KARABOYAS GC, 1965, BIOCHEMISTRY-US, V4, P462, DOI 10.1021/bi00879a014; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; KRUEGER RJ, 1983, J BIOL CHEM, V258, P159; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; MENDELSON C, 1975, BIOCHIM BIOPHYS ACTA, V411, P222, DOI 10.1016/0304-4165(75)90302-5; MERTZ LM, 1989, ENDOCR RES, V15, P101, DOI 10.1080/07435808909039091; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PEDERSEN RC, 1987, SCIENCE, V236, P188, DOI 10.1126/science.3563495; PEDERSEN RC, 1983, P NATL ACAD SCI-BIOL, V80, P1882, DOI 10.1073/pnas.80.7.1882; PON LA, 1986, J BIOL CHEM, V261, P3309; PON LA, 1986, ENDOCR RES, V12, P429, DOI 10.3109/07435808609035449; PRIVALLE CT, 1983, P NATL ACAD SCI-BIOL, V80, P702, DOI 10.1073/pnas.80.3.702; PYTHON CP, 1993, ENDOCRINOLOGY, V132, P1489, DOI 10.1210/en.132.4.1489; REDDY SV, 1993, BIOTECHNIQUES, V15, P444; RESKO JA, 1974, ENDOCRINOLOGY, V94, P128, DOI 10.1210/endo-94-1-128; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALA GB, 1979, J BIOL CHEM, V254, P3861; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHWAIGER M, 1987, J CELL BIOL, V105, P235, DOI 10.1083/jcb.105.1.235; SIMBENI R, 1991, J BIOL CHEM, V266, P10047; SIMBENI R, 1990, J BIOL CHEM, V265, P281; SIMPSON ER, 1972, EUR J BIOCHEM, V28, P442, DOI 10.1111/j.1432-1033.1972.tb01931.x; STOCCO DM, 1993, ENDOCRINOLOGY, V133, P2827, DOI 10.1210/en.133.6.2827; STOCCO DM, 1993, J STEROID BIOCHEM, V46, P337, DOI 10.1016/0960-0760(93)90223-J; STOCCO DM, 1991, ENDOCRINOLOGY, V128, P1918, DOI 10.1210/endo-128-4-1918; STOCCO DM, 1988, BIOCHEM J, V249, P95, DOI 10.1042/bj2490095; STOCCO DM, 1991, J BIOL CHEM, V266, P19731; STOCCO DM, 1992, J STEROID BIOCHEM, V43, P319, DOI 10.1016/0960-0760(92)90167-H; STOCCO DM, 1990, CELL SIGNAL, V2, P161, DOI 10.1016/0898-6568(90)90019-7; STOCCO DM, 1993, ENDOCRINOLOGY, V132, P959, DOI 10.1210/en.132.3.959; STONE D, 1954, ARCH BIOCHEM BIOPHYS, V51, P457, DOI 10.1016/0003-9861(54)90501-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANAMERONGEN A, 1989, BIOCHIM BIOPHYS ACTA, V1004, P36, DOI 10.1016/0005-2760(89)90209-9; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x	71	962	992	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28314	28322						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961770				2022-12-27	WOS:A1994PV77200081
J	GUO, W; JORGENSEN, AO; CAMPBELL, KP				GUO, W; JORGENSEN, AO; CAMPBELL, KP			CHARACTERIZATION AND ULTRASTRUCTURAL-LOCALIZATION OF A NOVEL 90-KDA PROTEIN UNIQUE TO SKELETAL-MUSCLE JUNCTIONAL SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; PURIFIED RYANODINE RECEPTOR; DEPENDENT CA-2+ CHANNEL; DIHYDROPYRIDINE RECEPTOR; 1,4-DIHYDROPYRIDINE RECEPTOR; BIOCHEMICAL-CHARACTERIZATION; GLYCOPROTEIN TRIADIN; TRANSVERSE TUBULES; FOOT PROTEIN; KINASE	Monoclonal antibodies were used to identify and characterize a novel 90 kDa protein that was specifically localized to the junctional sarcoplasmic reticulum of rabbit skeletal muscle. Biochemical experiments show that the 90 kDa protein is an integral membrane protein of the junctional face membrane and is a substrate for the intrinsic protein kinase in triads. Immunofluorescence staining of serial transverse sections of skeletal muscle with a monoclonal antibody to the 90 kDa protein showed preferential staining of type II ''fast'' fibers. Specific labeling was confined to the interphase between the A- and I-bands, where the triad structure is localized. Immunoelectron microscopical labeling further indicates that the 90 kDa protein, like the ryanodine receptor/Ca2+-release channel and triadin, is confined to the terminal cisternae of the sarcoplasmic reticulum. Western blot analysis with a combination of monoclonal antibodies against the 90 kDa protein shows that it is specifically expressed in skeletal muscle but not in cardiac muscle or brain. Similarly, specific immunofluorescence labeling to the 90 kDa protein was not detected in ventricular myocytes or vascular smooth muscle cells. The junctional localization and phosphorylation of this protein suggest that it may play an important regulatory or structural role in the skeletal muscle triad junction.	UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, HHMI, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, IOWA CITY, IA 52242 USA; UNIV TORONTO, DEPT ANAT, TORONTO M5S 1A8, ON, CANADA	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa; University of Toronto				Campbell, Kevin/0000-0003-2066-5889				BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BRANDT NR, 1990, J MEMBRANE BIOL, V113, P237, DOI 10.1007/BF01870075; CALA SE, 1993, J BIOL CHEM, V268, P2969; CAMPBELL KP, 1980, J MEMBRANE BIOL, V56, P241, DOI 10.1007/BF01869479; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; CAMPBELL KP, 1982, J BIOL CHEM, V257, P1238; CAMPBELL KP, 1980, BIOCHIM BIOPHYS ACTA, V602, P97, DOI 10.1016/0005-2736(80)90293-X; CASWELL AH, 1991, BIOCHEMISTRY-US, V30, P7507, DOI 10.1021/bi00244a020; CHU A, 1990, BIOCHEMISTRY-US, V29, P5899, DOI 10.1021/bi00477a003; EISENBERG BR, 1983, HDB PHYSL, P75; FLUCHER BE, 1990, NEURON, V5, P339, DOI 10.1016/0896-6273(90)90170-K; FOSSET M, 1983, J BIOL CHEM, V258, P6086; FRANZINIARMSTRONG C, 1987, J CELL BIOL, V105, P49, DOI 10.1083/jcb.105.1.49; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IKEMOTO N, 1991, BIOCHEMISTRY-US, V30, P5230, DOI 10.1021/bi00235a017; IMAGAWA T, 1987, J BIOL CHEM, V262, P8333; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1988, METHOD ENZYMOL, V157, P490; JORGENSEN AO, 1979, J CELL BIOL, V80, P372, DOI 10.1083/jcb.80.2.372; JORGENSEN AO, 1987, J HISTOCHEM CYTOCHEM, V35, P723, DOI 10.1177/35.7.2953782; JORGENSEN AO, 1989, J CELL BIOL, V109, P135, DOI 10.1083/jcb.109.1.135; JORGENSEN AO, 1990, J CELL BIOL, V110, P1173, DOI 10.1083/jcb.110.4.1173; JORGENSEN AO, 1983, J CELL BIOL, V97, P1573, DOI 10.1083/jcb.97.5.1573; KAWAMOTO RM, 1986, J CELL BIOL, V103, P1405, DOI 10.1083/jcb.103.4.1405; KIM DH, 1986, J BIOL CHEM, V261, P1674; KIM KC, 1990, BIOCHEMISTRY-US, V29, P9281, DOI 10.1021/bi00491a025; KNUDSON CM, 1989, J BIOL CHEM, V264, P10795; KNUDSON CM, 1993, J BIOL CHEM, V268, P12637; KNUDSON CM, 1993, J BIOL CHEM, V268, P12646; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LEDDY JJ, 1993, BIOCHEM J, V295, P849, DOI 10.1042/bj2950849; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; MacLennan D., 1983, CALCIUM CELL FUNCT, V4, P151; MACLENNAN DH, 1971, P NATL ACAD SCI USA, V68, P1231, DOI 10.1073/pnas.68.6.1231; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1975, BIOCHIM BIOPHYS ACTA, V389, P51, DOI 10.1016/0005-2736(75)90385-5; MITCHELL RD, 1983, J BIOL CHEM, V258, P9867; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; ROSEMBLATT M, 1981, J BIOL CHEM, V256, P8140; SHARP AH, 1987, J BIOL CHEM, V262, P12309; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; TUANA BS, 1984, J BIOL CHEM, V259, P6979; VOLPE P, 1992, P NATL ACAD SCI USA, V89, P6142, DOI 10.1073/pnas.89.13.6142; WADA I, 1991, J BIOL CHEM, V266, P19599; WANG JX, 1992, NATURE, V359, P739, DOI 10.1038/359739a0	49	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28359	28365						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961775				2022-12-27	WOS:A1994PV77200087
J	HETTASCH, JM; GREENBERG, CS				HETTASCH, JM; GREENBERG, CS			ANALYSIS OF THE CATALYTIC ACTIVITY OF HUMAN FACTOR XIIIA BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MAGNETIC-RESONANCE SPECTROSCOPY; CALCIUM-INDUCED DISSOCIATION; COAGULATION FACTOR-XIIIA; MEDIATED CROSS-LINKING; PLASMA FACTOR-XIII; TISSUE TRANSGLUTAMINASE; ENDOTHELIAL-CELLS; TERMINAL DIFFERENTIATION; LIVER TRANSGLUTAMINASE	Factor XIIIa (FXIIIa) stabilizes fibrin clots by covalently cross-linking fibrin molecules. The purpose of this study was to determine the amino acid requirements at the active site of FXIIIa for catalysis. We selected amino acids 310-317 (Arg-Tyr-Gly-Gln-Cys-Trp-Val-Phe) in the human FXIII A-chain sequence for analysis based on the high degree of sequence homology among the different transglutaminases. We converted each amino acid in this region to Ala by site-directed mutagenesis. These recombinant FXIIIA chain mutants were expressed in Escherichia coli using the pTrc99A expression vector. FXIIIa activity was assessed by measuring the incorporation of 5-(biotinamido)pentylamine into N,N'-dimethylcasein in a solid-phase microtiter plate assay. The Cys-314 --> Ala mutation yielded a recombinant protein with no FXIIIa activity. We also found that changing Gly-312 and Val-316 to Ala resulted in 22 and 65% decreases in activity, respectively. The other five mutations near the active-site Cys resulted in FXIIIa molecules in which the activity was reduced > 95%. The mechanism of SH protease catalysis is similar to transglutaminase catalysis in that both form thioester intermediates. His and Asp residues may stabilize this enzyme-substrate intermediate. Therefore, we performed site-directed mutagenesis on several His residues (His-342, His-373, and His-450) as well as Asp-396 in human FXIII. We found that changing His-342 to Ala reduced catalytic activity by 85%, while the His-373 --> Ala mutant had no activity. In contrast, changing His-450 to Ala reduced FXIIIa activity by only 15%. We also examined the activity of all the mutants in a fibrin crosslinking assay. Four of the mutations (Phe-317 --> Ala, Tyr-315 --> Ala, Gln-313 --> Ala, and Asp-396 --> Ala), in which the activity toward the small primary amine was reduced by > 95%, were still capable of cross-linking the gamma-chain of fibrin. Even though these four mutants produced gamma-gamma dimers, they were not capable of forming higher molecular weight cross-linked products. Finally, we found that the binding of all the mutants to fibrin was similar to that of wild-type FXIIIa. In conclusion, we demonstrated that changing the specific amino acids Arg-310-Phe-317 to Ala substantially reduced FXIIIa activity. In addition, full catalytic activity was dependent on His-342, His-373, and Asp-396. These findings provide new insights into the catalytic mechanism of FXIIIa.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710	Duke University; Duke University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038245, P50HL026309, P60HL028391] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-26309, HL-28391, HL-38245] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHYUTHAN KE, 1993, J BIOL CHEM, V268, P21284; AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; ALAOUI SE, 1992, FEBS LETT, V311, P174; ASZODI A, 1992, 3RD INT C TRANSGL PR, P52; BARRY ELR, 1988, J BIOL CHEM, V263, P10464; BARRY ELR, 1989, J BIOL CHEM, V264, P4179; BECK E, 1961, THROMB DIATH HAEMOST, V6, P485; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BISHOP P, 1993, THROMB HAEMOSTASIS, V69, P123; BOWNESS JM, 1987, J BIOL CHEM, V262, P1022; CHUNG SI, 1974, J BIOL CHEM, V249, P940; CHUNG SI, 1970, J BIOL CHEM, V245, P6424; COOKE RD, 1974, BIOCHEM J, V141, P683, DOI 10.1042/bj1410683; COOKE RD, 1974, BIOCHEM J, V141, P79, DOI 10.1042/bj1410079; CURTIS CG, 1974, BIOCHEM J, V141, P683; DUCKERT F, 1972, ANN NY ACAD SCI, V202, P190, DOI 10.1111/j.1749-6632.1972.tb16331.x; Eadie GS, 1942, J BIOL CHEM, V146, P85; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FOLK JE, 1969, J BIOL CHEM, V244, P3707; FOLK JE, 1966, J BIOL CHEM, V241, P3238; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GENTILE V, 1991, J BIOL CHEM, V266, P478; GORMAN JJ, 1981, J BIOL CHEM, V256, P2712; GROSS M, 1974, J BIOL CHEM, V249, P3021; GROSS M, 1973, J BIOL CHEM, V248, P1301; GROSS M, 1973, J BIOL CHEM, V248, P6534; GRUNDMANN U, 1986, P NATL ACAD SCI USA, V83, P8024, DOI 10.1073/pnas.83.21.8024; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HO KC, 1992, J BIOL CHEM, V267, P12660; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P6900, DOI 10.1021/bi00370a025; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; JOHNSON FA, 1981, BIOCHEMISTRY-US, V20, P52, DOI 10.1021/bi00504a600; JOHNSON FA, 1981, BIOCHEMISTRY-US, V20, P44, DOI 10.1021/bi00504a008; KIM HC, 1991, J BIOL CHEM, V266, P536; KINSELLA MG, 1990, J BIOL CHEM, V265, P17891; KINSELLA MG, 1986, J CELL BIOL, V102, P679, DOI 10.1083/jcb.102.3.679; KNOX P, 1986, J CELL BIOL, V102, P2318, DOI 10.1083/jcb.102.6.2318; KORSGREN C, 1990, P NATL ACAD SCI USA, V87, P613, DOI 10.1073/pnas.87.2.613; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI TS, 1994, PROTEIN EXPRES PURIF, V5, P125, DOI 10.1006/prep.1994.1019; LAI TS, 1993, THROMB HAEMOSTASIS, V69, P2472; LEWIS SD, 1981, BIOCHEMISTRY-US, V20, P48, DOI 10.1021/bi00504a009; MARTINEZ J, 1989, J BIOL CHEM, V264, P20502; MENARD R, 1991, BIOCHEMISTRY-US, V30, P5531, DOI 10.1021/bi00236a028; MENTER DG, 1992, CELL BIOPHYS, V18, P123; MICANOVIC R, 1994, J BIOL CHEM, V269, P9190; MOSHER DF, 1979, J CLIN INVEST, V64, P781, DOI 10.1172/JCI109524; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; PIACENTINI M, 1991, CELL TISSUE RES, V263, P227, DOI 10.1007/BF00318764; PISANO JJ, 1968, SCIENCE, V160, P892, DOI 10.1126/science.160.3830.892; POLGAR L, 1974, FEBS LETT, V47, P15, DOI 10.1016/0014-5793(74)80415-1; RICE RH, 1978, J CELL BIOL, V76, P705, DOI 10.1083/jcb.76.3.705; RISINGER MA, 1992, 3RD INT C TRANSGL PR, P8; SAKATA Y, 1980, J CLIN INVEST, V65, P290, DOI 10.1172/JCI109671; SAKATA Y, 1982, J CLIN INVEST, V69, P536, DOI 10.1172/JCI110479; SANE DC, 1991, BIOCHEM BIOPH RES CO, V174, P465, DOI 10.1016/0006-291X(91)91439-J; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTIAGO MA, 1992, CIRCULATION S1, V86, P1852; SCHWARTZ ML, 1973, J BIOL CHEM, V248, P1395; SINGER MA, 1992, DEV BIOL, V154, P143, DOI 10.1016/0012-1606(92)90055-L; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W; SLUYTERMAN LAA, 1976, EUR J BIOCHEM, V71, P383, DOI 10.1111/j.1432-1033.1976.tb11125.x; SUNG LA, 1990, P NATL ACAD SCI USA, V87, P955, DOI 10.1073/pnas.87.3.955; TA BM, 1990, J CELL SCI, V95, P631; TAKAGI T, 1974, BIOCHEMISTRY-US, V13, P750, DOI 10.1021/bi00701a018; TAKAHASHI N, 1986, P NATL ACAD SCI USA, V83, P8019, DOI 10.1073/pnas.83.21.8019; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; TOKUNAGA F, 1993, J BIOL CHEM, V268, P262; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TYRRELL DJ, 1988, J BIOL CHEM, V263, P3464; UEGAMA M, 1978, JPN J EXP MED, V48, P135	71	25	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28309	28313						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961769				2022-12-27	WOS:A1994PV77200080
J	KOSAKO, H; GOTOH, Y; NISHIDA, E				KOSAKO, H; GOTOH, Y; NISHIDA, E			MITOGEN-ACTIVATED PROTEIN-KINASE KINASE IS REQUIRED FOR THE MOS-INDUCED METAPHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE THREONINE KINASE; MAMMALIAN SOMATIC-CELLS; PHASE MAP KINASE; XENOPUS-OOCYTES; SIGNAL TRANSDUCTION; ONCOGENE PRODUCT; MEIOTIC MATURATION; SKELETAL-MUSCLE; FROG OOCYTES; GENE-PRODUCT	The product of the c-mos proto-oncogene functions not only as an initiator of oocyte maturation but also as a component of cytostatic factor that causes the natural arrest of the unfertilized egg at the second meiotic metaphase. It has been shown that Mos can phosphorylate and activate mitogen-activated protein (MAP) kinase kinase (MAPKK) in vitro, leading to activation of MAP kinase. In this study, by using an anti-MAPKK antibody that can specifically inhibit Xenopus MAPKK activity, we have shown that MAPKK mediates the cytostatic factor activity of Mos. Coinjection of this anti-MAPKK antibody with the bacterially expressed Mos protein into a two cell embryo prevented the Mos-induced cleavage arrest as well as the Mos-induced MAP kinase activation. The analysis of individual embryos indicated that the degree of the cleavage arrest was correlated with the extent of the MAP kinase activation in the Mos- and the Mos/antibody-injected embryos. These observations suggest the involvement of a signal transmission pathway consisting of Mos, MAPKK and MAP kinase in the metaphase arrest.	KYOTO UNIV,INST VIRUS RES,DEPT GENET & MOLEC BIOL,SAKYO KU,KYOTO 60601,JAPAN; UNIV TOKYO,FAC SCI,DEPT BIOCHEM & BIOPHYS,TOKYO 113,JAPAN	Kyoto University; University of Tokyo								Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; AHN NG, 1993, P NATL ACAD SCI USA, V90, P5143, DOI 10.1073/pnas.90.11.5143; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ASHWORTH A, 1992, ONCOGENE, V7, P2555; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1994, ONCOGENE, V9, P1891; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; Masui Y, 1979, Int Rev Cytol, V57, P185, DOI 10.1016/S0074-7696(08)61464-3; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NAKIELNY S, 1992, FEBS LETT, V308, P183, DOI 10.1016/0014-5793(92)81271-M; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SHIRAKABE K, 1992, J BIOL CHEM, V267, P16685; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0	57	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28354	28358						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961774				2022-12-27	WOS:A1994PV77200086
J	EGLI, CM; BRAUS, GH				EGLI, CM; BRAUS, GH			UNCOUPLING OF MESSENGER-RNA 3' CLEAVAGE AND POLYADENYLATION BY EXPRESSION OF A HAMMERHEAD RIBOZYME IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA POLYADENYLATION; SACCHAROMYCES-CEREVISIAE; POLY(A) POLYMERASE; 3'-END FORMATION; DNA FRAGMENT; SITE; INVITRO; SEQUENCE; GENE; END	An artificial messenger RNA containing a derivative of a tobacco ringspot virus ribozyme was expressed in the bakers' yeast Saccharomyces cerevisiae. This mRNA was able to cleave itself efficiently in vivo. Using this system, the two steps of mRNA 3' processing, i.e. cleavage and the addition of a poly(A) tail, can be separated in yeast in vivo. The ribozyme cleaved transcript was shown to be polyadenylated. The poly(A) tail length was similar to the poly(A) tail length of an endogenous yeast mRNA. Therefore, cleavage of the precursor RNA at the polyadenylation site and the addition of adenosine residues to the 5' product require independent cellular machineries in yeast and can be separately analyzed. This is in contrast to higher eukaryotes where both processes are coupled.	UNIV ERLANGEN NURNBERG,INST MICROBIOL BIOCHEM & GENET,D-91058 ERLANGEN,GERMANY; ETH ZURICH,INST MICROBIOL,CH-8092 ZURICH,SWITZERLAND	University of Erlangen Nuremberg; Swiss Federal Institutes of Technology Domain; ETH Zurich			Braus, Gerhard/ABC-6293-2021; Braus, Gerhard H/G-3999-2012	Braus, Gerhard/0000-0002-3117-5626; Braus, Gerhard H/0000-0002-3117-5626				ABE A, 1990, EMBO J, V9, P3691, DOI 10.1002/j.1460-2075.1990.tb07581.x; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; BRAUS G, 1985, ARCH MICROBIOL, V142, P383, DOI 10.1007/BF00491908; BUTLER JS, 1988, SCIENCE, V242, P1270, DOI 10.1126/science.2848317; BUTLER JS, 1990, MOL CELL BIOL, V10, P2599, DOI 10.1128/MCB.10.6.2599; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; ECKNER R, 1991, EMBO J, V10, P3513, DOI 10.1002/j.1460-2075.1991.tb04915.x; FAHRNER K, 1980, NUCLEIC ACIDS RES, V8, P5725, DOI 10.1093/nar/8.23.5725; FAVOLORO J, 1980, METHOD ENZYMOL, V65, P718; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GERSTEL B, 1992, MOL MICROBIOL, V6, P2339, DOI 10.1111/j.1365-2958.1992.tb01409.x; GIEBEL LB, 1990, NUCLEIC ACIDS RES, V18, P4947, DOI 10.1093/nar/18.16.4947; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GRONER B, 1975, BIOCHEMISTRY-US, V13, P5378; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HENIKOFF S, 1983, CELL, V33, P607, DOI 10.1016/0092-8674(83)90441-5; HUMPHREY T, 1988, TRENDS GENET, V4, P243, DOI 10.1016/0168-9525(88)90028-5; HYMAN LE, 1991, MOL CELL BIOL, V11, P2004, DOI 10.1128/MCB.11.4.2004; IRNIGER S, 1992, MOL CELL BIOL, V12, P2322, DOI 10.1128/MCB.12.5.2322; IRNIGER S, 1991, MOL CELL BIOL, V11, P3060, DOI 10.1128/MCB.11.6.3060; IRNIGER S, 1993, CURR GENET, V23, P201, DOI 10.1007/BF00351496; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; LINGNER J, 1991, J BIOL CHEM, V266, P8741; MANLEY JL, 1988, BIOCHIM BIOPHYS ACTA, V950, P1, DOI 10.1016/0167-4781(88)90067-X; MIOZZARI G, 1978, J BACTERIOL, V153, P163; MOORE CL, 1984, CELL, V36, P581, DOI 10.1016/0092-8674(84)90337-4; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; RAVE N, 1979, NUCLEIC ACIDS RES, V6, P3559, DOI 10.1093/nar/6.11.3559; RUSSO P, 1991, EMBO J, V10, P563, DOI 10.1002/j.1460-2075.1991.tb07983.x; SADHALE PP, 1992, MOL CELL BIOL, V12, P4262, DOI 10.1128/MCB.12.10.4262; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; WAHLE E, 1991, EMBO J, V10, P4251, DOI 10.1002/j.1460-2075.1991.tb05003.x; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; YU K, 1989, MOL CELL BIOL, V9, P2431, DOI 10.1128/MCB.9.6.2431; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2; ZITOMER RS, 1976, J BIOL CHEM, V251, P6320	46	15	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27378	27383						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961648				2022-12-27	WOS:A1994PV77100038
J	CAO, GQ; CHENG, SY; WHITLEY, P; VONHEIJNE, G; KUHN, A; DALBEY, RE				CAO, GQ; CHENG, SY; WHITLEY, P; VONHEIJNE, G; KUHN, A; DALBEY, RE			SYNERGISTIC INSERTION OF 2 HYDROPHOBIC REGIONS DRIVES SEC-INDEPENDENT MEMBRANE-PROTEIN ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; M13 PROCOAT; PLASMA-MEMBRANE; EXPORT; DOMAIN; FRAGMENTS; TOPOLOGY; RESIDUES	We have studied the membrane insertion of two proteins from the inner membrane of Escherichia coli, both with two transmembrane segments connected by a short periplasmic loop: the M13 procoat protein and a mutant ''inverted'' leader peptidase. Neither molecule depends on the Sec machinery for insertion. We show that the introduction of a charged residue in the second transmembrane segment completely blocks insertion of both proteins. In contrast, a Sec-dependent procoat mutant, where the periplasmic region has been lengthened, inserts into the membrane even in the presence of a charged residue in the second hydrophobic domain. In addition, a large deletion within the second transmembrane domain of the leader peptidase mutant allows membrane translocation, but only under conditions where the SecA protein is functional. Furthermore, we show that the first hydrophobic domain is required for insertion of the short periplasmic loop of the ''inverted'' leader peptidase. These results suggest that Sec-independent insertion occurs by a synergistic entry of the two neighboring hydrophobic domains into the lipid bilayer.	OHIO STATE UNIV,DEPT CHEM,COLUMBUS,OH 43210; KAROLINSKA INST,NOVUM,CTR STRUCT BIOCHEM,S-14157 HUDDINGE,SWEDEN; UNIV KARLSRUHE,DEPT APPL MICROBIOL,D-76128 KARLSRUHE,GERMANY	Ohio State University; Karolinska Institutet; Helmholtz Association; Karlsruhe Institute of Technology			von Heijne, Gunnar/AAH-9389-2019; von Heijne, Gunnar/F-5576-2011	von Heijne, Gunnar/0000-0002-4490-8569				ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; DALBEY RE, 1987, SCIENCE, V235, P783, DOI 10.1126/science.3544218; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FREUDL R, 1989, J MOL BIOL, V205, P771, DOI 10.1016/0022-2836(89)90321-5; GALLUSSER A, 1990, EMBO J, V9, P2723, DOI 10.1002/j.1460-2075.1990.tb07459.x; GELLER BL, 1985, J BIOL CHEM, V260, P3281; ITO K, 1980, J BIOL CHEM, V255, P2123; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; KUHN A, 1986, EMBO J, V5, P3681, DOI 10.1002/j.1460-2075.1986.tb04699.x; KUHN A, 1988, EUR J BIOCHEM, V177, P267, DOI 10.1111/j.1432-1033.1988.tb14372.x; KUHN A, 1987, SCIENCE, V238, P1413, DOI 10.1126/science.3317833; KUHN A, 1986, NATURE, V322, P335, DOI 10.1038/322335a0; Maniatis T., 1982, MOL CLONING; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; ROHRER J, 1990, SCIENCE, V250, P1418, DOI 10.1126/science.2124001; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WOLFE PB, 1985, J BIOL CHEM, V260, P1836; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	25	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26898	26903						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929429				2022-12-27	WOS:A1994PQ93100050
J	PLANGGER, A; MALICKI, D; WHITNEY, M; PAULSEN, R				PLANGGER, A; MALICKI, D; WHITNEY, M; PAULSEN, R			MECHANISM OF ARRESTIN-2 FUNCTION IN RHABDOMERIC PHOTORECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; RETINAL-S-ANTIGEN; LIGHT-INDUCED BINDING; PHOSPHORYLATED RHODOPSIN; ALPHA-TRANSDUCIN; 48-KDA PROTEIN; DROSOPHILA; MEMBRANES; KINASE; HOMOLOG	Arrestins have emerged as one family of proteins that mediate the inactivation of G-protein-coupled receptors. We have isolated cDNA clones encoding two arrestin isoforms of the dipteran visual system, Calliphora arrestin 1 (Arrl) and arrestin 2 (Arr2). Microsequencing established that the arr2 gene encodes the Calliphora 49-kDa protein characterized previously as a photoreceptor-specific protein that undergoes reversible binding to light-activated rhodopsin and thereby activates the phosphorylation of metarhodopsin. Ultrastructural localization of Arr2 to the rhabdomeral part of the photoreceptor cell and quantitation of the amount of Arr2 bound suggest that Arr2 directly interacts with light-activated rhodopsin. In a reconstituted system containing affinity purified Arr2 and isolated rhabdomeric membranes, Arr2 binds to non-phosphorylated and phosphorylated metarhodopsin with comparable affinity. Reaction time courses reveal that Arr2 binding precedes phosphorylation of metarhodopsin, contrary to what has been reported so far for vertebrate photoreceptors. The phosphorylation-independent binding of Arr2 to metarhodopsin provides a mechanism for the rapid inactivation of the long-lived activated rhodopsin state which is characteristic for invertebrate photoreceptors. The dephosphorylation of rhodopsin is catalyzed by a Ca2+-dependent protein phosphatase which is shown here for the first time to exist in a membrane-associated form. Only metarhodopsin molecules with bound Arr2 are resistant to dephosphorylation. Thus, in fly photoreceptors, Arr2 acts as a regulatory protein that controls the phosphorylation as well as the dephosphorylation of the light-activated visual pigment.	UNIV KARLSRUHE, INST ZOOL 1, D-76128 KARLSRUHE, GERMANY; UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT NEUROSCI, LA JOLLA, CA 92093 USA	Helmholtz Association; Karlsruhe Institute of Technology; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego								ABE T, 1990, EXP EYE RES, V51, P111, DOI 10.1016/0014-4835(90)90178-W; ATON BR, 1986, BIOCHEMISTRY-US, V25, P677, DOI 10.1021/bi00351a025; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BENTROP J, 1993, EUR J BIOCHEM, V216, P67, DOI 10.1111/j.1432-1033.1993.tb18117.x; BENTROP J, 1986, EUR J BIOCHEM, V161, P61, DOI 10.1111/j.1432-1033.1986.tb10124.x; BINDER BM, 1990, J BIOL CHEM, V265, P15333; BROWN NG, 1992, EUR J BIOCHEM, V208, P659, DOI 10.1111/j.1432-1033.1992.tb17232.x; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; DANSCHER G, 1981, HISTOCHEMISTRY, V71, P81, DOI 10.1007/BF00592572; DEVARY O, 1987, P NATL ACAD SCI USA, V84, P6939, DOI 10.1073/pnas.84.19.6939; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; HAMDORF K, 1977, BIOPHYS STRUCT MECH, V3, P163, DOI 10.1007/BF00535813; Hamdorf K., 1973, P155; HAMDORF K, 1989, BIOL SIGNAL PROCESSI, P65; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; HUBER A, 1994, EUR J CELL BIOL, V63, P219; HUBER A, 1990, J BIOL CHEM, V265, P17906; HYDE DR, 1990, P NATL ACAD SCI USA, V87, P1008, DOI 10.1073/pnas.87.3.1008; KAHANA A, 1992, VISUAL NEUROSCI, V9, P595, DOI 10.1017/S0952523800001838; KRISHNAN R, 1990, NUCLEIC ACIDS RES, V18, P5894, DOI 10.1093/nar/18.19.5894; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; LEVINE H, 1990, MECH DEVELOP, V33, P19, DOI 10.1016/0925-4773(90)90131-5; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MATSUMOTO H, 1982, SCIENCE, V217, P839, DOI 10.1126/science.7100927; MILLER JA, 1975, J BIOL CHEM, V250, P4427; OLDENBURG KR, 1990, EXP EYE RES, V51, P463, DOI 10.1016/0014-4835(90)90159-R; ONDEK B, 1992, J BIOL CHEM, V267, P16460; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P15334; Paulsen R., 1987, Photobiochemistry and Photobiophysics, V1987, P261; PAULSEN R, 1984, J COMP PHYSIOL, V155, P47, DOI 10.1007/BF00610930; PAULSEN R, 1983, EUR J BIOCHEM, V137, P609, DOI 10.1111/j.1432-1033.1983.tb07869.x; PAULSEN R, 1984, J COMP PHYSIOL, V155, P39, DOI 10.1007/BF00610929; PAULSEN R, 1988, 21 P YAM C, P227; PFISTER C, 1985, SCIENCE, V228, P891, DOI 10.1126/science.2988124; PLANGGER A, 1992, COLLOQ INSE, V221, P369; PULLEN N, 1993, BIOCHEMISTRY-US, V32, P3958, DOI 10.1021/bi00066a016; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEMER J, 1985, MOL MECHANISMS PHOTO, P303; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P1003, DOI 10.1073/pnas.87.3.1003; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TERAKITA A, 1993, VISION RES, V33, P2421, DOI 10.1016/0042-6989(93)90120-L; TSUDA M, 1988, GENE, V73, P11, DOI 10.1016/0378-1119(88)90308-3; WAKABAYASHI S, 1982, J BIOL CHEM, V257, P9335; WILDEN U, 1986, FEBS LETT, V207, P292, DOI 10.1016/0014-5793(86)81507-1; WISTOW GJ, 1986, FEBS LETT, V196, P23, DOI 10.1016/0014-5793(86)80207-1; YAMADA T, 1990, SCIENCE, V248, P483, DOI 10.1126/science.2158671; YAMAKI K, 1988, FEBS LETT, V234, P39, DOI 10.1016/0014-5793(88)81298-5; YAMAKI K, 1987, BIOCHEM BIOPH RES CO, V142, P904, DOI 10.1016/0006-291X(87)91499-9	53	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26969	26975						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929436				2022-12-27	WOS:A1994PQ93100059
J	WALTENBERGER, J; CLAESSONWELSH, L; SIEGBAHN, A; SHIBUYA, M; HELDIN, CH				WALTENBERGER, J; CLAESSONWELSH, L; SIEGBAHN, A; SHIBUYA, M; HELDIN, CH			DIFFERENT SIGNAL-TRANSDUCTION PROPERTIES OF KDR AND FLT1, 2 RECEPTORS FOR VASCULAR ENDOTHELIAL GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; FACTOR BETA-RECEPTOR; B-TYPE RECEPTOR; PDGF RECEPTOR; CELL GROWTH; PERMEABILITY FACTOR; HUMAN-PLATELETS; PHOSPHATIDYLINOSITOL KINASE; TUMOR-METASTASIS; SRC FAMILY	Vascular endothelial growth factor (VEGF) is a homodimeric peptide growth factor which binds to two structurally related tyrosine kinase receptors denoted Flt1 and KDR. In order to compare the signal transduction via these two receptors, the human Flt1 and KDR proteins were stably expressed in porcine aortic endothelial cells. Binding analyses using I-125-VEGF revealed K-d values of 16 pM for Flt1 and 760 pM for KDR. Cultured human umbilical vein endothelial (HUVE) cells were found to express two distinct populations of binding sites with affinities similar to those for Flt1 and KDR, respectively. The KDR expressing cells showed striking changes in cell morphology, actin reorganization and membrane ruffling, chemotaxis and mitogenicity upon VEGF stimulation, whereas Flt1 expressing cells lacked such responses. KDR was found to undergo ligand-induced autophosphorylation in intact cells, and both Flt1 and KDR were phosphorylated in vitro in response to VEGF, however, KDR much more efficiently than Flt1. Neither the receptor-associated activity of phosphatidylinositol 3'-kinase nor tyrosine phosphorylation of phospholipase C-gamma were affected by stimulation of Flt1 or KDR expressing cells, and phosphorylation of GTPase activating protein was only slightly increased. Members of the Src family such as Fyn and Yes showed an increased level of phosphorylation upon VEGF stimulation of cells expressing Flt1 but not in cells expressing KDR. The maximal responses in HDR expressing porcine aortic endothelial cells were obtained at higher VEGF concentrations as compared to HUVE cells, i.e. in the presence of Flt1. This difference could possibly be explained by the formation of heterodimeric complexes between KDR and Flt1, or other molecules, in HUVE cells.	LUDWIG INST CANC RES,CTR BIOMED,S-75124 UPPSALA,SWEDEN; UNIV UPPSALA HOSP,DEPT CLIN CHEM,S-75185 UPPSALA,SWEDEN; UNIV TOKYO,INST MED SCI,TOKYO 108,JAPAN	Ludwig Institute for Cancer Research; Uppsala University; Uppsala University Hospital; University of Tokyo	WALTENBERGER, J (corresponding author), UNIV ULM,MED CTR,DEPT INTERNAL MED 2,ROBERT KOCH STR 8,D-89081 ULM,GERMANY.		; Waltenberger, Johannes/I-1813-2013	Claesson-Welsh, Lena/0000-0003-4275-2000; Waltenberger, Johannes/0000-0002-2417-9880				BIKFALVI A, 1991, J CELL PHYSIOL, V149, P50, DOI 10.1002/jcp.1041490108; BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; BOURASSA C, 1988, ANAL BIOCHEM, V169, P356, DOI 10.1016/0003-2697(88)90295-3; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1993, ONCOGENE, V8, P1293; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; Eriksson A, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209008867; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HUDLICKA O, 1992, PHYSIOL REV, V72, P369, DOI 10.1152/physrev.1992.72.2.369; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KARNOVASKY MORRIS J., 1967, J CELL BIOL, V35, P213, DOI 10.1083/jcb.35.1.213; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LADOUX A, 1993, BIOCHEM BIOPH RES CO, V195, P1005, DOI 10.1006/bbrc.1993.2144; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MCCARTHY SA, 1991, TRENDS PHARMACOL SCI, V12, P462, DOI 10.1016/0165-6147(91)90637-8; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; MORI S, 1991, J BIOL CHEM, V266, P21158; MORI S, 1992, J BIOL CHEM, V267, P6429; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; OBERG C, 1994, GROWTH FACTORS, V10, P115, DOI 10.3109/08977199409010985; OELRICHS RB, 1993, ONCOGENE, V8, P11; Ostman A, 1989, GROWTH FACTORS, V1, P271, DOI 10.3109/08977198908998003; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SARZANI R, 1992, BIOCHEM BIOPH RES CO, V186, P706, DOI 10.1016/0006-291X(92)90804-T; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHEARMAN MS, 1993, EMBO J, V12, P3817, DOI 10.1002/j.1460-2075.1993.tb06060.x; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SIEGBAHN A, 1990, J CLIN INVEST, V85, P916, DOI 10.1172/JCI114519; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; WENNSTROM S, 1994, ONCOGENE, V9, P651; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WILKINSON PC, 1982, CHEMOTAXIS INFLAMMAT, P35; YAMANE A, 1994, ONCOGENE, V9, P2683	67	1438	1540	2	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26988	26995						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929439				2022-12-27	WOS:A1994PQ93100062
J	KUUSK, V; MCINTIRE, WS				KUUSK, V; MCINTIRE, WS			INFLUENCE OF MONOVALENT CATIONS ON THE ULTRAVIOLET-VISIBLE SPECTRUM OF TRYPTOPHAN TRYPTOPHYLQUINONE-CONTAINING METHYLAMINE DEHYDROGENASE FROM BACTERIUM W3A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTROSCOPY; PARACOCCUS-DENITRIFICANS; ACTIVE-SITE; OBLIGATE METHYLOTROPH; QUINONE COFACTOR; PURIFICATION; PROTEINS; ENZYME; SELECTIVITY; CONSTANTS	The influence of the monovalent cations on the UV-visible spectra of the methylamine dehydrogenase (MADH) from bacterium W3A1 was investigated. The spectra for the oxidized and 1- and 2-electron-reduced forms, unperturbed by bound cations, were obtained for the enzyme, and the extinction coefficients for these forms were determined. The binding of the following cations was investigated: Li+, Na+, K+, Rb+, Cs+, NH4+, (CH3N+, and (CH3N+. It was shown that each cation produced unique spectral changes, some of which were pH-dependent. Except for NH4+, all spectral changes produced by binding of the monovalent cations can be explained by assuming two different binding sites in MADH (type I and type II sites). Na+ and K+ displayed monophasic binding to the type II site, (CH3)(3)NH+ and (CH3N+ displayed monophasic binding to the type I site, and Li+, Rb+, and Cs+ displayed either monophasic or biphasic binding to one or both sites depending on pH. The pH dependence for binding to the two sites is different, i.e. plots of log(K-d) versus pH have negative slopes approximate to 1 for the type II site, whereas the negative slope is significantly less than 1 (0.6-0.8) for the type I site. This difference leads to pH-dependent changes in spectral features produced by binding of Li+, Rb+, and Cs+. The spectral changes seen during titrations with NH4+ were unlike those seen for any other cation. The binding of NH4+ was biphasic, and the spectra produced in each phase were unaffected by pH. It is assumed that this cation binds to the tryptophan tryptophylquinone cofactor to produce the iminoquinone in the first phase and then binds to the type I monovalent cation binding site in the second phase. It is suggested that binding of NH4+ (and CH3NH3+) to the type I site is a prelude to binding to the cofactor.	VET AFFAIRS MED CTR,DIV MOLEC BIOL 151S,SAN FRANCISCO,CA 94121; NO CALIF INST RES EDUC,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANESTHESIA,SAN FRANCISCO,CA 94143	US Department of Veterans Affairs; Veterans Health Administration (VHA); Northern California Institute for Research & Education; University of California System; University of California San Francisco; University of California System; University of California San Francisco								BACKES G, 1991, BIOCHEMISTRY-US, V30, P9201, DOI 10.1021/bi00102a011; BADGER J, 1994, BIOPHYS J, V66, P286, DOI 10.1016/S0006-3495(94)80795-7; BASHFORD D, 1993, BIOCHEMISTRY-US, V32, P8045, DOI 10.1021/bi00082a027; BURROWS AL, 1991, EUR J BIOCHEM, V199, P73, DOI 10.1111/j.1432-1033.1991.tb16093.x; CHEN LY, 1991, FEBS LETT, V287, P163, DOI 10.1016/0014-5793(91)80041-Z; CHISTOSERDOV AY, 1991, J BACTERIOL, V173, P5901, DOI 10.1128/jb.173.18.5901-5908.1991; DAVIDSON VL, 1990, BIOCHEMISTRY-US, V29, P10786, DOI 10.1021/bi00500a010; EDMONDSON DE, 1973, FEBS LETT, V64, P255; EISENMAN G, 1987, ANNU REV BIOPHYS BIO, V16, P205; Eisenman G., 1961, S MEMBRANE TRANSPORT, P163; HINTON JF, 1986, BIOPHYS J, V50, P539, DOI 10.1016/S0006-3495(86)83492-0; HUIZINGA EG, 1992, BIOCHEMISTRY-US, V31, P9789, DOI 10.1021/bi00155a036; HUSAIN M, 1987, BIOCHEMISTRY-US, V26, P4139, DOI 10.1021/bi00387a059; HUSAIN M, 1987, J BACTERIOL, V169, P1712, DOI 10.1128/jb.169.4.1712-1717.1987; ITOH S, 1992, J AM CHEM SOC, V114, P7294, DOI 10.1021/ja00044a050; KANKARE JJ, 1970, ANAL CHEM, V42, P1322, DOI 10.1021/ac60294a012; KENNEY WC, 1983, BIOCHEMISTRY-US, V22, P3858, DOI 10.1021/bi00285a022; KIRUKHIN MY, 1990, METHOD ENZYMOL, V188, P247; KUMPF RA, 1993, SCIENCE, V261, P1708, DOI 10.1126/science.8378771; LAWTON SA, 1985, BIOCHEM J, V228, P719, DOI 10.1042/bj2280719; Malinowski ER., 1991, FACTOR ANAL CHEM, V2; MATSUMOTO T, 1978, BIOCHIM BIOPHYS ACTA, V522, P291, DOI 10.1016/0005-2744(78)90063-3; MCINTIRE WS, 1991, BIOCHEMISTRY-US, V30, P125, DOI 10.1021/bi00215a019; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; MCINTIRE WS, 1987, J BIOL CHEM, V262, P11012; MCINTIRE WS, 1987, APPL ENVIRON MICROB, V53, P2183, DOI 10.1128/AEM.53.9.2183-2188.1987; MCWHIRTER RB, 1989, PQQ AND QUINOPROTEINS, P259; MEHTA RJ, 1977, CAN J MICROBIOL, V23, P402, DOI 10.1139/m77-059; MILLER C, 1993, SCIENCE, V261, P1692, DOI 10.1126/science.8397443; SHIRAI S, 1978, J BIOCHEM, V83, P1599, DOI 10.1093/oxfordjournals.jbchem.a132071; SLEATH PR, 1985, J AM CHEM SOC, V107, P3328, DOI 10.1021/ja00297a044; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040; VELLIEUX FMD, 1986, EUR J BIOCHEM, V154, P383, DOI 10.1111/j.1432-1033.1986.tb09409.x; YAMASHITA MM, 1990, P NATL ACAD SCI USA, V87, P5648, DOI 10.1073/pnas.87.15.5648	35	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26136	26143						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929326				2022-12-27	WOS:A1994PQ93000032
J	PAUL, MF; ACKERMANN, S; YUE, J; ARSELIN, G; VELOURS, J; TZAGOLOFF, A				PAUL, MF; ACKERMANN, S; YUE, J; ARSELIN, G; VELOURS, J; TZAGOLOFF, A			CLONING OF THE YEAST ATP3 GENE CODING FOR THE GAMMA-SUBUNIT OF F1 AND CHARACTERIZATION OF ATP3 MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL-MEMBRANE SYSTEM; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; ADENOSINE-TRIPHOSPHATASE; OXIDATIVE-PHOSPHORYLATION; SEQUENCE-ANALYSIS; EPSILON-SUBUNIT; STRUCTURAL GENE; COUPLING FACTOR; BETA-SUBUNIT	Saccharomyces cerevisiae pet mutants, of complementation group G115, are deficient in mitochondrial ATPase and have properties indicative of defective F-1. In this study we show that C287/LU1, a mutant belonging to group G115, is complemented by the yeast nuclear ATP3 gene coding for the gamma-subunit of the mitochondrial F-1- ATPase. The amino-terminal sequence of the mature gamma-subunit matches the sequence encoded by ATP3 starting with the 34th amino acid confirming the identity of the gene, and earlier evidence indicating that this F-1 component is synthesized as a precursor with a long amino-terminal extension. The properties of the mitochondrial ATPase have been studied in C287/LU1 with an Ala(273) --> Val substitution in the carboxyl-terminal region of the gamma-subunit and in W303 Delta ATP3, a mutant lacking the gamma-subunit as a result of a deletion in ATP3. Both strains have negligible ATPase activity but near normal concentrations of the alpha- and beta-subunits of F-1. In W303 Delta ATP3, the subunits do not form a stable F-1 oligomer nor are they firmly associated with F-0. This is not true of C287/LU1, which was found to assemble an F-1-F-0 complex. These data indicate that the yeast gamma-subunit has dual functions, one in catalysis of ATP hydrolysis/synthesis and the second in assembly/stability of F-1.	INST BIOCHIM & GENET CELLULAIRE, F-33077 BORDEAUX, FRANCE		PAUL, MF (corresponding author), COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022174, R01HL022174] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22174] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ARSELIN G, 1991, J BIOL CHEM, V266, P723; BOTSTEIN D, 1982, MOL BIOL YEAST SACCH, P607; CATTERALL WA, 1971, J BIOL CHEM, V246, P4987; COX GB, 1992, MOL MECHANISMS BIOEN, P283; DUNN SD, 1980, J BIOL CHEM, V255, P113; DYER MR, 1989, BIOCHEMISTRY-US, V28, P3670, DOI 10.1021/bi00435a008; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FUTAI M, 1977, BIOCHEM BIOPH RES CO, V79, P1231, DOI 10.1016/0006-291X(77)91138-X; GUELIN E, 1993, J BIOL CHEM, V268, P161; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; IWAMOTO A, 1990, J BIOL CHEM, V265, P5043; KANAZAWA H, 1983, ARCH BIOCHEM BIOPHYS, V223, P521, DOI 10.1016/0003-9861(83)90617-3; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIN AS, 1980, P NATL ACAD SCI-BIOL, V77, P3998, DOI 10.1073/pnas.77.7.3998; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACCECCHINI ML, 1979, P NATL ACAD SCI USA, V76, P343, DOI 10.1073/pnas.76.1.343; Maniatis T., 1982, MOL CLONING; MASON JG, 1990, PLANT MOL BIOL, V14, P1007, DOI 10.1007/BF00019397; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; NORAIS N, 1991, J BIOL CHEM, V266, P16541; NORTHROP FD, 1985, J MOL BIOL, V184, P677; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; PULLMAN ME, 1960, J BIOL CHEM, V235, P3322; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SARASTE M, 1981, NUCLEIC ACIDS RES, V9, P5287, DOI 10.1093/nar/9.20.5287; SCHATZ G, 1968, J BIOL CHEM, V243, P2192; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; STONE KL, 1989, TECHNIQUES PROTEIN C, P377; TAKEDA M, 1985, J BIOL CHEM, V260, P5458; TAKEDA M, 1986, J BIOL CHEM, V261, P5126; ten Berge A M, 1974, Mol Gen Genet, V131, P113; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; Tzagoloff A, 1979, Methods Enzymol, V55, P351; TZAGOLOFF A, 1971, J BIOL CHEM, V246, P7328; VELOURS J, 1988, EUR J BIOCHEM, V170, P637, DOI 10.1111/j.1432-1033.1988.tb13745.x; YOKOYAMA K, 1989, J BIOL CHEM, V264, P21837; YOSHIDA M, 1977, J BIOL CHEM, V252, P3480	44	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26158	26164						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929329				2022-12-27	WOS:A1994PQ93000035
J	JACOB, KK; STANLEY, FM				JACOB, KK; STANLEY, FM			THE INSULIN AND CAMP RESPONSE ELEMENTS OF THE PROLACTIN GENE ARE OVERLAPPING SEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-ACTING ELEMENTS; PROXIMAL REGION; THYROID-HORMONE; EXPRESSION; TRANSCRIPTION; PROMOTER; BINDING; DNA; CELLS; BASAL	Prolactin gene expression is affected by numerous signals, but many of the promoter elements required for these responses have not been clearly identified. This report identifies sequences within the prolactin gene promoter that are required for the responses to cAMP and insulin. The cAMP response element, -101 to -92 shares a 6 of 8 base pair homology with previously identified cAMP response elements. Mutation of this element also results in a >100-fold decrease in basal prolactin gene expression. This is characteristic of cAMP response elements, but the importance of this element to basal prolactin gene transcription was previously unrecognized. The insulin response element, -97 to -67, is not homologous to previously reported insulin response elements and mediates the 10-fold increases in prolactin gene expression due to insulin observed in GH cells. These elements also function to mediate insulin and cAMP responses from the heterologous Delta MTV-CAT reporter plasmid. Together, insulin and cAMP increase prolactin gene expression additively. The clustering of these elements may provide clues to the independent and possible coordinate regulation by these effecters.	NYU,MED CTR,DEPT MED,NEW YORK,NY 10016; NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	New York University; New York University				Stanley, Frederick/0000-0002-3684-2168	NIDDK NIH HHS [DK 43365] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043365] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANCROFT FC, 1981, FUNCTIONALLY DIFFERE, P47; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; DEMDEN MC, 1992, MOL ENDOCRINOL, V6, P581, DOI 10.1210/me.6.4.581; FLUG F, 1987, J BIOL CHEM, V262, P6373; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; JOHNSON TM, 1993, J BIOL CHEM, V268, P464; KEECH CA, 1989, MOL ENDOCRINOL, V3, P832, DOI 10.1210/mend-3-5-832; LEONARD J, 1992, P NATL ACAD SCI USA, V89, P6247, DOI 10.1073/pnas.89.14.6247; LIANG J, 1992, MOL ENDOCRINOL, V6, P885, DOI 10.1210/me.6.6.885; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAURER RA, 1987, MOL CELL BIOL, V7, P4247, DOI 10.1128/MCB.7.12.4247; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NAZRIN N, 1990, P NATL ACAD SCI USA, V87, P5273; OBRIEN RM, 1991, P NATL ACAD SCI USA, V88, P6580, DOI 10.1073/pnas.88.15.6580; PEERS B, 1991, J BIOL CHEM, V266, P18127; PEERS B, 1992, EUR J BIOCHEM, V210, P53, DOI 10.1111/j.1432-1033.1992.tb17389.x; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; STANLEY F, 1988, J BIOL CHEM, V263, P13444; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; WEBER JL, 1984, MOL CELL BIOCHEM, V65, P171; WEIH F, 1990, GENE DEV, V4, P1437, DOI 10.1101/gad.4.8.1437; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237	27	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25515	25520						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929252				2022-12-27	WOS:A1994PQ49100045
J	KERY, V; BUKOVSKA, G; KRAUS, JP				KERY, V; BUKOVSKA, G; KRAUS, JP			TRANSSULFURATION DEPENDS ON HEME IN ADDITION TO PYRIDOXAL 5'-PHOSPHATE - CYSTATHIONINE BETA-SYNTHASE IS A HEME PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOPROTEIN H-450; CULTURED-CELLS; HUMAN-LIVER; RAT-LIVER; ENZYMES; LIGAND; CDNA; ADENOSYLMETHIONINE; ADENOSYLETHIONINE; CYTOCHROME-P-450	The first committed step of transsulfuration is catalyzed by cystathionine beta-synthase (CBS), a known pyridoxal 5'-phosphate (PLP) enzyme. The inferred amino acid sequences of rat liver CBS and rat liver hemoprotein H-450 are identical. We now confirm the presence of heme b in rat and human liver CBS. Heme almost entirely accounts for the visible spectrum of CBS rather than PLP. Human CBS, expressed in Escherichia coli, acquires heme b from the host bacteria. delta-Aminolevulinate supplementation during bacterial growth increases both the heme saturation and the specific activity of the homogeneous enzyme more than 3-fold. 1 mol of the 63-kDa CBS subunit binds 1 mol of each (heme and PLP). The presence of heme is required for PLP binding, and the amount of PLP bound is limited by the heme content. Removal of PLP, but not heme, from CBS is reversible. These findings suggest that heme is functionally incorporated into CBS only during protein folding. This report describes the first instance of an enzyme that depends upon both heme and PLP for its function.	UNIV COLORADO,SCH MED,DEPT PEDIAT,DENVER,CO 80262; UNIV COLORADO,SCH MED,DEPT CELLULAR & STRUCT BIOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								Adams E, 1979, Methods Enzymol, V62, P407; ADAMS E, 1969, ANAL BIOCHEM, V31, P484, DOI 10.1016/0003-2697(69)90291-7; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BORCSOK E, 1982, ARCH BIOCHEM BIOPHYS, V213, P695, DOI 10.1016/0003-9861(82)90600-2; BRAUNSTEIN AE, 1976, BIOCHIMIE, V58, P5, DOI 10.1016/S0300-9084(76)80351-3; BUKOVSKA G, 1994, IN PRESS PROTEIN EXP; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; DOSS M, 1971, H-S Z PHYSIOL CHEM, V352, P725, DOI 10.1515/bchm2.1971.352.1.725; DUNN MF, 1990, BIOCHEMISTRY-US, V29, P8958; FINKELSTEIN JD, 1984, BIOCHEM BIOPH RES CO, V118, P14, DOI 10.1016/0006-291X(84)91060-X; FINKELSTEIN JD, 1975, BIOCHEM BIOPH RES CO, V66, P81, DOI 10.1016/S0006-291X(75)80297-X; GRABOWSKI R, 1993, TRENDS BIOCHEM SCI, V18, P297, DOI 10.1016/0968-0004(93)90040-T; HASEGAWA T, 1984, J BIOCHEM-TOKYO, V96, P265, DOI 10.1093/oxfordjournals.jbchem.a134822; ISHIHARA S, 1990, J BIOCHEM-TOKYO, V108, P899, DOI 10.1093/oxfordjournals.jbchem.a123310; KIM IC, 1982, J BIOL CHEM, V257, P1063; KIM IC, 1976, BIOCHEMISTRY-US, V15, P4925, DOI 10.1021/bi00667a027; KIMURA H, 1971, J BIOCHEM-TOKYO, V69, P711, DOI 10.1093/oxfordjournals.jbchem.a129520; Kozich Viktor, 1992, Human Mutation, V1, P113, DOI 10.1002/humu.1380010206; KRAUS J, 1978, J BIOL CHEM, V253, P6523; KRAUS JP, 1993, HUM MOL GENET, V2, P1633, DOI 10.1093/hmg/2.10.1633; KRAUS JP, 1983, ARCH BIOCHEM BIOPHYS, V222, P44, DOI 10.1016/0003-9861(83)90500-3; LIPSON MH, 1980, ARCH BIOCHEM BIOPHYS, V204, P486, DOI 10.1016/0003-9861(80)90060-0; MORINO Y, 1984, METHOD ENZYMOL, V106, P116; MORRISON M, 1965, ANAL BIOCHEM, V12, P77, DOI 10.1016/0003-2697(65)90144-2; Mudd Sh, 1989, METABOLIC BASIS INHE, V1, P693; OMURA T, 1984, J BIOCHEM-TOKYO, V96, P1491, DOI 10.1093/oxfordjournals.jbchem.a134978; ROPER MD, 1992, ARCH BIOCHEM BIOPHYS, V298, P514, DOI 10.1016/0003-9861(92)90443-Z; SCHELLHORN HE, 1988, J BACTERIOL, V170, P78, DOI 10.1128/jb.170.1.78-83.1988; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SKOVBY F, 1984, J BIOL CHEM, V259, P588; SONO M, 1982, J BIOL CHEM, V257, P8308; SWAROOP M, 1992, J BIOL CHEM, V267, P11455	32	153	159	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25283	25288						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929220				2022-12-27	WOS:A1994PQ49100010
J	KUNG, C; HAYES, E; MANN, KG				KUNG, C; HAYES, E; MANN, KG			A MEMBRANE-MEDIATED CATALYTIC EVENT IN PROTHROMBIN ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FACTOR-V; GAMMA-CARBOXYGLUTAMIC ACID; COAGULATION FACTOR VA; PHOSPHOLIPID-VESICLES; PHASE-TRANSITIONS; ACTIVE-SITE; FACTOR-XA; PHOSPHATIDYLCHOLINE LIPOSOMES; FLUORESCENCE DEPOLARIZATION; COFACTOR DEPENDENCE	Prothrombinase assembly takes place on the surface of unsaturated phosphatidylcholine (PC), phosphatidyl-serine (PS) membranes in the presence of Ca2+, through the rapid association of membrane-bound factor Va and factor Xa. The present study uses saturated PCPS (75:25, w/w) vesicles to study prothrombinase assembly and catalytic properties in order to differentiate the influences of the membrane upon catalyst assembly, substrate delivery, and peptide bond cleavage. In contrast to studies using unsaturated phospholipid, prothrombin activation studies using saturated PCPS (75:25, w/w) (C14:0, C16:0, and C18:0) revealed up to a 20-fold decrease in prothrombinase activity. C18:0 membranes support at least 50% of the prothrombinase binding capacity (K-dVa-Xa = 1 nM and n(Va-Xa) = 1.1) of C18:1 PCPS (75:25, w/w). Thus, the 95% loss in activity cannot be explained by gross alterations in catalyst concentration or assembly. Stopped-flow studies with saturated lipids demonstrate that factor Va, factor Xa, and prothrombin have decreased k(on) values. Compensatory changes in k(off) leave the K-d values for these protein-lipid interactions almost unchanged relative to unsaturated PCPS. The profoundly decreased activation rate on saturated phospholipid membranes as compared to unsaturated phospholipids is in part due to slowed substrate/enzyme delivery caused by the saturated lipids. However, studies using prethrombin-1 and C18:0 PCPS (75:25, w/w) also revealed a 15-fold decrease in activity for preassembled prothrombinase. Although there was a slight change in K-m (+2-fold), the major cause of the decrease is an 18-fold decrease in k(cat). Similar differences for K-m and k(cat) values were obtained for prothrombin. Substrate delivery is thus only partially responsible for the diminished prothrombinase activity observed with saturated phospholipids. Since the activity of prothrombinase is decreased for both prothrombin and, prethrombin-1 principally by reducing k(cat), it appears that catalyst formation on saturated phospholipids somehow compromises the proteolytic activity of the enzyme complex. This implies that the phospholipid bilayer serves not merely as a surface for condensing the proteins but also as a functional element of the prothrombinase enzyme.	UNIV VERMONT,COLL MED,DEPT BIOCHEM,BURLINGTON,VT 05405	University of Vermont					NHLBI NIH HHS [P01HL46703] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; BUTENAS S, 1992, BIOCHEMISTRY-US, V31, P5399, DOI 10.1021/bi00138a023; COOPER RA, 1978, BIOCHEMISTRY-US, V17, P327, DOI 10.1021/bi00595a021; CUTSFORTH GA, 1989, BIOCHEMISTRY-US, V28, P7453, DOI 10.1021/bi00444a045; CUTSFORTH GA, 1991, THROMB HAEMOSTASIS, V65, P8582; DOMBROSE FA, 1979, J BIOL CHEM, V254, P5027; Fersht A., 1985, ENZYME STRUCTURE MEC; GERADS I, 1990, BIOCHEMISTRY-US, V29, P7967, DOI 10.1021/bi00486a027; GIESEN PLA, 1991, J BIOL CHEM, V266, P1379; Gomori G, 1942, J LAB CLIN MED, V27, P955; GOVERSRIEMSLAG JWP, 1992, BIOCHEMISTRY-US, V31, P10000, DOI 10.1021/bi00156a020; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; HIGGINS DL, 1985, J BIOL CHEM, V260, P3604; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; ISAACS BS, 1986, BIOCHEMISTRY-US, V25, P4958, DOI 10.1021/bi00365a036; Jesty J, 1976, Methods Enzymol, V45, P95; JONES ME, 1985, THROMB RES, V39, P711, DOI 10.1016/0049-3848(85)90255-5; JONES ME, 1986, BIOCHEMISTRY-US, V25, P567, DOI 10.1021/bi00351a009; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P486, DOI 10.1021/bi00168a013; KALAFATIS M, 1990, J BIOL CHEM, V265, P21580; KRIEG UC, 1987, BIOCHEMISTRY-US, V26, P103, DOI 10.1021/bi00375a015; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; KRISHNASWAMY S, 1993, METHOD ENZYMOL, V222, P260; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPE PD, 1984, J BIOL CHEM, V259, P9959; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; LECOMPTE MF, 1987, J BIOL CHEM, V262, P1935; LECOMPTE MF, 1994, J BIOL CHEM, V269, P1905; LENTZ BR, 1976, BIOCHEMISTRY-US, V15, P4529, DOI 10.1021/bi00665a030; LENTZ BR, 1976, BIOCHEMISTRY-US, V15, P4521, DOI 10.1021/bi00665a029; LENTZ BR, 1989, BIOCHEMISTRY-US, V28, P7459; MALHOTRA OP, 1985, J BIOL CHEM, V260, P279; Mann K G, 1976, Methods Enzymol, V45, P123; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1990, BLOOD, V76, P1; MANN KG, 1992, SEMIN HEMATOL, V29, P213; MANN KG, 1990, BLOOD, V76, P755; MANN KG, 1987, PROTEASES BIOL CONTR, P235; MAYER LD, 1983, BIOCHIM BIOPHYS ACTA, V734, P48, DOI 10.1016/0005-2736(83)90073-1; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NESHEIM ME, 1981, J BIOL CHEM, V256, P6537; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NESHEIM ME, 1983, J BIOL CHEM, V258, P5386; ODEGAARD BH, 1987, J BIOL CHEM, V262, P11237; ORTEL TL, 1992, J BIOL CHEM, V267, P4189; PEI G, 1993, J BIOL CHEM, V268, P3226; ROSING J, 1988, BIOCHEMISTRY-US, V27, P8, DOI 10.1021/bi00401a002; ROSING J, 1988, BIOCHEMISTRY-US, V27, P9048, DOI 10.1021/bi00425a025; ROSING J, 1993, J BIOL CHEM, V268, P21130; SEELIG A, 1977, BIOCHEMISTRY-US, V16, P45, DOI 10.1021/bi00620a008; Shattil S J, 1978, Prog Hemost Thromb, V4, P59; STUBBS CD, 1983, ESSAYS BIOCHEM, V19, P1; TANS G, 1979, EUR J BIOCHEM, V95, P449, DOI 10.1111/j.1432-1033.1979.tb12984.x; TENDIAN SW, 1990, BIOCHEMISTRY-US, V29, P6720, DOI 10.1021/bi00480a023; TOWBIN H, 1979, P NATL ACAD SCI USA, V19, P665; TRACY PB, 1986, BIOCH PLATELETS, P295; WALKER RK, 1993, J BIOL CHEM, V268, P13920; WEI GJ, 1982, BIOCHEMISTRY-US, V21, P1949, DOI 10.1021/bi00537a039; WILLIAMS EB, 1989, J BIOL CHEM, V264, P7536; WILLIAMS EB, 1993, METHOD ENZYMOL, V222, P503; WU JR, 1991, BIOPHYS J, V60, P70, DOI 10.1016/S0006-3495(91)82031-8	65	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25838	25848						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929289				2022-12-27	WOS:A1994PQ49100089
J	LEE, CW; LEE, KH; LEE, SB; PARK, D; RHEE, SG				LEE, CW; LEE, KH; LEE, SB; PARK, D; RHEE, SG			REGULATION OF PHOSPHOLIPASE C-BETA-4 BY RIBONUCLEOTIDES AND THE ALPHA-SUBUNIT OF G(Q)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; LIGHT-MEDIATED BREAKDOWN; RECOMBINANT-GQ-ALPHA; ROD OUTER SEGMENTS; G-PROTEIN; C ISOZYMES; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; LIMULUS PHOTORECEPTORS; NORPA GENE; SF9 CELLS	The fourth member of mammalian beta-type phospholipase C isozymes, PLC-beta 4, was recently purified from bovine retina, and the corresponding cDNA was cloned from rat brain and sequenced. PLC-beta 4 has now been shown to differ from the other three mammalian beta-type isozymes (PLC-beta 1, -beta 2, and -beta 3) in that it is selectively inhibited by ribonucleotides. The inhibition requires the 5'-phosphate and 2'-hydroxyl groups of ribose as well as the base moiety. Thus, deoxyribonucleotides and ribose B-phosphate were not inhibitory. The monophosphate, diphosphate, and triphosphate nucleoside derivatives were all inhibitory, whereas cyclic nucleotides were ineffective. Purine nucleotides were more potent inhibitors than pyrimidine nucleotides; the 50% inhibitory concentrations were 20-30 mu M for AMP and GMP, and 100-200 mu M for UMP and CMP. Unlike the other beta-type isozymes, PLC-beta 4 contains the GX(4)GKS consensus sequence for the recognition of the phosphoryl group of nucleotides. In the absence of ribonucleotides, the specific activity of PLC-beta 4 toward phosphatidylinositol 4,5-bisphosphate was four to five times the average specific activity of PLC-beta 1 and PLC-beta 3. Thus, nucleotide-dependent inhibition may serve to reduce the activity of PLC-beta 4 in the absence of a hormonal signal. The regulation of PLC-beta 4 by G-proteins was also studied. Similar to the other three PLC-beta isozymes, PLC-beta 4 was activated by the alpha subunit of G(q) but not by the transducin alpha subunit. However, unlike other PLC-beta isozymes, PLC-beta 4 was not responsive to activation by G beta gamma subunits.	NHLBI,BIOCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								Anderson R.E., 1988, Progress in Retinal Research, V8, P211, DOI 10.1016/0278-4327(88)90026-0; ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; BERNSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BROWN JE, 1984, NATURE, V311, P160, DOI 10.1038/311160a0; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FEIN A, 1986, TRENDS NEUROSCI, V9, P110, DOI 10.1016/0166-2236(86)90037-8; FERREIRA PA, 1993, P NATL ACAD SCI USA, V90, P6042, DOI 10.1073/pnas.90.13.6042; GHALAYINI A, 1984, BIOCHEM BIOPH RES CO, V124, P503, DOI 10.1016/0006-291X(84)91582-1; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAYASHI F, 1985, BIOCHEM BIOPH RES CO, V128, P954, DOI 10.1016/0006-291X(85)90139-1; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HURLEY JB, 1987, ANNU REV PHYSIOL, V49, P793; INOUE H, 1985, BIOCHEM BIOPH RES CO, V132, P513, DOI 10.1016/0006-291X(85)91163-5; JHON DY, 1993, J BIOL CHEM, V268, P6654; JIANG HP, 1994, J BIOL CHEM, V269, P7593; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KAUPP UB, 1992, ANNU REV PHYSIOL, V54, P153; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOZASA T, 1993, P NATL ACAD SCI USA, V90, P9176, DOI 10.1073/pnas.90.19.9176; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEE CW, 1993, J BIOL CHEM, V268, P21318; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; MILLAR FA, 1988, BIOCHIM BIOPHYS ACTA, V970, P205, DOI 10.1016/0167-4889(88)90180-2; MIN DS, 1993, J BIOL CHEM, V268, P12207; NORTHUP JK, 1983, J BIOL CHEM, V258, P1361; PAK WL, 1991, PHOTOCHEM PHOTOBIOL, V53, P871, DOI 10.1111/j.1751-1097.1991.tb09901.x; PARK D, 1992, J BIOL CHEM, V267, P16048; PARK DG, 1993, J BIOL CHEM, V268, P4573; PUGH E, 1988, NATURE, V334, P16, DOI 10.1038/334016a0; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WILLARDSON BM, 1993, J BIOL CHEM, V268, P6371; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811; ZHU LQ, 1993, J BIOL CHEM, V268, P15994	49	94	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25335	25338						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929227				2022-12-27	WOS:A1994PQ49100018
J	MASUOKA, J; SALTMAN, P				MASUOKA, J; SALTMAN, P			ZINC(II) AND COPPER(II) BINDING TO SERUM-ALBUMIN - A COMPARATIVE-STUDY OF DOG, BOVINE, AND HUMAN ALBUMIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE; EQUILIBRIUM; ANALOGS; ABSENCE	Metal binding strategies employing low molecular weight chelators and equilibrium dialysis were used to investigate several unresolved aspects of zinc and copper binding to serum albumin. Direct measurement of histidine binding to bovine serum albumin when the histidine is presented either as a metal chelate or alone provides no evidence for an albumin-metal-histidine ternary complex. Using previously determined intrinsic constants for Zn(II) and Cu(II), we have measured zinc binding to bovine serum albumin in the presence of saturating amounts of copper. The results of these experiments unambiguously show that zinc and copper bind at separate noninteracting sites on this protein. The intrinsic constants for zinc and copper binding to dog serum albumin have been determined. Contrary to previous reports, we find that dog serum albumin has a specific high affinity site for copper, log(10)K 10.17 for Cu(II) compared to 6.85 for Zn(II) at the separate site.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK012386] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 12386-25] Funding Source: Medline; NIGMS NIH HHS [GM 07313] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPLETON DW, 1971, J BIOL CHEM, V246, P5040; BRESLOW E, 1964, J BIOL CHEM, V239, P3252; DIXON JW, 1972, BIOCHEM BIOPH RES CO, V48, P197, DOI 10.1016/0006-291X(72)90362-2; GIROUX E, 1981, J INORG BIOCHEM, V14, P359, DOI 10.1016/S0162-0134(00)80292-5; GORESKY CA, 1968, CAN J PHYSIOL PHARM, V46, P771, DOI 10.1139/y68-120; GOUMAKOS W, 1991, BIOCHEM CELL BIOL, V69, P809, DOI 10.1139/o91-121; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; KLOTZ IM, 1982, SCIENCE, V217, P1247, DOI 10.1126/science.6287580; KLOTZ IM, 1952, J AM CHEM SOC, V74, P5537, DOI 10.1021/ja01141a523; KOLTHOFF IM, 1957, J AM CHEM SOC, V79, P2656, DOI 10.1021/ja01567a087; KOLTHOFF IM, 1958, J AM CHEM SOC, V80, P5673, DOI 10.1021/ja01554a023; KOLTUN WL, 1963, J BIOL CHEM, V238, P124; KRUCK TPA, 1973, CAN J CHEM, V51, P3549, DOI 10.1139/v73-529; LAKUSTA H, 1979, J INORG BIOCHEM, V11, P303, DOI 10.1016/S0162-0134(00)80185-3; LAU SJ, 1971, J BIOL CHEM, V246, P5938; LAU SJ, 1974, J BIOL CHEM, V249, P5878; LAUSSAC JP, 1984, BIOCHEMISTRY-US, V23, P2832, DOI 10.1021/bi00307a046; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALMSTROM BG, 1953, ARCH BIOCHEM BIOPHYS, V46, P345, DOI 10.1016/0003-9861(53)90207-0; MASUOKA J, 1993, J BIOL CHEM, V268, P21533; MONTASER A, 1992, P SOC EXP BIOL MED, V200, P321, DOI 10.3181/00379727-200-43437; OSTERBERG R, 1971, ACTA CHEM SCAND, V25, P3827, DOI 10.3891/acta.chem.scand.25-3827; PETERS T, 1967, J BIOL CHEM, V242, P1574; PETERS T, 1960, BIOCHIM BIOPHYS ACTA, V39, P546, DOI 10.1016/0006-3002(60)90215-8; PETTIT LD, 1976, J CHEM SOC DALTON, P588, DOI 10.1039/dt9760000588; RAKHIT G, 1981, J INORG BIOCHEM, V15, P233, DOI 10.1016/S0162-0134(00)80158-0; RAO MSN, 1958, J AM CHEM SOC, V80, P3226, DOI 10.1021/ja01546a014; RYALL RG, 1974, COMPETITIVE DIALYSIS; SARKAR B, 1968, CAN J BIOCHEM CELL B, V46, P601, DOI 10.1139/o68-092; SASSKORTSAK A, 1967, CAN MED ASSOC J, V96, P361; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Smith RM, 1974, CRITICAL STABILITY C, V1-6; Spiro TG, 1969, STRUCT BOND, V6, P117	33	141	144	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25557	25561						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929257				2022-12-27	WOS:A1994PQ49100051
J	POWELL, WS; GRAVELLE, F; GRAVEL, S				POWELL, WS; GRAVELLE, F; GRAVEL, S			PHORBOL-MYRISTATE ACETATE STIMULATES THE FORMATION OF 5-OXO-6,8,11,14-EICOSATETRAENOIC ACID BY HUMAN NEUTROPHILS BY ACTIVATING NADPH OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD POLYMORPHONUCLEAR LEUKOCYTES; ARACHIDONIC-ACID; INHIBITOR DIPHENYLENEIODONIUM; STRUCTURAL-ANALYSIS; METABOLISM; LEUKOTRIENE; TRANSFORMATION; CYTOKINEPLASTS; MECHANISM; CALCIUM	We have shown previously that human neutrophil microsomes contain a highly specific dehydrogenase which, in the presence of NADP(+), converts 5S-hydroxy-6,8,11,14-eicosatetraenoic acid (5S-HETE) to its 5-oxo metabolite, 5-oxo-ETE, a potent agonist of these cells. However, intact neutrophils convert SS-HETE principally to its psi-oxidation product, 5,20-diHETE, and to only small amounts of 5-oxo-ETE. Phorbol myristate acetate (PMA) dramatically shifts the metabolism of 5S-HETE by intact cells so that 5-oxo-ETE is the major metabolite. The objective of this investigation was to determine the mechanism for the stimulatory effect of PMA on 5-oxo-ETE formation. The possibility that oxidants released in response to PMA nonenzymatically oxidized 5S-HETE was ruled out, since PMA did not appreciably stimulate the formation of 5-oxo-ETE from 5R-HETE. On the other hand, inhibition of NADPH oxidase either by diphenylene iodonium or by mild heating nearly completely prevented the stimulatory effect of PMA on the formation of 5-oxo-ETE. The possibility that this effect was mediated by superoxide seems unlikely, since it was still observed, although somewhat attenuated, in the presence of superoxide dismutase. Moreover, superoxide generated by another mechanism (xanthine/xanthine oxidase) did not appreciably affect the formation of 5-oxo-ETE by neutrophils, However, phenazine methosulfate, which can nonenzymatically convert NADPH to NADP(+), mimicked the effect of PMA on 5-oxo-ETE formation by intact neutrophils. It is concluded that PMA acts by activating NADPH oxidase, resulting in conversion of NADPH to NADP(+), which enhances the formation of 5-oxo-ETE and reduces the formation of 5,20-diHETE. Serum-treated zymosan has an effect on the metabolism of 5S-HETE similar to that of PMA in that it also stimulates the formation of 5-oxo-ETE and inhibits that of 5,20 diHETE.			POWELL, WS (corresponding author), MCGILL UNIV,DEPT MED,RESP HLTH NETWORK CTR EXELLENCE,MEAKINS CHRISTIE LABS,3626 ST URBAIN ST,MONTREAL H2X 2P2,PQ,CANADA.		Powell, William/AAE-9000-2020	Powell, William/0000-0002-8507-4038				BORGEAT P, 1981, PROSTAG LEUKOTR ESS, V6, P557, DOI 10.1016/0161-4630(81)90117-8; BORGEAT P, 1979, J BIOL CHEM, V254, P7865; BORGEAT P, 1976, J BIOL CHEM, V251, P7816; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BREZINSKI ME, 1990, P NATL ACAD SCI USA, V87, P6248, DOI 10.1073/pnas.87.16.6248; COLLETTE J, 1956, J AM CHEM SOC, V78, P3819, DOI 10.1021/ja01596a070; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; DAVIS G, 1983, BIOCHIM BIOPHYS ACTA, V724, P456, DOI 10.1016/0005-2728(83)90106-8; DYETT DE, 1986, J CLIN INVEST, V77, P34, DOI 10.1172/JCI112297; ELLIS JA, 1988, BIOCHEM J, V251, P887, DOI 10.1042/bj2510887; ERICKSON RW, 1992, J CLIN INVEST, V89, P1587, DOI 10.1172/JCI115753; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; GIBIAN MJ, 1987, ANAL BIOCHEM, V163, P343, DOI 10.1016/0003-2697(87)90234-X; GOETZL EJ, 1980, J IMMUNOL, V125, P1789; GORDON JA, 1989, AM J PHYSIOL, V256, pC1, DOI 10.1152/ajpcell.1989.256.1.C1; HANSSON G, 1981, FEBS LETT, V130, P107, DOI 10.1016/0014-5793(81)80676-X; JUBIZ W, 1982, J BIOL CHEM, V257, P6106; MAAS RL, 1982, J BIOL CHEM, V257, P7056; MALAWISTA SE, 1985, INFLAMMATION, V9, P99, DOI 10.1007/BF00915416; MALAWISTA SE, 1986, BLOOD CELLS, V12, P167; MALAWISTA SE, 1982, J CELL BIOL, V95, P960, DOI 10.1083/jcb.95.3.960; MULLER M, 1992, INFECT IMMUN, V60, P2536, DOI 10.1128/IAI.60.6.2536-2540.1992; NACCACHE PH, 1984, J CELL PHYSIOL, V118, P13, DOI 10.1002/jcp.1041180104; OFLAHERTY JT, 1988, J IMMUNOL, V140, P4323; OFLAHERTY JT, 1986, J IMMUNOL, V137, P3277; OFLAHERTY JT, 1993, BIOCHEM BIOPH RES CO, V192, P129, DOI 10.1006/bbrc.1993.1391; PALMBLAD J, 1981, BLOOD, V58, P658; POWELL WS, 1994, BIOCHEMISTRY-US, V33, P3927, DOI 10.1021/bi00179a019; POWELL WS, 1984, J BIOL CHEM, V259, P3082; POWELL WS, 1993, J BIOL CHEM, V268, P9280; POWELL WS, 1992, J BIOL CHEM, V267, P19233; POWELL WS, 1987, ANAL BIOCHEM, V164, P117, DOI 10.1016/0003-2697(87)90375-7; POWELL WS, 1993, J LEUKOCYTE BIOL S, V137; RAGAN CI, 1977, BIOCHEM J, V163, P605, DOI 10.1042/bj1630605; RICHARDS CF, 1986, BIOCHIM BIOPHYS ACTA, V875, P569, DOI 10.1016/0005-2760(86)90079-2; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SERHAN CN, 1989, BIOCHIM BIOPHYS ACTA, V1004, P158, DOI 10.1016/0005-2760(89)90264-6; SMITH PJ, 1961, NATURE, V190, P84, DOI 10.1038/190084a0; SOBERMAN RJ, 1987, J BIOL CHEM, V262, P12421; STENSON WF, 1979, J CLIN INVEST, V64, P1457, DOI 10.1172/JCI109604; YEA CM, 1990, BIOCHEM J, V265, P95, DOI 10.1042/bj2650095	41	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25373	25380						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929234				2022-12-27	WOS:A1994PQ49100025
J	SCHROEDER, SC; WANG, CK; WEIL, PA				SCHROEDER, SC; WANG, CK; WEIL, PA			IDENTIFICATION OF THE CIS-ACTING DNA-SEQUENCE ELEMENTS REGULATING THE TRANSCRIPTION OF THE SACCHAROMYCES-CEREVISIAE GENE ENCODING TBP, THE TATA BOX-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; STEM-LOOP MUTATION; S-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; ACANTHAMOEBA-CASTELLANII; LESS PROMOTER; FACTOR-TFIIIB; LACZ FUSIONS; CYC1 GENE; YEAST	TBP, the TATA-box binding protein, plays a key role in eukaryotic gene transcription since it is required for transcription initiation by all three eukaryotic nuclear DNA-dependent RNA polymerases. In order to gain insight into the mechanisms of regulation of this key basal transcription factor, we undertook a mutational analysis of the sequences involved in directing transcription of the gene encoding TBP in Saccharomyces cerevisiae. An extensive family of mutations in the promoter of the gene encoding TBP were fused to the Escherichia coli reporter gene lacZ, transferred back into yeast, and assayed for their ability to direct expression of beta-galactosidase. Levels of beta-galactosidase activity measured from yeast transformed with this family of constructs indicate that both positive- and negative-acting cis-elements located within 400 nucleotides of the transcription start site are involved in regulating transcription of the TBP-encoding gene. Analyses of RNA prepared from these same cells showed that specific transcription initiation is maintained in the mutant reporter constructs and that RNA levels mirror beta-galactosidase levels. In order to corroborate the results of these mutational analyses of the TBP-encoding gene, in vivo cis-element occupancy was examined using several different footprinting reagents. The patterns of protection observed demonstrated that the sequence elements implicated in the control of TBP gene transcription by reporter gene analyses appear to be bound by protein(s) in vivo. Interesting sequence similarities were noted between two TBP-gene regulatory elements and 5'-flanking sequences of genes encoding several other basal transcription factors.	VANDERBILT UNIV, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA; ROCKEFELLER UNIV, BIOCHEM LAB, NEW YORK, NY 10021 USA	Vanderbilt University; Rockefeller University					NIDDK NIH HHS [DK42502] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BREWER AC, 1990, NUCLEIC ACIDS RES, V18, P5574, DOI 10.1093/nar/18.18.5574; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DENSMORE L, 1991, MOL CELL BIOL, V11, P154, DOI 10.1128/MCB.11.1.154; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; HUET J, 1992, NUCLEIC ACIDS RES, V20, P6451, DOI 10.1093/nar/20.24.6451; HUIBREGTSE JM, 1989, MOL CELL BIOL, V9, P3244, DOI 10.1128/MCB.9.8.3244; JANTZEN HM, 1992, GENE DEV, V6, P1950, DOI 10.1101/gad.6.10.1950; JONES JS, 1988, NUCLEIC ACIDS RES, V16, P7119, DOI 10.1093/nar/16.14.7119; KAMBADUR R, 1990, P NATL ACAD SCI USA, V97, P9168; KARNITZ L, 1989, MOL CELL BIOL, V9, P1929, DOI 10.1128/MCB.9.5.1929; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIU F, 1993, NUCLEIC ACIDS RES, V21, P4321, DOI 10.1093/nar/21.18.4321; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; MCANDREW MB, 1993, GENE, V124, P165, DOI 10.1016/0378-1119(93)90390-O; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; NAUMOVSKI L, 1985, MOL CELL BIOL, V5, P17, DOI 10.1128/MCB.5.1.17; PINTO L, 1992, CELL, V68, P677; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMMEN KA, 1992, NUCLEIC ACIDS RES, V20, P5889, DOI 10.1093/nar/20.22.5889; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; WONG JM, 1992, NUCLEIC ACIDS RES, V20, P4817, DOI 10.1093/nar/20.18.4817; YAMASHITA S, 1993, SCIENCE, V261, P463, DOI 10.1126/science.8332911; YOON H, 1992, GENE DEV, V6, P2463, DOI 10.1101/gad.6.12b.2463; ZENZIEGREGORY B, 1993, MOL CELL BIOL, V13, P3841, DOI 10.1128/MCB.13.7.3841; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	57	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28335	28346						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961772				2022-12-27	WOS:A1994PV77200084
J	CHAPMAN, ER; AN, S; BARTON, N; JAHN, R				CHAPMAN, ER; AN, S; BARTON, N; JAHN, R			SNAP-25, A T-SNARE WHICH BINDS TO BOTH SYNTAXIN AND SYNAPTOBREVIN VIA DOMAINS THAT MAY FORM COILED COILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTOSOMAL-ASSOCIATED PROTEIN; INTEGRAL MEMBRANE-PROTEIN; SYNAPTIC VESICLES; LEUCINE ZIPPER; FUSION; PALMITOYLATION; YEAST; CDNA; IDENTIFICATION; MACHINERY	The membrane proteins SNAP-25, syntaxin, and synaptobrevin (vesicle associated membrane protein) have recently been implicated as central elements of an exocytotic membrane fusion complex in neurons. Here we report that SNAP-25 binds directly to both syntaxin and synaptobrevin. The SNAP-25-binding domain of syntaxin lies between residues 199 and 243, within the region previously shown to mediate synaptobrevin binding (Calakos, N., Bennett, M. K., Peterson, K. E., and Scheller, R. H. (1994) Science 263, 1146-1149). The syntaxin-binding domain of SNAP-25 encompasses most of the amino-terminal half of SNAP-25, including its putative palmitoylation sites. Truncation of the carboxyl-terminal 9 residues of SNAP-25, which yields a fragment corresponding to that generated by botulinum neurotoxin A, diminishes the interaction of SNAP-25 with synaptobrevin, but not with syntaxin. Sequence analysis revealed that the regions that mediate the interaction between SNAP-25 and syntaxin contain heptad repeats characteristic of certain classes of alpha-helices. Similar repeats are also present at the carboxyl terminus of SNAP-25 and in synaptobrevin. These domains have a moderate to high probability of forming coiled coils. We conclude that SNAP-25 can interact with both syntaxin and synaptobrevin and that binding may be mediated by alpha-helical domains that form intermolecular coiled-coil structures.	YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510	Yale University; Yale University	CHAPMAN, ER (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,BOYER CTR MOLEC MED,RM 247,NEW HAVEN,CT 06511, USA.			Jahn, Reinhard/0000-0003-1542-3498; Chapman, Edwin/0000-0001-9787-8140				BARK IC, 1993, J MOL BIOL, V233, P67, DOI 10.1006/jmbi.1993.1485; BARK IC, 1994, GENE AMST, V132, P291; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BINZ T, 1994, J BIOL CHEM, V269, P1617; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HESS DT, 1992, J NEUROSCI, V12, P4634; HUTTNER WB, 1993, NATURE, V365, P104, DOI 10.1038/365104a0; INOUE A, 1992, J BIOL CHEM, V267, P10613; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCMAHON H, 1993, NATURE, V364, P356; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; RISINGER C, 1993, J BIOL CHEM, V268, P24408; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SPRING J, 1993, TRENDS BIOCHEM SCI, V18, P124, DOI 10.1016/0968-0004(93)90018-I; SUDHOF TC, 1993, CELL, V75, P1; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803	44	262	265	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27427	27432						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961655				2022-12-27	WOS:A1994PV77100045
J	SHACHAR, I; RABINOVICH, E; KEREM, A; BARNUN, S				SHACHAR, I; RABINOVICH, E; KEREM, A; BARNUN, S			THIOL-REDUCING AGENTS AND CALCIUM PERTURBANTS ALTER INTRACELLULAR SORTING OF IMMUNOGLOBULIN-M	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; CHAIN BINDING-PROTEIN; ENDOPLASMIC-RETICULUM; LYMPHOCYTES-B; SECRETORY PROTEINS; HEAVY-CHAINS; IGM; DEGRADATION; RECEPTOR; CELL	The secretory form of IgM (sIgM) undergoes developmentally regulated intracellular sorting and transport, as demonstrated by the distinct assembly patterns and intracellular fate exhibited by its mu heavy chain (mu s) In the 38C B lymphocytes, mu s-containing monomers are retained and degraded intracellularly, whereas in the 38C-derived D2 hybridoma, mu s-containing polymers are secreted. Here we show that sorting of sIgM is impaired in the presence of the thiol-reducing agent beta-mercaptoethanol or when cellular calcium sequestration is perturbed either with the Ca2+ ionophore A23187 or with thapsigargin, an inhibitor of endoplasmic reticulum Ca2+-ATPase. Under these conditions, sIgM evades retention/degradation in the 38C cells, resulting in its enhanced secretion. Conversely, in the D2 cells, secretion is strongly attenuated, and sIgM is partly degraded. Both cell types secrete unusually processed sIgM, which is completely resistant to endoglycosidase H, unlike the partially sensitive sIgM secreted in the usual manner, indicating terminal glycosylation of all carbohydrate moieties of mu s. Moreover, secretion is no longer restricted to fully assembled polymeric sIgM, and in both cell types under Ca2+ perturbation preferentially hemimeric and monomeric assembly intermediates are detected in the medium. Our results suggest that the intracellular fate of sIgM is collectively determined by several sorting events that confer sIgM retention/degradation, ensure sIgM secretion from D2 cells, and prevent the arrival of assembly intermediates to the cell surface. All of these sorting events appear to require high Ca2+ concentration and oxidizing thiol redox state, the conditions that prevail in the lumen of the endoplasmic reticulum. Thus, thiol and calcium are implicated as modulators of intracellular traffic.	TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT BIOCHEM,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University								AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; AMITAY R, 1991, J BIOL CHEM, V266, P12568; AMITAY R, 1992, J BIOL CHEM, V267, P20694; ANDREWS SB, 1988, P NATL ACAD SCI USA, V85, P1682, DOI 10.1073/pnas.85.5.1682; BAUMANN O, 1991, P NATL ACAD SCI USA, V88, P741, DOI 10.1073/pnas.88.3.741; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BRENCKLE R, 1980, ARCH BIOCHEM BIOPHYS, V201, P160, DOI 10.1016/0003-9861(80)90499-3; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; DAHMS NM, 1986, J BIOL CHEM, V261, P3186; DAVIS AC, 1989, MOL IMMUNOL, V26, P147, DOI 10.1016/0161-5890(89)90096-5; DAVIS AC, 1988, EUR J IMMUNOL, V18, P1001, DOI 10.1002/eji.1830180705; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FREEDMAN RB, 1984, TRENDS BIOCHEM SCI, V9, P438, DOI 10.1016/0968-0004(84)90152-X; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LODISH HF, 1992, J BIOL CHEM, V267, P12753; MACER DRJ, 1988, J CELL SCI, V91, P61; MELNICK J, 1992, J BIOL CHEM, V267, P21303; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RABINOVICH E, 1993, J BIOL CHEM, V268, P24145; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; ROTHMAN JE, 1987, CELL, V50, P521, DOI 10.1016/0092-8674(87)90024-9; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SHACHAR I, 1992, J BIOL CHEM, V267, P24241; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; SOMLYO AP, 1985, NATURE, V314, P622, DOI 10.1038/314622a0; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TARTAKOFF AM, 1977, J EXP MED, V146, P1332, DOI 10.1084/jem.146.5.1332; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; VONFIGURA K, 1986, ANN REV BIOCH, V55, P67; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; WORMALD MR, 1991, EUR J BIOCHEM, V198, P131, DOI 10.1111/j.1432-1033.1991.tb15995.x; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	53	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27344	27350						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961645				2022-12-27	WOS:A1994PV77100033
J	CHEN, QM; KINCH, MS; LIN, TH; BURRIDGE, K; JULIANO, RL				CHEN, QM; KINCH, MS; LIN, TH; BURRIDGE, K; JULIANO, RL			INTEGRIN-MEDIATED CELL-ADHESION ACTIVATES MITOGEN-ACTIVATED PROTEIN-KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TYROSINE KINASE; MAP KINASE; EXTRACELLULAR-MATRIX; SIGNAL TRANSDUCTION; GROWTH-FACTOR; GENE-EXPRESSION; PHOSPHORYLATION; RECEPTOR; FIBRONECTIN; INVITRO	Integrins can function as signal-transducing receptors capable of modulating cell growth and gene expression (Juliano, R. L., and Haskill, S. (1993) J. Cell Biol. 120, 577-585; Hynes, R. O. (1992) Cell 69, 11-25). An early event in integrin signaling in fibroblasts and other cells involves activation of pp125(FAK), a cytoplasmic tyrosine kinase (Hanks, S. K., Calalb, M. B., Harper, M. C., and Patel, S. K. (1992) Proc. Natl. Acad. Sci. U. S. A, 89, 8487-8491; Schaller, M. D., Borgman, C. A., Cobb, B. S., Vines, R. R., Reynolds, A. B., and Parsons, J. T. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5192-5196). Here we report a novel aspect of integrin-mediated signal transduction. We demonstrate that adhesion of cells to substrata coated with extracellular matrix proteins, or with a synthetic peptide containing the RGD sequence, can cause activation of mitogen-activated protein (MAP) kinases in 3T3 or REF52 fibroblasts. Activation of MAP kinases seems to depend on integrin engagement rather than simply on cell attachment. Thus, MAP kinases are activated when cells adhere to substrata coated with the integrin ligands fibronectin or laminin, but not when cells adhere to poly-D-lysine, a nonspecific adhesion-promoting polypeptide. Treatment of cells with cytochalasin D, an inhibitor of actin microfilament assembly, almost completely blocks adhesion-induced MAP kinase activation, indicating a critical role for the cytoskeleton. In REF52 cells, we have observed that activation of MAP kinases is accompanied by redistribution of the protein to the nucleus, suggesting that the activated kinases may impinge on factors regulating gene expression. Thus, integrin-mediated cell adhesion seems a sufficient stimulus to cause activation and nuclear translocation of MAP kinases. This may have important implications for the regulation of cell growth and differentiation by the extracellular matrix.	UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine				Kinch, Michael/0000-0003-3939-3756				AHN NG, 1991, J BIOL CHEM, V266, P4220; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COHEN P, 1992, CELL, V71, P335; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DHAWAN J, 1990, J BIOL CHEM, V265, P9015; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FRANKI N, 1992, AM J PHYSIOL, V263, pC995, DOI 10.1152/ajpcell.1992.263.5.C995; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MORTARINI R, 1992, CANCER RES, V52, P4499; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHREINER C, 1991, CANCER RES, V51, P1738; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SYMINGTON BE, 1992, J BIOL CHEM, V267, P25744; VARNER JA, 1992, MOL BIOL CELL, V3, pA232; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877	37	610	616	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26602	26605						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929388				2022-12-27	WOS:A1994PQ93100004
J	OETJEN, E; DIEDRICH, T; EGGERS, A; ECKERT, B; KNEPEL, W				OETJEN, E; DIEDRICH, T; EGGERS, A; ECKERT, B; KNEPEL, W			DISTINCT PROPERTIES OF THE CAMP-RESPONSIVE ELEMENT OF THE RAT INSULIN-I GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-ISLET CELLS; PROTEIN-PROTEIN INTERACTIONS; TRANSCRIPTION FACTOR-II; DNA-BINDING PROTEINS; GLUCAGON GENE; CYCLIC-AMP; MEMBRANE DEPOLARIZATION; NUCLEAR FACTORS; CYCLOSPORINE-A; FACTOR CREB	The cAMP response element (CRE)-binding transcription factor CREB can mediate induction of gene transcription in response to calcium as well as to cAMP. Since the rat insulin I gene 5'-flanking region contains a CRE with an octamer-like motif (TGACGTCC), CREB binding and cAMP/calcium responsiveness of the insulin CRE were investigated. In an electrophoretic mobility shift assay and in Southwestern blot experiments, bacterially expressed recombinant CREB bound to the insulin CRE as it did to the rat glucagon and rat somatostatin gene CREs. However, in nuclear extracts of the pancreatic islet cell Line HIT, protein complexes binding to the insulin CRE did not contain proteins with CREB-like immunoreactivity, although these bound to the glucagon and somatostatin CREs. When reporter fusion genes were transfected into HIT cells, the isolated insulin CRE increased basal activity and mediated transcriptional activation by cAMP. However, cAMP stimulation of transcription through the insulin CRE was weak when compared with the response through the glucagon and somatostatin CREs. Furthermore, the insulin CRE did not confer responsiveness to membrane depolarization and calcium influx, in contrast to the glucagon and somatostatin CREs. These results demonstrate that the functional properties of the rat insulin I gene CRE are different from those of the rat glucagon and somatostatin CREs which may be explained by a distinct pattern of nuclear protein binding and suggest the existence of post-translational mechanisms that decrease the binding of cellular CREB to the insulin CRE.	UNIV GOTTINGEN,DEPT BIOCHEM PHARMACOL,D-37070 GOTTINGEN,GERMANY	University of Gottingen								ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK DL, 1991, TRENDS NEUROSCI, V14, P411, DOI 10.1016/0166-2236(91)90033-Q; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRUCKER DJ, 1991, ENDOCRINOLOGY, V128, P394, DOI 10.1210/endo-128-1-394; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; EFRAT S, 1991, J BIOL CHEM, V266, P11141; FEHMANN HC, 1992, ENDOCRINOLOGY, V130, P159, DOI 10.1210/en.130.1.159; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; GIDDINGS SJ, 1989, J BIOL CHEM, V264, P9462; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODISON S, 1992, BIOCHEM J, V285, P563, DOI 10.1042/bj2850563; HABENER JF, 1991, ENDOCRINE PANCREAS, P53; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HAMMONDS P, 1987, FEBS LETT, V213, P149, DOI 10.1016/0014-5793(87)81481-3; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; HOLZ GG, 1992, TRENDS BIOCHEM SCI, V17, P388, DOI 10.1016/0968-0004(92)90006-U; IMAI E, 1993, J BIOL CHEM, V268, P5353; INAGAKI N, 1992, P NATL ACAD SCI USA, V89, P1045, DOI 10.1073/pnas.89.3.1045; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; KNEPEL W, 1991, MOL ENDOCRINOL, V5, P1457, DOI 10.1210/mend-5-10-1457; KNEPEL W, 1990, MOL CELL BIOL, V10, P6799, DOI 10.1128/MCB.10.12.6799; LAIMINS L, 1986, P NATL ACAD SCI USA, V83, P3151, DOI 10.1073/pnas.83.10.3151; LEVY J, 1975, BIOCHEM PHARMACOL, V24, P235, DOI 10.1016/0006-2952(75)90282-8; LIU F, 1993, J BIOL CHEM, V268, P6714; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MILLER CP, 1993, MOL CELL BIOL, V13, P7080, DOI 10.1128/MCB.13.11.7080; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1990, J BIOL CHEM, V265, P1465; POWERS AC, 1989, J BIOL CHEM, V264, P10048; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SCHATZ H, 1972, ACTA ENDOCRINOL-COP, V26, P237; SCHWANINGER M, 1993, J BIOL CHEM, V268, P23111; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; SCHWANINGER M, 1993, N-S ARCH PHARMACOL, V348, P541; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VALLEJO M, 1992, J BIOL CHEM, V267, P12876; VANNGUYEN T, 1990, J NEUROSCI, V10, P2825; WOLLHEIM CB, 1990, BIOCHEM SOC T, V18, P111, DOI 10.1042/bst0180111	55	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27036	27044						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929445				2022-12-27	WOS:A1994PQ93100068
J	PERRELLA, MA; MAKI, T; PRASAD, S; PIMENTAL, D; SINGH, K; TAKAHASHI, N; YOSHIZUMI, M; ALALI, A; HIGASHIYAMA, S; KELLY, RA; LEE, ME; SMITH, TW				PERRELLA, MA; MAKI, T; PRASAD, S; PIMENTAL, D; SINGH, K; TAKAHASHI, N; YOSHIZUMI, M; ALALI, A; HIGASHIYAMA, S; KELLY, RA; LEE, ME; SMITH, TW			REGULATION OF HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH-FACTOR MESSENGER-RNA LEVELS BY HYPERTROPHIC STIMULI IN NEONATAL AND ADULT-RAT CARDIAC MYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN RECEPTOR; SMOOTH-MUSCLE CELLS; VENTRICULAR MYOCYTES; MYOCARDIAL-CELLS; MESSENGER-RNA; EXPRESSION; INDUCTION; EGF; PROTEIN; CULTURE	Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a recently characterized member of the EGF family of peptide signaling factors that acts as an early response gene to growth stimuli in vascular smooth muscle cells, as well as being a potent mitogen for these cells. As many of these growth stimuli also induce a hypertrophic response in heart muscle, we examined the regulation of HB-EGF mRNA abundance and function in primary cultures of neonatal rat ventricular myocytes and adult rat ventricular myocytes (ARVM). HB-EGF mRNA levels increased 40- and 6- fold in neonatal rat ventricular myocytes and ARVM, respectively, following a 2-4-h exposure to the alpha-adrenergic agonist phenylephrine, a known hypertrophic stimulus for these cells. Phenylephrine had no effect an HB-EGF mRNA stability, and induction of HB-EGF could be blocked completely by actinomycin D. HB-EGF mRNA abundance was also increased 15-fold in ARVM maintained in defined medium that had been induced to contract at 3 Hz by continual uniform electric field stimulation, a mechanical stimulus that we have shown preserves contractile function and induces cell growth in vitro. To determine whether cardiac myocytes would respond to exogenous HB-EGF, quiescent ARVM were exposed to defined medium conditioned by transfected COS MT cells overexpressing HB-EGF. These myocytes exhibited nearly a S-fold increase in protein content at 24 h compared with unstimulated control ARVM exposed to medium conditioned by COS cells transfected with the plasmid vector alone. Thus, neonatal and adult cardiac muscle cells respond to both neurohumoral and mechanical growth stimuli with a marked increase in HB-EGF mRNA, which may act as an early response gene to facilitate hypertrophic growth in these cells.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,CARDIOVASC BIOL LAB,BOSTON,MA 02115; OSAKA UNIV,SCH MED,DEPT BIOCHEM,OSAKA 565,JAPAN	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Osaka University					FOGARTY INTERNATIONAL CENTER [F05TW004685] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036141] Funding Source: NIH RePORTER; FIC NIH HHS [FO5 TW04685] Funding Source: Medline; NHLBI NIH HHS [R37-HL36141] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM JA, 1993, BIOCHEM BIOPH RES CO, V190, P125, DOI 10.1006/bbrc.1993.1020; BALLIGAND JL, 1993, J CLIN INVEST, V91, P2314, DOI 10.1172/JCI116461; BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; BERGER HJ, 1994, AM J PHYSIOL, V266, pH341, DOI 10.1152/ajpheart.1994.266.1.H341; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUGAISKY LB, 1989, CIRC RES, V64, P493, DOI 10.1161/01.RES.64.3.493; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAYCOMB WC, 1980, DEV BIOL, V80, P466, DOI 10.1016/0012-1606(80)90419-4; DLUZ SM, 1993, J BIOL CHEM, V268, P18330; EID H, 1992, CIRC RES, V71, P40, DOI 10.1161/01.RES.71.1.40; ELLINGSEN O, 1993, AM J PHYSIOL, V265, pH747, DOI 10.1152/ajpheart.1993.265.2.H747; FEN Z, 1993, BIOCHEMISTRY-US, V32, P7932, DOI 10.1021/bi00082a014; GERARD RD, 1985, MOL CELL BIOL, V5, P3231, DOI 10.1128/MCB.5.11.3231; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; KRAMER BK, 1992, CIRCULATION, V85, P350, DOI 10.1161/01.CIR.85.1.350; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LINDPAINTNER K, 1991, CIRC RES, V68, P905, DOI 10.1161/01.RES.68.4.905; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; NISHIDA M, 1993, AM J PHYSIOL, V264, pH639, DOI 10.1152/ajpheart.1993.264.2.H639; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; RESTON JT, 1991, BIOCHIM BIOPHYS ACTA, V1088, P270, DOI 10.1016/0167-4781(91)90063-R; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHUBEITA HE, 1990, J BIOL CHEM, V265, P2055; SIMPSON P, 1982, CIRC RES, V50, P101, DOI 10.1161/01.RES.50.1.101; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; SIMPSON PC, 1989, ANNU REV PHYSIOL, V51, P189, DOI 10.1146/annurev.ph.51.030189.001201; SPEIR E, 1992, CIRC RES, V71, P251, DOI 10.1161/01.RES.71.2.251; SPRINGHORN JP, 1992, J BIOL CHEM, V267, P14360; TEMIZER DH, 1992, J BIOL CHEM, V267, P24892; VOLZ A, 1991, J MOL CELL CARDIOL, V23, P161, DOI 10.1016/0022-2828(91)90103-S; YOSHIZUMI M, 1992, J BIOL CHEM, V267, P9467	38	39	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27045	27050						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929446				2022-12-27	WOS:A1994PQ93100069
J	RUCKMAN, J; RINGQUIST, S; BRODY, E; GOLD, L				RUCKMAN, J; RINGQUIST, S; BRODY, E; GOLD, L			THE BACTERIOPHAGE-T4 REGB RIBONUCLEASE - STIMULATION OF THE PURIFIED ENZYME BY RIBOSOMAL-PROTEIN-S1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; ENDONUCLEOLYTIC CLEAVAGE; BINDING-SITE; QBETA REPLICASE; EXPRESSION; ENDORIBONUCLEASE; POLYMERASE; REGION; DECAY	Infection of Escherichia coli by bacteriophage T4 induces a mRNA ribonuclease activity that shows specificity for cleavage within the sequence GGAG. Substrates of the activity in vivo include a number of phage mRNAs that are cleaved at GGAGs within the Shine/Dalgarno domains of their translation initiation regions. Induction of the ribonuclease depends on the product of the T4 gene regB. We describe here the overproduction and extensive purification of the RegB protein. RegB precisely co-purifies with an activity that cleaves within the sequence GGAG in oligonucleotide and polynucleotide RNAs and is therefore likely to constitute the sequence-specific catalytic component of the observed activity. We further report that the low cleavage rate observed with our preparations of purified RegB is substantially increased (1-2 orders of magnitude) by the addition of E. coli ribosomal protein S1. We discuss the implications of this observation for the mechanism of action of the RegB ribonuclease in vitro and in vivo.	UNIV COLORADO, DEPT MOLEC CELLULAR & DEV BIOL, BOULDER, CO 80309 USA; CNRS, CTR GENET MOLEC, F-91190 GIF SUR YVETTE, FRANCE	University of Colorado System; University of Colorado Boulder; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay					NIGMS NIH HHS [GM-19963, GM-28685] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019963, R01GM028685, R37GM019963] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL JCA, 1989, EMBO J, V8, P3401, DOI 10.1002/j.1460-2075.1989.tb08504.x; BEAR DG, 1976, P NATL ACAD SCI USA, V73, P1824, DOI 10.1073/pnas.73.6.1824; BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; Bremer H., 1987, ESCHERICHIA COLI SAL, V2, P1527, DOI [10.1046/j.1365-2486.2000.06017.x, DOI 10.1046/J.1365-2486.2000.06017.X]; CANNISTRARO VJ, 1986, J MOL BIOL, V192, P257, DOI 10.1016/0022-2836(86)90363-3; DEUTSCHER MP, 1984, P NATL ACAD SCI-BIOL, V81, P4290, DOI 10.1073/pnas.81.14.4290; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; DRAPER DE, 1978, J MOL BIOL, V122, P339; DUBE SK, 1970, NATURE, V226, P820, DOI 10.1038/226820a0; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; EILAM Y, 1971, BIOCHEMISTRY-US, V10, P1489, DOI 10.1021/bi00784a034; GAVRILOVA LP, 1966, J MOL BIOL, V16, P473, DOI 10.1016/S0022-2836(66)80186-9; GESTELAND RF, 1966, J MOL BIOL, V18, P356, DOI 10.1016/S0022-2836(66)80253-X; Higgins CF, 1992, CURR OPIN GENET DEV, V2, P739, DOI 10.1016/S0959-437X(05)80134-0; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; INOUYE H, 1974, EUR J BIOCHEM, V45, P109, DOI 10.1111/j.1432-1033.1974.tb03535.x; JACOB WF, 1987, P NATL ACAD SCI USA, V84, P4757, DOI 10.1073/pnas.84.14.4757; KAMEN R, 1972, EUR J BIOCHEM, V31, P44, DOI 10.1111/j.1432-1033.1972.tb02498.x; Kennell D, 1986, MAXIMIZING GENE EXPR, P101; KING TC, 1987, ESCHERICHIA COLI SAL, P703; LUNDBERG U, 1990, EMBO J, V9, P2731, DOI 10.1002/j.1460-2075.1990.tb07460.x; MACKIE GA, 1991, J BACTERIOL, V173, P2488, DOI 10.1128/jb.173.8.2488-2497.1991; MCPHEETERS DS, 1986, NUCLEIC ACIDS RES, V14, P5813, DOI 10.1093/nar/14.14.5813; MEISSNER PS, 1987, P NATL ACAD SCI USA, V84, P4171, DOI 10.1073/pnas.84.12.4171; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MUDD EA, 1988, EMBO J, V7, P3601, DOI 10.1002/j.1460-2075.1988.tb03238.x; NELSON MA, 1982, MOL GEN GENET, V188, P60, DOI 10.1007/BF00332996; NORMANLY J, 1986, P NATL ACAD SCI USA, V83, P6548, DOI 10.1073/pnas.83.17.6548; PORTIER C, 1987, EMBO J, V6, P2165, DOI 10.1002/j.1460-2075.1987.tb02484.x; REGNIER P, 1991, J MOL BIOL, V217, P283, DOI 10.1016/0022-2836(91)90542-E; RINGQUIST S, 1992, MOL MICROBIOL, V6, P1219, DOI 10.1111/j.1365-2958.1992.tb01561.x; RUCKMAN J, 1989, New Biologist, V1, P54; RUCKMAN JL, 1993, THESIS U COLORADO BO; Sambrook J, 1989, MOL CLONING LABORATO; SANSON B, 1993, J MOL BIOL, V233, P429, DOI 10.1006/jmbi.1993.1522; SCHMEISSNER U, 1984, J MOL BIOL, V176, P39, DOI 10.1016/0022-2836(84)90381-4; SHINEDLING S, 1987, T4 NEWS, V1, P4; SINGER BS, 1991, GENE, V106, P1, DOI 10.1016/0378-1119(91)90558-S; SMITH FL, 1969, COLD SPRING HARB SYM, V34, P91, DOI 10.1101/SQB.1969.034.01.014; STEITZ JA, 1975, P NATL ACAD SCI USA, V72, P4734, DOI 10.1073/pnas.72.12.4734; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUBRAMANIAN AR, 1983, PROG NUCLEIC ACID RE, V28, P101, DOI 10.1016/S0079-6603(08)60085-9; THOMAS JO, 1978, J MOL BIOL, V123, P163, DOI 10.1016/0022-2836(78)90319-4; UZAN M, 1988, P NATL ACAD SCI USA, V85, P8895, DOI 10.1073/pnas.85.23.8895; VALERIE K, 1986, NUCLEIC ACIDS RES, V14, P8637, DOI 10.1093/nar/14.21.8637; VENKATESH TV, 1993, J BACTERIOL, V175, P1844, DOI 10.1128/JB.175.6.1844-1846.1993; WAHBA AJ, 1974, J BIOL CHEM, V249, P3314; Wiberg J. S., 1983, BACTERIOPHAGE T4, P193	49	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26655	26662						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929399				2022-12-27	WOS:A1994PQ93100015
J	SCHULTZCHERRY, S; RIBEIRO, S; GENTRY, L; MURPHYULLRICH, JE				SCHULTZCHERRY, S; RIBEIRO, S; GENTRY, L; MURPHYULLRICH, JE			THROMBOSPONDIN BINDS AND ACTIVATES THE SMALL AND LARGE FORMS OF LATENT TRANSFORMING GROWTH-FACTOR-BETA IN A CHEMICALLY-DEFINED SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; MOLECULAR-WEIGHT COMPLEX; HAMSTER OVARY CELLS; ENDOTHELIAL-CELLS; TGF-BETA; MANNOSE 6-PHOSPHATE; FACTOR-BETA-1 PRECURSOR; HUMAN-PLATELETS; RECOMBINANT; PROLIFERATION	Transforming growth factor-beta (TGF-beta) is a potent growth regulatory protein normally secreted by cells in a latent form. Primary regulation of TGF-beta activity occurs through factors which control the processing of the latent to the biologically active molecule. Thrombospondin (TSP), a platelet alpha-granule and extracellular matrix protein, forms specific complexes with active TGF-beta in platelet releasate and activates endogenous latent TGF-beta secreted by endothelial cells via a cell- and protease-independent mechanism. In order to better understand TSP-mediated activation of cell-secreted latent TGF-beta, we examined the consequences of interactions of the large (platelet-derived) and small (recombinant) forms of latent TGF-beta with TSP in a chemically defined system. Data from these studies show that interactions between TSP and both forms of latent TGF-beta result in the generation of biologically active TGF-beta as assayed by the ability of NRK-49F cells to form colonies in soft agar, by the ability to compete for binding to TGF-beta receptors on endothelial cells, and by an enzyme linked immunosorbent assay selective for the active form of TGF-beta. Activation of latent TGF-beta by TSP stripped of associated TGF-beta activity (sTSP) is time- and concentration-dependent, but temperature-independent. The mechanism whereby sTSP activates latent TGF-beta appears to involve the direct binding of sTSP to the latent molecule as shown by gel permeation chromatography. In addition, a polyclonal antibody specific for the amino-terminal region of the latency-associated peptide (amino acids 81-94) inhibits sTSP-mediated activation of latent TGF-beta in both the chemically defined system and in endothelial cell conditioned medium. These data and the observation that similar concentrations of sTSP activate latent TGF-beta in both the chemically defined system and in the endothelial cell system indicate that there is a common mechanism by which TSP activates the small, large, and endothelial cell-derived latent TGF-beta complexes. The ability of TSP to convert latent TGF-beta to biologically active TGF-beta suggests that TSP is a major regulatory factor in the control of TGF-beta activity.	UNIV ALABAMA, DEPT PATHOL, DIV MOLEC & CELLULAR PATHOL, BIRMINGHAM, AL 35294 USA; MED COLL OHIO, DEPT BIOCHEM & MOLEC BIOL, TOLEDO, OH 43699 USA	University of Alabama System; University of Alabama Birmingham			Schultz-Cherry, Stacey/N-2506-2018		NATIONAL CANCER INSTITUTE [R01CA060848] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044575, R01HL050061] Funding Source: NIH RePORTER; NCI NIH HHS [CA 60848] Funding Source: Medline; NHLBI NIH HHS [HL44575, HL50061] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLENHOFFMANN BL, 1988, MOL CELL BIOL, V8, P4234, DOI 10.1128/MCB.8.10.4234; ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; BAGAVANDOSS P, 1990, BIOCHEM BIOPH RES CO, V170, P867, DOI 10.1016/0006-291X(90)92171-U; BARNARD JA, 1990, BIOCHEM BIOPH RES CO, V163, P56; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; Brownh PD, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037500; BRUNNER AM, 1988, MOL CELL BIOL, V8, P2229, DOI 10.1128/MCB.8.5.2229; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; FLAUMENHAFT R, 1993, J CELL BIOL, V120, P995, DOI 10.1083/jcb.120.4.995; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GENTRY LE, 1987, MOL CELL BIOL, V7, P3418, DOI 10.1128/MCB.7.10.3418; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; HUBER D, 1991, BIOCHEM J, V277, P165, DOI 10.1042/bj2770165; JULLIEN P, 1989, INT J CANCER, V43, P886, DOI 10.1002/ijc.2910430525; KESKIOJA J, 1987, J CELL BIOCHEM, V33, P95, DOI 10.1002/jcb.240330204; KOVACINA KS, 1989, BIOCHEM BIOPH RES CO, V160, P393, DOI 10.1016/0006-291X(89)91669-0; LAHAV J, 1993, BIOCHIM BIOPHYS ACTA, V1182, P1, DOI 10.1016/0925-4439(93)90146-R; MAJACK RA, 1986, P NATL ACAD SCI USA, V83, P9050, DOI 10.1073/pnas.83.23.9050; MASSAGUE J, 1992, CANCER SURV, V12, P81; MILLER DM, 1992, MOL ENDOCRINOL, V6, P694, DOI 10.1210/me.6.5.694; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; MIYAZONO K, 1989, NATURE, V338, P158, DOI 10.1038/338158a0; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MOSHER DF, 1990, ANNU REV MED, V41, P85; MULLER G, 1987, P NATL ACAD SCI USA, V84, P5600, DOI 10.1073/pnas.84.16.5600; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; MURPHYULLRICH JE, 1993, J BIOL CHEM, V268, P26784; OKADA F, 1989, FEBS LETT, V242, P240, DOI 10.1016/0014-5793(89)80477-6; OLOFSSON A, 1992, J BIOL CHEM, V267, P19482; PHAN SH, 1989, BIOCHEM BIOPH RES CO, V163, P56, DOI 10.1016/0006-291X(89)92098-6; PIRCHER R, 1986, BIOCHEM BIOPH RES CO, V136, P30, DOI 10.1016/0006-291X(86)90872-7; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1988, ADV CANCER RES, V51, P107, DOI 10.1016/S0065-230X(08)60221-3; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SATO Y, 1993, J CELL BIOL, V123, P1249, DOI 10.1083/jcb.123.5.1249; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SHA X, 1989, MOL ENDOCRINOL, V3, P1090, DOI 10.1210/mend-3-7-1090; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; VOGEL T, 1993, J CELL BIOCHEM, V53, P74, DOI 10.1002/jcb.240530109; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646	45	243	251	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26775	26782						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929413				2022-12-27	WOS:A1994PQ93100032
J	ARORA, N; WILLIAMSON, LC; LEPPLA, SH; HALPERN, JL				ARORA, N; WILLIAMSON, LC; LEPPLA, SH; HALPERN, JL			CYTOTOXIC EFFECTS OF A CHIMERIC PROTEIN CONSISTING OF TETANUS TOXIN LIGHT-CHAIN AND ANTHRAX TOXIN LETHAL FACTOR IN NONNEURONAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; PROTECTIVE ANTIGEN; NEUROTRANSMITTER RELEASE; ESCHERICHIA-COLI; SPINAL-CORD; INHIBITS EXOCYTOSIS; BOTULINUM TOXINS; HEAVY-CHAIN; CYCLIC-AMP; FUSION	The light chain of tetanus toxin is a zinc endoprotease that inhibits neurotransmitter release by selective proteolysis of the synaptic vesicle-associated protein synaptobrevin/vesicle-associated membrane protein. Cellubrevin is a homologue of synaptobrevin that is found in most cell types and is also a substrate for tetanus toxin. The lack of receptors for tetanus toxin on most cell types has made studies of tetanus toxin action in non-neuronal cells difficult. To characterize tetanus toxin effects in non-neuronal cells, a fusion protein consisting of the 254 amino-terminal amino acids of lethal factor (LF) of anthrax toxin and tetanus toxin light chain (LC) was prepared. This protein (LF-LC) inhibited evoked glycine release from primary spinal cord neurons at concentrations between 1.0 and 100 ng/ml. LF-LC was cytotoxic to RAW 264.7, ANA-1 cells (mouse macrophage cell lines), and Chinese hamster ovary cells in a dose-dependent manner. These effects required the presence of protective antigen, the receptor binding component of anthrax toxin. In contrast, LF-LC was not cytotoxic to RBL-2H3, Vero, or mouse hybridoma cell lines. Mutagenesis of conserved amino acids (His(237) and Glu(234)) in the zinc-binding motif of LC resulted in fusion proteins having no biological activity. LF LC did not inhibit regulated secretion of serotonin in RBL-2H3 cells or constitutive secretion in any non-neuronal cell lines as measured in several different assays. We suggest that the cytotoxic effects of LF-LC result from inhibition of a specific intracellular membrane fusion event mediated by cellubrevin.	US FDA, CTR BIOL EVALUAT & RES, DIV BACTERIAL PROD, BETHESDA, MD 20892 USA; NIDR, MICROBIAL ECOL LAB, BETHESDA, MD 20892 USA; NICHHD, DEV NEUROBIOL LAB, BETHESDA, MD 20892 USA	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								AHNERTHILGER G, 1989, FEBS LETT, V242, P245, DOI 10.1016/0014-5793(89)80478-8; ARORA N, 1993, J BIOL CHEM, V268, P3334; ARORA N, 1992, J BIOL CHEM, V267, P15542; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BITTNER MA, 1989, J NEUROCHEM, V53, P966, DOI 10.1111/j.1471-4159.1989.tb11800.x; CAIN CC, 1992, J BIOL CHEM, V267, P11681; EISEL U, 1986, EMBO J, V5, P2495, DOI 10.1002/j.1460-2075.1986.tb04527.x; EISEL U, 1993, EMBO J, V12, P3365, DOI 10.1002/j.1460-2075.1993.tb06010.x; ESCUYER V, 1991, INFECT IMMUN, V59, P3381, DOI 10.1128/IAI.59.10.3381-3386.1991; EZZELL JW, 1992, J GEN MICROBIOL, V138, P543, DOI 10.1099/00221287-138-3-543; FAIRWEATHER NF, 1986, NUCLEIC ACIDS RES, V14, P7809, DOI 10.1093/nar/14.19.7809; GOTTESMAN S, 1990, METHOD ENZYMOL, V185, P119; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HABIG WH, 1986, J NEUROCHEM, V47, P930; HALPERN JL, 1989, INFECT IMMUN, V57, P18, DOI 10.1128/IAI.57.1.18-22.1989; HANNA PC, 1993, P NATL ACAD SCI USA, V90, P10198, DOI 10.1073/pnas.90.21.10198; HARRISSMITH PW, 1958, J GEN MICROBIOL, V19, P91, DOI 10.1099/00221287-19-1-91; HELTING TB, 1979, J BIOL CHEM, V254, P728; HO JL, 1985, J INFECT DIS, V152, P922, DOI 10.1093/infdis/152.5.922; HOGY B, 1992, TOXICON, V30, P63, DOI 10.1016/0041-0101(92)90502-V; HOHNEZELL B, 1993, FEBS LETT, V336, P175, DOI 10.1016/0014-5793(93)81635-D; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; KENIMER JG, 1983, INFECT IMMUN, V42, P942, DOI 10.1128/IAI.42.3.942-948.1983; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; KLIMPEL KR, 1993, ANN M AM SOC MICROBI; KURAZONO H, 1992, J BIOL CHEM, V267, P14721; Leppla S.H., 1991, SOURCEBOOK BACTERIAL, P277; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; LEPPLA SH, 1988, METHOD ENZYMOL, V165, P103; Leppla SH, 1988, BACTERIAL PROTEIN TO, P111; LINK E, 1993, J BIOL CHEM, V268, P18423; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; LITWACK G, 1955, P SOC EXP BIOL MED, V89, P401; MAEYAMA K, 1988, J IMMUNOL, V140, P3919; MATSUDA M, 1974, BIOCHEM BIOPH RES CO, V57, P1257, DOI 10.1016/0006-291X(74)90831-6; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MOCHIDA S, 1989, FEBS LETT, V253, P47, DOI 10.1016/0014-5793(89)80926-3; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MORRIS NP, 1980, J BIOL CHEM, V255, P6071; NOVAK JM, 1992, J BIOL CHEM, V267, P17186; ODA T, 1993, J BIOL CHEM, V268, P12596; PITZURRA L, 1989, INFECT IMMUN, V57, P2452, DOI 10.1128/IAI.57.8.2452-2456.1989; PITZURRA L, 1993, INFECT IMMUN, V61, P3605, DOI 10.1128/IAI.61.9.3605-3610.1993; RANSOM BR, 1977, J NEUROPHYSIOL, V40, P1132, DOI 10.1152/jn.1977.40.5.1132; ROA M, 1985, J BIOL CHEM, V260, P6827; SANDERS D, 1992, N-S ARCH PHARMACOL, V346, P358; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1992, EMBO J, V11, P3577, DOI 10.1002/j.1460-2075.1992.tb05441.x; SMITH H, 1962, J GEN MICROBIOL, V29, P517, DOI 10.1099/00221287-29-3-517; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STECHER B, 1992, BIOCHEM J, V283, P899, DOI 10.1042/bj2830899; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WILLIAMSON LC, 1992, J NEUROCHEM, V59, P2148; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WRIGHT JF, 1992, J BIOL CHEM, V267, P9053; [No title captured]; [No title captured]	58	47	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26165	26171						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929330				2022-12-27	WOS:A1994PQ93000036
J	CASTEELS, P; ROMAGNOLO, J; CASTLE, M; CASTEELSJOSSON, K; ERDJUMENTBROMAGE, H; TEMPST, P				CASTEELS, P; ROMAGNOLO, J; CASTLE, M; CASTEELSJOSSON, K; ERDJUMENTBROMAGE, H; TEMPST, P			BIODIVERSITY OF APIDAECIN-TYPE PEPTIDE ANTIBIOTICS - PROSPECTS OF MANIPULATING THE ANTIBACTERIAL SPECTRUM AND COMBATING ACQUIRED-RESISTANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HONEYBEE APIS-MELLIFERA; ANTIMICROBIAL ACTIVITY; SALMONELLA-TYPHIMURIUM; SARCOPHAGA-PEREGRINA; PROTEIN; MEMBRANE; ANALOGS; BACTENECINS; DEFENSINS; MAGAININS	Insects have a unique repertoire of peptide antibiotics but, to date, prospects of clinical applications are not clear. Apidaecin, a small peptide isolated from honeybees, inhibits viability of Gram-negative bacteria; lethal activity is near immediate, independent of a conventional ''lytic'' mechanism, and involves stereoselective recognition of target molecules. Here we report structural analysis of 14 naturally occurring apidaecin-type peptides and the existence of evolutionarily conserved (''constant'') regions. By detailed analysis of activities against clinically relevant bacteria, we demonstrate that the diversity of the intervening (''variable'') regions confers specificity to the antibacterial spectrum of each homolog. As a result, apidaecin homolog-based antibiograms (using 16 peptides) differ markedly between bacterial strains, contrasting the most between Yersinia enterocolitica and Campylobacter jejuni. Furthermore, in at least one instance, acquired resistance to apidaecin could be negated by minor substitutions in the variable regions. The delineation in a short peptide of constant and variable regions, responsible for, respectively, general antibacterial capacity and specificity of the antibacterial spectrum, is unprecedented. Taken together, we provide evidence that antibacterial spectra of apidaecin-type peptides can be manipulated, and that, in some cases, resistance can be countered and perhaps prevented. The current findings will guide rational design of second generation peptide antibiotics for clinical trials.	CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Cornell University	CASTEELS, P (corresponding author), MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.			Erdjument-Bromage, Hediye/0000-0003-0224-3594				AGERBERTH B, 1991, EUR J BIOCHEM, V202, P849, DOI 10.1111/j.1432-1033.1991.tb16442.x; AMSTERDAM D, 1991, ANTIBIOTICS LABORATO; ANDREU D, 1985, BIOCHEMISTRY-US, V24, P1683, DOI 10.1021/bi00328a017; BESSALLE R, 1990, FEBS LETT, V274, P151, DOI 10.1016/0014-5793(90)81351-N; Borror DJ, 1981, INTRO STUDY INSECTS; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULET P, 1993, J BIOL CHEM, V268, P14893; CASTEELS P, 1994, BIOCHEM BIOPH RES CO, V199, P339, DOI 10.1006/bbrc.1994.1234; CASTEELS P, 1989, EMBO J, V8, P2387, DOI 10.1002/j.1460-2075.1989.tb08368.x; CASTEELS P, 1990, EUR J BIOCHEM, V187, P381, DOI 10.1111/j.1432-1033.1990.tb15315.x; CASTEELS P, 1993, J BIOL CHEM, V268, P7044; CASTEELS P, 1990, THESIS GHENT STATE U; CASTEELSJOSSON K, 1993, EMBO J, V12, P1569, DOI 10.1002/j.1460-2075.1993.tb05801.x; CHEN HC, 1988, FEBS LETT, V236, P462, DOI 10.1016/0014-5793(88)80077-2; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; CRUCIANI RA, 1991, P NATL ACAD SCI USA, V88, P3792, DOI 10.1073/pnas.88.9.3792; DELORENZO V, 1985, ANTIMICROB AGENTS CH, V27, P666, DOI 10.1128/AAC.27.4.666; ERDJUMENTBROMAG.H, 1993, TECHNIQUES PROTEIN C, V4, P419; FRANK RW, 1990, J BIOL CHEM, V265, P18871; GEROMANOS S, 1994, TECHNIQUES PROTEIN C, V5, P143; HARLOW E, 1988, ANTIBODIES LABORATOR; HENZEL WJ, 1990, ANAL BIOCHEM, V187, P228, DOI 10.1016/0003-2697(90)90448-I; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HOLDEN C, 1989, SCIENCE, V246, P754, DOI 10.1126/science.2814497; Holt J., 1994, BERGEYS MANUAL DETER; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; KEPPI E, 1989, ARCH INSECT BIOCHEM, V10, P229, DOI 10.1002/arch.940100306; KONISKY J, 1982, ANNU REV MICROBIOL, V36, P125, DOI 10.1146/annurev.mi.36.100182.001013; LEE S, 1986, BIOCHIM BIOPHYS ACTA, V862, P211, DOI 10.1016/0005-2736(86)90485-2; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; LI ZQ, 1988, FEBS LETT, V231, P299, DOI 10.1016/0014-5793(88)80837-8; MATSUYAMA K, 1990, J BIOCHEM-TOKYO, V108, P128, DOI 10.1093/oxfordjournals.jbchem.a123151; MILLER SI, 1990, INFECT IMMUN, V58, P3706, DOI 10.1128/IAI.58.11.3706-3710.1990; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; OHTA M, 1992, ANTIMICROB AGENTS CH, V36, P1460, DOI 10.1128/AAC.36.7.1460; OKADA M, 1985, BIOCHEM J, V229, P453, DOI 10.1042/bj2290453; SKERLAVAJ B, 1990, INFECT IMMUN, V58, P3724, DOI 10.1128/IAI.58.11.3724-3730.1990; STEINER H, 1988, BIOCHIM BIOPHYS ACTA, V939, P260, DOI 10.1016/0005-2736(88)90069-7; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; VAARA M, 1981, FEBS LETT, V129, P145, DOI 10.1016/0014-5793(81)80777-6; VILJANEN P, 1988, INFECT IMMUN, V56, P2324, DOI 10.1128/IAI.56.9.2324-2329.1988; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; WESTERHOFF HV, 1989, P NATL ACAD SCI USA, V86, P6597, DOI 10.1073/pnas.86.17.6597	43	78	94	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26107	26115						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929322				2022-12-27	WOS:A1994PQ93000028
J	HANFORD, DS; THUERAUF, DJ; MURRAY, SF; GLEMBOTSKI, CC				HANFORD, DS; THUERAUF, DJ; MURRAY, SF; GLEMBOTSKI, CC			BRAIN NATRIURETIC PEPTIDE IS INDUCED BY ALPHA(1)-ADRENERGIC AGONISTS AS A PRIMARY RESPONSE GENE IN CULTURED RAT CARDIAC MYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ADRENERGIC STIMULATION; MESSENGER-RNA STABILITY; IMMEDIATE-EARLY GENE; C-FOS; VENTRICULAR CARDIOCYTES; RECEPTOR ACTIVATION; ENDOTHELIAL-CELLS; GROWTH-FACTORS; ATRIAL; EXPRESSION	To better understand the molecular basis for increased atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP) expression during overload-induced cardiac hypertrophy, we studied the induction of the genes in primary myocardial cells by the alpha(1)-adrenergic agonist, phenylephrine (PE), a potent hypertrophic agent. PE augmented the transcription of both genes to similar extents, although the time course of mRNA accumulation differed. Increases in ANF mRNA were evident only after 6-8 h of PE exposure, when transcript levels were 2-4-fold over control. However, similar increases in BNP mRNA were observed as soon as 1 h of PE exposure. Moreover, while ANF mRNA levels continued to increase through 24 h of PE treatment, maximal levels of BNP mRNA (8-10-fold over control) were observed at 4 h, after which transcript levels declined to about 3-fold over control. The early induction of the BNP mRNA by PE was independent of protein synthesis, whereas the late induction of both genes required protein synthesis. Interestingly, the early BNP induction was only partially blocked by the transcription inhibitor, actinomycin D, indicating that, in part, the inductive effects of PE might be the result of transcript stabilization. Indeed, the BNP transcript, which was shown to possess a half-life of less than 1 h in control cells, was stabilized by the addition of PE, while the ANF transcript possessed a half-life of at least 24 h under all conditions. These data indicate that the induction of BNP by alpha(1)-adrenergic agonists has characteristics of both a primary and secondary response gene, while ANF is a typical secondary response gene. Moreover, alpha(1)-adrenergic stimulation enhances BNP expression through both transcriptional activation and transcript stabilization, while ANF expression is enhanced primarily transcriptionally.	SAN DIEGO STATE UNIV, DEPT BIOL, SAN DIEGO, CA 92182 USA; SAN DIEGO STATE UNIV, INST MOLEC BIOL, SAN DIEGO, CA 92182 USA	California State University System; San Diego State University; California State University System; San Diego State University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46345] Funding Source: Medline; NINDS NIH HHS [NS-25037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMARA FM, 1993, NUCLEIC ACIDS RES, V21, P4803, DOI 10.1093/nar/21.20.4803; ARGENTIN S, 1991, J BIOL CHEM, V266, P23315; BELASCO J, 1993, CONTROL MRNA STABILI; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; CUI MZ, 1994, ARTERIOSCLER THROMB, V14, P807, DOI 10.1161/01.ATV.14.5.807; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; EMORI T, 1993, ENDOCRINOLOGY, V133, P2474, DOI 10.1210/en.133.6.2474; FALVEY E, 1991, FASEB J, V5, P309, DOI 10.1096/fasebj.5.3.2001790; GARDNER DG, 1988, J CLIN INVEST, V82, P1275, DOI 10.1172/JCI113726; GLEMBOTSKI CC, 1993, J BIOL CHEM, V268, P20646; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HARROLD S, 1991, ANAL BIOCHEM, V198, P19, DOI 10.1016/0003-2697(91)90500-S; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOLT EH, 1994, J NEUROCHEM, V62, P1239; HORIO T, 1993, METABOLISM, V42, P94, DOI 10.1016/0026-0495(93)90178-Q; HUANG LY, 1993, J BIOL CHEM, V268, P25769; HUGHES P, 1993, NEUROSCIENCE, V57, P319, DOI 10.1016/0306-4522(93)90065-N; ITOH H, 1989, BIOCHEM BIOPH RES CO, V161, P732, DOI 10.1016/0006-291X(89)92661-2; ITOH H, 1992, HYPERTENSION, V19, P758, DOI 10.1161/01.HYP.19.6.758; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KANGAWA K, 1984, NATURE, V312, P152, DOI 10.1038/312152a0; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KOHNO M, 1992, AM HEART J, V123, P1382, DOI 10.1016/0002-8703(92)91049-7; KOHNO M, 1992, AM J MED, V92, P29, DOI 10.1016/0002-9343(92)90011-Y; KOHNO M, 1993, AM J PHYSIOL, V265, pE673, DOI 10.1152/ajpendo.1993.265.5.E673; KOJIMA M, 1989, BIOCHEM BIOPH RES CO, V159, P1420, DOI 10.1016/0006-291X(89)92268-7; KOMATSU Y, 1991, ENDOCRINOLOGY, V129, P1104, DOI 10.1210/endo-129-2-1104; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; LAPOINTE MC, 1993, MOL ENDOCRINOL, V7, P1284, DOI 10.1210/me.7.10.1284; LAPOINTE MC, 1990, HYPERTENSION, V15, P20, DOI 10.1161/01.HYP.15.1.20; MANTYMAA P, 1993, ENDOCRINOLOGY, V133, P1470, DOI 10.1210/en.133.3.1470; MCDONOUGH PM, 1992, J BIOL CHEM, V267, P11665; MCDONOUGH PM, 1994, J BIOL CHEM, V269, P9466; MCMAHON SB, 1992, FASEB J, V6, P2707, DOI 10.1096/fasebj.6.9.1612295; MUKOYAMA M, 1991, J CLIN INVEST, V87, P1402, DOI 10.1172/JCI115146; MUKOYAMA M, 1990, NEW ENGL J MED, V323, P757; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PAEK I, 1987, MOL CELL BIOL, V7, P1496, DOI 10.1128/MCB.7.4.1496; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; RUSKOAHO H, 1992, PHARMACOL REV, V44, P479; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHIAVI SC, 1994, J BIOL CHEM, V269, P3441; SCHIAVI SC, 1992, BIOCHIM BIOPHYS ACTA, V1114, P95, DOI 10.1016/0304-419X(92)90009-N; SEHGAL PB, 1978, BIOCHEM PHARMACOL, V27, P2475, DOI 10.1016/0006-2952(78)90313-1; SEI CA, 1991, J BIOL CHEM, V266, P15910; SEIDMAN CE, 1988, P NATL ACAD SCI USA, V85, P4104, DOI 10.1073/pnas.85.11.4104; SEILHAMER JJ, 1989, BIOCHEM BIOPH RES CO, V165, P650, DOI 10.1016/S0006-291X(89)80015-4; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; STEINHELPER ME, 1993, CIRC RES, V72, P984, DOI 10.1161/01.RES.72.5.984; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; SUZUKI E, 1992, CIRC RES, V71, P1039, DOI 10.1161/01.RES.71.5.1039; TAKAHASHI T, 1992, CIRC RES, V71, P9, DOI 10.1161/01.RES.71.1.9; THIBAULT G, 1992, AM J PHYSIOL, V263, pR301, DOI 10.1152/ajpregu.1992.263.2.R301; THUERAUF DJ, 1994, J BIOL CHEM, V269, P17772; YAMAMOTO KR, 1976, ANNU REV BIOCHEM, V45, P721, DOI 10.1146/annurev.bi.45.070176.003445	61	72	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26227	26233						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929338				2022-12-27	WOS:A1994PQ93000046
J	LALONDE, JM; LEVENSON, MA; ROE, JJ; BERNLOHR, DA; BANASZAK, LJ				LALONDE, JM; LEVENSON, MA; ROE, JJ; BERNLOHR, DA; BANASZAK, LJ			ADIPOCYTE LIPID-BINDING PROTEIN COMPLEXED WITH ARACHIDONIC-ACID - TITRATION CALORIMETRY AND X-RAY CRYSTALLOGRAPHIC STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS; PROGRAM	The association of the adipocyte lipid-binding protein (ALBP) with arachidonic acid (all cis, 20:4 Delta(5,8,11,14)) and oleic acid (cis, 18:1 Delta(9)) has been examined by titration calorimentry. In addition, the crystal structure of ALBP with bound arachidonic acid has also been obtained. Crystallographic analysis of the arachidonic acid.ALBP complex along with the previously reported oleic acid-ALBP structure (Xu, Z., Bernlohr, D. A., and Banaszak, L. J. (1993) J. Biol. Chem. 268, 7874-7884) provides a framework for the molecular examination of protein-lipid association. Isothermal titration calorimetry revealed high affinity association of both unsaturated fatty acids with the protein. The calorimetric data yielded the following thermodynamic parameters for arachidonic acid: K-d= 4.4 mu M, n = 0.8, Delta G = -7370 cal/mol, Delta H = -6770 cal/mol, and T Delta S = +600 cal/mol. For oleic acid, the thermodynamic parameters were K-d = 2.4 mu M, n = 0.9, Delta G = -7770 cal/mol, Delta H = -6050 cal/mol, and T Delta S = +1720 cal/mol. The identification of thermodynamically dominating enthalpic factors for both fatty acids are consistent with the crystallographic studies demonstrating the interaction of the fatty acid carboxylate with a combination of Arg(106), Arg(126), and Tyr(128). The crystallographic refinement of the protein-arachidonate complex was carried out to 1.6 Angstrom with the resultant R factor of 0.19. Within the cavity of the crystalline binding protein, the arachidonate was found in a hairpin conformation. The conformation of the bound ligand is consistent with acceptable torsional angles and the four cis double bonds in arachidonate. These results demonstrate that arachidonate is a ligand for ALBP. They provide thermodynamic and structural data concerning the physical basis for protein-lipid interaction and suggest that intracellular lipid-binding proteins may mediate the biological effects of polyunsaturated fatty acids in vivo.	UNIV MINNESOTA,SCH MED,DEPT BIOCHEM,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,COLL BIOL SCI,DEPT BIOCHEM,ST PAUL,MN 55108; UNIV MINNESOTA,COLL BIOL SCI,INST HUMAN GENET,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NIGMS NIH HHS [GM13925] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM013925] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMSSON S, 1962, ACTA CRYSTALLOGR, V15, P1261, DOI 10.1107/S0365110X62003321; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; BUELT MK, 1990, BIOCHEMISTRY-US, V29, P7408, DOI 10.1021/bi00484a008; ERNST J, 1979, Z NATURFORSCH B, V34, P706, DOI 10.1515/znb-1979-0512; HYMAN BT, 1982, BIOCHIM BIOPHYS ACTA, V713, P375, DOI 10.1016/0005-2760(82)90256-9; JAKOBY MG, 1993, BIOCHEMISTRY-US, V32, P872, DOI 10.1021/bi00054a019; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LALONDE JM, 1994, BIOCHEMISTRY-US, V33, P4885, DOI 10.1021/bi00182a017; MEAD JF, 1986, LIPIDS CHEM BIOCH NU, P44; REID T, 1991, J BIOL CHEM, V266, P16580; RICH MR, 1993, BIOCHIM BIOPHYS ACTA, V1178, P87, DOI 10.1016/0167-4889(93)90113-4; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SERRERO G, 1992, ENDOCRINOLOGY, V131, P2545, DOI 10.1210/en.131.6.2545; SHA RS, 1993, J BIOL CHEM, V268, P7885; TEBBEYPW, 1994, J BIOL CHEM, V269, P639; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; XU ZH, 1993, J BIOL CHEM, V268, P7874; XU ZH, 1991, J BIOL CHEM, V266, P14367	20	91	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25339	25347						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929228				2022-12-27	WOS:A1994PQ49100019
J	PEYTON, M; MOSS, LG; TSAI, MJ				PEYTON, M; MOSS, LG; TSAI, MJ			2 DISTINCT CLASS-A HELIX-LOOP-HELIX TRANSCRIPTION FACTORS, E2A AND BETA1, FORM SEPARATE DNA-BINDING COMPLEXES ON THE INSULIN GENE E BOX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE DIFFERENTIATION PROGRAM; CELL-SPECIFIC TRANSCRIPTION; ENHANCER-BINDING; MOLECULAR CHARACTERIZATION; SEX DETERMINATION; CONTROL REGION; MYOGENIN GENE; II GENE; PROTEINS; EXPRESSION	Mutations in the RIPE3a element have shown it to be crucial for efficient tissue-specific expression of the insulin gene. In order to isolate factors binding to this element, we used a labeled RIPE3 probe to screen an expression library derived from a hamster insulinoma cell line. We isolated a clone encoding beta-cell E-box transcriptional activator1 (BETA1). This clone is a member of the class A subfamily of the helix-loop-helix superfamily of transcriptional activators, as determined both by sequence analysis and by functional association with a class B member (myogenin). This clone is related to, but distinct from, other clones isolated from the same library which are also capable of binding RIPE3a. Analysis showed these additional clones to be the hamster homologs of E12 and E47 (German, M. S., Blaner, M. A., Nelson, C., Moss, L. G., and Rutter, W.J (1991) Mol. Endocrinol. 5, 292-299). Antibodies were raised against BETA1 and against a common epitope of E12 and E47 to determine which proteins were contained in the native RIPE3a binding complex. Using these antibodies, we were able to separate the complex into major and minor fractions which contained either E12/47 or BETA1, respectively. Thus, these two gene products are found in separate fractions of the tissue-specific binding activity and are therefore both likely to be important in insulin gene regulation.	BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030	Baylor College of Medicine	PEYTON, M (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.		Peyton, Michael/A-8728-2008		NICHD NIH HHS [HD17379] Funding Source: Medline; NIDDK NIH HHS [DK43129] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017379, R37HD017379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043129] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; ARONHEIM A, 1991, NUCLEIC ACIDS RES, V19, P3893, DOI 10.1093/nar/19.14.3893; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BEGLEY CG, 1992, P NATL ACAD SCI USA, V89, P38, DOI 10.1073/pnas.89.1.38; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; CRONMILLER C, 1988, GENE DEV, V2, P1666, DOI 10.1101/gad.2.12a.1666; CROWE DT, 1989, MOL CELL BIOL, V9, P1784, DOI 10.1128/MCB.9.4.1784; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; GOBEL V, 1992, CELL GROWTH DIFFER, V3, P143; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; HWUNG YP, 1990, MOL CELL BIOL, V10, P1784, DOI 10.1128/MCB.10.4.1784; JAVAUX F, 1991, NUCLEIC ACIDS RES, V19, P1121, DOI 10.1093/nar/19.5.1121; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; KARLSSON O, 1989, MOL CELL BIOL, V9, P823, DOI 10.1128/MCB.9.2.823; KLEIN ES, 1993, GENE DEV, V7, P55, DOI 10.1101/gad.7.1.55; KOZAK M, 1990, NUCLEIC ACIDS RES, V18, P2828, DOI 10.1093/nar/18.9.2828; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LESHKOWITZ D, 1991, MOL CELL BIOL, V11, P1547, DOI 10.1128/MCB.11.3.1547; Maniatis T., 1982, MOL CLONING; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MOSS LG, 1988, MOL CELL BIOL, V8, P2620, DOI 10.1128/MCB.8.6.2620; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; NIELSEN AL, 1992, MOL CELL BIOL, V12, P3449, DOI 10.1128/MCB.12.8.3449; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; OHLSSON H, 1988, P NATL ACAD SCI USA, V85, P4228, DOI 10.1073/pnas.85.12.4228; PARK CW, 1992, J BIOL CHEM, V267, P15642; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RASHBASS J, 1992, EMBO J, V11, P2981, DOI 10.1002/j.1460-2075.1992.tb05368.x; REDDY KJ, 1988, ANAL BIOCHEM, V168, P324, DOI 10.1016/0003-2697(88)90325-9; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SHIEH SY, 1991, J BIOL CHEM, V266, P16708; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; STEINER DF, 1985, ANNU REV GENET, V19, P463, DOI 10.1146/annurev.ge.19.120185.002335; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WALKER MD, 1990, NUCLEIC ACIDS RES, V18, P1159, DOI 10.1093/nar/18.5.1159; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WHELAN J, 1990, MOL CELL BIOL, V10, P1564, DOI 10.1128/MCB.10.4.1564; WIENTRAUB H, 1991, SCIENCE, V251, P761; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; ZHANG Y, 1991, NUCLEIC ACIDS RES, V19, P4555, DOI 10.1093/nar/19.16.4555; ZHUANG Y, 1992, P NATL ACAD SCI USA, V89, P12132, DOI 10.1073/pnas.89.24.12132	66	45	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25936	25941						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929299				2022-12-27	WOS:A1994PQ49100102
J	SONVEAUX, N; CONRATH, K; CAPIAU, C; BRASSEUR, R; GOORMAGHTIGH, E; RUYSSCHAERT, JM				SONVEAUX, N; CONRATH, K; CAPIAU, C; BRASSEUR, R; GOORMAGHTIGH, E; RUYSSCHAERT, JM			THE TOPOLOGY OF THE S-PROTEIN IN THE YEAST-DERIVED HEPATITIS-B SURFACE-ANTIGEN PARTICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REFLECTION INFRARED-SPECTROSCOPY; SECONDARY STRUCTURE; ENVELOPE PROTEINS; VIRUS; ORIENTATION; SEQUENCE; EPITOPES; CARRIER	Hepatitis B surface antigen particles are highly immunogenic and have been shown to provide a suitable support for the presentation of foreign epitopes. More information about the topology of their constitutive protein, the S (small envelope) protein, is a prerequisite to any rational attempt to replace region of this protein with foreign epitopes without modifying the assembly of the particle. The topology of the S protein within the lipid membrane was investigated here by combining extensive proteolysis of the external protein domains with proteinase K and (FTIR-ATR). The proteolytic hydrolysis of the S protein and the identification of the digestion products allowed characterization of the membrane-protected regions of the protein. FTIR spectra of the digested hepatitis B particles revealed that the peptides associated with the particles are rich in cu-helix structure. The kinetic of H-2/H exchange provided evidence that a large fraction of the native S protein is poorly accessible to the aqueous medium.	FREE UNIV BRUSSELS,CHIM PHYS MACROMOLEC INTERFACES LAB,B-1050 BRUSSELS,BELGIUM; SMITHKLINE BEECHAM BIOL,B-1330 RIXENSART,BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel; GlaxoSmithKline				Goormaghtigh, Erik/0000-0002-2071-2262				AGGERBECK LP, 1985, VIROLOGY, V141, P155, DOI 10.1016/0042-6822(85)90192-8; BRUSS V, 1991, P NATL ACAD SCI USA, V88, P1059, DOI 10.1073/pnas.88.3.1059; CABIAUX V, 1989, J BIOL CHEM, V264, P4928; CHALLOU N, 1994, BIOCHEMISTRY-US, V33, P6902, DOI 10.1021/bi00188a020; DELPEYROUX F, 1988, J VIROL, V62, P1836, DOI 10.1128/JVI.62.5.1836-1839.1988; DELPEYROUX F, 1986, SCIENCE, V233, P472, DOI 10.1126/science.2425433; DELPEYROUX F, 1990, J VIROL, V64, P6090, DOI 10.1128/JVI.64.12.6090-6100.1990; DEMEUTTER J, 1989, BIOCHIM BIOPHYS ACTA, V1006, P147; DUMONT ME, 1985, J MEMBRANE BIOL, V88, P233, DOI 10.1007/BF01871088; EBLE BE, 1987, MOL CELL BIOL, V7, P3591, DOI 10.1128/MCB.7.10.3591; EBLE BE, 1986, MOL CELL BIOL, V6, P1454, DOI 10.1128/MCB.6.5.1454; FRINGELI UP, 1981, MEMBRANE SPECTROSCOP, P270; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GOORMAGHTIGH E, 1987, BIOCHEMISTRY-US, V26, P1789, DOI 10.1021/bi00380a043; GOORMAGHTIGH E, 1993, BIOCHEMISTRY-US, V32, P6104, DOI 10.1021/bi00074a023; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; GOORMAGHTIGH E, 1991, EUR J BIOCHEM, V195, P421, DOI 10.1111/j.1432-1033.1991.tb15721.x; GOORMAGHTIGH E, 1990, MOL DESCRIPTION BIOL, P285; Guerrero E., 1988, VIRAL HEPATITIS LIVE, P606; HARFORD N, 1987, POSTGRAD MED J, V63, P65; HAUSER P, 1987, POSTGRAD MED J, V63, P83; HEERMANN KH, 1984, J VIROL, V52, P396, DOI 10.1128/JVI.52.2.396-402.1984; HOWARD CR, 1988, VIRAL HEPATITIS LIVE, P1094; IONESCUMATIU I, 1983, J IMMUNOL, V130, P1947; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCALEER WJ, 1984, NATURE, V307, P178, DOI 10.1038/307178a0; MICHEL ML, 1993, RES VIROLOGY, V144, P263, DOI 10.1016/S0923-2516(06)80038-5; MICHEL ML, 1988, P NATL ACAD SCI USA, V85, P7957, DOI 10.1073/pnas.85.21.7957; PETERSON DL, 1982, J BIOL CHEM, V257, P414; PETERSON DL, 1987, BIOESSAYS, V6, P258, DOI 10.1002/bies.950060604; PETERSON DL, 1981, J BIOL CHEM, V256, P6975; PETRE J, 1987, POSTGRAD MED J, V63, P70; RUTGERS T, 1988, BIO-TECHNOL, V6, P1065, DOI 10.1038/nbt0988-1065; SCHLIENGER K, 1992, J VIROL, V66, P2570, DOI 10.1128/JVI.66.4.2570-2576.1992; STIRK HJ, 1992, INTERVIROLOGY, V33, P148, DOI 10.1159/000150244; SUSI H, 1967, J BIOL CHEM, V242, P5460; TIOLLAIS P, 1984, ADV HEPATITIS RES, P9; UEDA K, 1991, J VIROL, V65, P3521, DOI 10.1128/JVI.65.7.3521-3529.1991; VALENZUELA P, 1982, NATURE, V298, P347, DOI 10.1038/298347a0; VANDEKERCKHOVE J, 1985, EUR J BIOCHEM, V152, P9, DOI 10.1111/j.1432-1033.1985.tb09157.x; VANDENBUSSCHE G, 1992, BIOCHEMISTRY-US, V31, P9169, DOI 10.1021/bi00153a008	41	24	26	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25637	25645						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929267				2022-12-27	WOS:A1994PQ49100063
J	BOMMINENI, VR; CHOWDHURY, NR; WU, GY; WU, CH; FRANKI, N; HAYS, RM; CHOWDHURY, JR				BOMMINENI, VR; CHOWDHURY, NR; WU, GY; WU, CH; FRANKI, N; HAYS, RM; CHOWDHURY, JR			DEPOLYMERIZATION OF HEPATOCELLULAR MICROTUBULES AFTER PARTIAL-HEPATECTOMY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED GENE DELIVERY; RAT HEPATOCYTES; INVIVO; RECEPTOR; TRANSPORT; DYNEIN; LIVER; TRANSLOCATION; PERSISTENCE; ENDOCYTOSIS	Asialoglycoproteins (ASG) are internalized by hepatocytes by ASG receptor (ASGR)-mediated endocytosis. We have shown previously that when a plasmid DNA, pAlb(9-12)CAT (expressing chloramphenicol acetyltransferase driven by an albumin promoter enhancer), was complexed with an ASG-polylysine conjugate and injected intravenously in rats, 80% of the DNA was internalized by the liver. In normal recipient rats, over 95% of the internalized DNA was degraded in 4 h; the plasmid was undetectable after 48 h. In contrast, when 66% hepatectomy was performed 20 min after DNA administration, the internalized DNA persisted for several weeks in cytoplasmic vesicles (Chowdhury, N. R., Wu, C. H., Wu, B. Y., Yerneni, P. C., Bommineni, V.R., and Chowdhury, J. R. (1993) J. Biol. Chem. 268, 11265-11271). Since microtubules are required for the translocation of ligand-containing endosomes to lysosomes, the site of ligand degradation, we hypothesized that persistence of the endocytosed DNA might be related to changes in microtubular structure and function. To test this hypothesis, we examined hepatocellular microtubules by immunofluorescence confocal microscopy. Liver from untreated rats or sham-operated controls showed a network of fibrillar microtubules throughout the cytoplasm. The extent of the microtubular network was substantially reduced 3-6 h after 66% hepatectomy. By 24 h, microtubules had regenerated. Intraportal infusion of cycloheximide (250 mg/kg body weight) 15 min before 66% hepatectomy, prevented microtubular disruption, indicating that protein synthesis is required for this process. Immunotransblot analysis showed that hepatic alpha-tubulin concentration remained unchanged through microtubular disassembly and subsequent reassembly, which is consistent with conservation and reutilization of tubulin released by depolymerization of microtubules.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,MARION BESSIN LIVER RES CTR,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DIV GASTROINTESTINAL & LIVER DIS,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,DIV NEPHROL,BRONX,NY 10461; UNIV CONNECTICUT,CTR HLTH,DEPT MED,DIV GASTROENTEROL,FARMINGTON,CT 06030	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Connecticut					NIDDK NIH HHS [R01-DK 46057, R01-DK 39137] Funding Source: Medline; PHS HHS [R01 03858] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046057, R01DK039137] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN RD, 1985, J CELL BIOL, V100, P1736, DOI 10.1083/jcb.100.5.1736; CASSIMERIS L, 1988, J CELL BIOL, V107, P2223, DOI 10.1083/jcb.107.6.2223; CHOWDHURY NR, 1993, J BIOL CHEM, V268, P11265; COLLINS CA, 1989, CELL MOTIL CYTOSKEL, V14, P491, DOI 10.1002/cm.970140407; GOLTZ JS, 1992, P NATL ACAD SCI USA, V89, P7026, DOI 10.1073/pnas.89.15.7026; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM W, 1990, NATURE, V346, P318; HERMAN B, 1984, J CELL BIOL, V98, P565, DOI 10.1083/jcb.98.2.565; HIROKAWA N, 1989, CELL MOVEMENT KINESI, V2, P383; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; OKA JA, 1983, BIOCHIM BIOPHYS ACTA, V763, P368, DOI 10.1016/0167-4889(83)90098-8; PORTER ME, 1989, ANNU REV CELL BIOL, V5, P119; ROZDZIAL MM, 1986, CELL, V47, P1061, DOI 10.1016/0092-8674(86)90821-4; SCHMID K, 1967, BIOCHEM J, V104, P361, DOI 10.1042/bj1040361; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STOLLMAN YR, 1985, HEPATOLOGY, V5, P798, DOI 10.1002/hep.1840050515; WAYNFORTH HB, 1980, EXPT SURGICAL TECHNI, P137; Weigel P H, 1993, Subcell Biochem, V19, P125; WHITEHEAD PH, 1966, BIOCHIM BIOPHYS ACTA, V124, P209, DOI 10.1016/0304-4165(66)90336-9; WILSON JM, 1992, J BIOL CHEM, V267, P11483; WILSON JM, 1992, J BIOL CHEM, V267, P963; WOLKOFF AW, 1984, J CELL BIOL, V98, P375, DOI 10.1083/jcb.98.2.375; WU CH, 1989, J BIOL CHEM, V264, P16985; WU GY, 1988, J BIOL CHEM, V263, P14621; WU GY, 1991, J BIOL CHEM, V266, P14338	28	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25200	25205						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929209				2022-12-27	WOS:A1994PQ49000100
J	SHAPER, NL; HARDUINLEPERS, A; SHAPER, JH				SHAPER, NL; HARDUINLEPERS, A; SHAPER, JH			MALE GERM-CELL EXPRESSION OF MURINE BETA-4-GALACTOSYLTRANSFERASE - A 796-BASE PAIR GENOMIC REGION, CONTAINING 2 CAMP-RESPONSIVE ELEMENT (CRE)-LIKE ELEMENTS, MEDIATES MALE GERM CELL-SPECIFIC EXPRESSION IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; MESSENGER-RNA; BETA-GALACTOSIDASE; TRANSCRIPTION FACTORS; MOUSE; PROMOTER; GENE; TESTIS; SPERM; BETA-1,4-GALACTOSYLTRANSFERASE	In murine somatic cells, transcription of the single gene encoding beta 4-galactosyltransferase results in two transcripts of 4.1 and 3.9 kilobases (kb), as a consequence of the use of two transcriptional start sites that are located on exon one separated by 200 base pairs (bp). In early male germ cell development, spermatogonia use only the 4.1-kb start site to yield a transcript that is identical to its somatic cell counterpart. As these cells enter meiosis, there is a switch from the use of this somatic cell start site to the exclusive use, beginning in pachytene spermatocytes, of a male germ cell-specific start site. Germ cell specific transcripts are distinguished from their somatic counterparts by an additional similar to 560 nucleotides of 5'-untranslated sequence that is located immediately upstream and contiguous with the transcriptional start site defined for the 4.1-kb mRNA (Harduin-Lepers, A., Shaper, N. L., Mahoney, J. A., and Shaper, J. H. (1992) Glycobiology 2, 361-368). This observation predicts the use of a different upstream male germ cell-specific promoter. In this study we show that a 796-bp fragment containing 543 bp of genomic sequence upstream of the germ cell specific transcriptional start site and 253 bp of flanking downstream sequence, directs expression of the reporter gene, beta-galactosidase, exclusively to the pachytene spermatocytes and round spermatids of transgenic mice. This pattern of cell type-specific expression of the transgene is comparable with that of the endogenous beta 4-galactosyltransferase gene.	JOHNS HOPKINS UNIV,CTR ONCOL,SCH MED,CELL STRUCT & FUNCT LAB,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University			Harduin-Lepers, Anne/O-7503-2017	Harduin-Lepers, Anne/0000-0002-1233-3799	NCI NIH HHS [CA45799] Funding Source: Medline; NICHD NIH HHS [NICHD P30 HD06268-19] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD006268] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA045799] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; BOER PH, 1987, MOL CELL BIOL, V7, P3107, DOI 10.1128/MCB.7.9.3107; BRODBECK U, 1967, J BIOL CHEM, V242, P1391; CHENG A, 1994, CELL BIOL, V125, P867; FIRE A, 1992, GENET ANAL-BIOMOL E, V9, P151, DOI 10.1016/1050-3862(92)90042-4; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; GALCHEVAGARGOVA Z, 1993, MOL ENDOCRINOL, V7, P979, DOI 10.1210/me.7.8.979; GEBARA MM, 1992, MOL CELL BIOL, V12, P1422, DOI 10.1128/MCB.12.4.1422; GHOSH D, 1993, NUCLEIC ACIDS RES, V21, P3117, DOI 10.1093/nar/21.13.3117; HAKE LE, 1993, J BIOL CHEM, V268, P4788; HARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14348; HARDUINLEPERS A, 1992, GLYCOBIOLOGY, V2, P361, DOI 10.1093/glycob/2.4.361; HOGAN B, 1986, MANIPULATING MOUSE E, P174; HOWARD T, 1993, MOL CELL BIOL, V13, P18, DOI 10.1128/MCB.13.1.18; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; IANNELLO RC, 1993, J BIOL CHEM, V268, P22581; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; JOZIASSE DH, 1992, J BIOL CHEM, V267, P5534; LALLI E, 1994, J BIOL CHEM, V269, P17359; LANGFORD KG, 1991, J BIOL CHEM, V266, P15559; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; OKO R, 1993, J CELL BIOL, V123, P809, DOI 10.1083/jcb.123.4.809; QUERALT R, 1993, GENE, V133, P197, DOI 10.1016/0378-1119(93)90638-J; RUSSO RN, 1990, J BIOL CHEM, V265, P3324; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SEARLE PF, 1984, MOL CELL BIOL, V4, P1221, DOI 10.1128/MCB.4.7.1221; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHAPER NL, 1990, P NATL ACAD SCI USA, V87, P791, DOI 10.1073/pnas.87.2.791; SHUR BD, 1982, J CELL BIOL, V95, P567, DOI 10.1083/jcb.95.2.567; TAKAKUBO F, 1992, EXP CELL RES, V199, P39, DOI 10.1016/0014-4827(92)90459-L; TAMURA TA, 1992, J BIOL CHEM, V267, P4327; TERUYA JH, 1990, MOL CELL BIOL, V10, P2315, DOI 10.1128/MCB.10.5.2315; THOREY IS, 1992, DEV DYNAM, V195, P100, DOI 10.1002/aja.1001950204; TOUSSAINT C, 1994, J BIOL CHEM, V269, P13318; VANDERHOORN FA, 1992, P NATL ACAD SCI USA, V89, P703, DOI 10.1073/pnas.89.2.703; WASSARMAN PM, 1988, ANNU REV BIOCHEM, V57, P415, DOI 10.1146/annurev.bi.57.070188.002215; WASSARMAN PM, 1985, COLD SPRING HARB SYM, V50, P11, DOI 10.1101/SQB.1985.050.01.004; WILKIE TM, 1986, DEV BIOL, V118, P9, DOI 10.1016/0012-1606(86)90068-0; YOUNG DC, 1993, ANAL BIOCHEM, V215, P24, DOI 10.1006/abio.1993.1549; ZAMBROWICZ BP, 1994, BIOL REPROD, V50, P65, DOI 10.1095/biolreprod50.1.65; ZAMBROWICZ BP, 1993, P NATL ACAD SCI USA, V90, P5071, DOI 10.1073/pnas.90.11.5071; ZINN SA, 1991, J BIOL CHEM, V266, P23850	44	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25165	25171						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929205				2022-12-27	WOS:A1994PQ49000095
J	TZAHAR, E; LEVKOWITZ, G; KARUNAGARAN, D; YI, L; PELES, E; LAVI, S; CHANG, D; LIU, NL; YAYON, A; WEN, DZ; YARDEN, Y				TZAHAR, E; LEVKOWITZ, G; KARUNAGARAN, D; YI, L; PELES, E; LAVI, S; CHANG, D; LIU, NL; YAYON, A; WEN, DZ; YARDEN, Y			ERBB-3 AND ERBB-4 FUNCTION AS THE RESPECTIVE LOW AND HIGH-AFFINITY RECEPTORS OF ALL NEU DIFFERENTIATION FACTOR HEREGULIN ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; HUMAN-BREAST; MAMMARY-TUMORS; LIGAND; HEREGULIN; PROTEIN; CANCER; MEMBER; FAMILY; HER4/P180(ERBB4)	Neu differentiation factor (NDF or heregulin) elevates tyrosine phosphorylation of the ErbB-2 receptor tyrosine kinase, and it was, therefore, thought to function as a ligand of this receptor. However, several lines of evidence raised the possibility that the interaction between NDF and ErbB-2 involves another molecule, which belongs to the family of epidermal growth factor receptors. To address this question we constructed soluble chimeric proteins between alkaline phosphatase and the extracellular domains of ErbB-2 and either ErbB-3 or ErbB-4, two newly recognized members of the epidermal growth factor receptor family. Using the soluble proteins we found that beta isoforms of NDF specifically bind to the ErbB-3 and ErbB-4 receptors but not to the soluble ErbB-2 protein, When ectopically expressed in monkey fibroblasts, the full-length ErbB-3 and ErbB-4 receptors conferred specific binding to NDF. In these cells ErbB-3 displayed lower ligand binding affinity than ErbB-4, but like the latter receptor it preferred to bind the beta isoform over the alpha class of NDFs. These results indicate that both ErbB-3 and ErbB-4 function as physiological receptors of all NDF isoforms and suggest that a still unknown ligand of ErbB-2 exists.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320	Weizmann Institute of Science; Amgen			Karunagaran, Devarajan/A-8148-2010; YARDEN, YOSEF/K-1467-2012; Levkowitz, Gil/AAB-9441-2019	Karunagaran, Devarajan/0000-0001-9331-8947; Levkowitz, Gil/0000-0002-3896-1881; Peles, Elior/0000-0002-3325-0597				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BACUS SS, 1993, CANCER RES, V53, P5251; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; DIFIORE PP, 1992, EMBO J, V11, P3927, DOI 10.1002/j.1460-2075.1992.tb05486.x; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUANG SS, 1992, J BIOL CHEM, V267, P11508; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LONARDO F, 1990, New Biologist, V2, P992; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; PELES E, 1992, J BIOL CHEM, V267, P12266; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; TARAKHOVSKY A, 1991, ONCOGENE, V6, P2187; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027	31	260	282	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25226	25233						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929212				2022-12-27	WOS:A1994PQ49000104
J	LIU, J; LAUE, TM; CHOI, HU; TANG, LH; ROSENBERG, L				LIU, J; LAUE, TM; CHOI, HU; TANG, LH; ROSENBERG, L			THE SELF-ASSOCIATION OF BIGLYCAN FROM BOVINE ARTICULAR-CARTILAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCANS; MOLECULAR-WEIGHT; I BIGLYCAN; PG-I; DECORIN; FIBRONECTIN; ADHESION; TENDON; FIBROBLASTS; PROTEIN	Biglycan is a small dermatan sulfate proteoglycan present in the extracellular matrix of a variety of connective tissues. Sedimentation velocity and equilibrium studies were carried out to determine the monomer molecular weight of biglycan in denaturing solvents and to define the oligomeric states of biglycan in physiologic solvents in the presence and absence of Zn2+. In 6 M guanidine chloride, biglycan is a monomer with s(20,w)(0) = 2.9 S and M(z) = 93,100 (where M(z) is z-average molecular weight). In 0.15 m NaCl, 50 mM Tris, pH 7.5, in the absence of divalent metal ions, and at concentrations above 1 mg/ml, biglycan is predominantly dimer (s(20,w)(0) = 4.8 S). Under these same conditions in solvent containing 5 mM Zn2+, biglycan exists predominantly as a hexamer, with s(20,w)(0) = 9.4 S and M(z) approximate to 600,000. In either case, the oligomers dissociate reversibly. In order to determine whether the glycosaminoglycan chains or the core protein was responsible for self-association, sedimentation velocity and sedimentation equilibrium studies were conducted on the isolated components. Dermatan sulfate chains prepared from biglycan, examined in both denaturing and physiologic solvents, show no significant difference in molecular weight (M(z) approximate to 22,000), whether or not the solvents contain Zn2+. However, biglycan core protein strongly self-associated in physiologic solvents. Thus, the self-association of biglycan appears to be mediated by the core protein and not by its glycosaminoglycan chains.	UNIV NEW HAMPSHIRE,DEPT BIOCHEM & MOLEC BIOL,DURHAM,NH 03824; MONTEFIORE MED CTR,ORTHOPAED RES LAB,BRONX,NY 10467	University System Of New Hampshire; University of New Hampshire; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine			Laue, Tom/AAI-5136-2020	Laue, Tom/0000-0003-3571-9368	NIAMS NIH HHS [AR21498, AR34614] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR034614, R37AR021498] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARAKAWA T, 1987, J BIOL CHEM, V262, P7484; BIDANSET DJ, 1992, J CELL BIOL, V118, P1523, DOI 10.1083/jcb.118.6.1523; CANN JR, 1970, INTERACTING MACROMOL, P93; CHOI HU, 1989, J BIOL CHEM, V264, P2876; COSTER L, 1987, J BIOL CHEM, V262, P3809; DURSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; FISHER LW, 1989, J BIOL CHEM, V264, P4571; JARVELAINEN HT, 1991, J BIOL CHEM, V266, P23274; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KAWAHARA K, 1966, J BIOL CHEM, V241, P3228; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Laue T. M., 1992, ANAL ULTRACENTRIFUGA, P63; LAUE TM, 1994, PROG COLL POL SCI S, V94, P74; LAUE TM, 1992, SHORT COLUMN EQUILIB; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; LIU J, 1993, THESIS U NEW HAMPSHI; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; PERLMANN GE, 1948, J AM CHEM SOC, V70, P2719, DOI 10.1021/ja01188a027; ROARK DE, 1969, ANN NY ACAD SCI, V164, P245, DOI 10.1111/j.1749-6632.1969.tb14043.x; ROSENBERG L, 1993, DERMATAN SULPHATE PR, P225; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; SCOTT PG, 1989, MATRIX, V9, P284, DOI 10.1016/S0934-8832(89)80004-6; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; VOGEL KG, 1986, J BIOL CHEM, V261, P1334; VOGEL KG, 1985, J BIOL CHEM, V260, P9298; VOGEL KG, 1987, J BIOL CHEM, V262, P13607; WASTESON A, 1971, BIOCHEM J, V122, P477, DOI 10.1042/bj1220477; WHINNA HC, 1993, J BIOL CHEM, V268, P3920; WINNEMOLLER M, 1991, EUR J CELL BIOL, V54, P10; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YPHANTIS DA, 1960, ANN NY ACAD SCI, V88, P586, DOI 10.1111/j.1749-6632.1960.tb20055.x	32	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28366	28373						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961776				2022-12-27	WOS:A1994PV77200088
J	MCMASTER, CR; BELL, RM				MCMASTER, CR; BELL, RM			PHOSPHATIDYLCHOLINE BIOSYNTHESIS IN SACCHAROMYCES-CEREVISIAE - REGULATORY INSIGHTS FROM STUDIES EMPLOYING NULL AND CHIMERIC SN-1,2-DIACYLGLYCEROL CHOLINEPHOSPHOTRANSFERASE AND ETHANOLAMINEPHOSPHOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODING CHOLINEPHOSPHATE CYTIDYLYLTRANSFERASE; DEPENDENT PROTEIN-KINASE; CROSS-PATHWAY REGULATION; EPT1 GENE-PRODUCTS; PHOSPHOLIPID BIOSYNTHESIS; PHOSPHATIDYLSERINE DECARBOXYLASE; COORDINATE REGULATION; ESCHERICHIA-COLI; PHOSPHATIDYLETHANOLAMINE METHYLTRANSFERASE; NUCLEOTIDE-SEQUENCE	The Saccharomyces cerevisiae CPT1 and EPT1 genes encode distinct choline- and choline/ethanolamine-phosphotransferases, respectively. In vitro, each gene product accounts for 50% of the measurable cholinephosphotransferase activity. Strains containing null mutations in the CPT1 and EPT1 loci were used to investigate the function of each gene product in vivo. The CPT1 gene product was responsible for 95% of phosphatidylcholine (PC) synthesis via the CDP-choline pathway in vivo. The EPT1 gene product accounted for only 5% of PC synthesis in vivo. Chimeric CPT1/EPT1 enzymes with diacylglycerol and CDP-aminoalcohol specificities both similar and distinct from the parental enzymes were used to determine the specific segments of the CPT1/EPT1 gene products required to restore PC synthesis to cpt(-) cells in vivo. Only chimeras expressing the CDP-aminoalcohol specificity region of CPT1 were capable of PC synthesis via the CDP-choline pathway in vivo. Analysis of phospholipids extracted from wild type, cpt(-), and ept(-) cells labeled with P-32(i) indicated an intact CPT1 gene product was required for the pleiotropic regulation of phospholipid synthesis by inositol. Chimeric CPT1/EPT1 enzymes expressed in a cpt(-) background mapped the regulatory region of the CPT1 gene product required for the inositol-dependent regulation of phospholipid synthesis to the CDP-aminoalcohol binding domain of CPT1. Strains harboring dysfunctional cholinephosphotransferase enzymes also displayed decreased levels of choline uptake, suggesting that a feedback loop exists to coordinate choline uptake with ongoing PC biosynthesis. The data also implicate the CPT1 gene product in PC biosynthesis from an endogenous source of choline derived from turnover of PC via the phosphatidylserine-dependent route for PC synthesis.	DUKE UNIV, MED CTR, DEPT MOLEC CANC BIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University; Duke University				McMaster, Christopher/0000-0003-0822-5776	NIGMS NIH HHS [GM20015] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020015] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; AMES BN, 1960, J BIOL CHEM, V235, P769; BAILIS AM, 1992, NUCLEIC ACIDS RES, V20, P1411, DOI 10.1093/nar/20.6.1411; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CARSON MA, 1984, J BIOL CHEM, V259, P6267; CLANCEY CJ, 1993, J BIOL CHEM, V268, P24580; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; EXTON JH, 1990, J BIOL CHEM, V265, P1; GAYNOR PM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P326, DOI 10.1016/0167-4781(91)90197-T; Henry S. A., 1982, MOL BIOL YEAST SACCH, P101; HJELMSTAD RH, 1988, J BIOL CHEM, V263, P19748; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P4357; HJELMSTAD RH, 1994, J BIOL CHEM, V269, P20995; HJELMSTAD RH, 1987, J BIOL CHEM, V262, P3909; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P5094; HJELMSTAD RH, 1990, J BIOL CHEM, V265, P1755; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; HOMANN MJ, 1987, J BACTERIOL, V169, P3276, DOI 10.1128/jb.169.7.3276-3280.1987; HOSAKA K, 1981, EUR J BIOCHEM, V116, P1, DOI 10.1111/j.1432-1033.1981.tb05292.x; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; HOSAKA K, 1992, J BIOCHEM-TOKYO, V111, P352, DOI 10.1093/oxfordjournals.jbchem.a123761; HOSAKA K, 1987, EUR J BIOCHEM, V162, P7, DOI 10.1111/j.1432-1033.1987.tb10533.x; HOSAKA K, 1980, J BACTERIOL, V143, P176, DOI 10.1128/JB.143.1.176-181.1980; HOSHIZAKI DK, 1990, J BIOL CHEM, V265, P4736; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KINNEY AJ, 1990, J BACTERIOL, V172, P1133, DOI 10.1128/jb.172.2.1133-1136.1990; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; LAMPING E, 1991, J BACTERIOL, V173, P6432, DOI 10.1128/jb.173.20.6432-6437.1991; LETTS VA, 1985, J BACTERIOL, V163, P560, DOI 10.1128/JB.163.2.560-567.1985; LOEWY BS, 1984, MOL CELL BIOL, V4, P2479, DOI 10.1128/MCB.4.11.2479; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGRAW P, 1989, GENETICS, V122, P317; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; NIKAWA J, 1990, J BIOL CHEM, V265, P15996; NIKAWA J, 1983, EUR J BIOCHEM, V131, P223, DOI 10.1111/j.1432-1033.1983.tb07253.x; NIKAWA JI, 1986, J BACTERIOL, V166, P328, DOI 10.1128/jb.166.1.328-330.1986; NIKOLOFF DM, 1991, ANNU REV GENET, V25, P559; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; POOLE MA, 1986, J BACTERIOL, V168, P668, DOI 10.1128/jb.168.2.668-672.1986; QUINLAN JJ, 1992, J BIOL CHEM, V267, P18013; SUMMERS EF, 1988, GENETICS, V120, P909; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; TSUKAGOSHI Y, 1987, EUR J BIOCHEM, V169, P477, DOI 10.1111/j.1432-1033.1987.tb13635.x; TSUKAGOSHI Y, 1991, J BACTERIOL, V173, P2134, DOI 10.1128/jb.173.6.2134-2136.1991; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P33; White DA, 1973, FORM FUNCTION PHOSPH, P441; WHITE MJ, 1991, ADV MICROB PHYSIOL, V32, P1, DOI 10.1016/S0065-2911(08)60004-1; WHITE MJ, 1991, J BIOL CHEM, V266, P863; YAMASHITA S, 1980, EUR J BIOCHEM, V104, P611, DOI 10.1111/j.1432-1033.1980.tb04465.x; YAMASHITA S, 1982, EUR J BIOCHEM, V128, P589; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	55	66	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28010	28016						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961735				2022-12-27	WOS:A1994PV77200039
J	SAPRU, MK; ZHOU, GC; GOLDMAN, D				SAPRU, MK; ZHOU, GC; GOLDMAN, D			PROTEIN-TYROSINE PHOSPHATASES SPECIFICALLY REGULATE MUSCLE ADULT-TYPE NICOTINIC ACETYLCHOLINE-RECEPTOR GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SUBUNIT MESSENGER-RNA; ALPHA-SUBUNIT; ELECTRICAL-ACTIVITY; SKELETAL-MUSCLE; GAMMA-SUBUNIT; REPORTER GENE; KINASE-C; PROMOTER; TRANSCRIPTION; PHOSPHORYLATION	Innervation of skeletal muscles results in expression of adult-type nicotinic acetylcholine receptors (alpha(2) beta epsilon delta) beneath the neuromuscular junction. This local expression is largely a result of selective induction of adult-type nicotinic acetylcholine receptor (nAChR) genes in endplate-associated myonuclei. The molecular mechanism by which the nerve induces gene expression in these nuclei is not known. We have shown previously that ionophore-induced calcium influx across the plasma membrane preferentially decreases expression from the adult-type specific nAChR epsilon-subunit gene (Walke, W, Staple, J., Adams, L., Gnegy, M., Chahine, K., and Goldman, D. (1994) J. Biol. Chem. 269, 19447-19456). Here we provide evidence that the genes encoding adult-type nAChRs are specifically regulated by protein-tyrosine phosphatase activity. Orthovanadate, a specific protein-tyrosine phosphatase inhibitor, caused increased expression of the epsilon-subunit gene in rat primary myotubes and was able to completely block the suppressive effects of increased calcium influx on epsilon-suibunit RNA expression. Overexpression of protein-tyrosine phosphatases selectively decreased expression from the adult-type nAChR genes with no effect on the embryonic-type specific gamma-subunit gene. These results demonstrate that protein-tyrosine phosphatases regulate mammalian adult-type nAChR gene expression and suggest a mechanism by which muscle innervation selectively regulates gene expression in endplate-associated myonuclei.	UNIV MICHIGAN,MENTAL HLTH RES INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan								BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRENNER HR, 1990, NATURE, V344, P544, DOI 10.1038/344544a0; CHAHINE KG, 1993, J BIOL CHEM, V268, P2893; CHAHINE KG, 1992, DEVELOPMENT, V115, P213; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CORFAS G, 1993, P NATL ACAD SCI USA, V90, P1624, DOI 10.1073/pnas.90.4.1624; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GILMOUR BP, 1991, J BIOL CHEM, V266, P19871; GOLDMAN D, 1988, NEURON, V1, P329, DOI 10.1016/0896-6273(88)90081-5; GOLDMAN D, 1989, NEURON, V3, P219, DOI 10.1016/0896-6273(89)90035-4; HALL ZW, 1993, NEURON S, V10, P99; HUANG CF, 1992, NEURON, V9, P671, DOI 10.1016/0896-6273(92)90030-H; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KLARSFELD A, 1985, P NATL ACAD SCI USA, V82, P4558, DOI 10.1073/pnas.82.13.4558; KLARSFELD A, 1989, NEURON, V2, P1229, DOI 10.1016/0896-6273(89)90307-3; KWAK SP, 1994, J BIOL CHEM, V269, P3596; LAU KHW, 1989, BIOCHEM J, V257, P23, DOI 10.1042/bj2570023; LAUFER R, 1991, EUR J BIOCHEM, V202, P813, DOI 10.1111/j.1432-1033.1991.tb16437.x; MARTINOU JC, 1991, P NATL ACAD SCI USA, V88, P7669, DOI 10.1073/pnas.88.17.7669; MERLIE JP, 1989, NEURON, V2, P1295, DOI 10.1016/0896-6273(89)90067-6; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MISHRA S, 1993, BIOCHEM BIOPH RES CO, V191, P1066, DOI 10.1006/bbrc.1993.1325; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; PERIASAMY M, 1984, J BIOL CHEM, V259, P3595; SACCOMANNO CF, 1992, BIOTECHNIQUES, V13, P847; SANES JR, 1991, DEVELOPMENT, V113, P1181; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SIMON AM, 1992, DEVELOPMENT, V114, P545; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; THOMSEN DR, 1984, P NATL ACAD SCI-BIOL, V81, P659, DOI 10.1073/pnas.81.3.659; TONKS NK, 1988, J BIOL CHEM, V263, P6731; USDIN TB, 1986, J CELL BIOL, V103, P493, DOI 10.1083/jcb.103.2.493; WALKE W, 1994, J BIOL CHEM, V269, P19447; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	41	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27811	27814						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961707				2022-12-27	WOS:A1994PV77200008
J	MORDENTE, A; SANTINI, SA; MIGGIANO, GAD; MARTORANA, GE; PETITTI, T; MINOTTI, G; GIARDINA, B				MORDENTE, A; SANTINI, SA; MIGGIANO, GAD; MARTORANA, GE; PETITTI, T; MINOTTI, G; GIARDINA, B			THE INTERACTION OF SHORT-CHAIN COENZYME-Q ANALOGS WITH DIFFERENT REDOX STATES OF MYOGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTENTIAL PROTECTIVE MECHANISM; VITAMIN-E; LIPID-PEROXIDATION; FERRYL-MYOGLOBIN; REPERFUSION INJURY; UBIQUINOL HOMOLOGS; MOLECULAR-OXYGEN; RAT-HEART; TROLOX-C; REDUCTION	Two equivalent oxidation of metmyoglobin (Mb(III)) by hydrogen peroxide (H2O2) yields an oxoferryl moiety (Mb(IV)) plus a protein radical which presumably originates from the conversion of tyrosines to tyrosyl radicals (.Mb(IV)). In the absence of electron donors, Mb(III) oxidation is followed by (i) heme degradation or (ii) tyrosyl radical-dependent reactions, such as irreversible dimerization or covalent binding of the heme group to the apoprotein. Moreover, the oxidizing equivalents of H2O2-activated Mb(III) promote the peroxidative decomposition of polyunsaturated fatty acids. In this study, water soluble short chain coenzyme Q analogs (CoQ(1)H(2) and CoQ(2)H(2)) were found to reduce the oxoferryl moiety, preventing heme degradation and regenerating Mb(III) and, more slowly, Mb(II)O(2). CoQ(1)H(2) and CoQ(2)H(2) were also found to reduce tyrosyl radicals generated by UV irradiation of tyrosine solutions. Accordingly, CoQ(1)H(2) and CoQ(2)H(2) effectively prevented tyrosyl radical-dependent reactions such as the dimerization of sperm whale myoglobin and heme-apoprotein covalent binding in horse heart myoglobin. By competing for the oxidizing equivalents of hypervalent myoglobin, CoQ(1)H(2) and CoQ(2)H(2) also prevented the peroxidation of arachidonic acid. Collectively, these studies suggest that the proposed function of coenzyme Q as a naturally occurring antioxidant might well relate to its ability of reducing H2O2-activated myoglobin. Coenzyme Q should therefore mitigate cardiac or muscular dysfunctions that are caused by an abnormal generation of H2O2.	UNIV CATTOLICA SACRO CUORE, SCH MED, INST PHARMACOL, I-00168 ROME, ITALY; UNIV CATTOLICA SACRO CUORE, SCH MED, INST CHEM & CLIN CHEM, I-00168 ROME, ITALY	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	MORDENTE, A (corresponding author), UNIV CATTOLICA SACRO CUORE, SCH MED, INST BIOL CHEM, LARGO F VITO 1, I-00168 ROME, ITALY.		Petitti, Tommasangelo/J-5023-2012; Mordente, Alvaro/AAB-7290-2019; Petitti, Tommasangelo/AAN-1884-2021	Petitti, Tommasangelo/0000-0002-5585-9475; Minotti, Giorgio/0000-0002-5678-6175; MORDENTE, Alvaro/0000-0003-3260-9796				ABERG F, 1992, ARCH BIOCHEM BIOPHYS, V295, P230, DOI 10.1016/0003-9861(92)90511-T; ARDUINI A, 1992, FREE RADICAL BIO MED, V13, P449, DOI 10.1016/0891-5849(92)90185-J; ARDUINI A, 1990, ARCH BIOCHEM BIOPHYS, V281, P41, DOI 10.1016/0003-9861(90)90410-Z; ARDUINI A, 1990, FREE RADICAL BIO MED, V9, P511, DOI 10.1016/0891-5849(90)90130-B; Ascoli F, 1981, Methods Enzymol, V76, P72; BENDAHAN D, 1992, NEUROLOGY, V42, P1203, DOI 10.1212/WNL.42.6.1203; BEYER RE, 1990, FREE RADICAL BIO MED, V8, P545, DOI 10.1016/0891-5849(90)90154-B; Buege J A, 1978, Methods Enzymol, V52, P302; CATALANO CE, 1989, J BIOL CHEM, V264, P10534; EDDY L, 1990, AM J PHYSIOL, V259, pC995, DOI 10.1152/ajpcell.1990.259.6.C995; FORSMARK P, 1991, FEBS LETT, V285, P39, DOI 10.1016/0014-5793(91)80720-N; GALARIS D, 1989, ARCH BIOCHEM BIOPHYS, V273, P497, DOI 10.1016/0003-9861(89)90509-2; GALARIS D, 1989, BIOCHEM BIOPH RES CO, V160, P1162, DOI 10.1016/S0006-291X(89)80125-1; GALARIS D, 1989, FREE RADICAL BIO MED, V6, P473, DOI 10.1016/0891-5849(89)90039-7; GIULIVI C, 1992, ARCH BIOCHEM BIOPHYS, V299, P302, DOI 10.1016/0003-9861(92)90279-6; GIULIVI C, 1993, ARCH BIOCHEM BIOPHYS, V303, P152, DOI 10.1006/abbi.1993.1266; GREENBERG SM, 1988, MED CLIN N AM, V72, P243, DOI 10.1016/S0025-7125(16)30792-1; GRISHAM M B, 1985, Journal of Free Radicals in Biology and Medicine, V1, P227, DOI 10.1016/0748-5514(85)90122-9; HOLLER TP, 1989, ANAL BIOCHEM, V180, P326, DOI 10.1016/0003-2697(89)90440-5; INGOLD KU, 1993, P NATL ACAD SCI USA, V90, P45, DOI 10.1073/pnas.90.1.45; JANIG GR, 1984, BIOCHIM BIOPHYS ACTA, V787, P8, DOI 10.1016/0167-4838(84)90102-X; KAGAN VE, 1990, FREE RADICAL BIO MED, V9, P117, DOI 10.1016/0891-5849(90)90114-X; KANNER J, 1985, ARCH BIOCHEM BIOPHYS, V237, P314, DOI 10.1016/0003-9861(85)90282-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDI L, 1991, FREE RADICAL RES COM, V14, P1, DOI 10.3109/10715769109088935; LENAZ G, 1992, BIOCHEM CELL BIOL, V70, P504, DOI 10.1139/o92-078; MATSUSHIMA T, 1992, J THORAC CARDIOV SUR, V103, P945; MINOTTI G, 1993, CHEM RES TOXICOL, V6, P134, DOI 10.1021/tx00032a001; MITSOS SE, 1988, LAB INVEST, V59, P824; MORDENTE A, 1992, BIOCHIM BIOPHYS ACTA, V1100, P235, DOI 10.1016/0167-4838(92)90477-U; MORDENTE A, 1993, CLIN INVESTIGATOR, V71, pS92; MUKAI K, 1992, J BIOL CHEM, V267, P22277; NOHL H, 1992, FREE RADICAL RES COM, V16, P409, DOI 10.3109/10715769209049191; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; RADI R, 1991, J BIOL CHEM, V266, P22028; Rieske J. S., 1967, METHOD ENZYMOL, V10, P239; ROMERO FJ, 1992, J BIOL CHEM, V267, P1680; RYAN TP, 1992, CRIT REV TOXICOL, V22, P119, DOI 10.3109/10408449209146308; SHIMOMURA Y, 1991, BIOCHEM BIOPH RES CO, V176, P349, DOI 10.1016/0006-291X(91)90931-V; STOCKER R, 1993, BIOCHIM BIOPHYS ACTA, V1158, P15, DOI 10.1016/0304-4165(93)90090-U; TAKAHASHI T, 1993, LIPIDS, V28, P803, DOI 10.1007/BF02536234; TEW D, 1988, J BIOL CHEM, V263, P17880; TURNER JJO, 1991, BIOCHEM J, V277, P833, DOI 10.1042/bj2770833; TURRENS JF, 1982, ARCH BIOCHEM BIOPHYS, V217, P411, DOI 10.1016/0003-9861(82)90519-7; WAZAWA T, 1992, BIOPHYS J, V63, P544, DOI 10.1016/S0006-3495(92)81608-9; WU F, 1994, BBA-MOL BASIS DIS, V1225, P158, DOI 10.1016/0925-4439(94)90073-6; YU L, 1986, BIOCHIM BIOPHYS ACTA, V848, P305, DOI 10.1016/0005-2728(86)90204-5	47	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27394	27400						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961650				2022-12-27	WOS:A1994PV77100040
J	NASSAR, GM; MORROW, JD; ROBERTS, LJ; LAKKIS, FG; BADR, KF				NASSAR, GM; MORROW, JD; ROBERTS, LJ; LAKKIS, FG; BADR, KF			INDUCTION OF 15-LIPOXYGENASE BY INTERLEUKIN-13 IN HUMAN BLOOD MONOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RETICULOCYTE LIPOXYGENASE; ATHEROSCLEROTIC LESIONS; CYTOKINE PRODUCTION; GENE-EXPRESSION; MESSENGER-RNA; CELL FUNCTION; ACID; MACROPHAGES; OXYGENATION	15-lipoxygenase (15-LO) catalyzes hydroperoxidation of fatty acids, a reaction of potential relevance to inflammation, membrane remodeling, and atherosclerosis. In human leukocytes, 15-lipoxygenation of arachidonic acid produces 15-(S)hydroxyeicosatetraenoic acid and lipoxin A4, which suppress white cell chemotaxis, adherence, and activation, and antagonize proinflammatory leukotrienes. Interleukin (IL)-13, produced by T-helper subset 2 (TH-2) lymphocytes, specifically and potently induced 15-LO gene expression and enzyme activity in human monocytes. Among other TH-2 lymphokines, this induction of 15-LO is shared by IL-4 but not by IL-10. Interferon-gamma, a product of TH-1 lymphocytes, blocked IL-13-mediated induction of 15-LO. The induction of the anti-inflammatory 15-LO pathway by IL-13 reveals a new facet of IL-13 biology that supports its role as a cytokine with potential to down-regulate inflammatory pathways. The contrasting effects of interferon-gamma and IL-13 on 15-LO induction demonstrate mechanisms by which T-lymphocyte subsets may modulate macrophage/monocyte function in inflammation or atherosclerosis.	EMORY UNIV,DEPT MED,DIV RENAL,ATLANTA,GA 30033; VET AFFAIRS MED CTR,ATLANTA,GA 30033; VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232	Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Vanderbilt University; Vanderbilt University			Nassar, George/T-2400-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043883] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK43883] Funding Source: Medline; NIGMS NIH HHS [GM15431] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADR KF, 1992, J AM SOC NEPHROL, V3, P907; BADR KF, 1992, KIDNEY INT, V42, pS101; BREZINSKI ME, 1990, P NATL ACAD SCI USA, V87, P6248, DOI 10.1073/pnas.87.16.6248; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLOTTA F, 1994, J BIOL CHEM, V269, P12403; CONARD DJ, 1992, P NATL ACAD SCI USA, V89, P217; DWORSKI R, 1994, AM J RESP CRIT CARE, V149, P953, DOI 10.1164/ajrccm.149.4.8143061; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FISHER DB, 1992, KIDNEY INT, V41, P1155; FITCH FW, 1993, ANNU REV IMMUNOL, V11, P29, DOI 10.1146/annurev.immunol.11.1.29; FORDHUTCHINSON AW, 1991, EICOSANOIDS, V4, P65; KATOH T, 1994, KIDNEY INT, V46, P341, DOI 10.1038/ki.1994.280; KLAUSNER JM, 1990, CANCER-AM CANCER SOC, V66, P2357, DOI 10.1002/1097-0142(19901201)66:11<2357::AID-CNCR2820661118>3.0.CO;2-J; KUHN H, 1990, J BIOL CHEM, V265, P18351; LAKKIS FG, 1993, BIOCHEM BIOPH RES CO, V197, P612, DOI 10.1006/bbrc.1993.2523; LEGRAND AB, 1991, J BIOL CHEM, V266, P7570; LEVY BD, 1993, J CLIN INVEST, V92, P1572, DOI 10.1172/JCI116738; MALEFYT RD, 1993, J IMMUNOL, V151, P6370; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MESLIER N, 1992, AM J RESP CELL MOL, V6, P93, DOI 10.1165/ajrcmb/6.1.93; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MURRAY JJ, 1988, ARCH BIOCHEM BIOPHYS, V265, P514, DOI 10.1016/0003-9861(88)90156-7; NIGMAN S, 1990, J CELL PHYSL, V143, P512; Papayianni A., 1993, Journal of the American Society of Nephrology, V4, P627; POWRIE F, 1993, IMMUNOL TODAY, V14, P270, DOI 10.1016/0167-5699(93)90044-L; RAPOPORT SM, 1986, BIOCHIM BIOPHYS ACTA, V864, P471, DOI 10.1016/0304-4157(86)90006-7; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SERHAN CN, 1994, BBA-LIPID LIPID MET, V1212, P1, DOI 10.1016/0005-2760(94)90185-6; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V157, P457, DOI 10.1016/S0006-291X(88)80271-7; SIGAL E, 1990, J BIOL CHEM, V265, P5113; SPARROW CP, 1988, J LIPID RES, V29, P745; WONG HL, 1993, J EXP MED, V177, P775, DOI 10.1084/jem.177.3.775; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959	36	206	209	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27631	27634						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961680				2022-12-27	WOS:A1994PV77100073
J	STOVER, DR; LIEBETANZ, J; LYDON, NB				STOVER, DR; LIEBETANZ, J; LYDON, NB			CDC2-MEDIATED MODULATION OF PP60(C-SRC) ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TRANSFORMING PROTEIN; EXPRESS HIGH-LEVELS; C-SRC; TYROSINE PHOSPHORYLATION; GENE-PRODUCT; KINASE-C; PP60C-SRC; ACTIVATION; MITOSIS; SITES	Following complete dephosphorylation, purified p60(c-src) was rephosphorylated with Csk. The Csk-phosphorylated form was isolated and found to be essentially inactive. Both the dephosphorylated p60(c-src) (Src A) and the inactive, phosphorylated pp60(c-src) (Src B) were then used to explore the regulatory role of other kinases and phosphatases. Phosphorylation by Cdc2 partially reactivated Csk-inactivated pp60(c-src). This reactivation occurred in the absence of Tyr-527 dephosphorylation. Moreover, phosphorylation of Csk-treated pp60(c-src) by Cdc2 also facilitated complete reactivation by the protein-tyrosine phosphatase CD45 or by a synthetic phosphopeptide corresponding to the C-terminal, regulatory phosphorylation site (Tyr-527). These data indicate that the Src homology 2 domain of Csk-phosphorylated pp60(c-scr) was more accessible for intermolecular interactions and that Tyr-527 was more readily dephosphorylated after treatment with Cdc2. In conjunction with in vivo studies, these data suggest that Cdc2 is involved in the regulation of pp60(c-src) during mitosis.			STOVER, DR (corresponding author), CIBA GEIGY AG,DEPT RES,DIV PHARMACEUT,K125420,CH-4002 BASEL,SWITZERLAND.							BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BAGRODIA S, 1994, J BIOL CHEM, V269, P10247; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COLLETT MS, 1979, P NATL ACAD SCI USA, V76, P3159, DOI 10.1073/pnas.76.7.3159; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COUSSENS PM, 1985, MOL CELL BIOL, V5, P2753, DOI 10.1128/MCB.5.10.2753; CROSS FR, 1984, MOL CELL BIOL, V4, P1824; DRUCKER BJ, 1989, NEW ENGL J MED, V321, P1383; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAECH S, 1993, ONCOGENE, V8, P575; KARESS RE, 1981, CELL, V24, P155, DOI 10.1016/0092-8674(81)90511-0; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2567; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LYDON NB, 1992, BIOCHEM J, V287, P985, DOI 10.1042/bj2870985; MOYERS JS, 1993, MOL CELL BIOL, V13, P2391, DOI 10.1128/MCB.13.4.2391; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; SHENOY S, 1992, P NATL ACAD SCI USA, V89, P7237, DOI 10.1073/pnas.89.15.7237; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; STOVER DR, 1993, TECHNIQUES PROTEIN C, V4, P193; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633	28	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26885	26889						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929427				2022-12-27	WOS:A1994PQ93100048
J	CUERVO, AM; TERLECKY, SR; DICE, JF; KNECHT, E				CUERVO, AM; TERLECKY, SR; DICE, JF; KNECHT, E			SELECTIVE BINDING AND UPTAKE OF RIBONUCLEASE-A AND GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE BY ISOLATED RAT-LIVER LYSOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; PROTEIN TRANSLOCATION; AUTOPHAGIC VACUOLE; PRECURSOR PROTEIN; DEGRADATION; MITOCHONDRIA; IMPORT; PROTEOLYSIS; MECHANISMS; MEMBRANE	Ribonuclease A (RNase A) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) are selectively taken up and degraded by isolated rat liver lysosomes by very similar processes. The uptake and degradation of both of these proteins are stimulated by the heat shock cognate protein of 73 kDa and ATP/Mg2+. Both binding and uptake of RNase A and GAPDH by lysosomes are saturable, and uptake of RNase A and GAPDH requires a protease-sensitive component within the lysosomal membrane. GAPDH competes for binding and uptake of RNase A by lysosomes and vice versa while another protein, ovalbumin, does not compete. RNase S-peptide (amino acids 1-20 of RNase A) also competes for RNase A binding and uptake by lysosomes, while RNase S-protein (amino acids 21-124 of RNase A) does not compete. The uptake of RNase A by lysosomes appears to involve an intermediate step in which approximately 2 kDa of the polypeptide's COOH terminus remains outside lysosomes while the remainder is inside the lysosomal lumen.	FDN VALENCIANA INVEST BIOMED,INST INVEST CITOL,E-46010 VALENCIA,SPAIN; TUFTS UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02111	Tufts University			Knecht, Erwin/K-2432-2014; Knecht, Erwin/A-9366-2014	Knecht, Erwin/0000-0002-7208-3832; Cuervo, Ana Maria/0000-0002-0771-700X	NIA NIH HHS [AG06116] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG006116, R37AG006116] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHLBERG J, 1982, LAB INVEST, V47, P523; ANIENTO F, 1993, J BIOL CHEM, V268, P10463; BACKER JM, 1983, P NATL ACAD SCI-BIOL, V80, P2166, DOI 10.1073/pnas.80.8.2166; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; BUEHNER M, 1974, J MOL BIOL, V90, P25, DOI 10.1016/0022-2836(74)90254-X; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; DETER RL, 1971, J CELL BIOL, V48, P473, DOI 10.1083/jcb.48.3.473; Dice J F, 1990, Semin Cell Biol, V1, P449; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; DICE JF, 1987, FASEB J, V1, P349, DOI 10.1096/fasebj.1.5.2824267; DOHERTY FJ, 1989, BIOCHEM J, V263, P47, DOI 10.1042/bj2630047; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935; HARE JF, 1990, BIOCHIM BIOPHYS ACTA, V1031, P71, DOI 10.1016/0304-4157(90)90003-U; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; KOPITZ J, 1990, J CELL BIOL, V111, P941, DOI 10.1083/jcb.111.3.941; Marzella L, 1987, LYSOSOMES THEIR ROLE, P319; MORIMOTO T, 1983, METHOD ENZYMOL, V97, P408; MORTIMORE GE, 1987, ANNU REV NUTR, V7, P539, DOI 10.1146/annurev.nu.07.070187.002543; MORTIMORE GE, 1989, DIABETES METAB REV, V5, P49, DOI 10.1002/dmr.5610050105; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; PAK YK, 1990, J BIOL CHEM, V265, P14298; Pfeifer U., 1987, LYSOSOMES THEIR ROLE, P3; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; SCHATZ G, 1993, PROTEIN SCI, V2, P141; Seglen P O, 1990, Semin Cell Biol, V1, P441; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; TERLECKY SR, 1993, J BIOL CHEM, V268, P23490; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; UENO T, 1991, J BIOL CHEM, V266, P18995; VARGAS JL, 1990, EUR J BIOCHEM, V188, P99, DOI 10.1111/j.1432-1033.1990.tb15376.x; VESTWEBER D, 1988, J CELL BIOL, V107, P2037, DOI 10.1083/jcb.107.6.2037; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229	35	107	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26374	26380						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929357				2022-12-27	WOS:A1994PQ93000067
J	HUANG, S; FORTUNE, KP; WANK, SA; KOPIN, AS; GARDNER, JD				HUANG, S; FORTUNE, KP; WANK, SA; KOPIN, AS; GARDNER, JD			MULTIPLE AFFINITY STATES OF DIFFERENT CHOLECYSTOKININ RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; FUNCTIONAL EXPRESSION; GASTRIN RECEPTOR; ANTAGONIST RADIOLIGAND; MOLECULAR-CLONING; PARIETAL-CELLS; CCK; BINDING; BRAIN; L365,260	We transfected COS cells with cDNA for rat cholecystokinin-A (CCK-A) and different CCK-B receptors and measured binding of I-125-CCK-8, [H-3]L-364,718 and [H-3]L-365,260 to characterize the different affinity states for each type of CCH receptor. Rat CCK-A and CCK-B receptors, canine CCK-B receptors and canine mutant CCK-B (M-CCK-B) receptors in which the leucine in position 355 was replaced by valine each existed in three differ ent affinity states for CCK-8, high affinity, low affinity, and very ion: affinity. In rat CCK-A and probably CCK-B receptors, most were in the very low affinity state, whereas with canine CCK-B and M-CCK-B receptors, most were in the low affinity state. Studies with CCK receptor agonists, CCK-8, gastrin, and CCK-JMV-180, in conjunction with CCK receptor antagonists, L-364,718 and L-365,260, showed a different pattern of affinities for these ligands at the different CCK receptors. Thus, each transfected CCK receptor can exist in three different affinity states for CCK-8 and has a characteristic pattern of interaction with different ligands. This ability to exist in multiple affinity states is an intrinsic property of the CCK receptor molecule itself.	ST LOUIS UNIV,HLTH SCI CTR,DEPT INTERNAL MED,ST LOUIS,MO 63104; NIDDK,DIGEST DIS BRANCH,BETHESDA,MD 20892; TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV GASTROENTEROL,BOSTON,MA 02111; TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,CTR GASTROENTEROL RES ABSORPY,BOSTON,MA 02111; TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,CTR SECRETORY PROC DIGEST DIS,BOSTON,MA 02111	Saint Louis University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University					NHLBI NIH HHS [HL23632] Funding Source: Medline; NIEHS NIH HHS [ES00210] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; CHANG RSL, 1989, MOL PHARMACOL, V35, P803; CHANG RSL, 1986, MOL PHARMACOL, V30, P212; HUANG SC, 1989, AM J PHYSIOL, V257, pG169, DOI 10.1152/ajpgi.1989.257.1.G169; JENSEN RT, 1989, TRENDS PHARMACOL SCI, V10, P418, DOI 10.1016/0165-6147(89)90192-2; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; LEE YM, 1993, J BIOL CHEM, V268, P8164; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PISEGNA JR, 1992, BIOCHEM BIOPH RES CO, V189, P296, DOI 10.1016/0006-291X(92)91557-7; PRESTI ME, 1993, AM J PHYSIOL, V264, pG399, DOI 10.1152/ajpgi.1993.264.3.G399; ROCHE S, 1991, AM J PHYSIOL, V260, pG182, DOI 10.1152/ajpgi.1991.260.2.G182; SOLL AH, 1984, J CLIN INVEST, V73, P1434, DOI 10.1172/JCI111348; TALKAD VD, 1994, P NATL ACAD SCI USA, V91, P1868, DOI 10.1073/pnas.91.5.1868; TALKAD VD, 1994, IN PRESS BIOCH BIOPH; VINAYEK R, 1993, BIOCHIM BIOPHYS ACTA, V1176, P183, DOI 10.1016/0167-4889(93)90195-U; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; WANK SA, 1992, P NATL ACAD SCI USA, V89, P8691, DOI 10.1073/pnas.89.18.8691; YU DH, 1987, AM J PHYSIOL, V253, pG793, DOI 10.1152/ajpgi.1987.253.6.G793	19	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26121	26126						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929324				2022-12-27	WOS:A1994PQ93000030
J	VALCARCE, C; HOLMGREN, A; STENFLO, J				VALCARCE, C; HOLMGREN, A; STENFLO, J			CALCIUM-DEPENDENT INTERACTION BETWEEN GAMMA-CARBOXYGLUTAMIC ACID-CONTAINING AND N-TERMINAL EPIDERMAL GROWTH FACTOR-LIKE MODULES IN FACTOR-X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FACTOR-IX; BOVINE FACTOR-X; BLOOD-COAGULATION FACTOR; EGF-LIKE DOMAIN; STUART FACTOR; CONTAINING REGION; BINDING-SITE; CA2+ BINDING; LIGHT CHAIN; FACTOR-VA	The N-terminal epidermal growth factor (EGF)-like module in factor X binds a single ca(2+) with low affinity (K-d = 2.2 mM). When it is linked to the gamma-carboxyglutamic acid (Gla)-containing module, however, the affinity increases approximately 20-fold (K-d = 120 mu M), indicating an interaction between the two modules and making the site in the N-terminal EGF-like module essentially saturated at physiological Ca2+ concentrations. We have now used the thioredoxin system to probe Ca2+-induced conformational changes and interaction between modules in the light chain of factor X. Thioredoxin, in conjunction with thioredoxin reductase and NADPH, allows direct measurements of the rate and extent of disulfide bond reduction. Most disulfide bonds accessible to the reducing agent were found to be located in the light chain of the protein. Moreover, those disulfide bonds that were resistant to reduction by thioredoxin in the presence of Ca2+, but were readily reduced in the absence of the metal ion, were located in the N-terminal EGF-like module and in the Gla module, whereas disulfide bonds in the C-terminal EGF-like module appeared to be equally accessible whether Ca2+ was present or not. Comparison of the rate of disulfide bond reduction in the isolated modules with that in mixtures of modules indicated that a Ca2+-dependent interaction occurred between the Gla and the N-terminal EGF-like module. This interaction was mediated by the C-terminal alpha-helical part of the Gla module. The affinity between the modules was low and could not be determined accurately owing to competing equilibria, presumably Ca2+ dependent aggregation of the isolated Gla module. By comparing the rates of disulfide bond reduction in Gla module containing fragments before and after decarboxylation of Gla, we could demonstrate that Ca2+ binding to sites in the Gla module as well as to the single site in the EGF-like module contribute to the interaction between the two modules.	LUND UNIV,MALMO GEN HOSP,DEPT CLIN CHEM,S-21401 MALMO,SWEDEN; KAROLINSKA INST,MED NOBEL INST BIOCHEM,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN	Lund University; Karolinska Institutet								BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; BARON M, 1992, PROTEIN SCI, V1, P81; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; ENFIELD DL, 1980, BIOCHEMISTRY-US, V19, P659, DOI 10.1021/bi00545a009; FUJIKAWA K, 1972, BIOCHEMISTRY-US, V11, P4882, DOI 10.1021/bi00776a002; FUNG MR, 1984, NUCLEIC ACIDS RES, V12, P4481, DOI 10.1093/nar/12.11.4481; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GIANNELLI F, 1993, NUCLEIC ACIDS RES, V21, P3075, DOI 10.1093/nar/21.13.3075; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HANDFORD PA, 1991, NATUREJ, V351, P84; HARLOS K, 1987, NATURE, V330, P82, DOI 10.1038/330082a0; HENRIKSEN RA, 1975, ARCH BIOCHEM BIOPHYS, V170, P149, DOI 10.1016/0003-9861(75)90106-X; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; HOLMGREN A, 1984, METHOD ENZYMOL, V107, P295; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; JACKSON CM, 1972, BIOCHEMISTRY-US, V11, P4873, DOI 10.1021/bi00776a001; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; LIN SW, 1990, J BIOL CHEM, V265, P144; MANN KG, 1990, BLOOD, V76, P1; MEDVED LV, 1994, BIOCHEMISTRY-US, V33, P478, DOI 10.1021/bi00168a012; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PERSSON E, 1991, J BIOL CHEM, V266, P2444; PERSSON E, 1993, J BIOL CHEM, V268, P22531; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SAVIDGE G, 1979, THROMB RES, V16, P587, DOI 10.1016/0049-3848(79)90204-4; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; STENFLO J, 1976, J BIOL CHEM, V251, P355; Stenflo J., 1994, MOL BASIS BLOOD DIS, P565; SUGO T, 1986, J BIOL CHEM, V261, P5116; SUGO T, 1984, J BIOL CHEM, V259, P5705; TITANI K, 1975, P NATL ACAD SCI USA, V72, P3082, DOI 10.1073/pnas.72.8.3082; VALCARCE C, 1993, J BIOL CHEM, V268, P26673; VALCARCE C, 1994, METHDOS ENZYMOL, V222, P416; VYSOTCHIN A, 1993, J BIOL CHEM, V268, P8436; [No title captured]	39	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26011	26016						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929311				2022-12-27	WOS:A1994PQ93000015
J	TOURNIER, JM; POLETTE, M; HINNRASKY, J; BECK, J; WERB, Z; BASBAUM, C				TOURNIER, JM; POLETTE, M; HINNRASKY, J; BECK, J; WERB, Z; BASBAUM, C			EXPRESSION OF GELATINASE-A, A MEDIATOR OF EXTRACELLULAR-MATRIX REMODELING, BY TRACHEAL GLAND SEROUS CELLS IN CULTURE AND IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; IV COLLAGENASE; TISSUE INHIBITOR; MONOCLONAL-ANTIBODIES; MAMMARY-GLAND; METALLOPROTEINASES; PROTEIN; DEGRADATION; PROGELATINASE; LOCALIZATION	Tracheal gland morphogenesis and gland hypertrophy in disease involve the penetration of epithelial cells into the submucosa, a process that requires digestion of the basal lamina and the surrounding extracellular matrix. We observed that bovine tracheal gland cells invaded collagen substrates and were inhibited from doing so in the presence of a metalloproteinase inhibitor GM6001. The gland cells, but not bovine tracheal surface epithelial cells, secreted a 72-kDa metalloproteinase. The purified enzyme could be activated with 4-aminophenylmercuric acetate and converted to an active 65-kDa form that was far more effective in degrading denatured collagen (gelatin) than nondenatured type I and IV collagens and was ineffective in degrading intact interstitial collagen fibers. At 25 degrees C, the initial rate of degradation of acid-solubilized type I collagen was approximately 50 mg of type I collagen cleaved per min per mg of enzyme, whereas acid-solubilized type IV collagen was degraded at approximately 250 mg cleaved per min per mg of enzyme. In contrast, at the same temperature, heat-denatured type I collagen was degraded 1000-fold more rapidly, while heat-denatured type IV collagen was cleaved 50-fold more rapidly, The activity of the enzyme was maximal at pH 7-8 and was completely abolished by the metalloproteinase inhibitors EDTA and 1,10-phenanthroline. In immunoblots, the enzyme was recognized by an antibody directed against human gelatinase A, the 72-kDa gelatinase. The purified enzyme disrupted the distribution pattern of type IV collagen in the gland basal lamina, as well as of interstitial collagen in the underlying stromal tissue, as shown in tissue sections by immunocytochemistry. Using an antibody directed against the purified enzyme, we also showed by immunocytochemistry that the gelatinase was present in tracheal tissue and was specifically located at the periphery of some tracheal gland acini. Northern blots showed higher concentrations of gelatinase A mRNA in glands than in epithelium microdissected from adult cow tracheas, These data indicate that gelatinase A is a specialized product of the tracheal gland epithelial cell, a cell type normally invasive as part of its developmental program; the enzyme may play an important role in normal gland development and disease-associated hypertrophy.	UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,RADIOBIOL & ENVIRONM HLTH LAB,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; INSERM,U314,F-51092 REIMS,FRANCE	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Institut National de la Sante et de la Recherche Medicale (Inserm)			POLETTE, Myriam/P-5147-2016; Tournier, Jean-Marie/P-5667-2016	POLETTE, Myriam/0000-0001-8173-3246	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010306] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43762, HL24136] Funding Source: Medline; NIDCR NIH HHS [DE10306] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BASBAUM CB, 1981, CELL TISSUE RES, V220, P481, DOI 10.1007/BF00216752; BENALI R, 1993, AM J PHYSIOL, V8, pL183; BIRKEDALHANSEN H, 1987, METHOD ENZYMOL, V144, P140; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BOWES D, 1977, THORAX, V32, P163, DOI 10.1136/thx.32.2.163; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHER U., 1961, THORAX, V16, P219, DOI 10.1136/thx.16.3.219; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CRAIG FM, 1991, BIOCHIM BIOPHYS ACTA, V1074, P243, DOI 10.1016/0304-4165(91)90159-E; CURRY VA, 1992, BIOCHEM J, V285, P143, DOI 10.1042/bj2850143; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; FINKBEINER WE, 1988, AM J PATHOL, V131, P290; FINKBEINER WE, 1986, IN VITRO CELL DEV B, V22, P561, DOI 10.1007/BF02623514; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; HOYHTYA M, 1988, FEBS LETT, V233, P109, DOI 10.1016/0014-5793(88)81365-6; INFELD MD, 1993, AM J RESP CELL MOL, V8, P69, DOI 10.1165/ajrcmb/8.1.69; JACQUOT J, 1990, FEBS LETT, V269, P65, DOI 10.1016/0014-5793(90)81119-9; JEFFERY PK, 1992, EUR RESPIR J, V5, P93; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB D, 1969, BRIT MED J, V1, P33, DOI 10.1136/bmj.1.5635.33; LEFEBVRE O, 1992, J CELL BIOL, V119, P997, DOI 10.1083/jcb.119.4.997; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; LIM M, 1993, PEDIATR PULM S, V9, P183; MACKAY AR, 1990, CANCER RES, V50, P5997; MACKAY AR, 1990, J BIOL CHEM, V265, P21929; MCDONNELL S, 1990, CANCER METAST REV, V9, P305; MEYRICK B, 1977, MUCUS HLTH DISEASE, V2, P61; MOLL UM, 1990, CANCER RES, V50, P6162; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; NAGASE H, 1991, BIOCHEM SOC T, V19, P715, DOI 10.1042/bst0190715; NILES R, 1988, IN VITRO CELL DEV B, V24, P457; OVERALL C, 1991, J CELL BIOL, V115, P139; PETERKOFSKY B, 1982, METHOD ENZYMOL, V82, P453; REID L, 1963, BRIT J EXP PATHOL, V44, P437; REID LM, 1954, LANCET, V1, P275; ROMANIC AM, 1994, J CELL BIOL, V125, P1165, DOI 10.1083/jcb.125.5.1165; SALONEN J, 1991, MATRIX, V11, P43, DOI 10.1016/S0934-8832(11)80226-X; SCHULTZ GS, 1992, INVEST OPHTH VIS SCI, V33, P3325; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; TALHOUK RS, 1991, DEVELOPMENT, V112, P439; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TOS M, 1968, Anatomischer Anzeiger, V123, P376; TOURNIER JM, 1992, AM J RESP CELL MOL, V6, P461, DOI 10.1165/ajrcmb/6.5.461; TOURNIER JM, 1990, AM REV RESPIR DIS, V141, P1280, DOI 10.1164/ajrccm/141.5_Pt_1.1280; TOURNIER JM, 1991, AM REV RESPIR DIS, V143, P403; WERB Z, 1975, BIOCHEM J, V151, P645, DOI 10.1042/bj1510645; WERB Z, 1993, TXB RHEUMATOLOGY, P248; WU R, 1985, J CELL PHYSIOL, V125, P167, DOI 10.1002/jcp.1041250202	52	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25454	25464						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929245				2022-12-27	WOS:A1994PQ49100038
J	IIDA, N; LOKESHWAR, VB; BOURGUIGNON, LYW				IIDA, N; LOKESHWAR, VB; BOURGUIGNON, LYW			MAPPING THE FODRIN BINDING DOMAIN IN CD45, A LEUKOCYTE MEMBRANE-ASSOCIATED TYROSINE PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMON ANTIGEN CD45; T-CELL RECEPTOR; SIGNAL TRANSDUCTION; HUMAN-PLACENTA; MESSENGER-RNA; BRAIN FODRIN; PROTEIN; KINASE; FAMILY; PHOSPHORYLATION	CD45 belongs to a family of high molecular mass leukocyte glycoproteins. It contains both an intrinsic protein tyrosine phosphatase (PTPase) activity and a cytoskeleton binding site in its cytoplasmic domain. Certain cytoskeletal proteins, such as fodrin (a spectrin like molecule), are known to play an important role in the regulation of CD45's PTPase activity. In this study we mapped the fodrin binding domain of CD45 by deleting various portions of the cytoplasmic region, followed by the expression of these truncated cDNAs using an in vitro transcription/translation system. The results of these experiments indicate that the CD45 fodrin binding domain resides between amino acids 825 and 939. Construction of a fusion protein encoding the region between amino acids 825 and 939 shows that this particular sequence itself is sufficient for fodrin binding. Further analyses indicate that the sequence ((930)EENKKKNRN(939)S) in CD45 has good sequence homology with the spectrin binding domain found in the MSP1 glycoprotein of the malarial parasite. Biochemical studies, using binding competition assays, and a synthetic peptide containing the sequence (930)EENKKKNRN(939)S, support the conclusion that the sequence between amino acids 930 and 939 is a critical part of CD45's fodrin binding domain. Further analyses indicate that this sequence is also involved in the fodrin-induced up-regulation of CD45 PTPase activity. Therefore, we suggest that fodrin binding to this domain is required for the onset of CD45-mediated signal transduction and leukocyte activation.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT R124,MIAMI,FL 33101	University of Miami					NCI NIH HHS [1F32CA06057] Funding Source: Medline; NIGMS NIH HHS [GM 36353] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036353] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKBAR AN, 1988, J IMMUNOL, V140, P2171; BARCLAY AN, 1987, EMBO J, V6, P1259, DOI 10.1002/j.1460-2075.1987.tb02362.x; BENNETT V, 1983, METHOD ENZYMOL, V96, P314; BEVERLEY PCL, 1992, BIOCHEM SOC T, V20, P184, DOI 10.1042/bst0200184; BOTTOMLY K, 1989, EUR J IMMUNOL, V19, P617, DOI 10.1002/eji.1830190407; BOURGUIGNON LYW, 1985, J CELL BIOL, V101, P477, DOI 10.1083/jcb.101.2.477; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; GLENNEY JR, 1982, J BIOL CHEM, V257, P9781; GLENNEY JR, 1982, P NATL ACAD SCI-BIOL, V79, P4002, DOI 10.1073/pnas.79.13.4002; GLENNY JR, 1980, CELL, V28, P843; HALL LR, 1988, J IMMUNOL, V141, P2781; HERRERA S, 1993, EMBO J, V12, P1607, DOI 10.1002/j.1460-2075.1993.tb05805.x; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; JOHNSON NA, 1989, J BIOL CHEM, V264, P6220; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KANNER SB, 1992, BIOCHEM SOC T, V20, P178, DOI 10.1042/bst0200178; KORETZKY GA, 1992, J IMMUNOL, V149, P1138; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P21551; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; MASEN D, 1992, BIOCHEM SOC T, V20, P188; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MORIMOTO C, 1985, J IMMUNOL, V134, P1508; MUSTELIN T, 1990, ONCOGENE, V5, P809; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OSTERGAARD HL, 1991, SCIENCE, V253, P1423, DOI 10.1126/science.1654595; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; POT DA, 1992, J BIOL CHEM, V267, P140; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; RUDD CE, 1987, J EXP MED, V166, P1758, DOI 10.1084/jem.166.6.1758; SAGA Y, 1990, IMMUNOGENETICS, V31, P296, DOI 10.1007/BF02115003; SAITO H, 1992, BIOCHEM SOC T, V20, P165, DOI 10.1042/bst0200165; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; SUCHARD SJ, 1987, BIOCHIM BIOPHYS ACTA, V896, P35, DOI 10.1016/0005-2736(87)90353-1; TAN XH, 1993, J BIOL CHEM, V268, P6835; THOMAS ML, 1987, P NATL ACAD SCI USA, V84, P5360, DOI 10.1073/pnas.84.15.5360; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; VALAREVIC S, 1993, SCIENCE, V260, P541	49	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28576	28583						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961804				2022-12-27	WOS:A1994PU16800013
J	NUSSENZVEIG, DR; THAW, CN; GERSHENGORN, MC				NUSSENZVEIG, DR; THAW, CN; GERSHENGORN, MC			INHIBITION OF INOSITOL PHOSPHATE 2ND MESSENGER FORMATION BY INTRACELLULAR LOOP ONE OF A HUMAN CALCITONIN RECEPTOR - EXPRESSION AND MUTATIONAL ANALYSIS OF SYNTHETIC RECEPTOR GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; SIGNAL-TRANSDUCTION; ADENYLYL CYCLASE; BOVINE RHODOPSIN; CLONING; CELLS; CDNA; CALCIUM; SYSTEMS; GROWTH	Receptors for calcitonin (CTRs) have been cloned from several species, and two isoforms have been found to be expressed in human tissue. One human CTR isoform (hCTR-1) contains a 16-amino acid insertion in its first intracellular (I1) loop that is not present in porcine CTR (pCTR), rat CTR, or the other human CTR (hCTR-2). To facilitate the study of CTRs by mutational analysis, we have constructed synthetic hCTR-1 and hCTR-2 genes. Activation of hCTR-1 expressed transiently in COS-I cells stimulates the formation of cAMP but not of inositol phosphates (IPs) whereas pCTR, a chimeric CTR in which the I1 loop of pCTR was substituted for the I1 loop of hCTR-1, and hCTR-2 stimulate cAMP and IP formation. A series of chimeric CTRs in which intracellular loops 1, 2, and 3 and the carboxyl tail of pCTR were substituted individually or in combination for those of hCTR-1 were constructed. All chimeras stimulated cAMP formation whereas chimeras containing the I1 loop of hCTR-1 with its Is-amino acid insertion were incapable of stimulating IP formation. There was no correlation between maximal stimulation of cAMP and IP formation by these CTRs. Thus, an inserted sequence in the I1 loop of hCTR-1 abolishes stimulation of the IP signal transduction pathway while allowing stimulation of the cAMP pathway.	CORNELL UNIV,COLL MED,DEPT MED,DIV MOLEC MED,NEW YORK,NY 10021; NEW YORK HOSP,NEW YORK,NY 10021	Cornell University; NewYork-Presbyterian Hospital					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046652] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 46652, DK 07313] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BLACK J, 1989, SCIENCE, V245, P486, DOI 10.1126/science.2569237; BRENNERGATI L, 1988, J CLIN INVEST, V82, P1144, DOI 10.1172/JCI113672; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; CONCHON S, 1994, BIOCHEM BIOPH RES CO, V199, P1347, DOI 10.1006/bbrc.1994.1379; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FORCE T, 1992, AM J PHYSIOL, V262, pF1110, DOI 10.1152/ajprenal.1992.262.6.F1110; FRENDO JL, 1994, FEBS LETT, V342, P214, DOI 10.1016/0014-5793(94)80503-2; GORN AH, 1992, J CLIN INVEST, V90, P1726, DOI 10.1172/JCI116046; IMAI A, 1987, METHOD ENZYMOL, V141, P100; KHORANA HG, 1979, SCIENCE, V203, P614, DOI 10.1126/science.366749; KOSUGI S, 1994, FEBS LETT, V341, P162, DOI 10.1016/0014-5793(94)80449-4; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; MCCUAIG KA, 1994, P NATL ACAD SCI USA, V91, P5051, DOI 10.1073/pnas.91.11.5051; NODA K, 1994, J BIOL CHEM, V269, P6743; PRESNELL SR, 1988, NUCLEIC ACIDS RES, V16, P1693, DOI 10.1093/nar/16.5.1693; SAKMAR TP, 1988, NUCLEIC ACIDS RES, V16, P6361, DOI 10.1093/nar/16.14.6361; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; Sambrook J, 1989, MOL CLONING LABORATO; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; SEXTON PM, 1993, MOL ENDOCRINOL, V7, P815, DOI 10.1210/me.7.6.815; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; STROOP SD, 1993, J BIOL CHEM, V268, P19927; SVOBODA M, 1993, BIOCHEM BIOPH RES CO, V191, P479, DOI 10.1006/bbrc.1993.1243; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q	32	78	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28123	28129						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961748				2022-12-27	WOS:A1994PV77200054
J	STOFFEL, RH; RANDALL, RR; PREMONT, RT; LEFKOWITZ, RJ; INGLESE, J				STOFFEL, RH; RANDALL, RR; PREMONT, RT; LEFKOWITZ, RJ; INGLESE, J			PALMITOYLATION OF G-PROTEIN-COUPLED RECEPTOR KINASE, GRK6 - LIPID MODIFICATION DIVERSITY IN THE GRK FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-ADRENERGIC-RECEPTOR; HUMAN BETA-2-ADRENERGIC RECEPTOR; GAMMA-SUBUNITS; SF9 CELLS; EXPRESSION; PHOSPHORYLATION; ISOPRENYLATION; IDENTIFICATION; RHODOPSIN; CLONING	GRK6, a 66-kDa serine/threonine protein kinase, is a recently identified member of the G protein-coupled receptor kinase (GRK) family. GRKs are involved in the phosphorylation of seven-transmembrane receptors, a process mediating desensitization of signal transduction. An important feature of these enzymes is their membrane-associated nature, which for some members is stimulus dependent. The structural basis for this membrane association previously has been shown in different members of the GRK family to include isoprenylation, G protein beta gamma-binding domains, and basic regions to provide electrostatic interactions with phospholipids. We provide evidence that another mechanism includes fatty acid acylation. GRK6, but not other GRKs tested, incorporated tritium after incubation with [H-3]palmitate in Sf9 and in COS-7 cells overexpressing the kinase. The incorporated radioactivity was released from the protein by neutral hydroxylamine, indicating the presence of a thioester bond, and was confirmed as palmitic acid by high performance liquid chromatography analysis. Site-directed mutagenesis defined the region of palmitate attachment as a cluster of 3 cysteines (Cys(561), Cys(562), and Cys(565)) the carboxyl-terminal domain of the kinase, consistent with the location of the membrane targeting domains of GRKs 1, 2, 3, and 5. Palmitoylation of GRK6 appears essential for membrane association, since palmitoylated kinase was found only in the membrane fraction. This lipid modification provides a structural basis for potential regulation of the subcellular distribution of GRK6 through acylation/deacylation cycles.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University; Howard Hughes Medical Institute; Duke University			Lefkowitz, Robert/AAW-2649-2021	Premont, Richard/0000-0002-8053-5026	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; CAMP LA, 1993, J BIOL CHEM, V268, P22566; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; HALLAK H, 1994, J BIOL CHEM, V269, P4713; HARIBABU B, 1993, P NATL ACAD SCI USA, V90, P9398, DOI 10.1073/pnas.90.20.9398; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; INGLESE J, 1993, J BIOL CHEM, V268, P23735; JAMES G, 1990, METHODS COMPANION ME, P270; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LIU YC, 1993, BIOCHEMISTRY-US, V32, P10714, DOI 10.1021/bi00091a023; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; MORRISON DF, 1991, J BIOL CHEM, V266, P20118; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; NG GYK, 1993, BIOCHEMISTRY-US, V32, P11727, DOI 10.1021/bi00094a032; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Sambrook J, 1989, MOL CLONING LABORATO; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; UVCHINNIKOV YA, 1988, FEBS LETT, V230, P1; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6	31	119	122	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27791	27794						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961702				2022-12-27	WOS:A1994PV77200003
J	THOMAS, CE; OHLWEILER, DF; KALYANARAMAN, B				THOMAS, CE; OHLWEILER, DF; KALYANARAMAN, B			MULTIPLE MECHANISMS FOR INHIBITION OF LOW-DENSITY-LIPOPROTEIN OXIDATION BY NOVEL CYCLIC NITRONE SPIN TRAPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERCHOLESTEROLEMIC WATANABE RABBITS; HERITABLE HYPERLIPIDEMIC RABBIT; SUPEROXIDE-DISMUTASE; PROBUCOL; ATHEROSCLEROSIS; COPPER; ANTIOXIDANTS; PEROXIDATION; CHOLESTEROL; MACROPHAGES	Oxidation of low density Lipoproteins (LDL) may be a critical atherogenic event owing to the diverse array of biologic effects attributed to modified LDL, Recently, we and others have demonstrated that the lipophilic nitrone spin trap alpha-phenyl-N-tert-butyl nitrone (PBN) can inhibit Cu2+-dependent LDL oxidation while the related, more hydrophilic analog alpha-(4-pyridyl-1-oxide)-N-tert-butyl nitrone is ineffective. Because the inhibitory activity of PBN is relatively weak as compared to hydrophobic phenolic antioxidants, we have synthesized a number of cyclic analogues of PBN that encompass a wide range of hydrophobicity and examined their ability to inhibit LDL oxidation in vitro. Formation of a six-membered ring by a bond formed from one methyl of the tert-butyl group to the aromatic ring yielded MDL 101,002, which was 3- and 24-fold more active than PBN against Cu2+ and 2,2'-azobis-2-amidinopropane hydrochloride-dependent oxidation, respectively. The effect of aromatic substituents was examined and, in general, activity positively correlated with hydrophobicity, particularly with Cu2+. Electron spin resonance (ESR) spectroscopy demonstrated that the PBN adduct in oxidized LDL is composed of a mobile component (exposed to the LDL aqueous phase) and an immobilized component, localized in the lipid-protein interface or in the bulk lipid. The most active cyclic nitrones exhibited only highly immobilized adducts, suggesting they are buried within the particle. Studies with MDL 105,185 (which is a chloro-substituted nitrone containing a seven-membered ring rather than six-membered as for MDL 101,002) demonstrated radical trapping in both the lipid and apoprotein fractions. Compounds in which a spirocyclohexyl ring was substituted for the gem-dimethyl methylene (MDL 102,832 and 101,694) formed hydrophobic Cu2+ complexes that were observed in the lipid fraction by ESR. This result was confirmed by fractionation of LDL oxidation reaction mixtures and spectrophotometric quantitation of associated Cu2+. Th, ability to bind Cu2+ was dependent upon the presence of the spirocyclohexyl ring. These data demonstrate that cyclic nitrones can inhibit LDL oxidation at exceedingly low concentrations by multiple mechanisms: 1) trapping of lipid-derived radicals, 2) trapping of apoprotein B-derived radicals, and 3) binding of Cu2+ ions. It is suggested that this new class of highly potent spin traps may be used as effective radical traps in free radical biology and medicine.	MED COLL WISCONSIN,BIOPHYS RES INST,MILWAUKEE,WI 53226	Medical College of Wisconsin	THOMAS, CE (corresponding author), MERRELL DOW PHARMACEUT INC,RES INST,2110 E GALBRAITH RD,CINCINNATI,OH 45215, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047250] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01008] Funding Source: Medline; NHLBI NIH HHS [HL47250] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLA G, 1991, ARTERIOSCLER THROMB, V11, P1700, DOI 10.1161/01.ATV.11.6.1700; CARDIN AD, 1984, METHOD PHARMACOL, V5, P146; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; Carr A. A., 1994, US Patent, Patent No. [5,292,746, 5292746]; ERICKSON MC, 1992, ARCH BIOCHEM BIOPHYS, V292, P427, DOI 10.1016/0003-9861(92)90012-L; GAZIANO JM, 1990, CIRCULATION, V82, P201; HANNA PM, 1992, ARCH BIOCHEM BIOPHYS, V296, P640, DOI 10.1016/0003-9861(92)90620-C; JACKSON RL, 1993, MED RES REV, V13, P161, DOI 10.1002/med.2610130204; JEWETT SL, 1989, EUR J BIOCHEM, V180, P569, DOI 10.1111/j.1432-1033.1989.tb14683.x; KALYANARAMAN B, 1991, FEBS LETT, V280, P17, DOI 10.1016/0014-5793(91)80194-8; KALYANARAMAN B, 1993, BIOCHIM BIOPHYS ACTA, V1168, P220, DOI 10.1016/0005-2760(93)90128-V; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; KU G, 1992, J BIOL CHEM, V267, P14183; LEHR HA, 1991, J CLIN INVEST, V88, P9, DOI 10.1172/JCI115309; LIAO F, 1991, J CLIN INVEST, V87, P2253, DOI 10.1172/JCI115261; MAKINO K, 1990, BIOCHEM BIOPH RES CO, V172, P1073, DOI 10.1016/0006-291X(90)91556-8; MAO SJT, 1991, ARTERIOSCLER THROMB, V11, P1266, DOI 10.1161/01.ATV.11.5.1266; MAO SJT, 1991, J MED CHEM, V34, P298, DOI 10.1021/jm00105a046; MCLEAN LR, 1989, BIOCHEMISTRY-US, V28, P321, DOI 10.1021/bi00427a043; MCLEAN LR, 1992, J BIOL CHEM, V267, P12291; RESSOUCHE E, 1993, J AM CHEM SOC, V115, P3610, DOI 10.1021/ja00062a026; ROSENFELD ME, 1991, J CLIN INVEST, V87, P90, DOI 10.1172/JCI115006; SIMPSON JA, 1990, FREE RADICAL RES COM, V10, P303, DOI 10.3109/10715769009149899; SIMPSON JA, 1992, BIOCHEM J, V282, P621, DOI 10.1042/bj2820621; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1989, J BIOL CHEM, V264, P15216; THOMAS CE, 1992, BIOCHIM BIOPHYS ACTA, V1128, P50, DOI 10.1016/0005-2760(92)90256-U; THOMAS CE, 1994, J LIPID RES, V35, P417; THOMAS CE, 1994, J LIPID RES, V35, P610; VERLANGIERI AJ, 1992, J AM COLL NUTR, V11, P131; Weindruch R., 1993, FREE RADICALS AGING, P269	31	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28055	28061						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961741				2022-12-27	WOS:A1994PV77200045
J	ZHANG, HY; KOMANO, H; FULLER, RS; GANDY, SE; FRAIL, DE				ZHANG, HY; KOMANO, H; FULLER, RS; GANDY, SE; FRAIL, DE			PROTEOLYTIC PROCESSING AND SECRETION OF HUMAN BETA-AMYLOID PRECURSOR PROTEIN IN YEAST - EVIDENCE FOR A YEAST SECRETASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PREPRO-ALPHA-FACTOR; SACCHAROMYCES-CEREVISIAE; KEX2 PROTEASE; ALZHEIMERS-DISEASE; CLEAVAGE; GLYCOSYLATION; LOCALIZATION; SUBUNITS; RELEASE; PEPTIDE	Human beta-amyloid precursor protein (APP), the transmembrane precursor of the Alzheimer's disease beta-amyloid peptide, was expressed in the yeast Saccharomyces cerevisiae by fusion to prepro-alpha-factor, From analysis of protease deficient yeast strains, the fusion protein underwent partial processing by Kex2 protease to generate full-length APP and a fraction of the molecules were degraded in the vacuole. A soluble APP ectodomain fragment bearing lumenal but not cytosolic epitopes was released into the media, indicating cleavage by a ''membrane protein-solubilizing proteinase'' or ''secretase'' activity. Yeast cells contained a C-terminal APP fragment that co-migrated with authentic C-terminal fragment derived from alpha-secretase cleavage of full-length APP in human cells. The N-terminal sequence of immunoaffinity purified C-terminal APP fragment from yeast was identical to that reported in mammalian and insect cells. These results demonstrate the existence of a secretase activity in yeast. Furthermore, this yeast secretase activity may be related to an APP processing activity present in metazoan cells.	ABBOTT LABS,DEPT CORP MOLEC BIOL,DIV PHARMACEUT PROD,ABBOTT PK,IL 60064; STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305; CORNELL UNIV,COLL MED,DEPT NEUROL & NEUROSCI,PROGRAM NEUROSCI,NEW YORK,NY 10021	Abbott Laboratories; Stanford University; Cornell University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039697, R55GM039697] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R55AG011508, R01AG011508] Funding Source: NIH RePORTER; NIA NIH HHS [AG11508] Funding Source: Medline; NIGMS NIH HHS [GM39697] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BODOVITZ S, 1994, IN PRESS J NEUROCHEM; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; BRAKE AJ, 1990, METHOD ENZYMOL, V185, P408; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; EGELMITANI M, 1990, YEAST, V6, P127, DOI 10.1002/yea.320060206; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P7080, DOI 10.1073/pnas.80.23.7080; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FRAIL DE, 1993, MOL PHARMACOL, V44, P1113; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; GANDY S, 1992, TRENDS PHARMACOL SCI, V13, P108, DOI 10.1016/0165-6147(92)90039-9; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JULIUS D, 1983, CELL, V32, P839, DOI 10.1016/0092-8674(83)90070-3; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; PRICE DL, 1993, P NATL ACAD SCI USA, V90, P6381, DOI 10.1073/pnas.90.14.6381; RAMABHADRAN TV, 1993, J BIOL CHEM, V268, P2009; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; Rose MD., 1990, METHODS YEAST GENETI; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; WANG R, 1991, J BIOL CHEM, V266, P16960; WILCOX CA, 1991, J CELL BIOL, V115, P297, DOI 10.1083/jcb.115.2.297; WILCOX CA, 1992, MOL BIOL CELL, V3, P1353, DOI 10.1091/mbc.3.12.1353; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x	29	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27799	27802						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961704				2022-12-27	WOS:A1994PV77200005
J	ORNELASSOARES, A; DELENCASTRE, H; DEJONGE, BLM; TOMASZ, A				ORNELASSOARES, A; DELENCASTRE, H; DEJONGE, BLM; TOMASZ, A			REDUCED METHICILLIN RESISTANCE IN A NEW STAPHYLOCOCCUS-AUREUS TRANSPOSON MUTANT THAT INCORPORATES MURAMYL DIPEPTIDES INTO THE CELL-WALL PEPTIDOGLYCAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSERTIONAL INACTIVATION; STRAIN; TN551	Screening of a new Tn551 library constructed in the background of a highly methicillin-resistant Staphylococcus aureus strain identified a new insertion site located on the SmaI B-fragment of the chromosome that reduced the minimal inhibitory concentration of the parent (1600 mu g/ml) to 25-50 mu g/ml in the mutant and caused heterogeneous expression of resistance and abnormality in peptidoglycan composition (absence of the unsubstituted pentapeptide and incorporation of alanylglutamate- and alanylisoglutamate-containing muropeptides). There was an accumulation of large amounts of the UDP-linked muramyl dipeptide in the cytoplasmic wall precursor pool of the mutant. Reduced (heterogeneous) antibiotic resistance and all the biochemical abnormalities were reproduced in genetic backcrosses by transduction with phage 80 alpha. Mutant RUSA235 appears to be impaired in the biosynthesis of the staphylococcal cell wall precursor muropeptide before the lysine addition step. We propose to provisionally call the gene inactivated in this mutant femF.	ROCKEFELLER UNIV, MICROBIOL LAB, NEW YORK, NY 10021 USA; UNIV NOVA LISBOA, INST TECNOL QUIM & BIOL, P-2780 OEIRAS, PORTUGAL	Rockefeller University; Universidade Nova de Lisboa			DeJonge, Boudewijn/AAR-6717-2020	Tomasz, Alexander/0000-0003-1520-1983; Ornelas-Soares, Antonio/0000-0002-2080-2858; /0000-0001-6816-8932	NIAID NIH HHS [R01 AI16794] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERGERBACHI B, 1983, J BACTERIOL, V154, P479; BERGERBACHI B, 1992, ANTIMICROB AGENTS CH, V36, P1367, DOI 10.1128/AAC.36.7.1367; BERGERBACHI B, 1990, MOL BIOL STAPHYLOCOC, P509; CHATTERJ.AN, 1972, J BACTERIOL, V11, P220, DOI 10.1128/JB.111.1.220-230.1972; DEJONGE BLM, 1993, J BACTERIOL, V175, P2779, DOI 10.1128/JB.175.9.2779-2782.1993; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11255; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11248; DELENCASTRE H, 1991, ANTIMICROB AGENTS CH, V35, P632, DOI 10.1128/AAC.35.4.632; DELENCASTRE H, 1994, J ANTIMICROB CHEMOTH, V33, P7, DOI 10.1093/jac/33.1.7; DELENCASTRE H, 1994, EUR J CLIN MICROBIOL, V13, P64, DOI 10.1007/BF02026129; FLOURET B, 1981, ANAL BIOCHEM, V114, P59, DOI 10.1016/0003-2697(81)90451-6; GHUYSEN JM, 1966, METHOD ENZYMOL, V8, P684; GOOD CM, 1972, J BACTERIOL, V11, P231, DOI 10.1128/JB.111.1.231-241.1972; GUSTAFSON J, 1994, J BACTERIOL, V176, P1460, DOI 10.1128/jb.176.5.1460-1467.1994; HANDWERGER S, 1994, J BACTERIOL, V176, P260, DOI 10.1128/JB.176.1.260-264.1994; HARTMAN BJ, 1986, ANTIMICROB AGENTS CH, V29, P85, DOI 10.1128/AAC.29.1.85; KORNBLUM J, 1986, EUR J CLIN MICROBIOL, V5, P714, DOI 10.1007/BF02013311; MATTHEWS P, 1990, ANTIMICROB AGENTS CH, V34, P1777, DOI 10.1128/AAC.34.9.1777; ORNELASSOARES A, 1993, J BIOL CHEM, V268, P26268; OSHIDA T, 1992, J BACTERIOL, V174, P4952, DOI 10.1128/JB.174.15.4952-4959.1992; PATTEE PA, 1981, J BACTERIOL, V145, P479, DOI 10.1128/JB.145.1.479-488.1981; Sambrook J, 1989, MOL CLONING LABORATO; TOMASZ A, 1990, MOL BIOL STAPHYLOCOC, P565	23	55	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27246	27250						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961632				2022-12-27	WOS:A1994PV77100017
J	POMBO, CM; BONVENTRE, JV; AVRUCH, J; WOODGETT, JR; KYRIAKIS, JM; FORCE, T				POMBO, CM; BONVENTRE, JV; AVRUCH, J; WOODGETT, JR; KYRIAKIS, JM; FORCE, T			THE STRESS-ACTIVATED PROTEIN-KINASES ARE MAJOR C-JUN AMINO-TERMINAL KINASES ACTIVATED BY ISCHEMIA AND REPERFUSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOONCOGENE EXPRESSION; CEREBRAL-ISCHEMIA; GENE-EXPRESSION; RENAL ISCHEMIA; GERBIL BRAIN; MAP KINASES; PHOSPHORYLATION; FOS; TRANSCRIPTION; TYROSINE	The signal transduction pathways that mediate activation of trans acting factors controlling an organ's response to ischemia are unknown. The stress-activated protein kinases (SAPKs), a subfamily of the extracellular signal-regulated kinases (ERKs), phosphorylate c-Jun within the amino-terminal transactivation domain and are activated in response to a variety of cellular stresses. We determined whether SAPKs are activated in response to ischemia, an extreme, albeit common, pathophysiologic stress. Rats underwent 40 min of renal ischemia followed by reperfusion for 0, 5, 20, or 90 min. SAPKs were immunoprecipitated from kidney lysates and kinase activity assayed with recombinant GST-c-Jun(1-135), containing the amino-terminal transactivation domain of c-Jun as substrate. SAPKs were not activated by ischemia alone, but reperfusion for as little as 5 min was associated with a 4.6-fold increase in kinase activity. Kinase activity was increased 7.6-fold at 20 min following reperfusion and remained elevated at 90 min of reperfusion (4.9-fold). In contrast, activity of the related ERR-1 and -2 was increased only 1.3-fold and only at the 5-min reperfusion time point. When SAPKs were immunodepleted from kidney extracts prior to incubation of the extracts with agarose-coupled GST-c-Jun(1-135), it was found that SAPKs accounted for the majority of the amino-terminal c-Jun kinase activity of kidney at 5 min following reperfusion. In Madin-Darby canine kidney epithelial cells, ATP repletion, following ATP depletion induced by chemical anoxia, was associated with a 9-15-fold activation of SAPKs with a similar time course of activation to that seen in the kidney after ischemia and reperfusion. In conclusion, the SAPKs are markedly activated very early after reperfusion of ischemic kidney and following ATP repletion of anoxic cells in culture. We propose that this activation of SAPKs may trigger part of the kidney's early genetic response to ischemia, possibly by enhancing trans acting activity of c-Jun.	MASSACHUSETTS GEN HOSP, MED SERV, CARDIAC UNIT, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, MED SERV, DIABET UNIT, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, MED SERV, RENAL UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02114 USA; PRINCESS MARGARET HOSP, ONTARIO CANC INST, TORONTO M4X 1K9, ON, CANADA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre			Pombo, Celia M/L-4479-2014; Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797; Pombo, Celia M/0000-0003-2541-9468; Force, Thomas/0000-0002-0450-8659	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041513, K08DK001986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046577, R29GM046577] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK01986, DK41513] Funding Source: Medline; NIGMS NIH HHS [GM46577] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; AN G, 1993, ANN NEUROL, V33, P457, DOI 10.1002/ana.410330508; ARMSTRONG S, 1994, CARDIOVASC RES, V28, P72, DOI 10.1093/cvr/28.1.72; ASSELIN C, 1989, ONCOGENE RES, V5, P67; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BONIECE IR, 1993, J NEUROSCI, V13, P4220; BONVENTRE JV, 1991, CELL REGUL, V2, P251, DOI 10.1091/mbc.2.3.251; BONVENTRE JV, 1993, KIDNEY INT, V43, P1160, DOI 10.1038/ki.1993.163; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRAND T, 1992, CIRC RES, V71, P1351, DOI 10.1161/01.RES.71.6.1351; CAMPOSGONZALEZ R, 1992, J NEUROCHEM, V59, P1955, DOI 10.1111/j.1471-4159.1992.tb11032.x; CARDELL M, 1993, J NEUROCHEM, V61, P1308, DOI 10.1111/j.1471-4159.1993.tb13623.x; CHURN SB, 1993, BIOCHEM BIOPH RES CO, V193, P934, DOI 10.1006/bbrc.1993.1715; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLESPIE JG, 1992, FEBS LETT, V306, P59, DOI 10.1016/0014-5793(92)80837-7; HANSON SK, 1994, STROKE, V25, P446; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KELLY KJ, 1994, P NATL ACAD SCI USA, V91, P812, DOI 10.1073/pnas.91.2.812; KINDY MS, 1991, J MOL NEUROSCI, V2, P217; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; MAIESE K, 1993, J NEUROSCI RES, V36, P77, DOI 10.1002/jnr.490360109; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; OUELLETTE AJ, 1990, J CLIN INVEST, V85, P766, DOI 10.1172/JCI114502; PARRATT JR, 1994, TRENDS PHARMACOL SCI, V15, P19, DOI 10.1016/0165-6147(94)90129-5; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; ROSENBERG ME, 1991, KIDNEY INT, V39, P1156, DOI 10.1038/ki.1991.146; SAFIRSTEIN R, 1990, KIDNEY INT, V37, P1515, DOI 10.1038/ki.1990.143; SHACKELFORD DA, 1993, J NEUROCHEM, V61, P738; SHERIDAN AM, 1993, AM J PHYSIOL, V265, pF342, DOI 10.1152/ajprenal.1993.265.3.F342; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; WEBSTER KA, 1994, CIRC RES, V74, P679, DOI 10.1161/01.RES.74.4.679; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; WITZGALL R, 1994, J CLIN INVEST, V93, P2175, DOI 10.1172/JCI117214	42	248	259	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26546	26551						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929379				2022-12-27	WOS:A1994PQ93000092
J	DANCIS, A; HAILE, D; YUAN, DS; KLAUSNER, RD				DANCIS, A; HAILE, D; YUAN, DS; KLAUSNER, RD			THE SACCHAROMYCES-CEREVISIAE COPPER TRANSPORT PROTEIN (CTR1P) - BIOCHEMICAL, CHARACTERIZATION, REGULATION BY COPPER, AND PHYSIOLOGICAL-ROLE IN COPPER UPTAKE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU,ZN SUPEROXIDE-DISMUTASE; WILSON DISEASE GENE; IRON UPTAKE; METALLOTHIONEIN GENE; FERRIC REDUCTASE; YEAST; EXPRESSION; METABOLISM; MUTANTS; ENCODES	The CTR1 gene of Saccharomyces cerevisiae encodes a protein required for high affinity copper uptake. The protein is expressed on the plasma membrane, is heavily glycosylated with O-linkages, and exists as an oligomer in vivo. The transcript abundance is strongly regulated by copper availability, being induced by copper deprivation and repressed by copper excess. Regulation occurs at very low, nontoxic levels of available copper and is independent of ACE1, the trans-inducer of yeast metallothionein. Expression of Ctr1p is limiting for copper uptake, since overexpression from a 2 mu high copy number plasmid increases copper uptake. Mutations in CTR1 result in altered cellular responses to extracellular copper, demonstrating a physiologic role for CTR1 in the delivery of copper to the cytosol. A copper dependent reporter gene construct, CUP1-lacZ, is not expressed in CTR1 mutants to the same level as in wild-type strains, and Cu,Zn superoxide dismutase activity is deficient in these mutants. The growth arrest that occurs in CTR1 mutants grown aerobically in copper-deficient media is attributable to the defect in Cu,Zn superoxide dismutase activity.	NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CHANG EC, 1991, J BIOL CHEM, V266, P4417; CHELLY J, 1993, NAT GENET, V5, P317, DOI 10.1038/ng1293-317; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; EIDE D, 1992, J BIOL CHEM, V267, P20774; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; GRECO MA, 1990, J BACTERIOL, V172, P317, DOI 10.1128/JB.172.1.317-325.1990; GREEN NM, 1992, ACTA PHYSIOL SCAND, V146, P59; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; Halliwell B, 1988, FREE RADICALS BIOL M; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; KEPES F, 1988, J BIOL CHEM, V263, P9155; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Kosman Daniel J., 1994, V11, P1; KRAMER RA, 1984, P NATL ACAD SCI-BIOL, V81, P367, DOI 10.1073/pnas.81.2.367; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; Lesuisse Emmanuel, 1994, V11, P149; LIN CM, 1993, J GEN MICROBIOL, V139, P1605, DOI 10.1099/00221287-139-7-1605; LINDER MC, 1991, BIOCH COPPER, P1; LIU XF, 1992, J BIOL CHEM, V267, P18298; Miller J.H., 1972, EXPT MOL GENETICS; NIELANDS JB, 1987, IRON TRANSPORT MICRO, P3; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; ORLEAN P, 1991, METHOD ENZYMOL, V194, P682; OSHUMI Y, 1988, J BACTERIOL, V170, P2676; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER JC, 1991, METHOD ENZYMOL, V194, P373; Serrano R, 1991, MOL CELLULAR BIOL YE, P523; SHERMAN F, 1989, LABORATORY COURSE MA; SIKORSKI RS, 1989, GENETICS, V122, P19; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YANG WM, 1991, MOL CELL BIOL, V11, P3676, DOI 10.1128/MCB.11.7.3676; ZHOU PB, 1993, BIOFACTORS, V4, P105	44	355	362	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25660	25667						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929270				2022-12-27	WOS:A1994PQ49100066
J	MACCOLL, R; LAM, I; CHOI, CY; KIM, J				MACCOLL, R; LAM, I; CHOI, CY; KIM, J			EXCITON SPLITTING IN PHYCOERYTHRIN-545	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE ANALYSIS; C-PHYCOCYANIN; ENERGY-TRANSFER; AGMENELLUM-QUADRUPLICATUM; CRYPTOMONAD BILIPROTEINS; FORSTER TRANSFER; ALLOPHYCOCYANIN; LOCALIZATION; FLUORESCENCE; RESOLUTION	Phycoerythrin 545 is a biliprotein having a polypep tide structure of alpha(2) beta(2) and each alpha and beta polypeptide has chromophores. Circular dichroism (CD) and absorption spectroscopy in the visible region together with various biochemical protocols have been used to study these chromophores. The CD spectrum exhibits overlapping positive and negative bands. Exciton splitting between closely-spaced pairs of chromophores produces a CD spectrum that has positive and negative bands of equal rotational strengths, a conservative spectrum. Alternatively, any positive or negative band could arise from a single chromophore, The results of this study demonstrate that exciton splitting is the likely cause of the negative and corresponding positive bands. The CD spectra of the separated alpha and beta polypeptides, under conditions where the polypeptide structure is denatured, have no negative bands. When the polypeptides are allowed to refold individually, the chromophores on the beta polypeptide regain a combination of negative and positive CD bands. The spectrum of the alpha polypeptide shows no evidence of exciton splitting under these refolding conditions. In another approach, urea is added to the protein in low concentrations, which result in changes in the conformation and perhaps association of the protein. A difference CD spectrum of native protein minus protein in 0.8 M urea shows a spectrum characteristic of exciton splitting. Moveover, the remaining CD spectra in 0.8, 1.6, or 2.4 M urea still show the possibility of further exciton splitting, but at slightly different wavelengths from the spectrum that is deleted by 0.8 M urea. This finding may suggest that there are two types of exciton splitting.	SUNY ALBANY,DEPT BIOMED SCI,ALBANY,NY 12201	State University of New York (SUNY) System; State University of New York (SUNY) Albany	MACCOLL, R (corresponding author), NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,BOX 509,ALBANY,NY 12201, USA.							BECK WF, 1992, J PHYS CHEM-US, V96, P4658, DOI 10.1021/j100190a094; CSATORDAY K, 1988, PHOTOCHEM PHOTOBIOL, V47, P285, DOI 10.1111/j.1751-1097.1988.tb02728.x; CSATORDAY K, 1984, BIOCHEMISTRY-US, V23, P6466, DOI 10.1021/bi00321a029; DEBRECZENY MP, 1993, J PHYS CHEM-US, V97, P9852, DOI 10.1021/j100140a050; DUERRING M, 1991, J MOL BIOL, V217, P577, DOI 10.1016/0022-2836(91)90759-Y; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; GANTT E, 1971, J CELL BIOL, V48, P280, DOI 10.1083/jcb.48.2.280; GANTT E, 1979, BIOCH PHYSL PROTOZOA, V1, P121; GILLBRO T, 1993, BIOCHIM BIOPHYS ACTA, V1140, P321, DOI 10.1016/0005-2728(93)90072-N; GODOVAC-ZIMMERMANN J, 1992, BIOCHIM BIOPHYS ACTA, V1120, P117, DOI 10.1016/0167-4838(92)90432-D; GUARDFRIAR D, 1986, PHOTOCHEM PHOTOBIOL, V43, P81, DOI 10.1111/j.1751-1097.1986.tb05594.x; HOLZWARTH AR, 1991, PHYSIOL PLANTARUM, V83, P518, DOI 10.1111/j.1399-3054.1991.tb00129.x; HUANG C, 1987, BIOCHEMISTRY-US, V26, P243, DOI 10.1021/bi00375a033; JUNG J, 1980, BIOCHEMISTRY-US, V19, P24, DOI 10.1021/bi00542a005; KNOX RS, 1993, PHOTOCHEM PHOTOBIOL, V57, P40, DOI 10.1111/j.1751-1097.1993.tb02252.x; LANGER E, 1980, Z NATURFORSCH C, V35, P367; LICHTLE C, 1992, BIOL CELL, V74, P187, DOI 10.1016/0248-4900(92)90024-U; LUDWIG M, 1989, J CELL BIOL, V108, P875, DOI 10.1083/jcb.108.3.875; MACCOLL R, 1983, ARCH MICROBIOL, V135, P194, DOI 10.1007/BF00414479; MACCOLL R, 1992, J LUMIN, V51, P21, DOI 10.1016/0022-2313(92)90015-2; MACCOLL R, 1983, J BIOL CHEM, V258, P4327; MACCOLL R, 1981, ARCH BIOCHEM BIOPHYS, V208, P42, DOI 10.1016/0003-9861(81)90121-1; MACCOLL R, 1980, BIOCHEMISTRY-US, V19, P2817, DOI 10.1021/bi00553a043; MacColl R., 1987, PHYCOBILIPROTEINS; MALAK H, 1991, BIOCHIM BIOPHYS ACTA, V1059, P165, DOI 10.1016/S0005-2728(05)80201-4; MCKAY RML, 1992, J PHYCOL, V28, P64, DOI 10.1111/j.0022-3646.1992.00064.x; MUCKLE G, 1977, Z NATURFORSCH C, V32, P957; REITH M, 1990, PLANT MOL BIOL, V15, P585, DOI 10.1007/BF00017833; SAUER K, 1988, BIOCHIM BIOPHYS ACTA, V936, P157, DOI 10.1016/0005-2728(88)90232-0; SCHEER H, 1977, Z NATURFORSCH C, V32, P513; SCHIRMER T, 1986, J MOL BIOL, V188, P651, DOI 10.1016/S0022-2836(86)80013-4; SCHIRMER T, 1987, J MOL BIOL, V196, P677, DOI 10.1016/0022-2836(87)90040-4; SHARKOV AV, 1992, CHEM PHYS LETT, V191, P633, DOI 10.1016/0009-2614(92)85601-6; SHARKOV AV, 1992, 1921 P SOC PHOT INST, P136; SPEARBERNSTEIN L, 1989, J PHYCOL, V25, P412, DOI 10.1111/j.1529-8817.1989.tb00245.x; WEDEMAYER GJ, 1992, J BIOL CHEM, V267, P7315; XIE XL, 1992, P SOC PHOTO-OPT INS, V1640, P690; Zuber H, 1987, LIGHT REACTIONS, P197	38	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25465	25469						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929246				2022-12-27	WOS:A1994PQ49100039
J	HAYES, KL; LEONG, L; HENRIKSEN, RA; BOUCHARD, BA; OUELLETTE, L; CHURCH, WR; TRACY, PB				HAYES, KL; LEONG, L; HENRIKSEN, RA; BOUCHARD, BA; OUELLETTE, L; CHURCH, WR; TRACY, PB			ALPHA-THROMBIN-INDUCED HUMAN PLATELET ACTIVATION RESULTS SOLELY FROM FORMATION OF A SPECIFIC ENZYME-SUBSTRATE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUICK-I; RECEPTOR ACTIVATION; AGONIST PEPTIDES; PHOSPHOLIPASE-C; FACTOR-XA; BINDING; DYSTHROMBIN; SITE; IDENTIFICATION; AGGREGATION	Prior studies using the mutant thrombin, thrombin Quick I, indicate that this protease induces maximum platelet aggregation and intraplatelet [Ca2+] fluxes at agonist concentrations where dissociable, equilibrium platelet binding is undetectable and led to the conclusion that thrombin interaction with its platelet ''receptor'' is best described kinetically by formation of an enzyme-substrate complex. This conclusion was substantiated further in the present studies by demonstrating that both thrombin Quick I and thrombin mimicked the thrombin receptor agonist peptide in the induction of the platelet activation-dependent events required for functional Prothrombinase assembly and that a rabbit antibody raised against KATNATLDPRSFLLR, a pentadecapeptide which represents amino acids 32-46 in the platelet thrombin receptor/substrate and spans the thrombin cleavage site, inhibited both thrombin- and thrombin Quick I-induced platelet activation responses equivalently. The antipeptide antibody had a more pronounced inhibitory effect on the rate of the thrombin-induced response rather than the magnitude of the response suggesting competition for the cleavage site, consistent with the observation that pretreatment of metabolically-inhibited platelets with thrombin, which was removed by washing, eliminated specific antibody binding due to removal and/or masking of antibody epitopes. Concentrations of the antipeptide antibody that inhibited thrombin- and thrombin Quick I-induced increases in intracellular [Ca2+] nux by as much as 97% did not alter the dissociable equilibrium binding of I-125-FPR-thrombin to platelets. These combined data indicate that the hydrolytic event initiated by thrombin or thrombin Quick I interaction with the platelet receptor/substrate for thrombin is unrelated to the dissociable equilibrium binding of thrombin to membrane sites described previously by classical receptor-ligand binding analyses.	UNIV VERMONT,COLL MED,DEPT BIOCHEM,BURLINGTON,VT 05405; UNIV VERMONT,CELL & MOLEC BIOL PROGRAM,BURLINGTON,VT 05405; E CAROLINA UNIV,SCH MED,DEPT MED,GREENVILLE,NC 27858	University of Vermont; University of Vermont; University of North Carolina; East Carolina University				Leong, Lilley/0000-0003-1041-0110	NHLBI NIH HHS [HL-45194, HL-46703] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045194, P01HL046703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER RJ, 1983, ARCH BIOCHEM BIOPHYS, V222, P266, DOI 10.1016/0003-9861(83)90524-6; BAJAJ SP, 1981, PREP BIOCHEM, V11, P394; Bauminger S, 1980, Methods Enzymol, V70, P151; BERNDT MC, 1981, PLATELETS BIOL PATHO, P43; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BRASS LF, 1992, J BIOL CHEM, V267, P13795; CHAO BH, 1992, BIOCHEMISTRY-US, V31, P6175, DOI 10.1021/bi00142a001; CHURCH WR, 1988, J BIOL CHEM, V263, P6259; DEGAN SJF, 1983, BIOCHEMISTRY-US, V22, P2087; DEMARCO L, 1990, J CLIN INVEST, V86, P25, DOI 10.1172/JCI114692; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; DEMARCO L, 1994, J BIOL CHEM, V269, P6478; FENTON JW, 1977, CHEM BIOL THROMBIN, P43; GRECO NJ, 1991, P SOC EXP BIOL MED, V198, P792; HARMON JT, 1985, BIOCHEMISTRY-US, V24, P58, DOI 10.1021/bi00322a010; HENRIKSEN RA, 1980, J CLIN INVEST, V66, P934, DOI 10.1172/JCI109961; HENRIKSEN RA, 1983, J BIOL CHEM, V258, P3717; HENRIKSEN RA, 1988, BIOCHEMISTRY-US, V27, P9160, DOI 10.1021/bi00426a013; HENRIKSEN RA, 1987, J BIOL CHEM, V262, P4664; HOLMSEN H, 1974, BIOCHEM J, V144, P385, DOI 10.1042/bj1440385; HUANG RS, 1991, J BIOL CHEM, V266, P18435; HUI KY, 1992, BIOCHEM BIOPH RES CO, V184, P790, DOI 10.1016/0006-291X(92)90659-9; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; HUNG DT, 1992, J CLIN INVEST, V89, P444, DOI 10.1172/JCI115604; ISHII K, 1993, J BIOL CHEM, V268, P9780; JAMIESON GA, 1978, J CLIN INVEST, V61, P861, DOI 10.1172/JCI109000; KNUPP CL, 1985, BLOOD, V65, P578; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONG L, 1992, BIOCHEMISTRY-US, V31, P2567, DOI 10.1021/bi00124a017; Mann K G, 1976, Methods Enzymol, V45, P123; MARTIN BM, 1976, BIOCHEMISTRY-US, V15, P4886, DOI 10.1021/bi00667a021; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; OWEN W G, 1973, Thrombosis Research, V3, P705, DOI 10.1016/0049-3848(73)90017-0; RITTENHOUSE SE, 1983, P NATL ACAD SCI-BIOL, V80, P5417, DOI 10.1073/pnas.80.17.5417; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SEILER SM, 1992, BIOCHEM BIOPH RES CO, V182, P1296, DOI 10.1016/0006-291X(92)91873-O; SHUMAN MA, 1976, BLOOD, V47, P43; STONE SR, 1991, BIOCHEMISTRY-US, V30, P6392, DOI 10.1021/bi00240a007; TAM SW, 1979, J BIOL CHEM, V254, P8723; TOLLEFSEN DM, 1974, J BIOL CHEM, V249, P2646; TRACY PB, 1982, BLOOD, V60, P59; TRACY PB, 1992, METHOD ENZYMOL, V215, P329; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WORKMAN EF, 1977, J BIOL CHEM, V252, P7118	46	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28606	28612						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961808				2022-12-27	WOS:A1994PU16800017
J	ORTIZ, JA; GILGOMEZ, G; CASAROLIMARANO, RP; VILARO, S; HEGARDT, FG; HARO, D				ORTIZ, JA; GILGOMEZ, G; CASAROLIMARANO, RP; VILARO, S; HEGARDT, FG; HARO, D			TRANSFECTION OF THE KETOGENIC MITOCHONDRIAL 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A SYNTHASE CDNA INTO MEV-1 CELLS CORRECTS THEIR AUXOTROPHY FOR MEVALONATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAT-LIVER; GENE-EXPRESSION; INTESTINE; COA	A somatic cell mutant of the Chinese hamster ovary (CHO)-K1 (called Mev-1), auxotrophic for mevalonate by virtue of a complete lack of detectable cytosolic 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) synthase activity, was transfected with a plasmid containing the cDNA for ketogenic mitochondrial HMG-CoA synthase under the control of SV40 early promoter. The resulting stable cell line (Mev-SM) was able to grow in the absence of mevalonate. Analysis by Western blot showed that the new cell line strongly expressed mitochondrial HMG-CoA synthase protein. Immunocytochemical studies using specific antibodies against mitochondrial HMG-CoA synthase showed that the protein was located exclusively inside the mitochondria. The prototroph cell line Mev-SM can incorporate labeled ac etate into cholesterol in the absence of mevalonate. These results show that the new cell, line may circumvent the lack of cytosolic HMG-CoA synthase activity by producing cholesterol-convertible HMG-CoA inside the mitochondria.	UNIV BARCELONA,SCH PHARM,DEPT BIOCHEM & MOLEC BIOL,E-08028 BARCELONA,SPAIN; UNIV BARCELONA,SCH BIOL,CELL BIOL UNIT,E-08028 BARCELONA,SPAIN	University of Barcelona; University of Barcelona			Casaroli-Marano, Ricardo Pedro/D-4535-2014; Gil-Gomez, G/H-6307-2014; Haro, Diego/I-4623-2015	Casaroli-Marano, Ricardo Pedro/0000-0003-1812-9323; Gil-Gomez, G/0000-0002-9790-7308; Haro, Diego/0000-0001-9147-0486; Ortiz, Jose A./0000-0003-0505-3032				AYTE J, 1990, P NATL ACAD SCI USA, V87, P3874, DOI 10.1073/pnas.87.10.3874; BEISIEGEL U, 1982, J BIOL CHEM, V257, P3150; CLINKENBEARD KD, 1975, J BIOL CHEM, V250, P3108; DASHTI N, 1979, BIOCHEM MED METAB B, V22, P365, DOI 10.1016/0006-2944(79)90024-3; ERICSSON J, 1993, BIOCHIMIE, V75, P167, DOI 10.1016/0300-9084(93)90074-3; FOLCH J, 1951, J BIOL CHEM, V191, P833; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; LOWE DM, 1985, BIOCHEM J, V232, P37, DOI 10.1042/bj2320037; PIGNATARO OP, 1983, MOL CELL ENDOCRINOL, V33, P53, DOI 10.1016/0303-7207(83)90056-4; ROYO T, 1993, J LIPID RES, V34, P867; RUNQUIST M, 1994, J BIOL CHEM, V269, P5804; Sambrook J, 1989, MOL CLONING LABORATO; SCHNITZERPOLOKO.R, 1981, J BIOL CHEM, V257, P472; SCHNITZERPOLOKOFF R, 1987, J CELL BIOCHEM, V35, P93, DOI 10.1002/jcb.240350203; SERRA D, 1993, ARCH BIOCHEM BIOPHYS, V301, P445, DOI 10.1006/abbi.1993.1169; THUMELIN S, 1993, BIOCHEM J, V292, P493, DOI 10.1042/bj2920493; WILLIAMS.DH, 1968, BIOCHEM J, V108, P353, DOI 10.1042/bj1080353	17	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28523	28526						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961793				2022-12-27	WOS:A1994PU16800001
J	DANESCH, U; WEBER, PC; SELLMAYER, A				DANESCH, U; WEBER, PC; SELLMAYER, A			ARACHIDONIC-ACID INCREASES C-FOS AND EGR-1 MESSENGER-RNA IN 3T3 FIBROBLASTS BY FORMATION OF PROSTAGLANDIN E(2) AND ACTIVATION OF PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; EPIDERMAL GROWTH-FACTOR; SMOOTH-MUSCLE CELLS; SIGNAL TRANSDUCTION; GENE-TRANSCRIPTION; MESSENGER-RNA; PHORBOL ESTER; ADENYLATE-CYCLASE; HUMAN MONOCYTES; EXPRESSION	Studying Swiss 3T3 fibroblasts, we report that arachidonic acid strongly stimulates mRNA levels of the growth-associated immediate early genes c-fos and Egr-1. Structurally related compounds like arachidonic acid methyl ester, arachidonyl alcohol, or eicosatetraynoic acid are ineffective, indicating a specific role of free unesterified arachidonic acid or an arachidonic acid metabolite in c-fos and Egr-1 mRNA accumulation. Blocking the conversion of arachidonic acid to prostaglandins by inhibiting cyclooxygenase abolishes arachidonic acid induced accumulation of c-fos and Egr-1 mRNA. Inhibition of the lipoxygenase or cytochrome P-450 epoxygenase pathways has no significant effect on arachidonic acid-induced c-fos and Egr-1 mRNA levels, indicating that prostaglandin synthesis is necessary for the increase in c-fos and Egr-1 mRNA. Reversed phase high performance liquid chromatography revealed prostaglandin E(2) (PGE(2)) as the major arachidonic acid metabolite in Swiss 3T3 fibroblasts. When added to the cells, PGE(2) stimulates c-fos and Egr-1 mRNA levels to the same degree as arachidonic acid, Also, the inhibition of arachidonic acid-stimulated c-fos and Egr-1 mRNA accumulation by indomethacin is reversed by PGE(2). Contrary to reports that PGE(2) caused an increase in cAMP levels in Swiss 3T3 fibroblasts, we found that arachidonic acid and PGE(2) only minimally increase cAMP levels as compared with untreated cells. In contrast, inhibition of protein kinase C by calphostin C and chelerythrine or down-regulation with phorbol 12-myristate 13 acetate drastically reduces PGE(2) and arachidonic acid induced c-fos and Egr-1 mRNA levels. These data indicate that arachidonic acid exerts its stimulatory effect on c-fos and Egr-1 mRNA via synthesis of PGE(2) and subsequent activation of protein kinase C, probably through a PGE(2) receptor coupled to phospholipase C.	UNIV MUNICH,KREISLAUFKRANKHEITEN,KLINIKUM INNENSTADT,INST PROPHYLAXE & EPIDEMIOL,D-80336 MUNICH,GERMANY	University of Munich								BELL RM, 1991, J BIOL CHEM, V266, P4661; BLACK FM, 1990, BIOCHEM J, V266, P661, DOI 10.1042/bj2660661; BUTCHER RD, 1993, CANCER RES, V53, P3405; CLARKE SD, 1993, PROG LIPID RES, V32, P139, DOI 10.1016/0163-7827(93)90013-M; COWLEN MS, 1992, CANCER RES, V52, P6912; DAMRON DS, 1993, J BIOL CHEM, V268, P27335; DANESCH U, 1992, J BIOL CHEM, V267, P7185; DAVIES P, 1992, INFLAMMATION BASIC P, P123; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DOOLAN CM, 1994, BRIT J PHARMACOL, V111, P509, DOI 10.1111/j.1476-5381.1994.tb14766.x; GUSOVSKY F, 1991, MOL PHARMACOL, V40, P633; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; HANDLER JA, 1990, J BIOL CHEM, V265, P3669; HORIGUCHI J, 1989, MOL CELL BIOL, V9, P252, DOI 10.1128/MCB.9.1.252; JUMP DB, 1993, P NATL ACAD SCI USA, V90, P8454, DOI 10.1073/pnas.90.18.8454; KACICH RL, 1988, MOL ENDOCRINOL, V2, P73, DOI 10.1210/mend-2-1-73; NAOR Z, 1991, MOL CELL ENDOCRINOL, V80, pC181, DOI 10.1016/0303-7207(91)90135-F; NEGISHI M, 1989, J BIOL CHEM, V264, P3916; NOLAN RD, 1988, MOL PHARMACOL, V33, P650; ORDWAY RW, 1989, SCIENCE, V244, P1176, DOI 10.1126/science.2471269; RAO GN, 1993, ONCOGENE, V8, P2759; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; ROLAPLESZCZYNSKI M, 1992, BLOOD, V80, P1004; SAKATA A, 1987, J IMMUNOL, V138, P4353; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SHIER WT, 1980, P NATL ACAD SCI-BIOL, V77, P137, DOI 10.1073/pnas.77.1.137; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; STANKOVA J, 1992, BIOCHEM J, V282, P625; STONE RM, 1990, BLOOD, V76, P1225; SUMIDA C, 1993, PROSTAG LEUKOTR ESS, V48, P117, DOI 10.1016/0952-3278(93)90019-S; TEBBEY PW, 1992, BIOCHIM BIOPHYS ACTA, V1171, P27, DOI 10.1016/0167-4781(92)90136-N; TOMASKA L, 1993, J BIOL CHEM, V268, P5317; ZOR U, 1991, BIOCHIM BIOPHYS ACTA, V1091, P385, DOI 10.1016/0167-4889(91)90204-B	35	100	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27258	27263						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961634				2022-12-27	WOS:A1994PV77100019
J	DESROSIERS, C; FERNANDEZ, CA; DAVID, F; BRUNENGRABER, H				DESROSIERS, C; FERNANDEZ, CA; DAVID, F; BRUNENGRABER, H			REVERSIBILITY OF THE MITOCHONDRIAL ISOCITRATE DEHYDROGENASE REACTION IN THE PERFUSED-RAT-LIVER - EVIDENCE FROM ISOTOPOMER ANALYSIS OF CITRIC-ACID CYCLE INTERMEDIATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							KREBS CYCLE; HEPATIC GLUCONEOGENESIS; METABOLISM	The reversal of the mitochondrial isocitrate dehydrogenase reaction was investigated in rat livers perfused with [U-C-13(5)]glutamate or [U-C-13(5)]glutamine. The mass isotopomer distribution of citric acid cycle intermediates extracted from the livers was determined by gas chromatography-mass spectrometry. Citrate was enriched in an isotopomer containing five C-13. The formation of this isotopomer can only be explained by the reversal of the isocitrate dehydrogenase reaction. Calculation of kinetic parameters from the mass isotopomer data reveals a rapid interconversion of isocitrate and alpha-ketoglutarate. This interconversion results in an isotopic exchange between carbon 6 of citrate and mitochondrial CO2 that can affect the calculation of citric acid cycle kinetic parameters. Thus, the reversal of the isocitrate dehydrogenase reaction should be included in isotope labeling models of the citric acid cycle.	CASE WESTERN RESERVE UNIV, DEPT NUTR, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT BIOMED ENGN, CLEVELAND, OH 44106 USA; UNIV MONTREAL, DEPT NUTR, MONTREAL H3C 3J7, PQ, CANADA	Case Western Reserve University; Case Western Reserve University; Universite de Montreal			Rosiers, Christine Des/O-6285-2014		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035543] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 35543] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARANYAI JM, 1989, BIOCHEM J, V258, P121, DOI 10.1042/bj2580121; DALZIEL K, 1968, BIOCHEM J, V110, P223, DOI 10.1042/bj1100223; DALZIEL K, 1975, ENZYMES, V13, P1; DESROSIERS C, 1994, 1994 P S INT FED AUT, P354; DIDONATO L, 1993, J BIOL CHEM, V268, P4170; ESENMO E, 1992, AM J PHYSIOL, V263, pE36, DOI 10.1152/ajpendo.1992.263.1.E36; Fansler B., 1969, METHODS ENZYMOL, V13, P26; FERNANDEZ CA, 1994, 1994 P S INT FED AUT, P3657; GABRIEL JL, 1986, METABOLISM, V35, P661, DOI 10.1016/0026-0495(86)90175-7; Haft DE, 1965, J BIOL CHEM, V240, P613; HANSFORD RG, 1975, J BIOL CHEM, V250, P8361; HEATH DF, 1985, BIOCHEM J, V227, P851, DOI 10.1042/bj2270851; HOEK JB, 1988, BIOCHEM J, V254, P1; KATZ J, 1993, J BIOL CHEM, V268, P25509; KELLEHER JK, 1985, AM J PHYSIOL, V248, pE252, DOI 10.1152/ajpendo.1985.248.2.E252; LANDAU BR, 1993, AM J PHYSIOL, V265, pE636, DOI 10.1152/ajpendo.1993.265.4.E636; Lee W. N. P., 1989, J BIOL CHEM, V264, P13002; LEE WNP, 1993, J BIOL CHEM, V268, P25522; MAGNUSSON I, 1991, J BIOL CHEM, V266, P6975; NICHOLLS DG, 1969, BIOCHEM J, V114, P215, DOI 10.1042/bj1140215; PLAUT GWE, 1967, BIOCHEM BIOPH RES CO, V28, P628, DOI 10.1016/0006-291X(67)90360-9; REYNOLDS CH, 1978, BIOCHEM J, V171, P733, DOI 10.1042/bj1710733; ROBINSON JB, 1985, J BIOL CHEM, V260, P800; ROSIERS CD, 1988, ANAL BIOCHEM, V173, P96, DOI 10.1016/0003-2697(88)90165-0; ROSIERS CD, 1991, J BIOL CHEM, V266, P1574; SAZANOV LA, 1994, FEBS LETT, V344, P109, DOI 10.1016/0014-5793(94)00370-X; SMITH CM, 1979, EUR J BIOCHEM, V97, P283, DOI 10.1111/j.1432-1033.1979.tb13113.x; Veech R L, 1981, Curr Top Cell Regul, V18, P151; WANDERS RJA, 1981, EUR J BIOCHEM, V116, P609, DOI 10.1111/j.1432-1033.1981.tb05379.x	29	69	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27179	27182						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961626				2022-12-27	WOS:A1994PV77100007
J	MANT, A; NIELSEN, VS; KNOTT, TG; MOLLER, BL; ROBINSON, C				MANT, A; NIELSEN, VS; KNOTT, TG; MOLLER, BL; ROBINSON, C			MULTIPLE MECHANISMS FOR THE TARGETING OF PHOTOSYSTEM-I SUBUNIT-F, SUBUNIT-H, SUBUNIT-K, SUBUNIT-L, AND SUBUNIT-N INTO AND ACROSS THE THYLAKOID MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; ENTIRE PRECURSOR POLYPEPTIDES; CHLOROPHYLL A/B-PROTEIN; HORDEUM-VULGARE L; TRANSIT PEPTIDE; CDNA CLONE; NUCLEOTIDE-SEQUENCE; PROTON GRADIENT; PSI-K; BARLEY	The photosystem I (PSI) complex in higher plants contains eight nuclear-encoded subunits, of which two (PSI-F and -N) are synthesized with bipartite presequences containing cleavable thylakoid transfer sequences. Previous studies on four other chloroplast proteins bearing bipartite presequences have shown that they are transported across the thylakoid membrane by two distinct mechanisms. One mechanism is Delta pH dependent and hence sensitive to uncouplers, whereas the other is inhibited by azide. We show that PSI-F is targeted by the latter pathway, since its translocation across the thylakoid membrane is inhibited by azide but not by nigericin. Translocation is furthermore unaffected by the presence of high concentrations of the lumenal 23-kDa photosystem II (PSII) protein, which is known to be transported by the Delta pH dependent pathway. In contrast, translocation of PSI-N across the thylakoid membrane is completely blocked by saturating concentrations of pre-23-kDa protein. Three proteins are now known to be synthesized with thylakoid transfer signals in both higher plants and cyanobacteria (PSI-F, plastocyanin, and the 33-kDa PSII protein), and all three are transported by the azide-sensitive, possibly sec-dependent pathway. In contrast, PSI-N and the 23-kDa and 16-kDa PSII proteins (transported by the Delta pH-driven pathway in higher plants) are all absent in cyanobacteria. These data suggest that the Delta pH-dependent translocation mechanism for these proteins may also have arisen relatively recently during the evolution of the chloroplast. Three additional PSI proteins (PSI-H, -K, and -L) are synthesized in the cytosol with stroma-targeting presequences and hence integrate into the thylakoid membrane by means of information in the mature proteins. We show that the integration mechanisms are insensitive to azide in each case, and nigericin causes only a slight inhibition of integration in each case. We therefore suggest that these proteins are targeted into the thylakoid membrane by a separate pathway(s).	ROYAL VET & AGR UNIV, DEPT PLANT BIOL, PLANT BIOCHEM LAB, DK-1871 FREDERIKSBERG C, DENMARK	University of Copenhagen	MANT, A (corresponding author), UNIV WARWICK, DEPT BIOL SCI, COVENTRY CV4 7AL, W MIDLANDS, ENGLAND.		Møller, Birger Lindberg/GQI-1792-2022; Møller, Birger Lindberg/H-2657-2014	Møller, Birger Lindberg/0000-0002-3252-3119; Møller, Birger Lindberg/0000-0002-3252-3119; Mant, Alexandra/0000-0001-7169-209X				ANDERSEN B, 1993, PIGMENT PROTEIN COMP, P383; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; BRIGGS LM, 1990, PLANT MOL BIOL, V15, P633, DOI 10.1007/BF00017837; BROCK IW, 1993, PLANT MOL BIOL, V23, P717, DOI 10.1007/BF00021527; CHITNIS PR, 1987, PLANT MOL BIOL, V10, P3, DOI 10.1007/BF00014181; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CLINE K, 1986, J BIOL CHEM, V261, P4804; FRANZEN LG, 1989, MOL GEN GENET, V219, P137; GAVEL Y, 1991, FEBS LETT, V282, P41, DOI 10.1016/0014-5793(91)80440-E; GOLBECK JH, 1991, CURR TOP BIOENERG, V16, P83; HAGEMAN J, 1990, PLANT CELL, V2, P479, DOI 10.1105/tpc.2.5.479; HAGEMAN J, 1986, NATURE, V324, P567, DOI 10.1038/324567a0; HE WZ, 1992, FEBS LETT, V308, P298, DOI 10.1016/0014-5793(92)81297-Y; HENRY R, 1994, J BIOL CHEM, V269, P10189; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; HULFORD A, 1994, J BIOL CHEM, V269, P3251; JAMES HE, 1989, J BIOL CHEM, V264, P19573; KIRWIN PM, 1989, EMBO J, V8, P2251, DOI 10.1002/j.1460-2075.1989.tb08349.x; KJAERULFF S, 1993, J BIOL CHEM, V268, P18912; KLOSGEN RB, 1992, PLANT MOL BIOL, V18, P1031, DOI 10.1007/BF00019226; KNOETZEL J, 1993, PLANT MOL BIOL, V22, P337, DOI 10.1007/BF00014940; KNOTT TG, 1994, J BIOL CHEM, V269, P7843; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; KUHN A, 1988, EUR J BIOCHEM, V177, P267, DOI 10.1111/j.1432-1033.1988.tb14372.x; KUWABARA T, 1987, P NATL ACAD SCI USA, V84, P8230, DOI 10.1073/pnas.84.23.8230; LAGOUTTE B, 1988, FEBS LETT, V232, P275, DOI 10.1016/0014-5793(88)80752-X; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; MICHL D, 1994, EMBO J, V13, P1310, DOI 10.1002/j.1460-2075.1994.tb06383.x; MOULD RM, 1991, J BIOL CHEM, V266, P17286; MOULD RM, 1991, J BIOL CHEM, V266, P12189; MUNCH S, 1988, CURR GENET, V14, P511, DOI 10.1007/BF00521277; NIELSEN VS, 1994, J BIOL CHEM, V269, P3762; OKKELS JS, 1988, FEBS LETT, V237, P108, DOI 10.1016/0014-5793(88)80181-9; OKKELS JS, 1992, PLANT MOL BIOL, V18, P989, DOI 10.1007/BF00019215; OKKELS JS, 1991, J BIOL CHEM, V266, P6767; OKKELS JS, 1989, FEBS LETT, V250, P575, DOI 10.1016/0014-5793(89)80799-9; ROBINSON C, 1994, EMBO J, V13, P279, DOI 10.1002/j.1460-2075.1994.tb06260.x; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; STEPPUHN J, 1988, FEBS LETT, V237, P218, DOI 10.1016/0014-5793(88)80205-9; THEG SM, 1989, J BIOL CHEM, V264, P6730; VIITANEN PV, 1988, J BIOL CHEM, V263, P15000; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P1165; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; ZILBER AL, 1992, PLANT PHYSIOL, V99, P901, DOI 10.1104/pp.99.3.901	45	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27303	27309						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961641				2022-12-27	WOS:A1994PV77100027
J	SLOAN, IS; HOROWITZ, PM; CHIRGWIN, JM				SLOAN, IS; HOROWITZ, PM; CHIRGWIN, JM			RAPID SECRETION BY A NONCLASSICAL PATHWAY OF OVEREXPRESSED MAMMALIAN MITOCHONDRIAL RHODANESE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CATHEPSIN-D; MOLECULAR CHAPERONES; LIVER RHODANESE; PROTEINS; CELL; EXPRESSION; CDNA; THIOREDOXIN; MEMBRANES; SEQUENCE	Rhodanese is a small (33 kDa) monomeric sulfurtransferase which is synthesized on cytoplasmic ribosomes and imported into the mitochondrial matrix without cleavage of its amino terminus. When we transfected mammalian cell lines with rhodanese cDNA under the control of an efficient viral promoter, up to 40% of the overexpressed protein was secreted into the medium. This secretion was not the result of cell lysis, did not occur via the endoplasmic reticulum, and did not require the amino-terminal mitochondrial import signal. Addition of a carboxyl-terminal peptide extension did not block secretion, nor did a number of inhibitors of cellular sorting processes. Rhodanese polypeptide is known to associate with chaperonin proteins. In the absence of available mitochondrial import sites, such a complex in the cytoplasm of transfected cells could deliver unfolded rhodanese to export pores on the inner surface of the plasma membrane. This mechanism could contribute to the nonclassical secretion of cytoplasmically synthesized interleukins, growth factors, and lectins.	UNIV TEXAS,HLTH SCI CTR,DEPT MED,DIV ENDOCRINOL,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284; AUDIE L MURPHY MEM VET ADM MED CTR,RES SERV,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 05729] Funding Source: Medline; NIGMS NIH HHS [GM 25177] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOGGARAM V, 1985, BIOCHEM BIOPH RES CO, V130, P407, DOI 10.1016/0006-291X(85)90431-0; BRANDEN CI, 1980, Q REV BIOPHYS, V13, P317, DOI 10.1017/S0033583500001712; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHOTHIA C, 1990, ANNU REV BIOCHEM, V59, P1007, DOI 10.1146/annurev.bi.59.070190.005043; CRAIG EA, 1993, SCIENCE, V260, P1902, DOI 10.1126/science.8100364; DEHOOP MJ, 1992, BIOCHEM J, V286, P657, DOI 10.1042/bj2860657; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FAUST PL, 1987, J CELL BIOL, V105, P1937, DOI 10.1083/jcb.105.5.1937; FENTON WA, 1984, J BIOL CHEM, V259, P6616; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; Kuchler Karl, 1993, Trends in Cell Biology, V3, P421, DOI 10.1016/0962-8924(93)90030-5; KUDLICKI W, 1994, J BIOL CHEM, V269, P16549; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; Linstedt R., 1993, J BIOL CHEM, V268, P11750; McNeil Paul L., 1993, Trends in Cell Biology, V3, P302, DOI 10.1016/0962-8924(93)90012-P; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MIGNATTI P, 1991, J CELL BIOCHEM, V47, P201, DOI 10.1002/jcb.240470303; MILLER DM, 1991, J BIOL CHEM, V266, P4686; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; NEUPERT W, 1993, PHILOS T ROY SOC B, V339, P355, DOI 10.1098/rstb.1993.0034; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; REDDY SV, 1993, BIOTECHNIQUES, V15, P444; RUBARTELLI A, 1992, J BIOL CHEM, V267, P24161; SACHDEV D, 1991, ADV EXP MED BIOL, V306, P335; Sambrook J, 1989, MOL CLONING LABORATO; SATO S, 1993, EXP CELL RES, V207, P8, DOI 10.1006/excr.1993.1157; TARENTINO A, 1991, LABORATORY METHODS V, P299; VERNER K, 1993, TRENDS BIOCHEM SCI, V18, P366, DOI 10.1016/0968-0004(93)90090-A; WEILAND KL, 1991, BIOCHEM J, V275, P227, DOI 10.1042/bj2750227; WENG L, 1978, J BIOL CHEM, V253, P8109; WESTLEY J, 1983, FUND APPL TOXICOL, V3, P377, DOI 10.1016/S0272-0590(83)80008-6; Westley J, 1981, Methods Enzymol, V77, P285; WIENHUES U, 1992, BIOESSAYS, V14, P17, DOI 10.1002/bies.950140105; YOUNG PR, 1988, J CELL BIOL, V107, P447, DOI 10.1083/jcb.107.2.447	46	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27625	27630						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961679				2022-12-27	WOS:A1994PV77100072
J	BARROW, RT; PARKER, ET; KRISHNASWAMY, S; LOLLAR, P				BARROW, RT; PARKER, ET; KRISHNASWAMY, S; LOLLAR, P			INHIBITION BY HEPARIN OF THE HUMAN BLOOD-COAGULATION INTRINSIC PATHWAY FACTOR-X ACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT HEPARIN; PORCINE FACTOR-VIII; FACTOR-IXA; PHOSPHOLIPID-VESICLES; DERMATAN SULFATE; MEMBRANE-SURFACE; COFACTOR-II; THROMBIN; BINDING; PURIFICATION	The effect of heparin and other glycosaminoglycans on the activation of factor X by the phospholipid membrane-bound human factor IXa-factor VIIIa complex (intrinsic fXase) was studied. Standard heparin inhibited purified intrinsic fXase by 50% at approximately 0.08 unit/ml (0.4 mu g/ml), which is below the normal range of heparin concentrations achieved during antithrombotic therapy (0.2-0.7 unit/ml). Kinetic and binding experiments revealed that heparin behaves as a partial noncompetitive inhibitor. The inhibition constant of heparin with low affinity for antithrombin was indistinguishable from heparin with high affinity for antithrombin (K-i = 20 nM). Additionally, ''low molecular weight'' heparin, which also is used as an antithrombotic drug, was a potent inhibitor of intrinsic fXase (K-i = 60 nM). Dermatan sulfate inhibited intrinsic fXase much more weakly than standard heparin (IC50 = 80 mu g/ml). The IC50 of the other mammalian glycosaminoglycans, chondroitin sulfate, keratan sulfate, and hyaluronic acid, were greater than 100 mu g/ml. Purified prothrombinase and extrinsic fXase were not inhibited by heparin. We propose that part of the antithrombotic action of heparin and low molecular weight heparin is due to antithrombin-independent inhibition of intrinsic fXase and that heparin with low affinity for antithrombin may be useful as an antithrombotic agent.	EMORY UNIV,DEPT MED,ATLANTA,GA 30322	Emory University					NHLBI NIH HHS [HL46215, HL47465] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046215, R01HL047465] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRADEGORDON P, 1986, BIOCHEMISTRY-US, V25, P4033, DOI 10.1021/bi00362a007; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BARROW RT, 1994, J BIOL CHEM, V269, P593; Bevington P.R., 1969, DATA REDUCTION ERROR; BJORK I, 1982, MOL CELL BIOCHEM, V48, P161, DOI 10.1007/BF00421226; BJORK I, 1989, HEPARIN CHEM BIOL PR, P229; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BREYER HG, 1991, SEMIN THROMB HEMOST, V17, P336, DOI 10.1055/s-2007-1002631; Brinkhous KM, 1939, AM J PHYSIOL, V125, P683, DOI 10.1152/ajplegacy.1939.125.4.683; BROZE GJ, 1993, BLOOD, V82, P1679; CURTIS JE, 1994, J BIOL CHEM, V269, P6246; DOL F, 1989, BLOOD, V74, P1577; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; HOLMER E, 1989, HEPARIN CHEM BIOL PR, P575; JORGENSEN LN, 1993, BRIT J SURG, V80, P689, DOI 10.1002/bjs.1800800607; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3807; LAMPHEAR BJ, 1992, J BIOL CHEM, V267, P3725; LEIZOROVICZ A, 1992, BMJ-BRIT MED J, V305, P913, DOI 10.1136/bmj.305.6859.913; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; Lundblad R L, 1976, Methods Enzymol, V45, P156; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; OFOSU FA, 1982, THROMB RES, V28, P487, DOI 10.1016/0049-3848(82)90165-7; OLSON ST, 1991, J BIOL CHEM, V266, P6342; PRANDONI P, 1992, BRIT J SURG, V79, P505, DOI 10.1002/bjs.1800790610; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; SEGEL IH, 1974, ENZYME KINETICS BEHA, P100; THOMAS DP, 1981, THROMB HAEMOSTASIS, V46, P185; TOLLEFSEN DM, 1982, J BIOL CHEM, V257, P2162; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433	36	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26796	26800						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929416				2022-12-27	WOS:A1994PQ93100035
J	GARMROUDI, F; MACDONALD, RG				GARMROUDI, F; MACDONALD, RG			LOCALIZATION OF THE INSULIN-LIKE GROWTH-FACTOR-II (IGF-II) BINDING CROSS-LINKING SITE OF THE IGF-II MANNOSE 6-PHOSPHATE RECEPTOR TO EXTRACELLULAR REPEATS 10-11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-6-PHOSPHATE RECEPTOR; BETA-GALACTOSIDASE; ALPHA-SUBUNIT; AFFINITY; PROTEINS; CELLS; EXPRESSION; MYOBLASTS; SEQUENCE; MUTANTS	The insulin-like growth factor II (IGF-II) binding/cross-linking domain of the IGF-II/Man-6-P receptor was mapped by sequencing receptor fragments covalently attached to IGF-II. Rat placental or bovine liver receptors were purified by by pwntamannosyl-6-phosphate-Sepharose chromatography, affinity-labeled with I-125-IGF-II using disuccinimidyl tartrate, and digested with endoproteinase Glu-C. Analysis of small scale digests by gel electrophoresis revealed radiolabeled bands of similar to 17 kDa (rat) or similar to 18 kDa (bovine). For purification and sequencing of these radiolabeled receptor fragments, three receptor preparations were analyzed The initial digests were fractionated by gel filtration followed by reverse-phase high performance Liquid chromatography (HPLC), but the final purification steps differed somewhat in the three studies, using combinations of two-dimensional HPLC, gel electrophoresis, and electroblotting. Multiple sequences detected in each of these samples were unscrambled by computer-assisted and manual methods and by comparison with the quantity of labeled IGF-II present to identify sequences corresponding to fragments of the receptor covalently attached to IGF-II. The sequence, S(H)VNSXPMF, located in the COOH-terminal end of extracellular repeat 10 and beginning with serine 1488 of the bovine receptor, was the only receptor sequence common to all the samples and was the best candidate for the IGF-II cross-linked peptide by quantitative analysis. These data indicate residues within repeats 10-11 are likely to be important for IGF-II binding. We conclude that cross-linking between IGF-II and its receptor involves one or more of the 4 lysine residues located within extracellular repeat 11.	UNIV NEBRASKA,MED CTR,DEPT BIOCHEM & MOLEC BIOL,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044212] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-44212] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEUKERS MW, 1991, ENDOCRINOLOGY, V128, P1201, DOI 10.1210/endo-128-2-1201; BRAULKE T, 1988, BIOCHEM BIOPH RES CO, V150, P1287, DOI 10.1016/0006-291X(88)90769-3; BROWN WJ, 1984, CELL, V36, P295, DOI 10.1016/0092-8674(84)90223-X; BURGISSER DM, 1991, J BIOL CHEM, V266, P1029; CARMONA C, 1987, NUCLEIC ACIDS RES, V15, P675; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1994, J BIOL CHEM, V269, P3802; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; EWTON DZ, 1987, ENDOCRINOLOGY, V120, P115, DOI 10.1210/endo-120-1-115; JEFFREY AM, 1975, BIOCHEM BIOPH RES CO, V62, P608, DOI 10.1016/0006-291X(75)90442-8; KIESS W, 1987, J BIOL CHEM, V262, P12745; KIESS W, 1990, EUR J BIOCHEM, V190, P71, DOI 10.1111/j.1432-1033.1990.tb15547.x; KIESS W, 1989, J BIOL CHEM, V264, P4710; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LOBEL P, 1988, J BIOL CHEM, V263, P2563; MACDONALD RG, 1989, J BIOL CHEM, V264, P3256; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MACDONALD RG, 1987, MOL BIOL RECEPTORS T, P49; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOOS M, 1988, J BIOL CHEM, V263, P6005; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MOTTOLA C, 1984, J BIOL CHEM, V259, P2705; MURAYAMA Y, 1990, J BIOL CHEM, V265, P17456; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; NISSLEY P, 1991, ADV EXP MED BIOL, V293, P311; OKA Y, 1985, J BIOL CHEM, V260, P9435; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; RINDERKNECHT E, 1978, FEBS LETT, V89, P283, DOI 10.1016/0014-5793(78)80237-3; SAKANO KI, 1991, J BIOL CHEM, V266, P20626; SZEBENYI G, 1994, GENOMICS, V19, P120, DOI 10.1006/geno.1994.1021; TONG PY, 1988, J BIOL CHEM, V263, P2585; VARKI A, 1983, J BIOL CHEM, V258, P2808; WAHEED A, 1988, BIOCHEM BIOPH RES CO, V152, P1248, DOI 10.1016/S0006-291X(88)80419-4; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; WU DG, 1990, P NATL ACAD SCI USA, V87, P3151, DOI 10.1073/pnas.87.8.3151; YIP CC, 1988, BIOCHEM BIOPH RES CO, V157, P321, DOI 10.1016/S0006-291X(88)80050-0	40	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26944	26952						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929433				2022-12-27	WOS:A1994PQ93100056
J	GLANVILLE, RW; QIAN, RQ; MCCLURE, DW; MASLEN, CL				GLANVILLE, RW; QIAN, RQ; MCCLURE, DW; MASLEN, CL			CALCIUM BINDING, HYDROXYLATION, AND GLYCOSYLATION OF THE PRECURSOR EPIDERMAL GROWTH FACTOR-LIKE DOMAINS OF FIBRILLIN-1, THE MARFAN GENE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FACTOR-IX; EGF-LIKE DOMAINS; BETA-HYDROXYASPARTIC ACID; COAGULATION FACTOR-X; BOVINE FACTOR-X; MISSENSE MUTATION; MICROFIBRILS; SEQUENCE; ELASTIN; RESIDUES	The extracellular matrix protein fibrillin-1 is a major component of elastic microfibrils, which are complex assemblies of several proteins and are found in most connective tissues, frequently associated with elastin. Fibrillin-1 contains 43 precursor epidermal growth factor-like (pEGF) domains that have a consensus sequence for calcium binding. The calcium binding potential of a fibrillin-1 pepsin fragment (PF2) was quantitatively analyzed using microvolume equilibrium dialysis. Peptide sequence data and pepsin fragment size determination indicate that PF2 contains seven pEGF domains, each with the calcium binding consensus sequence. Scatchard plot analysis of the calcium binding data shows that PF2 has six to seven high affinity binding sites with a K-d = 250 mu M at pH 7.5. There is a second overlapping consensus sequence in the pEGF domains for beta-hydroxylation of a specific Asp/Asn residue. Five partially hydroxylated Asn residues have been identified by protein sequence analysis of fibrillin-1 fragments. This is the first demonstration of this modification in a connective tissue protein. The calcium binding consensus sequence also contains a conserved Ser residue with an apparently novel modification, which causes the Ser residue to behave like an Asp residue during protein sequencing. Marfan syndrome, a heritable disorder of connective tissue, is known to be associated with mutations in the FBN1 gene. Most of these mutations have been found in pEGF domains, frequently substituting Cys for another amino acid, destroying the pEGF motif secondary structure along with its calcium binding potential. Other mutations cause the substitution of single amino acids in the calcium binding consensus sequence, which could affect calcium binding but also the hydroxylation of Asp/Asn residues or the modification of Ser residues.	PORTLAND STATE UNIV, DEPT CHEM, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT MED, DEPT MOLEC & MED GENET, DIV ENDOCRINOL METAB & CLIN NUTR, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, UNIV CONGENITAL HEART RES CTR, PORTLAND, OR 97201 USA	Portland State University; Oregon Health & Science University; Oregon Health & Science University	GLANVILLE, RW (corresponding author), SHRINERS HOSP CRIPPLED CHILDRENS, DEPT RES, 3101 SW SAM JACKSON PK RD, PORTLAND, OR 97201 USA.		Qian, Rui/GQB-5129-2022					AOYAMA T, 1993, HUM MOL GENET, V2, P2135, DOI 10.1093/hmg/2.12.2135; BARON M, 1992, PROTEIN SCI, V1, P81; CLEARY EG, 1983, INT REV CONNECT TISS, V10, P97; COLOMBATTI A, 1987, COLLAGEN REL RES, V7, P259; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; Dietz Harry C., 1992, Human Mutation, V1, P366, DOI 10.1002/humu.1380010504; DIETZ HC, 1992, J CLIN INVEST, V89, P1674, DOI 10.1172/JCI115766; DIETZ HC, 1993, GENOMICS, V17, P468, DOI 10.1006/geno.1993.1349; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; Fullmer H M, 1974, J Oral Pathol, V3, P291, DOI 10.1111/j.1600-0714.1974.tb01724.x; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; HARRIS RJ, 1993, BIOCHEMISTRY-US, V32, P6539, DOI 10.1021/bi00077a007; HAYWARD C, 1994, HUM MOL GENET, V3, P373, DOI 10.1093/hmg/3.2.373; HEWETT DR, 1993, HUM MOL GENET, V2, P475, DOI 10.1093/hmg/2.4.475; HORRIGAN SK, 1992, J BIOL CHEM, V267, P10087; IWANAGA S, 1991, FIBRINOGEN THROMBOSI, P121; KAINULAINEN K, 1994, NAT GENET, V6, P64, DOI 10.1038/ng0194-64; KIELTY CM, 1993, FEBS LETT, V336, P323, DOI 10.1016/0014-5793(93)80829-J; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; LI ZY, 1988, CURR EYE RES, V7, P1163, DOI 10.3109/02713688809033220; MADDOX BK, 1989, J BIOL CHEM, V264, P21381; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MASLEN CL, 1993, DNA CELL BIOL, V12, P561, DOI 10.1089/dna.1993.12.561; Mecham RP, 1991, ANN N Y ACAD SCI, V624, P137; MORRIS NP, 1986, J BIOL CHEM, V261, P5638; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PERSSON E, 1991, J BIOL CHEM, V266, P2444; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SAWADA H, 1991, CELL STRUCT FUNCT, V16, P455, DOI 10.1247/csf.16.455; SELANDER M, 1990, BIOCHEMISTRY-US, V29, P8111, DOI 10.1021/bi00487a018; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; STENFLO J, 1988, J BIOL CHEM, V263, P21; STENFLO J, 1987, P NATL ACAD SCI USA, V84, P368, DOI 10.1073/pnas.84.2.368; SUGO T, 1984, J BIOL CHEM, V259, P5705; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6	43	50	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26630	26634						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929395				2022-12-27	WOS:A1994PQ93100011
J	CHEN, ZG; LI, Y; CHEN, E; HALL, DL; DARKE, PL; CULBERSON, C; SHAFER, JA; KUO, LC				CHEN, ZG; LI, Y; CHEN, E; HALL, DL; DARKE, PL; CULBERSON, C; SHAFER, JA; KUO, LC			CRYSTAL-STRUCTURE AT 1.9-ANGSTROM RESOLUTION OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV)-II PROTEASE COMPLEXED WITH L-735,524, AN ORALLY BIOAVAILABLE INHIBITOR OF THE HIV PROTEASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASE	L-735,524 is a potent, orally bioavailable inhibitor of human immunodeficiency virus (HIV) protease currently in a Phase II clinical trial. We report here the three-dimensional structure of L-735,524 complexed to HIV-2 protease at 1.9-Angstrom resolution, as well as the structure of the native HIV-2 protease at 2.5-Angstrom resolution. The structure of HIV-2 protease is found to be essentially identical to that of HIV-1 protease. In the crystal lattice of the HIV-2 protease complexed with L-735,524, the inhibitor is chelated to the active site of the homodimeric enzyme in one orientation. This feature allows an unambiguous assignment of protein-ligand interactions from the electron density map. Both Fourier and difference Fourier maps reveal clearly the closure of the flap domains of the protease upon L-735,524 binding. Specific interactions between the enzyme and the inhibitor include the hydroxy group of the hydroxyaminopentane amide moiety of L-735,524 ligating to the carboxyl groups of the essential Asp-25 and Asp-25' enzymic residues and the amide oxygens of the inhibitor hydrogen bonding to the backbone amide nitrogen of Ile-50 and Ile-50' via an intervening water molecule. A second bridging water molecule is found between the amide nitrogen N2 of L-735,524 and the carboxyl oxygen of Asp 29'. Although other hydrogen bonds also add to binding, an equally significant contribution to affinity arises from hydrophobic interactions between the protease and the inhibitor throughout the pseudo-symmetric S1/S1', S2/S2', and S3/S3' regions of the enzyme. Except for its pyridine ring, all lipophilic moieties (t-butyl, indanyl, benzyl, and piperidyl) of L-735,524 are rigidly defined in the active site.			CHEN, ZG (corresponding author), MERCK SHARP & DOHME LTD,RES LABS,DEPT BIOL CHEM,W POINT,PA 19486, USA.							ARGOS P, 1979, BIOCHEMISTRY-US, V18, P4951, DOI 10.1021/bi00589a025; CRAIG JC, 1993, ANTIVIR CHEM CHEMOTH, V4, P335, DOI 10.1177/095632029300400605; DIANZANI F, 1993, ANTIVIR CHEM CHEMOTH, V4, P329, DOI 10.1177/095632029300400604; GHOSH AK, 1994, J MED CHEM, V37, P2506, DOI 10.1021/jm00042a002; JACOBSEN H, 1993, J CELL BIOCH E S, V17, P90; MULICHAK AM, 1993, J BIOL CHEM, V268, P13103; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; SPINELLI S, 1991, BIOCHIMIE, V73, P1391, DOI 10.1016/0300-9084(91)90169-2; TONG L, 1993, P NATL ACAD SCI USA, V90, P8387, DOI 10.1073/pnas.90.18.8387; VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096	10	159	165	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26344	26348						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929352				2022-12-27	WOS:A1994PQ93000062
J	GONZALEZRUBIO, C; JIMENEZCLAVERO, MA; FONTAN, G; LOPEZTRASCASA, M				GONZALEZRUBIO, C; JIMENEZCLAVERO, MA; FONTAN, G; LOPEZTRASCASA, M			THE INHIBITORY EFFECT OF FACTOR-J ON THE ALTERNATIVE COMPLEMENT PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C3 NEPHRITIC FACTOR; BOUND C3B; FACTOR-B; AMPLIFICATION CONVERTASE; 3RD COMPONENT; SIALIC-ACID; FACTOR-H; ACTIVATION; RECOGNITION; BETA-1H	Factor J (FJ) is a cationic glycoprotein with inhibitory activity in C1, the first component of the classical complement pathway. This study demonstrates that FJ is able to regulate the activity of the alternative complement pathway. FJ inhibits the generation of fluid phase and cell-bound alternative pathway C3 convertase, C3b,Bb (C3-cleaving enzyme). Thus, FJ interferes with the generation of alternative pathway C3 convertase when sheep erythrocytes bearing antibody and activated C3 and C4 (EAC4b,3b) are incubated with the individual complement components, factors B, D, and P. FJ accelerates the decay of C3 convertase with a time course similar to that of factor H, and when both regulators are present together, the decay of enzyme activity is faster than when they are added separately. Furthermore, FJ is able to inhibit the cleavage of C3 by factor B in a fluid-phase assay. FJ prevents the initiation of alternative pathway activation in ''more stabilized systems'' with well known activators of alternative pathway C3 convertase such as C3 nephritic factor (an autoantibody against alternative pathway C3 convertase), cobra venom factor, and rabbit erythrocytes. In these systems, FJ has no effect on C3 convertase stabilized by rabbit erythrocytes or cobra venom factor. In contrast, FJ promotes the dissociation of C3 convertase stabilized by C3 nephritic factor, but with much lower efficiency than in preventing initiation. Direct interac tion of FJ with individual components of C3 convertase was shown by a solid-phase binding assay using plates coated with C3, C3b, B, Bb, or FJ. FJ inhibitory activity in the alternative pathway can be modulated by polyanions like heparin. FJ-mediated inhibition in the alternative complement pathway can be modified by surface interactions, as occurs during alternative pathway C3 convertase activation. Thus, when FJ is adsorbed by and eluted from hydroxylapatite and reverse phase columns, its inhibitory effect on more stabilized systems is lost. This loss of inhibitory activity is fully reversed when FJ is rechromatographed on heparin-Sepharose or Sepharose columns. Taking into account these data, FJ may be included in the group of highly charged molecules that inhibit the activation of classical and alternative complement pathways (i.e. eosinophil major basic protein, protamine, and heparin).	HOSP LA PAZ,UNIDAD INMUNOL,E-28046 MADRID,SPAIN	Hospital Universitario La Paz			López-Trascasa, Margarita/L-2699-2014; Jimenez-Clavero, Miguel Angel/E-3048-2010	López-Trascasa, Margarita/0000-0001-8594-282X; Jimenez-Clavero, Miguel Angel/0000-0003-2125-9743				CARRENO MP, 1989, EUR J IMMUNOL, V19, P2145, DOI 10.1002/eji.1830191126; CYONG JC, 1982, J EXP MED, V155, P587, DOI 10.1084/jem.155.2.587; DAHA MR, 1976, J IMMUNOL, V116, P1; Edens E, 1993, COMPLEMENT PROFILES, V1, P96; FEARON DT, 1977, P NATL ACAD SCI USA, V74, P1683, DOI 10.1073/pnas.74.4.1683; FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971; FISHELSON Z, 1987, MOL IMMUNOL, V24, P987, DOI 10.1016/0161-5890(87)90011-3; GIGLI I, 1969, J EXP MED, V129, P679, DOI 10.1084/jem.129.4.679; HORSTMANN RD, 1985, J IMMUNOL, V134, P1101; HUDSON L, 1989, PRACTICAL IMMUNOLOGY, P34; HUDSON L, 1989, PRACTICAL IMMUNOLOGY, P49; Jimenez-Clavero M. A., 1993, Molecular Immunology, V30, P21, DOI 10.1016/0161-5890(93)90242-4; JIMENEZCLAVERO MA, 1994, CLIN BIOCHEM, V27, P169, DOI 10.1016/0009-9120(94)90051-5; JOINER KA, 1988, ANNU REV MICROBIOL, V42, P201, DOI 10.1146/annurev.mi.42.100188.001221; KAZATCHKINE MD, 1979, J EXP MED, V150, P1202, DOI 10.1084/jem.150.5.1202; KAZATCHKINE MD, 1979, J IMMUNOL, V122, P75; KERR MA, 1981, METHOD ENZYMOL, V80, P102; KOSKI CL, 1985, J IMMUNOL, V134, P1810; LACHMANN PJ, 1975, CLIN EXP IMMUNOL, V21, P109; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRIS JD, 1984, J BIOL CHEM, V259, P2685; LESAVRE PH, 1979, J IMMUNOL, V123, P529; LESAVRE PH, 1978, J EXP MED, V148, P1498, DOI 10.1084/jem.148.6.1498; Liszewski M. Kathryn, 1993, P917; LOPEZTRASCASA M, 1989, J BIOL CHEM, V264, P16214; LOPEZTRASCASA M, 1987, J IMMUNOL METHODS, V98, P77, DOI 10.1016/0022-1759(87)90438-8; MANGHAM DC, 1993, J CLIN PATHOL, V46, P517, DOI 10.1136/jcp.46.6.517; NAGAKI K, 1978, INT ARCH ALLER A IMM, V57, P221, DOI 10.1159/000232106; NICHOLSON-WELLER A, 1991, Complement and Inflammation, V8, P198; NILSSON UR, 1965, J EXP MED, V122, P277, DOI 10.1084/jem.122.2.277; OHI H, 1990, J IMMUNOL METHODS, V131, P71, DOI 10.1016/0022-1759(90)90234-M; PANGBURN MK, 1989, J IMMUNOL, V142, P2759; PANGBURN MK, 1991, J BIOL CHEM, V266, P16847; PANGBURN MK, 1978, P NATL ACAD SCI USA, V75, P2416, DOI 10.1073/pnas.75.5.2416; PANGBURN MK, 1980, J IMMUNOL, V124, P977; PANGBURN MK, 1984, SPRINGER SEMIN IMMUN, V7, P163, DOI 10.1007/BF01893019; ROOS MH, 1982, NATURE, V298, P854, DOI 10.1038/298854a0; SAHU A, 1993, MOL IMMUNOL, V30, P679, DOI 10.1016/0161-5890(93)90079-Q; SAKAI K, 1973, J IMMUNOL, V110, P1010; SANCHEZCORRAL P, 1989, J IMMUNOL METHODS, V122, P105, DOI 10.1016/0022-1759(89)90340-2; SANCHEZCORRAL P, 1990, MOL IMMUNOL, V27, P891, DOI 10.1016/0161-5890(90)90156-T; SEGURADO OG, 1992, CLIN EXP IMMUNOL, V87, P410; VOGEL CW, 1985, DEV COMP IMMUNOL, V9, P311, DOI 10.1016/0145-305X(85)90122-3; VOGEL CW, 1984, J IMMUNOL METHODS, V73, P203, DOI 10.1016/0022-1759(84)90045-0; WEILER JM, 1988, J IMMUNOL, V140, P1605; WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268; WEILER JM, 1983, IMMUNOPHARMACOLOGY, V6, P245, DOI 10.1016/0162-3109(83)90024-3	47	6	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26017	26024						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929312				2022-12-27	WOS:A1994PQ93000016
J	CHEFALO, PJ; YANG, JM; RAMAIAH, KVA; GEHRKE, L; CHEN, JJ				CHEFALO, PJ; YANG, JM; RAMAIAH, KVA; GEHRKE, L; CHEN, JJ			INHIBITION OF PROTEIN-SYNTHESIS IN INSECT CELLS BY BACULOVIRUS-EXPRESSED HEME-REGULATED EIF-2-ALPHA KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION FACTOR-II; CONTROLLED TRANSLATIONAL REPRESSOR; ALPHA-SUBUNIT; FACTOR EIF-2; HELA-CELLS; PHOSPHORYLATION; GCN2; YEAST; FACTOR-2-ALPHA; ACTIVATION	To study further the regulation of the hems-regulated eIF-2 alpha kinase (HRI), we have produced functional wild type HRI using the baculovirus expression system. The amount of recombinant HRI protein expressed in insect cells is approximately 10 times higher than levels in reticulocytes. Baculovirus-expressed HRI (BV-HRI) is indistinguishable from HRI purified from rabbit reticulocytes, It is active both as an autokinase and an eIF-2 alpha kinase. BV-HRI is regulated by heme in vitro as well as in intact insect cells. Coexpression of the wild type HRI with the inactive K199R HRI, S51A eIF-2 alpha, or interleukin-1 beta (IL-1 beta) results in diminished expression of these proteins. Expression of wild type HRI also results in severe inhibition of general protein synthesis in Sf9 cells when compared with cells expressing K199R HRI or IL-beta. In addition, the guanine nucleotide exchange activity of eIF-2B is suppressed in Sf9 cells expressing wild type HRI but not in cells expressing the K199R HRI or IL-1 beta. Furthermore, expression of wild type HRI is increased by coexpression with the nonphosphorylatable S51A eIF-2 alpha or by the addition of hemin, which inhibits HRI activity. These results provide evidence that translational regulation by phosphorylation of eIF-2 alpha and sequestration of eIF-2B can operate in insect cells.	MIT,HARVARD MIT DIV HLTH SCI & TECHNOL,CAMBRIDGE,MA 02139	Harvard University; Massachusetts Institute of Technology (MIT)				Ramaiah, Kolluru/0000-0002-3478-5294	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042504] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK016272] Funding Source: Medline; NIGMS NIH HHS [GM42504, R01 GM042504] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBER GN, 1993, P NATL ACAD SCI USA, V90, P4621, DOI 10.1073/pnas.90.10.4621; BARBER GN, 1992, VIROLOGY, V191, P670, DOI 10.1016/0042-6822(92)90242-H; BOAL TR, 1993, BIOCHIM BIOPHYS ACTA, V1176, P257, DOI 10.1016/0167-4889(93)90053-R; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P315, DOI 10.1073/pnas.88.2.315; CHEN JJ, 1989, J BIOL CHEM, V264, P9559; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CHEN JJ, 1993, TRANSLATIONAL REGULA, V2, P349; CHOI SY, 1992, J BIOL CHEM, V267, P286; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; COLTHURST DR, 1987, EUR J BIOCHEM, V166, P357, DOI 10.1111/j.1432-1033.1987.tb13523.x; CROSBY JS, 1994, MOL CELL BIOL, V14, P3906, DOI 10.1128/MCB.14.6.3906; DEALDANA CRV, 1993, P NATL ACAD SCI USA, V90, P7215; DEBENEDETTI A, 1986, J BIOL CHEM, V261, P338; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DUNCAN R, 1985, J BIOL CHEM, V260, P5486; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; FAGARD R, 1981, P NATL ACAD SCI-BIOL, V78, P866, DOI 10.1073/pnas.78.2.866; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; GROSS M, 1978, BIOCHIM BIOPHYS ACTA, V520, P650, DOI 10.1016/0005-2787(78)90150-8; GROSS M, 1987, BIOCHIM BIOPHYS ACTA, V908, P123, DOI 10.1016/0167-4781(87)90051-0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; JACKSON RJ, 1985, BIOCHIM BIOPHYS ACTA, V826, P224, DOI 10.1016/0167-4781(85)90010-7; Jackson RJ, 1991, TRANSLATION EUKARYOT, P193; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KIMBALL SR, 1990, J BIOL CHEM, V265, P16794; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LONDON IM, 1987, ENZYMES, V18, P359; MAO XH, 1992, J BIOL CHEM, V267, P20444; MATTS RL, 1984, J BIOL CHEM, V259, P6708; MATTS RL, 1992, J BIOL CHEM, V267, P18160; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MURTHARIEL P, 1993, J BIOL CHEM, V268, P12946; PAL JK, 1991, BIOCHEMISTRY-US, V30, P2555, DOI 10.1021/bi00223a037; QU SM, 1994, GENE, V140, P239, DOI 10.1016/0378-1119(94)90550-9; RAMAIAH KVA, 1994, MOL CELL BIOL, V14, P4546, DOI 10.1128/MCB.14.7.4546; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; THOMIS DC, 1992, P NATL ACAD SCI USA, V89, P10837, DOI 10.1073/pnas.89.22.10837; TRACHSEL H, 1978, P NATL ACAD SCI USA, V75, P3654, DOI 10.1073/pnas.75.8.3654; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; YANG JM, 1992, J BIOL CHEM, V267, P20519	45	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25788	25794						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929284				2022-12-27	WOS:A1994PQ49100083
J	DATTA, PK; BAGCHI, S				DATTA, PK; BAGCHI, S			REPRESSION OF TRANSFORMING GROWTH-FACTOR-BETA-1 PROMOTER BY THE ADENOVIRUS ONCOGENE E1A - IDENTIFICATION OF A UNIQUE GC-RICH SEQUENCE AS A TARGET FOR E1A REPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E2F TRANSCRIPTION FACTOR; RETINOBLASTOMA GENE-PRODUCT; FACTOR-BETA-1 GENE; FUNCTIONAL DOMAINS; BINDING-ACTIVITY; INFECTED CELLS; CYCLIN-A; PROTEINS; ENHANCER; EXPRESSION	The transforming growth factor beta 1 (TGF-beta 1) is a key regulator of proliferation and differentiation in a wide variety of cell types. It is a potent growth inhibitor for most epithelial, endothelial, lymphoid, and myeloid cells. In the present study, we showed that a DNA virus oncoprotein, E1A strongly repressed the activity of the TGF-beta 1 promoter in a variety of cell lines. Interestingly, this repression was specific for 12 S E1A because 13 S E1A was much less active in this assay. Analysis of a series of E1A mutants showed that the repression was dependent on the amino terminus and the conserved region 1 of the E1A protein. To identify the target sequence for E1A repression in the TGF-beta 1 promoter, a series of mutant promoters were analyzed and a 10-base pair GC-rich sequence between -91 and -82 was found to be the major target for E1A repression of the promoter. Using chimeric reporter constructs, we provide evidence that the 10-base pair GC-rich sequence is sufficient to impart sequence-specific E1A repression to a heterologous promoter. Additionally, we suggest that the mechanism of E1A repression through this GC-rich element does not involve abrogation of the retinoblastoma control of the TGF-beta 1 promoter.	UNIV ILLINOIS, COLL DENT, CTR MOLEC BIOL ORAL DIS, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital								BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BERK AJ, 1992, TRANSCRIPTIONAL REGU, V2; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEN ST, 1992, J VIROL, V66, P7452, DOI 10.1128/JVI.66.12.7452-7460.1992; COUREY AJ, 1993, TRANSCRIPTIONAL REGU, V2, P743; DYSON N, 1992, CANCER SURV, V12, P161; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; GEISER AG, 1991, MOL CELL BIOL, V11, P84, DOI 10.1128/MCB.11.1.84; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1991, MOL CELL BIOL, V11, P5222, DOI 10.1128/MCB.11.10.5222; KIM SJ, 1989, J BIOL CHEM, V264, P402; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; MASSAGUE J, 1992, CANCER SURV, V12, P81; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MOSES HL, 1985, CANCER CELL, V3, P65; NAKAJIMA T, 1992, MOL CELL BIOL, V12, P2837, DOI 10.1128/MCB.12.6.2837; NEVINS JR, 1989, ADV VIRUS RES, V37, P35; NEVINS JR, 1992, SCIENCE, V258, P424; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; SHIPLEY GD, 1986, CANCER RES, V46, P2068; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	47	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25392	25399						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929236				2022-12-27	WOS:A1994PQ49100028
J	DEY, S; DOU, DX; ROSEN, BP				DEY, S; DOU, DX; ROSEN, BP			ATP-DEPENDENT ARSENITE TRANSPORT IN EVERTED MEMBRANE-VESICLES OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED ARSENATE RESISTANCE; ANION PUMP; TRANSLOCATING ATPASE; ARSB PROTEIN; MOLECULAR CHARACTERIZATION; EXPRESSION; OPERON; CONSTRUCTION; SYSTEMS; CLONING	Resistance to toxic oxyanions of arsenic and antimony in Escherichia coli results from active efflux of these anions out of the cell. Extrusion is an active process mediated by an ATP-dependent pump composed of two types of subunits, the integral membrane ArsB protein and the catalytic ArsA subunit. An in vitro assay for transport in everted membrane vesicles of E. coli was developed, Uptake of (AsO2-)-As-73, by everted vesicles was time- and temperature-dependent and required both pump subunits. Transport required ATP; no other nucleotide, including GTP, CTP, UTP, or the nonhydrolyzable analog adenosine 5'-O-(thiotriphosphate), could substitute for ATP. Protonophores, ionophores, or inhibitors of other types of ion-motive ATPases did not inhibit arsenite uptake. The sulfhydryl reagent N-ethylmaleimide was a potent inhibitor of ATP-dependent arsenite accumulation in vesicles. The apparent K-m values for ATP and arsenite were approximately 2 and 0.1 mM, respectively. Antimonite, the most potent activator of the ArsA ATPase, inhibited arsenite uptake with an apparent K-i of 10 mu M.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM, DETROIT, MI 48201 USA	Wayne State University				Rosen, Barry P./0000-0002-5230-4271	NIAID NIH HHS [AI19793] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019793] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMBUDKAR SV, 1984, J BIOL CHEM, V259, P6142; ANGOV E, 1988, J BACTERIOL, V170, P459, DOI 10.1128/jb.170.1.459-462.1988; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHEN CM, 1986, J BIOL CHEM, V261, P5030; DEY S, 1994, IN PRESS MOL BIOCH P; DEY S, 1994, IN PRESS ARCH BIOCH; DOU DX, 1992, J BIOL CHEM, V267, P25768; FRANCISCO MJDS, 1989, MOL MICROBIOL, V3, P15, DOI 10.1111/j.1365-2958.1989.tb00098.x; HEDGES RW, 1973, J BACTERIOL, V115, P459, DOI 10.1128/JB.115.1.459-460.1973; HSU CM, 1989, J BIOL CHEM, V264, P17349; KAUR P, 1992, PLASMID, V27, P29, DOI 10.1016/0147-619X(92)90004-T; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MOBLEY HLT, 1983, MOL GEN GENET, V191, P421, DOI 10.1007/BF00425757; MOBLEY HLT, 1982, P NATL ACAD SCI-BIOL, V79, P6119, DOI 10.1073/pnas.79.20.6119; ODEN KL, 1994, MOL MICROBIOL, V12, P301, DOI 10.1111/j.1365-2958.1994.tb01018.x; OUELLETTE M, 1991, RES MICROBIOL, V142, P737, DOI 10.1016/0923-2508(91)90089-S; OWOLABI JB, 1990, J BACTERIOL, V172, P2367, DOI 10.1128/jb.172.5.2367-2371.1990; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PERLIN DS, 1986, ARCH BIOCHEM BIOPHYS, V248, P53, DOI 10.1016/0003-9861(86)90400-5; REAY PF, 1977, ANAL BIOCHEM, V78, P557, DOI 10.1016/0003-2697(77)90117-8; ROSEN BP, 1992, ANN NY ACAD SCI, V671, P257, DOI 10.1111/j.1749-6632.1992.tb43801.x; ROSEN BP, 1984, BIOCHEM BIOPH RES CO, V124, P760, DOI 10.1016/0006-291X(84)91023-4; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; ROSEN BP, 1990, PHILOS T ROY SOC B, V326, P455, DOI 10.1098/rstb.1990.0024; SANFRANCISCO MJD, 1990, NUCLEIC ACIDS RES, V18, P619; TISA LS, 1990, J BIOENERG BIOMEMBR, V22, P493, DOI 10.1007/BF00762959; TISA LS, 1990, J BIOL CHEM, V265, P190; WANG HF, 1993, BIOCHEM BIOPH RES CO, V192, P1093, DOI 10.1006/bbrc.1993.1529; WANG ZL, 1993, TOXICOL APPL PHARM, V118, P80, DOI 10.1006/taap.1993.1012; WU JH, 1992, J BIOL CHEM, V267, P12570	33	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25442	25446						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929243				2022-12-27	WOS:A1994PQ49100036
J	DIAS, JA; ZHANG, YQ; LIU, XX				DIAS, JA; ZHANG, YQ; LIU, XX			RECEPTOR-BINDING AND FUNCTIONAL-PROPERTIES OF CHIMERIC HUMAN FOLLITROPIN PREPARED BY AN EXCHANGE BETWEEN A SMALL HYDROPHILIC INTERCYSTEINE LOOP OF HUMAN FOLLITROPIN AND HUMAN LUTROPIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; HUMAN CHORIOGONADOTROPIN-BETA; HUMAN CHORIONIC-GONADOTROPIN; GLYCOPROTEIN HORMONES; BIOLOGICAL-ACTIVITY; ALPHA-SUBUNIT; MUTAGENESIS; SEQUENCE; PITUITARY; REGION	The family of pituitary/placental glycoprotein hormones includes follicle-stimulating hormone (follitropin, FSH), luteinizing hormone (lutropin, LH), chorionic gonadotropin (choriogonadotropin, CG), and thyroid-stimulating hormone (thyrotropin, TSH). These glycoproteins are heterodimeric, with an cu-subunit of identical primary structure and a hormone-specific beta-subunit which is believed to confer receptor specificity. Previous studies demonstrated that substitution of hFSH beta residues 88-108 in place of the carboxyl terminus of hCG beta, residues 94-145, conferred to human (h) CG an FSH receptor binding specificity. To more finely map the LH/FSH receptor binding specificity determinant, hFSH beta residues (DSDS91)-D-88, within the small hydrophilic intercysteine loop, and residues (95)TVRGLG(100) COOH-terminal to the loop were switched to hLH beta residues (94)RRST(97) and residues (101)GGPKDH(106), respectively. Substitution of hLH beta residues (94)RRST(97) in place of hFSH beta residues (DSDS91)-D-88 did not affect FSH receptor binding or activation but, remarkably, conferred LH receptor binding activity to the chimera. This chimera retained the ability to stimulate progesterone production in a Y1 cell line which expresses human FSH receptor. Replacing hFSH beta residues (95)TVRGLG(100) with hLH beta residues (101)GGPKDH(106) diminished FSH receptor binding activity but did not confer LH receptor binding to the chimera. This study suggests that amino acids within hFSH beta residues (95)TVRGLG(100) are important for FSH binding specificity and that hLH beta residues (94)RRST(97) are involved in LH receptor binding specificity. Thus, although the hFSH beta and hLH beta subunits may fold similarly, the loci of receptor binding specificity are not entirely homologous.	SUNY ALBANY,SCH PUBL HLTH,ALBANY,NY 12201	State University of New York (SUNY) System; State University of New York (SUNY) Albany	DIAS, JA (corresponding author), NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,EMPIRE STATE PLAZA,POB 509,ALBANY,NY 12201, USA.			Dias, James A/0000-0002-9792-5469	NICHD NIH HHS [HD-18407] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018407] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAENZIGER JU, 1988, BIOCHIM BIOPHYS ACTA, V947, P287, DOI 10.1016/0304-4157(88)90012-3; BIRKEN S, 1986, J BIOL CHEM, V261, P719; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; CHEN F, 1991, J BIOL CHEM, V266, P19357; CHEN F, 1991, BIOCHEMISTRY-US, V30, P10171, DOI 10.1021/bi00106a014; CHEN F, 1992, J MOL ENDOCRINOL, V8, P87, DOI 10.1677/jme.0.0080087; CHEN F, 1991, J BIOL CHEM, V266, P6904; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; DIAS JA, 1984, BIOL REPROD, V31, P975, DOI 10.1095/biolreprod31.5.975; DIAS JA, 1992, TRENDS ENDOCRIN MET, V3, P24, DOI 10.1016/1043-2760(92)90088-I; GRISWOLD MD, 1993, SERTOLI CELL, P494; HUANG JN, 1993, MOL CELL ENDOCRINOL, V90, P211, DOI 10.1016/0303-7207(93)90154-C; KELTON CA, 1992, MOL CELL ENDOCRINOL, V89, P141, DOI 10.1016/0303-7207(92)90220-Z; KEUTMANN HT, 1983, J BIOL CHEM, V258, P4521; KEUTMANN HT, 1992, MOL CELL ENDOCRINOL, V86, pC1, DOI 10.1016/0303-7207(92)90168-6; KEUTMANN HT, 1989, MOL ENDOCRINOL, V3, P526, DOI 10.1210/mend-3-3-526; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LIU C, 1993, J BIOL CHEM, V268, P21613; LUSTBADER JW, 1993, ENDOCR REV, V14, P291, DOI 10.1210/er.14.3.291; MORBECK DE, 1993, MOL CELL ENDOCRINOL, V97, P173, DOI 10.1016/0303-7207(93)90225-9; MORRIS JC, 1990, J BIOL CHEM, V265, P1881; MOYLE WR, 1991, J BIOL CHEM, V266, P10807; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; RICHARDS JS, 1980, PHYSIOL REV, V60, P51, DOI 10.1152/physrev.1980.60.1.51; ROOS P, 1964, BIOCHIM BIOPHYS ACTA, V82, P218, DOI 10.1016/0304-4165(64)90042-X; ROTH KE, 1993, ENDOCRINOLOGY, V132, P2571, DOI 10.1210/en.132.6.2571; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; SAIRAM MR, 1990, BIOCHEM CELL BIOL, V68, P889, DOI 10.1139/o90-131; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTACOLOMA TA, 1991, MOL CELL ENDOCRINOL, V78, P197, DOI 10.1016/0303-7207(91)90123-A; STRICKLAND TW, 1982, ENDOCRINOLOGY, V111, P95, DOI 10.1210/endo-111-1-95; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VAKHARIA DD, 1991, ENDOCRINOLOGY, V128, P1797, DOI 10.1210/endo-128-4-1797; VAKHARIA DD, 1992, MOL CELL ENDOCRINOL, V85, P89, DOI 10.1016/0303-7207(92)90128-S; VAKHARIA DD, 1990, ENDOCRINOLOGY, V127, P658, DOI 10.1210/endo-127-2-658; Ward D.N., 1979, ANIMAL MODELS RES FE, P151; WARD DN, 1990, GLYCOPROTEIN HORMONE, P81; WEINER RS, 1991, ENDOCRINOLOGY, V128, P1485, DOI 10.1210/endo-128-3-1485; WEINER RS, 1992, ENDOCRINOLOGY, V131, P1026, DOI 10.1210/en.131.3.1026; WUTHRICH K, 1989, SCIENCE, V243, P45, DOI 10.1126/science.2911719; YANAGISHITA M, 1978, ANAL BIOCHEM, V88, P1, DOI 10.1016/0003-2697(78)90393-7	43	72	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25289	25294						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929221				2022-12-27	WOS:A1994PQ49100011
J	HABIB, T; HERRERA, R; DECKER, SJ				HABIB, T; HERRERA, R; DECKER, SJ			ACTIVATORS OF PROTEIN-KINASE-C STIMULATE ASSOCIATION OF SHC AND THE PEST TYROSINE PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NUCLEOTIDE EXCHANGE FACTOR; SIGNAL TRANSDUCTION; CELLS; PHOSPHORYLATION; GRB2; RECEPTOR; RAS; EXPRESSION; TRANSFORMATION; CLONING	Using the yeast two-hybrid system, complementary DNA clones were isolated from a HeLa cell library encoding proteins that interacted with p52(shc). One of these clones encoded the non-catalytic, COOH-terminal half of the cytosolic protein tyrosine phosphatase PTP-PEST. Expression of truncated forms of p52(shc) in the two hybrid system revealed that the amino terminal half of p52(shc) was sufficient for interaction with PTP-PEST. The p52 and p66 forms of Shc, but not the p46 form, bound to a glutathione S-transferase fusion protein containing the region of PTP-PEST isolated from the two-hybrid screen. Similarly, when HeLa cell lysates were immunoprecipitated with PTP-PEST antiserum, p52(shc) and p66(shc) proteins, but not p46(shc), co-precipitated. Shc-PTP-PEST complex formation was stimulated 6-8 fold by the protein kinase C activator phorbol 12-myristate 13-acetate, while epidermal growth factor and serum had no effect. Phorbol 12-myristate 13-acetate also stimulated phosphorylation of p52(shc) and p66(shc). The muscarinic agonist carbachol (also an activator of protein kinase C) stimulated complex formation 3-5-fold in SH-SY5Y neuroblastoma cells. These results suggest a role for PTP-PEST in G protein receptor signaling and in cross-talk between G protein receptor and tyrosine kinase receptor pathways.	WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,ANN ARBOR,MI 48106; UNIV MICHIGAN,SCH MED,DEPT MICROBIOL,ANN ARBOR,MI 48104	Pfizer; University of Michigan System; University of Michigan								BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DECKER SJ, 1989, J BIOL CHEM, V264, P17641; DENHERTOG J, 1992, BIOCHEM BIOPH RES CO, V184, P1241, DOI 10.1016/S0006-291X(05)80015-4; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GIL J, 1991, J CELL BIOL, V113, P943, DOI 10.1083/jcb.113.4.943; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUTKIND JS, 1992, BIOCHEM BIOPH RES CO, V188, P155; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LAMBERT DG, 1990, BIOCHEM J, V265, P555, DOI 10.1042/bj2650555; OFFERMANNS S, 1993, BIOCHEM J, V294, P545, DOI 10.1042/bj2940545; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; Rose M. D., 1990, METHODS YEAST GENETI, P155; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; TAKEKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P1223, DOI 10.1016/0006-291X(92)92335-U; TURNER NA, 1994, BIOCHEM J, V297, P407, DOI 10.1042/bj2970407; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; YANG Q, 1993, J BIOL CHEM, V268, P6622	32	64	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25243	25246						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929214				2022-12-27	WOS:A1994PQ49100003
J	KLEIN, JC; BLEEKER, MJ; ROELEN, HCPF; RAFFERTY, JA; MARGISON, GP; BRUGGHE, HF; VANDENELST, H; VANDERMAREL, GA; VANBOOM, JH; KRIEK, E; BERNS, AJM				KLEIN, JC; BLEEKER, MJ; ROELEN, HCPF; RAFFERTY, JA; MARGISON, GP; BRUGGHE, HF; VANDENELST, H; VANDERMAREL, GA; VANBOOM, JH; KRIEK, E; BERNS, AJM			ROLE OF NUCLEOTIDE EXCISION-REPAIR IN PROCESSING OF O4-ALKYLTHYMINES IN HUMAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A XERODERMA-PIGMENTOSUM; SOLID-PHASE SYNTHESIS; ETHYL-N-NITROSOUREA; ESCHERICHIA-COLI; MAMMALIAN-CELLS; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; PLASMID DNA; RAT-LIVER; GENE; OLIGODEOXYNUCLEOTIDES	O-4-Alkylthymines have been implicated as potential carcinogenic DNA lesions. We have studied the effects of O-4-methylthymine, O-4-ethylthymine, and O-4-n-propyl-thymine in a model system in which a single lesion was located at a defined position on a SV40-based shuttle vector and have found large differences in the effects of these lesions in repair-proficient and nucleotide excision repair deficient cells. In repair-competent human HeLa cells, normal fibroblasts, and XP-A(2OS) revertant cells, all 3 residues were highly mutagenic; a mutation frequency of approximate to 20% was found for both O-4-methylthymine and O-4-ethylthymine, whereas that of O-4-n-propylthymine was approximate to 12%. These frequencies were independent of the activity of the O-6-alkylguanine DNA alkyltransferase. All three O-4-alkylthymines induced T --> C transitions exclusively. In nucleotide excision repair-deficient XP-A cells, however, these lesions were not mutagenic but strongly inhibited plasmid replication (>90%), These results indicate that O-4-alkylthymines are efficiently recognized by the nucleotide excision repair system and cause a complete cessation of plasmid replication if this system is deficient. Nevertheless, proficiency in the nucleotide excision repair pathway correlates with a high frequency of mutation induction by these lesions.	NETHERLANDS CANC INST, DIV MOLEC GENET, 1066 CX AMSTERDAM, NETHERLANDS; NETHERLANDS CANC INST, DIV MOLEC CARCINOGENESIS, 1066 CX AMSTERDAM, NETHERLANDS; LEIDEN STATE UNIV, GORLAEUS LABS, 2300 RA LEIDEN, NETHERLANDS; CHRISTIE HOSP NATL HLTH SERV TRUST, PATERSON INST CANC RES, CRC, DEPT CARCINOGENESIS, MANCHESTER M20 9BX, LANCS, ENGLAND	Netherlands Cancer Institute; Netherlands Cancer Institute; Leiden University; Leiden University - Excl LUMC; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research			Margison, Geoff/E-4146-2019					BECKER RA, 1985, CARCINOGENESIS, V6, P313, DOI 10.1093/carcin/6.2.313; BELT PBG, 1991, DEV EPSTEIN BARR VIR, P73; BODELL WJ, 1979, NUCLEIC ACIDS RES, V6, P2819, DOI 10.1093/nar/6.8.2819; BOYLE JM, 1987, J CELL SCI, P147; BREDBERG A, 1986, P NATL ACAD SCI USA, V83, P8273, DOI 10.1073/pnas.83.21.8273; BRENT TP, 1988, P NATL ACAD SCI USA, V85, P1759, DOI 10.1073/pnas.85.6.1759; BRONSTEIN SM, 1992, CANCER RES, V52, P2008; BRONSTEIN SM, 1991, CANCER RES, V51, P5188; BUBLEY GJ, 1991, MOL CARCINOGEN, V4, P397, DOI 10.1002/mc.2940040512; BURNS PA, 1988, CANCER RES, V48, P4455; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DENENGELSE L, 1986, CARCINOGENESIS, V7, P393; DOLAN ME, 1988, CARCINOGENESIS, V9, P2139, DOI 10.1093/carcin/9.11.2139; DOLAN ME, 1988, MUTAT RES, V193, P131, DOI 10.1016/0167-8817(88)90043-0; ELLISON KS, 1989, P NATL ACAD SCI USA, V86, P8620, DOI 10.1073/pnas.86.22.8620; FAN CY, 1990, NUCLEIC ACIDS RES, V18, P5723, DOI 10.1093/nar/18.19.5723; GRAVES RJ, 1989, CARCINOGENESIS, V10, P661, DOI 10.1093/carcin/10.4.661; HALL J, 1985, CARCINOGENESIS, V6, P209, DOI 10.1093/carcin/6.2.209; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KLEIN JC, 1992, NUCLEIC ACIDS RES, V20, P4437, DOI 10.1093/nar/20.17.4437; KLEIN JC, 1990, NUCLEIC ACIDS RES, V18, P4131, DOI 10.1093/nar/18.14.4131; KOIKE G, 1990, J BIOL CHEM, V265, P14754; MAH MCM, 1991, P NATL ACAD SCI USA, V88, P10193, DOI 10.1073/pnas.88.22.10193; MCCARTHY TV, 1984, EMBO J, V3, P545, DOI 10.1002/j.1460-2075.1984.tb01844.x; MORIMOTO K, 1985, CARCINOGENESIS, V6, P1027, DOI 10.1093/carcin/6.7.1027; MORTEN JEN, 1988, CARCINOGENESIS, V9, P45, DOI 10.1093/carcin/9.1.45; PEGG AE, 1990, CHEM CARCINOGENESIS, V2, P103; PRESTON BD, 1987, J BIOL CHEM, V262, P13821; REBECK GW, 1988, P NATL ACAD SCI USA, V85, P3039, DOI 10.1073/pnas.85.9.3039; RICHARDSON FC, 1985, CARCINOGENESIS, V6, P625, DOI 10.1093/carcin/6.4.625; ROELEN HCPF, 1992, RECL TRAV CHIM PAY B, V111, P99; ROELEN HCPF, 1992, RECL TRAV CHIM PAY B, V111, P227; SAFFHILL R, 1985, CHEM-BIOL INTERACT, V53, P121, DOI 10.1016/S0009-2797(85)80090-9; SAFFHILL R, 1985, BIOCHIM BIOPHYS ACTA, V823, P111, DOI 10.1016/0304-419X(85)90009-5; SAMSON L, 1988, EMBO J, V7, P2261, DOI 10.1002/j.1460-2075.1988.tb03066.x; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SASSANFAR M, 1991, J BIOL CHEM, V266, P2767; SATOKATA I, 1990, P NATL ACAD SCI USA, V87, P9908, DOI 10.1073/pnas.87.24.9908; SATOKATA I, 1992, MUTAT RES, V273, P193, DOI 10.1016/0921-8777(92)90080-M; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SINGER B, 1989, P NATL ACAD SCI USA, V86, P8271, DOI 10.1073/pnas.86.21.8271; SINGER B, 1986, P NATL ACAD SCI USA, V83, P28, DOI 10.1073/pnas.83.1.28; SINGER B, 1986, CANCER RES, V46, P4879; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; WANI AA, 1990, CARCINOGENESIS, V11, P1419, DOI 10.1093/carcin/11.8.1419; XIAO W, 1991, EMBO J, V10, P2179, DOI 10.1002/j.1460-2075.1991.tb07753.x; YAROSH DB, 1985, CARCINOGENESIS, V6, P949, DOI 10.1093/carcin/6.7.949	49	36	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25521	25528						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929253				2022-12-27	WOS:A1994PQ49100046
J	TAN, SY; ASO, T; CONAWAY, RC; CONAWAY, JW				TAN, SY; ASO, T; CONAWAY, RC; CONAWAY, JW			ROLES FAR BOTH THE RAP30 AND RAP74 SUBUNITS OF TRANSCRIPTION FACTOR IIF IN TRANSCRIPTION INITIATION AND ELONGATION BY RNA-POLYMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI SIGMA-70; MAJOR LATE PROMOTER; PREINITIATION COMPLEX; FUNCTIONAL-PROPERTIES; ACCURATE INITIATION; FACTOR-SII; CHAIN ELONGATION; FACTOR-EPSILON; FACTOR-DELTA; MINIMAL SET	Mammalian transcription factor IIF (TFIIF) is a heterodimer composed of similar to 30-kDa (RAP30) and similar to 70-kDa (RAP74) subunits. TFIIF has been shown to bind RNA polymerase II and control the activity of the enzyme in both the initiation and elongation stages of transcription. Although previous studies have established a role for RAP30 in assembly of the preinitiation complex and in transcription initiation, information on the function of RAP74 in these processes has been lacking. Using a highly purified transcription system and assays that permit sensitive measurement of the contributions of both RAP30 and RAP74 to TFIIF function, we have investigated the roles of these TFIIF subunits in transcription initiation and elongation. Results of template competition experiments indicate that both RAP30 and RAP74 contribute to the formation of stable preinitiation intermediates containing RNA polymerase II. Investigation of the role of TFIIF in transcription initiation indicates that both RAP30 and RAP74 function in synthesis of the first few phosphodiester bonds of nascent transcripts and in formation of Sarkosyl-resistant preinitiation intermediates. Finally, kinetic experiments indicate that both RAP30 and RAP74 function in TFIIF-mediated stimulation of the rate of RNA chain elongation by RNA polymerase II.	OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,OKLAHOMA CITY,OK 73104	Oklahoma Medical Research Foundation				Conaway, Joan/0000-0002-2786-0663	NIGMS NIH HHS [GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628, R01GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASO T, 1994, EMBO J, V13, P435, DOI 10.1002/j.1460-2075.1994.tb06278.x; ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; BURTON ZF, 1986, EMBO J, V5, P2923, DOI 10.1002/j.1460-2075.1986.tb04588.x; CAI H, 1987, J BIOL CHEM, V262, P298; CHANG CH, 1993, J BIOL CHEM, V268, P20482; CONAWAY JW, 1990, J BIOL CHEM, V265, P7564; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONAWAY JW, 1990, J BIOL CHEM, V265, P7552; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DEDRICK RL, 1985, BIOCHEMISTRY-US, V24, P2245, DOI 10.1021/bi00330a019; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLORES O, 1989, J BIOL CHEM, V264, P8913; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1988, J BIOL CHEM, V263, P10812; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; GARRETT KP, 1992, J BIOL CHEM, V267, P23942; GREENBLATT J, 1991, TRENDS BIOCHEM SCI, V16, P408, DOI 10.1016/0968-0004(91)90165-R; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HENRY NL, 1992, J BIOL CHEM, V267, P23388; HINKLE DC, 1972, J MOL BIOL, V70, P157, DOI 10.1016/0022-2836(72)90531-1; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KASH SF, 1993, MOL CELL BIOL, V13, P2718, DOI 10.1128/MCB.13.5.2718; KEPHART DD, 1994, J BIOL CHEM, V269, P13536; KILLEEN M, 1992, J BIOL CHEM, V267, P9463; KILLEEN MT, 1992, MOL CELL BIOL, V12, P30, DOI 10.1128/MCB.12.1.30; KITAJIMA S, 1990, NUCLEIC ACIDS RES, V18, P4843, DOI 10.1093/nar/18.16.4843; KORNBERG RD, 1993, TRANSCRIPTION MECHAN; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; MOTE J, 1994, J MOL BIOL, V236, P725, DOI 10.1006/jmbi.1994.1185; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON MG, 1991, NATURE, V354, P369; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; PUGH BF, 1992, J BIOL CHEM, V267, P679; REINBERG D, 1987, J BIOL CHEM, V262, P331; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SEKIMIZU K, 1976, BIOCHEMISTRY-US, V15, P5064, DOI 10.1021/bi00668a018; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1994, TRANSCRIPTION MECHAN, P27; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SOPTA M, 1985, J BIOL CHEM, V260, P353; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; TAN S, IN PRESS P NATL ACAD; TAN SY, 1994, BIOTECHNIQUES, V16, P824; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027	67	86	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25684	25691						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929273				2022-12-27	WOS:A1994PQ49100069
J	AINSZTEIN, AM; PURICH, DL				AINSZTEIN, AM; PURICH, DL			STIMULATION OF TUBULIN POLYMERIZATION BY MAP-2 - CONTROL BY PROTEIN-KINASE C-MEDIATED PHOSPHORYLATION AT SPECIFIC SITES IN THE MICROTUBULE-BINDING REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMER NEUROFIBRILLARY TANGLES; TAU-PROTEIN; RAT-BRAIN; INVITRO; DOMAIN; NEUROFILAMENTS; SEQUENCE; QUANTITATION; POLYMERASE; MECHANISM	Microtubule-associated protein-2 (MAP-2) is extensively phosphorylated on serine and threonine residues, and such modifications affect various cellular processes, including microtubule dynamics. Although MAP-2 phosphorylation has been studied both in vitro and in vivo, nothing is known about the exact location of phosphorylated sites influencing the strength of MAP-2 for microtubules, we focused on understanding the effect of protein kinase C phosphorylation on MTBR binding to taxol-stabilized microtubules. We used bacterially expressed MAP-2 MTBR, containing newly introduced CNBr-cleavable methionyl residues, as well as mass spectrometry and site-specific mutagenesis to locate and confirm assignments of critical phosphorylation sites. We report on the localization and role of phosphoryls on two specific residues (Ser-1703 and Ser-1711) in terms of kinase-mediated control of MTBR-stimulated tubulin polymerization. Ser-1703 is situated in the so-called first inter-repeat, and Ser-1711 is located in the second nonidentical repeat. Upon more extensive protein kinase C action, microtubule binding can be abolished by phosphorylation at Ser-1728, but this effect is conditionally dependent on the phosphorylation state at Ser-1703 and/or Ser-1711. Our results suggest that in vivo binding of MAP-2 to microtubules may be controlled by protein kinase C action at these residues, and the strategy presented in this report may facilitate future studies with other kinases.	UNIV FLORIDA, HLTH SCI CTR, COLL MED, DEPT BIOCHEM & MOLEC BIOL, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044823] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-44823] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AAMODT EJ, 1984, BIOCHEMISTRY-US, V23, P6023, DOI 10.1021/bi00320a019; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT R, 1994, J BIOL CHEM, V269, P11776; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CHAIT BT, 1993, SCIENCE, V262, P89, DOI 10.1126/science.8211132; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; CORREAS I, 1992, J BIOL CHEM, V267, P15721; DAMMERMAN M, 1989, J NEUROSCI RES, V24, P487, DOI 10.1002/jnr.490240405; DEANS NL, 1992, BIOCHEM J, V286, P243, DOI 10.1042/bj2860243; EIPPER BA, 1972, P NATL ACAD SCI USA, V69, P2283, DOI 10.1073/pnas.69.8.2283; FLYNN G, 1987, BIOCHEM BIOPH RES CO, V148, P1453, DOI 10.1016/S0006-291X(87)80295-4; FLYNN G, 1987, J BIOL CHEM, V262, P15443; GOLDENRING JR, 1985, J NEUROCHEM, V45, P900, DOI 10.1111/j.1471-4159.1985.tb04078.x; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; GOODMAN DBP, 1970, P NATL ACAD SCI USA, V67, P652, DOI 10.1073/pnas.67.2.652; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOSHI M, 1988, EUR J BIOCHEM, V174, P225, DOI 10.1111/j.1432-1033.1988.tb14086.x; JAMESON L, 1981, P NATL ACAD SCI-BIOL, V78, P3413, DOI 10.1073/pnas.78.6.3413; JOLY JC, 1990, BIOCHEMISTRY-US, V29, P8916, DOI 10.1021/bi00490a006; JOLY JC, 1989, J CELL BIOL, V109, P2289, DOI 10.1083/jcb.109.5.2289; KARR TL, 1979, J BIOL CHEM, V254, P6107; KERYER G, 1993, P NATL ACAD SCI USA, V90, P5418, DOI 10.1073/pnas.90.12.5418; KOSIK KS, 1988, J NEUROCHEM, V51, P587, DOI 10.1111/j.1471-4159.1988.tb01079.x; KRISTOPEIT SM, 1984, THROMB RES, V36, P133, DOI 10.1016/0049-3848(84)90335-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATUS A, 1990, J PHYSIOL-PARIS, V84, P131; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RAFFAELLI N, 1992, FEBS LETT, V296, P21, DOI 10.1016/0014-5793(92)80394-V; RAPPAPOR.L, 1972, FEBS LETT, V26, P349, DOI 10.1016/0014-5793(72)80609-4; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SLOBODA RD, 1975, P NATL ACAD SCI USA, V72, P177, DOI 10.1073/pnas.72.1.177; SOIFER D, 1972, BIOCHIM BIOPHYS ACTA, V271, P182, DOI 10.1016/0005-2795(72)90146-8; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THEURKAUF WE, 1983, J BIOL CHEM, V258, P7883; TSUYAMA S, 1987, J BIOL CHEM, V262, P10886; VALLEE R, 1980, FED PROC, V39, P1818; VALLEE RB, 1977, J BIOL CHEM, V252, P377; WALLIS KT, 1993, J BIOL CHEM, V268, P15158; WHITE HD, 1980, J BIOL CHEM, V255, P486; WICHE G, 1989, BIOCHEM J, V259, P1; WIDMER HR, 1993, J NEUROCHEM, V60, P2111, DOI 10.1111/j.1471-4159.1993.tb03496.x; YAMAUCHI PS, 1987, J BIOL CHEM, V262, P3369	46	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28465	28471						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961787				2022-12-27	WOS:A1994PV77200101
J	CHANG, SC; HOANG, B; THOMAS, JT; VUKICEVIC, S; LUYTEN, FP; RYBA, NJP; KOZAK, CA; REDDI, AH; MOOS, M				CHANG, SC; HOANG, B; THOMAS, JT; VUKICEVIC, S; LUYTEN, FP; RYBA, NJP; KOZAK, CA; REDDI, AH; MOOS, M			CARTILAGE-DERIVED MORPHOGENETIC PROTEINS - NEW MEMBERS OF THE TRANSFORMING GROWTH-FACTOR-BETA SUPERFAMILY PREDOMINANTLY EXPRESSED IN LONG BONES DURING HUMAN EMBRYONIC-DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE OSTEOGENIC PROTEIN; VENTRALIZING FACTOR; INDUCTIVE PROTEIN; RNA; MOUSE; FAMILY; BMP-2A; OP-1; GENE; DIFFERENTIATION	Partially purified extracts from newborn calf articular cartilage were found to induce cartilage and bone when subcutaneously implanted in rats. This activity showed characteristics of bone morphogenetic proteins (BMPs). Degenerate oligonucleotide primer sets derived from the highly conserved carboxyl-terminal region of the BMP family were designed and used in reverse transcription-polymerase chain reactions with poly(A)(+) RNA from articular cartilage as template to determine which BMPs are produced by chondrocytes. Two novel members of the transforming growth factor-beta (TGF-beta) superfamily were identified and designated cartilage-derived morphogenetic protein-1 (CDMP-1) and -2 (CDMP-2). Their carboxyl-terminal TGF-beta domains are 82% identical, thus defining a novel subfamily most closely related to BMP-B, BMP-6, and osteogenic protein-1. Northern analyses showed that both genes are predominantly expressed in cartilaginous tissues. In situ hybridization and immunostaining of sections from human embryos showed that CDMP-1 was predominantly found at the stage of precartilaginous mesenchymal condensation and throughout the cartilaginous cores of the developing long bones, whereas CDMP-2 expression was restricted to the hypertrophic chondrocytes of ossifying long bone centers. Neither gene was detectable in the axial skeleton during human embryonic development. The cartilage-specific localization pattern of these novel TGF-beta superfamily members, which contrasts with the more ubiquitous presence of other BMP family members, suggests a potential role for these proteins in chondrocyte differentiation and growth of long bones.	NIDR,BONE RES BRANCH,DEV BIOL PROGRAM,BETHESDA,MD 20892; NIDR,IMMUNOL LAB,BETHESDA,MD 20892; US FDA,CTR BIOL EVALUAT & RES,DEV BIOL LAB,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,DEPT ORTHOPED SURG,MUSCULOSKELETAL BIOL LAB,BALTIMORE,MD 21205; NIAID,MOLEC MICROBIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); US Food & Drug Administration (FDA); Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Luyten, Frank/GPS-7793-2022; Vukicevic, Slobodan/AEG-2646-2022; Moos, Malcolm C/F-3673-2011	Vukicevic, Slobodan/0000-0003-4076-0285; Moos, Malcolm C/0000-0002-9575-9938; Ryba, Nicholas/0000-0002-2060-8393				ADAMSON MC, 1991, VIROLOGY, V183, P778, DOI 10.1016/0042-6822(91)91010-E; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALE L, 1992, DEVELOPMENT, V115, P573; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; Green EL, 1981, GENETICS PROBABILITY, P77; GRIMALDI JC, 1992, J IMMUNOL, V149, P3921; HAMMONDS RG, 1991, MOL ENDOCRINOL, V5, P149, DOI 10.1210/mend-5-1-149; HELDER MN, 1995, IN PRESS J HISTOCHEM; HELDER MN, IN PRESS J DENT RES; JONES CM, 1992, DEVELOPMENT, V115, P639; JOSEPH DR, 1990, MOL IMMUNOL, V30, P733; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUYTEN FP, 1989, J BIOL CHEM, V264, P13377; LUYTEN FP, 1994, EXP CELL RES, V210, P224, DOI 10.1006/excr.1994.1033; LUYTEN FP, 1992, J BIOL CHEM, V267, P3691; LYONS KM, 1990, DEVELOPMENT, V109, P833; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; OWENS EM, 1982, DEV BIOL, V91, P376, DOI 10.1016/0012-1606(82)90043-4; OZKAYNAK E, 1991, BIOCHEM BIOPH RES CO, V179, P116, DOI 10.1016/0006-291X(91)91342-A; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PARALKAR V, 1989, BIOCHEM BIOPH RES CO, V131, P37; PELTON RW, 1989, DEVELOPMENT, V106, P759; Reddi A. Hari, 1992, Current Opinion in Cell Biology, V4, P850; Sambrook J, 1989, MOL CLONING LABORATO; SAMPATH TK, 1987, P NATL ACAD SCI USA, V84, P7109, DOI 10.1073/pnas.84.20.7109; SAMPATH TK, 1992, J BIOL CHEM, V267, P20352; SAMPATH TK, 1990, J BIOL CHEM, V265, P13198; SAMPATH TK, 1993, P NATL ACAD SCI USA, V90, P6004, DOI 10.1073/pnas.90.13.6004; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGAL D, 1985, GENETICS, V109, P119; SIRACUSA LD, 1993, MAMM GENOME, V4, pS31, DOI 10.1007/BF00360828; SORGENTE N, 1972, BIOCHIM BIOPHYS ACTA, V282, P441; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VUKICEVIC S, 1994, BIOCHEM BIOPH RES CO, V198, P693, DOI 10.1006/bbrc.1994.1100; VUKICEVIC S, 1994, J HISTOCHEM CYTOCHEM, V42, P869, DOI 10.1177/42.7.8014470; VUKICEVIC S, 1989, P NATL ACAD SCI USA, V86, P8793, DOI 10.1073/pnas.86.22.8793; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	48	348	381	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28227	28234						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961761				2022-12-27	WOS:A1994PV77200069
J	DELEPELAIRE, P				DELEPELAIRE, P			PRTD, THE INTEGRAL MEMBRANE ATP-BINDING CASSETTE COMPONENT OF THE ERWINIA-CHRYSANTHEMI METALLOPROTEASE SECRETION SYSTEM, EXHIBITS A SECRETION SIGNAL-REGULATED ATPASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI HEMOLYSIN; MULTIDRUG-RESISTANCE; CLONING VEHICLES; OUTER-MEMBRANE; PROTEIN; CONSTRUCTION; PURIFICATION; PLASMIDS; DOMAIN; HLYB	We have overproduced, partially purified, and characterized PrtD, the ATP-binding cassette (ABC) integral membrane component from the metalloproteases secretion system of the Gram-negative phytopathogenic bacterium Erwinia chrysanthemi. These metalloproteases are secreted independently of the general export pathway encoded by the sec genes. They are secreted via a C-terminal secretion signal and by a secretion apparatus composed of two inner membrane proteins, PrtD and PrtE, and one outer membrane protein PrtF. PrtD is specifically labeled by 8-azido-ATP both in whole membrane vesicles and upon purification. The purified protein displays a low level of P-type ATPase activity. This activity is almost completely and specifically inhibited by the cognate C-terminal secretion signal of the PrtG and PrtB metalloproteases (half inhibition at 0.1 mu M) but not by a C-terminal secretion signal of a protein not secreted by the Prt translocator. A mutant PrtD protein bearing a point mutation in the ATP binding site (conserved lysine 370 of the Walker A box changed to arginine) has also been purified. It displays a lower level of ATPase activity which correlates with the lower level of secretion of the metalloproteases by a strain expressing this mutated protein.			DELEPELAIRE, P (corresponding author), INST PASTEUR,UNITE PHYSIOL CELLULAIRE,CNRS,URA 1300,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; DELEPELAIRE P, 1990, J BIOL CHEM, V265, P17118; DELEPELAIRE P, 1991, MOL MICROBIOL, V5, P2427, DOI 10.1111/j.1365-2958.1991.tb02088.x; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; GHIGO JM, 1994, J BIOL CHEM, V269, P8979; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HUGHES C, 1992, BIOESSAYS, V14, P519, DOI 10.1002/bies.950140804; KORONAKIS V, 1993, MOL MICROBIOL, V8, P1163, DOI 10.1111/j.1365-2958.1993.tb01661.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOFFE S, 1994, J BACTERIOL, V176, P5372; LETOFFE S, 1990, EMBO J, V9, P1375, DOI 10.1002/j.1460-2075.1990.tb08252.x; LETOFFE S, 1994, IN PRESS P NATL ACAD; Maniatis T., 1982, MOL CLONING; MESSING J, 1991, GENE, V100, P3, DOI 10.1016/0378-1119(91)90344-B; Miller J.H., 1972, EXPT MOL GENETICS; MORBACH S, 1993, J BIOL CHEM, V268, P18617; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; RICHET E, 1989, EMBO J, V8, P981, DOI 10.1002/j.1460-2075.1989.tb03461.x; SPRATT BG, 1986, GENE, V41, P337, DOI 10.1016/0378-1119(86)90117-4; THOMAS WD, 1992, J BACTERIOL, V174, P6771, DOI 10.1128/JB.174.21.6771-6779.1992; WANDERSMAN C, 1992, TRENDS GENET, V8, P317, DOI 10.1016/0168-9525(92)90264-5; WANDERSMAN C, 1990, P NATL ACAD SCI USA, V87, P4776, DOI 10.1073/pnas.87.12.4776; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WOLFF N, 1994, BIOCHEMISTRY-US, V33, P6792, DOI 10.1021/bi00188a007	30	52	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27952	27957						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961727				2022-12-27	WOS:A1994PV77200030
J	BHOGAL, N; DONNELLY, D; FINDLAY, JBC				BHOGAL, N; DONNELLY, D; FINDLAY, JBC			THE LIGAND-BINDING SITE OF THE NEUROKININ-2 RECEPTOR - SITE-DIRECTED MUTAGENESIS AND IDENTIFICATION OF NEUROKININ A BINDING RESIDUES IN THE HUMAN NEUROKININ 2 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION; AGONIST; DOMAINS	Thirteen residues in the human neurokinin 2 (NK2) receptor were identified as potential ligand-binding residues by molecular modeling and amino acid sequence analysis. Site directed mutagenesis was used to alter these residues in order to ascertain their importance in binding neurokinin A (NKA), the physiological peptide ligand for the NK2 receptor, and the non-peptide NK2 receptor selective antagonist SR48968. Four sites appear to be critical for NKA binding (Gln(109), His(198), Ile(202), and Gly(273)). The mutant receptors Gln(109) --> His, Ile(202) --> Val, Gly(273), Pro, and Gly(273), Thr maintain their affinity for SR48968, despite being unable to bind the peptide ligand. His(198) --> Ala and His(198) --> Leu no longer bind NRA or SR48968. We have also identified a residue (Leu(292)) which appears to play a minor role in the binding of substance P (SP) and neurokinin B (NKB) to the NK2 receptor. The mutant receptor Leu(292) --> Ser binds NKB and SP with approximately a B-fold greater affinity in comparison with the wild type receptor while the affinity of NKA remains unaffected. The results suggest that intramembranous residues, as well as residues which lie close to the extracellular side of transmembrane helices 3, 5, and 6, form part of the NK2 receptor binding site. Binding of SP and NKB to the NK2 receptor may also be influenced by residues near the extracellular side of helix 7. These results suggest that some regions of the binding site for NKA in the NK2 receptor are not used for binding SP in the NH1 receptor. However, it also seems that the NKA binding site includes regions that are also used by other G-protein-coupled receptors such as rhodopsin and the beta(2)-adrenergic receptors.	UNIV LEEDS,DEPT BIOCHEM & MOLEC BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	University of Leeds			Donnelly, Dan/O-5374-2015	Donnelly, Dan/0000-0001-6048-6995				Akrigg D., 1988, Nature, UK, V335, P745, DOI 10.1038/335745a0; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; DONNELLY D, 1994, RECEPTOR CHANNEL, V2, P61; FONG TM, 1994, J BIOL CHEM, V269, P2728; FONG TM, 1992, J BIOL CHEM, V267, P25668; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1993, NATURE, V362, P350; FONG TM, 1993, REGUL PEPTIDES, V46, P43, DOI 10.1016/0167-0115(93)90010-6; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; JOHNSON MS, 1993, J MOL BIOL, V233, P716, DOI 10.1006/jmbi.1993.1548; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MAGGIO JE, 1988, ANNU REV NEUROSCI, V11, P13, DOI 10.1146/annurev.neuro.11.1.13; MISUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRADER CD, 1991, J BIOL CHEM, V266, P5; STRADER CD, 1989, J BIOL CHEM, V264, P13572; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154	19	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27269	27274						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961636				2022-12-27	WOS:A1994PV77100021
J	CHEN, HS; PERDEW, GH				CHEN, HS; PERDEW, GH			SUBUNIT COMPOSITION OF THE HETEROMERIC CYTOSOLIC ARYL-HYDROCARBON RECEPTOR COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; NUCLEAR TRANSLOCATOR PROTEIN; AH-RECEPTOR; GLUCOCORTICOID RECEPTORS; 59-KILODALTON PROTEIN; STEROID-RECEPTORS; DIOXIN RECEPTOR; EXISTS; COMPONENT; HSP90	In a previous cross-linking study we have shown that the cytosolic aryl hydrocarbon receptor (AhR) complex has a heterotetrameric structure (Perdew, G. H. (1992) Biochem. Biophys. Res. Commun. 182, 55-62). In this report, both cross linked and [S-35]methionine-labeled Hepa 1c1c7 cytosol were used to characterize the subunit composition of the AhR complex by immunoprecipitation with an AhR polyclonal antibody followed by immunochemical analysis using antibodies against the AhR and 90-kDa heat shock protein (hsp90). Results indicated that the four subunits found in cross linking experiments were composed of three species: the AhR ligand binding subunit, hsp90, and an unknown 43-kDa protein. The stoichiometry of hsp90 present in each AhR complex was determined in two separate experiments: 1) from cross-linking experiments, stoichiometry was determined by quantitative immunoblotting with anti-AhR and anti-hsp90 antibodies followed by quantitation with I-125-counterantibody on protein blots; 2) using S-35-labeled Hepa 1 cytosol, the hsp90/AhR stoichiometry was determined by immunopurifying receptor complexes, and the amount of S-35-labeled AhR and hsp90 was assessed. The stoichiometry values obtained were 2.4 and 1.72 mol of hsp90/mol of AhR using each experimental approach, respectively.	PURDUE UNIV,DEPT FOODS & NUTR,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NIEHS NIH HHS [ES-04869] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004869, R29ES004869] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BRESNICK EH, 1990, BIOCHEMISTRY-US, V29, P520, DOI 10.1021/bi00454a028; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; KELLEY PM, 1982, MOL CELL BIOL, V2, P267, DOI 10.1128/MCB.2.3.267; LEGRAVEREND C, 1982, J BIOL CHEM, V257, P6402; MENDEL DB, 1988, J BIOL CHEM, V263, P6695; MOORE SK, 1989, J BIOL CHEM, V264, P5343; NEMOTO T, 1990, J BIOL CHEM, V265, P2268; PERDEW GH, 1993, EXP CELL RES, V209, P350, DOI 10.1006/excr.1993.1320; PERDEW GH, 1992, BIOCHEM BIOPH RES CO, V182, P55, DOI 10.1016/S0006-291X(05)80111-1; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PERDEW GH, 1994, ANAL BIOCHEM, V220, P214, DOI 10.1006/abio.1994.1323; PROBST MR, 1993, MOL PHARMACOL, V44, P511; PROKIPCAK RD, 1989, ARCH BIOCHEM BIOPHYS, V274, P648, DOI 10.1016/0003-9861(89)90480-3; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; REHBERGER P, 1992, P NATL ACAD SCI USA, V89, P8001, DOI 10.1073/pnas.89.17.8001; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; RIEHL RM, 1985, BIOCHEMISTRY-US, V24, P6586, DOI 10.1021/bi00344a042; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SINGH SS, 1993, ARCH BIOCHEM BIOPHYS, V305, P170, DOI 10.1006/abbi.1993.1407; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436	29	128	130	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27554	27558						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961671				2022-12-27	WOS:A1994PV77100062
J	CHUANG, LM; HAUSDORFF, SF; MYERS, MG; WHITE, MF; BIRNBAUM, MJ; KAHN, CR				CHUANG, LM; HAUSDORFF, SF; MYERS, MG; WHITE, MF; BIRNBAUM, MJ; KAHN, CR			INTERACTIVE ROLES OF RAS, INSULIN-RECEPTOR SUBSTRATE-1, AND PROTEINS WITH SRC HOMOLOGY-2 DOMAINS IN INSULIN SIGNALING IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; SH3 DOMAINS; BETA-SUBUNIT; MAP KINASE; ACTIVATION; BINDING; DISTINCT; TRANSDUCTION	Insulin receptor substrate-1 (IRS-1) serves as the major immediate substrate of insulin/insulin-like growth factor (IGF)-1 receptors and following tyrosine phosphorylation binds to specific Src homology-2 (SH2) domain-containing proteins including the p85 subunit of phosphatidylinositol (PI) 3-kinase and GRB2, a molecule believed to link IRS-1 to the Ras pathway. To investigate how these SH2-containing signaling molecules interact to regulate insulin/IGF-1 action, IRS-1, glutathione S-transferase (GST)-SH2 domain fusion proteins and Ras proteins were microinjected into Xenopus oocytes. We found that pleiotropic insulin actions are mediated by IRS-1 through two independent, but convergent, pathways involving PI 3-kinase and GRB2. Thus, microinjection of GST-fusion proteins of either p85 or GRB2 inhibited IRS-1-dependent activation of mitogen-activated protein (MAP) and S6 kinases and oocyte maturation, although only the GST-SH2 of p85 reduced insulin-stimulated PI 3-kinase activation. Co-injection of a dominant negative Ras (S17N) with IRS-1 inhibited insulin-stimulated MAP and S6 kinase activation. Microinjection of activated [Arg(12),Thr(59)]Ras increased basal MAP and S6 kinase activities and sensitized the oocytes to insulin-stimulated maturation without altering insulin-stimulated PI 3-kinase. The Ras-enhanced oocyte maturation response, but not the elevated basal level of MAP and S6 kinase, was partially blocked by the SH2-p85, but not SH2-GRB2. These data strongly suggest that IRS-1 can mediate many of insulin's actions on cellular enzyme activation and cell cycle progression requires binding and activation of multiple different SH2-domain proteins.	HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,DEPT MED,DIV RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Kahn, Ronald/AAY-2435-2021; Chuang, Lee-Ming/AAF-3324-2019	Kahn, Ronald/0000-0002-7583-9228; CHUANG, LEE-MING/0000-0003-0978-2662; Birnbaum, Morris/0000-0001-9972-8680	NIDDK NIH HHS [DK 33201, DK 43808, DK 39519] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039519, R01DK043808, R01DK033201] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDERSON NG, 1991, J BIOL CHEM, V266, P10131; ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; CAMPA MJ, 1992, P NATL ACAD SCI USA, V89, P7654, DOI 10.1073/pnas.89.16.7654; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; HELDIN CH, 1991, TRENDS BIOCHEM SCI, V16, P450, DOI 10.1016/0968-0004(91)90175-U; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELLICI G, 1992, CELL, V70, P93; PETRUZZELLI L, 1984, P NATL ACAD SCI-BIOL, V81, P3327, DOI 10.1073/pnas.81.11.3327; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUNG CK, 1994, J BIOL CHEM, V269, P12503; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOBE K, 1993, J BIOL CHEM, V268, P11167; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1989, J CELL BIOCHEM, V39, P429, DOI 10.1002/jcb.240390409; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597	50	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27645	27649						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961682				2022-12-27	WOS:A1994PV77100076
J	PENG, SB; ZHANG, Y; CRIDER, BP; WHITE, AE; FRIED, VA; STONE, DK; XIE, XS				PENG, SB; ZHANG, Y; CRIDER, BP; WHITE, AE; FRIED, VA; STONE, DK; XIE, XS			RECONSTITUTION OF THE RECOMBINANT 70-KDA SUBUNIT OF THE CLATHRIN-COATED VESICLE H+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON TRANSLOCATING COMPLEX; VACUOLAR ATPASE; ADENOSINE-TRIPHOSPHATASE; TONOPLAST ATPASE; BETA-SUBUNIT; CLONED GENES; A-SUBUNIT; IDENTIFICATION; PROTEIN; 5'-TRIPHOSPHATE	Vacuolar-type proton pumps are complex heterooligomers. When dissociated into subcomplexes and subunits, the partial reactions of ATP hydrolysis and transmembranous proton flow can be assigned to isolated domains. Data suggest that the molecular site of ATP hydrolysis resides within the 70-kDa subunit but that ATPase activity likely requires at least three additional subunits of 58, 40, and 33 kDa (Xie, X.-S., and Stone, D. K. (1988) J. Biol. Chem. 263, 9859-9867). We have now cloned and sequenced the 70-kDa subunit from bovine brain and have expressed the protein in insect Sf9 (Spodoptera frugiperda) cells with a recombinant baculovirus. When purified, the protein has no significant ATPase activity but can be photoaffinity labeled with [alpha(32)P]ATP and UV irradiation with an apparent K-d of 35 mu M. When reconstituted with biochemically prepared 58-, 40-, and 33-kDa polypeptides, the recombinant 70-kDa)a subunit restores Ca2+-activated ATP hydrolysis to a specific activity of 0.6 mu mol P-i.mg protein(-1).min(-1), thus demonstrating that ATP hydrolysis in vacuolar-type proton pumps is dependent upon both the 70-kDa subunit as well as multi-subunit interactions.			PENG, SB (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV MOLEC TRANSPORT,DALLAS,TX 75235, USA.				NIDDK NIH HHS [DK-33627] Funding Source: Medline; NINDS NIH HHS [NS-29542] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033627] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029542] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALPERN RA, 1990, KIDNEY, P318; ALSHAWI MK, 1990, J BIOL CHEM, V265, P5595; BERRIOS M, 1983, J BIOL CHEM, V258, P4548; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GU HH, 1993, J BIOL CHEM, V268, P7372; INATOMI KI, 1989, J BIOL CHEM, V264, P10954; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANDALA S, 1986, J BIOL CHEM, V261, P2850; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MATTSSON JP, 1994, J BIOL CHEM, V269, P24979; MORIYAMA Y, 1987, J BIOL CHEM, V262, P14723; PAN YX, 1991, FEBS LETT, V293, P89, DOI 10.1016/0014-5793(91)81158-5; PENG SB, 1994, J BIOL CHEM, V269, P11356; PENG SB, 1993, J BIOL CHEM, V268, P23519; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; STONE DK, 1984, J BIOL CHEM, V259, P2701; STONE DK, 1988, KIDNEY INT, V33, P403; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; Summers MD, 1987, TEXAS AGR EXPT STATI; SUN SZ, 1987, J BIOL CHEM, V262, P14790; TAKASE K, 1993, J BIOL CHEM, V268, P11610; VANHILLE B, 1993, J BIOL CHEM, V268, P7075; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; XIE XS, 1986, J BIOL CHEM, V261, P2492; XIE XS, 1994, J BIOL CHEM, V269, P25809; XIE XS, 1988, J BIOL CHEM, V263, P9859; XIE XS, 1993, J BIOL CHEM, V268, P25063; XIE XS, 1989, J BIOL CHEM, V264, P1710; YUE VT, 1977, BIOCHEMISTRY-US, V16, P4678, DOI 10.1021/bi00640a023; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	40	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27778	27782						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961699				2022-12-27	WOS:A1994PV77100096
J	PIKULA, S; HAYDEN, JB; AWASTHI, S; AWASTHI, YC; ZIMNIAK, P				PIKULA, S; HAYDEN, JB; AWASTHI, S; AWASTHI, YC; ZIMNIAK, P			ORGANIC ANION-TRANSPORTING ATPASE OF RAT-LIVER .2. FUNCTIONAL RECONSTITUTION OF ACTIVE-TRANSPORT AND REGULATION BY PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; DEPENDENT TRANSPORT; GLUTATHIONE; ACID; SECRETION; PROTEIN	We have previously purified to homogeneity from rat liver plasma membranes a 90-kDa glycoprotein with S-(2,4-dinitrophenyl)glutathione-stimulated ATPase activity and other properties which identify it as the multispecific organic anion transporter (MOAT) specific for the transport into bile of non-bile acid organic anions (Pikula, S., Hayden, J. B., Awasthi, S., Awasthi, Y. C., and Zimniak, P. (1994) J. Biol. Chem. 269, 27566-27573). In the present communication, we report the functional reconstitution of this protein into artificial proteoliposomes. The reconstituted protein catalyzed time and concentration-dependent up take of S-(2,4-dinitrophenyl) glutathione into the vesicles, The transport required the presence of ATP. Phosphorylation of the 90-kDa protein by protein kinase C prior to reconstitution more than tripled the V-max of transport but did not change the K-m for S-(2,4-dinitrophenyl)glutathione. The protein created and, at steady state, maintained a more than 200-fold and 500-fold S-(2,4-dinitrophenyl)glutathione gradient across the membrane for the unphosphorylated and phosphorylated form, respectively. The transport activity of the 90-kDa protein is sufficient to account for the hepatic secretory maximum of non-bile acid organic anions in the rat.	UNIV ARKANSAS MED SCI HOSP,DEPT MED,LITTLE ROCK,AR 72205; UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205; VET ADM JOHN MCCLELLAN MEM HOSP,LITTLE ROCK,AR 72205; UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,GALVESTON,TX 77555; UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77555; POLISH ACAD SCI,M NENCKI INST EXPTL BIOL,WARSAW,POLAND	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences			Awasthi, Sanjay/R-4904-2019	Pikula, Slawomir/0000-0003-4640-3094; Awasthi, Sanjay/0000-0002-5214-5717	NATIONAL CANCER INSTITUTE [R29CA063660] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032304] Funding Source: NIH RePORTER; NCI NIH HHS [CA-63660] Funding Source: Medline; NIGMS NIH HHS [GM-32304] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKERBOOM TPM, 1991, J BIOL CHEM, V266, P13147; BALLATORI N, 1992, AM J PHYSIOL, V263, pG617, DOI 10.1152/ajpgi.1992.263.5.G617; BALLATORI N, 1989, AM J PHYSIOL, V256, pG22, DOI 10.1152/ajpgi.1989.256.1.G22; Boyer J.L., 1986, PHYSL MEMBRANE DISOR, P609; DUX L, 1987, J BIOL CHEM, V262, P6439; ENGELMAN DM, 1969, NATURE, V223, P1279, DOI 10.1038/2231279a0; FERNANDEZCHECA JC, 1992, J BIOL CHEM, V267, P1667; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HINKLE PC, 1991, BIOCHEMISTRY-US, V30, P3576, DOI 10.1021/bi00228a031; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; KOBAYASHI K, 1990, J BIOL CHEM, V265, P7737; KUIPERS F, 1989, J LIPID RES, V30, P1835; KUIPERS F, 1992, AM J PHYSIOL, V262, pG267, DOI 10.1152/ajpgi.1992.262.2.G267; LABELLE EF, 1986, BIOCHEM J, V238, P443, DOI 10.1042/bj2380443; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Meier Peter J., 1993, P587; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; PIKULA S, 1994, J BIOL CHEM, V269, P27566; ROELOFSEN H, 1991, BIOCHEM J, V278, P637, DOI 10.1042/bj2780637; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; VINCE R, 1971, J MED CHEM, V14, P402, DOI 10.1021/jm00287a006; ZIMNIAK P, 1993, HEPATOLOGY, V17, P330, DOI 10.1002/hep.1840170226; ZIMNIAK P, 1993, SEMIN LIVER DIS, V13, P248, DOI 10.1055/s-2007-1007353	25	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27574	27579						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961674				2022-12-27	WOS:A1994PV77100065
J	RUSINOL, AE; CUI, Z; CHEN, MH; VANCE, JE				RUSINOL, AE; CUI, Z; CHEN, MH; VANCE, JE			A UNIQUE MITOCHONDRIA-ASSOCIATED MEMBRANE-FRACTION FROM RAT-LIVER HAS A HIGH-CAPACITY FOR LIPID-SYNTHESIS AND CONTAINS PRE-GOLGI SECRETORY PROTEINS INCLUDING NASCENT LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; ROUGH ENDOPLASMIC-RETICULUM; PERMEABILIZED ANIMAL-CELLS; LOW-DENSITY LIPOPROTEINS; SUBCELLULAR-LOCALIZATION; PHOSPHOLIPID-SYNTHESIS; PLASMA-MEMBRANE; TRANSPORT; INTERMEDIATE; COMPLEX	An endoplasmic reticulum-like membrane fraction, termed the ''mitochondria-associated membrane'' (MAM), that co-isolates with mitochondria from rat liver has been characterized. One potential function of the MAM is as a membrane bridge between the endoplasmic reticulum and mitochondria that may be involved in transfer of phospholipids between these two organelles (Vance, J. E. (1990) J. Biol. Chem. 265, 7248-7256). A polyclonal antibody directed against a peptide corresponding to the C terminus of phosphatidylethanolamine N-methyltransferase-2, a specific marker protein of the MAM (Cui, Z., Vance, J. E., Chen, M. H., Voelker, D. R., and Vance, D. E. (1993) J. Biol. Chem. 268, 16655-16663), was used in immunofluorescence and immunogold electron microscopy localization studies in rat hepatocytes. Immunoreactive protein was clustered in regions of the cell that did not correspond to the bulk of endoplasmic reticulum. A second potential role for the MAM, as a component of the secretory pathway that supplies lipids for assembly into very low density lipoproteins, has been examined. The MAM contains enzymes of similar, or higher, specific activities to those enzymes in the endoplasmic reticulum for the synthesis of phospholipids, triacylglycerols, cholesterol, and cholesteryl esters. Specific activities of diacylglycerol acyltransferase, acyl coenzyme A:cholesterol acyltransferase, and phosphatidylserine synthase (base exchange enzyme) are enriched 2.2-3.4-fold in the MAM compared with endoplasmic reticulum. In addition, the microsomal triacylglycerol transfer protein, which is required for the assembly/secretion of apolipoprotein B containing lipoproteins, was present in the MAM. Nascent apolipoprotein B-containing lipoproteins were isolated from the lumen of the MAM. These lipoproteins had the same average density and composition as nascent apolipoprotein B-containing lipoproteins isolated from heavy and light endoplasmic reticulum fractions, from the Golgi, and lipoproteins newly secreted by cultured rat hepatocytes. The MAM is a pre-Golgi compartment of the secretory route, as shown by pulse-chase studies with apolipoprotein B and albumin, as well as the sensitivity of luminal apolipoprotein B to endoglycosidase H.	UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON T6G 2S2,AB,CANADA; UNIV ALBERTA,DEPT MED,EDMONTON T6G 2S2,AB,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2S2,AB,CANADA; UNIV ALBERTA,SURG MED RES INST,EDMONTON T6G 2S2,AB,CANADA	University of Alberta; University of Alberta; University of Alberta; University of Alberta								ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; ARDAIL D, 1993, J BIOL CHEM, V268, P25985; BARANSKA J, 1989, BIOCHIM BIOPHYS ACTA, V619, P258; BECKERS CJM, 1990, J BIOL CHEM, V265, P18298; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1990, J BIOL CHEM, V265, P10556; CIANFLONE KM, 1990, J LIPID RES, V31, P2045; CROZE EM, 1984, J CELL PHYSIOL, V119, P46, DOI 10.1002/jcp.1041190109; CUI Z, 1993, J BIOL CHEM, V268, P16655; FRANKE WW, 1971, PROTOPLASMA, V73, P35, DOI 10.1007/BF01286409; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GEORGE R, 1990, BIOCHEM CELL BIOL, V68, P674, DOI 10.1139/o90-097; GIEROW P, 1989, BIOCHEM J, V262, P55, DOI 10.1042/bj2620055; HAJRA AK, 1986, METHOD ENZYMOL, V122, P50; HAMILTON RL, 1991, J LIPID RES, V32, P529; HASHIMOTO S, 1980, J BIOL CHEM, V255, P8678; HEIDER JG, 1983, J LIPID RES, V24, P1127; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; HOWELL KE, 1982, J CELL BIOL, V92, P833, DOI 10.1083/jcb.92.3.833; HUSSAIN MM, 1989, BIOCHIM BIOPHYS ACTA, V1101, P90; JANERO DR, 1983, J BIOL CHEM, V258, P4496; KARSTEN U, 1972, ANAL BIOCHEM, V46, P135, DOI 10.1016/0003-2697(72)90405-8; KATZ J, 1983, BIOCHEM J, V214, P795, DOI 10.1042/bj2140795; LANGE Y, 1993, J BIOL CHEM, V268, P13838; LODISH HF, 1987, J CELL BIOL, V104, P221, DOI 10.1083/jcb.104.2.221; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORRE DJ, 1971, PROTOPLASMA, V73, P43, DOI 10.1007/BF01286410; MOSES RL, 1982, VIRCHOWS ARCH B, V41, P95, DOI 10.1007/BF02890274; PICKETT CB, 1980, EXP CELL RES, V128, P343, DOI 10.1016/0014-4827(80)90070-1; REINHART MP, 1987, J BIOL CHEM, V262, P9649; RUSINOL A, 1993, J BIOL CHEM, V268, P3555; RUSINOL AE, 1993, J BIOL CHEM, V268, P25168; SARASTE J, 1991, J CELL SCI, V100, P415; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHORE GC, 1977, J CELL BIOL, V72, P714, DOI 10.1083/jcb.72.3.714; THOMAS J, 1980, BIOCHEM J, V190, P485, DOI 10.1042/bj1900485; VANCE DE, 1984, BIOCHIM BIOPHYS ACTA, V792, P39, DOI 10.1016/0005-2760(84)90280-7; VANCE JE, 1988, J BIOL CHEM, V263, P5898; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VANGOLDE LM, 1974, BIOCHIM BIOPHYS ACTA, V360, P179, DOI 10.1016/0005-2760(74)90168-4; VANGOLDE LM, 1971, BIOCHIM BIOPHYS ACTA, V249, P318, DOI 10.1016/0005-2736(71)90109-X; VOELKER DR, 1993, J BIOL CHEM, V268, P7069; VOELKER DR, 1990, J BIOL CHEM, V265, P14340; VOELKER DR, 1989, P NATL ACAD SCI USA, V86, P9921, DOI 10.1073/pnas.86.24.9921; VOELKER DR, 1991, BIOCH LIPIDS LIPOPRO, P489; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; YAO ZM, 1989, J BIOL CHEM, V264, P11373; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	52	353	358	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27494	27502						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961664				2022-12-27	WOS:A1994PV77100054
J	SKAUGEN, M; NISSENMEYER, J; JUNG, G; STEVANOVIC, S; SLETTEN, K; ABILDGAARD, CIM; NES, IF				SKAUGEN, M; NISSENMEYER, J; JUNG, G; STEVANOVIC, S; SLETTEN, K; ABILDGAARD, CIM; NES, IF			IN-VIVO CONVERSION OF L-SERINE TO D-ALANINE IN A RIBOSOMALLY SYNTHESIZED POLYPEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID-SEQUENCE; OPIOID-PEPTIDES; SKIN; EPIDERMIN; LANTIBIOTICS; PURIFICATION; BIOSYNTHESIS; PREPEPTIDE; DERMORPHIN; PHASE	In the course of characterizing the bacteriocin lactocin S and its encoding gene, we discovered three alanine for-serine substitutions which, apparently, is a violation of the genetic code. Subsequent chiral analysis of lactocin S hydrolysates revealed a correlation between D-alanine content and the three substitutions, implying a conversion of L-serine to D-alanine in lactocin S maturation. In order to explain this observation, we suggest a sequence of events initiated by the dehydration of serine, which is common in the biosynthesis of the lanthi- onine-containing polycyclic lantibiotics (Schnell, N., Entian, K.-D., Schneider, U., Gotz, F., Zahner, H., Hellner, R. & Jung, G. (1988) Nature 333, 276-278; Jung, G. (1991) Angew. Chem. Int. Ed. Engl. 30, 1051-1068; Bierbaum, G. and Sahl, H.-G. (1993) Zentralbl. Bakteriol. 278, 1-22) and completed by the stereospecific reduction of dehydroalanine residues. The occurrence of non-lanthionine a-carbon stereoinversion in lactocin S maturation substantiates the hypothetical alpha-epimerization scheme originally put forward by Bycroft (Bycroft, B. W. (1969) Nature 224, 595-597), and we propose a revision of this model to accommodate the lactocin S-type stereoinversion. Lactocin S is the first prokaryotic exception to the rule that only L-amino acids are included in ribosomally synthesized peptides.	UNIV OSLO, INST BIOCHEM, N-0317 OSLO, NORWAY; UNIV TUBINGEN, INST ORGAN CHEM, W-7400 TUBINGEN 1, GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM, D-69120 HEIDELBERG, GERMANY; UNIV OSLO, CTR BIOTECHNOL, N-0317 OSLO, NORWAY	University of Oslo; Eberhard Karls University of Tubingen; Helmholtz Association; German Cancer Research Center (DKFZ); University of Oslo	SKAUGEN, M (corresponding author), AGR UNIV NORWAY, MICROBIAL GENE TECHNOL LAB, POB 5051, N-1432 AS, NORWAY.		Nissen-Meyer, Jon/A-5581-2008; Nissen-Meyer, Jon/Y-8727-2019					ALLGAIER H, 1986, EUR J BIOCHEM, V160, P9, DOI 10.1111/j.1432-1033.1986.tb09933.x; BIERBAUM G, 1993, ZBL BAKT-INT J MED M, V278, P1; BROCCARDO M, 1981, BRIT J PHARMACOL, V73, P625, DOI 10.1111/j.1476-5381.1981.tb16797.x; BYCROFT BW, 1969, NATURE, V224, P595, DOI 10.1038/224595a0; FRANK H, 1977, J CHROMATOGR SCI, V15, P174, DOI 10.1093/chromsci/15.5.174; Graeffe T, 1991, NISIN NOVEL LANTIBIO, P260; GROSS E, 1971, J AM CHEM SOC, V93, P4634, DOI 10.1021/ja00747a073; GROSS E, 1973, H-S Z PHYSIOL CHEM, V354, P810; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; JUNG G, 1991, ANGEW CHEM INT EDIT, V30, P1051, DOI 10.1002/anie.199110513; KATZ E, 1977, BACTERIOL REV, V41, P449, DOI 10.1128/MMBR.41.2.449-474.1977; KELLNER R, 1988, EUR J BIOCHEM, V177, P53, DOI 10.1111/j.1432-1033.1988.tb14344.x; KUPKE T, 1993, FEMS MICROBIOL LETT, V112, P43, DOI 10.1016/0378-1097(93)90535-A; KUSTERS E, 1984, CHROMATOGRAPHIA, V18, P287, DOI 10.1007/BF02259079; MEYER HE, 1994, IN PRESS ANAL BIOCH; MIGNOGNA G, 1993, EMBO J, V12, P4829, DOI 10.1002/j.1460-2075.1993.tb06172.x; MOR A, 1992, TRENDS BIOCHEM SCI, V17, P481, DOI 10.1016/0968-0004(92)90333-5; MORTVEDT CI, 1990, J GEN MICROBIOL, V136, P1601, DOI 10.1099/00221287-136-8-1601; MORTVEDT CI, 1991, APPL ENVIRON MICROB, V57, P1829; MULDERS JWM, 1991, EUR J BIOCHEM, V201, P581, DOI 10.1111/j.1432-1033.1991.tb16317.x; RICHTER K, 1990, P NATL ACAD SCI USA, V87, P4836, DOI 10.1073/pnas.87.12.4836; RICHTER K, 1987, SCIENCE, V238, P200, DOI 10.1126/science.3659910; Sahl H. G., 1991, NISIN NOVEL LANTIBIO, P347; Sambrook J, 1989, MOL CLONING LABORATO; SCHNELL N, 1988, NATURE, V333, P276, DOI 10.1038/333276a0; SLETTEN K, 1974, EUR J BIOCHEM, V41, P117, DOI 10.1111/j.1432-1033.1974.tb03251.x; WEIL HP, 1990, EUR J BIOCHEM, V194, P217, DOI 10.1111/j.1432-1033.1990.tb19446.x	28	114	117	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27183	27185						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961627				2022-12-27	WOS:A1994PV77100008
J	ALMOND, BD; EIDELS, L				ALMOND, BD; EIDELS, L			THE CYTOPLASMIC DOMAIN OF THE DIPHTHERIA-TOXIN RECEPTOR (HE-EGF PRECURSOR) IS NOT REQUIRED FOR RECEPTOR-MEDIATED ENDOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; SENSITIVE MOUSE CELLS; GROWTH-FACTOR; INTRACELLULAR DEGRADATION; INTERNALIZATION SIGNAL; ENDOPLASMIC-RETICULUM; BACTERIAL TOXINS; LDL RECEPTOR; VERO CELLS; TYROSINE	Diphtheria toxin is believed to enter toxin-sensitive mammalian cells by receptor-mediated endocytosis employing the transmembrane cell surface precursor of heparin-binding epidermal growth factor-like growth factor as a receptor. To investigate the contribution of the receptor's cytoplasmic domain to the toxin internalization process, we constructed stable cell lines that express receptor molecules containing cytoplasmic domain mutations. Our results indicate that Tyr(192) and surrounding amino acid residues are important for high toxin sensitivity. Cells expressing mutant receptors are less sensitive to toxin and have fewer toxin-specific binding sites but internalize toxin at rates similar to those of cells expressing the intact receptor. This rate of internalization is much slower (1-2%/min) than that of classical endocytic receptors (10-50%/min). Our results are consistent with a model in which the cytoplasmic domain of the toxin receptor lacks a signal for rapid internalization. We suggest that toxin-receptor complexes, nevertheless, are internalized by receptor-mediated endocytosis by entrapment in clathrin-coated pits as part of bulk phase turnover of cell surface proteins. Although the rate is slow, successful intoxication occurs because a single internalized enzymatically-active toxin molecule is sufficient to inhibit protein synthesis in the cell.	UNIV TEXAS, SW MED CTR, DEPT MICROBIOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016805] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-16805] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWN JG, 1993, P NATL ACAD SCI USA, V90, P8184, DOI 10.1073/pnas.90.17.8184; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CIEPLAK W, 1987, J BIOL CHEM, V262, P13246; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89; DORLAND RB, 1979, J BIOL CHEM, V254, P1337; DOYLE C, 1986, J CELL BIOL, V103, P1193, DOI 10.1083/jcb.103.4.1193; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; EIDELS L, 1982, INFECT IMMUN, V37, P1054, DOI 10.1128/IAI.37.3.1054-1058.1982; EIDELS L, 1983, MICROBIOL REV, V47, P596, DOI 10.1128/MMBR.47.4.596-620.1983; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GRAHAM FL, 1980, INTRO MACROMOLECULES, V1, P3; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; IVESSA NE, 1989, J CELL BIOL, V109, P207; JADOT M, 1992, J BIOL CHEM, V267, P11069; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KEEN JH, 1982, P NATL ACAD SCI-BIOL, V79, P2912, DOI 10.1073/pnas.79.9.2912; KNIGHT PJK, 1994, MOL MICROBIOL, V11, P429, DOI 10.1111/j.1365-2958.1994.tb00324.x; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LE A, 1990, J BIOL CHEM, V265, P14001; LE AQ, 1992, J BIOL CHEM, V267, P1072; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MARNELL MH, 1984, INFECT IMMUN, V44, P145, DOI 10.1128/IAI.44.1.145-150.1984; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; MELBY EL, 1993, CANCER RES, V53, P1755; MIDDLEBROOK JL, 1978, J BIOL CHEM, V253, P7325; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; MIDDLEBROOK JL, 1977, CAN J MICROBIOL, V23, P183, DOI 10.1139/m77-026; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; MORRIS RE, 1985, INFECT IMMUN, V50, P721, DOI 10.1128/IAI.50.3.721-727.1985; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; NAGLICH JG, 1990, P NATL ACAD SCI USA, V87, P7250, DOI 10.1073/pnas.87.18.7250; NAGLICH JG, 1992, P NATL ACAD SCI USA, V89, P2170, DOI 10.1073/pnas.89.6.2170; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; PELCHENMATTHEWS A, 1989, EMBO J, V8, P3641, DOI 10.1002/j.1460-2075.1989.tb08538.x; PROIA RL, 1981, J BIOL CHEM, V256, P4991; ROSENBERG MW, 1992, CELL, V71, P1157; ROTH MG, 1993, ADV CELL MOL BIOL M, V1, P19; ROTHENBERGER S, 1987, CELL, V49, P423, DOI 10.1016/0092-8674(87)90295-9; ROTHMAN JE, 1987, CELL, V50, P521, DOI 10.1016/0092-8674(87)90024-9; Sambrook J, 1989, MOL CLONING LAB MANU, P82; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5	58	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26635	26641						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929396				2022-12-27	WOS:A1994PQ93100012
J	BAKKENIST, CJ; COTTERILL, S				BAKKENIST, CJ; COTTERILL, S			THE 50-KDA PRIMASE SUBUNIT OF DROSOPHILA-MELANOGASTER DNA-POLYMERASE-ALPHA - MOLECULAR CHARACTERIZATION OF THE GENE AND FUNCTIONAL ANALYSIS OF THE OVEREXPRESSED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE ESSENTIAL GENE; CELL NUCLEAR ANTIGEN; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; CALF THYMUS; BINDING; EXPRESSION; EMBRYOS; TRANSCRIPTION; REPLICATION	The gene encoding the 50-kDa subunit of Drosophila melanogaster DNA polymerase alpha has been cloned. A comparison of the predicted polypeptide sequence of the Drosophila protein with the equivalent subunits from mouse and yeast suggests that they are closely related and defines three conserved regions which are likely to be important for enzyme activity. The expression patterns of both the 50-kDa protein and its transcript (a single RNA message of 1.6 kilobases) throughout development are consistent with a role of the protein in DNA replication. When overexpressed and purified the 50-kDa subunit displays DNA primase activity. The products of the reaction, mainly oligoribonucleotides 12-14 nucleotides in length, plus dimers and some trimers, are similar to those synthesized by either the intact DNA polymerase alpha, or the biochemically isolated primase heterodimer. The isolated primase also shows similar sensitivity to antibodies, magnesium and monovalent cations, and the same nucleotide requirements as complexed forms of the primase. The isolated subunit, however, is more thermally labile, suggesting a role for the additional subunits in DNA polymerase alpha in stabilizing the primase activity of the 50-kDa primase subunit.	CHART,MARIS CURIE RES INST,OXTED RH8 0TL,SURREY,ENGLAND; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,LONDON SW7 2AZ,ENGLAND	Imperial College London								BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONAWAY RC, 1982, P NATL ACAD SCI-BIOL, V79, P2523, DOI 10.1073/pnas.79.8.2523; COPELAND WC, 1993, J BIOL CHEM, V268, P26179; COTTERILL S, 1987, J BIOL CHEM, V262, P16100; COTTERILL S, 1987, J BIOL CHEM, V262, P16105; COTTERILL SM, 1992, NUCLEIC ACIDS RES; DEAROLF CR, 1989, NATURE, V341, P340, DOI 10.1038/341340a0; FOIANI M, 1989, MOL CELL BIOL, V9, P3081, DOI 10.1128/MCB.9.7.3081; FOIANI M, 1989, J BIOL CHEM, V264, P2189; HIROSE F, 1993, J BIOL CHEM, V268, P2092; HOCHULI E, 1990, GENETIC ENG PRINCIPL, P12; HOHEISEL JD, 1991, J MOL BIOL, V220, P903, DOI 10.1016/0022-2836(91)90362-A; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; Kornberg A., 1991, DNA REPLICATION; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; LUCCHINI G, 1987, EMBO J, V6, P737, DOI 10.1002/j.1460-2075.1987.tb04815.x; MELOV S, 1992, J CELL SCI, V102, P847; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NASHEUER HP, 1988, J BIOL CHEM, V263, P8981; PLEVANI P, 1987, NUCLEIC ACIDS RES, V15, P7975; PRUSSAK CE, 1989, J BIOL CHEM, V264, P4957; SAMBROOK J, 1990, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOCANALE C, 1993, J BIOL CHEM, V268, P1343; SHEAFF RJ, 1993, BIOCHEMISTRY-US, V32, P3027, DOI 10.1021/bi00063a014; STUBER D, 1990, EUR J IMMUNOL, V20, P819, DOI 10.1002/eji.1830200416; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; YAMAGUCHI M, 1990, MOL CELL BIOL, V10, P872, DOI 10.1128/MCB.10.3.872	34	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26759	26766						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929411				2022-12-27	WOS:A1994PQ93100030
J	MAY, WS; TYLER, PG; ITO, T; ARMSTRONG, DK; QATSHA, KA; DAVIDSON, NE				MAY, WS; TYLER, PG; ITO, T; ARMSTRONG, DK; QATSHA, KA; DAVIDSON, NE			INTERLEUKIN-3 AND BRYOSTATIN-1 MEDIATE HYPERPHOSPHORYLATION OF BCL2-ALPHA IN ASSOCIATION WITH SUPPRESSION OF APOPTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PROGRAMMED CELL-DEATH; GENE-EXPRESSION; BCL-2 GENE; PHOSPHORYLATION; ACTIVATION; SURVIVAL; PREVENT; AGENTS	Using murine myeloid factor-dependent FDC-P1/ER cells, we demonstrate that the hematopoietic growth factors interleukin-3 and erythropoietin and bryostatin-1, a macrocyclic lactone natural product and potent activator of protein kinase C (PKC), suppress apoptosis and induce the rapid serine phosphorylation of Bcl2 alpha. Expression of recombinant wild type Bcl2 alpha in NFS/N1.H-7 cells confirms that murine Bcl2 alpha is phosphorylated following PKC activation. The PKC inhibitors H-7 and staurosporine, but not the protein kinase A inhibitor HA1004, block not only interleukin-3- and bryostatin-1-induced hyperphosphorylation of Bcl2 alpha but also their anti-apoptotic effect on growth factor-dependent cells, suggesting a role for activated PKC in both processes. A potential direct role for a classic isoform of PKC is indicated by the Ca2+-dependent nature of phosphorylation of Bcl2 alpha mediated by purified PKC in vitro. Comparative phosphopeptide maps confirm that Bcl2 alpha phosphorylation occurs on identical serine site(s) whether phosphorylation occurs in cells following agonist treatment or directly by PKC in vitro. These findings strongly support a role for activated PKC in growth factor-induced Bcl2 alpha phosphorylation as well as suppression of apoptosis.			MAY, WS (corresponding author), JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,424 N BOND ST,BALTIMORE,MD 21231, USA.				NATIONAL CANCER INSTITUTE [R01CA044649, R01CA058492, R01CA047993] Funding Source: NIH RePORTER; NCI NIH HHS [CA58492, CA44649, CA47993] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; ARMSTRONG DK, 1992, CANCER RES, V52, P3418; BOSWELL HS, 1990, EXP HEMATOL, V18, P794; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; FIELDS AP, 1989, J BIOL CHEM, V264, P21896; HARA T, 1990, SCIENCE, V247, P324; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOCKENBERRY D, 1990, NATURE, P334; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JARVIS WD, 1994, CANCER RES, V54, P1707; KRAFT AS, 1987, ONCOGENE, V1, P111; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; MAY WS, 1987, P NATL ACAD SCI USA, V84, P8483, DOI 10.1073/pnas.84.23.8483; MAY WS, 1987, J BIOL CHEM, V262, P16710; MAY WS, 1993, 3RD P INT C NEG REG, V229, P291; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PETTIT GR, 1982, J AM CHEM SOC, V104, P6846, DOI 10.1021/ja00388a092; RAJOTTE D, 1992, J BIOL CHEM, V267, P9980; SOZERI O, 1992, ONCOGENE, V7, P2259; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1987, J PATHOL, V153, P313, DOI 10.1002/path.1711530404	31	223	226	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26865	26870						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929424				2022-12-27	WOS:A1994PQ93100045
J	WHITESIDE, ST; KING, P; GOODBOURN, S				WHITESIDE, ST; KING, P; GOODBOURN, S			A TRUNCATED FORM OF THE IRF-2 TRANSCRIPTION FACTOR HAS THE PROPERTIES OF A POSTINDUCTION REPRESSOR OF INTERFERON-BETA GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATE VIRUS INDUCIBILITY; NF-KAPPA-B; REGULATORY ELEMENTS; IFN-ALPHA; PROMOTER; IDENTIFICATION; SEQUENCES; INDUCTION; CELLS; ENHANCER	The interferon-beta promoter binding protein, IRF-2, is proteolytically processed during induction by double-stranded RNA to leave an N-terminal fragment that can still bind to DNA. An N-terminal fragment that corresponds to the induction-specific product has a higher affinity for the promoter and is a more potent repressor of interferon-beta transcription than the full-length precursor. The kinetics of production of the cleavage product is slower than that of activation of interferon-beta transcription. These results suggest that cleavage of IRF-2 functions to generate a postinduction repressor of interferon-beta expression.	IMPERIAL CANC RES FUND,GENE EXPRESS LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK				Goodbourn, Stephen/0000-0002-4530-1179				COHEN L, 1992, VIROLOGY, V191, P589, DOI 10.1016/0042-6822(92)90234-G; Demaeyer E., 1988, INTERFERONS OTHER RE; DIMAIO D, 1982, P NATL ACAD SCI-BIOL, V79, P4030, DOI 10.1073/pnas.79.13.4030; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; Goodbourn S, 1990, Semin Cancer Biol, V1, P89; GOODBOURN S, 1985, CELL, V41, P509, DOI 10.1016/S0092-8674(85)80024-6; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; KELLER AD, 1988, P NATL ACAD SCI USA, V85, P3309, DOI 10.1073/pnas.85.10.3309; KUHL D, 1987, CELL, V50, P1057, DOI 10.1016/0092-8674(87)90172-3; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; MANIATIS T, 1988, HARVEY LECT, V82, P71; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NAF D, 1991, P NATL ACAD SCI USA, V88, P1369, DOI 10.1073/pnas.88.4.1369; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; PILON M, 1991, J IMMUNOL, V146, P1047; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; SAMBROOK J, 1989, MOL CLONIG LABORATOR; SLEI, 1986, UKL, V156, P251; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WHITESIDE ST, 1992, NUCLEIC ACIDS RES, V20, P1531, DOI 10.1093/nar/20.7.1531; WHITESIDE ST, 1992, REGULATION HUMAN BET; WHITTEMORE LA, 1990, MOL CELL BIOL, V10, P1329, DOI 10.1128/MCB.10.4.1329; WHITTEMORE LA, 1990, P NATL ACAD SCI USA, V87, P7799, DOI 10.1073/pnas.87.20.7799; YAMAMOTO H, 1994, ONCOGENE, V9, P1423; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	32	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27059	27065						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929448				2022-12-27	WOS:A1994PQ93100071
J	YIN, TG; TSANG, MLS; YANG, YC				YIN, TG; TSANG, MLS; YANG, YC			JAK1 KINASE FORMS COMPLEXES WITH INTERLEUKIN-4 RECEPTOR AND 4PS/INSULIN RECEPTOR SUBSTRATE-1-LIKE PROTEIN AND IS ACTIVATED BY INTERLEUKIN-4 AND INTERLEUKIN-9 IN T-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TYROSINE PHOSPHORYLATION; GAMMA-CHAIN; CELL-LINE; HEMATOPOIETIC-CELLS; IL-2 RECEPTOR; CLONING; MURINE	Interleukin (IL)-4 and IL-9 regulate the proliferation of T lymphocytes through interactions with their receptors, Previous studies have shown that unknown tyrosine kinases are involved in the proliferative signaling triggered by IL-4 and IL-9. Here we show that IL-4 and IL-9 induce overlapping (170, 130, and 125 kilodalton (kDa)) and distinct (45 and 88/90 kDa, respectively) protein tyrosine phosphorylation in T lymphocytes. We further identify the 170-kDa tyrosine-phosphorylated protein as 4PS/insulin receptor substrate-1-like (IRS-1L) protein and 130-kDa protein as JAK1 kinase. Furthermore, we demonstrate for the first time that JAK1 forms complexes with the IL-4 receptor and 4PS/IRS-1L protein following ligand-receptor interaction. In addition, we demonstrate that IL-9, but not IL-4, induced tyrosine phosphorylation of Stat 91 transcriptional factor. The overlapping and distinct protein tyrosine phosphorylation and activation of the same JAK1 kinase in T lymphocytes strongly suggests that IL-4 and IL-9 share the common signal transduction pathways and that the specificity for each cytokine could be achieved through the unique tyrosine-phosphorylated proteins triggered by individual cytokines.	INDIANA UNIV,SCH MED,MED CTR,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,MED CTR,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202; INDIANA UNIV,MED CTR,DEPT MED HEMATOL ONCOL,INDIANAPOLIS,IN 46202; RES & DEV SYST,MINNEAPOLIS,MN 55413	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043105] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL48819] Funding Source: Medline; NIDDK NIH HHS [R01DK43105] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARTGETSINGER LS, 1993, CELL, V74, P237; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DASILVA L, 1994, J BIOL CHEM, V269, P18267; HULTNER L, 1990, EUR J IMMUNOL, V20, P1413, DOI 10.1002/eji.1830200632; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; IZUHARA K, 1993, J BIOL CHEM, V268, P13097; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KIRKEN RA, 1994, J BIOL CHEM, V269, P19136; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; MIYAZAWA K, 1992, BLOOD, V80, P1685; MORIA AO, 1988, MOL CELL BIOL, V8, P2214; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; PAUL WE, 1991, BLOOD, V77, P1859; RENAULD JC, 1993, ADV IMMUNOL, V54, P79, DOI 10.1016/S0065-2776(08)60533-7; RENAULD JC, 1992, P NATL ACAD SCI USA, V89, P5690, DOI 10.1073/pnas.89.12.5690; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; UYTTENHOVE C, 1988, P NATL ACAD SCI USA, V85, P6934, DOI 10.1073/pnas.85.18.6934; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YIN TG, 1994, EXP HEMATOL, V22, P467	35	125	130	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26614	26617						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929391				2022-12-27	WOS:A1994PQ93100007
J	FURUKAWA, Y; TERUI, Y; SAKOE, K; OHTA, M; SAITO, M				FURUKAWA, Y; TERUI, Y; SAKOE, K; OHTA, M; SAITO, M			THE ROLE OF CELLULAR TRANSCRIPTION FACTOR E2F IN THE REGULATION OF CDC2 MESSENGER-RNA EXPRESSION AND CELL-CYCLE CONTROL OF HUMAN HEMATOPOIETIC-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA-SUSCEPTIBILITY GENE; COLONY-STIMULATING FACTOR; DNA-BINDING ACTIVITY; LINE JOSK-I; PROTEIN-KINASE; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; CHROMATIN STRUCTURE; MAMMALIAN-CELLS; PRODUCT	cdc2 mRNA transcripts were detected in immature bone marrow cells and became undetectable along with differentiation. Peripheral blood resting cells did not express cdc2 mRNA,but it was induced in T-lymphocytes when the cells reentered the cell cycle in response to specific mitogens. In contrast, cdc2 mRNA could not be induced in granulocytes and monocytes even after the culture with the appropriate stimulants. In order to investigate the mechanism of the regulation of cdc2 mRNA expression in hematopoietic cells, we isolated the 5'-flanking sequence of the cdc2 gene and found the putative E2F binding site at the position of nucleotides -124 to -117. The binding of E2F at this region was detected by a gel-retardation assay and DNaseI footprinting in phytohemagglutinin stimulated T-lymphocytes, which was coincident with the expression of cdc2 mRNA. E2F binding was not observed in both granulocytes and monocytes. Transient chloramphenicol acetyltransferase assay revealed that the region containing E2F binding site had a strong promoter activity, and introduction of the mutation at the E2F binding site resulted in a significant loss of the activity. E2F-1 and DP-1 mRNAs were not detectable in granulocytes, monocytes and resting T-lymphocytes but were induced after the mitogenic stimulation of T-lymphocytes. The induction of E2F activity preceded the appearance of cdc8 mRNA, which is consistent with the role of E2F in the regulation of cdc2 mRNA expression. These results suggest that cdc2 mRNA expression is related to the cell cycling of normal human hematopoietic cells and that E2F plays some roles in the regulation of its expression.	JICHI MED SCH,INST HEMATOL,DIV HEMOPOIESIS,MINAMI KAWACHI,TOCHIGI 32904,JAPAN	Jichi Medical University			Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418				AGLIETTA M, 1989, J CLIN INVEST, V83, P551, DOI 10.1172/JCI113917; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BRUMLEY RL, 1991, NUCLEIC ACIDS RES, V19, P4121, DOI 10.1093/nar/19.15.4121; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CHODOSH LA, 1992, SHORT PROTOCOLS MOL, P12; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DURKACZ B, 1986, EMBO J, V5, P369, DOI 10.1002/j.1460-2075.1986.tb04221.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FORS L, 1990, NUCLEIC ACIDS RES, V18, P2793, DOI 10.1093/nar/18.9.2793; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; FURUKAWA Y, 1987, CANCER RES, V47, P2589; FURUKAWA Y, 1992, J BIOL CHEM, V267, P17121; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HASHINAKA K, 1988, BIOCHEMISTRY-US, V27, P5906, DOI 10.1021/bi00416a013; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; Hunt T, 1991, Semin Cell Biol, V2, P213; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KITAGAWA S, 1984, J CLIN INVEST, V73, P1062, DOI 10.1172/JCI111291; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KU DH, 1993, J BIOL CHEM, V268, P2255; LAPIDOTLIESON Y, 1992, P NATL ACAD SCI USA, V89, P579, DOI 10.1073/pnas.89.2.579; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LOWREY CH, 1992, P NATL ACAD SCI USA, V89, P1143, DOI 10.1073/pnas.89.3.1143; LUBBERT M, 1991, BLOOD, V78, P345; MCGOWAN CH, 1990, MOL CELL BIOL, V10, P3847, DOI 10.1128/MCB.10.7.3847; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NEVINS JR, 1992, SCIENCE, V258, P424; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; OGAWA M, 1993, BLOOD, V81, P2844; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SUDA T, 1983, J CELL PHYSIOL, V117, P308, DOI 10.1002/jcp.1041170305; SUZUKI K, 1989, J EXP MED, V169, P1895, DOI 10.1084/jem.169.6.1895; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; YAMAMOTO M, 1994, EXP CELL RES, V210, P94, DOI 10.1006/excr.1994.1014; YUO A, 1992, BLOOD, V79, P1553	64	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26249	26258						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929342				2022-12-27	WOS:A1994PQ93000050
J	NISHIMURA, M; FEDOROV, S; UYEDA, K				NISHIMURA, M; FEDOROV, S; UYEDA, K			GLUCOSE-STIMULATED SYNTHESIS OF FRUCTOSE 2,6-BISPHOSPHATE IN RAT-LIVER - DEPHOSPHORYLATION OF FRUCTOSE 6-PHOSPHATE,2-KINASE-FRUCTOSE 2,6-BISPHOSPHATASE AND ACTIVATION BY A SUGAR-PHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AD-LIBITUM; PHOSPHORYLATION; HEPATOCYTES; GLYCOLYSIS; CYCLE; METABOLISM; MECHANISM; 2-KINASE; BINDING; LEVEL	The effect of glucose on hepatic fructose (Fru) 2,6-P-2 in starved rats was investigated. When livers were perfused with high glucose (40 mM), hexose-P in the liver increased immediately reaching the maximum within in 2 min, but Fru 2,6-P-2 after a lag period of 4 min increased linearly. The activation of Fru 6-P,2-kinase and inactivation of Fru 2,6-Pase also showed a similar lag period. Determination of the phosphate contents of the bifunctional enzyme after 10 min of glucose perfusion revealed that 90% of the enzyme was in the dephospho form while only 10% of the control liver enzyme was dephosphorylated. Comparison of crude extracts of liver perfused with either high glucose or normal glucose (5.6 mM) showed that high glucose livers contained 50% higher protein phosphatase activity, which dephosphorylated the bifunctional enzyme. Subcellular fractionation of the ex tract showed that activation of the protein phosphatase occurred in the cytosol. Desalting of the cytosolic fraction resulted in a 50% loss of the protein phosphatase activity. The low molecular weight activator in the cytosol was isolated, and by various chemical and enzymatic methods it was identified as xylulose 5-P. The activation of protein phosphatase by xylulose 5-P showed a highly sigmoidal saturation curve. The rate of formation of xylulose 5-P in the perfused liver showed a lag period of approximately 2 min, and after 4 min its concentration reached 10 mu M, the minimum concentration necessary for the activation of the protein phosphatase. We conclude that the mechanism of glucose-induced Fru 2,6-P-2 synthesis was not due to increased Fru 6-P as generally thought but occurred as a result of dephosphorylation of Fru 6-P,2-kinase:Fru 2,6-Pase. Moreover, the dephosphorylation was enhanced by increased xylulose 5-P, which activated a specific protein phosphatase. The results suggest a mechanism for coordinated regulation of glycolysis and the pentose shunt pathway that is mediated by xylulose 5-P.	DEPT VET AFFAIRS MED CTR,DALLAS,TX 75216; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75216	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ABE Y, 1994, IN PRESS BIOCHEMISTR; BONTEMPS F, 1978, BIOCHEM J, V174, P603, DOI 10.1042/bj1740603; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSCHIAZZO H, 1970, Proceedings of the National Academy of Sciences of the United States of America, V65, P383, DOI 10.1073/pnas.65.2.383; BUSTOS R, 1989, FEBS LETT, V251, P143, DOI 10.1016/0014-5793(89)81444-9; CASAZZA JP, 1986, J BIOL CHEM, V261, P690; CASAZZA JP, 1986, BIOCHEM J, V236, P635, DOI 10.1042/bj2360635; Corbin J D, 1974, Methods Enzymol, V38, P287; ELMAGHRABI MR, 1982, P NATL ACAD SCI-BIOL, V79, P315, DOI 10.1073/pnas.79.2.315; FILLAT C, 1993, ARCH BIOCHEM BIOPHYS, V300, P564, DOI 10.1006/abbi.1993.1078; FRANCOIS J, 1987, EUR J BIOCHEM, V164, P369, DOI 10.1111/j.1432-1033.1987.tb11067.x; FURUYA E, 1982, P NATL ACAD SCI-BIOL, V79, P325, DOI 10.1073/pnas.79.2.325; HERS HG, 1976, ANNU REV BIOCHEM, V45, P167, DOI 10.1146/annurev.bi.45.070176.001123; HUE L, 1981, J BIOL CHEM, V256, P8900; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; HUE L, 1984, BIOCHEM J, V224, P779, DOI 10.1042/bj2240779; Hue L, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P247; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; KATZ J, 1978, J BIOL CHEM, V253, P4530; KHYM JX, 1975, CLIN CHEM, V21, P1245; KITAJIMA S, 1984, J BIOL CHEM, V259, P6896; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lowry O. H., 1972, FLEXIBLE SYSTEM ENZY, P146; MALAISSE WJ, 1982, DIABETES, V31, P90, DOI 10.2337/diabetes.31.1.90; NEELY P, 1981, DIABETES, V30, P1062, DOI 10.2337/diabetes.30.12.1062; NORDLIE RC, 1980, J BIOL CHEM, V255, P1834; OGAWA A, 1993, BIOCHEM MOL BIOL INT, V30, P83; RICHARDS CS, 1980, BIOCHEM BIOPH RES CO, V109, P394; Roach P. J., 1986, ENZYMES, VXVII, P499; SAKAKIBARA R, 1984, J BIOL CHEM, V259, P41; STALMANS W, 1987, Diabetes Metabolism Reviews, V3, P127; STALMANS W, 1976, CURR TOP CELL REGUL, V11, P51; THOMAS H, 1986, ANAL BIOCHEM, V154, P50, DOI 10.1016/0003-2697(86)90494-X; THOMAS H, 1986, FED PROC, V45, P1013; TOMINAGA N, 1993, J BIOL CHEM, V268, P15951; UYEDA K, 1978, J BIOL CHEM, V253, P8319; VANSCHAFTINGEN E, 1981, BIOCHEM BIOPH RES CO, V103, P362, DOI 10.1016/0006-291X(81)91701-0; VANSCHAFTINGEN E, 1980, BIOCHEM J, V192, P887, DOI 10.1042/bj1920887	38	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26100	26106						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929321				2022-12-27	WOS:A1994PQ93000027
J	ONEAL, KD; YULEE, LY				ONEAL, KD; YULEE, LY			DIFFERENTIAL SIGNAL-TRANSDUCTION OF THE SHORT, NB2, AND LONG PROLACTIN RECEPTORS - ACTIVATION OF INTERFERON REGULATORY FACTOR-I AND CELL-PROLIFERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; STIMULATING FACTOR-RECEPTOR; FACTOR-I; LYMPHOMA-CELLS; ERYTHROPOIETIN RECEPTOR; TYROSINE KINASE; CYTOPLASMIC REGION; GENE-EXPRESSION; BETA-CHAIN; T-CELLS	An Nb2 prolactin receptor (PRL-R) cDNA has been cloned from the PRL-dependent Nb2-11C cell line, and the protein-coding region is identical to that of the PRL-R isolated from the PRL-independent cell line Nb2-Sp. Short, Nb2, and long forms of the PRL-R were analyzed for signal transduction to the immediate-early gene, interferon regulatory factor-1 (IRF-1) and for cellular proliferation. Receptor and IRF-1-CAT reporter constructs were transiently cotransfected into the interleukin-3 dependent cell lines FDC-P1 and BaF3. The Nb2 PRL-R induced IRF-1-CAT 14.3-fold on addition of PRL, while the long PRL-R induced IRF-1-CAT 5.6-fold in FDC-P1 cells. The short PRL-R did not activate the IRF-1 promoter. Stable transfectants were also generated by selecting for growth in PRL. Only the Nb2 and long forms were able to convert the IL-3-dependent cells to PRL-dependence. IRF-1-CAT was induced in these cell lines by the Nb2 PRL-R 10- to 12-fold and long PRL-R 3- to 3.5-fold. Overall, the Nb2 form is more efficient than the long form by about 3-fold at inducing IRF-1-CAT. A PRL dose-response growth curve showed that the Nb2 form requires 20-fold less PRL for half maximal growth than the long form. A PRL dose-response for IRF-1-CAT activity gave similar results, indicating a tight correlation between IRF-1 induction and cell proliferation. These results show that the short PRL-R does not signal to IRF-1 or for growth, and that the Nb2 PRL-R signals more efficiently than the long PRL-R.	BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MICROBIOL & IMMUNOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine					NIDDK NIH HHS [R01-DK44625] Funding Source: Medline; NIMH NIH HHS [F30-MH10343] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044625] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F30MH010343] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; ALI S, 1991, J BIOL CHEM, V266, P20110; ALI S, 1992, MOL ENDOCRINOL, V6, P1242, DOI 10.1210/me.6.8.1242; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; ASHKENAZI A, 1987, BIOCHEM INT, V14, P1065; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMBACH WR, 1989, GENE DEV, V3, P1199, DOI 10.1101/gad.3.8.1199; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; COLOSI P, 1993, J BIOL CHEM, V268, P12617; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS JA, 1989, MOL ENDOCRINOL, V3, P674, DOI 10.1210/mend-3-4-674; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ELSHOLTZ HP, 1986, BIOCHEM CELL BIOL, V64, P381, DOI 10.1139/o86-053; FRIESEN HG, 1991, PROG NEUROENDOCRINIM, V4, P1; FUH G, 1993, J BIOL CHEM, V268, P5376; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; GAGNERAULT MC, 1993, J IMMUNOL, V150, P5673; GALA RR, 1993, ENDOCRINOLOGY, V133, P1617, DOI 10.1210/en.133.4.1617; GELLER DA, 1993, SURGERY, V114, P235; GERTLER A, 1985, ENDOCRINOLOGY, V116, P1636, DOI 10.1210/endo-116-4-1636; GOUT PW, 1980, CANCER RES, V40, P2433; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HOBBS AA, 1982, J BIOL CHEM, V257, P3598; JAHN GA, 1991, ENDOCRINOLOGY, V128, P2976, DOI 10.1210/endo-128-6-2976; KURAMOCHI S, 1990, J MOL BIOL, V216, P567, DOI 10.1016/0022-2836(90)90384-X; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MORI H, 1991, INT IMMUNOL, V3, P149, DOI 10.1093/intimm/3.2.149; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NAGANO M, 1994, J BIOL CHEM, V269, P13337; ONEAL KD, 1991, MOL CELL ENDOCRINOL, V82, P127, DOI 10.1016/0303-7207(91)90023-L; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PELLEGRINI I, 1992, MOL ENDOCRINOL, V6, P1023, DOI 10.1210/me.6.7.1023; RILLEMA JA, 1992, ENDOCRINOLOGY, V131, P973, DOI 10.1210/en.131.2.973; RUI H, 1992, J BIOL CHEM, V267, P24076; RUI H, 1994, J BIOL CHEM, V269, P5364; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SCHWARZ LA, 1992, MOL CELL ENDOCRINOL, V86, P103, DOI 10.1016/0303-7207(92)90180-E; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; SHIU RPC, 1983, ENDOCRINOLOGY, V113, P159, DOI 10.1210/endo-113-1-159; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; STEVENS AM, 1994, MOL ENDOCRINOL, V8, P345, DOI 10.1210/me.8.3.345; STEVENS AM, 1992, MOL ENDOCRINOL, V6, P2236, DOI 10.1210/me.6.12.2236; TOO CKL, 1990, ENDOCRINOLOGY, V126, P1368, DOI 10.1210/endo-126-3-1368; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087; ZHANG R, 1990, BIOCHEM BIOPH RES CO, V168, P415, DOI 10.1016/0006-291X(90)92337-Y; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	60	100	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26076	26082						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929319				2022-12-27	WOS:A1994PQ93000024
J	SUH, TT; NERLOV, C; DANO, K; DEGEN, JL				SUH, TT; NERLOV, C; DANO, K; DEGEN, JL			THE MURINE UROKINASE-TYPE PLASMINOGEN-ACTIVATOR RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 DNA-POLYMERASE; MESSENGER-RNA; CELLULAR RECEPTOR; BOUND UROKINASE; BINDING-PROTEIN; GLYCOSYL-PHOSPHATIDYLINOSITOL; POLY(DC-DA) SEQUENCE; ENDOTHELIAL-CELLS; MOUSE GENOME; MEMBRANE	The murine urokinase-type plasminogen activator receptor (uPAR) gene has been isolated and its complete nucleotide sequence established. The gene is organized into seven exons comprising 9.5% of the 13,207-base pair region that spans the interval between the transcription initiation and polyadenylation sites. The region upstream of the transcription initiation site lacks TATA- or CCAAT-like elements but is flanked by a G+C-rich region, which contains a number of potential regulatory elements including Sp1 and AP1 binding motifs. The close association of both Sp1 and AP1 sites within the proximal promoter region is consistent with the observation that the murine uPAR gene is inducible by phorbol esters. The major functional domains of the encoded protein, including the signal peptide, three cysteine-rich internal repeats, and the glycolipid anchor attachment motif, are encoded by separate exons. Based on the organization of the murine uPAR gene and the distribution of protein domains within the exons in the Ly-6 family of genes, it appears that the uPAR gene evolved secondarily to two internal duplication events within a Ly-6-like ancestral gene. The cloned and sequenced murine uPAR gene will be a valuable tool in understanding the regulation and biological roles of uPAR in that it will permit detailed studies of gene expression and uPAR-dependent processes in vitro, as well as the generation of both gain-of-function and loss-of-function mutants in transgenic mice.	CHILDRENS HOSP RES FDN,DIV BASIC SCI RES,TCHRF 2025,CINCINNATI,OH 45229; RIGSHOSP,FINSEN LAB,DK-2100 COPENHAGEN 0,DENMARK	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Rigshospitalet; University of Copenhagen								ALBRECHT JC, 1992, VIROLOGY, V190, P527, DOI 10.1016/0042-6822(92)91247-R; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BLAKE CCF, 1978, NATURE, V273, P267, DOI 10.1038/273267a0; BLASI F, 1990, CELL DIFFER DEV, V32, P247, DOI 10.1016/0922-3371(90)90037-W; BOTHWELL A, 1988, J IMMUNOL, V140, P2815; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CASEY JR, 1994, BLOOD, V84, P1151; COLLEN D, 1987, MOL BASIS BLOOD DISE, P662; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; CUBELLIS MV, 1986, J BIOL CHEM, V261, P5819; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637; DEGEN SJF, 1986, J BIOL CHEM, V261, P6972; DEGEN SJF, 1987, BIOCHEMISTRY-US, V26, P8270, DOI 10.1021/bi00399a038; DOOLITTLE WF, 1978, NATURE, V272, P581, DOI 10.1038/272581a0; ELLIS V, 1991, SEMIN THROMB HEMOST, V17, P194, DOI 10.1055/s-2007-1002609; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEDMAN S, 1990, IMMUNOGENETICS, V31, P104, DOI 10.1007/BF00661220; FUSE N, 1990, EUR J BIOCHEM, V193, P629, DOI 10.1111/j.1432-1033.1990.tb19380.x; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; HAMADA H, 1984, MOL CELL BIOL, V4, P2622, DOI 10.1128/MCB.4.12.2622; HAMADA H, 1984, MOL CELL BIOL, V4, P2610, DOI 10.1128/MCB.4.12.2610; HEBERT CA, 1988, J CELL BIOL, V106, P1241, DOI 10.1083/jcb.106.4.1241; HTUN H, 1984, P NATL ACAD SCI-BIOL, V81, P7288, DOI 10.1073/pnas.81.23.7288; HURST HC, 1984, NUCLEIC ACIDS RES, V12, P4313, DOI 10.1093/nar/12.10.4313; IKUYAMA S, 1992, MOL ENDOCRINOL, V6, P793, DOI 10.1210/me.6.5.793; INGOLIA TD, 1981, NUCLEIC ACIDS RES, V9, P1627, DOI 10.1093/nar/9.7.1627; KALB VF, 1983, NUCLEIC ACIDS RES, V11, P2177, DOI 10.1093/nar/11.7.2177; KING D, 1986, MOL CELL BIOL, V6, P209, DOI 10.1128/MCB.6.1.209; KRAMEROV DA, 1979, NUCLEIC ACIDS RES, V6, P697, DOI 10.1093/nar/6.2.697; KRAYEV AS, 1982, NUCLEIC ACIDS RES, V10, P7461, DOI 10.1093/nar/10.23.7461; KRISTENSEN P, 1991, J CELL BIOL, V115, P1763, DOI 10.1083/jcb.115.6.1763; LAFYATIS R, 1990, J BIOL CHEM, V265, P19128; LAFYATIS R, 1991, NUCLEIC ACIDS RES, V19, P6419, DOI 10.1093/nar/19.23.6419; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; LUND LR, 1991, J BIOL CHEM, V266, P5177; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MOLLER LB, 1992, EUR J BIOCHEM, V208, P493, DOI 10.1111/j.1432-1033.1992.tb17213.x; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NERLOV C, 1991, ONCOGENE, V6, P1583; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; OSSOWSKI L, 1988, J CELL BIOL, V107, P2437, DOI 10.1083/jcb.107.6.2437; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PEPPER MS, 1987, J CELL BIOL, V105, P2535, DOI 10.1083/jcb.105.6.2535; PETRANKA JG, 1992, P NATL ACAD SCI USA, V89, P7876, DOI 10.1073/pnas.89.17.7876; PLOUG M, 1993, J BIOL CHEM, V268, P17539; PLOUG M, 1991, J BIOL CHEM, V266, P1926; POLLANEN J, 1987, J CELL BIOL, V104, P1085, DOI 10.1083/jcb.104.4.1085; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; PULLEYBLANK DE, 1985, CELL, V42, P271, DOI 10.1016/S0092-8674(85)80122-7; PYKE C, 1991, AM J PATHOL, V138, P1059; PYKE C, 1993, FEBS LETT, V326, P69, DOI 10.1016/0014-5793(93)81763-P; RYSKOV AP, 1983, NUCLEIC ACIDS RES, V11, P6541, DOI 10.1093/nar/11.18.6541; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1989, J BIOL CHEM, V264, P6447; TONE M, 1992, J MOL BIOL, V227, P971, DOI 10.1016/0022-2836(92)90239-G; UNKELESS JC, 1974, J EXP MED, V139, P834, DOI 10.1084/jem.139.4.834; Vassalli J D, 1992, Curr Top Microbiol Immunol, V181, P65; WILLIAMS AF, 1988, IMMUNOGENETICS, V27, P265, DOI 10.1007/BF00376121	73	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					25992	25998						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929309				2022-12-27	WOS:A1994PQ93000012
J	WEIS, BC; COWAN, AT; BROWN, N; FOSTER, DW; MCGARRY, JD				WEIS, BC; COWAN, AT; BROWN, N; FOSTER, DW; MCGARRY, JD			USE OF A SELECTIVE INHIBITOR OF LIVER CARNITINE PALMITOYLTRANSFERASE-I (CPT-I) ALLOWS QUANTIFICATION IF ITS CONTRIBUTION TO TOTAL CPT-I ACTIVITY IN RAT-HEART - EVIDENCE THAT THE DOMINANT CARDIAC CPT-I ISOFORM IS IDENTICAL TO THE SKELETAL-MUSCLE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; MALONYL-COA; MITOCHONDRIAL; TISSUES; CLONING; SENSITIVITY; EXPRESSION; SYSTEM; FORM	It has recently been established that rat heart mitochondria contain two isoforms of carnitine palmitoyltransferase I (CPT I), the minor 88-kDa variant being identical to liver CPT I (L-CPT I) and the dominant 82-kDa form resembling the skeletal muscle enzyme (M-CPT I) (Weis, B. C., Esser, V., Foster, D. W., and McGarry, J. D. (1994) J. Biol. Chem. 269, 18712-18715). To quantify the functional contribution of L-CPT I to overall CPT I activity in heart mitochondria a selective inhibitor of the former was needed. The dinitrophenol analog of 2[6-(4-chlorophenoxy)hexyl] oxirane a carboxylic acid (etomoxir) (DNP-Et) was found to have this property. When liver and skeletal muscle mitochondria were exposed to DNP-Et in the presence of ATP and CoASH, the DNP-Et-CoA formed completely inhibited liver CPT I while leaving the muscle enzyme unaffected. Similar treatment of heart mitochondria blocked only the L-CPT I component. This had the effect of shifting the apparent K-m for carnitine from similar to 200 to similar to 500 mu M and the I-50 value for malonyl-CoA (the concentration needed to suppress enzyme activity by 50%) from similar to 0.18 to similar to 0.06 mu M, i.e. the heart system now behaved exactly the same as that from skeletal muscle. Taking the K-m for carnitine of L-CPT I and M-CPT I to be 30 and 500 mu M, respectively, it could be calculated that the former contributes similar to 2% to the total CPT I in heart. When the 82-kDa CPT I isoforms of heart and skeletal muscle were labeled with [H-3]etomoxir and then exposed to trypsin, the fragmentation patterns obtained were identical and quite distinct from that given by CPT I from liver. We conclude that (i) DNP-Et, unlike other agents of the oxirane carboxylic acid class, has remarkable inhibitory selectivity for L-CPT I over M-CPT I; (ii) the previously puzzling observation that rat heart CPT I displays kinetic characteristics intermediate between those of the enzymes from liver and skeletal muscle is entirely accounted for by the low level expression of L-CPT I in the cardiac myocyte; and (iii) the dominant 82-kDa CPT I isoform in heart is identical to the muscle enzyme. The data reaffirm that, in contrast to CPT II, CPT I exists in at least two isoforms and that both are present in rat heart.	UNIV TEXAS, SW MED CTR, SW MED SCH, DEPT INTERNAL MED, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, SW MED SCH, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, SW MED SCH, GIFFORD LABS DIABET RES, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018573, R37DK018573] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18573] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AWAN MM, 1993, BIOCHEM J, V295, P61, DOI 10.1042/bj2950061; CHUNG CH, 1992, BIOCHEMISTRY-US, V31, P9777, DOI 10.1021/bi00155a034; DECLERCQ PE, 1987, J BIOL CHEM, V262, P9812; DEMAUGRE F, 1991, J CLIN INVEST, V87, P859, DOI 10.1172/JCI115090; ESSER V, 1993, J BIOL CHEM, V268, P5817; ESSER V, 1993, J BIOL CHEM, V268, P5810; FINOCCHIARO G, 1991, P NATL ACAD SCI USA, V88, P661, DOI 10.1073/pnas.88.2.661; FOLEY JE, 1992, DIABETES CARE, V15, P773, DOI 10.2337/diacare.15.6.773; KERNER J, 1994, J BIOL CHEM, V269, P8209; KOLODZIEJ MP, 1992, BIOCHEM J, V282, P415, DOI 10.1042/bj2820415; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MURTHY MSR, 1990, BIOCHEM J, V268, P599, DOI 10.1042/bj2680599; SADDIK M, 1993, J BIOL CHEM, V268, P25836; SAGGERSON D, 1992, ADV ENZYME REGUL, V32, P285; SAGGERSON ED, 1981, FEBS LETT, V129, P229, DOI 10.1016/0014-5793(81)80171-8; WEIS BC, 1994, J BIOL CHEM, V269, P18712; WOELTJE KF, 1990, J BIOL CHEM, V265, P10720; WOELTJE KF, 1990, J BIOL CHEM, V265, P10714; WOLF HPO, 1982, DIABETOLOGIA, V22, P456, DOI 10.1007/BF00282590	20	109	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26443	26448						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929365				2022-12-27	WOS:A1994PQ93000077
J	FURUHASHI, M; ANDO, H; BIELINSKA, M; PIXLEY, MR; SHIKONE, T; HSUEH, AJW; BOIME, I				FURUHASHI, M; ANDO, H; BIELINSKA, M; PIXLEY, MR; SHIKONE, T; HSUEH, AJW; BOIME, I			MUTAGENESIS OF CYSTEINE RESIDUES IN THE HUMAN GONADOTROPIN ALPHA-SUBUNIT - ROLES OF INDIVIDUAL DISULFIDE BONDS IN SECRETION, ASSEMBLY, AND BIOLOGIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; LUTEINIZING-HORMONE LH; HAMSTER OVARY CELLS; GLYCOPROTEIN HORMONES; RECEPTOR-BINDING; BETA-SUBUNIT; MAMMALIAN-CELLS; EXPRESSION; SEQUENCE; LUTROPIN	Human chorionic gonadotropin (hCG) is a member of a family of heterodimeric glycoprotein hormones that contain a common alpha subunit but differ in their hormone specific beta subunits. Site-directed mutagenesis was used to examine the role of the five disulfide bonds in the alpha subunit on the folding, assembly with the hCG beta subunit, and in cases where dimer formation occurred, receptor binding and signal transduction. Cysteine residues in the disulfide bonds formed by cysteines 7-31, 10-60, 28-82, 59-87, and 32-84 (Lapthorn, A., Harris, D. Littlejohn, A., Lustbader, J. Canfield, R., Machin, K., Morgan, F., and Isaacs, N. (1994) Nature 369, 455-461) were converted to alanine, and these mutants were transfected alone or together with the wild-type hCG beta gene into Chinese hamster ovary cells. The a Cys-10, 28, 60, 82, and 84 mutants were not secreted and in most cases were degraded at a faster rate than the native subunit. In addition, these mutants failed to assemble with the hCG beta subunit. Mutants with alterations at alpha Cys-7, 31, 32, 59, or 87 were secreted and combined with the beta subunit. Heterodimers containing a 7-31 double mutant bound to human lutropin-chorionic gonadotropin receptor expressed in transfected human fetal kidney cells, and stimulated cAMP comparable to wild-type hCG. Dimers containing the beta subunit with either single mutant alpha 59, alpha 87, alpha 32, or the alpha 59-87 double mutant showed much lower affinity for the receptor than wild-type hCG. These results suggest that disulfide bonds associated with alpha 7, alpha 31, alpha 59, alpha 87, and alpha 32 are not essential for the alpha subunit to fold into a form that will combine with the hCG beta subunit and to produce a biologically active dimer. This contrasts with observations of the hCG beta subunit where all the disulfide bonds are required for efficient combination and folding (Suganuma, N., Mat zuk, M., and Boime, I. (1989) J. Biol. Chem. 264, 19302-19307). In addition, the lack of secretion of some mutants reflects previous observations that proteins which do not fold correctly are rapidly degraded. Thus, alpha subunit mutants which fold properly are secreted and can form heterodimers.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; STANFORD UNIV,DEPT GYNECOL & OBSTET,DIV REPROD BIOL,STANFORD,CA 94305	Washington University (WUSTL); Stanford University					NICHD NIH HHS [HD-92922, HD-23398] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023398] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; BEDOWS E, 1993, J BIOL CHEM, V268, P11655; BIELINSKA M, 1990, Journal of Cell Biology, V111, p330A; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN F, 1992, MOL ENDOCRINOL, V6, P914, DOI 10.1210/me.6.6.914; CORLESS CL, 1987, J BIOL CHEM, V262, P14197; CORLESS CL, 1985, ENDOCRINOLOGY, V117, P1699, DOI 10.1210/endo-117-4-1699; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EHRLICH PH, 1985, AM J REPROD IM MIC, V8, P48; FENG P, 1990, J BIOL CHEM, V265, P2022; GIUDICE LC, 1979, J BIOL CHEM, V254, P1164; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOSHINA H, 1982, P NATL ACAD SCI-BIOL, V79, P7649, DOI 10.1073/pnas.79.24.7649; HUTH JR, 1992, J BIOL CHEM, V267, P21396; JIA XC, 1991, MOL ENDOCRINOL, V5, P759, DOI 10.1210/mend-5-6-759; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LEINUNG MC, 1991, P NATL ACAD SCI USA, V88, P9707, DOI 10.1073/pnas.88.21.9707; LUSTBADER J, 1987, J BIOL CHEM, V262, P14204; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MATZUK MM, 1989, J CELL BIOL, V109, P1429, DOI 10.1083/jcb.109.4.1429; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6354, DOI 10.1073/pnas.84.18.6354; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MISE T, 1980, J BIOL CHEM, V255, P8516; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; RAO MC, 1977, ENDOCRINOLOGY, V101, P512, DOI 10.1210/endo-101-2-512; REED DK, 1991, J BIOL CHEM, V266, P14251; RUDDON RW, 1981, J BIOL CHEM, V256, P1389; Ryan R. J., 1990, GLYCOPROTEIN HORMONE, P71; RYAN RJ, 1987, RECENT PROG HORM RES, V43, P383; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; WEINER RS, 1991, ENDOCRINOLOGY, V128, P1485, DOI 10.1210/endo-128-3-1485; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585	37	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25543	25548						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929256				2022-12-27	WOS:A1994PQ49100049
J	GADBUT, AP; GALPER, JB				GADBUT, AP; GALPER, JB			A NOVEL M(3) MUSCARINIC ACETYLCHOLINE-RECEPTOR IS EXPRESSED IN CHICK ATRIUM AND VENTRICLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROPERTIES; ADENYLATE-CYCLASE; HEART; CLONING; CELLS; CDNA; GENE; HYDROLYSIS; PROTEINS; SUBTYPES	Prior studies have suggested that heart expresses only the M(2) isoform of the muscarinic receptor (Peralta, E. G., Ashkenazi, A., Winslow, J. W., Smith, D. H., Ramachandran, J., and Capon, D, J. (1987) EMBO J. 6, 3923-3929). Tietje and Nathanson (Tietje, K. M., and Nathanson, N. M. (1991) J. Biol. Chem. 266, 17382-17387) have recently demonstrated that the chick heart may be unique since it expresses both the M(2) and M(4) isoforms of the muscarinic receptor. In this study, in order to determine whether other isoforms of the muscarinic receptor were present in the chick heart, a chick M(3) muscarinic recep tor was cloned, characterized, and its expression in chick tissues determined. Using a human M(3) muscarinic receptor cDNA as a probe, a 2.4-kilobase pair cDNA was isolated from a chick brain cDNA library which contained an open reading frame coding for a 639 amino acid protein. This protein demonstrated an 87 and 86% homology to the human and rat M(3) muscarinic receptor, respectively. Chinese hamster ovary (CHO-GRA) cells were stably transfected with the chick M(3) muscarinic receptor and one clone (CHO-CM3) expressed the M(3) receptor, as measured by the binding of quinuclidinly benzilate at 116 +/- 14 (+/-S.E., n = 3) fmol/mg protein with a K-d of 76 +/- 17 pM. This receptor demonstrated a rank order of potency for muscarinic antagonist binding characteristic for the M(3) receptor: with high affinity binding for hexahydrosiladifenidol, K-d: 16 +/- 2 nM (+/-S.E., n = 3); intermediate affinity for pirenzepine, K-d: 383 +/- 47 nM, and low affinity for methoctramine, K-d: 533 +/- 185 nM (+/-S.E., n = 3). Carbamylcholine stimulation of CHO-CM3 cells resulted in a 1.6-fold increase in cyclic AMP accumulation and a 3.5-fold increase in a pertussis toxin-insensitive inositol phosphate release. These data demonstrate that the chick M(3) muscarinic receptor has the properties characteristic of M(3) receptors from other species. RNase protection studies demonstrated the presence of M(3) muscarinic receptor mRNA in the brain, atria, and ventricle of chicks 17 days in ovo. Hence, the chick heart appears to have the unique capacity to express mRNAs coding not only for the M(2) and M(4) muscarinic receptors but also for the M(3) muscarinic receptor.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NHLBI NIH HHS [NHLBI HL36014, HL08463] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008463, R01HL036014] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BARNETT JV, 1990, BIOCHEM J, V271, P437, DOI 10.1042/bj2710437; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; DEHAAN RL, 1967, DEV BIOL, V16, P216, DOI 10.1016/0012-1606(67)90025-5; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GALPER JB, 1980, J BIOL CHEM, V255, P9571; GALPER JB, 1977, J BIOL CHEM, V252, P8692; HALVORSEN SW, 1981, J BIOL CHEM, V256, P7941; HAMBERGER U, 1945, J MORPHOL, V88, P49; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LIANG BT, 1986, J BIOL CHEM, V261, P9011; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSH JD, 1987, AM J PHYSIOL, V252, pC47, DOI 10.1152/ajpcell.1987.252.1.C47; MASTERS SB, 1985, BIOCHEM J, V227, P933, DOI 10.1042/bj2270933; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TIETJE KM, 1991, J BIOL CHEM, V266, P17382; TIETJE KM, 1990, J BIOL CHEM, V265, P2828	28	31	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25823	25829						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929287				2022-12-27	WOS:A1994PQ49100087
J	JENNENS, ML; LOWE, ME				JENNENS, ML; LOWE, ME			A SURFACE LOOP COVERING THE ACTIVE-SITE OF HUMAN PANCREATIC LIPASE INFLUENCES INTERFACIAL ACTIVATION AND LIPID-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LIPOPROTEIN-LIPASE; TRIGLYCERIDE LIPASE; PROCOLIPASE COMPLEX; CATALYTIC SITE; GENE FAMILY; INVITRO; MUTAGENESIS; DIGESTION; SUBSTRATE; COLIPASE	The distinguishing feature of lipases is their increased activity at an oil-wafer interface, termed interfacial activation. X-ray crystallography of lipases suggested a mechanism for interfacial activation by revealing conformational changes in several surface loops that cover the active site. In one conformation, these loops prevented substrate from entering the active site, and, in the other conformation, movement of the loops opened the active site. We tested the role of the major surface loop, the lid domain, in human pancreatic lipase (hPL) function by creating deletions in this region and expressing the mutant proteins in baculovirus infected insect cells. The mutants were tested for activity against tributyrin and triolein, colipase interaction, interfacial activation, and binding to tributyrin. The purified mutants had decreased activity against both tributyrin and triolein compared to wild-type hPL and did not show a preference for either substrate. Although colipase was required for maximum activity in the presence of bile salts, the mutants had significant activity against tributyrin, but not triolein, in the absence of colipase. Both mutants were active against monomers of tributyrin demonstrating that they did not require an interface for activity. Finally, both mutants had decreased binding to tributyrin particles. These results suggest that the lid domain in hPL mediates interfacial activation and influences interfacial binding.			JENNENS, ML (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110, USA.				NIDDK NIH HHS [DK42120] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042120] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNBACK S, 1990, J CLIN INVEST, V85, P1221, DOI 10.1172/JCI114556; BORGSTROM B, 1975, J LIPID RES, V16, P411; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; DEREWENDA U, 1992, BIOCHEMISTRY-US, V31, P1532, DOI 10.1021/bi00120a034; DEREWENDA ZS, 1991, J BIOL CHEM, V266, P23112; DUGI KA, 1992, J BIOL CHEM, V267, P25086; FAUSTINELLA F, 1992, BIOCHEMISTRY-US, V31, P7219, DOI 10.1021/bi00147a002; GROCHULSKI P, 1993, J BIOL CHEM, V268, P12843; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HJORTH A, 1993, BIOCHEMISTRY-US, V32, P4702, DOI 10.1021/bi00069a003; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; LINDSTROM MB, 1988, BIOCHIM BIOPHYS ACTA, V959, P178, DOI 10.1016/0005-2760(88)90029-X; LOWE ME, 1989, J BIOL CHEM, V264, P20042; LOWE ME, 1992, J BIOL CHEM, V267, P17069; PAYNE RM, 1994, AM J PHYSIOL, V266, pG914, DOI 10.1152/ajpgi.1994.266.5.G914; THIRSTRUP K, 1993, FEBS LETT, V327, P79, DOI 10.1016/0014-5793(93)81044-Z; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; VANTILBEURGH H, 1992, NATURE, V359, P159, DOI 10.1038/359159a0; Verger R, 1980, Methods Enzymol, V64, P340; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	24	49	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25470	25474						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929247				2022-12-27	WOS:A1994PQ49100040
J	CAZENAVE, C; FRANK, P; TOULME, JJ; BUSEN, W				CAZENAVE, C; FRANK, P; TOULME, JJ; BUSEN, W			CHARACTERIZATION AND SUBCELLULAR-LOCALIZATION OF RIBONUCLEASE-H ACTIVITIES FROM XENOPUS-LAEVIS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-RNA HYBRIDS; ESCHERICHIA-COLI; CALF THYMUS; REVERSE TRANSCRIPTASES; SUBSTRATE-SPECIFICITY; SEROLOGICAL ANALYSIS; MESSENGER-RNAS; MITOCHONDRIA; REPLICATION; TRANSLATION	Ribonuclease H activities present in fully grown Xenopus oocytes were investigated by using either liquid assays or renaturation gel assays. Whereas the test in solution detected an apparently unique class I ribonuclease H activity, the activity gels did not detect this enzyme but another one with the molecular weight expected for a class II ribonuclease H. The ribonuclease HI was found to be primarily concentrated in the germinal vesicle, but around 5% of this activity was detected in the cytoplasm and may correspond to the activity involved in antisense oligonucleotide-mediated destruction of messenger RNAs. The concentration of this class I ribonuclease H in oocytes is similar to that in somatic cells. The class II ribonuclease H remained undetectable by the test in solution because its activity was cryptic. On activity gel, a polypeptide with the apparent molecular mass of 32 kDa, expected for a ribonuclease HII, was found to be concentrated in mitochondria although no RNase H activity could be detected by using the liquid assay. Based on sedimentation studies, we hypothesize that the apparent absence of RNase H activity in solution could be the result of the association of this 32-kDa polypeptide with other polypeptides, or possibly nucleic acids, to form a multimer of, until now, unknown function.	UNIV TUBINGEN,LEHRSTUHL ALLGEMEINE GENET,INST BIOL,D-72076 TUBINGEN,GERMANY	Eberhard Karls University of Tubingen	CAZENAVE, C (corresponding author), UNIV BORDEAUX 2,INSERM,U386,LAB MOLEC BIOPHYS,146 RUE LEO SAIGNAT,F-33076 BORDEAUX,FRANCE.			Toulme, Jean-jacques/0000-0002-8432-5034				BENARTZI H, 1993, J BIOL CHEM, V268, P16465; BERKOWER I, 1973, J BIOL CHEM, V248, P5914; BERTRAND JR, 1989, BIOCHEM BIOPH RES CO, V164, P311, DOI 10.1016/0006-291X(89)91719-1; BOIZIAU C, 1991, NUCLEIC ACIDS RES, V19, P1113, DOI 10.1093/nar/19.5.1113; BOUWMEESTER T, 1994, ONCOGENE, V9, P1029; BRUN G, 1981, EUR J BIOCHEM, V118, P407; BUSEN W, 1977, EUR J BIOCHEM, V74, P203, DOI 10.1111/j.1432-1033.1977.tb11382.x; BUSEN W, 1975, EUR J BIOCHEM, V52, P179, DOI 10.1111/j.1432-1033.1975.tb03985.x; BUSEN W, 1980, J BIOL CHEM, V255, P9434; BUSEN W, 1982, J BIOL CHEM, V257, P7106; BUSEN W, 1995, IN PRESS RIBONUCLEAS; CATHALA G, 1979, J BIOL CHEM, V254, P7353; CAZENAVE C, 1987, NUCLEIC ACIDS RES, V15, P4717, DOI 10.1093/nar/15.12.4717; CAZENAVE C, 1993, BIOCHIMIE, V75, P113, DOI 10.1016/0300-9084(93)90032-N; CAZENAVE C, 1991, ANTISENSE NUCLEIC AC; CHASE JW, 1972, DEV BIOL, V27, P504, DOI 10.1016/0012-1606(72)90189-3; COHEN HJ, 1972, J BIOL CHEM, V247, P7759; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; COTE J, 1993, SCIENCE, V261, P765, DOI 10.1126/science.7688144; CROUCH R J, 1990, New Biologist, V2, P771; Crouch R. J., 1982, NUCLEASES, P211; CROUCH RJ, 1995, IN PRESS RIBONUCLEAS; DASGUPTA S, 1987, CELL, V51, P1113, DOI 10.1016/0092-8674(87)90597-6; DASH P, 1987, P NATL ACAD SCI USA, V84, P7896, DOI 10.1073/pnas.84.22.7896; DRUMMOND DR, 1985, NUCLEIC ACIDS RES, V13, P7375, DOI 10.1093/nar/13.20.7375; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; EDER PS, 1993, BIOCHIMIE, V75, P123, DOI 10.1016/0300-9084(93)90033-O; EDER PS, 1991, J BIOL CHEM, V266, P6472; FRANK P, 1993, BIOCHEM BIOPH RES CO, V196, P1552, DOI 10.1006/bbrc.1993.2428; FRANK P, 1991, THESIS U TUBINGEN GE; FU TB, 1992, J VIROL, V66, P4271, DOI 10.1128/JVI.66.7.4271-4278.1992; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; GURDON JB, 1974, CONTROL GENE EXPRESS; HAUSEN P, 1970, EUR J BIOCHEM, V14, P278, DOI 10.1111/j.1432-1033.1970.tb00287.x; HENRY CM, 1973, BIOCHEM BIOPH RES CO, V50, P603, DOI 10.1016/0006-291X(73)91287-4; IBORRA F, 1979, J BIOL CHEM, V254, P920; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Langdon RG, 1966, METHODS ENZYMOL, V9, DOI DOI 10.1016/0076-6879(66)09030-X; LASKEY RA, 1979, BR SOC DEV BIOL S, V4, P65; LEWIN B, 1990, GENES, V4; MARINOS E, 1985, CELL DIFFER DEV, V16, P139, DOI 10.1016/0045-6039(85)90527-5; MILLER HI, 1973, J BIOL CHEM, V248, P2621; MOELLING K, 1971, NATURE, V234, P240; OCUINN G, 1973, BIOCHIM BIOPHYS ACTA, V324, P78, DOI 10.1016/0005-2787(73)90253-0; OGAWA T, 1984, P NATL ACAD SCI-BIOL, V81, P1040, DOI 10.1073/pnas.81.4.1040; RONG YW, 1990, BIOCHEMISTRY-US, V29, P383, DOI 10.1021/bi00454a012; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SARNGADHARAN MG, 1975, J BIOL CHEM, V250, P365; SAWAI Y, 1978, BIOCHEM BIOPH RES CO, V84, P313, DOI 10.1016/0006-291X(78)90172-9; SAWAI Y, 1977, LIFE SCI, V21, P1351, DOI 10.1016/0024-3205(77)90018-2; SAWAI Y, 1978, BIOCHIM BIOPHYS ACTA, V518, P181, DOI 10.1016/0005-2787(78)90128-4; SEIDEL CW, 1994, NUCLEIC ACIDS RES, V22, P1456, DOI 10.1093/nar/22.8.1456; SOLARI A, 1982, NUCLEIC ACIDS RES, V14, P4397; SORIANO L, 1974, NUCLEIC ACIDS RES, V1, P1085, DOI 10.1093/nar/1.9.1085; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; STEIN H, 1969, SCIENCE, V166, P393, DOI 10.1126/science.166.3903.393; Stick R, 1989, MOL BIOL FERTILIZATI, P153; STRAVIANOPOULOS J, 1978, P NATL ACAD SCI USA, V75, P4140; VONWIRTH H, 1989, EUR J BIOCHEM, V184, P321, DOI 10.1111/j.1432-1033.1989.tb15022.x; VONWIRTH H, 1991, EXPERIENTIA, V47, P92, DOI 10.1007/BF02041264; WANG H, 1993, J BIOL CHEM, V268, P18951; WYERS F, 1973, EUR J BIOCHEM, V35, P270, DOI 10.1111/j.1432-1033.1973.tb02835.x; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	64	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25185	25192						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929207				2022-12-27	WOS:A1994PQ49000098
J	GULLBERG, U; LINDMARK, A; NILSSON, E; PERSSON, AM; OLSSON, I				GULLBERG, U; LINDMARK, A; NILSSON, E; PERSSON, AM; OLSSON, I			PROCESSING OF HUMAN CATHEPSIN-G AFTER TRANSFECTION TO THE RAT BASOPHILIC MAST-CELL TUMOR LINE RBL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL PEPTIDASE-I; LYSOSOMAL-ENZYMES; POLYMORPHONUCLEAR LEUKOCYTES; NEUTROPHIL ELASTASE; MYELOID CELLS; GRANULES; BIOSYNTHESIS; SPECIFICITY; PROTEINASES; ACTIVATION	The azurophil granules of neutrophil granulocytes contain neutral proteases such as leukocyte elastase and cathepsin G. These are synthesized as inactive precursors, but following proteolytic processing, they are stored in granules as active enzymes. We describe the establishment of a transgenic cellular model for expression of the human myeloid serine protease cathepsin G. The cDNA for preprocathepsin G was stably expressed in the rat basophilic/mast cell line RBL-1 and the translation product was characterized by use of biosynthetic labeling followed by immunoprecipitation, SDS-polyacrylamide gel electrophoresis, and fluorography. Conversion into complex form of an asparagine-linked carbohydrate unit of approximately 3.5 kDa was shown, as judged by the products obtained upon treatment with endoglycosidase H and N-glycanase. Proteolytic processing of 32.5 kDa procathepsin G into a 31-kDa form, within 1-2 h after synthesis, was demonstrated by pulse-chase experiments. Further processing into a 30-kDa form also occurred to a minor extent. The processed forms were enzymatically active, as judged by affinity for the serine protease inhibitors diisopropylfluorophosphate phosphate and aprotinin. Translocation of processed forms of cathepsin G to high density fractions, indicating targeting of the protease to granules, was demonstrated by subcellular fractionation. The weak base NH4Cl was shown to delay the processing and enzymatic activation of cathepsin G, whereas the monovalent ionophore monensin completely inhibited both events. Our data demonstrate that human cathepsin G transfected to rat RBL-1 cells, is proteolytically processed into enzymatically active forms and that subcellular transfer to granular organelles occurs. As the processing of transgenic human cathepsin G corresponds to that of endogenous protease of myeloid cells, the model should provide new unique possibilities to further characterize the activation and granular targeting of myeloid serine proteases.	LUND UNIV,DEPT MED,DIV HEMATOL,S-22185 LUND,SWEDEN	Lund University								BAINTON DF, 1971, J EXP MED, V134, P907, DOI 10.1084/jem.134.4.907; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P187; BROWN GR, 1993, J IMMUNOL, V150, P4733; Elsbach P, 1992, INFLAMMATION BASIC P, P603; GABAY JE, 1993, CURR OPIN IMMUNOL, V5, P97, DOI 10.1016/0952-7915(93)90087-9; GANZ T, 1993, BLOOD, V82, P641; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; HUDIG D, 1993, CURR OPIN IMMUNOL, V5, P90, DOI 10.1016/0952-7915(93)90086-8; HULTBERG B, 1976, BIOCHEM J, V155, P599, DOI 10.1042/bj1550599; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LINDMARK A, 1994, J LEUKOCYTE BIOL, V55, P50, DOI 10.1002/jlb.55.1.50; LINDMARK A, 1990, BLOOD, V76, P2374; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; NAUSEEF WM, 1988, EUR J HAEMATOL, V40, P97; OLSSON I, 1974, BLOOD, V44, P235, DOI 10.1182/blood.V44.2.235.235; SALVESEN G, 1987, BIOCHEMISTRY-US, V26, P2289, DOI 10.1021/bi00382a032; SALVESEN G, 1990, BIOCHEMISTRY-US, V29, P5304, DOI 10.1021/bi00474a013; SALVESEN G, 1991, BIOMED BIOCHIM ACTA, V50, P665; SINAH S, 1987, P NATL ACAD SCI USA, V84, P2228; URATA H, 1993, J BIOL CHEM, V268, P24318; VALORE EV, 1992, BLOOD, V79, P1538; von Figura K, 1991, Curr Opin Cell Biol, V3, P642, DOI 10.1016/0955-0674(91)90035-W; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WATOREK W, 1993, BIOL CHEM H-S, V374, P885	27	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25219	25225						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929211				2022-12-27	WOS:A1994PQ49000103
J	PARK, MH; WOLFF, EC; LEE, YB; FOLK, JE				PARK, MH; WOLFF, EC; LEE, YB; FOLK, JE			ANTIPROLIFERATIVE EFFECTS OF INHIBITORS OF DEOXYHYPUSINE SYNTHASE - INHIBITION OF GROWTH OF CHINESE-HAMSTER OVARY CELLS BY GUANYL DIAMINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR EIF-4D; MURINE LEUKEMIA-CELLS; POSTTRANSLATIONAL FORMATION; SACCHAROMYCES-CEREVISIAE; HYPUSINE MODIFICATION; AMINO-ACID; PROTEIN; POLYAMINES; SPERMIDINE; IDENTIFICATION	Certain guanyl diamines are effective inhibitors of deoxyhypusine synthase (Jakus, J., Wolff, E. C., Park, M. H., and Folk, J. E. (1993) J. Biol. Chem. 268, 18151-13159), the first enzyme involved in the biosynthesis of the unusual amino acid hypusine (N-epsilon-(4-amino-2-hydroxybutyl)lysine). Evidence that hypusine is implicated in cell growth prompted this study of the cellular effects of these inhibitors. In Chinese hamster ovary (CHO) cells, inhibition of hypusine biosynthesis followed by progressive arrest in cellular proliferation was observed with both N-mono- and N,N'-bisguanyl derivatives of 1,6-diaminohexane, 1,7-diaminoheptane and 1,8-diaminooctane. Cells treated with these compounds showed no significant change in polyamine distribution, suggesting that the observed growth inhibition is not mediated through an interference with polyamine metabolism. N-1-guanyl-1,7-diaminoheptane, the most potent inhibitor of deoxyhypusine synthase both in vitro and in cells, exhibited the highest antiproliferative activity toward CHO cells. No early cytotoxic effects were observed with this inhibitor, and its antiproliferative activity appeared to be reversible. Transport studies showed that N-1-guanyl-1,7-diaminoheptane is actively taken up by the polyamine transport system. Mutant CHO cells defective in polyamine transport were found to be resistant to growth inhibition by this compound. The findings suggest that the antiproliferative effect of N-1-guanyl-1,7-diaminoheptane is exerted intracellularly through inhibition of hypusine synthesis.			PARK, MH (corresponding author), NIDR,CELLULAR DEV & ONCOL LAB,ENZYME CHEM SECT,BLDG 30,RM 211,30 CONVENT DR,MSC 4330,BETHESDA,MD 20892, USA.							ABBRUZZESE A, 1986, J BIOL CHEM, V261, P3085; BYERS TL, 1987, AM J PHYSIOL, V252, pC663, DOI 10.1152/ajpcell.1987.252.6.C663; BYERS TL, 1993, BIOCHEM J, V290, P115, DOI 10.1042/bj2900115; BYERS TL, 1992, BIOCHEM J, V287, P717, DOI 10.1042/bj2870717; CHEN KY, 1983, BIOCHIM BIOPHYS ACTA, V756, P395, DOI 10.1016/0304-4165(83)90350-1; CLARKE DD, 1959, ARCH BIOCHEM BIOPHYS, V79, P338, DOI 10.1016/0003-9861(59)90413-8; COOPER HL, 1983, P NATL ACAD SCI-BIOL, V80, P1854, DOI 10.1073/pnas.80.7.1854; COOPER HL, 1982, CELL, V29, P791, DOI 10.1016/0092-8674(82)90441-X; DUNCAN RF, 1986, J BIOL CHEM, V261, P2903; FOLK JE, 1980, J BIOL CHEM, V255, P3695; GERNER EW, 1986, BIOCHEM J, V239, P379, DOI 10.1042/bj2390379; GRETTIE DP, 1978, ADV POLYAMINE RES, V2, P13; JAKUS J, 1993, J BIOL CHEM, V268, P13151; JANNE J, 1991, ANN MED, V23, P241, DOI 10.3109/07853899109148056; KANG HA, 1994, J BIOL CHEM, V269, P3934; MANDEL JL, 1978, J CELL PHYSIOL, V97, P335, DOI 10.1002/jcp.1040970308; MCKAY AF, 1959, J AM CHEM SOC, V81, P4328, DOI 10.1021/ja01525a057; MURPHEY RJ, 1987, J BIOL CHEM, V262, P15033; PARK MH, 1983, METHOD ENZYMOL, V94, P458; PARK MH, 1982, J BIOL CHEM, V257, P7217; PARK MH, 1993, TRENDS BIOCHEM SCI, V18, P475, DOI 10.1016/0968-0004(93)90010-K; PARK MH, 1989, J BIOL CHEM, V264, P18531; PARK MH, 1993, BIOFACTORS, V4, P95; PARK MH, 1988, J BIOL CHEM, V263, P15264; PARK MH, 1981, P NATL ACAD SCI-BIOL, V78, P2869, DOI 10.1073/pnas.78.5.2869; PARK MH, 1987, J BIOL CHEM, V262, P12730; PORTER CW, 1993, CANCER RES, V53, P581; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; Seiler N., 1987, INHIBITION POLYAMINE, P49; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P18527; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TORRELIO BM, 1987, BIOCHEM BIOPH RES CO, V145, P1335, DOI 10.1016/0006-291X(87)91584-1; TORRELIO BM, 1984, EXP CELL RES, V154, P454, DOI 10.1016/0014-4827(84)90169-1; WOHL T, 1993, MOL GEN GENET, V241, P305; WOLFF EC, 1990, J BIOL CHEM, V265, P4793	35	137	143	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27827	27832						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961711				2022-12-27	WOS:A1994PV77200012
J	DEY, NB; BOUNELIS, P; FRITZ, TA; BEDWELL, DM; MARCHASE, RB				DEY, NB; BOUNELIS, P; FRITZ, TA; BEDWELL, DM; MARCHASE, RB			THE GLYCOSYLATION OF PHOSPHOGLUCOMUTASE IS MODULATED BY CARBON SOURCE AND HEAT-SHOCK IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; SARCOPLASMIC-RETICULUM; RESERVE CARBOHYDRATE; TREHALOSE; YEAST; PHOSPHOPROTEIN; ACCEPTOR; GLUCOSYLPHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE; TRANSPORT	Phosphoglucomutase is the acceptor for UDP-glucose:glycoprotein glucose-1-phosphotransferase and contains Glc in a phosphodiester linkage to O-linked Man. In this study, we have characterized the glycosylation of phosphoglucomutase by Saccharomyces cerevisiae in response to heat shock and growth in media containing carbon sources other than Glc. Phosphoglucomutase synthesized under these conditions is underglucosylated relative to that synthesized during logarithmic growth in Glc. The underglucosylation results in increased UDP-glucose:glycoprotein glucose-1-phosphotransferase acceptor activity in in vitro assays and a newly appearing less negatively charged form of phosphoglucomutase resolvable by anion exchange chromatography. Utilizing a yeast strain in which phosphoglucomutase is overexpressed via a multicopy plasmid, metabolic labeling of the enzyme with [S-35]Met and [H-3]Man increased in response to heat shock, whereas [H-3]Glc labeling decreased. The glucosylation state of phosphoglucomutase was also compared in cells grown in media containing various carbon sources and was found to be lowest in cells utilizing Gal as the sole carbon source compared with Glc or;lactate. In mammalian cells, the glucosylation of phosphoglucomutase has been shown to be sensitive to changes in cytoplasmic Ca2+ and to correlate with a change in its membrane association. The change in phosphoglucomutase's oligosaccharide in Saccharomyces cerevisiae may be important to alterations in its distribution under conditions of nutrient deprivation or metabolic stress.	UNIV ALABAMA,DEPT BIOCHEM & MOLEC GENET,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	DEY, NB (corresponding author), UNIV ALABAMA,DEPT CELL BIOL,BASIC HLTH SCI BLDG,RM 690,BIRMINGHAM,AL 35294, USA.			Bedwell, David/0000-0002-6605-818X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK042017, P01DK038518] Funding Source: NIH RePORTER; NEI NIH HHS [EY 06714] Funding Source: Medline; NIDDK NIH HHS [DK 38518, DK 42017] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATTFIELD PV, 1987, FEBS LETT, V225, P259, DOI 10.1016/0014-5793(87)81170-5; BENEDETTI A, 1985, BIOCHIM BIOPHYS ACTA, V816, P267, DOI 10.1016/0005-2736(85)90494-8; BOLES E, 1994, EUR J BIOCHEM, V220, P83, DOI 10.1111/j.1432-1033.1994.tb18601.x; CAPUTTO R, 1950, J BIOL CHEM, V184, P333; DOUGLAS HC, 1961, BIOCHIM BIOPHYS ACTA, V52, P209, DOI 10.1016/0006-3002(61)90924-6; EILAM Y, 1985, J GEN MICROBIOL, V131, P623; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HOTTIGER T, 1987, J BACTERIOL, V169, P5518, DOI 10.1128/jb.169.12.5518-5522.1987; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KIM DH, 1986, J BIOL CHEM, V261, P1674; LEE YS, 1992, J BIOL CHEM, V267, P21080; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; MARCHASE RB, 1987, BIOCHIM BIOPHYS ACTA, V916, P157, DOI 10.1016/0167-4838(87)90103-8; MARCHASE RB, 1990, ARCH BIOCHEM BIOPHYS, V280, P122, DOI 10.1016/0003-9861(90)90526-5; MARCHASE RB, 1993, J BIOL CHEM, V268, P8341; MELDOLESI J, 1990, BIOCHIM BIOPHYS ACTA, V1055, P130, DOI 10.1016/0167-4889(90)90113-R; OH D, 1990, MOL CELL BIOL, V10, P1415, DOI 10.1128/MCB.10.4.1415; QUICK CB, 1974, EUR J BIOCHEM, V42, P511, DOI 10.1111/j.1432-1033.1974.tb03366.x; RAY WJ, 1972, CARBOXYLATION DECARB, P407; Rose MD., 1990, METHODS YEAST GENETI; SATIR BH, 1990, J CELL BIOL, V111, P901, DOI 10.1083/jcb.111.3.901; SRISOMSAP C, 1989, J BIOL CHEM, V264, P20540; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEYNA NA, 1994, J NEUROCHEM, V62, P456; WIEMKEN A, 1990, ANTON LEEUW INT J G, V58, P209, DOI 10.1007/BF00548935; WINKLER K, 1991, FEBS LETT, V291, P269, DOI 10.1016/0014-5793(91)81299-N; WOLF BA, 1986, J BIOL CHEM, V261, P6284	28	26	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27143	27148						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929458				2022-12-27	WOS:A1994PQ93100082
J	SHAO, HN; LOU, LD; PANDEY, A; PASQUALE, EB; DIXIT, VM				SHAO, HN; LOU, LD; PANDEY, A; PASQUALE, EB; DIXIT, VM			CDNA CLONING AND CHARACTERIZATION OF A LIGAND FOR THE CEK5 RECEPTOR PROTEIN-TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GENE	We have isolated a murine cDNA encoding a ligand for the Cek5 receptor protein-tyrosine kinase (RPTK), a member of the Eph/Eck RPTK subfamily. Sequence analysis predicts an open reading frame of 345 amino acids with a predicted molecular mass of 38 kDa. Metabolic labeling and immunoprecipitation of cells transfected with a cDNA encoding the Cek5 ligand revealed the mature protein to have an apparent molecular mass of 45 kDa. The extracellular domain of the Cek5 ligand shows a 27% sequence identity at the protein level to B61, a ligand for the related Eck RPTK (Bartley, T. D., et al. (1994) Nature 368, 558-560). Consistent with the presence of a transmembrane domain, now cytometry analysis revealed the Cek5 ligand to be expressed on the cell surface. The expressed Cek5 ligand is functionally active as it induces autophosphorylation of the Cek5 RPTK	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; LA JOLLA CANC RES FDN,LA JOLLA,CA 92037	University of Michigan System; University of Michigan; Sanford Burnham Prebys Medical Discovery Institute			dixit, vishva m/A-4496-2012; Pandey, Akhilesh/B-4127-2009	dixit, vishva m/0000-0001-6983-0326; Pandey, Akhilesh/0000-0001-9943-6127	NATIONAL CANCER INSTITUTE [R01CA056721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039255] Funding Source: NIH RePORTER; NCI NIH HHS [CA56721] Funding Source: Medline; NIDDK NIH HHS [DK39255] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6314; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1994, DEV BIOL, V163, P491, DOI 10.1006/dbio.1994.1165; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SMITH PL, 1994, J BIOL CHEM, V269, P15162; VANDERGEER P, 1994, IN PRESS ANN REV CEL, V10; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	18	77	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26606	26609						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929389				2022-12-27	WOS:A1994PQ93100005
J	BUBB, MR; KNUTSON, JR; PORTER, DK; KORN, ED				BUBB, MR; KNUTSON, JR; PORTER, DK; KORN, ED			ACTOBINDIN INDUCES THE ACCUMULATION OF ACTIN DIMERS THAT NEITHER NUCLEATE POLYMERIZATION NOR SELF-ASSOCIATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACANTHAMOEBA-CASTELLANII; MONOMERIC ACTIN; FLUORESCENCE; BINDING; DIFFUSION; SPECTROSCOPY; INHIBITION	Actobindin purified from Acanthamoeba castellanii inhibits the nucleation, but not the elongation, phase of actin polymerization. Previously, we had speculated that actobindin, which can simultaneously bind two actin monomers (Bubb, M. R., Lewis, M. S., and Kern, E. D. (1991) J. Biol. Chem. 266, 3820-3826), might preferentially interact with small oligomers and inhibit their ability to elongate (Lambooy, P. K., and Kern, E. D. (1988) J. Biol. Chem. 263, 12836-12843). In the accompanying paper (Bubb, M. R., Lewis, M. S., and Kern, E. D. (1994) J. Biol. Chen. 269, 25587-25591), we show that under non-polymerizing conditions, actobindin binds to covalently cross-linked actin dimers with higher affinity than to two actin monomers, The sedimentation velocity and fluorescence anisotropy experiments described in this paper show that actobindin prevents the formation of actin oligomers larger than an actin dimer under conditions in which, in the absence of actobindin, actin rapidly polymerizes to F-actin with no detectable small oligomers. Moreover, the molar concentration of actin dimer formed in the presence of actobindin can exceed the total actobindin concentration. These results indicate that actobindin does not form a stable complex with native actin dimer but, rather, causes the accumulation of dimers that are unable to nucleate polymerization or self-associate.	NHLBI,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Korn, Edward D/F-9929-2012	Korn, Edward/0000-0003-3867-6295				ATTRI AK, 1991, J BIOL CHEM, V266, P6815; BUBB MR, 1991, J BIOL CHEM, V266, P3820; BUBB MR, 1994, J BIOL CHEM, V269, P25587; CLAGUE MJ, 1991, BIOCHEMISTRY-US, V30, P5491, DOI 10.1021/bi00236a023; CREETH J. M., 1967, PROGR BIOPHYS MOL BIOL, V17, P217, DOI 10.1016/0079-6107(67)90008-9; DELATORRE JG, 1988, DYNAMIC PROPERTIES B, P3; FECHHEIMER M, 1993, J CELL BIOL, V123, P1, DOI 10.1083/jcb.123.1.1; GOLDBERG RJ, 1953, J PHYS CHEM-US, V57, P194, DOI 10.1021/j150503a014; HARVEY SC, 1977, ARCH BIOCHEM BIOPHYS, V179, P391, DOI 10.1016/0003-9861(77)90126-6; HOLLIDAY LS, 1993, BIOCHEM BIOPH RES CO, V196, P569, DOI 10.1006/bbrc.1993.2287; KABSCH W, 1992, ANNU REV BIOPH BIOM, V21, P49, DOI 10.1146/annurev.biophys.21.1.49; KAWASAKI Y, 1976, BIOCHIM BIOPHYS ACTA, V446, P166, DOI 10.1016/0005-2795(76)90108-2; KIRKWOOD JG, 1954, J POLYM SCI, V12, P1, DOI 10.1002/pol.1954.120120102; KNUTSON JR, 1982, BIOCHEMISTRY-US, V21, P4671, DOI 10.1021/bi00262a024; KNUTSON JR, 1983, CHEM PHYS LETT, V102, P501, DOI 10.1016/0009-2614(83)87454-5; LAMBOOY PK, 1988, J BIOL CHEM, V263, P12836; LAMBOOY PK, 1986, J BIOL CHEM, V261, P7150; LEWIS MS, 1963, BIOCHEMISTRY-US, V2, P34, DOI 10.1021/bi00901a008; MIHASHI K, 1975, FEBS LETT, V52, P8, DOI 10.1016/0014-5793(75)80625-9; MIHASHI K, 1964, ARCH BIOCHEM BIOPHYS, V107, P441, DOI 10.1016/0003-9861(64)90300-5; MONTAGUE C, 1983, J MUSCLE RES CELL M, V4, P95, DOI 10.1007/BF00711960; MURAMATSU N, 1988, ANAL BIOCHEM, V168, P345, DOI 10.1016/0003-2697(88)90328-4; RIGLER R, 1973, Q REV BIOPHYS, V6, P139, DOI 10.1017/S003358350000113X; SCHACHMAN HK, 1959, ULTRACENTRIFUGATION, P75; TAWADA K, 1978, EUR J BIOCHEM, V88, P411, DOI 10.1111/j.1432-1033.1978.tb12463.x; TOBACMAN LS, 1982, J BIOL CHEM, V257, P4166; VANCOMPERNOLLE K, 1991, J BIOL CHEM, V266, P15427; WEGENER WA, 1979, J CHEM PHYS, V70, P622, DOI 10.1063/1.437541	28	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25592	25597						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929262				2022-12-27	WOS:A1994PQ49100057
J	GAO, JL; MURPHY, PM				GAO, JL; MURPHY, PM			HUMAN CYTOMEGALOVIRUS OPEN READING FRAME US28 ENCODES A FUNCTIONAL BETA-CHEMOKINE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN INTERLEUKIN-8 RECEPTOR; HERPESVIRUS SAIMIRI; VIRUS; EXPRESSION; INFECTION; HOMOLOGS; CLONING	Human cytomegalovirus infects epithelial, smooth muscle, and white blood cells in vivo causing acute, latent, and chronic infections. A data base search that the amino acid sequence of the putative protein encoded by open reading frame US28 of human cytomegalovirus is similar to 30% identical to those of the mammalian leukocyte receptors for alpha and beta chemokines. This suggested that US28 was originally copied from a human chemokine receptor gene, perhaps to provide the virus with a selective advantage through molecular mimicry. Chemokines regulate the trafficking and activation of mammalian leukocytes and activate calcium-mobilizing, heptahelical, G protein-coupled receptors. We now show that US28 encodes a promiscuous calcium-mobilizing receptor for the beta chemokines RANTES (regulated upon activation, normal T expressed and secreted), macrophage inflammatory protein-1 alpha, and monocyte chemoattractant protein-1, but not for the alpha chemokines interleukin-8 or gamma IP10. The chemokine selectivity of the US28 product is distinct from that of known mammalian beta chemokine receptors. This finding suggests a role for beta chemokines in the pathogenesis of human cytomegalovirus infection by transmembrane signaling via the product of US28.	NIAID,HOST DEF LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Gao, Ji-Liang/Y-4397-2019					AHUJA SK, 1994, IMMUNOL TODAY, V15, P281, DOI 10.1016/0167-5699(94)90008-6; AHUJA SK, 1993, J BIOL CHEM, V268, P20691; ALBRECHT T, 1990, INTERVIROLOGY, V31, P68, DOI 10.1159/000150140; ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; ALFORD CA, 1990, VIROLOGY, P1981; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; DUNLOP DJ, 1992, BLOOD, V79, P2221; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GOODING LR, 1992, CELL, V71, P5; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1993, CELL, V72, P823, DOI 10.1016/0092-8674(93)90571-7; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NICHOLAS J, 1992, NATURE, V355, P362, DOI 10.1038/355362a0; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SCHRIER RD, 1985, SCIENCE, V230, P1048, DOI 10.1126/science.2997930; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; UPTON C, 1992, SCIENCE, V258, P1369, DOI 10.1126/science.1455233; VALYINAGY T, 1988, ARCH VIROL, V101, P199, DOI 10.1007/BF01311001; WELCH AR, 1991, J VIROL, V65, P3915, DOI 10.1128/JVI.65.7.3915-3918.1991	26	286	297	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28539	28542						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961796				2022-12-27	WOS:A1994PU16800005
J	HARDY, TA; HUANG, DQ; ROACH, PJ				HARDY, TA; HUANG, DQ; ROACH, PJ			INTERACTIONS BETWEEN CAMP-DEPENDENT AND SNF1 PROTEIN-KINASES IN THE CONTROL OF GLYCOGEN ACCUMULATION IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; REGULATORY SUBUNIT; ADENYLATE-CYCLASE; CATABOLITE REPRESSION; INVERTASE EXPRESSION; NUTRIENT LIMITATION; GLUCOSE REPRESSION; POLYUBIQUITIN GENE; BRANCHING ENZYME; ESCHERICHIA-COLI	The synthesis of glycogen in Saccharomyces cerevisiae is stimulated by nutrient limitation and requires both glycogen synthase and the glycogen branching enzyme. Of the two glycogen synthase genes present in yeast, GSY2 appears to be more important for the accumulation of glycogen upon entry into stationary phase. In cells grown on glucose, GSY2 mRNA levels increased approximately 10-fold during the transition from logarithmic to stationary phase. Growth of cells in glycerol, however, resulted in constitutive expression of GSY2 mRNA and the corresponding protein, GS-2, suggestive of glucose repression of GSY2. Mutants defective in the SNF1 gene, which encodes a protein kinase important in glucose repression mechanisms, are known not to accumulate glycogen. A modest 2-4-fold decrease in total GS-2 level was observed, and upon entry into stationary phase, the enzyme was blocked in the inactive, phosphorylated state in snf1 strains. The GS-2 protein is thought to be regulated by covalent phosphorylation of three COOH-terminal sites (Hardy, T.A., and Roach, P. J. (1993) J. Biol. Chem. 268, 23799-23805), removal of which results in constitutively active glycogen synthase that bypasses phosphorylation controls. Expression of COOH-terminally truncated GS-2 in snf1 cells restored glycogen accumulation, and so we propose that the SNF1 kinase controls the phosphorylation state of GS-2. Cyclic AMP pathways also exert control over glycogen accumulation. In bcy1 cells, which have constitutively active cyclic AMP-dependent protein kinase, greatly reduced levels of both GS-2 message and protein were observed. With wild type GSY2 placed under control of the ADH1 promoter, bcy1 cells did not accumulate glycogen despite increased GS-2. Overexpression of truncated GS-2, however, resulted in definite though reduced glycogen accumulation; the glycogen synthesized was structurally distinct from wild type with properties characteristic of less branched polysaccharide. We conclude that the cAMP pathway controls both the expression and the phosphorylation state of GS-2. Furthermore, other factor(s) necessary for glycogen biosynthesis, such as the branching enzyme GLC3, must also be under negative control by the cAMP pathway. The results demonstrate interactive controls of GS-2 by the cAMP-dependent and SNF1 protein kinases.	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis					NIDDK NIH HHS [DK 42576] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042576] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BISSINGER PH, 1989, MOL CELL BIOL, V9, P1309, DOI 10.1128/MCB.9.3.1309; BOORSTEIN WR, 1990, EMBO J, V9, P2543, DOI 10.1002/j.1460-2075.1990.tb07435.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANNON JF, 1994, GENETICS, V136, P485; CANNON JF, 1987, MOL CELL BIOL, V7, P2653, DOI 10.1128/MCB.7.8.2653; CANNON JF, 1990, J BIOL CHEM, V265, P11897; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHESTER VE, 1968, J GEN MICROBIOL, V51, P47, DOI 10.1099/00221287-51-1-49; CIRIACY M, 1977, MOL GEN GENET, V154, P213, DOI 10.1007/BF00330840; DENIS CL, 1983, J BIOL CHEM, V258, P1165; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; ELDER RT, 1983, P NATL ACAD SCI-BIOL, V80, P2432, DOI 10.1073/pnas.80.9.2432; ERASO P, 1984, EUR J BIOCHEM, V141, P195, DOI 10.1111/j.1432-1033.1984.tb08174.x; ESTRUCH F, 1990, NUCLEIC ACIDS RES, V18, P6959, DOI 10.1093/nar/18.23.6959; FARKAS I, 1991, J BIOL CHEM, V266, P15602; FARKAS I, 1990, J BIOL CHEM, V265, P20879; FENG ZH, 1991, J BIOL CHEM, V266, P23796; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FRANCOIS J, 1988, EUR J BIOCHEM, V174, P551, DOI 10.1111/j.1432-1033.1988.tb14134.x; FRANCOIS J, 1987, EUR J BIOCHEM, V164, P369, DOI 10.1111/j.1432-1033.1987.tb11067.x; FRANCOIS JM, 1992, EMBO J, V11, P87, DOI 10.1002/j.1460-2075.1992.tb05031.x; GANCEDO JM, 1992, EUR J BIOCHEM, V206, P297, DOI 10.1111/j.1432-1033.1992.tb16928.x; HADFIELD C, 1986, GENE, V45, P149, DOI 10.1016/0378-1119(86)90249-0; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARDY TA, 1993, J BIOL CHEM, V268, P23799; HUBBARD EJA, 1992, GENETICS, V130, P71; HWANG PK, 1989, MOL CELL BIOL, V9, P1659, DOI 10.1128/MCB.9.4.1659; Johnston M., 1992, MOL CELLULAR BIOL YE, P193; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; PITCHER J, 1988, EUR J BIOCHEM, V176, P391, DOI 10.1111/j.1432-1033.1988.tb14294.x; POLAKIS ES, 1965, BIOCHEM J, V97, P284, DOI 10.1042/bj0970284; POSAS F, 1991, FEBS LETT, V279, P341, DOI 10.1016/0014-5793(91)80183-4; REIMANN EM, 1993, ADV PROTEIN PHOSPHAT, V7, P173; ROTHMANDENES LB, 1970, P NATL ACAD SCI USA, V66, P967, DOI 10.1073/pnas.66.3.967; ROWEN DW, 1992, MOL CELL BIOL, V12, P22, DOI 10.1128/MCB.12.1.22; RUSSELL M, 1993, MOL BIOL CELL, V4, P757, DOI 10.1091/mbc.4.7.757; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULLER HJ, 1991, J BACTERIOL, V173, P2045, DOI 10.1128/jb.173.6.2045-2052.1991; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; TANAKA K, 1988, EMBO J, V7, P495, DOI 10.1002/j.1460-2075.1988.tb02837.x; TATCHELL K, 1985, P NATL ACAD SCI USA, V82, P3785, DOI 10.1073/pnas.82.11.3785; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; THOMPSONJAEGER S, 1991, GENETICS, V129, P697; THON VJ, 1992, J BIOL CHEM, V267, P15224; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TRUMBLY RJ, 1992, MOL MICROBIOL, V6, P15, DOI 10.1111/j.1365-2958.1992.tb00832.x; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; ZIMMERMANN FK, 1977, MOL GEN GENET, V151, P95, DOI 10.1007/BF00446918	53	109	109	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27907	27913						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961723				2022-12-27	WOS:A1994PV77200024
J	MONDESERT, O; MORENO, S; RUSSELL, P				MONDESERT, O; MORENO, S; RUSSELL, P			LOW-MOLECULAR-WEIGHT PROTEIN-TYROSINE PHOSPHATASES ARE HIGHLY CONSERVED BETWEEN FISSION YEAST AND MAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P80CDC25 MITOTIC INDUCER; CATALYTIC MECHANISM; NEGATIVE REGULATION; ACTIVATES P34CDC2; CELL-DIVISION; KINASE; WEE1; MITOSIS; PHOSPHORYLATION; INACTIVATION	Cdc25 protein phosphatase dephosphorylates tyrosine 15 of Cdc2, thereby activating Cdc2/cyclin B kinase, which then brings about mitosis. A fission yeast (Schizosaccharomyces pombe) cDNA expression library was screened for clones that rescue cdc25-22. In addition to the cdc25(+) and pyp3(+) protein-tyrosine phosphatase genes, a third gene was discovered. This gene, named stp1(+) (Small tyrosine phosphatase), encodes a similar to 17.5-kDa protein that is similar to 42% identical to members of an unusual class of small (similar to 18 kDa) cytosolic phosphatases previously known to exist only in mammalian species. The biological functions of these proteins are unknown, but they have vigorous protein-tyrosine phosphatase activity in vitro and have a sequence motif, Cys-X(5)-Arg, that is present at the active sites of all known types of protein-tyrosine phosphatases. Sequence homology between S. pombe Stp1 and its mammalian homologs is particularly high in the active site region of the proteins. Rescue of cdc25-22 by overproduction of Stp1 protein is probably due to an ability of Stp1 to dephosphorylate tyrosine 15 of Cdc2. Disruption of stp1(+) causes no obvious phenotype. The fact that Stp1 homologs are highly conserved between yeast and man suggests that they have important functions.	SCRIPPS RES INST, DEPT MOLEC, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; UNIV OXFORD, DEPT BIOCHEM, IMPERIAL CANC RES FUND, CELL CYCLE GRP, OXFORD OX1 1QU, ENGLAND	Scripps Research Institute; Scripps Research Institute; University of Oxford			Moreno, Sergio/K-3671-2014	Moreno, Sergio/0000-0002-8039-1413				CIRRI P, 1993, EUR J BIOCHEM, V214, P647, DOI 10.1111/j.1432-1033.1993.tb17965.x; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; DISSING J, 1991, J BIOL CHEM, V266, P20619; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FEILOTTER H, 1991, GENETICS, V127, P309; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MILLAR JBA, 1992, EMBO J, V11, P4933, DOI 10.1002/j.1460-2075.1992.tb05600.x; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PARKER LL, 1993, NATURE, V363, P736, DOI 10.1038/363736a0; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; RUGGIERO M, 1993, FEBS LETT, V326, P294, DOI 10.1016/0014-5793(93)81811-D; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SHIOZAKI K, 1994, MOL CELL BIOL, V14, P3742, DOI 10.1128/MCB.14.6.3742; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WO YYP, 1992, BIOCHEMISTRY-US, V31, P1712, DOI 10.1021/bi00121a019; WU L, 1993, NATURE, V363, P738, DOI 10.1038/363738a0	29	47	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27996	27999						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961734				2022-12-27	WOS:A1994PV77200037
J	PHILIPSON, LH; ROSENBERG, MP; KUZNETSOV, A; LANCASTER, ME; WORLEY, JF; ROE, MW; DUKES, ID				PHILIPSON, LH; ROSENBERG, MP; KUZNETSOV, A; LANCASTER, ME; WORLEY, JF; ROE, MW; DUKES, ID			DELAYED RECTIFIER K+ CHANNEL OVEREXPRESSION IN TRANSGENIC ISLETS AND BETA-CELLS ASSOCIATED WITH IMPAIRED GLUCOSE RESPONSIVENESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INSULIN-SECRETING CELLS; SINGLE PANCREATIC-ISLETS; POTASSIUM CHANNEL; ELECTRICAL-ACTIVITY; CYTOPLASMIC CA2+; B-CELLS; OSCILLATIONS; EXPRESSION; LINES; MICE	Glucose stimulation of pancreatic beta-cell insulin secretion is closely coupled to alterations in ion channel conductances and intracellular Ca2+ ([Ca2+](i)). To further examine this relationship after augmentation of voltage-dependent K+ channel expression, transgenic mice were produced which specifically overexpress a human insulinoma-derived, tetraethylammonium (TEA)-insensitive delayed rectifier K+ channel in their pancreatic beta-cells as shown by immunoblot of isolated islets and immunohistochemical analysis of pancreas sections. Whole-cell current recordings confirmed the presence of high amplitude TEA-resistant K+ currents in transgenic islet cells, whose expression correlated with hyperglycemia and hypoinsulinemia. Stable overexpression of the channel in insulinoma cells attenuated glucose-activated increases in [Ca2+](i) and prevented the induction of TEA-dependent [Ca2+](i) oscillations. These results, employing the first ion channel transgenic mouse, demonstrate the importance of membrane potential regulation in excitation-secretion coupling in the pancreatic beta-cells.	GLAXO INC,RES INST,DEPT PHARMACOL,RES TRIANGLE PK,NC 27709; GLAXO INC,RES INST,DEPT CELL PHYSIOL,RES TRIANGLE PK,NC 27709	GlaxoSmithKline; GlaxoSmithKline	PHILIPSON, LH (corresponding author), UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044840] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44840] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMMALA C, 1991, NATURE, V353, P849, DOI 10.1038/353849a0; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; ATTALI B, 1993, J BIOL CHEM, V268, P24283; ATWATER I, 1983, CELL CALCIUM, V4, P451, DOI 10.1016/0143-4160(83)90021-0; BOYD AE, 1992, J CELL BIOCHEM, V48, P234, DOI 10.1002/jcb.240480303; COOK DL, 1984, NATURE, V312, P446; DAMBRA R, 1990, ENDOCRINOLOGY, V126, P2815, DOI 10.1210/endo-126-6-2815; DUKES ID, 1994, J BIOL CHEM, V269, P10979; DUKES ID, 1993, AM J PHYSIOL, V264, pE348, DOI 10.1152/ajpendo.1993.264.3.E348; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; ERICKSON RP, 1985, BIOSCIENCE REP, V5, P1087, DOI 10.1007/BF01119630; FATHERAZI S, 1991, J MEMBRANE BIOL, V120, P105, DOI 10.1007/BF01872393; GILON P, 1993, J BIOL CHEM, V268, P22265; HELLMAN B, 1992, BIOCHIM BIOPHYS ACTA, V1113, P295, DOI 10.1016/0304-4157(92)90003-S; HENQUIN JC, 1990, PFLUG ARCH EUR J PHY, V416, P568, DOI 10.1007/BF00382691; KEAHEY HH, 1989, DIABETES, V38, P188, DOI 10.2337/diabetes.38.2.188; MADSEN OD, 1985, ENDOCRINOLOGY, V113, P2135; MEDA P, 1982, J CELL BIOL, V92, P221, DOI 10.1083/jcb.92.1.221; ORCI L, 1973, EXPERIENTIA, V29, P1015, DOI 10.1007/BF01930436; OSBORN L, 1987, MOL CELL BIOL, V7, P326, DOI 10.1128/MCB.7.1.326; PHILIPSON LH, 1991, P NATL ACAD SCI USA, V88, P53, DOI 10.1073/pnas.88.1.53; PHILIPSON LH, 1993, BIOCHIM BIOPHYS ACTA, V1153, P111, DOI 10.1016/0005-2736(93)90282-5; PLANT TD, 1988, J PHYSIOL-LONDON, V404, P731, DOI 10.1113/jphysiol.1988.sp017316; ROE MW, 1993, J BIOL CHEM, V268, P9953; ROJAS E, 1994, ENDOCRINOLOGY, V134, P1771, DOI 10.1210/en.134.4.1771; RORSMAN P, 1989, J GEN PHYSIOL, V91, P243; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SATIN LS, 1989, J MEMBRANE BIOL, V112, P213, DOI 10.1007/BF01870952; SATIN LS, 1989, PFLUG ARCH EUR J PHY, V414, P1, DOI 10.1007/BF00585619; SHERMAN A, 1991, BIOPHYS J, V59, P547, DOI 10.1016/S0006-3495(91)82271-8; SMITH PA, 1990, J GEN PHYSIOL, V95, P1041, DOI 10.1085/jgp.95.6.1041; SNYDERS DJ, 1992, MOL PHARMACOL, V41, P322; WORLEY JF, 1994, J BIOL CHEM, V269, P14359	33	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27787	27790						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961701				2022-12-27	WOS:A1994PV77200002
J	SCHOLZEN, T; SOLURSH, M; SUZUKI, S; REITER, R; MORGAN, JL; BUCHBERG, AM; SIRACUSA, LD; IOZZO, RV				SCHOLZEN, T; SOLURSH, M; SUZUKI, S; REITER, R; MORGAN, JL; BUCHBERG, AM; SIRACUSA, LD; IOZZO, RV			THE MURINE DECORIN - COMPLETE CDNA CLONING, GENOMIC ORGANIZATION, CHROMOSOMAL ASSIGNMENT, AND EXPRESSION DURING ORGANOGENESIS AND TISSUE DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCAN; HUMAN-COLON-CARCINOMA; MESSENGER-RNA LEVELS; GROWTH-FACTOR-BETA; CORE PROTEIN; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; LOCALIZATION; SEQUENCE; BIGLYCAN	Decorin, a proteoglycan known to interact with collagen and growth factors, may play key roles during ontogenesis, tissue remodeling, and cancer. We have deciphered the complete protein sequence of the murine decorin by cDNA cloning, elucidated its gene structure and chromosomal location, and investigated its expression in the developing embryo. The decorin protein and the gene were highly conserved vis a vis the human counterpart; however, the murine gene lacked a leader exon, exon Ib, which was found only in the human. Using interspecific backcrossing, we assigned the gene to chromosome 10 just proximally to the Steel gene locus. In situ hybridization studies of developing mouse embryos showed a distinct pattern of expression with a progressive increase of decorin mRNA during ontogenesis. At early stages (day 11 postconception), decorin was detectable only in the floor plate region. Subsequently (days 13-16 postconception), decorin expression was especially prominent in the meninges and mesothelial linings of pericardium, pleura, and coelomic cavity, as well as in the dermis and subepithelial layers of the intestine and urinary bladder. In contrast, the major parenchymal organs were only weakly positive for decorin mRNA. These findings suggest that decorin may play a role in epithelial/mesenchymal interactions during organ development and shaping.	THOMAS JEFFERSON UNIV, DEPT PATHOL & CELL BIOL, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, PHILADELPHIA, PA 19107 USA; UNIV IOWA, DEPT BIOL SCI, IOWA CITY, IA 52242 USA; UNIV SO CALIF, DOHENY EYE INST, LOS ANGELES, CA 90033 USA	Jefferson University; Jefferson University; University of Iowa; Doheny Eye Institute; University of Southern California			Iozzo, Renato/AAS-1980-2020	Scholzen, Thomas/0000-0002-5556-9144; Buchberg, Arthur/0000-0002-0543-5631; Iozzo, Renato/0000-0002-5908-5112	NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47282, CA-39481] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADANY R, 1991, BIOCHEM J, V276, P301, DOI 10.1042/bj2760301; ADANY R, 1990, J BIOL CHEM, V265, P11389; ASUNDI VK, 1992, EUR J CELL BIOL, V59, P314; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P20613; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BRANDAN E, 1992, J NEUROSCI RES, V32, P51, DOI 10.1002/jnr.490320107; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DANIELSON KG, 1993, GENOMICS, V15, P146, DOI 10.1006/geno.1993.1022; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; DIETRICH W, 1993, GENETIC MAPS; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FISHER LW, 1989, J BIOL CHEM, V264, P4571; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; HANEMANN CO, 1993, J HISTOCHEM CYTOCHEM, V41, P1383, DOI 10.1177/41.9.8354878; HAUSSER H, 1989, BIOCHEM J, V263, P137, DOI 10.1042/bj2630137; IOZZO R V, 1982, Journal of Biological Chemistry, V257, P11135; IOZZO RV, 1993, EXPERIENTIA, V49, P447, DOI 10.1007/BF01923588; IOZZO RV, 1989, J CELL BIOCHEM, V39, P355, DOI 10.1002/jcb.240390403; KAHARI VM, 1991, J BIOL CHEM, V266, P10608; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KRESSE H, 1993, EXPERIENTIA, V49, P403, DOI 10.1007/BF01923585; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LI W, 1992, ARCH BIOCHEM BIOPHYS, V296, P190, DOI 10.1016/0003-9861(92)90562-B; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MARINI JC, 1993, GENOMICS, V15, P200, DOI 10.1006/geno.1993.1034; MEYER DH, 1992, HEPATOLOGY, V16, P204, DOI 10.1002/hep.1840160131; NADEAU JH, 1992, MAMM GENOME, V3, P480, DOI 10.1007/BF00778825; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; SANTRA M, 1994, J BIOL CHEM, V269, P579; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; SCHONHERR E, 1993, BIOCHEM J, V290, P893, DOI 10.1042/bj2900893; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SIMIONESCU D, 1989, MATRIX, V9, P301, DOI 10.1016/S0934-8832(89)80006-X; SIRACUSA LD, 1989, GENETICS, V122, P669; SUZUKI HR, 1991, DEV BIOL, V148, P375, DOI 10.1016/0012-1606(91)90345-4; SWALLA BJ, 1988, DEV BIOL, V125, P51, DOI 10.1016/0012-1606(88)90057-7; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VONIOZZO R, 1982, LAB INVEST, V47, P124; WINNEMOLLER M, 1992, EUR J CELL BIOL, V59, P47; WINNEMOLLER M, 1991, EUR J CELL BIOL, V54, P10; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	45	114	121	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28270	28281						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961765				2022-12-27	WOS:A1994PV77200075
J	CHEN, ZQ; CRIPPEN, K; GULATI, S; BANERJEE, R				CHEN, ZQ; CRIPPEN, K; GULATI, S; BANERJEE, R			PURIFICATION AND KINETIC MECHANISM OF A MAMMALIAN METHIONINE SYNTHASE FROM PIG-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; COBALAMIN; DISEASE; HOMOCYSTEINEMIA; BINDING; STATE	Porcine hepatic methionine synthase has been purified to near homogeneity. The enzyme is isolated in two forms which were purified similar to 9,000- and similar to 7,000-fold and were obtained in 0.9 and 2.5% overall yield, respectively. The mammalian enzyme from pig liver is a large monomelic protein with a molecular mass of 151-155 bDa. It is characterized by the absence of any metals other than cobalt which is associated with the cofactor, cobalamin. This enzyme, like the methionine synthase from Escherichia coli is dependent on S-adenosylmethionine for activity. The steady state kinetic studies demonstrate that the reaction operates via an ordered sequential mechanism in which binding of CH3-H-4- folate precedes homocysteine, and methionine is released prior to H-4-folate.	UNIV NEBRASKA,DEPT BIOCHEM,LINCOLN,NE 68583	University of Nebraska System; University of Nebraska Lincoln			Crippen, Kent/AAI-3712-2020	Crippen, Kent/0000-0002-8981-2376	NIDDK NIH HHS [DK45776] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045776, R29DK045776] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P11101, DOI 10.1021/bi00502a013; BANERJEE RV, 1990, FASEB J, V4, P1450, DOI 10.1096/fasebj.4.5.2407589; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRATTSTROM LE, 1984, STROKE, V15, P1012, DOI 10.1161/01.STR.15.6.1012; BURKE GT, 1971, BIOCHEMISTRY-US, V10, P3079; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; DRUMMOND JT, 1993, BIOCHEMISTRY-US, V32, P9290, DOI 10.1021/bi00087a005; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FRASCA V, 1988, BIOCHEMISTRY-US, V27, P8458, DOI 10.1021/bi00422a025; GIANNOTTI C, 1982, ELECTRONIC SPECTRA B, P394; HATCH FT, 1961, J BIOL CHEM, V236, P1095; JONES JB, 1977, COMMUN SOIL SCI PLAN, V8, P349, DOI 10.1080/00103627709366727; MANGUM JH, 1971, BIOCHEMISTRY-US, V10, P3765, DOI 10.1021/bi00796a019; MATTHEWS RG, 1986, METHIONINE BIOSYNTHE, P697; MELLMAN IS, 1977, P NATL ACAD SCI USA, V74, P916, DOI 10.1073/pnas.74.3.916; ROSENBERG LE, 1983, METABOLIC BASIS INHE, P474; SCHRAUZER GN, 1968, J AM CHEM SOC, V90, P2441, DOI 10.1021/ja01011a054; SMITH MR, 1984, THESIS B YOUNG U; TAYLOR RT, 1967, J BIOL CHEM, V242, P1502; UTLEY CS, 1985, J BIOL CHEM, V260, P3656; WILCKEN DEL, 1983, METABOLISM, V32, P363, DOI 10.1016/0026-0495(83)90045-8; WILCKEN DEL, 1976, J CLIN INVEST, V57, P1079, DOI 10.1172/JCI108350	22	55	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27193	27197						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961628				2022-12-27	WOS:A1994PV77100010
J	HEIN, L; ISHII, K; COUGHLIN, SR; KOBILKA, BK				HEIN, L; ISHII, K; COUGHLIN, SR; KOBILKA, BK			INTRACELLULAR TARGETING AND TRAFFICKING OF THROMBIN RECEPTORS - A NOVEL MECHANISM FOR RESENSITIZATION OF A G-PROTEIN-COUPLED RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; CELLS; MEMBRANE; INTERNALIZATION; ACTIVATION; MICROSCOPY; CYCLASE	The receptor for the protease thrombin is a member of the G protein-coupled receptor family, but is activated by a unique proteolytic mechanism. The irreversibility of this proteolytic mechanism and the fact that the ligand is tethered to its receptor raise special questions about inactivation of cleaved receptors and recovery of thrombin responsiveness. We compared the intracellular trafficking of the thrombin receptor to that of the beta(2)-adrenergic receptor in transfected Rat1 fibroblasts. In unstimulated cells almost all beta(2) receptors were located on the plasma membrane; by contrast, part of a cell's thrombin receptors were found in an intracellular membrane compartment which co-localized with Golgi markers. Stimulation by agonist caused internalization and subsequent recycling of the beta(2)-adrenergic receptor, but most activated thrombin receptors were internalized and targeted to lysosomes. The intracellular pool of thrombin receptors found in unstimulated cells was protected from activation by thrombin, but was translocated to the plasma membrane upon activation of cell surface thrombin receptors. Replenishment of plasma membrane thrombin receptors correlated with recovery of thrombin responsiveness. These observations reveal a novel trafficking mechanism for resensitizing the thrombin receptor as opposed to the internalization/recycling pathway of other G protein-coupled receptors.	STANFORD UNIV,SCH MED,BECKMAN CTR B157,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DIV CARDIOVASC MED,STANFORD,CA 94305; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; Stanford University; Stanford University; University of California System; University of California San Francisco				Kobilka, Brian/0000-0001-5958-3990	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044907] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44907] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAFFY G, 1994, J BIOL CHEM, V269, P8483; BRASS LF, 1991, J BIOL CHEM, V266, P958; BROOKER G, 1990, P NATL ACAD SCI USA, V87, P2813, DOI 10.1073/pnas.87.7.2813; BURKE B, 1982, EMBO J, V1, P1621, DOI 10.1002/j.1460-2075.1982.tb01364.x; COUGHLIN SR, 1993, THROMB HAEMOSTASIS, V66, P184; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUNG DT, 1992, J BIOL CHEM, V267, P20831; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; ISHII K, 1994, J BIOL CHEM, V269, P1125; ISHII K, 1993, J BIOL CHEM, V268, P9780; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; LEWIS V, 1985, J CELL BIOL, V100, P1839, DOI 10.1083/jcb.100.6.1839; LIMBIRD LE, 1980, P NATL ACAD SCI-BIOL, V77, P775, DOI 10.1073/pnas.77.2.775; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NIGGLI E, 1990, CELL CALCIUM, V11, P121, DOI 10.1016/0143-4160(90)90065-3; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PAGANO RE, 1988, BIOCHEMISTRY-US, V27, P1909; Sambrook J, 1989, MOL CLONING LABORATO; SENGELOV H, 1994, BIOCHEM J, V299, P473, DOI 10.1042/bj2990473; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; YU SS, 1993, J BIOL CHEM, V268, P337; ZONZASTROW M, 1993, J BIOL CHEM, V268, P763	24	214	217	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27719	27726						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961693				2022-12-27	WOS:A1994PV77100087
J	DE, A; BOYADJIEVA, NI; PASTORCIC, M; REDDY, BV; SARKAR, DK				DE, A; BOYADJIEVA, NI; PASTORCIC, M; REDDY, BV; SARKAR, DK			CYCLIC-AMP AND ETHANOL INTERACT TO CONTROL APOPTOSIS AND DIFFERENTIATION IN HYPOTHALAMIC BETA-ENDORPHIN NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICOTROPIN-RELEASING FACTOR; PROOPIOMELANOCORTIN GENE-EXPRESSION; ADENYLATE-CYCLASE; PRENATAL ETHANOL; ALCOHOL DEPENDENCE; ANTERIOR-PITUITARY; BINDING-PROTEIN; FEMALE RATS; CELL-DEATH; EXPOSURE	In this study we have determined the role of cyclic AMP on the function and differentiation of beta-endorphin (beta-EP) neurons in rat fetal hypothalamic cell cultures. Addition of Bt(2)cAMP or the cAMP elevating agent, forskolin, in cultures, dose and time dependently increased beta-endorphin secretion. The increased beta-EP secretion after Bt(2)cAMP or forskolin treatment was associated with proopiomelanocortin gene expression, enhanced neurite growth, and increased neuronal viability. Determination of internucleosomal cleavage of DNA by agarose gel electrophoresis revealed that apoptosis occurred in hypothalamic neurons during the first 6-8 days in culture. Addition of Bt(2)cAMP during this developmental period inhibited DNA degradation in hypothalamic neurons. Furthermore, incubation with various doses of ethanol, which is known to reduce intracellular levels of Bt(2)cAMP, increased DNA degradation in these cells. Ethanol-induced DNA degradation was blocked by concomitant incubation with Bt(2)cAMP. Histochemical identification of apoptotic cells following ethanol and Bt(2)cAMP treatments further revealed that apoptosis occurred in beta-EP neurons during the developmental period, and that ethanol increased and Bt(2)cAMP reduced apoptotic beta-EP cell numbers. These results suggest that ethanol neurotoxicity on beta-EP neurons during early neuronal differentiation involves an apoptotic process and that the cAMP signaling system plays an important role in controlling apoptosis and differentiation of the beta-EP neuronal system.	WASHINGTON STATE UNIV, DEPT VET & COMPARAT ANAT PHARMACOL & PHYSIOL, PULLMAN, WA 99164 USA	Washington State University			Sarkar, Dipak K/O-7942-2017	Sarkar, Dipak K/0000-0003-3237-9871	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008757] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA08757] Funding Source: Medline; NINDS NIH HHS [NS05130] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abel E. L., 1984, FETAL ALCOHOL SYNDRO; ADAMS ML, 1991, ALCOHOL CLIN EXP RES, V15, P685, DOI 10.1111/j.1530-0277.1991.tb00580.x; ALTSHULER HL, 1980, LIFE SCI, V26, P679, DOI 10.1016/0024-3205(80)90257-X; AMALRIC M, 1987, PSYCHOPHARMACOLOGY, V91, P14, DOI 10.1007/BF00690919; BILEZIKJIAN LM, 1983, ENDOCRINOLOGY, V113, P1726, DOI 10.1210/endo-113-5-1726; BLUM M, 1989, METHOD ENZYMOL, V168, P618; BOUTILLIER AL, 1992, J BIOL CHEM, V267, P23520; BOUTILLIER AL, 1991, MOL ENDOCRINOL, V5, P1301, DOI 10.1210/mend-5-9-1301; CHARNESS ME, 1989, EXPERIENTIA, V45, P418, DOI 10.1007/BF01952023; CHARNESS ME, 1988, BIOCHEM BIOPH RES CO, V155, P138, DOI 10.1016/S0006-291X(88)81060-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COMPTON MM, 1986, ENDOCRINOLOGY, V118, P38, DOI 10.1210/endo-118-1-38; DANIEL V, 1973, P NATL ACAD SCI USA, V70, P76, DOI 10.1073/pnas.70.1.76; DURNAM DM, 1983, ANAL BIOCHEM, V131, P385, DOI 10.1016/0003-2697(83)90188-4; FROEHLICH JC, 1990, PHARMACOL BIOCHEM BE, V35, P385, DOI 10.1016/0091-3057(90)90174-G; Goldstein DB, 1983, PHARM ALCOHOL; GORDON AS, 1986, P NATL ACAD SCI USA, V83, P2105, DOI 10.1073/pnas.83.7.2105; GRUOL DJ, 1989, MOL ENDOCRINOL, V3, P2119, DOI 10.1210/mend-3-12-2119; HANDA RJ, 1985, LIFE SCI, V37, P1683, DOI 10.1016/0024-3205(85)90295-4; HUNT WA, 1981, FED PROC, V40, P2077; HYNIE S, 1980, ACTA PHARMACOL TOX, V47, P58; KIZAKI H, 1990, J BIOL CHEM, V265, P5280; KORNET M, 1991, PSYCHOPHARMACOLOGY, V104, P367, DOI 10.1007/BF02246038; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LEVIN N, 1991, FRONT NEUROENDOCRIN, V12, P1; LEVIN N, 1989, ENDOCRINOLOGY, V125, P2957, DOI 10.1210/endo-125-6-2957; LUNDBLAD JR, 1988, ENDOCR REV, V9, P135, DOI 10.1210/edrv-9-1-135; MCCONKEY DJ, 1990, J IMMUNOL, V145, P1227; MCGIVERN RF, 1986, PSYCHONEUROENDOCRINO, V11, P105, DOI 10.1016/0306-4530(86)90036-3; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MEZEY E, 1985, BRAIN RES, V328, P341, DOI 10.1016/0006-8993(85)91046-7; NAKANISHI S, 1979, NATURE, V278, P423, DOI 10.1038/278423a0; NIRENBERG M, 1983, SCIENCE, V222, P794, DOI 10.1126/science.6314503; ODONOHUE TL, 1982, PEPTIDES, V3, P353, DOI 10.1016/0196-9781(82)90098-5; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; PASTORCIC M, 1986, MOL CELL BIOL, V6, P2784, DOI 10.1128/MCB.6.8.2784; PRATT RM, 1975, P NATL ACAD SCI USA, V72, P874, DOI 10.1073/pnas.72.3.874; RABIN RA, 1981, J PHARMACOL EXP THER, V216, P129; RAIZADA MK, 1990, AM J PHYSIOL, V258, pC109, DOI 10.1152/ajpcell.1990.258.1.C109; REDDY BV, 1993, ALCOHOL CLIN EXP RES, V17, P1261, DOI 10.1111/j.1530-0277.1993.tb05239.x; REDEI E, 1989, ALCOHOL CLIN EXP RES, V13, P439, DOI 10.1111/j.1530-0277.1989.tb00350.x; RIVIER C, 1984, J PHARMACOL EXP THER, V229, P127; Robison G A, 1970, Adv Biochem Psychopharmacol, V3, P11; ROSSIER J, 1977, P NATL ACAD SCI USA, V74, P5162, DOI 10.1073/pnas.74.11.5162; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; SAITO T, 1985, J NEUROCHEM, V44, P1037, DOI 10.1111/j.1471-4159.1985.tb08722.x; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SANDMAN CA, 1981, PHARMACOL THERAPEUT, V13, P39, DOI 10.1016/0163-7258(81)90066-8; SARKAR DK, 1990, ENDOCRINOLOGY, V126, P349, DOI 10.1210/endo-126-1-349; SARKAR DK, 1985, ENDOCRINOLOGY, V116, P2080, DOI 10.1210/endo-116-5-2080; SARKAR DK, 1988, NEUROENDOCRINE CONTR, P47; SCHMIDT M J, 1970, Developmental Psychology, V3, P53, DOI 10.1002/dev.420030108; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SPANAGEL R, 1991, PSYCHOPHARMACOLOGY, V104, P51, DOI 10.1007/BF02244553; STREISSGUTH AP, 1989, ANN NY ACAD SCI, V562, P145, DOI 10.1111/j.1749-6632.1989.tb21013.x; TAYLOR AN, 1986, ALCOHOL, V3, P255, DOI 10.1016/0741-8329(86)90034-0; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; WALKER C, 1983, J IMMUNOL, V130, P1770; WAND GS, 1991, ALCOHOL CLIN EXP RES, V15, P705, DOI 10.1111/j.1530-0277.1991.tb00583.x; Ward I L, 1983, Monogr Neural Sci, V9, P169; WEINBERG J, 1989, ALCOHOL CLIN EXP RES, V13, P73, DOI 10.1111/j.1530-0277.1989.tb00287.x; WIDMAIER EP, 1989, ENDOCRINOLOGY, V124, P583, DOI 10.1210/endo-124-2-583; WILCOX JN, 1986, J NEUROSCI RES, V16, P89, DOI 10.1002/jnr.490160109; YANG ZY, 1993, J NEUROENDOCRINOL, V5, P371, DOI 10.1111/j.1365-2826.1993.tb00497.x; Zagon I S, 1983, Monogr Neural Sci, V9, P159	66	73	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26697	26704						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929402				2022-12-27	WOS:A1994PQ93100021
J	SCHMIDT, WK; MOORE, HPH				SCHMIDT, WK; MOORE, HPH			SYNTHESIS AND TARGETING OF INSULIN-LIKE GROWTH-FACTOR-I TO THE HORMONE STORAGE GRANULES IN AN ENDOCRINE CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; PLASMA-MEMBRANE PROTEINS; B SECRETOGRANIN-I; SECRETORY GRANULES; CHROMOGRANIN-B; INTRACELLULAR-TRANSPORT; NUCLEOTIDE-SEQUENCE; HUMAN PREPROINSULIN; HUMAN PROINSULINS; RECEPTOR-BINDING	Export of growth factors is generally believed to be restricted to the constitutive secretory pathway, whereas peptide hormones are typically secreted in a regulated manner. Here we show that insulin-like growth factor (IGF)-I, a growth factor released constitutively from the liver, is synthesized and secreted from the mouse pituitary AtT-20 cell line via the regulated pathway. IGF-I production is 1500-fold less than the peptide hormone ACTH. Secretagogue induces IGF-I secretion in a manner similar to ACTH. Like ACTH, IGF-I is sorted into the regulated pathway >35-fold more efficiently than a constitutively secreted protein. Dense core granules isolated from cells transfected with a human IGF-I cDNA contain both ACTH and human IGF-I. AtT-20 cells also synthesize IGF-binding proteins, and at least one of these is secreted by the regulated pathway. Human IGF-I does not exhibit milieu-induced, concentration-dependent aggregation, in contrast to secretogranin II which sorts by a proposed aggregation mechanism. These data suggest that I) growth factors are not solely released from tissues via the constitutive pathway, 2) IGF-I may contain information for correct granular targeting, and 3) IGF-I may be sorted by a mechanism distinct from that proposed for the secretogranins.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035239] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35239] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUADO F, 1992, NEUROSCI LETT, V135, P171, DOI 10.1016/0304-3940(92)90429-B; ARVAN P, 1991, J BIOL CHEM, V266, P14171; BAGNELL CA, 1991, STEROIDS, V56, P242, DOI 10.1016/0039-128X(91)90041-S; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BAYNE ML, 1987, P NATL ACAD SCI USA, V84, P2638, DOI 10.1073/pnas.84.9.2638; BEDARKAR S, 1977, NATURE, V270, P449, DOI 10.1038/270449a0; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P7873, DOI 10.1093/nar/14.20.7873; BELL GI, 1979, NATURE, V282, P525, DOI 10.1038/282525a0; BICHELL DP, 1992, MOL ENDOCRINOL, V6, P1899, DOI 10.1210/me.6.11.1899; BLUNDELL TL, 1978, P NATL ACAD SCI USA, V75, P180, DOI 10.1073/pnas.75.1.180; BLUNDELL TL, 1980, NATURE, V287, P781, DOI 10.1038/287781a0; BOWSHER RR, 1991, ENDOCRINOLOGY, V128, P805, DOI 10.1210/endo-128-2-805; BRION C, 1992, J BIOL CHEM, V267, P1477; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CASTLE AM, 1992, J BIOL CHEM, V267, P13093; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; CHAVEZ RA, 1994, METHOD CELL BIOL, V43, P263; CLEMMONS DR, 1993, ANN NY ACAD SCI, V692, P10; DERCOLE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P935, DOI 10.1073/pnas.81.3.935; FADEN VF, 1975, RADIOIMMUNOASSAY DAT; FAGIN JA, 1987, ENDOCRINOLOGY, V120, P2037, DOI 10.1210/endo-120-5-2037; FIELDER PJ, 1992, ENDOCRINOLOGY, V131, P261, DOI 10.1210/en.131.1.261; FIELDER PJ, 1993, GROWTH REGULAT, V77, P1683; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GORR SU, 1989, AM J PHYSIOL, V257, pE247, DOI 10.1152/ajpendo.1989.257.2.E247; GRIMES M, 1992, J CELL BIOL, V117, P539, DOI 10.1083/jcb.117.3.539; GUMBINER B, 1981, P NATL ACAD SCI-BIOL, V78, P318, DOI 10.1073/pnas.78.1.318; JANSEN M, 1983, NATURE, V306, P609, DOI 10.1038/306609a0; KIZER JS, 1991, BIOCHEM BIOPH RES CO, V174, P586, DOI 10.1016/0006-291X(91)91457-N; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; LEBLOND FA, 1993, BIOCHEM J, V291, P289, DOI 10.1042/bj2910289; LEROITH D, 1993, ANN NY ACAD SCI, V692, P1; Leroith Derek, 1992, Biological Signals, V1, P173; Miller SG, 1990, CURR OPIN CELL BIOL, V2, P642, DOI 10.1016/0955-0674(90)90105-N; MOORE HPH, 1986, NATURE, V321, P443, DOI 10.1038/321443a0; MOORE HPH, 1985, J CELL BIOL, V101, P1773, DOI 10.1083/jcb.101.5.1773; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; MURRAYRUST J, 1992, BIOESSAYS, V14, P325, DOI 10.1002/bies.950140507; NEERMANARBEZ M, 1993, J BIOL CHEM, V268, P16248; ORCI L, 1984, P NATL ACAD SCI-BIOL, V81, P6743, DOI 10.1073/pnas.81.21.6743; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; POWELL SK, 1988, J CELL BIOL, V106, P1843, DOI 10.1083/jcb.106.6.1843; QUINN D, 1991, J CELL BIOL, V113, P987, DOI 10.1083/jcb.113.5.987; ROSA P, 1989, J CELL BIOL, V109, P17, DOI 10.1083/jcb.109.1.17; ROY P, 1991, MOL CELL ENDOCRINOL, V82, P237, DOI 10.1016/0303-7207(91)90037-S; SALAMERO J, 1990, P NATL ACAD SCI USA, V87, P7717, DOI 10.1073/pnas.87.19.7717; SARA VR, 1990, PHYSIOL REV, V70, P591, DOI 10.1152/physrev.1990.70.3.591; SAUCAN L, 1992, HEPATOLOGY, V15, P714, DOI 10.1002/hep.1840150427; SOSSIN WS, 1990, J CELL BIOL, V110, P1, DOI 10.1083/jcb.110.1.1; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; SURES I, 1980, SCIENCE, V208, P57, DOI 10.1126/science.6927840; TAM WWH, 1993, EUR J CELL BIOL, V62, P294; TOOZE J, 1987, J CELL BIOL, V105, P1215, DOI 10.1083/jcb.105.3.1215; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; TURKEWITZ AP, 1991, EMBO J, V10, P1979, DOI 10.1002/j.1460-2075.1991.tb07727.x; YOO SH, 1990, J BIOL CHEM, V265, P14414; ZAPF J, 1986, HORM RES, V24, P121, DOI 10.1159/000180551	59	27	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27115	27124						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929455				2022-12-27	WOS:A1994PQ93100079
J	SONG, CZ; HANADA, K; YANO, K; MAEDA, Y; YAMAMOTO, K; MURAMATSU, M				SONG, CZ; HANADA, K; YANO, K; MAEDA, Y; YAMAMOTO, K; MURAMATSU, M			HIGH CONSERVATION OF SUBUNIT COMPOSITION OF RNA-POLYMERASE-I(A) BETWEEN YEAST AND MOUSE AND THE MOLECULAR-CLONING OF MOUSE RNA-POLYMERASE-I 40-KDA SUBUNIT RPA40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MONOCLONAL-ANTIBODIES; ALPHA-SUBUNIT; TRANSCRIPTION; SEQUENCE; GENE; INITIATION; PROTEIN; COMMON; RPC40	Mouse RNA polymerase I (or A) was purified from an ascites cell line MH134 to virtual homogeneity using a novel purification procedure and examined for subunit composition. In marked contrast to older purifications that reported 5-8 subunits, polymerase I was found to have 11 subunits with remarkable correspondence to those of yeasts. The cDNA encoding a 40-kDa subunit of this enzyme, designated RPA40, was isolated. It predicts a polypeptide of 355 amino acids (M(r), = 40,065) and is encoded by a single copy gene. Protein sequence analysis reveals that RPA40 is the homolog of yeast RPC40, having homology 60 alpha subunit of Escherichia coli RNA polymerase, yeast RPB3, and human RPB33 RNA polymerase II subunits. The high conservation of this subunit among distant eukaryotes and different RNA polymerases suggests functional importance of this protein as a core subunit.	SAITAMA MED SCH,DEPT BIOCHEM,MOROYAMA,SAITAMA 35004,JAPAN; UNIV TOKYO,SCH MED,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; KYOWA HAKKO KOGYO CO LTD,TOKYO RES LAB,MACHIDA,TOKYO 194,JAPAN	Saitama Medical University; University of Tokyo; Kyowa Kirin Ltd			Hanada, Kenichi/L-2481-2013; Hanada, Ken-ichi/A-4642-2008	Hanada, Kenichi/0000-0003-2959-1257; 				AHEARN JM, 1987, J BIOL CHEM, V262, P10695; AOTA S, 1988, NUCLEIC ACIDS RES, V16, pR315, DOI 10.1093/nar/16.suppl.r315; BATEMAN E, 1986, CELL, V47, P445, DOI 10.1016/0092-8674(86)90601-X; BUHLER JM, 1980, J BIOL CHEM, V255, P9949; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; CARLES C, 1991, J BIOL CHEM, V266, P24092; CHAMBERLIN M, 1976, RNA POLYM; DEQUARDCHABLAT M, 1991, J BIOL CHEM, V266, P15300; EVERS R, 1989, CELL, V56, P585, DOI 10.1016/0092-8674(89)90581-3; FIRE A, 1984, J BIOL CHEM, V259, P2509; GISSINGER F, 1972, EUR J BIOCHEM, V28, P277, DOI 10.1111/j.1432-1033.1972.tb01911.x; GUNDELFINGER E, 1982, FEBS LETT, V142, P7, DOI 10.1016/0014-5793(82)80207-X; HUET J, 1982, J BIOL CHEM, V257, P2613; KATO H, 1986, MOL CELL BIOL, V6, P3418, DOI 10.1128/MCB.6.10.3418; KEDINGER C, 1974, EUR J BIOCHEM, V44, P421, DOI 10.1111/j.1432-1033.1974.tb03500.x; KOLODZIEJ P, 1989, MOL CELL BIOL, V9, P5387, DOI 10.1128/MCB.9.12.5387; KOLODZIEJ PA, 1991, MOL CELL BIOL, V11, P4669, DOI 10.1128/MCB.11.9.4669; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MANN C, 1987, CELL, V48, P627, DOI 10.1016/0092-8674(87)90241-8; MARTINDALE DW, 1990, NUCLEIC ACIDS RES, V18, P2953, DOI 10.1093/nar/18.10.2953; MATSUI T, 1976, EUR J BIOCHEM, V71, P351, DOI 10.1111/j.1432-1033.1976.tb11121.x; OVCHINNIKOV YA, 1977, FEBS LETT, V76, P108, DOI 10.1016/0014-5793(77)80131-2; PATI UK, 1990, J BIOL CHEM, V265, P8400; RIFTINA F, 1990, BIOCHEMISTRY-US, V29, P4440, DOI 10.1021/bi00470a026; RIFTINA F, 1989, BIOCHEMISTRY-US, V28, P3299, DOI 10.1021/bi00434a027; RIVA M, 1982, J BIOL CHEM, V257, P4570; ROEDER RG, 1969, NATURE, V224, P234, DOI 10.1038/224234a0; SCHWARTZ LB, 1974, J BIOL CHEM, V249, P5898; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SKLAR VEF, 1975, P NATL ACAD SCI USA, V72, P348, DOI 10.1073/pnas.72.1.348; THURIAUX P, 1992, MOL CELLULAR BIOL YE; TOWER J, 1987, CELL, V50, P873, DOI 10.1016/0092-8674(87)90514-9; VENEZIA ND, 1990, J BIOL CHEM, V265, P8122; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; YURA T, 1979, ANNU REV GENET, V13, P59, DOI 10.1146/annurev.ge.13.120179.000423	36	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26976	26981						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929437				2022-12-27	WOS:A1994PQ93100060
J	ZHANG, ZT; HARMS, E; VANETTEN, RL				ZHANG, ZT; HARMS, E; VANETTEN, RL			ASP(129) OF LOW-MOLECULAR-WEIGHT PROTEIN-TYROSINE-PHOSPHATASE IS INVOLVED IN LEAVING GROUP PROTONATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BOVINE HEART; ACID-PHOSPHATASE; EXPRESSION; INTERMEDIATE; DEPENDENCE; CLONING	Site-directed mutagenesis was used to explore the functions of a number of acidic residues of bovine low molecular weight protein tyrosine phosphatase. Residues Asp-129, Asp-56, and Asp-92 were mutated to Ala or Asn. The mutant enzymes D56A, D56N, and D92A showed no significant changes in V-max values, although they did exhibit significantly altered K-m values. In contrast, the D129A mutant enzyme exhibited a greater than 2000-fold reduction in V-max, using p-nitrophenyl phosphate as a substrate. The V-max values of D129A also exhibited a leaving group dependence, an altered solvent isotope effect of V-max(H)/V-max(D) of 0.78, and a lack of dependence on the presence of alternative phosphate acceptor alcohols, all properties that distinguish this mutant from wild type enzyme. The differences are due to a change of the rate-limiting step of the catalytic reaction. Asp-129 is concluded to be the proton donor to the leaving group in the phosphorylation step, and its mutation to alanine results in a reduced V-max value and a change in the rate-limiting step of the catalysis from dephosphorylation to phosphorylation. Mechanistic considerations suggest that other phosphotyrosyl phosphatases having cysteine at the active site may be expected to have a similar requirement for a proton donor.	PURDUE UNIV, DEPT CHEM, W LAFAYETTE, IN 47907 USA; PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus				zhang, zhongtao/0000-0002-1910-4753				BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BROCKLEHURST K, 1988, BIOCHEM J, V250, P761, DOI 10.1042/bj2500761; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; COOK PF, 1991, ENZYME MECHANISM ISO, P202; DAVIS JP, 1994, J BIOL CHEM, V269, P8734; DAVIS JP, 1994, BIOCHEMISTRY-US, V33, P1278, DOI 10.1021/bi00171a031; GUAN KL, 1991, J BIOL CHEM, V266, P17026; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOGAN TM, 1994, BIOCHEMISTRY-US, V33, P11087, DOI 10.1021/bi00203a005; LUTZ RA, 1985, CLIN CHEM, V31, P656; OSTANIN K, 1993, J BIOL CHEM, V268, P20778; RAUGEI G, 1991, BIOCHEM INT, V23, P317; SAINI MS, 1981, J BIOL CHEM, V256, P453; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; WO YYP, 1992, BIOCHEMISTRY-US, V31, P1712, DOI 10.1021/bi00121a019; WO YYP, 1992, J BIOL CHEM, V267, P10856; ZHANG M, 1994, BIOCHEMISTRY-US, V33, P11097, DOI 10.1021/bi00203a006; ZHANG ZY, 1991, BIOCHEMISTRY-US, V30, P8954, DOI 10.1021/bi00101a006; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; ZHANG ZY, 1991, J BIOL CHEM, V266, P1516; ZHANG ZY, 1990, THESIS PURDUE U W LA	23	62	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					25947	25950						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929301				2022-12-27	WOS:A1994PQ93000002
J	ZHANG, C; LAMBERT, MP; BUNCH, C; BARBER, K; WADE, WS; KRAFFT, GA; KLEIN, WL				ZHANG, C; LAMBERT, MP; BUNCH, C; BARBER, K; WADE, WS; KRAFFT, GA; KLEIN, WL			FOCAL ADHESION KINASE EXPRESSED BY NERVE-CELL LINES SHOWS INCREASED TYROSINE PHOSPHORYLATION IN RESPONSE TO ALZHEIMERS A-BETA PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMYLOID PLAQUE CORE; EXTRACELLULAR-MATRIX; PROTEIN; DISEASE; DIFFERENTIATION; NEUROTOXICITY; INVITRO; NEUROPEPTIDES; PURIFICATION; FIBRONECTIN	A beta is a 39-43-amino acid peptide that accumulates as extracellular aggregates in Alzheimer's disease-afflicted brain tissue. Contact between these aggregates and neurons is potentially pathogenic, although little is known about the cellular transduction mechanisms. We have investigated the impact of A beta aggregates on the neuronal control of protein tyrosine phosphorylation, which underlies signal transduction for multiple families of growth factor and adhesion receptors. Added to cultures of rat and human nerve cell lines, A beta aggregates evoked a non-desensitizing increase (1.3-3.6-fold) in tyrosine phosphorylation in a band at 118 kDa. The 118-kDa protein was determined by immunoprecipitation to be pp125(FAK), not previously documented in cells of neuronal lineage. Immunoblots with anti-focal adhesion kinase (FAK) showed that A beta aggregates had no effect on FAK protein levels. The increase in FAK tyrosine phosphorylation occurred at doses of A beta aggregates that evoked lactate dehydrogenase release; evoked tyrosine phosphorylation preceded the first detectable lactate dehydrogenase release by 4 h. Like degeneration, the FAK response was dependent on A beta aggregation and neuronal differentiation. Since tyrosine phosphorylation of FAK is essential to its activity as a transduction component of integrin-, peptide-, and lysophosphatidic acid-mediated signaling, the data establish a link between A beta aggregates and signal transduction pathways implicated in diverse cell functions including neurite outgrowth, control of the cell cycle, and apoptosis.	NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,EVANSTON,IL 60208; ABBOTT LABS,DIV PHARMACEUT PROD,ABBOTT PK,IL 60064	Northwestern University; Abbott Laboratories								ADAMS JC, 1993, DEVELOPMENT, V117, P1183; ANDRE E, 1993, BIOCHEM BIOPH RES CO, V190, P140, DOI 10.1006/bbrc.1993.1022; BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CARRI NG, 1992, INT J DEV NEUROSCI, V10, P393, DOI 10.1016/0736-5748(92)90029-Y; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; GHISO J, 1992, BIOCHEM J, V288, P1053, DOI 10.1042/bj2881053; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOREVIC PD, 1986, J NEUROPATH EXP NEUR, V45, P647, DOI 10.1097/00005072-198611000-00004; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HARDY J, 1992, NAT GENET, V1, P233, DOI 10.1038/ng0792-233; IQBAL K, 1991, MOL NEUROBIOL, V5, P399, DOI 10.1007/BF02935561; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KOSIK K, 1992, NEUROBIOL AGING, V13, P535, DOI 10.1016/0197-4580(92)90052-Y; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; LAMBERT MP, 1994, IN PRESS J NEUROSCI; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MANESS PF, 1986, J NEUROSCI RES, V16, P127, DOI 10.1002/jnr.490160113; MANESS PF, 1992, DEV NEUROSCI-BASEL, V14, P257, DOI 10.1159/000111670; MARX J, 1992, SCIENCE, V257, P1336, DOI 10.1126/science.257.5075.1336-a; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; PAHLMAN S, 1984, CELL DIFFER DEV, V14, P135, DOI 10.1016/0045-6039(84)90038-1; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; REID DM, 1993, NEUROSCIENCE, V56, P529, DOI 10.1016/0306-4522(93)90353-H; ROHER A, 1986, P NATL ACAD SCI USA, V83, P2662, DOI 10.1073/pnas.83.8.2662; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7845; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; WALLAAS SI, 1988, BRAIN RES, V427, P215; WATT FM, 1993, J CELL SCI, V106, P175; WHITSON JS, 1990, NEUROSCI LETT, V110, P319, DOI 10.1016/0304-3940(90)90867-9; WHITSON JS, 1989, SCIENCE, V243, P1488, DOI 10.1126/science.2928783; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	44	97	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25247	25250						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929215				2022-12-27	WOS:A1994PQ49100004
J	MOLLARD, P; THELER, JM; GUERINEAU, N; VACHER, P; CHIAVAROLI, C; SCHLEGEL, W				MOLLARD, P; THELER, JM; GUERINEAU, N; VACHER, P; CHIAVAROLI, C; SCHLEGEL, W			CYTOSOLIC CA2+ OF EXCITABLE PITUITARY-CELLS AT RESTING POTENTIALS IS CONTROLLED BY STEADY-STATE CA2+ CURRENTS SENSITIVE TO DIHYDROPYRIDINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; PANCREATIC BETA-CELLS; ACTIVATED CALCIUM CHANNELS; ADRENAL CHROMAFFIN CELLS; ELECTRICAL-ACTIVITY; BOVINE LACTOTROPHS; CA-2+; GLUCOSE; TRANSIENTS; DOPAMINE	Different elements of voltage-gated Ca2+ influx and their role for cytosolic-free Ca2+, [Ca2+](i), were studied in cells of the pituitary line GH3B6. Single cell monitoring of [Ca2+](i) with the fluorescent probe indo-1, as well as fast on-line ratio [Ca2+](i) imaging with fura-2, were combined with electrophysiological recordings using the perforated patch configuration of the patch clamp technique. [Ca2+](i) signals are generated by Ca2+ influx both during action potentials and in between. Steady state Ca2+ influx at resting potentials (-60 to -40 mV) was voltage-gated and sensitive to the dihydropyridine antagonist PN 200-110. Ca2+ influx could be demonstrated in physiological conditions as inward Ca2+ currents of maximally 10 pA, which were triggered when stepping up the holding voltage beyond a narrow threshold around -50 mV. Inward currents were well correlated with [Ca2+](i) elevations (R = -0.8; p < 0.001). It is concluded that dihydropyridine-sensitive, low threshold voltage-gated steady state Ca2+ currents, which may be tonically activated at resting potentials, provide for [Ca2+](i) signaling in excitable endocrine cells in a mode that parallels the modulation of Ca2+ influx during action potentials.	UNIV GENEVA, DEPT MED, RECH MED FDN, CH-1211 GENEVA, SWITZERLAND; UNIV BORDEAUX 2, NEUROPHYSIOL LAB, CNRS, URA 1200, F-33076 BORDEAUX, FRANCE; UNIV GENEVA, DIV BIOCHIM CLIN, CH-1211 GENEVA, SWITZERLAND	University of Geneva; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; University of Geneva			Vacher, Pierre/N-2243-2018	VACHER, Pierre/0000-0003-3503-7981; Guerineau, Nathalie/0000-0003-2517-4210				AKERMAN SN, 1991, ENDOCRINOLOGY, V129, P475, DOI 10.1210/endo-129-1-475; ARMSTRONG D, 1987, P NATL ACAD SCI USA, V84, P2518, DOI 10.1073/pnas.84.8.2518; ARMSTRONG DL, 1991, ANN NY ACAD SCI, V635, P26, DOI 10.1111/j.1749-6632.1991.tb36478.x; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; CHIAVAROLI C, 1992, EUR J PHARM-MOLEC PH, V227, P173, DOI 10.1016/0922-4106(92)90125-F; COHEN CJ, 1987, J PHYSIOL-LONDON, V387, P195, DOI 10.1113/jphysiol.1987.sp016570; CORCUFF JB, 1993, J BIOL CHEM, V268, P22313; DEAN PM, 1970, J PHYSIOL-LONDON, V210, P255, DOI 10.1113/jphysiol.1970.sp009207; DOUGLAS WW, 1978, J PHYSIOL-LONDON, V285, P171, DOI 10.1113/jphysiol.1978.sp012565; DUFY B, 1979, SCIENCE, V204, P509, DOI 10.1126/science.107590; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUERINEAU N, 1991, ENDOCRINOLOGY, V129, P409, DOI 10.1210/endo-129-1-409; GUERINEAU N, 1990, FEBS LETT, V276, P111, DOI 10.1016/0014-5793(90)80520-S; HESS P, 1984, NATURE, V311, P538, DOI 10.1038/311538a0; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; ISRAEL JM, 1987, J PHYSIOL-LONDON, V390, P1, DOI 10.1113/jphysiol.1987.sp016682; KIDOKORO Y, 1975, NATURE, V258, P741, DOI 10.1038/258741a0; Lussier B. T., 1993, Society for Neuroscience Abstracts, V19, P1333; MATTESON DR, 1986, J GEN PHYSIOL, V87, P161, DOI 10.1085/jgp.87.1.161; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MOLLARD P, 1991, EUR J PHARM-MOLEC PH, V206, P271, DOI 10.1016/0922-4106(91)90109-U; MOLLARD P, 1988, ENDOCRINOLOGY, V123, P721, DOI 10.1210/endo-123-2-721; MOLLARD P, 1989, BIOCHEM BIOPH RES CO, V164, P1045, DOI 10.1016/0006-291X(89)91775-0; NOWYCKY MC, 1985, P NATL ACAD SCI USA, V82, P2178, DOI 10.1073/pnas.82.7.2178; OSULLIVAN AJ, 1989, EMBO J, V8, P401, DOI 10.1002/j.1460-2075.1989.tb03391.x; OZAWA S, 1981, BRAIN RES, V209, P240, DOI 10.1016/0006-8993(81)91188-4; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; SCHERUBL H, 1991, P ROY SOC B-BIOL SCI, V245, P127, DOI 10.1098/rspb.1991.0098; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; SMITH PA, 1989, NATURE, V342, P550, DOI 10.1038/342550a0; SMITH PA, 1990, FEBS LETT, V261, P187, DOI 10.1016/0014-5793(90)80667-8; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; TALO A, 1990, J GEN PHYSIOL, V96, P1085, DOI 10.1085/jgp.96.5.1085; THELER JM, 1992, J BIOL CHEM, V267, P18110; THELER JM, 1991, J RECEPTOR RES, V11, P627, DOI 10.3109/10799899109066431; VONRUDEN L, 1993, SCIENCE, V262, P1061, DOI 10.1126/science.8235626; WINIGER BP, 1988, BIOCHEM J, V255, P161, DOI 10.1042/bj2550161; ZOREC R, 1991, J GEN PHYSIOL, V97, P473, DOI 10.1085/jgp.97.3.473	40	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25158	25164						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929204				2022-12-27	WOS:A1994PQ49000094
J	AGUIRRE, KM; MCCORMICK, RJ; SCHWARZBAUER, JE				AGUIRRE, KM; MCCORMICK, RJ; SCHWARZBAUER, JE			FIBRONECTIN SELF-ASSOCIATION IS MEDIATED BY COMPLEMENTARY SITES WITHIN THE AMINO-TERMINAL ONE-THIRD OF THE MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA FIBRONECTIN; MATRIX ASSEMBLY DOMAIN; CELL-BINDING DOMAIN; EXTRACELLULAR-MATRIX; MONOCLONAL-ANTIBODY; IONIC-STRENGTH; I COLLAGEN; FRAGMENT; RECEPTOR; MODULES	The formation of a fibrillar fibronectin (FN) extracellular matrix requires self-association of FN dimers. In this report, we show that the major sites for self-association are the amino-terminal repeats I-1-5 and the first type III repeats. Recombinant FNs and fragments were generated by baculovirus expression of cysteine-rich domains and by bacterial expression of type III repeats as fusion proteins with maltose binding protein. When recombinant polypeptides were immobilized on microtiter wells, FN bound to 70-kDa amino-terminal fragment and to fusion proteins containing repeats III1-2 and III1-6 but not to other type III repeats. Similar results were obtained with a gel overlay assay. finding was concentration-dependent and saturable. The amino-terminal binding site for III1-2 was further localized to repeats I-1-5. Therefore, at least two different sites for FN-FN interaction reside near the amino terminus of the molecule. A model for the regulation of FN matrix assembly is proposed based on intramolecular interactions between these amino terminal sites.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Princeton University				Schwarzbauer, Jean/0000-0003-1012-7593	NCI NIH HHS [CA44627] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044627] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; BARRY ELR, 1989, J BIOL CHEM, V264, P4179; BENECKY MJ, 1990, BIOCHEMISTRY-US, V29, P3082, DOI 10.1021/bi00464a027; BUSHUEV VN, 1985, FEBS LETT, V189, P276, DOI 10.1016/0014-5793(85)81039-5; CHERNOUSOV MA, 1987, FEBS LETT, V217, P124, DOI 10.1016/0014-5793(87)81255-3; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; DZAMBA BJ, 1993, J CELL BIOL, V121, P1165, DOI 10.1083/jcb.121.5.1165; EHRISMANN R, 1981, J BIOL CHEM, V256, P4056; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; ERICKSON HP, 1983, J BIOL CHEM, V258, P4539; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; GOSWAMI BB, 1991, BIOTECHNIQUES, V10, P626; HOCKING DC, 1994, J BIOL CHEM, V269, P19183; HOMANDBERG GA, 1986, BIOCHEMISTRY-US, V25, P6917, DOI 10.1021/bi00370a027; ICHIHARATANAKA K, 1992, FEBS LETT, V299, P155, DOI 10.1016/0014-5793(92)80236-A; INGHAM KC, 1988, J BIOL CHEM, V263, P4624; KHAN MY, 1990, BIOCHEM J, V270, P33, DOI 10.1042/bj2700033; KOTELIANSKY VE, 1981, EUR J BIOCHEM, V119, P619, DOI 10.1111/j.1432-1033.1981.tb05652.x; LIMPER AH, 1991, J BIOL CHEM, V266, P9697; MCDONALD JA, 1982, J CELL BIOL, V92, P485, DOI 10.1083/jcb.92.2.485; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCDONALD JA, 1988, ANNU REV CELL BIOL, V4, P183, DOI 10.1146/annurev.cb.04.110188.001151; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; MOSHER DF, 1993, CURR OPIN STRUC BIOL, V3, P214, DOI 10.1016/S0959-440X(05)80155-1; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; ROCCO M, 1987, EMBO J, V6, P2343, DOI 10.1002/j.1460-2075.1987.tb02510.x; ROCCO M, 1984, FEBS LETT, V178, P327, DOI 10.1016/0014-5793(84)80627-4; SCHWARZBAUER JE, 1989, J CELL BIOL, V109, P3445, DOI 10.1083/jcb.109.6.3445; SCHWARZBAUER JE, 1993, MOL BIOL CELL, V4, P941, DOI 10.1091/mbc.4.9.941; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; SJOBERG B, 1987, ARCH BIOCHEM BIOPHYS, V255, P347, DOI 10.1016/0003-9861(87)90402-4; SOTTILE J, 1993, BIOCHEMISTRY-US, V32, P1641, DOI 10.1021/bi00057a031; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; WILLIAMS EC, 1982, J BIOL CHEM, V257, P4973; WU CY, 1993, J BIOL CHEM, V268, P21883	42	137	137	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27863	27868						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961716				2022-12-27	WOS:A1994PV77200017
J	HELAAKOSKI, T; VEIJOLA, J; VUORI, K; REHN, M; CHOW, LT; TAILLONMILLER, P; KIVIRIKKO, KI; PIHLAJANIEMI, T				HELAAKOSKI, T; VEIJOLA, J; VUORI, K; REHN, M; CHOW, LT; TAILLONMILLER, P; KIVIRIKKO, KI; PIHLAJANIEMI, T			STRUCTURE AND EXPRESSION OF THE HUMAN GENE FOR THE ALPHA-SUBUNIT OF PROLYL 4-HYDROXYLASE - THE 2 ALTERNATIVELY SPLICED TYPES OF MESSENGER-RNA CORRESPOND TO 2 HOMOLOGOUS EXONS THE SEQUENCES OF WHICH ARE EXPRESSED IN A VARIETY OF TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; HORMONE-BINDING-PROTEIN; BETA-SUBUNIT; ENDOPLASMIC-RETICULUM; MOLECULAR-CLONING; YEAST; DNA; POLYPEPTIDE; RESIDENT; CLONES	Prolyl 4-hydroxylase, an alpha(2) beta(2) tetramer, plays a central role in collagen synthesis as it catalyzes the formation of 4-hydroxyproline residues by the hydroxylation of proline in X-Pro-Gly sequences. We report here that the human gene for the catalytically important alpha subunit is more than 69 kilobase pairs and consists of 16 exons. The exons that encode solely protein sequences vary from 54 to 240 base pairs (bp), and the introns vary from 750 to more than 16,000 bp. The 133 bp of 5'-untranslated sequences of the mRNA are coded by two exons, and these sequences contain inverted repeats with a potential for stem-loop formation, which may be involved in translational control of the expression of this gene. The 5'-flanking region contains a TATA motif at -29 relative to the major transcription site but no CCAAT motif. The 5'-flanking region and the downstream sequences contain several motifs that may act as binding sites for various transcription factors. Evidence has previously been reported for a mutually exclusive alternative splicing of RNA transcripts of this gene. The present data indicate that the mutually exclusive sequences found in the mRNAs are coded by two consecutive, homologous 71-bp exons 9 and 10. These exons are identical in their first 5 bp and the overall identity between them is 61% at the nucleotide level and 58% at the level of the coded amino acids. Both types of mRNA were found to be expressed in all of the tissues studied, but in some tissues the type coding for exon 9 or 10 sequences was more abundant than the other type.	UNIV OULU, DEPT MED BIOCHEM, SF-90220 OULU, FINLAND; UNIV OULU, BIOCTR, COLLAGEN RES UNIT, SF-90220 OULU, FINLAND; UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA	University of Oulu; University of Oulu; University of Rochester; Washington University (WUSTL)				Pihlajaniemi, Taina/0000-0002-1664-9045	NCI NIH HHS [CA36200] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANAND R, 1990, NUCLEIC ACIDS RES, V18, P1951, DOI 10.1093/nar/18.8.1951; BASSUK JA, 1989, P NATL ACAD SCI USA, V86, P7382, DOI 10.1073/pnas.86.19.7382; Blanchard M M, 1993, PCR Methods Appl, V2, P234; BROWNSTEIN BH, 1989, SCIENCE, V244, P1348, DOI 10.1126/science.2544027; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CHENG SY, 1987, J BIOL CHEM, V262, P11221; CHOW LT, 1981, ELECTRON MICROS, V1, P139; DURSO M, 1993, CLONING YAC VECTORS, P50; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; KAO WWY, 1988, CONNECT TISSUE RES, V18, P157, DOI 10.3109/03008208809016805; KERE J, 1992, GENOMICS, V14, P241, DOI 10.1016/S0888-7543(05)80212-5; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; KIVIRIKKO KI, 1990, ANN NY ACAD SCI, V580, P132, DOI 10.1111/j.1749-6632.1990.tb17925.x; KOIVU J, 1987, J BIOL CHEM, V262, P6447; Maniatis T., 1982, MOL CLONING; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, J BIOL CHEM, V266, P19645; PAJUNEN L, 1989, AM J HUM GENET, V45, P829; PARKKONEN T, 1988, BIOCHEM J, V256, P1005, DOI 10.1042/bj2561005; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; PIHLAJANIEMI T, 1987, METHOD ENZYMOL, V145, P213; POUSTKA A, 1984, P NATL ACAD SCI-BIOL, V81, P4129, DOI 10.1073/pnas.81.13.4129; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TASANEN K, 1988, J BIOL CHEM, V263, P16218; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800	34	23	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27847	27854						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961714				2022-12-27	WOS:A1994PV77200015
J	HUTCHISON, KA; DITTMAR, KD; PRATT, WB				HUTCHISON, KA; DITTMAR, KD; PRATT, WB			ALL OF THE FACTORS REQUIRED FOR ASSEMBLY OF THE GLUCOCORTICOID RECEPTOR INTO A FUNCTIONAL HETEROCOMPLEX WITH HEAT-SHOCK PROTEIN-90 ARE PREASSOCIATED IN A SELF-SUFFICIENT PROTEIN-FOLDING STRUCTURE, A FOLDOSOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGESTERONE-RECEPTOR; HSP90; COMPLEX; EXISTS; HSP70; RECONSTITUTION; ASSOCIATION; CYTOSOL; HSP56	The hormone-binding domain of the glucocorticoid receptor must be bound to heat shock protein (hsp) 90 for it to have a high-affinity steroid binding conformation. We have recently demonstrated that hsp70 is required for cell-fi ee assembly of the receptor hsp90 complex and concomitant activation of steroid binding activity (Hutchison, K.A, Dittmar, K. D., Czar, M. J., and Pratt, W. B. (1994) J. Biol. Chem. 269, 5043-5049). hsp90 and hsp70 are known to exist together in a cytosolic complex containing several other proteins, and in this work we ask if all of the factors required for proper receptor folding and heterocomplex assembly are preassociated in this multiprotein complex. The multiprotein complex was immunoadsorbed to protein A-agarose from rabbit reticulocyte lysate using the 3G3 monoclonal IgM directed against hsp90. When this immunopellet is mixed with immunadsorbed mouse glucocorticoid receptor and incubated at 30 degrees C with ATP/Mg2+ and KCl, the receptor is converted to the steroid binding conformation. When the immunoadsorbed multiprotein hsp90 complex is washed extensively, it loses a weakly bound protein (not hsp70 or hsp90) that is required for receptor activation. This protein factor is contained in a Centricon C-100 filtrate of lysate which reconstitutes the receptor activating activity of the washed hsp90 complex. The hsp90 complex can be released from the 3G3 antibody, and in the presence of the protein factor in the Centricon C-100 filtrate it converts the receptor into a functional heterocomplex with hsp90. The results support the proposal that the various components of reticulocyte lysate that are required to refold the glucocorticoid receptor to the steroid binding state are preassociated with each other, acting as a self-sufficient protein folding machine.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NCI NIH HHS [CA28010] Funding Source: Medline; NIDDK NIH HHS [DK31573] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031573, R01DK031573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RUFF VA, 1992, J BIOL CHEM, V267, P21285; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SCHERRER LC, 1992, BIOCHEMISTRY-US, V31, P7325, DOI 10.1021/bi00147a017; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; YEM AW, 1992, J BIOL CHEM, V267, P2868	18	88	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27894	27899						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961721				2022-12-27	WOS:A1994PV77200022
J	TREMETHICK, DJ				TREMETHICK, DJ			HIGH-MOBILITY GROUP PROTEIN-14 AND PROTEIN-17 CAN SPACE NUCLEOSOMAL PARTICLES DEFICIENT IN HISTONES H2A AND H2B CREATING A TEMPLATE THAT IS TRANSCRIPTIONALLY ACTIVE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; RNA POLYMERASE-II; CHROMATIN STRUCTURE; CHROMOSOMAL-PROTEINS; DNA; INVITRO; CORE; BINDING; COMPLEX; HMG-17	Recently, using a well defined nucleosomal assembly system, we demonstrated that high mobility group proteins (HMGs) 14 and 17 can organize nucleosomes into a regular array with a nucleosomal repeat length of 160-165 base pairs in vitro. Interestingly, such a short repeat length has been described for lower eukaryotes and for active chromatin. To begin to investigate how these proteins may prevent the close packing of nucleosomes, assembly reactions were carried out in which the relative amounts of HMGs 14 and 17, histones H2A and H2B, and the N1/N2-(H3, H4) complex were varied in assembly reactions. Under conditions in which histones H2A and H2B were Limiting and in the absence of HMGs 14 and 17, micrococcal nuclease digestion of the assembled product produced a ladder of DNA fragments that was much less well defined and which included DNA that was associated with subnucleosomal structures. The apparent repeat length for this chromatin template was around 125 base pairs. Most interestingly, when HMGs 14 and 17 were added to this assembly reaction, ''nucleosome-like'' structures were reassembled as shown by the restoration of a regular, well defined ladder of DNA fragments upon micrococcal nuclease digestion. The apparent repeat length increased from 125 to approximately 145 base pairs. Analysis of the protein composition of chromatin formed in the presence or absence of HMGs 14 and 17 reveals that HMGs 14 and 17 might be able to substitute for a histone H2A-H2B dimer in a H2A/H2B-deficient nucleosome. The ability to form a regularly spaced nucleosomal template is also lost when excess HMGs 14 and 17 are used in assembly reactions. Spacing can be restored by the addition of poly(glutamate,alanine), a chemical polymer of negative charge, which may indicate that carrier proteins (specific or nonspecific) may be required for the proper incorporation of all chromatin assembly components into chromatin in vivo. Finally, although the mechanism of action is not known, HMGs 14 and 17 can partially overcome inhibition of initiation of transcription caused by the formation of nucleosomal particles deficient in histones H2A and H2B.			TREMETHICK, DJ (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,POB 334,CANBERRA,ACT 2601,AUSTRALIA.			Tremethick, David/0000-0001-5274-8078				ALBRIGHT SC, 1980, J BIOL CHEM, V255, P3673; ALMOUZNI G, 1990, NUCLEIC ACIDS RES, V18, P5767, DOI 10.1093/nar/18.19.5767; ALMOUZNI G, 1991, MOL CELL BIOL, V11, P655, DOI 10.1128/MCB.11.2.655; BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; BRAWLEY JV, 1992, BIOCHEMISTRY-US, V31, P364, DOI 10.1021/bi00117a008; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; COOK GR, 1986, J BIOL CHEM, V261, P6185; CRIPPA MP, 1992, J MOL BIOL, V228, P442, DOI 10.1016/0022-2836(92)90833-6; CRIPPA MP, 1993, EMBO J, V12, P3855, DOI 10.1002/j.1460-2075.1993.tb06064.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; DREW HR, 1993, J MOL BIOL, V230, P824, DOI 10.1006/jmbi.1993.1204; EINICK L, 1985, EXP CELL RES, V156, P295; ESPEL E, 1987, BIOCHIM BIOPHYS ACTA, V909, P190, DOI 10.1016/0167-4781(87)90077-7; FARNHAM PJ, 1986, MOL CELL BIOL, V6, P2392, DOI 10.1128/MCB.6.7.2392; GODDE JS, 1992, J MOL BIOL, V226, P1009, DOI 10.1016/0022-2836(92)91049-U; GONZALEZ PJ, 1990, J BIOL CHEM, V265, P8225; HANSEN JC, 1994, P NATL ACAD SCI USA, V91, P2339, DOI 10.1073/pnas.91.6.2339; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HAYES JJ, 1994, IN PRESS P NATL ACAD; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1993, PHILOS T ROY SOC B, V339, P263, DOI 10.1098/rstb.1993.0024; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; MARDIAN JKW, 1980, SCIENCE, V209, P1534, DOI 10.1126/science.7433974; PRUSS D, 1993, BIOCHEMISTRY-US, V32, P6810, DOI 10.1021/bi00078a002; SASI R, 1982, J BIOL CHEM, V257, P1448; SEALE RL, 1983, BIOCHEMISTRY-US, V22, P5008, DOI 10.1021/bi00290a020; SHICK VV, 1985, J MOL BIOL, V185, P329, DOI 10.1016/0022-2836(85)90407-3; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; THOMAS JO, 1976, FEBS LETT, V66, P274, DOI 10.1016/0014-5793(76)80521-2; TREMETHICK DJ, 1992, J BIOL CHEM, V267, P15041; TREMETHICK DJ, 1986, J BIOL CHEM, V261, P6986; TREMETHICK DJ, 1993, J BIOL CHEM, V268, P11389; VILLEPONTEAU B, 1992, BIOCHEMISTRY-US, V31, P1554, DOI 10.1021/bi00120a037; WEISBROD S, 1981, CELL, V23, P391, DOI 10.1016/0092-8674(81)90134-3; WOLFFE A P, 1990, New Biologist, V2, P211; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZUCKER K, 1990, J BIOL CHEM, V265, P14487	38	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28436	28442						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961785				2022-12-27	WOS:A1994PV77200097
J	HAATAJA, S; TIKKANEN, K; NILSSON, U; MAGNUSSON, G; KARLSSON, KA; FINNE, J				HAATAJA, S; TIKKANEN, K; NILSSON, U; MAGNUSSON, G; KARLSSON, KA; FINNE, J			OLIGOSACCHARIDE-RECEPTOR INTERACTION OF THE GAL-ALPHA-1-4GAL BINDING ADHESIN OF STREPTOCOCCUS-SUIS - COMBINING SITE ARCHITECTURE AND CHARACTERIZATION OF 2 VARIANT ADHESIN SPECIFICITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ERYTHROCYTES; MANNOSE; TOXIN; VEROTOXIN-1; GALABIOSE; BACTERIA; PROTEINS; LECTINS; ANTIGEN	The sugar binding specificities of two groups of Streptococcus suis, a pig pathogen that causes meningitis also in man, were determined. Both the group represented by a recently characterized strain inhibitable by galactose and N-acetylgalactosamine (type P-N) and the group inhibitable by galactose (type P-O) were found by hemagglutination and solid-phase binding inhibition experiments to recognize the disaccharide Gal alpha 1-4Gal of the P-1 and P-k blood group antigens. Both types preferred the disaccharide in terminal position. P-N showed some, whereas P-O showed almost no, binding to the globoside oligosaccharide containing an additional GalNAc beta 1-3 residue. The complete hydrogen bonding patterns were determined by using deoxy and other synthetic derivatives of the receptor disaccharide, and the constructed models of the interactions were compared with that of Escherichia coli PapG(396) adhesin. The essential hydroxyls for binding were the HO-4', HO-6', HO-2, and HO-3 hydroxyls on the beta' alpha-side of the Gal alpha 1-4Gal molecule. Type P, adhesin also formed weak interactions with the hydroxyls HO-6 and HO-3'. The mechanism differed from that of E. coli, which binds to a cluster of five hydroxyls (HO-6, HO-2', HO-3', HO-4', and HO-6') and thus to a different part of the receptor disaccharide. These results represent the first example of the comparison of the saccharide receptor hydrogen bonding patterns of two bacterial organisms of different origin and show that the same saccharide may be recognized by two different binding mechanisms.	UNIV TURKU,INST BIOMED,DEPT CHEM,SF-20520 TURKU,FINLAND; UNIV KUOPIO,DEPT BIOCHEM & BIOTECHNOL,SF-70211 KUOPIO,FINLAND; LUND UNIV,LUND INST TECHNOL,S-22100 LUND,SWEDEN; GOTHENBURG UNIV,DEPT MED BIOCHEM,S-41390 GOTHENBURG,SWEDEN	University of Turku; University of Eastern Finland; Lund University; University of Gothenburg	HAATAJA, S (corresponding author), UNIV TURKU,INST BIOMED,DEPT MED BIOCHEM,SF-20520 TURKU,FINLAND.		Haataja, Sauli/AAR-5103-2020; Nilsson, Ulf J./L-3219-2014; Finne, Jukka/B-6881-2008	Nilsson, Ulf J./0000-0001-5815-9522; Finne, Jukka/0000-0002-8076-3344				ANGSTROM J, 1986, ARCH BIOCHEM BIOPHYS, V251, P440, DOI 10.1016/0003-9861(86)90350-4; ANIANSSON G, 1990, MICROB PATHOGENESIS, V8, P315, DOI 10.1016/0882-4010(90)90090-D; ARENDS JP, 1988, REV INFECT DIS, V10, P131; BHATTACHARYYA L, 1988, EUR J BIOCHEM, V176, P207, DOI 10.1111/j.1432-1033.1988.tb14270.x; BOYD B, 1993, J EXP MED, V177, P1745, DOI 10.1084/jem.177.6.1745; BURKERT U, 1982, YIU MONOGRAPH, V177; DAHMEN J, 1984, CARBOHYD RES, V129, P63, DOI 10.1016/0008-6215(84)85299-4; DEGRANDIS S, 1989, J BIOL CHEM, V264, P12520; FIRON N, 1982, BIOCHEM BIOPH RES CO, V105, P1426, DOI 10.1016/0006-291X(82)90947-0; FRANCOISGERARD C, 1979, BIOCHEM J, V177, P679, DOI 10.1042/bj1770679; FRICK IM, 1992, P NATL ACAD SCI USA, V89, P8532, DOI 10.1073/pnas.89.18.8532; Gray G R, 1978, Methods Enzymol, V50, P155; HAATAJA S, 1993, J BIOL CHEM, V268, P4311; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; KARLSSON KA, 1987, METHOD ENZYMOL, V138, P212; KIHLBERG J, 1989, J AM CHEM SOC, V111, P6364, DOI 10.1021/ja00198a056; KORHONEN TK, 1985, ENTEROBACTERIAL SURF, P301; KURL DN, 1989, INFECT IMMUN, V57, P384, DOI 10.1128/IAI.57.2.384-389.1989; LEE RT, 1991, J BIOL CHEM, V266, P4810; LEMIEUX RU, 1989, CHEM SOC REV, V18, P347, DOI 10.1039/cs9891800347; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; MARCUS DM, 1976, P NATL ACAD SCI USA, V73, P3263, DOI 10.1073/pnas.73.9.3263; MATROSOVICH MN, 1989, FEBS LETT, V252, P1, DOI 10.1016/0014-5793(89)80879-8; NILSSON U, 1994, ACTA CHEM SCAND, V48, P356, DOI 10.3891/acta.chem.scand.48-0356; NILSSON U, 1994, CARBOHYD RES, V252, P137; NILSSON U, 1994, CARBOHYD RES, V252, P117; NOWICKI B, 1985, FEMS MICROBIOL LETT, V26, P35; PAULSEN H, 1988, CARBOHYD RES, V175, P163, DOI 10.1016/0008-6215(88)80168-X; Race RR., 1975, BLOOD GROUPS MAN; SIHVONEN L, 1988, ACTA VET SCAND, V29, P9; Stahl E., 1962, DUNNSCHICHTCHROMATOG; STROMBERG N, 1990, EMBO J, V9, P2001, DOI 10.1002/j.1460-2075.1990.tb08328.x; STROMBERG N, 1991, P NATL ACAD SCI USA, V88, P9340, DOI 10.1073/pnas.88.20.9340; SVENSSON G, 1986, CARBOHYD RES, V146, P29, DOI 10.1016/0008-6215(86)85021-2; YIU SCK, 1992, ANAL BIOCHEM, V202, P188, DOI 10.1016/0003-2697(92)90226-W	35	54	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27466	27472						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961660				2022-12-27	WOS:A1994PV77100050
J	KINANE, TB; FINDER, JD; KAWASHIMA, A; BROWN, D; ABBATE, M; SHANG, C; FREDERICKS, WJ; RAUSCHER, FJ; SUKHATME, VP; ERCOLANI, L				KINANE, TB; FINDER, JD; KAWASHIMA, A; BROWN, D; ABBATE, M; SHANG, C; FREDERICKS, WJ; RAUSCHER, FJ; SUKHATME, VP; ERCOLANI, L			GROWTH OF LLC-PK1 RENAL-CELLS IS MEDIATED BY EGR-1 UP-REGULATION OF G-PROTEIN ALPHA-I-2 PROTOONCOGENE TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC FINGER PROTEIN; MULTICELLULAR DEVELOPMENT; SIGNAL TRANSDUCTION; GENE PROMOTER; SUBUNIT; IDENTIFICATION; DICTYOSTELIUM; PRODUCT; DIFFERENTIATION; LOCALIZATION	The early growth response zinc finger transcription factor (EGR-1) and the heterotrimeric guanine nucleotide binding protein encoded by the protooncogene G alpha i-2 each play pivotal roles in signaling pathways that control cell growth and differentiation. The G alpha i-2 gene 5'-flanking region contains a putative binding site (5'-CGCCCCCGC-3') for EGR-1 that may allow it to be a target gene for EGR-1 mitogenic signaling. We now demonstrate in LLC-PK1 renal cells the temporal expression of EGR-1 protein by immunoblotting and immunocytochemistry coincident with the maximal activation of the G alpha i-2 gene during cell growth. To determine whether G alpha i-2 or EGR-1 influence epithelial cell growth, LLC-PK1 cells were transiently transfected with plasmids encoding cDNAs for G alpha i-2 (pRSV G alpha i-2) or EGR-1 (pRSV EGR-1) driven by a viral Rous sarcoma promoter enhancer to overexpress each protein. Following transfection, cell growth was examined in media containing either 10 or 0.1% fetal bovine serum. Only cells transfected with plasmids encoding G alpha i-2 and EGR-1 had growth rates greater than that of serum replete cohorts. To assess whether EGR-1 was contributing to the transcriptional activation of the G alpha i-2 gene, cells were cotransfected with pRSV EGR-1 and plasmids encoding firefly luciferase reporter genes fused to 5'-flanking areas of the G alpha i-2 gene containing either the EGR-1 binding site or a mutated EGR-1 binding site (5'-AAAAACCGC-3'). A 320% enhancement of G alpha i-2 transcription was found only in LLC-PK1 cells following their transfection with plasmids that contained both the EGR-1 binding site and overexpressed EGR-1 protein. Utilizing mobility shift assays, which compared nuclear extracts from cells before and after cell polarization, a probe containing the EGR-1 motif detected induced nuclear protein complexes during transcriptional activation of the G alpha i-2 gene. An anti-EGR-1 antibody specifically retarded the mobility of the induced nuclear complexes, indicating that the EGR-1 protein was a component of these complexes. These data provide direct evidence for a novel mitogenic signaling pathway coupling proximal signaling events that activate EGR-1 gene expression to a target protooncogene G alpha i-2 that is participatory for growth and differentiation in renal cells.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT MED,RENAL UNIT,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT PEDIAT,PEDIAT PULM UNIT,BOSTON,MA 02114; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,RENAL UNIT,BOSTON,MA 02114	The Wistar Institute; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School			Sukhatme, Vikas/W-2776-2019; Finder, Jonathan/AAB-2651-2021	Shang, Charles/0000-0003-4450-9557	NIDDK NIH HHS [F32 DK-08838, DK-02271, DK-42543] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008838, R01DK042543, K08DK002271] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBAUMER L, 1990, CRIT REV BIOCHEM MOL, V25, P225, DOI 10.3109/10409239009090610; BONVENTRE JV, 1991, CELL REGUL, V2, P251, DOI 10.1091/mbc.2.3.251; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; FIRTEL RA, 1989, CELL, V58, P235, DOI 10.1016/0092-8674(89)90837-4; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUPTA MP, 1991, J BIOL CHEM, V266, P12813; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HADWIGER JA, 1991, P NATL ACAD SCI USA, V88, P8213, DOI 10.1073/pnas.88.18.8213; HADWIGER JA, 1992, GENE DEV, V6, P38, DOI 10.1101/gad.6.1.38; HOLTZMAN EJ, 1991, J BIOL CHEM, V266, P1763; HOLTZMAN EJ, 1993, J BIOL CHEM, V268, P3964; KINANE TB, 1993, J BIOL CHEM, V268, P24669; LAMORTE VJ, 1992, J BIOL CHEM, V267, P691; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MOXHAM CM, 1992, SCIENCE, V258, P1373; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; OUELLETE AJ, 1990, J CLIN INVEST, V85, P755; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; SAATCIOGLU F, 1990, J BIOL CHEM, V265, P9251; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; WATKINS DC, 1993, SCIENCE, V260, P991	30	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27503	27509						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961665				2022-12-27	WOS:A1994PV77100055
J	BUSH, AI; PETTINGELL, WH; DEPARADIS, M; TANZI, RE; WASCO, W				BUSH, AI; PETTINGELL, WH; DEPARADIS, M; TANZI, RE; WASCO, W			THE AMYLOID BETA-PROTEIN PRECURSOR AND ITS MAMMALIAN HOMOLOGS - EVIDENCE FOR A ZINC-MODULATED HEPARIN-BINDING SUPERFAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ALZHEIMERS-DISEASE; HUMAN PLATELETS; PURIFICATION; CDNA; GENE; EXPRESSION	The Alzheimer beta-amyloid precursor protein (APP) contains an ectodomain zinc binding site that has been reported to modulate the heparin affinity and protease-inhibitory properties of the molecule. This motif, GVEFVCCP, is highly conserved in amyloid precursor-like proteins 1 and 2 (APLP1 and APLP2), as well as in the Drosophila and Caenorhabditis elegans APP-like proteins (APPL and APL-1). To determine whether the function of this domain is preserved in the human APP-like proteins, the effect of zinc in modulating the elution profile of these proteins upon heparin-Sepharose chromatography was studied. Both APLP1 and APLP2 bound heparin-Sepharose and had NaCl elution profiles similar to that of APP. As previously reported for APP, zinc increased the recovery of APLP1 and APLP2 upon heparin-Sepharose chromatography. APP, APLP1, and APLP2 all bind zinc-chelating Sepharose, indicating that the zinc binding motif may be functionally conserved in these proteins. Additionally, APP, APLP1, and APLP2 migrate at higher molecular sizes (approximate to 40 kDa) on SDS-polyacrylamide gel electrophoresis than their predicted molecular sizes. We report data that compare the physicochemical properties of APP to its novel APLP homologues and indicate that these molecules behave as a family of zinc-modulated, heparin-binding proteins.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,GENET & AGING LAB,BOSTON,MA 02129	Harvard University; Harvard Medical School; Massachusetts General Hospital			Bush, Ashley I/A-1186-2007; Bush, Ashley/Y-2457-2019; Tanzi, Rudolph/AAE-9622-2019	Bush, Ashley I/0000-0001-8259-9069; Bush, Ashley/0000-0001-8259-9069; Tanzi, Rudolph/0000-0002-7032-1454; Paradis, Marc d./0000-0003-2387-3157	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030428] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011899] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG11899-01] Funding Source: Medline; NINDS NIH HHS [R01 NS30428-03] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BUSH AI, 1992, ANN NEUROL, V32, P57, DOI 10.1002/ana.410320110; BUSH AI, 1994, J BIOL CHEM, V269, P12152; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; BUSH AI, 1990, J BIOL CHEM, V265, P15977; BUSH AI, 1993, J BIOL CHEM, V268, P16109; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; DAIGLE I, 1993, P NATL ACAD SCI USA, V90, P12045, DOI 10.1073/pnas.90.24.12045; DYRKS T, 1992, J BIOL CHEM, V267, P18210; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KOMIYAMA Y, 1992, THROMB RES, V66, P397, DOI 10.1016/0049-3848(92)90289-M; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; MOIR RD, 1992, J NEUROCHEM, V59, P1490, DOI 10.1111/j.1471-4159.1992.tb08465.x; MULTHAUP G, 1994, AMYLOID PROTEIN PREC, P76; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; ROCH JM, 1992, J BIOL CHEM, V267, P2214; ROSEN DR, 1989, P NATL ACAD SCI USA, V86, P2478, DOI 10.1073/pnas.86.7.2478; SAITO F, 1993, MOL BRAIN RES, V19, P171, DOI 10.1016/0169-328X(93)90164-K; SCHUBERT D, 1989, P NATL ACAD SCI USA, V86, P2066, DOI 10.1073/pnas.86.6.2066; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; SMALL DH, 1994, J NEUROSCI, V14, P2117; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; 1991, PROGRAM MANUAL GCG P	31	111	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26618	26621						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929392				2022-12-27	WOS:A1994PQ93100008
J	MACMILLAN, DK; HILL, E; SALA, A; SIGAL, E; SHUMAN, T; HENSON, PM; MURPHY, RC				MACMILLAN, DK; HILL, E; SALA, A; SIGAL, E; SHUMAN, T; HENSON, PM; MURPHY, RC			EOSINOPHIL 15-LIPOXYGENASE IS A LEUKOTRIENE A(4) SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID METABOLISM; POLYMORPHONUCLEAR LEUKOCYTES; MAMMALIAN LIPOXYGENASES; MEMBRANE ASSOCIATION; A4-SYNTHASE ACTIVITY; GAS-CHROMATOGRAPHY; 5-LIPOXYGENASE; CELLS; PURIFICATION; 12-LIPOXYGENASE	5-Lipoxygenase is the first committed enzyme in the leukotriene biosynthetic pathway and is known to catalyze not only the first oxygenation of arachidonate to form 5(S)-hydroperoxyeicosatetraenoic acid (5(S)-HPETE), but also dehydration of this intermediate into leukotriene A(4) (LTA(4)) by an activity termed leukotriene A(4) synthase. Inhibition of cytosolic B-lipoxygenase prepared from human blood granulocytes with zileuton (100 mu m) was virtually complete, but LTA(4) synthase activity was only inhibited by 47%. Structural characterization of eicosanoids synthesized in these preparations revealed an abundance of 15-lipoxygenase metabolites including 15-HETE when arachidonate was used as substrate and 5(S),15(S)-dihydroxy-6,8,11,13(E,E,Z,Z) satetraenoic acid when 5(S)-HPETE was used as substrate. When neutrophils were prepared that contained less than 1% eosinophil contamination, zileuton was found to almost completely inhibit all 5-lipoxygenase, as well as LTA(4) synthase products. Immunochemical analysis of the supernatants from purified neutrophils and eosinophils confirmed the previous observation that neutrophils do not express 15-lipoxygenase. Incubation of 5(S)-HPETE with recombinant mammalian 15-lipoxygenase resulted in the formation of B-trans-LTB(4) and 6-trans-12-epi-LTB(4) as LTA(4) products, as well as the 12 lipoxygenase product 5(S),12(S) diHPETE. The mechanism of action of 15-lipoxygenase acting as an LTA(4) synthase is proposed to involve removing the pro-R hydrogen atom at carbon-10 of 5(S)-HPETE, which is antarafacial to the hydroperoxy group to yield LTA(4).	NATL JEWISH CTR IMMUNOL & RESP MED, DENVER, CO 80206 USA; SYNTEX INC, DISCOVERY RES, PALO ALTO, CA 94303 USA	National Jewish Health; Syntex Corporation			Sala, Angelo/H-5478-2019; Murphy, Robert/AAO-5349-2020	Murphy, Robert/0000-0002-9430-6515; MacMillan, Denise/0000-0002-8424-6651; Sala, Angelo/0000-0001-9290-0257	NHLBI NIH HHS [HL34303] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALAZY M, 1986, ANAL CHEM, V58, P1098, DOI 10.1021/ac00297a026; BORGEAT P, 1988, PROSTAGLANDINS, V35, P723, DOI 10.1016/0090-6980(88)90145-1; BORGEAT P, 1979, J BIOL CHEM, V254, P2643; CARTER GW, 1991, J PHARMACOL EXP THER, V256, P929; DIXON RAF, 1988, P NATL ACAD SCI USA, V85, P416, DOI 10.1073/pnas.85.2.416; HADA T, 1991, BIOCHIM BIOPHYS ACTA, V1083, P89, DOI 10.1016/0005-2760(91)90128-5; HASLETT C, 1985, AM J PATHOL, V119, P101; HILL E, 1992, J BIOL CHEM, V267, P22048; HILL E, 1994, IN PRESS ADV PROSTAG; KUHN H, 1993, BIOCHIM BIOPHYS ACTA, V1169, P80, DOI 10.1016/0005-2760(93)90085-N; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAAS RL, 1982, J BIOL CHEM, V257, P7056; MCGUIRE J, 1985, J BIOL CHEM, V260, P8316; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; MORITA E, 1990, SCAND J IMMUNOL, V32, P497, DOI 10.1111/j.1365-3083.1990.tb03190.x; MURPHY RC, 1979, P NATL ACAD SCI USA, V76, P4275, DOI 10.1073/pnas.76.9.4275; MURPHY RC, 1992, TREATISE PULMONARY T, V1, P427; NADEL JA, 1991, J CLIN INVEST, V87, P1139, DOI 10.1172/JCI115110; RADMARK O, 1984, BIOCHIM BIOPHYS ACTA, V792, P324, DOI 10.1016/0005-2760(84)90200-5; REDDANNA P, 1990, METHOD ENZYMOL, V187, P268; ROUZER CA, 1987, P NATL ACAD SCI USA, V84, P7393, DOI 10.1073/pnas.84.21.7393; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SCOTT WA, 1982, J EXP MED, V155, P1148, DOI 10.1084/jem.155.4.1148; SHIMIZU T, 1986, P NATL ACAD SCI USA, V83, P4175, DOI 10.1073/pnas.83.12.4175; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V150, P376, DOI 10.1016/0006-291X(88)90531-1; SIGAL E, 1990, J BIOL CHEM, V265, P5113; SIGAL E, 1991, AM J PHYSIOL, V260, pL13, DOI 10.1152/ajplung.1991.260.2.L13; SIGAL E, 1988, J BIOL CHEM, V263, P5328; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; SOK DE, 1983, BIOCHEM BIOPH RES CO, V110, P273, DOI 10.1016/0006-291X(83)91291-3; TAKAHASHI Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P613, DOI 10.1016/0003-9861(88)90294-9; VANDERDONK EMM, 1992, BIOCHIM BIOPHYS ACTA, V1128, P14, DOI 10.1016/0005-2760(92)90252-Q; VANDERHOEK JY, 1984, J BIOL CHEM, V259, P6752; VANOS CPA, 1981, BIOCHIM BIOPHYS ACTA, V663, P177, DOI 10.1016/0005-2760(81)90204-6; WALSTRA P, 1987, BIOCHEM BIOPH RES CO, V149, P258, DOI 10.1016/0006-291X(87)91633-0; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WISEMAN JS, 1987, BIOCHEMISTRY-US, V26, P5684, DOI 10.1021/bi00392a016; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9	38	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26663	26668						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929400				2022-12-27	WOS:A1994PQ93100016
J	NORREGAARD, A; VILSEN, B; ANDERSEN, JP				NORREGAARD, A; VILSEN, B; ANDERSEN, JP			TRANSMEMBRANE SEGMENT M3 IS ESSENTIAL TO THAPSIGARGIN SENSITIVITY OF THE SARCOPLASMIC-RETICULUM CA2+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CA2+ TRANSPORT ATPASE; FUNCTIONAL CONSEQUENCES; ALPHA-SUBUNIT; AMINO-ACIDS; CA-2+-ATPASE; INHIBITION; NA+,K+-ATPASE; PHOSPHORYLATION; MUTATIONS; DOMAIN	Five different chimeric fusion proteins between the sarcoplasmic reticulum Ca2+-ATPase and the rat kidney alpha 1 isoform of the Na+,K+-ATPase were expressed in COS-1 cells and analyzed functionally. In two chimeras, the only Na+,K+-ATPase-derived part consisted of the region corresponding to the third transmembrane segment. These proteins phosphorylated from ATP in the presence of a high Ca2+ concentration and from P-i in the absence of Ca2+, but the phosphorylation displayed strongly reduced sensitivity to inhibition by thapsigargin. In two other chimeras, the N-terminal two-thirds of the molecule were derived from Na+,K+-ATPase, except the region containing the fourth transmembrane segment. These proteins were unable to phosphorylate from ATP but phosphorylated from P-i, the latter reaction being insensitive to inhibition by thapsigargin. In the last chimera, the N-terminal two-thirds of the molecule were derived from Na+,K+-ATPase, except the region corresponding to both the third and the fourth transmembrane segments. This chimera phosphorylated from P-i in a reaction that was fully sensitive to inhibition by thapsigargin. It can be concluded that the third transmembrane segment is indispensable to thapsigargin sensitivity of the Ca2+-ATPase and most likely, therefore, constitutes a major binding region for thapsigargin.	AARHUS UNIV,INST PHYSIOL,DANISH BIOMEMBRANE RES CTR,DK-8000 AARHUS C,DENMARK	Aarhus University				Andersen, Jens Peter/0000-0003-0654-4300; Vilsen, Bente/0000-0002-4727-9382				ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; DEJESUS F, 1993, FEBS LETT, V332, P229, DOI 10.1016/0014-5793(93)80638-B; DEMEIS L, 1992, FEBS LETT, V299, P33, DOI 10.1016/0014-5793(92)80093-V; GREEN NM, 1989, BIOCHEM SOC T, V17, P972, DOI 10.1042/bst0170972; ISHII T, 1993, P NATL ACAD SCI USA, V90, P8881, DOI 10.1073/pnas.90.19.8881; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; NORREGAARD A, 1993, FEBS LETT, V336, P248, DOI 10.1016/0014-5793(93)80813-A; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUMBILLA C, 1993, J BIOL CHEM, V268, P21185; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VILSEN B, 1992, FEBS LETT, V314, P301, DOI 10.1016/0014-5793(92)81494-7; VILSEN B, 1989, J BIOL CHEM, V264, P21024; Witcome M., 1992, BIOCHEM J, V283, P525	22	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26598	26601						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929387				2022-12-27	WOS:A1994PQ93100003
J	KAWAMURA, K; WATANABE, K; SUZUKI, T; YAMAKAWA, T; KAMIYAMA, T; NAKAGAWA, H; TSURUFUJI, S				KAWAMURA, K; WATANABE, K; SUZUKI, T; YAMAKAWA, T; KAMIYAMA, T; NAKAGAWA, H; TSURUFUJI, S			CDNA CLONING AND EXPRESSION OF A NOVEL HUMAN DESMOCOLLIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; TUMOR-NECROSIS-FACTOR; DESMOSOMAL CADHERINS; CYTOPLASMIC DOMAINS; HUMAN KERATINOCYTES; CHEMOTACTIC FACTOR; ACTIVATING FACTOR; MESSENGER-RNA; FAMILY; TYPE-1	We have cloned a human cDNA encoding for a novel transmembrane protein from a bladder carcinoma cell line (HT-1376) cDNA library. Sequence analysis of this clone revealed an open reading frame of 2,691 bases encoding a protein of 896 amino acids. Sequence comparison showed that this clone has significant homology to desmocollins, intercellular adhesion molecules belonging to the cadherin superfamily. This protein consists of a signal peptide of 30 amino acids, a precursor segment of 105 amino acids, and a mature protein of 761 amino acids. We expressed this cDNA clone in COS1 cells and found that the predicted cell adhesion molecule remained in the membrane fraction. Antibodies recognizing the predicted mature adhesion molecule of the protein stained antigens along the cell boundaries of both HT-1376 cells and normal human keratinocytes resembling the pattern of desmosome localization. These findings suggest that our clone might be a new member of the desmocollin family, and we have tentatively called this clone human desmocollin type 4.	INST CYTOSIGNAL RES INC,SHINAGAWA KU,TOKYO 140,JAPAN; TOYAMA MED & PHARMACEUT UNIV,FAC PHARMACEUT SCI,SUGITANI,TOYAMA 93001,JAPAN	University of Toyama								ANSEL J, 1990, J INVEST DERMATOL, V94, P101; BUXTON RS, 1993, J CELL BIOL, V121, P481, DOI 10.1083/jcb.121.3.481; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN SM, 1983, J BIOL CHEM, V258, P2621; COLDITZ I, 1989, AM J PATHOL, V134, P755; COLLINS JE, 1991, J CELL BIOL, V113, P381, DOI 10.1083/jcb.113.2.381; COWIN P, 1984, J CELL SCI, V70, P41; COWIN P, 1983, NATURE, V302, P148, DOI 10.1038/302148a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GAWKRODGER DJ, 1987, J INVEST DERMATOL, V88, P3469; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; KAPLAN G, 1986, P NATL ACAD SCI USA, V83, P3469, DOI 10.1073/pnas.83.10.3469; KING IA, 1993, GENOMICS, V18, P185, DOI 10.1006/geno.1993.1453; KOCH PJ, 1992, P NATL ACAD SCI USA, V89, P353, DOI 10.1073/pnas.89.1.353; KUPPER TS, 1986, J EXP MED, V164, P2095, DOI 10.1084/jem.164.6.2095; MANSOURI A, 1988, DIFFERENTIATION, V38, P67, DOI 10.1111/j.1432-0436.1988.tb00593.x; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MECHANIC S, 1991, P NATL ACAD SCI USA, V88, P4476, DOI 10.1073/pnas.88.10.4476; NICKOLOFF BJ, 1991, AM J PATHOL, V138, P129; OZAWA M, 1990, J CELL BIOL, V111, P1645, DOI 10.1083/jcb.111.4.1645; PARKER AE, 1991, J BIOL CHEM, V266, P10438; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARZ MA, 1990, ANNU REV CELL BIOL, V6, P461, DOI 10.1146/annurev.cb.06.110190.002333; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THEIS DG, 1993, INT J DEV BIOL, V37, P101; TROYANOVSKY SM, 1993, CELL, V72, P561, DOI 10.1016/0092-8674(93)90075-2; TURCK M, 1964, J CLIN INVEST, V41, P1760; WADA KN, 1990, NUCLEIC ACIDS RES, V18, P2367, DOI 10.1093/nar/18.suppl.2367; WATANABE K, 1987, BIOCHEM BIOPH RES CO, V149, P989, DOI 10.1016/0006-291X(87)90506-7; WATANABE K, 1989, J BIOL CHEM, V264, P19559; WATANABE K, 1991, EXP MOL PATHOL, V55, P30, DOI 10.1016/0014-4800(91)90016-Q; YOSHIDA C, 1982, CELL, V28, P217, DOI 10.1016/0092-8674(82)90339-7; YOSHIDANORO C, 1984, DEV BIOL, V101, P19, DOI 10.1016/0012-1606(84)90112-X	35	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26295	26302						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929347				2022-12-27	WOS:A1994PQ93000056
J	TSANEVA, IR; WEST, SC				TSANEVA, IR; WEST, SC			TARGETED VERSUS NON-TARGETED DNA HELICASE ACTIVITY OF THE RUVA AND RUVB PROTEINS OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINATION FACTOR-RHO; SYNTHETIC HOLLIDAY JUNCTIONS; BRANCH MIGRATION; FUNCTIONAL INTERACTIONS; GENETIC-RECOMBINATION; RECA PROTEIN; K-12 REVEALS; REPAIR; RESOLUTION; INVITRO	The RuvA and RuvB proteins of Escherichia coli promote the branch migration of Holliday junctions in vitro. To understand the relationship between branch migration and the intrinsic 5' --> 3' DNA helicase activity of RuvAB, the requirements and substrate specificity of the helicase reaction have been studied in more detail. We find that RuvAB-mediated DNA unwinding and branch migration reactions show similar requirements for Mg2+ and ATP and are inhibited to a similar extent by ADP and ATP gamma S (adenosine 5'-O-(3-thiotriphosphate)). The helicase activity, measured by the dissociation of a short fragment from circular single-stranded DNA, requires both RuvA and RuvB and is stimulated by subsaturating concentrations of single-strand binding protein (SSB). In contrast, saturating concentrations of SSB are inhibitory. Using substrates that contain a DNA junction, which permits the specific binding of RuvA, we find that the RuvA and RuvB proteins promote two types of helicase reactions: nonspecific reactions, which are sensitive to inhibition by stoichiometric amounts of SSB, and junction-targeted reactions, which are not inhibited by SSB. Using three-armed structures, we observe that junction-targeted reactions display a polarity and result in asymmetric product formation. Junction-specific binding and the subsequent initiation of DNA unwinding are Likely to represent early steps in the process of branch migration.	IMPERIAL CANC RES FUND, CLARE HALL LABS, S MIMMS EN6 3LD, HERTS, ENGLAND					West, Stephen/0000-0001-8848-9418				BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BENSON FE, 1988, NUCLEIC ACIDS RES, V16, P1541, DOI 10.1093/nar/16.4.1541; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; CONNOLLY B, 1990, P NATL ACAD SCI USA, V87, P8476, DOI 10.1073/pnas.87.21.8476; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; DUNDERDALE HJ, 1994, J BIOL CHEM, V269, P5187; DUNDERDALE HJ, 1994, CURR OPIN GENET DEV, V4, P221, DOI 10.1016/S0959-437X(05)80048-6; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P121, DOI 10.1021/bi00116a018; GEISELMANN J, 1992, PROTEIN SCI, V1, P861, DOI 10.1002/pro.5560010704; GOGOL EP, 1991, J MOL BIOL, V221, P1127, DOI 10.1016/0022-2836(91)80116-C; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; LLOYD RG, 1993, EMBO J, V12, P17, DOI 10.1002/j.1460-2075.1993.tb05627.x; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1988, TRENDS BIOCHEM SCI, V13, P250; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1991, PROG NUCLEIC ACID RE, V40, P289; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1987, J BIOL CHEM, V262, P2066; MITCHELL AH, 1994, J MOL BIOL, V243, P208, DOI 10.1006/jmbi.1994.1648; MULLER B, 1993, J BIOL CHEM, V268, P17185; MULLER B, 1993, J BIOL CHEM, V268, P17179; PARSONS CA, 1990, J BIOL CHEM, V265, P9285; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; RADDING CM, 1991, J BIOL CHEM, V266, P5355; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; SHARPLES GJ, 1990, MOL GEN GENET, V221, P219, DOI 10.1007/BF00261724; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; SHINAGAWA H, 1988, J BACTERIOL, V170, P4322, DOI 10.1128/jb.170.9.4322-4329.1988; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; TAKAHAGI M, 1991, J BACTERIOL, V173, P5747, DOI 10.1128/jb.173.18.5747-5753.1991; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WEST SC, 1994, CELL, V76, P9, DOI 10.1016/0092-8674(94)90168-6; WEST SC, 1981, NATURE, V290, P29, DOI 10.1038/290029a0; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WHITBY MC, 1993, CELL, V75, P341, DOI 10.1016/0092-8674(93)80075-P	43	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26552	26558						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929380				2022-12-27	WOS:A1994PQ93000093
J	HOLWERDA, BC; WITTWER, AJ; DUFFIN, KL; SMITH, C; TOTH, MV; CARR, LS; WIEGAND, RC; BRYANT, ML				HOLWERDA, BC; WITTWER, AJ; DUFFIN, KL; SMITH, C; TOTH, MV; CARR, LS; WIEGAND, RC; BRYANT, ML			ACTIVITY OF 2-CHAIN RECOMBINANT HUMAN CYTOMEGALOVIRUS PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 PROTEASE; ESCHERICHIA-COLI; ASSEMBLY PROTEIN; CLEAVAGE SITES; GENE; IDENTIFICATION; SEQUENCE; DOMAIN; EXPRESSION; QUANTITIES	The human cytomegalovirus U(L)80 protease was expressed in Escherichia coli and purified by metal-chelate chromatography using a histidine tag engineered at the amino terminus. Cleavage of the 30-kDa protease at an internal site, VEA/A(144), resulted in the recovery of 16- plus 14-kDa two chain protease. The amino-terminal 16-kDa chain and the carboxyl-terminal 14-kDa chain remained associated as an active enzyme that was modified specifically at Ser(132) on the 16-kDa chain by [H-3]diisopropyl fluorophosphate. Disruption of the cleavage site by mutation from VEA/A to AEA/A facilitated the recovery of active 30-kDa one-chain enzyme that could be similarly modified at Ser(132) by [3H]diisopropyl fluorophosphate. Both one- and two-chain enzymes cleaved recombinant assembly protein at the maturation site, VNA/S, and a peptide, GVVNASARL, mimicking this site. Internal processing does not inactivate the protease but forms a two-chain enzyme that retains activity.			HOLWERDA, BC (corresponding author), SEARLE RES & DEV, 700 CHESTERFIELD PKWY N, ST LOUIS, MO 63198 USA.							BAUM EZ, 1993, J VIROL, V67, P497, DOI 10.1128/JVI.67.1.497-506.1993; BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCK PJ, 1994, J VIROL, V68, P2937, DOI 10.1128/JVI.68.5.2937-2946.1994; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; DAQUILA RT, 1987, J VIROL, V61, P1291, DOI 10.1128/JVI.61.4.1291-1295.1987; DECKMAN IC, 1992, J VIROL, V66, P7362, DOI 10.1128/JVI.66.12.7362-7367.1992; DIIANNI CL, 1993, J BIOL CHEM, V268, P2048; DIIANNI CL, 1994, J BIOL CHEM, V269, P12672; DIIANNI CL, 1993, J BIOL CHEM, V268, P25449; GOA M, 1994, J VIROL, V68, P3702; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; JONES TR, 1994, J VIROL, V68, P3742, DOI 10.1128/JVI.68.6.3742-3752.1994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU FY, 1991, J VIROL, V65, P5149, DOI 10.1128/JVI.65.10.5149-5156.1991; LIU FY, 1993, J VIROL, V67, P1300, DOI 10.1128/JVI.67.3.1300-1309.1993; LIU FY, 1992, P NATL ACAD SCI USA, V89, P2076, DOI 10.1073/pnas.89.6.2076; LOUTSCH JM, 1994, IN PRESS BIOCH BIOPH; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCANN PJ, 1994, J VIROL, V68, P526, DOI 10.1128/JVI.68.1.526-529.1994; OBUKOWICZ MG, 1992, APPL ENVIRON MICROB, V58, P1511, DOI 10.1128/AEM.58.5.1511-1523.1992; OLINS PO, 1990, METHOD ENZYMOL, V185, P115; PRESTON VG, 1992, VIROLOGY, V186, P87, DOI 10.1016/0042-6822(92)90063-U; PRESTON VG, 1983, J VIROL, V45, P1056, DOI 10.1128/JVI.45.3.1056-1064.1983; SARDANA VV, 1994, J BIOL CHEM, V269, P14337; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; WEINHEIMER SP, 1993, J VIROL, V67, P5813, DOI 10.1128/JVI.67.10.5813-5822.1993; WELCH AR, 1991, P NATL ACAD SCI USA, V88, P10792, DOI 10.1073/pnas.88.23.10792; WELCH AR, 1991, J VIROL, V65, P4091, DOI 10.1128/JVI.65.8.4091-4100.1991; WELCH AR, 1993, J VIROL, V67, P7360, DOI 10.1128/JVI.67.12.7360-7372.1993; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	31	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25911	25915						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929296				2022-12-27	WOS:A1994PQ49100098
J	PARK, JE; CHEN, HH; WINER, J; HOUCK, KA; FERRARA, N				PARK, JE; CHEN, HH; WINER, J; HOUCK, KA; FERRARA, N			PLACENTA GROWTH-FACTOR - POTENTIATION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR BIOACTIVITY, IN-VITRO AND IN-VIVO, AND HIGH-AFFINITY BINDING TO FLT-1 BUT NOT TO FLK-1/KDR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; CELL GROWTH; PERMEABILITY FACTOR; DEVELOPMENTAL EXPRESSION; INDUCED ANGIOGENESIS; FACTOR-ALPHA; IDENTIFICATION; MEMBRANE; FAMILY; SITES	The recently identified placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family of growth factors. PlGF displays a 53% identity with the platelet-derived growth factor-like region of VEGF. By alternative splicing of RNA two PlGF isoforms are generated: PlGF(131) (PlGF-1) and PlGF(152) (PlGF-2). Relative to PlGF(131), PlGF(152) has a 21-amino acid insertion enriched in basic amino acids. Little is known at the present time about the significance and function of these proteins. To assess their potential role, we cloned the cDNAs coding for both isoforms, expressed them in mammalian cells, and purified to apparent homogeneity the recombinant proteins. Like VEGF, the PlGF isoforms are homodimeric glycoproteins. PlGF(131) is a non-heparin binding protein, whereas PlGF(152) strongly binds to heparin. We examined the ability of PlGF to bind to soluble VEGF receptors, Flt-1 and Flk-1/KDR, and characterized the binding of PlGF to endothelial cells. While the PlGF proteins bound with high affinity to Flt-1, they failed to bind to Flk-1/KDR. Binding of I-125-PlGF to human endothelial cells revealed two classes of sites, having high and low affinity. The high affinity site is consistent with Flt-1; the identity of the low affinity site remains to be determined. Purified PlGF isoforms had little or no direct mitogenic or permeability-enhancing activity. However, they were able to significantly potentiate the action of low concentrations of VEGF in vitro and, more strikingly in vivo.	GENENTECH INC, DEPT CARDIOVASC RES, San Francisco, CA 94080 USA	Roche Holding; Genentech			Houck, Keith/G-8654-2014	Houck, Keith/0000-0002-0055-2249				AMENTO EP, 1991, CIBA F SYMP, V157, P115; BARLEON B, 1994, J CELL BIOCHEM, V54, P56, DOI 10.1002/jcb.240540107; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Basset DL, 1943, AM J ANAT, V73, P251, DOI 10.1002/aja.1000730206; BREIER G, 1992, DEVELOPMENT, V114, P521; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Donner MW., 1980, PLACENTAL VASCULATUR; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERRARA N, 1991, METHOD ENZYMOL, V198, P391; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Gilbert Scott F., 1988, DEV BIOL; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KRAUS ET, 1990, ANDERSONS PATHOLOGY, P1706; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MYOKEN Y, 1991, P NATL ACAD SCI USA, V88, P5819, DOI 10.1073/pnas.88.13.5819; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RAVINDRATH N, 1992, ENDOCRINOLOGY, V94, P1192; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHIBUYA M, 1990, ONCOGENE, V5, P519; SU W, 1991, P NATL ACAD SCI USA, V88, P10870, DOI 10.1073/pnas.88.23.10870; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; TESSLER S, 1994, J BIOL CHEM, V269, P12456; YANG EY, 1990, J CELL BIOL, V111, P731, DOI 10.1083/jcb.111.2.731	48	873	920	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25646	25654						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929268				2022-12-27	WOS:A1994PQ49100064
J	BAROUCH, W; PRASAD, K; GREENE, LE; EISENBERG, E				BAROUCH, W; PRASAD, K; GREENE, LE; EISENBERG, E			ATPASE ACTIVITY ASSOCIATED WITH THE UNCOATING OF CLATHRIN BASKETS BY HSP70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK RESPONSE; COATED VESICLES; BOVINE BRAIN; ASSEMBLY PROTEIN; STRESS PROTEINS; DISSOCIATION; BINDING; TRANSLOCATION; POLYPEPTIDES; HYDROLYSIS	In the presence of ATP, bovine brain hsp70 has been shown to remove clathrin from bovine brain clathrin-coated vesicles in a rapid stoichiometric initial burst followed by slow steady-state uncoating. In addition, it has been found recently that a 100-kDa cofactor is required for hsp70 to uncoat clathrin baskets prepared with the assembly protein AP-2. In this study the ATPase activity associated with uncoating was investigated, with baskets formed from clathrin and assembly proteins. Mixed assembly proteins or assembly protein AP-2 could not be used in ATPase studies because they activated the hsp70 ATPase activity even in the absence of clathrin. However, this was not the case with assembly protein AP(180). A stoichiometric initial burst of ATP hydrolysis was found to accompany the initial burst of uncoating of AP(180)-clathrin baskets by hsp70, with 1 mol of hydrolyzed ATP/mol of released clathrin heavy chain. Furthermore, the presence of a 100-kDa cofactor was needed for both processes. These results suggest that an initial burst of uncoating occurs with all clathrin baskets, that an initial burst of ATP hydrolysis accompanies this initial burst of uncoating, and that a 100-kDa cofactor is required for both.	NHLBI,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								AHLE S, 1990, J CELL BIOL, V111, P19, DOI 10.1083/jcb.111.1.19; BAROUCH W, 1994, FASEB J, V8, pA1312; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CHOCK SP, 1979, J BIOL CHEM, V254, P3229; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; CYR DM, 1992, J BIOL CHEM, V267, P20927; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GAO BC, 1994, BIOCHEMISTRY-US, V33, P2048, DOI 10.1021/bi00174a010; GAO BC, 1993, J BIOL CHEM, V268, P8507; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREENE LE, 1990, J BIOL CHEM, V265, P6682; GREENE LE, 1994, IN PRESS J BIOL CHEM; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; LINDNER R, 1992, J BIOL CHEM, V267, P16567; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PATZER EJ, 1982, J CELL BIOL, V93, P230, DOI 10.1083/jcb.93.1.230; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PLEASURE IT, 1993, NATURE, V365, P459, DOI 10.1038/365459a0; PRASAD K, 1988, BIOCHEMISTRY-US, V27, P6098, DOI 10.1021/bi00416a040; PRASAD K, 1993, J BIOL CHEM, V268, P23758; PRASAD K, 1991, BIOCHEMISTRY-US, V30, P5590, DOI 10.1021/bi00236a036; PRASAD K, 1994, J BIOL CHEM, V269, P6931; Prasad K., 1993, Molecular Biology of the Cell, V4, p214A; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID SL, 1985, J BIOL CHEM, V260, P44; SCHORUDER H, 1993, EMBO J, V12, P4137; SCHRODER S, 1991, J BIOL CHEM, V266, P7910	36	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28563	28568						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961802				2022-12-27	WOS:A1994PU16800011
J	SIEBERT, A; LOTTSPEICH, F; NELSON, N; BETZ, H				SIEBERT, A; LOTTSPEICH, F; NELSON, N; BETZ, H			PURIFICATION OF THE SYNAPTIC VESICLE-BINDING PROTEIN PHYSOPHILIN - IDENTIFICATION AS 39-KDA SUBUNIT OF THE VACUOLAR H+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON PUMP; ADENOSINE-TRIPHOSPHATASE; TRANSMITTER SECRETION; PRESYNAPTIC MEMBRANE; NERVE-TERMINALS; SYNAPTOPHYSIN; MEDIATOPHORE; RELEASE; ELECTROPHORESIS; IDENTIFICATION	Physophilin is a 36-kDa polypeptide originally identified in synaptic plasma membrane fractions, which binds to synaptic vesicles and has been implicated in vesicle docking and/or exocytosis during neurotransmitter release. Here we report on the purification, amino acid sequence analysis, and subcellular localization of physophilin. Physophilin was enriched from detergent extracts of crude synaptic plasma membranes by a combination of cation exchange and lentil-lectin chromatography. Sequence analysis of peptides generated after sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed that physophilin is identical to the 39-kDa subunit (Ac39) of the vacuolar H+-ATPase. This was confirmed further by Western blot analysis with an Ac39-specific antiserum and by vesicle binding assays with recombinant Ac39 protein. Subcellular fractionation showed that Ac39 is enriched in synaptic vesicles, with lesser amounts being present in synaptic plasma membrane fractions. These results argue against a docking role of physophilin/Ac39 in synaptic vesicle exocytosis.	MAX PLANCK INST BRAIN RES,NEUROCHEM ABT,D-60528 FRANKFURT 71,GERMANY; MAX PLANCK INST BIOCHEM,BINDEGEWEBSFORSCH ABT,D-82152 MARTINSRIED,GERMANY; ROCHE INST MOLEC BIOL,NUTLEY,NJ 07110	Max Planck Society; Max Planck Society								ADACHI I, 1990, J BIOL CHEM, V265, P967; ALDER J, 1992, SCIENCE, V257, P657, DOI 10.1126/science.1353905; ALDER J, 1992, NEURON, V9, P759, DOI 10.1016/0896-6273(92)90038-F; ALMERS W, 1990, NEURON, V4, P813, DOI 10.1016/0896-6273(90)90134-2; ANTOLOVIC R, 1991, EUR J BIOCHEM, V199, P195, DOI 10.1111/j.1432-1033.1991.tb16109.x; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1988, J BIOL CHEM, V263, P8796; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BETZ H, 1990, BIOCHEMISTRY-US, V29, P3591, DOI 10.1021/bi00467a001; BIRMAN S, 1990, FEBS LETT, V261, P303, DOI 10.1016/0014-5793(90)80577-6; BROCHIER G, 1993, BIOL CELL, V78, P145, DOI 10.1016/0248-4900(93)90125-X; DERMIETZEL R, 1989, FEBS LETT, V253, P1, DOI 10.1016/0014-5793(89)80917-2; ECKERSKORN C, 1989, CHROMATOGRAPHIA, V28, P92, DOI 10.1007/BF02290390; FLOOR E, 1990, J NEUROCHEM, V55, P1663, DOI 10.1111/j.1471-4159.1990.tb04954.x; FORGAC M, 1992, J EXP BIOL, V172, P155; HEUSER JE, 1981, J CELL BIOL, V88, P564, DOI 10.1083/jcb.88.3.564; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; ISRAEL M, 1987, J NEUROCHEM, V49, P975, DOI 10.1111/j.1471-4159.1987.tb00989.x; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; JESSELL TM, 1993, CELL, V72, P1, DOI 10.1016/S0092-8674(05)80025-X; KELLY RB, 1988, NEURON, V1, P431, DOI 10.1016/0896-6273(88)90174-2; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON E, 1986, ANAL BIOCHEM, V155, P243, DOI 10.1016/0003-2697(86)90432-X; LEITCH B, 1990, EXP CELL RES, V190, P218, DOI 10.1016/0014-4827(90)90189-H; LEROY C, 1992, EUR J NEUROSCI, V5, P1539; MARQUEZSTERLING N, 1991, EUR J CELL BIOL, V56, P19; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; NELSON N, 1991, TRENDS PHARMACOL SCI, V12, P71, DOI 10.1016/0165-6147(91)90501-I; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; NELSON N, 1993, J PHYSIOLOGY-PARIS, V87, P171, DOI 10.1016/0928-4257(93)90028-R; NELSON N, 1992, Current Opinion in Cell Biology, V4, P654, DOI 10.1016/0955-0674(92)90086-R; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PERIN MS, 1991, J BIOL CHEM, V266, P3877; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; REHM H, 1986, EMBO J, V5, P535, DOI 10.1002/j.1460-2075.1986.tb04243.x; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; THOMAS L, 1990, J CELL BIOL, V111, P2041, DOI 10.1083/jcb.111.5.2041; WANG SY, 1988, J BIOL CHEM, V263, P17638; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; WOLF ME, 1989, J NEUROSCI, V9, P94; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; XIE XS, 1986, J BIOL CHEM, V261, P2492	47	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28329	28334						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961771				2022-12-27	WOS:A1994PV77200083
J	TUCKER, AL; ROBEVA, AS; TAYLOR, HE; HOLETON, D; BOCKNER, M; LYNCH, KR; LINDEN, J				TUCKER, AL; ROBEVA, AS; TAYLOR, HE; HOLETON, D; BOCKNER, M; LYNCH, KR; LINDEN, J			A(1) ADENOSINE RECEPTORS - 2 AMINO-ACIDS ARE RESPONSIBLE FOR SPECIES-DIFFERENCES IN LIGAND RECOGNITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; SITE-DIRECTED MUTAGENESIS; MOLECULAR-CLONING; CHEMICAL MODIFICATION; ANTAGONIST BINDING; HUMAN BRAIN; ADENOSINE-A1-RECEPTOR CDNA; FUNCTIONAL EXPRESSION; A1; AGONISTS	Species differences in ligand binding to A, adenosine receptors were localized to the seventh transmembrane (TM7) region based on the binding of [8-S-3]cyclopentyl-1,3-dipropylxanthine and three other ligands to wild type and six bovine/canine interspecies receptor chimeras expressed in COS-1 cells. Subsequent site-directed mutagenesis experiments identified amino acid 270 (isoleucine/methionine, bovine/canine) as being primarily responsible for species differences in the binding of N-6-adenine-substituted compounds, R-N-6-phenylisopropyladenosine (R-PIA) and (S)-N-6-endonorbornan-2-yl-9-methyladenine, and the C-8-substituted xanthine, [H-3]cyclopentyl-1,3-dipropylxanthine. These data are consistent with the hypothesis that the N-6 region of adenines and the C-8-region of xanthines bind to the same region of the receptor. A second TM7 amino acid, 277 (serine/threonine, bovine/canine), selectively influences the binding of the ribose-substituted adenosine analog, 5'-N-ethylcarboxamidoadenosine to a variable extent, depending on the nature of amino acid 270. We hypothesize that amino acid 270 of the A, receptor interacts with the N-6 region of adenosine, while amino acid 277 is important, especially in the absence of an N-6 substitution, for interactions with a distinct nucleoside region, possibly on the ribose.	UNIV VIRGINIA,HLTH SCI CTR,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT BIOCHEM,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT INTERNAL MED,DIV CARDIOVASC,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia; University of Virginia					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037942] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL37942] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRINGTON WW, 1989, J BIOL CHEM, V264, P13157; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; BELLARDINELLI L, 1989, PROG CARDIOVASC DIS, V32, P73; BHATTACHARYA S, 1993, GENE, V128, P285, DOI 10.1016/0378-1119(93)90576-O; BRUNS RF, 1980, P NATL ACAD SCI-BIOL, V77, P5547, DOI 10.1073/pnas.77.9.5547; CRONSTEIN BN, 1990, J CLIN INVEST, V85, P1150, DOI 10.1172/JCI114547; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; DUDLEY MW, 1993, DRUG DEVELOP RES, V28, P237, DOI 10.1002/ddr.430280309; FERKANY JW, 1986, DRUG DEVELOP RES, V9, P85, DOI 10.1002/ddr.430090202; FREDHOLM BB, 1988, TRENDS PHARMACOL SCI, V9, P130, DOI 10.1016/0165-6147(88)90194-0; FURLONG TJ, 1992, MOL BRAIN RES, V15, P62, DOI 10.1016/0169-328X(92)90152-2; GARRITSEN A, 1990, BIOCHEM PHARMACOL, V40, P835, DOI 10.1016/0006-2952(90)90324-E; GARRITSEN A, 1990, BIOCHEM PHARMACOL, V40, P827, DOI 10.1016/0006-2952(90)90323-D; GUAN XM, 1992, MOL PHARMACOL, V41, P695; IJzerman A P, 1992, Drug Des Discov, V9, P49; JACOBSON KA, 1992, MOL PHARMACOL, V42, P123; KAO HT, 1992, FEBS LETT, V307, P324, DOI 10.1016/0014-5793(92)80705-L; KLOTZ KN, 1988, J BIOL CHEM, V263, P17522; KLOTZ KN, 1991, N-S ARCH PHARMACOL, V343, P196, DOI 10.1007/BF00168610; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LINDEN J, 1982, J CYCLIC NUCL PROT, V8, P163; LINDEN J, 1993, MOL PHARMACOL, V44, P524; LINDEN J, 1991, FASEB J, V5, P2668, DOI 10.1096/fasebj.5.12.1916091; Linden Joel, 1994, P401; LINK R, 1992, MOL PHARMACOL, V42, P16; LITMAN BJ, 1982, VISION RES, V22, P1439, DOI 10.1016/0042-6989(82)90206-1; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MURPHY KMM, 1982, MOL PHARMACOL, V22, P250; OKSENBERG D, 1992, NATURE, V360, P161, DOI 10.1038/360161a0; OLAH ME, 1992, J BIOL CHEM, V267, P10764; OLSSON RA, 1990, PHYSIOL REV, V70, P761, DOI 10.1152/physrev.1990.70.3.761; PEET NP, 1990, J MED CHEM, V33, P3127, DOI 10.1021/jm00174a004; PIERCE KD, 1992, BIOCHEM BIOPH RES CO, V187, P86, DOI 10.1016/S0006-291X(05)81462-7; PRATER MR, 1992, MOL PHARMACOL, V42, P765; RAMKUMAR V, 1993, J BIOL CHEM, V268, P16887; SALESSE R, 1991, BIOCHIMIE, V73, P109, DOI 10.1016/0300-9084(91)90083-D; SALVATORE CA, 1993, P NATL ACAD SCI USA, V90, P10365, DOI 10.1073/pnas.90.21.10365; Segaloff D L, 1992, Oxf Rev Reprod Biol, V14, P141; STOWELL CP, 1978, ANAL BIOCHEM, V85, P572, DOI 10.1016/0003-2697(78)90256-7; STRADER CD, 1988, J BIOL CHEM, V263, P10267; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; TAYLOR MD, 1986, J MED CHEM, V29, P346, DOI 10.1021/jm00153a008; TOWNSENDNICHOLSON A, 1994, J BIOL CHEM, V269, P2373; TOWNSENDNICHOLSON A, 1992, MOL BRAIN RES, V16, P365, DOI 10.1016/0169-328X(92)90248-A; TUCKER AL, 1993, CARDIOVASC RES, V27, P62, DOI 10.1093/cvr/27.1.62; TUCKER AL, 1992, FEBS LETT, V297, P107, DOI 10.1016/0014-5793(92)80338-H; UKENA D, 1986, FEBS LETT, V209, P122, DOI 10.1016/0014-5793(86)81096-1; VANDERWENDEN EM, 1992, J MED CHEM, V35, P629, DOI 10.1021/jm00082a003; WESS J, 1992, J BIOL CHEM, V267, P19133; YAKEL JL, 1993, MOL PHARMACOL, V43, P277	51	82	91	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27900	27906						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961722				2022-12-27	WOS:A1994PV77200023
J	WHITTERS, EA; MCGEE, TP; BANKAITIS, VA				WHITTERS, EA; MCGEE, TP; BANKAITIS, VA			PURIFICATION AND CHARACTERIZATION OF A LATE GOLGI COMPARTMENT FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID TRANSFER PROTEIN; YEAST SECRETORY PATHWAY; MEMBRANE-PROTEIN; SUBCELLULAR ORGANIZATION; GUANOSINE DIPHOSPHATASE; KEX2 PROTEASE; GENE-PRODUCT; TRANSPORT; APPARATUS; COMPLEX	We have devised a method for obtaining highly enriched membranes of a late yeast Golgi compartment, operationally defined by their containing the Kex2p protease, and generated four hybridoma cell Lines that produced monoclonal antibodies directed against distinct Golgi membrane proteins (GMPs) (GMP(36), GMP(51), GMP(77), and GMP(95)). Immunofluorescence and subcellular fractionation data indicated that, of the four GMPs analyzed, only GMP(51) exhibited essentially an absolute colocalization with Kex2p. Also, as in the case of Kex2p, retention of GMP(51) in yeast Golgi membranes was dependent on clathrin function. In contrast, the remaining three GMPs exhibited substantial, but not absolute, colocalization with Kex2p. The collective data are most consistent with a model where GMP(36), GMP(77), and GMP(95) are present in all Kex2p-containing membranes, but Kex2p is present in only a subpopulation of membranes that contain these GMPs, thereby suggesting that either these particular GMPs exhibit overlapping distributions in compartments of the yeast Golgi complex or are also present in non-Golgi compartments. These findings are not consistent with the view that resident yeast Golgi proteins are generally restricted to a specific Golgi subcompartment, but they are consistent with the view that Golgi compartmental identity is determined by the relative mixtures of Golgi proteins that reside within individual cisternae.	UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham				McGee, Todd/0000-0002-3901-1001	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044530] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-44530] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BOWSER R, 1991, J CELL BIOL, V112, P1117, DOI 10.1083/jcb.112.6.1117; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; CUNNINGHAM KW, 1989, YEAST, V5, P25, DOI 10.1002/yea.320050105; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; Franzusoff A, 1992, Semin Cell Biol, V3, P309, DOI 10.1016/1043-4682(92)90018-Q; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HARLOW E, 1988, ANTIBODIES LAB MANUA, P121; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MONTELARO RC, 1987, ELECTROPHORESIS, V8, P432, DOI 10.1002/elps.1150080912; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PAYNE GS, 1989, SCIENCE, V245, P1358, DOI 10.1126/science.2675311; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PREUSS D, 1992, MOL BIOL CELL, V3, P789, DOI 10.1091/mbc.3.7.789; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P358; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; ROBERTS CJ, 1992, J CELL BIOL, V119, P69, DOI 10.1083/jcb.119.1.69; ROSE M, 1992, CELL, V57, P1211; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHEKMAN R, 1985, ANNU REV CELL BIOL, V1, P115, DOI 10.1146/annurev.cellbio.1.1.115; SEEGER M, 1992, J CELL BIOL, V118, P531, DOI 10.1083/jcb.118.3.531; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SKINNER HB, 1993, EMBO J, V12, P4775, DOI 10.1002/j.1460-2075.1993.tb06166.x; SLUSAREWICZ P, 1994, J CELL BIOL, V124, P405, DOI 10.1083/jcb.124.4.405; WHITTERS EA, 1993, J CELL BIOL, V122, P79, DOI 10.1083/jcb.122.1.79; YANAGISAWA K, 1990, J BIOL CHEM, V265, P19351	42	20	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28106	28117						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961747				2022-12-27	WOS:A1994PV77200052
J	AMATAYAKULCHANTLER, S; QIAN, SW; GAKENHEIMER, K; BOTTINGER, EP; ROBERTS, AB; SPORN, MB				AMATAYAKULCHANTLER, S; QIAN, SW; GAKENHEIMER, K; BOTTINGER, EP; ROBERTS, AB; SPORN, MB			[SER(77)] TRANSFORMING GROWTH-FACTOR-BETA-1 - SELECTIVE BIOLOGICAL-ACTIVITY AND RECEPTOR-BINDING IN MINK LUNG EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; II RECEPTOR; CRYSTAL-STRUCTURE; CLONING; KINASE; SUPERFAMILY; GROWTH-FACTOR-BETA-2; IDENTIFICATION; EXPRESSION; TGF-BETA-1	Transforming growth factor-beta 1 (TGF-beta 1) is a homodimeric protein stabilized by a single disulfide bridge between Cys(77) on the respective monomers and two paired complementary hydrophobic interfaces between the two subunits. A TGF-beta 1 mutant with Cys(77) replaced by serine has been expressed in stably transfected Chinese hamster ovary cells and purified to homogeneity. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis confirms that the sole interchain disulfide bond in TGF-beta 1 has been eliminated. It is 20% as potent as native TGF-beta 1 in the induction of plasminogen activator inhibitor-1 promoter expression in mink lung epithelial cells (Mv1Lu), although it is less than 1% as potent as native TGF-beta 1 in inhibition of growth in the same cell line. The mutant acts as a full agonist in both bioassays. [Ser(77)]TGF-beta 1 binds to soluble type II receptors and competes with native TGF-beta 1 in sandwich-enzyme-linked immunosorbent assays; however, in Mv1Lu cells, the mutant shows preferential cross-linking to type I rather than type II receptors. [Ser(77)]TGF-beta 1 is a useful tool for understanding the different ligand-receptor complexes and numerous biological activities of this multifunctional cytokine.			AMATAYAKULCHANTLER, S (corresponding author), NCI,CHEMOPREVENT LAB,BLDG 41,RM C-629,BETHESDA,MD 20892, USA.							ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; ANDERSSON M, 1992, J BIOL CHEM, V267, P11260; ARCHER SJ, 1993, BIOCHEMISTRY-US, V32, P1164, DOI 10.1021/bi00055a022; ARCHER SJ, 1993, BIOCHEMISTRY-US, V32, P1152, DOI 10.1021/bi00055a021; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BRUNNER AM, 1992, MOL ENDOCRINOL, V6, P1691, DOI 10.1210/me.6.10.1691; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; Danielpour D, 1989, GROWTH FACTORS, V2, P61, DOI 10.3109/08977198909069082; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; DAOPIN S, 1992, SCIENCE, V255, P306; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FROLIK CA, 1984, J BIOL CHEM, V259, P995; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HUSKENHINDI P, 1994, J BIOL CHEM, V269, P19380; KENNEY WC, 1994, J BIOL CHEM, V269, P12351; KONDAIAH P, 1988, J BIOL CHEM, V263, P18313; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MASON AJ, 1994, MOL ENDOCRINOL, V8, P325, DOI 10.1210/me.8.3.325; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MCPHERRON AC, 1993, J BIOL CHEM, V268, P3444; PARKS WP, 1976, CELL, V8, P87, DOI 10.1016/0092-8674(76)90189-6; QIAN SW, 1992, P NATL ACAD SCI USA, V89, P6290, DOI 10.1073/pnas.89.14.6290; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Roberts AB, 1990, PEPTIDE GROWTH FACTO, P419; ROBERTSON DM, 1992, ENDOCRINOLOGY, V130, P1680, DOI 10.1210/en.130.3.1680; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SPORN MB, 1990, CELL REGUL, V1, P875, DOI 10.1091/mbc.1.12.875; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	35	28	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27687	27691						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961688				2022-12-27	WOS:A1994PV77100082
J	HIRATSUKA, T				HIRATSUKA, T			NUCLEOTIDE-INDUCED CLOSURE OF THE ATP-BINDING POCKET IN MYOSIN SUBFRAGMENT-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; ADENOSINE-TRIPHOSPHATASE; SPATIAL PROXIMITY; CROSS-LINKING; FLUORESCENCE; PROTEINS; DOMAINS; ACTIN; THIOL; SITE	The hydrophobic fluorescent dye 3-[4-(3-phenyl-2-pyrazolin-1-yl)benzene-1 sulfonylamido]phenylboronic acid (PPBA) stoichiometrically binds to myosin subfragment-1 (S-1) with a dissociation constant (K-d) of 26 mu M. Upon addition of nucleotides to the complex of S-1 with PPBA, the PPBA-binding site is converted to a more firm hydrophobic pocket accompanied by a large ffuorescence change. For the complex formed with ATP, binding of the dye is competitive with respect to ATP with a K-i of 0.8 mu M. This competition was confirmed by the result that the K-d value of S-1 with ATP was increased 3.3-fold by the addition of PPBA. The dye bound to S-1 senses ATP hydrolysis but has no effect on the binding of actin to S-1. Measurements of acrylamide fluorescence quenching of the complexes have revealed that the Stern-Volmer quenching constant of the dye is reduced by a factor of 2.7 during ATP hydrolysis. These results together with the fluorescent properties of the complexes suggest that the ATP-binding pocket of S-1 is closed and/or tightened during ATP hydrolysis.			HIRATSUKA, T (corresponding author), ASAHIKAWA MED COLL,DEPT CHEM,ASAHIKAWA,HOKKAIDO 078,JAPAN.							BRAND L, 1967, BIOCHEMISTRY-US, V6, P3510, DOI 10.1021/bi00863a024; CHANCE B, 1957, ARCH BIOCHEM BIOPHYS, V71, P130, DOI 10.1016/0003-9861(57)90015-2; CHAUSSEPIED P, 1986, P NATL ACAD SCI USA, V83, P2037, DOI 10.1073/pnas.83.7.2037; COLLINS JH, 1975, J BIOL CHEM, V250, P5915; DRYDEN DTF, 1992, EUR J BIOCHEM, V208, P115, DOI 10.1111/j.1432-1033.1992.tb17164.x; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; EINARSSON R, 1974, EUR J BIOCHEM, V49, P41, DOI 10.1111/j.1432-1033.1974.tb03809.x; Fiske CH, 1925, J BIOL CHEM, V66, P375; GALLOP PM, 1982, SCIENCE, V217, P166, DOI 10.1126/science.6178158; HIRATSUKA T, 1986, BIOCHEMISTRY-US, V25, P2101, DOI 10.1021/bi00356a039; HIRATSUKA T, 1987, BIOCHEMISTRY-US, V26, P3168, DOI 10.1021/bi00385a034; HIRATSUKA T, 1992, J BIOL CHEM, V267, P14949; HIRATSUKA T, 1988, BIOCHEMISTRY-US, V27, P4110, DOI 10.1021/bi00411a030; HIRATSUKA T, 1990, J BIOL CHEM, V265, P18786; HUBER R, 1979, TRENDS BIOCHEM SCI, V4, P271, DOI 10.1016/0968-0004(79)90298-6; JANIN J, 1983, PROG BIOPHYS MOL BIO, V42, P21, DOI 10.1016/0079-6107(83)90003-2; KATO A, 1980, BIOCHIM BIOPHYS ACTA, V624, P13, DOI 10.1016/0005-2795(80)90220-2; LARSSONRAZNIKIEWICZ M, 1978, BIOCHIM BIOPHYS ACTA, V523, P94, DOI 10.1016/0005-2744(78)90012-8; LU RC, 1986, P NATL ACAD SCI USA, V83, P6392, DOI 10.1073/pnas.83.17.6392; MADSEN NB, 1983, BIOCHEMISTRY-US, V22, P4460, DOI 10.1021/bi00288a017; MUELLER H, 1962, BIOCHEM J, V85, P431, DOI 10.1042/bj0850431; PARKER CA, 1960, ANALYST, V85, P587, DOI 10.1039/an9608500587; PERRY SV, 1955, METHOD ENZYMOL, V2, P582, DOI 10.1016/S0076-6879(55)02258-1; PFISTER K, 1978, P NATL ACAD SCI USA, V75, P145, DOI 10.1073/pnas.75.1.145; PICOT D, 1991, EUR J BIOCHEM, V196, P329, DOI 10.1111/j.1432-1033.1991.tb15821.x; RAJASEKHARAN KN, 1989, J BIOL CHEM, V264, P10810; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REES MK, 1967, J BIOL CHEM, V242, P4449; REISLER E, 1974, BIOCHEMISTRY-US, V13, P3837, DOI 10.1021/bi00716a001; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STEITZ TA, 1982, CIBA F S, V93, P25; SUTOH K, 1988, BIOCHEMISTRY-US, V27, P2964, DOI 10.1021/bi00408a045; VARLEY PG, 1991, J MOL BIOL, V220, P531, DOI 10.1016/0022-2836(91)90028-5; WAGNER PD, 1977, J MOL BIOL, V109, P455, DOI 10.1016/S0022-2836(77)80023-5; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WELLS JA, 1982, METHOD ENZYMOL, V85, P93; WERBER MM, 1972, BIOCHEMISTRY-US, V11, P2872, DOI 10.1021/bi00765a021; WRBA A, 1990, BIOCHEMISTRY-US, V29, P7584, DOI 10.1021/bi00485a007	39	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27251	27257						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961633				2022-12-27	WOS:A1994PV77100018
J	SOLCA, FF; LURIE, DI; DILTZ, CD; JOHNSON, RS; KUMAR, S; RUBEL, EW; FISCHER, EH				SOLCA, FF; LURIE, DI; DILTZ, CD; JOHNSON, RS; KUMAR, S; RUBEL, EW; FISCHER, EH			IDENTIFICATION AND PURIFICATION OF A CHICKEN BRAIN NEUROGLIA-ASSOCIATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPSE-SPECIFIC PROTEIN; REACTIVE ASTROCYTES; TYROSINE-PHOSPHATASE; F1-20 PROTEIN; TAU-PROTEIN; EXPRESSION; CELLS; MICROGLIA; DISEASE; BINDING	The identification, purification, and biochemical characterization of specific markers for neuroglial cells in the central nervous system is an essential step toward a better understanding of the function of glial cells. This manuscript reports the identification and purification of a neuroglia-associated protein (NAP-185) with an apparent molecular mass of 185 kDa. While its expression is not restricted to the brain, it was first identified in a specific subpopulation of glial cells when chick brain stem sections were analyzed with an affinity-purified rabbit antiserum raised against the catalytic domain of the T-cell protein tyrosine phosphatase. This 185-kDa antigen was purified to apparent homogeneity and confirmed to be responsible for the neuroglial staining observed. In spite of its immunological relation to T-cell protein tyrosine phosphatase, purified NAP-185 failed to display tyrosine phosphatase activity. The primary sequence of five NAP-185-derived peptides shows that this protein has not yet been characterized and that it is possibly related to AP180, a clathrin-associated protein.	UNIV WASHINGTON,VIRGINIA MERRILL BLOEDEL HEARING RES CTR,DEPT OTOLARYNGOL HEAD & NECK SURG,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	SOLCA, FF (corresponding author), UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195, USA.			Lurie, Diana/0000-0002-4486-4869	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07902] Funding Source: Medline; NIGMS NIH HHS [GM42508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS PC, 1987, ANAL BIOCHEM, V161, P524, DOI 10.1016/0003-2697(87)90484-2; ANNAERT WG, 1993, J NEUROCHEM, V60, P1746, DOI 10.1111/j.1471-4159.1993.tb13399.x; [Anonymous], [No title captured]; BARK IC, 1994, P NATL ACAD SCI USA, V91, P4621, DOI 10.1073/pnas.91.11.4621; BARRES BA, 1991, J NEUROSCI, V11, P3685; BLACK JA, 1988, GLIA, V1, P169, DOI 10.1002/glia.440010302; BORN DE, 1985, J COMP NEUROL, V231, P435, DOI 10.1002/cne.902310403; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CANCILLA PA, 1993, ASTROCYTES PHARM FUN, P383; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; DAUM G, 1993, ANAL BIOCHEM, V211, P50, DOI 10.1006/abio.1993.1231; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; GARD AL, 1993, ASTROCYTES PHARM FUN, P331; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; KAWAJA MD, 1991, NEURON, V7, P1019, DOI 10.1016/0896-6273(91)90346-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LOWE J, 1989, J PATHOL, V159, P143, DOI 10.1002/path.1711590209; Luna LG, 1968, MANUAL HISTOLOGIC ST, V3; LURIE DI, 1994, J COMP NEUROL, V346, P276, DOI 10.1002/cne.903460207; MARTIN DL, 1992, GLIA, V5, P81, DOI 10.1002/glia.440050202; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; MYERS KJ, 1993, J IMMUNOL, V151, P2252; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; PEARCE B, 1993, ASTROCYTES PHARM FUN, P47; Prochiantz A, 1988, Ann N Y Acad Sci, V540, P52, DOI 10.1111/j.1749-6632.1988.tb27051.x; ROTT O, 1993, J IMMUNOL, V150, P87; SHIGEMATSU K, 1992, J NEUROSCI RES, V31, P443, DOI 10.1002/jnr.490310306; SOUSA R, 1992, J NEUROSCI, V12, P2130; THOMASREETZ AC, 1994, FASEB J, V8, P209, DOI 10.1096/fasebj.8.2.7907072; ZANDER NF, 1991, BIOCHEMISTRY-US, V30, P6964, DOI 10.1021/bi00242a022; ZHOU SB, 1992, J NEUROSCI, V12, P2144	35	2	2	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27559	27565						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961672				2022-12-27	WOS:A1994PV77100063
J	CASTELEIN, H; GULICK, T; DECLERCQ, PE; MANNAERTS, GP; MOORE, DD; BAES, MI				CASTELEIN, H; GULICK, T; DECLERCQ, PE; MANNAERTS, GP; MOORE, DD; BAES, MI			THE PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR REGULATES MALIC ENZYME GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; BETA-OXIDATION PATHWAY; A-I GENE; THYROID-HORMONE; RESPONSE ELEMENT; FATTY-ACIDS; CLOFIBRIC ACID; RXR-ALPHA; SUPERFAMILY; RAT	A new regulatory element for peroxisome proliferator activated receptor (PPAR)/retinoid X receptor (RXR) heterodimers was found in the promoter of the melic enzyme gene. Similar to previously characterized peroxisome proliferator response elements (PPREs), it consists of a direct repeat of sequences related to the half-site consensus AGGTCA with an interspacing of 1 base pair. Specific binding of PPAR/RXR heterodimers to this element was demonstrated. Furthermore, this sequence conferred ciprofibrate responsiveness of a reporter through the homologous malic enzyme or heterologous thymidine kinase promoters. This PPRE presumably mediates the transcriptional effects of peroxisome proliferators on malic enzyme expression. The presence of a PPRE in the promoter of this lipogenic enzyme suggests a broader function for the PPAR in the regulation of lipid metabolism.	CATHOLIC UNIV LEUVEN,FAC PHARMACEUT SCI,CLIN CHEM LAB,B-3000 LOUVAIN,BELGIUM; CATHOLIC UNIV LEUVEN,FAC MED,PHARMACOL LAB,B-3000 LOUVAIN,BELGIUM; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114	KU Leuven; KU Leuven; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School				Baes, Myriam/0000-0002-2525-2269				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; BRENT GA, 1989, J BIOL CHEM, V264, P178; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CASTELEIN H, 1993, FEBS LETT, V332, P24, DOI 10.1016/0014-5793(93)80474-9; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; DREYER C, 1993, BIOL CELL, V77, P67, DOI 10.1016/S0248-4900(05)80176-5; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; HAWKINS JM, 1987, DRUG METAB REV, V18, P441, DOI 10.3109/03602538708994130; HERTZ R, 1991, BIOCHEM J, V274, P745, DOI 10.1042/bj2740745; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; ISSEMANN I, 1993, BIOCHIMIE, V75, P251, DOI 10.1016/0300-9084(93)90084-6; ISSEMANN I, 1993, J MOL ENDOCRINOL, V11, P37, DOI 10.1677/jme.0.0110037; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; POGNONEC P, 1991, NUCLEIC ACIDS RES, V19, P6650, DOI 10.1093/nar/19.23.6650; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; RAISHER BD, 1992, J BIOL CHEM, V267, P20264; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STAELS B, 1992, ARTERIOSCLER THROMB, V12, P286, DOI 10.1161/01.ATV.12.3.286; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	39	145	148	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26754	26758						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929410				2022-12-27	WOS:A1994PQ93100029
J	SCHLICHTING, I; YANG, XJ; MILES, EW; KIM, AY; ANDERSON, KS				SCHLICHTING, I; YANG, XJ; MILES, EW; KIM, AY; ANDERSON, KS			STRUCTURAL AND KINETIC-ANALYSIS OF A CHANNEL-IMPAIRED MUTANT OF TRYPTOPHAN SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SALMONELLA-TYPHIMURIUM; MECHANISM	Substrate channeling is a process by which two sequential enzymes interact to transfer a metabolite (or intermediate) from one enzyme active site to the next without allowing free diffusion of the metabolite. Channeling is thought to play an important role in metabolic regulation and cellular modulation of enzymatic activities. Although there are numerous examples of sequential enzyme pairs in glycolysis and other biosynthetic pathways that are thought to exhibit channeling, this is as yet controversial. Tryptophan synthase is considered the best example for an enzyme displaying channeling behavior between subunits. Tryptophan synthase is an alpha(2) beta(2) tetrameric enzyme complex, which catalyzes the last two steps in the biosynthesis of L-tryptophan. The alpha subunit catalyzes the cleavage of indole-3-glycerol phosphate to indole and glyceraldehyde-3-phosphate; the beta subunit catalyzes the condensation of indole with serine to form tryptophan, in a reaction mediated by pyridoxal phosphate. The inability to trap free indole in the steady-state reaction and analysis of the kinetics of single turnover reactions have led to the postulate that indole may pass directly from the alpha to the beta site without diffusion through solution (Demoss, J. A. (1962) Biochim. Biophys. Acta 62, 279-293; Matchett, W. M. (1974) J. Biol. Chem. 249, 4041-4049). The crystal structure of tryptophan synthase from Salmonella typhimurium has provided additional support for substrate channeling by elucidating a 25-Angstrom hydrophobic tunnel connecting the two catalytic sites (Hyde, C. C., Ahmed, S. A., Padlan, E. A., Miles, E. W., and Davies, D. R. (1988) J. Biol. Chem. 263, 17857-17871). The structure suggests that mutation of a residue lining the tunnel to a more bulky residue might impede or block the passage of indole during catalysis thus enabling detection of indole during a single enzyme turnover. A mutant of tryptophan synthase has been prepared in which one of the residues lining the tunnel, beta Cys-170, has been replaced with a bulkier tryptophan residue. Kinetic and structural analyses of the beta C170W mutant by rapid chemical quench methods and x-ray crystallographic analysis show both the transient formation of indole and the obstruction of the tunnel, thus providing direct evidence for the substrate channeling mechanism.	YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; MAX PLANCK INST MED RES,BIOPHYS ABT,D-69120 HEIDELBERG,GERMANY; NIH,BETHESDA,MD 20892	Yale University; Max Planck Society; National Institutes of Health (NIH) - USA			Schlichting, Ilme/I-1339-2013		NIGMS NIH HHS [GM45343] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045343] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED SA, 1985, J BIOL CHEM, V260, P3716; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; CREIGHTO.TE, 1970, EUR J BIOCHEM, V13, P1, DOI 10.1111/j.1432-1033.1970.tb00892.x; DEMOSS JA, 1962, BIOCHIM BIOPHYS ACTA, V62, P279, DOI 10.1016/0006-3002(62)90041-0; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; MATCHETT WH, 1974, J BIOL CHEM, V249, P4041; YANOFSKY C, 1958, BIOCHIM BIOPHYS ACTA, V28, P640, DOI 10.1016/0006-3002(58)90533-X	11	28	28	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26591	26593						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929385				2022-12-27	WOS:A1994PQ93100001
J	BETTS, L; SPREMULLI, LL				BETTS, L; SPREMULLI, LL			ANALYSIS OF THE ROLE OF THE SHINE-DALGARNO SEQUENCE AND MESSENGER-RNA SECONDARY STRUCTURE ON THE EFFICIENCY OF TRANSLATIONAL INITIATION IN THE EUGLENA-GRACILIS CHLOROPLAST ATPH MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; PROTEIN-SYNTHESIS INVITRO; RIBOSOME-BINDING-SITE; MESSENGER-RNA; ESCHERICHIA-COLI; PHENOTYPIC SELECTION; MICROCOCCUS-LUTEUS; SYNTHASE SUBUNITS; BACILLUS-SUBTILIS; RECOGNITION	Chloroplast mRNAs in Euglena gracilis fall into two classes. One class has a Shine-Dalgarno sequence 5' to the AUG start codon while the other group of mRNAs does not have any conserved sequence elements near the start codon. The chloroplast mRNA encoding the atpH gene has been selected as an example of a message which has a Shine-Dalgarno sequence (GGAGUU) located in the initiation region. Mutations in the Shine-Dalgarno sequence result in 2-5-fold reductions in the efficiency of the message in initiation complex formation depending on the precise mutation. Secondary structure mapping of the initiation region of the atpH mRNA suggests that a number of mRNA conformations are present in an equilibrium mixture. Mutations in the Shine-Dalgarno sequence had little effect on the overall structure of the mRNA Directed mutations which place the Shine-Dalgarno sequence into a region of higher secondary structure drastically reduce the activity of the message. The monocistronic form of the atpH mRNA has a 5'-untranslated leader region slightly over 70 nucleotides in length. Deletions in the leader suggest that a minimum length of 10 bases 5' to the start codon is important for activity in initiation. The presence of the full leader increased efficiency in initiation about 2-fold compared to messages with leaders 25-40 residues in length.	UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT CHEM, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024963] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24963] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONHAMSMITH PC, 1989, NUCLEIC ACIDS RES, V17, P2057, DOI 10.1093/nar/17.5.2057; BONI IV, 1991, NUCLEIC ACIDS RES, V19, P155, DOI 10.1093/nar/19.1.155; BORISOVA GP, 1979, NUCLEIC ACIDS RES, V6, P1761, DOI 10.1093/nar/6.5.1761; COX GB, 1987, J BACTERIOL, V169, P2945, DOI 10.1128/jb.169.7.2945-2949.1987; COZENS AL, 1987, J MOL BIOL, V194, P359, DOI 10.1016/0022-2836(87)90667-X; DESMIT MH, 1990, PROG NUCLEIC ACID RE, V38, P1; DESMIT MH, 1994, J MOL BIOL, V235, P173, DOI 10.1016/S0022-2836(05)80024-5; DRAGER R, 1993, THESIS U ARIZONA; DRAGER RG, 1993, CURR GENET, V23, P271, DOI 10.1007/BF00351506; FARWELL MA, 1991, J BACTERIOL, V173, P3514, DOI 10.1128/jb.173.11.3514-3522.1991; FARWELL MA, 1992, MOL MICROBIOL, V6, P3375, DOI 10.1111/j.1365-2958.1992.tb02205.x; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GRAVES MC, 1983, ARCH BIOCHEM BIOPHYS, V222, P192, DOI 10.1016/0003-9861(83)90516-7; GREN EJ, 1984, BIOCHIMIE, V66, P1, DOI 10.1016/0300-9084(84)90188-3; KNAPP G, 1989, METHOD ENZYMOL, V180, P192; KOO JS, 1994, J BIOL CHEM, V269, P7501; KOO JS, 1994, J BIOL CHEM, V269, P7494; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LASO MRV, 1993, J BIOL CHEM, V268, P6453; LOOMAN AC, 1986, NUCLEIC ACIDS RES, V14, P5481, DOI 10.1093/nar/14.13.5481; LOWMAN HB, 1986, J BIOL CHEM, V261, P5396; POTTS M, 1992, SCIENCE, V256, P1690, DOI 10.1126/science.256.5064.1690; RINGQUIST S, 1992, MOL MICROBIOL, V6, P1219, DOI 10.1111/j.1365-2958.1992.tb01561.x; RUF M, 1988, FEBS LETT, V240, P41, DOI 10.1016/0014-5793(88)80336-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ VP, 1990, J MOL BIOL, V211, P427, DOI 10.1016/0022-2836(90)90363-Q; SHELNESS GS, 1985, J BIOL CHEM, V260, P8637; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; STEEGE DA, 1982, J BIOL CHEM, V257, P430; STEITZ JA, 1969, NATURE, V224, P957, DOI 10.1038/224957a0; SUTTLE DP, 1973, BIOCHEM BIOPH RES CO, V51, P376, DOI 10.1016/0006-291X(73)91268-0; VELLANOWETH RL, 1992, MOL MICROBIOL, V6, P1105, DOI 10.1111/j.1365-2958.1992.tb01548.x; WANG CC, 1989, NUCLEIC ACIDS RES, V17, P9735, DOI 10.1093/nar/17.23.9735; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	38	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26456	26463						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929367				2022-12-27	WOS:A1994PQ93000079
J	NOLAN, DP; REVELARD, P; PAYS, E				NOLAN, DP; REVELARD, P; PAYS, E			OVEREXPRESSION AND CHARACTERIZATION OF A GENE FOR A CA2+-ATPASE OF THE ENDOPLASMIC-RETICULUM IN TRYPANOSOMA-BRUCEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORMS; MEMBRANE CA-2+-TRANSPORTING ATPASE; AMINO-ACID-SEQUENCE; SARCOPLASMIC-RETICULUM; PLASMA-MEMBRANE; MOLECULAR-CLONING; CALCIUM HOMEOSTASIS; SCHIZOSACCHAROMYCES-POMBE; ADENOSINE-TRIPHOSPHATASE; SKELETAL-MUSCLE	Procyclic forms of Trypanosoma brucei were stably transformed with an expression vector containing a gene for a P-type ATPase (tba1) cloned from T. brucei genomic DNA. Transformation with this gene resulted specifically in a 4-5-fold increase in the cellular Ca2+-ATPase activity. Subcellular fractionation studies revealed this increase to be enriched in the microsomal fraction. There was no detectable change in the plasma membrane Ca2+-ATPase activity of the transformants. Western blot analysis of subcellular fractions using antibodies raised against the recombinant tba1 gene product also demonstrated a significant enrichment of a protein with a M(r) of 115,000 in the microsomal fraction of transformed cells. This protein was not detected in purified plasma membranes. Significantly, the increased Ca2+-ATPase activity possessed a high affinity for Ca2+. The activity was sensitive to the classical P-type ATPase inhibitor vanadate, anti-tba1 antibodies, as well as low concentrations of thapsigargin, a specific inhibitor of endoplasmic reticulum Ca2+-ATPases. Taken together, these data demonstrated that the tba1 gene codes for a high affinity Ca2+-ATPase of the endoplasmic reticulum, with properties similar to those reported for the sarcoplasmic/endoplasmic reticulum family of Ca2+ pumps from higher eukaryotes. In addition, these results have identified the tba1 gene product as potentially important element, in conjunction with the mitochondrial membrane potential and the plasma membrane Ca2+ pump, in the pathways of cellular Ca2+ homeostasis in these protozoans.	UNIV BRUSSELS,DEPT MOLEC BIOL,B-1640 RHODE ST GENESE,BELGIUM					Nolan, Derek/0000-0002-3742-4304				Andersen JP, 1990, CURR OPIN CELL BIOL, V2, P722, DOI 10.1016/0955-0674(90)90116-V; BENAIM J, 1993, BIOCHEM J, V296, P759; BOWLES DJ, 1982, FEBS LETT, V139, P17, DOI 10.1016/0014-5793(82)80477-8; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURK SE, 1989, J BIOL CHEM, V264, P18561; CARAFOLI E, 1991, ANNU REV PHYSIOL, V53, P531, DOI 10.1146/annurev.physiol.53.1.531; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DEMEIS L, 1990, J BIOL CHEM, V265, P18848; DOLAN MT, 1986, J CELL SCI, V80, P123; DUNN MJ, 1989, PROTEIN PURIFICATION, P13; GHISLAIN M, 1987, J BIOL CHEM, V262, P17549; GHISLAIN M, 1990, J BIOL CHEM, V265, P18400; GHISLAIN M, 1991, J BIOL CHEM, V266, P18276; GREEB J, 1989, J BIOL CHEM, V264, P18569; HARLOW E, 1988, ANTIBODIES LABORATOR; JACKSON DG, 1985, BIOCHEM J, V230, P195, DOI 10.1042/bj2300195; JACKSON DG, 1993, J BIOL CHEM, V268, P8085; LEBERER E, 1986, EUR J BIOCHEM, V156, P489, DOI 10.1111/j.1432-1033.1986.tb09607.x; LEE MGS, 1990, SCIENCE, V250, P1583, DOI 10.1126/science.2177225; LELOIR LF, 1957, METHOD ENZYMOL, V3, P840, DOI 10.1016/S0076-6879(57)03459-X; LOTERSZTAJN S, 1981, J BIOL CHEM, V256, P1209; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1988, J BIOL CHEM, V263, P15024; LYTTON J, 1989, J BIOL CHEM, V264, P7059; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MACARA IG, 1980, TRENDS BIOCHEM SCI, V5, P92, DOI 10.1016/0968-0004(80)90256-X; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; Maniatis T., 1982, MOL CLONING; Martell A. E., 1971, SPECIAL PUBLICATION, V17; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MCLAUGHLIN J, 1985, MOL BIOCHEM PARASIT, V15, P189, DOI 10.1016/0166-6851(85)90119-7; MEADE JC, 1989, MOL BIOCHEM PARASIT, V33, P81, DOI 10.1016/0166-6851(89)90045-5; MEADE JC, 1991, MOL BIOCHEM PARASIT, V45, P29, DOI 10.1016/0166-6851(91)90024-Z; METZ DC, 1992, J BIOL CHEM, V267, P20620; MORENO SNJ, 1992, J BIOL CHEM, V267, P6020; NOLAN DP, 1992, EUR J BIOCHEM, V209, P207, DOI 10.1111/j.1432-1033.1992.tb17278.x; OKOROKOV LA, 1993, EUR J BIOCHEM, V216, P573, DOI 10.1111/j.1432-1033.1993.tb18176.x; OPPERDOES FR, 1981, MOL BIOCHEM PARASIT, V4, P291, DOI 10.1016/0166-6851(81)90062-1; OPPERDOES FR, 1977, EUR J BIOCHEM, V76, P21, DOI 10.1111/j.1432-1033.1977.tb11566.x; OPPERDOES FR, 1981, MOL BIOCHEM PARASIT, V4, P311, DOI 10.1016/0166-6851(81)90063-3; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PERSHADSINGH HA, 1980, J BIOL CHEM, V255, P4087; PRADOFIGUEROA M, 1994, MOL BIOCHEM PARASIT, V63, P255, DOI 10.1016/0166-6851(94)90061-2; REVELARD P, 1991, MOL BIOCHEM PARASIT, V46, P241, DOI 10.1016/0166-6851(91)90048-B; ROLIN S, 1990, EXP PARASITOL, V71, P350, DOI 10.1016/0014-4894(90)90041-A; RUBEN L, 1992, EXP PARASITOL, V74, P332, DOI 10.1016/0014-4894(92)90157-6; RUBEN L, 1991, J BIOL CHEM, V266, P24351; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SACHS G, 1991, Current Opinion in Cell Biology, V3, P685, DOI 10.1016/0955-0674(91)90042-W; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SCHLESSER A, 1988, J BIOL CHEM, V263, P19480; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SIDDIQUI AA, 1990, MOL BIOCHEM PARASIT, V40, P95, DOI 10.1016/0166-6851(90)90083-X; SILLEN LG, 1971, SPECIAL PUBLICATION, V26; SIMONIDES WS, 1990, ANAL BIOCHEM, V191, P321, DOI 10.1016/0003-2697(90)90226-Y; SKERJANC IS, 1993, J BIOL CHEM, V268, P15944; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; STEIGER RF, 1980, EUR J BIOCHEM, V105, P163, DOI 10.1111/j.1432-1033.1980.tb04486.x; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOYOFUKU T, 1992, J BIOL CHEM, V267, P14490; VERCESI AE, 1993, J BIOL CHEM, V268, P8564; VERCESI AE, 1992, MOL BIOCHEM PARASIT, V56, P251, DOI 10.1016/0166-6851(92)90174-I; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VOORHEIS HP, 1981, EUR J BIOCHEM, V116, P471, DOI 10.1111/j.1432-1033.1981.tb05360.x; VOORHEIS HP, 1977, BIOCHEM J, V180, P11; WANG T, 1979, BIOCHEM BIOPH RES CO, V91, P356, DOI 10.1016/0006-291X(79)90626-0; YAMAMOTO H, 1989, J BIOCHEM-TOKYO, V106, P1121, DOI 10.1093/oxfordjournals.jbchem.a122976	76	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26045	26051						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929316				2022-12-27	WOS:A1994PQ93000020
J	PTAK, C; PRENDERGAST, JA; HODGINS, R; KAY, CM; CHAU, V; ELLISON, MJ				PTAK, C; PRENDERGAST, JA; HODGINS, R; KAY, CM; CHAU, V; ELLISON, MJ			FUNCTIONAL AND PHYSICAL CHARACTERIZATION OF THE CELL-CYCLE UBIQUITIN-CONJUGATING ENZYME CDC34 (UBC3) - IDENTIFICATION OF A FUNCTIONAL DETERMINANT WITHIN THE TAIL THAT FACILITATES CDC34 SELF-ASSOCIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; SACCHAROMYCES-CEREVISIAE; RNA-POLYMERASE; GENE-PRODUCTS; RAD6 PROTEIN; SYSTEM; DOMAIN; E2; DEGRADATION; EXPRESSION	Like several other ubiquitin-conjugating enzymes, the yeast cell cycle enzyme CDC34 (UBCS) has a carboxyl terminal extension or tail. These tails appear to carry out unique functions that can vary from one ubiquitin-conjugating enzyme to the next. Using biophysical techniques we have determined that the tail of CDC34 constitutes a highly structured and extended domain. Although the tail of CDC34 is the largest tail identified to date (125 residues), we have found that only 39 residues lying adjacent to the catalytic domain are necessary and sufficient for full cell cycle function and that this region fulfills a novel function that may be common to the tails of other ubiquitin-conjugating enzymes. Cross-linking studies demonstrate that this region facilitates a physical interaction between CDC34 monomers in vitro. Furthermore, phenotypic analysis of various CDC34 derivatives expressed in different cdc34 mutant strains indicates that this region facilitates the same interaction in vivo. Based on these findings, it appears that the cell cycle function of CDC34 is dependent upon the ability of CDC34 monomers to interact with one another and that this interaction is mediated by a small region of the CDC34 tail. The similarity of this region with sequences contained within the tails of the UBC1 and UBC6 enzymes suggests that these tails may function in a similar manner.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2H7,AB,CANADA; WAYNE STATE UNIV,SCH MED,DEPT PHARMACOL,DETROIT,MI 48201	University of Alberta; Wayne State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047604] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47604] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Chervenka C. H., 1969, MANUAL METHODS ANAL; COOK WJ, 1992, J BIOL CHEM, V267, P16467; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; FINLEY D, 1992, MOL CELLULAR BIOL YE, V2, P539; GIROD PA, 1993, J BIOL CHEM, V268, P955; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GONDA DK, 1989, J BIOL CHEM, V264, P16700; HAAS AL, 1991, J BIOL CHEM, V266, P5104; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser Mark, 1992, Current Opinion in Cell Biology, V4, P1024, DOI 10.1016/0955-0674(92)90135-Y; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JENTSCH S, 1990, TRENDS BIOL SCI, V15, P105; KOLMAN CJ, 1992, EMBO J, V11, P3081, DOI 10.1002/j.1460-2075.1992.tb05380.x; MORRISON A, 1988, MOL CELL BIOL, V8, P1179, DOI 10.1128/MCB.8.3.1179; PICKART CM, 1985, J BIOL CHEM, V260, P1573; SCHACHMAN HK, 1959, ULTRACENTRIFUGATION, P236; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; Sherman F., 1981, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SILVER ET, 1992, EMBO J, V11, P3091, DOI 10.1002/j.1460-2075.1992.tb05381.x; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUNG P, 1988, GENE DEV, V2, P1476, DOI 10.1101/gad.2.11.1476; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Tanford C., 1961, PHYSICAL CHEM MACROM, P317; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K	29	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26539	26545						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929378				2022-12-27	WOS:A1994PQ93000091
J	BENOV, LT; FRIDOVICH, I				BENOV, LT; FRIDOVICH, I			ESCHERICHIA-COLI EXPRESSES A COPPER-CONTAINING AND ZINC-CONTAINING SUPEROXIDE-DISMUTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOBACTERIUM-LEIOGNATHI; CAULOBACTER-CRESCENTUS; GENE-TRANSFER; BRUCELLA-ABORTUS; BACTERIOCUPREIN; BACTERIUM; PONYFISH; CLONING; MUTANTS; ENZYME	A mutant of Escherichia coli, unable to produce manganese- or iron-containing superoxide dismutase (SOD), was found to contain modest levels of an SOD that was judged to be a copper and zinc-containing SOD on the basis of inhibition by cyanide and inactivation by either H2O2 or diethyldithiocarbamate. Moreover, the diethyldithiocarbamate-inactivated enzyme could be reactivated with Cu(II), and this reconstituted enzyme, like the native enzyme, was unaffected by EDTA and was inhibited by cyanide. This enzyme was, furthermore, selectively released by osmotic shock, in keeping with a periplasmic localization, and it was strongly induced during aerobic growth. This enzyme was also present in the SOD-competent parental strain. Failure to detect it previously can be attributed to its periplasmic localization, thermal lability, sensitivity to pH, and to its relative paucity. It will now be interesting to explore the phenotypic consequences imposed by the absence of this SOD.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; MED UNIV STARA ZAGORA, DEPT BIOPHYS, BU-6000 STARA ZAGORA, BULGARIA	Duke University; Trakia University			Benov, Ludmil/AAD-3714-2020	Benov, Ludmil/0000-0002-0205-0146	FIC NIH HHS [1 F05 TW04975] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004975] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		BANNISTER JV, 1985, P NATL ACAD SCI USA, V82, P149, DOI 10.1073/pnas.82.1.149; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BEAUCHAMP CO, 1973, BIOCHIM BIOPHYS ACTA, V317, P50, DOI 10.1016/0005-2795(73)90198-0; BECK BL, 1990, BIOCHEMISTRY-US, V29, P372, DOI 10.1021/bi00454a010; BRICKER BJ, 1990, INFECT IMMUN, V58, P2935, DOI 10.1128/IAI.58.9.2935-2939.1990; BUTLER J, 1975, BIOCHIM BIOPHYS ACTA, V408, P215, DOI 10.1016/0005-2728(75)90124-3; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CORNISHBOWDEN A, 1985, EUR J BIOCHEM, V151, P333, DOI 10.1111/j.1432-1033.1985.tb09105.x; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; FARR SB, 1986, P NATL ACAD SCI USA, V83, P8268, DOI 10.1073/pnas.83.21.8268; FORMAN HJ, 1973, J BIOL CHEM, V248, P2645; HIRATA F, 1975, J BIOL CHEM, V250, P5960; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; KANEMATSU S, 1978, ARCH BIOCHEM BIOPHYS, V185, P473, DOI 10.1016/0003-9861(78)90191-1; KLUG D, 1972, J BIOL CHEM, V247, P4839; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LANGFORD PR, 1992, J GEN MICROBIOL, V138, P517, DOI 10.1099/00221287-138-3-517; LEUNISSEN JAM, 1986, J MOL EVOL, V23, P250, DOI 10.1007/BF02115581; LUNN CA, 1982, J BIOL CHEM, V257, P1424; MARTIN JP, 1981, J BIOL CHEM, V256, P6080; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MISRA HP, 1979, J BIOL CHEM, V254, P1623; PUGET K, 1974, BIOCHEM BIOPH RES CO, V58, P830, DOI 10.1016/S0006-291X(74)80492-4; PUGET K, 1974, BIOCHIMIE, V56, P1255, DOI 10.1016/S0300-9084(74)80019-2; RAJAGOPALAN KV, 1985, CRC HDB METHODS OXYG, P21; STEFFENS GJ, 1983, H-S Z PHYSIOL CHEM, V364, P675, DOI 10.1515/bchm2.1983.364.1.675; STEINMAN HM, 1990, J BACTERIOL, V172, P2901, DOI 10.1128/jb.172.6.2901-2910.1990; STEINMAN HM, 1987, J BIOL CHEM, V262, P1882; STEINMAN HM, 1982, J BIOL CHEM, V257, P283; STEINMAN HM, 1985, J BACTERIOL, V162, P1255, DOI 10.1128/JB.162.3.1255-1260.1985; STEINMAN HM, 1993, J BACTERIOL, V175, P1198, DOI 10.1128/JB.175.4.1198-1202.1993; TATUM FM, 1992, INFECT IMMUN, V60, P2863, DOI 10.1128/IAI.60.7.2863-2869.1992; Tsuchihashi M, 1923, BIOCHEM Z, V140, P63; WEISIGER RA, 1973, J BIOL CHEM, V248, P3582	34	169	171	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25310	25314						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929223				2022-12-27	WOS:A1994PQ49100014
J	BOREN, J; RUSTAEUS, S; OLOFSSON, SO				BOREN, J; RUSTAEUS, S; OLOFSSON, SO			STUDIES ON THE ASSEMBLY OF APOLIPOPROTEIN-B-100-CONTAINING AND APOLIPOPROTEIN-B-48-CONTAINING VERY-LOW-DENSITY LIPOPROTEINS IN MCA-RH7777 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; HEP G2 CELLS; ENDOPLASMIC-RETICULUM; MESSENGER-RNA; RAT-LIVER; APO-B-100-CONTAINING LIPOPROTEINS; APO-B; GROWTH-HORMONE; SECRETION; LINE	The mechanisms by which apolipoprotein B-100 (apoB-100) and apoB-48 assemble lipoproteins have been studied in the McA-RH7777 cell line. After incubation for 2 h with 360 mu M oleic acid, the McA-RH7777 cells secreted apoB-100 mainly on very low density lipoprotein (VLDL) particles, as judged from sucrose gradient and sequential ultracentrifugation. ApoB-48 was secreted on both VLDL and on denser, high density lipoprotein (HDL)-like lipoproteins. Both apoB-48 and apoB-100 occurred on VLDL particles in the luminal content of the total microsomal fraction. In addition, both proteins were present on denser particles, in particular, those that banded in the HDL region. The denser particles containing apoB-48 were secreted from the cells, whereas those containing apoB-100 were retained in the cell and degraded. Pulse-chase experiments showed that apoB-100 on VLDL was present in the secretory pathway already after a labeling period as short as 3 min. Thus, this particle was the first apoB-100 containing lipoprotein that could be detected in the microsomal fraction of the cell. The assembly of labeled apoB-100 VLDL was acutely (within min) and completely blocked by cycloheximide, if the cycloheximide was added after the pulse labeling period. If, on the other hand, a 15-min chase was introduced after the labeling period, there was no effect of cycloheximide on the assembly of apoB-100 VLDL. A 15-min chase is enough to allow the pulse-labeled apoB nascent polypeptides to be completed to apoB-100. These results indicated that the assembly of apoB-100 containing VLDL is dependent upon ongoing protein biosynthesis during the time when the nascent polypeptide elongate. After this period, the assembly and secretion of the particles are independent of ongoing protein biosynthesis. The first apoB-48-containing particle seen in the luminal content of the microsomal fraction was the HDL-like particle. Pulse-chase experiments as well as experiments with different lengths of the radioactive pulse indicated that the formation of apoB-48-containing VLDL was delayed compared with the formation of the apoB-48-containing HDL-like particle and also in relation to the assembly of the different apoB-100-containing particles, including VLDL. After a 30-min pulse with [S-35]methionine followed by a 120-min chase the secretory pathway of the cell was depleted of almost all lipoproteins except the HDL-like apoB-48-containing particle. During a new chase of 180 min in the presence of oleic acid, this HDL-like particle was to a large degree converted to apoB-48-containing VLDL. This conversion was partially inhibited by cycloheximide. Thus, contrary to apoB-100 VLDL the formation of apoB-48 VLDL was influenced by cycloheximide after the completion of the apolipoprotein. Together these results indicated that apoB-48 VLDL is formed in at least two steps. The first step is the formation of a precursor HDL-like particle. This HDL particle is then converted, in a second step, to apoB-48 VLDL.	GOTHENBURG UNIV,DEPT BIOCHEM MED,S-41390 GOTHENBURG,SWEDEN; GOTHENBURG UNIV,WALLENBERG LAB,S-41390 GOTHENBURG,SWEDEN	University of Gothenburg; University of Gothenburg								ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; BLACKHART BD, 1990, J BIOL CHEM, V265, P8358; BOREN J, 1993, ARTERIOSCLER THROMB, V13, P1743, DOI 10.1161/01.ATV.13.12.1743; BOREN J, 1991, PROG LIPID RES, V30, P205, DOI 10.1016/0163-7827(91)90017-Y; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1993, BIOCHEM SOC T, V21, P487, DOI 10.1042/bst0210487; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; DAVIDSON NO, 1990, MOL ENDOCRINOL, V4, P779, DOI 10.1210/mend-4-5-779; FAINARU M, 1977, METABOLISM, V26, P999, DOI 10.1016/0026-0495(77)90017-8; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GLICKMAN RM, 1986, P NATL ACAD SCI USA, V83, P5296, DOI 10.1073/pnas.83.14.5296; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; JAVITT NB, 1990, FASEB J, V4, P161, DOI 10.1096/fasebj.4.2.2153592; KANE JP, 1980, P NATL ACAD SCI-BIOL, V77, P2465, DOI 10.1073/pnas.77.5.2465; LAU PP, 1991, J BIOL CHEM, V266, P20550; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; LEVY E, 1987, J LIPID RES, V28, P1263; OLOFSSON SO, 1980, BIOCHEMISTRY-US, V19, P1059, DOI 10.1021/bi00547a002; PELHAM HRB, 1989, BIOCHEM SOC T, V17, P795, DOI 10.1042/bst0170795; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTHMAN JE, 1987, CELL, V50, P521, DOI 10.1016/0092-8674(87)90024-9; SCOTT J, 1989, MOL BIOL MED, V6, P65; SJOBERG A, 1992, ENDOCRINOLOGY, V130, P3356, DOI 10.1210/en.130.6.3356; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; TANABE S, 1993, CELL DEV BIOL, V25, P1129; THRIFT RN, 1986, J LIPID RES, V27, P236; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTESTEN M, 1985, EUR J BIOCHEM, V149, P461, DOI 10.1111/j.1432-1033.1985.tb08947.x; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WINDMUELLER HG, 1985, J LIPID RES, V26, P70; YAO ZM, 1991, J BIOL CHEM, V266, P3300	35	189	190	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25879	25888						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929292				2022-12-27	WOS:A1994PQ49100094
J	JACOBS, M; FREEDMAN, SJ; FURIE, BC; FURIE, B				JACOBS, M; FREEDMAN, SJ; FURIE, BC; FURIE, B			MEMBRANE-BINDING PROPERTIES OF THE FACTOR-IX GAMMA-CARBOXYGLUTAMIC ACID-RICH DOMAIN PREPARED BY CHEMICAL SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FACTOR-IX; INVITRO ANTICOAGULANT ACTIVITY; BETA-HYDROXYASPARTIC ACID; COAGULATION FACTOR-IX; ACTIVATED PROTEIN-C; PHOSPHOLIPID-VESICLES; BLOOD-COAGULATION; CONFORMATIONAL TRANSITIONS; CALCIUM-BINDING; METAL-IONS	The fully gamma-carboxylated peptides based upon the complete and truncated Gla/aromatic amino acid stack domains of human Factor IX were prepared by solid phase peptide synthesis using Fmoc (N-(9-fluorenyl)methoxycarbonyl) chemistry. A 47-residue peptide Factor IX-(1-47) and a 42-residue peptide Factor IX-(1-42), both containing 12 residues of L-gamma-carboxyglutamic acid, were purified by high performance liquid chromatography and oxidized to form the disulfide bond. Quantitative gamma-carboxyglutamic acid analysis of Factor IX-(1-47) and Factor IX-(1-42) indicated the presence of 12.1 and 11.2 gamma-carboxyglutamic acid residues/mol of peptide, respectively; no glutamic acid was detected. As monitored by fluorescence quenching, calcium ions induced the prototypical conformational transition in Factor IX-(1-47), but not in Factor IX-(1-42), that is observed with Factor IX. Half-maximal quenching of the intrinsic fluorescence of Factor IX-(1-47) was observed at Ca(II) concentrations of about 50 mu M. Factor IX-(1-47) bound to the conformation-specific antibodies, anti-Factor IX:Mg(II) and anti-Factor IX:Ca(II)-specific in the presence of metal ions. Factor IX-(1-47) bound to phospholipid membranes, as monitored by energy transfer from intrinsic fluorophores to dansyl (5-dimethylaminonaphthalene-1-sulfonyl)-phosphatidylethanolamine incorporated into a lipid bilayer composed of phosphatidylserine:phosphatidylcholine. In contrast, Factor IX-(1-42) bound poorly to these same membranes, Factor IX-(1-47) did not inhibit Factor XIa activation of Factor IX but did inhibit the activation of Factor X by Factor Ma bound to Factor VIII in the presence of calcium ions and phospholipid. These results show that phospholipid membrane binding is a property of the Gla/aromatic amino acid stack domain and that the Factor IX-(1-47) peptide, prepared by chemical synthesis, preserves the membrane binding properties and the metal-induced conformational transitions observed in native Factor IX. These results indicate that Factor IX-(1-47) but not Factor IX-(1-42) is a suitable model for structural studies of Factor IX-membrane interaction.	TUFTS UNIV NEW ENGLAND MED CTR, CTR HEMOSTASIS & THROMBOSIS RES, DIV HEMATOL ONCOL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT MED, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts University					NHLBI NIH HHS [HL42443] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL042443] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMPHLETT GW, 1978, J BIOL CHEM, V253, P6774; AMPHLETT GW, 1981, ARCH BIOCHEM BIOPHYS, V208, P576, DOI 10.1016/0003-9861(81)90546-4; ASTERMARK J, 1994, J BIOL CHEM, V269, P3682; ASTERMARK J, 1992, J BIOL CHEM, V267, P3249; BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; BAJAJ SP, 1982, J BIOL CHEM, V257, P4127; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BEALS JM, 1986, BIOCHEM J, V236, P861, DOI 10.1042/bj2360861; BOROWSKI M, 1986, J BIOL CHEM, V261, P4969; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CHOO KH, 1982, NATURE, V299, P178, DOI 10.1038/299178a0; COLPITTS TL, 1994, BIOCHEMISTRY-US, V33, P3501, DOI 10.1021/bi00178a006; FERNLUND P, 1983, J BIOL CHEM, V258, P2509; FREEDMAN SJ, 1994, IN PRESS CIRCULATION; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; FURIE BC, 1979, J BIOL CHEM, V254, P2521; GILBERT GE, 1990, J BIOL CHEM, V265, P815; JONES ME, 1985, BIOCHEMISTRY-US, V24, P8064, DOI 10.1021/bi00348a034; KOTKOW KJ, 1993, J BIOL CHEM, V268, P15633; KOTKOW KJ, 1993, METHOD ENZYMOL, V45, P435; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; KUSTER H, 1992, J BIOL CHEM, V267, P12782; KUWADA M, 1983, ANAL BIOCHEM, V131, P173, DOI 10.1016/0003-2697(83)90150-1; LIEBMAN HA, 1987, J BIOL CHEM, V262, P7605; MANN KG, 1982, BIOPHYS J, V37, P106, DOI 10.1016/S0006-3495(82)84624-9; MARTIN DMA, 1993, BIOCHEMISTRY-US, V32, P13949, DOI 10.1021/bi00213a026; MCMULLEN BA, 1983, BIOCHEM BIOPH RES CO, V115, P8, DOI 10.1016/0006-291X(83)90961-0; MEDVED LV, 1994, BIOCHEMISTRY-US, V33, P478, DOI 10.1021/bi00168a012; MORITA T, 1984, J BIOL CHEM, V259, P5698; NELSESTUEN GL, 1981, BIOCHEMISTRY-US, V20, P351, DOI 10.1021/bi00505a019; RABIET MJ, 1987, J BIOL CHEM, V262, P14895; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWALBE RA, 1989, J BIOL CHEM, V264, P20288; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; TAI MM, 1984, J BIOL CHEM, V259, P4162; VYSOTCHIN A, 1993, J BIOL CHEM, V268, P8436; WINSHIP PR, 1991, BRIT J HAEMATOL, V77, P102, DOI 10.1111/j.1365-2141.1991.tb07955.x; ZHANG L, 1990, BIOCHEMISTRY-US, V29, P10828, DOI 10.1021/bi00500a016; ZHANG L, 1992, BLOOD, V80, P942; ZHANG L, 1991, BIOCHEMISTRY-US, V30, P6696, DOI 10.1021/bi00241a009	41	48	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25494	25501						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929250				2022-12-27	WOS:A1994PQ49100043
J	MORGAN, PJ; HYMAN, SC; BYRON, O; ANDREW, PW; MITCHELL, TJ; ROWE, AJ				MORGAN, PJ; HYMAN, SC; BYRON, O; ANDREW, PW; MITCHELL, TJ; ROWE, AJ			MODELING THE BACTERIAL PROTEIN TOXIN, PNEUMOLYSIN, IN ITS MONOMERIC AND OLIGOMERIC FORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE-MEMBRANES; STREPTOLYSIN-O; STREPTOCOCCUS-PNEUMONIAE; PERFRINGOLYSIN-O	Pneumolysin is a member of the family of related bacterial thiol-activated toxins, which share structural similarities and a proposed common cytolytic mechanism. Currently the molecular mechanism of membrane damage caused by these toxins remains a matter of controversy. A prerequisite for defining this mechanism is a detailed knowledge of the monomeric and oligomeric pneumolysin structures. We present for the first time details of the monomeric structure of a thiol-activated toxin, pneumolysin. Electron microscope images of metal-shadowed pneumolysin monomers show an asymmetric molecule composed of four domains. We have studied the conformation of pneumolysin monomer by low resolution hydrodynamic bead modeling procedures. The bead model dimensions and shape are derived solely from the electron micrographs. The bead model has been evaluated in terms of the predicted solution properties, which in turn have been compared to the experimental values of the sedimentation coefficient, s(20,w)(0), obtained by analytical ultracentrifugation and the intrinsic viscosity, [eta]. Pneumolysin oligomers, observed as ring- and are-shaped structures, were also examined by electron microscopy. Metal shadowing and negative staining methods were used to establish the overall dimensions of the oligomer and were used to produce a morphological model for the oligomer, incorporating monomer subunits based on the hydrodynamic bead model.	UNIV LEICESTER, DEPT BIOCHEM, NCMH, LEICESTER LE1 7RH, LEICS, ENGLAND; UNIV LEICESTER, SCH BIOL SCI, ELECTRON MICROSCOPE LABS, LEICESTER LE1 7RH, LEICS, ENGLAND	University of Leicester; University of Leicester	MORGAN, PJ (corresponding author), UNIV LEICESTER, DEPT MICROBIOL & IMMUNOL, POB 148, UNIV RD, LEICESTER LE1 9HN, LEICS, ENGLAND.		Andrew, Peter W/G-7526-2012	Byron, Olwyn/0000-0001-7857-4520; Mitchell, Timothy/0000-0002-8309-5556				Alouf JE, 1991, SOURCEBOOK BACTERIAL, P147; AUSTRIAN R, 1981, REV INFECT DIS, V3, P183; BERRY AM, 1989, INFECT IMMUN, V57, P2037, DOI 10.1128/IAI.57.7.2037-2042.1989; BHAKDI S, 1985, INFECT IMMUN, V47, P52; COWELL JL, 1978, BIOCHIM BIOPHYS ACTA, V507, P230, DOI 10.1016/0005-2736(78)90419-4; DELATORRE JG, 1981, Q REV BIOPHYS, V14, P81, DOI 10.1017/S0033583500002080; DELATORRE JG, 1989, ROY SOC CH, V74, P3; DOURMASHKIN RR, 1966, AM J MED, V41, P699, DOI 10.1016/0002-9343(66)90031-3; DUNCAN JL, 1975, J CELL BIOL, V67, P160, DOI 10.1083/jcb.67.1.160; HARRIS RW, 1991, J BIOL CHEM, V266, P6936; KLUG A, 1969, NOBEL S, V11, P425; MITCHELL TJ, 1989, BIOCHIM BIOPHYS ACTA, V1007, P67, DOI 10.1016/0167-4781(89)90131-0; MITSUI K, 1979, BIOCHIM BIOPHYS ACTA, V558, P307, DOI 10.1016/0005-2736(79)90265-7; MORGAN PJ, 1993, BIOCHEM J, V296, P671, DOI 10.1042/bj2960671; MORGAN PJ, 1994, BACTERIAL PROTEIN S, V24, P333; NIEDERMEYER W, 1985, TOXICON, V23, P425, DOI 10.1016/0041-0101(85)90026-1; OLOFSSON A, 1993, FEBS LETT, V319, P125, DOI 10.1016/0014-5793(93)80050-5; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; ROCCO M, 1993, PROTEIN SCI, V2, P2154, DOI 10.1002/pro.5560021215; ROTTEM S, 1982, J BACTERIOL, V152, P888; ROWE AJ, 1984, TECHNIQUES PROTEIN E, P29; SAUNDERS FK, 1989, INFECT IMMUN, V57, P2547, DOI 10.1128/IAI.57.8.2547-2552.1989; SEKIYA K, 1993, J BACTERIOL, V175, P5953, DOI 10.1128/JB.175.18.5953-5961.1993; SZUCHET-DERECHIN S., 1966, European Polymer Journal, V2, P115, DOI 10.1016/0014-3057(66)90067-X; TANFORD C, 1955, J PHYS CHEM-US, V59, P798, DOI 10.1021/j150530a027; TANFORD C, 1963, PHYSICAL CHEM MACROM; TRANUMJENSEN J, 1978, SCAND J IMMUNOL, V7, P45, DOI 10.1111/j.1365-3083.1978.tb00425.x; WILMSEN HU, 1992, EMBO J, V11, P2457, DOI 10.1002/j.1460-2075.1992.tb05310.x	28	55	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25315	25320						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929224				2022-12-27	WOS:A1994PQ49100015
J	GILBERT, MT; SUN, JD; YAN, Y; ODDOUX, C; LAZARUS, A; TANSEY, WP; LAVIN, TN; CATANZARO, DF				GILBERT, MT; SUN, JD; YAN, Y; ODDOUX, C; LAZARUS, A; TANSEY, WP; LAVIN, TN; CATANZARO, DF			RENIN GENE PROMOTER ACTIVITY IN GC CELLS IS REGULATED BY CAMP AND THYROID-HORMONE THROUGH PIT-1-DEPENDENT MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PIT-1; RAT GROWTH-HORMONE; THYROTROPIN-BETA-GENE; HUMAN PROLACTIN GENE; POU-DOMAIN; ANGIOTENSIN SYSTEM; RESPONSE ELEMENTS; DNA-SEQUENCES; EXPRESSION; BINDING	Transcriptional activity of human renin gene (hREN) 5'-flanking DNA sequences in pituitary cells is highly dependent on binding of the pituitary-specific transcription factor Pit-1. Pit-1 has been implicated in cAMP regulation of a number of pituitary genes and has also been shown to interact with thyroid hormone (T-3) receptors in mediating T-3 responsiveness of the rat growth hormone gene. In the present study we examine the effects of forskolin and T-3 on the expression of luciferase hybrid genes containing hREN 5'-flanking DNAs (hREN.luc) transiently transfected into the pituitary cell line GC. Basal activities of all hREN.luc constructs transfected into cells grown in media containing serum stripped of hormones were low. Addition of forskolin stimulated expression up to 48 fold, depending on the hREN sequences present. The hREN sequence -148 to +18 was sufficient for both maximal expression and maximal stimulation by forskolin. Mutagenesis of the Pit-1 site between -82 and -58 reduced forskolin induction 4-5-fold. In addition to the Pit-1 site, the sequence between -148 and -98 was also required for maximal activity and forskolin induction. T-3 on its own had no effect on hREN promoter activity in GC cells, but suppressed the effects of forskolin. Gel mobility shift and Western blot analyses indicated that forskolin treatment had no effect on Pit-1 DNA binding or Pit-1 levels. However, T-3 reduced Pit-1 levels which was reflected in lower DNA binding under the conditions employed. Taken together, these findings emphasize the importance of cAMP-dependent mechanisms in directing renin gene expression.	CORNELL UNIV, COLL MED, CTR CARDIOVASC, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT MED, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT PHYSIOL, NEW YORK, NY 10021 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Cornell University; Cornell University; Cornell University; Cold Spring Harbor Laboratory					NHLBI NIH HHS [HL18323] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018323] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BURT DW, 1989, J BIOL CHEM, V264, P7357; CATANZARO DF, 1985, ENDOCRINOLOGY, V117, P872, DOI 10.1210/endo-117-3-872; CHURCHILL PC, 1985, AM J PHYSIOL, V249, pF175, DOI 10.1152/ajprenal.1985.249.2.F175; DANA S, 1989, MOL ENDOCRINOL, V3, P815, DOI 10.1210/mend-3-5-815; DARBRE A, 1986, PRACTICAL PROTEIN CH, P284; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; DUNCAN KG, 1990, P NATL ACAD SCI USA, V87, P7588, DOI 10.1073/pnas.87.19.7588; ELIAS AN, 1986, HORM METAB RES, V18, P349, DOI 10.1055/s-2007-1012312; EVERETT AD, 1990, J CLIN INVEST, V86, P169, DOI 10.1172/JCI114680; FOX SR, 1990, MOL ENDOCRINOL, V4, P1069, DOI 10.1210/mend-4-7-1069; HARO JM, 1992, J ENDOCRINOL INVEST, V15, P605, DOI 10.1007/BF03344933; HAUGEN BR, 1993, J BIOL CHEM, V268, P20818; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HOGGARD N, 1991, MOL ENDOCRINOL, V5, P1748, DOI 10.1210/mend-5-11-1748; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JIMENEZ E, 1982, REV ESP FISIOL, V38, P35; JIMENEZ E, 1984, ACTA ENDOCRINOL-COP, V105, P505, DOI 10.1530/acta.0.1050505; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KIM MK, 1993, J BIOL CHEM, V268, P23366; KING IN, 1993, J BIOL CHEM, V268, P495; KONZAK KE, 1992, MOL ENDOCRINOL, V6, P241, DOI 10.1210/me.6.2.241; KURTZ A, 1989, REV PHYSIOL BIOCH P, V113, P1; LIN CJ, 1992, NATURE, V360, P765, DOI 10.1038/360765a0; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MASON ME, 1993, BIOCHEMISTRY-US, V32, P8932, DOI 10.1021/bi00085a026; MONTIEL M, 1984, J ENDOCRINOL INVEST, V7, P559, DOI 10.1007/BF03349486; MORRIS AE, 1992, NUCLEIC ACIDS RES, V20, P1355, DOI 10.1093/nar/20.6.1355; NAGAMINE Y, 1985, P NATL ACAD SCI USA, V82, P4606, DOI 10.1073/pnas.82.14.4606; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; PEERS B, 1991, J BIOL CHEM, V266, P18127; PRACYK JB, 1991, J DEV PHYSIOL, V16, P251; RESNICK LM, 1982, LIFE SCI, V30, P585, DOI 10.1016/0024-3205(82)90273-9; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; RICHARDS AM, 1985, CLIN EXP HYPERTENS A, V7, P1499, DOI 10.3109/10641968509073606; RUIZ M, 1987, J ENDOCRINOL, V115, P311, DOI 10.1677/joe.0.1150311; SCHADLOW VC, 1992, MOL BIOL CELL, V3, P941, DOI 10.1091/mbc.3.8.941; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; SEEBURG PH, 1977, NATURE, V270, P486, DOI 10.1038/270486a0; SERNIA C, 1993, CARDIOVASC RES, V27, P423, DOI 10.1093/cvr/27.3.423; SHEPARD AR, 1994, J BIOL CHEM, V269, P1804; SIGMUND CD, 1990, J BIOL CHEM, V265, P19916; STEINFELDER HJ, 1991, P NATL ACAD SCI USA, V88, P3130, DOI 10.1073/pnas.88.8.3130; STEINFELDER HJ, 1992, P NATL ACAD SCI USA, V89, P5942, DOI 10.1073/pnas.89.13.5942; SUN JD, 1993, J BIOL CHEM, V268, P1505; SUN JD, 1994, CIRC RES, V75, P624, DOI 10.1161/01.RES.75.4.624; TANSEY WP, 1993, J BIOL CHEM, V268, P14906; TANSEY WP, 1991, J BIOL CHEM, V266, P9805; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x; YAN GZ, 1991, MOL ENDOCRINOL, V5, P1488, DOI 10.1210/mend-5-10-1488	52	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28049	28054						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961740				2022-12-27	WOS:A1994PV77200044
J	RIBAS, JC; FUJIMURA, T; WICKNER, RB				RIBAS, JC; FUJIMURA, T; WICKNER, RB			ESSENTIAL RNA-BINDING AND PACKAGING DOMAINS OF THE GAG-POL FUSION PROTEIN OF THE L-A DOUBLE-STRANDED-RNA VIRUS OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROTAVIRUS NONSTRUCTURAL PROTEIN; HEPATITIS-B VIRUS; CONSENSUS SEQUENCE; VIRAL-RNA; YEAST; EXPRESSION; INVITRO; ENCAPSIDATION; REPLICATION; POLYMERASE	The crucial process in the assembly of the L-A double-stranded RNA virus is the recognition of its (+) single-stranded RNA by the Gag-Pol protein. The Pol region of this protein has RNA binding activity and is necessary for RNA packaging. Here we show that there are actually two in vitro RNA-binding domains of Pol (residues 172-190 and 770-819), and both are necessary for viral propagation, (but not for particle assembly). Furthermore, the N-terminal RNA-binding domain is necessary for in vivo packaging of viral (+) single-stranded RNA. We precisely define the extent of the Pol packaging domain (residues 67-213), which includes the N-terminal RNA-binding domain. This suggests that the N-terminal RNA-binding domain is responsible for binding the genomic RNA in the process of packaging and that additional surrounding residues are responsible for the specificity of binding.			RIBAS, JC (corresponding author), NIDDK,BIOCHEM PHARMACOL LAB,GENET SIMPLE EUKARYOTES SECT,BETHESDA,MD 20892, USA.		Ribas, Juan C/C-9864-2015; Fujimura, Tsutomu/K-5807-2014	Ribas, Juan C/0000-0001-6430-0895; Fujimura, Tsutomu/0000-0002-9457-6769				BARTENSCHLAGER R, 1990, J VIROL, V64, P5324, DOI 10.1128/JVI.64.11.5324-5332.1990; BLANC A, 1994, MOL CELL BIOL, V14, P2664, DOI 10.1128/MCB.14.4.2664; BROTTIER P, 1992, J GEN VIROL, V73, P1931, DOI 10.1099/0022-1317-73-8-1931; BRUENN JA, 1991, NUCLEIC ACIDS RES, V19, P217, DOI 10.1093/nar/19.2.217; CHEN D, 1990, VIROLOGY, V176, P143; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; DINMAN JD, 1991, P NATL ACAD SCI USA, V88, P174, DOI 10.1073/pnas.88.1.174; ESTEBAN R, 1989, EMBO J, V8, P947, DOI 10.1002/j.1460-2075.1989.tb03456.x; ESTEBAN R, 1988, J VIROL, V62, P1278, DOI 10.1128/JVI.62.4.1278-1285.1988; ESTEBAN R, 1988, P NATL ACAD SCI USA, V85, P4411, DOI 10.1073/pnas.85.12.4411; FUJIMURA T, 1992, J BIOL CHEM, V267, P2708; FUJIMURA T, 1992, NATURE, V359, P746, DOI 10.1038/359746a0; FUJIMURA T, 1988, CELL, V55, P663, DOI 10.1016/0092-8674(88)90225-5; FUJIMURA T, 1990, CELL, V62, P819, DOI 10.1016/0092-8674(90)90125-X; FUJIMURA T, 1988, J BIOL CHEM, V263, P454; FUJIMURA T, 1989, J BIOL CHEM, V264, P10872; GORELICK RJ, 1988, P NATL ACAD SCI USA, V85, P8420, DOI 10.1073/pnas.85.22.8420; HATTON T, 1992, J VIROL, V66, P5232, DOI 10.1128/JVI.66.9.5232-5241.1992; HIRSCH RC, 1990, NATURE, V344, P552, DOI 10.1038/344552a0; HUA J, 1994, IN PRESS J VIROL, V68; ICHO T, 1989, J BIOL CHEM, V264, P6716; KATTOURA MD, 1992, VIROLOGY, V191, P698, DOI 10.1016/0042-6822(92)90245-K; KLEBE RJ, 1983, GENE, V25, P333, DOI 10.1016/0378-1119(83)90238-X; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUBAN J, 1991, J VIROL, V65, P3203, DOI 10.1128/JVI.65.6.3203-3212.1991; MANDECKI W, 1986, GENE, V43, P131, DOI 10.1016/0378-1119(86)90016-8; MATTION NM, 1992, VIROLOGY, V190, P68, DOI 10.1016/0042-6822(92)91193-X; PETRIE BL, 1984, VIRUS RES, V1, P133, DOI 10.1016/0168-1702(84)90069-8; PONCET D, 1993, J VIROL, V67, P3159, DOI 10.1128/JVI.67.6.3159-3165.1993; RIBAS JC, 1992, P NATL ACAD SCI USA, V89, P2185, DOI 10.1073/pnas.89.6.2185; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; VALLE RPC, 1993, J VIROL, V67, P2764, DOI 10.1128/JVI.67.5.2764-2771.1993; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WICKNER RB, 1991, J VIROL, V65, P155, DOI 10.1128/JVI.65.1.155-161.1991; WICKNER RB, 1992, ANNU REV MICROBIOL, V46, P347, DOI 10.1146/annurev.micro.46.1.347; WICKNER RB, 1976, GENETICS, V82, P429; WICKNER RB, 1995, IN PRESS FIELDS VIRO	39	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28420	28428						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961783				2022-12-27	WOS:A1994PV77200095
J	TAKAKUWA, Y; NISHINO, H; ISHIBE, Y; ISHIBASHI, T				TAKAKUWA, Y; NISHINO, H; ISHIBE, Y; ISHIBASHI, T			PROPERTIES AND KINETICS OF MEMBRANE-BOUND ENZYMES WHEN BOTH THE ENZYME AND SUBSTRATE ARE COMPONENTS OF THE SAME MICROSOMAL MEMBRANE - STUDIES OF LATHOSTEROL 5-DESATURASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL CARRIER PROTEIN; RAT-LIVER MICROSOMES; SUPERNATANT PROTEIN; LATERAL DIFFUSION; INTERMEMBRANE TRANSFER; BILAYER-MEMBRANES; CALF BRAIN; RECEPTORS; SQUALENE; CYCLASE	Microsomes isolated from rat liver contain an NADH-dependent lathosterol B-desaturation system that catalyzes the introduction of a Delta(5) bond into lathosterol to form 7-dehydrocholesterol. Microsomes were preloaded in vitro with liposomes composed of lathosterol and phosphatidylcholine in the presence of a high-speed supernatant (S-105) protein prior to enzyme assay. The desaturation led to a reaction that occurred in two distinct phases. That is, there was an initial burst of product formation over an approximate time scale of 5 min that fell off, thereafter to a steady state rate for over 30 min. The latter steady state phase was slower than the burst phase, because lateral diffusion of the lathosterol substrate must occur before the next reaction can take place. The total amount of the burst, which may be obtained by extrapolating the linear part of the curve in the steady state phase back to zero time, provides a means of obtaining the enzyme concentration in terms of functional active sites. It was found that the kinetics between enzyme and substrate within the same membrane also followed the usual kinetic formalism of a Michaelis-Menten type reaction as in nonaggregated homogenous solution.	HOKKAIDO UNIV,SCH MED,DEPT BIOCHEM,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University								BLOCH K, 1965, SCIENCE, V150, P19, DOI 10.1126/science.150.3692.19; BURTON P, 1985, J BIOL CHEM, V260, P7289; DELISI C, 1976, J THEOR BIOL, V62, P159, DOI 10.1016/0022-5193(76)90056-4; DEMPSEY ME, 1981, J BIOL CHEM, V256, P1867; DEMPSEY ME, 1964, J BIOL CHEM, V239, P1381; DVORNIK D, 1966, BIOCHEMISTRY-US, V5, P1060, DOI 10.1021/bi00867a035; FRIEDLANDER EJ, 1980, J BIOL CHEM, V255, P8042; GUTFREUND H, 1972, ENZYMES PHYSICAL PRI, P69; HACKENBROCK CR, 1981, TRENDS BIOCHEM SCI, V6, P151, DOI 10.1016/0968-0004(81)90056-6; HANSKI E, 1979, BIOCHEMISTRY-US, V18, P846, DOI 10.1021/bi00572a017; HONJO K, 1985, J BIOCHEM, V97, P955, DOI 10.1093/oxfordjournals.jbchem.a135137; INOUYE K, 1977, J BIOCHEM-TOKYO, V82, P961, DOI 10.1093/oxfordjournals.jbchem.a131800; ISHIBASHI T, 1983, EUR J BIOCHEM, V132, P23, DOI 10.1111/j.1432-1033.1983.tb07320.x; ISHIBASHI T, 1981, J BIOL CHEM, V256, P2962; ISHIBASHI T, 1986, LIPIDS, V21, P191, DOI 10.1007/BF02534820; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLER WL, 1967, BIOCHEMISTRY-US, V6, P2673, DOI 10.1021/bi00861a005; PARRY G, 1976, FEBS LETT, V67, P123, DOI 10.1016/0014-5793(76)80348-1; REDDY VVR, 1976, EUR J BIOCHEM, V69, P577, DOI 10.1111/j.1432-1033.1976.tb10943.x; RIMON G, 1978, NATURE, V276, P394, DOI 10.1038/276394a0; RITTER MC, 1971, J BIOL CHEM, V246, P1536; SAAT YA, 1976, J BIOL CHEM, V251, P5155; SANDHOFF K, 1978, P NATL ACAD SCI USA, V75, P122, DOI 10.1073/pnas.75.1.122; SCHEEL G, 1982, EUR J BIOCHEM, V127, P245, DOI 10.1111/j.1432-1033.1982.tb06862.x; STRITTMATTER P, 1975, P NATL ACAD SCI USA, V72, P2658, DOI 10.1073/pnas.72.7.2658; TRIVEDI A, 1986, BIOCHEM CELL BIOL, V64, P1195, DOI 10.1139/o86-157; VAZ WLC, 1984, FEBS LETT, V174, P199, DOI 10.1016/0014-5793(84)81157-6; VAZ WLC, 1982, CELL SURF REV, V8, P83	28	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27889	27893						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961720				2022-12-27	WOS:A1994PV77200021
J	LAPIDOT, A; GOPHER, A				LAPIDOT, A; GOPHER, A			CEREBRAL METABOLIC COMPARTMENTATION - ESTIMATION OF GLUCOSE FLUX VIA PYRUVATE-CARBOXYLASE PYRUVATE-DEHYDROGENASE BY C-13 NMR ISOTOPOMER ANALYSIS OF D-[U-C-13]GLUCOSE METABOLITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; CHROMATOGRAPHY-MASS-SPECTROMETRY; PRODUCER STREPTOMYCES-PARVULUS; RAT-BRAIN; SPECTROSCOPY; INVIVO; PATHWAYS; BIOSYNTHESIS; PRECURSORS; GLUTAMATE	A method is presented for determining the compartmentation of amino acid metabolism in the brain. C-13 NMR spectroscopy, and more specifically, homonuclear C-13-C-13 spin coupling patterns of C-13-labeled amino acids were used to measure the relative flux of label from D-[U-C-13]glucose through the anaplerotic pathway versus the oxidative pathway. Glucose flux through the pyruvate carboxylase pathway was quantitated following primed dose constant infusion of D-[U-C-13]glucose to young rabbits at a rate of 1 mg/kg body weight per min. We demonstrate, for the first time, that multiplet spectra of three adjacent C-13 isoptomers in 1,2,3-C-13(3) in glutamine and glutamate, which are derived from [1,2,3-C-13(3)]-pyruvate, present different isotopomer populations in glutamine in comparison to that in glutamate. This is due to two different metabolic compartments characterized by the presence or absence of glutamine synthetase activity and two different tricarboxylic acid cycles, one preferentially mediated by pyruvate carboxylase and the other by pyruvate dehydrogenase. Our results indicate that the anaplerotic pathway accounts for 34% of glutamine synthesis and only 16% of glutamate and gamma-aminobutyric acid syntheses in metabolic and isotopic steady state conditions. These results support the concept, and provide a quantitative measure, that glutamine and/or tricarboxylic acid cycle intermediates are supplied by astrocytes to neurons to replenish the neurotransmitter pool of gamma-aminobutyric acid and glutamate.			LAPIDOT, A (corresponding author), WEIZMANN INST SCI, DEPT ORGAN CHEM, IL-76100 REHOVOT, ISRAEL.							BADARGOFFER RS, 1990, BIOCHEM J, V266, P133, DOI 10.1042/bj2660133; BECKMANN N, 1991, BIOCHEMISTRY-US, V30, P6362, DOI 10.1021/bi00240a002; BERL S, 1969, HDB NEUROCHEMISTRY, V2, P447; BRAINARD JR, 1989, J NEUROCHEM, V53, P1285, DOI 10.1111/j.1471-4159.1989.tb07426.x; BRAND A, 1992, BIOCHIMIE, V74, P941, DOI 10.1016/0300-9084(92)90078-S; CERDAN S, 1990, J BIOL CHEM, V265, P12916; FITZPATRICK SM, 1990, J CEREBR BLOOD F MET, V10, P170, DOI 10.1038/jcbfm.1990.32; GARFINKEL D, 1966, J BIOL CHEM, V241, P3918; GOPHER A, 1990, P NATL ACAD SCI USA, V87, P5449, DOI 10.1073/pnas.87.14.5449; GOPHER A, 1991, 10 ANN SCI M SOC MAG, P1050; GOPHER A, 1990, 9TH ANN SCI M SOC MA, P1110; Hertz L., 1988, GLUTAMINE GLUTAMATE, P39; INBAR L, 1988, J BIOL CHEM, V263, P16014; INBAR L, 1988, J BACTERIOL, V170, P4055, DOI 10.1128/jb.170.9.4055-4064.1988; INBAR L, 1991, J BACTERIOL, V173, P7790, DOI 10.1128/jb.173.24.7790-7801.1991; INBAR L, 1987, EUR J BIOCHEM, V162, P621, DOI 10.1111/j.1432-1033.1987.tb10684.x; KALDERON B, 1986, FEBS LETT, V204, P29, DOI 10.1016/0014-5793(86)81381-3; KALDERON B, 1987, FEBS LETT, V213, P209, DOI 10.1016/0014-5793(87)81493-X; KALDERON B, 1989, P NATL ACAD SCI USA, V86, P4690, DOI 10.1073/pnas.86.12.4690; KALDERON B, 1988, BIOMED ENVIRON MASS, V16, P305, DOI 10.1002/bms.1200160158; KALDERON B, 1989, AM J PHYSIOL, V257, pE346, DOI 10.1152/ajpendo.1989.257.3.E346; LAPIDOT A, 1986, TRENDS BIOTECHNOL, V4, P2, DOI 10.1016/0167-7799(86)90126-5; LAPIDOT A, 1990, J INHERIT METAB DIS, V13, P466, DOI 10.1007/BF01799504; LAPIDOT A, 1991, 10TH ANN SCI M SOC M, P444; LAPIDOT A, 1992, 11TH ANN SCI M SOC M, P2110; LONDON RE, 1988, PROG NUCL MAG RES SP, V20, P337, DOI 10.1016/0079-6565(88)80010-4; MALLOY CR, 1988, J BIOL CHEM, V263, P6964; McIlwain H., 1985, BIOCH CENTRAL NERVOU, V5th ed.; SHANK RP, 1993, J NEUROCHEM, V61, P315, DOI 10.1111/j.1471-4159.1993.tb03570.x	29	140	141	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27198	27208						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961629				2022-12-27	WOS:A1994PV77100011
J	SHIH, A; LARAMEE, GR; SCHMELZER, CH; BURTON, LE; WINSLOW, JW				SHIH, A; LARAMEE, GR; SCHMELZER, CH; BURTON, LE; WINSLOW, JW			MUTAGENESIS IDENTIFIES AMINO-TERMINAL RESIDUES OF NERVE GROWTH-FACTOR NECESSARY FOR TRK RECEPTOR-BINDING AND BIOLOGICAL-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; HOMOLOG-SCANNING MUTAGENESIS; NEUROTROPHIC FACTOR; MOLECULAR-CLONING; FACTOR FAMILY; BIOCHEMICAL-CHARACTERIZATION; PROTOONCOGENE PRODUCT; RECOMBINANT HUMAN; NGF RECEPTOR	Limited proteolysis and site-directed mutagenesis of human nerve growth factor (hNGF) was utilized to determine the role of the NH2 terminus in p140(TrkA) (TrkA) receptor function. Purified (6-118)hNGF, representing deletion of the first 5 NH2-terminal residues, is 9-fold less potent than (1-118)hNGF in displacing I-125-hNGF from TrkA. The deletion of a further 4 residues to form (10-118)hNGF is nearly 300-fold less potent. (6-118)hNGF is only 2-4-fold less potent than (1-118)hNGF in eliciting TrkA autophosphorylation and PC12 cell neurite outgrowth, suggesting that the first 5 residues of the NH2 terminus are necessary for full TrkA binding activity but may be less critical for potent receptor activation and intracellular signaling. In contrast, purified mutant H4D results in a nearly 1000-fold loss in TrkA binding at 4 degrees C relative to (1-118)hNGF, at least 10-fold less potency of TrkA autophosphorylation, and 30-fold loss of potency in PC12 cell differentiation. NH2-terminal hBDNF/hNGF and hNT3/hNGF chimeric mutants further affected these activities suggesting that the NH2-terminal sequence specificity of hNGF contributes to structural interactions necessary for TrkA receptor binding and ligand-induced signaling. The potency of binding of all hNGF variants to the low affinity NGF receptor p75 was largely unaffected indicating distinct structural contributions of the NH2-terminal region of hNGF to the binding to TrkA versus p75.	GENENTECH INC,DEPT NEUROSCI,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PROC SCI,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech								BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BURTON LE, 1992, J NEUROCHEM, V59, P1937, DOI 10.1111/j.1471-4159.1992.tb11030.x; CAMERINI D, 1991, J IMMUNOL, V147, P3165; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; COLLAWN JF, 1988, J BIOL CHEM, V263, P8625; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEVOS AM, 1992, SCIENCE, V255, P257; EIGENBROT C, 1992, Current Opinion in Biotechnology, V3, P333, DOI 10.1016/0958-1669(92)90160-K; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; ESCANDON E, 1993, J NEUROSCI RES, V34, P601, DOI 10.1002/jnr.490340602; GIBBBS CS, 1991, J BIOL CHEM, V266, P3923; Gorman CM, 1990, DNA PROTEIN ENG TECH, V2, P1; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; IBANEZ CF, 1991, EMBO J, V10, P2105, DOI 10.1002/j.1460-2075.1991.tb07743.x; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAHLE P, 1992, J BIOL CHEM, V267, P22707; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KASHIO Y, 1990, FEBS LETT, V266, P187; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; ROSENTHAL A, 1991, ENDOCRINOLOGY, V129, P1289, DOI 10.1210/endo-129-3-1289; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHMELZER CH, 1992, J NEUROCHEM, V59, P1675, DOI 10.1111/j.1471-4159.1992.tb10998.x; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; SUTER U, 1992, J NEUROSCI, V12, P306; SUTTER A, 1979, J BIOL CHEM, V254, P5972; TAYLOR RAV, 1992, SOC NEUR ABS, V17, P712; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VROEGOP S, 1992, J PROTEIN CHEM, V11, P71, DOI 10.1007/BF01025094; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	61	58	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27679	27686						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961687				2022-12-27	WOS:A1994PV77100081
J	VANCURA, A; HALDAR, D				VANCURA, A; HALDAR, D			PURIFICATION AND CHARACTERIZATION OF GLYCEROPHOSPHATE ACYLTRANSFERASE FROM RAT-LIVER MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SN-GLYCEROL 3-PHOSPHATE; MEMBRANE PHOSPHOLIPID-SYNTHESIS; SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; ESCHERICHIA-COLI; DIHYDROXYACETONE PHOSPHATE; COENZYME-A; GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; PHOSPHATIDYLINOSITOL SYNTHASE; ENZYMES; PROTEIN	Glycerophosphate acyltransferase (GAT) catalyzes the conversion of sn-glycerol 3-phosphate to lysophospha tidic acid (LPA), the first and committed step of triacyl glycerol and phospholipid synthesis. In spite of the important regulatory roles GAT may play in this biosynthetic pathway, little information is available on the structure, biochemical properties, and regulation of GAT from eukaryotic cells. We solubilized GAT from rat Liver mitochondrial membranes and purified it to an apparent homogeneity by hydroxylapatite chromatography, preparative isoelectric focusing, and gel filtration. The enzyme is composed of a single polypeptide of 85 kDa as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and gel filtration chromatography of the native protein. The GAT activity was completely lost during the purification procedure and required addition of exogenous phospholipids for its reconstitution. Since a high phospholipid to detergent ratio was needed for full reactivation, it is concluded that GAT requires ''lipid boundary'' for reconstitution. The ability of different phospholipids to reactivate GAT decreased in the following order: phosphatidylglycerol (PG), phosphatidylethanolamine (PE), phosphatidylcholine (PC), asolectin, phosphatidylinositol (PI), phosphatidylserine (PG), and cardiolipin. 1,2-Dioleoyl derivatives of PG; and PE were more effective in reconstituting the GAT activity than corresponding dipalmitoyl derivatives. The GAT activation was further increased by using a combination of PG and PE or PG and PC. Regardless of the phospholipid used for reconstitution, palmitoyl-CoA was the best acyl donor and LPA was the only reaction product.	ST JOHNS UNIV, DEPT BIOL SCI, JAMAICA, NY 11439 USA	Saint John's University				Vancura, Ales/0000-0002-5895-1218	NIGMS NIH HHS [GM-46692] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046692] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAELEE M, 1990, J BIOL CHEM, V265, P7221; BATES EJ, 1979, BIOCHEM J, V182, P751, DOI 10.1042/bj1820751; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; Bell RM, 1983, ENZYMES, V16, P87; BRINDLEY DN, 1982, PHOSPHOLIPIDS NEW CO, V4, P179; Chapman D., 1984, BIOL MEMBR, VV, P1; COLEMAN RA, 1984, BIOCHEM J, V217, P391, DOI 10.1042/bj2170391; COLEMAN RA, 1983, J BIOL CHEM, V258, P450; CORTESE JD, 1982, BIOCHEMISTRY-US, V21, P3899, DOI 10.1021/bi00259a027; DAAE LNW, 1973, BIOCHIM BIOPHYS ACTA, V306, P186, DOI 10.1016/0005-2760(73)90224-5; DATTA NS, 1984, FEBS LETT, V176, P264, DOI 10.1016/0014-5793(84)80954-0; Dennis EA, 1983, ENZYMES, P307; DUROCHER V, 1990, CAN J PHYSIOL PHARM, V68, P1255, DOI 10.1139/y90-188; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; GREEN PR, 1981, J BIOL CHEM, V256, P1151; HAJRA AK, 1978, J NEUROCHEM, V31, P125, DOI 10.1111/j.1471-4159.1978.tb12440.x; HALDAR D, 1979, J BIOL CHEM, V254, P4502; HALDAR D, 1992, METHOD ENZYMOL, V209, P64; HJELMSTAD RH, 1991, BIOCHEMISTRY-US, V30, P1731, DOI 10.1021/bi00221a001; KELKER HC, 1979, J BIOL CHEM, V254, P5364; KIMELBERG HK, 1977, CELL SURF REV, V3, P205; KLUYTMANS JH, 1974, PREP BIOCHEM, V4, P141, DOI 10.1080/00327487408068769; LARSON TJ, 1980, J BIOL CHEM, V255, P9421; LICHTENBERG D, 1983, BIOCHIM BIOPHYS ACTA, V737, P285, DOI 10.1016/0304-4157(83)90004-7; LIGHTNER VA, 1980, J BIOL CHEM, V255, P9413; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MONROY G, 1973, J BIOL CHEM, V248, P2845; MONROY G, 1972, J BIOL CHEM, V247, P6884; NIMMO HG, 1978, BIOCHEM J, V176, P607, DOI 10.1042/bj1760607; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SAGGERSON ED, 1987, BIOCHEM J, V243, P289, DOI 10.1042/bj2430289; SALEM L, 1962, J CHEM PHYS, V37, P2100, DOI 10.1063/1.1733431; SANDERMANN H, 1986, PROGR PROTEIN LIPID, V2, P197; SCHEIDELER MA, 1991, J BIOL CHEM, V266, P14321; SCHEIDELER MA, 1986, J BIOL CHEM, V261, P990; SCHEIDELER MA, 1989, J BIOL CHEM, V264, P12455; SHIN DH, 1991, J BIOL CHEM, V266, P23834; STERN W, 1978, J BIOL CHEM, V253, P8047; THOMAS PD, 1990, J BIOL CHEM, V265, P2684; TILLMAN TS, 1986, J BIOL CHEM, V261, P9144; VANCURA A, 1991, BIOCHEM BIOPH RES CO, V175, P339, DOI 10.1016/S0006-291X(05)81240-9; VANCURA A, 1992, J BIOL CHEM, V267, P14353; VANDEENEN LLM, 1965, PROGR CHEM FATS OTHE, V8; WHITAKER JR, 1980, ANAL BIOCHEM, V109, P156, DOI 10.1016/0003-2697(80)90024-X; WILKISON WO, 1988, J BIOL CHEM, V263, P14505; WOOD R, 1969, ARCH BIOCHEM BIOPHYS, V131, P478, DOI 10.1016/0003-9861(69)90420-2; YAMASHITA S, 1972, EUR J BIOCHEM, V31, P565, DOI 10.1111/j.1432-1033.1972.tb02566.x; YET SF, 1993, BIOCHEMISTRY-US, V32, P9486, DOI 10.1021/bi00087a029	49	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27209	27215						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961630				2022-12-27	WOS:A1994PV77100012
J	MASER, RL; MAGENHEIMER, BS; CALVET, JP				MASER, RL; MAGENHEIMER, BS; CALVET, JP			MOUSE PLASMA GLUTATHIONE-PEROXIDASE - CDNA SEQUENCE-ANALYSIS AND RENAL PROXIMAL TUBULAR EXPRESSION AND SECRETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; POLYCYSTIC KIDNEY-DISEASE; IMMUNOLOGICAL INVESTIGATIONS; TISSUE DISTRIBUTION; MESSENGER-RNA; SELENIUM; ACID; GENE; SELENOCYSTEINE; IDENTIFICATION	A mouse kidney cDNA isolated by differential screening was found to be highly homologous to rat, human, and bovine plasma glutathione peroxidase (GPx) sequences. Analysis of the full-length coding region sequence demonstrated an in-frame selenocysteine-encoding opal codon and putative signal sequence, suggesting that the sequence represents the mouse homolog of plasma GPx. The level of expression of plasma GPx in various mouse tissues and during development was investigated by Northern blot analysis. Plasma GPx mRNA was observed to be very abundant in kidney compared with placenta, epididymis, intestine, lung, heart, testis, ovary, salivary gland, spleen, thymus, stomach, brain, and fetal kidney and could not be detected in pancreas or in Liver except from pregnant mice. In addition, plasma GPx mRNA levels were shown to increase during postnatal development of the kidney. In situ hybridization localized plasma GPx mRNA to proximal tubules, while primary cell culture demonstrated that plasma GPx is synthesized and secreted by proximal tubular epithelial cells. The relative abundance of plasma GPx mRNA in mouse kidney suggests that proximal tubules may be the primary source of the enzyme detectable in plasma and further suggests that plasma GPx has an important function in protecting the kidney from oxidative damage.	UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,KANSAS CITY,KS 66160	University of Kansas; University of Kansas Medical Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037100] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37100] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATSCHUL SF, 1990, J MOL BIOL, V215, P403; Ausubel FM., 1988, CURRENT PROTOCOLS MO; AVISSAR N, 1991, J NUTR, V121, P1243, DOI 10.1093/jn/121.8.1243; AVISSAR N, 1989, BLOOD, V73, P318; AVISSAR N, 1994, AM J PHYSIOL, V266, pC367, DOI 10.1152/ajpcell.1994.266.2.C367; AVISSAR N, 1994, ARCH BIOCHEM BIOPHYS, V309, P239, DOI 10.1006/abbi.1994.1108; AVISSAR N, 1989, J BIOL CHEM, V264, P15850; Bard JBL, 1992, CURR OPIN GENET DEV, V2, P589, DOI 10.1016/S0959-437X(05)80177-7; BEDNARCZUK TA, 1991, BIOTECHNIQUES, V10, P478; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU FF, 1992, BLOOD, V79, P3233; CHU FF, 1993, J BIOL CHEM, V268, P2571; DEAR TN, 1991, BIOCHEMISTRY-US, V30, P10376, DOI 10.1021/bi00107a003; DELEEUW WJF, 1989, NUCLEIC ACIDS RES, V17, P10137, DOI 10.1093/nar/17.23.10137; DICKESON SK, 1989, J BIOL CHEM, V264, P16557; DORFMAN DM, 1989, BIOTECHNIQUES, V7, P568; EBERLE JR, 1993, BIOTECHNIQUES, V14, P408; ESWORTHY RS, 1991, ARCH BIOCHEM BIOPHYS, V286, P330, DOI 10.1016/0003-9861(91)90048-N; FAURE J, 1991, BIOL REPROD, V44, P13, DOI 10.1095/biolreprod44.1.13; FORSTROM JW, 1978, BIOCHEMISTRY-US, V17, P2639, DOI 10.1021/bi00606a028; GATTONE VH, 1988, LAB INVEST, V59, P231; GESEK FA, 1987, AM J PHYSIOL, V253, pF358, DOI 10.1152/ajprenal.1987.253.2.F358; GHYSELINCK NB, 1991, J REPROD FERTIL, V93, P461; GONZALEZ IL, 1986, AM J HUM GENET, V38, P419; HARDING MA, 1992, KIDNEY INT, V41, P317, DOI 10.1038/ki.1992.44; HARDING MA, 1991, DEV BIOL, V146, P483, DOI 10.1016/0012-1606(91)90249-3; HOJO Y, 1987, SCI TOTAL ENVIRON, V65, P85, DOI 10.1016/0048-9697(87)90163-X; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRINSKY NI, 1992, P SOC EXP BIOL MED, V200, P248; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADDIPATI KR, 1987, J BIOL CHEM, V262, P17398; MARTINALONSO JM, 1993, J BIOCHEM-TOKYO, V114, P284, DOI 10.1093/oxfordjournals.jbchem.a124168; MASER R L, 1992, Journal of the American Society of Nephrology, V3, P299; PERRY ACF, 1992, BIOCHEM J, V285, P863, DOI 10.1042/bj2850863; Pertoft H., 1982, CELL SEPARATION METH, P115; RANKIN CA, 1992, J CELL PHYSIOL, V152, P578, DOI 10.1002/jcp.1041520318; ROVERI A, 1992, J BIOL CHEM, V267, P6142; Sambrook J, 1989, MOL CLONING LABORATO; SCHUCKELT R, 1991, FREE RADICAL RES COM, V14, P343, DOI 10.3109/10715769109093424; STRIKER GE, 1985, LAB INVEST, V53, P122; SUNDE RA, 1990, ANNU REV NUTR, V10, P451, DOI 10.1146/annurev.nu.10.070190.002315; TAKAHASHI K, 1990, J BIOCHEM-TOKYO, V108, P145, DOI 10.1093/oxfordjournals.jbchem.a123172; TAKAHASHI K, 1986, BLOOD, V68, P640; TAKAHASHI K, 1987, ARCH BIOCHEM BIOPHYS, V256, P677, DOI 10.1016/0003-9861(87)90624-2; TAUB M, 1984, METHODS SERUM FREE C, P3; THOMAS JP, 1990, J BIOL CHEM, V265, P454; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; VENUTI SE, 1988, BIOCHIM BIOPHYS ACTA, V946, P119, DOI 10.1016/0005-2736(88)90464-6; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YAMAMOTO Y, 1993, ARCH BIOCHEM BIOPHYS, V305, P541, DOI 10.1006/abbi.1993.1458; YOSHIMURA S, 1991, J BIOCHEM-TOKYO, V109, P918, DOI 10.1093/oxfordjournals.jbchem.a123480	54	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27066	27073						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929449				2022-12-27	WOS:A1994PQ93100072
J	CHANG, MS; MCNINCH, J; BASU, R; SIMONET, S				CHANG, MS; MCNINCH, J; BASU, R; SIMONET, S			CLONING AND CHARACTERIZATION OF THE HUMAN NEUTROPHIL-ACTIVATING PEPTIDE (ENA-78) GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PLATELET FACTOR-IV; GROWTH STIMULATORY ACTIVITY; AMINO-ACID-SEQUENCE; BETA-THROMBOGLOBULIN; INTERLEUKIN-8 GENE; NUCLEAR FACTOR; MESSENGER-RNA; INFLAMMATORY CYTOKINES; ENHANCER	The neutrophil-activating peptide (ENA-78) is an inflammatory chemokine which is produced concomitantly with interleukin-8 (IL-8) in response to stimulation with either interleukin-1 (IL-1 beta) or tumor necrosis factor-alpha (TNF-alpha). We have identified a full-length ENA-78 cDNA and isolated its genomic clone. The gene was found to consist of four exons and three introns and its structure resembles the IL-8 gene. The human ENA-78 gene was mapped to chromosome 4q13-q21, the same locus as several other inflammatory cytokine genes. The transcription initiation site was mapped to a position 96 base pairs (bp) upstream from the translation initiation site. A fusion gene containing 125 bp upstream of exon 1 linked to a luciferase reporter gene was expressed in the human embryonic 293 cell line. The expression of the reporter gene was induced by TNF-alpha, IL-1 beta, or phorbol 12-myristate 13-acetate. The 125-bp promoter region contained the cis-regulatory elements for enhancer binding protein-like factor (C/EBP) and the nuclear factor (NF-kappa B). Transfection of 293 cells with deletion mutants demonstrated that the NF-kappa B element, but not the C/EBP site, is sufficient for expression and induction by either TNF-alpha or IL-1 beta. In contrast, the IL-8 gene requires both elements. This report demonstrates that ENA-78 and IL-8 genes shared great similarity in genomic structure and chromosome location. However, these two genes may be regulated by distinct mechanisms.			CHANG, MS (corresponding author), AMGEN INC,DEPT DEV BIOL,14-1-B-219,1840 DEHAVILLAND DR,THOUSAND OAKS,CA 91320, USA.							AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; CHANG MS, 1994, BLOOD, V83, P3199; DEUEL TF, 1977, P NATL ACAD SCI USA, V74, P2256, DOI 10.1073/pnas.74.6.2256; EISMAN R, 1990, BLOOD, V76, P336; GRIFFIN CA, 1987, CYTOGENET CELL GENET, V45, P67, DOI 10.1159/000132431; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; MAHE Y, 1991, J BIOL CHEM, V266, P13759; MAJUMDAR S, 1991, J BIOL CHEM, V266, P5785; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MODI WS, 1990, HUM GENET, V84, P185; MOSER B, 1990, J EXP MED, V171, P1797, DOI 10.1084/jem.171.5.1797; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHRODER JM, 1990, J EXP MED, V171, P1091, DOI 10.1084/jem.171.4.1091; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; TUNNACLIFFE A, 1992, BLOOD, V79, P2896; URBAN MB, 1991, NEW BIOL, V3, P279; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355	30	99	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25277	25282						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929219				2022-12-27	WOS:A1994PQ49100009
J	COHEN, DM; CHIN, WW; GULLANS, SR				COHEN, DM; CHIN, WW; GULLANS, SR			HYPEROSMOTIC UREA INCREASES TRANSCRIPTION AND SYNTHESIS OF EGR-1 IN MURINE INNER MEDULLARY COLLECTING DUCT (MIMCD3) CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY ALDOSE REDUCTASE; RENAL EPITHELIAL-CELLS; ZINC FINGER PROTEIN; GROWTH FACTOR-II; DNA-BINDING; INOSITOL COTRANSPORTER; MOLECULAR-CLONING; PROMOTER REGION; OSMOTIC-STRESS; GENE-PRODUCT	It was previously shown that when cells of renal epithelial origin are exposed to hyperosmotic urea in concentrations unique to the renal medulla, abundance of mRNA encoding the immediate-early gene product Egr-1 is up-regulated. This phenomenon appears restricted to cells of renal epithelial origin. In the present study, the newly isolated murine renal inner medullary cell line mIMCD3 was used to determine whether the urea-induced increase in Egr-1 mRNA abundance is associated with increased expression of functional protein product, and whether this increase is transcriptionally mediated. In Western analysis, urea (200 mM) increased Egr-1 immunoreactivity 3-fold relative to sham-treated cells. [S-35]Methionine pulse-labeling followed by immunoprecipitation confirmed that this increased immunoreactivity was associated with increased de novo Egr-1 protein synthesis. Electrophoretic mobility shift assay demonstrated that urea treatment induced a commensurate increase in specific DNA binding activity for the Egr-1 consensus sequence. In addition, the increase in Egr-1 mRNA expression accompanying urea treatment was a consequence of enhanced transcription, as determined by nuclear run-off assay. Taken together, these data indicate that hyperosmotic urea increases both Egr-1 transcription and new protein synthesis in renal epithelial cells in culture, and that this newly synthesized Egr-1 is a functional DNA-binding protein. To our knowledge, this is the first example of urea-inducible gene transcription. In addition, Egr-1 represents the first eukaryotic transcription factor transcriptionally activated by a hyperosmotic stressor.	BRIGHAM & WOMENS HOSP, HOWARD HUGHES MED INST, DIV GENET, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	COHEN, DM (corresponding author), BRIGHAM & WOMENS HOSP, DIV RENAL, 75 FRANCIS ST, BOSTON, MA 02115 USA.				NIDDK NIH HHS [DK-36031, DK-02188] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036031, K08DK002188] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOUBY N, 1985, KIDNEY INT, V28, P456, DOI 10.1038/ki.1985.152; BOUBY N, 1987, KIDNEY INT       S22, V32, pS57; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COHEN DM, 1993, AM J PHYSIOL, V264, pF601, DOI 10.1152/ajprenal.1993.264.4.F601; COHEN DM, 1991, AM J PHYSIOL, V261, pC594, DOI 10.1152/ajpcell.1991.261.4.C594; COHEN DM, 1993, AM J PHYSIOL, V264, pF593, DOI 10.1152/ajprenal.1993.264.4.F593; COHEN DM, 1993, CELLULAR MOL PHYSL C, P363; COWLEY BD, 1990, AM J PHYSIOL, V258, pF154, DOI 10.1152/ajprenal.1990.258.1.F154; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; FEI HH, 1993, BIOTECHNIQUES, V15, P838; GARCIAPEREZ A, 1989, J BIOL CHEM, V264, P16815; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GREENBERG ME, 1993, CURRENT PROTOCOLS MO; GSTRAUNTHALER GJA, 1988, RENAL PHYSIOL BIOCH, V11, P1; GUPTA MP, 1991, J BIOL CHEM, V266, P12813; HANDLER JS, 1993, AM J PHYSIOL, V265, pC1449, DOI 10.1152/ajpcell.1993.265.6.C1449; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; JACK RS, 1990, BIOCHEM BIOPH RES CO, V169, P840, DOI 10.1016/0006-291X(90)91969-Y; KNEPPER MA, 1991, KIDNEY, P445; KWON HM, 1992, J BIOL CHEM, V267, P6297; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P7456; LIM RW, 1987, ONCOGENE, V1, P263; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORIYAMA T, 1990, AM J PHYSIOL, V259, pF847, DOI 10.1152/ajprenal.1990.259.5.F847; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; NAKANISHI T, 1989, AM J PHYSIOL, V257, pC795, DOI 10.1152/ajpcell.1989.257.4.C795; PALMITER RD, 1985, NATURE, V316, P457, DOI 10.1038/316457a0; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; ROTWEIN P, 1990, DNA CELL BIOL, V9, P725, DOI 10.1089/dna.1990.9.725; SMARDO FL, 1992, AM J PHYSIOL, V262, pC776, DOI 10.1152/ajpcell.1992.262.3.C776; SOARES MB, 1986, J MOL BIOL, V192, P737, DOI 10.1016/0022-2836(86)90025-2; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; TOBACK FG, 1980, P NATL ACAD SCI-BIOL, V77, P6654, DOI 10.1073/pnas.77.11.6654; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; UCHIDA S, 1993, J CLIN INVEST, V91, P1604, DOI 10.1172/JCI116367; WERNER H, 1990, BIOCHEM BIOPH RES CO, V169, P1021, DOI 10.1016/0006-291X(90)91996-6; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649; YAMAUCHI A, 1993, AM J PHYSIOL, V264, pF20; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	51	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25865	25870						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929290				2022-12-27	WOS:A1994PQ49100092
J	XIE, XS; CRIDER, BP; MA, YM; STONE, DK				XIE, XS; CRIDER, BP; MA, YM; STONE, DK			ROLE OF A 50-57-KDA POLYPEPTIDE HETERODIMER IN THE FUNCTION OF THE CLATHRIN-COATED VESICLE PROTON PUMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; AMINO-ACID SEQUENCE; MOLECULAR-CLONING; TRANSLOCATING COMPLEX; ADENOSINE-TRIPHOSPHATASE; SACCHAROMYCES-CEREVISIAE; CHROMAFFIN GRANULES; CDNA SEQUENCE; HIGHER-PLANT; SUBUNIT	The vacuolar-type proton-translocating ATPase of clathrin-coated vesicles is composed of an integral membrane proton channel (V-B) and a peripheral catalytic sector (V-C). Native enzyme can catalyze the hydrolysis of both MgATP and CaATP and support proton pumping when reconstituted into liposomes. In contrast, isolated V-C catalyzes only Ca2+-activated ATP hydrolysis and cannot support proton pumping when reconstituted into liposomes (Xie, X.-S., and Stone, D. K. (1988) J. Biol. Chem. 263, 9859-9867). We now report that solubilized isolated V-C can be reassembled with purified V-B to restore properties of native enzyme, including Mg2+-activated ATP hydrolysis and proton-pumping capability. Investigation of this reassembly revealed that a heterodimer, composed of polypeptides of 50 and 57 kDa, stimulates Ca2+-activated ATPase activity of isolated V, 2-fold and Mg2+-activated ATPase activity catalyzed by the reassembled pump 9-fold. Moreover, this heterodimer stimulated proton transport by the reassembled pump >20-fold. When Separated from the proton pump, the dimer has no detectable kinase activity. Maximal stimulation occurs at a molar ratio of heterodimer to reassembled pump of 3, implying a structural, nonenzymatic mechanism. These data indicate that the 50-kDa and/or the 57-kDa polypeptide likely plays an essential and potentially regulatory role in the function of the proton-translocating ATPase of clathrin-coated vesicles.			XIE, XS (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV MOLEC TRANSPORT,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033627] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK RO1 33627] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERN RA, 1909, KIDNEY, P318; BELTRAN C, 1992, ACTA PHYSIOL SCAND, V146, P41; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; FORGAC M, 1992, J EXP BIOL, V172, P155; GRAF R, 1994, J BIOL CHEM, V269, P3767; HANADA H, 1991, BIOCHEM BIOPH RES CO, V176, P1062, DOI 10.1016/0006-291X(91)90391-J; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; HO MN, 1993, J BIOL CHEM, V268, P18286; INATOMI KI, 1989, J BIOL CHEM, V264, P10954; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1989, J BIOL CHEM, V264, P19236; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1987, J BIOL CHEM, V262, P3864; KEILY B, 1968, J BIOL CHEM, V243, P129; KIBAK H, 1992, J BIOENERG BIOMEMBR, V24, P415, DOI 10.1007/BF00762534; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI S, 1991, J BIOL CHEM, V266, P16078; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MATTSSON JP, 1994, J BIOL CHEM, V269, P24979; MEAGHER L, 1990, NUCLEIC ACIDS RES, V18, P6712, DOI 10.1093/nar/18.22.6712; MEYERS M, 1993, J BIOL CHEM, V268, P9184; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; NANDI PK, 1982, P NATL ACAD SCI-BIOL, V79, P5881, DOI 10.1073/pnas.79.19.5881; NELSON H, 1990, J BIOL CHEM, V265, P20390; NEZU J, 1992, J BIOCHEM, V112, P212, DOI 10.1093/oxfordjournals.jbchem.a123879; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; PARRY RV, 1989, J BIOL CHEM, V264, P20025; PENG SB, 1994, J BIOL CHEM, V269, P11356; PENG SB, 1993, J BIOL CHEM, V268, P23519; PERCY JM, 1985, BIOCHEM J, V231, P557, DOI 10.1042/bj2310557; PERIN MS, 1991, J BIOL CHEM, V266, P3877; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; STONE DK, 1984, J BIOL CHEM, V259, P2701; STONE DK, 1988, KIDNEY INT, V33, P403; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; SUN SZ, 1987, J BIOL CHEM, V262, P14790; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; TAKASE K, 1994, J BIOL CHEM, V269, P11037; THURIEAU C, 1988, DNA-J MOLEC CELL BIO, V7, P663, DOI 10.1089/dna.1988.7.663; WAGNER MC, 1989, CELL MOTIL CYTOSKEL, V12, P195, DOI 10.1002/cm.970120403; WANG SY, 1988, J BIOL CHEM, V263, P17638; XIE XS, 1986, J BIOL CHEM, V261, P2492; XIE XS, 1986, P NATL ACAD SCI USA, V83, P8913, DOI 10.1073/pnas.83.23.8913; XIE XS, 1988, J BIOL CHEM, V263, P9859; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	52	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25809	25815						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929286				2022-12-27	WOS:A1994PQ49100085
J	CASTEELSJOSSON, K; ZHANG, W; CAPACI, T; CASTEELS, P; TEMPST, P				CASTEELSJOSSON, K; ZHANG, W; CAPACI, T; CASTEELS, P; TEMPST, P			ACUTE TRANSCRIPTIONAL RESPONSE OF THE HONEYBEE PEPTIDE-ANTIBIOTICS GENE REPERTOIRE AND REQUIRED POSTTRANSLATIONAL CONVERSION OF THE PRECURSOR STRUCTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INDUCIBLE ANTIBACTERIAL PEPTIDES; INSECT IMMUNITY; SARCOPHAGA-PEREGRINA; PHORMIA-TERRANOVAE; SIGNAL SEQUENCE; APIS-MELLIFERA; ALPHA-FACTOR; DNA-BINDING; FLESH FLY	The cell free immune repertoire of honeybees (Apis mellifera) consists of four polypeptides that are induced by bacterial infection and, through complementarity, provide broad-spectrum antibacterial defense. apidaecin is overproduced by a combination of low threshold transcriptional activation and a unique, genetically encoded amplification mechanism. In contrast, sizable experimental infections are required for induction of the normally silent hymenoptaecin, abaecin, and bee defensin genes; even so, bee defensin transcription is minimal and delayed, and only minute quantities of corresponding peptide are produced. The specific, temporal organization of the multi component immune response in bees has therefore likely been selected to cope with infection of prevalent, plant-associated Gram-negative bacteria. Post-translational processing and modifications are substantially different for each of the four antibacterial peptides. While no similarities were observed among precursor structures of the various bee peptides, surprisingly, the signal sequences of abaecin (bee) and drosocin (Drosophila) shared unmistakable homology, possibly indicating common ancestral secretion/processing mechanisms. Finally, we report that bee defensin contains a typical disulfide-rich structure (40 amino acids) but also a unique, amphipathic, putatively amidated carboxyl-terminal tail (10 amino acids). We speculate that this structure is a ''co-drug'' assembled by fusing ''disulfide-rich'' and ''alpha-helical'' class peptide antibiotics, a novel concept in naturally occurring antibacterials.	CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Cornell University	CASTEELSJOSSON, K (corresponding author), MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA08748-29] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BLOMBACK B, 1967, METHOD ENZYMOL, V11, P398; BOMAN HG, 1991, EUR J BIOCHEM, V201, P23, DOI 10.1111/j.1432-1033.1991.tb16252.x; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; BULET P, 1993, J BIOL CHEM, V268, P14893; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CASTEELS P, 1994, BIOCHEM BIOPH RES CO, V199, P339, DOI 10.1006/bbrc.1994.1234; CASTEELS P, 1989, EMBO J, V8, P2387, DOI 10.1002/j.1460-2075.1989.tb08368.x; CASTEELS P, 1990, EUR J BIOCHEM, V187, P381, DOI 10.1111/j.1432-1033.1990.tb15315.x; CASTEELS P, 1993, J BIOL CHEM, V268, P7044; CASTEELS P, 1988, EUROPEAN RES VARROAT, P105; CASTEELSJOSSON K, 1993, EMBO J, V12, P1569, DOI 10.1002/j.1460-2075.1993.tb05801.x; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; DIMARCQ JL, 1990, EMBO J, V9, P2507, DOI 10.1002/j.1460-2075.1990.tb07430.x; DORSETT D, 1989, GENE DEV, V3, P454, DOI 10.1101/gad.3.4.454; EIPPER BA, 1983, P NATL ACAD SCI-BIOL, V80, P5144, DOI 10.1073/pnas.80.16.5144; ENGSTROM P, 1984, EMBO J, V3, P3347, DOI 10.1002/j.1460-2075.1984.tb02302.x; ENGSTROM Y, 1993, J MOL BIOL, V232, P327, DOI 10.1006/jmbi.1993.1392; FINNEY M, 1992, CURRENT PROTOCOLS MO; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; FUJIWARA S, 1990, J BIOL CHEM, V265, P11333; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GRILLI M, 1993, INT REV CYTOL, V143, P1; GUNNE H, 1993, EUR J BIOCHEM, V214, P287, DOI 10.1111/j.1432-1033.1993.tb17923.x; HOFFMANN JA, 1993, FEBS LETT, V325, P63, DOI 10.1016/0014-5793(93)81414-U; HOFFMANN JA, 1992, IMMUNOL TODAY, V13, P411, DOI 10.1016/0167-5699(92)90092-L; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HULTMARK D, 1993, TRENDS GENET, V9, P178, DOI 10.1016/0168-9525(93)90165-E; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; KANAI A, 1990, MOL CELL BIOL, V10, P6114, DOI 10.1128/MCB.10.12.6114; KANOST MR, 1988, ARCH INSECT BIOCHEM, V8, P147, DOI 10.1002/arch.940080302; KAPPLER C, 1993, EMBO J, V12, P1561, DOI 10.1002/j.1460-2075.1993.tb05800.x; KATOPODIS AG, 1991, BIOCHEMISTRY-US, V30, P6189, DOI 10.1021/bi00239a016; KOBAYASHI A, 1993, MOL CELL BIOL, V13, P4049, DOI 10.1128/MCB.13.7.4049; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMBERT J, 1989, P NATL ACAD SCI USA, V86, P262, DOI 10.1073/pnas.86.1.262; MAHBUBANI MH, 1991, BIOTECHNIQUES, V10, P48; MATSUYAMA K, 1988, J BIOL CHEM, V263, P17112; NANBU R, 1993, J BIOCHEM-TOKYO, V114, P432, DOI 10.1093/oxfordjournals.jbchem.a124193; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; REICHHART JM, 1989, EUR J BIOCHEM, V182, P423, DOI 10.1111/j.1432-1033.1989.tb14848.x; Sambrook J, 1989, MOL CLONING LABORATO; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SINGH A, 1983, NUCLEIC ACIDS RES, V11, P4049, DOI 10.1093/nar/11.12.4049; STEINER D F, 1991, Current Biology, V1, P375, DOI 10.1016/0960-9822(91)90198-6; STORICI P, 1993, BIOCHEM BIOPH RES CO, V196, P1058, DOI 10.1006/bbrc.1993.2358; SUN SC, 1992, EUR J BIOCHEM, V204, P885, DOI 10.1111/j.1432-1033.1992.tb16708.x; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WATERS MG, 1988, J BIOL CHEM, V263, P6209; WICKER C, 1990, J BIOL CHEM, V265, P22493	52	111	120	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28569	28575						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961803				2022-12-27	WOS:A1994PU16800012
J	KIM, JY; SHISHIDO, T; JIANG, XL; ADEREM, A; MCLAUGHLIN, S				KIM, JY; SHISHIDO, T; JIANG, XL; ADEREM, A; MCLAUGHLIN, S			PHOSPHORYLATION, HIGH IONIC-STRENGTH, AND CALMODULIN REVERSE THE BINDING OF MARCKS TO PHOSPHOLIPID-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PROMINENT CELLULAR SUBSTRATE; LARGE UNILAMELLAR VESICLES; BACTERIAL LIPOPOLYSACCHARIDE; MEMBRANE PHOSPHOLIPIDS; PLASMA-MEMBRANE; RAT-BRAIN; ACTIVATION; FAMILY; EXTRUSION	The myristoylated alanine-rich protein kinase C substrate (MARCKS) is a major cellular substrate of protein kinase C (PKC), and PKC phosphorylation produces translocation of MARCKS from membrane to cytoplasm in many cells. Our working hypothesis is that binding of MARCKS to biological membranes requires both hydrophobic insertion of its myristoyl chain into the lipid bilayer and electrostatic interaction of its basic domain with acidic lipids. We tested this hypothesis by measuring the binding of murine MARCKS to large unilamellar phospholipid vesicles (LUVs). me estimated the partition coefficient of the myristoyl moiety of MARCKS (K-H) by measuring the binding of MARCKS to electrically neutral LUVs (K-H = 3 x 10(3) M(-1)). We examined the effect of electrostatic interactions by measuring the binding of MARCKS to LUVs containing 20% acidic lipid and obtained four results. First, incorporating 20% acidic lipid into the LUVs increased binding of MARCKS about 100-fold. Second, PKC phosphorylation, which added 3 negatively charged phosphate groups to the basic domain, reduced 20-fold the binding of MARCKS to these negatively charged vesicles. Third, increasing the KCl concentration from 0.1 to 0.5 M reduced the binding 15-fold. Fourth, Ca2+-calmodulin reduced the binding 20-fold We present a simple theoretical model that explains these results, which are all consistent with the working hypothesis.	SUNY STONY BROOK,HLTH SCI CTR,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794; ROCKEFELLER UNIV,SIGNAL TRANSDUCT LAB,NEW YORK,NY 10021	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Rockefeller University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025032, R37AI025032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024971, R01GM024971] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-25032] Funding Source: Medline; NIGMS NIH HHS [GM24971] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BUSER CA, 1994, IN PRESS BIOCHEMISTR; DEVAUX PF, 1992, ANNU REV BIOPH BIOM, V21, P417, DOI 10.1146/annurev.bb.21.060192.002221; DURONIO RJ, 1992, P NATL ACAD SCI USA, V89, P4129, DOI 10.1073/pnas.89.9.4129; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HEEMSKERK FMJ, 1993, BIOCHEM BIOPH RES CO, V190, P236, DOI 10.1006/bbrc.1993.1036; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; KAIBUCHI K, 1981, J BIOL CHEM, V256, P7146; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MCLAUGHLIN S, 1977, CURR TOP MEMBR TRANS, V9, P1; MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P13; MOSIOR M, 1992, BIOCHIM BIOPHYS ACTA, V1105, P185, DOI 10.1016/0005-2736(92)90178-O; MUI BLS, 1993, BIOPHYS J, V64, P443, DOI 10.1016/S0006-3495(93)81385-7; NAKAOKA T, 1993, J BIOCHEM-TOKYO, V114, P449, DOI 10.1093/oxfordjournals.jbchem.a124196; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; REED JC, 1991, CELL SIGNAL, V3, P569, DOI 10.1016/0898-6568(91)90033-Q; ROSEN A, 1989, J BIOL CHEM, V264, P9118; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; SAWAI T, 1993, J BIOL CHEM, V268, P1995; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	39	184	184	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28214	28219						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961759				2022-12-27	WOS:A1994PV77200067
J	LEIER, I; JEDLITSCHKY, G; BUCHHOLZ, U; COLE, SPC; DEELEY, RG; KEPPLER, D				LEIER, I; JEDLITSCHKY, G; BUCHHOLZ, U; COLE, SPC; DEELEY, RG; KEPPLER, D			THE MRP GENE ENCODES AN ATP-DEPENDENT EXPORT PUMP FOR LEUKOTRIENE C-4, AND STRUCTURALLY RELATED CONJUGATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PLASMA-MEMBRANE VESICLES; MULTIDRUG-RESISTANCE; RAT-LIVER; CANALICULAR TRANSPORT; MASTOCYTOMA-CELLS; SDZ PSC-833; GLUTATHIONE; BIOSYNTHESIS; GLYCOPROTEIN; CYCLOSPORINS	The multidrug resistance-associated protein (MRP) is the product of an ATP-binding cassette transporter gene overexpressed in some tumor cells resistant to antineoplastic agents. We studied the transport function of MRP in membrane vesicles prepared from HeLa cells transfected with an MRP expression vector and overexpressing this 190-kDa membrane glycoprotein. ATP-dependent primary-active transport into the vesicles was demonstrated for leukotriene C-4 (LTC(4)), LTD(4), LTE(4), and S-(2,4-dinitrophenyl)glutathione with relative rates, at a substrate concentration of 50 nM, of 1.0, 0.27, 0.14, and 0.16, respectively. The endogenous glutathione conjugate LTC(4) had the highest affinity for this transporter with a K-m of 97 nM. The K-m for ATP was 19 mu M. Direct photoaffinity labeling with [H-8]LTC(4) labeled a 190-kDa membrane protein predominantly in the MRP-transfected HeLa cells. ATP-dependent LTC(4) transport was effectively inhibited by the LTD(4) receptor antagonist MR 571, whereas cyclosporin A and, particularly its analog PSC 833 were much less potent. The respective K-i values were 0.6, 5, and 27 mu M, respectively. In addition, MK 571 preferentially inhibited photoaffinity labeling of the 190-kDa protein in the MRP transfectants. Our results provide direct evidence that the MRP gene encodes a primary-active ATP-dependent export pump for conjugates of lipophilic compounds with glutathione and several other anionic residues. We conclude that the biosynthetic release of LTC(4) from cells is mediated by the 190-kDa product of the MRP gene.	QUEENS UNIV, CANC RES LABS, KINGSTON K7L 3N6, ON, CANADA	Queens University - Canada	LEIER, I (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM, DIV TUMOR BIOCHEM, NEUENHEIMER FELD 280, D-69120 HEIDELBERG, GERMANY.		Deeley, Roger/J-4828-2012; Keppler, Dietrich/A-5528-2013; Cole, Susan P.C./I-6389-2017	Keppler, Dietrich/0000-0003-2964-2333; Cole, Susan P.C./0000-0001-6571-6884				AKERBOOM TPM, 1991, J BIOL CHEM, V266, P13147; BARRAND MA, 1993, EUR J CANCER, V29A, P408, DOI 10.1016/0959-8049(93)90397-X; BOESCH D, 1991, EXP CELL RES, V196, P26, DOI 10.1016/0014-4827(91)90452-Z; BOESCH D, 1991, CANCER RES, V51, P4226; BOHME M, 1993, FEBS LETT, V333, P193, DOI 10.1016/0014-5793(93)80403-H; BUCHLER M, 1994, EUR J BIOCHEM, V224, P345, DOI 10.1111/j.1432-1033.1994.00345.x; COLE SPC, 1992, CAN J PHYSIOL PHARM, V70, P313, DOI 10.1139/y92-040; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FALK E, 1989, EUR J BIOCHEM, V186, P741, DOI 10.1111/j.1432-1033.1989.tb15268.x; FERNANDEZCHECA JC, 1992, J BIOL CHEM, V267, P1667; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRANT CE, 1994, CANCER RES, V54, P357; HANDE K, 1988, CANCER RES, V48, P1829; HEIJN M, 1992, AM J PHYSIOL, V262, pC104, DOI 10.1152/ajpcell.1992.262.1.C104; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HUBER M, 1987, HEPATOLOGY, V7, P224, DOI 10.1002/hep.1840070204; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; Jansen Peter L. M., 1993, P721; JEDLITSCHKY G, 1994, BIOCHEM PHARMACOL, V48, P1113, DOI 10.1016/0006-2952(94)90147-3; JENSSON H, 1985, METHOD ENZYMOL, V113, P504; JONES TR, 1989, CAN J PHYSIOL PHARM, V67, P17, DOI 10.1139/y89-004; KEPPLER D, 1992, REV PHYSIOL BIOCH P, V121, P1, DOI 10.1007/BFb0033192; KITAMURA T, 1990, P NATL ACAD SCI USA, V87, P3557, DOI 10.1073/pnas.87.9.3557; KOBAYASHI K, 1988, FEBS LETT, V240, P55, DOI 10.1016/0014-5793(88)80339-9; KRISHNAMACHARY N, 1993, CANCER RES, V53, P3658; LAM BK, 1989, J BIOL CHEM, V264, P12885; LAM BK, 1992, P NATL ACAD SCI USA, V89, P11598, DOI 10.1073/pnas.89.23.11598; LEIER I, 1994, EUR J BIOCHEM, V220, P599, DOI 10.1111/j.1432-1033.1994.tb18661.x; MIRSKI SEL, 1987, CANCER RES, V47, P2594; MROSS K, 1990, EUR J CLIN PHARMACOL, V39, P507; MURPHY RC, 1979, P NATL ACAD SCI USA, V76, P4275, DOI 10.1073/pnas.76.9.4275; NICHOLSON DW, 1992, J BIOL CHEM, V267, P17849; PENROSE JF, 1992, P NATL ACAD SCI USA, V89, P11603, DOI 10.1073/pnas.89.23.11603; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHAUB T, 1991, FEBS LETT, V279, P83, DOI 10.1016/0014-5793(91)80256-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNER BM, 1983, J IMMUNOL METHODS, V63, P1, DOI 10.1016/0022-1759(83)90204-1; TWENTYMAN PR, 1992, BIOCHEM PHARMACOL, V43, P109, DOI 10.1016/0006-2952(92)90668-9; VANDERBLIEK AM, 1989, ADV CANCER RES, V52, P165; ZAMAN GJR, 1993, CANCER RES, V53, P1747; ZHOU XJ, 1990, EUR J DRUG METAB PH, V15, P323, DOI 10.1007/BF03190222	42	797	811	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27807	27810						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961706				2022-12-27	WOS:A1994PV77200007
J	METZLER, DE; METZLER, CM; MOLLOVA, ET; SCOTT, RD; TANASE, S; KOGO, K; HIGAKI, T; MORINO, Y				METZLER, DE; METZLER, CM; MOLLOVA, ET; SCOTT, RD; TANASE, S; KOGO, K; HIGAKI, T; MORINO, Y			NMR-STUDIES OF H-1 RESONANCES IN THE 10-18-PPM RANGE FOR CYTOSOLIC ASPARTATE-AMINOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; ELONGATION-FACTOR TU; EXCHANGEABLE PROTONS; PYRIDOXAL-PHOSPHATE; THERMUS-THERMOPHILUS; INORGANIC-PHOSPHATE; HISTIDINE-RESIDUES; ESCHERICHIA-COLI; ACTIVE-SITE; BINDING	Continuing a previous investigation (Kintanar, A., Metzler, C. M., Metzler, D. E., and Scott, R. D. (1991) J. Biol. Chem. 266, 17222-17229), we have recorded H-1 NMR spectra at 500 MHz in the 10-18-ppm range for the 93-kDa porcine cytosolic aspartate aminotransferase and for four specific mutant forms of the enzyme in which histidine 68 has been replaced by lysine or histidine 143, 189, or 193 has been replaced by glutamine. We have correlated resonances for apoenzyme, pyridoxamine and pyridoxal phosphate forms, and dicarboxylate complexes and have assigned imidazole RM resonances of active site histidines. The chemical shifts of several resonances undergo pH-dependent changes around the pK(a) of the Schiff base proton at the active site. Other resonances shift upon binding of dicarboxylates or other ligands. Phosphate or carboxylate ions, which can also occupy the site of the substrate's ac-carboxylate, cause rapid exchange of the Schiff base proton. Although most resonances in the 10-18-ppm range disappear rapidly in D2O, a few are retained for months in the presence of the dicarboxylate inhibitor glutarate. We demonstrate that changes in chemical shifts and in exchange rates are sensitive indicators of electronic interactions of the enzyme with ligands and of conformational change. Nuclear Overhauser effects from NR protons have allowed us to identify resonances of CH protons of the imidazole rings of histidines 143, 189, and 193. Observed and predicted chemical shifts have been compared. We conclude that the net charge on this histidine cluster is zero but that some negative charge from the aspartate 222 carboxylate is donated inductively into the histidine 143 ring. Studies of the related enzyme from Escherichia coli are provided in an accompanying paper (Metzler, D. E., Metzler, C. M., Scott, R. D., Mollova, E. T., Kagamiyama, H., Yano, T., Kuramitsu, S., Hayashi, H., Hirotsu, R., and Miyahara, I. (1994) J. Biol. Chem. 269, 28027-28033). Our approach should be applicable to the study of active sites of a broad range of relatively large proteins.	IOWA STATE UNIV SCI & TECHNOL, CHEM INSTRUMENT SERV, AMES, IA 50011 USA; KUMAMOTO UNIV, SCH MED, DEPT BIOCHEM, KUMAMOTO 860, JAPAN	Iowa State University; Kumamoto University	METZLER, DE (corresponding author), IOWA STATE UNIV SCI & TECHNOL, DEPT BIOCHEM & BIOPHYS, 4106 MOLEC BIOL BLDG, AMES, IA 50011 USA.				NIDDK NIH HHS [DK01549] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK001549] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDRESCU AT, 1993, BIOCHEMISTRY-US, V32, P1707, DOI 10.1021/bi00058a003; Arnone A, 1985, TRANSAMINASES, P138; BACHOVCHIN WW, 1988, BIOCHEMISTRY-US, V27, P7689, DOI 10.1021/bi00420a018; FIRSOV LM, 1994, EUR J BIOCHEM, V223, P293, DOI 10.1111/j.1432-1033.1994.tb18994.x; FUKUMOTO Y, 1991, J BIOL CHEM, V266, P4187; FURBISH FS, 1969, BIOCHEMISTRY-US, V8, P5169, DOI 10.1021/bi00840a071; GLICKSON JD, 1971, J AM CHEM SOC, V93, P4031; GRIFFIN JH, 1973, BIOCHEMISTRY-US, V12, P2096, DOI 10.1021/bi00735a012; HOUSE KL, 1993, BIOCHEMISTRY-US, V32, P3468, DOI 10.1021/bi00064a034; IRIARTE A, 1985, J BIOL CHEM, V260, P7457; JENKINS WT, 1980, ARCH BIOCHEM BIOPHYS, V205, P579, DOI 10.1016/0003-9861(80)90141-1; JIN P, 1989, THESIS IOWA STATE U; KINTANAR A, 1991, J BIOL CHEM, V266, P17222; KOGO K, 1991, SEIKAGAKU, V63, P653; KOGO K, 1992, SEIKAGU, V64, P703; KRUDY GA, 1992, BIOCHEMISTRY-US, V31, P1595, DOI 10.1021/bi00121a003; LIMMER S, 1992, BIOCHEMISTRY-US, V31, P2970, DOI 10.1021/bi00126a018; LOWRY DF, 1992, BIOCHEMISTRY-US, V31, P2977, DOI 10.1021/bi00126a019; LUMB KJ, 1994, J MOL BIOL, V235, P1072, DOI 10.1006/jmbi.1994.1058; MARKLEY JL, 1975, ACCOUNTS CHEM RES, V8, P70, DOI 10.1021/ar50086a004; MARKLEY JL, 1978, BIOCHEMISTRY-US, V17, P4648, DOI 10.1021/bi00615a010; MARTINEZCARRION M, 1967, J BIOL CHEM, V242, P2397; METZLER CM, 1991, BIOCHEM BIOPH RES CO, V178, P385, DOI 10.1016/0006-291X(91)91825-W; METZLER CM, 1987, ANAL BIOCHEM, V166, P313, DOI 10.1016/0003-2697(87)90580-X; METZLER DE, 1994, J BIOL CHEM, V269, P28027; METZLER DE, 1994, IN PRESS MODERN ENZY; MORINO Y, 1984, J BIOL CHEM, V259, P3877; NAGASHIMA F, 1989, BIOCHEMISTRY-US, V28, P1153, DOI 10.1021/bi00429a033; OSAPAY K, 1991, J AM CHEM SOC, V113, P9436, DOI 10.1021/ja00025a002; OVCHINNIKOV YA, 1973, FEBS LETT, V29, P31, DOI 10.1016/0014-5793(73)80008-0; PELTON JG, 1993, PROTEIN SCI, V2, P543; PFISTER K, 1978, P NATL ACAD SCI USA, V75, P145, DOI 10.1073/pnas.75.1.145; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; REDFIELD AG, 1990, BIOCHEMISTRY-US, V29, P3509, DOI 10.1021/bi00466a013; ROBILLAR.G, 1974, J MOL BIOL, V86, P519, DOI 10.1016/0022-2836(74)90178-8; ROBILLARD G, 1972, J MOL BIOL, V71, P501; ROBILLARD G, 1974, J MOL BIOL, V86, P554; SCOTT RD, 1991, INT UNION B, V199, P129; SILVA MM, 1990, ABSTR AM CRYST ASS, V18, P69; SKLENAR V, 1987, J MAGN RESON, V74, P469, DOI 10.1016/0022-2364(87)90269-1; STELLWAG.E, 1973, J MOL BIOL, V75, P683, DOI 10.1016/0022-2836(73)90301-X; STOESZ JD, 1979, BIOCHEMISTRY-US, V18, P4669, DOI 10.1021/bi00588a030; TANASE S, 1988, SEIKAGAKU, V60, P651; TANASE S, 1994, VITAM B6 CARBONYL CA; VERGE D, 1979, FEBS LETT, V100, P265, DOI 10.1016/0014-5793(79)80348-8; Wuthrich K., 1986, NMR PROTEINS NUCL AC; Yang B I, 1979, Methods Enzymol, V62, P528	47	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28017	28026						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961736				2022-12-27	WOS:A1994PV77200040
J	TANG, AH; TU, CPD				TANG, AH; TU, CPD			BIOCHEMICAL-CHARACTERIZATION OF DROSOPHILA GLUTATHIONE S-TRANSFERASES D1 AND D21	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXIDASE-ACTIVITY; 3-DIMENSIONAL STRUCTURE; INSECTICIDE RESISTANCE; INTRONLESS GENE; MUSCA-DOMESTICA; RAT-LIVER; RESOLUTION; ENZYMES; COMPLEX; SPECIFICITIES	The genomic DNA for the two Drosophila genes, gstD1 and gstD21, were engineered for expression in Escherichia coli by polymerase chain reaction using a pair of specially designed primers. This newly designed expression system produced consistently high yields of the recombinant glutathione S-transferases (GSTs), which were purified to electrophoretic homogeneity by S-hexyl-GSH affinity chromatography. Consistent with their differences in size, GST D1 and GST D21 displayed different mobilities on SDS-polyacrylamide gel electrophoresis. Circular dichroism spectrometry revealed some differences in the protein secondary structural organization between the two GST D isozymes. Polyclonal antibodies against GST D1 and GST D21 revealed that they are immunologically distinct hom each other. The GST D1 antiserum cross-reacted weakly with GST D21, but the GST D21 antiserum had no detectable crossreactivity with GST D1. The amino acid sequences of GST D1 and GST D21 have 70% identity. GST D1 is active toward CDNB with 17% of the catalytic efficiency of the human alpha GST121, whereas CDNB is a poor substrate for GST D21. Both GST D1 and GST D21 have similar levels of GSH peroxidase activity against cumene hydroperoxide. Another major difference in substrate specificities between GST D1 and GST D21 is in the activity of 1,1,1-trichloro-2,2-bis-(p-chlorophenyl)ethane (DDT) dehydrochlorinase, which exists only in the GST D1 isozyme. This is the first definitive demonstration that DDT dehydrochlorinase activity is an intrinsic property of a Drosophila GST. Our results suggest that GST D1 may play a role in DDT metabolism in Drosophila.	PENN STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, PAUL M ALTHOUSE LAB 401, UNIVERSITY PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park			Tang, Amy/L-3226-2016	Tang, Amy/0000-0002-5772-2878	NCRR NIH HHS [2S07 RR07082] Funding Source: Medline; NIEHS NIH HHS [ES 05661] Funding Source: Medline; NIGMS NIH HHS [GM 49205] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005661] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049205] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD S, 1989, ARCH INSECT BIOCHEM, V12, P31, DOI 10.1002/arch.940120104; AHMAD S, 1987, ARCH INSECT BIOCHEM, V6, P85, DOI 10.1002/arch.940060203; ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; BALABASKARAN S, 1970, BIOCHEM J, V117, P989, DOI 10.1042/bj1170989; BEALL C, 1992, BIOCHEM GENET, V30, P515, DOI 10.1007/BF01037590; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BURGESS JR, 1989, BIOCHEM BIOPH RES CO, V158, P497, DOI 10.1016/S0006-291X(89)80076-2; CHOW NWI, 1988, J BIOL CHEM, V263, P12797; CLARK AG, 1989, COMP BIOCHEM PHYS B, V92, P419, DOI 10.1016/0305-0491(89)90114-4; CLARK AG, 1984, PESTIC BIOCHEM PHYS, V22, P249, DOI 10.1016/0048-3575(84)90018-X; COCHRANE BJ, 1987, INSECT BIOCHEM, V17, P731, DOI 10.1016/0020-1790(87)90043-6; COCHRANE BJ, 1992, ACS SYM SER, V505, P53; DESMIT MH, 1990, PROG NUCLEIC ACID RE, V38, P1; FOURNIER D, 1992, J BIOL CHEM, V267, P1840; Habig W H, 1981, Methods Enzymol, V77, P398; HARTZ D, 1990, RIBOSOME, P275; HIRATSUKA A, 1990, J BIOL CHEM, V265, P11973; Innis MA, 1990, PCR PROTOCOLS GUIDE, P1, DOI [10.1016/0167-7799(90)90215-J, DOI 10.1016/0167-7799(90)90215-J]; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KIMURA T, 1965, WHO B, V32, P557; KLEPPE K, 1971, J MOL BIOL, V56, P341, DOI 10.1016/0022-2836(71)90469-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; LIPKE H, 1959, J BIOL CHEM, V234, P2123; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MCCARTHY JEG, 1990, TRENDS GENET, V6, P78, DOI 10.1016/0168-9525(90)90098-Q; MORROW CS, 1990, CANCER CELL-MON REV, V2, P15; MORTON RA, 1993, GENOME, V36, P1, DOI 10.1139/g93-001; OPPENOORTH F. J., 1965, ENTOMOL EXPAPPL, V8, P293, DOI 10.1007/BF00344541; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; PLAPP FW, 1984, PESTIC BIOCHEM PHYS, V22, P194, DOI 10.1016/0048-3575(84)90089-0; PRITSOS CA, 1988, COMP BIOCHEM PHYS C, V90, P423, DOI 10.1016/0742-8413(88)90021-7; PROHASKA JR, 1980, BIOCHIM BIOPHYS ACTA, V611, P87, DOI 10.1016/0005-2744(80)90045-5; REDDY CC, 1983, ARCH BIOCHEM BIOPHYS, V224, P87, DOI 10.1016/0003-9861(83)90192-3; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SIMMONS TW, 1989, COMP BIOCHEM PHYS B, V94, P323, DOI 10.1016/0305-0491(89)90350-7; Simons P C, 1981, Methods Enzymol, V77, P235; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; SOHAL RS, 1988, EXP GERONTOL, V23, P211, DOI 10.1016/0531-5565(88)90008-3; STERNBURG J, 1954, J AGR FOOD CHEM, V2, P1125, DOI 10.1021/jf60042a008; STORMO GD, 1986, MAXIMIZING GENE EXPR, P195; SUNDSETH SS, 1989, PESTIC BIOCHEM PHYS, V33, P176, DOI 10.1016/0048-3575(89)90008-4; TERRIERE LC, 1984, ANNU REV ENTOMOL, V29, P71, DOI 10.1146/annurev.en.29.010184.000443; TOUNG YPS, 1991, BIOCHEM BIOPH RES CO, V178, P1205, DOI 10.1016/0006-291X(91)91021-4; TOUNG YPS, 1993, J BIOL CHEM, V268, P9737; TOUNG YPS, 1990, P NATL ACAD SCI USA, V87, P31, DOI 10.1073/pnas.87.1.31; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; TSUKAMOTO M., 1960, Botyu-Kagaku = Scientific Insect Control, V25, P156; TU CPD, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P379; TU CPD, 1985, J BIOL CHEM, V260, P9961; WATERS LC, 1988, PESTIC BIOCHEM PHYS, V30, P214, DOI 10.1016/0048-3575(88)90036-3; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577; WEINHOLD LC, 1990, COMP BIOCHEM PHYS B, V95, P355, DOI 10.1016/0305-0491(90)90088-B	60	109	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27876	27884						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961718				2022-12-27	WOS:A1994PV77200019
J	CHAE, HZ; CHUNG, SJ; RHEE, SG				CHAE, HZ; CHUNG, SJ; RHEE, SG			THIOREDOXIN-DEPENDENT PEROXIDE REDUCTASE FROM YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL HYDROPEROXIDE REDUCTASE; FLAVOPROTEIN DISULFIDE OXIDOREDUCTASES; SACCHAROMYCES-CEREVISIAE; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; OXIDATIVE STRESS; SEQUENCE; PROTEIN; CLONING; ACIDS	A 25-kDa antioxidant enzyme that provides protection against oxidation systems capable of generating reactive oxygen and sulfur species has previously been identified. The nature of the oxidant eliminated by and the physiological source of reducing equivalents for, this enzyme, however, were not known. The 25-kDa enzyme is now shown to be a peroxidase that reduces H2O2 and alkyl hydroperoxides with the use of hydrogens provided by thioredoxin, thioredoxin reductase, and NADPH. This protein is the first peroxidase to be identified that uses thioredoxin as the immediate hydrogen donor and is thus named thioredoxin peroxidase (TPx). TPx exists as a dimer of identical 25-kDa subunits that contain 2 cysteine residues, Cys(47) and Cys(170). Cys(47)-SH appears to be the site of oxidation by peroxides, and the oxidized Cys(47) probably reacts with Cys(170)-SH of the other subunit to form an intermolecular disulfide. Mutant TPx proteins lacking either Cys(47) or Cys(170), therefore, do not exhibit thioredoxin-coupled peroxidase activity. The TPx disulfide is specifically reduced by thioredoxin, but can also be reduced (less effectively) by a small molecular size thiol. The Saccharomyces cerevisiae thioredoxin reductase gene was also cloned and sequenced, and the deduced amino sequence was shown to be 51% identical with that of the Escherichia coli enzyme.	NHLBI,BIOCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; CHAUDIERE J, 1984, J BIOL CHEM, V259, P1043; CLAIBORNE A, 1992, TRENDS BIOCHEM SCI, V17, P183, DOI 10.1016/0968-0004(92)90263-9; Flohe L., 1989, GLUTATHIONE CHEM BIO, P644; FURTER R, 1986, NUCLEIC ACIDS RES, V14, P6357, DOI 10.1093/nar/14.16.6357; GAN ZR, 1991, J BIOL CHEM, V266, P1692; HALL DE, 1971, EUR J BIOCHEM, V23, P328, DOI 10.1111/j.1432-1033.1971.tb01625.x; HALLIWELL B, 1984, METHOD ENZYMOL, V105, P47; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIM KW, 1988, J BIOL CHEM, V263, P4704; LIM YS, 1993, BIOCHEM BIOPH RES CO, V107, P279; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; POOLE LB, 1989, J BIOL CHEM, V264, P12330; PORQUE P G, 1970, Journal of Biological Chemistry, V245, P2363; RHEE SG, 1985, METHOD ENZYMOL, V113, P213; ROSS D, 1985, J BIOL CHEM, V260, P5028; RUSSEL M, 1988, J BIOL CHEM, V263, P9015; SPERANZA ML, 1973, BIOCHIM BIOPHYS ACTA, V327, P274, DOI 10.1016/0005-2744(73)90410-5; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STORZ G, 1989, J BACTERIOL, V171, P2049, DOI 10.1128/jb.171.4.2049-2055.1989; TARTAGLIA LA, 1990, J BIOL CHEM, V265, P10535; THURMAN RG, 1972, EUR J BIOCHEM, V25, P420, DOI 10.1111/j.1432-1033.1972.tb01711.x; YIM MB, 1994, J BIOL CHEM, V269, P1621	27	830	855	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27670	27678						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961686				2022-12-27	WOS:A1994PV77100080
J	EMA, M; OHE, N; SUZUKI, M; MIMURA, J; SOGAWA, K; IKAWA, S; FUJIIKURIYAMA, Y				EMA, M; OHE, N; SUZUKI, M; MIMURA, J; SOGAWA, K; IKAWA, S; FUJIIKURIYAMA, Y			DIOXIN BINDING ACTIVITIES OF POLYMORPHIC FORMS OF MOUSE AND HUMAN ARYLHYDROCARBON RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON HYDROXYLASE; XENOBIOTIC RESPONSIVE ELEMENTS; SQUAMOUS-CELL CARCINOMA; HEAT-SHOCK PROTEIN; AH-RECEPTOR; DNA RECOGNITION; GLUCOCORTICOID RECEPTOR; LIGAND-BINDING; P-450C GENE; LUNG-CANCER	The genetic difference in the susceptibility of mice to environmental toxicities induced by dioxin and related chemicals is governed by polymorphism of the arylhydrocarbon receptor (AhR) (Poland, A., and Knutson, C. (1982) Annu. Rev. Pharmacol. Toxicol. 22, 517-554). cDNA cloning of AhR cDNA from responder (C57BL/6) and nonresponder (DBA/2J) mice allowed us to analyze the structure and function of these AhRs. Both of the AhRs, which were expressed in COS-7 cells transfected with their expression plasmids, showed a clear 9 S complex with 2,3,7,8-[H-3]tetrachlorodibenzo-p-dioxin (TCDD) in a linear glycerol gradient centrifugation, consistent with the result of the endogenously expressed AhR in Hepa-1 cells. This result provides the first direct evidence that the cDNA-encoded protein binds the ligand specifically. Scatchard plot analysis revealed that the dissociation constant (K-d) of C57BL AhR for TCDD is 0.27 nM, while that of DBA AhR is elevated up to six times that high. Chimeric plasmids between the tno cDNAs and site-directed mutagenesis revealed two critical alterations responsible for the reduced ligand binding activity: an Ala(375) to Val alteration and an elongated carboxyl-terminal sequence due to a T to C mutation at the first letter of the termination codon of C57BL AhR. Two variants with reduced and intermediate ligand binding activity were also found in human AhRs with amino acid alterations equivalent to those of the DBA AhR. Importance of the amino acid at position 381 of human AhR (equivalent to position 375 of mouse AhR) in the ligand binding was confirmed by the fact that the mutation of Val(381) to Asp completely abolished the ligand binding activity of human AhR.	TOHOKU UNIV, FAC SCI, DEPT CHEM, SENDAI, MIYAGI 980, JAPAN; INST DEV AGING & CANC, SENDAI, MIYAGI 980, JAPAN	Tohoku University			Mimura, Junsei/E-7893-2013; 井川, 俊太郎/L-5911-2015	Ema, Masatsugu/0000-0003-0645-6183				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BRADFIELD CA, 1988, MOL PHARMACOL, V34, P229; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CHANG CY, 1993, PHARMACOGENETICS, V3, P312, DOI 10.1097/00008571-199312000-00005; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; CUTHILL S, 1987, J BIOL CHEM, V262, P3477; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DOLWICK KM, 1993, MOL PHARMACOL, V44, P911; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HARPER PA, 1988, CANCER RES, V48, P2388; HARRIS M, 1989, CANCER RES, V49, P4531; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; ITOH S, 1993, NUCLEIC ACIDS RES, V21, P3578, DOI 10.1093/nar/21.15.3578; JACKSON FR, 1986, NATURE, V320, P185, DOI 10.1038/320185a0; KOURI RE, 1982, CANCER RES, V42, P5030; LANDERS JP, 1991, BIOCHEM J, V276, P273, DOI 10.1042/bj2760273; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAKACHI K, 1991, CANCER RES, V51, P5177; NEBERT DW, 1972, NATURE-NEW BIOL, V236, P107, DOI 10.1038/newbio236107a0; NEMOTO T, 1990, J BIOL CHEM, V265, P2269; OKEY AB, 1989, MOL PHARMACOL, V35, P823; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1987, MOL PHARMACOL, V32, P471; PROKIPCAK RD, 1988, ARCH BIOCHEM BIOPHYS, V267, P811, DOI 10.1016/0003-9861(88)90091-4; REDDY P, 1986, CELL, V46, P53, DOI 10.1016/0092-8674(86)90859-7; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT JV, 1993, J BIOL CHEM, V268, P22203; SHIELDS PG, 1993, CANCER EPIDEM BIOMAR, V2, P481; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THOMAS PE, 1972, BIOCHEM GENET, V6, P157, DOI 10.1007/BF00486400; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251	45	265	275	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27337	27343						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961644				2022-12-27	WOS:A1994PV77100032
J	ORR, JW; NEWTON, AC				ORR, JW; NEWTON, AC			REQUIREMENT FOR NEGATIVE CHARGE ON ACTIVATION LOOP OF PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CELLS; PHOSPHOLIPIDS; FAMILY; SITE	Increasing evidence has implicated a post-translational phosphorylation in the production of a catalytically competent protein kinase C. Here we present structural and biochemical evidence that Thr(500) of protein kinase C-beta II is the residue phosphorylated by another kinase. Modeling studies indicate that this residue is part of a ''lip'' structure at the entrance of the catalytic site; phosphorylation on this lip, or ''activation loop,'' is central to the regulation of three kinases whose structures have been elucidated (Taylor, S. S., and Radzio-Andzelm, E. (1994) Structure 2, 345-355). Biochemical data reveal that mutation of Thr(500) to an acidic residue (Glu) results in expression of catalytically active protein kinase C in COS cells. In contrast, mutation of this residue to a neutral, non-phosphorylatable residue (Val) results in expression of inactive enzyme. Thus, negative charge at position 500 is required for catalytically competent protein kinase C-beta II. These data suggest that signal processing by protein kinase C cannot occur until the enzyme is first phosphorylated by a protein kinase C kinase.	INDIANA UNIV,DEPT CHEM,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington					NIGMS NIH HHS [GM 43154] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043154, R01GM043154] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORNER C, 1989, J BIOL CHEM, V264, P13902; CAZAUBON S, 1990, EUR J BIOCHEM, V194, P799, DOI 10.1111/j.1432-1033.1990.tb19472.x; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ONO Y, 1988, J BIOL CHEM, V263, P6927; ORR JW, 1994, J BIOL CHEM, V269, P8383; ORR JW, 1992, J BIOL CHEM, V267, P15263; SCHAEFFER E, 1989, CELL, V57, P403, DOI 10.1016/0092-8674(89)90915-X; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; STRAUS D, 1985, P NATL ACAD SCI USA, V82, P2272, DOI 10.1073/pnas.82.8.2272; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; WATANABE M, 1994, J BIOL CHEM, V269, P16829; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG J, 1993, P NATL ACAD SCI USA, V90, P6130, DOI 10.1073/pnas.90.13.6130	22	130	134	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27715	27718						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961692				2022-12-27	WOS:A1994PV77100086
J	TAYLOR, JM; JACOBMOSIER, GG; LAWTON, RG; REMMERS, AE; NEUBIG, RR				TAYLOR, JM; JACOBMOSIER, GG; LAWTON, RG; REMMERS, AE; NEUBIG, RR			BINDING OF AN ALPHA(2) ADRENERGIC-RECEPTOR 3RD INTRACELLULAR LOOP PEPTIDE TO G-BETA AND THE AMINO-TERMINUS OF G-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOPSIN TRANSDUCIN INTERACTIONS; GAMMA SUBUNIT COMPLEX; G-PROTEINS; SYNTHETIC PEPTIDES; CARBOXYL TERMINUS; CROSS-LINKING; BOVINE BRAIN; ADENYLATE-CYCLASE; HIGH-AFFINITY; SITE	The structural basis of receptor-G protein interactions was examined using a photoaffinity derivative of a G protein-activating receptor-derived peptide (Q peptide) from the carboxyl-terminal region of the third intracellular loop of alpha(2) adrenergic receptor. A diazopyruvoyl photoaffinity derivative of this peptide (DAP-Q) was cross-linked to purified bovine brain G(o). Specific, competable cross-linking of 750 nM DAP-Q to sites on both the alpha(o) and beta subunits was observed. No specific cross-linking was seen with non-target proteins or heat-denatured G protein subunits. I-125-DAP-Q labeled the 2-kDa amino-terminal fragment of alpha(o) as determined by protease digestion of the cross-linked G protein followed by gel electrophoresis or high pressure liquid chromatography purification and mass spectroscopy of the radiolabeled proteolysis fragment. The functional significance of incorporation into beta gamma subunit is supported by the absolute requirement of beta gamma subunit for DAP-Q stimulation of G(o)/G(i) GTPase. Thus, specific interactions of G protein-coupled receptors with the beta subunit of G protein, in addition to those with the alpha subunit, appear to be important for receptor-G protein coupling.	UNIV MICHIGAN,DEPT PHARMACOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT INTERNAL MED HYPERTENS,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Taylor, Joan/0000-0002-8794-5167; Remmers, Ann/0000-0002-2465-7651; Neubig, Richard/0000-0003-0501-0008	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00042] Funding Source: Medline; NHLBI NIH HHS [HLGM46417] Funding Source: Medline; NIAMS NIH HHS [P60-AR20557] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; DALMAN HM, 1991, FASEB J, V5, pA1594; DERETIC D, 1987, J BIOL CHEM, V262, P10839; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GOODFELLOW VS, 1989, BIOCHEMISTRY-US, V28, P6346, DOI 10.1021/bi00441a030; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HARRISON JK, 1989, BIOCHEMISTRY-US, V28, P6023, DOI 10.1021/bi00440a045; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P12655; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HIRSCH JP, 1991, GENE DEV, V5, P467, DOI 10.1101/gad.5.3.467; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; IKEZU T, 1992, FEBS LETT, V311, P29, DOI 10.1016/0014-5793(92)81359-T; IM MJ, 1988, FEBS LETT, V227, P225, DOI 10.1016/0014-5793(88)80903-7; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KIM MH, 1987, BIOCHEMISTRY-US, V26, P3664, DOI 10.1021/bi00386a061; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KWON G, 1993, BIOCHEMISTRY-US, V32, P2401, DOI 10.1021/bi00060a035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG JC, 1989, J RECEPTOR RES, V9, P313, DOI 10.3109/10799898909066061; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MCCONAHEY P, 1980, IMMUNOCHEMICAL TEC A, V70, P210; MOSIER GJ, 1995, IN PRESS J ORG CHEM; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; PALM D, 1990, FEBS LETT, V261, P294, DOI 10.1016/0014-5793(90)80575-4; PALM D, 1989, FEBS LETT, V254, P89, DOI 10.1016/0014-5793(89)81015-4; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17040; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; ROOF DJ, 1985, J BIOL CHEM, V260, P6242; Roth J, 1975, Methods Enzymol, V37, P223; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRADER CD, 1987, J BIOL CHEM, V262, P16439; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; TAYLOR JM, 1994, PEPTIDES, V15, P829, DOI 10.1016/0196-9781(94)90038-8; TAYLOR JM, 1993, J CELL BIOCHEM, V17, pA133; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; WADE SM, 1994, MOL PHARMACOL, V45, P1191; WAKAMATSU K, 1993, J CELL BIOCHEM, V17, pA364; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044	51	99	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27618	27624						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961678				2022-12-27	WOS:A1994PV77100071
J	BENKE, D; FRITSCHY, JM; TRZECIAK, A; BANNWARTH, W; MOHLER, H				BENKE, D; FRITSCHY, JM; TRZECIAK, A; BANNWARTH, W; MOHLER, H			DISTRIBUTION, PREVALENCE, AND DRUG-BINDING PROFILE OF GAMMA-AMINOBUTYRIC-ACID TYPE-A RECEPTOR SUBTYPES DIFFERING IN THE BETA-SUBUNIT VARIANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA-A-RECEPTOR; REGION-SPECIFIC EXPRESSION; RAT-BRAIN; BENZODIAZEPINE RECEPTORS; MESSENGER-RNAS; MONOCLONAL-ANTIBODIES; CHANNEL COMPLEX; ALPHA-3 SUBUNIT; ISO-OLIGOMERS; 2 FORMS	Native gamma-aminobutyric acid type A (GABA(A)) receptors containing different beta-subunit variants were identified immunobiochemically with antisera recognizing selectively the beta 1-, beta 2-, or beta 3-subunit. As determined by immunoprecipitation, the beta 2-subunit was present in 55-60% of GABA(A) receptors, while only minor receptor populations contained the beta 1-subunit (16-18%) or the beta 3-subunit (19-25%). Since the sum of these values amounts to about 100%, it is concluded that GABA(A) receptors largely contain only a single type of beta-subunit. Pharmacologically, receptors containing the beta 2-subunit differed from those containing the beta 1- or beta 3-subunit by their differential affinities for benzodiazepine receptor ligands. The subunit composition was analyzed biochemically in receptors immunoprecipitated by the beta 2-subunit antiserum. The beta 2-subunit was preferentially associated with the alpha 1-subunit (rarely with the alpha 2-subunit) and with the gamma 2-subunit; negligible or no immunoreactivity was detected for the alpha 3-, alpha 5-, or beta 1-subunit. A stringent co-expression of alpha 1- and beta 2-subunits was confirmed by double immunofluorescence staining on the cellular level. Neurons expressing the beta 3-subunit immunoreactivity were largely double labeled by the alpha 2-subunit antiserum, Thus, the subunit combinations alpha 1 beta 2 gamma 2 and alpha 2 beta 3 gamma 2 represent two main GABA(A) receptor subtypes, which together amount to 75-85% of the diazepam-sensitive GABA(A) receptors.	ETH ZURICH, INST PHARMACOL, CH-8057 ZURICH, SWITZERLAND; UNIV ZURICH, CH-8057 ZURICH, SWITZERLAND; F HOFFMANN LA ROCHE & CO LTD, PHARMA RES DEPT, CH-4002 BASEL, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; Roche Holding				Fritschy, Jean-Marc/0000-0002-8552-3702				AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; BACKUS KH, 1993, NEUROREPORT, V5, P285, DOI 10.1097/00001756-199312000-00026; BATESON AN, 1991, J NEUROCHEM, V56, P1437, DOI 10.1111/j.1471-4159.1991.tb11443.x; BENKE D, 1991, J RECEPTOR RES, V11, P407, DOI 10.3109/10799899109066418; BENKE D, 1991, J BIOL CHEM, V266, P4478; BENKE D, 1991, Molecular Neuropharmacology, V1, P103; BUCHSTALLER A, 1991, FEBS LETT, V287, P27, DOI 10.1016/0014-5793(91)80008-Q; BUREAU M, 1990, MOL PHARMACOL, V37, P497; DEBLAS AL, 1988, J NEUROSCI, V8, P602; DOBLE A, 1992, TRENDS PHARMACOL SCI, V13, P76, DOI 10.1016/0165-6147(92)90027-4; DUGGAN MJ, 1991, J BIOL CHEM, V266, P24778; DUGGAN MJ, 1992, J NEUROCHEM, V58, P72, DOI 10.1111/j.1471-4159.1992.tb09278.x; DUGGAN MJ, 1990, J BIOL CHEM, V265, P3831; ENDO S, 1993, J NEUROCHEM, V60, P1388, DOI 10.1111/j.1471-4159.1993.tb03300.x; ENDO S, 1991, ADV EXP MED BIOL, P375; EWERT M, 1990, J CELL BIOL, V110, P2043, DOI 10.1083/jcb.110.6.2043; EWERT M, 1992, BRAIN RES, V569, P57, DOI 10.1016/0006-8993(92)90368-J; FRITSCHY JM, 1992, P NATL ACAD SCI USA, V89, P6726, DOI 10.1073/pnas.89.15.6726; GAO B, 1993, NEUROSCIENCE, V54, P881, DOI 10.1016/0306-4522(93)90582-Z; HADINGHAM KL, 1993, MOL PHARMACOL, V44, P1211; HARVEY RJ, 1994, J NEUROCHEM, V62, P10; HERB A, 1992, P NATL ACAD SCI USA, V89, P1433, DOI 10.1073/pnas.89.4.1433; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KOFUJI P, 1991, J NEUROCHEM, V56, P713, DOI 10.1111/j.1471-4159.1991.tb08209.x; LAURIE DJ, 1992, J NEUROSCI, V12, P4151; LOLAIT SJ, 1989, FEBS LETT, V258, P17, DOI 10.1016/0014-5793(89)81605-9; LUDDENS H, 1994, MOL PHARMACOL, V45, P810; LUDDENS H, 1991, TRENDS PHARMACOL SCI, V12, P49, DOI 10.1016/0165-6147(91)90495-E; LUDDENS H, 1990, NATURE, V346, P648, DOI 10.1038/346648a0; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MACHU TK, 1993, J NEUROCHEM, V61, P2034, DOI 10.1111/j.1471-4159.1993.tb07439.x; MARKSITZER R, 1993, J RECEPTOR RES, V13, P467, DOI 10.3109/10799899309073673; MCKERNAN RM, 1991, NEURON, V7, P667, DOI 10.1016/0896-6273(91)90379-E; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MERTENS S, 1993, J BIOL CHEM, V268, P5965; MOHLER H, 1981, J NEUROCHEM, V37, P714; MOHLER H, 1992, ARZNEIMITTELFORSCH, V42-1, P211; MOHLER H, 1991, FIDIA RES F S SERIES, V7, P111; PEREZVELAZQUEZ JL, 1993, NATURE, V361, P457, DOI 10.1038/361457a0; PERSOHN E, 1992, J COMP NEUROL, V326, P193, DOI 10.1002/cne.903260204; POLLARD S, 1993, J BIOL CHEM, V268, P3753; POLLARD S, 1991, FEBS LETT, V295, P81, DOI 10.1016/0014-5793(91)81390-T; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; PUIA G, 1991, MOL PHARMACOL, V39, P691; RICHARDS JG, 1987, J NEUROSCI, V7, P1866; SCHOCH P, 1983, EUR J PHARMACOL, V95, P323, DOI 10.1016/0014-2999(83)90656-8; SIEGHART W, 1992, TRENDS PHARMACOL SCI, V13, P446, DOI 10.1016/0165-6147(92)90142-S; SIGEL E, 1993, FEBS LETT, V324, P140, DOI 10.1016/0014-5793(93)81380-I; SOMOGYI P, 1982, NEUROSCIENCE, V7, P1779, DOI 10.1016/0306-4522(82)90035-5; VALEYEV AY, 1993, J PHARMACOL EXP THER, V265, P985; WAFFORD KA, 1992, FEBS LETT, V313, P113, DOI 10.1016/0014-5793(92)81424-K; WAFFORD KA, 1994, NEURON, V12, P775, DOI 10.1016/0896-6273(94)90330-1; WAFFORD KA, 1993, MOL PHARMACOL, V44, P437; WHITING P, 1990, P NATL ACAD SCI USA, V87, P9966, DOI 10.1073/pnas.87.24.9966; Wisden W, 1992, Curr Opin Neurobiol, V2, P263, DOI 10.1016/0959-4388(92)90113-Y; WISDEN W, 1991, FEBS LETT, V289, P227, DOI 10.1016/0014-5793(91)81076-K; WISDEN W, 1992, J NEUROSCI, V12, P1040; YMER S, 1990, EMBO J, V9, P3261, DOI 10.1002/j.1460-2075.1990.tb07525.x; YMER S, 1989, EMBO J, V8, P1665, DOI 10.1002/j.1460-2075.1989.tb03557.x; ZEZULA J, 1991, BRAIN RES, V563, P325, DOI 10.1016/0006-8993(91)91556-G; ZHANG JH, 1991, J COMP NEUROL, V303, P637, DOI 10.1002/cne.903030409; ZIMPRICH F, 1991, NEUROSCI LETT, V127, P125, DOI 10.1016/0304-3940(91)90910-L	62	165	169	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27100	27107						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929453				2022-12-27	WOS:A1994PQ93100077
J	DUPRET, JM; GOODFELLOW, GH; JANEZIC, SA; GRANT, DM				DUPRET, JM; GOODFELLOW, GH; JANEZIC, SA; GRANT, DM			STRUCTURE-FUNCTION STUDIES OF HUMAN ARYLAMINE N-ACETYLTRANSFERASES NAT1 AND NAT2 - FUNCTIONAL-ANALYSIS OF RECOMBINANT NAT1/NAT2 CHIMERAS EXPRESSED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LIVER; ACETYLATION PHARMACOGENETICS; SALMONELLA-TYPHIMURIUM; REVERSE TRANSCRIPTASES; CATALYTIC MECHANISM; ACTIVATION; PHENOTYPE; GENOTYPE; GENE; POLYMORPHISM	The human arylamine N-acetyltransferases NAT1 and NAT2 catalyze the biotransformation of primary aromatic amine or hydrazine drugs and xenobiotics. These enzymes share 81% amino acid sequence identity, yet differ markedly with respect to their acceptor substrate selectivities and intrinsic in vitro stabilities. To define the contribution of large regions of NAT1 and NAT2 polypeptide structure to enzyme integrity and catalytic specificity, we used selected restriction endonuclease digestions and fragment religation into the tao promoter-based phagemid pKEN2 to construct a panel of 18 NAT1/NAT2 hybrid gene vectors for heterologous expression in Escherichia coli. Induction of hybrid gene expression in recombinant transformants of E. coli strain XA90 led to the production of soluble, catalytically active acetylating enzymes in all cases. Chimeric proteins produced in this fashion were then compared to wild-type NAT1 and NAT2 with respect to their enzyme kinetic constants (apparent K-m, V-max, and V-max/K-m) for the NAT1-selective and NAT2-selective substrates p-aminosalicylic acid and sulfamethazine, respectively, and for their in vitro stabilities at 37 degrees C. The ratio of the V-max/K-m for sulfamethazine to that for p-aminosalicylic acid allowed for the unambiguous classification of each enzyme as either NAT1 or NAT2 type, except for one novel chimera possessing a low Michaelis constant and a high maximal velocity for the acetylation of both substrates. A central region (amino acids 112-210) within the 290-residue polypeptide appeared to play a role in determining NAT1- or NAT2-type behavior. On the other hand, the region (residues 47-111) encompassing the putative active site cysteine (Cys(68)) was important in contributing to a low apparent K-m for p-aminosalicylic acid but not for sulfamethazine, while amino acids 211-250 affected K-m for sulfamethazine and 251-290 influenced K-m for both substrates. Maximal velocities were highest for both substrates when the central 112-210 amino acid region was derived from NAT1. Finally, the region from amino acids 211-250 in NAT2 was important in determining its greater intrinsic enzyme stability than that exhibited by NAT1.	HOSP SICK CHILDREN, RES INST, DIV CLIN PHARMACOL & TOXICOL, TORONTO M5G 1X8, ON, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								ANDRES HH, 1985, ANAL BIOCHEM, V145, P367, DOI 10.1016/0003-2697(85)90376-8; BELL DA, 1993, CARCINOGENESIS, V14, P1689, DOI 10.1093/carcin/14.8.1689; BLOSTEIN R, 1993, J BIOL CHEM, V268, P10654; BLUM M, 1991, P NATL ACAD SCI USA, V88, P5237, DOI 10.1073/pnas.88.12.5237; BLUM M, 1990, DNA CELL BIOL, V9, P193, DOI 10.1089/dna.1990.9.193; DENECKE B, 1993, J BIOL CHEM, V268, P18076; DUPRET JM, 1992, J BIOL CHEM, V267, P7381; EVANS DAP, 1989, PHARMACOL THERAPEUT, V42, P157; Grant D, 1992, J BASIC CLIN PHYSL S, V3, P244; GRANT DM, 1990, J CLIN INVEST, V85, P968, DOI 10.1172/JCI114527; GRANT DM, 1993, PHARMACOGENETICS, V3, P45, DOI 10.1097/00008571-199302000-00005; GRANT DM, 1992, CANCER RES, V52, P3961; GRANT DM, 1989, FEBS LETT, V244, P203, DOI 10.1016/0014-5793(89)81193-7; GRANT DM, 1991, MOL PHARMACOL, V39, P184; GRANT DM, 1993, HUMAN PROTEIN DATA, V2; HEIN DW, 1993, CARCINOGENESIS, V14, P1633, DOI 10.1093/carcin/14.8.1633; HEIN DW, 1988, BIOCHIM BIOPHYS ACTA, V948, P37, DOI 10.1016/0304-419X(88)90004-2; HICKMAN D, 1991, BIOCHEM PHARMACOL, V42, P1007, DOI 10.1016/0006-2952(91)90282-A; HOFSTEE BHJ, 1952, SCIENCE, V116, P329, DOI 10.1126/science.116.3013.329; LIN HJ, 1993, AM J HUM GENET, V52, P827; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; MITRA B, 1993, BIOCHEMISTRY-US, V32, P12959, DOI 10.1021/bi00211a003; OHSAKO S, 1990, J BIOL CHEM, V265, P4630; Sambrook J, 1989, MOL CLONING LABORATO; SASAKI Y, 1991, J BIOL CHEM, V266, P13243; SHAHARABANY M, 1992, J BIOL CHEM, V267, P3674; SHIH CK, 1991, P NATL ACAD SCI USA, V88, P9878, DOI 10.1073/pnas.88.21.9878; SOUICH PD, 1979, CLIN PHARMACOL THER, V25, P172; VATSIS KP, 1991, P NATL ACAD SCI USA, V88, P6333, DOI 10.1073/pnas.88.14.6333; VATSIS KP, 1993, ARCH BIOCHEM BIOPHYS, V301, P71, DOI 10.1006/abbi.1993.1116; WATANABE M, 1992, J BIOL CHEM, V267, P8429; WEBER WW, 1985, PHARMACOL REV, V37, P25; WEBER WW, 1987, ACETYLATOR GENES DRU; WOLFSON AJ, 1993, BIOCHEMISTRY-US, V32, P5327, DOI 10.1021/bi00071a007	34	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26830	26835						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929420				2022-12-27	WOS:A1994PQ93100040
J	PLATT, FM; NEISES, GR; KARLSSON, GB; DWEK, RA; BUTTERS, TD				PLATT, FM; NEISES, GR; KARLSSON, GB; DWEK, RA; BUTTERS, TD			N-BUTYLDEOXYGALACTONOJIRIMYCIN INHIBITS GLYCOLIPID BIOSYNTHESIS BUT DOES NOT AFFECT N-LINKED OLIGOSACCHARIDE PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAUCHER DISEASE; SECRETORY GLYCOPROTEINS; ENDOPLASMIC-RETICULUM; GLUCOSIDASE; 1-DEOXYNOJIRIMYCIN; COMPLEX; BUTYLDEOXYNOJIRIMYCIN; GLUCOSYLTRANSFERASE; GLYCOSPHINGOLIPIDS; GLUCOCEREBROSIDE	We have previously reported that the imino sugar N-butyldeoxynojirimycin (NB-DNJ) inhibits glycolipid biosynthesis, in addition to its known activity as an inhibitor of the N-linked oligosaccharide processing enzyme alpha-glucosidase I. In an attempt to dissociate these two activities and identify an inhibitor which was more selective for the glycolipid biosynthetic pathway, several imino sugars have been N-alkylated and tested for inhibitory activity. The galactose analogue N-butyldeoxygalactonojirimycin (NB-DGJ) was found to be a potent inhibitor of glycolipid biosynthesis but in contrast to NB-DNJ had no effect on the maturation of N-linked oligosaccharides or on lysosomal glucocerebrosidase. The effect of increasing N-alkyl chain length on glycolipid inhibition was investigated. Nonalkylated DGJ, the N-methyl and N-ethyl derivatives, were noninhibitory. However, N-propylation resulted in partial inhibition while the N-butyl and N-hexyl derivatives resulted in maximal inhibition. Increasing alkyl chain length also resulted in increased potency of glucosyltransferase inhibition. In an in vitro Gaucher's disease model NB-DGJ was as effective as NB-DNJ in preventing glycolipid storage and may represent a more selective potential therapeutic agent than NB-DNJ for the management of this and other glycosphingolipidoses.	MONSANTO CO,ST LOUIS,MO 63198	Monsanto	PLATT, FM (corresponding author), UNIV OXFORD,INST GLYCOBIOL,DEPT BIOCHEM,S PARKS RD,OXFORD OX1 3QU,ENGLAND.		Platt, Frances/G-1004-2010	Platt, Frances/0000-0001-7614-0403				Barranger J. A., 1989, METABOLIC BASIS INHE, P1677; BASU S, 1973, J BIOL CHEM, V248, P1388; BEUTLER E, 1992, SCIENCE, V256, P794, DOI 10.1126/science.1589760; BEUTLER E, 1993, P NATL ACAD SCI USA, V90, P5384, DOI 10.1073/pnas.90.12.5384; BUTTERS TD, 1981, IN VITRO CELL DEV B, V17, P831, DOI 10.1007/BF02618451; BUTTERS TD, 1991, BIOCHEM J, V279, P189, DOI 10.1042/bj2790189; COSTE H, 1985, BIOCHIM BIOPHYS ACTA, V814, P1, DOI 10.1016/0005-2736(85)90412-2; DALE GL, 1976, P NATL ACAD SCI USA, V73, P4672, DOI 10.1073/pnas.73.12.4672; DATEMA R, 1987, PHARMACOL THERAPEUT, V33, P221, DOI 10.1016/0163-7258(87)90066-0; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FLEET GWJ, 1988, FEBS LETT, V237, P128, DOI 10.1016/0014-5793(88)80185-6; FODDY L, 1986, BIOCHEM J, V233, P697, DOI 10.1042/bj2330697; FOLCH J, 1957, J BIOL CHEM, V226, P497; FURBISH FS, 1977, P NATL ACAD SCI USA, V74, P3560, DOI 10.1073/pnas.74.8.3560; GROSS V, 1983, J BIOL CHEM, V258, P2203; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HIRAIZUMI S, 1993, J BIOL CHEM, V268, P9927; INOKUCHI JI, 1987, J LIPID RES, V28, P565; JACOB GS, 1992, NATURAL PRODUCTS AS ANTIVIRAL AGENTS, P137; KARLSSON GB, 1993, J BIOL CHEM, V268, P570; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KARPAS A, 1988, P NATL ACAD SCI USA, V85, P9229, DOI 10.1073/pnas.85.23.9229; Khan S.H., 1992, GLYCOCONJUGATES COMP, P361; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEMANSKY P, 1984, J BIOL CHEM, V259, P129; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; MIZUOCHI T, 1988, BIOCHEM J, V254, P599, DOI 10.1042/bj2540599; Mizuochi T, 1988, Biomed Chromatogr, V2, P260; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; OSIECKINEWMAN K, 1987, BIOCHIM BIOPHYS ACTA, V915, P87, DOI 10.1016/0167-4838(87)90128-2; PEYRIERAS N, 1983, EMBO J, V2, P823, DOI 10.1002/j.1460-2075.1983.tb01509.x; PLATT FM, 1994, J BIOL CHEM, V269, P8362; PLATT FM, 1992, EUR J BIOCHEM, V208, P187, DOI 10.1111/j.1432-1033.1992.tb17173.x; SAUNIER B, 1982, J BIOL CHEM, V257, P4155; SCHWEDEN J, 1986, ARCH BIOCHEM BIOPHYS, V248, P335, DOI 10.1016/0003-9861(86)90429-7; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; TAN A, 1991, J BIOL CHEM, V266, P14504; TRINCHERA M, 1991, J BIOL CHEM, V266, P20907; TYBULEWICZ VLJ, 1992, NATURE, V357, P407, DOI 10.1038/357407a0; WANG YF, 1993, TETRAHEDRON LETT, V34, P403; WINCHESTER B, 1992, GLYCOBIOLOGY, V2, P199, DOI 10.1093/glycob/2.3.199	41	168	191	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27108	27114						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929454				2022-12-27	WOS:A1994PQ93100078
J	WAEBER, G; THOMPSON, N; HAEFLIGER, JA; NICOD, P				WAEBER, G; THOMPSON, N; HAEFLIGER, JA; NICOD, P			CHARACTERIZATION OF THE MURINE HIGH K(M) GLUCOSE-TRANSPORTER GLUT2 GENE AND ITS TRANSCRIPTIONAL REGULATION BY GLUCOSE IN A DIFFERENTIATED INSULIN-SECRETING CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; PYRUVATE-KINASE GENE; MESSENGER-RNA; DIABETIC HYPERGLYCEMIA; RESPONSE ELEMENT; RAT ISLETS; CYCLIC-AMP; EXPRESSION; PROMOTER; BINDING	In pancreatic beta-cells, high K-m glucose transporter GLUT2 catalyzes the first step in glucose-induced insulin secretion by glucose uptake. Expression of the transporter has been reported to be modulated by glucose either at the protein or mRNA levels. In this study we used the differentiated insulinoma cell Line INS-1 which expresses high levels of GLUT2 and show that the expression of GLUT2 is regulated by glucose at the transcriptional level. By run-on transcription assays we showed that glucose induced GLUT2 gene transcription 3-4-fold in INS-1 cells which was paralleled by a 1.7-2.3-fold increase in cytoplasmic GLUT2 mRNA levels. To determine whether glucose regulatory sequences were present in the promoter region of GLUT2, we cloned and characterized a 1.4-kilobase region of mouse genomic DNA located 5' of the translation initiation site. By RNase protection assays and primer extension, we determined that multiple transcription initiation sites were present at positions -55, -64, and -115 from the first coding ATG and which were identified in liver, intestine, kidney, and beta-cells mRNAs. Plasmids were constructed with the mouse promoter region linked to the reporter gene chloramphenicol acetyltransferase (CAT), and transiently and stably transfected in the INS-1 cells. Glucose induced a concentration dependent increase in CAT activity which reached a maximum of 3.6-fold at 20 mM glucose. Similar CAT constructs made of the human GLUT2 promoter region and the CAT gene displayed the same glucose-dependent increase in transcriptional activity when transfected into INS-1 cells. Comparison of the mouse and human promoter regions revealed sequence identity restricted to a few stretches of sequences which suggests that the glucose responsive element(s) may be conserved in these common sequences.			WAEBER, G (corresponding author), CHU VAUDOIS, DEPT INTERNAL MED, 19-533, CH-1011 LAUSANNE, SWITZERLAND.			Haefliger, Jacques-Antoine/0000-0003-2732-1667; Waeber, Gerard/0000-0003-4193-788X				ASANO T, 1992, DIABETES, V41, P22, DOI 10.2337/diabetes.41.1.22; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; CHEN L, 1990, P NATL ACAD SCI USA, V87, P4088, DOI 10.1073/pnas.87.11.4088; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; FERRER J, 1993, DIABETES, V42, P1273, DOI 10.2337/diabetes.42.9.1273; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; GOTOH M, 1987, TRANSPLANTATION, V43, P725, DOI 10.1097/00007890-198705000-00024; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HEIMBERG H, 1993, EMBO J, V12, P2873, DOI 10.1002/j.1460-2075.1993.tb05949.x; IMAFAWA M, 1987, CELL, V51, P251; INAGAKI N, 1992, DIABETES, V41, P592, DOI 10.2337/diabetes.41.5.592; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JOHNSON JH, 1990, SCIENCE, V250, P546, DOI 10.1126/science.2237405; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; Locker J, 1990, DNA Seq, V1, P3, DOI 10.3109/10425179009041342; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MARIE S, 1993, J BIOL CHEM, V268, P23881; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; MORGAN WD, 1987, MOL CELL BIOL, V7, P1129, DOI 10.1128/MCB.7.3.1129; OHNEDA M, 1993, DIABETES, V42, P1065, DOI 10.2337/diabetes.42.7.1065; ORCI L, 1990, J CLIN INVEST, V86, P1615, DOI 10.1172/JCI114883; ORCI L, 1990, P NATL ACAD SCI USA, V87, P9953, DOI 10.1073/pnas.87.24.9953; POSTIC C, 1993, BIOCHEM J, V293, P119, DOI 10.1042/bj2930119; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; SUZUE K, 1989, NUCLEIC ACIDS RES, V17, P10099, DOI 10.1093/nar/17.23.10099; TAKEDA J, 1993, DIABETES, V42, P773, DOI 10.2337/diabetes.42.5.773; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; THORENS B, 1990, P NATL ACAD SCI USA, V87, P6492, DOI 10.1073/pnas.87.17.6492; THORENS B, 1992, J CLIN INVEST, V90, P77, DOI 10.1172/JCI115858; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; VANNICE JL, 1984, P NATL ACAD SCI-BIOL, V81, P4241, DOI 10.1073/pnas.81.14.4241; YASUDA K, 1992, DIABETES, V41, P76, DOI 10.2337/diabetes.41.1.76	37	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26912	26919						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929431				2022-12-27	WOS:A1994PQ93100052
J	GRAHAM, LA; HILL, KJ; STEVENS, TH				GRAHAM, LA; HILL, KJ; STEVENS, TH			VMA7 ENCODES A NOVEL 14-KDA SUBUNIT OF THE SACCHAROMYCES-CEREVISIAE VACUOLAR H+-ATPASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTON-TRANSLOCATING ATPASE; ADENOSINE-TRIPHOSPHATASE; GENE ENCODES; YEAST; MEMBRANE; SEQUENCE; PROTEIN	The Saccharomyces cerevisiae vacuolar proton-translocating ATPase (V-ATPase) is composed of at least 10 subunits belonging to either the peripheral V-1 or integral membrane V-0 subcomplex. We have characterized a novel 14-kDa V-ATPase subunit (Vma7p), encoded by the VMA7 gene, which exhibits features common to both V-1 and V-0 subunit proteins. Vma7p is a hydrophilic protein of 118 amino acids with a predicted molecular mass of 13,452 Da. Vacuolar membranes isolated from a vma7 Delta null mutant contained no V-ATPase activity. Western analysis of vma7 Delta cells revealed greatly reduced levels of the remaining V-0 complex V-ATPase subunits, but normal levels of the V-1 subunits. However, the V-1 subunits failed to associate with the vacuolar membrane. Unlike the integral membrane subunits of the V-0 complex, Vma7p was easily stripped from vacuolar membranes. Density gradient fractionation revealed that Vma7p associated only with the fully assembled V-ATPase and did not associate with a separate lower density V-0 subcomplex fraction. The unique properties of the Vma7p may reflect a critical role in stabilizing the V-0 complex and bridging the V-1 and V-0 complexes to form a functional V-ATPase complex.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA	University of Oregon				Stevens, Tom/0000-0001-6427-6848	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038006] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRE B, 1990, NUCLEIC ACIDS RES, V18, P3049, DOI 10.1093/nar/18.10.3049; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GRAF R, 1994, J BIOL CHEM, V269, P3767; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; HIRATA R, 1993, J BIOL CHEM, V268, P961; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; HOLZENBURG A, 1993, EUR J BIOCHEM, V213, P21, DOI 10.1111/j.1432-1033.1993.tb17730.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4134, DOI 10.1021/bi00313a019; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1989, J BIOL CHEM, V264, P1775; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SIKORSKI RS, 1989, GENETICS, V122, P19; TAKASE K, 1994, J BIOL CHEM, V269, P11037; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737	29	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					25974	25977						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929308				2022-12-27	WOS:A1994PQ93000009
J	GREEN, SA; LIGGETT, SB				GREEN, SA; LIGGETT, SB			A PROLINE-RICH REGION OF THE 3RD INTRACELLULAR LOOP IMPARTS PHENOTYPIC BETA(1)-VERSUS BETA(2)-ADRENERGIC RECEPTOR COUPLING AND SEQUESTRATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; BETA-2-ADRENERGIC RECEPTORS; STRUCTURAL BASIS; LIGAND-BINDING; GS; AFFINITY	beta-Adrenergic receptor (beta AR) subtypes differ not only by characteristic ligand affinities but also in the manner and extent to which they mediate agonist-promoted events such as activation of adenylyl cyclase and receptor tor sequestration. We utilized mutagenesis and recombinant expression in Chinese hamster fibroblasts to examine the effect of an unusual proline-rich 24-amino acid sequence (PARPPSPSPSPVPAPAPPPGPPRP) present in the third intracellular loop of the beta(1)AR, but not in the beta(2)AR, on the aforementioned receptor-mediated events. Cells expressing the wild type beta(2)AR stimulated adenylyl cyclase in response to the agonist isoproterenol with an EC(50) similar to 5 fold lower than that observed with the beta(1)AR (0.53 +/- 0.14 versus 2.47 +/- 0.52 nM, p < 0.01). Deletion of the proline-rich sequence from the beta(1)AR resulted in an improvement in isoproterenol-stimulated adenylyl cyclase to an EC(50) value intermediate to that observed in the wild type receptors (1.14 +/- 0.08 nM, p < 0.05 versus wild-type beta(1)AR). In contrast, insertion of this sequence into the beta(2)AR impaired its ability to mediate this process. Similar results were observed for receptor sequestration. Wild-type beta(1)- and beta(2)AR underwent maximal agonist-promoted sequestration of 25.9 +/- 4.0 and 60.0 +/- 3.3%, respectively. Deletion of the proline-rich region from the beta(1)AR improved maximal sequestration to 43.0 +/- 2.7% (p < 0.01 versus wild-type beta(1)AR), while insertion of the sequence into the beta(2)AR impaired sequestration to 39.9 +/- 2.7% (p < 0.001 versus wild-type beta(2)AR). We conclude that the distinct phenotypic patterns observed for these two agonist-promoted events in the beta(1)AR and beta(2)AR subtypes are partially due to the conformational effects of this proline-rich third intracellular loop sequence. Such regions, which are also found in some other G-protein-coupled receptors, may represent a general motif responsible for attenuating certain agonist-promoted receptor events.	UNIV CINCINNATI,MED CTR,DEPT PULM MED,CINCINNATI,OH 45267; UNIV CINCINNATI,MED CTR,DEPT MOLEC GENET,CINCINNATI,OH 45267; UNIV CINCINNATI,MED CTR,DEPT PHARMACOL,CINCINNATI,OH 45267	University of Cincinnati; University of Cincinnati; University of Cincinnati			liggett, stephen b/E-7453-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496, R01HL045967] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL45967, P01 HL41496] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELEAN A, 1980, J BIOL CHEM, V255, P7108; EASON MG, 1992, J BIOL CHEM, V267, P25473; FRIELLE T, 1988, P NATL ACAD SCI USA, V85, P9494, DOI 10.1073/pnas.85.24.9494; GREEN SA, 1993, J BIOL CHEM, V268, P23116; GREEN SA, 1992, MOL PHARMACOL, V41, P889; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; KENT RS, 1980, MOL PHARMACOL, V17, P14; LEVY FO, 1993, P NATL ACAD SCI USA, V90, P10798, DOI 10.1073/pnas.90.22.10798; LICHTER JB, 1993, HUM MOL GENET, V2, P767, DOI 10.1093/hmg/2.6.767; LIGGETT SB, 1989, MOL PHARMACOL, V36, P641; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LIGGETT SB, 1993, CATECHOLAMINES, P279; Liggett SB, 1993, REGULATION CELLULAR, P71; PERKINS JP, 1991, MECHANISMS LIGAND IN, P125; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRADER CD, 1987, J BIOL CHEM, V262, P16439; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; VANTOL HHM, 1992, NATURE, V358, P149; YU SS, 1993, J BIOL CHEM, V268, P337	23	92	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26215	26219						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929336				2022-12-27	WOS:A1994PQ93000044
J	SUPEK, F; SUPEKOVA, L; NELSON, N				SUPEK, F; SUPEKOVA, L; NELSON, N			FEATURES OF VACUOLAR H+-ATPASE REVEALED BY YEAST SUPPRESSOR MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMAFFIN-GRANULE MEMBRANES; TRANSMEMBRANE ALPHA-HELICES; SACCHAROMYCES-CEREVISIAE; SUBUNIT-C; MUTATIONAL ANALYSIS; PROTON-ATPASES; MOLECULAR-GENETICS; NEUROSPORA-CRASSA; V-ATPASES; ACIDIFICATION	The yeast Saccharomyces cerevisiae serves as an excellent model for the study of the structure and function of proteins. Numerous amino acid substitutions in the proteolipid subunit of yeast vacuolar H+-ATPase have been reported. Suppressed variants for several of the inactive mutants were selected after subjecting them to chemical or polymerase chain reaction mutagenesis and screening for second site suppressors. Suppressors for the mutation GLn(90) to Lys change were intragenic and resulted from the changes: Ala(14) to Val, Val(74) to Ile, Ile(89) to Leu, and Ile(89) to Met. These residues are found on three different transmembrane segments but presumably at the same surface of the membrane. A new inactive proteolipid mutation was constructed by changing Val(138) to, Leu. This residue is situated in the middle of the fourth transmembrane segment, neighboring Glu(137) which is the potential dicyclohexylcarbodiimide-binding site. The intragenic suppressor mutations for the above amino acid replacement resulted in changes of Val(55) to Ala, Met(59) to Val, or Ile(130) to Thr. These residues are found in the second and fourth transmembrane segments, presumably on the same interface. It seems as if all those internal suppressor mutations compensate for the volume changes caused by the original displacement of the given amino acid. Five glycine residues, situated on the same face of the third transmembrane helix, were changed to valine and all these mutants were inactive. A suppressor mutation to one of those mutants (Gly(101) to Val) was identified as substitution of Ile(134) to Val. The structural and functional implications of these findings are discussed.	ROCHE INST MOLEC BIOL,ROCHE RES CTR,NUTLEY,NJ 07110	Roche Holding								ANRAKU Y, 1992, J EXP BIOL, V172, P67; ANRAKU Y, 1991, BIOCHIM BIOPHYS ACTA, V1093, P169, DOI 10.1016/0167-4889(91)90119-I; ANRAKU Y, 1991, NEW ERA BIOENERGETIC, P133; ARAI H, 1987, J BIOL CHEM, V262, P11006; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BELTRAN C, 1992, ACTA PHYSIOL SCAND, V146, P41; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; DSCHIDA WJ, 1992, J BIOL CHEM, V267, P18783; FINBOW ME, 1991, PROTEIN ENG, V5, P7; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FOURY F, 1990, J BIOL CHEM, V265, P18554; FRAGA D, 1994, J BIOL CHEM, V269, P2562; GIRVIN ME, 1993, BIOCHEMISTRY-US, V32, P12167, DOI 10.1021/bi00096a029; GIRVIN ME, 1994, BIOCHEMISTRY-US, V33, P665, DOI 10.1021/bi00169a006; HANADA H, 1991, BIOCHEM BIOPH RES CO, V176, P1062, DOI 10.1016/0006-291X(91)90391-J; IIDA H, 1990, J BIOL CHEM, V265, P13391; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11259, DOI 10.1021/bi00093a001; JONES PC, 1994, IN PRESS BIOCH SOC T; KANE PM, 1992, J EXP BIOL, V172, P93; KLIONSKY DJ, 1992, J BIOL CHEM, V267, P3416; LAI S, 1991, J BIOL CHEM, V266, P16078; LEE JI, 1992, J BIOL CHEM, V267, P20758; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MILLER MJ, 1990, P NATL ACAD SCI USA, V87, P4900, DOI 10.1073/pnas.87.13.4900; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; NAKAJIMASHIMADA J, 1991, P NATL ACAD SCI USA, V88, P6878, DOI 10.1073/pnas.88.15.6878; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1989, J BIOENERG BIOMEMBR, V21, P553, DOI 10.1007/BF00808113; NELSON N, 1991, TRENDS PHARMACOL SCI, V12, P71, DOI 10.1016/0165-6147(91)90501-I; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; NELSON N, 1992, Current Opinion in Cell Biology, V4, P654, DOI 10.1016/0955-0674(92)90086-R; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; OHYA Y, 1991, J BIOL CHEM, V266, P13971; Sambrook J, 1989, MOL CLONING LABORATO; STEVENS TH, 1992, J EXP BIOL, V172, P47; SUPEK F, 1992, ANN NY ACAD SCI, V671, P284, DOI 10.1111/j.1749-6632.1992.tb43803.x; SUTTON R, 1981, FEBS LETT, V130, P103, DOI 10.1016/0014-5793(81)80675-8; SZE H, 1992, J EXP BIOL, V172, P123; TAIZ L, 1991, PLANT PHYSL; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.bi.55.070186.001341; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; ZHANG JM, 1992, J BIOL CHEM, V267, P9773	53	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26479	26485						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929369				2022-12-27	WOS:A1994PQ93000082
J	OGRADY, P; KRUEGER, NX; STREULI, M; SAITO, H				OGRADY, P; KRUEGER, NX; STREULI, M; SAITO, H			GENOMIC ORGANIZATION OF THE HUMAN LAR PROTEIN-TYROSINE-PHOSPHATASE GENE AND ALTERNATIVE SPLICING IN THE EXTRACELLULAR FIBRONECTIN TYPE-III DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE COMMON ANTIGEN; IMMUNOGLOBULIN SUPERFAMILY; RNA; EXPRESSION; CLONING; REGION; CONSERVATION; PROMOTER; SYSTEM; USAGE	The structure of the human leukocyte-common antigen-related molecule (LAR) protein tyrosine phosphatase gene was elucidated using phage and cosmid genomic DNA clones. The LAR gene is composed of 33 exons spanning over 85 kilobase pairs. Exon 2 encodes the signal sequence and the first four amino acids in the mature LAR protein. The three immunoglobulin-like domains are encoded by exons 3-7, and the eight fibronectin type III (Fn-III) domains by exons 8-17. Exons 18-22 encode the juxtamembrane and transmembrane domains, and exons 23-33 encode the two conserved tyrosine phosphatase domains and the entire 3'-untranslated region. Exon 1, which presumably encodes the 5'-untranslated sequence, has not been identified. Reverse transcription-polymerase chain reaction analysis revealed the alternative splicing of a mini exon (exon 13) in the Fn-III domain 5 of human LAR and other related genes (rat LAR, rat PTP sigma, and human PTP delta). RNase protection analysis showed that the human LAR mRNA in which exon 13 is spliced out is the major mRNA species in all cell lines examined. Reverse transcription-polymerase chain reaction analysis revealed further alternative splicing of LAR mRNA involving the Fn-III domains 4, 5, 6, and 7 in various combinations. These findings will facilitate the understanding of the physiological functions of the LAR extracellular domain.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Saito, Haruo/AAF-6113-2019	Saito, Haruo/0000-0001-7891-1689	NCI NIH HHS [CA-51132] Funding Source: Medline; NIAID NIH HHS [AI-26598] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051132] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026598] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; CHO HJ, 1992, BIOCHEMISTRY-US, V31, P133, DOI 10.1021/bi00116a019; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN IR, 1993, P NATL ACAD SCI USA, V90, P10404, DOI 10.1073/pnas.90.21.10404; DUFOUR S, 1988, TRENDS GENET, V4, P198, DOI 10.1016/0168-9525(88)90076-5; GULCHER JR, 1991, P NATL ACAD SCI USA, V88, P9438, DOI 10.1073/pnas.88.21.9438; HALL LR, 1988, J IMMUNOL, V141, P2781; JOHNSON NA, 1989, J BIOL CHEM, V264, P6220; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LONGO FM, 1993, J BIOL CHEM, V268, P26503; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIZUNO K, 1993, MOL CELL BIOL, V13, P5513, DOI 10.1128/MCB.13.9.5513; OWENS GC, 1987, P NATL ACAD SCI USA, V84, P294, DOI 10.1073/pnas.84.1.294; PAN MG, 1993, J BIOL CHEM, V268, P19284; POT DA, 1992, J BIOL CHEM, V267, P140; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; SAGA Y, 1988, MOL CELL BIOL, V8, P4889, DOI 10.1128/MCB.8.11.4889; Saito H, 1993, Semin Cell Biol, V4, P379, DOI 10.1006/scel.1993.1045; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARZBAUER JE, 1991, BIOESSAYS, V13, P527, DOI 10.1002/bies.950131006; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1992, EMBO J, V11, P897, DOI 10.1002/j.1460-2075.1992.tb05128.x; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TABOR S, 1989, J BIOL CHEM, V264, P6447; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WALTON KM, 1993, NEURON, V11, P387, DOI 10.1016/0896-6273(93)90193-U; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WONG ECC, 1993, GENOMICS, V17, P33, DOI 10.1006/geno.1993.1279; YAN H, 1993, J BIOL CHEM, V268, P24880; YU Q, 1992, ONCOGENE, V7, P1051; ZHANG WR, 1993, L11587 GENB DAT ACC	41	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25193	25199						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929208				2022-12-27	WOS:A1994PQ49000099
J	BECKERANDRE, M; WIESENBERG, I; SCHAERENWIEMERS, N; ANDRE, E; MISSBACH, M; SAURAT, JH; CARLBERG, C				BECKERANDRE, M; WIESENBERG, I; SCHAERENWIEMERS, N; ANDRE, E; MISSBACH, M; SAURAT, JH; CARLBERG, C			PINEAL-GLAND HORMONE MELATONIN BINDS AND ACTIVATES AN ORPHAN OF THE NUCLEAR RECEPTOR SUPERFAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							9-CIS RETINOIC ACID; SIGNALING PATHWAYS; MAMMALIAN-TISSUES; RESPONSE PATHWAY; HIGH-AFFINITY; VITAMIN-D; LOCALIZATION; LIGAND; ASSAY; SITES	Nuclear orphan receptors are members of the superfamily of structurally related, ligand-inducible tran scription factors for which no ligand has yet been identified. Over the past few years many nuclear orphan receptors have been cloned, but only for the retinoid X receptor (RXR) has a natural ligand (9 cis-retinoic acid) been found. Here we report the identification of melatonin as a ligand for the recently cloned orphan receptor retinoid Z receptor beta (RZR beta). We found RZR beta expression in the rat brain nearly coincident with binding sites for the pineal gland hormone melatonin (5-methoxy-N-acetyltryptamine). We show here binding and activation of RZR beta by melatonin with K-d and EC(50) values in the low nanomolar range. A nuclear signaling pathway for melatonin may contribute to some of the diverse and profound effects of this hormone, for example, in the context of circadian rhythmicity.	HOP CANTONAL GENEVA,DERMATOL CLIN,CH-1211 GENEVA 14,SWITZERLAND; GLAXO INST MOLEC BIOL SA,CH-1228 PLAN LES OUATES,SWITZERLAND; CIBA GEIGY AG,PHARMA FORSCH,CH-4002 BASEL,SWITZERLAND; UNIV ZURICH,INST HIRNFORSCH,CH-8029 ZURICH,SWITZERLAND	University of Geneva; GlaxoSmithKline; Novartis; University of Zurich			Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				ACUNACASTROVIEJ.D, 1993, RES COMMUN CHEM PATH, V2, P253; ACUNACASTROVIEJO D, 1994, J PINEAL RES, V16, P100, DOI 10.1111/j.1600-079X.1994.tb00089.x; BECKERANDRE M, 1993, METHOD ENZYMOL, V218, P420; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CARLBERG C, 1993, BIOCHEM J, V295, P343, DOI 10.1042/bj2950343; DUBOCOVICH ML, 1987, P NATL ACAD SCI USA, V84, P3916, DOI 10.1073/pnas.84.11.3916; EBISAWA T, 1994, P NATL ACAD SCI USA, V91, P6133, DOI 10.1073/pnas.91.13.6133; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KENNAWAY DJ, 1992, MOL CELL ENDOCRINOL, V88, pC1, DOI 10.1016/0303-7207(92)90002-N; KRAUSE DN, 1991, ANNU REV PHARMACOL, V31, P549; LAITINEN JT, 1990, ENDOCRINOLOGY, V126, P2110, DOI 10.1210/endo-126-4-2110; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MENENDEZPELAEZ A, 1993, J PINEAL RES, V15, P59, DOI 10.1111/j.1600-079X.1993.tb00511.x; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P373, DOI 10.1002/jcb.240530415; MORGAN PJ, 1994, NEUROCHEM INT, V24, P101, DOI 10.1016/0197-0186(94)90100-7; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; OMALLEY BW, 1992, MOL ENDOCRINOL, V6, P1359, DOI 10.1210/me.6.9.1359; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHRADER M, 1993, J BIOL CHEM, V268, P17830; SCHRADER M, 1994, J BIOL CHEM, V269, P5501; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SUGDEN D, 1994, NEUROCHEM INT, V24, P147, DOI 10.1016/0197-0186(94)90101-5	30	373	387	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28531	28534						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961794				2022-12-27	WOS:A1994PU16800003
J	KIM, SY; KIM, IG; CHUNG, SI; STEINERT, PM				KIM, SY; KIM, IG; CHUNG, SI; STEINERT, PM			THE STRUCTURE OF THE TRANSGLUTAMINASE-1 ENZYME - DELETION CLONING REVEALS DOMAINS THAT REGULATE ITS SPECIFIC ACTIVITY AND SUBSTRATE-SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HUMAN EPIDERMAL TRANSGLUTAMINASE; PIG LIVER TRANSGLUTAMINASE; HUMAN FACTOR-XIII; KERATINOCYTE TRANSGLUTAMINASE; CORNIFIED ENVELOPE; GUINEA-PIG; MOLECULAR-CLONING; SQUAMOUS DIFFERENTIATION; PROTRANSGLUTAMINASE-E	Transglutaminase 1 (TGase1) is one of three known enzymes involved in terminal differentiation in stratified squamous epithelia, possibly in the formation of a cornified cell envelope. Because the intact enzyme is particularly difficult to isolate in quantity from keratinocytes for characterization, comparatively little is known about its properties. We have expressed the full-length as well as a series of deletion forms of this enzyme in a bacterial system and analyzed their enzymatic properties. The specific activity of the full-length enzyme isolated and purified from the bacterial lysate was comparable to that of the native enzyme of keratinocytes. Analysis of several deletion constructs demonstrated that removal of the first 60-109 residues, which include sequences involved in membrane association, results in upwards of a 10-fold increase in the specific activity. Deletions beyond residue 109, into sequences conserved within the TGase family of proteins, result in lass of activity. Similarly, as many as 240 residues can be removed from its carboxyl-terminal end before activity is lost. Thus, a molecule of 466 residues, containing virtually only the conserved core sequences of TGases, retains a specific activity comparable to the intact enzyme. In addition, the various deletion forms display wide variations in substrate specificity toward a series of synthetic peptide substrates, designed from possible target TGase1 substrate proteins of epithelia. The data show that sequences between residues 62 and 92 are important in defining the substrate specificity of the TGase1 enzyme system. Furthermore, it may now be possible to design an enzyme with a defined substrate specificity. Together, these data suggest TGase1 has recruited additional sequences on its amino terminus in relation to other members of the TGase family, which have the net effect of permitting sequestration onto membranes, changing its specific activity and modifying its likely substrate specificities.	NIAMS,SKIN BIOL BRANCH,BETHESDA,MD 20892; NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								BOHN H, 1971, BLUT, V22, P237, DOI 10.1007/BF01678915; CARDINALI M, 1990, CANCER RES, V50, P8010; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; CHANG SK, 1986, J BIOL CHEM, V261, P8112; CHEN R, 1970, P NATL ACAD SCI USA, V66, P472, DOI 10.1073/pnas.66.2.472; CHUNG SI, 1972, ANN NY ACAD SCI, V202, P240, DOI 10.1111/j.1749-6632.1972.tb16338.x; CHUNG SI, 1972, P NATL ACAD SCI USA, V69, P303, DOI 10.1073/pnas.69.2.303; CHUNG SI, 1970, J BIOL CHEM, V245, P681; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; CURTIS CG, 1974, BIOCHEMISTRY-US, V13, P3257, DOI 10.1021/bi00713a012; FLOYD EE, 1989, MOL CELL BIOL, V9, P4846, DOI 10.1128/MCB.9.11.4846; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; FOLK JE, 1973, ADV ENZYMOL RAMB, V38, P109; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; FOLK JE, 1969, J BIOL CHEM, V244, P3707; GENTILE V, 1991, J BIOL CHEM, V266, P478; GRANT FJ, 1994, BIOCHEM BIOPH RES CO, V203, P1117, DOI 10.1006/bbrc.1994.2298; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HEINS S, 1993, J CELL BIOL, V123, P1517, DOI 10.1083/jcb.123.6.1517; HO KC, 1992, J BIOL CHEM, V267, P12660; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; HOHL D, 1991, J BIOL CHEM, V266, P6626; HOHL D, 1992, NAT GENET, V1, P91; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P4633, DOI 10.1021/bi00364a027; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P6900, DOI 10.1021/bi00370a025; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2195, DOI 10.1128/MCB.8.5.2195; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM HC, 1991, J BIOL CHEM, V266, P536; KIM IG, 1993, J BIOL CHEM, V268, P12682; KIM IG, 1992, J BIOL CHEM, V267, P7710; KORAGREN C, 1990, P NATL ACAD SCI USA, V87, P613; LICHTI U, 1985, J BIOL CHEM, V260, P1422; Liem RKH, 1993, CURR OPIN CELL BIOL, V5, P12, DOI 10.1016/S0955-0674(05)80003-1; LOEWY AG, 1961, J BIOL CHEM, V236, P2625; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; MICHEL S, 1992, J INVEST DERMATOL, V98, P364, DOI 10.1111/1523-1747.ep12499806; MICHEL S, 1987, J INVEST DERMATOL, V88, P301, DOI 10.1111/1523-1747.ep12466177; NEGI M, 1985, J INVEST DERMATOL, V85, P75, DOI 10.1111/1523-1747.ep12275357; OGAWA H, 1976, J BIOL CHEM, V251, P7281; PARENTEAU NL, 1986, DIFFERENTIATION, V33, P130, DOI 10.1111/j.1432-0436.1986.tb00418.x; PARK SC, 1988, J CELL BIOL, V107, P139; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; PHILLIPS MA, 1992, J BIOL CHEM, V267, P2282; Polakowska R. R., 1991, PHYSL BIOCH MOL BIOL, P168; POLAKOWSKA RR, 1992, P NATL ACAD SCI USA, V89, P4476, DOI 10.1073/pnas.89.10.4476; Reichert Uwe, 1993, P107; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RICE RH, 1990, BIOCHEM J, V265, P351, DOI 10.1042/bj2650351; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT R, 1988, J INVEST DERMATOL, V90, P475, DOI 10.1111/1523-1747.ep12460936; SCHROEDER WT, 1992, J INVEST DERMATOL, V99, P27, DOI 10.1111/1523-1747.ep12611394; SCHWARTZ ML, 1971, J BIOL CHEM, V246, P5851; STEVEN AC, 1994, J CELL SCI, V107, P693; SUNG LA, 1990, P NATL ACAD SCI USA, V87, P955, DOI 10.1073/pnas.87.3.955; TAKAGI T, 1974, BIOCHEMISTRY-US, V13, P750, DOI 10.1021/bi00701a018; TAKAHASHI M, 1992, FEBS LETT, V308, P79, DOI 10.1016/0014-5793(92)81055-Q; TAKAHASHI N, 1986, P NATL ACAD SCI USA, V83, P8019, DOI 10.1073/pnas.83.21.8019; THACHER SM, 1989, J INVEST DERMATOL, V92, P578; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; WANG M, 1994, IN PRESS GENOMICS; YAFFE MB, 1992, J BIOL CHEM, V267, P12233; YAMANISHI K, 1991, BIOCHEM BIOPH RES CO, V175, P906, DOI 10.1016/0006-291X(91)91651-R; YAMANISHI K, 1992, J BIOL CHEM, V267, P17858; YONEDA K, 1993, P NATL ACAD SCI USA, V90, P10754, DOI 10.1073/pnas.90.22.10754; ZETTERGREN JG, 1984, P NATL ACAD SCI-BIOL, V81, P238, DOI 10.1073/pnas.81.1.238	68	75	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27979	27986						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961731				2022-12-27	WOS:A1994PV77200034
J	LI, H; DONG, LQ; WHITLOCK, JP				LI, H; DONG, LQ; WHITLOCK, JP			TRANSCRIPTIONAL ACTIVATION FUNCTION OF THE MOUSE AH RECEPTOR NUCLEAR TRANSLOCATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIOXIN-RESPONSIVE ENHANCER; PROTEIN-DNA INTERACTIONS; ARYL-HYDROCARBON HYDROXYLASE; MECHANISM; BINDING; CLONING; ARNT; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; RECOGNITION; MUTAGENESIS	We cloned from mouse hepatoma cells a cDNA which encodes the Ah receptor nuclear translocator (Arnt). Sequence comparisons reveal 89% nucleotide and 92% amino acid identity between mouse and human Amt. Transfection of the cDNA into Amt-defective mouse hepatoma cells fully restores their responsiveness to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), indicating that the cDNA encodes a functional Arnt protein. Transfection of the cDNA into wild type mouse hepatoma cells increases the magnitude, but not the sensitivity, of the transcriptional response to TCDD. Analyses of mutants indicate that Arnt has a modular organization. The unit that mediates both heterodimerization with the liganded Ah receptor and DNA recognition is functionally distinct from the unit that mediates transcriptional activation. A 96-amino acid, C-terminal domain of Arnt, which includes a glutamine-rich region, confers transcriptional activation capability upon the protein.			LI, H (corresponding author), STANFORD UNIV,SCH MED,DEPT MOLEC PHARMACOL,STANFORD,CA 94305, USA.				NATIONAL CANCER INSTITUTE [R01CA053887, R35CA053887] Funding Source: NIH RePORTER; NCI NIH HHS [CA 53887] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bailar J C 3rd, 1991, N Engl J Med, V324, P260, DOI 10.1056/NEJM199101243240409; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DULAU L, 1989, NUCLEIC ACIDS RES, V17, P2873, DOI 10.1093/nar/17.7.2873; ELFERINK CJ, 1994, RECEPTOR, V4, P157; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; FISHER JM, 1990, J BIOL CHEM, V265, P9676; FISHER JM, 1989, MOL CARCINOGEN, V1, P216, DOI 10.1002/mc.2940010403; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HANKINSON O, 1983, SOMAT CELL GENET, V9, P497, DOI 10.1007/BF01543050; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; JOHNSON ES, 1992, CRIT REV TOXICOL, V21, P451, DOI 10.3109/10408449209089883; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; MILLER AG, 1983, J BIOL CHEM, V258, P3523; OKEY AB, 1993, TRENDS PHARMACOL SCI, V15, P226; PETERSON RE, 1993, CRIT REV TOXICOL, V23, P283, DOI 10.3109/10408449309105013; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1976, J BIOL CHEM, V251, P4936; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003	36	92	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28098	28105						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961746				2022-12-27	WOS:A1994PV77200051
J	MCCORMICK, ML; ROEDER, TL; RAILSBACK, MA; BRITIGAN, BE				MCCORMICK, ML; ROEDER, TL; RAILSBACK, MA; BRITIGAN, BE			EOSINOPHIL PEROXIDASE-DEPENDENT HYDROXYL RADICAL GENERATION BY HUMAN EOSINOPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPIN TRAPPING EVIDENCE; HUMAN-NEUTROPHILS; MONONUCLEAR PHAGOCYTES; STAPHYLOCOCCUS-AUREUS; ENDOTHELIAL-CELLS; SUPEROXIDE ANION; XANTHINE-OXIDASE; IRON; MYELOPEROXIDASE; THIOCYANATE	Eosinophil production of superoxide (O-2-radical anion) and hydrogen peroxide (H2O2) is important in host defense. The present study assessed the potential of eosinophils to generate another potent cytotoxic species, the hydroxyl radical ((OH)-O-.). (OH)-O-. formation by phorbol myristate acetate (PMA)-stimulated eosinophils was demonstrated using an alpha-(4-pyridyl-1-oxide)-N-tert-butyl nitrone/ethanol spin trapping system. Additionally, (OH)-O-. was spin trapped following the addition of purified eosinophil peroxidase (EPO) to a cell-free O-2-radical anion/H2O2 generating systems. Effects of superoxide dismutase, catalase, azide, aminotriazole, chloride-depleted buffer, and extensive metal chelation were consistent with (OH)-O-. formation via the reaction of O-2-radical anion and EPO-generated hypohalous acid. Under chloride-depleted conditions, physiologic concentrations of Br- increased (OH)-O-. formation by both PMA-stimulated eosinophils and the cell-free EPO system. Physiologic concentrations of SCN-, however, did not increase (OH)-O-. formation, and in the presence of both Br- and SCN-, (OH)-O-. formation was similar to SCN- only. Eosinophils appear to form (OH)-O-. via an EPO-dependent mechanism, the magnitude of which varies with the availability of various EPO substrates. Given the highly reactive nature of this radical and the ability of EPO to adhere to cell membranes, even small amounts of (OH)-O-. formed at such sites could contribute to eosinophil-mediated cytotoxicity.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,CTR CARDIOVASC,IOWA CITY,IA 52242; VET ADM MED CTR,RES SERV,IOWA CITY,IA 52242; VET ADM MED CTR,DEPT INTERNAL MED,IOWA CITY,IA 52242	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)					NHLBI NIH HHS [HL44275, HL07121] Funding Source: Medline; NIAID NIH HHS [AI28412] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL044275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI028412] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUNE TM, 1977, EUR J BIOCHEM, V80, P209, DOI 10.1111/j.1432-1033.1977.tb11873.x; BOZEMAN PM, 1990, J IMMUNOL METHODS, V126, P125, DOI 10.1016/0022-1759(90)90020-V; BRITIGAN BE, 1992, BLOOD, V79, P699; BRITIGAN BE, 1992, J CLIN INVEST, V90, P2187, DOI 10.1172/JCI116104; BRITIGAN BE, 1988, J EXP MED, V168, P2367, DOI 10.1084/jem.168.6.2367; BRITIGAN BE, 1990, J BIOL CHEM, V265, P17533; BRITIGAN BE, 1990, J BIOL CHEM, V265, P2650; BRITIGAN BE, 1986, J BIOL CHEM, V261, P4426; BYNOE LA, 1991, BIOCHEM BIOPH RES CO, V179, P1305, DOI 10.1016/0006-291X(91)91715-O; CANDEIAS LP, 1993, FEBS LETT, V333, P151, DOI 10.1016/0014-5793(93)80394-A; CAPPELLETTI P, 1992, AM J CLIN PATHOL, V98, P615, DOI 10.1093/ajcp/98.6.615; COHEN HJ, 1978, J CLIN INVEST, V61, P1081, DOI 10.1172/JCI109007; COHEN MS, 1992, J INFECT DIS, V166, P1375, DOI 10.1093/infdis/166.6.1375; FINKELSTEIN E, 1979, MOL PHARMACOL, V16, P676; FINKELSTEIN E, 1982, MOL PHARMACOL, V21, P262; FINKELSTEIN E, 1980, J AM CHEM SOC, V102, P4994, DOI 10.1021/ja00535a029; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; GANNON DE, 1987, LAB INVEST, V57, P37; GLEICH GJ, 1984, ANNU REV IMMUNOL, V2, P429, DOI 10.1146/annurev.immunol.2.1.429; Haber F., 1934, P R SOC LOND A, V147, P332, DOI [10.1098/rspa.1934.0221, DOI 10.1098/RSPA.1934.0221, DOI 10.1098/rspa.1934.0221]; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HASSAN HM, 1980, J BACTERIOL, V141, P156, DOI 10.1128/JB.141.1.156-163.1980; HIMMELHOCH SR, 1969, BIOCHEMISTRY-US, V8, P914, DOI 10.1021/bi00831a022; JONG EC, 1980, J IMMUNOL, V124, P1949; JONG EC, 1980, J IMMUNOL, V124, P1378; JORG A, 1982, BIOCHIM BIOPHYS ACTA, V701, P185, DOI 10.1016/0167-4838(82)90112-1; KAUR H, 1988, ANAL BIOCHEM, V172, P360, DOI 10.1016/0003-2697(88)90456-3; KLEBANOFF SJ, 1988, ARCH BIOCHEM BIOPHYS, V264, P600, DOI 10.1016/0003-9861(88)90326-8; LOCKSLEY RM, 1982, J CLIN INVEST, V69, P1099, DOI 10.1172/JCI110545; LONG CA, 1980, J PHYS CHEM-US, V84, P555, DOI 10.1021/j100442a023; MAYENO AN, 1989, J BIOL CHEM, V264, P5660; NAGANO T, 1985, Journal of Free Radicals in Biology and Medicine, V1, P39, DOI 10.1016/0748-5514(85)90027-3; NOGUEIRA NM, 1982, J IMMUNOL, V128, P1705; PETRECCIA DC, 1987, J LEUKOCYTE BIOL, V41, P283, DOI 10.1002/jlb.41.4.283; POU S, 1989, ANAL BIOCHEM, V177, P1, DOI 10.1016/0003-2697(89)90002-X; RAMOS CL, 1992, J BIOL CHEM, V267, P8307; RAMSEY PG, 1982, J IMMUNOL, V128, P415; REPINE JE, 1981, J BIOL CHEM, V256, P7094; ROBERTS RL, 1985, BLOOD, V65, P433; ROOT RK, 1981, REV INFECT DIS, V3, P565; SINGH S, 1988, ANAL BIOCHEM, V171, P47, DOI 10.1016/0003-2697(88)90123-6; SLUNGAARD A, 1991, J BIOL CHEM, V266, P4903; THOMAS EL, 1986, J BIOL CHEM, V261, P9694; THOMAS MJ, 1986, BIOCHEMISTRY-US, V25, P8042, DOI 10.1021/bi00372a037; THOMAS MJ, 1993, FREE RADICAL BIO MED, V15, P477, DOI 10.1016/0891-5849(93)90210-L; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WINTERBOURN CC, 1986, J CLIN INVEST, V78, P545, DOI 10.1172/JCI112607; ZABUCCHI G, 1992, BLOOD, V80, P2903; ZARLEY JH, 1991, J CLIN INVEST, V88, P1511, DOI 10.1172/JCI115461	49	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27914	27919						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961724				2022-12-27	WOS:A1994PV77200025
J	BRUSTOVETSKY, N; KLINGENBERG, M				BRUSTOVETSKY, N; KLINGENBERG, M			THE RECONSTITUTED ADP/ATP CARRIER CAN MEDIATE H+ TRANSPORT BY FREE FATTY-ACIDS, WHICH IS FURTHER STIMULATED BY MERSALYL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ADP ATP CARRIER; PHOSPHOLIPID-BILAYER MEMBRANES; ADENINE-NUCLEOTIDE TRANSLOCASE; BEEF-HEART MITOCHONDRIA; BROWN ADIPOSE-TISSUE; UNCOUPLING PROTEIN; SUBMITOCHONDRIAL PARTICLES; PERMEABILITY TRANSITION; PROTON CONDUCTANCE	In a reconstituted system, the participation of the ATP/ADP carrier (AAC) in the free fatty acid (FFA)-induced proton transport was demonstrated (i) by direct measuring of the proton transport through the membranes of AAC proteoliposomes and (ii) by monitoring of the transmembrane potential Delta psi in AAC-cytochrome-c oxidase (COX)-coreconstituted proteoliposomes. FFA increased the initial rate of proton transport in AAC proteoliposomes and decreased Delta psi in AAC-COX proteoliposomes. Inhibitors of AAC suppressed the effects of FFA, Without AAC or with inactive AAC, FFA cannot maintain proton leakage through the membrane. In these cases, even a small increase of Delta psi was induced by FFA These results demonstrate for the first time with purified components a participation of AAC in FFA-induced proton transport supporting an earlier suggestion (Skulachev, V. P. (1991) FEBS Lett. 294, 158-162). Mersalyl treatment of the AAC-COX proteoliposomes resulted in an increase of the AAC-mediated protonophoric action of FFA. Mersalyl also sensitized the protonophoric action of the FFA against nucleotides so that even guanine nucleotides, which are inactive in transport, become inhibitory. The effect of mersalyl is rationalized in terms of a specific interaction with cysteine 159 being attracted as anion by surrounding positive charges. This might open a gate similarly as suggested for eosin 5-maleimide interaction (Majima, E., Koike, H., Hong, Y.-M., Shinohara, Y., and Terada, Il. (1993) J. Biol. Chem. 268, 22181-22187) and, thus, transform the AAC into unidirectional transport mode.			BRUSTOVETSKY, N (corresponding author), UNIV MUNICH, INST PHYS BIOCHEM, GOETHESTR 33, D-80336 MUNICH, GERMANY.							AHMED I, 1990, BIOCHIM BIOPHYS ACTA, V1024, P298, DOI 10.1016/0005-2736(90)90358-U; ANDREYEV AY, 1988, FEBS LETT, V226, P265, DOI 10.1016/0014-5793(88)81436-4; ANDREYEV AY, 1989, EUR J BIOCHEM, V182, P585, DOI 10.1111/j.1432-1033.1989.tb14867.x; AQUILA H, 1982, H-S Z PHYSIOL CHEM, V363, P345; Bernardi G, 1971, METHOD ENZYMOL, V22, P325; BISACCIA F, 1988, BIOCHIM BIOPHYS ACTA, V933, P229, DOI 10.1016/0005-2728(88)90030-8; BISACCIA F, 1989, BIOCHIM BIOPHYS ACTA, V977, P171, DOI 10.1016/S0005-2728(89)80068-4; BISACCIA F, 1985, BIOCHIM BIOPHYS ACTA, V810, P362, DOI 10.1016/0005-2728(85)90222-1; BLAIR PV, 1967, METHOD ENZYMOL, V10, P78; BRANDOLIN G, 1980, BIOCHIM BIOPHYS ACTA, V592, P592, DOI 10.1016/0005-2728(80)90103-6; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; BRUSTOVETSKY N, 1993, NEW PERSPECTIVES MIT, P51; BRUSTOVETSKY NN, 1990, FEBS LETT, V272, P190, DOI 10.1016/0014-5793(90)80481-W; COTY WA, 1974, J BIOL CHEM, V249, P2593; CROMPTON M, 1988, BIOCHEM J, V255, P357; DALBON P, 1988, BIOCHEMISTRY-US, V27, P5141, DOI 10.1021/bi00414a029; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEDUKHOVA VI, 1991, FEBS LETT, V295, P51, DOI 10.1016/0014-5793(91)81382-I; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P268, DOI 10.1016/0005-2736(90)90176-O; Errede B, 1978, Methods Enzymol, V53, P40; Fiske CH, 1925, J BIOL CHEM, V66, P375; FOWLER LR, 1962, BIOCHIM BIOPHYS ACTA, V64, P170, DOI 10.1016/0006-3002(62)90770-9; GAWAZ M, 1990, J BIOL CHEM, V265, P14202; GRIFFITHS D, 1961, J BIOL CHEM, V236, P1850; GRINIUS LL, 1970, BIOCHIM BIOPHYS ACTA, V216, P1, DOI 10.1016/0005-2728(70)90153-2; GUTKNECHT J, 1987, P NATL ACAD SCI USA, V84, P6443, DOI 10.1073/pnas.84.18.6443; GUTKNECHT J, 1988, J MEMBRANE BIOL, V106, P83, DOI 10.1007/BF01871769; HALESTRAP AP, 1976, BIOCHEM J, V156, P181, DOI 10.1042/bj1560181; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HARRIS EJ, 1979, BIOCHEM J, V182, P455, DOI 10.1042/bj1820455; HUTHER FJ, 1984, EUR J BIOCHEM, V143, P79, DOI 10.1111/j.1432-1033.1984.tb08343.x; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; KAMP F, 1992, P NATL ACAD SCI USA, V89, P11367, DOI 10.1073/pnas.89.23.11367; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; KLINGENBERG M, 1985, ENZYMES BIOL MEMBR, V4, P511; KOHNKE D, 1993, FEBS LETT, V336, P90, DOI 10.1016/0014-5793(93)81616-8; KOHNKE D, 1993, BIOL CHEM HOPPESEYLE, V374, P144; KRAMER R, 1980, FEBS LETT, V119, P257, DOI 10.1016/0014-5793(80)80266-3; KRISHNAMOORTHY G, 1984, BIOCHEMISTRY-US, V23, P1640, DOI 10.1021/bi00303a009; LABONIA N, 1988, BIOCHEM J, V254, P139, DOI 10.1042/bj2540139; LEQUOC K, 1988, ARCH BIOCHEM BIOPHYS, V265, P249, DOI 10.1016/0003-9861(88)90125-7; LOWRY C, 1984, MOL CELL BIOL, V8, P4651; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Macedo Denise Vaz De, 1993, European Journal of Biochemistry, V215, P595, DOI 10.1111/j.1432-1033.1993.tb18070.x; MAJIMA E, 1993, J BIOL CHEM, V268, P22181; MARTYN A, 1991, BIOCHEM SOC T, V19, pS257; MAYINGER P, 1989, FEBS LETT, V244, P421, DOI 10.1016/0014-5793(89)80576-9; MCLAUGHLIN SGA, 1980, PHYSIOL REV, V60, P825, DOI 10.1152/physrev.1980.60.3.825; NOVGORODOV SA, 1992, J BIOL CHEM, V267, P16274; PALMIERI F, 1974, BIOCHIM BIOPHYS ACTA, V333, P195, DOI 10.1016/0005-2728(74)90004-8; PANDE SV, 1976, J BIOL CHEM, V251, P6683; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHONFELD P, 1992, FEBS LETT, V303, P190, DOI 10.1016/0014-5793(92)80516-J; SCHONFELD P, 1990, FEBS LETT, V264, P246, DOI 10.1016/0014-5793(90)80259-L; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; STRIELEMAN PJ, 1985, J BIOL CHEM, V260, P3402; THOMAS AP, 1981, BIOCHEM J, V196, P471, DOI 10.1042/bj1960471; TIKHONOVA IM, 1994, FEBS LETT, V337, P231, DOI 10.1016/0014-5793(94)80197-5; VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P1456, DOI 10.1073/pnas.78.3.1456; WINKLER E, 1994, J BIOL CHEM, V269, P2508; WINKLER E, 1992, EUR J BIOCHEM, V207, P135, DOI 10.1111/j.1432-1033.1992.tb17030.x; WOITCZAK L, 1993, BIOCHIM BIOPHYS ACTA, V1183, P41, DOI 10.1016/0005-2728(93)90004-Y	63	106	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27329	27336						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961643				2022-12-27	WOS:A1994PV77100031
J	CHENG, JB; GUFFANTI, AA; KRULWICH, TA				CHENG, JB; GUFFANTI, AA; KRULWICH, TA			THE CHROMOSOMAL TETRACYCLINE RESISTANCE LOCUS OF BACILLUS-SUBTILIS ENCODES A NA+/H+ ANTIPORTER THAT IS PHYSIOLOGICALLY IMPORTANT AT ELEVATED PH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; STAPHYLOCOCCUS-AUREUS; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; TRANSPOSON TN10; GENE; DNA; DETERMINANTS; PROTEIN; EFFLUX	The chromosomal tetB(L) gene of Bacillus subtilis encodes a transporter that catalyzes Na+/H+ antiport even more actively than tetracycline/H+ antiport, as shown by assays of membrane antiporter activity upon transformation of Na+/H+ antiporter-deficient Escherichia coli with the cloned gene; the transformation results in a substantial increase in Na+ resistance as well as detectable resistance to low tetracycline concentrations. Transpositional disruption of the chromosomal tetB(L) locus of B. subtilis led to reduced rates of electrogenic Na+ efflux and revealed a physiological role for this locus in Na+ resistance and Na+-dependent pH homeostasis at pH 8.5. The mutant phenotype was reversed by transformation with a plasmid expressing the cloned tetB(L) gene. Energy-dependent tetracycline efflux rates in the wild type were greater than in the transposition mutant but were not sufficient to confer resistance to the antibiotic. TetB(L) is also inferred to have a modest capacity for K+ efflux, since the transposition mutant is slightly impaired in K+-dependent pH homeostasis at pH 8.5 and grew better than the wild type at pH 7 on limiting K+ concentrations.	CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								AMANO H, 1991, BIOCHIM BIOPHYS ACTA, V1088, P251, DOI 10.1016/0167-4781(91)90061-P; AMBUDKAR SV, 1984, J BIOL CHEM, V259, P6142; AMBUDKAR SV, 1990, BACTERIA, V12, P247; BURDETT V, 1982, J BACTERIOL, V149, P995, DOI 10.1128/JB.149.3.995-1004.1982; CAMILLI A, 1990, J BACTERIOL, V172, P3738, DOI 10.1128/jb.172.7.3738-3744.1990; DOSCH DC, 1984, J BACTERIOL, V160, P1188, DOI 10.1128/JB.160.3.1188-1190.1984; DUBNAU D, 1971, J MOL BIOL, V56, P209, DOI 10.1016/0022-2836(71)90460-8; DUBNAU D, 1984, CRIT REV BIOCH, V16, P102; GARCIA ML, 1983, J BACTERIOL, V156, P1151, DOI 10.1128/JB.156.3.1151-1157.1983; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; GRIFFITH JK, 1988, J BACTERIOL, V170, P598, DOI 10.1128/jb.170.2.598-604.1988; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GUAY GG, 1993, J BACTERIOL, V175, P4927, DOI 10.1128/JB.175.15.4927-4929.1993; GUFFANTI AA, 1991, J GEN MICROBIOL, V137, P2375, DOI 10.1099/00221287-137-10-2375; HILLEN W, 1982, J BIOL CHEM, V257, P6605; IVES CL, 1990, J BACTERIOL, V172, P4936, DOI 10.1128/jb.172.9.4936-4944.1990; IVES CL, 1990, GENE, V94, P115, DOI 10.1016/0378-1119(90)90476-8; IVES CL, 1989, J BACTERIOL, V171, P1801, DOI 10.1128/jb.171.4.1801-1810.1989; IVEY DM, 1991, J BIOL CHEM, V266, P23483; JIA ZP, 1992, EMBO J, V11, P1631, DOI 10.1002/j.1460-2075.1992.tb05209.x; KRULWICH TA, 1989, J BIOENERG BIOMEMBR, V21, P663, DOI 10.1007/BF00762685; KRULWICH TA, 1983, BIOCHIM BIOPHYS ACTA, V726, P245, DOI 10.1016/0304-4173(83)90011-3; KRULWICH TA, 1985, J BIOL CHEM, V260, P4055; KRULWICH TA, 1994, IN PRESS J EXP BIOL, V196; LEVY SB, 1989, J ANTIMICROB CHEMOTH, V24, P1, DOI 10.1093/jac/24.1.1; LEVY SB, 1989, ANTIMICROB AGENTS CH, V33, P1373, DOI 10.1128/AAC.33.8.1373; LEWIS K, 1994, TRENDS BIOCHEM SCI, V19, P119, DOI 10.1016/0968-0004(94)90204-6; MACNAB RM, 1987, BIOPHYS J, V52, P637, DOI 10.1016/S0006-3495(87)83255-1; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MCMURRY LM, 1992, J BACTERIOL, V174, P6294, DOI 10.1128/JB.174.19.6294-6297.1992; MOJUMDAR M, 1988, J BACTERIOL, V170, P5522, DOI 10.1128/jb.170.12.5522-5528.1988; NGUYEN TT, 1983, GENE, V25, P83, DOI 10.1016/0378-1119(83)90170-1; OHYAMA T, 1992, J BACTERIOL, V174, P7743, DOI 10.1128/JB.174.23.7743-7749.1992; PADAN E, 1993, J BIOENERG BIOMEMBR, V25, P647; PADAN E, 1989, J BIOL CHEM, V267, P11064; QUIRK PG, 1993, J BACTERIOL, V175, P647, DOI 10.1128/JB.175.3.647-654.1993; SAKAGUCHI R, 1988, BIOCHIM BIOPHYS ACTA, V949, P49, DOI 10.1016/0167-4781(88)90053-X; SALYERS AA, 1990, MOL MICROBIOL, V4, P151, DOI 10.1111/j.1365-2958.1990.tb02025.x; Sambrook J, 1989, MOL CLONING LABORATO; SAUNDERS JR, 1984, BRIT MED BULL, V40, P54, DOI 10.1093/oxfordjournals.bmb.a071948; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; SCHULDINER S, 1993, ALKALI CATION TRANSP, P25; SCHWARZ S, 1992, ANTIMICROB AGENTS CH, V36, P580, DOI 10.1128/AAC.36.3.580; SHERIDAN RP, 1991, MOL MICROBIOL, V5, P895, DOI 10.1111/j.1365-2958.1991.tb00763.x; SHISHIDO K, 1983, PLASMID, V10, P224, DOI 10.1016/0147-619X(83)90036-7; SPEER BS, 1992, CLIN MICROBIOL REV, V5, P387, DOI 10.1128/CMR.5.4.387-399.1992; SPIZIZEN J, 1958, P NATL ACAD SCI USA, V44, P1072, DOI 10.1073/pnas.44.10.1072; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WILLIAMS G, 1979, MOL GEN GENET, V177, P23, DOI 10.1007/BF00267249; WILSON CR, 1985, J BACTERIOL, V163, P445, DOI 10.1128/JB.163.2.445-453.1985; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809; YAMAGUCHI A, 1992, FEBS LETT, V307, P229, DOI 10.1016/0014-5793(92)80773-A; YAMAGUCHI A, 1991, FEBS LETT, V282, P415, DOI 10.1016/0014-5793(91)80527-A; YAMAGUCHI A, 1991, ANTIMICROB AGENTS CH, V35, P53, DOI 10.1128/AAC.35.1.53; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P7490; ZILBERSTEIN D, 1982, J BIOL CHEM, V257, P3687	56	74	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27365	27371						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961647				2022-12-27	WOS:A1994PV77100036
J	GIDHJAIN, M; ZHANG, YP; VANPOELJE, PD; LIANG, JY; HUANG, SH; KIM, JY; ELLIOTT, JT; ERION, MD; PILKIS, SJ; ELMAGHRABI, MR; LIPSCOMB, WN				GIDHJAIN, M; ZHANG, YP; VANPOELJE, PD; LIANG, JY; HUANG, SH; KIM, JY; ELLIOTT, JT; ERION, MD; PILKIS, SJ; ELMAGHRABI, MR; LIPSCOMB, WN			THE ALLOSTERIC SITE OF HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE - ANALYSIS OF 6 AMP SITE MUTANTS BASED ON THE CRYSTAL-STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T7 RNA-POLYMERASE; ESCHERICHIA-COLI; FRUCTOSE 2,6-BISPHOSPHATE; EXPRESSION; REFINEMENT	The molecular structure of human liver fructose-1,6-bisphosphatase complexed with AMP was determined by x-ray diffraction using molecular replacement, starting from the pig kidney enzyme AMP complex. Of the 34 amino acid residues which differ between these two sequences, only one interacts with AMP; Met(30) in pig kidney is Leu(30) in human liver. From this analysis, six sites in which side chains of amino acid residues are in contact with AMP Ala(24), Leu(30), Thr(31), Tyr(113), Arg(140), and Met(177), were mutated by polymerase chain reaction. The wild-type and mutant forms were expressed in Escherichia coli, purified, and their kinetic properties determined. Circular dichroism spectra of the mutants were indistinguishable from that of the wild-type enzyme. Kinetic analyses revealed that all forms had similar turnover numbers, K-m values for fructose 2,6-bisphosphate, and inhibition constants for fructose 2,6-bisphosphate. Apparent K-i values for AMP inhibition of the Leu(30) --> Phe and Met(177) --> Ala mutants were similar to those of the wild-type enzyme, but the apparent K-i values for the Arg(140) --> Ala and Ala(24) --> Phe mutants were 7-to 20-fold higher, respectively. The Thr(31) --> Ser mutant exhibited a 5-fold increase in apparent K-i for AMP, while mutation of Thr(31) to Ala increased the apparent K-i 120-fold. AMP inhibition of the Tyr(113) --> Phe mutant was undetectable even at millimolar AMP concentrations. Fructose 2,6-bisphosphate potentiated AMP inhibition of the mutants to the same extent as for the wild-type enzyme, except in the case of the Thr(31) --> Ala and Tyr(113) --> Phe mutants. Thus, the Met(177) --> Ala mutant suggests that the side chain beyond C alpha is not needed for AMP binding, and that the Leu(30) --> Phe mutant preserves the AMP contacts with these side chains. Thr(31), Tyr(113), and Arg(140) form key hydrogen bonds to AMP consistent with strong side chain interactions in the wild-type enzyme. Finally, the absence of any effect of fructose 2,6-bisphosphate on AMP inhibition observed in the Thr(31) --> Ala mutant may be an important clue relating to the mechanism of synergism of these two inhibitors.	SUNY STONY BROOK,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794; GENSIA INC,SAN DIEGO,CA 92121; HARVARD UNIV,DEPT CHEM,GIBBS CHEM LAB,CAMBRIDGE,MA 02138	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Harvard University					NIDDK NIH HHS [DK 38354] Funding Source: Medline; NIGMS NIH HHS [GM 06920] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038354, R37DK038354] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM006920, R37GM006920] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABUL J, 1983, ARCH BIOCHEM BIOPHYS, V225, P944, DOI 10.1016/0003-9861(83)90109-1; BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHEN M, 1994, J BIOL CHEM, V269, P5554; ELMAGHRABI MR, 1992, J BIOL CHEM, V267, P6526; ELMAGHRABI MR, 1993, J BIOL CHEM, V268, P9466; ELMAGHRABI MR, 1991, BIOCHEM BIOPH RES CO, V176, P137, DOI 10.1016/0006-291X(91)90900-R; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KE H, 1989, J MOL BIOL, V212, P513; KE HM, 1990, P NATL ACAD SCI USA, V87, P5243, DOI 10.1073/pnas.87.14.5243; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIANG JY, 1993, P NATL ACAD SCI USA, V90, P21312; LIANG JY, 1992, P NATL ACAD SCI USA, V89, P2402; LIU F, 1990, FRUCTOSE 2 6 BISPHOS, P17; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCUS F, 1990, ARCH BIOCHEM BIOPHYS, V279, P151, DOI 10.1016/0003-9861(90)90475-E; MOFFATT BA, 1987, CELL, V49, P221, DOI 10.1016/0092-8674(87)90563-0; PILKIS SJ, 1981, J BIOL CHEM, V256, P1489; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; PONTREMOLI S., 1966, BIOCHEMISTRY, V5, P3568, DOI 10.1021/bi00875a027; RAO SN, 1980, ACTA CRYSTALLOGR A, V36, P878, DOI 10.1107/S0567739480001854; SEDIVY JM, 1986, P NATLA CAD SCI US, V225, P1656; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKETA K, 1965, J BIOL CHEM, V240, P651; VANSCHAFTINGEN E, 1980, BIOCHEM J, V192, P263, DOI 10.1042/bj1920263; ZHANG YP, 1993, BIOCHEMISTRY-US, V32, P1844, DOI 10.1021/bi00058a019	27	67	71	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27732	27738						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961695				2022-12-27	WOS:A1994PV77100089
J	JAMES, GL; BROWN, MS; COBB, MH; GOLDSTEIN, JL				JAMES, GL; BROWN, MS; COBB, MH; GOLDSTEIN, JL			BENZODIAZEPINE PEPTIDOMIMETIC BZA-5B INTERRUPTS THE MAP KINASE ACTIVATION PATHWAY IN H-RAS-TRANSFORMED RAT-1 CELLS, BUT NOT IN UNTRANSFORMED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE-2; GROWTH-FACTOR; PROTEIN FARNESYLTRANSFERASE; TYROSINE PHOSPHORYLATION; P21RAS; REQUIREMENT; INHIBITION; BINDING; MUTANTS; BRAIN	A benzodiazepine peptidomimetic, BZA-5B, inhibits farnesylation of H-Ras and normalizes the morphology of Rat-1 cells transformed with H-Ras(V12) at concentrations that do not affect the growth of untransformed Rat-1 cells. In the current experiments, we show that BZA-5B decreases the active forms of enzymes in the mitogen-activated protein (MAP) kinase signaling cascade, including Raf, MAP kinase kinase (MEK), and MAP kinase, in cells transformed with H-Ras(V12). BZA-5B had no effect on these enzymes in cells transformed with H-Ras(V12,189), which is geranylgeranylated rather than farnesylated. In cells transformed with H-Ras(V12), BZA-5B reduced the activities of enzymes in the MAP kinase pathway at concentrations that only partially blocked farnesylation of H-Ras(V12), suggesting that nonfarnesylated H-Ras(V12) is a dominant inhibitor of the action of farnesylated H-Ras(V12) in the BZA-5B treated cells. In untransformed Rat-1 cells, BZA-5B did not inhibit MAP kinase activity nor did it prevent the acute activation triggered by epidermal growth factor, even though farnesylated endogenous H-Ras was no longer detectable. These data raise the possibility that untransformed cells contain a form of Ras (K-Ras or N-Ras) whose prenylation is not inhibited by BZA-5B, thus allowing them to resist the effects of BZA-5B.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	JAMES, GL (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.			Cobb, Melanie/0000-0003-0833-5473	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128, R01DK034128] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline; NIDDK NIH HHS [DK34128] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BROWN MS, 1993, NATURE, V366, P14, DOI 10.1038/366014a0; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MICHAELI T, 1989, EMBO J, V8, P3039, DOI 10.1002/j.1460-2075.1989.tb08454.x; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NEWMAN CMH, 1993, BIOCHIM BIOPHYS ACTA, V1155, P79, DOI 10.1016/0304-419X(93)90023-6; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sambrook J, 1989, MOL CLONING LABORATO; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STACEY DW, 1991, ONCOGENE, V6, P2297; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STEVENS RC, 1990, BIOCHEMISTRY-US, V29, P7691, DOI 10.1021/bi00485a019; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230	39	105	136	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27705	27714						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961691				2022-12-27	WOS:A1994PV77100085
J	LEMAIRE, M; SCHMITTER, JM; ISSAKIDIS, E; MIGINIACMASLOW, M; GADAL, P; DECOTTIGNIES, P				LEMAIRE, M; SCHMITTER, JM; ISSAKIDIS, E; MIGINIACMASLOW, M; GADAL, P; DECOTTIGNIES, P			ESSENTIAL HISTIDINE AT THE ACTIVE-SITE OF SORGHUM LEAF NADP-DEPENDENT MALATE-DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SITE; CORN LEAVES; AMINO-ACID; ENZYME; PHOTOSYNTHESIS; CHLOROPLASTS; PURIFICATION; THIOREDOXINS; MUTAGENESIS; SEQUENCE	Chloroplastic NADP-dependent malate dehydrogenase (NADP-MDH) is a key enzyme in the photosynthetic CO2 fixation pathway of C-4-plants. The presence of a histidine at its active site has been proposed, based on sequence alignment with nonchloroplastic NAD-dependent malate dehydrogenases. In order to investigate this hypothesis, the effect of diethylpyrocarbonate on the sorghum leaf enzyme has been tested. Diethylpyrocarbonate strongly inhibited NADP-MDH activity, its effect being dramatically decreased in the presence of substrates and reversed by hydroxylamine. When diethylpyocarbonate inactivated NADP-MDH was cleaved with trypsin, one peptide with increased absorbance at 240 nm was detected. Sequencing of this peptide and analysis by mass spectrometry demonstrated that histidine 229 was modified by diethylpyrocarbonate. This amino acid was changed to an alanine by site-directed mutagenesis, and the modified protein was produced in Escherichia coli. It was similar to the plant enzyme except that it was totally inactive. Taken together, these results indicate that His(229) is an essential residue in the active site of sorghum NADP-MDH.	UNIV PARIS 11, INST BIOTECHNOL PLANTES, CNRS, URA 1128, F-91405 ORSAY, FRANCE; ECOLE POLYTECH, BIOCHIM LAB, F-91128 PALAISEAU, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Institut Polytechnique de Paris				Issakidis-Bourguet, Emmanuelle/0000-0002-6144-4364				BANASZAK LJ, 1975, ENZYMES, V11, P369; BIRKTOFT JJ, 1983, J BIOL CHEM, V258, P472; BONINO MJBD, 1986, ANAL BIOCHEM, V157, P8; BURSTEIN Y, 1974, BIOCHEMISTRY-US, V13, P205, DOI 10.1021/bi00698a030; CRETIN C, 1990, EUR J BIOCHEM, V192, P299, DOI 10.1111/j.1432-1033.1990.tb19227.x; DECOTTIGNIES P, 1988, J BIOL CHEM, V263, P11780; DEKA RK, 1992, J BIOL CHEM, V267, P22237; DELAMOTTEGUERY F, 1991, EUR J BIOCHEM, V196, P287; GLEASON WB, 1994, BIOCHEMISTRY-US, V33, P2078, DOI 10.1021/bi00174a014; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HATCH MD, 1970, ANN REV PLANT PHYSIO, V21, P141, DOI 10.1146/annurev.pp.21.060170.001041; HATCH MD, 1969, BIOCHEM BIOPH RES CO, V34, P589, DOI 10.1016/0006-291X(69)90778-5; HOLBROOK JJ, 1974, BIOCHEM J, V139, P797, DOI 10.1042/bj1390797; HOLMGREN A, 1968, EUR J BIOCHEM, V6, P475, DOI 10.1111/j.1432-1033.1968.tb00470.x; ISSAKIDIS E, 1994, J BIOL CHEM, V269, P3511; ISSAKIDIS E, 1992, J BIOL CHEM, V267, P21577; JACKSON RM, 1992, J COMPUT AID MOL DES, V6, P1, DOI 10.1007/BF00124383; JACQUOT JP, 1978, FEBS LETT, V96, P243, DOI 10.1016/0014-5793(78)80410-4; JACQUOT JP, 1991, EUR J BIOCHEM, V199, P47, DOI 10.1111/j.1432-1033.1991.tb16090.x; JACQUOT JP, 1994, IN PRESS METHODS ENZ; JACQUOT JPP, 1981, PLANT PHYSIOL, V68, P300, DOI 10.1104/pp.68.2.300; JOHNSON HS, 1970, BIOCHEM J, V119, P273, DOI 10.1042/bj1190273; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARROUQUERE J, 1965, B SOC CHIM FR, V5, P382; MAEDA K, 1986, EUR J BIOCHEM, V154, P197, DOI 10.1111/j.1432-1033.1986.tb09379.x; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; Miles E W, 1977, Methods Enzymol, V47, P431; PERROTRECHENMANN C, 1983, PLANT SCI LETT, V30, P219, DOI 10.1016/0304-4211(83)90221-3; Sambrook J, 1989, MOL CLONING LABORATO; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WOLOSIUK RA, 1977, FEBS LETT, V81, P253, DOI 10.1016/0014-5793(77)80529-2	31	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27291	27296						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961639				2022-12-27	WOS:A1994PV77100025
J	INADA, M; CROWL, RM; BEKKERS, ACAPA; VERHEIJ, H; WEISS, J				INADA, M; CROWL, RM; BEKKERS, ACAPA; VERHEIJ, H; WEISS, J			DETERMINANTS OF THE INHIBITORY-ACTION OF PURIFIED 14-KDA PHOSPHOLIPASES A(2) ON CELL-FREE PROTHROMBINASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY-INCREASING PROTEIN; PORCINE PANCREATIC PHOSPHOLIPASE-A2; NAJA-NIGRICOLLIS VENOM; ESCHERICHIA-COLI; SNAKE-VENOM; UNILAMELLAR VESICLES; ENZYMATIC-ACTIVITY; BINDING-SITE; FACTOR-VA; MEMBRANE	It has been suggested (Kini, R. R., and Evans, H. J. (1987) J. Biol. Chem. 262, 14402-14407) that the anticoagulant activity of members of the 14-kDa phospholipase A(2) (PLA(2)) family depends on the presence of basic residues within a variable surface region (residues 54-77) distinct from both the conserved catalytic machinery and surface sites mediating the antibacterial action of these enzymes (see Weiss, J., Inada, M., Elsbach, P., and Crowl, R. M. (1994) J. Biol. Chem. 269, 26331-26337). To further define the determinants of the anticoagulant activity of PLA(2), we have analyzed the inhibitory effects of purified native and recombinant PLA(2) on cell-free prothrombinase. Both native and recombinant wildtype pig pancreas (net charge -1) and human ''secretory'' PLA(2) (net charge +15) produced similar dose-dependent inhibition of prothrombinase activity that was significantly less potent than a toxic PLA(2) purified from snake venom. Site specific mutations that either increased or decreased PLA(2) activity toward bactericidal/permeability-increasing protein-treated Escherichia coli by up to 50-fold had no effect on antiprothrombinase activity. In contrast, substitution of Arg for Asp-59/Gly for Ser-60 in the pig PLA(2) increased antiprothrombinase activity by 5-10-fold without affecting catalytic activity toward a range of phospholipid substrates or antibacterial activity. Comparison of antiprothrombinase activity of catalytically active and inactive forms of the PLA(2) and under a range of phospholipid conditions revealed that the potent antiprothrombinase activity of native toxic venom PLA(2) and of the D59R.S60G mutant pancreatic PLA(2) reflect combined catalytic and noncatalytic actions, the latter apparently dependent on basic residues at discrete surface sites in the enzyme.	NYU, SCH MED, DEPT MICROBIOL, NEW YORK, NY 10016 USA; HOFFMANN LA ROCHE INC, ROCHE RES CTR, NUTLEY, NJ 07110 USA; UNIV UTRECHT, CTR BIOMEMBRANES & LIPID ENZYMOL, DEPT BIOCHEM, UTRECHT, NETHERLANDS	New York University; Roche Holding; Utrecht University				Weiss, Jerrold/0000-0003-1476-4485	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018571] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 18571] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CIRINO G, 1993, THROMB RES, V70, P337, DOI 10.1016/0049-3848(93)90106-X; CONDREA E, 1981, TOXICON, V19, P705, DOI 10.1016/0041-0101(81)90108-2; CONDREA E, 1983, TOXICON, V21, P209, DOI 10.1016/0041-0101(83)90005-3; CUTSFORTH GA, 1989, BIOCHEMISTRY-US, V28, P7453, DOI 10.1021/bi00444a045; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DEKRUIJFF B, 1975, BIOCHIM BIOPHYS ACTA, V406, P6, DOI 10.1016/0005-2736(75)90038-3; ELSBACH P, 1991, METHOD ENZYMOL, V197, P24; ELSBACH P, 1979, J BIOL CHEM, V254, P1000; FORST S, 1986, BIOCHEMISTRY-US, V25, P4309, DOI 10.1021/bi00363a020; FORST S, 1987, BIOCHIM BIOPHYS ACTA, V920, P221, DOI 10.1016/0005-2760(87)90098-1; FOX JEB, 1991, J BIOL CHEM, V266, P13289; FRANCK PFH, 1985, J CLIN INVEST, V75, P183, DOI 10.1172/JCI111672; GERADS I, 1990, BIOCHEMISTRY-US, V29, P7967, DOI 10.1021/bi00486a027; GILFILLAN AM, 1983, J LIPID RES, V24, P1651; GOVERSRIEMSLAG JWP, 1992, BIOCHEMISTRY-US, V31, P10000, DOI 10.1021/bi00156a020; HAMILTON KK, 1990, J BIOL CHEM, V265, P3809; HANASAKI K, 1992, J BIOL CHEM, V267, P6414; HAWROT E, 1978, J BIOL CHEM, V253, P8213; HIGGINS DL, 1985, J BIOL CHEM, V260, P3604; KINI RM, 1987, J BIOL CHEM, V262, P14402; KINI RM, 1989, TOXICON, V27, P613, DOI 10.1016/0041-0101(89)90013-5; KINI RM, 1986, TOXICON, V24, P895; KINI RM, 1986, TOXICON, V24, P527, DOI 10.1016/0041-0101(86)90173-X; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; LAMBEAU G, 1990, J BIOL CHEM, V265, P9526; LICHTENBERG D, 1986, J BIOL CHEM, V261, P5334; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANN KG, 1990, BLOOD, V76, P1; MENASHE M, 1986, J BIOL CHEM, V261, P5328; Nieuwenhuizen W, 1974, Methods Enzymol, V32, P147; PEI G, 1993, J BIOL CHEM, V268, P3226; ROSING J, 1980, J BIOL CHEM, V255, P274; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SIMS PJ, 1989, J BIOL CHEM, V264, P17049; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; STEFANSSON S, 1990, BIOCHEMISTRY-US, V29, P7742, DOI 10.1021/bi00485a024; STEFANSSON S, 1989, THROMB RES, V55, P481, DOI 10.1016/0049-3848(89)90056-X; TOHKIN M, 1993, J BIOL CHEM, V268, P2865; VADAS P, 1992, LIFE SCI, V50, P807, DOI 10.1016/0024-3205(92)90186-S; VERHEIJ HM, 1980, EUR J BIOCHEM, V112, P25, DOI 10.1111/j.1432-1033.1980.tb04982.x; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; VOLWERK JJ, 1974, BIOCHEMISTRY-US, V13, P1446, DOI 10.1021/bi00704a020; WAITE M, 1990, BIOCH MOL BIOL PHYSL; WEISS J, 1991, J BIOL CHEM, V266, P4162; WEISS J, 1994, J BIOL CHEM, V269, P26331	47	40	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26338	26343						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929351				2022-12-27	WOS:A1994PQ93000061
J	SHI, MM; KUGELMAN, A; IWAMOTO, T; TIAN, L; FORMAN, HJ				SHI, MM; KUGELMAN, A; IWAMOTO, T; TIAN, L; FORMAN, HJ			QUINONE-INDUCED OXIDATIVE STRESS ELEVATES GLUTATHIONE AND INDUCES GAMMA-GLUTAMYLCYSTEINE SYNTHETASE-ACTIVITY IN RAT LUNG EPITHELIAL L2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSIVE ELEMENT; HUMAN OVARIAN-CANCER; MESSENGER-RNA; INDUCTION; KIDNEY; ACTIVATION; INCREASE; IDENTIFICATION; FIBROBLASTS; PROTECTION	Glutathione (GSH) is one of the most important physiological antioxidants involved in detoxification of hydrogen peroxide and lipid hydroperoxide. Previous studies have shown that cells can maintain and even increase cellular GSH content in response to sublethal oxidative stress. We hypothesized that gamma-glutamylcysteine synthetase (gamma GCS), the rate-limiting enzyme in de novo GSH synthesis, could be induced by oxidative stress. Rat lung epithelial L2 cells were challenged with 2,3-dimethoxy-1,4 naphthoquinone (DMNQ), which generates O-2(radical anion) and H2O2 continuously through redox cycling. Exposure of confluent L2 cells with sublethal doses of DMNQ caused sustained elevation of cellular GSH levels over a 24-h period (to 2.5-fold with 10 mu M). DMNQ caused increases in gamma GCS activity (70% at 24 h with 10 mu M), the gamma GCS catalytic heavy subunit (gamma GCS-HS) protein level, and gamma GCS-HS mRNA content (similar to 4 fold after 6 h with 10 mu M). The elevation of gamma GCS-HS mRNA by DMNQ was eliminated by co-incubation with actinomycin D. Nuclear run-on experiments demonstrated that the transcriptional rate of the gamma GCS-HS gene was increased by 3- or 6 h exposure to 10 mu M DMNQ. Our results suggested that the induction of de novo GSH synthesis by naphthoquinone-induced oxidative stress is associated with the transcriptional activation of the gamma GCS-HS gene and the subsequent elevation in gamma GCS activity. Unlike simpler quinones, DMNQ cannot form a GSH conjugate. Thus, the induction of gamma GCS-HS gene transcription does not require formation of an electrophile-glutathione conjugate.	UNIV SO CALIF,SCH PHARM,DEPT MOLEC PHARMACOL & TOXICOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90033; KANSAS STATE UNIV AGR & APPL SCI,DEPT BIOCHEM,MANHATTAN,KS 66506	University of Southern California; University of Southern California; University of Southern California; Kansas State University				Forman, Henry Jay/0000-0001-5838-2791	NIEHS NIH HHS [ES05511] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005511, R56ES005511] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BAILEY HH, 1992, CANCER RES, V52, P5115; BANNAI S, 1989, J BIOL CHEM, V264, P18480; BORROZ KI, 1994, TOXICOL APPL PHARM, V126, P150, DOI 10.1006/taap.1994.1101; BRUNMARK A, 1989, FREE RADICAL BIO MED, V7, P435, DOI 10.1016/0891-5849(89)90126-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLERCH LB, 1992, J BIOL CHEM, V267, P2853; DARLEYUSMAR VM, 1991, BIOCHEM J, V278, P429, DOI 10.1042/bj2780429; DENEKE SM, 1989, AM J PHYSIOL, V257, pL265, DOI 10.1152/ajplung.1989.257.4.L265; DOUGLAS WHJ, 1974, IN VITRO CELL DEV B, V10, P230; DOUGLAS WHJ, 1976, ENVIRON HEALTH PERSP, V16, P83, DOI 10.2307/3428588; EATON DL, 1994, TOXICOL APPL PHARM, V126, P145, DOI 10.1006/taap.1994.1100; FAVREAU LV, 1993, J BIOL CHEM, V268, P19875; GANT TW, 1988, CHEM-BIOL INTERACT, V65, P157, DOI 10.1016/0009-2797(88)90052-X; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; HAGEN TM, 1988, KIDNEY INT, V34, P74, DOI 10.1038/ki.1988.147; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1988, P NATL ACAD SCI USA, V85, P2464, DOI 10.1073/pnas.85.8.2464; KUGELMAN A, 1994, IN RPESS AM J RESPIR, V11; LEE FYF, 1989, BRIT J CANCER, V60, P291, DOI 10.1038/bjc.1989.273; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MOORE WR, 1989, P NATL ACAD SCI USA, V86, P1461, DOI 10.1073/pnas.86.5.1461; OGINO T, 1989, BIOCHIM BIOPHYS ACTA, V1006, P131, DOI 10.1016/0005-2760(89)90334-2; OHNO K, 1990, BIOCHEM BIOPH RES CO, V168, P551, DOI 10.1016/0006-291X(90)92356-5; POOT M, 1987, EUR J BIOCHEM, V162, P287, DOI 10.1111/j.1432-1033.1987.tb10598.x; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEELIG GF, 1984, J BIOL CHEM, V259, P9345; SHI M, 1993, FREE RADICAL BIO MED, V15, P57, DOI 10.1016/0891-5849(93)90125-E; SHI MM, 1994, IN PRESS AM J PHYSL, V267; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TALALAY P, 1988, P NATL ACAD SCI USA, V85, P8261, DOI 10.1073/pnas.85.21.8261; WOODS JS, 1992, ARCH BIOCHEM BIOPHYS, V296, P350, DOI 10.1016/0003-9861(92)90583-I; YAN N, 1990, J BIOL CHEM, V265, P1588	36	298	306	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26512	26517						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929374				2022-12-27	WOS:A1994PQ93000087
J	TZAGOLOFF, A; YUE, J; JANG, J; PAUL, MF				TZAGOLOFF, A; YUE, J; JANG, J; PAUL, MF			A NEW MEMBER OF A FAMILY OF ATPASES IS ESSENTIAL FOR ASSEMBLY OF MITOCHONDRIAL RESPIRATORY-CHAIN AND ATP-SYNTHETASE COMPLEXES IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME QH2-CYTOCHROME-C REDUCTASE; MEMBRANE SYSTEM; PUTATIVE ATPASES; GENE-EXPRESSION; YEAST REQUIRES; PROTEIN FAMILY; NUCLEAR; MUTANTS; DNA; IDENTIFICATION	Respiration-defective pet mutants of Saccharomyces cerevisiae, assigned to complementation group G25, are grossly deficient in mitochondrial respiratory and ATPase complexes. This phenotype is usually found in strains impaired in mitochondrial protein synthesis. The G25 mutants, however, synthesize all of the proteins encoded by mitochondrial DNA. The mutants are also able to import and process cytoplasmically derived subunits of these enzymes. These results are most compatible with the idea that the gene defined by G25 mutants (RCA1) codes for a protein essential for the assembly of functional respiratory and ATPase complexes. The RCA1 gene has been cloned by complementation of an rca1 mutant with a yeast genomic library. The sequence of the encoded product shows Rca1 protein to be a new member of a recently described family of ATPases. The Rca1 protein is a mitochondrial membrane protein and is the third known member of this family implicated to function in the biogenesis of mitochondria. The primary structure of Rca1 protein indicates several distinct domains in addition to the common purine nucleotide binding region shared by all members of this protein family. One, located in the amino-terminal half, contains two hydrophobic stretches of sufficient length to span a membrane lipid bilayer.			TZAGOLOFF, A (corresponding author), COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA.				NHLBI NIH HHS [R01 HL022174, HL22174] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022174, R01HL022174] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ALLISON DS, 1986, P NATL ACAD SCI USA, V83, P9011, DOI 10.1073/pnas.83.23.9011; Berden J.A., 1988, MOL BASIS BIOMEMBRAN, P195; BOTSTEIN D, 1982, MOL BIOL YEAST SACCH, P607; COSTANZO MC, 1986, EMBO J, V5, P3637, DOI 10.1002/j.1460-2075.1986.tb04693.x; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; DOUGLAS MG, 1976, P NATL ACAD SCI USA, V73, P1083, DOI 10.1073/pnas.73.4.1083; DUJON B, 1981, MOL BIOL YEAST SACCH, P506; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZOWSKA J, 1980, CELL, V22, P333, DOI 10.1016/0092-8674(80)90344-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MURTIF VL, 1985, P NATL ACAD SCI USA, V82, P5617, DOI 10.1073/pnas.82.17.5617; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; MYERS AM, 1987, J BIOL CHEM, V262, P3388; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; NOBREGA FG, 1992, EMBO J, V11, P3821, DOI 10.1002/j.1460-2075.1992.tb05474.x; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PILLAR T, 1983, J BIOL CHEM, V258, P7954; PON L, 1991, MOL CELLULAR BIOL YE, P333; PRATJE E, 1986, EMBO J, V5, P1313, DOI 10.1002/j.1460-2075.1986.tb04361.x; REPETTO B, 1991, MOL CELL BIOL, V11, P3931, DOI 10.1128/MCB.11.8.3931; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHULZE M, 1989, MOL GEN GENET, V216, P37, DOI 10.1007/BF00332228; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; ten Berge A M, 1974, Mol Gen Genet, V131, P113; THORSNESS PE, 1993, MOL CELL BIOL, V13, P5418, DOI 10.1128/MCB.13.9.5418; TOMOYASU T, 1993, J BACTERIOL, V175, P1344, DOI 10.1128/JB.175.5.1344-1351.1993; TZAGOLOFF A, 1989, EUR J BIOCHEM, V179, P365, DOI 10.1111/j.1432-1033.1989.tb14562.x; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; Tzagoloff A, 1990, Prog Nucleic Acid Res Mol Biol, V39, P129, DOI 10.1016/S0079-6603(08)60625-X; WU M, 1989, J BIOL CHEM, V264, P11122; WU M, 1987, J BIOL CHEM, V262, P12275	50	85	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26144	26151						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929327				2022-12-27	WOS:A1994PQ93000033
J	HIGAZI, AAR; BARGHOUTI, II				HIGAZI, AAR; BARGHOUTI, II			INACTIVATION OF HUMAN ANAPHYLATOXIN C5A AND C5A DES-ARG THROUGH CLEAVAGE BY THE PLASMINOGEN-ACTIVATOR ACTIVITY OF A HUMAN FIBROSARCOMA CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY-CHROMATOGRAPHY; EXTRACELLULAR-MATRIX; PERITONEAL-FLUID; TUMOR INVASION; UROKINASE; PURIFICATION; CANCER; DIFFERENTIATION; FIBRINOLYSIS; DEGRADATION	The HT-1080 human fibrosarcoma cell line exhibited a plasminogen-dependent ability to inactivate recombinant anaphylatoxin C5a or zymosan-activated serum. The inactivation was obtained at physiological levels of both plasminogen (2 mu M) and C5a (1-5 nM). Inactivated C5a and zymosan activated serum were no longer able to induce chemotaxis and degranulation of neutrophils. Inactivation of C5a paralleled the emergence of plasmin activity, assayed by cleavage of the synthetic substrate H-D-valyl-L-leucyl-L-lysine-p-nitroanilide (S-2251). Both C5a inactivation and S-2251 cleavage were inhibited by the plasmin inhibitor alpha(2)-antiplasmin, the urokinase inhibitor amiloride, and by anti-urokinase antibodies. In a cell-free system, inactivation of C5a was shown to depend on the simultaneous presence of urokinase and plasminogen and was inhibited by alpha(2)-antiplasmin and by anti-urokinase antibodies. SDS-polyacrylamide electrophoresis demonstrated the cleavage of C5a by the plasminogen activation system and inhibition of the cleavage by amiloride. Amino acid sequencing of the band corresponding to the C5a degradation product revealed that C5a was cleaved at positions Lys(14)-His(15) and Arg(40)-Ile(41); cleavage at position Arg(40)-Ile(41) seemed to be responsible for the loss of activity. Since neoplastic cells extensively produce and exhibit plasminogen activator activity, the present observations suggest that plasminogen activation may, by inactivation of C5a, reduce the anti-tumor immune response and support the immunological escape phenomenon of tumors.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem	HIGAZI, AAR (corresponding author), HADASSAH UNIV HOSP,DEPT CLIN BIOCHEM,POB 12000,IL-91120 JERUSALEM,ISRAEL.							AYESH SK, 1990, J IMMUNOL, V144, P3066; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; DAMERAU B, 1986, MOL IMMUNOL, V23, P433, DOI 10.1016/0161-5890(86)90141-0; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; ELLIS V, 1991, J BIOL CHEM, V266, P12752; FAUVE RM, 1974, P NATL ACAD SCI USA, V71, P4052, DOI 10.1073/pnas.71.10.4052; FERNANDEZ HN, 1978, J IMMUNOL, V120, P109; Fidler I J, 1978, Adv Cancer Res, V28, P149, DOI 10.1016/S0065-230X(08)60648-X; GERARD C, 1985, J BIOL CHEM, V260, P2613; GERARD NP, 1989, J BIOL CHEM, V264, P1760; GOLDSTEIN IM, 1992, INFLAMMATION BASIC P, P55; HART DA, 1992, FIBRINOLYSIS, V6, P11, DOI 10.1016/0268-9499(92)90087-X; HUGLI TE, 1984, SPRINGER SEMIN IMMUN, V7, P193; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAHONEY MJ, 1962, CANCER RES, V22, P334; MARKUS G, 1984, SEMIN THROMB HEMOST, V10, P61, DOI 10.1055/s-2007-1004408; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATZNER Y, 1984, J LAB CLIN MED, V103, P227; MAYER M, 1990, CLIN BIOCHEM, V23, P197, DOI 10.1016/0009-9120(90)90601-P; MOORE M, 1985, IMMUNOLOGY; MULLINS DE, 1983, BIOCHIM BIOPHYS ACTA, V695, P177, DOI 10.1016/0304-419X(83)90011-2; NEUMAN T, 1989, J NEUROSCI RES, V23, P274, DOI 10.1002/jnr.490230305; NIELSEN LS, 1982, BIOCHEMISTRY-US, V21, P6410, DOI 10.1021/bi00268a014; OSSOWSKI L, 1991, CANCER RES, V51, P274; PAULI BU, 1983, CANCER METAST REV, V2, P129, DOI 10.1007/BF00048966; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; REICH R, 1988, CANCER RES, V48, P3307; RIJKEN DC, 1981, J BIOL CHEM, V256, P7035; SAKSELA O, 1985, BIOCHIM BIOPHYS ACTA, V823, P35, DOI 10.1016/0304-419X(85)90014-9; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; VERSTRAETE M, 1986, BLOOD, V67, P1529; WALLEN P, 1978, PROGR CHEM FIBRINOLY, V3, P167; WARD PA, 1970, J IMMUNOL, V104, P535; WILSON EL, 1983, BLOOD, V61, P568; WOOLLEY DE, 1984, CANCER METAST REV, V3, P361, DOI 10.1007/BF00051460; WRIGHT DG, 1977, J IMMUNOL, V119, P1068; WUN TC, 1982, J BIOL CHEM, V257, P7262	40	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25529	25533						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929254				2022-12-27	WOS:A1994PQ49100047
J	PATTERTON, D; SHI, YB				PATTERTON, D; SHI, YB			THYROID HORMONE-DEPENDENT DIFFERENTIAL REGULATION OF MULTIPLE ARGINASE GENES DURING AMPHIBIAN METAMORPHOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS; NUCLEOTIDE-SEQUENCE; LIVER ARGINASE; MAMMARY-GLAND; RECEPTOR; TISSUES; EXPRESSION; LARVAL; CDNA	We have cloned three nonhepatic arginase genes in Xenopus laevis. The deduced amino acid sequences of the three arginases are almost identical and share about 60% identity with mammalian as well as Xenopus liver arginase, Both the liver and nonhepatic arginase genes are activated early during embryogenesis. The liver arginase gene is strongly expressed in tadpole liver, but weakly in other tissues. In contrast, the nonhepatic arginase genes have the strongest expression in the tadpole tail. During metamorphosis, the liver and nonhepatic arginase genes show distinct regulation patterns. In the intestine, both types of arginase genes are activated during the remodeling period. In the tail, the liver arginase gene is activated during tail resorption, whereas the nonhepatic ones are highly expressed throughout all stages examined. Finally, in the hindlimb, the liver arginase is up-regulated slightly during development, whereas the nonhepatic ones have low levels of expression until the end of metamorphosis. During 3,5,3'-L-triiodothyronine (T-3)-induced metamorphosis, the nonhepatic arginase genes are activated very quickly, whereas the liver arginase gene is a late T-3 response gene. These differential regulation patterns during normal and T-3-induced metamorphosis suggest potential functions for the arginases during tissue remodeling.	NICHHD, MOLEC EMBRYOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Shi, Yun-Bo/0000-0002-6330-0639				COHEN PP, 1970, SCIENCE, V168, P533, DOI 10.1126/science.168.3931.533; DIMITROV S, 1993, DEV BIOL, V160, P214, DOI 10.1006/dbio.1993.1299; DODD MHI, 1976, PHYSIOLOGY AMPHIBIA, V3, P467; GLASS RD, 1973, J BIOL CHEM, V248, P5785; HARAGUCHI Y, 1987, P NATL ACAD SCI USA, V84, P412, DOI 10.1073/pnas.84.2.412; HELBING C, 1992, DEV GENET, V13, P289, DOI 10.1002/dvg.1020130406; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; HERZFELD A, 1976, BIOCHEM J, V153, P469, DOI 10.1042/bj1530469; ISHIZUYAOKA A, 1987, ANAT ANZEIGER, V164, P81; JACKSON MJ, 1986, ANNU REV GENET, V20, P431, DOI 10.1146/annurev.ge.20.120186.002243; KANAMORI A, 1992, J BIOL CHEM, V267, P739; KAWAHARA A, 1991, DEVELOPMENT, V112, P933; KAWAMOTO S, 1987, J BIOL CHEM, V262, P6280; LELOUP J, 1977, CR ACAD SCI D NAT, V284, P2261; MARSHALL JA, 1978, J EXP ZOOL, V203, P31, DOI 10.1002/jez.1402030104; MCAVOY JW, 1977, J EXP ZOOL, V202, P129, DOI 10.1002/jez.1402020115; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; PATTERTON D, 1994, IN PRESS DEV BIOL; SCHNEIDER MJ, 1991, MOL ENDOCRINOL, V5, P201, DOI 10.1210/mend-5-2-201; SHI YB, 1990, GENE DEV, V4, P1107, DOI 10.1101/gad.4.7.1107; SHI YB, 1994, DEV BIOL, V161, P48, DOI 10.1006/dbio.1994.1006; SHI YB, 1993, J BIOL CHEM, V268, P20312; SHI YB, 1994, BBA-GENE STRUCT EXPR, V1217, P227, DOI 10.1016/0167-4781(94)90042-6; SHI YB, 1994, TRENDS ENDOCRIN MET, V5, P14, DOI 10.1016/1043-2760(94)90116-3; SKRZYPEKOSIECKA I, 1983, ACTA BIOCHIM POL, V30, P83; Smith-Gill S.J., 1981, P491; SPECTOR EB, 1983, PEDIATR RES, V17, P941, DOI 10.1203/00006450-198312000-00003; STEWART JA, 1977, J NEUROCHEM, V29, P657, DOI 10.1111/j.1471-4159.1977.tb07783.x; SUMRADA RA, 1984, J BACTERIOL, V160, P1078, DOI 10.1128/JB.160.3.1078-1087.1984; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TAKIGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8789, DOI 10.1093/nar/16.18.8789; WEBER R, 1967, BIOCHEMISTRY ANIMAL, V2, P227; WEISS JB, 1984, CONNECTIVE TISSUE MA, P17; XU QL, 1993, EUR J BIOCHEM, V211, P891, DOI 10.1111/j.1432-1033.1993.tb17622.x; YAOITA Y, 1990, GENE DEV, V4, P1917, DOI 10.1101/gad.4.11.1917; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; YIP MCM, 1972, BIOCHEM J, V127, P893, DOI 10.1042/bj1270893; YOSHIZATO K, 1989, INT REV CYTOL, V119, P97	38	43	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25328	25334						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929226				2022-12-27	WOS:A1994PQ49100017
J	SCHMITZ, ML; SILVA, MAD; ALTMANN, H; CZISCH, M; HOLAK, TA; BAEUERLE, PA				SCHMITZ, ML; SILVA, MAD; ALTMANN, H; CZISCH, M; HOLAK, TA; BAEUERLE, PA			STRUCTURAL AND FUNCTIONAL-ANALYSIS OF THE NF-KAPPA-B P65 C-TERMINUS - AN ACIDIC AND MODULAR TRANSACTIVATION DOMAIN WITH THE POTENTIAL TO ADOPT AN ALPHA-HELICAL CONFORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SUBUNIT; TUMOR-NECROSIS-FACTOR; TRANSCRIPTIONAL ACTIVATION; ONCOGENE PRODUCT; V-REL; PROTEIN; GAL4; VP16; CLONING; EXPRESSION	The p65 subunit of the NF-kappa B transcription factor contains in its C-terminal 120 amino acids at least two transcription activation domains. One domain (TA(1)) is contained within only the 30 C-terminal amino acids. Structural studies employing CD and NMR spectroscopy revealed that the TA(1) domain is unstructured. NMR analysis of a protein corresponding to the C-terminal 123 amino acids also showed a random coil conforma tion. However, a portion of TA(1) was found to adopt an alpha-helical conformation in the presence of hydrophobic solvents. Transcriptional analysis of point mutants revealed the functional importance of two evolutionary conserved sequence repeats, which are located in the conditionally alpha-helical region of TA(1). These repeats acted synergistically in transcription activation. The inhibitory effect of some mutants indicated secondary structure constraints on TA(1) in intact cells. Inverting the sequence of two acidic activation domains significantly reduced their transactivating potential, suggesting that amino acid composition is not solely essential for activity; a defined primary structure is necessary as well. Acidic sequence motifs related in primary structure and squelching activity to those of TA(1) are present in the activation domains of VP16, c-Rel, and several other transcription factors. We propose a model suggesting that primarily unstructured acidic activation domains can adopt a secondary structure upon contacting their target molecules by an ''induced fit'' mechanism.	UNIV MUNICH,INST BIOCHEM,D-82152 MARTINSRIED,GERMANY; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	University of Munich; Max Planck Society	SCHMITZ, ML (corresponding author), UNIV FREIBURG,INST BIOCHEM,HERMANN HERDER STR 7,D-79104 FREIBURG,GERMANY.		Silva Ferraz, Marcos/X-9172-2018; Silva, Marcos/C-7260-2015; Schmitz, M. Lienhard/D-9328-2017; Ferraz, Marcos A.S. Silva/ABG-4813-2020	Silva Ferraz, Marcos/0000-0001-6898-9132; Schmitz, M. Lienhard/0000-0002-6984-7192; Ferraz, Marcos A.S. Silva/0000-0001-6898-9132				ALTMANN H, 1994, P NATL ACAD SCI USA, V91, P3901, DOI 10.1073/pnas.91.9.3901; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; EBINA Y, 1983, J BIOL CHEM, V258, P3258; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GOLEMIS E, 1993, MOL CELL BIOL, V12, P3006; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HARDWICK JM, 1992, J VIROL, V66, P5500, DOI 10.1128/JVI.66.9.5500-5508.1992; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hochuli E, 1990, Genet Eng (N Y), V12, P87; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KING DS, 1990, INT J PEPT PROT RES, V36, P255; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OEHLER T, 1992, MOL CELL BIOL, V12, P5508, DOI 10.1128/MCB.12.12.5508; OHARE P, 1992, BIOCHEMISTRY-US, V31, P4150, DOI 10.1021/bi00131a035; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WUTHRICH K, 1982, J MOL BIOL, V155, P311, DOI 10.1016/0022-2836(82)90007-9; Wuthrich K., 1986, NMR PROTEINS NUCL AC	60	140	144	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25613	25620						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929265				2022-12-27	WOS:A1994PQ49100060
J	MULLIN, NP; HALL, KT; TAYLOR, ME				MULLIN, NP; HALL, KT; TAYLOR, ME			CHARACTERIZATION OF LIGAND-BINDING TO A CARBOHYDRATE-RECOGNITION DOMAIN OF THE MACROPHAGE MANNOSE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEINS; RAT; LECTIN; GLYCOPROTEINS; POLYPEPTIDE; CALCIUM	The extracellular portion of the macrophage mannose receptor, an endocytic receptor involved in clearance of glycoconjugates, contains eight domains related to the Ca2+-dependent carbohydrate-recognition domains (CRDs) of other C-type animal lectins. The characteristics of ligand binding to an expressed form of one of these CRDs (CRD-4) have been investigated. The expressed domain was found to be a monomer in solution. Results of a solid phase binding assay and a protease resistance assay show that CRD-4 of the mannose recep tor undergoes a conformational rearrangement upon binding of Ca2+, correlating with its ability to bind sugar. CRD-4 requires two Ca2+ for sugar binding, even though sequence comparisons with other C-type CRDs suggested that it might bind only one Ca2+. The results are consistent with a ternary complex being formed between CRD-4, sugar, and Ca2+ as is seen in the crystal structure of the CRD of rat mannose-binding protein in complex with an oligosaccharide. The stability of Ca2+ binding is shown to be pH-dependent, a result that is pertinent to release of ligand by the receptor in the endosome. However, CRD-4 retains sugar binding activity at a lower pH than does the whole receptor, suggesting that the conformational change in this CRD alone may not be sufficient to allow release of ligand in the endosomes.	UNIV OXFORD, DEPT BIOCHEM, INST GLYCOBIOL, OXFORD OX1 3QU, ENGLAND	University of Oxford				Mullin, Nicholas/0000-0003-4802-440X				AGRWAL N, 1993, J BIOL CHEM, V268, P14932; ANDERSEN TT, 1982, J BIOL CHEM, V257, P8036; BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; DRICKAMER K, 1981, J BIOL CHEM, V256, P5827; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; GHRAYEB J, 1984, EMBO J, V3, P2437, DOI 10.1002/j.1460-2075.1984.tb02151.x; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; IOBST ST, 1994, J BIOL CHEM, V269, P15505; JERNIGAN R, 1994, CURR OPIN STRUC BIOL, V4, P256, DOI 10.1016/S0959-440X(94)90317-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENNARTZ MR, 1987, J BIOL CHEM, V262, P9942; LOEB JA, 1988, J BIOL CHEM, V263, P9752; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; NAYAL M, 1994, P NATL ACAD SCI USA, V91, P817, DOI 10.1073/pnas.91.2.817; OTTER M, 1991, J BIOL CHEM, V266, P13931; SCHEIN CH, 1988, BIO-TECHNOL, V6, P291, DOI 10.1038/nbt0388-291; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; STAHL PD, 1990, AM J RESP CELL MOL, V2, P317, DOI 10.1165/ajrcmb/2.4.317; STAHL PD, 1980, TRENDS BIOCHEM SCI, V5, P194, DOI 10.1016/0968-0004(80)90238-8; TAKAGI H, 1988, BIO-TECHNOL, V6, P948, DOI 10.1038/nbt0888-948; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WILLIAMS MJ, 1994, J MOL BIOL, V235, P1302, DOI 10.1006/jmbi.1994.1083	32	54	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28405	28413						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961781				2022-12-27	WOS:A1994PV77200093
J	TIAN, SS; ZINN, K				TIAN, SS; ZINN, K			AN ADHESION MOLECULE-LIKE PROTEIN THAT INTERACTS WITH AND IS A SUBSTRATE FOR A DROSOPHILA RECEPTOR-LINKED PROTEIN-TYROSINE-PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH CONE MEMBRANES; NERVOUS-SYSTEM AXONS; T-CELL ACTIVATION; EMBRYONIC CNS; FASCICLIN-III; GENE; KINASE; MELANOGASTER; SUBSET; LOCALIZATION	Receptor-Linked protein tyrosine phosphatases (R-PTPs) are a large and diverse group of transmembrane signaling molecules. In Drosophila, four R-PTPs are localized to central nervous system axons in the embryo and may participate in assembly of the central nervous system axon array. In this paper, we identify and characterize a transmembrane glycoprotein, gp150, that selectively interacts with the catalytic domain of the axonal R-PTP DPTP10D. gp150 does not bind to a cysteine-to-serine active site mutant, and binding is inhibited by vanadate, suggesting that it interacts with the active site. It has an extracellular domain composed of 18 leucine-rich repeats, which are found in many adhesion molecules. Its short cytoplasmic domain contains 4 tyrosine residues in sequence contexts that suggest that they could interact with SH2 domain-containing effector molecules. The overall organization of the tyrosine motifs resembles that of antigen recognition activation motif signaling elements from receptors in the vertebrate immune system. The cytoplasmic domain of gp150 is a good substrate for v-Abl tyrosine kinase, and phosphorylated gp150 can be dephosphorylated efficiently in vitro by DPTP10D. We suggest that DPTP10D may function in vivo to regulate phosphorylation of gp150 and thereby control its interactions with downstream effecters.	CALTECH, DEPT BIOL 21676, PASADENA, CA 91125 USA	California Institute of Technology					NINDS NIH HHS [NS28182] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028182] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BOGAERT T, 1987, CELL, V51, P929, DOI 10.1016/0092-8674(87)90580-0; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHANG Z, 1993, DEV BIOL, V160, P315, DOI 10.1006/dbio.1993.1310; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; DESAI CJ, 1994, IN PRESS J NEUROSCI; ELDON E, 1994, DEVELOPMENT, V120, P885; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; HARIHARAN IK, 1991, P NATL ACAD SCI USA, V88, P11266, DOI 10.1073/pnas.88.24.11266; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; KEITH FJ, 1990, EMBO J, V9, P4299, DOI 10.1002/j.1460-2075.1990.tb07878.x; KOLANUS W, 1992, EMBO J, V11, P4861, DOI 10.1002/j.1460-2075.1992.tb05592.x; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LEPTIN M, 1989, CELL, V56, P401, DOI 10.1016/0092-8674(89)90243-2; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MCLAUGHLIN S, 1993, J BIOL CHEM, V268, P6839; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; OON SH, 1993, J BIOL CHEM, V268, P23964; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAMBROOK J, 1989, MOL CONING LABORATOR; SAP J, 1994, MOL CELL BIOL, V14, P1; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; WALTON KM, 1993, NEURON, V11, P387, DOI 10.1016/0896-6273(93)90193-U; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; YANG XO, 1992, SCIENCE, V257, P680, DOI 10.1126/science.1496382; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0; Zinn Kai, 1993, Seminars in Cell Biology, V4, P397, DOI 10.1006/scel.1993.1047	54	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28478	28486						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961789				2022-12-27	WOS:A1994PV77200103
J	PAILLART, JC; MARQUET, R; SKRIPKIN, E; EHRESMANN, B; EHRESMANN, C				PAILLART, JC; MARQUET, R; SKRIPKIN, E; EHRESMANN, B; EHRESMANN, C			MUTATIONAL ANALYSIS OF THE BIPARTITE DIMER LINKAGE STRUCTURE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GENOMIC RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLONEY MURINE LEUKEMIA; PACKAGING SIGNAL; CIS ELEMENTS; VIRAL-RNA; DIMERIZATION; PROTEIN; HIV-1; SEQUENCES; RECOMBINATION; RETROVIRUSES	The genome of all retroviruses consists in two homologous RNA molecules associated near their 5' end in a region called the dimer linkage structure. Dimerization of genomic RNA is thought to be important for several functions of the retroviral cycle such as encapsidation, reverse transcription, and translation. In human immunodeficiency virus type 1 (HIV-1), a region downstream of the splice donor site was initially postulated to mediate dimerization. However, we recently showed that the dimerization initiation site is located upstream of the splice donor site and suggested that dimerization may initiate through a loop-loop interaction. Here, we show that single base mutations in the palindromic loop of the dimerization initiation site completely abolish dimerization, while introduction of compensatory mutations restores the process. Furthermore, two single nucleotide mutants that are unable to form homodimers efficiently codimerize, while the wild type RNA and the compensatory mutant, which both form homodimers, are unable to codimerize. These results unambiguously prove the interaction between the palindromic loops of each monomer. By contrast, none of the deletions that we introduced downstream of the splice donor site abolishes dimerization. However, deletions of two purine tracts located in the vicinity of the initiation codon of the gag gene significantly decrease the thermal stability of the HIV-1 RNA dimer.	INST BIOL MOLEC & CELLULAIRE, CNRS, UPR 9002, F-67084 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Paillart, Jean-Christophe/A-4171-2010	Paillart, Jean-Christophe/0000-0003-1647-8917; Marquet, Roland/0000-0002-4209-3976				ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; ALIZON M, 1986, CELL, V46, P63, DOI 10.1016/0092-8674(86)90860-3; AWANG G, 1993, BIOCHEMISTRY-US, V32, P11453, DOI 10.1021/bi00093a024; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; BENDER W, 1976, CELL, V7, P595, DOI 10.1016/0092-8674(76)90210-5; BENDER W, 1978, J VIROL, V25, P888, DOI 10.1128/JVI.25.3.888-896.1978; BIETH E, 1990, NUCLEIC ACIDS RES, V18, P119, DOI 10.1093/nar/18.1.119; CANAANI E, 1973, P NATL ACAD SCI USA, V70, P401, DOI 10.1073/pnas.70.2.401; CLAVEL F, 1990, J VIROL, V64, P5230, DOI 10.1128/JVI.64.10.5230-5234.1990; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; EHRESMANN B, 1992, B I PASTEUR, V90, P109; FU W, 1994, J VIROL, V68, P5013, DOI 10.1128/JVI.68.8.5013-5018.1994; FU W, 1993, J VIROL, V67, P5443, DOI 10.1128/JVI.67.9.5443-5449.1993; HARRISON GP, 1992, J VIROL, V66, P4144, DOI 10.1128/JVI.66.7.4144-4153.1992; HAYASHI T, 1993, FEBS LETT, V327, P213, DOI 10.1016/0014-5793(93)80172-Q; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; LEVER A, 1989, J VIROL, V63, P4085, DOI 10.1128/JVI.63.9.4085-4087.1989; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; Maniatis T., 1982, MOL CLONING; MARQUET R, 1994, NUCLEIC ACIDS RES, V22, P145, DOI 10.1093/nar/22.2.145; MARQUET R, 1991, NUCLEIC ACIDS RES, V19, P2349, DOI 10.1093/nar/19.9.2349; MURTI KG, 1981, J VIROL, V37, P411, DOI 10.1128/JVI.37.1.411-419.1981; PRATS AC, 1991, NUCLEIC ACIDS RES, V19, P3533, DOI 10.1093/nar/19.13.3533; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; PRATS AC, 1990, J VIROL, V64, P774, DOI 10.1128/JVI.64.2.774-783.1990; RIPPE K, 1992, EMBO J, V11, P3777, DOI 10.1002/j.1460-2075.1992.tb05463.x; ROY C, 1990, NUCLEIC ACIDS RES, V18, P7287, DOI 10.1093/nar/18.24.7287; SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945; SUNDQUIST WI, 1993, P NATL ACAD SCI USA, V90, P3393, DOI 10.1073/pnas.90.8.3393; TEMIN HM, 1991, TRENDS GENET, V7, P71, DOI 10.1016/0168-9525(91)90048-U; WEISS S, 1993, NUCLEIC ACIDS RES, V21, P4879, DOI 10.1093/nar/21.21.4879	31	190	191	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27486	27493						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961663				2022-12-27	WOS:A1994PV77100053
J	PALEJWALA, VA; PANDYA, GA; BHANOT, OS; SOLOMON, JJ; MURPHY, HS; DUNMAN, PM; HUMAYUN, MZ				PALEJWALA, VA; PANDYA, GA; BHANOT, OS; SOLOMON, JJ; MURPHY, HS; DUNMAN, PM; HUMAYUN, MZ			UVM, AN ULTRAVIOLET-INDUCIBLE RECA-INDEPENDENT MUTAGENIC PHENOMENON IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC ETHENOCYTOSINE; EXOCYCLIC DNA ADDUCTS; M13 VIRAL-DNA; SOS MUTAGENESIS; VINYL-CHLORIDE; LIGHT MUTAGENESIS; CYCLOBUTANE DIMER; POLYMERASE-II; 2-STEP MODEL; POLB GENE	Most mutagenic DNA lesions are noninstructive in the sense that template instruction is either missing or inaccessible during DNA replication, leading to replication arrest. According to the SOS hypothesis, arrested replication induces the expression of SOS factors that force replication past stalled sites at the cost of mutagenesis. We have recently shown that prior UV irradiation of Delta recA cells, in which the SOS pathway does not function, enhances mutagenesis at an ethenocytosine residue borne on a circular gapped duplex DNA vector, indicating the existence of an SOS-independent inducible mutagenic phenomenon termed UVM (UV modulation of mutagenesis). In the previous experiments, mutation fixation was expected to occur during gap-filling DNA synthesis. To test whether UVM is observable during normal replication by DNA polymerase III, we have examined mutagenesis at an epsilon C residue borne on M13 single-stranded DNA. By analyzing mutation frequency and specificity using a multiplex sequence assay, we now show that UVM is observable in UV-irradiated recA(+), and in Delta recA cells. These data indicate that UV irradiation induces a previously unrecognized mutagenic mechanism in Escherichia coli, and that this mechanism is manifested during gap-filling DNA synthesis as well as during normal DNA replication.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT MICROBIOL & MOLEC GENET,NEWARK,NJ 07103; NYU,SCH MED,DEPT MICROBIOL & MOLEC GENET,AZ LANZA RES LABS,TUXEDO PK,NY 10987	Rutgers State University New Brunswick; Rutgers State University Medical Center; New York University					NATIONAL CANCER INSTITUTE [R01CA047234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000260, R01ES005694] Funding Source: NIH RePORTER; NCI NIH HHS [CA47234] Funding Source: Medline; NIEHS NIH HHS [ES05694, ES00260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BANERJEE SK, 1990, J BACTERIOL, V172, P2105, DOI 10.1128/jb.172.4.2105-2112.1990; BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; BARRIO JR, 1972, BIOCHEM BIOPH RES CO, V46, P597, DOI 10.1016/S0006-291X(72)80181-5; BASU AK, 1993, BIOCHEMISTRY-US, V32, P12793, DOI 10.1021/bi00210a031; BATES H, 1991, MUTAT RES, V250, P199, DOI 10.1016/0027-5107(91)90176-O; BATES H, 1991, BIOCHIMIE, V73, P485, DOI 10.1016/0300-9084(91)90116-I; BATTISTA JR, 1990, P NATL ACAD SCI USA, V87, P7190, DOI 10.1073/pnas.87.18.7190; BHANOT OS, 1990, BIOCHEMISTRY-US, V29, P10357, DOI 10.1021/bi00497a010; BHANOT OS, 1992, NUCLEIC ACIDS RES, V20, P587, DOI 10.1093/nar/20.3.587; BONNER CA, 1990, P NATL ACAD SCI USA, V87, P7663, DOI 10.1073/pnas.87.19.7663; BRIDGES BA, 1985, P NATL ACAD SCI USA, V82, P4193, DOI 10.1073/pnas.82.12.4193; BRIDGES BA, 1984, MOL GEN GENET, V196, P364, DOI 10.1007/BF00328073; BRIDGES BA, 1992, MOL GEN GENET, V233, P331, DOI 10.1007/BF00265428; BRIDGES BA, 1985, MUTAT RES, V150, P133, DOI 10.1016/0027-5107(85)90110-1; CHEN H, 1989, J BIOL CHEM, V264, P20591; COHENFIX O, 1992, P NATL ACAD SCI USA, V89, P3300, DOI 10.1073/pnas.89.8.3300; DEFAIS M, 1971, VIROLOGY, V43, P495, DOI 10.1016/0042-6822(71)90321-7; DONNELLY CE, 1992, J BACTERIOL, V174, P3133, DOI 10.1128/jb.174.10.3133-3139.1992; DORPER T, 1983, NUCLEIC ACIDS RES, V11, P2575, DOI 10.1093/nar/11.9.2575; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; GREEN T, 1978, CHEM-BIOL INTERACT, V22, P211, DOI 10.1016/0009-2797(78)90126-6; HORSFALL MJ, 1994, J MOL BIOL, V235, P465, DOI 10.1006/jmbi.1994.1006; IWASAKI H, 1990, J BACTERIOL, V172, P6268, DOI 10.1128/jb.172.11.6268-6273.1990; JACOBSEN JS, 1990, BIOCHEMISTRY-US, V29, P496, DOI 10.1021/bi00454a025; JACOBSEN JS, 1989, GENETICS, V121, P213; KUSMIEREK JT, 1982, BIOCHEMISTRY-US, V21, P5717, DOI 10.1021/bi00265a050; LASPIA MF, 1989, J MOL BIOL, V207, P53, DOI 10.1016/0022-2836(89)90440-3; LEITHAUSER MT, 1990, CARCINOGENESIS, V11, P463, DOI 10.1093/carcin/11.3.463; LIU SK, 1990, J BACTERIOL, V172, P6135, DOI 10.1128/jb.172.10.6135-6138.1990; LIVNEH Z, 1993, CRIT REV BIOCHEM MOL, V28, P465, DOI 10.3109/10409239309085136; Model P., 1988, BACTERIOPHAGES, P375; MURLI S, 1993, CURR OPIN GENET DEV, V3, P719, DOI 10.1016/S0959-437X(05)80089-9; Narang S A, 1980, Methods Enzymol, V65, P610; PALEJWALA VA, 1993, BIOCHEMISTRY-US, V32, P4105, DOI 10.1021/bi00066a036; PALEJWALA VA, 1993, BIOCHEMISTRY-US, V32, P4112, DOI 10.1021/bi00066a037; PALEJWALA VA, 1991, BIOCHEMISTRY-US, V30, P8736, DOI 10.1021/bi00100a004; Radman M, 1974, MOL ENV ASPECTS MUTA, P128; Radman M., 1975, MOL MECHANISMS REPAI, P355; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; SAHASRABUDHE SR, 1991, GENETICS, V129, P981; SAMBAMURTI K, 1988, GENETICS, V120, P863; SIMHA D, 1991, BIOCHEMISTRY-US, V30, P8727, DOI 10.1021/bi00100a003; TESSMAN I, 1991, MOL GEN GENET, V227, P144, DOI 10.1007/BF00260719; TESSMAN I, 1992, P NATL ACAD SCI USA, V89, P1159, DOI 10.1073/pnas.89.4.1159; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WALKER GC, 1987, ESCHERICHIA COLI SAL, P1346; WEIGLE JJ, 1953, P NATL ACAD SCI USA, V39, P628, DOI 10.1073/pnas.39.7.628; WITKIN EM, 1991, BIOCHIMIE, V73, P133, DOI 10.1016/0300-9084(91)90196-8; WITKIN EM, 1976, BACTERIOL REV, V40, P869, DOI 10.1128/MMBR.40.4.869-907.1976	49	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27433	27440						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961656				2022-12-27	WOS:A1994PV77100046
J	RAMAN, B; RAO, CM				RAMAN, B; RAO, CM			CHAPERONE-LIKE ACTIVITY AND QUATERNARY STRUCTURE OF ALPHA-CRYSTALLIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; CALF-LENS; B-CRYSTALLIN; MOLECULAR CHAPERONE; GAMMA-CRYSTALLIN; CATARACT FORMATION; LIGHT-SCATTERING; CONFORMATION; EXPRESSION; STABILITY	alpha-Crystallin has been shown to function as a molecular chaperone in preventing thermal aggregation of crystallins and other proteins. The molecular mechanism of this protection is not yet clear. gamma-Crystallin aggregates upon exposure to UV light. We have investigated the effect of the presence of alpha-crystallin in the photoaggregation process and find that alpha-crystallin does not prevent photoaggregation at low temperatures. The protection starts around 30 degrees C and steeply increases with temperature. The plot of protection ability versus temperature is sigmoidal, indicating a structural transition. Perturbation of the quaternary structure of alpha by non-thermal mode, such as 3 M urea, also results in enhanced protection. Pyrene, a hydrophobic fluorophore, is sparingly soluble in water. alpha-Crystallin enhances the solubility of pyrene by severalfold. Temperature dependence of this solubilization shows a transition around 30 degrees C (another at about 50 degrees C). Fluorescence intensity ratio of third and first peaks of pyrene emission (I-3/I-1,), indicative of hydrophobicity of the reporting area, also shows similar transitions suggesting enhanced hydrophobicity Gel filtration experiments of irradiated samples indicate the complex formation between gamma- and alpha-crystallins. alpha-Crystallin does not prevent cold precipi tation of gamma-crystallin. On the basis of these results, we hypothesize that alpha-crystallin prevents aggregation of non-native structures by providing appropriately placed hydrophobic surfaces. A structural transition above 30 degrees C enhances the protective ability, perhaps by increasing or reorganizing the hydrophobic surfaces. A similar temperature dependence has been reported for GroEL. Whether a structural switch, either activated by temperature, solvent conditions, or small molecule binding, forms a part of the general mechanism of chaperone activity needs to be investigated.	CTR CELLULAR & MOLEC BIOL,HYDERABAD 500007,ANDHRA PRADESH,INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)								ANDLEY UP, 1988, CURR EYE RES, V7, P571, DOI 10.3109/02713688809031813; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; CHAKRABARTI B, 1986, J INDIAN CHEM SOC, V63, P131; CLARK JI, 1980, BIOCHEM BIOPH RES CO, V95, P482, DOI 10.1016/0006-291X(80)90763-9; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; De Jong W.W., 1981, MOL CELLULAR BIOL EY, P221, DOI DOI 10.1146/ANNUREV.ECOLSYS.33.020602.095451; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HANSEN JE, 1994, J BIOL CHEM, V269, P6286; HANSEN JE, 1993, J BIOL CHEM, V268, P21632; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HUBBARD TJP, 1991, PROTEIN ENG, V4, P711, DOI 10.1093/protein/4.7.711; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P1732; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MANDAL K, 1988, PHOTOCHEM PHOTOBIOL, V47, P583, DOI 10.1111/j.1751-1097.1988.tb08848.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MERCK KB, 1993, J BIOL CHEM, V268, P1046; NAKAJIMA A, 1976, J MOL SPECTROSC, V61, P467, DOI 10.1016/0022-2852(76)90336-2; NAKAJIMA A, 1976, J LUMIN, V11, P429, DOI 10.1016/0022-2313(76)90027-2; RAO CM, 1994, INVEST OPHTH VIS SCI, V35, P1905; RAO CM, 1993, INVEST OPHTH VIS SCI, V34, P988; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; SIEZEN RJ, 1978, EUR J BIOCHEM, V91, P387, DOI 10.1111/j.1432-1033.1978.tb12691.x; SIEZEN RJ, 1980, EUR J BIOCHEM, V111, P435, DOI 10.1111/j.1432-1033.1980.tb04958.x; SIEZEN RJ, 1978, EUR J BIOCHEM, V91, P397, DOI 10.1111/j.1432-1033.1978.tb12692.x; SIEZEN RJ, 1985, P NATL ACAD SCI USA, V82, P1701, DOI 10.1073/pnas.82.6.1701; SPECTOR A, 1967, J BIOL CHEM, V242, P3594; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; THOMSON JA, 1985, EXP EYE RES, V40, P393, DOI 10.1016/0014-4835(85)90152-6; THOMSON JA, 1984, J BIOL CHEM, V259, P4339; THOMSON JA, 1983, EXP EYE RES, V37, P367, DOI 10.1016/0014-4835(83)90173-2; VANDENOETELAAR PJM, 1985, J BIOL CHEM, V260, P4030; WALKER ML, 1989, EXP EYE RES, V48, P375, DOI 10.1016/S0014-4835(89)80006-5; WALSH MT, 1991, J BIOL CHEM, V266, P20079	40	207	210	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27264	27268						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961635				2022-12-27	WOS:A1994PV77100020
J	FEJESTOTH, G; CHEN, WR; RUSVAI, E; MOSER, T; NARAYFEJESTOTH, A				FEJESTOTH, G; CHEN, WR; RUSVAI, E; MOSER, T; NARAYFEJESTOTH, A			DIFFERENTIAL EXPRESSION OF AE1 IN RENAL HCO3-SECRETING AND HCO3-REABSORBING INTERCALATED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-EXCHANGE PROTEIN; MESSENGER-RNA; ALKALI LOADS; H+-ATPASE; KIDNEY; CDNA; RAT; TRANSPORT; PRINCIPAL; CLONING	The cortical collecting duct of the kidney contains two types of intercalated cells that transport HCO3 in opposite directions. HCO3 reabsorption takes place in the alpha-type intercalated cells, which express a Cl/HCO3 exchanger on the basolateral membrane. This exchanger is the product of the anion exchanger 1 (AE1) or band 3 gene. HCO3 secretion occurs in the beta-intercalated cells, which have a Cl/HCO3 exchanger on the apical membrane. Based on studies in an immortalized cell line, recently it was proposed that the apical anion exchanger of beta-intercalated cells is also AE1 (van Adelsberg, J. S., Edwards, J. C., and Al-Awqati, Q. (1993) J. Biol. Chem. 268, 11283-11289). In the present study we reinvestigated this issue by determining the distribution of AE1 mRNA and protein in the two intercalated cell types using cells freshly isolated from the native epithelium. Using quantitative reverse transcriptase polymerase chain reaction, we found that alpha-intercalated cells, isolated from rabbit kidney by fluorescence-activated cell sorting, have high levels of AE1 mRNA, whereas beta-intercalated cells express very low levels. The ratio of AE1 mRNA levels in alpha- versus beta-intercalated cells averaged 10.1 +/- 2.6. In addition, metabolic acidosis increased the levels of AE1 mRNA by 3-5-fold in cortical collecting duct cells. This difference was confirmed by Northern blotting. Western blotting using an antibody against rabbit AE1 revealed a major immunoreactive product with a molecular weight of similar to 110 kDa in cortical collecting duct cells. Deglycosylation reduced the size of the immunoreactive product to similar to 90 kDa, which is compatible with the presence of a truncated form of AE1. Metabolic acidosis increased the intensity of the AE1 immunoreactive band. The level of AE1-immunoreactive protein was significantly higher in alpha-intercalated cells than in beta-intercalated cells. In aggregate, these data provide evidence for the differential expression of AE1 in HCO3-reabsorbing versus HCO, secreting renal intercalated cells both at the mRNA and at the protein level. These results give no support to the concept that AE1 functions both as a basolateral and an apical anion exchanger in cortical collecting duct cells.			FEJESTOTH, G (corresponding author), DARTMOUTH COLL SCH MED,DEPT PHYSIOL,LEBANON,NH 03756, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039523, R01DK045647, R01DK041841] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 45647, DK 41841, DK 39523] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPER S L, 1991, Journal of the American Society of Nephrology, V2, P693; ALPER SL, 1988, J BIOL CHEM, V263, P17092; ALPER SL, 1991, ANNU REV PHYSIOL, V53, P549, DOI 10.1146/annurev.physiol.53.1.549; Ausubel F.M., 1989, CURRENT PROTOCOLS MO, V2; BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BASTANI B, 1991, J CLIN INVEST, V88, P126, DOI 10.1172/JCI115268; BROSIUS FC, 1989, J BIOL CHEM, V264, P7784; BROWN D, 1988, NATURE, V331, P622, DOI 10.1038/331622a0; CHOW A, 1992, AM J PHYSIOL, V263, pG345, DOI 10.1152/ajpgi.1992.263.3.G345; DASILVA JCT, 1991, AM J PHYSIOL, V260, pF204, DOI 10.1152/ajprenal.1991.260.2.F204; FEJESTOTH G, 1993, PEDIATR NEPHROL, V7, P780, DOI 10.1007/BF01213359; FEJESTOTH G, 1992, P NATL ACAD SCI USA, V89, P5487, DOI 10.1073/pnas.89.12.5487; FEJESTOTH G, 1989, AM J PHYSIOL, V256, pF742, DOI 10.1152/ajprenal.1989.256.4.F742; FEJESTOTH G, 1987, AM J PHYSIOL, V253, pF1302, DOI 10.1152/ajprenal.1987.253.6.F1302; FEJESTOTH G, 1994, IN PRESS J AM SOC NE; FEJESTOTH G, 1991, J TISSUE CULT METHOD, V13, P173; HAMM LL, 1992, KIDNEY PHYSL PATHOPH, P2581; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOPITO RR, 1987, P NATL ACAD SCI USA, V84, P7149, DOI 10.1073/pnas.84.20.7149; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; MCKINNEY TD, 1977, J CLIN INVEST, V60, P766, DOI 10.1172/JCI108830; NARAYFEJESTOTH A, 1991, J TISSUE CULT METHOD, V13, P179; SCHUSTER VL, 1986, AM J PHYSIOL, V251, pC347, DOI 10.1152/ajpcell.1986.251.3.C347; SCHUSTER VL, 1991, AM J PHYSIOL, V260, pF506, DOI 10.1152/ajprenal.1991.260.4.F506; SCHUSTER VL, 1993, ANNU REV PHYSIOL, V55, P267, DOI 10.1146/annurev.ph.55.030193.001411; SCHWARTZ GJ, 1985, NATURE, V318, P368, DOI 10.1038/318368a0; TODDTURLA KM, 1993, AM J PHYSIOL, V264, pF781, DOI 10.1152/ajprenal.1993.264.5.F781; VANADELSBERG JS, 1993, J BIOL CHEM, V268, P11283	29	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26717	26721						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929405				2022-12-27	WOS:A1994PQ93100024
J	SHIBANUMA, M; MASHIMO, J; KUROKI, T; NOSE, K				SHIBANUMA, M; MASHIMO, J; KUROKI, T; NOSE, K			CHARACTERIZATION OF THE TGF-BETA-1-INDUCIBLE HIC-5 GENE THAT ENCODES A PUTATIVE NOVEL ZINC-FINGER PROTEIN AND ITS POSSIBLE INVOLVEMENT IN CELLULAR SENESCENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-BETA; TGF-BETA; MAMMALIAN-CELLS; LUNG FIBROBLASTS; II RECEPTORS; INHIBITION; EXPRESSION; TRANSCRIPTION; KINASE; DNA	Transforming growth factor (TGF) beta 1 is a potent cytokine that inhibits the growth of several types of cells. Our earlier study suggested that the mouse osteoblastic cell line, MC3T3-E1, was sensitive to growth inhibition by TGF beta 1 and that this effect was partly mediated by H2O2. To identify the molecules that participate in the negative regulation of growth by these stimuli, we carried out differential screening of cDNA libraries and isolated a set of genes induced by TGF beta 1. Among the clones isolated, one originally named tsc-5 was found to be induced by H2O2 as well as TGF beta 1. Analysis of this cDNA renamed hic (hydrogen peroxide-inducible clone)-5 suggested that Hic-5 protein has four LIM motifs, each of which contained two (or one) putative zinc fingers. The expression of hic-5 mRNA was repressed in Ki-ras-transformed mouse fibroblasts and in several cell lines established from human tumor. On the other hand, its expression was augmented in the in vitro senescent process of human diploid fibroblasts. Among the mouse organs examined, hic-5 was highly expressed in the lung and spleen. Finally, a colony formation assay using an hic-5 expression vector driven by the cytomegalovirus promoter suggested that hic-5 overexpression had a cytostatic effect on cellular growth, depending upon the cell type. Although the relationship between hic-5 function and the signal transduction pathway of TGF beta 1 remains unresolved, these results implied that hic-5 has some role in the growth-inhibitory pathway associated with in vitro senescence, and that down-regulation of hic-5 contributes to tumorigenesis.	UNIV TOKYO,INST MED SCI,DEPT CANC CELL RES,MINATO KU,TOKYO 108,JAPAN	University of Tokyo	SHIBANUMA, M (corresponding author), SHOWA UNIV,SCH PHARMACEUT SCI,DEPT MICROBIOL,SHINAGAWA KU,HATANODAI 1-5-8,TOKYO 142,JAPAN.		Kuroki, Toshio/A-9500-2011	Kuroki, Toshio/0000-0001-6369-4351				ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BOS JL, 1989, CANCER RES, V49, P4682; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GARCIA AM, 1994, J CELL BIOCHEM     S, V18, P168; GAUL U, 1987, CELL, V50, P639, DOI 10.1016/0092-8674(87)90037-7; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KESKIOJA J, 1988, J BIOL CHEM, V263, P3111; KIMCHI A, 1992, J CELL BIOCHEM, V50, P1, DOI 10.1002/jcb.240500102; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LEWIS SA, 1985, J CELL BIOL, V101, P852, DOI 10.1083/jcb.101.3.852; LI PM, 1991, P NATL ACAD SCI USA, V88, P9210, DOI 10.1073/pnas.88.20.9210; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MAEHARA Y, 1985, BIOCHEM BIOPH RES CO, V131, P800, DOI 10.1016/0006-291X(85)91310-5; Maniatis T., 1982, MOL CLONING; MARK J, 1993, SCIENCE, V261, P1385; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NAMBA M, 1985, INT J CANCER, V35, P275, DOI 10.1002/ijc.2910350221; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NOSE K, 1989, MOL CARCINOGEN, V2, P208, DOI 10.1002/mc.2940020407; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; SALDER L, 1992, J CELL BIOL, V119, P1573; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SHIBANUMA M, 1993, EUR J BIOCHEM, V217, P13, DOI 10.1111/j.1432-1033.1993.tb18212.x; SHIBANUMA M, 1987, EUR J BIOCHEM, V164, P15, DOI 10.1111/j.1432-1033.1987.tb10985.x; SHIBANUMA M, 1992, J BIOL CHEM, V267, P10219; SHIBANUMA M, 1991, CELL GROWTH DIFFER, V2, P583; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; THOMPSON KL, 1988, J BIOL CHEM, V263, P19519; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	49	182	193	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26767	26774						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929412				2022-12-27	WOS:A1994PQ93100031
J	YOKOYAMA, K; YASUMOTO, K; SUZUKI, H; SHIBAHARA, S				YOKOYAMA, K; YASUMOTO, K; SUZUKI, H; SHIBAHARA, S			CLONING OF THE HUMAN DOPACHROME TAUTOMERASE/TYROSINASE-RELATED PROTEIN-2 GENE AND IDENTIFICATION OF 2 REGULATORY REGIONS REQUIRED FOR ITS PIGMENT CELL-SPECIFIC EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-2; RAT HEME OXYGENASE; MOUSE TYROSINASE; MAMMALIAN MELANOGENESIS; MALIGNANT-MELANOMA; CONVERSION FACTOR; PROMOTER ACTIVITY; BROWN LOCUS; METAL-IONS; WILD-TYPE	We have cloned and sequenced the human genomic DNA segments encoding the 5'-flanking region and the first two exons of the DOPAchrome tautomerase (DT)/tyrosinase-related protein 2 (TRP-2) gene. The DT gene is a member of the tyrosinase gene family and specifically expressed in melanin-producing cells. A transcriptional initiation site of the DT gene was identified by S1 nuclease-mapping and primer-extension analyses using RNA prepared from human pigmented melanoma cells. To study the mechanism for pigment cell-specific expression of the human DT gene, we analyzed the promoter function of its 5'-flanking region by transient expression assays. The fusion genes, containing the DT gene promoter upstream hom a firefly luciferase reporter gene, were introduced into human pigmented melanoma cells and HeLa cells, and the pigment cell-specific promoter activity was evaluated by comparing the luciferase activity expressed in both cell lines. A series of 5' deletion studies of the human DT gene promoter revealed that the 32-bp element, located between -447 and -415, is sufficient to confer pigment cell-specific expression of a reporter gene on a homologous promoter, but not on a heterologous simian virus 40 promoter, Internal deletion studies using a homologous or a heterologous promoter revealed that the pigment cell-specific expression of a reporter gene mediated by the 32-bp element is dependent on the presence of another region of the DT gene spanning from -268 to -56, which was termed the proximal region. However, the proximal region by itself is not sufficient to confer cell type-specific expression. These results indicate that the presence of two regulatory regions, the 32-bp element and the proximal region, is required for pigment cell-specific expression of the DT gene. Both regulatory regions contain a CANNTG motif, a well known binding site for a large family of transcription factors possessing a basic helix-loop-helix structure.	TOHOKU UNIV,SCH MED,DEPT APPL PHYSIOL & MOLEC BIOL,AOBA KU,SENDAI,MIYAGI 98077,JAPAN	Tohoku University			Shibahara, Shigeki/M-3644-2014	Yasumoto, Ken-ichi/0000-0002-8090-1161				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AROCA P, 1990, BIOCHIM BIOPHYS ACTA, V1035, P266, DOI 10.1016/0304-4165(90)90088-E; BARBER JI, 1984, J INVEST DERMATOL, V83, P145, DOI 10.1111/1523-1747.ep12263381; BENNETT DC, 1990, DEVELOPMENT, V110, P471; BOUCHARD B, 1994, EUR J BIOCHEM, V219, P127, DOI 10.1111/j.1432-1033.1994.tb19922.x; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; BRUGGEN J, 1981, CANCER IMMUNOL IMMUN, V10, P121; CHAKRABORTY AK, 1992, FEBS LETT, V302, P126, DOI 10.1016/0014-5793(92)80421-C; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HASUMI K, 1978, CANCER-AM CANCER SOC, V42, P2675, DOI 10.1002/1097-0142(197812)42:6<2675::AID-CNCR2820420624>3.0.CO;2-G; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INOUE S, 1987, BIOCHEM PHARMACOL, V36, P3537, DOI 10.1016/0006-2952(87)90340-6; JACKSON IJ, 1988, P NATL ACAD SCI USA, V85, P4392, DOI 10.1073/pnas.85.12.4392; JARA JR, 1990, BIOCHIM BIOPHYS ACTA, V1035, P276, DOI 10.1016/0304-4165(90)90089-F; KORNER AM, 1980, J INVEST DERMATOL, V75, P192, DOI 10.1111/1523-1747.ep12522650; KORNER AM, 1985, J INVEST DERMATOL, V85, P229, DOI 10.1111/1523-1747.ep12276688; KWON BS, 1989, J INVEST DERMATOL, V93, P589, DOI 10.1111/1523-1747.ep12319693; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEONARD LJ, 1988, BIOCHEMISTRY-US, V27, P6156, DOI 10.1021/bi00416a049; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MULLER RM, 1987, J BIOL CHEM, V262, P6795; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PALUMBO A, 1991, BIOCHIM BIOPHYS ACTA, V1115, P1, DOI 10.1016/0304-4165(91)90003-Y; PAWELEK JM, 1990, BIOCHEM BIOPH RES CO, V166, P1328, DOI 10.1016/0006-291X(90)91011-G; PAWELEK JM, 1991, PIGM CELL RES, V4, P53, DOI 10.1111/j.1600-0749.1991.tb00315.x; SAKAI J, 1994, J BIOL CHEM, V269, P2173; Sambrook J, 1989, MOL CLONING LABORATO; SHIBAHARA S, 1986, NUCLEIC ACIDS RES, V14, P2413, DOI 10.1093/nar/14.6.2413; SHIBAHARA S, 1990, EUR J BIOCHEM, V189, P455, DOI 10.1111/j.1432-1033.1990.tb15510.x; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; SHIBAHARA S, 1991, J BIOL CHEM, V266, P15895; SHIBATA K, 1992, J BIOL CHEM, V267, P20584; SHIBATA K, 1992, BIOCHEM BIOPH RES CO, V184, P568, DOI 10.1016/0006-291X(92)90627-W; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEEL KP, 1992, DEVELOPMENT, V115, P1111; TAKEDA A, 1989, BIOCHEM BIOPH RES CO, V162, P984, DOI 10.1016/0006-291X(89)90770-5; YAMAMOTO H, 1989, JPN J GENET, V64, P121, DOI 10.1266/jjg.64.121; YOKOYAMA K, 1994, BBA-GENE STRUCT EXPR, V1217, P317, DOI 10.1016/0167-4781(94)90292-5; ZDARSKY E, 1990, GENETICS, V126, P443	42	102	113	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27080	27087						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929451				2022-12-27	WOS:A1994PQ93100074
J	AHUJA, SK; SHETTY, A; TIFFANY, HL; MURPHY, PM				AHUJA, SK; SHETTY, A; TIFFANY, HL; MURPHY, PM			COMPARISON OF THE GENOMIC ORGANIZATION AND PROMOTER FUNCTION FOR HUMAN INTERLEUKIN-8 RECEPTOR-A AND RECEPTOR-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO TERMINUS; HUMAN DNA; GENE; EXPRESSION; SEQUENCE; NEUTROPHIL; CLONING; PROTEIN; CLUSTER; CELLS	Human neutrophils are highly responsive to the chemokine interleukin-8 (IL-8) owing to high levels of expression of two related receptors encoded by the single copy genes il8ra and il8rb located on chromosome 2q34-q35. To identify nuclear factors that regulate the expression of IL-8 receptors, we have first defined the organization of both genes and characterized their functional promoters. il8ra and il8rb span similar to 4 and 12 kilobase pairs of genomic DNA, respectively. In both cases, the open reading frame resides on a single exon. In contrast, the 5'-untranslated regions are more complex. For il8ra, it is formed from two exons, whereas for il8rb, seven distinct neutrophil mRNAs are formed by alternative splicing of 11 exons. One of the splice variants, designated IL8RB3, is the predominant form for il8rb. Two equally abundant mRNAs for il8ra, 2.0 and 2.4 kilobases in length, are expressed in neutrophils and arise from usage of two alternative polyadenylation signals. Primer extension analysis identified two major transcription start points for il8ra and 11 for il8rb. Regions extending 300 base pairs (bp) upstream from exon 1 of il8ra and 81 bp upstream from exon 3 of il8rb have limited sequence similarity but had strong constitutive promoter activity when cloned upstream from a chloramphenicol acetyltransferase-encoding reporter gene and transiently transfected into surrogate myeloid (HL-60, and U-937) and lymphoid (Jurkat) cell lines. Neither of these regions has sequences corresponding to classic promoter elements. In contrast, a region 643 base pairs upstream from exon 1 of il8rb had relatively low levels of constitutive promoter activity in all three cell environments, and a conserved TATA element is located 47 bp upstream of the 5'-end of exon 1. Thus, despite marked differences in the complexity of their genomic organization, il8ra and il8rb encode products that are similar in structure, function, and the major cell type of expression.			AHUJA, SK (corresponding author), NIAID,HOST DEF LAB,BLDG 10,RM 11N113,BETHESDA,MD 20892, USA.							AHUJA SK, 1992, NAT GENET, V2, P31, DOI 10.1038/ng0992-31; CALABRETTA B, 1982, NATURE, V296, P219, DOI 10.1038/296219a0; CERRETTI DP, 1993, MOL IMMUNOL, V30, P359; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P389; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; GEISER T, 1993, J BIOL CHEM, V268, P15419; GERARD NP, 1993, BIOCHEMISTRY-US, V32, P1243, DOI 10.1021/bi00056a007; HEIKKILA P, 1993, J BIOL CHEM, V268, P24677; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; KERNEN P, 1991, J CLIN INVEST, V87, P2012, DOI 10.1172/JCI115230; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEE J, 1992, J BIOL CHEM, V267, P16283; LEVY LS, 1990, J GEN VIROL, V71, P1613, DOI 10.1099/0022-1317-71-7-1613; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MOSER B, 1993, BIOCHEM J, V294, P285, DOI 10.1042/bj2940285; MURPHY PM, 1993, GENE, V133, P285, DOI 10.1016/0378-1119(93)90653-K; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; MUTCH H, 1993, FEBS LETT, V322, P129; PEREZ HD, 1992, BIOCHEMISTRY-US, V31, P11595, DOI 10.1021/bi00161a044; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEBOK K, 1993, J IMMUNOL, V150, P1524; SHIMADA T, 1989, J BIOL CHEM, V264, P20171; SPRENGER H, 1994, J BIOL CHEM, V269, P11065	27	64	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26381	26389						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929358				2022-12-27	WOS:A1994PQ93000068
J	ELIASSON, R; PONTIS, E; SUN, XY; REICHARD, P				ELIASSON, R; PONTIS, E; SUN, XY; REICHARD, P			ALLOSTERIC CONTROL OF THE SUBSTRATE-SPECIFICITY OF THE ANAEROBIC RIBONUCLEOTIDE REDUCTASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The reduction of ribonucleotides is catalyzed by different enzymes in aerobic and anaerobic Escherichia coli, each with a different primary and quaternary structure. Here, we describe the allosteric regulation of the substrate specificity of the anaerobic ribonucleoside triphosphate reductase. The enzyme reduced ribonucleotides at a low basal rate. Reduction was stimulated up to 10-fold by an appropriate modulator (dGTP for ATP reduction, ATP for CTP and UTP reduction, and dTTP for GTP reduction). dGTP and dTTP inhibited the reduc tion of the ''incorrect'' substrate; dATP inhibited reduction of all four. From kinetic, effector binding, and competition experiments we conclude that the enzyme has two classes of sites, one that binds ATP and dATP and regulates pyrimidine ribonucleotide reduction (''pyrimidine site''), the other that binds dATP, dGTP, and dTTP and regulates purine ribonucleotide reduction (''purine site''). This model differs slightly from the model for the aerobic reductase, but the physiological consequences remain the same and explain how a single enzyme can provide a balanced supply of the four dNTPs. The similarity of a highly sophisticated control mechanism for the aerobic and anaerobic enzymes suggests that both arose by divergent evolution from a common ancestor, in spite of their different structures.	KAROLINSKA INST, MED NOBEL INST, DEPT BIOCHEM 1, MBB, S-17177 STOCKHOLM, SWEDEN; UNIV STOCKHOLM, DEPT BIOL MOLEC, S-10691 STOCKHOLM, SWEDEN	Karolinska Institutet; Stockholm University								BECK WS, 1967, J BIOL CHEM, V242, P3148; BLAKLEY RL, 1965, J BIOL CHEM, V240, P2173; BOOKER S, 1993, P NATL ACAD SCI USA, V90, P8352, DOI 10.1073/pnas.90.18.8352; BROWN NC, 1969, J MOL BIOL, V46, P39, DOI 10.1016/0022-2836(69)90056-4; CHEN AK, 1974, BIOCHEMISTRY-US, V13, P654, DOI 10.1021/bi00701a004; HARDER J, 1992, J BIOL CHEM, V267, P25548; KIM JJ, 1977, ARCH BIOCHEM BIOPHYS, V182, P674, DOI 10.1016/0003-9861(77)90548-3; MONOD J, 1961, COLD SPRING HARB SYM, V26, P389, DOI 10.1101/SQB.1961.026.01.048; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; ORMO M, 1990, ANAL BIOCHEM, V189, P138, DOI 10.1016/0003-2697(90)90059-I; REICHARD P, 1993, J BIOL CHEM, V268, P8383; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; SUN XY, 1993, P NATL ACAD SCI USA, V90, P577, DOI 10.1073/pnas.90.2.577; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025	15	43	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26052	26057						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929317				2022-12-27	WOS:A1994PQ93000021
J	HEATH, RJ; JACKOWSKI, S; ROCK, CO				HEATH, RJ; JACKOWSKI, S; ROCK, CO			GUANOSINE TETRAPHOSPHATE INHIBITION OF FATTY-ACID AND PHOSPHOLIPID-SYNTHESIS IN ESCHERICHIA-COLI IS RELIEVED BY OVEREXPRESSION OF GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE (PLSB)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARRIER PROTEIN SYNTHETASE; SN-GLYCEROL 3-PHOSPHATE; RELA GENE; SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; STRINGENT RESPONSE; PPGPP; SPOT; BIOSYNTHESIS; MUTANTS; INVIVO	The accumulation of the alarmone guanosine-3',5'-bispyrophosphate (ppGpp) in response to amino acid starvation or energy source depletion mediates the coordinate inhibition of macromolecular and membrane phospholipid biosynthesis in Escherichia coli. Accumulation of ppGpp triggered by the induced expression of either the relA gene or an unregulated, truncated relA gene that encodes a constitutively active ppGpp synthetase I, inhibited both de novo fatty acid and phospholipid biosynthesis and the incorporation of exogenous fatty acids into phospholipid. ppGpp inhibition of fatty acid and phospholipid synthesis was associated with an accumulation of long-chain acyl-ACP, the end products of fatty acid biosynthesis, and substrates for the sn-glycerol-3-phosphate acyltransferase (the plsB gene product). Overexpression of the plsB gene product relieved the inhibition of fatty acid and phospholipid synthesis, prevented the accumulation of long-chain acyl-ACPs, and allowed an increase in cell size following elevation of intracellular ppGpp. However, stable RNA accumulation and cell division were still blocked by ppGpp accumulation. These data show that the sn-glycerol-3-phosphate acyltransferase mediates the ppGpp dependent regulation of fatty acid and phospholipid biosynthesis in E. coli.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, CTR HLTH SCI, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center			Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429; Heath, Richard/0000-0002-1795-1254	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM034496] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 34496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL RM, 1974, J BACTERIOL, V117, P1065, DOI 10.1128/JB.117.3.1065-1076.1974; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUUSCHEDE H, 1977, J BACTERIOL, V129, P1020; CASHEL M, 1969, J BIOL CHEM, V244, P3133; CASHEL M, 1987, ESCHERICHIA COLI SAL, V2, P1410; CHIN DT, 1988, J BIOL CHEM, V263, P11718; CLEWELL DB, 1969, P NATL ACAD SCI USA, V69, P2110; COOPER CL, 1987, J BACTERIOL, V169, P605, DOI 10.1128/jb.169.2.605-611.1987; CRONAN JE, 1978, ANNU REV BIOCHEM, V47, P163, DOI 10.1146/annurev.bi.47.070178.001115; DAGNOLO G, 1973, BIOCHIM BIOPHYS ACTA, V326, P155, DOI 10.1016/0005-2760(73)90241-5; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; GENTRY DR, 1993, J BACTERIOL, V175, P7982, DOI 10.1128/JB.175.24.7982-7989.1993; GOLDEN NG, 1972, J BIOL CHEM, V247, P6651; HASELTIN.WA, 1972, NATURE, V238, P381, DOI 10.1038/238381a0; HASELTINE WA, 1973, P NATL ACAD SCI USA, V70, P1564, DOI 10.1073/pnas.70.5.1564; HERNANDEZ VJ, 1991, J BIOL CHEM, V266, P5991; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; JIANG P, 1994, J BACTERIOL, V176, P2814, DOI 10.1128/JB.176.10.2814-2821.1994; JUSTESEN J, 1986, BIOCHIMIE, V68, P715, DOI 10.1016/S0300-9084(86)80165-1; KAINUMAKURODA R, 1980, J BACTERIOL, V142, P362, DOI 10.1128/JB.142.1.362-365.1980; LAFFLER T, 1974, CELL, V1, P27, DOI 10.1016/0092-8674(74)90151-2; LIGHTNER VA, 1980, J BIOL CHEM, V255, P9413; LUEKING DR, 1975, J BIOL CHEM, V250, P4911; MERLIE JP, 1973, J BACTERIOL, V116, P355, DOI 10.1128/JB.116.1.355-366.1973; Miller J.H., 1972, EXPT MOL GENETICS; NUNN WD, 1976, BIOCHEMISTRY-US, V15, P2546, DOI 10.1021/bi00657a009; NUNN WD, 1976, J MOL BIOL, V102, P167, DOI 10.1016/0022-2836(76)90080-2; NUNN WD, 1974, J BIOL CHEM, V249, P3994; PEDERSEN FS, 1977, EUR J BIOCHEM, V76, P91, DOI 10.1111/j.1432-1033.1977.tb11573.x; POLAKIS SE, 1973, J BIOL CHEM, V248, P7957; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; RAY TK, 1975, J BIOL CHEM, V250, P8422; ROCK CO, 1981, J BIOL CHEM, V256, P736; ROCK CO, 1981, J BIOL CHEM, V256, P2669; ROCK CO, 1982, J BIOL CHEM, V257, P10759; ROCK CO, 1979, J BIOL CHEM, V254, P7116; SCHREIBER G, 1991, J BIOL CHEM, V266, P3760; SCHULZ H, 1975, J BIOL CHEM, V250, P2299; SEYFZADEH M, 1993, P NATL ACAD SCI USA, V90, P11004, DOI 10.1073/pnas.90.23.11004; SNIDER MD, 1979, J BIOL CHEM, V254, P7197; SOKAWA Y, 1968, BIOCHEM BIOPH RES CO, V33, P108, DOI 10.1016/0006-291X(68)90263-5; SPENCER A, 1977, J BACTERIOL, V130, P114, DOI 10.1128/JB.130.1.114-117.1977; STEIN JP, 1976, BIOCHEM BIOPH RES CO, V73, P881, DOI 10.1016/0006-291X(76)90204-7; SVITIL AL, 1993, J BIOL CHEM, V268, P2307; TEDIN K, 1992, J BIOL CHEM, V267, P2337; VALLARI DS, 1982, ARCH BIOCHEM BIOPHYS, V218, P402, DOI 10.1016/0003-9861(82)90361-7; XIAO H, 1991, J BIOL CHEM, V266, P5980	48	88	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26584	26590						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929384				2022-12-27	WOS:A1994PQ93000097
J	HEINS, L; MENTZEL, H; SCHMID, A; BENZ, R; SCHMITZ, UK				HEINS, L; MENTZEL, H; SCHMID, A; BENZ, R; SCHMITZ, UK			BIOCHEMICAL, MOLECULAR, AND FUNCTIONAL-CHARACTERIZATION OF PORIN ISOFORMS FROM POTATO MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C REDUCTASE; OUTER-MEMBRANE CHANNEL; MATRIX PROTEIN PORIN; ESCHERICHIA-COLI; PROCESSING PEPTIDASE; LIVER-MITOCHONDRIA; NEUROSPORA-CRASSA; ION SELECTIVITY; YEAST MUTANT; VDAC	The mitochondrial outer membrane of eukaryotic cells contains a voltage-dependent anion channel termed porin. In the organisms studied so far only one type of porin has been identified at the protein level. Here we present a biochemical and molecular genetic analysis of two different porin polypeptides of M(r) 34,000 and 36,000 from the outer membranes of potato mitochondria (termed POM 34 and POM 36, respectively). N-terminal sequencing and the use of labeled oligonucleotide mixtures derived from these amino acid sequences allowed the isolation of cDNA clones encoding the 34- and 36-kDa proteins. They have similar steady state protein levels and share about 75% identical amino acids suggesting that they represent isoforms. In addition, a third cDNA clone coding for a slightly different isoform of the 36-kDa protein was characterized. The polypeptides encoded by the three cDNA clones share the highest degree of sequence identity with mitochondrial porins from fungi and mammals. Tentative models of the secondary structure of the 34- and 36-kDa proteins suggest the occurrence of a 16-stranded beta-barrel typical for bacterial and mitochondrial porins. Purification of the 34-kDa protein by hydroxyapatite chromatography allowed conductance measurements in artificial bilayers. The 34-kDa protein is a voltage-dependent, channel-forming component with single channel conductances of 3.5 and 2.0 nanosiemens in 1 M KCl. In spite of the striking functional similarities to mitochondrial porins from other organisms neither the 34- nor the 36-kDa proteins are able to complement the respiratory defect of a yeast por(-) mutant.	INST GENBIOL FORSCH BERLIN GMBH,D-14195 BERLIN,GERMANY; UNIV WURZBURG,THEODOR BOVERI INST BIOZENTRUM,LEHRSTUHL BIOTECHNOL,D-97074 WURZBURG,GERMANY	University of Wurzburg				Benz, Roland/0000-0002-9510-9265				ALJAMAL JA, 1993, PLANT PHYSIOL, V102, P615, DOI 10.1104/pp.102.2.615; BENZ R, 1979, BIOCHIM BIOPHYS ACTA, V551, P238, DOI 10.1016/0005-2736(89)90002-3; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1992, J BIOENERG BIOMEMBR, V24, P33, DOI 10.1007/BF00769528; BENZ R, 1994, BBA-REV BIOMEMBRANES, V1197, P167, DOI 10.1016/0304-4157(94)90004-3; BENZ R, 1985, CRC CR REV BIOCH MOL, V19, P145, DOI 10.3109/10409238509082542; BENZ R, 1985, J BACTERIOL, V162, P722, DOI 10.1128/JB.162.2.722-727.1985; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; BLUMENTHAL A, 1993, PLANT PHYSIOL, V101, P579, DOI 10.1104/pp.101.2.579; BRAUN HP, 1992, MOL GEN GENET, V231, P217, DOI 10.1007/BF00279794; BRAUN HP, 1994, PLANTA, V193, P99, DOI 10.1007/BF00191612; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; COLOMBINI M, 1987, BIOCHIM BIOPHYS ACTA, V905, P279, DOI 10.1016/0005-2736(87)90456-1; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DAUM G, 1952, J BIOL CHEM, V267, P13028; DEPINTO V, 1991, BIOCHIM BIOPHYS ACTA, V1061, P279, DOI 10.1016/0005-2736(91)90293-H; DEPINTO V, 1987, BIOCHIM BIOPHYS ACTA, V894, P109, DOI 10.1016/0005-2728(87)90180-0; DEPINTO V, 1991, BIOCHEMISTRY-US, V30, P10191, DOI 10.1021/bi00106a017; DIHANICH M, 1987, EMBO J, V6, P723, DOI 10.1002/j.1460-2075.1987.tb04813.x; DIHANICH M, 1989, EUR J BIOCHEM, V181, P703, DOI 10.1111/j.1432-1033.1989.tb14780.x; EMMERMANN M, 1991, CURR GENET, V20, P405, DOI 10.1007/BF00317069; EMMERMANN M, 1993, J BIOL CHEM, V268, P18936; FIEK C, 1982, BIOCHIM BIOPHYS ACTA, V688, P429, DOI 10.1016/0005-2736(82)90354-6; FREITAG H, 1982, EUR J BIOCHEM, V123, P629; HA HJ, 1993, J BIOL CHEM, V268, P12143; KAYSER H, 1989, BIOL CHEM H-S, V370, P1265; KLEENE R, 1987, EMBO J, V6, P2627, DOI 10.1002/j.1460-2075.1987.tb02553.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIU MY, 1992, J BIOENERG BIOMEMBR, V24, P41, DOI 10.1007/BF00769529; LUDWIG O, 1989, BIOCHIM BIOPHYS ACTA, V978, P319, DOI 10.1016/0005-2736(89)90131-4; MANNELLA CA, 1992, TRENDS BIOCHEM SCI, V17, P315, DOI 10.1016/0968-0004(92)90444-E; MANNELLA CA, 1989, FEBS LETT, V253, P231, DOI 10.1016/0014-5793(89)80965-2; MIHARA K, 1985, EMBO J, V4, P769, DOI 10.1002/j.1460-2075.1985.tb03695.x; NAKASHIMA RA, 1986, BIOCHEMISTRY-US, V25, P1015, DOI 10.1021/bi00353a010; PENG SZ, 1992, J BIOENERG BIOMEMBR, V24, P27, DOI 10.1007/BF00769527; PFALLER R, 1990, EXPERIENTIA, V46, P4509; ROISE D, 1988, J BIOENERG BIOMEMBR, V63, P27; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID A, 1992, BIOCHIM BIOPHYS ACTA, V1112, P174, DOI 10.1016/0005-2736(92)90389-4; SMACK DP, 1985, PLANT PHYSIOL, V79, P1094, DOI 10.1104/pp.79.4.1094; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; TROLL H, 1992, J BIOL CHEM, V267, P21072; VOGEL H, 1986, J MOL BIOL, V190, P191, DOI 10.1016/0022-2836(86)90292-5; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242	46	80	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26402	26410						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929361				2022-12-27	WOS:A1994PQ93000071
J	SLIVA, D; WOOD, TJJ; SCHINDLER, C; LOBIE, PE; NORSTEDT, G				SLIVA, D; WOOD, TJJ; SCHINDLER, C; LOBIE, PE; NORSTEDT, G			GROWTH-HORMONE SPECIFICALLY REGULATES SERINE-PROTEASE INHIBITOR GENE-TRANSCRIPTION VIA GAMMA-ACTIVATED SEQUENCE-LIKE DNA ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE RECEPTOR SUPERFAMILY; TYROSINE PHOSPHORYLATION; INTERFERON-GAMMA; BINDING PROTEINS; SIGNAL-TRANSDUCTION; KINASE; JAK2; IDENTIFICATION; PROMOTERS; INVITRO	Growth hormone activates gene transcription of the serine protease inhibitors (SPI) 2.1 and 2.2 by an unknown mechanism. In order to define the promoter regions responsible for this effect and to characterize the transcription factors involved, we have performed gel electrophoresis mobility shift assays on nuclear extracts from cells lines transfected with growth hormone receptor cDNA. We have identified a 9-base pair DNA element, the SPI-GLE 1, which forms a complex with nuclear proteins following activation by growth hormone and which, when placed upstream of a minimal thymidine kinase promoter, drives chloramphenicol acetyltransferase expression in a growth hormone dependent fashion. This element is similar to those from several genes regulated by other cytokines including interferon. The growth hormone-induced complexes formed were dependent on tyrosine phosphorylation but did not contain the interferon-gamma-activated transcription factor Stat 91. Competition studies with oligonucleotides similar to the SPI-GLE 1 reveal the sequence of a consensus element that specifically binds growth hormone-regulated nuclear proteins.	KAROLINSKA INST,NOVUM,CTR BIOTECHNOL,S-14157 HUDDINGE,SWEDEN; KAROLINSKA INST,NOVUM,DEPT MED NUTR,S-14157 HUDDINGE,SWEDEN; COLUMBIA UNIV,COLL PHYS & SURG,DEPT MOLEC MED,NEW YORK,NY 10032	Karolinska Institutet; Karolinska Institutet; Columbia University								AGUET M, 1990, J INTERFERON RES, V10, P551, DOI 10.1089/jir.1990.10.551; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; AUSUBEL FM, 1990, CURRENT PROTOCOL MOL; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENBERG B, 1994, J MOL ENDOCRINOL, V12, P39, DOI 10.1677/jme.0.0120039; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MATTHEWS LS, 1989, J BIOL CHEM, V264, P9905; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MOLLER C, 1994, MOL CELL ENDOCRINOL, V99, P111, DOI 10.1016/0303-7207(94)90153-8; MOLLER C, 1992, J BIOL CHEM, V267, P23403; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; PAQUEREAU L, 1992, EUR J BIOCHEM, V209, P1053, DOI 10.1111/j.1432-1033.1992.tb17381.x; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; RAUGHT B, 1994, MOL CELL BIOL, V14, P1752, DOI 10.1128/MCB.14.3.1752; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; WANG XZ, 1994, P NATL ACAD SCI USA, V91, P1391, DOI 10.1073/pnas.91.4.1391; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WATSON CJ, 1991, NUCLEIC ACIDS RES, V19, P6603, DOI 10.1093/nar/19.23.6603; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WONG P, 1994, MOL CELL BIOL, V14, P914, DOI 10.1128/MCB.14.2.914; YOON JB, 1990, J BIOL CHEM, V265, P19947; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	44	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26208	26214						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929335				2022-12-27	WOS:A1994PQ93000043
J	LOPASCHUK, GD; WITTERS, LA; ITOI, T; BARR, R; BARR, A				LOPASCHUK, GD; WITTERS, LA; ITOI, T; BARR, R; BARR, A			ACETYL-COA CARBOXYLASE INVOLVEMENT IN THE RAPID MATURATION OF FATTY-ACID OXIDATION IN THE NEWBORN RABBIT HEART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARNITINE PALMITOYLTRANSFERASE-I; COENZYME-A CARBOXYLASE; MALONYL-COA; ENERGY SUBSTRATE; PROTEIN-KINASE; MESSENGER-RNA; PIG HEARTS; FETAL; METABOLISM; RAT	Fatty acid oxidation rapidly increases in the rabbit heart following birth. By inhibiting carnitine palmitoyltransferase 1 (CPT1), malonyl-CoA is a potent regulator of fatty acid oxidation in the heart. We therefore addressed the hypothesis that a decrease in acetyl-CoA carboxylase (ACC) activity and/or malonyl-CoA inhibition of CPT1 could account for the increase in the ability of the heart to oxidize fatty acids following birth. ACC activity and expression, malonyl-CoA levels, and mitochondrial CPT1 activity were measured in hearts from 1-day, 7-day, and 6-week-old rabbits. CPT1 activity and sensitivity to malonyl-CoA inhibition did not differ between 1-day, 7-day, or 6-week hearts (the IC50 for malonyl-CoA was 32.0 +/- 1.5, 36.0 +/- 0.3, and 36.3 nM respectively). Western blot analysis with streptavidin showed that all hearts expressed similar amounts of both a 265-kDa (ACC-265) and 280-kDa isoform (ACC-280) of ACC. A progressive and significant decrease in malonyl-CoA levels was seen in 1-day, 7-day, and g-week hearts (47 +/- 2, 40 +/- 2, and 26 +/- 2 nmol/g dry weight, respectively), paralleling a decline in ACC activity. We hypothesized that these developmental changes could be due to changes in hormonal regulation of cardiac ACC in the postnatal period. In isolated hearts from 1-day-old rabbits, the fatty acid oxidation rate was 9.01 +/- 1.10 nmol.g dry weight(-1).min(-1). Glucagon (1 ng/ml) did not alter this rate (11.03 +/- 1.42 nmol.g dry weight(-1).min(-1)), but insulin (100 microunits/ml) resulted in a significant decrease in rate. (4.81 +/- 0.82 nmol.g dry weight(-1).min(-1)). ACC activity was markedly elevated in 1-day-old hearts perfused with insulin compared to control hearts or glucagon perfused hearts (0.415 +/- 0.052, 0.095 +/- 0.018, and 0.133 +/- 0.013 nmol of malonyl-CoA produced.g dry weight(-1).min(-1), respectively). Malonyl-CoA levels were also markedly elevated in 1-day hearts perfused with insulin (123.0 +/- 8.3, 2.0 +/- 0.4, and 1.8 +/- 0.6 nmol/g dry weight in insulin, control, and glucagon hearts, respectively). In 7-day old rabbit hearts, the basal fatty acid oxidation rate had increased to 24.5 +/- 4.8 nmol.mg(-1). min(-1). In contrast to the 1-day-old hearts, insulin had no significant effect on fatty acid oxidation, although glucagon resulted in a significant increase in rates (38.9 +/- 12.2 and 80.7 +/- 9.1 nmol.g dry weight(-1) min(-1), respectively). Both ACC activity and malonyl-CoA levels were low in 7-day-old hearts and were also not dramatically altered by insulin or glucagon. Taken together these data suggest that the increase in fatty acid oxidation following birth is not due to a decreased sensitivity of CPT1 to malonyl-CoA inhibition, but rather to a decrease in malonyl-CoA production by ACC. The decrease in circulating insulin combined with the increase in glucagon seen in rabbits immediately following birth may result in a decrease in ACC activity and malonyl-CoA levels in the newborn heart. This may relieve the inhibition of CPT1 resulting in an increase in fatty acid oxidation. Low ACC activity and lack of sensitivity to insulin activation in 7-day-old hearts may ensure that fatty acid oxidation remains an important source of ATP production in the maturing heart.	UNIV ALBERTA, DEPT PEDIAT, LIPID & LIPOPROT RES GRP, EDMONTON T6G 2S2, AB, CANADA; UNIV ALBERTA, DEPT PHARMACOL, LIPID & LIPOPROT RES GRP, EDMONTON T6G 2S2, AB, CANADA; DARTMOUTH COLL, SCH MED, DEPT MED, DIV ENDOCRINE METAB, HANOVER, NH 03755 USA; DARTMOUTH COLL, SCH MED, DEPT BIOCHEM, DIV ENDOCRINE METAB, HANOVER, NH 03755 USA	University of Alberta; University of Alberta; Dartmouth College; Dartmouth College	LOPASCHUK, GD (corresponding author), UNIV ALBERTA, CARDIOVASC DIS RES GRP, 423 HERITAGE MED RES BLDG, EDMONTON T6G 2S2, AB, CANADA.				NIDDK NIH HHS [DK35712] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035712] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASCUITTO RJ, 1989, AM J PHYSIOL, V256, pH9, DOI 10.1152/ajpheart.1989.256.1.H9; AWAN MM, 1993, BIOCHEM J, V295, P61, DOI 10.1042/bj2950061; BIANCHI A, 1992, J CELL BIOCHEM, V48, P86, DOI 10.1002/jcb.240480113; BIANCHI A, 1990, J BIOL CHEM, V265, P1502; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMER J, 1981, BIOCHIM BIOPHYS ACTA, V665, P628, DOI 10.1016/0005-2760(81)90282-4; BREUER E, 1968, BIOL NEONATORUM, V12, P54; COOK GA, 1984, J BIOL CHEM, V259, P2030; COOK GA, 1992, MOL CELL BIOCHEM, V116, P39, DOI 10.1007/BF01270567; DAVIES SP, 1990, EUR J BIOCHEM, V187, P183, DOI 10.1111/j.1432-1033.1990.tb15293.x; ESSER V, 1993, J BIOL CHEM, V268, P5817; FISHER DJ, 1981, PEDIATR RES, V15, P843, DOI 10.1203/00006450-198115050-00003; FISHER DJ, 1980, AM J PHYSIOL, V238, pH399, DOI 10.1152/ajpheart.1980.238.3.H399; GHADIMINEJAD I, 1991, BIOCHIM BIOPHYS ACTA, V1083, P166, DOI 10.1016/0005-2760(91)90038-J; GIRARD J, 1992, PHYSIOL REV, V72, P507, DOI 10.1152/physrev.1992.72.2.507; HARDIE DG, 1989, PROG LIPID RES, V28, P117, DOI 10.1016/0163-7827(89)90010-6; ITOI T, 1988, H JPN PEDIATR SOC, V92, P1879; IVERSON AJ, 1990, BIOCHEM J, V269, P365, DOI 10.1042/bj2690365; JONES CT, 1985, PHYSIOL REV, V65, P357, DOI 10.1152/physrev.1985.65.2.357; KERNER J, 1994, J BIOL CHEM, V269, P8209; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; KING MT, 1988, METHOD ENZYMOL, V166, P70; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPASCHUK GD, 1990, AM J PHYSIOL, V258, pH1274, DOI 10.1152/ajpheart.1990.258.5.H1274; LOPASCHUK GD, 1991, AM J PHYSIOL, V261, pH1698, DOI 10.1152/ajpheart.1991.261.6.H1698; LOPEZCASILLAS F, 1989, J BIOL CHEM, V264, P7176; LUO X, 1989, P NATL ACAD SCI USA, V86, P1511; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MEDINA JM, 1985, BIOL NEONATE, V48, P237, DOI 10.1159/000242176; PAPE ME, 1988, ARCH BIOCHEM BIOPHYS, V267, P104, DOI 10.1016/0003-9861(88)90013-6; PRIPBUUS C, 1990, BIOCHEM J, V269, P409, DOI 10.1042/bj2690409; ROLPH TP, 1983, J DEV PHYSIOL, V5, P31; SADDIK M, 1993, J BIOL CHEM, V268, P25836; SIM ATR, 1988, FEBS LETT, V233, P294, DOI 10.1016/0014-5793(88)80445-9; THAMPY KG, 1985, J BIOL CHEM, V260, P6318; THAMPY KG, 1989, J BIOL CHEM, V264, P17631; TOMEC RJ, 1975, ARCH BIOCHEM BIOPHYS, V170, P716, DOI 10.1016/0003-9861(75)90169-1; TRUMBLE GE, 1991, LIFE SCI, V49, P39, DOI 10.1016/0024-3205(91)90577-X; WARSHAW JB, 1970, J CELL BIOL, V44, P354, DOI 10.1083/jcb.44.2.354; WERNER JC, 1981, AM J PHYSIOL, V241, pE364, DOI 10.1152/ajpendo.1981.241.5.E364; WERNER JC, 1987, PEDIATR RES, V22, P552, DOI 10.1203/00006450-198711000-00016; WERNER JC, 1989, AM J PHYSIOL, V256, pE315, DOI 10.1152/ajpendo.1989.256.2.E315; WINZ R, 1994, J BIOL CHEM, V269, P14438; WITTELS B, 1965, J CLIN INVEST, V44, P1639, DOI 10.1172/JCI105270; WITTERS LA, 1994, ARCH BIOCHEM BIOPHYS, V308, P413, DOI 10.1006/abbi.1994.1058; WITTERS LA, 1992, J BIOL CHEM, V267, P2864; WITTERS LA, 1988, P NATL ACAD SCI USA, V85, P5473, DOI 10.1073/pnas.85.15.5473; WOOD JM, 1975, J BIOL CHEM, V250, P3062	49	116	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25871	25878						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929291				2022-12-27	WOS:A1994PQ49100093
J	MIOTTO, G; VENERANDO, R; MARIN, O; SILIPRANDI, N; MORTIMORE, GE				MIOTTO, G; VENERANDO, R; MARIN, O; SILIPRANDI, N; MORTIMORE, GE			INHIBITION OF MACROAUTOPHAGY AND PROTEOLYSIS IN THE ISOLATED RAT HEPATOCYTE BY A NONTRANSPORTABLE DERIVATIVE OF THE MULTIPLE ANTIGEN PEPTIDE LEU(8)-LYS(4)-LYS(2)-LYS-BETA-ALA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID CONTROL; SOLID-PHASE SYNTHESIS; PROTEIN-DEGRADATION; HEPATIC PROTEOLYSIS; PLASMA-MEMBRANE; LIVER; LEUCINE; DEPRIVATION; MECHANISM; SPECIFICITY	The multiple antigen peptide derivative, Leu(8)-Lys(4)-Lys(2)-Lys-beta Ala (Leu(8)-MAP), was synthesized by attaching the carboxyl of leucine to the NH2 termini of a branched lysine core, termed MAP, creating a molecule of about 1900 Da with 8 leucine residues. On a molar basis (independent pendent of the number of leucine substitutions), Leu(8)-MAP was as effective as leucine in suppressing macroautophagy and proteolysis; moreover, it exhibited the same apparent K-m (about 0.1 mM). The effect was specific for leucine since Ile(8)-MAP was inactive. It is of interest, though, that Leu(8)-MAP did not elicit the multiphasic response typical of leucine but instead evoked the single site inhibition normally seen with leucine plus the coregulator alanine. Some free leucine was produced from Leu(8)-MAP during hepatocyte incubations, but the amounts were insufficient to account for the inhibition. Although this degradation created species of Leu-MAP that had lost 1-3 residues of leucine, their inhibitory effectiveness was not diminished. Because the extracellular/intracellular distribution ratio of [H-3]-Leu(8)-MAP was 100:1 or greater, the direct transport of Leu(8)-MAP across the plasma membrane into the cytosolic compartment can be excluded. Hence, cytosolic concentrations of Leu(8)-MAP will be at least 100-fold smaller than those of leucine under conditions of comparable proteolytic inhibition. For these and related reasons, effects attributable to the recognition of Leu(8)-MAP cannot be explained by signals generated within the cytosol. They could, however, be mediated from site(s) on the plasma membrane or within associated vesicles.	PENN STATE UNIV, COLL MED, DEPT CELLULAR & MOLEC PHYSIOL, HERSHEY, PA 17033 USA; UNIV PADUA, DIPARTIMENTO CHIM BIOL, I-35121 PADUA, ITALY	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Padua			Miotto, Giovanni/S-1903-2016	Miotto, Giovanni/0000-0002-4278-4873				ATHERTON E, 1989, SOLID PHASE PEPTIDE, P47; CHUA BHL, 1994, J MOL CELL CARDIOL, V26, P743, DOI 10.1006/jmcc.1994.1089; DRYLAND A, 1986, J CHEM SOC PERK T 1, P125, DOI 10.1039/p19860000125; HIRSIMAKI P, 1983, PATHOBIOLOGY CELL ME, V3, P201; KADOWAKI M, 1994, J BIOL CHEM, V269, P3703; KADOWAKI M, 1992, J BIOL CHEM, V267, P22060; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; Krebs H.A., 1974, REGULATION HEPATIC M, P726; MIOTTO G, 1992, J BIOL CHEM, V267, P22066; MITCH WE, 1984, BIOCHEM J, V222, P579, DOI 10.1042/bj2220579; MORTIMORE GE, 1988, J BIOL CHEM, V263, P2506; MORTIMORE GE, 1991, J BIOL CHEM, V266, P1021; MORTIMORE GE, 1989, DIABETES METAB REV, V5, P49, DOI 10.1002/dmr.5610050105; MORTIMORE GE, 1987, J BIOL CHEM, V262, P16322; MORTIMORE GE, 1994, BIOCHEM BIOPH RES CO, V203, P200, DOI 10.1006/bbrc.1994.2168; MORTIMORE GE, 1988, METHOD ENZYMOL, V166, P461; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; POSO AR, 1982, BIOCHEM BIOPH RES CO, V107, P1433, DOI 10.1016/S0006-291X(82)80159-9; POSO AR, 1984, P NATL ACAD SCI-BIOL, V81, P4270, DOI 10.1073/pnas.81.14.4270; POSO AR, 1982, J BIOL CHEM, V257, P2114; SCHWORER CM, 1981, J BIOL CHEM, V256, P7652; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SEGLEN PO, 1980, BIOCHIM BIOPHYS ACTA, V630, P103, DOI 10.1016/0304-4165(80)90141-5; TAPUHI Y, 1981, ANAL BIOCHEM, V115, P123, DOI 10.1016/0003-2697(81)90534-0; TISCHLER ME, 1982, J BIOL CHEM, V257, P1613; VENERANDO R, 1994, AM J PHYSIOL, V266, pC455, DOI 10.1152/ajpcell.1994.266.2.C455; WERT JJ, 1992, BIOCHEM BIOPH RES CO, V186, P1327, DOI 10.1016/S0006-291X(05)81551-7	27	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25348	25353						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929229				2022-12-27	WOS:A1994PQ49100020
J	MISRA, RP; BONNI, A; MIRANTI, CK; RIVERA, VM; SHENG, M; GREENBERG, ME				MISRA, RP; BONNI, A; MIRANTI, CK; RIVERA, VM; SHENG, M; GREENBERG, ME			L-TYPE VOLTAGE-SENSITIVE CALCIUM-CHANNEL ACTIVATION STIMULATES GENE-EXPRESSION BY A SERUM RESPONSE FACTOR-DEPENDENT PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS TRANSCRIPTION; MULTIPLE SEQUENCE ELEMENTS; IMMEDIATE EARLY GENES; DNA-BINDING ACTIVITY; PROTEIN-KINASE; MESSENGER-RNA; HIPPOCAMPAL-NEURONS; SIGNALING PATHWAYS; PRIMARY CULTURES; MAMMALIAN-CELLS	A mechanism by which calcium-induced signals are transduced to the nucleus to activate transcription of the c-fos proto-oncogene has been characterized. The serum response element (SRE), a region of the c-fos gene which controls growth factor-induced transcription, is now shown to mediate c-fos transcription in response to activation of L-type voltage-sensitive calcium channels. Calcium-dependent transcriptional activation through the SRE is mediated by the serum response factor (SRF). Membrane depolarization induces phosphorylation of SRF at Ser-103, an event shown to enhance the ability of SRF to bind the SRE. Ca2+-induced SRF phosphorylation occurs via a pathway that may involve Ca2+/calmodulin-dependent kinases.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Miranti, Cindy/AAJ-3783-2020	Rivera, Victor/0000-0002-7258-3001	NINDS NIH HHS [NS28829] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS028829, R01NS028829] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BOULDEN AM, 1992, MOL CELL BIOL, V12, P4769, DOI 10.1128/MCB.12.10.4769; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; GAUTHIERROUVIERE C, 1991, CELL REGUL, V2, P575, DOI 10.1091/mbc.2.7.575; Ginty D D, 1992, Curr Opin Neurobiol, V2, P312, DOI 10.1016/0959-4388(92)90121-Z; GINTY DD, 1991, J BIOL CHEM, V266, P15325; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; HENSON PI, 1992, ANNU REV BIOCHEM, V61, P559; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; LEREA LS, 1993, NEURON, V10, P31, DOI 10.1016/0896-6273(93)90239-N; LEREA LS, 1992, J NEUROSCI, V12, P2973, DOI 10.1523/JNEUROSCI.12-08-02973.1992; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; METZ R, 1991, ONCOGENE, V6, P2165; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OHTA Y, 1990, P NATL ACAD SCI USA, V87, P5341, DOI 10.1073/pnas.87.14.5341; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SZEKELY AM, 1989, MOL PHARMACOL, V35, P401; SZEKELY AM, 1990, MOL PHARMACOL, V38, P624; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1990, CANCER BIOL, V1, P47; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191	50	143	143	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25483	25493						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929249				2022-12-27	WOS:A1994PQ49100042
J	SKURAT, AV; WANG, Y; ROACH, PJ				SKURAT, AV; WANG, Y; ROACH, PJ			RABBIT SKELETAL-MUSCLE GLYCOGEN-SYNTHASE EXPRESSED IN COS CELLS - IDENTIFICATION OF REGULATORY PHOSPHORYLATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; PHOSPHOSERINE RESIDUES INVIVO; MULTISITE PHOSPHORYLATION; MOLECULAR MECHANISM; HORMONAL-CONTROL; RAT HEPATOCYTES; LIVER; INSULIN; INACTIVATION; SUBSTRATE	Rabbit skeletal muscle glycogen synthase contains multiple sites for phosphorylation. To investigate the relative importance of these sites, the enzyme was overexpressed in COS M9 cells, and Ser --> Ala mutations were introduced singly, or in combinations, at nine known phosphorylation sites. Overexpressed wild-type enzyme had a very low -/+ glucose-6-P activity ratio of similar to 0.01, indicative that the glycogen synthase is in a highly phosphorylated state. No single Ser --> Ala mutation was able to cause a substantial increase in activity ratio; rather, simultaneous mutation at both NH2- and COOH-terminal sites was needed. The most effective combinations were mutations at site 3a (Ser-640) or site 3b (Ser-644) together with site 2 (Ser-7). The results were consistent with site 2 phosphorylation being a prerequisite for phosphorylation of site 2a (Ser-10). Mutation of site 5 (Ser-656) perturbed COOH-terminal phosphorylation but did not prevent inactivation. Expression of the most active mutants correlated with increased glycogen accumulation in the COS M9 cells. In summary, we con elude that (i) the sites most important for activating the enzyme are sites 2, 2a, 3a, and 3b; (ii) removal of phosphate from both NH2- and COOH-terminal sites is required for activation; and (iii) sites 3a and/or 3b can be phosphorylated in COS cells by mechanisms that do not depend on phosphorylation of site 5.			SKURAT, AV (corresponding author), INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027221, R01DK027221] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK27221] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD Z, 1984, J BIOL CHEM, V259, P8743; AKATSUKA A, 1984, J BIOL CHEM, V259, P7878; ARMSTRONG DJ, 1989, ARCH BIOCHEM BIOPHYS, V275, P16, DOI 10.1016/0003-9861(89)90344-5; BAI G, 1990, J BIOL CHEM, V265, P7843; Bailey J. Martyn, 1993, Biochemical Society Transactions, V21, p124S; Bergmeyer H. U., 1974, METHOD ENZYMAT AN, V3, P1196; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN NE, 1971, BIOCHIM BIOPHYS ACTA, V242, P69, DOI 10.1016/0005-2744(71)90088-X; BROWNER MF, 1989, P NATL ACAD SCI USA, V86, P1443, DOI 10.1073/pnas.86.5.1443; CAO YJ, 1993, J BIOL CHEM, V268, P21717; CARLING D, 1989, BIOCHIM BIOPHYS ACTA, V1012, P81, DOI 10.1016/0167-4889(89)90014-1; COHEN P, 1982, EUR J BIOCHEM, V124, P21, DOI 10.1111/j.1432-1033.1982.tb05902.x; COHEN P, 1982, NATURE, V296, P613, DOI 10.1038/296613a0; Cohen P., 1986, ENZYMES, VXVII, P461; DEPAOLIROACH AA, 1983, J BIOL CHEM, V258, P702; EMBI N, 1981, EUR J BIOCHEM, V115, P405, DOI 10.1111/j.1432-1033.1981.tb05252.x; ERIKSON E, 1988, 2ND MESSENGERS PHOSP, V12, P135; FARKAS I, 1991, J BIOL CHEM, V266, P15602; FARKAS I, 1990, J BIOL CHEM, V265, P20879; FERNANDEZNOVELL JM, 1992, BIOCHEM J, V281, P443, DOI 10.1042/bj2810443; FERNANDEZNOVELL JM, 1992, BIOCHEM J, V288, P497, DOI 10.1042/bj2880497; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; FRIEDMAN DL, 1963, BIOCHEMISTRY-US, V2, P669, DOI 10.1021/bi00904a009; HARDY TA, 1993, J BIOL CHEM, V268, P23799; Higuchi R., 1989, PCR TECHNOLOGY, P61; HUANG KP, 1983, J BIOL CHEM, V258, P7094; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE RD, 1989, BIOCHEM INT, V18, P961; LAWRENCE JC, 1983, J BIOL CHEM, V258, P710; LOMAKO J, 1988, Biofactors, V1, P261; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; Maniatis T., 1982, MOL CLONING; NAKIELNY S, 1991, EUR J BIOCHEM, V199, P713, DOI 10.1111/j.1432-1033.1991.tb16175.x; NIMMO HG, 1974, FEBS LETT, V47, P162, DOI 10.1016/0014-5793(74)80450-3; NIMMO HG, 1976, EUR J BIOCHEM, V68, P21, DOI 10.1111/j.1432-1033.1976.tb10761.x; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; PARKER PJ, 1982, EUR J BIOCHEM, V124, P47, DOI 10.1111/j.1432-1033.1982.tb05904.x; PICTON C, 1982, FEBS LETT, V150, P191, DOI 10.1016/0014-5793(82)81332-X; PICTON C, 1982, EUR J BIOCHEM, V124, P37, DOI 10.1111/j.1432-1033.1982.tb05903.x; PITCHER J, 1988, EUR J BIOCHEM, V176, P391, DOI 10.1111/j.1432-1033.1988.tb14294.x; POULTER L, 1988, EUR J BIOCHEM, V175, P497, DOI 10.1111/j.1432-1033.1988.tb14222.x; Roach P. J., 1986, ENZYMES, VXVII, P499; ROACH PJ, 1978, J CYCLIC NUCL PROT, V4, P245; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHEORAIN VS, 1984, J BIOL CHEM, V259, P7024; SHEORAIN VS, 1985, J BIOL CHEM, V260, P1567; SKURAT AV, 1993, J BIOL CHEM, V268, P14701; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; VARDANIS A, 1992, BIOCHEM CELL BIOL, V70, P523, DOI 10.1139/o92-081; VISCUPIC E, 1992, J BIOL CHEM, V267, P25759; WANG YH, 1986, J BIOL CHEM, V261, P6909; WANG YH, 1993, J BIOL CHEM, V268, P23876; WOODGETT JR, 1982, FEBS LETT, V148, P5, DOI 10.1016/0014-5793(82)81231-3; ZHANG WM, 1989, FASEB J, V3, P2532, DOI 10.1096/fasebj.3.13.2509275; ZHANG WM, 1993, ARCH BIOCHEM BIOPHYS, V304, P219, DOI 10.1006/abbi.1993.1342	60	86	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25534	25542						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929255				2022-12-27	WOS:A1994PQ49100048
